NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
NCT03912571,Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment,,Recruiting,No Results Available,Sleep Disorder,Diagnostic Test: Structural 3T MRI|Diagnostic Test: MRI Based Perfusion Imaging|Diagnostic Test: VR-CO2 MRI Scans,Decreased cerebral blood flow (CBF)|Measure of vasoreactivity to CO2 (VRCO2)|Increase in cortical AB plaque burden,New York University School of Medicine,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,95,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,12-00041,13-Nov-11,May-19,May-19,11-Apr-19,null,11-Apr-19,"NYU Langone Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03912571
NCT03840759,Short-term Effects of an Inpatient Geriatric Consultation Team on Geriatric Syndrome Patients,,Completed,No Results Available,Depression|Senile Dementia,Other: inpatient geriatric consultation team,readmission rate|mortality rate,Chang Gung Memorial Hospital,All,65 Years and older   (Older Adult),Not Applicable,59,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMRPG8F1571,1-Jan-17,31-Dec-17,31-Dec-17,15-Feb-19,null,15-Feb-19,,,https://ClinicalTrials.gov/show/NCT03840759
NCT03794141,Genetic Information as a Life Style Change Motivator,APOE4MOT,"Active, not recruiting",No Results Available,"Health Behavior|Alzheimer Disease, Protection Against",Behavioral: information on the risk gene status|Behavioral: life style advise,"Number of participants with good quality of dietary fat|Dietary habits, number of participants|Food choice questionnaire, health and taste attitude|Food involvement and Food mavenism, scale 1-5|Health concern, scale 1-9|Life-orientation test, scale 1-5|Locus of Control, state-trait anxiety inventory, Three-Factor Eating Questionnaire (TFEQ) scale 1-4|weight kg|height m|Waist circumference, cm|Visceral fat level (1-30)|blood pressure, mmHg|Serum lipid levels mmol/L|Blood glucose levels, mmol/L|Serum lipid peroxidation, MDA/µM|Serum Sensitive C reactive protein, mg/L|Serum Hemoglobin, g/L|Serum Alkaline phosphatase, U/L|Serum Alanine aminotransferase, U/L|Serum haptoglobin, g/L|Plasma thyrotropin, mU/L|serum APOE protein, mg/L|serum brain-derived neurotrophic factor, ng/ml|serum Fatty acids, g/100g fatty acids|serum Carotenoids, retinol and α-tocopherol, Plasma total phenolics ng/µl|Blood cell count|APOE and BDNF genotype|Body mass index",Natural Resources Institute Finland|University of Turku|University of Eastern Finland|Academy of Finland,All,40 Years to 60 Years   (Adult),Not Applicable,333,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,41007-00040400,2-Jan-17,30-Mar-19,31-Jul-19,4-Jan-19,null,4-Jan-19,,,https://ClinicalTrials.gov/show/NCT03794141
NCT03786510,A Study on the Effectiveness of Multidomain Intervention Program for Reducing Risks of Dementia,,Completed,No Results Available,Alzheimer Disease,Behavioral: Active control|Behavioral: Intensive + Maintenance program|Behavioral: Intensive program only,Changes from baseline Australian National University Alzheimer's Disease Index (ANU-ADRI) at 4 weeks and 24 week|Changes from baseline Short Physical Performance Battery (SPPB) at 4 weeks and 24 week|Changes from baseline total score in the CERAD neuropsychological battery at 4 weeks and 24 week|Changes from baseline Color Word Stroop Test (CWST) at 4 weeks and 24 week|Changes from baseline Seoul-Instrumental Activities of Daily Living (S-IADL) at 4 weeks and 24 week|Changes from baseline EuroQol Five-Dimensional Questionnaire (EQ-5D) at 4 weeks and 24 week|Changes from baseline Motivation to Change Lifestyle and Health Behaviors for Dementia Risk Reduction Scale (MCLHB-DRR) scale at 4 weeks and 24 week,Seoul National University Hospital|Seoul Metropolitan Government,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,MDP_AD,1-Nov-16,31-Jul-17,31-Jul-17,25-Dec-18,null,25-Dec-18,"Seoul National University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03786510
NCT03770182,Brain Stimulation for Neurological Patients,,Recruiting,No Results Available,Alzheimer Disease,Device: NEUROLITH,Consortium to Establish a Registry for Alzheimer's Disease (CERAD) - Corrected Total Score|Alzheimer's Disease Assessment Scale (ADAS)|Neuropsychological Test Battery Vienna (NTBV)|CERAD|Clock drawing test|Forgetfulness assessment inventory (FAI)|Instrumental Activities of Daily Living Scale (IADL) - Patient|IADL- Patient|Beck Depression Inventory (BDI)|Prosopagnosia index (PI20)|Neuropsychiatric Inventory (NPI) (Care Taker)|IADL (Care Taker)|anatomical Magnetic Resonance Imaging (MRI)|functional Magnetic Resonance Imaging (fMRI),Storz Medical AG|Medical University of Vienna,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",TPS-AD-Vienna,24-Jan-17,1-Jan-20,1-Jan-20,10-Dec-18,null,13-Dec-18,"Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT03770182
NCT03752463,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer Disease,Drug: DAOI-A group|Drug: DAOI-B group|Drug: DAOI-C group|Drug: Placebo oral capsule,"Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24|Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input at week 8, 16 and 24|Change from baseline in speed of processing (Category Fluency) at week 24|Change from baseline in working memory (Wechsler Memory Scale, Spatial Span) at week 24|Change from baseline in verbal learning and memory tests (Wechsler Memory Scale, Word Listing) at week 24","Chang Gung Memorial Hospital|Ministry of Science and Technology, Taiwan",All,"50 Years to 100 Years   (Adult, Older Adult)",Phase 2,160,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",105-3412C,22-May-15,31-Dec-19,31-Dec-19,26-Nov-18,null,26-Nov-18,"Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",,https://ClinicalTrials.gov/show/NCT03752463
NCT03741543,Learning and Coping With Early Stage Dementia,,"Active, not recruiting",No Results Available,Dementia|Alzheimer Disease|Vascular Dementia,Other: A 12-week health promotion course,The users experiences from an educative intervention in early-stage dementia|Change in cognitive function|Change in depressive symptoms|Change in self-rated health|Change in managing personal activities of daily life|Change in managing instrumental activities of daily life|Change in neuropsychiatric symptoms|Change in carer stress/burden,Helse Stavanger HF|Norwegian Extra Foundation for Health and Rehabilitation|Nasjonalforeningen for folkehelsen,All,65 Years and older   (Older Adult),Not Applicable,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,sus2018mk01,3-Mar-14,14-Jun-21,31-Dec-21,15-Nov-18,null,15-Nov-18,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03741543/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03741543
NCT03734289,Improving Family Quality of Life Through Training to Reduce Care-Resistant Behaviors by People With AD and TBI,,Recruiting,No Results Available,Dementia|Traumatic Brain Injury,Behavioral: Caregiver Coaching,Change in Zarit Burden Interview|Change in Dementia Quality of Life (DEMQOL/DEMQOL proxy)|Change in Neuropsychiatric Inventory|Change in Family Quality of Life (Dementia or TBI versions)|Change in Connor-Davidson Resilience Scale (CD-RISC),University of Alabama at Birmingham,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB-160819003|W81XWH-16-1-0527,1-Feb-17,31-Aug-19,31-Dec-19,7-Nov-18,null,7-Nov-18,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT03734289
NCT03732053,The Effectiveness of Global Postural Reeducation on Alzheimer Disease Patients,GPR,Completed,No Results Available,Alzheimer's Type Dementia|Cognitive Decline|Postural; Strain,Other: GPR Intervention Research group,Cognitive Abilities Measurement|Quality of Life in Alzheimer's disease (QoL-AD) Questionnaire|Geriatric Depression Scale (GDS) Questionnaire|Barthel Index (BI)|Neuropsychiatric Inventory (NPI)|Tinetti Scale (TS),Universidad Católica San Antonio de Murcia,All,"40 Years to 95 Years   (Adult, Older Adult)",Not Applicable,135,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,BJ8674287,5-Dec-16,10-Mar-17,3-Jul-17,6-Nov-18,null,15-Nov-18,,,https://ClinicalTrials.gov/show/NCT03732053
NCT03690193,Feasibility and Efficacy of the Ketogenic Diet in Alzheimer's Disease,KDRAFT,Completed,No Results Available,Alzheimer Disease,Behavioral: Ketogenic Diet,Proportion of days positive for urinary ketone production|Change in blood ketone levels induced by ketogenic diet|Change in cognitive performance on the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog)|Change in cognitive performance on the Mini-Mental State Exam (MMSE)|Dietary intake characterization prior to and after ketogenic diet initiation,University of Kansas Medical Center,All,"Child, Adult, Older Adult",Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13796,3-Dec-13,6-Jan-17,6-Jan-17,1-Oct-18,null,1-Oct-18,,,https://ClinicalTrials.gov/show/NCT03690193
NCT03682185,The Healthy Patterns Study,,Recruiting,No Results Available,Dementia|Alzheimer Disease|Circadian Rhythm Disorders|Circadian Rhythm Sleep Disorder|Insomnia|Hypersomnia|Cognitive Impairment|Cognitive Decline|Mild Cognitive Impairment|Frontotemporal Dementia|Neurocognitive Disorders|Vascular Dementia|Sleep Disorder|Memory Impairment,Behavioral: Attention-Control Condition|Behavioral: Timed Activity Intervention,CRS Symptoms from actigraphy|QOL-AD|Neuropsychiatric Inventory (NPI),University of Pennsylvania,All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 3,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,825000,1-May-16,31-May-21,31-May-21,24-Sep-18,null,24-Sep-18,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03682185
NCT03665909,A Proactive Health Monitoring Intervention for Dementia Caregivers,,"Active, not recruiting",No Results Available,Dementia|Alzheimer Disease,Other: Remote activity monitoring system,"Nursing home utilization at 18 months for the person with ADRD|Perceptions of change in caregiver self-efficacy|Perceptions of change in caregiver competence|Perceptions of change in caregiver burden|Perceptions of change in caregiver role captivity|Change in caregiver role overload|Change in frequency/perceptions caregiver depressive symptom severity|Perceived acceptability/utility of remote activity monitoring at 6-, 12-, and 18-months",University of Minnesota - Clinical and Translational Science Institute,All,"21 Years and older   (Adult, Older Adult)",Phase 3,170,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R18HS022836,1-Apr-14,3-Mar-20,3-Mar-20,11-Sep-18,null,12-Sep-18,,,https://ClinicalTrials.gov/show/NCT03665909
NCT03656042,To Evaluate the Efficacy and Safety/Tolerability Profiles of G-CSF in Subjects With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Filgrastim (75mcg/0.3ml),"Alzheimer's Disease Assessment Scale, Cognitive subscale ─ Chinese version (ADAS-Cog-C)|Mini-mental State Examination (MMSE)|Clinical Dementia Rating Scale (CDR)|AD Cooperative Study - Clinical Global Impression of change (ADCS-CGIC )|Lawton and Brody Scale for Instrumental Activities of Daily Living (IADL)|Neuropsychiatric Inventory (NPI)|Ten-point clock test (TPCT)|CD34+ cell number for G-CSF treatment group|Trail making test (TMT)(Part A))|Change from baseline in whole brain volume determined by MRI",Chang Gung Memorial Hospital,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,96-0272A-ASAD-061202,Mar-09,Jul-14,Aug-14,3-Sep-18,null,3-Sep-18,"Chang Gung Memorial Hospital, Taoyuan, Taiwan R.o.c, Taiwan",,https://ClinicalTrials.gov/show/NCT03656042
NCT03656159,Evaluation of a New CBT for People With Alzheimer's Disease and Their Caregivers,,Recruiting,No Results Available,Alzheimer Disease,Behavioral: Cognitive-Behavioral group therapy|Behavioral: Non directive support Group,"Change in psychological distress assessed by Kessler Psychological Distress Scale (K10) (for patients with AD and caregivers)|Change in intensity of anxious symptoms assessed by Geriatric Anxiety Inventory (GAI) (for patients with AD only)|Change in severity of worries assessed by Abbreviated Penn State Worry Questionnaire (PSWQ-A) (for patients with AD and caregivers)|Change in intensity of depressive symptoms assessed by Geriatric Depression Scale (GDS-15) (for patients with AD only)|Change in severity of depression assessed by Patient Health Questionnaire (PHQ-9) (for patients with AD and caregivers)|Change in quality of sleep assessed by Insomnia Severity Index (ISI) (for patients with AD and caregivers)|Change in level of functioning assessed by Disability Assessment for Dementia (DAD) (for caregivers only)|Change in quality of life assessed by Quality of Life-Alzheimer's Disease (QOL-AD) (for patients with AD and caregivers)|Change in quality of life assessed by Short-Form Health Survey (SF-12) (for caregivers only)|Change in satisfaction with life assessed by Satisfaction with life 5-scale (SWLS) (for patients with AD only)|Change in pleasant activities assessed by a questionnaire from ""Entrevue Profil du Loisir, version 4.0"" (for patients with AD and caregivers)|Change in medication taken and support received (for patients with AD and caregivers)|Change in sociovocational integration assessed by Community Integration Questionnaire (CIQ) (for patients with AD only)|Change in general cognitive functioning assessed by The Montreal Cognitive Assessment (MoCA) (for patients with AD only)|Change in language and semantic memory assessed by Boston Naming Test (for patients with AD only)|Change in language and semantic memory assessed by verbal fluency test (for patients with AD only)|Change in episodic memory assessed by Rey Auditory Verbal Learning Test (RAVLT) (for patients with AD only)|Change in memory assessed by Famous Faces Test (for patients with AD only)|Change in memory assessed by Self-evaluation Questionnaire (QAM-A) (for patients with AD only)|Change in short-term memory assessed by digit span subtest from The Wechsler Memory Scale (WMS-III) (for patients with AD only)|Change in memory and visuocontructional praxis assessed by Rey-Osterrieth Complex Figure (for patients with AD only)|Change in executive functions assessed by Frontal Assessment Battery (FAB) (for patients with AD only)|Change in executive functions assessed by Trail Making Test A and B (for patients with AD only)|Change in executive functions assessed by Stroop-Victoria (for patients with AD only)|Change in visuoperceptive and visuospatial functions assessed by Clock drawings (for patients with AD only)",Dr Sébastien Grenier|Alzheimer Society of Canada|Université de Montréal|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal,All,"Child, Adult, Older Adult",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CRIUGM-006,Jan-17,Dec-19,Jun-20,3-Sep-18,null,3-Sep-18,"Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03656159
NCT03622814,Partners at Meals - Respite Care and Home (PAM),PAM,"Active, not recruiting",No Results Available,"Dementia, Alzheimer Type|Weight Loss",Behavioral: Partners at Meals|Behavioral: Enhanced Usual Condition,Weight maintenance,Medical University of South Carolina,null,"Child, Adult, Older Adult",Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,Pro00064441,15-Aug-17,31-May-21,31-May-21,9-Aug-18,null,13-Aug-18,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT03622814
NCT03611439,Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients,,Completed,No Results Available,Alzheimer Disease|Alzheimer Dementia,Dietary Supplement: ReBuilder|Dietary Supplement: Placebo,Change From Baseline Mini Mental State Exam (MMSE) Scores|Change From Baseline Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Scores|Change From Baseline Clinical Dementia Rating Sum of Boxes (CDR-SB) Scores,Genescient Corporation,All,"Child, Adult, Older Adult",Not Applicable,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Genescient,1-Oct-13,25-Dec-15,25-Dec-15,2-Aug-18,null,2-Aug-18,,,https://ClinicalTrials.gov/show/NCT03611439
NCT03554226,Agitation and Aggressivity in Alzheimer's Disease Patients: A Cohort Study,A3C,"Active, not recruiting",No Results Available,Alzheimer Disease,Behavioral: NeuroPsychiatric Inventory Clinician (NPI-C),Severity of A/A with NeuroPsychiatric Inventory Clinician (NPI-C)|The clinical relevance of the change observed by the clinician with Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)|Cohen-Mansfield Agitation Inventory|Quality of Life QoL-AD,"University Hospital, Toulouse|Ethypharm",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,330,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RC31/14/7163|2014-A00673-44,1-Nov-14,31-Dec-18,31-Dec-18,13-Jun-18,null,13-Jun-18,"Toulouse University Hospital (CHU de Toulouse), Toulouse, France",,https://ClinicalTrials.gov/show/NCT03554226
NCT03549078,A Multidimensional Behavioral Intervention for Those at Risk for Alzheimer's Dementia,,Recruiting,No Results Available,Functional Aging|Subjective Cognitive Concerns|Compensation Strategies|Brain Health Activities,Behavioral: Intervention,Everyday Compensation Questionnaire|Everyday Cognition|Beck Depression Inventory|Beck Anxiety Inventory|List learning task|Executive function task|psychomotor speed task|GRIT,"University of California, Davis",All,65 Years and older   (Older Adult),Not Applicable,120,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,967764,1-Jan-17,31-Oct-19,31-Oct-19,7-Jun-18,null,7-Jun-18,"University of California Davis, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT03549078
NCT03542656,Application of Amyloid PET in Cerebral Amyloid Angiopathy,CAA,Recruiting,No Results Available,Cerebral Amyloid Angiopathy|Intracranial Hemorrhages|Alzheimer Disease,Drug: amyloid PET,PET imaging,National Taiwan University Hospital,All,"20 Years and older   (Adult, Older Adult)",Phase 3,160,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,201404065MIND,11-Sep-14,17-Feb-16,Dec-19,31-May-18,null,31-May-18,"National Taiwan Univeristy Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT03542656
NCT03507192,Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.,,Recruiting,No Results Available,Mild Cognitive Impairment|Alzheimer Dementia,Device: Muscle relaxation using full body massage machine,cortical thickiness in 3D MRI|functional connectivity in functional MRI,Samsung Medical Center,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2017-05-135,25-Sep-17,31-Dec-19,31-Dec-19,24-Apr-18,null,14-Mar-19,"Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03507192
NCT03487380,Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease,MiDCR,Recruiting,No Results Available,Alzheimer Disease|Intestinal Microbiota,Procedure: Fecal sample collection,"analysis of the taxonomic and functional composition of the microbiome|to determine if there is a specific modification of the composition of the intestinal microbiota of patients with Alzheimer's disease, compared to control group.|create a prognostic score of DCR based on clinical data, including the responses to the MMSE, BREF and MNA questionnaires, and taking into account the microbiota analysis",Nantes University Hospital,All,70 Years to 90 Years   (Older Adult),Not Applicable,300,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RC17_0162|2017-A02246-47,4-Sep-17,Sep-20,Sep-20,4-Apr-18,null,1-May-19,"CHU de Angers, Angers, France|CHU de Nantes, Nantes, France",,https://ClinicalTrials.gov/show/NCT03487380
NCT03456349,Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care,,Completed,No Results Available,Alzheimer's Disease,Drug: HTL0018318|Drug: Placebo,"Treatment emergent adverse events (TEAEs), Safety and Tolerability",Heptares Therapeutics Limited|Allergan,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HTL0018318-202|2017-000649-34,10-Nov-17,16-Jul-18,16-Jul-18,7-Mar-18,null,20-Jul-18,"Syneos, Prague, Czechia|Syneos, Warsaw, Poland|Syneos, Bratislava, Slovakia|Syneos, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT03456349
NCT03424200,Coaching for Cognition in Alzheimer's (COCOA),,Recruiting,No Results Available,Alzheimer Disease|Cognitive Impairment,Behavioral: Routine care|Other: Coaching plus routine care,Coaching for Cognitive Decline|Diagnosis of Alzheimer's Disease|Memory Performance Index|FAST Stage,Hoag Memorial Hospital Presbyterian|Institute for Systems Biology|Arivale,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,COCOA,1-Nov-17,1-Nov-22,1-Nov-22,6-Feb-18,null,7-Feb-19,"Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",,https://ClinicalTrials.gov/show/NCT03424200
NCT03422250,Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia,NetCogBs,Completed,No Results Available,"Alzheimer Disease|Frontotemporal Dementia, Behavioral Variant",Device: transcranial direct current stimulation (tDCS),Change from baseline in clinical disease severity|Change from baseline in behavioral symptom severity|Change from baseline in functional connectivity|Change from baseline in perfusion|Change from baseline in cognition: memory|Change from baseline in cognition: language|Change from baseline in cognition: executive function|Change from baseline in cognition: visuospatial function|Change from baseline in cognition: emotion recognition|Change from baseline in structural connectivity,IRCCS Centro San Giovanni di Dio Fatebenefratelli,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",GR-2011-02349787,8-Jun-15,3-Nov-18,3-Nov-18,5-Feb-18,null,20-Nov-18,"IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy",,https://ClinicalTrials.gov/show/NCT03422250
NCT03420807,Retinal Metabolic Imaging of Alzheimer Patient,,Recruiting,No Results Available,Alzheimer Disease,Device: MHRC,Retinal beta-amyloid detection,Optina Diagnostics Inc.|McGill University|Polytechnique Montreal|Sunnybrook Health Sciences Centre,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,50,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,71317,4-Dec-17,31-Jan-19,31-Mar-19,2-Feb-18,null,2-Feb-18,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03420807
NCT03417219,Mobile Tablet Education to Advance Caregiver Health,MTEACHing,Completed,No Results Available,Dementia,Behavioral: Education and Skill Building Rehabilitation-mobile (ESBR-m)|Behavioral: Usual Care (UC),Change from Baseline Zarit Burden Interview (ZBI) at 4 months|Change from Baseline Center for Epidemiological Studies-Depression (CES-D) at 4 months|Change from Baseline Perceived Stress Scale (PSS) at 4 months,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,16,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,E1710-P|1I21RX001710,1-Jan-15,31-Dec-17,30-Jun-18,31-Jan-18,null,6-Jul-18,"VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT03417219
NCT03417986,Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers,drainAD,"Active, not recruiting",No Results Available,Alzheimer Disease,Drug: TEP,Efflux of Amyloid beta peptides (Group mean changes from baseline)|Scores obtained in psychometric tests [Cognition]|Incidence of Treatment-Emergent Adverse Events [Safety and tolerability]|Cerebrospinal fluid (CSF) levels of Tau,Immungenetics AG,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMU-AD-001,24-Nov-17,Jul-21,Jul-21,31-Jan-18,null,27-Feb-19,"Klinik für Psychiatrie und Psychotherapie Universitätsmedizin Göttingen, Göttingen, Germany|Zentralinstitut für seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg,, Mannheim, Germany",,https://ClinicalTrials.gov/show/NCT03417986
NCT03402659,"Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease",REVERSE-SD,"Active, not recruiting",No Results Available,Alzheimer Disease,Drug: neflamapimod|Other: placebo,Improvement in total and delayed recall on the Hopkins Verval Learning Test - Revised (HVLT-R)|Wechsler Memory Scale (WMS) Immediate and delayed Recall|Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Mini-Mental State Examination (MMSE)|Cerebrospinal fluid phospho-tau|Cereberspinal fluid amyloid beta 1-40,"EIP Pharma, LLC|Worldwide Clinical Trials|VU University Medical Center",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,161,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EIP-VX17-745-304,29-Dec-17,30-Jun-19,31-Jul-19,18-Jan-18,null,14-Mar-19,"Alliance for Research, Long Beach, California, United States|Pacific Research Network, San Diego, California, United States|CITrials, Santa Ana, California, United States|Southern California Research, LLC, Simi Valley, California, United States|Viking Clinical Research, Temecula, California, United States|Miami Dade Medical Research Institute, Miami, Florida, United States|Sensible Healthcare, LLC, Ocoee, Florida, United States|Anchor Neuroscience, Pensacola, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Florida Premier Research Institute, Winter Park, Florida, United States|Northwest Clinical Trials, Boise, Idaho, United States|MassGeneral Institute for Neurodegenerative Disease, Charlestown, Massachusetts, United States|Manhattan Behavioral Medicine, New York, New York, United States|Alzheimer's Memory Center and Research Institute, Charlotte, North Carolina, United States|Northwest Clinical Research Center, Seattle, Washington, United States|Neuro HK, s.r.o. POLIKLINIKA CHOCEŇ, a.s., Choceň, Czechia|Cerebrovaskulární poradna s.r.o., Moravská Ostrava, Czechia|Clintrial S.R.O, Prague, Czechia|Private Psychiatric Centre, Prague, Czechia|Vestra Clinics S.R.O, Rychnov Nad Kněžnou, Czechia|CCBR Clinical Research, Aalborg, Aalborg, Denmark|CCBR Clinical Research, Ballerup, Ballerup, Denmark|CCBR Clinical Research, Vejle, Vejle, Denmark|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Alzheimer Research Center, Amsterdam, Netherlands|Amphia Ziekhuis, Breda, Netherlands|MAC Clinical Research Tankersley, Barnsley, United Kingdom|Re:Cognition Health Birmingham, Birmingham, United Kingdom|MAC Clinical Research Blackpool, Blackpool, United Kingdom|Fulbourn Hospital, Cambridge, United Kingdom|MAC Clinical Research Leeds, Leeds, United Kingdom|MAC Clinical Research Liverpool, Liverpool, United Kingdom|Re:Cognition Health London, London, United Kingdom|St. Pancras Clinical Research, London, United Kingdom|MAC Clinical Research Manchester, Manchester, United Kingdom|Re:Cognition Health Plymouth, Plymouth, United Kingdom|5 Boroughs/North West Boroughs Healthcare NHS Foundation Trust, Warrington, United Kingdom",,https://ClinicalTrials.gov/show/NCT03402659
NCT03393520,"Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",,Recruiting,No Results Available,Agitation in Patients With Dementia of the Alzheimer's Type,Drug: Placebo|Drug: AVP-786,Change from Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score|Change from Baseline to Week 12 in the Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change for Agitation (mADCS-CGIC-Agitation) Score|Change from Baseline to Week 12 in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score|Change from Baseline to Week 12 in the NPI Caregiver Distress Score|Change from Baseline to Week 12 in the NPI Aberrant Motor Behavior Domain Score|Change from Baseline to Week 12 in the NPI Irritability/Lability Domain Score|Change from Baseline to Week 12 in the NPI Total Score|Change from Baseline to Week 12 in the Clinical Global Impression of Severity (CGIS)-Agitation Domain Score|Change from Baseline to Week 12 in the ADCS-CGIC for Overall Clinical Status Rating|Change from Baseline to Week 12 in the Patient Global Impression of Change (PGIC) Scale Score|Change from Baseline to Week 12 in the Dementia Quality of Life (DEMQOL) Scale Score|Change from Baseline to Week 12 in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Dimension Scores|Change from Baseline to Week 12 in the Resource Utilization in Dementia (RUD) Scale Score,Avanir Pharmaceuticals,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,412,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",17-AVP-786-305|2017-001339-38,13-Oct-17,Jun-21,Jun-21,8-Jan-18,null,7-Mar-19,"Onyx Clinical Research, LLC, Caro, Michigan, United States|Galen Research, Chesterfield, Missouri, United States|Australian Alzheimer's Research Foundation, Nedlands, Australia|Neuro Trials Victoria Pty Ltd, Noble Park, Australia|Center for Mental Health - Ruse, Ruse, Bulgaria|Medical Center Sveti Naum, Sofia, Bulgaria|Medica Plus Medical Center, Veliko Tarnovo, Bulgaria|Semmelweis Egyetem, Budapest, Hungary|Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz, Debrecen, Hungary|Valeomed Egeszsegugyi es Szolgaltato Kft, Esztergom, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Nyíregyháza, Hungary|PsychoTech, Pécs, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, Hungary|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Italy|Fondazione Santa Lucia - Istituto di Ricovero e Cura a Carattere Scientifico, Roma, Italy|Centrum Medyczne Euromedis, Szczecin, Poland|Cape Trial Centre, Cape Town, South Africa|Fundació ACE, Barcelona, Spain|Fundació Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|MAC Clinical Research - Barnsley, Barnsley, United Kingdom|Research Institute for the Care of Older People, Bath, United Kingdom|MAC Clinical Research - Blackpool, Blackpool, United Kingdom|MAC Clinical Research - Cannock, Cannock, United Kingdom|MAC Clinical Research - Leeds, Leeds, United Kingdom|Re-Cognition Health - London, London, United Kingdom|South London and Maudsley NHS Foundation Trust, London, United Kingdom|MAC Clinical Research - Manchester, Manchester, United Kingdom|Southern Health NHS Foundation Trust, Southampton, United Kingdom|Avon and Wiltshire Mental Health Partnership NHS Trust, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT03393520
NCT03387267,Videofluoroscopic Swallowing Study (VFSS),PORSCHE,Terminated,No Results Available,Stroke|Parkinson Disease|Multiple Sclerosis|Oropharyngeal Dysphagia|Alzheimer Disease|Dementia,Device: Dysphagia Detection System,The primary efficacy of the Dysphagia Detection System (DDS) will be measured as the sensitivity & specificity obtained from comparing the DDS swallow safety outcome simultaneously to the VFSS swallow safety outcome for thin barium (THIN-Ba) stimuli|The sensitivity & specificity DDS for swallow safety using MILD-Ba will be measured as the sensitivity & specificity obtained from comparing the DDS predicted swallow safety outcome with the VFSS swallow safety outcome for MILD-Ba|The sensitivity & specificity DDS for swallow efficiency using THIN-Ba will be measured as the sensitivity & specificity obtained from comparing the DDS predicted swallow efficiency outcome with the VFSS swallow efficiency outcome for THIN-Ba|The sensitivity & specificity DDS for swallow efficiency using MILD-Ba will be measured as the sensitivity & specificity obtained from comparing the DDS predicted swallow efficiency outcome with the VFSS swallow efficiency outcome for MILD-Ba|The sensitivity & specificity DDS for swallow safety using MOD-Ba will be measured as the sensitivity & specificity obtained from comparing the DDS predicted swallow safety outcome with the VFSS swallow safety outcome for MOD-Ba|The sensitivity & specificity DDS for swallow efficiency using MOD-Ba will be measured as the sensitivity & specificity obtained from comparing the DDS predicted swallow efficiency outcome with the VFSS swallow efficiency outcome for MOD-Ba,Nestlé|Cytel Inc.|Regulatory and Clinical Research Institute Inc|Nestec Ltd.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,442,Industry|Other,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Screening,16.21.CLI,24-Oct-17,23-Jul-18,23-Jul-18,2-Jan-18,null,31-Jan-19,"Rancho Research Institute, Rancho Los Amigos National Rehabilitation Center, Downey, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Medstar Rehabilitation Hospital, Washington, District of Columbia, United States|Shirley Ryan AbilityLab, Chicago, Illinois, United States|Marionjoy Rehabilitation Hospital, Wheaton, Illinois, United States|Kentucky Clinic, Lexington, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|New York Presbyterian/Weill Cornell Medical Center, New York, New York, United States|New York Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States|The Burke Medical Research Institute, White Plains, New York, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Helsinki University Central Hospital, Helsinki, Finland",,https://ClinicalTrials.gov/show/NCT03387267
NCT03382353,EMuNI Project: Multiple Nonpharmacological Interventions,EMuNI,"Active, not recruiting",No Results Available,Lifestyle Risk Reduction,Dietary Supplement: Nutritional supplementation|Behavioral: Educational training|Behavioral: Counselling on a brain-healthy diet|Behavioral: Physical exercise training|Behavioral: Computerized cognitive training,Cognitive functions|Basic imaging marker 1|Basic imaging marker 2|Basic imaging marker 3,IRCCS Centro San Giovanni di Dio Fatebenefratelli|Ospedale San Raffaele|Istituto Di Ricerche Farmacologiche Mario Negri,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,GR-2011-02350494,Jan-16,Jun-17,Jun-18,22-Dec-17,null,22-Dec-17,"IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy|Ospedale San Raffaele, Milan, Italy",,https://ClinicalTrials.gov/show/NCT03382353
NCT03378037,The Effects of Acupuncture on the Risk of AD After TBI,,Recruiting,No Results Available,"Brain Injuries, Traumatic",Procedure: Acupuncture,Decreased plasma levels of Aβ peptide|Decreased plasma levels of tau|Decreased plasma levels of glial fibrillary acidic protein (GFAP)|Increased white matter integrity,China Medical University Hospital,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,76,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CMUH106-REC2-139,25-Dec-17,Jun-20,Jun-20,19-Dec-17,null,8-Mar-18,"China Medical University Hospital, Taichung, Taiwan",,https://ClinicalTrials.gov/show/NCT03378037
NCT03378245,"Telemedicine-based, Multidisciplinary-team, Intervention to Reduce Unnecessary Hospitalizations",TeleNH,Enrolling by invitation,No Results Available,Dementia Alzheimers|Disruptive Behavior,Behavioral: Behavioral modification and education on pharmacologic treatments.,Change in the Neuropsychiatric Inventory (NPI) total score|Change in the Resource Utilization in Dementia - Formal Care (RUD-FOCA)|Change in Quality of Life in Alzheimers Dementia (QoL-AD),Richard Ronan Murphy|University of Kentucky,All,"Child, Adult, Older Adult",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care,13-0664-P3H,Sep-13,Dec-18,Dec-18,19-Dec-17,null,19-Dec-17,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT03378245
NCT03378453,Narcolepsy Protect Against Alzheimer's Disease?,PROTECMAN,Completed,No Results Available,Narcolepsy|Amyloid Pathology,Device: PET-scan18F-AV-45,Mean of cortical SuVr based of the PET-scan18F-AV-45 imaging|Mean regional SuVr with PET-scan AV45|CSF Amyloid Aβ42|CSF Amyloid Aβ40|CSF Tau protein|CSF Orexin concentration|Night-time sleep duration|Day-time sleep duration|Cataplexy|Epworth sleepiness scale (ESS)|Beck Depression Inventory (BDI)|European Quality of Life Dimension (EQL-5),"University Hospital, Montpellier",All,65 Years to 85 Years   (Older Adult),Not Applicable,38,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,9636,7-Apr-16,Nov-17,Nov-17,19-Dec-17,null,19-Dec-17,"Montpellier University Hospital, Gui de Chauliac, Montpellier, France",,https://ClinicalTrials.gov/show/NCT03378453
NCT03375697,"A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease",,Recruiting,No Results Available,Alzheimer Disease,Drug: JNJ-63733657|Drug: Placebo,"Single Ascending Dose (SAD) (Part 1): Number of Subjects With Adverse Events as a Measure of Safety and Tolerability of JNJ-63733657|Multiple Ascending Dose (MAD) (Part 2): Number of Subjects With Adverse Events as a Measure of Safety and Tolerability of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Maximum Observed Serum Concentration (Cmax) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Area Under the Serum Concentration-time Curve From Time Zero to Time of the Last Observed Quantifiable Concentration (AUC [0-Last]) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-63733657|MAD (Part 2): Area Under the Serum JNJ-63733657 Concentration-time Curve During a Dosing Interval (t) (AUC tau)|MAD (Part 2): Accumulation Ratio (R)|SAD (Part 1) and MAD (Part 2): Total Systemic Clearance (CL) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Volume of Distribution at Steady-State (Vss) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Terminal Half-Life(t[1/2]) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): JNJ-63733657 Concentration in Cerebrospinal Fluid (CSF)|SAD (Part 1) and MAD (Part 2): Number of Subjects With Anti-JNJ-6373365 Antibodies as a Measure of Immunogenicity|SAD (Part 1) and MAD (Part 2): Percent Change From Baseline in Total, Free, and Bound tau Biomarker Fragments in CSF","Janssen Research & Development, LLC",All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 1,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR108392|63733657EDI1001|2017-003852-21,22-Dec-17,20-Dec-19,21-Dec-19,18-Dec-17,null,20-May-19,"Clinical Pharmacology Unit, Merksem, Belgium|Klinik für Neurodegenerative Erkrankungen und Gerontopsychiatrie, Bonn, Germany|CTC North GmbH & Co. KGim Spectrum am UKE, Hamburg, Germany|Universitätsklinikum des Saarlandes, Homburg / Saar, Germany|Centre for Human Drug Research, Leiden, Netherlands|Hosp. Clinico San Carlos, Madrid, Spain|Hosp. Univ. I Politecni La Fe, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT03375697
NCT03373604,Imaging Tau in Alzheimer's Disease and Normal Aging,,Enrolling by invitation,No Results Available,Alzheimer Disease,Drug: 18F-MK-6240|Procedure: Lumbar Puncture (optional),18F-MK-6240 binding (standardized uptake value ratio)|Correlation of 18F-MK-6240 binding and CSF markers of neurodegeneration and inflammation.,William Charles Kreisl|National Institute on Aging (NIA)|Columbia University,All,"50 Years to 100 Years   (Adult, Older Adult)",Phase 2,175,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AAAR4352|K23AG052633-02|2R56AG034189-06A1|K24AG045334|R01AG055299|R01AG050440-02S1,11-Dec-17,20-Aug-21,20-Aug-21,14-Dec-17,null,1-Aug-18,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03373604
NCT03371420,PET Imaging of Subjects Using 124I-PU-AD,,"Active, not recruiting",No Results Available,Lymphoma|Solid Malignancy|Alzheimer Disease|Myeloma,Drug: PU-AD|Device: PET Scan|Other: Blood Draws,Pharmacokinetic profile of 124I-PU-AD: area under the curve (AUC)|Pharmacokinetic profile of 124I-PU-AD: maximum plasma concentration (Cmax)|Pharmacokinetic profile of 124I-PU-AD: trough plasma concentration (Cmin)|Pharmacokinetic profile of 124I-PU-AD: plasma half-life (T1/2)|Pharmacokinetic profile of 124I-PU-AD: time to maximum plasma concentration (Tmax)|Incidence of adverse events,"Samus Therapeutics, Inc.|Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University|Rockefeller University",All,"21 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,10,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PU-AD-00-001,Apr-16,Apr-19,Aug-19,13-Dec-17,null,15-Mar-19,"Memorial Sloan Kettering, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03371420
NCT03367403,A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ),,Recruiting,No Results Available,Alzheimer Disease,Drug: LY3002813|Drug: Placebo,Change from Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) Score|Change from Baseline in the Alzheimer's Disease Assessment Scale—Cognitive Subscale (ADAS-Cog13) Score|Change from Baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Score|Change from Baseline in the Mini Mental State Examination (MMSE) Score|Change from Baseline in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL) Score|Change from Baseline in Brain Amyloid Plaque Deposition as Measured by Florbetapir F18 Positron Emission Tomography (PET) Scan|Change from Baseline in Brain Tau Deposition as Measured by Flortaucipir F18 PET Scan|Change from Baseline in Brain Volume as Measured by volumetric Magnetic Resonance Imaging (vMRI),Eli Lilly and Company,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,266,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",16933|I5T-MC-AACG,18-Dec-17,15-Oct-20,16-Sep-21,8-Dec-17,null,17-Apr-19,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|Irvine Clinical Research Center, Irvine, California, United States|Institute for Memory Impairment & Neurological Disorders, Irvine, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pacific Research Network Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Associated Neurologists, PC - Danbury, Danbury, Connecticut, United States|KI Health Partners, LLC d/b/a NE Inst. for Clin. Res., Stamford, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Merritt Island Medical Research LLC, Merritt Island, Florida, United States|Pharmax Research Clinic, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Compass Research, Orlando, Florida, United States|Palm Beach Neurological Group, Palm Beach Gardens, Florida, United States|Quantum Laboratories, Pompano Beach, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Axiom Research, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Compass Research, The Villages, Florida, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology, Indianapolis, Indiana, United States|University of Kansas Hospital, Fairway, Kansas, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|McLean Hospital, Belmont, Massachusetts, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Donald S Marks, Plymouth, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Behavioral Health Center Research, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Piedmont Medical Research, Winston-Salem, North Carolina, United States|Insight Clinical Trials, Beachwood, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Texas Neurology, PA, Dallas, Texas, United States|Houston Methodist, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|Cognition Health, Fairfax, Virginia, United States|National Clinical Research - Richmond, Richmond, Virginia, United States|Bruyere Research Institute, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Clinique de la Memoire de l'Outaouais, Gatineau, Quebec, Canada|DIEX Recherche Sherbrooke, Inc, Sherbrooke, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03367403
NCT03363269,Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer Disease,Drug: ID1201,Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) at 12 Weeks,IlDong Pharmaceutical Co Ltd,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,116,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ID-BOA-201,12-Apr-16,31-Dec-18,31-Dec-18,6-Dec-17,null,3-Sep-18,"Dong-A University Hospital, Busan, Korea, Republic of|Changwon Fatima Hospital, Changwon, Korea, Republic of|Kangwon National University Hospital, Chuncheon, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea, Republic of|Myongji Hospital, Goyang, Korea, Republic of|Hanyang University Guri Hospital, Guri, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Hanyang University Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|KunKuk University Hospital, Seoul, Korea, Republic of|Ajou University Medical Center, Suwon, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03363269
NCT03361410,Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year,,Recruiting,No Results Available,Mild Cognitive Impairment,Dietary Supplement: Grape Powder|Dietary Supplement: Placebo Powder,Regional Cerebral Metabolism|Changes in neuropsychological performance measures|Changes in neuropsychological performance measures: Mini-Mental State Examination|Changes in neuropsychological performance measures: Wechsler Adult Intelligence Scale (WAIS-III) Digit Span|Changes in neuropsychological performance measures: Trail Making Test Part B|Changes in neuropsychological performance measures: Functional Activities Questionnaire|Changes in neuropsychological performance measures: Verbal Memory|Changes in neuropsychological performance measures: Non-Verbal Memory|Changes in neuropsychological performance measures: Verbal Function|Changes in neuropsychological performance measures: Stroop Interference|Changes in neuropsychological performance measures: Problem Solving|Changes in neuropsychological performance measures: Visual Spatial Processing,"University of California, Los Angeles|California Table Grape Commission",All,65 Years to 85 Years   (Older Adult),Phase 2,32,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",17-001290,18-Nov-17,May-19,May-19,4-Dec-17,null,8-May-18,"University of California, Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT03361410
NCT03357328,Therapy Light Rooms for Improved Sleep in Dementia Patients,DEMLIGHT,Completed,No Results Available,Sleep Fragmentation|Behavioural and Psychiatric Symptoms of Dementia|Dementia,Other: Therapy light room|Other: Standard light,Change in actigraphy recorded sleep and circadian rhythm|Change in proxy-rated sleep|Change in circadian rhythm of core body temperature|Change in the Neuropsychiatric Inventory - Nursing Home version (NPI-NH)|Change in the Cohen-Mansfield Agitation Inventory (CMAI)|Change in the Cornell Scale of Depression in Dementia (CSDD)|Change in the Quality of Life in Late-Stage Dementia (QUALID)|Change in the Mobilization-Observation-Behaviour-Intensity-Dementia 2 (MOBID-2)|Change in the Mini Mental State Examination (MMSE)|Change in the Functional Assessment Staging (FAST)|Change in the Physical Self-Maintenance Scale|Clinical Global Impression of Change (CGIC)|Change in the Resource Utilization in Dementia - Formal Care (RUD-FOCA)|Change in general health|Change in burden of care|Change in staff alertness|Change in staff sleep|Change in staff fatigue|Change in staff mental health|Change in staff health related quality of life,University of Bergen,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",UBergenDEM.LIGHT|2016/2246,25-Sep-17,21-Apr-18,24-Apr-18,29-Nov-17,null,7-May-18,"University of Bergen, Bergen, Hordaland, Norway",,https://ClinicalTrials.gov/show/NCT03357328
NCT03352258,Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer Disease,Radiation: Low dose radiotherapy,Safety and adverse event associated with low dose brain RT|Change in brain amyloid deposits|Neuropsychological performances,"Thomas Zilli|University Hospital, Geneva",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017-01715,17-Nov-17,30-Dec-19,30-Dec-20,24-Nov-17,null,30-Apr-18,"Geneva University Hospital, Geneva 14, Switzerland",,https://ClinicalTrials.gov/show/NCT03352258
NCT03352739,Fornix and NbM as Targets of Stimulation In Alzheimer's Disease,FANTASIA,Recruiting,No Results Available,Alzheimer Disease,"Device: DBS of the fornix, power on|Device: DBS of the NbM, power on|Device: DBS of the fornix, power off|Device: DBS of the NbM, power off",Cognitive outcome|Neuroplasticity outcome|Functional outcome|Safety outcome,"Xuanwu Hospital, Beijing|Beijing Pins Medical Co., Ltd",All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",XuanwuH,1-Dec-17,1-Dec-19,1-Dec-20,24-Nov-17,null,11-Jan-18,"Xuanwu Hospital, Capital Medical University., Beijing, China",,https://ClinicalTrials.gov/show/NCT03352739
NCT03333096,Assessing Neurovisual Function in Patients With Cognitive Impairment,,Recruiting,No Results Available,Glaucoma|Mild Cognitive Impairment|Glaucoma and Mild Cognitive Impairment|Healthy,Device: Ocusweep test battery|Diagnostic Test: Neuropsychological test battery,Perception speed|Evidence of cognitive impairment measured by MoCA-test|Evidence of impaired attentional ability - Cognitive profile|Evidence of impaired Executive Functioning - Cognitive profile 1/2|Evidence of impaired Executive Functioning - Cognitive profile 2/2|Evidence of impaired Visuoconstructive abilities - Cognitive profile|Evidence of slow reaction time - Cognitive profile|Evidence of impaired visual attention measured by UFOV-test - Cognitive Profile|Evidence of glaucomatous visual field defects 1/2|Evidence of glaucomatous visual field defects 2/2|Contrast Sensitivity - Ocusweep|Visual Acuity- Ocusweep|Visual Search - Ocusweep Neural|Memory guided saccades - Ocusweep Neural|Anti-saccades - Ocusweep Neural|Prosaccade - Ocusweep Neural,Turku University Hospital|Ocuspecto Oy|European Commission,All,65 Years and older   (Older Adult),Not Applicable,60,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,T212/2017,1-Dec-17,1-Jan-19,1-Jan-19,6-Nov-17,null,16-Feb-18,"Turku University Hospital, Turku, Finland",,https://ClinicalTrials.gov/show/NCT03333096
NCT03328195,Vielight Neuro RX Gamma - Feasibility Pilot,,Recruiting,No Results Available,Alzheimer Disease,Device: Neuro RX Gamma synchronous|Device: Sham|Device: Neuro RX Gamma asynchronous,Change in the Severe Impairment Battery (SIB) score - An assessment of Severe Dementia in the elderly.|Device safety according to the number of device-related adverse events|Change in the Severe Impairment Battery score - An assessment of Severe Dementia in the elderly.|Change in the Alzheimer's Disease Cooperative Study - Activities of Daily Living for Severe Alzheimer's Disease (ADL SAD) score|Change in the Neuropsychiatric Inventory (NPI) score which assesses behavioral changes in neurologic illnesses based on a standardized caregiver interview.|Change in the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS CGIC) score.|Change in the Electroencephalogram's (EEG) overall power spectral density,Vielight Inc.,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P17.02,4-Dec-17,May-19,May-19,1-Nov-17,null,26-Nov-18,"Chatham Kent Clinical Trials Research Centre, Chatham, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03328195
NCT03324711,"Psychometric Validation of the ""Antillanisée"" Version of the Mini Mental State Examination (MMSEa)",MMENSEA,Recruiting,No Results Available,Elderly Patients|Cognitive Disorder|Alzheimer Disease,"Diagnostic Test: ""Antillanisée"" Mini Mental State Examination (MMSEa)",Evaluation of the psychometric properties of the questionnaire MMSEa|Evaluation of the psychometric properties of questionnaire SPPB,University Hospital Center of Martinique,All,65 Years and older   (Older Adult),Not Applicable,300,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,15/B/26,Nov-16,Nov-18,May-20,30-Oct-17,null,30-Oct-17,"CHU de Martinique, Fort-de-France, Martinique, France",,https://ClinicalTrials.gov/show/NCT03324711
NCT03325205,MR Guided tDCS in Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer's Disease,Other: Anodal tDCS|Other: Sham tDCS,Performance on Neuropsychological tests|Hippocampal volume,University of Tromso|Helse Nord,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2017/794 (REK),22-Aug-17,30-Jun-19,30-Dec-20,30-Oct-17,null,30-Oct-17,"Department of Psychology, University of Northern Norway, Tromsø, Norway",,https://ClinicalTrials.gov/show/NCT03325205
NCT03325556,Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis,,Recruiting,No Results Available,Dementia-related Psychosis,Drug: Placebo|Drug: Pimavanserin 34 mg|Drug: Pimavanserin 20 mg,Time from randomization to relapse in the double-blind period|Time from randomization to discontinuation from the double-blind period for any reason,ACADIA Pharmaceuticals Inc.,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,356,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ACP-103-045|2017-002227-13,27-Sep-17,Mar-20,Mar-20,30-Oct-17,null,26-Apr-19,"ATP Clinical Research Inc., Costa Mesa, California, United States|The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States|Neuro-Pain Medical Center, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Associated Neurologists, P.C., Danbury, Connecticut, United States|Ki Health Partners, LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States|Visionary Investigators Network (Aventura Neurologic Associates), Aventura, Florida, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Premier Clinical Research Institute, Inc., Miami, Florida, United States|Visionary Investigators Network (First Choice Neurology Group), Miami, Florida, United States|Novel Clinical Research Center, LLC, Miami, Florida, United States|Collier Neurologic Specialists LLC, Naples, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|Quantum Laboratories, Pompano Beach, Florida, United States|Neuroscience Research Institute, Winfield, Illinois, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|Acadia Hospital, Bangor, Maine, United States|Alzheimer Disease Center, Quincy, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Millennium Psychiatric Associates, LLC; DBA Millennium Center for Clinical Research, Saint Louis, Missouri, United States|Neurology Center of Las Vegas, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Einstein Clinical, LLC, Phillipsburg, New Jersey, United States|BioBehavioral Health, Toms River, New Jersey, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Dayton Center for Neurological Disorders, Centerville, Ohio, United States|Neuro-Behavioral Clinical Research, Inc., North Canton, Ohio, United States|Drexel University Neurology Department, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Abington Neurological Associates Ltd., Willow Grove, Pennsylvania, United States|Metrolina Neurological Associates, PA, Indian Land, South Carolina, United States|BG Neurology LLC, Spartanburg, South Carolina, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|Advanced Clinical Research Associates, Plano, Texas, United States|University of Virginia Adult Neurology, Charlottesville, Virginia, United States|Mental Health Center - Ruse EOOD, Russe, Bulgaria|MHAT Lyulin EAD - Department of Neurology Diseases, Sofia, Bulgaria|MHAT-Targovishte AD, Psychiatry Department, Targovishte, Bulgaria|DCC - Mladost M Varna OOD, Varna, Bulgaria|Psicomed Estudios Medicos, Antofagasta, Chile|Biomedica Research Group, Santiago, Chile|Especialidades Médicas L y S, Santiago, Chile|Fakultni nemocnice Hradec Kralove, Hradec Králové, Czechia|Clintrial s.r.o., Praha 10, Czechia|AD71, s.r.o., Praha 10, Czechia|Vestra Clinics, s.r.o, Rychnov nad Kněžnou, Czechia|CHU Henri Mondor - Centre d'investigation clinique Henri Mondor (CIC), Creteil Cedex, France|Centre Memoire Ressources Recherche (CMRR), Hopital F. MITTERRAND, Dijon Cedex, France|Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital de La Timone - Service de Neurologie et Pathologie du Mouvement du Pr Azulay, Marseille, France|Institut Claude Pompidou - Centre Mémoire de Ressources et de Recherche (CMRR), Nice, France|Centre de Recherche du Gerontopole - CHU de Toulouse, Toulouse, France|Zentrum für klinische Forschung Dr. med. Irma Schöll, Bad Homburg, Germany|Pharmakologisches Studienzentrum Chemnitz GmbH, Mittweida, Germany|Klinik für Psychiatrie und Psychotherapie der Universität Tübingen, Tuebingen, Germany|IRCCS Fatebenefratelli Dipartimento di Ricerca Clinica per la Malattia di Alzheimer, Brescia, Italy|Azienda Ospedaliera di Padova Clinica Neurologica, Padova, Italy|IRCCS Istituto Neurologico Casimiro Mondino, Pavia, Italy|IRCCS San Raffaele Pisanna, Rome, Italy|IRCCS Fondazione Santa Lucia, Dipartimento di Neurologia e Psichiatria, Rome, Italy|Universita degli Studi di ROMA ""La Sapienza"" Dipartimento di NEUROLOGIA E PSICHIATRIA, Rome, Italy|Azienda Ospedaliero-Universitaria Citta della Salute a della Scienza di Torino - c/o Presidio Ospedaliero Molinette Clinica Neurologica I, Torino, Italy|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Przychodnia Śródmieście Sp. z o.o., Bydgoszcz, Poland|ISPL Wieslaw Jerzy Cubala, Gdańsk, Poland|Care Clinic, Katowice, Poland|Specjalistyczna Praktyka Lekarska, Lublin, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski, Olsztyn, Poland|NZOZ Neuro-Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy, Poznan, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Euromedis Sp z. o. o., Szczecin, Poland|Ośrodek Badań Klinicznych CLINSANTE S.C. Ewa Galczak-Nowak Małgorzata Trzaska, Toruń, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Clinical center of Serbia, Clinic for Neurology, Belgrade, Serbia|Military Medical Academy, Clinic for Neurology, Belgrade, Serbia|Clinical Hospital Center Dr Dragisa Misovic-Dedinje, Belgrade, Serbia|Institut of Mental Health, Belgrade, Serbia|Psychiatric Clinic, Military Medical Academy, Belgrade, Serbia|Clinic for Psychiatry, Clinical Center Kragujevac, Kragujevac, Serbia|Department of addictive disorders of the Clinic for Psychiatry, Clinical center Kragujevac, Kragujevac, Serbia|Clinic for Psychiatry, Nis, Serbia|MUDr. Beata Dupejova, neurologicka ambulancia s.r.o, Banska Bystrica, Slovakia|Epamed s.r.o., Psychiatricka ambulancia, Košice, Slovakia|NEURES s.r.o. neurologicka ambulancia, Krompachy, Slovakia|Centrum Zdravia R.B.K., s.r.o., Svidnik, Slovakia|Crystal Comfort, s.r.o., Vranov nad Toplou, Slovakia|Clinica IINA, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital General de Cataluña, Sant Cugat Del Vallès, Spain|Estudio de Psiquiatría, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Municipal Institution ""Odesa Regional Psychiatric Hospital #2"", Female Gerontological Department # 5, Male Gerontological Department #1, Oleksandrivka, Odessa Region, Ukraine|Communal Institution ""Dnipropetrovsk Regional Clinical Hospital n.a. I. I. Mechnikov"", Dnipro, Ukraine|Municipal Institution of Health Care ""Kharkiv Regional Clinical Psychiatric Hospital #3"", Kharkiv, Ukraine|State Institution ""Institute of Neurology, Psychiatry, and Narcology of the National Academy of Medical Sciences of Ukraine"", Department of Clinical, Social, and Paediatric Psychiatry, Kharkiv, Ukraine|Kherson Regional Psychiatric Hospital, Kherson, Ukraine|Ukrainian Scientific Research Institute of Social and Forensic Psychiatry and Narcology of Ministry of Healthcare of Ukraine, Kiev, Ukraine|Lviv Regional State Clinical Psychiatric Hospital, Lviv, Ukraine|Municipal Institution ""Odesa Regional Medical Center of Mental Health"", Department #18, Odesa, Ukraine|Poltava Regional Clinical Psychiatric Hospital named after O.F. Maltsev, Poltava, Ukraine|Municipal Institution ""Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I.Yushchenko"", Male Department #14, Female Department #15, Vinnytsya National Medical University n.a. M.I.Pyrogov, Department of Psychiatry, Narcology and Psychotherapeutic, Vinnytsya, Ukraine|Municipal Institution ""Zaporizhzhya Regional Clinical Hospital of Zaporizhzhya Regional Council"", Zaporizhzhya, Ukraine|Royal United Hospital - The Research Institute for the Care of Older People (RICE) Centre, Bath, United Kingdom|MAC Clinical Research - Blackpool, Blackpool, United Kingdom|St. Margaret's Hospital, Mental Health Unit, Epping, United Kingdom|Stobhill Hospital, Glasgow, United Kingdom|Re:Cognition Health Ltd., London, United Kingdom|MAC Clinical Research - Manchester, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT03325556
NCT03322462,Tau Screening Study in Patients With Early Symptomatic AD,,Completed,No Results Available,Alzheimer Disease,Drug: 18F-AV-1451,Completion of a flortaucipir F18 PET scan,Avid Radiopharmaceuticals,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,153,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-1451-A23,26-Oct-17,31-Aug-18,31-Aug-18,26-Oct-17,null,24-Oct-18,"Pacific Research Network, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Brain Matters Research, Delray Beach, Florida, United States|Bioclinica (Compass Research), Orlando, Florida, United States|Axiom Clinical Research, Tampa, Florida, United States|Boston Center for Memory, Newton, Massachusetts, United States|PMG Research, Winston-Salem, North Carolina, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|The Memory Clinic, Bennington, Vermont, United States|Toronto Memory Program, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03322462
NCT03313518,Therapeutic Role of Transcranial DCS in Alzheimer,,Completed,No Results Available,Alzheimer Disease,Device: tDCS|Device: Sham tDCS,"Change in measurement of improvement in cognitive function by using MMSE|Change in measurement of improvement in cognitive function by cornell Scale|The change of measurement of brain damage biomarkers modulation in plasma (i.e. Tau, Beta-Amyloid, Lipid Peroxidation) cornell Scale",Assiut University,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",tDCS in Alzheimer,12-Aug-16,10-Oct-17,10-Oct-17,18-Oct-17,null,18-Oct-17,,,https://ClinicalTrials.gov/show/NCT03313518
NCT03307993,Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: Idalopirdine,5-HT6 Receptor Occupancy (RO)|Idalopirdine plasma concentration (CPET),H. Lundbeck A/S,All,"50 Years and older   (Adult, Older Adult)",Phase 1,3,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17475A,22-Sep-17,19-Feb-18,19-Feb-18,12-Oct-17,null,4-Apr-18,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03307993
NCT03308032,Self-Directed Online Training for Chinese Caregivers,,Enrolling by invitation,No Results Available,Dementia|Alzheimer Disease,Behavioral: Intervention|Behavioral: Control,Change in Stress Level,"Environment and Health Group, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,NIH 1R43HL115924-01,1-Sep-16,5-Mar-18,30-Jul-18,12-Oct-17,null,12-Oct-17,,,https://ClinicalTrials.gov/show/NCT03308032
NCT03305809,A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB),PRESENCE,Recruiting,No Results Available,Lewy Body Dementia,Drug: LY3154207|Drug: Placebo,Change from Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB)|Change from Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score|Change from Baseline on the CDR-CCB Power of Attention (PoA) Composite Score|Change from Baseline in the 13-item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog13)|Change from Screening in the Montreal Cognitive Assessment (MoCA) Score|Change from Baseline in the Neuropsychiatric Inventory (NPI) Total Score|Change from Baseline in the Epworth Sleepiness Scale (ESS) Score|Change from Baseline in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score|Change from Baseline in the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) Total Score|Change from Baseline in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test Score|Change from Baseline in Systolic Blood Pressure (SBP) to Week 12|Change from Baseline in SBP to 8 Hours Post Dose|Change from Baseline in Pulse Rate to Week 12|Change from Baseline in Pulse Rate to 8 Hours Post Dose|Change from Week 12 in the Physician Withdrawal Checklist (PWC)-20 Total Score|Pharmacokinetics (PK): Steady-State Trough Plasma Concentrations of LY3154207,Eli Lilly and Company,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,340,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",16261|I7S-MC-HBEH,9-Nov-17,6-Dec-19,6-Dec-19,10-Oct-17,null,13-May-19,"University of Alabama Birmingham, Birmingham, Alabama, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Mayo Clinic of Scottsdale, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona Health Sciences, Tucson, Arizona, United States|Parkinson'S & Movement Disorder Institute, Fountain Valley, California, United States|University of California, Irvine, Irvine, California, United States|Collaborative Neuroscience Network - CNS, Long Beach, California, United States|University of Southern California School of Medicine, Los Angeles, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Stanford Neuroscience Health Center, Palo Alto, California, United States|SC3 Research Group Inc Pasadena, Pasadena, California, United States|SC3 Research Group Inc Reseda, Reseda, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Neurological Research, Denver, Colorado, United States|Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Hartford Healthcare Chase Movement Disorders Center, Vernon, Connecticut, United States|Christiana Care Health Service, Newark, Delaware, United States|Georgetown University Hospital, Washington, District of Columbia, United States|JEM Research Institute, Atlantis, Florida, United States|Parkinson's Disease and Movement Disorders, Boca Raton, Florida, United States|University of Florida - Gainesville, Gainesville, Florida, United States|ClinCloud, LLC, Maitland, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|VIN - Victor Faradji, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, Orlando, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|Visionary Investigators Network -VIN-Margarita Almeida, Pembroke Pines, Florida, United States|Axiom Research, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Central DuPage Hospital, Winfield, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology, Indianapolis, Indiana, United States|University of Kansas School of Medicine, Kansas City, Kansas, United States|Maine Neurology, Scarborough, Maine, United States|New England Neurological Associates, PC, Methuen, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|QUEST Research Institute, Farmington Hills, Michigan, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cleveland Clinic of Las Vegas, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Dent Neurological Institute, Amherst, New York, United States|Alzheimer's Disease and Memory Disorders Center, Buffalo, New York, United States|Adirondack Medical Research, Glens Falls, New York, United States|NYU Langone, New York, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Penn State Univ. Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Neurology, PA, Dallas, Texas, United States|Neurology Consultants of Dallas, PA, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist, Houston, Texas, United States|Sentara Neurology Specialists, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Evergreen Professional Plaza, Kirkland, Washington, United States|University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States|Toronto Memory Program, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|UHN-Toronto Western Hospital, Toronto, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Canada|Santa Cruz Behavioral PSC, Bayamón, Puerto Rico|Cortex, PSC, Las Piedras, Puerto Rico|Instituto de Neurologia Dra. Ivonne Fraga, San Juan, Puerto Rico|University of Puerto Rico, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT03305809
NCT03298672,"Safety, Tolerability, and Pharmacokinetics Study of NDX-1017",,Recruiting,No Results Available,Alzheimer Disease,Drug: NDX-1017|Drug: Placebo,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].|Maximum observed plasma concentration (Cmax).|Time to maximum observed plasma concentration (Tmax).|Plasma concentration at the end of the dosing interval (Ctrough).|Area under the plasma concentration time curve (AUC).|Half-life (t1/2).,"M3 Biotechnology, Inc.|Alzheimer’s Drug Discovery Foundation|Biotrial Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,116,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NDX-1017-0101-01,9-Oct-17,Jul-19,Jul-19,2-Oct-17,null,9-Apr-19,"Biotrial Inc., Newark, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT03298672
NCT03299062,"Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders",,Recruiting,No Results Available,Alzheimer Disease|Neurodegenerative Diseases,Diagnostic Test: Cytology and Immunohistochemistry,Alpha-synuclein levels from nasal swabs,University of Arkansas,All,"19 Years to 89 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,206829,14-Nov-17,1-Jun-19,1-Jun-19,2-Oct-17,null,16-Apr-19,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT03299062
NCT03290274,Clinical Trial to Evaluate the Efficacy and Security of Deep Brain Stimulation in Alzheimer´s Disease,ECP-EA,Recruiting,No Results Available,Alzheimer Disease,Device: Deep brain stimulation (fornix)|Device: Deep brain stimulation (Basal nucleus of Meynert),Security,"Hospital San Carlos, Madrid",All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,6,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ECP-EA,1-Mar-17,1-Dec-19,1-Dec-19,21-Sep-17,null,21-Sep-17,"Hospital Clinico San Carlos, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03290274
NCT03290326,tACS for Amyloid-β Reduction in Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer Disease,Device: Transcranial Alternating Current Stimulation (tACS),Incidence of Treatment-Emergent Adverse Events|PET Amyloid burden|EEG gamma-band spectral power|Adas-Cog score,Beth Israel Deaconess Medical Center,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017P000373,27-Nov-17,26-Aug-19,1-Sep-19,21-Sep-17,null,13-Dec-18,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03290326
NCT03288363,Transcranial Direct Current Stimulation and Early Alzheimer's Disease (tDCS-AD),tDCS-AD,Recruiting,No Results Available,Alzheimer Disease,Device: tDCS,"Comparing between the active tDCS group with the placebo tDCS group, the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) score, 12 weeks after the start of the course, in subjects with early Alzheimer's disease",Benjamin CALVET|Centre Hospitalier Esquirol,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2016-A01527-44,6-Jun-17,6-Jun-19,6-Dec-19,20-Sep-17,null,5-Apr-18,"Centre Hospitalier Esquirol, Limoges, France",,https://ClinicalTrials.gov/show/NCT03288363
NCT03289143,A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: RO7105705|Drug: Placebo|Drug: [18F]GTP1,Change from baseline on the CDR-Sum of Boxes|Percentage of Participants with Adverse Events|Change From Baseline on the Repeatable Battery for Assessment of Neuropsychological Status (RBANS)|Change from baseline on the Alzheimer's Disease Assessment Scale−Cognitive Subscale 13|Change from baseline on the Amsterdam Instrumental Activity of Daily Living questionnaire|Change from baseline on the Alzheimer's Disease Cooperative Study Group−Activities of Daily Living Inventory|Serum concentrations of RO7105705 at specified timepoints|Presence of anti-drug antibodies during the study relative to their presence at baseline,"Genentech, Inc.",All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,360,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GN39763|2017-001800-31,4-Oct-17,24-Jun-20,20-Sep-22,20-Sep-17,null,11-Apr-19,"University of Alabama at Birmingham, Birmingham, Alabama, United States|California Clinical Trials, Glendale, California, United States|University of California Irvine, Irvine, California, United States|Pharmacology Research Inst, Newport Beach, California, United States|Stanford Neuroscience Health Center (SNHC), Palo Alto, California, United States|Pacific Research Network - PRN, San Diego, California, United States|Neurological Research Inst, Santa Monica, California, United States|Collaborative Neuroscience Network Inc., Torrance, California, United States|Molecular NeuroImaging, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|JEM Research LLC, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Compass Research East, LLC, Orlando, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University; Global Health, Atlanta, Georgia, United States|Rush Alzheimer's Disease Cntr., Chicago, Illinois, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Brigham & Women's Hosp; TIMI Study Grp, Boston, Massachusetts, United States|Alzheimers Disease Center, Quincy, Massachusetts, United States|Health Partners Institute for Education and Research, Saint Paul, Minnesota, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Albany Medical College; Neurology, Albany, New York, United States|Empire Neurology PC; MS Center of Northeastern NY, Latham, New York, United States|Columbia Univ Medical Center, New York, New York, United States|University of Rochester; AD-CARE, Rochester, New York, United States|Summit Research Network Inc., Portland, Oregon, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Neurology Clinic PC, Cordova, Tennessee, United States|New Orleans Center For Clinical Research, Knoxville, Tennessee, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|St Vincents Medical Centre, Darlinghurst, New South Wales, Australia|Southern Neurology, Kogarah, New South Wales, Australia|Queensland University of Technology, Mermaid Waters, Queensland, Australia|Eastern Clinical Research Unit; Pharmacy, Box Hill, Victoria, Australia|HammondCare Aged Psychiatry Clinical Trials, Malvern, Victoria, Australia|The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit, Melbourne, Victoria, Australia|Neuro Trials Victoria, Noble Park, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|UZ Brussel, Brussel, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|AZ Delta Campus Westlaan, Roeselare, Belgium|Vancouver Island Health Research Centre, Victoria, British Columbia, Canada|JBN Medical Diagnostic Services; Clinical Trials Division, Burlington, Ontario, Canada|Parkwood Institute, Mental Health Care Building, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Recherches Neuro-Hippocame, Gatineau, Quebec, Canada|Center For Clinical and Basic Research (Ccbr); Site Management Organisation, Aalborg, Denmark|CCBR - Ballerup - DK, Ballerup, Denmark|CCBR - Vejle - DK, Vejle, Denmark|Groupe Hospitalier Pellegrin; Service de Neurologie - 3ème étage, Bordeaux, France|Hopital Neurologique Pierre Wertheimer, Bron, France|Hopital Roger Salengro, Lille, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France|Hopital Gui de Chauliac; Neurologie, Montpellier, France|Hopital Fernand Widal Centre, Paris, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|CHU Rennes - Hopital Hôtel Dieu, Rennes, France|CHU Hautepierre; ACTR Association Recherche Clinique Rhumatologie, Strasbourg, France|CHU Strasbourg - Hôpital Hautepierre, Strasbourg, France|Hopital de La Grave, Toulouse, France|Hopital des Charpennes, Villeurbanne, France|Klinikum Bayreuth; Krankenhaus Hohe Warte, Bayreuth, Germany|Praxis Dr. med. Volker Shumann, Berlin, Germany|Studienambulanz emovis GmbH; St. Joseph Krankenhaus, Berlin, Germany|Charite Campus Benjamin Franklin, Berlin, Germany|Neurologisch-psychiatrische Praxis am Brosepark, Berlin, Germany|Bezirkskrankenhaus Günzburg, Günzburg, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz; Kardiologie, Mainz, Germany|Klinikum rechts der Isar der TU München; Klinik & Poliklinik für Neurologie, München, Germany|Universitätsklinikum Münster, Stabsstelle Apotheke, Münster, Germany|ZNS Siegen im MVZ Weidenau, Siegen, Germany|Universitätsklinik Tübingen; Psychiatrie und Psychotherapie, Tubingen, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Azienda Ospedaliera Città della Salute e della Scienza di Torino; Radiology, Torino, Abruzzo, Italy|Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy|Ospedale San Giovanni Calibita Fatebenefratell;Neurologia, Roma, Lazio, Italy|Ente Ospedaliero Ospedali Galliera; Neurologia, Genova, Liguria, Italy|Azienda Ospedaliero Universitaria San Martino; Dip. di Neuroscienze Oftalmologia e Genetica, Genova, Liguria, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, Italy|IRCCS Centro San Giovanni di Dio FBF, Brescia, Lombardia, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia, Italy|IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA, Pozzilli, Molise, Italy|Az. Osp. C. Panico; Rep. Ematologia E Trapianto, Tricase - LE, Puglia, Italy|Jeroen Bosch Ziekenhuis, 'S Hertogenbosch, Netherlands|Brain Research Center B.V, Amsterdam, Netherlands|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|PALLMED Sp. z o.o. prowadząca NZOZ DOM SUE RYDER, Bydgoszcz, Poland|NZOZ VITO-MED Sp.z o.o., Gliwice, Poland|M.A. - LEK A.M.Maciejowscy SC., Katowice, Poland|Novo-Med Zielinski i wspolnicy Sp. j., Katowice, Poland|Malopolskie Centrum Medyczne, Krakow, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4; Klinika Nefrologii, Lublin, Poland|NEURO - KARD Ośrodek Badań Klinicznych, Poznań, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Senior Sp. Z O.O. Poradnia Psychogeriatryczna, Sopot, Poland|EroMedis, Szczecin, Poland|AMED Medical Center, Warszawa, Poland|mMED Maciej Czarnecki, Warszawa, Poland|NZOZ WCA, Wrocław, Poland|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Clinica Universitaria de Navarra; Servicio de Neurología, Pamplona, Navarra, Spain|Hospital Virgen del Puerto, Plasencia, Palencia, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital Perpetuo Socorro, Servicio de Geriatria, Albacete, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Fundación ACE; Servicio de Neurología, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Neurologia, Cordoba, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital de Cantoblanco; Servicio de Geriatria, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Dr. Peset; Servicio de Neurologia, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Länssjukhuset Ryhov, Jönköping, Sweden|Länssjukhuset Kalmar; Oncology, Kalmar, Sweden|Skane University Hospital Malmo/Lund, Dept.of Hematology and Coagulation Disorders, Malmö, Sweden|Sahlgrenska Univ Hospital Mölndal; Department of Nephrology, Mölndal, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Murray Royal Hospital; Psychiatry of Old Age (POA) Hub, Dundee, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|The National Hospital for Neurology & Neurosurgery, London, GT LON, United Kingdom|RE:Cognition Health, London, United Kingdom|Charing Cross Hospital; Dept of Neurosciences, London, United Kingdom|Derriford Hospital; Neurology, Plymouth, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Re:Cognition Health Guildford, Surrey, United Kingdom|Victoria Centre; Kingshill Research Centre, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT03289143
NCT03287765,Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans,ADRC proj 1,Recruiting,No Results Available,Alzheimer Disease,Drug: 18F-AV-1451,"Examine the association among T807-PET measures of PHF-tau.|Characterize the amount and spatial distribution of T807-PET measures in healthy aging. preclinical AD, and early symptomatic AD.|Characterize the amount and spatial distribution of T807-PET measures in preclinical AD.|Characterize the amount and spatial distribution of T807-PET measures in early symptomatic AD.|Examine the association among T807-PET measures of concentrations of CSF biomarkers. and cognitive performance.|Examine the association among T807-PET measures of cognitive performance.|Evaluate the change in T807-PET measures over time in asymptomatic amyloid-positive individuals and its association with changes in concentrations of CSF biomarkers.",Washington University School of Medicine,All,65 Years and older   (Older Adult),Phase 2,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"IND123119,Protocol F",May-16,May-21,Nov-21,19-Sep-17,null,24-Jan-19,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03287765
NCT03283059,Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer Disease,Drug: Octohydroaminoacridine Succinate|Drug: Aricept|Drug: Placebos,Alzheimer's Disease Assessment Scale-Cognitive section (ADAS-Cog)|Clinician's Interview Based Impression of Change - plus (CIBIC+)|Activities of Daily Living (ADL)|Neuropsychiatric Inventory (NPI),"Shanghai Mental Health Center|Changchun Huayang High-tech Co., Ltd|Jiangsu Sheneryang High-tech Co., Ltd",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,600,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,OHAAS-III,16-Aug-17,16-Sep-19,16-Feb-20,14-Sep-17,null,10-Oct-17,"Shanghai Mental Health Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03283059
NCT03283449,Tau PET Imaging in Atypical Dementias,,Recruiting,No Results Available,Primary Progressive Aphasia With Suspected Alzheimer's Disease,Drug: 18F-AV-1451|Device: PET,Tau levels in PPA participants,Northwestern University|National Institute on Aging (NIA),All,"20 Years to 100 Years   (Adult, Older Adult)",Phase 1,70,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,STU00200893|R01AG056258,Feb-16,Feb-22,1-Feb-23,14-Sep-17,null,8-Jun-18,"Cognitive Neurology and Alzheimer's Disease Center - Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03283449
NCT03282097,Decisions About Cancer Screening in Alzheimer's Disease,DECAD,Recruiting,No Results Available,"Cancer, Breast",Behavioral: DECAD decision aid|Other: Home safety guide,Decisional conflict Scale|Change in Decision-making self-efficacy|Record of mammogram,Indiana University,Female,75 Years and older   (Older Adult),Not Applicable,426,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,1501278953,17-Nov-17,Oct-21,Oct-22,13-Sep-17,null,1-Aug-18,"Alzheimer's Association, Indianapolis, Indiana, United States|Eskenazi Health, Indianapolis, Indiana, United States|IU Health, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT03282097
NCT03279523,F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected,,Recruiting,No Results Available,Alzheimer Disease|HIV,Drug: F 18 T807,"Perform human in vivo tau imaging using F 18 T807 in 30 older (≥ 40 years old) HIV+ participants and 30 HIV- controls.|: Correlate regional quantitative T807 binding potentials (BPs) with cognitive impairment, as documented by neuropsychological performance tests, in HIV+ and HIV- individuals.",Washington University School of Medicine,All,"40 Years and older   (Adult, Older Adult)",Phase 2,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IND 123119 Protocol G,May-16,May-21,Nov-21,12-Sep-17,null,24-Jan-19,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03279523
NCT03277573,Salsalate in Patients Mild to Moderate Alzheimer's Disease,SAL-AD,Recruiting,No Results Available,Alzheimer Disease,Drug: Salsalate|Drug: Placebo,Incidence of Treatment-Emergent Adverse Events|Changes in Pharmacokinetic properties of Salsalate in Plasma and Cerebrospinal Fluid|Changes in Pharmacodynamic properties of Salsalate in Cerebrospinal Fluid,"Adam Boxer|University of California, San Francisco",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",UC-SAL-AD-001,21-Jul-17,21-Jul-19,21-Oct-19,11-Sep-17,null,3-May-18,"University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03277573
NCT03274817,A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol,,Recruiting,No Results Available,Alzheimer Disease,Drug: Escitalopram Pill|Drug: Venlafaxine Pill|Drug: Placebo Oral Tablet,Z-score for the hippocampal region of interest in the theta band|Multivariate Z score for overall theta abnormality in the frontal and parieto-temporal regions;|Probability of deterioration from logistic regression predictive of future decline;|Z-score coherence (synchrony) between right central and parietal regions across all bands;|Mean frequency across the total EEG brain spectrum.|Metabolic reduction in the hippocampal formation (a region including the hippocampal subiculum and the entorhinal cortex) assessed bilaterally.|Brief Cognitive Rating Scale Axes I to V total scores|The Mini-Mental State Examination (MMSE) total scores|MAC-Q total score,New York University School of Medicine,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1,31,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention",09-0228,11-Jul-17,Jan-19,Jan-19,7-Sep-17,null,22-Oct-18,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03274817
NCT03270137,Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer Disease,AD-EMTr,"Active, not recruiting",No Results Available,Alzheimer Disease|Transcranial Magnetic Stimulation,Device: repetitive transcranial magnetic stimulation- IDLPFC|Device: repetitive transcranial magnetic stimulation - Six regions,Changes on cognitive functioning (ADAS-cog)|Changes on cognitive effects (Mini Mental State)|Changes on behavioral symptoms (NPI)|Changes on depression symptoms (GDS-Yesavage)|Changes on effects on functionality (IDDD)|Changes on Clinical Global Impression (CGI),"Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente|National Council of Science and Technology, Mexico",All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,19,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,SIC-16-001,10-Mar-16,28-Feb-17,31-Aug-17,1-Sep-17,null,1-Sep-17,,,https://ClinicalTrials.gov/show/NCT03270137
NCT03269149,Tango for Alzheimer's Disease Patients' Caregivers,,Recruiting,No Results Available,Alzheimer's Disease,Other: Adapted Tango Dance|Behavioral: Educational lectures,Change in interleukin-7|Change in interleukin-8|Change in interleukin-9|Change in Interleukin-10|Change in interferon induced protein 10|Change in macrophage derived chemokine|Change in monocyte chemoattractant protein 1|Change in transforming growth factor alpha|Change in tumor necrosis factor alpha|Change in C-reactive protein|Change in serum amyloid protein|Change in Montreal Cognitive Assessment (MoCA)|Change in the Tower of London test|Change in the Stroop interference test|Change in Trails B test|Change in Digit Span test|Change in Buschke Selective Reminding Test|Change in Reverse Corsi Blocks test|Change in Brooks spatial memory test|Change in the Body position spatial task (BPST)|Change in Fullerton Advanced Balance Scale|Change in 30-second chair stand|Change in gait speed|Change in Positive Aspects of Caregiving (PAC) Scale|Change in Pearlin Caregiver Stress Scale|Change in the Zarit Burden Interview|Change in the Center for Epidemiologic Studies Depression Scale (CES-D)|Change in DEMQOL: Dementia Quality of Life measure (Carer v4),Emory University,Female,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IRB00097348,19-Sep-17,Jul-19,Jul-19,31-Aug-17,null,22-Aug-18,"Atlanta VA Medical Center, Emory University, Executive Park, Wesley Woods, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03269149
NCT03259958,A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®,,Completed,No Results Available,Alzheimer's Disease,Drug: Donepezil TDS|Drug: Aricept,"PK, AUC|PK, Cmax|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|PI assessment of local skin irritation response to TDS|PI assessment of TDS Adhesion",Corium International Inc.,All,"30 Years and older   (Adult, Older Adult)",Phase 1,86,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P-16010,30-Oct-17,13-Mar-18,14-Mar-18,24-Aug-17,null,1-Aug-18,"Celerion Inc., Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03259958
NCT03250741,Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease,DOPAD,Completed,No Results Available,Alzheimer Disease,Drug: Rotigotine transdermal patch|Other: Placebo,Global cognition|Frontal cognitive functions|Activities of daily living|Neurophysiological markers of cortical activity|Neuropsychiatric evaluation,I.R.C.C.S. Fondazione Santa Lucia,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,94,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EudraCT 2015-002965-43,Jun-16,Nov-18,Nov-18,16-Aug-17,null,17-Dec-18,"Santa Lucia Foundation, Rome, Italy",,https://ClinicalTrials.gov/show/NCT03250741
NCT03249688,Multimodal Preventive Trial for Alzheimer's Disease,MIND-ADmini,Recruiting,No Results Available,Alzheimer Disease; Prodromal,Other: Regular health advice|Behavioral: Multidomain lifestyle|Dietary Supplement: Medical food,Recruitment rate|Overall adherence to the intervention|Retention rate|Adherence to intervention components|Adherence to healthy lifestyle changes,Karolinska Institutet|University of Eastern Finland|INSERM-University of Toulouse|Saarland University,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",E0750301,16-Oct-17,1-Sep-19,1-Sep-19,15-Aug-17,null,19-Sep-18,"Karolinska University Hospital, Huddinge, Sweden",,https://ClinicalTrials.gov/show/NCT03249688
NCT03244917,Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias,TRAIN-AD,Recruiting,No Results Available,"Dementia|Infection, Bacterial",Behavioral: TRAIN-AD,Total antimicrobial use|Antimicrobial use when minimal criteria are absent|Burdensome interventions|Advance care planning,"Hebrew Rehabilitation Center, Boston",All,"21 Years and older   (Adult, Older Adult)",Not Applicable,480,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",TRAIN-AD,15-Oct-17,Aug-20,Mar-21,10-Aug-17,null,26-Feb-19,"Hebrew SeniorLife, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03244917
NCT03239561,Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants,,Completed,No Results Available,Alzheimer Disease,Drug: [18F]MNI-1020,Standardized Uptake Value Ratio (SUVR) of [18F]MNI-1020|Plasma Concentration of 18F]MNI-1020 in AD Participants Compared With age Matched Healthy Participants|Number of Participants With Adverse Events|Distribution of tau (Using [18F]MNI-1020) Compared to Amyloid Beta (Using Florbetapir) in Participants With Probable AD,"Janssen Research & Development, LLC",All,"50 Years and older   (Adult, Older Adult)",Early Phase 1,15,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CR108349|64326067EDI0001,6-Sep-17,30-Apr-18,30-Apr-18,4-Aug-17,null,12-Sep-18,"Molecular NeuroImaging, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03239561
NCT03233646,OCTA in Mild Cognitive Impairment and Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer Disease|Mild Cognitive Impairment|Retinal Vascular,Device: Retinal Imaging,Foveal avascular zone|Vessel Density|Choroidal Thickness,Duke University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,450,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,Pro00082598,20-Jul-17,1-Apr-21,1-Apr-21,28-Jul-17,null,8-Apr-19,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03233646
NCT03227185,Supporting Episodic Memory With Transcranial Direct Current Stimulation in Healthy Controls and Dementia Patients,,Recruiting,No Results Available,Healthy|Mild Cognitive Impairment|Alzheimer Disease,Device: real anodal transcranial direct current stimulation (tDCS)|Device: sham transcranial direct current stimulation (tDCS),Episodic memory performance - learning curve|Episodic memory performance - delayed recall 1|Episodic memory performance - delayed recall 2|Neurotransmitter levels,University of Bern,All,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,110,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",3351|2016-02175,1-Oct-17,31-Oct-19,29-Feb-20,24-Jul-17,null,15-Feb-19,"University Hospital of Old Age Psychiatry and Psychotherapy, Bern, Switzerland",,https://ClinicalTrials.gov/show/NCT03227185
NCT03226522,Addressing Dementia Via Agitation-Centered Evaluation,ADVANCE,Recruiting,No Results Available,"Agitation in Patients With Dementia of the Alzheimer's Type|Alzheimer Disease|Agitation,Psychomotor",Drug: AXS-05|Drug: Bupropion|Drug: Placebo,Cohen-Mansfield Agitation Inventory (CMAI),"Axsome Therapeutics, Inc.",All,65 Years to 90 Years   (Older Adult),Phase 2|Phase 3,435,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AXS-05-AD-301,13-Jul-17,Aug-19,Sep-19,21-Jul-17,null,28-Mar-19,"Axsome Study Site, Phoenix, Arizona, United States|Axsome study site, Scottsdale, Arizona, United States|Axsome study site, Scottsdale, Arizona, United States|Axsome Study Site, Tucson, Arizona, United States|Axsome Study Site, Little Rock, Arkansas, United States|Axsome study site, Canoga Park, California, United States|Axsome study site, Costa Mesa, California, United States|Axsome study site, Fresno, California, United States|Axsome study site, Long Beach, California, United States|Axsome study site, Long Beach, California, United States|Axsome study site, Riverside, California, United States|Axsome study site, Sacramento, California, United States|Axsome study site, Santa Ana, California, United States|Axsome study site, Sherman Oaks, California, United States|Axsome study site, Simi Valley, California, United States|Axsome study site, Temecula, California, United States|Axsome study site, Ventura, California, United States|Axsome Study Site, Colorado Springs, Colorado, United States|Axsome study site, Cromwell, Connecticut, United States|Axsome study site, New London, Connecticut, United States|Axsome study site, Boca Raton, Florida, United States|Axsome study site, Boynton Beach, Florida, United States|Meridian Research, Brooksville, Florida, United States|Axsome Study Site, Coconut Creek, Florida, United States|Axsome study site, Hallandale Beach, Florida, United States|Axsome study site, Hialeah, Florida, United States|Axsome Study Site, Lake City, Florida, United States|Axsome study site, Miami, Florida, United States|Axsome study site, Miami, Florida, United States|Axsome study site, Pensacola, Florida, United States|Axsome study site, Spring Hill, Florida, United States|Axsome study site, Tampa, Florida, United States|Axsome study site, Tampa, Florida, United States|Axsome study site, Atlanta, Georgia, United States|Axsome study site, Decatur, Georgia, United States|Axsome Study Site, Honolulu, Hawaii, United States|Axsome study site, Boise, Idaho, United States|Axsome Study Site, Flossmoor, Illinois, United States|Axsome study site, Avon, Indiana, United States|Axsome Study Site, Overland Park, Kansas, United States|Axsome Study Site, Topeka, Kansas, United States|Axsome study site, Baton Rouge, Louisiana, United States|Axsome Study Site, Lake Charles, Louisiana, United States|Axsome study site, Chesterfield, Missouri, United States|Axsome study site, Las Vegas, Nevada, United States|Axsome Study Site, Princeton, New Jersey, United States|Axsome study site, Toms River, New Jersey, United States|Axsome study site, Brooklyn, New York, United States|Axsome study site, New York, New York, United States|Axsome study site, New York, New York, United States|Axsome study site, Staten Island, New York, United States|Axsome study site, Charlotte, North Carolina, United States|Axsome Study Site, Winston-Salem, North Carolina, United States|Axsome study site, Cincinnati, Ohio, United States|Axsome study site, Shaker Heights, Ohio, United States|Axsome study site, DeSoto, Texas, United States|Axsome study site, Wichita Falls, Texas, United States|Axsome study site, Orem, Utah, United States|Axsome Study Site, Charlottesville, Virginia, United States|Axsome study site, Bellevue, Washington, United States|Axsome study site, Spokane, Washington, United States|Axsome study site, Caulfield, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT03226522
NCT03221296,Fall Prevention - Vestibular Rehabilitation,,Completed,No Results Available,Alzheimer Dementia (AD)|Vascular Dementia,Behavioral: Vestibular Training (Intervention Group),"Number of falls/near fall experiences through the Falls Video Analysis Questionnaire (FVAQ)|Change in levels of dizziness through the Dizziness Handicap Inventory (DHI)|Change in perceived level of confidence through the Activities Specific Balance Confidence Scale (ABC)|Change in quality of life through The Geriatric Depression Scale (GDS)|Cognitive status through the Montreal Cognitive Assessment (MoCA)|Change in physical functioning through the head impulse test (HIT)|Number of patients who can successfully complete Head Impulse Test (HIT)|Number of patients who can successfully complete Head Shake Test (HST)|Number of patients who can successfully complete Dynamic Gait Index (DGI)|Number of patients who can successfully complete the test of dynamic visual acuity (DVA)|Number of patients who can successfully complete the modified clinical test of sensory interaction on balance (mCTSIB)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Dizziness Handicap Inventory (DHI)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Montreal Cognitive Assessment (MoCA)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Quality of Life in Alzheimer's Disease (QOL-AD)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the World Health Organization Quality of Life - BREF (WHOQOL-BREF)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Activities Specific Balance Confidence scale (ABC)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Geriatric Depression Scale (GDS)|Number of patients who successfully adhered to the vestibular rehabilitation program through the Problematic Experiences of Therapy scale (PETs)|Attrition Rate|Number of patients willing to participate|Change in quality of life through The World Health Organization Quality of Life - BREF (WHOQOL-BREF)|Change in quality of life through The Quality of Life in Alzheimer's Disease (QOL-AD)|Change in physical functioning through the head shake test (HST)|Change in physical functioning through the dynamic visual acuity (DVA)|Change in physical functioning through the modified clinical test of sensory interaction on balance (mCTSIB)|Change in physical functioning through the dynamic gait index (DGI)","University Health Network, Toronto",All,65 Years and older   (Older Adult),Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,17-5055,27-Jun-17,23-Aug-18,23-Aug-18,18-Jul-17,null,11-Oct-18,"Toronto Western Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03221296
NCT03218982,Vietnamese Caregiver Intervention Study,,Recruiting,No Results Available,Alzheimer's Disease (Incl Subtypes)|Cognitive Impairment,Behavioral: Enhanced psycho-education about dementia and caregiving,randomization|retention|caregiver intervention adherence|treatment fidelity|administration of study measures|Acceptability|Alzheimer's Disease Knowledge Scale (ADKS)|Caregiver Self-Efficacy|Center for Epidemiological Studies Depression (CES-D) scale|Zarit Burden Inventory (ZBI)|Quality of Life - Alzheimer's Disease (QoL-AD)|Perceived Stress Scale,"University of California, Davis|National Institute on Aging (NIA)|Alzheimer's Association",All,"21 Years and older   (Adult, Older Adult)",Not Applicable,24,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,823071|K01AG052646,22-May-17,30-Jun-20,30-Jun-20,17-Jul-17,null,1-May-19,"University of California, Davis, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT03218982
NCT03208491,AZ@GAME-Eco: Economic Assessment of Serious Games for the Management of Alzheimer's Disease and Related Disorders,AZ@GAME-Eco,Unknown status,No Results Available,Alzheimer Disease,Other: serious games use|Other: usual care,cost utility ratio,Centre Hospitalier Universitaire de Nice,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,136,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,16-PRME-01,30-Sep-17,30-Mar-18,30-Dec-18,5-Jul-17,null,5-Jul-17,,,https://ClinicalTrials.gov/show/NCT03208491
NCT03204604,The Brain Ketone Body Challenge Imaging Study,,Withdrawn,No Results Available,Alzheimer Disease,Dietary Supplement: Challenge A - low calorie Ensure®|Dietary Supplement: Challenge B - Ensure® plus ketone esters (KE)|Procedure: PET Scan|Behavioral: Cognitive Testing - FCSRT|Behavioral: Story Recall|Behavioral: BVRT|Behavioral: CogState One Card Learning,Primary Outcome - Brain Ketone Utilization|Secondary Outcome - Memory Composite Score,Wake Forest University Health Sciences,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",IRB00036958,8-Aug-16,Mar-19,Mar-19,2-Jul-17,null,19-Mar-19,"Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03204604
NCT03197740,"A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease",,Recruiting,No Results Available,Alzheimer Disease,Drug: Donepezil patch|Drug: aricept Tab,ADAS-cog|CIBIC-plus,Icure Pharmaceutical Inc.,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,346,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IPI-003,12-Oct-17,31-Mar-19,30-Nov-19,23-Jun-17,null,20-Feb-19,"46 Sites including Konkuk University Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03197740
NCT03185182,Diagnostic Imaging for Clear Cell Renal Cell Carcinoma,RCCSCAN,Recruiting,No Results Available,Clear Cell Renal Cell Carcinoma,Drug: Ioflupane I123,ccRCC detection|non-ccRCC negative for ioflupane I123,Region Skane|Lund University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RCCSCAN|2016-005182-31,1-Aug-17,Jun-18,Sep-18,14-Jun-17,null,27-Sep-17,"Skåne University hospital SUS, Lund, Sweden",,https://ClinicalTrials.gov/show/NCT03185182
NCT03185208,Lithium As a Treatment to Prevent Impairment of Cognition in Elders,LATTICE,Recruiting,No Results Available,Mild Cognitive Impairment,Drug: Lithium Carbonate|Drug: Placebo oral capsule,Change from baseline cognitive testing measures over 2 years|Change from baseline biomarker values over 2 years|Change from baseline brain volume values over 2 years as measured by structural imaging (7T MRI)|Change from baseline brain integrity measures over 2 years as measured by structural imaging (7T MRI)|Change from baseline cerebrospinal phospho tau levels over 2 years,Ariel Gildengers|National Institute on Aging (NIA)|University of Pittsburgh,All,"60 Years and older   (Adult, Older Adult)",Phase 4,80,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",PRO17030527|R01AG055389-01,1-Sep-17,31-Mar-22,31-Mar-22,14-Jun-17,null,31-Jan-19,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03185208
NCT03186989,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease",,Recruiting,No Results Available,Mild Alzheimer's Disease,Drug: IONIS MAPTRx|Other: Placebo,Incidence and severity of adverse events that are related to treatment with IONIS MAPTRx|Pharmacokinetics (PK) after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx (trough concentration)|Pharmacokinetics (PK) after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx (maximum observed drug concentration or Cmax)|Pharmacokinetics after ascending dose-levels of multiple IT bolus administrations on IONIS MAPTRx (time taken to reach maximal concentration or Tmax)|Pharmacokinetics after ascending dose-levels of multiple IT bolus administrations on IONIS MAPTRx (Plasma terminal elimination half-life (t1/2λz)|Pharmacokinetics after ascending dose-levels of multiple IT bolus administrations on IONIS MAPTRx (Partial areas under the plasma concentration-time curve from zero time (predose) to selected times (t) after the IT administration (AUCt),"Ionis Pharmaceuticals, Inc.",All,"50 Years to 74 Years   (Adult, Older Adult)",Phase 1|Phase 2,44,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",ISIS 814907-CS1|NL60032.000.16|2016-002713-22,5-Jun-17,31-Jan-20,29-Feb-20,14-Jun-17,null,25-Mar-19,"Montreal Neurological Hospital, Montréal, Canada|Clinical Research Services Turku CRST, Turku, Finland|Charite - Universitaetsmedizin Berlin Campus Mitte, Berlin, Germany|St Josef Hospital, Bochum, Germany|Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany|MVZ Mittweida Gbr, Mittweida, Germany|Universittsklinikum Ulm, Ulm, Germany|VU University Medical Center, Amsterdam, Netherlands|QPS Netherlands BV, Groningen, Netherlands|Minnesmottagningen, Mölndal, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|Royal Liverpool University Hospital, Liverpool, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Sheffield Institute for Translational Neuroscience (SITraN), Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT03186989
NCT03184467,Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients,,Recruiting,No Results Available,Alzheimer Disease,Drug: Normal Saline 0.9%|Drug: GV1001 0.56 mg|Drug: GV1001 1.12 mg,SIB (Severe Impairment Battery)|K-MMSE (Korean-Mini-Mental State Examination)|CDR-SOB (Clinical Dementia Rating-Sum of Box)|NPI (Neuropsychiatric Inventory)|GDS (Global Deterioration Scale)|ADCS-ADL-severe (Alzheimer's Disease Cooperative Study-Activities of Daily Living scale-severe)|CIBIC-plus (Clinician Interview-Based Impression of Change-Plus),GemVax & Kael,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,90,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KG 6/2016,Jun-17,Jun-19,Jun-19,12-Jun-17,null,12-Jun-17,"Hanyang University Guri Hospital, Guri-si, Gyunggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03184467
NCT03179501,"NP001, Alzheimer's Disease, and Blood Markers of Inflammation",,Terminated,No Results Available,Alzheimer Disease,Drug: NP001|Drug: Placebo,Inflammatory monocyte-associated biomarkers|Adverse Events,"Beau Nakamoto|Neuraltus Pharmaceuticals, Inc.|University of Hawaii",All,"55 Years and older   (Adult, Older Adult)",Phase 1,4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",H039,1-Sep-17,31-Jul-18,31-Jul-18,7-Jun-17,null,22-Oct-18,"University of Hawaii Clinics at Kakaako, Honolulu, Hawaii, United States",,https://ClinicalTrials.gov/show/NCT03179501
NCT03174938,The Swedish BioFINDER 2 Study,BioFINDER2,Recruiting,No Results Available,Dementia|Alzheimer Disease|Parkinson Disease|Lewy Body Disease|Parkinson-Dementia Syndrome|Frontotemporal Degeneration|Semantic Dementia|Progressive Nonfluent Aphasia|Progressive Supranuclear Palsy|Corticobasal Degeneration|Multiple System Atrophy|Mild Cognitive Impairment,"Diagnostic Test: Flutemetamol F18 Injection|Diagnostic Test: [18F]-RO6958948|Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau|Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau",Clinical diagnosis|Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Rate of cognitive decline as measured by MMSE.|Rate of cognitive decline as measured in ADL-function.|Rate of volume change of structural MRI measures and amyloid PET|Rates of change on cerebrospinal fluid AD biomarkers,Skane University Hospital|Lund University,All,"20 Years to 100 Years   (Adult, Older Adult)",Not Applicable,1505,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,BioFINDER 2,15-May-17,31-Dec-28,31-Dec-28,5-Jun-17,null,17-Apr-18,"Memory Clinic, Skåne University Hospital, Malmö, Sweden|Memory Clinic, Hospital of Ängelholm, Ängelholm, Sweden",,https://ClinicalTrials.gov/show/NCT03174938
NCT03175874,Autophagy and Pathological Aging,AVP,Recruiting,No Results Available,Osteoporosis,Procedure: Hip bone sampling,Quantification of autophagy|Bone mineral density|25 OH vitamin D (ng/ml).,Centre Hospitalier Universitaire de Nice,Female,65 Years and older   (Older Adult),Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,17-PP-03,20-Dec-17,Feb-20,Feb-20,5-Jun-17,null,7-Feb-18,"BREUIL, Nice, France",,https://ClinicalTrials.gov/show/NCT03175874
NCT03172117,Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.,,Recruiting,No Results Available,Alzheimer's Disease,Biological: human umbilical cord blood derived mesenchymal stem cells|Other: Normal saline 2mL,Change from the baseline in ADAS-Cog|Change from the baseline in S-IADL|Change from the baseline in K-MMSE|Change from the baseline in CGA-NPI|ADAS-Cog Response Rate|Change in CDR-SOB|Change in CIBIC-plus|Change in Florbetaben-PET|Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)|Change from baseline in MRI (DTI mapping)|Change from the baseline in CSF biomarkers,Medipost Co Ltd.,All,"50 Years to 86 Years   (Adult, Older Adult)",Phase 1|Phase 2,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP-CR-010-F/U,19-May-17,31-Dec-21,31-Dec-21,1-Jun-17,null,17-Aug-18,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03172117
NCT03168997,Memantine Treatment in Alzheimer's Disease Patients,,Unknown status,No Results Available,Alzheimer Disease,Drug: Memantine Hydrochloride,ADAS-cog change,"Wei Cuibai|Xuanwu Hospital, Beijing",All,"50 Years and older   (Adult, Older Adult)",Phase 4,222,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,17237T,15-Jul-17,30-Sep-18,31-Dec-18,30-May-17,null,30-May-17,,,https://ClinicalTrials.gov/show/NCT03168997
NCT03160027,Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia),PBM Dementia,"Active, not recruiting",No Results Available,"Dementia, Alzheimer Type",Device: Vielight Neuro Gamma,"Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)|Change in clock-drawing test|Change in Default Mode Network (DMN) functional connectivity, as measured by resting state functional Magnetic Resonance Imaging (rs-fMRI) on a 3 Tesla MRI scanner|Change in cerebral perfusion, as measured by arterial spin labeled (ASL) perfusion MRI on a 3 Tesla MRI scanner|Change in Quality of Life Scale in Alzheimer's Disease (QOL-AD)|Change in Quality of Life Scale in Alzheimer's Disease (QOL-AD) from the caregiver's perspective about the individual with dementia|Change in Caregiver Burden Inventory (CBI).|Change in Neuropsychiatric Inventory (NPI) from the caregiver's perspective about the individual with dementa|Change in Positive Aspects of Caregiving Scale|Change in Geriatric Depression Scale (GDS) - short form in the caregivers","University of California, San Francisco",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-21406,15-May-17,30-Jul-19,30-Nov-19,19-May-17,null,28-Sep-18,"San Francisco Veterans Affairs Medical Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03160027
NCT03151382,A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease,,Unknown status,No Results Available,Alzheimer Disease|Cognitive Function,Drug: Tandospirone Citrate|Drug: Donepezil Hydrochloride,Change of ADAS-cog total score|NPI scale total score|HAMA total score|FAB score|relative power|the image of PET|MMSE score,Zhejiang Provincial People’s Hospital,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 4,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SED-AD|SED-AD-2016-001,20-May-17,31-Dec-17,30-Jun-18,12-May-17,null,12-May-17,,,https://ClinicalTrials.gov/show/NCT03151382
NCT03149380,Effectiveness of Alzheimer's Universe (Www.AlzU.Org) on Knowledge and Behavior,,Recruiting,No Results Available,"Alzheimer Disease|Alzheimer Disease, Late Onset|Memory Loss|Patient Education as Topic",Behavioral: Web-based education,Knowledge of AD Preventative behaviors|Willingness to Engage in AD Preventative behaviors|Participant Satisfaction|Behavioral Assessments,Weill Medical College of Cornell University,All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,10000,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1311014539,Jan-17,Dec-20,Oct-24,11-May-17,null,29-Aug-18,"Weill Medical College of Cornell University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03149380
NCT03144921,EPIC: An Intervention for Early-stage AD Dyads,,Recruiting,No Results Available,Dementia|Alzheimer Disease|Memory Loss,Behavioral: psychoeducational skills training intervention,EP and CP Emotional well-being|EP Quality of Life|Knowledge and Use of Services for People with Dementia and their Care Partners|Communication Skills and Support within the Dyad|EP and CP Care preparedness,Arizona State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,320,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00005510,9-Oct-17,May-21,May-21,9-May-17,null,1-Feb-18,"Arizona State University College of Nursing and Health Innovation, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03144921
NCT03131453,A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease,Generation S2,Recruiting,No Results Available,Alzheimer's Disease,Drug: CNP520 50mg|Drug: CNP520 15mg|Other: Placebo to CNP520,"Time to event|Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score|Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score|Change on the Total Scale score and individual neurocognitive domain index scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Change in the Everyday Cognition scale (ECog) total scores|Change in cerebral amyloid angiopathy (CAA)|Change on volume of brain regions|Change in amyloid deposition as measured by standardized uptake ratio (SUVR) of positron emission tomography (PET) scan with amyloid radiotracer|Change in CSF levels of Aβ40, Aβ42|Change in CSF levels of total tau and phosphorylated tau|Number of participants with adverse events as a measure of safety|Change in neurofibrillary tangle burden as measured by standardized uptake ratio (SUVR) of PET scans with tau radiotracer (where available)",Novartis Pharmaceuticals|Amgen|Banner Alzheimer's Institute|Novartis,All,"60 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,2000,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCNP520A2202J|2016-002976-28,3-Aug-17,30-Jul-24,31-Mar-25,27-Apr-17,null,16-May-19,"Banner Alzheimer's Institute, 901 East Willetta Street, Phoenix, Arizona, United States|Novartis Investigative Site, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Building B, Sun City, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Beverly Hills, California, United States|ATP Clinical Research Inc, 3151 Airway Avenue T 3, Costa Mesa, California, United States|Novartis Investigative Site, Garden Grove, California, United States|Irvine Center for Clinical Res, 2515 McCabe Way, Irvine, California, United States|Torrance Clinical Research Institute, 25043 Narbonne Avenue, Lomita, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Oxnard, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, San Diego, California, United States|Syrentis Clinical Research, 1401 N Tustin Ave, Suite 130, Santa Ana, California, United States|Novartis Investigative Site, Sebastopol, California, United States|Mountain Neurological Research, 350 Market Street, Suite 316, Basalt, Colorado, United States|Colorado Springs Neurological, 2312 North Nevada Avenue, Suite 100, Colorado Springs, Colorado, United States|Denver Neurological Clinic, 950 E Harvard Ave, Denver, Colorado, United States|Yale University, One Church Street, Suite 600, New Haven, Connecticut, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Atlantis, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Brain Matters Research, Inc., 800 NW 17th Avenue, Delray Beach, Florida, United States|Infinity Clinical Research LLC, 4925 Sheridan Street, Suite 200, Hollywood, Florida, United States|Alzheimer's Research and Treatment Center, 5065 State Road 7, Suite 102, Lake Worth, Florida, United States|Meridien Research, 2300 Maitland center, Pkwy Ste 230, Maitland, Florida, United States|Novartis Investigative Site, Melbourne, Florida, United States|Novartis Investigative Site, Merritt Island, Florida, United States|Novartis Investigative Site, Miami Beach, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|New Horizon Research Center, 11880 SW 40 St., Suite 405, Miami, Florida, United States|Miami-Dade Medical Research, 8955 SW 87 CT, Suite 112, Miami, Florida, United States|Compass Research, LLC,100 West Gore Street, Suite 202, Orlando, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Ormond Beach, Florida, United States|Novartis Investigative Site, Palm Beach Gardens, Florida, United States|Novartis Investigative Site, Port Orange, Florida, United States|Roskamp Institute, Inc., 2040 Whitfield Avenue, Sarasota, Florida, United States|Novartis Investigative Site, Tallahassee, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Columbus, Georgia, United States|Novartis Investigative Site, Decatur, Georgia, United States|Hawaii Pacific Neuroscience, 2230 Liliha st 104, Honolulu, Hawaii, United States|Advanced Clinical Research, 2950 E Magic View Dr, Suite 182, Meridian, Idaho, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Alexian Brothers Neuroscience, 800 Biesterfield Rd, Neuroscience Institute Brock, Elk Grove Village, Illinois, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Fairway, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Lexington, Kentucky, United States|Novartis Investigative Site, Bangor, Maine, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|QUEST Research Institute, 28595 Orchard Lake Road, Suite 301, Farmington Hills, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Hattiesburg Clinic, 415 South 28th Avenue, Hattiesburg, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Eatontown, New Jersey, United States|Novartis Investigative Site, West Long Branch, New Jersey, United States|Albuquerque Neuroscience, 101 Hospital Loop ne, 209 209, Albuquerque, New Mexico, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, East Syracuse, New York, United States|Novartis Investigative Site, Latham, New York, United States|NYU Langone Medical Center, 145 East 32nd Street, 2nd Floor, Room 226, New York, New York, United States|Novartis Investigative Site, Orangeburg, New York, United States|Novartis Investigative Site, Rochester, New York, United States|ANI Neurology, PLLC dba Alzhe, 7809 Sardis Road, Charlotte, North Carolina, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research LLC, 1705 E 19th ST., STE 406/408, Tulsa, Oklahoma, United States|Summit Research Network, 2701 NW Vaughn St, Suite 350, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Jenkintown, Pennsylvania, United States|Abington Neurological Associate Ltd., 2325 Maryland Road, Suite 100, Willow Grove, Pennsylvania, United States|Rhode Island Hospital and Memory Research Institute, 1018 Waterman Ave, East Providence, Rhode Island, United States|Butler Hospital, 345 Blackstone Blvd., Providence, Rhode Island, United States|Roper Hospital, 316 Calhoun Street 5th Floor, Charleston, South Carolina, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Bennington, Vermont, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Middleton, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Cordoba, ARG, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Mar del Plata, Argentina|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Heidelberg West, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, Kentville, Nova Scota, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Toronto Memory Program, 1 Valleybrook Drive Suite 400, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Gatineau, Quebec, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Kuopio, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Strasbourg, Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, PARIS Cedex 13, France|Novartis Investigative Site, Rouen, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Villeurbanne, France|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Boblingen, Germany|Novartis Investigative Site, Halle Saale, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Reykjavik, Iceland|Novartis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Milan, Italy|Novartis Investigative Site, Tōon, Ehime, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Kodaira, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Suwon, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Culiacan, Sinaloa, Mexico|Novartis Investigative Site, Aguascalientes, Mexico|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Hertogenbosch, Netherlands|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Matosinhos, Portugal|Novartis Investigative Site, Torres Vedras, Portugal|Novartis Investigative Site, Guaynabo, Puerto Rico|Inspira Clinical Research, Ave Hostos 405, San Juan, Puerto Rico|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Rosebank, Johannesburg, South Africa|Novartis Investigative Site, Cape Town, Western Cape, South Africa|Novartis Investigative Site, George, ZAF, South Africa|Novartis Investigative Site, Terrassa, Barcelona, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Donostia-San Sebastian, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Basel, CH, Switzerland|Novartis Investigative Site, Geneve, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Kaoshiung, Taiwan|Novartis Investigative Site, New Taipei City, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Exeter, Devon, United Kingdom|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, London, GBR, United Kingdom|Novartis Investigative Site, Guildford, Surrey, United Kingdom|Novartis Investigative Site, Avon, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Dundee, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03131453
NCT03132272,Immunoadsorption for Treatment of Alzheimer's Disease,IMAD,Recruiting,No Results Available,Alzheimer Dementia,Device: Immunoadsorption with Globaffin,"Changes in cerebral blood flow, estimated by Arterial Spin Labeling MRI|Cognition (changes/improvement/impairment)|Vascular effects|Renal function|Laboratory parameters in liquor associated with Alzheimer's disease",University Medicine Greifswald,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201503IMAD|CIV-16-02-014668,Jul-16,31-Mar-19,31-Dec-19,27-Apr-17,null,31-Oct-18,"University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany",,https://ClinicalTrials.gov/show/NCT03132272
NCT03129269,Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults,COGFRAIL,Recruiting,No Results Available,Frail Elderly,Procedure: MRI and PET scan,Amyloid physiological parameter|Change in cognitive function with Clinical Dementia Rating Scale (CDR)|Changes in functional capacities with scales IADL|Changes in functional capacities with scales ADL|Changes in functional capacities with scales SPPB,"University Hospital, Toulouse|MSDAVENIR",All,70 Years and older   (Older Adult),Not Applicable,345,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,RC31/16/8753,2-Jan-17,30-Sep-18,31-Dec-21,26-Apr-17,null,26-Apr-17,"Toulouse University Hospital (CHU de Toulouse), Toulouse, France",,https://ClinicalTrials.gov/show/NCT03129269
NCT03130036,Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning,,Completed,No Results Available,Alzheimer Disease|Mild Cognitive Impairment,Other: Low-Carbohydrate Diet|Other: Low-Fat Diet,Brain biodistribution of [11C]AcAc/[18F]FDG,Wake Forest University Health Sciences,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,34,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science,IRB00033365,9-Jun-15,Jun-17,Jun-17,26-Apr-17,null,1-Aug-18,"Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03130036
NCT03124550,Development of An Exergame for Caregivers of Individuals With Alzheimer's Disease or Related Dementias,,Recruiting,No Results Available,"Sedentary Lifestyle|Stress, Psychological",Behavioral: Exergame Experience,Number of steps|Exercise Intensity|Exercise self-efficacy|Number of social contacts,Brandeis University|National Institute on Aging (NIA),All,"Child, Adult, Older Adult",Not Applicable,20,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Exergame #17065|5P30AG048785,11-May-17,Jul-19,Jul-20,24-Apr-17,null,11-Jan-19,"Northeastern University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03124550
NCT03123224,The COACH Project: Combined Online Assistance for Caregiver Health,COACH,Recruiting,No Results Available,"Traumas, Brain|Alzheimer Disease|Dementia|Head Injury|Concussion, Brain|TBI",Behavioral: Combined Aerobic and Resistance Exercise + Caregiver Skills Training|Behavioral: Stretching Balance and Flexibility + Caregiver Skills Training,Caregiver Burden using Zarit Burden Inventory,Palo Alto Veterans Institute for Research|United States Department of Defense,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,200,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FAI0003AGG|W81XWH-15-1-0246,Aug-15,Jul-18,Jul-18,21-Apr-17,null,18-Jan-18,"VA Palo Alto Health Care System, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT03123224
NCT03121950,Movement and Music Intervention for Individuals With Dementia,,Unknown status,No Results Available,Dementia With Lewy Bodies|Dementia,Other: Dance|Other: music,Change in time to complete the Timed up and go cognitive|Change in score on the Montreal Cognitive Assessment,Ohio State University,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2016H0211,1-Apr-17,30-Dec-17,30-Dec-18,20-Apr-17,null,21-Apr-17,"Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03121950
NCT03119961,Blood Brain Barrier Opening in Alzheimer' Disease,BOREAL1,Recruiting,No Results Available,Alzheimer Disease,Device: SONOCLOUD®,Florbetapir SUVr and Fluorodeoxyglucose MUV changes in BBB opening region of interest (ROI)|Adverse events recording,Assistance Publique - Hôpitaux de Paris|CarThera|BPIfrance,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P150101|2016-004145-82|B2016-A01637-44,26-Jun-17,1-Apr-19,1-Jul-19,19-Apr-17,null,3-Aug-17,"APHP - Pitié-Salpêtrière Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03119961
NCT03117738,A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer Disease,Drug: AstroStem|Other: Placebo-Control,"Treatment related adverse events|ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale)|MMSE (Mini-mental status examination)|CDR-SOB (Clinical Dementia Rating-Sum of Boxes)|NPI (Neuropsychiatric Inventory)|GDS (Geriatric Depression Scale)|ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)|C-SSRS (Columbia Suicide Severity Rating Scale)|MRI Scan|Biomarkers: Amyloid beta 40, Amyloid beta 42, Amyloid precursor protein intracellular domain (AICD), soluble neuregulin-1 (sNRG-1)",Nature Cell Co. Ltd.,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,21,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AST-ADP2-US01,3-Apr-17,Aug-19,Sep-19,18-Apr-17,null,9-May-19,"ATP Clinical Research, Costa Mesa, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Valden Medical, Honolulu, Hawaii, United States",,https://ClinicalTrials.gov/show/NCT03117738
NCT03117829,Study: Diet and Exercise Study to Improve Brain Blood Flow: Blood Flow Improvement Trial,BFIT,"Active, not recruiting",No Results Available,PreDiabetes,Behavioral: Diet and Exercise,Brain blood flow,"University of Wisconsin, Madison",All,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2016-1202,15-Mar-17,18-Dec-18,21-Jun-19,18-Apr-17,null,8-Jan-19,"University of Wisconsin-Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03117829
NCT03118947,A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease,,Completed,No Results Available,Agitation and Aggression in Alzheimer's Disease,Drug: Pimavanserin,Treatment emergent adverse events (TEAEs),ACADIA Pharmaceuticals Inc.,All,"50 Years and older   (Adult, Older Adult)",Phase 2,79,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ACP-103-033|2016-001128-78,23-Feb-17,25-Feb-19,25-Feb-19,18-Apr-17,null,2-May-19,"ATP Clinical Research, Inc., Costa Mesa, California, United States|Neuro-Pain Medical Center, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Pacific Clinical Research Network, San Diego, California, United States|Clinical Research Unit, Washington, District of Columbia, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Quantum Laboratories Inc., Deerfield Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Collier Neurologic Specialists LLC, Naples, Florida, United States|Acadia Hospital, Bangor, Maine, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|ANI Neurology, PLLC dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Abington Neurological Associates, Ltd., Willow Grove, Pennsylvania, United States|Insite Clinical Research, LLC, DeSoto, Texas, United States|Pharmaceutical Research Associates, Inc., Salt Lake City, Utah, United States|Psicomed Estudios Médicos, Antofagasta, Chile|Biomedica Research Group, Santiago, Chile|Especialidades Medicas L y S, Santiago, Chile|CHU de Toulouse - Cite de la sante - Gerontople, Toulouse, Cedex 9, France|Centro de Atencion Especializada Oroitu, Algorta, Viscaya, Spain|Hospital General Universitario de Elche, Elche, Spain|Hospital Universitari Mutua de Terrassa, Terrassa, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|RICE-The Research Institute for the Care of Older People, The RICE Centre, The Royal United Hospital, Bath, United Kingdom|West London Cognitive Disorders Treatment & Research Unit, Lakeside Mental Health Unit, West Middlesex University Hosp. Site, Isleworth, United Kingdom|Greater Manchester Mental Health NHS Foundation Trust, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT03118947
NCT03113812,Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients,,Completed,No Results Available,Alzheimer's Disease,Drug: ABvac40|Drug: Placebo,number of participants with adverse events,Araclon Biotech S.L.,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AB1203,1-Jan-14,30-Jul-15,30-Jul-15,14-Apr-17,null,14-Apr-17,,,https://ClinicalTrials.gov/show/NCT03113812
NCT03114657,A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD),CREAD 2,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: Crenezumab|Drug: Placebo,Change from Baseline to Week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Scale Score|Change from Baseline to Week 105 in Alzheimer's Disease Assessment Scale-Cognition 13 (ADAS-Cog-13) and Alzheimer's Disease Assessment Scale-Cognition 11 (ADAS-Cog-11) Subscale Score|Change from Baseline to Week 105 in Clinical Dementia Rating-Global Score (CDR-GS) and Mini Mental State Exam MMSE|Change from Baseline to Week 105 on Function as assessed by (ADCS-ADL) Total Score and Its (ADCS-iADL) and by the Functional Activities Questionnaire (FAQ) total score|Change from Baseline to Week 105 on a Measure of Dependence Level Assessed from the ADCS-ADL Score|Change from Baseline to Week 105 on Behavior in Neuropsychiatric Inventory Questionnaire (NPI-Q) Total Score|Quality of Life-Alzheimer's Disease (QoL-AD) Scale Score|Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) Scale Score|European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Domain Scores|Percentage of Participants with Adverse Event (AEs) and Serious Adverse Event (SAEs)|Percentage of Participants with Anti-Crenezumab Antibodies|Serum Concentration of Crenezumab|Plasma Amyloid Beta (Abeta) Concentrations|Change from Baseline to Week 105 in Brain Volume as Determined by Magnetic Resonance Imaging (MRI)|Cerebrospinal Fluid (CSF) concentration of Crenezumab|Brain Amyloid Load Over Time Measured by Amyloid-PET|Brain Tau Load Over Time Measured by Tau-PET|Cerebrospinal Fluid (CSF) Markers of Disease Over Time,Hoffmann-La Roche,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,750,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BN29553|2016-003288-20,29-Mar-17,29-May-19,29-May-19,14-Apr-17,null,12-Apr-19,"Imaging End Points Clinical Research, Scottsdale, Arizona, United States|Radiant Research, Inc., Tempe, Arizona, United States|Health Initiatives Research, PLLC, Fayetteville, Arkansas, United States|NEA Baptist Clinic, Jonesboro, Arkansas, United States|Clinical Trials Inc., Little Rock, Arkansas, United States|The Research Center of Southern California, LLC, Carlsbad, California, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Senior Clinical Trials, Laguna Hills, California, United States|Uci Medical Center, Orange, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|Desert Valley Medical Group, Rancho Mirage, California, United States|Anderson Clinical Research, Inc., Redlands, California, United States|University of California, Davis; Alzheimers Disease Center, Department of Neurology, Sacramento, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|UCSF - Memory and Aging Center, San Francisco, California, United States|IMMUNOe Research Centers, Centennial, Colorado, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|JEM Research LLC, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Neurology Associates Of Ormond Beach, Ormond Beach, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Columbus Memory Center, Columbus, Georgia, United States|Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States|Advanced Clinical Research, Meridian, Idaho, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|McLean Hospital; First Episode Clinic, Belmont, Massachusetts, United States|Alzheimers Disease Center; Neurology, Winchester, Massachusetts, United States|Health Partners Institute for Education and Research, Saint Paul, Minnesota, United States|Precise Research Centers, Flowood, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Nebraska Medical Center; Dept of Neurological Sciences, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|State University of New York at Buffalo; Department of Neurology, Buffalo, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center; Monroe Community Hospital, Rochester, New York, United States|Burke Rehabilitation Hospital, White Plains, New York, United States|Behavioral Health Research, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Ohio Clinical Research Partners, LLC, Canton, Ohio, United States|Dayton Center for Neuro Disorders, Centerville, Ohio, United States|Carl and Edyth Lindner Center at Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati; Department of Psychiatry and Behavioral Neuroscience, Cincinnati, Ohio, United States|Ohio State University; College of Medicine, Columbus, Ohio, United States|Ips Research Company, Oklahoma City, Oklahoma, United States|Summit Research Network Inc., Portland, Oregon, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|Drexel Univ College of Med; Clinical Research Group, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Northeastern Pennsylvania Memory, Plains, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Neurology Clinic PC, Cordova, Tennessee, United States|Senior Adults Specialty Research, Austin, Texas, United States|Gadolin Research, LLC, Beaumont, Texas, United States|Texas Neurology PA, Dallas, Texas, United States|Kerwin Research Center, LLC, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine, Houston, Texas, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Sentara Medical Group, Norfolk, Virginia, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Frontier Institute, Spokane, Washington, United States|Hospital Italiano, Buenos Aires, Argentina|Universidad Maimonides, Caba, Argentina|Hospital Sirio Libanes, Caba, Argentina|DAMIC, Cordoba, Argentina|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Central Coast Neurosciences Research, Erina, New South Wales, Australia|Hornsby Ku-ring-gai Hospital; Division of Rehabilitation & Aged Care, Hornsby, New South Wales, Australia|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|St Vincent's Hospital Melbourne; Clinical Neuroscience and Neurological Research, Fitzroy, Victoria, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Royal Melbourne Hospital; Department of Neurology, Parkville, Victoria, Australia|AZ Sint Jan, Brugge, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CCBR - Brasilia, Brasilia, DF, Brazil|Hospital das Clinicas - UFMG, Belo Horizonte, MG, Brazil|Instituto de Neurologia de Curitiba, Curitiba, PR, Brazil|Centro Psiquiatria Sandra Ruschel Ltda, Rio de Janeiro, RJ, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Clínica Dr. Norton Sayeg LTDA - EPP, Sao Paulo, SP, Brazil|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Vancouver Island Health Authority, Victoria, British Columbia, Canada|True North Clinical Research-Halifax, Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|Jbn Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Providence Care; Mental Health Services, Kingston, Ontario, Canada|Parkwood Hospital; Geriatric Medicine, London, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Devonshire Clinical Research Inc., Woodstock, Ontario, Canada|Clinique NeuroOutaouais, Gatineau, Quebec, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|ALPHA Recherche Clinique, Quebec, Canada|Peking University Sixth Hospital; Department of Psychiatry, Beijing, China|Beijing Union Hospital, Beijing, China|Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Shanghai Mental Health Center, Shanghai, China|Tianjin Medical University General Hospital, Tianjin (天津), China|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus N, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|Laane-Tallinna Keskhaigla, Tallinn, Estonia|Hopital Pellegrin; Cmrr Aquitaine, Bordeaux, France|Hôpital de Jour du Centre pour Personnes Âgées; Louis Pasteur Neurologie, Colmar, France|Hopital Roger Salengro; Service de Neurologie, Lille, France|CHU de Limoges Hopital Dupuytren; Service de Medecine Geriatrique, Limoges, France|Hopital Broca, Paris, France|CH Pitie Salpetriere; IM2A, Paris, France|Hôpital Maison Blanche, Reims, France|CHU Rennes - Hopital Pontchaillou, Rennes cedex 09, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, France|Hop Guillaume Et Rene Laennec; Cmrr St Herblain, St Herblain, France|Hopital des Charpennes, Villeurbanne, France|ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic, Berlin, Germany|Klinikum Joh.Wolfg.Goethe-UNI Zentrum d. Psychiatrie Klinik f. Psychiatrie Psychosomatik, Frankfurt, Germany|Universitätsklinikum Freiburg, Zentrum für Geriatrie und Gerontologie, Freiburg, Germany|Universitätsklinikum des Saarlandes Klinik f. Psychiatrie und Psychotherapie, Homburg/Saar, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Pharmakologisches Studienzentrum, Mittweida, Germany|Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie, München, Germany|Naval Hospital of Athen;Neurology Clinic, Athens, Greece|Rambam Medical Center, Halfa, Israel|Sheba Medical Center; Psychiatry Department, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center; Department of Neurology, Tel Aviv, Israel|Azienda Ospedaliera Universitaria Policlinico Tor Vergata; Neurologia, Roma, Lazio, Italy|Policlinico Universitario Agostino Gemelli; UOC Neurologia, Roma, Lazio, Italy|Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy|Ospedale San Giovanni Calibita Fatebenefratell;Neurologia, Roma, Lazio, Italy|IRCCS ""Centro S. Giovanni di Dio"" Fatebenefratelli -UO Alzheimer, Brescia, Lombardia, Italy|Irccs Multimedica Santa Maria; Unita' Di Neurologia, Castellanza, Lombardia, Italy|IRCCS Ospedale San Raffaele; Centro Disturbi della Memoria, Milano, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale Neurologico Besta; UO Neuropatologia, Milano, Lombardia, Italy|Ospedale S. Maria Nascente; Fondazione Don Gnocchi; Dip. Neurologia Riabilitativa, Milano, Lombardia, Italy|Ospedale Casati Passirana di Rho; Centro Regionale Alzheimer, Passirana, Lombardia, Italy|IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA, Pozzilli, Molise, Italy|AO Città della Salute e della Scienza Osp.S.Giov.Battista Molinette; SC Geriatria, Torino, Piemonte, Italy|A.O. Universitaria Pisana; Neurologia, Pisa, Toscana, Italy|National Center for Geriatrics and Gerontology, Aichi, Japan|Hirosaki University Hospital, Aomori, Japan|Inage Neurology and Memory Clinic, Chiba, Japan|Fukuoka Mirai Hospital, Fukuoka, Japan|National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan|Sapporo Medical University Hospital, Hokkaido, Japan|Tsukazaki Hospital, Hyogo, Japan|Iwate Medical University Hospital, Iwate, Japan|Kagawa Prefectural Central Hospital, Kagawa, Japan|Fujisawa City Hospital, Kanagawa, Japan|National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan|Koseikai Takeda Hospital, Kyoto, Japan|Ijinkai Takeda General Hospital, Kyoto, Japan|Rakuwakai Otowarehabilitation Hospital, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|Saigata Medical Center, Niigata, Japan|Katayama Medical Clinic, Okayama, Japan|AMC Nishi Umeda Clinic, Osaka, Japan|Osaka Red Cross Hospital, Osaka, Japan|Osaka General Medical Center, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Asakayama General Hospital, Osaka, Japan|NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan|Showa University East Hospital, Tokyo, Japan|Ebara Hospital, Tokyo, Japan|Kanto Central Hospital, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Shinjuku Research Park Clinic, Tokyo, Japan|Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan|National Center of Neurology and Psychiatry, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|Tottori University Hospital, Tottori, Japan|Dong-A University Hospital, Busan, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Borame Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Investigacion Biomedica Elemental. Sapi de Cv, Guadalajara, Jalisco, Mexico|Hospital General de México, Mexico City, Mexico CITY (federal District), Mexico|Estimulacion Magnetica Trnscraneal de Mexico SC., Mexico City, Mexico|Centro de Estudios Clinicos y Especialidades Médicas, S.C., Monterrey, Mexico|Centro De Atencion E Investigacion Cardiovascular Del Potosi S.C., San Luis Potosí, Mexico|Akershus universitetssykehus HF; Nevroklinikken S203, Lørenskog, Norway|Oslo universitetssykehus HF Ullevål sykehus; Hukommelsesklinikken, Oslo, Norway|Clinica Internacional; Unidad De Investigacion, Lima, Peru|Clinica Anglo Americana; Centro de Investigacion Neurologia II CAA, Lima, Peru|Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia, Lima, Peru|NZOZ Dom Sue Ryder, Bydgoszcz, Poland|Centrum Medyczne Euromedis Sp. z o.o., Szczecin, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|NZOZ WCA, Wrocław, Poland|Hospital de Braga; Servico de Neurologia, Braga, Portugal|HUC; Servico de Neurologia, Coimbra, Portugal|Hospital Pedro Hispano; Servico de Neurologia, Matosinhos, Portugal|Hospital Geral de Santo Antonio; Servico de Neurologia, Porto, Portugal|LLC Baltic Medicine, Saint-Petersburg, Sankt Petersburg, Russian Federation|State Healthcare Institution of Sverdlovsk Region Sverdlovsk Regional Clinical Psychiatric Hospita, Yekaterinburg, Sverdlovsk, Russian Federation|Republican clinical hospital of regenerative treatment of Ministry of Health of Tatarstan republic, Kazan, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Institution of RAMS (Mental Health Research Center of RAMS), Moscow, Russian Federation|City Clinical Psychiatry Hospital #1, Nizhny Novgorod, Russian Federation|St Nicolas Psychiatric Hospital; Chair of Psychiatry and Narcology of St. Petersburg Medical Academy, St Petersburg, Russian Federation|Nebbiolo Center for Clinical Trials, Tomsk, Russian Federation|Clinic for Mental disorders Dr Laza Lazarevic, Belgrade, Serbia|Neurology clinic, Clinical Center of Serbia, Belgrade, Serbia|Clinic for neurology, Clinical Center Kragujevac, Kragujevac, Serbia|Flexivest Fourteen Research Centre, Cape Town, South Africa|Private Practice; the Osteoporosis Clinic, Johannesburg, South Africa|Hospital General Universitario de Elche; Servicio de Neurología, Elche, Alicante, Spain|Fundació ACE, BArcelon, Barcelona, Spain|Hospital General De Catalunya; Servicio de Neurologia, Sant Cugat del Valles, Barcelona, Spain|Hospital Mutua De Terrasa; Servicio de Neurologia, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto. Servicio de Neurología, Plasencia, Caceres, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Neurología, Santander, Cantabria, Spain|Hospital Santa Caterina, Unitat de Valoració de la memoria i les demencies, Salt, Girona, Spain|Policlínica Guipuzkoa; Servicio de Neurología, Donosti-San Sebastián, Guipuzcoa, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Neurologia, Santiago de Compostela, LA Coruña, Spain|Hospital San Pedro; Servicio de Neurología, Logroño, LA Rioja, Spain|Hospital Universitario de Getafe; Servicio de Geriatria, Getafe, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Neurologia, Pozuelo de Alarcon, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Neurología, Pamplona, Navarra, Spain|CAE Oroitu, BaraKaldo, Vizcaya, Spain|Hospital Perpetuo Socorro, Servicio de Geriatria, Albacete, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Hospital Clinic i Provincial; Servicio de Neurologia, Barcelona, Spain|Hospital Universitario de Burgos. Servicio de Neurología, Burgos, Spain|Hospital la Magdalena; Servicio de Neurologia, Castellon, Spain|Hospital Universitario Reina Sofia; Servicio de Neurologia, Cordoba, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, Spain|Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría; CSM La Alamedilla, Salamanca, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, Spain|Hospital Clínico Universitario de Valladolid; Servicio de Neurología, Valladolid, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmoe, Sweden|Sahlgrenska Academy University,Neuroscience and Physiology;Departmt of Psychiatry and Neurochemistry, Mölndal, Sweden|Changhua Christian Hospital; Neurology, Changhua County, Taiwan|Kaohsiung Medical University Hospital; Neurology, Kaohsiung, Taiwan|Chang Gung Memorial Foundation - Kaohsiung - Neurology, Kaohsiung, Taiwan|Taipei Medical University - Shuang Ho Hospital - Neurology, New Taipei City, Taiwan|National Taiwan University Hospital; Neurology, Taipei, Taiwan|Chang Gung Memorial Foundation - Linkou - Neurology, Taoyuan, Taiwan|Ankara University School of Medicine; Neurology, Ankara, Turkey|Hacettepe University Medical Faculty; Neurology, Ankara, Turkey|Akdeniz University School of Medicine, Neurology Department, Antalya, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, Turkey|The Rice Centre; Royal United Hospital, Bath, United Kingdom|The Fritchie Centre, Charlton Lane Centre, Charlon Lane, Leckhampton; The Fritchie Centre, Cheltenham, United Kingdom|Surrey and Borders NHS Foundation Trust; Brain Science Research Unit, Chertsey, United Kingdom|Sussex Partnership NHS Foundation Trust; Cognitive Treatment and Research unit, Crowborough, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|NHS Lothian - Western General Hospital; NHS Lothian - Western General Hospital, Edinburgh, United Kingdom|Queen Elizabeth University Hospital; Clinical Research Facility, Glasgow, United Kingdom|Crosshouse Hospital; NHS Ayrshire & Arran, Kilmarnock, United Kingdom|Royal Liverpool and Broadgreen University Hospital Trust, L7 8xp, United Kingdom|RE:Cognition Health, London, United Kingdom|Charing Cross Hospital; Imperial Memory Unit, Level 10 West, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|University Southampton NHS Foundation Trust; Wessex Neurologica Centre, Southampton, United Kingdom|University Hospital North Midlands, Stoke on Trent, United Kingdom|Re:Cognition Health Guildford, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT03114657
NCT03112096,A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer Disease,Drug: [18F]THK-5351,Pharmacokinetics: Maximum Serum Concentration (Cmax) of [18F]THK-5351|Assess global and regional tau deposition as measured by standard uptake value ratio (SUVR) of [18F]THK-5351|Correlation between standard uptake value ratio (SUVR) and distribution volume of ratio(DVR) of [18F]THK-5351 positron emission computed tomography|Optimal scanning time for brain imaging using F-18 THK-5351.|Concentrations of metabolite in plasma of [18F]THK-5351|Number of participants with treatment related adverse events as a measure of safety,Asan Foundation,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,THK-15001,17-May-17,30-Aug-18,30-Aug-18,13-Apr-17,null,24-May-18,"Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03112096
NCT03100617,Alzheimer's Family Caregiver Intervention in Vietnam,,Recruiting,No Results Available,Dementia Alzheimers,Behavioral: Psychosocial caregiver intervention,Caregiver burden,"University of California, Davis|University of South Carolina",All,"21 Years and older   (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1084736,26-Aug-17,18-Jun-18,18-Jun-19,4-Apr-17,null,4-Jul-18,"Vietnam National Geriatric Hospital, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT03100617
NCT03101085,S-Equol in Alzheimer's Disease 2 Trial,SEAD2,Recruiting,No Results Available,Alzheimer Disease,Drug: S-equol|Other: Placebo,Difference in cytochrome oxidase/citrate synthase (COX/CS) activity|Safety laboratories evaluation and participant/study partner reporting of symptoms or adverse events|Montreal Cognitive Assessment (MoCA) Determine if S-equol influences participant scores.|Alzheimer's Disease Assessment Scale-Cognitive Portion (ADASCog-11) Determine if S-equol influences participant scores.|Logical Memory Test (LMT) - immediate and delayed recall Determine if S-equol influences participant scores.|Stroop Test Determine if S-equol influences participant scores.|Pattern of COX activity changes while on the active treatment versus placebo arms of this crossover study.,"Russell Swerdlow, MD|Ausio Pharmaceuticals, LLC|University of Kansas Medical Center",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SEAD2,5-May-17,30-Sep-19,30-Oct-19,4-Apr-17,null,13-Mar-19,"Clinical and Translational Science Unit, Fairway, Kansas, United States|University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT03101085
NCT03094546,Polyamine-enriched Diet in Elderly Individuals With Subjective Cognitive Decline,SmartAge,Recruiting,No Results Available,Subjective Cognitive Decline (SCD),Dietary Supplement: Polyamine|Dietary Supplement: Placebo,Change in Memory performance from neuropsychological test|Change in Cognitive Function (from extended neuropsychological test battery)|Change in polyamine concentration|Change in inflammation|Change in Brain imaging biomarkers|Change in Autophagy processes,"Charite University, Berlin, Germany|Freie Universität, Institute of Biology/Genetic, Berlin, Germany|Karl-Fransens-Universität, Institute of Molecular Biosciences, Graz, Austria",All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SmartAge,Jan-17,Jun-19,Jun-20,29-Mar-17,null,30-Mar-17,"Charité University Medicine Berlin, CCM, Department of Neurology,, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT03094546
NCT03095417,Improving the Recovery and Outcome Every Day After the ICU,IMPROVE,Recruiting,No Results Available,Delirium|Alzheimer Disease,Behavioral: Physical Exercise Intervention|Behavioral: Cognitive Training Intervention|Behavioral: Stretching Control|Behavioral: Cognitive Control,Cognitive Status Outcome at 6 months|Cognitive Status Outcome at 3 months|Quality of Life Scores at 3 months|Quality of Life Scores at 6 months,Indiana University,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,344,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",1608126693,25-Sep-17,1-Jun-22,1-Jun-23,29-Mar-17,null,9-Nov-18,"Indiana University Health West Hospital, Avon, Indiana, United States|Indiana University Health North Hospital, Carmel, Indiana, United States|Indiana University Health Saxony Hospital, Fishers, Indiana, United States|Eskenazi Health, Indianapolis, Indiana, United States|Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States|Indiana University Health University Hospital, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT03095417
NCT03093519,A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Drug: KHK6640|Drug: Placebo,Number of Participants with Adverse Events,"Kyowa Hakko Kirin Co., Ltd",All,"55 Years to 84 Years   (Adult, Older Adult)",Phase 1,21,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",6640-003,3-Mar-17,6-Dec-17,6-Dec-17,28-Mar-17,null,20-Mar-18,"Closed information, Saitama, Japan",,https://ClinicalTrials.gov/show/NCT03093519
NCT03089918,A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain,,Completed,No Results Available,Alzheimer Disease,Drug: 11C-JNJ-63779586,Effective Radiation Dose Following Injection of 11C-JNJ-63779586 (Part A)|Total and Regional Brain Compartmental Kinetics for Volume of Distribution of 11C-JNJ-63779586 (Part B)|Percent Intact Tracer of 11C-JNJ-63779586 in Blood Samples (Part B)|Radiometabolite Fraction of 11C-JNJ-63779586 in Blood Samples (Part B)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability (Part A and Part B),"Janssen Research & Development, LLC",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,11,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CR108288|63779586NAP1001|2016-001756-21,17-May-17,24-Aug-18,24-Aug-18,24-Mar-17,null,23-Jan-19,"UZ Leuven, Leuven, Belgium|University of Antwerpen, Wilrijk, Belgium",,https://ClinicalTrials.gov/show/NCT03089918
NCT03090516,Clinical Study on Improving the Cognitive Function of Patients With Mild to Moderate Alzheimer's Disease by Using Ginkgo Biloba Dispersible Tablets,,Unknown status,No Results Available,Alzheimer's,Drug: Ginkgo biloba dispersible tablets|Drug: Donepezil|Drug: Ginkgo biloba dispersible tablets and Donepezil,Scales to assess|Electroencephalography P300|liver function (blood)|1.5T MRI changes|Alzheimer disease assessment scale (ADAS-cog)|activities of daily living scale (ADL)|Change in neuropsychiatrc interventory (NPI)|Change in geriatric depression scale (GDS)|renal function|ECG,The First Affiliated Hospital with Nanjing Medical University,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Ginkgo biloba,10-Aug-16,10-Mar-18,10-Mar-18,24-Mar-17,null,24-Mar-17,"Ting Wu, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT03090516
NCT03082755,Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer Disease,Drug: Gabapentin Enacarbil|Drug: Placebo Oral Tablet,Nighttime Agitation - Cohen Mansfield Agitation Inventory (CMAI) - Direct Observation|Nighttime Agitation - Cohen Mansfield Agitation Inventory (CMAI) - Caregiver Version.|Nighttime Agitation - Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC).|Sleep Disturbance - Direct Observation|Sleep Disturbance - Behavioral Indicators Test - Restless Legs (BIT-RL)|Sleep Disturbance - Micro-Mini Motionlogger® Actigraph,University of Texas at Austin|National Institute on Aging (NIA),All,"55 Years and older   (Adult, Older Adult)",Phase 4,136,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2016-09-0152|R01AG051588-02,1-Jul-17,31-Mar-21,31-Mar-22,17-Mar-17,null,13-Jul-18,"The University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT03082755
NCT03081533,Circle Dance for Family Caregivers of the Elderly With Alzheimer.,CircleCare,Recruiting,No Results Available,Family Caregiver,Other: Circle Dance Program (CircleCare),Brazilian Version of the Short Physical Performance Battery|Timed Up and Go Test|Addenbrooke's Cognitive Examination-Revised (ACE-R)|Zarit Burden Interview (ZBI)|Brazilian Perceived Stress Scale (BPSS-10)|Geriatric Depression Scale (GDS-15)|Quality of Life Scale in Alzheimer's disease (QoL-AD - caregiver's version)|Frailty Phenotype,Universidade Federal de Sao Carlos|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.|Universidade Estadual Paulista Júlio de Mesquita Filho,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,62112716.8.0000.5504,6-Sep-17,14-Jun-19,Jul-19,16-Mar-17,null,25-Mar-19,"Julimara Gomes dos Santos, Sao Carlos, SP, Brazil",,https://ClinicalTrials.gov/show/NCT03081533
NCT03080051,Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain,,Completed,No Results Available,Progressive Supranuclear Palsy|Alzheimer Disease|Healthy Volunteers,Drug: [18F]MNI-952|Drug: [18F]Florbetapir,"Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-952 binding/uptake and expressed in SUV by using established methods for normalization for 2 PSP, 2 AD, and 2 HV subjects.",Molecular NeuroImaging,All,"18 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,[18F]MNI-952,Aug-16,6-Mar-17,6-Mar-17,15-Mar-17,null,6-Oct-17,"Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03080051
NCT03076307,DAT SPECT and Procedural Motor Skills in Parkinson's Disease,,Completed,No Results Available,Parkinson Disease,Behavioral: Procedural Motor Skills with mirror-drawing of figures,Procedural motor performance (error and time) in PD group|Resting state EEG connectivity in PD and control groups|Difference >20% in error rate and speed improvement in control and PD groups,"University Hospital, Geneva",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science,CCER 2016-01469,18-Oct-16,20-May-17,19-Jul-17,10-Mar-17,null,21-Jul-17,"Division of Neurorehabilitation, Geneva University Hospitals, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT03076307
NCT03075241,Z-Drugs for Sleep Disorders in Alzheimer's Disease,,Recruiting,No Results Available,Sleep|Sleep Disorders|Insomnia|Alzheimer's Disease,Drug: Zolpidem|Drug: Zoplicone|Drug: Placebo,Nighttime Total Sleep Time|Daytime Total Sleep Time|Ratio of daytime to nighttime sleep|Nighttime Wake after Sleep Onset|Proportion of sleep time at nighttime|Proportion of patients with gain of at least 30 minutes in Total Sleep Time|Differences between sleep efficiency between the two treatments.|Nighttime Number of Awakenings,Brasilia University Hospital,All,"55 Years and older   (Adult, Older Adult)",Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ZOLP-001,Oct-16,Oct-18,Dec-18,9-Mar-17,null,25-Aug-17,"Geriatric Medical Centre, Brasilia, Distrito Federal, Brazil",,https://ClinicalTrials.gov/show/NCT03075241
NCT03073876,Detecting an Early Response to Donepezil With Measures of Visual Attention,,"Active, not recruiting",No Results Available,Alzheimer Disease,Drug: Donepezil Hydrochloride|Drug: Placebo,Change in Foreperiod Effect task from baseline to 6 weeks|Change in Attentional Blink task from baseline to 6 weeks|Change in Corert Orienting task from baseline to 6 weeks|Change of Foreperiod Effect task from baseline to 6 months|Change in Attentional Blink task from baseline to 6 months|Change of Covert Orienting task from baseline to 6 months|Change in Dementia Rating Scale|Change in Mini Mental Status Examination|Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale|Change in Clinical Dementia Rating|Change in Digit Span|Change in Hopkins Verbal Learning Test- Revised|Change in Language function assessed with the Letter and Category Fluency Test|Change in Executive function assessed with the Trail Making Test|Change in Visuospatial function assessed with Visual Form Discrimination,"New York University School of Medicine|Queens College, The City University of New York",All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 4,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",WUH 05030,1-Dec-05,8-Oct-09,31-Jul-19,8-Mar-17,null,11-Jan-19,"Winthrop-University Hospital, Mineola, New York, United States",,https://ClinicalTrials.gov/show/NCT03073876
NCT03070821,Therapy of Alzheimer's Disease With Neurofeedback,,Completed,No Results Available,Alzheimer Dementia (AD)|Elderly,Other: rtfMRI neurofeedback training|Device: 3T MRI,Visual and Verbal Memory Test (VVM)|Montreal Cognitive Assessment (MoCA)|Wechsler Memory Scale Revised (WMS-R)|Trail Making Test (TMT)|Visual Patterns Test (VPT)|Parahippocampal activation|Memory-related functional connectivity using Granger Causality Analysis (GCA)|Change of brain structure|Change of brain function,"University Hospital, Aachen|Alzheimer Forschung Initiative e.V.",All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,AFI 13812,30-Jan-13,30-Jun-16,30-Jun-16,6-Mar-17,null,6-Mar-17,,,https://ClinicalTrials.gov/show/NCT03070821
NCT03071224,Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein,,Recruiting,No Results Available,Alzheimer Disease|Healthy Volunteers,Drug: [18F] MNI-946|Drug: [18F]Florbetapir,To determine the longitudinal change in tau burden (including SUVR and tau distribution metrics) compared to baseline in AD subjects and in similarly aged HV subjects.,Invicro,All,"18 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,[18F] MNI-946,Jun-16,Jun-19,Jun-19,6-Mar-17,null,18-Apr-19,"Invicro, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03071224
NCT03069014,Study of LM11A-31-BHS in Mild-moderate AD Patients,,Recruiting,No Results Available,Mild to Moderate Alzheimer's Disease,Drug: 400mg LM11A-31-BHS|Drug: 800mg LM11A-31-BHS|Drug: Placebos,Number of AEs/SAEs within the 26-week study period|Statistically relevant changes in CSF-Biomarkers between baseline and final visit|Statistically relevant changes in working memory ability between baseline and final visit assessed with the Controlled Oral Word Association Test (COWAT)|Statistically relevant changes in word fluency between baseline and final visit assessed with the Category Fluency Test (CFT)|Statistically relevant changes in processing speed between baseline and final visit assessed with the Coding Test (Subtest of the Wechsler Adult Intelligence Scale)|Statistically relevant changes in executive functions between baseline and final visit assessed with the Digit Span test (Subtest of the Wechsler Adult Intelligence Scale),PharmatrophiX Inc.|National Institute on Aging (NIA),All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,190,Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NSC15001|2015-005263-16|1R01AG051596-01A1,15-Feb-17,10-Oct-19,31-Oct-19,3-Mar-17,null,17-Apr-19,"University Hospital Graz, Graz, Styria, Austria|Landeskrankenhaus Hall, Hall in Tirol, Tirol, Austria|Charles University, Praha, Hlavni Mesto Praha, Czechia|Neurology Clinic of Martin Urbanek, Brno, Jihomoravsky Kraj, Czechia|Vestra clinics s.r.o, Rychnov nad Kneznou, Kralovehadrecky Kraj, Czechia|NEUROHK s.r.o, Chocen, Pardubicky Kraj, Czechia|Nordwestkrankenhaus Sanderbusch, Sande, Friesland, Germany|Zentrum für klinische Forschung, Bad Homburg, Hesse, Germany|Studienzentrum Nordwest, Westerstede, Niedersachsen, Germany|Universitätsklinik Magdeburg, Klinik für Neurologie, Magdeburg, Sachsen Anthal, Germany|Sächsisches Krankenhaus Arnsdorf, Arnsdorf, Sachsen, Germany|Pharmakologisches Studienzentrum Chemnitz GmbH, Chemnitz, Sachsen, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Neurologie Sendlinger Strasse Studien- und Gedächtniszentrum München, München, Germany|LMU München Klinik für Psychiatrie und Psychotherapie, München, Germany|Fundació ACE, Barcelona, Catalonia, Spain|Fundación de Gestión Sanitaria del Hospital de la Santa Creu I Sant Pau, C, Barcelona, Catalonia, Spain|Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain|Hospital la Paz, Madrid, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Karolinska University, Stockholm, Stockholms Iän, Sweden",,https://ClinicalTrials.gov/show/NCT03069014
NCT03069391,The Interactive Physical and Cognitive Exercise System,iPACES™,"Active, not recruiting",No Results Available,"Alzheimer Disease, Early Onset|MCI|Aging|Mild Cognitive Impairment|Neurocognitive Disorder|Cognitive Impairment|Cognitive Change",Behavioral: physical exercise alone (PES) first|Device: cognitive exercise alone (iCE) first|Device: interactive Physical and Cognitive Exercise (iPACES™),executive function composite score|brain-derived neurotrophic factor (BDNF)|Sit-Stand Test,"Union College, New York|1st Playable Productions|Albany Medical College|Skidmore College|University of Illinois at Urbana-Champaign|National Institute on Aging (NIA)",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,31,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16028|1R41AG053120-01,4-Mar-17,30-Jun-20,30-Jun-20,3-Mar-17,null,3-May-18,"Healthy Aging & Neuropsychology Lab @ Union College, Schenectady, New York, United States",,https://ClinicalTrials.gov/show/NCT03069391
NCT03070535,APOE Genotype and Diet Influences on Alzheimer's Biomarkers,,Recruiting,No Results Available,Alzheimer's Disease; Dementia,Other: HIGH and LOW meal ingestion,Lipid biomarkers|APOE lipidation|Insulin,University of Washington,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,STUDY00001483,Sep-16,31-May-20,31-May-20,3-Mar-17,null,27-Oct-17,"University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03070535
NCT03058965,Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain,,Completed,No Results Available,Alzheimer Disease|Healthy Volunteers|Progressive Supranuclear Palsy,Drug: [18F]MNI-958|Drug: [18F]Florbetapir|Drug: DaTscan,"Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-958 binding/uptake and expressed in SUV by using established methods for normalization for 3 AD, 3 PSP, and 3 HV subjects.",Molecular NeuroImaging,All,"50 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,[18F]MNI-958,29-Nov-16,11-May-18,11-May-18,23-Feb-17,null,25-Mar-19,"Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03058965
NCT03061474,Nicotinamide as an Early Alzheimer's Disease Treatment,NEAT,Recruiting,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Drug: Nicotinamide|Drug: Placebo Comparator,Change in p-tau 231|Change in p-tau 181|Change in total tau,"University of California, Irvine",All,"50 Years and older   (Adult, Older Adult)",Phase 2,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20163246,12-Jul-17,30-Jun-20,30-Jun-20,23-Feb-17,null,25-Feb-19,"University of California, Irvine, Irvine, California, United States|University of California, Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT03061474
NCT03062449,Phase IIa L-serine Trial for eAD,LSPI-2,Recruiting,No Results Available,Alzheimer Disease,Drug: L-Serine|Other: Placebo Gummy,"Change in score on the Montreal Cognitive Assessment evaluation|Documentation of any adverse events|Changes in complete blood count, liver function test, basic metabolic panel measures.|Change in plasma biomarker levels.|Relationship between Montreal Cognitive Assessment score and plasma biomarker levels","Aleksandra Stark|Brain Chemistry Laboratories, Institute for Ethnomedicine|Dartmouth-Hitchcock Medical Center",All,"Child, Adult, Older Adult",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D16180,1-Mar-17,31-Aug-19,31-Aug-19,23-Feb-17,null,14-Jan-19,"Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States",,https://ClinicalTrials.gov/show/NCT03062449
NCT03056495,Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease,VostatAD01,Recruiting,No Results Available,Alzheimer Disease,Drug: N-hydroxy-N'-phenyl-octanediamide (Vorinostat),"Determination of the maximum-tolerated dose (MTD) in elderly subjects during dose escalation|Incidence of treatment - Emergent Adverse Events (Safety)|Quantification of Vorinostat concentration in blood - pharmacokinetics|association of alterations in the genome-wide transcriptome profile with the dose administered, toxicity and treatment response - pharmacodynamics","German Center for Neurodegenerative Diseases (DZNE)|University Hospital, Bonn|University of Göttingen",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1,44,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,VostatAD01|2014-005311-17,28-Sep-17,Jul-19,Oct-19,17-Feb-17,null,9-Nov-17,"German Center for Neurodegenerative Diseases, Bonn, Germany|University Medical Center Göttingen, Department of Psychiatry and Psychotherapy, Göttingen, Germany",,https://ClinicalTrials.gov/show/NCT03056495
NCT03056729,Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer's Disease,Drug: BIIB076|Drug: Placebo,Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Number of participants with clinically significant brain magnetic resonance imaging (MRI) abnormalities|BIIB076 serum pharmacokinetics (PK) concentration levels|PK parameter of BIIB076: Area under the concentration-time curve from time zero to infinity (AUCinf)|PK parameter of BIIB076: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)|PK parameter of BIIB076: Maximum observed concentration (Cmax)|PK parameter of BIIB076: Time to reach maximum observed concentration (Tmax)|PK parameter of BIIB076: Terminal elimination half-life (t1/2)|PK parameter of BIIB076: Clearance (CL)|PK parameter of BIIB076: Volume of distribution (Vd)|Number of participants with positive serum BIIB076 antibodies,Biogen,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",243HV101,17-Feb-17,2-Jul-19,2-Jul-19,17-Feb-17,null,10-Jan-19,"MD Clinical, Hallandale Beach, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Covance Evansville CRU, Evansville, Indiana, United States|Indiana University, Indianapolis, Indiana, United States|St Louis Clinical Trial, Saint Louis, Missouri, United States|Covance Dallas CRU, Dallas, Texas, United States|Covance CRU, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03056729
NCT03055741,Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA),,"Active, not recruiting",No Results Available,Mild-moderate Alzheimer's Disease,Drug: Donepezil|Drug: DHP1401|Drug: Placebo,Alzheimer's Disease Assessment Scale-cognition Korean version(ADAS-cog)|Clinical Dementia Rating Sum of Box Korean version(CDR-SB)|Neuropsychiatric Inventory-Q Korean version(NPI-Q)|K-MMSE|Korean Instrumental Activity of Daily Living(K-IADL)|Korean Trial Masking Test-elderly's version(K-TMT-e),"Daehwa Pharmaceutical Co., Ltd.",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,180,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1401CS-2,28-Dec-16,Mar-19,Jun-19,16-Feb-17,null,31-Aug-18,"The Catholic University of Korea, Bucheon, ST. Mary's Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of|Myongji Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Ajou University Medical Center, Suwon-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hospital, Gwangju-si, Jeollanam-do, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Daejeon Eulji Medical Center, Daejeon, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Chung-ang University Hospital, Seoul, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03055741
NCT03052712,Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies,GREFEXII,Recruiting,No Results Available,Alzheimer Disease|Parkinson Disease|Frontal Dementia|Huntington Disease|Traumatic Brain Injury|Stroke,Behavioral: social cognition,tests of social cognition (questionnaire),"Centre Hospitalier Universitaire, Amiens",All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1170,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PI2015_843_0031,9-Sep-16,9-Sep-19,9-Sep-19,14-Feb-17,null,4-Oct-18,"CHU Amiens, Amiens, France",,https://ClinicalTrials.gov/show/NCT03052712
NCT03049501,Caring for the Caregiver Network,,Completed,No Results Available,Caregivers of Alzheimer's Disease or Memory Problem Patients,Behavioral: Caregiving condition|Behavioral: Nutrition condition,Decrease in depression score as measured by CES-D|Decrease in caregiving burden as measured by Burden Inventory|Increase in caregiver's self report of Self-care|Improve in caregiver's self-report of Physical health|Improve caregiver's Self-efficacy|Improve positive aspects of caregiving,University of Miami|National Institute of Nursing Research (NINR),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,244,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",20130460|R01NR014434,Jul-13,20-Apr-18,20-Apr-18,10-Feb-17,null,15-May-18,"University of Miami Miller School of Medicine, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT03049501
NCT03046121,A Family-centered Intervention for Acutely-ill Persons With Dementia,,Recruiting,No Results Available,Alzheimer Disease,Behavioral: Family-centered Function-focused Care (Fam-FFC),physical function|functional performance|Physical activity|Delirium occurrence|Delirium severity|Behavior|Mood|Preparedness for caregiving|Caregiver Strain|Caregiver Burden|Desire to Institutionalize,Penn State University|National Institutes of Health (NIH),All,65 Years and older   (Older Adult),Not Applicable,438,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care",1R01AG054425-01A1,6-Nov-17,31-Jul-21,28-Feb-22,8-Feb-17,null,17-Jan-19,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03046121
NCT03044249,A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression,,Recruiting,No Results Available,Psychosis|Dementia|Aggression|Agitation|Alzheimer Dementia,Drug: MP-101|Drug: Placebo,Change from baseline in the Neuropsychiatric Inventory (NPI) - Psychosis subscale|Change from baseline in the Clinical Global Impression of Improvement (CGI-I)|Change from Baseline in NPI Total Score|Change from Baseline in NPI Core Total Score|Change from Baseline in NPI Caregiver Distress|Change from Baseline in NPI Domains|Number of Participants with any Treatment Emergent Adverse Event|Change from Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III|Population Pharmacokinetics: Plasma Levels of MP-101 and Metabolite,Mediti Pharma Inc.,All,"50 Years and older   (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MP-101-01,4-May-17,Jan-21,Jan-21,6-Feb-17,null,11-Feb-19,"Neuro-Therapeutics Inc, Pasadena, California, United States|Associated Neurologists of Southern CT, Fairfield, Connecticut, United States|Marcus Neuroscience Institute, Boca Raton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Galiz Research, Hialeah, Florida, United States|Galiz Research, Miami Springs, Florida, United States|CNS, Orlando, Florida, United States|Parkinson's Disease Treatment Center of SW Florida, Port Charlotte, Florida, United States|Meridien Research Inc, Saint Petersburg, Florida, United States|University of South Florida, Tampa, Florida, United States|College Park Family Care Neuro, Overland Park, Kansas, United States|J. Gary Booker, MD, Clinical Trials, Shreveport, Louisiana, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Clarity Clinical Research, East Syracuse, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Neurology Diagnostics Inc, Dayton, Ohio, United States|SKDS Research Inc., Newmarket, Ontario, Canada|Montreal Neurological Institute, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03044249
NCT03038035,The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study,ATHENE,Recruiting,No Results Available,Alzheimer Disease,Drug: MLC901|Drug: Placebo,"Evaluating the safety of MLC901 when it is given in combination with the standard treatment.The safety will be evaluated by adverse events, vital signs, ECG and laboratory tests, physical and neurological examinations at 6 months.|Evaluate the effect of MLC901 as add on therapy to standard treatments for 6 months on cognitive function in patients with mild to moderate AD using Alzheimer's Disease Assessment Scale- cognitive subscale (ADAS- Cog).|Evaluate the effect of MLC901 as add on therapy to standard treatments for 6 months on cognitive function in patients with mild to moderate AD using Mini Mental State Examination (MMSE).|Evaluate the long term safety of MLC901 as add-on treatment to standard treatments for up to 1 year in an open extension study with adverse events, vital signs, ECG and laboratory tests, physical and neurological examination at 1 year.|Evaluate the long term effect on disease progression of MLC901 as add-on treatment to standard treatments for up to 1 year in an open extension study by assessing Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (ADCS- CGIC).|Evaluate the long term effect on disease progression of MLC901 as add-on treatment to standard treatments for up to 1 year in an open extension study by assessing Alzheimer's Disease Cooperative Study- Activities of Daily Living Inventory (ADCS- ADL23)|Evaluate the long term effect on disease progression of MLC901 as add-on treatment to standard treatments for up to 1 year in an open extension study by assessing Neuropsychiatric Inventory (NPI).","National University Hospital, Singapore",All,"50 Years to 120 Years   (Adult, Older Adult)",Phase 2,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MLC901-2,Dec-16,Jun-18,Jun-19,31-Jan-17,null,31-Jan-17,"National University Hospital, Sg, Singapore",,https://ClinicalTrials.gov/show/NCT03038035
NCT03038282,Effects of Chromium on Insulin Resistance in Alzheimer Disease Patients,,Not yet recruiting,No Results Available,Alzheimer Disease,Dietary Supplement: Chromium Chloride|Other: Individual Exercise,Insulin Resistance|Change in chronic refractory mood disorders,Metabolic Therapy Inc.,All,65 Years and older   (Older Adult),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1R01TCR012617,20-Feb-17,20-Aug-19,20-Oct-19,31-Jan-17,null,31-Jan-17,,,https://ClinicalTrials.gov/show/NCT03038282
NCT03038334,Magnesium Sulfate for the Improvement of Cognition in Patients With Alzheimer Disease,,Not yet recruiting,No Results Available,Alzheimer Disease,Dietary Supplement: Magnesium sulfate,Change in amyloid deposit|Cognitive Function,Metabolic Therapy Inc.,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PR02TCR011-17,20-Feb-17,20-Aug-19,20-Oct-19,31-Jan-17,null,31-Jan-17,,,https://ClinicalTrials.gov/show/NCT03038334
NCT03035851,Aerobic Exercise for Older Adults at Increased Risk of Alzheimer's Disease and Related Dementias,BIMII,Recruiting,No Results Available,Alzheimer Disease|Dementia,Behavioral: Aerobic exercise|Behavioral: Stretch and Strength,"Change in Cognition Assessed by Neuropsychological Test Battery|Change in Cerebral Blood Flow Assessed by Transcranial Doppler Ultrasound|Change in Maximal Oxygen Uptake (VO2max) Assessed by Metabolic Cart|Change in Blood Biomarkers Assessed by Elisa Assays|Change in Risk/protective factors Assessed by Questionnaires|Change in Brain Structure and Function Assessed by Neuroimaging Modalities|Change in Sleep Quality Assessed by Polysomnography, Actigraphy and Questionnaires|Change in Health behaviour with appropriate support strategies",University of Calgary|Canadian Institutes of Health Research (CIHR),All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,264,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,REB 16-1199,Jan-17,Jun-20,Jan-21,30-Jan-17,null,16-Apr-19,"University of Calgary, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT03035851
NCT03036280,A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_,MissionAD2,Recruiting,No Results Available,Alzheimer's Disease,Drug: Elenbecestat (E2609)|Drug: Placebo,Change from Baseline in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score at 24 months|Time to worsening of Clinical Dementia Rating (CDR) score by 24 months|Time to conversion to dementia for participants who were not clinically staged as dementia at baseline based on clinical diagnosis|The rate of change over time (mean slope) based on the CDR-SB score over 24 months|Change from Baseline in CDR-SB at 27 months|Change from Baseline in the Alzheimer's Disease Assessment Scale-Cognition14 (ADAS-Cog14) score at 24 months|Change from Baseline in the Mini Mental State Examination (MMSE) score at 24 months|Change from Baseline in the Functional Assessment Questionnaire (FAQ) score at 24 months|Change from Baseline in ADAS-cog14 Word List (immediate recall and delayed recall) scores at 24 months,"Eisai Co., Ltd.|Biogen|Eisai Inc.",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1330,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E2609-G000-302|2016-004128-42,29-Dec-16,22-Jun-21,22-Jun-21,30-Jan-17,null,4-Feb-19,"Facility #1, Gilbert, Arizona, United States|Facility #1, Phoenix, Arizona, United States|Facility #1, Scottsdale, Arizona, United States|Facility #1, Little Rock, Arkansas, United States|Facility #1, Bellflower, California, United States|Facility #1, Glendale, California, United States|Facility #1, Irvine, California, United States|Facility #1, Laguna Hills, California, United States|Facility #1, Lomita, California, United States|Facility #1, Long Beach, California, United States|Facility #1, Los Angeles, California, United States|Facility #1, Oceanside, California, United States|Facility #1, Palo Alto, California, United States|Facility #1, Riverside, California, United States|Facility #2, Santa Ana, California, United States|Facility #1, Santa Ana, California, United States|Facility #1, Santa Monica, California, United States|Facility #1, New Haven, Connecticut, United States|Facility #1, Stamford, Connecticut, United States|Facility #1, Aventura, Florida, United States|Facility #1, Bradenton, Florida, United States|Facility #1, Doral, Florida, United States|Facility #1, Hialeah, Florida, United States|Facility #2, Hialeah, Florida, United States|Facility #2, Jacksonville, Florida, United States|Facility #1, Lake Worth, Florida, United States|Facility #1, Maitland, Florida, United States|Facility #1, Melbourne, Florida, United States|Facility #1, Miami Lakes, Florida, United States|Facility #1, Miami Springs, Florida, United States|Facility #10, Miami, Florida, United States|Facility #2, Miami, Florida, United States|Facility #7, Miami, Florida, United States|Facility #4, Miami, Florida, United States|Facility #6, Miami, Florida, United States|Facility #5, Miami, Florida, United States|Facility #3, Miami, Florida, United States|Facility #1, Miami, Florida, United States|Facility #2, Miami, Florida, United States|Facility #8, Miami, Florida, United States|Facility #9, Miami, Florida, United States|Facility #1, North Miami, Florida, United States|Facility #1, Ocala, Florida, United States|Facility #1, Orange City, Florida, United States|Facility #1, Orlando, Florida, United States|Facility #1, Ormond Beach, Florida, United States|Facility #1, Palmetto Bay, Florida, United States|Facility #1, Pembroke Pines, Florida, United States|Facility #1, Pinellas Park, Florida, United States|Facility #1, Saint Petersburg, Florida, United States|Facility #1, West Palm Beach, Florida, United States|Facility #1, Decatur, Georgia, United States|Facility #1, Newnan, Georgia, United States|Facility #1, Chicago, Illinois, United States|Facility #1, Elk Grove Village, Illinois, United States|Facility #1, Schaumburg, Illinois, United States|Facility #1, Wichita, Kansas, United States|Facility #1, Baton Rouge, Louisiana, United States|Facility #1, Plymouth, Massachusetts, United States|Facility #1, Hattiesburg, Mississippi, United States|Facility #1, Creve Coeur, Missouri, United States|Facility #1, Las Vegas, Nevada, United States|Facility #1, Toms River, New Jersey, United States|Facility #2, Toms River, New Jersey, United States|Facility #1, Albany, New York, United States|Facility #1, Glens Falls, New York, United States|Facility #1, Manhasset, New York, United States|Facility #1, Woodmere, New York, United States|Facility #1, Charlotte, North Carolina, United States|Facility #2, Charlotte, North Carolina, United States|Facility #1, Beachwood, Ohio, United States|Facility #1, Oklahoma City, Oklahoma, United States|Facility #1, Medford, Oregon, United States|Facility #1, Portland, Oregon, United States|Facility #1, Norristown, Pennsylvania, United States|Facility #1, Plains, Pennsylvania, United States|Facility #1, Knoxville, Tennessee, United States|Facility #1, Dallas, Texas, United States|Facility #1, DeSoto, Texas, United States|Facility #1, Greenville, Texas, United States|Facility #2, Greenville, Texas, United States|Facility #1, Houston, Texas, United States|Facility #1, Houston, Texas, United States|Facility #1, Mansfield, Texas, United States|Facility #1, Salt Lake City, Utah, United States|Facility #1, West Jordan, Utah, United States|Facility #2, Richmond, Virginia, United States|Facility #1, Richmond, Virginia, United States|Facility #1, Chatham, Ontario, Canada|Facility #3, Toronto, Ontario, Canada|Facility #1, Toronto, Ontario, Canada|Facility #1, Gatineau, Quebec, Canada|Facility #1, Greenfield Park, Quebec, Canada|Facility #1, Sherbrooke, Quebec, Canada|Facility #1, Verdun, Quebec, Canada|Facility #1, Santiago, Metropolitan Region, Chile|Facility #2, Santiago, Metropolitan Region, Chile|Facility #4, Santiago, Metropolitan Region, Chile|Facility #3, Santiago, Metropolitan Region, Chile|Facility #1, Antofagasta, Chile|Facility #3, Beijing, Beijing, China|Facility #5, Beijing, Beijing, China|Facility #2, Beijing, Beijing, China|Facility #1, Beijing, Beijing, China|Facility #4, Beijing, Beijing, China|Facility #7, Beijing, Beijing, China|Facility #8, Beijing, Beijing, China|Facility #6, Beijing, Beijing, China|Facility #1, Chongqing, Chongqing, China|Facility #1, Fuzhou, Fujian, China|Facility #1, Guangzhou, Guangdong, China|Facility #2, Guangzhou, Guangdong, China|Facility #5, Guangzhou, Guangdong, China|Facility #4, Guangzhou, Guangdong, China|Facility #3, Guangzhou, Guangdong, China|Facility #1, Shenzhen, Guangdong, China|Facility #1, Zhengzhou, Henan, China|Facility #1, Changchun, Jilin, China|Facility #1, Xi'ning City, Qinghai, China|Facility #1, Shanghai, Shanghai, China|Facility #3, Shanghai, Shanghai, China|Facility #7, Shanghai, Shanghai, China|Facility #4, Shanghai, Shanghai, China|Facility #2, Shanghai, Shanghai, China|Facility #1, Taiyuan, Shanxi, China|Facility #1, Xi'an, Shanxi, China|Facility #1, Chengdu, Sichuan, China|Facility #1, Tianjin, Tianjin, China|Facility #2, Hangzhou, Zheijang, China|Facility #1, Hangzhou, Zheijang, China|Facility #5, Shanghai, China|Facility #1, Zagreb, Croatia|Facility #2, Zagreb, Croatia|Facility #3, Zagreb, Croatia|Facility #4, Zagreb, Croatia|Facility #1, Brno, Czechia|Facility #2, Brno, Czechia|Facility #1, Praha 10, Czechia|Facility #1, Praha 6, Czechia|Facility #1, Rychnov nad Kneznou, Czechia|Facility #1, Ballerup, Copenhagen, Denmark|Facility #1, Vejle, Region Sonerjylland, Denmark|Facility #1, Aalborg, Denmark|Facility #1, Helsinki, Finland|Facility #1, Kuopio, Finland|Facility #1, Oulu, Finland|Facility #1, Turku, Finland|Facility #1, Aix-en-Provence, France|Facility #1, Limoges, France|Facility #1, Nice, France|Facility #1, Paris, France|Facility #1, Rouen, France|Facility #1, TOURS Cedex, France|Facility #1, Vienne, France|Facility #1, Villefranche-sur-Saône, France|Facility #1, Villeurbanne, France|Facility #1, Mannheim, Baden Wurttemberg, Germany|Facility #1, Muenchen, Bavaria, Germany|Facility #1, Munchen, Bayern, Germany|Facility #1, Koeln, Deutschland, Germany|Facility #1, Schwerin, Mecklenburg Vorpommern, Germany|Facility #1, Siegen, North Rhine-Westphalia, Germany|Facility #1, Mittweida, Saxony, Germany|Facility #1, Bochum, Germany|Facility #1, Freiburg, Germany|Facility #1, Hamburg, Germany|Facility #1, Ulm, Germany|Facility #1, Komarom, Esztergom, Hungary|Facility #2, Budapest, Hungary|Facility #1, Budapest, Hungary|Facility #1, Udine, Friuli-Venezia Giulia, Italy|Facility #1, Cefalu, Palermo, Italy|Facility #1, Ancona, Italy|Facility #2, Brescia, Italy|Facility #1, Chieti, Italy|Facility #3, Milano, Italy|Facility #2, Milano, Italy|Facility #1, Milano, Italy|Facility #1, Orbassano, Italy|Facility #1, Pisa, Italy|Facility #1, Pozzilli, Italy|Facility #1, Roma, Italy|Facility #2, Rome, Italy|Facility #1, Rome, Italy|Facility #1, Salerno, Italy|Facility #1, Torino, Italy|Facility #1, Verona, Italy|Facility #2, Verona, Italy|Eisai Trial Site 1, Nagoya, Aichi, Japan|Eisai Trial Site 1, Hirosaki-city, Aomori, Japan|Eisai Trial Site 2, Chiba-shi, Chiba, Japan|Eisai Trial Site 1, Chiba-shi, Chiba, Japan|Eisai Trial Site 1, Inzai, Chiba, Japan|Eisai Trial Site 1, Urayasu, Chiba, Japan|Eisai Trial Site 1, Koriyama, Fukushima, Japan|Eisai Trial Site 1, Isezaki-city, Gunma, Japan|Eisai Trial Site 1, Maebashi city, Gunma, Japan|Eisai Trial Site 3, Sapporo-shi, Hokkaido, Japan|Eisai Trial Site 2, Sapporo-shi, Hokkaido, Japan|Eisai Trial Site 1, Sapporo, Hokkaido, Japan|Eisai Trial Site 1, Toride, Ibaraki, Japan|Eisai Trial Site 1, Kanazawa-shi, Ishikawa, Japan|Eisai Trial Site 1, Morioka-shi, Iwate, Japan|Eisai Trial Site 1, Atsugi-shi, Kanagawa, Japan|Eisai Trial Site 1, Fujisawa-shi, Kanagawa, Japan|Eisai Trial Site 1, Kamakura-shi, Kanagawa, Japan|Eisai Trial Site 1, Kawasaki-shi, Kanagawa, Japan|Eisai Trial Site 1, Yokohama, Kanagawa, Japan|Eisai Trial Site 2, Yokohama, Kanagawa, Japan|Eisai Trial Site 1, Nagaoka, Niigata, Japan|Eisai Trial Site 1, Iruma-gun, Saitama, Japan|Eisai Trial Site 1, Kasukabe City, Saitama, Japan|Eisai Trial Site 1, Koshigaya-shi, Saitama, Japan|Eisai Trial Site 2, Koshigaya-shi, Saitama, Japan|Eisai Trial Site 1, Saitama city, Saitama, Japan|Eisai Trial Site 1, Shizuoka-city, Shizuoka, Japan|Eisai Trial Site 1, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 2, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 3, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 4, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 1, Hachioji, Tokyo, Japan|Eisai Trial Site 1, Katsushika-ku, Tokyo, Japan|Eisai Trial Site 1, Koto-ku, Tokyo, Japan|Eisai Trial Site 1, Minato-ku, Tokyo, Japan|Eisai Trial Site 1, Minato-ku, Tokyo, Japan|Eisai Trial Site 1, Mitaka City, Tokyo, Japan|Eisai Trial Site 1, Nerima-ku, Tokyo, Japan|Eisai Trial Site 2, Ota-ku, Tokyo, Japan|Eisai Trial Site 1, Ota-ku, Tokyo, Japan|Eisai Trial Site 1, Shibuya-ku, Tokyo, Japan|Eisai Trial Site 1, Shinagawa-ku, Tokyo, Japan|Eisai Trial Site 2, Shinagawa-ku, Tokyo, Japan|Eisai Trial Site 2, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site 1, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site 1, Chuo-ku, Japan|Facility #1, Seongnam, Gyeonggi, Korea, Republic of|Facility #1, Gwangju-si, Korea, Republic of|Facility #1, Incheon, Korea, Republic of|Facility #6, Seoul, Korea, Republic of|Facility #5, Seoul, Korea, Republic of|Facility #1, Seoul, Korea, Republic of|Facility #4, Seoul, Korea, Republic of|Facility #2, Seoul, Korea, Republic of|Facility #3, Seoul, Korea, Republic of|Facility #1, Guadalajara, Jalisco, Mexico|Facility #1, Monterrey, Nuevo Leon, Mexico|Facility #2, Monterrey, Nuevo Leon, Mexico|Facility #1, Mexico City, Mexico|Facility #1, Katowice, Silesia, Poland|Facility #1, Bialystok, Poland|Facility #1, Bydgoszcz, Poland|Facility #1, Krakow, Poland|Facility #2, Krakow, Poland|Facility #1, Pruszcz Gdanski, Poland|Facility #1, Warszawa, Poland|Facility #1, Guimaräes, Creixomil, Portugal|Facility #1, Braga, Portugal|Facility #1, Matosinhos, Portugal|Facility #1, Santa Maria da Feira, Portugal|Facility #1, Torres Vedras, Portugal|Facility #1, Singapore, Singapore|Facility #2, Singapore, Singapore|Facility #1, Svidnik, Slovak Republic, Slovakia|Facility #1, Banska Bystrica, Slovakia|Facility #2, Bratislava, Slovakia|Facility #1, Bratislava, Slovakia|Facility #3, Bratislava, Slovakia|Facility #1, Dubnica nad Vahom, Slovakia|Facility #1, Kosice, Slovakia|Facility #1, Rimavska Sobota, Slovakia|Facility #1, Roznava, Slovakia|Facility #1, Pinelands, Cape Town, South Africa|Facility #1, Johannesburg, Gauteng, South Africa|Facility #2, Cape Town, Western Cape, South Africa|Facility #1, Cape Town, Western Cape, South Africa|Facility #1, George, Western Cape, South Africa|Facility #1, Córdoba, Andalucia, Spain|Facility #2, Barcelona, Catalunya, Spain|Facility #1, San Sebastian, Gipuzkoa, Spain|Facility #1, Castilla Y Leon, Zamora, Spain|Facility #3, Barcelona, Spain|Facility #1, Barcelona, Spain|Facility #1, Madrid, Spain|Facility #4, Madrid, Spain|Facility #2, Madrid, Spain|Facility #3, Madrid, Spain|Facility #1, Salamanca, Spain|Facility #1, Sevilla, Spain|Facility #1, Changhua County, Taiwan|Facility #1, Changhua, Taiwan|Facility #2, Kaohsiung City, Taiwan|Facility #1, New Taipei City, Taiwan|Facility #1, Taichung City, Taiwan|Facility #1, Tainan City, Taiwan|Facility #2, Tainan City, Taiwan|Facility #1, Taipei, Taiwan|Facility #2, Taipei, Taiwan|Facility #1, Taiwan, Taiwan|Facility #1, Taoyuan City, Taiwan|Facility #1, Birmingham, United Kingdom|Facility #1, Guildford, United Kingdom",,https://ClinicalTrials.gov/show/NCT03036280
NCT03033875,"Testing Tele-Savvy, an On-line Psychoeducation Program for Dementia Family Caregivers",,Recruiting,No Results Available,Alzheimer Disease|Dementia,Behavioral: Tele-Savvy|Behavioral: Healthy Living Education Program,Change in Cornell Scale for Depression in Dementia (CSDD) Score|Change in Alzheimer's Disease Related Quality of Life (ADRQL) Score|Change in Perceived Stress Scale (PSS) Score|Change in Center for Epidemiological Studies Depression Scale - Revised (CESD-R) Score|Change in State-Trait Anxiety Inventory (STAI) Score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety - short form Score|Change in Zarit Burden Inventory (ZBI) Score|Change in Dyadic Relationship Scale Score|Change in Ways of Coping Scale Score|Change in Revised Memory and Behavior Problem Checklist (RMBPC) Score|Change in Self-Rated Health Score|Change in the Caregiver Assessment of Behavioral Skill - Self Report (CAB-SR) Measure Score|Change in the Pearlin Measure Score,Emory University|National Institute on Aging (NIA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,IRB00092812|1R01AG054079-01,18-May-17,30-Nov-20,30-Nov-20,27-Jan-17,null,25-Jun-18,"Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03033875
NCT03034746,Impact of Physical Activity on Successful Aging,,Completed,No Results Available,Alzheimer Disease|Cognitive Impairment|Physical Activity,Other: Physical activity (PA)|Other: cognitive treatment (CT),Mini Mental State Examination|Trail Making Test|Rivermead Behavioral Memory Test|Tower of London|Dual Task|Frontal Assessment Battery|Attention Matrix|Alzheimer's Disease Assessment Scale|6-Minute Walking Test|gait analysis by GAITRite® System|stabilometric assessments with Stability Line|Instrumental Activity in Daily Living Scale (IADL)|Neuropsychiatric Inventory Scale (NPI)|cerebral circulation|peripheral vascular function,Universita di Verona,All,65 Years to 90 Years   (Older Adult),Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PRIN_2010,Sep-13,May-16,Oct-16,27-Jan-17,null,30-Jan-17,,,https://ClinicalTrials.gov/show/NCT03034746
NCT03031184,Study of Mirtazapine for Agitation in Dementia,SYMBAD,Recruiting,No Results Available,Dementia,Drug: Mirtazapine|Other: Placebo,"Cohen Mansfield Agitation Inventory (CMAI) score (Long Form, 29 questions)","University of Sussex|Norwich Clinical Trials Unit|University of East Anglia|University of Cambridge|University College, London|London School of Economics and Political Science|University of Manchester|University of Newcastle Upon-Tyne|Birmingham and Solihull Mental Health NHS Foundation Trust|Alzheimer's Society|The Centre for Dementia Studies, Brighton and Sussex Medical School and SPFT",All,"18 Years and older   (Adult, Older Adult)",Phase 3,222,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15/SC/0606,Jan-17,Jan-20,Jul-20,25-Jan-17,null,28-Nov-18,"Sube Banerjee, Brighton, Sussex, United Kingdom",,https://ClinicalTrials.gov/show/NCT03031184
NCT03030105,Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers,,Completed,No Results Available,Alzheimer Disease,Drug: BPN14770|Drug: BPN14770 placebo|Drug: Donepezil|Drug: Donepezil placebo|Drug: Scopolamine 0.6 MG/ML|Drug: Scopolamine placebo,Groton Maze Learning Test (GMLT),Tetra Discovery Partners,All,18 Years to 55 Years   (Adult),Phase 1,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BPN14770-CNS-103,Jan-17,May-17,Jun-17,24-Jan-17,null,16-Oct-18,"ICON Early Phase Services, LLC, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT03030105
NCT03024944,TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind,TAUPET,Withdrawn,No Results Available,Diabetes Mellitus|Alzheimer Dementia,Drug: 18F-THK-5351,Amount of Tau Accumulation by Measuring Standardized Uptake Value Ratio (SUVR),Columbia University|National Institute on Aging (NIA),All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 2,0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AAAR1419|3R01AG050440,Dec-17,Jan-19,Jan-20,19-Jan-17,null,29-Dec-17,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03024944
NCT03022968,Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD),TEPTAU,Unknown status,No Results Available,Alzheimer Disease|Benson's Disease,Drug: [18F]T807 PET,Tau density on PET imaging|Tau distribution on PET imaging|p-tau CSF biomarkers|βamyloid CSF biomarkers|Cognitive profile with Hamilton depression scale (MADRS)|Cognitive profile with Mini mental state evaluation (MMSE),"University Hospital, Tours",All,"50 Years and older   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PHAO14-CH/TEPTAU,10-Jan-17,Jun-18,Sep-18,18-Jan-17,null,23-Feb-17,"University Hospital of Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT03022968
NCT03019536,A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer Disease,Drug: LY3303560 - IV|Drug: Placebo - IV|Drug: Florbetapir F 18|Drug: Flortaucipir F18,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics: Maximum Serum Concentration (Cmax) of LY3303560|Pharmacokinetics: Area Under the Serum Concentration Time Curve During the Dosing Interval (AUC) of LY3303560,Eli Lilly and Company,All,"50 Years and older   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",16452|I8G-MC-LMDD|2016-002102-39,31-Jan-17,4-Jun-19,5-Jun-20,12-Jan-17,null,4-Dec-18,"Bioclinica, Melbourne, Florida, United States|Bioclinica, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Bioclinica, The Villages, Florida, United States|Princeton Medical Institute, Princeton, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Bunkyo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kurume, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Bath, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03019536
NCT03016702,The Cognitive Resilience Study,CogRes,Completed,No Results Available,Alzheimer Disease,Other: Cognitive stress tests during functional MRI|Other: Cognitive stress tests during gait task,Change in reaction time during memory testing during fMRI|Change in reaction time during executive function testing during fMRI|Change in accuracy during memory testing during gait task|Change in reaction time during executive function testing during gait task|Change in accuracy during memory testing during fMRI|Change in accuracy during executive function testing during fMRI|Brain activation during memory testing during fMRI|Brain activation during executive function testing during fMRI|Change in gait performance provoked by memory dual tasking|Change in gait performance provoked by executive function dual tasking,Duke University|National Institute on Aging (NIA)|Bryan Alzheimer's Disease Research Center|Duke University Center for the Study of Aging and Human Development,All,"58 Years to 70 Years   (Adult, Older Adult)",Not Applicable,29,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",Pro00078117|P30AG028716-11S1|SPS # 224571,27-Feb-17,9-Aug-17,9-Aug-17,10-Jan-17,null,14-Aug-17,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03016702
NCT03011723,Tailored Music Therapy for Dementia,,Recruiting,No Results Available,"Alzheimer Dementia|Dementia, Vascular|Dementia, Lewy Body|Dementia Parkinson's Disease",Behavioral: Resource oriented music therapy,Change in communication behavior throughout the music therapy session compared to baseline(Communication in Dementia (CODEM))|Change in observed expression of emotion throughout the music therapy session compared to baseline(The Observed Emotion Rating Scale (OERS))|Change in self reported mood before and after the music therapy session (Visual Analogue Mood Scale (VAMS))|Change in Neuropsychiatric symptoms (NPI-Q)|Change in Quality of life in Alzheimer Dementia (QoL-AD)|Change in Relative Stress Scale (RSS)|Change in Music in Dementia Assessment Scales (MiDAS),University of Bergen|NKS Olaviken Alderspsykiatriske sykehus,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,UBergen 2016/1374,Jan-17,Apr-19,Apr-21,5-Jan-17,null,7-May-18,"NKS Olaviken Alderspsykiatriske sykehus, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT03011723
NCT03008161,Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer Disease,Drug: NPT088|Drug: Placebo,Number of patients with adverse events|Multiple dose pharmacokinetic (PK) serum concentrations of NPT088|Multiple dose PK CSF concentrations of NPT088|Multiple dose immunogenicity of NPT088,"Proclara Biosciences, Inc.|Alzheimer's Association",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,83,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NPT088-CL002,Dec-16,8-Feb-19,Apr-19,2-Jan-17,null,19-Mar-19,"ATP Clinical Research, Inc., Costa Mesa, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Southern California Research, Simi Valley, California, United States|Associated Neurologists of Southern Connecticut, Fairfield, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Indago Research and Health Center, Hialeah, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Compass Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Axiom Clinical Research, Tampa, Florida, United States|Compass-The Villages, The Villages, Florida, United States|Medical Research and Health Education Foundation, Columbus, Georgia, United States|NeuroStudies LLC, Decatur, Georgia, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Neurological Associates of Albany, Albany, New York, United States|Integrative Clinical Trials, Inc., Brooklyn, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Abington Neurological Associates, Ltd, Willow Grove, Pennsylvania, United States|Neurology Clinic, PC, Cordova, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03008161
NCT03001557,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,,"Active, not recruiting",No Results Available,Irregular Sleep-Wake Rhythm Disorder,Drug: Lemborexant 2.5 mg|Drug: Lemborexant 5 mg|Drug: Lemborexant 10 mg|Drug: Lemborexant 15 mg|Drug: Lemborexant-matched placebo,Change From Baseline of Mean Sleep Fragmentation Index (SFI) During Week 1 of Treatment|Change From Baseline of Mean SFI During Week 2 of Treatment|Change From Baseline of Mean SFI During Week 3 of Treatment|Change From Baseline of Mean SFI During Week 4 of Treatment|Change From Baseline of Mean Wake Fragmentation Index (WFI) During Week 1 of Treatment|Change From Baseline of Mean WFI During Week 2 of Treatment|Change From Baseline of Mean WFI During Week 3 of Treatment|Change From Baseline of Mean WFI During Week 4 of Treatment|Change From Baseline in the Mean Duration of Sleep Bouts (aMeanDurSB) During Week 1 of Treatment|Change From Baseline in the aMeanDurSB During Week 2 of Treatment|Change From Baseline in the aMeanDurSB During Week 3 of Treatment|Change From Baseline in the aMeanDurSB During Week 4 of Treatment|Change From Baseline in the Mean Duration of Wake Bouts (aMeanDurWB) During Week 1 of Treatment|Change From Baseline in the aMeanDurWB During Week 2 of Treatment|Change From Baseline in the aMeanDurWB During Week 3 of Treatment|Change From Baseline in the aMeanDurWB During Week 4 of Treatment|Change From Baseline of Mean Actigraphy Sleep Efficiency (aSE) During Week 1 of Treatment|Change From Baseline of Mean aSE During Week 2 of Treatment|Change From Baseline of Mean aSE During Week 3 of Treatment|Change From Baseline of Mean aSE During Week 4 of Treatment|Change From Baseline of Mean Actigraphy Wake Efficiency (aWE) During Week 1 of Treatment|Change From Baseline of Mean aWE During Week 2 of Treatment|Change From Baseline of Mean aWE During Week 3 of Treatment|Change From Baseline of Mean aWE During Week 4 of Treatment|Change From Baseline in Intradaily Variability (IV) Over Week 1 of Treatment|Change From Baseline in IV Over Week 2 of Treatment|Change From Baseline in IV Over Week 3 of Treatment|Change From Baseline in IV Over Week 4 of Treatment|Change From Baseline in Interdaily Stability (IS) Over Week 1 of Treatment|Change From Baseline in IS Over Week 2 of Treatment|Change From Baseline in IS Over Week 3 of Treatment|Change From Baseline in IS Over Week 4 of Treatment|Change From Baseline in the Activity Across the Least Active 5-hour Period per 24-hour Period (L5) Over Week 1 of Treatment|Change From Baseline in the Activity Across the Least Active 5-hour Period per 24-hour Period (L5) Over Week 2 of Treatment|Change From Baseline in the Activity Across the Least Active 5-hour Period per 24-hour Period (L5) Over Week 3 of Treatment|Change From Baseline in the Activity Across the Least Active 5-hour Period per 24-hour Period (L5) Over Week 4 of Treatment|Change From Baseline in the Activity During the Most Active 10-hour Period per 24-hour Period (Mean M10) Over Week 1 of Treatment|Change From Baseline in the Activity During the Most Active 10-hour Period per 24-hour Period (Mean M10) Over Week 2 of Treatment|Change From Baseline in the Activity During the Most Active 10-hour Period per 24-hour Period (Mean M10) Over Week 3 of Treatment|Change From Baseline in the Activity During the Most Active 10-hour Period per 24-hour Period (Mean M10) Over Week 4 of Treatment|Change From Baseline in the Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 (AMP) Over Week 1 of Treatment|Change From Baseline in the Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 (AMP) Over Week 2 of Treatment|Change From Baseline in the Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 (AMP) Over Week 3 of Treatment|Change From Baseline in the Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 (AMP) Over Week 4 of Treatment|Change From Baseline in the Relative Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 Divided by M10 Plus L5 (RA) Over Week 1 of Treatment|Change From Baseline in the Relative Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 Divided by M10 Plus L5 (RA) Over Week 2 of Treatment|Change From Baseline in the Relative Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 Divided by M10 Plus L5 (RA) Over Week 3 of Treatment|Change From Baseline in the Relative Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 Divided by M10 Plus L5 (RA) Over Week 4 of Treatment|Change From Baseline in the Neuropsychiatric Inventory (NPI-10) Total Score at Day 29|Change From Baseline in the Sleep Disorders Inventory (SDI) Score at Day 29|Number of Participants in Each Category of the Clinician's Global Impression of Change Irregular Sleep-Wake Rhythm Disorder (CGIC-ISWRD) Scale Overall Score at Day 29|Number of Participants With any Non-serious Adverse Event or any Serious Adverse Event,Eisai Inc.|Purdue Pharma LP,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E2006-G000-202|2017-003306-40,20-Dec-16,26-Jul-18,9-Apr-20,23-Dec-16,null,28-Aug-18,"Facility #1, Little Rock, Arkansas, United States|Facility #1, Rogers, Arkansas, United States|Facility #1, Springdale, Arkansas, United States|Facility #1, Costa Mesa, California, United States|Facility #1, Fullerton, California, United States|Facility #1, Glendale, California, United States|Facility #1, La Jolla, California, United States|Facility #1, San Diego, California, United States|Facility #1, Bradenton, Florida, United States|Facility #1, Brandon, Florida, United States|Facility #1, Brooksville, Florida, United States|Facility #1, Hallandale Beach, Florida, United States|Facility #1, Hialeah, Florida, United States|Meridien Research, Lakeland, Florida, United States|Facility #1, Miami Lakes, Florida, United States|Facility #1, Miami, Florida, United States|Facility #1, Miami, Florida, United States|Facility #1, Sunrise, Florida, United States|Facility #2, Tampa, Florida, United States|Facility #1, Atlanta, Georgia, United States|Facility #1, Columbus, Georgia, United States|Facility #1, Macon, Georgia, United States|Facility #1, Wichita, Kansas, United States|Facility #1, Belmont, Massachusetts, United States|Nevada Senior Services (NSS) Adult Day Care Center, Henderson, Nevada, United States|Facility #1, Las Vegas, Nevada, United States|Facility #1, Toms River, New Jersey, United States|Facility #2, Toms River, New Jersey, United States|Facility #1, Charlotte, North Carolina, United States|Facility #1, Raleigh, North Carolina, United States|Facility #1, Norristown, Pennsylvania, United States|Facility #1, Willow Grove, Pennsylvania, United States|Facility #1, Columbia, South Carolina, United States|Eisai Trial Site #1, Fujisawa, Kanagawa, Japan|Eisai Trial Site #1, Kawasaki-shi, Kanagawa, Japan|Eisai Trial Site #1, Wako, Saitama, Japan|Eisai Trial Site #1, Bunkyō-Ku, Tokyo, Japan|Eisai Trial Site #1, Kodaira, Tokyo, Japan|Eisai Trial Site #1, Setagaya, Tokyo, Japan|Eisai Trial Site #1, Shinjuku, Tokyo, Japan|Eisai Trial Site #1, Tachikawa-shi, Tokyo, Japan|Cognitive Treatment and Research Unit, Crowborough, East Sussex, United Kingdom|West London Cognitive Disorders Treatment and Research Unit, Isleworth, Hounslow, United Kingdom|University of Edinburgh - PPDS, Edinburgh, United Kingdom",,https://ClinicalTrials.gov/show/NCT03001557
NCT03002142,Auditory Rehabilitation and Cognition in Alzheimer Patients,RACO-MA,Recruiting,No Results Available,Alzheimer's Disease|Hearing Loss,Device: Hearing aids|Device: Placebo,"Changing score in Cognitive functions measured with Alzheimer's Disease Assessment Scale-cognitive scale|air and bone auditory thresholds (dB HL) measured at 500, 1000, 2000, 3000 and 4000 Hz|Speech recognition threshold (dB HL) measured by speech audiometry|Speech Discrimination Test (%) measured by speech audiometry|Dichotic test measured with audiometry|Amplification with hearing aids or placebo devices measured by tonal and speech audiometry (dB HL)|Devices tolerance measured with number of hours per day with hearing aids|Objective auditory thresholds measured with auditory brainstem responses (ms)|Objective auditory thresholds measured by Auditory steady state responses (in dB eHL)|Mini Mental State Examination (30 items, total score from 0-30)|Hearing Handicap Inventory for Elderly measured by questionnaire (10 items, total score from 0-40)|Hearing loss impact scale in adults measured by 2 questionnaire (Abbreviated Profile of Hearing Aid Benefit, 24 items) and Impact of hearing loss in adults (20 items, total score from 0-200)|Quality of life-Alzheimer disease scale measured by questionnaire (total score from 13-52)|Assessing caregiver burden measured by Zarit scale (22 items, total score from 0-88)|Depression in the elderly measured by Geriatric depression scale (30 items, total score from 0-30)|Executive functions measured by trail making test|Working memory and processing speed measured by Wechsler Adult Intelligence Scale|Speech comprehension measured by Beauregard tests|Hearing aids tolerance measured by Glagow hearing-aid benefit questionnaire","University Hospital, Tours",All,65 Years and older   (Older Adult),Not Applicable,184,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PHRI15-DB/RACO-MA,31-Mar-17,Feb-20,Feb-20,23-Dec-16,null,4-Aug-17,"FRANCE, France, Hopital Bretonneau, France",,https://ClinicalTrials.gov/show/NCT03002142
NCT03001232,The Effect of Movement-oriented Dementia Care on ADL and QoL of Dementia Patients in Nursing Homes,Solis MDC,Completed,No Results Available,Dementia,Behavioral: Movement-oriented Dementia Care,"Change from Baseline in Activities of Daily Living (ADL), measured with the Barthel Index.|Change from Baseline in Quality of Life (QoL), measured with the Qualidem|Change from Baseline in general cognitive functions, measured with the Severe Impairment Battery 8 (SIB-8).|Change from Baseline in mood, measured with the Cornell Scale for Depression in Dementia (CSDD).|Change from Baseline in behaviour, measured with the Apathy Evaluation Scale-10 (AES-10).|Change from Baseline in behaviour, measured with the Cohen-Mansfield Agitation Inventory (CMAI).|Change from Baseline in aerobic fitness, measured with the two minute walking test (2mWT).|Change from Baseline in functional mobility and fall risk, measured with the Timed up and go (TUG).|Change from Baseline in walking speed, measured with the ten meter timed walk.",VU University of Amsterdam|Zorggroep Solis,All,65 Years and older   (Older Adult),Not Applicable,66,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,METc Vumc: 2013.311/A2015.245,Mar-14,Mar-15,Mar-15,22-Dec-16,null,3-Feb-17,,,https://ClinicalTrials.gov/show/NCT03001232
NCT02997982,Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease,VALZ-Pilot,Recruiting,No Results Available,Alzheimer Disease|Mild Cognitive Impairment|Herpes Simplex,Drug: Valaciclovir 500Mg Tablet,Cerebrospinal fluid (CSF) Total Tau|Cerebrospinal fluid (CSF) Neurofilament light chain (NFL)|Cerebrospinal fluid (CSF) phosphorylated Tau (p-Tau)|Cerebrospinal fluid (CSF) Amyloid beta 1-42|PET/CT: [18F]-FHBG accumulation within the central nervous system (CNS)|PET/CT: Location of [18F]-FHBG accumulation|PET/CT: [18F]-FHBG accumulation|Mini Mental State Examination - Swedish Revision (MMSE-SR)|Cerebrospinal fluid (CSF) acyclovir concentration|Cerebrospinal fluid (CSF) 9-carboxymethoxymethylguanine (CMMG) concentration|Serum acyclovir concentration|Serum 9-carboxymethoxymethylguanine (CMMG) concentration|Proportion completing the [18F]-FHBG-PET/CT investigations|Proportion completing the 28 days treatment with valaciclovir at specified doses,Hugo Lovheim|Umeå University,All,65 Years and older   (Older Adult),Phase 2,36,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UmU-2016-390-31M|2016-002317-22,Dec-16,Apr-19,Apr-19,20-Dec-16,null,2-May-18,"Geriatric Centre, University Hospital in Umeå, Umeå, Västerbotten, Sweden",,https://ClinicalTrials.gov/show/NCT02997982
NCT02992132,Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE),,Terminated,Has Results,Agitation and Aggression in Alzheimer's Disease,Drug: Pimavanserin 34 mg|Drug: Pimavanserin 20 mg|Other: Placebo,Cohen-Mansfield Agitation Inventory (CMAI)|Zarit Burden Interview,ACADIA Pharmaceuticals Inc.,All,"50 Years and older   (Adult, Older Adult)",Phase 2,111,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ACP-103-032|2016-001127-32,Nov-16,25-Jan-18,16-Feb-18,14-Dec-16,28-Mar-19,28-Mar-19,"Costa Mesa, California, United States|Fresno, California, United States|Fullerton, California, United States|Los Angeles, California, United States|Pasadena, California, United States|San Diego, California, United States|Danbury, Connecticut, United States|Washington, District of Columbia, United States|Boca Raton, Florida, United States|Deerfield Beach, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|Atlanta, Georgia, United States|Bangor, Maine, United States|Quincy, Massachusetts, United States|Clinton Township, Michigan, United States|Flowood, Mississippi, United States|Jackson, Mississippi, United States|Eatontown, New Jersey, United States|Marlton, New Jersey, United States|Toms River, New Jersey, United States|Albuquerque, New Mexico, United States|Charlotte, North Carolina, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Jenkintown, Pennsylvania, United States|Norristown, Pennsylvania, United States|Willow Grove, Pennsylvania, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|DeSoto, Texas, United States|Salt Lake City, Utah, United States|Spokane, Washington, United States|Valdivia, Los Rios, Chile|Antofagasta, Chile|Santiago, Chile|Santiago, Chile|Toulouse, Cedex 9, France|Paris, France|Saint-Herblain, France|Strasbourg, France|Villeurbanne, France|Algorta, Vizcaya, Spain|Córdoba, Spain|Elche, Spain|Madrid, Spain|Palma de Mallorca, Spain|Pamplona, Spain|Santa Coloma De Gramenet, Spain|Terrassa, Spain|Zaragoza, Spain|Swindon, Wiltshire, United Kingdom|Bath, United Kingdom|Isleworth, United Kingdom|Manchester, United Kingdom|Northampton, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02992132/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02992132/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02992132
NCT02991235,Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer Disease,Dietary Supplement: PRJ212|Dietary Supplement: Placebo,Efficacy of PRJ212 versus placebo on the memory measured by Repeatable Battery for the Assessment of Neuropsychological Status (R-BANS).|Efficacy of PRJ212 versus placebo on the memory measured by Wechsler Memory Scale (WMS).|Efficacy of PRJ212 versus placebo on the memory measured by memory composite (R-BANS+WMS).,Bioiberica,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",BIO-PRJ-2015-01,Dec-16,Jul-18,Dec-18,13-Dec-16,null,19-Jan-18,"Fundació ACE, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02991235
NCT02987842,Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's Disease,,Unknown status,No Results Available,Mild Cognitive Impairment|Alzheimer Disease,Device: TruScan Neurofeedback,Memory performance|General cognitive performance improvement|qEEG,Beersheva Mental Health Center,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,BeershevaMHC,Dec-16,Dec-17,Dec-17,9-Dec-16,null,13-Dec-16,"Beer-Sheva Mental Health Center, Beer-Sheva, Israel",,https://ClinicalTrials.gov/show/NCT02987842
NCT02986932,Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents in Patients With Early Alzheimer's Disease,BBB-Alzheimers,Completed,No Results Available,Alzheimer Disease,Device: BBB opening,Change in contrast enhancement (intensity) following BBB disruption|Change in amyloid uptake|Adverse events|MMSE - Mini Mental State Examination|ADAS-Cog - Alzheimer's Disease Assessment Scale - Cognitive Behavior subscales|NPI - Neuropsychiatry Inventory|GDS - Geriatric Depression Scale|ADCS-ADL - Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory,InSightec,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,6,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AL001,Dec-16,Dec-17,Dec-17,8-Dec-16,null,14-Jun-18,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02986932
NCT02984540,Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease,BEAM,Completed,No Results Available,Mild Cognitive Impairment|Insulin Resistance,Other: Low-Carbohydrate Diet|Other: Low-Fat Diet,Change in spinal fluid levels of biomarkers associated with Alzheimer's disease|Change in memory composite score|Change in insulin sensitivity|change in 11C acetoacetate PET uptake,Wake Forest University Health Sciences,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB00029992,Feb-15,3-Apr-17,3-Apr-17,7-Dec-16,null,21-Dec-18,"Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02984540
NCT02978729,Telephone Versus Videoconference Communication for Remote Genetic Disclosure in the APOE4 Trial,CONNECT4APOE,Enrolling by invitation,No Results Available,Alzheimer Disease|Genetic Predisposition to Disease,Other: Two-way videoconference remote genetic counseling|Other: Telephone remote genetic counseling,"Satisfaction with genetic counseling services as measured by the Satisfaction with Genetic Services Scale|Satisfaction with genetic counseling services as measured by the Satisfaction with Remote Counseling Scale|Knowledge of Genetic Disease as measured by the Cancer Genetics Knowledge Scale|Disease-specific distress as measured by the Impact of Events Scale|Perceived risk of Alzheimers Disease as measured by questionnaire items measuring perceived risk in quantitative, qualitative, and relative terms|Responses to Genetic Testing as measured by the Impact of Genetic Testing for Alzheimer's disease (IGT-AD) scale|Depression as measured by the GDS Short Form|Anxiety as measured by the Mini State Trait Anxiety Inventory (mSTAI):|Knowledge of Genetic Disease as measured by the ClinSeq Knowledge Scale",University of Pennsylvania,All,"60 Years to 75 Years   (Adult, Older Adult)",Not Applicable,3000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,824225,Aug-16,Aug-21,Aug-21,1-Dec-16,null,15-Feb-19,,,https://ClinicalTrials.gov/show/NCT02978729
NCT02978768,Tai Chi 6-Form Sports Apparatus With Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Other: Exercise|Device: Computer-based cognitive training|Device: Physico-Mental rehabilitation Wii,Balance,Chang Gung Memorial Hospital,All,"59 Years to 92 Years   (Adult, Older Adult)",Not Applicable,67,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label),99-3780B,Aug-11,Jun-15,Jun-15,1-Dec-16,null,12-Dec-16,"Chang Gung Memorial Hospital, TaoYuan county, Taiwan",,https://ClinicalTrials.gov/show/NCT02978768
NCT02972658,A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia,,Terminated,No Results Available,Alzheimer's Disease,Drug: Lanabecestat,Delayed Start Analysis on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)|Delayed Start Analysis on the Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-iADL) Instrumental Items|Delayed Start Analysis on the Functional Activities Questionnaire (FAQ) Score|Delayed Start Analysis on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score|Delayed Start Analysis on the Mini-Mental Status Examination (MMSE)|Delayed Start Analysis on the ADAS-Cog13,Eli Lilly and Company|AstraZeneca,All,"55 Years and older   (Adult, Older Adult)",Phase 3,422,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",16557|I8D-MC-AZFD|2016-003440-36,15-Mar-17,2-Oct-18,2-Oct-18,23-Nov-16,null,26-Oct-18,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Pacific Research Network Inc, San Diego, California, United States|Mile High Research Center, Denver, Colorado, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Brain Matters Research, Delray Beach, Florida, United States|Compass Research, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|The Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Boston Center for Memory, Newton, Massachusetts, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester School of Medicine, Rochester, New York, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Lindner Research Center, Cincinnati, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Radiant Research, Greer, South Carolina, United States|Quillen College of Medicine, East TN State University, Johnson City, Tennessee, United States|The Memory Clinic, Bennington, Vermont, United States|Southern Neurology, Kogarah, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Eastern Clinical Research Unit, Box Hill, Victoria, Australia|Delmont Private Hospital, Glen Iris, Victoria, Australia|The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|Neuro Trials Victoria Pty Ltd, Noble Park, Australia|Jessa Ziekenhuis, Hasselt, Limburg, Belgium|Hopital Universitaire Brugmann Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Hospital Universitaire Erasme Brussel, Brussel, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|AZ Delta, Roeselare, Belgium|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|True North Clinical Research Halifax, LLC, Halifax, Nova Scotia, Canada|Elizabeth Bruyere Health Centre, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Clinique de la Memoire de l'Outaouais, Gatineau, Quebec, Canada|NeuroSearch Developements, Greenfield Park, Quebec, Canada|Hopital de L'Enfant Jesus, Quebec City, Quebec, Canada|Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada|Centre Hospitalier Universitaire La Timone, Marseille, Cedex 05, France|CHRU de Lille- Hôpital Roger Salengro, Lille, Cedex, France|CHU de Toulouse Hopital Purpan, Toulouse, Cedex, France|Hopital Neuro Pierre Wertheimer, Bron Cedex, France|Chu de Nantes Hopital Laennec, Cedex 1, France|CHU Bocage CMRR, Dijon, France|Hopital Broca, Paris, France|Hôpital de la Pitié-Salpêtrière, Paris, France|Hôpital Fernand Widal, Paris, France|Centre de Recherche Clinique du Gérontopôle Cité de la Santé, Toulouse, France|Hopital des Charpennes, Villeurbanne, France|Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Studien und Gedächtniszentrum München, München, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Gemeinschaftspraxis für Neurologie und Psychiatrie, Westerstede, Niedersachsen, Germany|DataMed Klinische Studien GmbH, Köln, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Neurologische Praxis Siegen, Siegen, Nordrhein-Westfalen, Germany|Pharm Studienzentrum Chemnitz, Mittweida, Sachsen, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|SE Neurologiai Klinika, Budapest, Hungary|National Institute for Longevity Sciences NCGG, Obu, Aichi, Japan|National Chiba-East-Hospital, Chuo-ku, Chiba, Japan|Tsukuba University Hospital, Tsukuba, Ibaraki, Japan|Iwate Medical University Hospital, Morioka, Iwate, Japan|Nihon Kokan Hospital, Kawasaki, Kanagawa, Japan|Katayama Medical Clinic, Kurashiki, Okayama, Japan|Shiroma Clinic, Urasoe, Okinawa, Japan|Sakaguchi Clinic, Sakai, Osaka, Japan|National Sanatorium Toneyama Hospital, Toyonaka, Osaka, Japan|Memory Clinic Ochanomizu, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-Ku, Tokyo, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|National Sanatorium Hokuriku Hospital, Nanto, Toyama, Japan|Fukuoka University Hospital, Fukuoka, Japan|Kyoto University Hospital, Kyoto, Japan|Utano Hospital, Kyoto, Japan|Osaka City University Hospital, Osaka, Japan|Dong-A University Medical Center, Seo-gu, Busan, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggido, Korea, Republic of|Inha University Hospital, Jung-gu, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Podlaskie Centrum Psychogeriatrii, Białystok, Podlaskie, Poland|NZOZ Dom Sue Ryder - Pallmed Sp. z o.o., Bydgoszcz, Poland|NZOZ Wielospecjalistyczna Poradnia Lekarska, Katowice, Poland|Centrum Zdrowia Psychicznego Biomed - Jan Latala, Kielce, Poland|Krakowska Akademia Neurologii, Krakow, Poland|Medycyna Milorzab, Lodz, Poland|Instytut Medycyny Wsi, Lublin, Poland|Centrum Medyczne Neuroprotect, Warszawa, Poland|Santa Cruz Behavioral PSC, Bayamón, Puerto Rico|SC Med Life SA, Bucuresti, Romania|SC Centrul Medical Sana SRL, Bucuresti, Romania|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Virgen Del Puerto, Plasencia, Caceres, Spain|Hospital Universitario De Getafe, Madrid, Getafe, Spain|CITA Alzheimer, San Sebastian, Guipuzcoa, Spain|Hospital Son Espases, Son Espases, Palma De Mallorca, Spain|Centro de Atencion Especializada (CAE) OROITU, Getxo, Vizcaya, Spain|Fundacion ACE-Institut Catala de Neurociences Aplicades, Barcelona, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital De La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Dr Pesset, Valencia, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Glasgow Memory Clinic, Scotland, Glasgow, United Kingdom|Re-Cognition Health Ltd, London, Greater London, United Kingdom|MAC Clinical Research-Manchester, Manchester, Greater Manchester, United Kingdom|MAC Clinical Research, Blackpool, Lancashire, United Kingdom|West London Mental Health NHS Trust, Isleworth, London, United Kingdom|MAC Clinical Research, Cannock, Staffordshire, United Kingdom|Re-Cognition Health Ltd, Guildford, Surrey, United Kingdom|MAC Clinical Research, Leeds, United Kingdom",,https://ClinicalTrials.gov/show/NCT02972658
NCT02968719,"A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®",,Completed,No Results Available,Alzheimer Disease,Drug: Donepezil TDS Version A|Drug: Donepezil TDS Version B|Drug: Aricept|Drug: Donepezil TDS Version D|Drug: Donepezil TDS Version E,Steady-state PK|PK (Part B)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 (Part A and B)|PI assessment of local skin irritation response to TDS (Part A and B)|PI assessment of TDS Adhesion per FDA UCM504157,Corium International Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,107,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P-15086,Nov-16,11-Jul-17,11-Jul-17,21-Nov-16,null,1-Aug-18,"Celerion, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT02968719
NCT02968875,"Alzheimer's Disease and Physiological, Cognitive Function and BDNF Levels of Plasma Adaptation After Exercise Training",MARAE,Completed,No Results Available,Alzheimer's Disease,Device: Endurance Training|Other: therapeutic education meetings,"Measuring the effect of a program of endurance training (ET), on the levels of plasma BDNF.|Measuring the effect of training on the psychological performance by using questionnaire MMSE|Measuring the effect of training on the psychological performance by using questionnaire: Rey auditory verbal learning test (RAVLT)|Measuring the effect of training on the psychological performance by using questionnaire: quality of life (QoL-AD)|Stress test|Measuring the effect of training on the physiological performance with a walk test of 6 minutes.",University Hospital Center of Martinique,All,18 Years to 60 Years   (Adult),Not Applicable,54,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,15/B/03,Jul-15,Dec-17,Feb-18,21-Nov-16,null,28-May-18,"CHU de Martinique, Fort-de-France, Martinique",,https://ClinicalTrials.gov/show/NCT02968875
NCT02959489,Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN),REVEAL-SCAN,Recruiting,No Results Available,Alzheimer Disease|Amyloid Beta-Peptides|Risk Assessment|Education|Neuropsychological Tests|Neuroimaging,Behavioral: Alzheimer's Disease Risk Disclosure|Behavioral: Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure,Change in baseline neuropsychological performance compared to 6 weeks and 6 months post-disclosure|Change in baseline measure scores on scales and questionnaires of psychological distress compared to 6 weeks and 6 months post-disclosure.|Change in baseline measures of health behaviors compared to 6 weeks and 6 months post-disclosure to determine the type and frequency of behavior changes in response to learning risk information.,Brigham and Women's Hospital|University of Pennsylvania|University of Michigan|Duke University|Boston University|National Institute on Aging (NIA),All,65 Years to 80 Years   (Older Adult),Not Applicable,270,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,RF1AG047866|1RF1AG047866-01A1,Nov-16,Jul-19,Dec-19,9-Nov-16,null,31-Aug-18,"Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Duke University, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02959489
NCT02959502,Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression,,Recruiting,No Results Available,Mild Cognitive Impairment|Major Depressive Disorder|Alzheimer's Dementia|Transcranial Direct Current Stimulation|tDCS,Other: Receive tDCS+CR|Other: Facilitate tDCS + CR,"Feasibility of training a facilitator (caregiver) to facilitate the administration of CR+tDCS to their ""patient"" partner as indicated by a positive response in the Perceived Competence Scale at 24 months from study baseline.|Assess change in Quality of Life Scale scores among patients between baseline and at the end of the 8-week course.|Measure the change in Quality of Life Scale scores among facilitators between baseline and at the end of the 8-week course.|Measure the change in cognition (as indicated by a change in the Sheehan Disability Scale) among patients between baseline and at the end of the 8-week course|Measure the change in cognition (as indicated by a change in the Sheehan Disability Scale) among facilitators between baseline and at the end of the 8-week course",Centre for Addiction and Mental Health|CAMH Foundation,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,069/2016,31-Oct-16,Nov-19,Nov-19,9-Nov-16,null,28-Feb-19,"Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02959502
NCT02958670,Imaging Tau Deposition in the Brain of Elderly Subjects,Add-Tau,Enrolling by invitation,No Results Available,Mild Cognitive Impairment|Healthy|Alzheimer Disease|Neurocognitive Disorders,Other: 18F-AV-1451 (Tau-PET tracer),Volume of Interest (VOI) or Voxel based assessment of 18F-AV-1451-PET-signal,University of Zurich|Avid Radiopharmaceuticals|Swiss Federal Institute of Technology,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,200,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,KEK-ZH_Nr_2016-01079_V5.0,Nov-16,Jun-21,Nov-23,8-Nov-16,null,19-Oct-18,"Institute for Regenerative Medicine (IREM), Schlieren, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT02958670
NCT02958930,Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease,,Completed,No Results Available,"Alzheimer Disease|Alzheimer Disease, Late Onset",Device: MemorEM 1000,ADAS-Cog|FDG-PET|Resting state fMRI|Diffusion Tensor Imaging (DTI)|Susceptibility-Weighted Imaging (SWI)|Blood and CSF beta-amyloid levels|Blood and CSF tau levels|Blood and CSF markers of immune function|Blood and CSF markers of oxidative stress|Adverse Event Assessment|ADCS-ADL score|MMSE score|Global Deterioration score|Hachinski score|Rey AVLT score|Trails A & B score|Digit span score|Clock draw score,"NeuroEM Therapeutics, Inc.|Byrd Alzheimer's Institute, University of South Florida|University Diagnostic Institute, Tampa|Invicro, Boston|Left Coast Engineering, Escondido",All,"63 Years and older   (Adult, Older Adult)",Not Applicable,8,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NeuroEM-001|EM 1000-1,1-Oct-17,4-Jan-19,11-Jan-19,8-Nov-16,null,23-Apr-19,"Byrd Alzheimer's Institute, University of South Florida, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT02958930
NCT02956486,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease,MissionAD1,Recruiting,No Results Available,Alzheimer's Disease,Drug: Elenbecestat (E2609)|Drug: Placebo,"Core Study: Change From Baseline in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score at 24 Months|Open-Label Extension Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs)|Open-Label Extension Phase: Number of Participants With Abnormal Clinically Significant Vital Signs Values|Open-Label Extension Phase: Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings|Open-Label Extension Phase: Number of Participants With Abnormal Physical Examination Findings|Open-Label Extension Phase: Number of Participants With Abnormal Neurological Examination Findings|Open-Label Extension Phase: Number of Participants With Abnormal Laboratory Safety Test Values|Open-Label Extension Phase: Number of Participants with Suicidal Ideation or Suicidal Behavior as Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)|Open-Label Extension Phase: Number of Events of Possible Signals of Drug Abuse Potential|Open-Label Extension Phase: Number of Participants With Abnormal Magnetic Resonance Imaging (MRI) Findings|Core Study: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at 24 Months|Core Study: Change From Baseline in Amyloid Positron Emission Tomography Standardized Uptake Value Ratio (PET SUVR) at 24 Months for Brain Amyloid Levels|Open-Label Extension Phase: Change From Core Study Baseline in CDR-SB at Month 12, 24|Open-Label Extension Phase: Change From Core Study Baseline in ADCOMS at Month 24|Open-Label Extension Phase: Change From Core Study Baseline in Mini Mental State Examination (MMSE) at Months 4, 8, 12, 16, 20, 24|Open-Label Extension Phase: Change From Core Study Baseline in Functional Assessment Questionnaire (FAQ) at Months 4, 8,12,16,20, 24|Open-Label Extension Phase: Change From Core Study Baseline in Alzheimer's Disease Assessment Scale-Cognition14 (ADAS-cog14) at Months 12, 24|Open-Label Extension Phase: Change From Core Study Baseline in ADAS-cog14 Word List (Immediate Recall and Delayed Recall) at Months 12, 24|Open-Label Extension Phase: Time to Conversion to Dementia for Participants who were not Clinically Staged as Dementia at Core Study Baseline Based on Clinical Diagnosis","Eisai Co., Ltd.|Biogen|Eisai Inc.",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1900,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E2609-G000-301|2016-003928-23,20-Oct-16,22-Jun-21,1-Sep-23,7-Nov-16,null,16-May-19,"Facility #1, Chandler, Arizona, United States|Facility #1, Colton, California, United States|Facility #1, Costa Mesa, California, United States|Facility #1, Fullerton, California, United States|Facility #1, Imperial, California, United States|Facility #1, Irvine, California, United States|Facility #1, Lemon Grove, California, United States|Facility #1, Oceanside, California, United States|Facility #2, Oceanside, California, United States|Facility #1, Oxnard, California, United States|Facility #1, Panorama City, California, United States|Facility #1, San Diego, California, United States|Facility #1, Yorba Linda, California, United States|Facility #1, Denver, Colorado, United States|Facility #1, Atlantis, Florida, United States|Facility #1, Aventura, Florida, United States|Facility #2, Aventura, Florida, United States|Facility #1, Boynton Beach, Florida, United States|Facility #1, Coral Gables, Florida, United States|Facility #2, Coral Gables, Florida, United States|Facility #3, Coral Gables, Florida, United States|Facility #1, Delray Beach, Florida, United States|Facility #1, Doral, Florida, United States|Facility #1, Hialeah, Florida, United States|Facility #2, Miami, Florida, United States|Facility #11, Miami, Florida, United States|Facility #9, Miami, Florida, United States|Facility #10, Miami, Florida, United States|Facility #4, Miami, Florida, United States|Facility #5, Miami, Florida, United States|Facility #1, Miami, Florida, United States|Facility #6, Miami, Florida, United States|Facility #3, Miami, Florida, United States|Facility #7, Miami, Florida, United States|Facility #8, Miami, Florida, United States|Facility #2, Orlando, Florida, United States|Facility #1, Orlando, Florida, United States|Facility #3, Orlando, Florida, United States|Facility #1, Palm Beach Gardens, Florida, United States|Facility #1, Pompano Beach, Florida, United States|Facility #1, Port Charlotte, Florida, United States|Facility #1, Port Orange, Florida, United States|Facility #1, Spring Hill, Florida, United States|Facility #1, Tampa, Florida, United States|Facility #2, Tampa, Florida, United States|Facility #1, The Villages, Florida, United States|Facility #1, Atlanta, Georgia, United States|Facility #1, Columbus, Georgia, United States|Facility #1, Decatur, Georgia, United States|Facility #1, Suwanee, Georgia, United States|Facility #1, Meridian, Idaho, United States|Facility #1, Northbrook, Illinois, United States|Facility #2, Wichita, Kansas, United States|Facility #1, Boston, Massachusetts, United States|Facility #1, Farmington Hills, Michigan, United States|Facility #1, Chesterfield, Missouri, United States|Facility #1, O'Fallon, Missouri, United States|Facility #2, Saint Louis, Missouri, United States|Facility #1, Saint Louis, Missouri, United States|Facility #3, Saint Louis, Missouri, United States|Facility #1, Saint Peters, Missouri, United States|Facility #1, Mount Arlington, New Jersey, United States|Facility #2, Springfield, New Jersey, United States|Facility #1, West Long Branch, New Jersey, United States|Facility #1, Amherst, New York, United States|Facility #1, Brooklyn, New York, United States|Facility #1, New York, New York, United States|Facility #1, Canton, Ohio, United States|Facility #1, Centerville, Ohio, United States|Facility #1, Cleveland, Ohio, United States|Facility #1, Dayton, Ohio, United States|Facility #1, Lakewood, Ohio, United States|Facility #1, Westerville, Ohio, United States|Facility #1, Oklahoma City, Oklahoma, United States|Facility #1, Portland, Oregon, United States|Facility #1, Jenkintown, Pennsylvania, United States|Facility #1, Media, Pennsylvania, United States|Facility #1, Philadelphia, Pennsylvania, United States|Facility #1, East Providence, Rhode Island, United States|Facility #1, Lincoln, Rhode Island, United States|Facility #1, Providence, Rhode Island, United States|Facility #1, Port Royal, South Carolina, United States|Facility #1, Cordova, Tennessee, United States|Facility #2, Nashville, Tennessee, United States|Facility #1, Nashville, Tennessee, United States|Facility #1, Austin, Texas, United States|Facility #1, Dallas, Texas, United States|Facility #1, Houston, Texas, United States|Facility #1, San Antonio, Texas, United States|Facility #3, San Antonio, Texas, United States|Facility #1, Salt Lake City, Utah, United States|Facility #1, Bennington, Vermont, United States|Facility #1, Hampton, Virginia, United States|Facility #1, Richland, Washington, United States|Facility #1, Madison, Wisconsin, United States|Facility #2, Caba, Buenos Aires, Argentina|Facility #1, Caba, Buenos Aires, Argentina|Facility #4, Caba, Buenos Aires, Argentina|Facility #3, Caba, Buenos Aires, Argentina|Facility #1, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #3, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #2, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #1, Cordoba, Capital, Argentina|Facility #1, Rosario, Santa Fe, Argentina|Facility #4, Buenos Aires, Argentina|Facility #5, Caba, Argentina|Facility #2, Cordoba, Argentina|Facility #3, Cordoba, Argentina|Facility #1, Santa Fe, Argentina|Facility #1, Darlinghurst, New South Wales, Australia|Facility #1, Macquarie Park, New South Wales, Australia|Facility #1, Tumbi Umbi, New South Wales, Australia|Facility #1, Brisbane, Queensland, Australia|Facility #1, Caulfield, Victoria, Australia|Facility #1, Geelong, Victoria, Australia|Facility #1, Heidelberg, Victoria, Australia|Facility #1, Malvern, Victoria, Australia|Facility #2, Melbourne, Victoria, Australia|Facility #1, Parkville, Victoria, Australia|Facility #1, Nedlands, Western Australia, Australia|Facility #3, Melbourne, Australia|Facility #1, Vienna, Austria|Facility #1, Wien, Austria|Facility #1, Pleven, Bulgaria|Facility #1, Plovdiv, Bulgaria|Facility #1, Ruse, Bulgaria|Facility #4, Sofia, Bulgaria|Facility #3, Sofia, Bulgaria|Facility #1, Sofia, Bulgaria|Facility #2, Sofia, Bulgaria|Facility #1, Varna, Bulgaria|Facility #1, Kamloops, British Columbia, Canada|Facility #1, Kelowna, British Columbia, Canada|Facility #1, West Vancouver, British Columbia, Canada|Facility #1, Halifax, Nova Scotia, Canada|Facility #1, Kentville, Nova Scotia, Canada|Facility #1, Ottawa, Ontario, Canada|Facility #1, Peterborough, Ontario, Canada|Facility #1, Montreal, Quebec, Canada|Facility #1, Sherbrooke, Quebec, Canada|Facility #1, Hradec Kralove, Czechia|Facility #1, Kladno, Czechia|Facility #1, Olomouc, Czechia|Facility #1, Praha 10, Czechia|Facility #1, Montpellier, Herault, France|Facility #1, Bordeaux, France|Facility #1, Bron Cedex, France|Facility #1, Marseille Cedex 05, France|Facility #1, Nantes, France|Facility #1, Paris, France|Facility #1, Rouen, France|Facility #1, Toulouse, France|Facility #1, Gunzburg, Bayern, Germany|Facility #1, Neuburg, Bayern, Germany|Facility #1, Hoppegarten, Brandenburg, Germany|Facility #1, Oranienburg, Brandenburg, Germany|Facility #1, Frankfurt, Hessen, Germany|Facility #1, Magdeburg, Sachsen-Anhalt, Germany|Facility #1, Leipzig, Saxony, Germany|Facility #1, Berlin, Germany|Facility #2, Berlin, Germany|Facility #1, Gera, Germany|Facility #1, Homburg/Saar, Germany|Facility #1, Schwerin, Germany|Facility #5, Athens, Greece|Facility #4, Athens, Greece|Eisai Trial Site 1, Anjo-shi, Aichi, Japan|Eisai Trial Site 1, Nagoya-shi, Aichi, Japan|Eisai Trial Site 1, Obu-shi, Aichi, Japan|Eisai Trial Site 1, Yoshida-gun, Fukui, Japan|Eisai Trail Site 1, Kitakyushu-shi, Fukuoka, Japan|Eisai Trial Site 1, Omuta-shi, Fukuoka, Japan|Eisai Trial Site 1, Fujioka-shi, Gunma, Japan|Eisai Trial Site 1, Otake-shi, Hiroshima, Japan|Eisai Trial Site 2, Himeji-shi, Hyogo, Japan|Eisai Trial Site 1, Himeji, Hyogo, Japan|Eisai Trial Site 1, Kobe, Hyogo, Japan|Facility #1, Miki, Kagawa, Japan|Eisai Trial Site 3, Takamatsu City, Kagawa, Japan|Eisai Trial Site 1, Fujisawa-shi, Kanagawa, Japan|Eisai Trial Site 4, Kyoto City, Kyoto, Japan|Eisai Trial Site 1, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 2, Kyoto-shi, Kyoto, Japan|Eisai Trial site 5, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 1, Shimogyo-ku, Kyoto, Japan|Eisai Trial Site 1, Higashimorokatagun, Miyazaki, Japan|Eisai Trial Site 1, Nishisonogi-gun, Nagasaki, Japan|Eisai Trial Site 2, Okayama-shi, Okayama-ken, Japan|Eisai Trial Site 1, Kurashiki-shi, Okayama, Japan|Eisai Trial Site 2, Kurashiki-shi, Okayama, Japan|Eisai Trial Site 1, Okayama-shi, Okayama, Japan|Eisai Trial Site 1, Hirakata, Osaka, Japan|Eisai Trial Site 1, Naniwa-Ku, Osaka, Japan|Eisai Trial Site 1, Osaka-shi, Osaka, Japan|Eisai Trial Site 3, Osaka-shi, Osaka, Japan|Eisai Trial Site 2, Osaka-shi, Osaka, Japan|Eisai Trial site 2, Sakai-shi, Osaka, Japan|Eisai Trial Site 1, Suita-shi, Osaka, Japan|Eisai Trial Site 2, Suita-shi, Osaka, Japan|Eisai Trial Site 1, Suminoe-ku, Osaka, Japan|Eisai Trial Site 1, Kanzaki-gun, Saga, Japan|Eisai Trial Site 1, Otsu-shi, Shiga, Japan|Eisai Trial Site 2, Otsu, Shiga, Japan|Eisai Trial Site 1, Tokushima-shi, Tokushima, Japan|Eisai Trial Site 1, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 2, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 1, Kodaira-shi, Tokyo, Japan|Eisai Trial Site 1, Minato-ku, Tokyo, Japan|Eisai Trial Site 1, Setagaya-ku, Tokyo, Japan|Eisai Trial Site 1, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site 1, Sumida-ku, Tokyo, Japan|Eisai Trial Site 1, Hofu-shi, Yamaguchi, Japan|Eisai Trial Site 1, Kumamoto, Japan|Eisai Trial Site 3, Kyoto, Japan|Eisai Trial Site 1, Osaka, Japan|Facility #1, Bucheon-si, Gyeonggi-do, Korea, Republic of|Facility #1, Seongnam, Gyeonggi, Korea, Republic of|Facility #1, Busan, Korea, Republic of|Facility #1, Incheon, Korea, Republic of|Facility #5, Seoul, Korea, Republic of|Facility #3, Seoul, Korea, Republic of|Facility #1, Seoul, Korea, Republic of|Facility #4, Seoul, Korea, Republic of|Facility #6, Seoul, Korea, Republic of|Facility #2, Seoul, Korea, Republic of|Facility #1, Katowice, Poland|Facility #1, Kielce, Poland|Facility #1, Krakow, Poland|Facility #1, Poznari, Poland|Facility #1, Poznań, Poland|Facility #1, Siemianowice Śląskie, Poland|Facility #1, Warszawa, Poland|Facility #1, Guimarães, Portugal|Facility #1, Moscow, Russian Federation|Facility #1, Bratislava, Slovakia|Facility #1, Elche, Alicante, Spain|Facility #1, Sant Cugat Del Valles, Barcelona, Spain|Facility #1, Getxo, Bizkaia, Spain|Facility #1, Donostia/San Sebastian, Gipuzkoa, Spain|Facility #1, Palma de Mallorca, Illes Balears, Spain|Facility #1, El Palmar, Murcia, Spain|Facility #1, Barcelona, Spain|Facility #2, Madrid, Spain|Facility #1, Madrid, Spain|Facility #1, Valencia, Spain|Facility #2, Valencia, Spain|Facility #1, Cambridge, Cambridgeshire, United Kingdom|Facility #1, Chester, Cheshire, United Kingdom|Facility #1, Winwick, Warrington, Cheshire, United Kingdom|Facility #1, Plymouth, Devon, United Kingdom|Facility #1, Bournemouth, Dorset, United Kingdom|Facility #1, Crowborough, East Sussex, United Kingdom|Facility #1, Manchester, Greater Manchester, United Kingdom|Facility #1, Southampton, Hampshire, United Kingdom|Facility #1, Glasgow, Lanarkshire, United Kingdom|Facility #1, Blackpool, Lancashire, United Kingdom|Facility #1, Preston, Lancashire, United Kingdom|Facility #2, London, Middlesex, United Kingdom|Facility #1, Bath, North East Somerset, United Kingdom|Facility #1, Northampton, Northamptonshire, United Kingdom|Facility #1, Oxford, Oxfordshire, United Kingdom|Facility #1, Aberdeen, Scotland, United Kingdom|Facility #1, Sheffield, South Yorkshire, United Kingdom|Facility #1, Leatherhead, Surrey, United Kingdom|Facility #1, Birmingham, West Midlands, United Kingdom|Facility #1, Swindon, Wilts, United Kingdom|Facility #2, Glasgow, United Kingdom|Facility #1, Guildford, United Kingdom|Facility #1, London, United Kingdom|Facility #4, London, United Kingdom|Facility #3, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02956486
NCT02955706,Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer Disease,Drug: Acetyl-L-Carnitine|Drug: Placebo of Acetyl-L-Carnitine,ADAS-cog|K-MMSE,"Dong-A ST Co., Ltd.",All,"50 Years and older   (Adult, Older Adult)",Phase 4,328,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NCT_ADC_IV,Apr-16,Sep-18,Feb-19,4-Nov-16,null,8-Nov-16,"Konkuk university medical center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02955706
NCT02951559,SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies,,Recruiting,No Results Available,Encephalopathy|HIV-encephalopathy|Alzheimer Dementia,Device: Nasal Brushing,Diagnostic concordance with gold standard diagnostic procedures|Side effects of the nasal brushing|Cytological and immunohistochemistry examination of nasal brushing smear (neuronal abnormalities and expression of specific markers according to the different aetiologies)|OM markers of neuronal damage and amyloid deposition,"University of Turin, Italy",All,"18 Years and older   (Adult, Older Adult)",Phase 4,250,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,SOLFAMU,Mar-16,Feb-21,Feb-21,1-Nov-16,null,3-May-18,"University of Torino, Torino, Italy",,https://ClinicalTrials.gov/show/NCT02951559
NCT02951598,A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD),GERAS-US,"Active, not recruiting",No Results Available,Alzheimer Disease|Mild Cognitive Impairment,Drug: Florbetapir F 18 PET Scan,Mean Economic Cost Associated with Amyloid Positive AD|Healthcare Resource Use by AD Cohort|Mean Economic Cost by AD Cohort|Bath Assessment of Subjective Quality of Life in Dementia (BASQID)|Mini-Mental State Examination (MMSE)|Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog14)|Neuropsychiatric Inventory (NPI)|Functional Activities Questionnaire (FAQ)|Cognitive Function Inventory (CFI)|Zarit Burden Interview (ZBI)|Percentage of Participants with a Change in Living Situation|Time to Transition Across Stages of AD|Desire to Institutionalize Scale (DTI),Eli Lilly and Company,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,1400,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,16466|H8A-US-B004,29-Oct-16,28-Oct-20,28-Oct-20,1-Nov-16,null,4-Dec-18,"California Pharmaceutical Research Institute, Anaheim, California, United States|Advanced Research Center, Anaheim, California, United States|Sun Valley Research Center, Imperial, California, United States|Global Clinical Trials, Irvine, California, United States|Irvine Clinical Research Center, Irvine, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Pacific Clinical Studies, Inc, Los Alamitos, California, United States|California Neurological Services, Inc., Panorama City, California, United States|Havana Research Institute, Pasadena, California, United States|Clinical Innovations, Inc., Riverside, California, United States|Breakthrough Clinical Trials, San Bernardino, California, United States|HB Clinical Trials, Santa Ana, California, United States|Ventura Clinical Trials, Ventura, California, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Visionary Investigators Network, Aventura, Florida, United States|Research Alliance, Clearwater, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Infinite Clinical Research, Doral, Florida, United States|International Research Partners, LLC., Doral, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|New Life Medical Research Center, Inc, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|South Florida Clinical Trials, Hialeah, Florida, United States|Van Buren Medical, Hollywood, Florida, United States|Clinical Research of Homestead, Homestead, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Universal Neurological Care, Jacksonville, Florida, United States|Sunrise Medical Research, Lauderdale Lakes, Florida, United States|Empire Clinical Research, Miami Lakes, Florida, United States|Biomed Research Institute, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Florida International Research Center, Miami, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|L&C Professional Medical Research Institute, Miami, Florida, United States|Genoma Research Group, Inc., Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Combined Research Orlando Phase I-IV LLC, Orlando, Florida, United States|Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Asclepes Research Centers Florida, Weeki Wachee, Florida, United States|Doctors Clinical Research, Atlanta, Georgia, United States|American Health Network, Franklin, Indiana, United States|American Research, LLC, Jeffersonville, Indiana, United States|Heartland Research Associates, Newton, Kansas, United States|Baptist Health Medical Group, Lexington, Kentucky, United States|NeuroMedical Clinic of Central Louisiana, Alexandria, Louisiana, United States|St. Agnes Medical Group, Catonsville, Maryland, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Psych Care Consultants Research, Saint Louis, Missouri, United States|Pyramid Clinical Research, Monroe, New Jersey, United States|Healthwise Medical Associates, PC, Brooklyn, New York, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|Adirondack Medical Center, Lake Placid, New York, United States|Mid Hudson Medical Research, PLLC, New Windsor, New York, United States|Onsite Clinical Solutions, LLC, Charlotte, North Carolina, United States|Onsite Clinical Solutions, LLC, Charlotte, North Carolina, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Coastal Carolina Healthcare, P.A., New Bern, North Carolina, United States|Dayton Center for Neurological Disorders, Centerville, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|Family Practice Center of Wooster, Wooster, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Wesley Neurology Clinic, Cordova, Tennessee, United States|Clinical Research Solutions, P.C., Knoxville, Tennessee, United States|Lakeside Life Center, Carrollton, Texas, United States|Univ Of Texas Southwestern at Dallas Childrens Med Ctr, Dallas, Texas, United States|The Clinical Research Group, Frisco, Texas, United States|Dallas Clinical Research, Greenville, Texas, United States|Highlands Medical Associates, P.A., Highlands, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|North Pointe Psychiatry, Lewisville, Texas, United States|Premier Clinical Research, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT02951598
NCT02947893,"Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease",AD,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: Placebo Capsule(s) Once a Day by Mouth|Drug: Nilotinib Capsule(s) Once a Day by Mouth,Safety will be measured by number of participants experiencing the occurrence of adverse events and/or abnormal laboratory values|Effects of Nilotinib treatment on measurement of Nilotinib in the CSF,Georgetown University,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,42,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2016-0315,Jan-17,Dec-19,Feb-20,28-Oct-16,null,13-Mar-19,"Georgetown University Medical Center, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT02947893
NCT02941289,"Visuospatial Attention, Eye Movements and Instrumental Activities of Daily Living (IADLs) in Alzheimer's Disease",ARVA-MA,Recruiting,No Results Available,Alzheimer's Disease,Procedure: visual search performance of everyday objects in realistic scenes,Total number of fixations during search|Total duration of fixations during search,Centre Hospitalier Universitaire de Nice,All,65 Years to 75 Years   (Older Adult),Not Applicable,64,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,16-AOI-06,Nov-16,May-17,May-19,21-Oct-16,null,23-Aug-17,"CHU de Nice, Nice, France",,https://ClinicalTrials.gov/show/NCT02941289
NCT02933177,Effectiveness of Flash Mediation Therapy,,Completed,No Results Available,Dementia,Behavioral: 2 months control condition - 4 months chariot-flash|Behavioral: 4 months control condition-2 months chariot flash,Change in number of disorders|Change in score of well-being|change in psychotropic drugs prescribed|change in score of BPSD|change in level of agitation|change in the number of administered psychotropic drugs.|The number of hospitalization|The number of fall,Hospices Civils de Lyon,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,241,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,69HCL16_0442,May-16,Mar-17,Mar-17,14-Oct-16,null,2-Dec-17,"Hôpital des Charpennes Centre de Recherche Clinique ""Vieillissement-Cerveau-Fragilité"", Lyon, France",,https://ClinicalTrials.gov/show/NCT02933177
NCT02928211,Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations,,Recruiting,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Device: Sapphire II|Drug: Aftobetin-HCl|Radiation: Positron Emission Tomography,"Paired pre-ligand and post ligand fluorescent uptake values (FUV)|Determination of success (yes or no)|The overall diagnostic precision for each combination of Aftobetin-HCl administrations and Fluorescent Uptake Value (FUV)|Estimates of sensitivity and specificity of MCI and mild AD subjects compared to cognitively normal subjects|Safety of Sapphire II procedure as determined by instances of Adverse Events|Characterization of maximal fluorescence after 1, or potentially 3, ointment administrations|Intra-class correlation of the repeatability of the Sapphire II measurements to verify the system's reliability for reproducible results|Correlation of FUV to PET amyloid status","Cognoptix, Inc.",All,"25 Years to 90 Years   (Adult, Older Adult)",Phase 1,105,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PRT-0036,Jul-16,Dec-18,Jan-19,10-Oct-16,null,22-Aug-18,"Neurology Research Institute, West Palm Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT02928211
NCT02925650,"Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease",DISCOVER,Recruiting,No Results Available,Alzheimer's Disease,Drug: Posiphen|Drug: Placebo,Safety and Tolerability: Reports of adverse events or study discontinuations|AUC of Posiphen and its metabolites in plasma and CSF|Fractional synthesis rate of Aβ40 in CSF using the SILK™ technique|Concentration of soluble biomarkers of Alzheimer's disease in CSF|Assessment of cognitive assessments|Assessment of mental status effects|Assessment of neuropsychiatric effects,QR Pharma Inc.|Alzheimer's Disease Cooperative Study (ADCS),All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,24,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",QR15001|ADC-042-DISC,2-Mar-17,31-Dec-19,31-Dec-19,6-Oct-16,null,2-May-19,"UCSD Alzheimer's Disease Research Center, La Jolla, California, United States|IU Health Partners, Adult Neurology Clinic, Indianapolis, Indiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Washington University Sleep Medicine Center, Brentwood, Missouri, United States|Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02925650
NCT02921672,Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline,,Completed,No Results Available,Alzheimer's Disease|Cognitive Impairment,Other: Mediterranean Diet,Number of participants completing the study,University of Kansas Medical Center|National Institute on Aging (NIA),All,65 Years and older   (Older Adult),Not Applicable,30,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,STUDY00003894|P30AG035982,Mar-16,22-Jun-18,Dec-18,3-Oct-16,null,6-Feb-19,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02921672
NCT02915939,The Residential Care Transition Module,RCTM,Recruiting,No Results Available,Alzheimer Disease|Dementia,Behavioral: The Residential Care Transition Module,Change in care-related strain|Change in burden: Zarit Burden Interview|Change in stress: Perceived Stress Scale,University of Minnesota - Clinical and Translational Science Institute|Johns Hopkins University|New York University School of Medicine|Benjamin Rose Institute|Emory University,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,R01AG048931,Dec-16,May-21,May-21,27-Sep-16,null,3-May-19,"University of Minnesota, School of Nursing, 6-153 Weaver-Densford Hall, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02915939
NCT02916056,2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension),,Terminated,No Results Available,Alzheimer's Disease,Drug: Azeliragon 5mg,Adverse Events|Clinical Safety Laboratory Tests|Electrocardiogram|Vital Signs|The slope of change over time in Alzheimer's Disease Assessment Scale - cognitive measure (ADAS-cog)|The slope of change over time in Clinical Dementia Rating Scale-Sum of Boxes (CDR-sb)|The slope of change over time in Mini-Mental State Exam (MMSE)|The slope of change over time in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale|The slope of change over time in Neuropsychiatric Inventory Questionnaire (NPI)|Change from baseline in measures of Alzheimer's Disease Assessment Scale - cognitive measure (ADAS-cog)|Change from baseline in measures of Mini-Mental State Exam (MMSE)|Change from baseline in measures of Clinical Dementia Rating (CDR) scale|Change from baseline in measures of Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale|Change from baseline in measures of Continuous Oral Word Association Task (COWAT)|Change from baseline in measures of Category Fluency Test (CFT)|Change from baseline in measures of Trail Making Test|Change from baseline in measures of Neuropsychiatric Inventory Questionnaire (NPI),vTv Therapeutics,All,"50 Years and older   (Adult, Older Adult)",Phase 3,298,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TTP488-303,Dec-16,1-Jun-18,1-Jun-18,27-Sep-16,null,17-May-19,"Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Bellflower, California, United States|Costa Mesa, California, United States|Fullerton, California, United States|Glendale, California, United States|Imperial, California, United States|Irvine, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Riverside, California, United States|San Bernardino, California, United States|Santa Ana, California, United States|Atlantis, Florida, United States|Delray Beach, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Lake Worth, Florida, United States|Miami Beach, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Sarasota, Florida, United States|Sunrise, Florida, United States|The Villages, Florida, United States|Columbus, Georgia, United States|Chicago, Illinois, United States|Fairway, Kansas, United States|Lexington, Kentucky, United States|Baltimore, Maryland, United States|Newton, Massachusetts, United States|Plymouth, Massachusetts, United States|Quincy, Massachusetts, United States|Hattiesburg, Mississippi, United States|Creve Coeur, Missouri, United States|Saint Louis, Missouri, United States|Princeton, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Lake Success, New York, United States|New York, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Shaker Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Portland, Oregon, United States|Plains, Pennsylvania, United States|East Providence, Rhode Island, United States|East Providence, Rhode Island, United States|Cordova, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Murray, Utah, United States|Kirkland, Washington, United States|Calgary, Alberta, Canada|Medicine Hat, Alberta, Canada|Chatham, Ontario, Canada|Toronto, Ontario, Canada|Gatineau, Quebec, Canada|Greenfield Park, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02916056
NCT02913664,Risk Reduction for Alzheimer's Disease,rrAD,Recruiting,No Results Available,Cognitively Normal Older Adults|Hypertension|Subjective Cognitive Decline|Family History of Alzheimer's Disease,"Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)|Behavioral: Aerobic Exercise Training|Other: Usual Care|Behavioral: Stretching Exercise|Drug: Atorvastatin",Change in global neurocognitive function|Domain-specific neurocognitive function assessed by using the tests included in the ADCS-PACC and NIH-TB Cognition.|Whole brain and hippocampal volume assessed via Magnetic Resonance Imaging (MRI).|Global and regional brain perfusion assessed via Magnetic Resonance Imaging (MRI).|Brain white matter hyperintensity (WMH) assessed via Magnetic Resonance Imaging (MRI).|Brain white matter microstructural integrity assessed via Magnetic Resonance Imaging (MRI).|Brain neural network functional connectivity assessed via functional Magnetic Resonance Imaging (MRI).|Patient-reported outcomes (PRO) of mental and physical health and health-related quality of life assessed by using NIH PROMIS.|Physical function assessed via the Short Physical Performance Battery (SPPB).|Dual task performance assessed via distracted and non-distracted 10 meter walk.,University of Texas Southwestern Medical Center|Texas Health Resources|University of Kansas Medical Center|Washington University School of Medicine|Pennington Biomedical Research Center|Michigan State University,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,640,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,RZNIA60,Sep-16,Sep-21,Sep-22,26-Sep-16,null,15-Feb-19,"University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02913664
NCT02912169,Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease,,Withdrawn,No Results Available,Alzheimer's Disease,Procedure: Liposuction under local anesthesia|Biological: Infusion of AD-SVF via IV and Intranasal,Clinical Improvement in Mini Mental State Examination (MMSE)|Adverse Event|Clinical Improvement in Functional Activities Questionnaire (FAQ)|Clinical Improvement in Activities of Daily Living Questionnaire (ADL)|Clinical Improvement in Geriatric Depression Scale (GDS),Ageless Regenerative Institute,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AD-US-ALZ-001,1-Nov-15,15-Nov-17,15-Nov-17,23-Sep-16,null,24-Nov-17,"Ageless Regenerative Institute LLC, Aventura, Florida, United States",,https://ClinicalTrials.gov/show/NCT02912169
NCT02912936,A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease,MINT-01,Recruiting,No Results Available,Alzheimer's Disease,Dietary Supplement: Ketogenic medium chain triglyceride drink (MCT drink)|Dietary Supplement: Placebo,"Number of participants with adverse events, serious adverse events|Plasma ketone concentrations in response to ascending dose of MCT|Area under the plasma concentration versus time curve (AUC) of MCT",University of British Columbia|Université de Sherbrooke,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H15-02537,Sep-16,Dec-19,Dec-19,23-Sep-16,null,5-Dec-18,"Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02912936
NCT02910739,An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016),,Completed,Has Results,Amnestic Mild Cognitive Impairment|Alzheimer's Disease|Prodromal Alzheimer's Disease,Drug: MK-8931,Area Under the Concentration Versus Time Curve of MK-8931 From 0 to Infinity (AUC0-∞)|Maximum Observed Plasma Concentration of MK-8931 (Cmax)|Area Under the Concentration Versus Time Curve of MK-8931 From 0 to the Time of the Last Quantifiable (Above LLOQ) Sample (AUC0-last)|Area Under the Concentration Versus Time Curve of MK-8931 From 0 to 24 Hours (AUC0-24hr)|Plasma Concentration of MK-8931 at 24 Hours (C24hr)|Apparent Clearance of MK-8931 After Extravascular Administration (CL/F)|Time to Maximum Observed MK-8931 Plasma Drug Concentration (Tmax)|Apparent Terminal Half-Life of MK-8931 (t1/2)|Apparent Volume of Distribution of MK-8931 During the Terminal Phase After Extravascular Administration (Vz/F)|Number of Participants Experiencing an Adverse Event|Number of Participants Discontinuing Study Due to an Adverse Event,Merck Sharp & Dohme Corp.,All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 1,16,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P08593|Celerion Project Number|Merck Protocol Number,11-Oct-16,3-Apr-17,12-Apr-17,22-Sep-16,1-Oct-18,1-Oct-18,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02910739/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02910739
NCT02908815,Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer's Disease,Device: rTMS active treatment|Device: rTMS sham treatment,Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) change|Stroop Test|Digit Span Test|Verbal Fluency Test (VFT)|Neuropsychiatric Inventory-Questionnaire (NPI-Q)|Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Zarit Burden Interview (ZBI)|Treatment Satisfaction Questionnaire for Medication (TSQM)|Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) effect over time|Semantic Fluency Test (SFT)|Clinical Dementia Rating (CDR) sum of boxes,University of Manitoba,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",B2016:077,Nov-16,Nov-20,Nov-20,21-Sep-16,null,17-Apr-19,"Monash University, Melbourne, Victoria, Australia|Riverview Health Center, Winnipeg, Manitoba, Canada|McGill University, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02908815
NCT02910102,Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia,,Completed,No Results Available,Alzheimer's Disease|Dementia With Lewy Bodies|Parkinson's Disease Dementia,Drug: RVT-101 35 mg|Drug: Placebo,"Change in quantitative gait measurements from baseline to the end of each double-blind treatment period based on computerized gait assessment tools.|Incidence of adverse events, and reported changes in physical examinations, vital signs, electrocardiograms, and clinical laboratory assessments from baseline to the end of each double-blind treatment period.",Axovant Sciences Ltd.,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RVT-101-2003,Oct-16,Nov-17,Nov-17,21-Sep-16,null,27-Dec-17,"US101, Phoenix, Arizona, United States|US118, Simi Valley, California, United States|US117, Temecula, California, United States|US115, Boca Raton, Florida, United States|US109, Hallandale Beach, Florida, United States|US116, Miami, Florida, United States|US108, Pensacola, Florida, United States|US106, Columbus, Georgia, United States|US107, Indianapolis, Indiana, United States|US102, Ann Arbor, Michigan, United States|US111, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02910102
NCT02907567,Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: CT1812|Drug: Placebo,Incidence and review of Treatment Emergent Adverse Events,Cognition Therapeutics,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,19,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COG0102,Sep-16,24-Aug-17,Sep-17,20-Sep-16,null,25-Jul-18,"Dr. Phillip Morris, Southport, Queensland, Australia|Austin Health, Ivanhoe, Victoria, Australia|Epworth Hospital, Melbourne, Victoria, Australia|The Royal Melbourne Hospital Hospital, Parkville, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT02907567
NCT02903862,Health-eBrain Study,HeB,Withdrawn,No Results Available,Depression and Burden in Caregivers,Behavioral: Mindoula|Device: DANA,Change from baseline M3 Behavioral Scale score over 12 weeks|Change from baseline Zarit Burden Inventory score over 12 weeks|Change from baseline PROMIS Sleep Disturbance Short Form 8a score over 12 weeks,"AnthroTronix, Inc.|Bright Focus Foundation|Mindoula Health Inc.|21st Century Brain Trust|Geoffrey Beene Foundation",All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,0,Industry|Other,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,091614A,Jul-16,Jul-17,Jul-17,16-Sep-16,null,3-Jul-18,"AnthroTronix Inc, Silver Spring, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02903862
NCT02899091,Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease,Biological: CB-AC-02|Biological: Placebo,Number of Adverse Events|Changes from the baseline in ADAS-Cog (Azheimer's disease Assessment Scale - Congintive Subscale) Score|Changes from the baseline in K-MMSE (Korean-Mini Mental Status Examination) Score|Changes from the baseline in GDS (Global Deterioration Scale)|Changes from the baseline in CDR (Clinical Dementia Rating) Score|Changes from the baseline in K-IADL (Korean Instrumental Activities of Daily Living) Score|Changes from the baseline in CGA-NPI (Caregiver Administered-Neuropsychiatric Inventory) Score|Change in CIBIC (Clinician Interview Based Impression of Change)-plus|Changes from the baseline in SF-36|Changes in Amyloid Beta and Tau amount (pg/mL) in CSF (Cerebrospinal fluid)|Change in Brain MRI (Magnetic Responance imaging)|Change from the baseline of CMRglc (cerebral metabolic rate for glucose ) analyzed with SPM (statistical parametric mapping) with Brain FDG PET imaging|Changes from the baseline of Amyloid amount analyzed with SPM (statistical parametric mapping) with amyloid PET imaging|Changes of band power in qEEG (Quantitative electroencephalography),"CHABiotech CO., Ltd",All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CHA-PAD-101,Sep-16,Mar-18,Jun-18,14-Sep-16,null,14-Sep-16,"Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02899091
NCT02899403,Neurophysiological Correlates of Cognitive Tasks in Healthy Volunteers -WP3 P003,PharmacogWP3,Recruiting,No Results Available,Alzheimer Disease|ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1 (Disorder),Other: Rapid Visual Information Processing (RVIP) test,EEG spectral power during RVIP task as compared to resting state|EEG spectral power during PRM task as compared to resting state|RVIP latency of responses|PRM number of errors|PRM latency of responses|difference between session 2 and session 1 EEG Spectral power during RVIP task,"University Hospital, Lille",Male,18 Years to 30 Years   (Adult),Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2013_45|2015-A00046-43,19-May-17,Dec-20,Dec-20,14-Sep-16,null,20-Apr-18,"Hôpital Cardiologique, CIC, Lille, France",,https://ClinicalTrials.gov/show/NCT02899403
NCT02891343,Effect of Hypoxia on Cognitive Assessment and Cerebral Activity in Healthy Volunteers,Hypoxia,Recruiting,No Results Available,Alteration of Cognitive Function|Hypoxia,Other: 2-hour period of hypoxia,the mean of response latency to the Rapid Visual Information Processing (RVIP) test of the CANTAB battery|The number of adverse events occuring during the period of hypoxia,"University Hospital, Lille",Male,18 Years to 30 Years   (Adult),Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2013_44|2014-A00513-44,Nov-15,Feb-20,Feb-20,7-Sep-16,null,20-Feb-19,"Centre d'Investigation Clinique, CHRU, Lille, France|Centre d'investigation Clinique, Marseille, France",,https://ClinicalTrials.gov/show/NCT02891343
NCT02886494,A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia,,Recruiting,No Results Available,Alzheimer's Disease or Vascular Dementia,Drug: BAC|Drug: Matched placebo,Change in Alzheimer Disease Assessment Scale-cognitive (ADAS-cog) score at Week 12 visit compared to baseline|Change in ADAS-cog score at all post treatment visits (except Week 12 visit) compared to baseline|Clinician's Interview Based Impression of Change-Plus Caregiver Input (CIBIC-plus) score at all post treatment visits|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) score at all post treatment visits compared to baseline|Change in Mini-Mental State Examination (MMSE) score at all post treatment visits compared to baseline|Change in Neuropsychiatric Inventory (NPI) score at all post treatment visits compared to baseline|Adverse event incidence,Charsire Biotechnology Corp.,All,"40 Years and older   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BAC-02,Dec-16,Nov-18,Nov-19,1-Sep-16,null,9-Mar-18,"Clinical Research Consortium, Tempe, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|Pacific Research Network, LLC, San Diego, California, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States|SPRI, Brooklyn, New York, United States|Wake Research Associates, Raleigh, North Carolina, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02886494
NCT02884492,Imaging Tau in Alzheimer's Disease and Normal Aging,,Terminated,Has Results,Alzheimer's Disease,Drug: 18F-THK-5351|Procedure: Lumbar Puncture (optional),18F-THK-5351 Standardized Uptake Value Ratio,William Charles Kreisl|National Institute on Aging (NIA)|Columbia University,All,"50 Years and older   (Adult, Older Adult)",Phase 2,17,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AAAQ7868|1K23AG052633-01,Jul-16,30-Jun-17,30-Jun-17,31-Aug-16,19-Nov-18,19-Nov-18,"Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02884492/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02884492
NCT02880956,A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: ABBV-8E12|Drug: placebo for ABBV-8E12,"Adverse Events|Clinical Dementia Rating - Sum of Boxes (CDR-SB)|University of California's Performance Based Skills Assessment, Brief Version (UPSA-Brief)|Serum concentration at the end of a dose interval (Ctrough) for ABBV-8E12|Area under the concentration time curve (AUC) for ABBV-8E12|Time to Cmax (Tmax) for ABBV-8E12|Maximum observed serum concentration (Cmax) for ABBV-8E12|Mini-Mental State Examination (MMSE)|24-Item Alzheimer's Disease Cooperative Study/Activities of Daily Living Scale Adapted for Patients with Mild Cognitive Impairment (ADCS-MCI-ADL-24)|Functional Activities Questionnaire (FAQ)|Repeatable Battery for Assessment of Neuropsychological Status (RBANS)|Alzheimer's Disease Cooperative Study Clinical Global Impression of Change for Mild Cognitive Impairment (ADCS-CGIC-MCI).|Alzheimer's Disease Assessment Scale (14-Item) Cognition Portion (ADAS-Cog-14)|Neuropsychiatry Inventory (NPI)",AbbVie,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M15-566|2016-001634-10,17-Oct-16,30-Apr-21,31-Jul-21,26-Aug-16,null,28-Mar-19,"Banner University MC Phoenix /ID# 151536, Phoenix, Arizona, United States|Banner Sun Health Res Inst /ID# 151895, Sun City, Arizona, United States|Irvine Clinical Research /ID# 162331, Irvine, California, United States|Ucsd /Id# 152467, La Jolla, California, United States|Ray Dolby Brain Health Center /ID# 154965, San Francisco, California, United States|Univ California, San Francisco /ID# 152053, San Francisco, California, United States|Brain Matters Research /ID# 147796, Delray Beach, Florida, United States|Southwest Florida Neuropsych /ID# 162332, Fort Myers, Florida, United States|Mayo Clinic /ID# 151236, Jacksonville, Florida, United States|Bioclinica Research /ID# 147804, Orlando, Florida, United States|University of South Florida /ID# 151890, Tampa, Florida, United States|Bioclinica Reseach /ID# 151633, The Villages, Florida, United States|Emory University Hospital /ID# 151492, Atlanta, Georgia, United States|Atlanta Center for Medical Res /ID# 151550, Atlanta, Georgia, United States|NeuroStudies.net, LLC /ID# 152746, Decatur, Georgia, United States|Great Lakes Clinical Trials /ID# 152754, Chicago, Illinois, United States|Advocate Lutheran General Hosp /ID# 152052, Park Ridge, Illinois, United States|Southern IL Univ School of Med /ID# 151769, Springfield, Illinois, United States|Indiana University /ID# 151861, Indianapolis, Indiana, United States|University of Kansas Medical Center - Alzheimer's Disease Center /ID# 151554, Fairway, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 152753, Lexington, Kentucky, United States|Johns Hopkins Bayview Med Cnt /ID# 151893, Baltimore, Maryland, United States|Massachusetts General Hospital /ID# 151770, Boston, Massachusetts, United States|Brigham and Women's Physicians /ID# 151882, Boston, Massachusetts, United States|Hattiesburg Clinic /ID# 202388, Hattiesburg, Mississippi, United States|Princeton Medical Institute /ID# 152934, Princeton, New Jersey, United States|Scott Research Inc. /ID# 151880, Laurelton, New York, United States|North Shore University Hospital /ID# 151632, New Hyde Park, New York, United States|Duke Univ Med Ctr /ID# 147828, Durham, North Carolina, United States|Oregon Health and Science University /ID# 151690, Portland, Oregon, United States|Keystone Clinical Studies LLC /ID# 202305, Norristown, Pennsylvania, United States|Rhode Island Hospital /ID# 151538, Providence, Rhode Island, United States|Vanderbilt Univ Med Ctr /ID# 154547, Nashville, Tennessee, United States|Kerwin Research Center /ID# 147815, Dallas, Texas, United States|Houston Methodist Hospital /ID# 154810, Houston, Texas, United States|McGovern Medical School /ID# 204860, Houston, Texas, United States|University of Utah /ID# 151858, Salt Lake City, Utah, United States|Integrated Neurology Services /ID# 154863, Alexandria, Virginia, United States|St. Vincent's Hospital, Darlinghurst /ID# 152632, Darlinghurst, New South Wales, Australia|Griffith University /ID# 152635, Southport, Queensland, Australia|Austin Hospital /ID# 152637, Heidelberg, Victoria, Australia|Royal Melbourne Hospital /ID# 202633, Parkville, Victoria, Australia|Australian Alzheimer's Res Fou /ID# 152634, Nedlands, Western Australia, Australia|Neurodegenerative Disorders Re /ID# 152826, West Perth, Western Australia, Australia|Cliniques Universitaires Saint Luc /ID# 152847, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Leuven /ID# 152642, Leuven, Belgium|CHC Liege /ID# 152846, Liege, Belgium|Parkwood Institute /ID# 164204, London, Ontario, Canada|Toronto Memory Program /ID# 147863, Toronto, Ontario, Canada|Rigshospitalet, Memory Clinic /ID# 153192, Copenhagen Ø, Hovedstaden, Denmark|Clinical Research Services Turku /ID# 152845, Turku, Varsinais-Suomi, Finland|Ita-Suomen Yliopisto /ID# 152959, Kuopio, Finland|AOU di Modena /ID# 152394, Modena, Emilia-Romagna, Italy|AO Univ Policlinico Agostino G /ID# 152396, Rome, Lazio, Italy|AOU Policlinico Umberto I /ID# 163144, Rome, Lazio, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 152391, Milano, Lombardia, Italy|IRCCS - San Giovanni di /ID# 152395, Brescia, Italy|Fondazione IRCCS Cà Granda Osp /ID# 152401, Milan, Italy|Azienda Ospedaliera di Perugia /ID# 152397, Perugia, Italy|National Hospital Organization Omuta Hospital /ID# 210478, Omuta-shi, Fukuoka, Japan|Hyogo Brain and Heart Center /ID# 209526, Himeji-shi, Hyogo, Japan|Shonan Kamakura General Hospital /ID# 210021, Kamakura-shi, Kanagawa, Japan|Rakuwakai Otowarehabilitation Hospital /ID# 209330, Kyoto-shi, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center /ID# 209289, Matsumoto-shi, Nagano, Japan|Osaka Saiseikai Nakatsu Hospital /ID# 209960, Osaka-shi, Osaka, Japan|MI Clinic /ID# 210134, Toyonaka-shi, Osaka, Japan|Shizuoka Institute of Epilepsy and Neurological Disorders /ID# 209208, Shizuoka-shi, Shizuoka, Japan|National Center of Neurology and Psychiatry /ID# 209179, Kodaira, Tokyo, Japan|Yamagata Tokushukai Hospital /ID# 209868, Yamagata-shi, Yamagata, Japan|Universitair Medisch Centrum Utrecht /ID# 163576, Utrecht, Netherlands|CGM Research Trust /ID# 152827, Burwood Christchurch, New Zealand|Fundacion CITA Alzheimer /ID# 152645, Donostia, Pais Vasco, Spain|Hospital Clinic de Barcelona /ID# 152646, Barcelona, Spain|Fundacio ACE /ID# 152643, Barcelona, Spain|Hospital Clin Univ San Carlos /ID# 153703, Madrid, Spain|Hospital Universitario Doce de /ID# 152647, Madrid, Spain|Sahlgrenska US Mölndal /ID# 154465, Mölndal, Vastra Gotalands Lan, Sweden|Karolinska University Hospital /ID# 156705, Huddinge, Sweden",,https://ClinicalTrials.gov/show/NCT02880956
NCT02878486,Intervention to Reduce Sedentary Time,ReST-MCI,Completed,No Results Available,Mild Cognitive Impairment,Device: Jawbone Up|Behavioral: Physical Activity Education|Device: ActivPAL,Average Daily Sitting Time|Number of sitting bouts greater than 30 min|Change in insulin levels|Change in glucose levels,University of Kansas Medical Center,All,"Child, Adult, Older Adult",Not Applicable,6,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,STUDY00003981,Aug-16,Jan-18,Jan-18,25-Aug-16,null,19-Oct-18,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02878486
NCT02874820,I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD,I2PETPG,Completed,No Results Available,Alzheimer Disease,Radiation: [11C]BU99008|Drug: Idazoxan,Density and distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP),Imperial College London|GlaxoSmithKline,Male,"50 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,2,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,16HH3243|MR/L01307X/1,Jul-16,Mar-17,Jul-17,22-Aug-16,null,7-Mar-18,"Centre for Neuropsychopharmacology; Division of Brain Sciences; Imperial College London; Burlington Danes Building; Hammersmith Hospital campus; 160 Du Cane Road, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02874820
NCT02873546,tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia,ALSTICO,Recruiting,No Results Available,Alzheimer's Disease|Progressive Primary Aphasia|Early or Mild State,Device: transcranial Direct Current Stimulation (tDCS),change from baseline cognitive functions at 3 weeks,Centre Hospitalier Universitaire de Besancon|Centre Hospitalier Universitaire Dijon|Assistance Publique - Hôpitaux de Paris,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",API/2011/24,19-Jul-13,31-Jan-18,31-Jul-18,19-Aug-16,null,13-Oct-17,"CHU Besancon - Clinical Psychiatric Department, Besancon, France|Hopital Universitaire Dijon, Dijon, France|Assistance Publique - Hôpitaux Paris, Paris, France",,https://ClinicalTrials.gov/show/NCT02873546
NCT02871427,Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder,,Terminated,No Results Available,Lewy Body Dementia|Dementia With Lewy Bodies|Parkinson's Disease Dementia|Visual Hallucinations|REM Sleep Behavior Disorder,Drug: Nelotanserin,"Long-term safety and tolerability will be evaluated based on incidence of adverse events (AEs) and significant changes in physical examinations, vital signs, ECGs, and clinical laboratory assessments over time during treatment.|Long-term effectiveness will be evaluated based on change in the frequency and severity of visual hallucinations (as recorded by patient's caregiver) and/or REM sleep behaviors (based on a clinical evaluator) over time during treatment.",Axovant Sciences Ltd.,All,"50 Years and older   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RVT-102-2003,20-Oct-16,17-Jan-19,17-Jan-19,18-Aug-16,null,27-Mar-19,"US120, Birmingham, Alabama, United States|US143, Little Rock, Arkansas, United States|US114, Boca Raton, Florida, United States|US180, Maitland, Florida, United States|US154, Ocala, Florida, United States|US113, Orlando, Florida, United States|US152, Ormond Beach, Florida, United States|US107, Indianapolis, Indiana, United States|US132, Lenexa, Kansas, United States|US103, Rochester, Minnesota, United States|US129, Lincoln, Nebraska, United States|US101, Chapel Hill, North Carolina, United States|US147, Fargo, North Dakota, United States|US111, Cincinnati, Ohio, United States|US104, Cleveland, Ohio, United States|US105, Columbus, Ohio, United States|US173, Lincoln, Rhode Island, United States|US128, Memphis, Tennessee, United States|US131, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02871427
NCT02868905,Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women,Oba,Unknown status,No Results Available,Obesity|Alzheimer's Disease,Procedure: Blood sample,"Methylation of CpG islands in genomic DNA and in 4 target genes involved in AD (APP, SorLA/LR11, BACE1, LRP) in obese and AD subjects|body mass index|visceral fat mass level|leptinemia by ELISA|insulinemia by ELISA|glycemia|triglyceridemia|HDL cholesterol level in blood|Reactive C protein level in blood","Central Hospital, Nancy, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,160,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2015-A01686-43,Sep-16,Sep-18,Sep-18,16-Aug-16,null,16-Aug-16,"CHRU de Nancy, Nancy, France",,https://ClinicalTrials.gov/show/NCT02868905
NCT02864303,Use of Saliva for Alzheimer's Disease Diagnosis,SalivALZ,Unknown status,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Other: Saliva samples,Aβ40 and Aβ42|Neuropsychologic tests|ApoE polymorphism,"University Hospital, Montpellier",All,"55 Years to 80 Years   (Adult, Older Adult)",Not Applicable,250,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),8835,Jun-12,Dec-18,Dec-18,12-Aug-16,null,22-Dec-16,"CHRU, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02864303
NCT02861846,Predictive Value of Biomarkers of the Alzheimer's Disease (AD) in Elderly Patients With New-onset Epilepsy,BIOMALEPSIE,Recruiting,No Results Available,Epilepsy,Biological: profile of CSF biomarkers of AD,The primary endpoint was the number of patients in a population of subjects older than 60 years with new-onset epilepsy but without cognitive impairment whose profile of the CSF biomarkers of the AD is suggestive of an AD.|changes in episodic verbal memory at 2 years|changes in visual recognition memory at 2 years|Evolution of DO 80 score|Evolution of categorical influences|Evolution of TOP 10 score|Changes in monthly frequency of seizures at 2 years,Hospices Civils de Lyon,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,69HCL16-0041|2016-A00563-48,1-Mar-17,1-Mar-22,1-Mar-22,10-Aug-16,null,30-Jan-19,"Hospices Civils de Lyon, Bron, France|CHU Gabriel- Montpied, Clermont-Ferrand, France|CHU des Alpes, Grenoble, France|CHU Hôpital Nord, Saint-Étienne, France",,https://ClinicalTrials.gov/show/NCT02861846
NCT02860065,CPC-201 Alzheimer's Disease Type Dementia: PET Study,,Withdrawn,No Results Available,Alzheimer's Disease,Drug: CPC-201|Other: Positron emission tomography (PET),Donepezil Maximum tolerated dose (MTD) change on imaging,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",All,"50 Years to 79 Years   (Adult, Older Adult)",Phase 2,0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPC-001-15,30-Sep-16,30-Jun-17,30-Jun-17,9-Aug-16,null,9-Aug-17,"Henry Ford Health System--West Bloomfield Hospital, West Bloomfield Township, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02860065
NCT02859207,A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects,,Completed,No Results Available,Early Alzheimer's Disease,Drug: E2609,"Mean maximum plasma concentration (Cmax) of E2609|Mean area under plasma concentration versus time curve from time zero to time of last quantifiable concentration (AUC(0-t)) of E2609|Mean area under plasma concentration versus time curve from time zero to infinity (AUC(0-inf)) of E2609|Mean time to reach maximum plasma concentration (tmax) of E2609 and its metabolites|Mean terminal phase plasma half-life (t1/2) of E2609 and its metabolites|Mean apparent total body clearance (CL/F) of E2609|Mean apparent volume of distribution (Vz/F) of E2609|Mean ratio of AUC(0-inf) of individual metabolite to AUC(0-inf) of E2609, corrected for molecular weight (AUC metabolite ratio)|Mean plasma protein unbound fraction (fu) of E2609|Mean Cmax values adjusted for unbound fraction in plasma (Cmaxu) of E2609|Mean AUC(0-inf) values adjusted by unbound fraction in plasma (AUCu) of E2609|Mean Apparent clearance relative to the unbound plasma concentration based on AUCu (CLu/F) of E2609|Number of participants with treatment emergent adverse events and serious adverse events",Eisai Inc.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,32,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E2609-A001-103,Aug-16,6-Dec-16,25-Jan-17,8-Aug-16,null,8-Jun-17,"Miami, Florida, United States|Orlando, Florida, United States|Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02859207
NCT02849639,The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression,INCREASE,Recruiting,No Results Available,Alzheimer's Disease|Dementia,Other: Placebo|Other: Medication Therapy Management (MTM)|Drug: Scopolamine patch,Medication Appropriateness Index scale|Cognitive Reserve: Trail Making Test B with and without the scopolamine patch|Cognitive Reserve: Montreal Cognitive Assessment|Cognitive Reserve: California Verbal Learning test|Perceived Health Status,Daniela Moga|National Institute on Aging (NIA)|University of Kentucky,All,65 Years to 101 Years   (Older Adult),Early Phase 1,90,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",16-0375-F2L INCREASE|1R01AG054130-01,4-Apr-17,Mar-21,Mar-21,29-Jul-16,null,28-Mar-19,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT02849639
NCT02848404,Therapeutic Efficacy of Categorical Language Fluency Smartphone Game Application,,Enrolling by invitation,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Device: Categorical Language Fluency Smartphone Application,Application usage log|Subjective Memory Complaint Questionnaire|Geriatric Depression Scale|Korean version of MMSE for dementia screening,"Seoul National University Bundang Hospital|Seoul National University|Ministry of Science, ICT and Future Planning",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-0028631,Jun-16,Dec-19,Mar-20,28-Jul-16,null,4-Apr-19,,,https://ClinicalTrials.gov/show/NCT02848404
NCT02846415,Play Intervention for Dementia for Promoting Cognitive Function: A Feasibility Study,,Completed,No Results Available,Dementia|Alzheimer Disease,Behavioral: Play Intervention for Dementia,Changes of Global Cognition measured with Montreal Cognitive Assessment Scale after 2 months of intervention|Changes of Global Cognition measured with Montreal Cognitive Scale after 3 months of intervention|Memory measured with Fuld Object Memory Evaluation|Verbal Fluency measured with Modified Verbal Fluency Test,The Hong Kong Polytechnic University,All,65 Years and older   (Older Adult),Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",4-ZZFU,1-Aug-16,30-Apr-17,31-Dec-17,27-Jul-16,null,12-Apr-18,"School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT02846415
NCT02843529,Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (Altoida™),AltoidaML,Enrolling by invitation,No Results Available,Alzheimer Disease|Mild Cognitive Impairment|Memory Disorders|Cognitive Impairment|Dementia|Presymptomatic Disease,"Other: Altoida: neuropsychological, EEG and CSF biomarkers","Change in sensitivity , specificity and accuracy of Altoida models|Change from Baseline in Clinical Measure 1|Change from Baseline in Clinical Measure 2|Change from Baseline in Clinical Measure 3|Change from Baseline in Clinical Measure 4|Change from Baseline in Clinical Measure 5|Change from Baseline in Clinical Measure 6|Change from Baseline in Clinical Measure 7|Change from Baseline in Cognitive Measure|Secondary resting state EEG endpoints|Secondary resting state auditory oddball ERP endpoints|Total Abeta 1-42 (Aβ42) amyloid deposition|Change of brain amyloid deposition|Change of CSF biomarkers tau and ptau181 values|MRI (Optional)",Altoida|Greek Alzheimer's Association and Related Disorders|University of Roma La Sapienza|IRCCS Centro San Giovanni di Dio Fatebenefratelli|Neuromed IRCCS|Swiss Federal Institute of Technology|Scripps Memorial Hospital|Global Brain Health Institute (GBHI)|Novartis|Research Center on Computational Biomarkers (RCCBM)|BiHELab - Bioinformatics and Human Electrophysiology Lab|Fundacion Clinic per a la Recerca Biomédica|Trinity College Dublin|University of Barcelona|SwissNeuroRadiologyInstitute (SNRI),All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,900,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,altoidaML01,11-May-15,3-Dec-19,3-Dec-19,26-Jul-16,null,20-May-19,,,https://ClinicalTrials.gov/show/NCT02843529
NCT02843906,"Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection?",BIPAGE,Unknown status,No Results Available,Senile Plaques|Tau Proteins|Alzheimer Disease|Bipolar Disorders|Mild Cognitive Impairment,Procedure: Lombar Punction|Radiation: Magnetic Resonance Imaging (MRI)|Radiation: Positron-Emission Tomography (TEP) /(FDG)|Other: Psychiatric tests|Other: Neuropsychological Tests|Genetic: Apolipoprotein (ApoE) detection,Functionnal/Cognitive evaluation|Psychatric evaluation|Brain MRI,"University Hospital, Grenoble|University Hospital, Tours|Assistance Publique - Hôpitaux de Paris|University Hospital, Marseille|Hospices Civils de Lyon|Centre Hospitalier Universitaire de Besancon|Central Hospital, Nancy, France|University Hospital, Clermont-Ferrand|Versailles Hospital|University Hospital, Montpellier|Reims University Hospital|Centre Hospitalier Princesse Grace",All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,180,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,38RC13.217,Jul-15,Jul-18,Jul-18,26-Jul-16,null,26-Jul-16,"University Hospital, Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT02843906
NCT02844855,Memory for Action in Neurological Patients,EMBODIMENT,Recruiting,No Results Available,Alzheimer Disease|Parkinson Disease,Behavioral: Cognitive tests,Number of correct answers,Centre Hospitalier Universitaire de Saint Etienne,All,"55 Years to 80 Years   (Adult, Older Adult)",Not Applicable,99,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1608068|2016-A00891-50,26-Dec-16,31-Aug-19,31-Aug-19,26-Jul-16,null,27-Jul-18,"CHU de Saint-Etienne, Saint-Etienne, France|Hcl - Cm2R, Villeurbanne, France",,https://ClinicalTrials.gov/show/NCT02844855
NCT02841605,Enteric Nervous System in Alzheimer Disease,ENTEROMA,Unknown status,No Results Available,Alzheimer Disease,Procedure: Rectosigmoidoscopy with colonic biopsies|Procedure: Colonoscopy with colonic biopsies,Presence of alpha-synuclein aggregates in colonic biopsies using immunohistochemistry,Nantes University Hospital,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,55,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),RC15_0458,Oct-16,May-19,May-19,22-Jul-16,null,22-Jul-16,"University Hospital, Nantes, France",,https://ClinicalTrials.gov/show/NCT02841605
NCT02840045,Development of a New Neuroimaging Method Aimed to Differentiate Mnesic Abilities of Alzheimer and Depressed Patients,RIHANNA,Recruiting,No Results Available,Alzheimer Disease|Depression,Device: high-density electroencephalography,Amplitude of event-related potentials|Spectral power,Centre Hospitalier Universitaire de Besancon,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,API/2014/51,20-Feb-15,20-Aug-18,20-Aug-18,21-Jul-16,null,9-Aug-17,"CHRU Besançon, Besancon, Franche-Comte, France",,https://ClinicalTrials.gov/show/NCT02840045
NCT02840279,A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects,,Completed,No Results Available,Alzheimer's Disease,Drug: BPN14770|Drug: Placebo,"Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Area Under the Curve from Time Zero to Twelve Hours [AUC0-12]|Area Under the Concentration Time Curve from Zero to 12 Hours, Corrected for Dose [AUC12/D]",Tetra Discovery Partners,All,"25 Years to 90 Years   (Adult, Older Adult)",Phase 1,77,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BPN14770-CNS-102,Jun-16,Nov-16,Dec-16,21-Jul-16,null,18-Jan-17,"Jasper Clinic, Kalamazoo, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02840279
NCT02839187,Neuro Imaging and Multimodal Alzheimer's Disease,NIMAD,Completed,No Results Available,Alzheimer Disease,Radiation: Neuroimaging,fixing the AV-45 during PET|Deposition of amyloid protein|Standard Cognitive function|Specific memory evaluation,"University Hospital, Toulouse",All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,59,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,07 306 02,Jun-10,May-12,May-12,20-Jul-16,null,11-May-17,"University Hospital of Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02839187
NCT02836054,Study of Degenerescence CSF Hallmarks in Older Bipolar Patients,BPL-1318,Recruiting,No Results Available,Bipolar Disorder|Alzheimer's Disease,Procedure: lumbar puncture (LP)|Procedure: brain MRI,"Profile 4 neurodegeneration's biomarkers of Alzheimer's disease dosed in cerebrospinal fluid of aged subjects with bipolar disorder : Total Tau proteins, phosphorylated Tau proteins, Aß40 and Aß1-42 concentration","University Hospital, Grenoble",All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,38RC13.408|2013-A00930-45,Nov-13,Dec-19,Dec-19,18-Jul-16,null,7-Jan-19,"University Hospital, Grenoble, Grenoble, Isère, France",,https://ClinicalTrials.gov/show/NCT02836054
NCT02832921,Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk,,Recruiting,No Results Available,Alzheimer's Disease (AD),Behavioral: cognitive training by virtual reality|Behavioral: watching a scientific TV documentary|Device: treadmill,change in overall cognition- measured by averaging z-scores from 14 paper and pencil neuropsychological tests covering episodic memory and executive functions cognitive domains.|change in cerebral blood flow from arterial spin labeling (ASL)|specific cognitive domains- average of z-scores of paper and pencil memory tests and of executive functions tests|blood oxygenation level dependent (BOLD) functional MRI (fMRI) signal in the fronto-parietal network associated with working memory|brain resting state functional connectivity by resting state network fMRI BOLD signal correlations|hippocampal volume|frontal inferior cortex volume|white matter hyperintensity (WMH) burden|diffusion-tensor imaging (DTI) measures,Sheba Medical Center,All,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",SHEBA-16-2988-MSB-CTIL,Jul-16,Jul-19,Aug-19,14-Jul-16,null,26-Jan-18,"Sheba Medical Center, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT02832921
NCT02833792,Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer Dementia,Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Other: Placebo,Safety of aMBMC administration|Efficacy of aMBMC administration,"Stemedica Cell Technologies, Inc.|Stemedica International SA",All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2,40,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,STEM105-M-AD,Jun-16,Dec-19,Jun-20,14-Jul-16,null,9-Apr-19,"John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California, United States",,https://ClinicalTrials.gov/show/NCT02833792
NCT02833870,Non-pharmacological Care of Alzheimer's Disease: Benefice of Musical Interventions,MusicAlzheimer,Completed,No Results Available,Alzheimer's Disease (AD) and Related Disorders,Behavioral: Musical intervention|Behavioral: Non-musical (cooking) intervention|Behavioral: Control with no intervention,Overall score in the Neuropsychiatric Inventory,CHU de Reims,All,"60 Years to 99 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",PO13125 252Au12,Sep-13,Jun-15,Jun-15,14-Jul-16,null,2-Jan-17,"Chu de Reims, Reims, France",,https://ClinicalTrials.gov/show/NCT02833870
NCT02831283,Imaging Inflammation in Alzheimer's Disease,,Enrolling by invitation,No Results Available,Alzheimer's Disease,Drug: 11C-PBR28|Drug: 18F-Florbetaben|Procedure: Lumbar puncture (optional),11C-PBR28 binding (standardized uptake value ratio)|18F-Florbetaben binding (standardized uptake value ratio)|Cerebral spinal fluid (CSF) biomarkers,William Charles Kreisl|National Institute on Aging (NIA)|Columbia University,All,"60 Years and older   (Adult, Older Adult)",Phase 2,100,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AAAO1151|1K23AG052633-01,Jun-16,Jun-21,Jun-21,13-Jul-16,null,31-Jan-19,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02831283
NCT02829801,Evaluation of the Animal Intervention Used as Therapy,ELIAUT,Recruiting,No Results Available,Alzheimer Disease,Behavioral: AAT and cognitive stimulation and rehabilitation of social tie.|Behavioral: Cognitive stimulation and rehabilitation of social tie.,evaluation of the changes of the well being from baseline until 3 months|evaluation of the changes of psycho-behavioral symptoms of dementia (PBSD) from baseline until 3 months|evaluation of the changes of depressive symptoms from baseline until 3 months|evaluation of the changes of the anxiety from baseline until 3 months|evaluation of the changes of cognitive performances from baseline until 2 months,Hospices Civils de Lyon,All,65 Years and older   (Older Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,69HCL15_678,2-Mar-16,2-May-19,2-May-19,12-Jul-16,null,9-Aug-17,"Hôpital des Charpennes, Villeurbanne, France",,https://ClinicalTrials.gov/show/NCT02829801
NCT02820896,A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Placebo|Drug: RO7105705,Number of Participants with Adverse Events|Number of Participants with Dose Limiting Adverse Events (DLAEs)|Change from Baseline in Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS) Score|Change From Baseline to Week 19 in Global Function as Assessed Using the Clinical Dementia Rating (CDR) Global Score in Alzheimer's Disease Participants|Percentage of Participants with Anti-Therapeutic Antibodies (ATAs)|Serum Concentration of RO7105705 - Single Dose Cohorts: IV Administration|Serum Concentration of RO7105705 - Single Dose Cohorts: SC Administration|Serum Concentration of RO7105705 - Multiple Dose Cohorts: IV Administration|Change From Baseline to Week 19 in Cognitive Function as Assessed Using the Mini-Mental State Examination (MMSE) in Alzheimer's Disease Participants,"Genentech, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,74,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN39058,29-Jun-16,26-Jun-17,26-Jun-17,1-Jul-16,null,21-Jul-17,"New Orleans Center for Clinical Research, Knoxville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02820896
NCT02820155,Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects,,Unknown status,No Results Available,Healthy,Drug: RGN1016|Drug: Placebo,Number of incidence of Adverse Events.|Area under the plasma concentration-time curve (AUC)|Time to peak drug concentration (Tmax)|Maximum Plasma Concentration (Cmax)|Half-life T1/2,National Taiwan University Hospital|National Taiwan University,Male,20 Years to 45 Years   (Adult),Phase 1,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",201412002MIPD,Jun-16,Feb-17,Feb-17,30-Jun-16,null,6-Jul-16,"National Taiwan University Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02820155
NCT02817074,MIND Diet Intervention and Cognitive Decline,MIND,"Active, not recruiting",No Results Available,Cognitive Decline|Dementia|Alzheimer Disease|Vascular Dementia,Behavioral: MIND Diet|Behavioral: Mild Weight Loss,Change in global cognitive score|Change in brain MRI total brain /intracranial volume (cubic centimeters) and hippocampal/intracranial volume (cubic centimeters),Rush University Medical Center|Harvard School of Public Health|Brigham and Women's Hospital|National Institute on Aging (NIA),All,65 Years to 84 Years   (Older Adult),Phase 3,604,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,R01 AG051641|1R01AG052583-01,Jan-17,Apr-21,Apr-21,29-Jun-16,null,26-Jun-18,"Rush University, Chicago, Illinois, United States|Harvard School of Public Health, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02817074
NCT02817906,"ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease",,Terminated,No Results Available,"Agitation in Dementia, Including Alzheimer's Disease",Drug: ITI-007|Drug: Placebo,Cohen-Mansfield Agitation Inventory - Community Version (CMAI-C)|Clinical Global Impression Scale for Severity of Illness (CGI-S),"Intra-Cellular Therapies, Inc.",All,"55 Years and older   (Adult, Older Adult)",Phase 3,177,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ITI-007-201,Jun-16,Dec-18,Dec-18,29-Jun-16,null,20-Dec-18,"Sun City, Arizona, United States|Little Rock, Arkansas, United States|Rogers, Arkansas, United States|Costa Mesa, California, United States|Glendale, California, United States|Irvine, California, United States|Lemon Grove, California, United States|Long Beach, California, United States|Oceanside, California, United States|Riverside, California, United States|Santa Ana, California, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Suwanee, Georgia, United States|Honolulu, Hawaii, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Marlton, New Jersey, United States|Toms River, New Jersey, United States|Brooklyn, New York, United States|Staten Island, New York, United States|Centerville, Ohio, United States|Dayton, Ohio, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02817906
NCT02813070,Comparison of PET Amyloid Imaging in Japanese and Western Subjects,,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease|Healthy,Drug: [18F] Flutemetamol,Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Non-Japanese Readers|Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Japanese Readers,GE Healthcare,All,"25 Years and older   (Adult, Older Adult)",Phase 2,70,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,GE067-017,Oct-12,May-13,May-13,24-Jun-16,5-Jun-17,5-Jun-17,,,https://ClinicalTrials.gov/show/NCT02813070
NCT02811653,Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease,TAMA,Recruiting,No Results Available,Alzheimer Disease,Device: Brain MRI|Other: neuropsychological evaluation|Biological: Blood,median SRT (simple reaction time) to a stimulus (in milliseconds),"Centre Hospitalier Universitaire, Amiens",All,"40 Years to 85 Years   (Adult, Older Adult)",Not Applicable,155,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PI2015_843_0003,Dec-15,Dec-19,Dec-19,23-Jun-16,null,23-Jun-16,"CHU Amiens, Amiens, France",,https://ClinicalTrials.gov/show/NCT02811653
NCT02802371,Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program,PHARMAID,Recruiting,No Results Available,Alzheimer Disease,Behavioral: Psychosocial intervention|Other: Pharmaceutical care and psychosocial support,caregiver's burden|caregiver's quality of life|caregiver's anxiety|caregiver's depression|patient's quality of life|patient's behavioral disorders|patient's functional autonomy|Occurrence of medical consultation|Occurrence of recourse to emergency service|Occurrence of hospitalizations|Occurrence of admission in institution,Hospices Civils de Lyon,All,65 Years and older   (Older Adult),Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,69HCL14_0450,Aug-16,Feb-20,Feb-20,16-Jun-16,null,10-Jan-19,"Pharmacy unit and Clinical Research Center VCF ("" Aging Brain Frailty "") University hospital of Lyon, Charpennes Hospital / University Lyon / INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, Villeurbanne, France",,https://ClinicalTrials.gov/show/NCT02802371
NCT02800395,Influence of Oxidative Stress and Nutrition Biomarkers on the Cognitive Decline Evolution in Alzheimer Disease,GERIOX,Recruiting,No Results Available,Alzheimer Disease,Procedure: Malnutrition screening and perioperative nutritional support,"Change (evolution) of patient's cognitive profile evaluation measured by MMSE score method during memory consultation follow-up, every 6 months until patient loss.|cognitive profile evaluation at inclusion phase|Présence of cardiovascular risk factor|treatment evaluation|Functionality|Presence of anomalies on cerebral imaging data that evoke neuro-degenerative pathology, by MRI",Hospices Civils de Lyon,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,350,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2014.86,Dec-14,Dec-24,Dec-24,15-Jun-16,null,20-Nov-18,"Service de Médecine Gériatrique. Groupement Hospitalier Sud. Hospices Civils de Lyon., Pierre Benite, France",,https://ClinicalTrials.gov/show/NCT02800395
NCT02795780,Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05,,Completed,No Results Available,Alzheimer's Disease,Drug: 18F-AV-1451,Change in tau deposition over time,Avid Radiopharmaceuticals,All,"50 Years and older   (Adult, Older Adult)",Phase 2,79,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-1451-A18,Aug-16,28-Aug-17,28-Aug-17,10-Jun-16,null,25-Oct-18,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Imaging Endpoints, Scottsdale, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Institute for Brain Aging and Dementia, UC Irvine, Irvine, California, United States|21st Century Oncology, Newport Beach, California, United States|Alzheimer's Disease Center, UC Davis, Sacramento, California, United States|California Medical Clinic for Headache, Santa Monica, California, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|University of South Florida Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|New York University Center for Brain Health, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02795780
NCT02793232,"Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.",,Completed,Has Results,Healthy Subjects,Drug: PF-06751979 single dose|Drug: Placebo single dose|Drug: PF-06751979 multiple ascending dose|Drug: Placebo multiple ascending dose|Drug: PF-06751979 multiple dose|Drug: Placebo multiple elderly dose,Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Abnormal Physical Examinations Findings|Number of Participants With Abnormal Neurological Examinations Findings|Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Baseline|Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Day 7|Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Day 14|Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Day 19|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By Telemetry|Number of Participants With Vital Sign Abnormalities|Number of Participants With Laboratory Abnormalities|Part A: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part A: Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of PF-06751979|Part A: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06751979|Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979|Part A: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06751979|Part A: Dose Normalized Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf [dn]) of PF-06751979|Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part A: Plasma Decay Half-Life (t1/2) of PF-06751979|Part A: Apparent Clearance (CL/F) of PF-06751979|Part A: Apparent Volume of Distribution (Vz/F) of PF-06751979|Part B: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part B: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979|Part B: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part B: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979|Part B: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau[dn]) of PF-06751979|Part B: Apparent Clearance (CL/F) of PF-06751979|Part B: Minimum Observed Plasma Concentration (Cmin) of PF-06751979|Part B: Peak-to-Trough Ratio of PF-06751979|Part B: Observed Accumulation Ratio (Rac) for AUCtau of PF-06751979|Part B: Observed Accumulation Ratio for Maximum Observed Plasma Concentration (Rac Cmax) of PF-06751979|Part B: Plasma Decay Half-Life (t1/2) of PF-06751979|Part B: Apparent Volume of Distribution (Vz/F) of PF-06751979|Part C: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part C: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979|Part C: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part C: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979|Part C: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau[dn]) of PF-06751979|Part C: Apparent Oral Clearance (CL/F)|Part C: Minimum Observed Plasma Concentration (Cmin) of PF-06751979|Part C: Peak-to-Trough Ratio of PF-06751979|Part C: Observed Accumulation Ratio (Rac) for AUCtau of PF-06751979|Part C: Observed Accumulation Ratio for Maximum Observed Plasma Concentration (Rac Cmax) of PF-06751979|Part C: Plasma Decay Half-Life (t1/2) of PF-06751979|Part C: Apparent Volume of Distribution (Vz/F) of PF-06751979|Part B: Amount of PF-06751979 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)|Part B: Percentage of Dose of PF-06751979 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)|Part B: Renal Clearance of PF-06751979|Part B: Percent Change From Baseline in Cerebrospinal Spinal Fluid (CSF) Amyloid Beta (ABeta) Fragments,Pfizer,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,46,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B8271004|2016-000325-39,13-Jun-16,5-Jan-17,5-Jan-17,8-Jun-16,17-Sep-18,17-Sep-18,"Pfizer Clinical Research Unit, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT02793232
NCT02792179,Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants,,Completed,No Results Available,Alzheimer's Disease,Drug: [18F]RO6958948,"Regional Standardized Uptake Value (SUV), as Assessed by the tau PET Brain Scan|Regional Standardized Uptake Value Ratios (SUVR), as Assessed by the Tau PET Brain Scan|Change in SUV for Different Brain Regions|Change in SUVR for Different Brain Regions|Percentage of Participants with Adverse Events",Hoffmann-La Roche,All,"25 Years and older   (Adult, Older Adult)",Phase 1,4,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,BP39126,19-Jul-16,28-Sep-16,28-Sep-16,7-Jun-16,null,1-Nov-17,"Johns Hopkins Medical Institutions, Johns Hopkins Outpatient Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02792179
NCT02792257,Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD),THC-AD,Recruiting,No Results Available,Alzheimer's Disease,Drug: Dronabinol (Marinol®)|Drug: Placebo,"Symptoms of agitation as measured by the Pittsburgh Agitation Scale|Symptoms of agitation as measured by the Neuropsychiatric Inventory, Clinician Version|Adverse events in Dronabinol treatment as compared to placebo",Johns Hopkins University|Mclean Hospital,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,160,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00052955,1-Mar-17,Aug-20,Dec-20,7-Jun-16,null,26-Jun-18,"Johns Hopkins University, Baltimore, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02792257
NCT02791191,A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia,NAVIGATE-AD,Terminated,No Results Available,Alzheimer's Disease,Drug: LY3202626|Drug: Placebo,"Change from Baseline in Positron Emission Tomography (PET) Standard Uptake Value Ratio (SUVr) of ¹⁸F-AV-1451|Percentage of Participants with Emergent Magnetic Resonance Imaging (MRI) Findings|Percentage of Participants with Amyloid-Related Imaging Abnormalities (ARIA)|Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Scores|Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve at Steady State of LY3202626|Change From Baseline in Plasma Amyloid Beta Aβ₁₋₄₀, ₁₋₄₂, and 1-x Concentration|Change from Baseline on the 13-item Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog₁₃)|Change from Baseline on the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-iADL)|Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)",Eli Lilly and Company,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,316,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",16223|I7X-MC-LLCF,16-Jun-16,2-Jul-18,2-Jul-18,6-Jun-16,null,23-Aug-18,"Irvine Clinical Research Center, Irvine, California, United States|Sutter Medical Group, Sacramento, California, United States|Pacific Research Network Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Ray Dolby Brain Health Center/Sutter Health/CPMC, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|North Bay Neuroscience Institute, Sebastopol, California, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Christiana Care Health Service, Wilmington, Delaware, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Compass Research, Melbourne, Florida, United States|Florida International Research Center, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Meridien Research, Spring Hill, Florida, United States|Axiom Research, Tampa, Florida, United States|United Osteoporosis Center, Gainesville, Georgia, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Center for Memory, Newton, Massachusetts, United States|Missouri Memory Center, Bolivar, Missouri, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Millenium Psychiatric Associates LLC, Creve Coeur, Missouri, United States|St Lukes Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pyramid Clinical Research, Monroe, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|Valley Medical Primary Care, Centerville, Ohio, United States|University of Cincinnati Health Neurology, Dayton, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Insight Clinical Trials, Shaker Heights, Ohio, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Clinical Trial Center, LLC, Psychiatry, Jenkintown, Pennsylvania, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Baylor AT&T Memory Center, Dallas, Texas, United States|Nantz National Alzheimer Center, Houston, Texas, United States|University of Texas Health Services Center - Houston, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chermside, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Darlinghurst, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erina, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Iris, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herston, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parkville, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Perth, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gatineau, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Verdun, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Akashi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hachioji, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ikeda, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kasukabe-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagoya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nerima-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Setagaya-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Takamatsu, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wako, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yokosuka-shi, Japan",,https://ClinicalTrials.gov/show/NCT02791191
NCT02789800,Patient-Centred Innovations for Persons With Multimorbidity - Quebec,PACEinMM-QC,"Active, not recruiting",No Results Available,Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Transient Ischemic Attacks|Ulcer|Gastroesophageal Reflux|Irritable Bowel|Crohn's Disease|Ulcerative Colitis|Diverticulosis|Chronic Hepatitis|Diabetes|Thyroid Disorder|Cancer|Kidney Disease|Urinary Tract Problem|Dementia|Alzheimer's Disease|Hyperlipidemia|HIV,Behavioral: DIMAC02,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes|Evaluation of Intervention Effectiveness - Change in Chronic Diseases|Evaluation of Intervention Effectiveness - Change in Health Status|Evaluation of Intervention Effectiveness - Change in Quality of Life|Evaluation of Intervention Effectiveness - Change in Psychological Well-being|Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours|Evaluation of Intervention Effectiveness - Equity|Demographics|Evaluation of Intervention Effectiveness - Change in Transitions of Care|Evaluation of Intervention Effectiveness - Change in Self-Efficacy|Evaluation of Intervention Effectiveness - Change in Patient-Centredness,"Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Western University, Canada|Agence de la Sante et des Services Sociaux du Saguenay-Lac-Saint-Jean",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1956,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2013-010,22-Apr-16,8-Mar-19,1-Mar-20,3-Jun-16,null,15-Dec-17,"Université de Sherbrooke, Chicoutimi, Quebec, Canada|CIUSSS du Sageunay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02789800
NCT02788513,BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,,Recruiting,No Results Available,Alzheimer Disease,Drug: BI 425809 dose 1|Drug: BI 425809 dose 2|Drug: BI 425809 dose 3|Drug: BI 425809 dose 4|Drug: Placebo,The change from baseline in ADAS-Cog11 (Alzheimer's Disease Assessment Scale-Cognitive subscale 11 item) total score|Change from baseline in the ADCS-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living) score|CIBIC+ (Clinician's Interview-Based Impression of Change) score,Boehringer Ingelheim,All,"55 Years and older   (Adult, Older Adult)",Phase 2,585,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1346.23|2015-005438-24,11-Aug-16,20-Sep-19,18-Oct-19,2-Jun-16,null,14-May-19,"Axiom Research LLC, Colton, California, United States|Alliance for Wellness, Long Beach, California, United States|Anderson Clinical Research, Redlands, California, United States|CITrials, Santa Ana, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Lighthouse Research Center, LLC, Jupiter, Florida, United States|Galiz Research, Miami, Florida, United States|Premier Clinical Research Institute, Miami, Florida, United States|Miami Jewish Health System, Miami, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Bioclinica Research, The Villages, Florida, United States|Neuro Trials Research Incorporated, Atlanta, Georgia, United States|Millennium Psychiatric Associates LLC, Saint Louis, Missouri, United States|University at Buffalo, The State University of New York, Buffalo, New York, United States|ANI Neurology, PLLC, dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Northeastern Pennsylvania Memory and Alzheimer Center, Plains, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|The Memory Clinic, Bennington, Vermont, United States|LKH-Univ. Hospital Graz, Graz, Austria|Medical University of Innsbruck, Innsbruck, Austria|SALK Christian-Doppler-Klinik,Paracel.Med.Privatuni.f.Neurol, Salzburg, Austria|Private Practice for Psychiatry and Neurology, Vienna, Austria|The Medical Arts Health Research Group, Kelowna, British Columbia, Canada|True North Clinical Research Halifax, Inc., Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Inc., Kentville, Nova Scotia, Canada|Chatham-Kent Clinical Trials Research Centre, Chatham, Ontario, Canada|Bluewater Clinical Research, Sarnia, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Clinique Neuro-Outaouais, Gatineau, Quebec, Canada|Diex Recherche, Sherbrooke, Quebec, Canada|Orton, Helsinki, Finland|University of Eastern Finland, Brain Research Unit, Kuopio, Finland|Terveystalo Lahti, Lahti, Finland|OYS, Neurologian tutkimusyksikkö, Oulu, Finland|CRST - Clinical Research Services Turku, Turku, Finland|HOP Pellegrin, Bordeaux, France|HOP Pierre Wertheimer, Bron, France|HOP Roger Salengro, Lille, France|HOP Gui de Chauliac, Montpellier, France|HOP Nord Laënnec, Nantes, France|HOP La Pitié Salpêtrière, Paris, France|CHU La Grave-Casselardit - Cité de la Santé, Toulouse, France|HOP de Brabois, Vandoeuvre les Nancy, France|HOP des Charpennes, Villeurbanne, France|Zentrum für klinische Forschung Dr. med. Irma Schöll & Kollegen, Bad Homburg, Germany|Praxis Dr. med. Volker Schumann, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Praxis Dr. Oehlwein, Gera, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|Pharmakologisches Studienzentrum Chemnitz, Mittweida, Germany|Institut für Psychogerontologie, Nürnberg, Germany|Neuropraxis München Süd, Unterhaching, Unterhaching, Germany|Naval Hospital of Athens, Athens, Greece|Eginition Hospital, Athens, Greece|University General Hospital Attikon, Athens, Greece|Athens Medical Center, Athens, Greece|University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece|University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece|Semmelweis University, Budapest, Hungary|CRU Ltd, Neurology Dept., Miskolc, Miskolc, Hungary|University of Szeged, Szeged, Hungary|IRCCS Fondazione Ospedale Maggiore, Milano, Italy|A.O. San Gerardo di Monza, Monza (MB), Italy|Azienda Ospedaliera Universitaria di Padova, Padova, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Fujita Health University Hospital, Aichi, Toyoake, Japan|Inage Neurology and Memory Clinic, Chiba, Chiba, Japan|Sapporo Medical University Hospital, Hokkaido, Sapporo, Japan|Kagawa University Hospital, Kagawa, Kita-gun, Japan|Nara Medical University Hospital, Nara, Kashihara, Japan|Katayama Medical Clinic, Okayama, Kurashiki, Japan|National Hospital Organization Hizen Psychiatric Center, Saga, Kanzaki-gun, Japan|National Center Neurology and Psychiatry, Tokyo, Kodaira, Japan|Showa University East Hospital, Tokyo, Shinagawa, Japan|Oslo Universitetssykehus HF, Hukommelsesklinikken, Oslo, Norway|St. Olavs Hospital, Universitetssykehuset i Trondheim, Trondheim, Norway|Podlassian Center of Psychogeriatry, Bialystok, Bialystok, Poland|Non-Public Outpat. Clinic ""Dom Sue Ryder"", PALLMED Sp. z o.o, Bydgoszcz, Poland|Non-Public Outpatient Clinic Neuro-Kard Ilkowski & Partners, Poznan, Poland|EUROMEDIS Sp. z o.o., Szczecin, Szczecin, Poland|Clin.Research Centre Clinsante SC Ewa Galczak-Nowak,Torun, Torun, Poland|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Sant Joan de Deu de Manresa, Manresa, Spain|Hospital Universitari General de Catalunya, Sant Cugat del Vallès, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|Royal Cornhill Hospital, Aberdeen, United Kingdom|Fulbourn Hospital, Cambridge, United Kingdom|Ninewells Hospital & Medical School, Dundee, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|University Hospital Crosshouse, Kilmarnock, United Kingdom|Warneford Hospital, Oxford, United Kingdom|Sheffield Memory Service, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT02788513
NCT02787746,Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease,STDMMAD,Completed,No Results Available,Alzheimer's Disease,Drug: Donepezil,Monitoring and recording the count and incidence of adverse events (AEs)|Monitor and record the number of patients withdrew from trial for adverse events|Change from baseline to 20 weeks in MMSE scores|Change from baseline to 20 weeks in ADL scores|Correlation analysis between Apo-E genotyping and adverse events of donepezil,"Beijing Friendship Hospital|Eisai China Inc.|Xuanwu Hospital, Beijing",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,241,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STD-CHINA-001,Apr-16,Jan-19,Mar-19,1-Jun-16,null,5-Mar-19,"Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT02787746
NCT02782975,"Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants",,Completed,No Results Available,Alzheimer's Disease,Drug: aducanumab,PK parameter of SC dose of aducanumab: Absolute Bioavailability|PK parameter of IV dose of aducanumab: Area under the concentration-time curve from time zero to infinity (AUCinf)|PK parameter of SC dose of aducanumab: Area under the concentration-time curve from time zero to infinity (AUCinf)|PK parameter of aducanumab: Maximum observed concentration (Cmax)|PK parameter of SC route of aducanumab: Time to reach maximum observed concentration (Tmax)|Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|PK parameter of aducanumab: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)|PK parameter of aducanumab: Terminal elimination half-life (t1/2)|PK parameter of aducanumab: Volume of distribution (Vd)|PK parameter of aducanumab: Apparent total body clearance (CL/F),Biogen,All,18 Years to 55 Years   (Adult),Phase 1,28,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,221HV102,May-16,Nov-16,Nov-16,26-May-16,null,13-Jan-17,"Research Site, Evansville, Indiana, United States|Research Site, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02782975
NCT02783573,A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia,DAYBREAK-ALZ,Terminated,No Results Available,Alzheimer's Disease,Drug: Lanabecestat|Drug: Placebo,Change from Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog-13) Score|Change from Baseline in Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-iADL) Instrumental Items Score|Change from Baseline in Functional Activities Questionnaire (FAQ) Score|Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score|Change from Baseline in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score|Change in Clinical Dementia Rating (CDR) Global Score|Change from Baseline in Neuropsychiatric Inventory (NPI) Score|Change from Baseline on the Mini-Mental State Examination (MMSE)|Change from Baseline in Concentration of Cerebrospinal fluid (CSF) Biomarker Aβ1-42|Change from Baseline in Concentration of CSF Biomarker Aβ1-40|Change from Baseline in CSF Biomarker Total Tau|Change from Baseline in CSF Biomarker Phosphorylated Tau|Change from Baseline in Brain Amyloid Burden using Florbetapir Amyloid Scan|Change from Baseline in Regional Cerebral Blood Flow (rCBF) using Florbetapir Perfusion Scan|Change from Baseline in Whole Brain Volume|Population Pharmacokinetics (PK): Apparent Oral Clearance of Lanabecestat|Population PK: Central Volume of Distribution of Lanabecestat,Eli Lilly and Company|AstraZeneca,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,5697,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",16024|I8D-MC-AZET|2015-005625-39,1-Jul-16,28-Sep-18,28-Sep-18,26-May-16,null,26-Oct-18,"Xenoscience, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|Four Peaks Neurology, Scottsdale, Arizona, United States|Arizona Neurology, Scottsdale, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|NEA Baptist Clinical, Jonesboro, Arkansas, United States|The Research Center of Southern California, Carlsbad, California, United States|WCCT Global, Costa Mesa, California, United States|Neuro-Pain Medical Center, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|California Research Foundation, San Diego, California, United States|Pacific Research Network Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Care Access Research, Santa Clarita, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Care Access Research, Valencia, California, United States|Associated Neurologists, PC - Danbury, Danbury, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Morton Plant Hospital, Clearwater, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Cohen Medical Associates P.A., Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, United States|Gregory A. Kirk MD LLC, Merritt Island, Florida, United States|University of Miami, Miami, Florida, United States|Allied Biomedical Research Institute, Inc., Miami, Florida, United States|Compass Research, Orlando, Florida, United States|Quantum Laboratories, Pompano Beach, Florida, United States|Charlotte Neurological Services, Port Charlotte, Florida, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Axiom Research, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Medical Research Health and Education Foundation, Inc, Columbus, Georgia, United States|Hawaii Medical Center, Honolulu, Hawaii, United States|Advanced Clinical Research LLC, Meridian, Idaho, United States|American Health Network, Avon, Indiana, United States|Josephson Wallack Munshower Neurology, Indianapolis, Indiana, United States|American Health Network, Muncie, Indiana, United States|University of Kansas Hospital, Fairway, Kansas, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Via Christi Research, Inc., Wichita, Kansas, United States|Baptist Health Medical Group, Lexington, Kentucky, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Maine Neurology, Scarborough, Maine, United States|Boston University Medical Center, Boston, Massachusetts, United States|Donald S Marks, Plymouth, Massachusetts, United States|Alzheimers Disease Center, Winchester, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Clinical Research Professionals, Saint Louis, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|New York University Medical Center, New York, New York, United States|Behavioral Health Center Research, Charlotte, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Wake Forest Baptist Univ CAR, Winston-Salem, North Carolina, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Insight Clinical Trials, Shaker Heights, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Summit Research Network Inc, Portland, Oregon, United States|Clinical Trial Center, LLC, Psychiatry, Jenkintown, Pennsylvania, United States|Pearl Clinical Research Inc., Norristown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Radiant Research, Greer, South Carolina, United States|Coastal Neurology PA, Port Royal, South Carolina, United States|Holston Medical Group Clinical Research, Kingsport, Tennessee, United States|Univ of North Texas Health Science Center, Fort Worth, Texas, United States|Texas Medical Research Associates, L.L.C., San Antonio, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|SSM Health Dean Medical Group, Madison, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|The Medical Arts Health Research Group, West Vancuver, British Columbia, Canada|True North Clinical Research Halifax, LLC, Halifax, Nova Scotia, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada|CSSS-Institut Universitaire Gériatric de Sherbrooke, Sherbrooke, Qubec, Canada|Recherches Neuro-Hippocampe Inc, Gastineau, Quebec, Canada|Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada|Douglas Hospital and Research Centre, Verdun, Quebec, Canada|Xuanwu Hospital-Capital Medical University, Beijing, Beijing, China|Beijing 301 Hospital, Beijing, Beijing, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Tangshan Worker Hospital, Tangshan, Hebei, China|Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med, Nanjing, Jiangsu, China|Zhongda Hospital-Southeast University, Nanjing, Jiangsu, China|Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|Qingdao Municipal Hospital, Qingdao, Shandong, China|Shanghai Tongji Hospital(CCBR site), Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China|The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China|Shanghai Huashan Hospital Affil to Fu Dan University, Shanghai, China|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Neurohk s.r.o., Chocen, Czechia|Neuropsychiatrie s.r.o, Hradec Kralove, Czechia|Brain-Soultherapy s.r.o, Kladno, Czechia|A-Shine s.r.o., Plzen, Czechia|Clintrial, s.r.o., Praha 10, Czechia|Neuropsychiatrie s.r.o, Praha 6, Czechia|Medical Services Prague s.r.o., Praha 6, Czechia|Axon Clinical, s.r.o., Praha 8, Czechia|CCBR-Alborg-DK, Alborg, Denmark|Center For Clinical and Basic Research, Ballerup, Denmark|Rigshospitalet, Copenhagen, Denmark|Center for Clinical and Basic Research -CCBR, Vejle, Denmark|Institut Claude Pompidou - CMRR, Nice, Alpes Maritimes, France|CHU Rennes/Hopital Sud, Rennes Cedex, Ille Et Vilaine, France|CHU Saint Etienne - Hopital Nord, Saint Priest en Jarez, Loire, France|Chu De Nancy Hop D'Adultes De Brabois, Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France|CHU d'Amiens-Picardie Hopital Sud, Amiens Cedex 1, France|CHU de Caen Hopital Cote de Nacre, Caen Cedex, France|APHM Hôpital de la Timone, Marseille, France|Hôpital de la Pitié-Salpêtrière, Paris, France|CHU Strasbourg Hôpital de Hautepierre, Strasbourg Cedex, France|Chu de Toulouse Hopital de La Grave, Toulouse Cedex, France|Praxis Dr. Erich Scholz, Böblingen, Baden-Württemberg, Germany|ISPG - Institut für Studien zur psychischen Gesundheit, Mannheim, Baden-Württemberg, Germany|Praxis für Neurologie und Psychiatrie Dr. med. Roth, Ostfildern, Baden-Württemberg, Germany|Neurozentrum Sophienstraße, Stuttgart, Baden-Württemberg, Germany|Klinikum der Universität München, München, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Neuropraxis München Süd, Unterhaching, Bayern, Germany|Diakoniekrankenhaus Henriettenstiftung Hannover, Hannover, Niedersachsen, Germany|MVZ LiO Berlin, Berlin, Germany|Policlinico Univ. Agostino Gemelli, Roma, Lazio, Italy|Spedali Civili - Universita degli Studi, Brescia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy|SDN - Istituto di Ricerca Diagnostica e Nucleare, Napoli, Italy|Azienda Ospedaliera - Universitaria Pisana, Pisa, Italy|IRCCS Santa Lucia, Roma, Italy|Universita La Sapienza, Roma, Italy|Azienda Ospedaliera Citta della Salute della Scienza Torino, Torino, Italy|Shinwakai Yachiyo Hospital, Anjo-shi, Aichi-Ken, Japan|Nagoya Ekisaikai Hospital, Nagoya-shi, Aichi-Ken, Japan|Kojunkai Daido Hospital, Nagoya-Shi, Aichi-Ken, Japan|Inage Neurology and Memory Clinic, Chiba-shi, Chiba-Ken, Japan|Ehime University Hospital, Toon-Shi, Ehime-Ken, Japan|Jisenkai Nanko Psychiatric Institute, Shirakawa-shi, Fukushima-Ken, Japan|Takeda General Hospital, Aizuwakamatsu, Fukushima, Japan|Koseikai Kusatsu Hospital, Hiroshima-shi, Hiroshima-Ken, Japan|NHO Hiroshima-Nishi Medical Center, Otaki-Shi, Hiroshima-Ken, Japan|Yokohama Hospital, Yokohama, Kanagawa, Japan|Koseikai Takeda Hospital, Kyoto-Shi, Kyoto-Fu, Japan|Uji Takeda Hospital, Uji-Shi, Kyoto-Fu, Japan|JADECOM Nara City Hospital, Nara-Shi, Nara-Ken, Japan|Nara Medical University Hospital, Kashihara, Nara, Japan|Oita University Hospital, Yufu-shi, Oita-Ken, Japan|Katayama Medical Clinic, Kurashiki-shi, Okayama-Ken, Japan|Himuro Neurology Clinic, Osaka-Shi, Osaka-Fu, Japan|Kotobukikai Tominaga Clinic, Osaka-shi, Osaka-Fu, Japan|Kousaiin Hospital, Suita-shi, Osaka-Fu, Japan|NHO Hizen Psychiatric Center, Kanzaki-gun, Saga-Ken, Japan|Shimizu Hospital, Shizuoka-shi, Shizuoka, Japan|Keikokai P-One Clinic, Hachioji-shi, Tokyo-To, Japan|Memory Clinic Ochanomizu, Bunkyo-ku, Tokyo, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Musashino Red Cross Hospital, Musashino, Tokyo, Japan|JOHAS Sanin Rosai Hospital, Yonago-shi, Tottori-Ken, Japan|Aomori Prefectural Centeral Hospital, Aomori, Japan|Ikeuchi Psycho Induced Internal Clinic, Kobe-shi, Japan|Yuge Hospital, Kumamoto, Japan|NHO Niigata Hospital, Niigata-Ken, Japan|NHO Hokkaido Medical Center, Sapporo-shi, Japan|Dong-A University Medical Center, Busan, Busan Gwang'yeogsi, Korea, Republic of|The Catholic University of Korea-Bucheon St. Mary's Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of|Myongji Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Universitario de Saltillo, Saltillo, Coahuila, Mexico|Mexico Centre for Clinical Research SA de CV, Mexico City, Distrito Federal, Mexico|Clinical Research Institute S C, Tlalnepantla, Edo De Mex, Mexico|Hospital Univ. Jose Eleuterio Gonzalez, Monterrey, N.l., Mexico|Instituto de Informacion en Salud Mental (INFOSAM), Monterrey, NL, Mexico|Accelerium Clinical Research, Monterrey, Nuevo Leon, Mexico|Centro de Estudios Clinicos y Esp Medicas SC, Monterrey, Nuevo Leon, Mexico|Avix Investigación Clínica, S.C, Monterrey, Nuevo León, Mexico|Emotional Brain B.V., Almere, Netherlands|Brain Research Center, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|EB Utrecht, Utrecht, Netherlands|Isala Klinieken, Zwolle, Netherlands|NZOZ Wroclawskie Centrum Alzheimerowskie, Wroclaw, Dolnoslaskie, Poland|Podlaskie Centrum Psychogeriatrii, Białystok, Podlaskie, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Pomorskie, Poland|NZOZ Mach-Med, Chorzow, Poland|Klinika Neurologii Neuro-Care, Katowice, Poland|Globe Badania Kliniczne SP Z O.O., Klodzko, Poland|Prywatny Gabinet Lekarski U.Chyrchel, Lublin, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Euromedis Sp. z o.o., Szczecin, Poland|Clinsante Centrum Medyczne, Torun, Poland|Centrum Medyczne, Warszawa, Poland|Specjalistyczny Osrodek Medycyny Wieku Dojrzalego SOMED, Warszawa, Poland|Hospital Fernando Fonseca, Amadora, Portugal|Hospital de Braga, Braga, Portugal|Hospitals da Universidade de Coimbra, Coimbra, Portugal|SAIH Republ. Clinical Hospital of the MoH of Republ. Tatarst, Kazan, Russian Federation|SIH Kemerovo Regional Clinical Hosptial, Kemerovo, Russian Federation|FSBIH Siberian Clinical Center of FMBA, Krasnoyarsk, Russian Federation|LLC City Neurological Centre Sibneuromed, Novosibirsk, Russian Federation|Novosibirsk State Medical University, Novosibirsk, Russian Federation|Ultramed, Omsk, Russian Federation|LLC Treatment and Rehabilitation, Rostov-on-Don, Russian Federation|RSBIH Smolensk Regional Clinical Hospital, Smolensk, Russian Federation|Bekhterev Psyconeurological Institute, St. Petersburg, Russian Federation|Central Medical Sanitary Hospital #122, St. Petersburg, Russian Federation|Regional State Institution of Healthcare Tomsk Clinica Psych, Tomsk, Russian Federation|Hospital Cardiovascular San Vicente, San Vicente del Raspeig, Alicante, Spain|Hospital General de Catalunya, Sant Cugat del Valles, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital Virgen Del Puerto, Plasencia, Caceres, Spain|Policlinica Guipuzcoa, Donostia, Guipuzcoa, Spain|Hospital Ntra Sra Perpetuo Socorro, Albacete, Spain|Hospital del Mar, Barcelona, Spain|Fundacion ACE-Institut Catala de Neurociences Aplicades, Barcelona, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Cardinal Tien Hospital, Sindian City, Taipei County, Taiwan|National Taiwan University Hospital, Douliou City, Yunlin County, Taiwan|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung, Taiwan|Taipei Medical University- Shuang Ho Hospital, New Taipei, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan City, Taiwan|Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom|Re-Cognition Health Ltd, Plymouth, Devon, United Kingdom|Glasgow Memory Clinic, Scotland, Glasgow, United Kingdom|Charlton Lane Hospital, Cheltenham, Gloucestershire, United Kingdom|Re-Cognition Health Ltd, Greater London, London, United Kingdom|Re-Cognition Health Ltd, Guildford, Surrey, United Kingdom|Murray Royal Hospital, Perth, Tayside Region, United Kingdom|Victoria Centre, Swindon, Wiltshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02783573
NCT02778581,Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment,,Unknown status,No Results Available,Cognitive Impairments|Alzheimer Disease,Dietary Supplement: Lipidic Blend 1|Dietary Supplement: Lipidic Blend 2|Dietary Supplement: Placebo,Changes in Mini-Mental State Examination (MMSE) score|Changes in Global Clinical Dementia Rating (CDR) score|Changes in systemic oxidative parameters in periferic blood samples (Nitric Oxyde)|Changes in systemic oxidative parameters in periferic blood samples (Malondialdehyde (MDA))|Changes in beta-amyloid protein concentration|Changes in TAU-Protein concentration|Changes in regular treatment for the cognitive impairment|Changes in dietetic habits|Changes in Barthel score|Changes in Morisky-Green score|changes in weight|Number of adverse events,Team Foods Colombia S.A.|Biopolis S.L.,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,110,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",ALZ-OIL.01,Mar-16,Apr-17,Jul-17,20-May-16,null,3-Jun-16,"Hospital Universitario Vinalopó, Elche, Alicante, Spain|Hospital Universitario de Torrevieja, Torrevieja,, Alicante, Spain",,https://ClinicalTrials.gov/show/NCT02778581
NCT02772185,Neurostimulation and Cognitive Intervention in Alzheimer's Disease,NeuroAD,Unknown status,No Results Available,Alzheimer's Disease,Device: active tDCS|Device: sham tDCS|Behavioral: real CT|Behavioral: placebo CT,Change in cognitive function assessed on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)|Change in cognitive ability assessed on the Wechsler Adult Intelligence Scale|Change in visuo-spatial working memory assessed on the Corsi block task|Change in verbal working memory assessed on the Digit Span task|Change in speed of cognitive processing and executive functioning assessed on the Trail Making Test|Change in executive function assessed on the Stroop Color and Word Test|Change in verbal fluency assessed on the FAS Verbal Fluency Test|Change in functional ability assessed on the Disability Assessment Dementia|Change in visual recognition assessed on the Poppelreuter-Ghent's Overlapping Figures test|Change in behavioral and psychological disturbances assessed on the Neuropsychiatric Inventory Questionnaire|Change in subjective burden among caregivers assessed on the Zarit Burden Interview|Change in electrical activity of the brain assessed on the Electroencephalogram (EEG)|Side Effects Questionnaire,Federal University of Paraíba,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NeuroAD,May-16,May-18,May-19,13-May-16,null,13-May-16,"Suellen Andrade, João Pessoa, PB, Brazil",,https://ClinicalTrials.gov/show/NCT02772185
NCT02772523,Control and Intervention Programme on Alzheimer's Disease Risk Factors,ALFAlife,"Active, not recruiting",No Results Available,Alzheimer's Disease,Other: Lifestyle recommendations,Change in Short Version of the Minnesota Leisure Time Physical Activity Questionnaire|Change in 14-item mediterranean diet Questionnaire|Change in Lifestyle Activities Questionnaire (LAQ),"Barcelonabeta Brain Research Center, Pasqual Maragall Foundation",All,"45 Years to 78 Years   (Adult, Older Adult)",Not Applicable,409,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ALFAlife/BBRC2015,May-16,Jan-18,May-19,13-May-16,null,29-Aug-18,"Barcelonabeta Brain Research Center, Barcelona, Catalonia, Spain",,https://ClinicalTrials.gov/show/NCT02772523
NCT02770482,Amyloid Beta-peptide 1-40 and Alzheimer's Disease,ADAB40,Unknown status,No Results Available,Alzheimer Disease,Biological: spinal fluid collection,Percentage of diagnostic certitude for AD (diagnosed cases),CHU de Reims,All,"Child, Adult, Older Adult",Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PA13050,Jun-14,Jun-16,null,12-May-16,null,27-May-16,"Chu de Reims, Reims, France",,https://ClinicalTrials.gov/show/NCT02770482
NCT02769000,Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's,,Recruiting,No Results Available,Alzheimer's Disease,Radiation: 10 GY in 5 daily fractions|Radiation: 20 GY in 10 daily fractions,Evaluate safety and toxicity/adverse events associated with delivery of low dose fractionated whole brain irradiation in subjects with early Alzheimer's dementia according to NINCDS-ADRDA Criteria.|Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using neurcognitive testing methods.|Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using psychological functioning tests.|Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using Quality of Life indices.,Virginia Commonwealth University,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HM20004955,May-16,Apr-20,Apr-20,11-May-16,null,2-Apr-19,"Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02769000
NCT02769065,Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants,,Terminated,No Results Available,Alzheimer Disease|Healthy Volunteers,Drug: TAK-071|Drug: Donepezil|Drug: TAK-071 Placebo|Drug: Donepezil Placebo,"Percentage of Participants who Experience at Least One Treatment-Emergent Adverse Event (TEAE)|Percentage of Participants who Meet the Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post-dose|Percentage of Participants who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose|Percentage of Participants who Meet the Markedly Abnormal Criteria for 12-lead ECG Parameters at Least Once Post-dose|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-071|Cmax: Maximum Observed Plasma Concentration for TAK-071|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for TAK-071|AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-071|AUCτ: Area Under the Plasma Concentration-time Curve from Time 0 to tau Over the Dosing Interval for TAK-071|Terminal Phase Elimination Half-life (T1/2) for TAK-071|Apparent Clearance (CL/F) for TAK-071|Accumulation Ratio Based on AUC (Rac[AUC] for TAK-071)|Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071|Amount of Drug Excreted in Urine From Time 0 to Time t (Ae[t]) for TAK-071|Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t (f[e,t]) for TAK-071|Renal Clearance (CL[R]) for TAK-071|CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071|CSF AUC12: Area Under the CSF Concentration-time Curve From Time 0 to 12 Hours for TAK-071|CSF AUC36: Area Under the CSF Concentration-time Curve From Time 0 to 36 Hours for TAK-071|CSF AUC12:plasma AUC12: Ratio of CSF AUC12 to the Plasma AUC12 for TAK-071|CSF AUC36:plasma AUC36: Ratio of CSF AUC36 to the Plasma AUC36 for TAK-071|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Donepezil|Cmax: Maximum Observed Plasma Concentration for Donepezil|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Donepezil|Ratio of Geometric Mean of AUC24 and Cmax|Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration (Vz/F) for TAK-071",Takeda,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,177,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TAK-071-1001|U1111-1176-7435,5-May-16,8-Jun-17,8-Jun-17,11-May-16,null,29-Mar-18,"Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT02769065
NCT02767609,Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging,,Completed,Has Results,Traumatic Brain Injury|Multiple Sclerosis|Alzheimer's Disease|Tumor,Device: Magnetic Resonance Imaging,Regional Cerebral Blood Flow Values of the Brain Measured Using Pseudo-continuous Arterial Spin Labeling (pCASL) MRI.,Loma Linda University,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,1,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,5140083,May-14,3-Mar-17,3-Mar-17,10-May-16,30-Apr-19,30-Apr-19,,"""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02767609/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02767609/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02767609
NCT02759159,The Study of Mechanism of Alzheimer's Disease Using Acupuncture Based on fMRI,,Unknown status,No Results Available,Alzheimer's Disease,Procedure: true acupuncture|Procedure: sham acupuncture,brain functional connectivity,"Xuanwu Hospital, Beijing",All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",81471649,Jun-16,Dec-18,Dec-18,3-May-16,null,5-Oct-16,"Xuanwu hospital, Beijing, Beijing, China|Dongfang Hospital,Beijing University of Chinese Medicine, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT02759159
NCT02759887,Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD),,Recruiting,No Results Available,Down Syndrome|Alzheimer's Dementia,Procedure: biospecimen collection|Other: cognitive assessments|Other: caregiver questionnaire|Procedure: Florbetapir F18 imaging|Procedure: MRI|Procedure: Fludeoxyglucose F18 (FDG)|Procedure: Tau Pet|Procedure: Actigraphy,Florbetapir PET - change between timeframes|tau PET - change between timeframes|FDG PET - change between timeframes|MRI - change between timeframes|dried blood spot collection (DBSC) analysis - change between timeframes,"St. Joseph's Hospital and Medical Center, Phoenix|Banner Alzheimer's Institute, Phoenix|Translational Genomics Research Institute (TGEN), Phoenix",All,"21 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PHX-16-0028-70-03,Nov-16,Mar-19,Jun-19,3-May-16,null,3-Nov-16,"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT02759887
NCT02760602,A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease,ExpeditionPRO,Terminated,Has Results,Alzheimer's Disease,Drug: Solanezumab|Drug: Placebo,Change From Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog14) Score|Change From Baseline on Alzheimer´s Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL)|Change From Baseline on the Mini Mental Status Examination (MMSE)|Change From Baseline on the Montreal Cognitive Assessment (MoCA)|Change From Baseline on the Functional Activities Questionnaire (FAQ)|Change From Baseline on the Neuropsychiatric Inventory (NPI)|Change From Baseline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)|Change From Baseline on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Change From Baseline on the Free and Cued Selective Reminding Test (FCSRT)|Change From Baseline on the Resource Utilization in Dementia-Lite (RUD-Lite)|Change From Baseline on the EuroQol 5-Dimensional Health-Related Quality of Life Scale (EQ-5D)|Change From Baseline on the Quality of Life in Alzheimer's Disease Scale (QoL-AD)|Change From Baseline in Concentration of Plasma Amyloid-β Peptide (Aβ) and Plasma Solanezumab|Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI)|Change From Baseline in Florbetapir Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVr)|Change From Baseline in Concentration of Cerebrospinal Fluid (CSF) Aβ and CSF Tau Proteins|Change From Baseline in Neocortical Tau Deposits Using 18F-AV-1451 PET,Eli Lilly and Company,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,26,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",16349|H8A-MC-LZBE|2016-000108-27,Jun-16,May-17,May-17,3-May-16,24-Jul-18,24-Jul-18,"Xenoscience, Phoenix, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|Arizona Health Sciences Center, Tucson, Arizona, United States|Parexel Early Phase Unit at Glendale, Glendale, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Desert Valley Research, Rancho Mirage, California, United States|Pacific Research Network Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|Apex Research Institute, Santa Ana, California, United States|Care Access Research LLC, Santa Clarita, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Care Access Research, Valencia, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Christiana Care Research Institute, Newark, Delaware, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Compass Research, Orlando, Florida, United States|Pensacola Research Consultants, Inc., Pensacola, Florida, United States|Quantum Laboratories, Pompano Beach, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Axiom Research, Tampa, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|United Osteoporosis Center, Gainesville, Georgia, United States|Christie Clinic, LLC, Champaign, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Central DuPage Hospital, Winfield, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology, Indianapolis, Indiana, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Baptist Health Medical Group, Lexington, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Maine Neurology, Scarborough, Maine, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|PharmaSite Research Inc, Baltimore, Maryland, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Donald S Marks, Plymouth, Massachusetts, United States|QUEST Research Institute, Farmington Hills, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|ClinVest, Bolivar, Missouri, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Millenium Psychiatric Associates LLC, Creve Coeur, Missouri, United States|St Lukes Hospital, Kansas City, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Healthy Perspectives Innovative Mental Health Services, PL, Nashua, New Hampshire, United States|ActivMed Practices & Research, Inc, Portsmouth, New Hampshire, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pyramid Clinical Research, Monroe, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|Richmond Behavorial Associates, Staten Island, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Piedmont Medical Research, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Insight Clinical Trials, Shaker Heights, Ohio, United States|Summit Research Network Inc, Portland, Oregon, United States|Center for Cognitive Health, Portland, Oregon, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Clinical Trial Center, LLC, Psychiatry, Jenkintown, Pennsylvania, United States|Northeastern Pennsylvania Memory & Alzheimer's Center, Plains, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Metrolina Neurological Research Institute, Indian Land, South Carolina, United States|Baylor AT&T Memory Center, Dallas, Texas, United States|Baylor AT&T Memory Center, Dallas, Texas, United States|FutureSearch Trials, Dallas, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Texas Health Services Center - Houston, Houston, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Univ of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|Sentara Medical Group, Norfolk, Virginia, United States|National Clinical Research - Richmond, Richmond, Virginia, United States|Evergreen Professional Plaza, Kirkland, Washington, United States|Dean Foundation for Health Research and Education, Middleton, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Gatineau, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Greenfield Park, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Halifax, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kentville, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., London, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ottawa, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Peterborough, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Sherbrooke, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuopio, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vaasa, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amiens, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bordeaux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bron, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chemnitz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monza, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pavia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Perugia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bunkyo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bunkyo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hachioji, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kamakura, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kodaira-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Koriyama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mitaka-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shinjuku-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Takamatsu, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tsu-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Białystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bydgoszcz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sopot, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warszawa, Poland|Santa Cruz Behavioral PSC, Bayamón, Puerto Rico|Cortex, PSC, Las Piedras, Puerto Rico|University Of Puerto Rico, Rio Piedras, Puerto Rico|Instituto de Neurologia Dra. Ivonne Fraga, San Juan, Puerto Rico|Latin Clinical Trial Center, San Juan, Puerto Rico|SomniCare Sleep Institute, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Castellon de la Plana, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getafe, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getxo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Sebastian, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmö, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mölndal, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umeå, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gwei Shan Township, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jhonghe City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bath, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelsea, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guildford, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scotland, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02760602/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02760602/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02760602
NCT02756858,An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: ANAVEX2-73,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Score from MMSE (Mini-mental state examination score)|Score from ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory)|HAM-D Score (Hamilton Psychiatric Rating Scale for Depression),Anavex Life Sciences Corp.,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,32,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANAVEX2-73-003,Mar-16,Nov-20,Nov-20,29-Apr-16,null,17-May-18,"Melbourne Health - The Royal Melbourne Hospital, Melbourne, Victoria, Australia|Austin Health - Heidelberg Repatriation Hospital, Melbourne, Victoria, Australia|Caulfield Hospital, Melbourne, Victoria, Australia|Nucleus Network- Centre for Clinical Studies, Melbourne, Victoria, Australia|St. Vincent's Hospital, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT02756858
NCT02754830,A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD),,Completed,No Results Available,Alzheimer's Disease,Drug: LY3303560 - IV|Drug: Saline Solution - IV|Drug: LY3303560 - SC,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (Serum): Area Under the Concentration Versus Time Curve from Time 0 to Infinity (AUC[0-∞]) of LY3303560|Pharmacokinetics (Serum): Maximum Drug Concentration (Cmax) of LY3303560|Pharmacokinetics (Cerebrospinal Fluid): Area Under the Concentration Versus Time Curve (AUC) of LY3303560|Pharmacokinetics (Cerebrospinal Fluid): Maximum Drug Concentration (Cmax) of LY3303560|Mean Change from Baseline in QT/QT Corrected (QTc) Interval,Eli Lilly and Company,All,"30 Years and older   (Adult, Older Adult)",Phase 1,110,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",16120|I8G-MC-LMDA,25-Apr-16,10-Jul-18,10-Jul-18,28-Apr-16,null,23-Jul-18,"Parexel Early Phase Unit at Glendale, Glendale, California, United States|PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02754830
NCT02750982,"Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.",,Completed,No Results Available,Alzheimer's Disease|Amyotrophic Lateral Sclerosis|Brain Injury|Huntington's Disease|Multiple Sclerosis|Parkinson's Disease|Stroke|Spinal Cord Injury,Other: Laughter Therapy,"Patient Health Questionnaire (PHQ-9, for depression)|Generalized Anxiety Disorder 7-item scale (GAD-7, for anxiety)|The General Self-Efficacy Scale (GSE)","Brown, Theodore R., M.D., MPH",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,TRBROWN201601,Jul-16,Aug-18,Aug-18,26-Apr-16,null,26-Sep-18,"Evergreen Healthcare, Kirkland, Washington, United States",,https://ClinicalTrials.gov/show/NCT02750982
NCT02750306,Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061),,Completed,No Results Available,Insomnia|Alzheimer's Disease,Drug: Suvorexant 10 mg|Drug: Suvorexant 20 mg|Drug: Placebo,Change from Baseline in PSG-derived TST at Week 4|Percentage of Participants Who Experienced One or More Adverse Events (AEs)|Percentage of Participants Who Discontinued Study Drug Due to an AE|Change from Baseline in PSG-derived Wakefulness After Persistent Sleep Onset (WASO) at Week 4,Merck Sharp & Dohme Corp.,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,285,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",4305-061|2015-003154-40|MK-4305-061,23-May-16,30-Sep-18,30-Sep-18,25-Apr-16,null,10-Oct-18,,,https://ClinicalTrials.gov/show/NCT02750306
NCT02746484,ABILITY - TelerehABILITation: TechnologY-enhanced Multi-domain at Home Continuum of Care Program,,Completed,No Results Available,Cognitive Impairments|Dementia|Alzheimer Disease,Other: Ability platform program|Other: Usual care program,activities of daily living|behavioral symptoms|cognitive domain (long-term memory)|cognitive domain (language)|cognitive domain (frontal-executive functions)|quality of life|coping strategies|global cognitive level|conversion rate MCI versus AD|cognitive domain - long term memory|cognitive domain - language|cognitive domain - frontal executive functions|caregiver quality of life|caregiver coping strategies|caregiver burden|caregiver affect,Fondazione Don Carlo Gnocchi Onlus|University of Milano Bicocca,All,65 Years to 85 Years   (Older Adult),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,FdG_AD_02,Apr-15,Oct-16,Oct-16,21-Apr-16,null,18-Jan-17,,,https://ClinicalTrials.gov/show/NCT02746484
NCT02742597,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,PACEinMM-ON,"Active, not recruiting",No Results Available,Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Transient Ischemic Attacks|Ulcer|Gastroesophageal Reflux|Irritable Bowel|Crohn's Disease|Ulcerative Colitis|Diverticulosis|Chronic Hepatitis|Diabetes|Thyroid Disorder|Cancer|Kidney Disease|Urinary Tract Problem|Dementia|Alzheimer's Disease|Hyperlipidemia|HIV|Multimorbidity,Behavioral: TIP / IMPACT Plus Care Coordination,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes|Evaluation of Intervention Effectiveness - Change in Transitions of Care|Evaluation of Intervention Effectiveness - Change in Self-Efficacy|Evaluation of Intervention Effectiveness - Change in Patient-Centredness|Evaluation of Intervention Effectiveness - Change in Chronic Diseases|Evaluation of Intervention Effectiveness - Change in Health Status|Evaluation of Intervention Effectiveness - Change in Quality of Life|Evaluation of Intervention Effectiveness - Change in Psychological Well-being|Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours|Evaluation of Intervention Effectiveness - Change in Equity|Evaluation of Intervention Effectiveness - Change in Demographics,"Lawson Health Research Institute|Western University, Canada|Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Sunnybrook Health Sciences Centre|St. Michael's Hospital, Toronto|University Health Network, Toronto|Toronto East General Hospital|Providence Healthcare|Mount Sinai Hospital, Canada|Toronto Central Community Care Access Centre|Women's College Hospital",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1980,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,104191,12-Jan-16,7-Apr-19,1-Mar-20,19-Apr-16,null,18-Dec-17,"Western University, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Providence Healthcare, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Central Community Care Access Centre, Toronto, Ontario, Canada|Toronto East General Hospital, Toronto, Ontario, Canada|University Hospital Network, Toronto, Ontario, Canada|Women's College Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02742597
NCT02740634,Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study,,Recruiting,No Results Available,Atypical Alzheimer's Disease|Logopenic Progressive Aphasia (LPA)|Posterior Cortical Atrophy (PCA),Drug: F-18 AV 1451|Drug: C-11 PiB,Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).|Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).|Rates of change in amyloid-PET burden over time.|Rates of change in tau-PET burden over time.,Mayo Clinic,All,"21 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,15-008682,May-16,Mar-21,Mar-21,15-Apr-16,null,4-Apr-19,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02740634
NCT02727699,"A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)",XanADu,Completed,No Results Available,"Dementia, Alzheimer Type",Drug: Xanamem™|Drug: Placebo (for Xanamem™),ADAS-Cog v14|AD COMposite Scores|RAVLT|CDR-SOB|MMSE|NPI|NTB - Executive Domain,Actinogen Medical|ICON Clinical Research,All,"50 Years and older   (Adult, Older Adult)",Phase 2,186,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ACW0002,23-Mar-17,15-Feb-19,15-Mar-19,5-Apr-16,null,9-May-19,"Tucson Neuroscience Research, LLC, Tucson, Arizona, United States|National Research Institute, Los Angeles, California, United States|PCND Neuroscience Research Institute, Poway, California, United States|Pacific Research Network, Inc., San Diego, California, United States|Research Alliance Inc., Clearwater, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|Compass Research LLC, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|NeuroStudies.Net, LLC, Decatur, Georgia, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Richmond Behavioral Associates, Staten Island, New York, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|The Clinical Trial Center, Jenkintown, Pennsylvania, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|KaRa Institute of Neurological Diseases, Macquarie Park, New South Wales, Australia|Central Coast Neurosciences Research, Tumbi Umbi, New South Wales, Australia|Medical & Cognitive Research Unit, Heidelberg Repatriation Hospital - Austin Health, Heidelberg West, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|The Research Institute for the Care of Older People, Bath, Combe Park, United Kingdom|Manchester Mental Health & Social Care Trust - Dementia Research Office - Park House North Manchester General Hospital, Manchester, Lancashire, United Kingdom|West London Mental Health Trust, Isleworth, London, United Kingdom|St Pancras Clinical Research, Kings Cross, London, United Kingdom|Institute of Clinical Sciences, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom|Centre for Clinical Brain Sciences, Centre for Dementia Prevention, The University of Edinburgh, Edinburgh, United Kingdom",,https://ClinicalTrials.gov/show/NCT02727699
NCT02726906,Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study,,Recruiting,No Results Available,"Aging|Cognitive Ability, General",Behavioral: Moderate-aerobic walking|Radiation: Positron Emission Tomography (PET) scan|Behavioral: Healthy living education|Device: Physical activity monitor,Functional Magnetic Resonance Imaging (fMRI) brain scan as a measure of brain function|Mnemonic Similarity Test as a measure of memory (cognition)|Positron Emission Tomography (PET) scan as a measure of tracer binding|Single-stage treadmill test and modified physical function test as measures of physical function|Brain-derived neurotropic factor (BDNF) as a measure from blood,University of Southern California,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,AG046928,Jul-16,Apr-20,Apr-20,4-Apr-16,null,14-Jun-18,"University of Southern California, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02726906
NCT02719327,Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid,BRAVE-EPA,Recruiting,No Results Available,Alzheimer's Disease,Drug: icosapent ethyl (IPE)|Other: gel cap placebo,Regional cerebral blood flow using arterial spin-labeling MRI|Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease|cognitive performance,"VA Office of Research and Development|University of Wisconsin, Madison",All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,150,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CLNA-001-15S|CX001261,8-Jun-17,30-Nov-21,30-Nov-21,25-Mar-16,null,17-Apr-19,"William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02719327
NCT02719938,Triggered Palliative Care for Advanced Dementia,,Completed,Has Results,Alzheimer Disease|Dementia,Behavioral: Specialty Palliative Care,Hospital / Emergency Visits Per 60 Days (no. of Events/Follow-up Days)|Patient Comfort End of Life in Dementia (CAD-EOLD)|Caregiver Strain|Percent of Participants With Referral to Hospice or Outpatient Palliative Care From Discharge to 60 Days Follow-Up|Percent of Participants With Physician Orders for Life Sustaining Treatment (POLST)|Number of Palliative Care Domains in Treatment Plan|Number of Participants With Burdensome Treatments,"University of North Carolina, Chapel Hill|Icahn School of Medicine at Mount Sinai|National Institute on Aging (NIA)",All,65 Years and older   (Older Adult),Not Applicable,62,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,15-1350|R21AG052140|Pilot & Exploratory Project,Mar-16,31-Oct-17,31-Oct-17,25-Mar-16,8-Jan-19,8-Jan-19,"University of North Carolina, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02719938/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02719938
NCT02720445,Memory Improvement Through Nicotine Dosing (MIND) Study,MIND,Recruiting,No Results Available,Mild Cognitive Impairment,Drug: Nicotine Transdermal Patch|Drug: Placebo Patch,Change from Baseline of the Conners Continuous Performance Task (CPT) to Month 25|Change from Baseline in Mild Cognitive Impairment - Clinical Global Impression of Change (MCI-CGIC) to Month 25|Change from Baseline in Cogstate Brief Battery (CBB) to Month 25|Change in Baseline in New York University (NYU) Paragraph Recall to Month 25|Change from Baseline in Clinical Dementia Rating Scale (CDR) - Sum of Boxes (SOB) to Month 25|Change in Baseline in Geriatric Depression Scale (GDS) to Month 25|Change in Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) to Month 25|Change from Baseline in Older Adult Self Report (OASR) / Older Adult Behavior Checklist (OABCL) to Month 25,University of Southern California|National Institute on Aging (NIA)|Vanderbilt University|Alzheimer's Therapeutic Research Institute,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,300,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATRI-002-NIC|R01AG047992|131918,13-Jan-17,Dec-19,Dec-19,25-Mar-16,null,5-Mar-19,"Perseverance Research Center, Scottsdale, Arizona, United States|Central Arkansas Veterans HS, North Little Rock, Arkansas, United States|USC Rancho Los Amigos, Downey, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Associated Neurologists, Danbury, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Brain Matters Research, Delray Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Advanced Clinical Research, Meridian, Idaho, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Cypress Medical Research Center, Wichita, Kansas, United States|Acadia Hospital, Bangor, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Bronson Lakeview Hospital, Kalamazoo, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Integrative Clinical Trials, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Rapid Medical Research, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|LeHigh Valley Hospital, Allentown, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|Glenn Biggs Institute at the University of Texas Health, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02720445
NCT02709356,Medium Chain Triglycerides and Brain Metabolism in Alzheimer's Disease,MCT-MA,Completed,No Results Available,Alzheimer's Disease,Dietary Supplement: 1-month of 60-40 MCT oil|Dietary Supplement: 1-month of C8 MCT oil,Quantification of brain glucose uptake|Quantification of brain acetoacetate uptake,Université de Sherbrooke|Fondation Vitae,All,65 Years and older   (Older Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2016-547,Oct-15,Feb-18,Feb-18,16-Mar-16,null,10-Oct-18,"Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02709356
NCT02710188,Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation,,Completed,No Results Available,Alzheimer's Disease,Drug: HTL0009936 modified release|Drug: HTL0009936 immediate release,Tlag|Frel|Tmax|Cmax|Concentration of HTL0009936 at 6 hours post dose (C6)|AUC (0-last)|AUC (0-inf)|AUC%extrap|Lambda-z|T1/2|Dose normalized AUC|Dose normalized Cmax|Concentration of HTL0009936 at 12 hours post dose (C12)|Concentration of HTL0009936 at 24 hours post dose (C24),Heptares Therapeutics Limited|Quotient Clinical,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,14,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9936-104|2015-004921-16,Feb-16,Jul-16,Aug-16,16-Mar-16,null,18-Oct-16,"Quotient Clinical, Ruddington, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT02710188
NCT02708186,Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD),,Completed,No Results Available,Dementia With Lewy Bodies|REM Sleep Behavior Disorder|Parkinson's Disease Dementia,Drug: Nelotanserin|Drug: Placebo,"Change in the frequency of REM sleep behaviors from baseline to the end of the treatment period (28 days) based on a clinical evaluator.|Change in the proportion of severe REM sleep behaviors from baseline to the end of the treatment period (28 days) based on a clinical evaluator.|Extrapyramidal signs are assessed with the motor subsection of the Unified Parkinson's Disease Rating Scale (UPDRS, Parts II and III)",Axovant Sciences Ltd.,All,"50 Years and older   (Adult, Older Adult)",Phase 2,29,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RVT-102-2002,Mar-16,May-18,May-18,15-Mar-16,null,23-Oct-18,"US120, Birmingham, Alabama, United States|US164, Phoenix, Arizona, United States|US145, Sun City, Arizona, United States|US143, Little Rock, Arkansas, United States|US122, Englewood, Colorado, United States|US180, Maitland, Florida, United States|US154, Ocala, Florida, United States|US113, Orlando, Florida, United States|US152, Ormond Beach, Florida, United States|US153, Tampa, Florida, United States|US163, Atlanta, Georgia, United States|US107, Indianapolis, Indiana, United States|US132, Lenexa, Kansas, United States|US129, Lincoln, Nebraska, United States|US101, Chapel Hill, North Carolina, United States|US159, New Bern, North Carolina, United States|US147, Fargo, North Dakota, United States|US111, Cincinnati, Ohio, United States|US104, Cleveland, Ohio, United States|US105, Columbus, Ohio, United States|US173, Lincoln, Rhode Island, United States|US128, Memphis, Tennessee, United States|US131, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02708186
NCT02708485,Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease,MAL,Completed,Has Results,Alzheimer's Disease,Other: Physical exercise,Brain Glucose Consumption|Brain Acetoacetate Consumption,Université de Sherbrooke,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-043,Apr-09,Jul-17,Jul-17,15-Mar-16,16-Oct-18,16-Oct-18,"Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02708485/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02708485
NCT02707458,Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration,DEPEND,Completed,No Results Available,Dementia of the Alzheimer Type|Age-related Cognitive Decline|Mild Cognitive Impairment Due to Alzheimer Disease,Drug: Probucol,Plasma concentration of probucol following test dose|Apolipoprotein concentration in CSF before and after treatment with probucol at individualized dose,Douglas Mental Health University Institute|Weston Brain Institute|McGill University,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,23,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,DEPEND,Apr-16,Mar-17,Mar-17,14-Mar-16,null,31-Jan-18,"Douglas Hospital Research Centre, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02707458
NCT02707978,F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD),,Withdrawn,No Results Available,Alzheimer Disease,Drug: F 18 T807,"F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.",Washington University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IND 123119 Protocol C,30-Sep-17,Sep-20,Dec-20,14-Mar-16,null,24-Jan-19,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02707978
NCT02702817,Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia,,Completed,No Results Available,Alzheimer Disease|Cognitive Decline Due to Alzheimer Disease|Mild Cognitive Impairment Due to Alzheimer Disease,Drug: Naproxen|Drug: Placebo,Trajectory of composite Alzheimer Progression Score (APS) from multiple cognitive and biomarker measures of pre-clinical Alzheimer's disease|frequency and severity of treatment-emergent adverse events|trajectory of cognitive abilities measured by global score on Repeatable Battery for Assessment of Neuropsychological Status|ratio of total and protein-bound naproxen concentrations as well as kinetics of drug accumulation and washout|biomarkers of inflammatory processes|CSF biomarkers of AD pathogenesis,Douglas Mental Health University Institute|McGill University|Johns Hopkins University,All,"55 Years and older   (Adult, Older Adult)",Phase 2,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",INTREPAD,1-Aug-12,31-Mar-17,15-Jul-17,9-Mar-16,null,1-Aug-17,"Douglas Hospital Research Centre, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02702817
NCT02703636,"NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.",ENA1stepswitch,Completed,No Results Available,Mild to Moderate Alzheimer's Disease,Drug: Rivastigmine Patch,"Change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE)|Monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs).|Change from baseline to Week 8 in Mini-Mental State Examination (MMSE) total score.|Change in Neuropsychiatric Inventory - 10 Item (NPI-10) score from baseline to week 8 and week 24|Change in QOL-AD score from baseline to week 24|Change in J-CGIC score from baseline to week 4, 8, 16 and 24|Change in as Modified Crichton Scale score from baseline to week 4, 8, 16 and 24|Formulation usability score up to week 24",Novartis Pharmaceuticals|Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,118,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713DJP02,9-May-16,7-May-18,7-May-18,9-Mar-16,null,12-Nov-18,"Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Aizuwakamatsu, Fukushima, Japan|Novartis Investigative Site, Tsukuba-city, Ibaraki, Japan|Novartis Investigative Site, Kita-gun, Kagawa, Japan|Novartis Investigative Site, Sagamihara-city, Kanagawa, Japan|Novartis Investigative Site, Kochi-city, Kochi, Japan|Novartis Investigative Site, Kurashiki-city, Okayama, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Kasukabe-city, Saitama, Japan|Novartis Investigative Site, Koshigaya-city, Saitama, Japan|Novartis Investigative Site, Fuji-city, Shizuoka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Hachioji-city, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Niigata, Japan|Novartis Investigative Site, Okayama, Japan|Novartis Investigative Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02703636
NCT02702102,Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies,,"Active, not recruiting",No Results Available,Diffuse Lewy Body Disease|Dementia With Lewy Bodies|Parkinson's Disease Dementia,Drug: 11C-PBR28,Absolute 11C-PBR28 binding (total distribution volume corrected for free fraction in plasma)|Relative 11C-PBR28 binding,William Charles Kreisl|National Institute on Aging (NIA)|Columbia University,All,"60 Years and older   (Adult, Older Adult)",Phase 2,16,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AAAQ0756|2P50AG008702-26,Dec-15,Sep-19,Sep-19,8-Mar-16,null,16-Nov-18,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02702102
NCT02697721,Powerful Tools for Caregivers of Dementia Patients,PTC-dementia,"Active, not recruiting",No Results Available,Caregivers|Dementia|Alzheimer Disease,Behavioral: Powerful Tools for Caregivers|Other: Control with delayed intervention,Caregiver Burden|Frequency and reaction to care recipient behavioral and psychological symptoms of dementia|Frequency of care recipient agitated behaviors|Activity parameters as assessed by FitBit|Depressive symptoms|Caregiving Self-Efficacy|Self-rated health|Life satisfaction|Perceived change|Neuropsychiatric symptoms in care recipients,Florida State University|Florida Department of Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6AZ09,Feb-16,30-May-18,Feb-19,3-Mar-16,null,21-Aug-18,"Florida State University College of Medicine, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT02697721
NCT02695004,"Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).",,Unknown status,No Results Available,Alzheimer's Disease,Drug: DKF-310|Drug: Placebo,AUC|Cmax,"Dongkook Pharmaceutical Co., Ltd.",Male,19 Years to 50 Years   (Adult),Phase 1,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",DKF-310-P1,Feb-16,Dec-17,Dec-17,1-Mar-16,null,1-Mar-16,"Seoul National Univ. Bundang Hospital, Seongnam, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02695004
NCT02690896,Caregiver Burden and Depression: Caring for Those Who Care for Others,,Recruiting,No Results Available,Dementia|Alzheimer's Disease,Behavioral: UCF Caregiver Support Group|Behavioral: Community Support Groups,Change in Long-Term Care Utilization based on Caregiver Report|Neuropsychiatric symptoms|Caregiver strain|Caregiver depression|Caregiver preparedness|Satisfaction Survey|Stress hormone level|Daily stress inventory|Subjective stress|Emotional affective state,University of Central Florida|Alzheimer's and Dementia Resource Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SBE-15-11548,24-Feb-16,Dec-18,Aug-20,24-Feb-16,null,15-Oct-18,"University of Central Florida, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT02690896
NCT02685787,Early Counseling and Support for Alzheimer's Disease Caregivers,D_CareGiver,Unknown status,No Results Available,Alzheimer's Disease,Behavioral: Psychosocial Intervention|Behavioral: Educational Intervention on AD,Care-giver burden measured with Zarit Burden Inventory (ZBI)|Care-giver burden measured with ZBI|Caregiver depression measured using the Hospital Anxiety and Depression Scale (HADS)|Behavioural and psychological symptoms of dementia (BPSD) using the Neuropsychiatric Inventory (NPI)|BPSD using the Revised Memory and Behaviour Checklist (RMBC)|Patient quality-of-life measure with Logdson's Quality of Life AD|Care-giver quality-of-life measure with Euro-Quality of Life,Azienda Sanitaria Locale N.1 dell'Umbria|Azienda Ospedaliera di Perugia|Azienda Ospedaliera di Terni|Azienda Unità Sanitaria Locale Umbria n. 2,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,230,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,GR-2009-1607340,Apr-12,Jan-17,Dec-17,19-Feb-16,null,19-Feb-16,"USL Umbria 1, Perugia, Italy",,https://ClinicalTrials.gov/show/NCT02685787
NCT02686190,Effects of Light-therapy in Alzheimer's Disease,ALZ-Light,Completed,No Results Available,Alzheimer's Disease,Other: Luxtherapy,score agitation / aggression scale NPI-nurse|score agitation-aggression scale NPI-nurse,Assistance Publique - Hôpitaux de Paris,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,91,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P081119|IDRCB,Jul-12,Apr-14,Dec-14,19-Feb-16,null,17-Mar-16,"Hôpital Charles Foix, Ivry-sur-Seine, France",,https://ClinicalTrials.gov/show/NCT02686190
NCT02686216,"Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )",PET,Completed,No Results Available,Alzheimer's Disease,Drug: F-18 THK-5351,The primary outcome measures are to evaluate the dosimetry of novel radiotracer F-18 THK-5351 in human.|Optimal scanning time for brain imaging using F-18 THK-5351.,Chang Gung Memorial Hospital,All,"20 Years to 90 Years   (Adult, Older Adult)",Phase 1,24,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,104-2710A,Dec-15,Apr-16,Nov-16,19-Feb-16,null,8-Feb-17,,,https://ClinicalTrials.gov/show/NCT02686216
NCT02681172,Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD,,Completed,Has Results,Alzheimer's Disease (AD),Drug: Neuraceq (florbetaben 18F)|Procedure: PET,Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan Outcomes|Number of Subjects With Improved Level of Physician Confidence in Diagnosis at Visit 3|Number of Participants With a Change of Management Plan Comparing Pre- and Post-scan Outcomes|Number of Subjects With Positive FBB PET Scan|Number of Subjects With Negative FBB PET Scans|Number of Subjects With Contraindicated or Failed Lumbar Puncture|Number of Subjects With Available CSF Analysis But Results Considered as Non-contributory by the Clinician|Number of Subjects Who Refused Lumbar Puncture.,Piramal Imaging Limited,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,218,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,FBB_01_02_2015|2015-002606-37,Oct-15,Sep-16,Nov-16,12-Feb-16,2-Nov-18,2-Nov-18,"Coordinating center (Hôpital de La Timone) and 18 associated centers in France, Marseille, France",,https://ClinicalTrials.gov/show/NCT02681172
NCT02675270,Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia,,Recruiting,No Results Available,"Aphasia, Primary Progressive|Anomia|Alzheimer Disease",Behavioral: Phonological|Behavioral: Orthographic|Behavioral: Semantic|Behavioral: Lexical|Behavioral: Untrained,Change in picture naming accuracy for words within each treatment condition during treatment|Change in picture naming accuracy for words within each treatment condition between baseline and first follow-up assessment|Change in picture naming accuracy for words within each treatment condition between baseline and second follow-up assessment,Georgetown University|National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institute on Aging (NIA)|Johns Hopkins University,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,85,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DC011317,Nov-11,Apr-21,Jun-22,5-Feb-16,null,24-Oct-18,"Georgetown University Medical Center, Washington, District of Columbia, United States|Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02675270
NCT02672306,Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease,SEESUPAD,"Active, not recruiting",No Results Available,Alzheimer's Disease,Biological: UCMSCs|Biological: Placebo,Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score|Change in Mini-Mental State Examination (MMSE) Score|Change in Clinician's Interview-Based Impression of Change (CIBIC-plus) Score|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score|Change in Neuropsychiatric Inventory (NPI) Score|Changes in AD Biomarkers,"South China Research Center for Stem Cell and Regenerative Medicine|Guangzhou General Hospital of Guangzhou Military Command of PLA|The Third Affiliated Hospital, SUN YAT-SEN University",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",UCMSC-1,20-Oct-17,Oct-18,Oct-19,3-Feb-16,null,26-Apr-18,"South China Research Center for Stem Cell and Regenerative Medicine,South China Institute of Biomedicine, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02672306
NCT02670993,Support by Singing Sessions on Physical and Moral Pain : Assessment of Its Effectiveness in Alzheimer's Disease,LACME,Completed,No Results Available,Alzheimer's Disease,Behavioral: Singing sessions.|Behavioral: Painting sessions.,Score at the EVS = simplified visual scale|Score at the EN (digital scale) scale|Score at the BPI (Brief Pain Inventory) scale : Brief pain Inventory,Centre Hospitalier Universitaire de Saint Etienne,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,59,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),1508071|2015-A01404-45,Jan-16,May-16,Jun-16,2-Feb-16,null,20-Sep-16,"Hospices civils de Lyon, Lyon, France|Chu Saint Etienne, Saint Etienne, France",,https://ClinicalTrials.gov/show/NCT02670993
NCT02670083,CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD),,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: Crenezumab|Drug: Placebo,"Change from baseline to Week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score|Change from Baseline to Week 105 on Cognition, as assessed by Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) (subscales) 13 (ADAS-Cog-13) and 11 (ADAS-Cog-11)|Change from Baseline to Week 105 on Severity of Dementia, Assessed Using the CDR-Gloal Score (CDR-GS)|Change from Baseline to Week 105 on Severity of Dementia, Assessed Using the Mini Mental State Evaluation (MMSE)|Change from Baseline to Week 105 on function as assessed by the ADCS-ADL total score and the ADCS-instrumental subscore|Change from Baseline to Week 105 on a measure of dependence derived from the ADCS-ADL score|Change from Baseline to Week 105 assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q)|Quality of Life-Alzheimer's Disease (QoL-AD) Scale Score|Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) Scale Score|EQ-5D Questionnaire Domain Score|Percentage of Participants with Adverse Event (AEs) and Serious Adverse Event (SAEs)|Percentage of Participants with Anti-Crenezumab Antibodies|Serum Concentration of Crenezumab|Plasma Amyloid Beta (Abeta) Concentrations|Change from Baseline to Week 105 in Brain Volume as Determined by Magnetic Resonance Imaging (MRI)|Cerebrospinal Fluid (CSF) Concentration of Crenezumab|Brain Amyloid Load Over Time Measured by Amyloid-PET|Brain Tau Load Over Time Measured by Tau-PET|Cerebrospinal Fluid (CSF) Markers of Disease Over Time",Hoffmann-La Roche,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,813,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BN29552,22-Mar-16,29-May-19,29-May-19,1-Feb-16,null,8-Mar-19,"Xenoscience, Phoenix, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|American Neuropsychiatric Research Institute Inc, Carson, California, United States|Pharmacology Research Inst, Encino, California, United States|Alliance for Wellness, dba Alliance for Research, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|USC Keck School Of Medicine, Los Angeles, California, United States|UCLA Medical Center, Department of Neurology, Los Angeles, California, United States|Pharmacology Research Inst, Newport Beach, California, United States|Shankle Clinic, Newport Beach, California, United States|Stanford Univ Medical Center, Palo Alto, California, United States|Anderson Clinical Research, Inc., Redlands, California, United States|University of California, Davis; Alzheimers Disease Center, Department of Neurology, Sacramento, California, United States|UCSF - Memory and Aging Center, San Francisco, California, United States|Neurological Research Inst, Santa Monica, California, United States|North Bay Neuro Science Institute, Sebastopol, California, United States|Collaborative Neuroscience Network Inc., Torrance, California, United States|Mile High Research Center, Denver, Colorado, United States|Associated Neurologists PC - Danbury, Danbury, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Cohen Medical Research Associates, LLC, Delray Beach, Florida, United States|Galiz Research, LLC, Hialeah, Florida, United States|Jacksonville Center For Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions Inc; Jacksonville Clinic, Jacksonville, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Merritt - Island Medical Research, Merritt Island, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center & Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Compass Research, The Villages, Florida, United States|Emory University, Atlanta, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|MidAmerica Neuroscience Institute, Prairie Village, Kansas, United States|Maine Research Associates, Auburn, Maine, United States|MMP Neurology, Scarborough, Maine, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research, Kalamazoo, Michigan, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, PA, West Long Branch, New Jersey, United States|Albuquerque Neuroscience Inc., Albuquerque, New Mexico, United States|Albany Medical Faculty Physicians COmmunity Division. The Neurology Group, Albany, New York, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Columbia University Medical Center, New York, New York, United States|South Shore Neurologic Associates P.C., Patchogue, New York, United States|Dent Neurological Institute, Williamsville, New York, United States|Behavioral Health Research, Charlotte, North Carolina, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|UC Health Neurology, Dayton, Ohio, United States|Insight Clinical Trials LLC, Shaker Heights, Ohio, United States|Oklahoma Clinical Research, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research LLC, Tulsa, Oklahoma, United States|Summit Research Network Inc., Portland, Oregon, United States|Neural Net Research; Neural Net Research, Portland, Oregon, United States|Drexel Univ College of Med; Clinical Research Group, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Roper Hospital Laboratory, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Senior Adults Specialty Research, Austin, Texas, United States|Kerwin Research Center, LLC, Dallas, Texas, United States|University of North Texas Health Science Center; Fort Worth Patient Care Center, Fort Worth, Texas, United States|Radiant Research, Inc., Salt Lake City, Utah, United States|Sentara Medical Group, Norfolk, Virginia, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Caulfield Hospital; Aged Psychiatry Research Unit, Caulfield, Victoria, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Neurodegenerative Disorders Research; Neurology, West Perth, Western Australia, Australia|LKH Hall;Abteilung für Psychiatrie und Psychotherapie A, Hall in Tirol, Austria|Konventhospital Barmherzige Brüder; Neurologie I, Linz, Austria|UZ Gent, Gent, Belgium|UMHAT Sveti Georgi Clinic of neurology, Plovdiv, Bulgaria|MHAT National Cardiology Hospital, EAD; Neurology, Sofia, Bulgaria|ACIBADEM CITY CLINIC TOKUDA HOSPITAL EAD; Clinic of Neurology and Sleep Medicine, Sofia, Bulgaria|Alexandrovska hospital; Neurology Department, Sofia, Bulgaria|Vancouver Hospital - UBC Hospital Site, Vancouver, British Columbia, Canada|Vancouver Island Health Authority, Victoria, British Columbia, Canada|Parkwood Hospital; Geriatric Medicine, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Devonshire Clinical Research Inc., Woodstock, Ontario, Canada|CHA Hopital de I enfant-Jesus, Quebec City, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada|ICIMED Instituto de Investigación en Ciencias Médicas, San Jose, Costa Rica|Hospital Clínica Biblica, San José, Costa Rica|Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia|Clinical Hospital Centre Zagreb;Clinic for Neurology, Zagreb, Croatia|The University Hospital Brno, Brno, Czechia|Charles University, Medical faculty, Hradec Kralove ;Department of Neurology, Hradec Králové, Czechia|General Teaching Hospital, Departmetn of Neurology, Praha, Czechia|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus C, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|Terveystalo Tampere, Tampere, Finland|CRST Oy, Turku, Finland|Hopital Avicenne; Neurologie, Bobigny, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France|Hopital Gui de Chauliac; Neurologie, Montpellier, France|Hopital Lariboisiere, Paris, France|CHU Poitiers - Hopital La Miletrie, Poitiers, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|CHU Toulouse - La Grave, Toulouse, France|Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Neurologie, Berlin, Germany|Universitätsklinikum ""Carl Gustav Carus""; Klinik und Poliklinik für Psychiatrie & Psychotherapie, Dresden, Germany|Evang. Krankenhaus Bethanien; Fachkrankenhaus für Psychiatrie, Psychosomatik und Psychotherapie, Greifswald, Germany|Neurologische Praxis Dr. Andrej Pauls, München, Germany|Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie, München, Germany|Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie, Münster, Germany|Steinwachs Klaus; Arztpraxis fur Neurologie u. Psychiatrie, Nürnberg, Germany|Klinik und Poliklinik für Psychiatrie und Psychotherapie der Uni. Regensburg am Bezirksklinikum, Regensburg, Germany|Universitätsklinikum Rostock Zentrum für Nervenheilkunde, Rostock, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, Germany|Forschungszentrum Ruhr, Witten, Germany|Prince of Wales Hospital; Dept. of Medicine & Therapeutics, Hong Kong, Hong Kong|Queen Mary Hospital, Division of Geriatric Medicine, Hong Kong, Hong Kong|Tuen Mun Hospital; Medicine & Geriatrics, Tuen Mun, Hong Kong|Dr. Kenessey Albert Korhaz-Rendelointezet; Pszichiatria I, Balassagyarmat, Hungary|Semmelweis University; Department of Neurology, Budapest, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak - Jósa András Oktatókórház; Pszichiátria, Nyíregyháza, Hungary|University of Szeged; Department of Psychiatry, Szeged, Hungary|Szent Borbala Korhaz; Neurologiai es Stroke Osztaly, Tatabánya, Hungary|Jávorszky Ödön Kórház, Neurológia és stroke osztály, VAC, Hungary|Azienda Sanitaria Provinciale Di Catanzaro-P.O. Giovanni Paolo II; Centro Regionale Di Neurogenetica, Lamezia Terme (CZ), Calabria, Italy|Fondazione Santa Lucia IRCCS; Neurologia e Riabilitazione Neurologica, Roma, Lazio, Italy|Ospedale San Giovanni Calibita Fatebenefratell;Neurologia, Roma, Lazio, Italy|Ente Ospedaliero Ospedali Galliera; Ambulatorio di Neurologia, Genova, Liguria, Italy|Irccs Aou San Martino - Ist; Dipartimento Di Medicina Interna, Genova, Liguria, Italy|Casa di Cura Policlinico; Dipartimento di Scienze Neuroriabilitative, Milano, Lombardia, Italy|Ospedale S. Maria Nascente; Fondazione Don Gnocchi; Dip. Neurologia Riabilitativa, Milano, Lombardia, Italy|Ospedale Casati Passirana di Rho; Centro Regionale Alzheimer, Passirana, Lombardia, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; S.C. Geriatria, Perugia, Umbria, Italy|National Center for Geriatrics and Gerontology, Aichi, Japan|Fukuoka Mirai Hospital, Fukuoka, Japan|Miyoshi Clinic of Neurology, Hananosato, Hiroshima, Japan|National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan|Sapporo Medical University Hospital, Hokkaido, Japan|Iwate Medical University Hospital, Iwate, Japan|Kagawa Prefectural Central Hospital, Kagawa, Japan|Fujisawa City Hospital, Kanagawa, Japan|Koseikai Takeda Hospital, Kyoto, Japan|Ijinkai Takeda General Hospital, Kyoto, Japan|Rakuwakai Otowarehabilitation Hospital, Kyoto, Japan|Mie University Hospital, Mie, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|Saigata Medical Center, Niigata, Japan|Katayama Medical Clinic, Okayama, Japan|AMC Nishi Umeda Clinic, Osaka, Japan|Osaka Red Cross Hospital, Osaka, Japan|Osaka General Medical Center, Osaka, Japan|Ebara Hospital, Tokyo, Japan|Kanto Central Hospital, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Shinjuku Research Park Clinic, Tokyo, Japan|Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan|National Center of Neurology and Psychiatry, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|Tottori University Hospital, Tottori, Japan|Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|KyungHee Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital; Dept of Neurology, Seoul, Korea, Republic of|Kaunas Medical University Hospital; Department of Neurology, Kaunas, Lithuania|Vilnius University Hospital Santariskiu Clinic, Vilnius, Lithuania|Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC, Culiacan, Mexico|Hospital Uni; Dr. Jose E. Gonzalez, Monterrey, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Universitario de Saltillo, Saltillo, Mexico|Niepubliczny Zaklad Opieki Zdrowotnej KENDRON ; Poradnia Neurologiczna, Bialystok, Poland|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|KOPERNICUS Podmiot Leczniczy Sp. z o.o., Gdansk, Poland|Centrum Neurologii Klinicznej, Krakow, Poland|NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek, Poznan, Poland|Clinical Research Center Sp. z o.o. MEDIC-R Spółka Komandytowa, Poznań, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Przychodnia Specjalistyczna PROSEN, Warszawa, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Optimum, Warszawa, Poland|Centralny Szpital Kliniczny MSWiA Klinika Neurologii, Warszawa, Poland|Uniwersytet Medyczny w Lodzi Katedra Psychiatrii, Łódź, Poland|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|Hospital Beatriz Angelo; Servico de Neurologia, Loures, Portugal|Republican clinical hospital of regenerative treatment of Ministry of Health of Tatarstan republic, Kazan, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Institution of RAMS (Mental Health Research Center of RAMS), Moscow, Russian Federation|SBEI of HPI The 1st Moscow State Medical University n.a. I.M. Sechenov of MOH of RF, Moscow, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|SHI City Psychoneurological Dispensary #7, St Petersburg, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|University Medical Centre, Ljubljana, Slovenia|University Medical Centre Maribor, Maribor, Slovenia|Fundació ACE, BArcelon, Barcelona, Spain|Hospital Universitari de Bellvitge; Servicio de Neurologia, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Sant Joan de Deu; Servicio de Neurología, Manresa, Barcelona, Spain|Hospital General De Catalunya; Servicio de Neurologia, Sant Cugat del Valles, Barcelona, Spain|Hospital Mutua De Terrasa; Servicio de Neurologia, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto. Servicio de Neurología, Plasencia, Caceres, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Neurología, Santander, Cantabria, Spain|Clinica Universitaria de Navarra; Servicio de Neurología, Pamplona, Navarra, Spain|Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría, Salamaca, Salamanca, Spain|Hospital General Universitario de Albacete; Servicio de Neurología, Albacete, Spain|Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, Spain|Hospital Universitario de Burgos. Servicio de Neurología, Burgos, Spain|Hospital Lucus Augusti; Servicio de Neurología, Lugo, Spain|Clinica Ruber, 4 planta; Servicio de Neurologia, Madrid, Spain|Universitario de La Princesa; Servicio de Neurología, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Neurologia, Malaga, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Neurología, Murcia, Spain|Hospital Universitario la Fe; Servicio de Neurologia, Valencia, Spain|Servicio de Neurología Hospital Viamed Montecanal., Zaragoza, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmoe, Sweden|Sahlgrenska Academy University,Neuroscience and Physiology;Departmt of Psychiatry and Neurochemistry, Mölndal, Sweden|Karolinska Uni Hospital, Huddinge; Dept. of Geriatric Med, Stockholm, Sweden|Universitäres Zentrum für Altersmedizin und Rehabilitation, Basel, Switzerland|Hacettepe University School of Medicine; Neurology, Ankara, Turkey|Osmangazi University School of Medicine,Neurology Department, Eskişehir, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, Turkey|Regional mental hospital; Department of psychiatry, psychology and sexology, Lviv, KIEV Governorate, Ukraine|National Medical Academy of Postgraduate Education named after P.L.Shupik; Neurology Department #1, Kiev, Ukraine|D.F.Chebotarev Institute of Gerontology NAMS;Depart of Age Physiology&Pathology of Nervous System, Kiev, Ukraine|Surrey and Borders NHS Foundation Trust; Brain Science Research Unit, Chertsey, United Kingdom|Coventry and Warwickshire Partnership NHS Trust, Coventry, United Kingdom|St George's Hospital, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Campus for Ageing and Vitality, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|Torbay Hospital, Torquay, United Kingdom",,https://ClinicalTrials.gov/show/NCT02670083
NCT02667496,Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,,Withdrawn,No Results Available,Dementia Alzheimer's Type,Drug: Sargramostim GZ402664|Drug: Placebo|Drug: Florbetapir F18,Change from baseline in standardized uptake value ratio as measured by PET using florbetapir F18 (Amyvid)|Number of patients experiencing treatment-emergent adverse events (TEAEs)|Change from baseline in CSF analysis|MRI to assess for emergence of amyloid related imaging abnormalities (ARIA)|Measurement of antidrug antibody levels,Sanofi|National Institute on Aging (NIA),All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,0,Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ACT14019|U1111-1163-0793|1UF1AG046143,Nov-16,31-Mar-17,31-Mar-17,29-Jan-16,null,7-Apr-17,"Investigational Site Number 840001, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02667496
NCT02663531,Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease,,Recruiting,No Results Available,Mild Cognitive Impairment|Alzheimer Disease|Healthy,Device: DVA|Device: FDOCT|Device: Pattern ERG|Device: Optical Coherence Tomography,Flicker induced increase in retinal blood flow,Medical University of Vienna,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,OPHT-180515,27-Sep-16,Sep-19,Sep-19,26-Jan-16,null,2-Apr-19,"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT02663531
NCT02656498,"[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease",,Recruiting,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment|Neurodegenerative Diseases,Drug: [18F]THK-5351,Cross-sectional [18F]THK-5351 Imaging Results|Assess the rate of change of tau deposition as measured by [18F]THK-5351 uptake (SUVR) over time|Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and neuropsychiatric test scores|Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and indices of structural MRI|Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and indices of functional MRI|Correlation between standard uptake value ratios (SUVR) and distribution of [18F]THK-5351 positron emission computed tomography and amyloid positron emission computed tomography,Jae Seung Kim|Korea Health Industry Development Institute|Samsung Medical Center|Asan Medical Center,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,180,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,THK-15002,Jan-16,Dec-19,Dec-19,15-Jan-16,null,19-Apr-18,"Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02656498
NCT02654574,"Comparison of Two Modes of Administration of the IADL Questionnaire, Assessing the Level of Functional Autonomy of Patients to Carry Out the Tasks of Daily Living: Randomized Controlled Trial Among Patients of a Memory Clinic",IADL,Completed,No Results Available,Alzheimer's Disease|Dementia Disorders,Other: IADL administration by phone,Degree of agreement (concordance) of the overall level of functional autonomy measured with two ways (face-to-face interview and by phone)|Consistency of the answers to each question of the IADL questionnaires between the two methods of administration,Hospices Civils de Lyon,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,299,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2014-867|2014-A00446-41,Jun-14,Apr-16,Apr-16,13-Jan-16,null,20-May-16,"Hospices Civils de Lyon - Hôpital Charpennes - Memory Research Centre Lyon, Clinical Research Centre (CVF), Villeurbanne, France",,https://ClinicalTrials.gov/show/NCT02654574
NCT02649985,Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease,,Recruiting,No Results Available,Multiple Sclerosis|Alzheimer's Disease,Drug: [F-18]PBR06,Tissue Volume of Distribution,Brigham and Women's Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2015P002329,Jan-16,30-Jun-19,30-Jun-19,8-Jan-16,null,22-May-18,"Partners MS Center, 60 Fenwood Road, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02649985
NCT02648672,BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects,,Completed,No Results Available,Alzheimer's Disease,Drug: BPN14770|Drug: Placebo,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Area Under the Curve from Time Zero Extrapolated to Infinity [AUC0-∞]|Maximum Concentration [Cmax],Tetra Discovery Partners,All,18 Years to 55 Years   (Adult),Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BPN14770-CNS-101,Dec-15,Feb-16,Jul-16,7-Jan-16,null,18-Jan-17,"Jasper Clinic, Kalamazoo, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02648672
NCT02648906,A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients,,Unknown status,No Results Available,Alzheimer Disease,Drug: Choline alfoscerate|Drug: Placebo,change of ADAS-cog score compared with Baseline,Daewoong Pharmaceutical Co. LTD.,All,"56 Years to 90 Years   (Adult, Older Adult)",Phase 4,128,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DWB_GTM001,Jul-15,Nov-18,null,7-Jan-16,null,2-Nov-16,"Seoul National University Bundang Hospital, Sungnam, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02648906
NCT02646982,Candesartan's Effects on Alzheimer's Disease And Related Biomarkers,CEDAR,Recruiting,No Results Available,Mild Cognitive Impairment,Drug: Placebo|Drug: Candesartan,"Change in the number hypotensive episodes|Change in the number of subjects with symptoms of hypotension|Changes in the levels of serum creatinine|Change in the levels of serum potassium|Number of subjects discontinuations of candesartan|Changes in cerebrospinal fluid (CSF) phospho-tau181P levels|Changes in cerebrospinal fluid (CSF) amyloid β1-42 levels|Changes in levels of cerebrospinal fluid cytokines|Change in arterial stiffness, assessed by Pulse Wave Velocity (PWV)|Changes in aortic stiffness, assessed by Augmentation Index|Changes in levels of circulating Endothelial Progenitor Cells (EPCs)|Change in Alzheimer's Disease Assessment Scale (ADAS-cog) scores|Change in Clinical Dementia Rating (CDR) scores|Change in executive function, assessed by the EXAMINER score|Change in executive function, assessed by the Spatial 1-Back test|Change in cerebral vasoreactivity, assessed by MRI|Change in white matter hyperintensities (WMH), assessed by structural MRI|Change in functional connectivity, assessed by rs-fMRI",Emory University,All,"50 Years and older   (Adult, Older Adult)",Phase 2,72,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00084574,Jun-16,Sep-21,Sep-21,6-Jan-16,null,18-Feb-19,"Emory University, Atlanta, Georgia, United States|Wesley Woods Center, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02646982
NCT02640092,Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants,,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: [18F]GTP1,Change in Standardized Uptake Value Ratio (SUVR) as Measured by [18F]GTP1|Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)13|Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Volumetric Magnetic Resonance Imaging (MRI) Measures|Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Cerebrospinal Fluid (CSF) Markers|Percentage of Participants With Adverse Events (AEs)|Test-Retest Variability Based on [18F]GTP1 PET Scans,"Genentech, Inc.",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,72,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,GN30009|G0097,23-Dec-15,11-Jun-19,11-Jun-19,28-Dec-15,null,11-Apr-19,"Molecular NeuroImaging, New Haven, Connecticut, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Acadia Clinical Research; Dr. Henderson's Office, Bangor, Maine, United States|Donald S. Marks, M.D., P.C.; Medical Center, Plymouth, Massachusetts, United States|Alzheimers Disease Center, Quincy, Massachusetts, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Advanced Medical Research, Maumee, Ohio, United States|Lehigh Center Clinical Research, Allentown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02640092
NCT02638519,HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer Disease,Other: Traditional Proton fMRI|Other: Hyperpolarized Xenon-129 fMRI|Drug: Hyperpolarized Xenon-129|Device: 1H-129Xe Dual-Tuned Quadrature Head Coil,Signal-to-Noise Ratio (SNR)|P-Value,Thunder Bay Regional Research Institute|Lakehead University|Thunder Bay Regional Health Sciences Centre,All,"18 Years to 85 Years   (Adult, Older Adult)",Early Phase 1,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RP-307-08312015,Jun-16,Jun-19,Jun-19,23-Dec-15,null,9-Aug-18,"Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02638519
NCT02626377,Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté,ICE,Recruiting,No Results Available,Breast Cancer|Colorectal Cancer|Prostate Cancer|Alzheimer Disease|Age-related Macular Degeneration|Parkinson Disease|Cardiac Disease|Ischemic Stroke|Hemorrhagic Stroke,Behavioral: Support provided by social worker|Other: Information booklet receipt,"(Interventional Study) Comparison of caregivers' HRQoL according to the allocated intervention by randomization based on summaries score the MOS SF36|(Observational study) Changes in HRQoL of patients' caregivers using the MOS SF36 questionnaire|(Observational study) Changes in HRQoL of cancer patients' caregivers using the CarGoQoL questionnaire|(Observational study) Changes in the coping strategies of patients' caregivers using the Borteyrou, Rascle and Truchot Questionnaire|(Observational study) Changes in feelings of anxiety and depression of patients' caregivers according to the HADs questionnaire|(Observational study) Changes in social support of patients' caregivers using the SSQ6 questionnaire|(Observational study) Changes in burden of patients' caregivers using the Zarit burden inventory|(Interventional Study) Comparison of caregivers' HRQoL according to the intervention allocated by randomization based on summaries score the MOS SF36|(Interventional Study) Changes in HRQoL of patients' caregivers according to the allocated intervention using the MOS SF36 questionnaire|(Interventional Study) Changes in HRQoL of cancer patients' caregivers according to the allocated intervention using the CarGoQol questionnaire|(Interventionnal Study) Changes in the coping strategies of patients' caregivers according to the allocated intervention using the Borteyrou, Rascle and Truchot Questionnaire|(Interventional Study) Changes in feelings of anxiety and depression of patients' caregivers according to the allocated intervention using the HADs Questionnaire|(Interventional Study) Changes in social supports of patients' caregivers according to the allocated intervention using the SSQ6 questionnaire|(Interventional Study) Changes in burden of patients' caregivers according to the allocated intervention using the Zarit burden inventory|(Interventional study) Efficiency of the intervention of a social worker for caregivers using a cost-utility analysis|(Observational study) Changes in the caregivers/patients' relationship using a qualitative approach (semi-structure interview)|(Observational study) Changes in the role of caregiver due to a situation generating a rupture (entry into an institution or death, disease remission) using a qualitative approach (semi-structure interview)","Centre Hospitalier Universitaire de Besancon|Methodological and quality of life unit in oncology (CHRU de Besançon)|University of Franche-Comté|University of Burgundy|Pôle de Gérontologie Interrégional Bourgogne et Franche-Comté|CARSAT Bourgogne et Franche-Comté|CCAS of Dijon|CCAS of Besançon|CCAS of Montbéliard|Burgundy Regional Council|Franche-Comté Regional Council|The Municipality of Besançon|The Municipality of Dijon|General Council of the Doubs|General Council of the Territoire de Belfort|Collectif Inter Associatif Sur la Sante Bourgogne|Union Régionale Interfédérale des Œuvres et Organismes Privés Sanitaires Bourgogne|Association Gérontopôle Pierre Pfitzenmeyer|Pôle de compétitivité Vitagora Goût-Nutrition-Santé|National Old Age Insurance Fund for Employees (CNAVTS)|Sheerbrooke Gérontopôle|France Alzheimer Côte-d’Or|Institut Régional de Vieillissement (IRV)|Novartis Pharmaceuticals|Roche Foundation|Ligue contre le cancer, France|National Cancer Institute, France|Quality of life and cancer clinical research platform|National Research Agency, France",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,7604,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,P/2014/231,Oct-15,Oct-25,Oct-25,10-Dec-15,null,12-Oct-17,"CHRU de Besançon, Besançon, France|Centre Georges François Leclerc, Dijon, France|CHU de DIJON, Dijon, France",,https://ClinicalTrials.gov/show/NCT02626377
NCT02626572,Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms,,Completed,No Results Available,Alzheimer's Disease,Drug: S47445 5mg|Drug: S47445 15mg|Drug: S47445 50mg|Drug: Placebo,"Change from baseline on 11-item ADAS-Cog|Activities of Daily Living: Disability Assessment for Dementia (DAD)|Cognition: 13-item ADAS-Cog|Cognition: Mini-Mental State Examination (MMSE)|Depressive symptoms: Cornell Scale for Depression in Dementia (CSDD)|Behavioural signs and symptoms: Neuropsychiatric Inventory (NPI)|Global Clinic Assessment of Change: Alzheimer's Disease Cooperative Studies-Clinical Global Impression of Change (ADCS-CGIC)|Functionality: Gait task (GT), measure of speed of walking (unit= meters/ seconds)|Adverse events|Vital signs: heart rate|Vital signs: body temperature|Vital signs: blood pressure|Vital signs: body weight|12-lead ECG|Biological laboratory parameters: number of participants with abnomal laboratory values|Cornell Scale for Depression in Dementia (CSDD, suicide item - item 16)",Institut de Recherches Internationales Servier|Servier,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,500,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CL2-47445-011|2014‐001519‐38,Feb-15,Sep-17,Sep-17,10-Dec-15,null,15-Aug-18,"Trial Tech Tecnologia em Pesquisa com Medicamentos, Curitiba, Brazil|Hospital Universitario Walter Cantidio, Fortaleza, Brazil|Clinilive - Centro de Pesquisas Clinicas, Maringa, Brazil|Hospital das Clinicas de Porto Alegre, Porto Alegre, Brazil|Hospital Oswaldo Cruz, Recife, Brazil|Instituto Américo Bairral de Psiquiatria, Centro de Pesquisa, Sao Paulo, Brazil|UNIFESP - Universidade Federal de Sao Paulo, Sao Paulo, Brazil|UMHAT Sveti Georgi, Plovdiv, Bulgaria|Medical University of Sofia, Aleksandrovska hospital, Sofia, Bulgaria|National Hospital of Cardiology, Sofia, Bulgaria|University Hospital Sveti Naum, Clinic of Neurology, Sofia, Bulgaria|MHAT Sveta Marina, Varna, Bulgaria|Clínica Oriente, Antofagasta, Chile|Biomedica Research Group, Santiago, Chile|Especialidades Medicas LYS, Santiago, Chile|Hospital Santiago Oriente, Santiago, Chile|Private practice, Santiago, Chile|Saint Anne s.r.o. Psychiatricka ambulance, Brno, Czechia|Brain-Soultherapy s.r.o., Kladno, Czechia|Bialbi s.r.o., Litomerice, Czechia|AD71 s.r.o. Psychiatricka ambulance - Sudkova, Praha, Czechia|CLINTRIAL s.r.o., Praha, Czechia|FORBELI s.r.o., Neurologicka ambulance, Praha, Czechia|Klinikum Altenburger Land GmbH Neurologische Klinik, Altenburg, Germany|Neuropsychiatrisches Facharztzentrum Stiepel, Bochum, Germany|Universitaetsklinikum des Saarlandes, Klinik für Psychiatrie und Psychotherapie, Homburg / Saar, Germany|ISPG Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany|Pharmakologisches Studienzentrum Chemnitz GmbH, Mittweida, Germany|Somni Bene, Institut fuer Medizinische Forschung und Schlafmedizin Schwerin GmbH, Schwerin, Germany|Universitaetsklinik ULM, Poliklinik Neurologie, Ulm, Germany|Private practice, Westerstede, Germany|Semmelweis Egyetem Neurologiai Klinika, Budapest, Hungary|Kenezy Gyula Korhaz es Rendelointezet, Debrecen, Hungary|Vaszary Kolos Korhaz Esztergom Neurologiai Osztaly, Esztergom, Hungary|Petz Aladar Megyei Oktato Korhaz Pszihiatriai, Mentalhygienes es Addiktologiai Osztaly, Gyor, Hungary|Private practice, Kalocsa, Hungary|B-A-Z Megyei Korhaz es Egyetemi Oktato Korhaz Stroke, Er- es Neurologiai, Toxikologiai Osztaly, Miskolc, Hungary|Josa Andras Oktatokorhaz Pszihiatriai Osztaly, Nyiregyhaza, Hungary|Pecsi Tudomanyegyetem, Klinikai Kozpont Pszich. es Pszichoter. Klinika, Pecs, Hungary|Szent-Gyorgyi Albert Klinikai Kozpont Pszichiatriai Klinika, Szeged, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz Pszichiatriai Osztaly, Szekesfehervar, Hungary|Memory Clinic Ochanomizu, Bunkyo-ku, Japan|Showakai Clinic, Kagoshima-shi, Japan|Rainbow & Sea Hospital, Karatsu-shi, Japan|Kokan Clinic, Kawasaki-shi, Japan|Social Medical Corporation Kojunkai Daido Hospital, Nagoya, Japan|Nakano General Hospital, Nakano-ku, Japan|Private practice, Saitama-shi, Japan|Private practice, Setagaya-ku, Japan|Seishinkai Okehazama Hospital, Toyoake-shi, Japan|Instituto Biomedico de Investigacion, Aguascalientes, Mexico|Centro de Estudios Clinicos Y Especialidades Medicas Sc, Monterrey, Mexico|Hospital Universitario de Nuevo León, Nuevo León, Mexico|University Hospital of Saltillo, Saltillo, Mexico|Nzoz Centrum Kultury, Higieny I Zdrowia Psychicznego, Bydgoszcz, Poland|Krakowska Akademia Neurologii Centrum Neurologii Klinicznej, Krakow, Poland|NZOZ Neuromed M. i M. Nastaj Sp. Partnerska, Lublin, Poland|Osrodek Alzheimerowski Sp. z o.o., Scinawa, Poland|SENIOR Poradnia Psychogeriatryczna, Sopot, Poland|Centrum Medyczne Neuroprotect, Warszawa, Poland|Interregional Clinico-Diagnostical Centre, Kazan, Russian Federation|First Moscow State Medical University n.a.I.M. Sechenov Clinic of Neurology, Moscow, Russian Federation|Scientific Center of Mental Health Sect of AD and associated disord. Dpt of gerontopsychiatry, Moscow, Russian Federation|Scientific Center of Mental Health Sect of psychosis of elderly ages Dpt of gerontopsychiatry, Moscow, Russian Federation|City geriatric medico-social centre, St. Petersburg, Russian Federation|Medical Military Academy n.a.S.M.Kirov, St. Petersburg, Russian Federation|Psychoneuropathology Dispensary N 10, St. Petersburg, Russian Federation|Co Ltd ""LION-MED"", Voronezh, Russian Federation|Private practice, Bratislava, Slovakia|INVESTA, spol. s r. o. Psychiatricka ambulancia, Kosice, Slovakia|NsP Svatej Barbory Psychiatricke oddelenie, Roznava, Slovakia|Iatros International, Bloemfontein, South Africa|Flexivest Fourteen Research Centre, Cape Town, South Africa|Umhlanga Hospital, Durban, South Africa|Excellentis Clinical Trial Consultants, George, South Africa|Apollo Clinical Research, Johannesburg, South Africa|Denmar Hospital, Pretoria, South Africa|Somerset West Trial Centre, Somerset West, South Africa",,https://ClinicalTrials.gov/show/NCT02626572
NCT02624778,A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD,,"Active, not recruiting",No Results Available,Alzheimer Disease,Biological: LY3002813|Drug: Placebo,Florbetapir Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVr)|Pharmacokinetics: Serum Concentrations of LY3002813|Change from Baseline in Incidence of Anti-Drug Antibodies,Eli Lilly and Company,All,"50 Years and older   (Adult, Older Adult)",Phase 1,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",16233|I5T-MC-AACD,22-Dec-15,4-Sep-19,6-May-20,8-Dec-15,null,4-Dec-18,"Brain Matters Research, Delray Beach, Florida, United States|Compass Research, Orlando, Florida, United States|Compass Research, The Villages, Florida, United States|SNBL Clinical Pharmacology Center Inc, Baltimore, Maryland, United States|St. Louis Clinical Trials, LC, Saint Louis, Missouri, United States|PRA Health Sciences, Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shinjuku-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Shinjuku-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Sumida-ku, Japan",,https://ClinicalTrials.gov/show/NCT02624778
NCT02621606,[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001),,Completed,Has Results,Alzheimer's Disease,Drug: [11C]MK-6884,Number of Participants Experiencing an Adverse Event (AE)|Number of Participants Discontinuing the Study Due to an Adverse Event (AE)|[Part 1] Mean Effective Dose of [11C]MK-6884|[Part 1] Mean Organ Effective Dose of [11C]MK-6884|[Part 2] Mean Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest (ROI)|[Part 2] Intra-subject Test-Retest (T-RT) Variability of Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest (ROI)|[Part 3] Mean Regional Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest,Merck Sharp & Dohme Corp.,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,6884-001|2015-001631-20|MK-6884-001,8-Jan-16,28-Dec-17,28-Dec-17,3-Dec-15,28-Feb-19,28-Feb-19,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02621606/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02621606
NCT02614131,A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD),,Terminated,No Results Available,Healthy|Alzheimer's Disease|Mild Cognitive Impairment,Drug: LY2599666|Drug: Solanezumab|Drug: Placebo SC|Drug: Placebo IV,Number of Participants With One or More Serious Adverse Event (SAE) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2599666 and Solanezumab|Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY2599666 and Solanezumab|Plasma Amyloid Beta (Abeta) Concentration,Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 1,130,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15491|I2L-MC-ALCA,Dec-15,Dec-16,Dec-16,25-Nov-15,null,10-Jan-17,"Parexel Early Phase Unit at Glendale, Glendale, California, United States|CRI Lifetree, Marlton,, New Jersey, United States|PRA Health Sciences, Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Kobe, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Shinjuku-Ku, Japan",,https://ClinicalTrials.gov/show/NCT02614131
NCT02615002,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: Piromelatine|Drug: Placebo,Change from baseline in Computerized neuropsychological test battery (cNTB)|Change from baseline in Global Impression of Change (CGIC)|Change from baseline in Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS-MCI-ADL)|Change from baseline in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog14)|Safety and tolerability of piromelatine,Neurim Pharmaceuticals Ltd.,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,500,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NeuP11-AD2,Nov-15,Apr-19,Apr-19,25-Nov-15,null,21-Mar-19,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Citrials Inc, Bellflower, California, United States|Alliance for Research, Long Beach, California, United States|Renew Behavioral Health, Inc, Long Beach, California, United States|ABS Health LLC, Pomona, California, United States|Anderson Clinical Research, Redlands, California, United States|Pacific Research Network, Inc, San Diego, California, United States|Sharp Mesa Vista Clinical research, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Research Center For Clinical Studies, Inc, Norwalk, Connecticut, United States|Pioneer Clinical research, Coconut Creek, Florida, United States|University of Miami, Coral Gables, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|New Life Medical Research Center, Hialeah, Florida, United States|Galiz reserach, Hialeah, Florida, United States|Biomed Research Institute, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Advanced Clinical research Network, Miami, Florida, United States|Medical Research Group of central Florida Inc., Orange City, Florida, United States|The Roskamp Institute, Inc, Sarasota, Florida, United States|Infinity Clinical Research, LLC., Sunrise, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|Rowe Neurology, Lenexa, Kansas, United States|KU School of Medicine-Wichita, Wichita, Kansas, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|Pharmasite Research INC, Baltimore, Maryland, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Precise Research Centers, Flowood, Mississippi, United States|Hattiesburg Clinic, P.A., Hattiesburg, Mississippi, United States|Galen Research, Chesterfield, Missouri, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|The Neurocognitive Institute, LLC, Mount Arlington, New Jersey, United States|Global Medical Institutes, Princeton, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|Dent Neurosciences Research Center, Inc, Amherst, New York, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|New Hope Clinical research, Charlotte, North Carolina, United States|Richard H. Weisler, M.D., P.A. & Associates, Raleigh, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Red river medical research Center, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, LLC., Tulsa, Oklahoma, United States|The Clinical research Center LLC, Jenkintown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Shepherd Clinical Research LLC, Lewisville, Texas, United States|Radiant Research, San Antonio, Texas, United States|Grayline Research Center, Wichita Falls, Texas, United States|Aspen Clinical research, Orem, Utah, United States|Wasatch Clinical Research LLC, Salt Lake City, Utah, United States|Zain Research, Llc, Richland, Washington, United States|SSM Health/Dean Medical Group, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02615002
NCT02612688,Pragmatic Trial of Video Education in Nursing Homes,PROVEN,Recruiting,No Results Available,"Alzheimer Disease|Dementia|Heart Failure|Pulmonary Disease, Chronic Obstructive",Behavioral: ACP Video Program,Hospital transfer rate in target cohort|Hospital transfer rate among long-stay residents without advanced illness|Hospital transfer rate among short-stay residents with advanced illness|Hospital transfer rate among short-stay residents without advanced illness|Proportion of target cohort that has an advance directive status|Proportion of long-stay residents without advanced illness that has an advance directive|Proportion of short-stay residents with advanced illness that has an advance directive|Proportion of short-stay residents without advanced illness that has an advance directive|Average time to switch advance directives in target cohort|Average time to switch advance directives among long-stay residents without advanced illness|Average time to switch advance directives among short-stay residents with advanced illness|Average time to switch advance directives among short-stay residents without advanced illness|Proportion of target cohort receiving any burdensome treatment|Proportion of long-stay residents without advanced illness receiving any burdensome treatment|Proportion of short-stay residents with advanced illness receiving any burdensome treatment|Proportion of short-stay residents without advanced illness receiving any burdensome treatment|Proportion of target cohort with any hospice enrollment|Proportion of long-stay residents without advanced illness with any hospice enrollment|Proportion of short-stay residents with advanced illness with any hospice enrollment|Proportion of short-stay residents without advanced illness with any hospice enrollment|Proportion of target cohort that has Medicare ACP billing codes|Proportion of long-stay residents without advanced illness that has Medicare ACP billing codes|Proportion of short-stay residents with advanced illness that has Medicare ACP billing codes|Proportion of short-stay residents without advanced illness that has Medicare ACP billing codes,Brown University|National Institute on Aging (NIA)|Hebrew SeniorLife|Massachusetts General Hospital|Genesis HealthCare|PruittHealth,All,65 Years and older   (Older Adult),Not Applicable,211469,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",4UH3AG049619-02,Mar-16,May-19,May-19,24-Nov-15,null,15-May-18,"PruittHealth, Norcross, Georgia, United States|Genesis HealthCare, Kennett Square, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02612688
NCT02612805,The Diabetes and Aquatic Training Study (DATS),DATS,Completed,No Results Available,"Diabetes Mellitus, Type 2",Other: Aerobic training|Other: Combined training|Other: Training placebo,"Changes in levels of glycated hemoglobin|Fasting plasma glucose.|Fasting insulin.|Insulin-resistance index (HOMA-IR).|Total cholesterol.|high density lipoprotein.|Low density lipoprotein.|Triglycerides.|Renin|High sensitive C-reactive protein.|Total testosterone.|Cortisol|Testosterone/cortisol ratio.|Peak oxygen uptake.|Oxygen uptake at the second ventilatory threshold.|Percentage of oxygen consumption in the second ventilatory threshold from the peak oxygen uptake.|Systolic blood pressure.|Diastolic blood pressure|Heart rate at rest.|Maximum dynamic muscle strength (1RM) in the knees extension exercise.|Maximum dynamic muscle strength (1RM) in the elbows flexion exercise.|Resistant dynamic muscle strength (maximal repetitions) in the knees extension exercise.|Resistant dynamic muscle strength (maximal repetitions) in the elbows flexion exercise.|Timed up and go test performed at the usual speed.|Timed up and go test performed at the maximal speed.|Sitting-rising test (SRT).|Overall quality of life and in physical, psychological, social relationships and environment domains, evaluated by instrument of World Health Organization (WHOQOL).|Depressive symptoms, evaluated by Depression Inventory Patient Health Questionnarie (PHQ-9)|Sleep quality, evaluated by Pittsburgh Sleep Scale|Levels of sleep Obstructive Apnea, evaluated by Berlin Questionnaire (BQ)|Physical activity levels, evaluated by International Physical Activity Questionnaire (IPAQ) - Short Form.",Hospital de Clinicas de Porto Alegre,All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,15-0380,Nov-15,Dec-15,May-16,24-Nov-15,null,16-Aug-16,,,https://ClinicalTrials.gov/show/NCT02612805
NCT02600130,Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer's Disease,Biological: Longeveron Mesenchymal Stem Cells|Biological: Placebo,To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease.|Preliminary efficacy will be determined by examining for changes in AD status and rate decline as assessed by the following.,Longeveron LLC,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",00-0000-01,Aug-16,Mar-20,Mar-20,9-Nov-15,null,17-Dec-18,"UCLA School of Medicine, Los Angeles, California, United States|Brain Matters Research, Delray Beach, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Miami Jewish Health, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02600130
NCT02593318,Trial of Oxaloacetate in Alzheimer's Disease (TOAD),TOAD,Completed,No Results Available,Alzheimer's Disease (AD),Drug: Oxaloacetate (OAA),"Change in Safety Assessments (safety labs, physical and neurological exams, vital signs, cognitive measures, signs and symptoms)|Change in brain glucose metabolic rate as determined by Fluorodeoxyglucose positron emission tomography (FDG PET)|Change in brain lactate levels as determined by magnetic resonance spectroscopy (MRS)|Correlation between oral OAA intake and plasma levels in 500 mg bid cohort|Correlation between oral OAA intake and plasma levels in 1000 mg bid cohort","Russell Swerdlow, MD|University of Kansas Medical Center",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00002242,Oct-15,Sep-18,Sep-18,2-Nov-15,null,12-Oct-18,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02593318
NCT02586909,12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension,,Terminated,No Results Available,Alzheimer's Disease,Drug: RVT-101 35 mg tablets,"Occurrence of adverse events (AEs) and or reported changes in physical examinations, vital signs measurements, electrocardiograms (ECGs), routine laboratory assessments",Axovant Sciences Ltd.,All,"50 Years to 86 Years   (Adult, Older Adult)",Phase 3,1100,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RVT-101-3002,Apr-16,Mar-18,Mar-18,27-Oct-15,null,20-Mar-18,"US112, Phoenix, Arizona, United States|US220, Tucson, Arizona, United States|US096, Rancho Mirage, California, United States|US195, Santa Ana, California, United States|US016, Simi Valley, California, United States|US106, Temecula, California, United States|US179, Hamden, Connecticut, United States|US171, Norwich, Connecticut, United States|US088, Atlantis, Florida, United States|US007, Brooksville, Florida, United States|US002, Hallandale Beach, Florida, United States|US140, Hialeah, Florida, United States|US216, Miami, Florida, United States|US110, Miami, Florida, United States|US172, North Palm Beach, Florida, United States|US003, Orlando, Florida, United States|US256, Pensacola, Florida, United States|US037, Tampa, Florida, United States|US042, Tampa, Florida, United States|US004, The Villages, Florida, United States|US048, Atlanta, Georgia, United States|US046, Atlanta, Georgia, United States|US217, Columbus, Georgia, United States|US111, Baton Rouge, Louisiana, United States|US095, Shreveport, Louisiana, United States|US116, Newton, Massachusetts, United States|US174, Quincy, Massachusetts, United States|US144, Hattiesburg, Mississippi, United States|US094, Las Vegas, Nevada, United States|US135, Berlin, New Jersey, United States|US197, Lawrenceville, New Jersey, United States|US057, Manchester, New Jersey, United States|US215, Mount Arlington, New Jersey, United States|US209, Toms River, New Jersey, United States|US036, West Long Branch, New Jersey, United States|US001, Albany, New York, United States|US049, Brooklyn, New York, United States|US097, New Hyde Park, New York, United States|US044, New York, New York, United States|US150, Chapel Hill, North Carolina, United States|US185, Charlotte, North Carolina, United States|US008, Cincinnati, Ohio, United States|US113, Cleveland, Ohio, United States|US119, Shaker Heights, Ohio, United States|US134, Portland, Oregon, United States|US169, Media, Pennsylvania, United States|US162, Plains, Pennsylvania, United States|US148, Willow Grove, Pennsylvania, United States|US043, San Antonio, Texas, United States|US143, Orem, Utah, United States|US149, Charlottesville, Virginia, United States|US170, Spokane, Washington, United States|AR130, La Plata, Buenos Aires, Argentina|AR101, Buenos Aires, Argentina|AR060, Buenos Aires, Argentina|AR084, Ciudad Autonoma de Buenos Aire, Argentina|AR027, Ciudad Autonoma de Buenos Aire, Argentina|AR012, Ciudad Autonoma de Buenos Aire, Argentina|AR160, Ciudad Autonoma de Buenos Aire, Argentina|AR028, Ciudad Autonoma de Buenos Aire, Argentina|AR035, Ciudad Autonoma de Buenos Aire, Argentina|AR040, Ciudad Autónoma de Buenos Aire, Argentina|AR081, Ciudad Autónoma de Buenos Aire, Argentina|AR051, Córdoba, Argentina|AR137, Córdoba, Argentina|AR126, Córdoba, Argentina|AR210, Mendoza, Argentina|AR219, Mendoza, Argentina|AR059, Santiago del Estero, Argentina|AU227, Caulfield, Australia|AU032, Heidelberg West, Australia|AU011, Hornsby, Australia|AU138, West Perth, Australia|BU125, Ruse, Bulgaria|BU131, Sofia, Bulgaria|BU073, Varna, Bulgaria|CA054, Kelowna, British Columbia, Canada|CA188, Kelowna, British Columbia, Canada|CA186, Penticton, British Columbia, Canada|CA141, West Vancouver, British Columbia, Canada|CA147, Newmarket, Ontario, Canada|CA196, North York, Ontario, Canada|CA236, Gatineau, Quebec, Canada|CH212, Antofagasta, II Región, Chile|CH076, Santiago, Region Metropolitana, Chile|CH061, Santiago, Región Metropolitana, Chile|CH075, Santiago, Región Metropolitana, Chile|CR069, Zagreb, Croatia|CR122, Zagreb, Croatia|CR070, Zagreb, Croatia|CZE128, Praha 10, Czechia|CZE132, Praha 2, Czechia|CZE129, Praha 6, Czechia|CZE207, Praha, Czechia|CZE161, Rychnov nad Kneznou, Czechia|FR231, Lille Cedex, France|FR182, Marseille Cedex 5, France|FR221, Paris Cedex, France|FR202, Villeurbanne, France|GE206, Bad Homburg, Germany|GE091, Berlin, Germany|GE071, Berlin, Germany|GE139, Berlin, Germany|GE230, Cologne, Germany|GE252, Ellwangen, Germany|GE180, Leipzig, Germany|GE228, Mannheim, Germany|GE017, Munchen, Germany|GE157, Nürnberg, Germany|GE098, Ulm, Germany|GE251, Westerstede, Germany|IT053, Brescia, Italy|IT124, Cefalu, Italy|IT030, Pavia, Italy|IT103, Perugia, Italy|IT072, Roma, Italy|IT029, Roma, Italy|IT183, Rome, Italy|IT175, Rome, Italy|IT085, Torino, Italy|SK066, Busan, Korea, Republic of|SK067, Seoul, Korea, Republic of|SK190, Seoul, Korea, Republic of|PO013, Bialystok, Poland|PO024, Bydgoszcz, Poland|PO010, Bydgoszcz, Poland|PO107, Katowice, Poland|PO092, Katowice, Poland|PO009, Poznan, Poland|PO014, Szczecin, Poland|PO074, Warszawa, Poland|SE164, Belgrade, Serbia|SE193, Belgrade, Serbia|SE090, Belgrade, Serbia|SE155, Kragujevac, Serbia|SE031, Novi Kneževac, Serbia|SE165, Vršac, Serbia|SI052, Singapore, Singapore|SI026, Singapore, Singapore|SL056, Banska Bystrica, Slovakia|SL200, Dubnica nad Vahom, Slovakia|SL078, Krompachy, Slovakia|SL078, Krompachy, Slovakia|SL077, Svidník, Slovakia|SP249, Alicante, Spain|SP176, Barcelona, Spain|SP022, Barcelona, Spain|SP021, Barcelona, Spain|SP250, Barcelona, Spain|SP194, Donostia, Gipuzkoa, Spain|SP222, Getxo-Vizcaya, Spain|SP184, Sant Cugat Del Valles, Barcelona, Spain|TA121, Taoyuan, Taiwan|UK063, Bath, United Kingdom|UK038, Blackpool, United Kingdom|UK233, Cambridge, United Kingdom|UK033, Carnoch, United Kingdom|UK211, Epping, United Kingdom|UK234, Guildford, United Kingdom|UK055, Leeds, United Kingdom|UK039, London, United Kingdom|UK034, Manchester, United Kingdom|UK087, Oxford, United Kingdom|UK235, Plymouth, United Kingdom|UK100, Sheffield, United Kingdom|UK064, Southampton, United Kingdom|UK152, Southampton, United Kingdom|UK153, Swindon, United Kingdom|UK154, Warrington, United Kingdom",,https://ClinicalTrials.gov/show/NCT02586909
NCT02585934,Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study,,Completed,Has Results,Alzheimer's Disease,Drug: RVT-101|Drug: Placebo,Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 Items (ADAS-Cog-11) Score Change From Baseline to Week 24|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score Change From Baseline to Week 24|Clinical Global Impression of Change - Plus Caregiver Interview (CIBIC+) Score at Week 24|The Dependence Scale (DS) Score Change From Baseline to Week 24|Neuropsychiatric Inventory (NPI) Score Change From Baseline to Week 24|ADAS-Cog-13 Score Change From Baseline to Week 24|Measurement of Concentrations of RVT-101 (Intepirdine) in Plasma,Axovant Sciences Ltd.,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1315,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RVT-101-3001,Oct-15,Sep-17,Sep-17,26-Oct-15,5-Dec-18,5-Dec-18,"US112, Phoenix, Arizona, United States|US220, Tucson, Arizona, United States|US168, Encino, California, United States|US117, Fullerton, California, United States|US214, Los Angeles, California, United States|US189, Pasadena, California, United States|US096, Rancho Mirage, California, United States|US0195, Santa Ana, California, United States|US016, Simi Valley, California, United States|US106, Temecula, California, United States|US179, Hamden, Connecticut, United States|US171, Norwich, Connecticut, United States|US088, Atlantis, Florida, United States|US007, Brooksville, Florida, United States|US002, Hallandale Beach, Florida, United States|US140, Hialeah, Florida, United States|US216, Miami, Florida, United States|US110, Miami, Florida, United States|US172, North Palm Beach, Florida, United States|US003, Orlando, Florida, United States|US256, Pensacola, Florida, United States|US037, Tampa, Florida, United States|US042, Tampa, Florida, United States|US004, The Villages, Florida, United States|US048, Atlanta, Georgia, United States|US046, Atlanta, Georgia, United States|US217, Columbus, Georgia, United States|US111, Baton Rouge, Louisiana, United States|US095, Shreveport, Louisiana, United States|US116, Newton, Massachusetts, United States|US174, Quincy, Massachusetts, United States|US144, Hattiesburg, Mississippi, United States|US094, Las Vegas, Nevada, United States|US135, Berlin, New Jersey, United States|US197, Lawrenceville, New Jersey, United States|US057, Manchester, New Jersey, United States|US215, Mount Arlington, New Jersey, United States|US209, Toms River, New Jersey, United States|US036, West Long Branch, New Jersey, United States|US001, Albany, New York, United States|US049, Brooklyn, New York, United States|US097, New Hyde Park, New York, United States|US177, New Windsor, New York, United States|US142, New York, New York, United States|US044, New York, New York, United States|US150, Chapel Hill, North Carolina, United States|US185, Charlotte, North Carolina, United States|US113, Beachwood, Ohio, United States|US136, Cincinnati, Ohio, United States|US008, Cincinnati, Ohio, United States|US119, Shaker Heights, Ohio, United States|US134, Portland, Oregon, United States|US169, Media, Pennsylvania, United States|US187, Philadelphia, Pennsylvania, United States|US162, Plains, Pennsylvania, United States|US148, Willow Grove, Pennsylvania, United States|US115, Houston, Texas, United States|US043, San Antonio, Texas, United States|US143, Orem, Utah, United States|US149, Charlottesville, Virginia, United States|US170, Spokane, Washington, United States|AR130, La Plata, Buenos Aires, Argentina|AR041, La Plata, Buenos Aires, Argentina|AR101, Buenos Aires, Argentina|AR060, Buenos Aires, Argentina|AR084, Ciudad Autónoma de Buenos Aire, Argentina|AR027, Ciudad Autónoma de Buenos Aire, Argentina|AR012, Ciudad Autónoma de Buenos Aire, Argentina|AR160, Ciudad Autónoma de Buenos Aire, Argentina|AR040, Ciudad Autónoma de Buenos Aire, Argentina|AR028, Ciudad Autónoma de Buenos Aire, Argentina|AR081, Ciudad Autónoma de Buenos Aire, Argentina|AR035, Ciudad Autónoma de Buenos Aire, Argentina|AR051, Cordoba, Argentina|AR137, Cordoba, Argentina|AR210, Mendoza, Argentina|AR219, Mendoza, Argentina|AR059, Santiago del Estero, Argentina|AU227, Caulfield, Australia|AU079, Chermside, Australia|AU032, Heidelberg West, Australia|AU062, Herston, Australia|AU011, Hornsby, Australia|AU138, West Perth, Australia|BU125, Ruse, Bulgaria|BU131, Sofia, Bulgaria|BU198, Sofia, Bulgaria|BU073, Varna, Bulgaria|CA151, Medicine Hat, Alberta, Canada|CA120, Kamloops, British Columbia, Canada|CA054, Kelowna, British Columbia, Canada|CA188, Kelowna, British Columbia, Canada|CA186, Penticton, British Columbia, Canada|CA141, West Vancouver, British Columbia, Canada|CA147, Newmarket, Ontario, Canada|CA196, North York, Ontario, Canada|CA237, Toronto, Ontario, Canada|CA236, Gatineau, Quebec, Canada|CH212, Antofagasta, II Región, Chile|CH076, Santiago, Region Metropolitana, Chile|CH061, Santiago, Región Metropolitana, Chile|CH075, Santiago, Región Metropolitana, Chile|CR069, Zagreb, Croatia|CR122, Zagreb, Croatia|CR068, Zagreb, Croatia|CR070, Zagreb, Croatia|CR083, Zagreb, Croatia|CZ128, Praha 10, Czechia|CZ207, Praha 10, Czechia|CZ132, Praha 2, Czechia|CZ129, Praha 6, Czechia|CZ161, Rychnov nad Kneznou, Czechia|FR231, Lille Cedex, France|FR182, Marseille Cedex 5, France|FR221, Paris Cedex, France|FR202, Villeurbanne, France|GE206, Bad Homburg, Germany|GE091, Berlin, Germany|GE071, Berlin, Germany|GE139, Berlin, Germany|GE230, Cologne, Germany|GE252, Ellwangen, Germany|GE180, Leipzig, Germany|GE228, Mannheim, Germany|GE017, Munchen, Germany|GE157, Nürnberg, Germany|GE098, Ulm, Germany|GE251, Westerstede, Germany|IT053, Brescia, Italy|IT124, Cefalù, Italy|IT030, Pavia, Italy|IT103, Perugia, Italy|IT072, Roma, Italy|IT183, Roma, Italy|IT029, Roma, Italy|IT175, Rome, Italy|IT085, Torino, Italy|SK066, Busan, Korea, Republic of|SK067, Seoul, Korea, Republic of|SK190, Seoul, Korea, Republic of|PO013, Bialystok, Poland|PO024, Bydgoszcz, Poland|PO010, Bydgoszcz, Poland|PO107, Katowice, Poland|PO092, Katowice, Poland|PO023, Krakow, Poland|PO025, Krakow, Poland|PO009, Poznan, Poland|PO014, Szczecin, Poland|PO074, Warszawa, Poland|SE164, Belgrade, Serbia|SE090, Belgrade, Serbia|SE166, Belgrade, Serbia|SE193, Belgrade, Serbia|SE155, Kragujevac, Serbia|SE031, Novi Knezevac, Serbia|SE165, Vrsac, Serbia|SI052, Singapore, Singapore|SI026, Singapore, Singapore|SL056, Banska Bystrica, Slovakia|SL192, Bratislava, Slovakia|SL200, Dubnica nad Váhom, Slovakia|SL191, Kosice, Slovakia|SL078, Krompachy, Slovakia|SL077, Svidnik, Slovakia|SP249, Alicante, Spain|SP176, Barcelona, Spain|SP022, Barcelona, Spain|SP021, Barcelona, Spain|SP250, Barcelona, Spain|SP019, Ceuta, Spain|SP194, Donostia, Spain|SP222, Getxo, Spain|SP018, Madrid, Spain|SP093, Madrid, Spain|SP184, Sant Cugat del Vallès, Spain|SP020, Terrassa, Spain|TA065, Kaohsiung, Taiwan|TA086, Taipei, Taiwan|TA121, Taoyuan, Taiwan|UK063, Bath, United Kingdom|UK038, Blackpool, United Kingdom|UK233, Cambridge, United Kingdom|UK033, Cannock, United Kingdom|UK211, Epping, United Kingdom|UK234, Guildford, United Kingdom|UK055, Leeds, United Kingdom|UK039, London, United Kingdom|UK034, Manchester, United Kingdom|UK229, Norwich, United Kingdom|UK087, Oxford, United Kingdom|UK235, Plymouth, United Kingdom|UK100, Sheffield, United Kingdom|UK064, Southampton, United Kingdom|UK152, Southampton, United Kingdom|UK153, Swindon, United Kingdom|UK154, Warrington, United Kingdom","""Study Protocol: Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/Prot_000.pdf|""Statistical Analysis Plan: Statistical Analysis Plan Document"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/SAP_001.pdf|""Statistical Analysis Plan: Statistical Analysis Plan Addendum Document"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02585934
NCT02585232,Optimizing Dementia Care,ODeC,Recruiting,No Results Available,"Alzheimer's Disease|Dementia|Dementia, Vascular|Caregivers|Veterans",Behavioral: Counseling (C)|Behavioral: Care Consultation (CC),Change from baseline in caregiver burden scores on the Zarit Caregiver Burden Inventory|Change from baseline in relationship strain on the Dyadic Adjustment Scale|Change from baseline in Quality of Life|Change from baseline depressive symptoms on the Cornell Scale for Depression in Dementia|Rates of placement in long-term care facilities at 12 months,VA Office of Research and Development,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,68,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,D1824-W,1-Oct-16,31-Dec-19,31-Oct-20,23-Oct-15,null,18-Feb-19,"Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, United States",,https://ClinicalTrials.gov/show/NCT02585232
NCT02580305,SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study,,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: SUVN-502|Drug: Placebo,Change in cognition|Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Change in functioning|Change in behavioural disturbance|Depression and Dementia|Risk of suicidality|Change in cognitive aspects of mental function|Safety and tolerability,Suven Life Sciences Limited,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,563,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CTP2S1502HT6,Sep-15,Apr-19,May-19,20-Oct-15,null,1-Nov-18,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Neuro-Pain Medical Center Inc, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|Easton Center for Alzheimer's Disease Research at UCLA, Los Angeles, California, United States|Paradigm Research, San Diego, California, United States|Associated Neurologists of South Connecticut, Fairfield, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Bradenton Research Center, Inc, Bradenton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Anchor Neuroscience, Pensacola, Florida, United States|Emerald Coast Center for Neurological Disorders, Pensacola, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|The Roskamp Institute, Inc., Sarasota, Florida, United States|Brain Matters Research, Stuart, Florida, United States|Neurology Clinical Research, Inc., Sunrise, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|University of South Florida - Byrd Alzheimer's Institute, Tampa, Florida, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Southern Illinois School of Medicine, Springfield, Illinois, United States|Indiana University Health - University Hospital, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|KU Medical Center Wichita Clinical Trial Unit, Wichita, Kansas, United States|University Of Kentucky, Lexington, Kentucky, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Acadia Hospital, Bangor, Maine, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Clinical Research Professionals, Saint Louis, Missouri, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Advanced Memory Research Institute of NJ, PC - Internal Medicine, Rahway, New Jersey, United States|Advanced Memory Research Institute, Toms River, New Jersey, United States|Biobehavioral Health, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|Mid Hudson Medical Research, New Windsor, New York, United States|New York University, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Upstate University Hospital (SUNY Health Science Center), Syracuse, New York, United States|Five Towns Neuroscience Research, Woodmere, New York, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|Alzheimer Memory Center, Charlotte, North Carolina, United States|Richard Weisler, MD, PA, Raleigh, North Carolina, United States|Ohio Clinical Research Partners, LLC, Canton, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|Cleveland Clinic Main Campus, Cleveland, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Northeastern Pennsylvania Memory and Alzheimers Center, Plains, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Shepherd Healthcare, Lewisville, Texas, United States|Radiant Research, Inc., San Antonio, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Center for Alzheimer's Care, Imaging and Research, Salt Lake City, Utah, United States|Independent Psychiatric Consultants, SC, dba, Waukesha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02580305
NCT02579252,24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease,ADAMANT,"Active, not recruiting",No Results Available,Alzheimer's Disease,Biological: AADvac1|Drug: Placebo,Safety (all-case treatment-emergent adverse events except local reactions)|Clinical Dementia Rating (CDR) Sum of Boxes|Custom cognitive battery (composite standard score)|Alzheimer's Disease Cooperative Study - Activities of Daily Living questionnaire (version for Mild Cognitive Impairment) (ADCS MCI ADL)|Immunogenicity,Axon Neuroscience SE,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,208,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AC-AD-003|2015-000630-30,Mar-16,Jun-19,Jun-19,19-Oct-15,null,29-Aug-17,"Ordination Dr. Bancher, Horn, Niederosterreich, Austria|Universitätsklinik für Neurologie, Graz, Steiermark, Austria|Abteilung Psychiatrie und Psychotherapie, LKH Hall, Hall in Tirol, Tirol, Austria|Universitätsklinikum Innsbruck, Innsbruck, Tirol, Austria|Fakultni nemocnice u sv. Anny v Brne, Mezinarodni centrum klinickeho vyzkumu (ICRC), Centrum pro kognitivni poruchy, Neuro 2, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Neurologicka Klinika, Hradec Kralove, Czechia|Narodni ustav dusevniho zdravi (NÚDZ), Department of cognitive disorders - AD Center, Klecany, Czechia|Vseobecna fakultni nemocnice v Praze, Praha, Czechia|Fakultni nemocnice v Motole, Praha, Czechia|Neuro Centrum Odenwald, Erbach, Rheinland-Pfalz, Germany|Arzneimittelforschung Leipzig (AFL), Leipzig, Sachsen, Germany|Universität Heidelberg, Zentralinstitut für Seelische Gesundheit, Mannheim, Germany|Klinikum rechts der Isar der Technischen Universität München, Klinik und Poliklinik fur Psychiatrie und Psychotherapie, München, Germany|Praxis Dr. Klaus Christian Steinwachs, Nürnberg, Germany|Universitätsklinikum Ulm, Klinik und Poliklinik für Neurologie, Ulm, Germany|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Pallmed prowadzacy NZOZ Dom Sue Ryder w Bydgoszczy Centrum Psychoneurologii Wieku Podeszlego, Bydgoszcz, Poland|Wielospecjalistyczna Poradnia Lekarska Synapsis, Katowice, Poland|Care Clinic, Katowice, Poland|Centrum Neurologii Klinicznej, Krakowska Akademia Neurologii, Kraków, Poland|KO-MED Centra Kliniczne Sp. z o.o., Lublin, Poland|Oddzial Neurologiczny, Olsztyn, Poland|NZOZ Neuro-Kard, Poznan, Poland|EUROMEDIS Sp. z o.o., Szczecin, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Wrocławskie Centrum Alzheimerowskie, Wroclaw, Poland|""Dr. Constantin Gorgos"" Psychiatry Hospital Titan, Bucharest, Romania|Neurologicka ambulancia, Banska Bystrica, Slovakia|Nestatna psychiatricka ambulancia, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, I. Neurologicka klinika LF UK a UNB, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Psychiatricka klinika LFUK a UNB, Bratislava, Slovakia|Univerzitna nemocnica L Pasteura Kosice, Psychiatricka klinika, Kosice, Slovakia|NEURES, s.r.o. Neurologicka ambulancia, Krompachy, Slovakia|Centrum zdravia R.B.K., s.r.o., Psychiatricka ambulancia, Svidnik, Slovakia|Pro Mente Sana S.R.O., Psychiatricka Ambulancia, Trencin, Slovakia|Fakultna nemocnica s poliklinikou Zilina, Psychiatricke oddelenie, Zilina, Slovakia|Univerzitetni klinični Center Ljubljana, Neurology Clinic, Ljubljana, Slovenia|University Clinical Centre Maribor, Maribor, Slovenia|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmö, Sweden|Sahlgrenska Universitetssjukhuset, Minnesmottagningen, Mölndal, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Akademiska Sjukhuset I Uppsala, Minnes-och geriatrikmottagningen, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT02579252
NCT02578303,Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations,VAAPS,Recruiting,No Results Available,Alzheimer Disease,Other: Vascular flow measurement by PC-MRI,Total arterial flowrate (measured by PC-MRI debit ml/Mn)|sleep apnea measured by elderly polygraphy (Number of apneas / night),Central Hospital Saint Quentin,All,75 Years to 120 Years   (Older Adult),Not Applicable,139,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RCB / N° 2014-A01617-40,May-15,1-Jan-20,1-Jan-20,16-Oct-15,null,18-Jul-18,"CH Saint-Quentin, Saint-Quentin, France",,https://ClinicalTrials.gov/show/NCT02578303
NCT02576639,Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age,,Completed,Has Results,Alzheimer's Disease,Drug: CNP520|Drug: Placebo,"Number of Subjects With Non-serious and Serious Adverse Events (AEs) and Deaths|Change From Baseline of Amyloid Beta (Aβ) 1-38 , Aβ 1-40 and Aβ 1-42 Cerebrospinal Fluid (CSF) Concentrations|Summary of Plasma PK Parameter: Cmax|Summary of Plasma PK Parameter: AUCtau|Summary of Plasma PK Parameter: Tmax|Summary of Plasma PK Parameter: Tlag|Summary of Plasma PK Parameter: T1/2|Summary of PK Parameter: CLss/F|Summary of Plasma PK Parameter: Racc|Summary of CSF PK Concentrations|Area-under-plasma Concentration Time Curve up to Infinity (AUCinf)|Apparent Volume of Distribution (Vz/F)",Novartis Pharmaceuticals|Novartis,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 2,124,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",CCNP520X2102|2013-005576-18,10-Aug-15,11-Mar-16,11-Mar-16,15-Oct-15,25-May-17,11-Aug-17,"Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Groningen, GZ, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Mid Glamorgan, United Kingdom",,https://ClinicalTrials.gov/show/NCT02576639
NCT02576821,Hippocampal Sclerosis and Amnesia Not Due to Alzheimer's Disease,ShaTau7,Recruiting,No Results Available,Patients With Cognitive Disturbances,Other: Neurological examinations|Other: Neuropsychological examinations|Other: Clinical examinations|Radiation: MRI 3T|Radiation: MRI 7T,7 tesla MRI.|3T MRI|7T MRI|CSF|Neuropsychological assessment|Clinical assessment|Genetic markers of bvFTD|Blood markers|Plasmatic progranulin levels|Regional glucose hypometabolism,Centre Hospitalier St Anne,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,140,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D14-P010,27-Jan-16,Jan-20,Oct-20,15-Oct-15,null,20-Oct-17,"Neurologie de la mémoire et du langage, Service de Neurologie, Centre Hospitalier Sainte-Anne, Paris, France",,https://ClinicalTrials.gov/show/NCT02576821
NCT02573740,"Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment",,Terminated,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Drug: ABT-957|Other: Placebo,Percentage of participants reporting treatment-emergent adverse events|Level of spectrin breakdown product-145 (SBDP-145),AbbVie,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,8,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",M13-730,Dec-15,Jun-16,Jun-16,12-Oct-15,null,1-Jul-16,"Site Reference ID/Investigator# 143180, Cypress, California, United States|Site Reference ID/Investigator# 143178, Orlando, Florida, United States|Site Reference ID/Investigator# 149484, The Villages, Florida, United States|Site Reference ID/Investigator# 143181, Marlton, New Jersey, United States|Site Reference ID/Investigator# 143182, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 149481, Dallas, Texas, United States|Site Reference ID/Investigator# 143254, Orem, Utah, United States|Site Reference ID/Investigator# 143179, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 143177, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT02573740
NCT02570997,Ascending Dose Study of CT1812 in Healthy Volunteers,,Completed,No Results Available,Cognitive Impairment,Drug: CT1812|Drug: Placebo,Incidence and review of Treatment Emergent Adverse Events [Safety and Tolerability],Cognition Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",Cog 0101,Sep-15,May-16,null,8-Oct-15,null,7-Sep-16,"Nucleus Network Limited, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT02570997
NCT02569398,An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia,EARLY,Completed,No Results Available,Asymptomatic Amyloid-positive,"Drug: Atabecestat, 5 mg|Drug: Atabecestat, 25 mg|Drug: Placebo",Change from Baseline in Preclinical Alzheimer Cognitive Composite (PACC) to Month 54|Change from Baseline in Cognitive Function Index (CFI) to Month 54|Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living - Prevention Instrument (ADCS-ADLPI) Total Score to Month 54|Change from Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Score to Month 51|Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score to Month 54|Change from Baseline in Neuropsychological Assessment Battery Daily Living Tests (NABDLTs) Score to Month 54|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Trough Plasma Concentration (Ctrough) of Atabecestat|Area Under the Plasma Concentration-Time Curve From 0 to tau Hours After Dosing (AUCtau)|Change in mean Cerebral Fibrillar Amyloid Accumulation|Change From Baseline of Neurodegeneration by Assessing Changes in Imaging Biomarkers,"Janssen Research & Development, LLC",All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,596,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR107373|2015-000948-42|54861911ALZ2003,29-Oct-15,20-Dec-18,20-Dec-18,6-Oct-15,null,21-Jan-19,"Birmingham, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Downey, California, United States|La Jolla, California, United States|Newport Beach, California, United States|Orange, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Lake Worth, Florida, United States|Melbourne, Florida, United States|Miami Beach, Florida, United States|Ocoee, Florida, United States|Orlando, Florida, United States|Ormond Beach, Florida, United States|Tampa, Florida, United States|The Villages, Florida, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Decatur, Georgia, United States|Arlington Heights, Illinois, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Elkhart, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Westwood, Kansas, United States|Lexington, Kentucky, United States|Baton Rouge, Louisiana, United States|Bangor, Maine, United States|Boston, Massachusetts, United States|Plymouth, Massachusetts, United States|Ann Arbor, Michigan, United States|Kalamazoo, Michigan, United States|Hattiesburg, Mississippi, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Amherst, New York, United States|New York, New York, United States|Orangeburg, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Syracuse, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Willow Grove, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Cordova, Tennessee, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States|Madison, Wisconsin, United States|Adelaide, Australia|Brisbane, Australia|Darlinghurst, Australia|East Gosford, Australia|Heidelberg, Australia|Herston, Australia|Subiaco, Australia|Tarren Point, Australia|Waratah, Australia|Antwerpen, Belgium|Baudour, Belgium|Brussel, Belgium|Edegem, Belgium|Liège, Belgium|Mons, Belgium|Gatineau, Canada|Toronto, Canada|Aalborg, Denmark|Ballerup, Denmark|København Ø, Denmark|Rødovre, Denmark|Kuopio N/A, Finland|Turku, Finland|Berlin, Germany|Essen, Germany|Halle, Germany|Homburg, Germany|Kiel, Germany|Mannheim, Germany|Mittweida, Germany|Stuttgart, Germany|Ulm, Germany|Chiba-Shi, Japan|Fukuoka-Shi, Japan|Hachioji-Shi, Japan|Iizuka-Shi, Japan|Osaka-Shi, Japan|Shibuya-Ku, Japan|Shinjuku-Ku, Japan|Shirakawa, Japan|Tokyo, Japan|Chihuahua, Mexico|Monterrey, Mexico|San Luis Potosi, Mexico|Tlalnepantla De Baz, Mexico|Amsterdam, Netherlands|Breda, Netherlands|S-Hertogenbosch, Netherlands|Utrecht, Netherlands|Barcelona, Spain|Getxo, Spain|Madrid, Spain|Manresa, Spain|San Sebastian, Spain|Terrassa, Spain|Valencia, Spain|Mölndal, Sweden|Birmingham, United Kingdom|Glasgow, United Kingdom|Guildford, United Kingdom|London, United Kingdom|Newcastle Upon Tyne, United Kingdom|Plymouth, United Kingdom|Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT02569398
NCT02565511,A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease,Generation S1,Recruiting,No Results Available,Alzheimer's Disease,Biological: CAD106 Immunotherapy|Other: Placebo to CAD106|Drug: CNP520|Other: Placebo to CNP520,Time to diagnosis of MCI due to Alzheimer's Disease (AD) or dementia due to Alzheimer's Disease|Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score|Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score|Number of participants with Adverse Events as a measure of Safety and Tolerability|Change on the Total Scale score and individual neurocognitive domain index scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Change in the Everyday Cognition scale (ECog) total scores|Change in Alzheimer's Disease related biomarkers|Change in APCC Test Score|Change in CDR-SOB|Aβ-specific immune response,Novartis Pharmaceuticals|Banner Alzheimer's Institute|National Institute on Aging (NIA)|Alzheimer's Association|Amgen|Novartis,All,"60 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,1340,Industry|Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAPI015A2201J|2015-002715-15|1UF1AG046150-01,30-Nov-15,30-Aug-24,31-Mar-25,1-Oct-15,null,2-May-19,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Scottsdale, Arizona, United States|Banner Sun City Research Institute, Sun City, Arizona, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|University of Southern California Keck School of Medicine Alzheimer Disease Research Center, Los Angeles, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Novartis Investigative Site, Sebastopol, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Novartis Investigative Site, Temecula, California, United States|Mountain Neurological Research Center, Basalt, Colorado, United States|Yale University Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Novartis Investigative Site, Washington, District of Columbia, United States|JEM Research Institute, Atlantis, Florida, United States|Florida Atlantic University, Clinical Translational Research Unit, Boca Raton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Meridien Research, Maitland, Florida, United States|Merritt Island Medical Research, Merritt Island, Florida, United States|Mount Sinai Medical Center - The Wien Center, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Compass Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Medical Research & Health Education Foundation, Inc., Columbus, Georgia, United States|NeuroStudies, Decatur, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Rush University Medical Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas Alzheimer's Disease Center, Fairway, Kansas, United States|Via Christi Research, Wichita, Kansas, United States|Sanders Brown Center on Aging, University of Kentucky, Lexington, Kentucky, United States|Northern Light Acadia Hospital, Bangor, Maine, United States|Brigham & Women's Hospital Center for Alzheimer Research and Treatment, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Boston University Alzheimer's Disease Center, Boston, Massachusetts, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Saint Louis University Department of Psychiatry, Saint Louis, Missouri, United States|Memory Disorders Program, Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Memory Enhancement Center, Eatontown, New Jersey, United States|The Memory Center of Northeastern New York, Latham, New York, United States|NYU Langone Medical Center, New York, New York, United States|The Nathan S. Kline Institute, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Duke University Medical center, Durham, North Carolina, United States|Triad Clinical Trials, LLC, Greensboro, North Carolina, United States|University Hospitals Cleveland Medical Center / Case Western Reserve University, Beachwood, Ohio, United States|Dayton Center for Neurological Disorders, Centerville, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Memory Health Center at Summit Research Network, Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis - CBRI, Charleston, South Carolina, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|CNS Healthcare, Memphis, Tennessee, United States|Vanderbilt Center for Cognitive Medicine, Nashville, Tennessee, United States|Senior Adults Specialty Research, Austin, Texas, United States|Kerwin Research Center & Memory Care, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Texas Health Science Center, Houston, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|Novartis Investigative Site, Spokane, Washington, United States|Universal Research Group, Tacoma, Washington, United States|The Medical College of WI, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Heidelberg Heights, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Novartis Investigative Site, Kentville, Nova Scota, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Gatineau, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Boblingen, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Gottingen, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Münster, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wenzenbach, Germany|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Terrassa, Barcelona, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Donostia-San Sebastian, Spain|Novartis Investigative Site, Basel, CH, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Westbruy On Trym, Bristol, United Kingdom|Novartis Investigative Site, Exeter, Devon, United Kingdom|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Guildford, Surrey, United Kingdom|Novartis Investigative Site, Avon, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Dundee, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02565511
NCT02563483,Yoga for Family Caregivers of Alzheimers Disease Patient,,Completed,No Results Available,Stress|Anxiety|Compassion,Behavioral: yoga and compassion meditation program,change in cortisol|change in stress|change in depression|change in anxiety|change in quality of life|change in vitality|change in attention|change in self-compassion,Federal University of São Paulo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,yoga caregivers,Sep-07,Feb-08,Nov-09,30-Sep-15,null,30-Sep-15,,,https://ClinicalTrials.gov/show/NCT02563483
NCT02562989,[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001),,Completed,Has Results,Alzheimer's Disease|Amnestic Mild Cognitive Impairment,"Drug: [18F]MK-6240, ~185 MBq|Drug: [18F]MK-6240, ~160 MBq",Number of Participants With Adverse Events (AEs)|Number of Participants Who Discontinued Study Due to an AE|Effective Dose of [18F]MK-6240|Organ Effective Dose of [18F]MK-6240|Standardized Uptake Value Ratio (SUVR) of [18F]MK-6240 in Brain Regions of Interest|Intra-subject Test-Retest (T-RT) Variability of Standardized Uptake Value Ratio (SUVR) in Brain Regions of Interest,Merck Sharp & Dohme Corp.,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,13,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,6240-001|2015-001659-58|MK-6240-001,19-Oct-15,27-Dec-16,27-Dec-16,29-Sep-15,23-Jul-18,18-Sep-18,,,https://ClinicalTrials.gov/show/NCT02562989
NCT02560753,Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: T3D-959,Change From Baseline (End of Treatment - Baseline) for FDG-PET Imaging With Whole Brain and White Matter as Reference Region|The Effect of Treatment With T3D-959 on Changes in Resting State Blood Oxygen Level Dependent (BOLD) Signal in Functional Magnetic Resonance Imaging (fMRI) of the Brain Areas Associated With Cognitive Tasks.|Change From Baseline in the Score of the Digit Symbol Substitution Test|Change From Baseline in the Total Score of the 11-item Alzheimer's Disease Assessment Scale - Cognitive Subscale,"T3D Therapeutics, Inc.",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,36,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,T3D959-201,Jul-15,30-May-16,30-Jun-16,25-Sep-15,30-Jul-18,30-Jul-18,"Brain Matters Research, Delray Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|New Hope Clinical Research, Charlotte, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02560753
NCT02557464,Identification of Early Markers of Alzheimer's Disease by Using Eye Tracking in Reading.,ADAL,Recruiting,No Results Available,Alzheimer's Disease,Behavioral: An eye tracking experiment|Behavioral: A neuropsychological evaluation,Eye tracking|The probability that the eyes skip the target word|the initial landing position of the eye in the target word (in letters)|the percentage of refixation done on the target word|the first fixation duration in the target word|the single fixation duration|the percentage of regressive saccade on the target word and the total viewing time|Neuropsychological tests scores,Centre Hospitalier Universitaire de Nice,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,15-AOI-04,10-Nov-15,10-Dec-15,Nov-17,23-Sep-15,null,23-Aug-17,"Institut Claude Pompidou, Nice, France",,https://ClinicalTrials.gov/show/NCT02557464
NCT02556502,18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study,MAF,Completed,No Results Available,Amyloid PET Imaging,Device: 18F-Florbetaben PET,number of positive or negative amyloid PET,"Central Hospital, Nancy, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2015-A01149-40,Nov-15,Nov-17,Nov-17,22-Sep-15,null,7-May-19,"CHRU Nancy, Vandoeuvre les Nancy, France",,https://ClinicalTrials.gov/show/NCT02556502
NCT02553928,Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer,,Completed,Has Results,Alzheimer Dementia (AD),Drug: Memantine (once daily)|Drug: Memantine (twice daily),Adverse Events|ADCS - CGIC Score at Week 12,H. Lundbeck A/S,All,"50 Years and older   (Adult, Older Adult)",Phase 4,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14603A,Oct-15,Jul-16,Jul-16,18-Sep-15,14-Mar-19,14-Mar-19,"CN001, Beijing, China|CN006, Fujian, China|CN004, Shandong, China|CN002, Tianjin, China|CN007, Xi'an, China|CN003, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT02553928
NCT02551809,"Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients",,Completed,No Results Available,Alzheimer's Disease,Biological: UB-311|Drug: Placebo,Tolerability and safety profile of UB-311 assessed via recording of all Adverse Events.|Immunogenicity of UB-311 measured by change from baseline in anti-Aβ antibody level|Change from baseline in cognitive: Alzheimer´s Disease Assessment Scale- Cognitive (ADAS-Cog)|Change from baseline in function: Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Change from baseline in cognition: Mini-Mental State Examination (MMSE)|Change from baseline in global assessment: Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Change from baseline in behavioral assessment: Neuropsychiatric Inventory (NPI)|Change of amyloid burden from baseline in 18F-AV-45 PET imaging in selected brain areas,United Neuroscience Ltd.,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,43,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",V203-AD,Oct-15,Aug-18,Aug-18,16-Sep-15,null,23-Jan-19,"Kaohsiung Chang Gung Memorial Hospital (KS-CGMH), Kaohsiung, Taiwan|National Taiwan University Hospital (NTUH), Taipei, Taiwan|Taipei Veterans General Hospital (TVGH), Taipei, Taiwan|Linkou Chang Gung Memorial Hospital (LK-CGMH), Taoyuan, Taiwan",,https://ClinicalTrials.gov/show/NCT02551809
NCT02549196,A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type,CPC-12,Completed,Has Results,Dementia of Alzheimer's Type,Drug: Donepezil|Drug: Solifenacin,Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort|Number of Participants With TEAEs Leading to Study Drug Discontinuation,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,28,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CPC-001-12,7-Oct-15,28-Sep-17,28-Sep-17,15-Sep-15,5-Mar-19,5-Mar-19,"Quantum Laboratories, Deerfield Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|PMG Research, Winston-Salem, North Carolina, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02549196/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02549196/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02549196
NCT02550665,Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg,ODESA,Completed,No Results Available,Alzheimer's Disease,Drug: donepezil,Incidence of treatment-emergent adverse events (safety and tolerability)|blood WBC|blood BUN|blood Creatinine|blood sodium|blood potassium|blood AST/ALT|weight loss|drug compliance (counting of residual drug)|heart rate on Electrocardiography (ECG),Asan Medical Center|Dong-A University|Myongji Hospital|Seoul National University Bundang Hospital|Seoul St. Mary's Hospital|Chung-Ang University|Eisai Inc.,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 3,176,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JHongLee,Dec-14,Aug-16,Oct-16,15-Sep-15,null,7-Aug-18,"Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02550665
NCT02547818,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,COGNITE,Recruiting,No Results Available,Alzheimer's Disease,Drug: ALZT-OP1a|Drug: ALZT-OP1b|Other: Placebo ALZT-OP1a|Other: Placebo ALZT-OP1b,Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Number of Treatment Emergent Adverse Events (TEAE),"AZTherapies, Inc.|PharmaConsulting Group|KCAS Bio|APCER Life Sciences",All,"55 Years to 79 Years   (Adult, Older Adult)",Phase 3,600,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AZT-001,Sep-15,Nov-19,Nov-19,11-Sep-15,null,5-Dec-18,"Cognitive Clinical Trials, Gilbert, Arizona, United States|Xenoscience, Phoenix, Arizona, United States|Cognitive Clinical Trials, Scottsdale, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Alliance Research Center, Laguna Hills, California, United States|Renew Behavioral Health, Long Beach, California, United States|Excell Research, Inc., Oceanside, California, United States|University of California Irvine School of Medicine, Orange, California, United States|Asclepes Research Center, Panorama City, California, United States|Artemis Clinical Research, Riverside, California, United States|CITrials, Riverside, California, United States|Northern California Research, Sacramento, California, United States|Syrentys Clinical Research, Santa Ana, California, United States|Mile High Research Center, Denver, Colorado, United States|TOPAZ Clinical Research, Apopka, Florida, United States|Parkinson's Disease & Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Finlay Medical Research Group, Green Acres, Florida, United States|Galiz Clinical Research, Hialeah, Florida, United States|Panax, Miami Lakes, Florida, United States|The Neurology Research Group, Miami, Florida, United States|Premier Clinical Research Institute, Miami, Florida, United States|Finlay Medical Research Group, Miami, Florida, United States|Next Phase Research Alliance - Cano Health, Miami, Florida, United States|IMIC, Inc., Miami, Florida, United States|Next Phase Research Alliance - MetroMed, Miami, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Pines Care Research Center, Pembroke Pines, Florida, United States|Neurostudies, Inc., Port Charlotte, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Axiom Clinical Research, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Columbus Research & Wellness Institute, Columbus, Georgia, United States|Behavioral Health Care Associates, Schaumburg, Illinois, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Coastal Health Care, Freeport, Maine, United States|Samuel and Alexia Bratton Memory Clinic, Easton, Maryland, United States|ActivMed Practices & Research, Inc., Methuen, Massachusetts, United States|The Alzheimer's Disease Center, Quincy, Massachusetts, United States|Bronson Neurobehavioral Health, Paw Paw, Michigan, United States|Cognitive Clinical Trials, Bellevue, Nebraska, United States|Cognitive Clinical Trials, Omaha, Nebraska, United States|ActivMed Practices & Research Inc., Portsmouth, New Hampshire, United States|Memory Enhancement Center of America, Eatontown, New Jersey, United States|AdvancedMed Research, Lawrenceville, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Albuquerque Neuroscience, Albuquerque, New Mexico, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Medical Research Network, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, New York, New York, United States|Winifred Masterson Burke Medical Research Institute, White Plains, New York, United States|ANI Neurology, PLLC Alzheimer's Memory Center, Charlotte, North Carolina, United States|Raleigh Neurological Associates, Raleigh, North Carolina, United States|PMG Winston-Salem, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Insight Clincial Trials, Shaker Heights, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, Inc., Tulsa, Oklahoma, United States|Pearl Clinical Research, Norristown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Metrolina Neurological Associates, PA, Rock Hill, South Carolina, United States|CNS Healthcare, Memphis, Tennessee, United States|Neurology Associates of Arlington, P.A., Mansfield, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|KaRa Institute of Neurological Diseases, Macquarie Park, New South Wales, Australia|Pacific Private Clinic, Southport, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Geelong Private Medical Centre, Geelong, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|UMBAL ""Dr. Georgi Stranski"" EAD, Pleven, Bulgaria|MHAT ""Central Onco Hospital"" Ltd., Plovdiv, Bulgaria|MBAL Ruse AD, Ruse, Bulgaria|""First MHAT - Sofia"" EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ""Aleksandrovska"" EAD, Sofia, Bulgaria|Heritage Medical Research Clinic, The University of Calgary, Calgary, Alberta, Canada|Okanagan Clinical Trials, Kelowna, Britsh Columbia, Canada|Montreal Neurological Research Institute, Québec, Montreal, Canada|True North Clinical Research, Halifax, Nova Scotia, Canada|True North Clinical Research, Kentville, Nova Scotia, Canada|JBN Medical, Burlington, Ontario, Canada|Chatham-Kent Clinical Trials, Chatam-Kent, Ontario, Canada|The Centre for Memory and Aging, East York, Ontario, Canada|Cliniuqe de la Memoire de l'Outouais, Gatineau, Quebec, Canada|Neurosanatio, s.r.o., Litomyšl, Czech Republic, Czechia|Neurologie MU - Ondrej Koci, s.r.o., Novy Bor, Czech Republic, Czechia|CT Center MaVfe, s.r.o, Olomouc, Czech Republic, Czechia|Vestra Clinics, s.r.o., Rychnov Nad Kněžnou, Czech Republic, Czechia|NEUROHK, s.r.o., Chocen, Czechia|Clinline Services s.r.o., Hostivice, Czechia|Psychiatricka ambulance, Hradec Kralove, Czechia|Psychiatricka ambulance Supervize s.r.o., Kutná Hora, Czechia|Krajska nemocnice Liberec a.s., Liberec, Czechia|A-shine, s.r.o., Plzen, Czechia|Clintrial.s.r.o., Praha, Czechia|Fakultni nemocnice v Motole Neurologicka klinika 2.LF UK a FN Motol, Praha, Czechia|INEP medical s.r.o., Praha, Czechia|Neurologia Klinika Semmelweis Egyetem, Budapest, Hungary|Orszagos Klinikai Idegtudomanyi Intezat, Budapest, Hungary|Vaszary Kolos Korhaz, Esztergom, Hungary|Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary|Petz Aladar Megyei Oktato Korhaz, Győr, Hungary|Cermed Pawel Hernik, Bialystok, Poland|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Przychondnia Srodmiescie, Bydgoszcz, Poland|Centrum Medyczne KERMED, Bydgoszcz, Poland|Szpital Powiatowy w Czeladzi, Czeladz, Poland|Centrum Zdrowia Psychicznego Biomed - Jan Latala, Kielce, Poland|Centrum Medyczne Plejady, Kraków, Poland|Centrum Opieki Zdrowotnej Orkan-Med, Ksawerow, Poland|Centrum Medyczne im. Dr Karola Jonschera w Lodzi, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin, Poland|CRC Sp. Zo.o., Poznan, Poland|Euromedis Sp. Zo.o, Szczecin, Poland",,https://ClinicalTrials.gov/show/NCT02547818
NCT02546310,Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects,,Completed,No Results Available,Alzheimer's Disease,Drug: HTL0009936|Drug: HTL0009936 matching placebo,"Blood oxygen level dependent (BOLD) signal in functional Magnetic Resonance Imaging (fMRI) of the brain areas associated with cognitive tasks|BOLD signal in fMRI in other brain regions involved in the regulation of cognitive processes during cognitive tasks|cerebral blood flow, assessed using Arterial Spin Labelling (ASL)|adverse events|blood pressure|12-lead electrocardiogram",Heptares Therapeutics Limited|P1vital Limited,All,65 Years to 80 Years   (Older Adult),Phase 1,54,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",9936-103,Oct-15,Feb-17,Feb-17,10-Sep-15,null,3-Feb-17,"Neuroscience and Psychiatry Unit, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02546310
NCT02541929,Fish Oil Brain Delivery Study,,"Active, not recruiting",No Results Available,Brain Health,Dietary Supplement: Docosahexaenoic acid,changes in DHA levels in the CSF following dietary DHA supplementation|Brain MRI,University of Southern California|Alzheimer's Association,All,"55 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,31,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",HS-14-00864,30-Jun-16,30-Nov-18,30-Sep-19,4-Sep-15,null,16-Apr-19,"USC Keck School of Medicine, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02541929
NCT02537938,Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose),,Completed,No Results Available,Alzheimer's Disease,Drug: NGP 555,Number of adverse events or safety outcomes,NeuroGenetic Pharmaceuticals Inc|WCCT Global,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",NGP 555-002,Jan-16,Dec-16,Dec-16,2-Sep-15,null,29-Mar-17,"WCCT Global, Cypress, California, United States",,https://ClinicalTrials.gov/show/NCT02537938
NCT02537496,Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Use of rTMS,rTMS-AD,Completed,No Results Available,Alzheimer's Disease,Procedure: Repetitive Transcranial Magnetic Stimulation|Procedure: Repetitive Transcranial Magnetic Stimulation - Sham,Change in N-back Task Performance|Changes in Theta Phase-Gamma Amplitude Coupling|Changes in DLPFC Neuroplasticity|Changes in Cognitive Function Measures Scores|Validating a new scale for insight in Alzheimer's disease.,Centre for Addiction and Mental Health|Brain & Behavior Research Foundation|University of Toronto,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",005/2015,14-Jan-16,10-Oct-18,10-Oct-18,1-Sep-15,null,28-Feb-19,"Center for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02537496
NCT02534480,Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose),,Completed,No Results Available,Alzheimer's Disease,Drug: NGP 555,Number of subjects with adverse events as a measure of safety and tolerability,NeuroGenetic Pharmaceuticals Inc,All,18 Years to 55 Years   (Adult),Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",NGP 555-001,Mar-15,Oct-15,Nov-15,27-Aug-15,null,13-Jan-16,"WCCT, Cypress, California, United States",,https://ClinicalTrials.gov/show/NCT02534480
NCT02531360,Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies,,Completed,No Results Available,Alzheimer's Disease (AD)|Progressive Supranuclear Palsy (PSP)|Cortical Basal Syndrome (CBS)|Frontal Temporal Dementia (FTD),Drug: [18F]MNI-815 (MNI-815),Brain uptake of [18F]MNI-815,Molecular NeuroImaging|Life Molecular Imaging SA,All,"50 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,7,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),MNI-815,May-15,Jul-16,Aug-16,24-Aug-15,null,16-Dec-16,"Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02531360
NCT02530255,Telomerase Activator and Retinal Amyloid,,"Active, not recruiting",No Results Available,Alzheimer Disease,Dietary Supplement: cycloastragenol|Dietary Supplement: placebo (for cycloastragenol),Retinal Amyloid Index (RAI)|Telomere length (kilobases),Chippewa Valley Eye Clinic|TA-Sciences,All,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAS-003-AD,1-Dec-16,31-Mar-18,31-Aug-18,21-Aug-15,null,2-Apr-18,"Chippewa Valley Eye Clinic, Eau Claire, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02530255
NCT02521558,Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease,CTAD,Recruiting,No Results Available,Memory Disorders|Mild Cognitive Impairment|Alzheimer's Disease,Behavioral: Intervention Group|Behavioral: Control Group,Changes in cognition as measured by the Mini Mental Status Exam|Changes in cognition as measured by the Montreal Cognitive Assessment|Changes in cognition as measured by the Consortium to Establish a Registry in Alzheimer's disease Word List Test|Changes in cognition as measured Letter and Category Fluency|Changes in cognition as measured by the Boston Naming Test (Short Form)|Changes in cognition as measured by the Trail Making Parts A & B|Changes in performance on cognitive rehabilitation tasks (composite measure of memory tasks),Boston University|Wallace H. Coulter Foundation,Female,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-34203,Sep-15,Sep-20,Sep-20,13-Aug-15,null,28-Sep-18,"Boston University School of Medicine, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02521558
NCT02521818,Dietary Treatments for Cognitive Impairment in Older Adults,,Recruiting,No Results Available,Mild Cognitive Impairment|Probable Alzheimer's Disease,Other: Modified Atkins Diet|Other: NIA Diet for Seniors,Feasibility for MAD Group|Feasibility for Control Group|Efficacy for Cognition|Efficacy for Function,Johns Hopkins University,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB00066092,Aug-15,Jun-19,Jun-19,13-Aug-15,null,28-Sep-18,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02521818
NCT02522091,"Cerebral Substrates of Prospective Memory in Young and Its Disruption in Normal Aging and in Alzheimer's Disease: A Study in Anatomical MRI, Diffusion Tensor MRI and Functional MRI",IMPRO,Unknown status,No Results Available,Alzheimer's Disease,Device: functional brain MRI|Other: Neuropsychology tests,measuring the amplitude of the BOLD signal (Blood Oxygen Level Dependent),"University Hospital, Caen",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,178,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,10-002,Nov-10,Dec-15,null,13-Aug-15,null,13-Aug-15,"Service de neurologie, Caen, CHU, France",,https://ClinicalTrials.gov/show/NCT02522091
NCT02520232,"Pathological and Non-pathological Aging, Physical Activity, Genotype and Cognition",VIAGECO,Completed,No Results Available,Alzheimer's Disease,Behavioral: Combination of aerobic and strength exercises|Behavioral: Stretching and balance exercise program,Executive functions (Mean z score)|Senior Fitness Test score|Body Mass Index|Energy expenditure related to physical activity (Actimetry)|Heart rate variability at rest|Blood pressure|Depression score|Self-efficacy score|Quality of life score|Stage of change score related to physical activity|Score at Verbal working-memory span|Reaction time in a two-choice reaction time task|Error rate in a two-choice reaction time task|Logic memory score|Grey and white matter volumes in regions of interest|Cerebral perfusion in the same regions of interest|Resting State Networks Activity|Brain glucose metabolism,"University Hospital, Bordeaux|Poitiers University Hospital|Centre National de la Recherche Scientifique, France|University of Poitiers|University of Bordeaux",All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,139,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,CHUBX 2013/22,Jun-15,10-Feb-17,11-May-18,11-Aug-15,null,25-Feb-19,"University Hospital Bordeaux, France, Bordeaux, France|University Hospital, Poitiers, Poitiers, France",,https://ClinicalTrials.gov/show/NCT02520232
NCT02518243,Safe & Easy for Alzheimer's Disease and Related Pathologies,SaFEE2,Unknown status,No Results Available,Cognitive Deterioration,Other: Patient's answer with non pharmacological therapeutic,Tolerance of the systems set up and use frequency evaluated using the Caregiver Questionnaire,Centre Hospitalier Universitaire de Nice,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,14-PP-08,Jun-15,Sep-16,null,7-Aug-15,null,7-Aug-15,"Ehpad Valrose, Nice, France",,https://ClinicalTrials.gov/show/NCT02518243
NCT02518412,Transcranial Direct Current Stimulation (tDCS) as a Cognitive Enhancer for Patients With Alzheimers Disease,tDCS,Unknown status,No Results Available,Alzheimer Disease,Other: tDCS|Other: Placebo tDCS,Neuropsychological testing,University of Tromso,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2012/1890(REK),May-13,Feb-16,Feb-16,7-Aug-15,null,11-Aug-15,"Department of Psychology, University of Tromsø, Tromsø, Norway",,https://ClinicalTrials.gov/show/NCT02518412
NCT02516046,18F-AV-1451 Autopsy Study,,Completed,No Results Available,Alzheimer's Disease,Drug: 18F-AV-1451,Diagnostic Performance Individual Readers (NFT Score)|Diagnostic Performance Individual Readers (NIA-AA Autopsy Diagnosis)|Diagnostic Performance (NFT Score)|Diagnostic Performance (NIA-AA Autopsy Diagnosis)|Inter-Reader Agreement (NFT Score)|Inter-Reader Agreement (NIA-AA Autopsy Diagnosis),Avid Radiopharmaceuticals,All,"50 Years and older   (Adult, Older Adult)",Phase 3,156,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-1451-A16,Sep-15,13-Jun-18,15-Jul-18,5-Aug-15,null,23-Jul-18,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Cherlin Research, Los Gatos, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|California Research Foundation, San Diego, California, United States|Pacific Research Network, San Diego, California, United States|Ray Dolby Brain Health Center, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Galiz Research, Hialeah, Florida, United States|Merritt Island Medical Research, Merritt Island, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|D de la Vega MD Research Group, Miami, Florida, United States|Bioclinica, Orlando, Florida, United States|Emory University Brain Health Center, Atlanta, Georgia, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Steinberg Diagnostics, Henderson, Nevada, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|Clarity Clinical Research, LLC, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Hospice of the Western Reserve, Cleveland, Ohio, United States|American Clinical Trials, LLC (Site 1216), Oklahoma City, Oklahoma, United States|Oklahoma Behavioral Health, Oklahoma City, Oklahoma, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Houston Methodist Research Institute, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|Overlake Internal Medicine Associates, PS, Bellevue, Washington, United States|University of Washington Medicine, Seattle, Washington, United States|University of Melbourne, Parkville, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT02516046
NCT02509117,First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979,,Completed,Has Results,Healthy Subjects,Drug: PF-06751979 single ascending dose|Drug: Placebo single dose|Drug: PF-06751979 multiple ascending dose|Drug: Placebo multiple dose|Drug: PF-06751979 multiple dose,"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Abnormal Physical Examinations Findings|Number of Participants With Abnormal Neurological Examinations Findings|Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) at Baseline|Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 7|Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 14|Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 19|Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Number of Participants With Laboratory Abnormalities|Number of Participants With Clinically Significant Changes From Baseline in Vital Signs|Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By Telemetry|Part A: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part A: Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of PF-06751979|Part A: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06751979|Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax)(dn) of PF-06751979|Part A: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)(Dn) of PF-06751979|Part A: Dose Normalized Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf)(Dn) of PF-06751979|Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part A: Plasma Decay Half-Life (t1/2) of PF-06751979|Part A: Apparent Oral Clearance (CL/F) of PF-06751979|Part A: Apparent Volume of Distribution (Vz/F) of PF-06751979|Part B: Apparent Volume of Distribution (Vz/F) of PF-06751979 at Day 14|Part B: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part B: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979|Part B: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part B: Dose Normalized Maximum Observed Plasma Concentration (Cmax)(Dn) of PF-06751979|Part B: Apparent Oral Clearance (CL/F) of PF-06751979|Part B: Minimum Observed Plasma Concentration (Cmin) of PF-06751979|Part B: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau)(Dn) of PF-06751979|Part B: Peak-to-Trough Ratio (PTR) of PF-06751979|Part B: Observed Accumulation Ratio (Rac) for AUCtau of PF-06751979 at Day 7, 14|Part B: Observed Accumulation Ratio for Maximum Observed Plasma Concentration (Rac Cmax) of PF-06751979 at Day 7, 14|Part B: Plasma Decay Half-Life (t1/2) of PF-06751979 at Day 14|Part B: Amount of PF-06751979 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)|Part B: Percentage of Dose of PF-06751979 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)|Part B: Renal Clearance of PF-06751979|Part B: Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) Fragments on Day 14|Part C: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part C: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979|Part C: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part C: Dose Normalized Maximum Observed Plasma Concentration (Cmax)(Dn) of PF-06751979|Part C: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau)(Dn) of PF-06751979|Part C: Apparent Oral Clearance (CL/F) of PF-06751979 on Day 14|Part C: Minimum Observed Plasma Concentration (Cmin) of PF-06751979 on Day 14|Part C: Peak-to-Trough Ratio (PTR) of PF-06751979 at Day 14|Part C: Observed Accumulation Ratio (Rac) for AUCtau of PF-06751979 at Day 14|Part C: Observed Accumulation Ratio for Maximum Observed Plasma Concentration (Rac Cmax) of PF 06751979 at Day 14|Part C: Apparent Volume of Distribution (Vz/F) of PF-06751979 at Day 14|Part C: Plasma Decay Half-Life (t1/2) of PF-06751979 at Day 14",Pfizer,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,55,Industry,Interventional,"Allocation: Randomized|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",B8271001,Jul-15,Jul-16,Jul-16,27-Jul-15,1-Nov-18,1-Nov-18,"California Clinical Trials Medical Group, Inc, Glendale, California, United States|Glendale Adventist Medical Center, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT02509117
NCT02503501,Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease,,"Active, not recruiting",No Results Available,Mild Cognitive Impairment|Alzheimer's Disease (AD),Drug: Insulin glulisine|Drug: Placebo,"Change in cognition as measured by the Alzheimer's Disease Assessment Scale - Cognitive 13 (ADAS-Cog 13)|Change in functional performance as measured by the Clinical Dementia Rating (CDR) Scale|Change in functional performance as measured by the Functional Activities Questionnaire (FAQ)|Change in auditory working memory as measured by the Digit Span subtest from the Wechsler Adult Intelligence Scale - 4th Edition (WAIS-IV)|Change in mental flexibility as measured by the Trail Making Test, Parts A and B|Change in executive functioning as measured by the Controlled Oral Word Association Test (COWAT)|Change in executive functioning as measured by the Animal Naming test|Change in memory functions as measured by the Weschler Memory Scale Logical Memory (WMS-LM)|Change in feelings of depression as measured by the Geriatric Depression Scale-15 (GDS)",HealthPartners Institute,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IN-INSUL-MCI-AD,Aug-15,May-19,May-19,21-Jul-15,null,13-Dec-18,"HealthPartners Riverside, Minneapolis, Minnesota, United States|HealthPartners Neuroscience Center, Saint Paul, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02503501
NCT02502253,BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM),BDPP,Recruiting,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,"Drug: grape seed polyphenolic extract, resveratrol","Assessment of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Confirm brain penetrance of BDPP by measuring levels of BDPP constituents in cerebrospinal fluid (CSF).|Evaluate BDPP effect on mood with Neuropsychiatric Inventory and Cornell Scale for Depression in Dementia.|Evaluate BDPP effect on cognition with a composite battery of memory, executive function, and attention measures (composite)",Johns Hopkins University|Icahn School of Medicine at Mount Sinai,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",IRB00062802,Jun-15,Jun-19,Oct-19,20-Jul-15,null,26-Jun-18,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02502253
NCT02502045,"Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's",,Completed,No Results Available,Alzheimer's Disease,Device: Morning Simulated Sunlight|Device: Non-therapeutic Red Light,Change in sleep characteristics,Yale University,Female,65 Years and older   (Older Adult),Not Applicable,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care",1310012895,May-12,Jan-16,Jan-16,17-Jul-15,null,20-Feb-17,"Botsford Continuing Care, Farmington Hills, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02502045
NCT02494531,Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging,AVILL,Recruiting,No Results Available,Alzheimer Disease,Radiation: Fluorodeoxyglucose-PET|Radiation: florbetapir F 18-PET,"Comparison of the amount of amyloid deposits using florbetapir-18 Fluor-PET between illiterate and literate MCI patients|Comparison of the amount of amyloid deposits using florbetapir-18 Fluor-PET between illiterate and literate AD patients,|Comparison of the amyloid deposit location between the 2 groups (literate and illiterate)|correlation between amyloid load and metabolism dysfunction using Fluorodeoxyglucose (FDG)-PET in each groups",Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P120134,May-15,Jan-19,Jan-20,10-Jul-15,null,5-Dec-16,"Hospital Avicenne-Neurology, Bobigny, France",,https://ClinicalTrials.gov/show/NCT02494531
NCT02492529,Knowing and Remembering: Cognitive and Neural Influences of Familiarity on Recognition Memory in Early Alzheimer's Disease,EPMR-MA,Completed,No Results Available,Alzheimer's Disease,Other: Neuropsychological tests|Device: A cranial MRI|Other: Experimental procedure,"Improvement of recognition memory accuracy measures under the familiarity condition as compared with the novel condition in the AD-MCI group|Significant effect of the familiarity vs novelty condition on the pattern of % BOLD signal change in across the brain in the AD-MCI group|Significant group effect on the pattern of % BOLD signal change in across the brain|Predictive validity of the brain % BOLD signal change pattern for participants clinical status (i.e. controls vs. AD-MCI)|Significant interaction between the kind of familiarity condition (i.e. novel, experimental or pre-experimental) and the estimates of recognition memory processes efficiency (i.e. respective contributions of recollection and familiarity, % correct)",Rennes University Hospital,All,"25 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2014-A01123-44|35RC14_9777_EPMR-MA,21-Jul-15,31-Dec-17,31-Dec-17,8-Jul-15,null,23-Jan-18,"Centre Hospitalier Universitaire, Rennes, France",,https://ClinicalTrials.gov/show/NCT02492529
NCT02489110,Webnovela for Hispanic Dementia Family Caregivers,,Completed,Has Results,Alzheimer's Disease|Dementia,Behavioral: Webnovela|Behavioral: Information,Stress on the Perceived Stress Scale|Caregiver Burden on the Revised Memory and Behavior Problems Checklist,"Photozig, Inc.|National Institute on Aging (NIA)|Stanford University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Industry|NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pz-A104a|R44AG041552,Jun-15,May-16,Sep-16,2-Jul-15,13-Sep-18,13-Sep-18,"Photozig, Inc., Moffett Field, California, United States",,https://ClinicalTrials.gov/show/NCT02489110
NCT02484547,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,EMERGE,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: Aducanumab (BIIB037)|Drug: Placebo,Change from baseline in CDR-SB score|Change from baseline in MMSE score|Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (13 items) (ADAS-Cog 13)|Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) (ADCS-ADL-MCI) score,Biogen,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1605,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",221AD302|2015-000967-15,30-Sep-15,30-Jan-20,30-Apr-22,29-Jun-15,null,24-Apr-19,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Xenoscience Inc., Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Institute for Memory Impairments, Irvine, California, United States|Renewal Behavioral Health, Long Beach, California, United States|USC Keck School of Medicine, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Excell Research, Inc., Oceanside, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Anderson Clinical Research, Redlands, California, United States|Pacific Research Network, San Diego, California, United States|University of California San Diego Medical Center, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|Stanford University Medical Center, Stanford, California, United States|University Of Colorado Denver, Aurora, Colorado, United States|IMMUNOe International Research Centers, Thornton, Colorado, United States|Associated Neurologists of Southern Connecticut, PC, Fairfield, Connecticut, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Florida Atlantic University, Boca Raton, Florida, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Quantum Laboratories Inc., Deerfield Beach, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Emory University Cognitive Neurology Clinic & ADRC, Atlanta, Georgia, United States|Medical Research Health and Education Foundation, Inc, Columbus, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Josephson, Wallack, Munshower Neurology, PC, Indianapolis, Indiana, United States|McLean Hospital, Belmont, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Hattiesburg Clinic, PA, Hattiesburg, Mississippi, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|ActivMed Practices & Research, Portsmouth, New Hampshire, United States|AdvanceMed Research, Lawrenceville, New Jersey, United States|Empire Neurology, PC, Latham, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Ohio State University Medical Center, Dublin, Ohio, United States|Lehigh Center for Clinical Research, LLC, Allentown, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Roper St. Francis Healthcare, North Charleston, South Carolina, United States|Senior Adult Specialty Research, Austin, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Clinical Neuroscience Research Association, Inc, Bennington, Vermont, United States|University of Washington Medical Center, Seattle, Washington, United States|Northwest Neurological, PLLC, Spokane, Washington, United States|A.Z. Klina, Brasschaat, Belgium|AZ Sint-Jan Brugge, Brugge, Belgium|Universitair Ziekenhuis Brussel, Bruxelles, Belgium|Centre Neurologique & de Réadaptation Fonctionnelle, Fraiture-en-Condroz, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|AZ Groeninge - Campus Kennedylaan, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|AZ Delta, Roeselare, Belgium|Health Research., Kamloops, British Columbia, Canada|Health Research, West Vancouver, British Columbia, Canada|True North Clinical Research - Halifax Inc., Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Inc, Kentville, Nova Scotia, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|St. Joseph's HC- Parkwood Institute, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Recherches Neuro-Hippocampe Inc., Gatineau, Quebec, Canada|Recherche Sepmus, Inc., Greenfield Park, Quebec, Canada|DIEX Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|Douglas Hospital Research Centre, Verdun, Quebec, Canada|Terveystalo Kamppi, Helsinki, Finland|Itä-Suomen yliopisto, Aivotutkimusyksikkö, Kuopio, Finland|CRST, Clinical Research Services Turku, Turku, Finland|Hôpital de la Timone, Marseille, Bouches-du-Rhône, France|CHU de Toulouse - Hôpital Purpan, Toulouse cedex 9, Haute Garonne, France|Centre de Recherche Clinique du Gérontopôle - Cité de la Santé, Toulouse, Haute Garonne, France|Hôpital Gui de Chauliac, Montpellier, Herault, France|CHU Rennes - Hopital Pontchaillou, Rennes cedex 09, Ille Et Vilaine, France|CHU Nantes - Hopital Nord Laënnec, Nantes cedex 1, Loire Atlantique, France|Hopital Roger Salengro - CHU Lille, Lille Cedex, Nord, France|Hôpital des Charpennes, Villeurbanne, Rhone, France|Hôpital Fernand Widal, Paris, France|Bezirkskrankenhaus Guenzburg, Guenzburg, Baden Wuerttemberg, Germany|ISPG - Institut fuer Studien zur Psychischen Gesundheit, Mannheim, Baden Wuerttemberg, Germany|Nervenfachaerztlichen Gemeinschaftspraxis Ulm, Ulm, Baden Wuerttemberg, Germany|Universitaetsklinikum Ulm, Ulm, Baden Wuerttemberg, Germany|Klinik Hohe Warte Bayreuth, Bayreuth, Bayern, Germany|Institut fuer Schlaganfall- und Demenzforschung (ISD), Muenchen, Bayern, Germany|Klinikum rechts der Isar der TU Muenchen, Muenchen, Bayern, Germany|Neuropraxis Muenchen Sued, Unterhaching, Bayern, Germany|Praxis Dr. Kluenemann, Wenzenbach, Bayern, Germany|Neuro Centrum Odenwald, Erbach, Hessen, Germany|Schwerpunktpraxis fuer Neurologie, Psychiatrie und Klinische Studien, Bielefeld, Nordrhein Westfalen, Germany|Universitaetsklinikum Duesseldorf AoeR, Duesseldorf, Nordrhein Westfalen, Germany|Universitaetsklinikum Muenster, Muenster, Nordrhein Westfalen, Germany|Zentrum f. Neurologisch- Psychiatrische Studien und Begutachtung, Siegen, Nordrhein Westfalen, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Rheinland Pfalz, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Sachsen, Germany|Kopfzentrum Leipzig, Leipzig, Sachsen, Germany|Klinikum Altenburger Land GmbH, Altenburg, Thueringen, Germany|emovis GmbH, Berlin, Germany|Neurologie im Tempelhofer Hafen, Berlin, Germany|Ospedale degli Infermi, Ponderano, Biella, Italy|Azienda Ospedaliera Card. G. Panico, Tricase, Lecce, Italy|ASST di Monza, Monza, Milano, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy|Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone, Palermo, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Italy|Fondazione Santa Lucia IRCCS, Roma, Italy|Umberto I Pol. di Roma-Università di Roma La Sapienza, Roma, Italy|Research Site, Obu-shi, Aichi-Ken, Japan|Research Site, Toon-shi, Ehime-Ken, Japan|Research Site, Fukuoka-shi, Fukuoka-Ken, Japan|Research Site, Kurume-shi, Fukuoka-Ken, Japan|Research Site, Otake-shi, Hiroshima-Ken, Japan|Research Site, Amagasaki-shi, Hyogo-Ken, Japan|Research Site, Himeji-shi, Hyogo-Ken, Japan|Research Site, Kobe-shi, Hyogo-Ken, Japan|Research Site, Kita-gun, Kagawa-Ken, Japan|Research Site, Kyoto-shi, Kyoto-Fu, Japan|Research Site, Kyoto-shi, Kyoto-Fu, Japan|Research Site, Tsu-shi, Mie-Ken, Japan|Research Site, Nishisonogi-gun, Nagasaki-Ken, Japan|Research Site, Yufu-shi, Oita-Ken, Japan|Research Site, Kurashiki-shi, Okayama-Ken, Japan|Research Site, Okayama-shi, Okayama-Ken, Japan|Research Site, Tsukubo-Gun, Okayama-Ken, Japan|Research Site, Kishiwada-shi, Osaka-Fu, Japan|Research Site, Osaka-shi, Osaka-Fu, Japan|Research Site, Osaka-shi, Osaka-Fu, Japan|Research Site, Osaka-shi, Osaka-Fu, Japan|Research Site, Osaka-shi, Osaka-Fu, Japan|Research Site, Sennan-shi, Osaka-Fu, Japan|Research Site, Suita-shi, Osaka-Fu, Japan|Research Site, Toyonaka-Shi, Osaka-Fu, Japan|Research Site, Iwata-shi, Shizuoka-Ken, Japan|Research Site, Shizuoka-shi, Shizuoka-Ken, Japan|Research Site, Shizuoka-shi, Shizuoka-Ken, Japan|Alzheimer Research Center, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Kennemer Gasthuis, Zuid, Haarlem, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|PALLMED Sp. z o.o., Bydgoszcz, Poland|COPERNICUS Podmiot Leczniczy Sp. z o. o.,, Gdansk, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Novo-Med Zielinski i wspolnicy Sp. j., Katowice, Poland|Neuro-Care Site Management Organization Gabriela Klodowska-Duda, Katowice, Poland|SPZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland|SPZOZ Centralny Szpital Kliniczny UM w Lodzi, Lodz, Poland|Centrum Diagnostyczno - Terapeutyczne ""MEDICUS"" Sp.z o.o., Lubin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland|Neurologiczny NZOZ Centrum Leczenia SM, Plewiska, Poland|NZOZ ""NEURO-KARD"", ""Ilkowski i Partnerzy"" Sp. Partn. Lek., Poznan, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|NZOZ ""SENIOR"" Poradnia Psychogeriatryczna, Sopot, Poland|Osrodek Badan Klinicznych EUROMEDIS, Szczecin, Poland|mMED Maciej Czarnecki, Warszawa, Poland|Wojewodzki Szpital Specjalistyczny we Wroclawiu, Wroclaw, Poland|Hospital General Universitario de Elche, Elche, Alicante, Spain|ALTHAIA Hospital Sant Joan de Deu, Manresa, Barcelona, Spain|Complejo Hospitalario de Caceres, Caceres, Cáceres, Spain|Hospital Universitario Reina Sofía, Cordoba, Córdoba, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Quiron Dexeus, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Skånes Universitetssjukhus, Malmö, Malmö, Sweden|Sahlgrenska Universitetssjukhuset, Mölndal Sjukhus, Mölndal, Sweden|Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Universitären Psychiatrischen Kliniken Basel (UPK), Basel, Switzerland|Inselspital - Universitaetsspital Bern, Bern, Switzerland|Medizinisches Zentrum MZB Biel, Biel/Bienne, Switzerland|Hôpitaux Universitaires de Genève - HUG, Geneve 14, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Ospedale Civico, Lugano, Switzerland|Institut fuer Regenerative Medizin (IREM) der Universitaet Zuerich, Zentrum fuer Praevention und Demenztherapie, Schlieren, Switzerland",,https://ClinicalTrials.gov/show/NCT02484547
NCT02477800,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,ENGAGE,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: Aducanumab (BIIB037)|Drug: Placebo,Change from baseline in CDR-SB score|Change from baseline in MMSE score|Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (13 items) (ADAS-Cog 13)|Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) (ADCS-ADL-MCI) score,Biogen,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1605,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",221AD301|2015-000966-72,31-Aug-15,30-Jan-20,30-Apr-22,23-Jun-15,null,24-Apr-19,"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|University of California - Los Angeles, Los Angeles, California, United States|UCSF - Memory and Aging Center, San Francisco, California, United States|California Neuroscience Research Medical Group Inc., Sherman Oaks, California, United States|Southern California Research LLC, Simi Valley, California, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Compass Research Main, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|USF Health Byrd Institute, Tampa, Florida, United States|Meridien Research, Tampa, Florida, United States|Compass Research Main, The Villages, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Cleveland Clinic Florida - Weston, Weston, Florida, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|Via Christi Research, a division of Via Christi Hospitals Wichita, Inc., Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Brigham & Women's Hosp End/Dbt, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Donald S. Marks, M.D., P.C., Plymouth, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Las Vegas Medical research, Las Vegas, Nevada, United States|Advanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|New York University Medical Center PRIME, New York, New York, United States|University of Rochester, Rochester, New York, United States|ANI Neurology, PLLC d/b/a Alzheimer's Memory Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, P.A., Raleigh, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Northeastern Pennsylvania Memory and Alzheimer's Center, Plains, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina (MUSC), Charleston, South Carolina, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|University of Tennessee Medical Center. Knoxville, Knoxville, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Central Coast Neurosciences Research, Gosford, East Gosford, New South Wales, Australia|Central Coast Neurosciences Research, Erina, New South Wales, Australia|KARA Institute for Neurological Diseases, North Ryde, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Toowoomba Base Hospital, Toowoomba, Queensland, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Neurodegenerative Disorders Research, West Perth, Western Australia, Australia|LKH - Universitaetsklinikum Graz, Graz, Austria|Christian-Doppler-Klinik - Universitätsklinikum Salzburg, Salzburg, Austria|Heritage Medical Research Clinic, Calgary, Alberta, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|UBC Hospital, Vancouver, British Columbia, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, Canada|The Montreal Neurological Institute, Montreal, Quebec, Canada|McGill Centre for Studies in Aging, Verdun, Quebec, Canada|CHU de Quebec - Hôpital de l' Enfant Jésus, Quebec, Canada|CCBR - Ballerup - DK, Ballerup, Denmark|Rigshospitalet, København Ø, Denmark|CCBR - Vejle - DK, Vejle, Denmark|CCBR - Ålborg - DK, Ålborg, Denmark|CHU Strasbourg - Hôpital Hautepierre, Strasbourg Cedex, Bas Rhin, France|Hopital Louis Pasteur Colmar, Strasbourg, Bas Rhin, France|Groupe Hospitalier Pellegrin - Hôpital Pellegrin, Bordeaux, Gironde, France|CHU Reims - Hôpital Maison Blanche, Reims, Marne, France|Hopital Neurologique Pierre Wertheimer, Bron Cedex, Rhone, France|Groupe hospitalier Broca - La Rochefoucauld - La Collégiale, Paris, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|Praxis Dr. Scholz, Boeblingen, Baden Wuerttemberg, Germany|Aerztliche Gemeinschaftspraxis, Ostfildern, Baden Wuerttemberg, Germany|Neuro MVZ Stuttgart, Stuttgart, Baden Wuerttemberg, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, Bayern, Germany|Praxis Dr. med. Bergmann, Neuburg, Bayern, Germany|Neurologische Gemeinschaftspraxis Kassel, Kassel, Hessen, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Niedersachsen, Germany|Universitaetsklinikum Aachen AOeR, Aachen, Nordrhein Westfalen, Germany|Universitaetsklinikum Bonn AoeR, Bonn, Nordrhein Westfalen, Germany|Universitaetsklinikum Koeln, Cologne, Nordrhein Westfalen, Germany|Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Ancona, Italy|Fondazione Istituto G.Giglio di Cefalù, Cefalù, Palermo, Italy|Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Italy|Ospedale San Raffaele, Milano, Italy|Casa di Cura del Policlinico, Milano, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Seconda Università degli Studi di Napoli, Napoli, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, Italy|Research Site, Chiba-Shi, Chiba-Ken, Japan|Research Site, Inzai-shi, Chiba-Ken, Japan|Research Site, Kurume-shi, Fukuoka-ken, Japan|Research Site, Aizuwakamatsu-shi, Fukushima-Ken, Japan|Research Site, Asahikawa-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Atsugi-shi, Kanagawa-Ken, Japan|Research Site, Kamakura-shi, Kanagawa-Ken, Japan|Research Site, Kawasaki-Shi, Kanagawa-Ken, Japan|Yokohama-shi, Kanagawa-ken, Japan|Research Site, Yokohama-shi, Kanagawa-Ken, Japan|Research Site, Yokohama-shi, Kanagawa-Ken, Japan|Research Site, Kyoto-shi, Kyoto-Fu, Japan|Research Site, Nagaoka-shi, Niigata-Ken, Japan|Research Site, Iruma-gun, Saitama-Ken, Japan|Research Site, Kasukabe-shi, Saitama-Ken, Japan|Research Site, Bunkyo-ku, Tokyo-To, Japan|Research Site, Shinjuku-ku (I), Tokyo-To, Japan|Research Site, Shinjuku-ku, Tokyo-To, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Yamagata-shi, Yamagata-Ken, Japan|Research Site, Itabashi-ku, Japan|Research Site, Itabashi-ku, Japan|Research Site, Kiyose-shi, Japan|Research Site, Kodaira-shi, Japan|Inha University Hospital, Incheon, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Hospital Professor Doutor Fernando Fonseca, E.P.E., Amadora, Portugal|Hospital de Braga, Braga, Portugal|Centro Hospitalar e Universitário de Coimbra E.P.E, Coimbra, Portugal|CUF Alvalade, Lisboa, Portugal|Hospital Beatriz Ângelo, Loures, Portugal|Campus Neurologico Senior, Torres Vedras, Portugal|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Fundacio ACE, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Clinica Ruber, Madrid, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan County, Taiwan|Southmead Hospital, Bristol, Avon, United Kingdom|Re:Cognition Health Ltd, London, Greater London, United Kingdom|Charing Cross Hospital, London, Greater London, United Kingdom|The National Hospital for Neurology and Neurosurgery Centre, London, Greater London, United Kingdom|Salford Royal, Salford, Greater Manchester, United Kingdom|The University of Edinburgh, Edinburgh, Lothian Region, United Kingdom|Manchester Royal Infirmary, Blackburn, Merseyside, United Kingdom|The RICE Centre, Bath, Somerset, United Kingdom|Glasgow Memory Clinic Ltd, Glasgow, Strathclyde, United Kingdom|Stobhill ACH Hospital, Glasgow, Strathclyde, United Kingdom|Ninewells Hospital, Dundee, Tayside Region, United Kingdom|Newcastle University, Newcastle upon Tyne, Tyne & Wear, United Kingdom|Kingshill Research Centre, Chippenham, Wiltshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02477800
NCT02474251,Brain Sleep Clearance of Amyloid-Beta Peptides,Brain SCRAPs,"Active, not recruiting",No Results Available,Obstructive Sleep Apnea|Alzheimer's Disease,Device: Continuous positive airway pressure device,CSF Aβ42/Aβ40 levels,New York University School of Medicine|National Institute on Aging (NIA),All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,38,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,14-01837|5R21AG049348-02,1-Oct-15,31-May-17,31-Jul-19,17-Jun-15,null,16-May-19,"Bellevue Hospital Center, New York, New York, United States|NYU Langone Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02474251
NCT02471196,Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease,Nebula,Completed,No Results Available,Alzheimer's Disease,Drug: ORM-12741|Drug: Placebo,"Efficacy on aggression/agitation symptoms measured by Neuropsychiatric Inventory Clinician Rating scale|Efficacy on aggression/agitation symptoms and overall clinical status measured by Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change|Efficacy on cognitive symptoms measured by Cognitive Drug Research computerized test battery|Efficacy on daily living measured by Alzheimer's Disease Co-operative Study - Activities of Daily Living inventory|Safety measured by assessing adverse events|Plasma concentrations of ORM ORM-12741, metabolites and possible other Alzheimer's disease medication|Efficacy on aggression/agitation symptoms measured by Cohen Mansfield Agitation Inventory|Efficacy on cognitive symptoms measured by Alzheimer's Disease Assessment Scale|Safety measured by vital signs|Safety measured by electrocardiogram|Safety measured by laboratory variables","Orion Corporation, Orion Pharma|Janssen Pharmaceuticals",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,308,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3098012,14-Aug-15,9-Oct-17,4-Dec-17,15-Jun-15,null,15-Feb-18,"Clinical Research Services Turku - CRST Oy, Turku, Finland",,https://ClinicalTrials.gov/show/NCT02471196
NCT02471833,Health Evaluation in African Americans Using RAS Therapy,HEART,Recruiting,No Results Available,Alzheimer's Disease,Drug: Telmisartan 20mg|Drug: Telmisartan 40mg|Drug: Placebo,Change in concentration of cerebrospinal fluid angiotensin metabolites|Change in levels of plasma angiotensinogen|Change in levels of plasma renin|Change in levels of plasma angiotensin converting enzyme|Change in levels of plasma aldosterone|Change in levels of cerebrospinal fluid amyloid β42|Change in levels of cerebrospinal fluid T-tau|Change in levels of cerebrospinal fluid P-tau|Change in arterial function|Flanker Inhibitory Control and Attention Test|Set-shifting Test|Spatial 1-Back Test|Montreal Cognitive Assessment|Mini Mental State Examination (MMSE)|Wechsler Adult Intelligence Scale (WAIS)-Working Memory subtests|Wechsler Memory Scale-III Faces Test|Wechsler Memory Scale-Revised Logical Memory Test|Rey Auditory Verbal Learning Test|Arterial Spin Labeling-Magnetic Resonance Imaging|Structural Magnetic Resonance Imaging and White Matter Hyperintensities,Emory University,All,"30 Years and older   (Adult, Older Adult)",Phase 1,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",IRB00080192,Apr-15,Apr-19,Apr-19,15-Jun-15,null,12-Dec-18,"Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02471833
NCT02462291,New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders),ABCD,Completed,Has Results,Alzheimer Disease|Behavioral Disorders|Cognitive Impairment,Other: Ecological Environmental therapy,Evaluations of Behavioral Disorders|Evaluation of Cognitive Status (Score 0-30)|Body Composition (Kilograms of Fat Free Mass)|Systolic Blood Pressure (mmHg)|Diastolic Blood Pressure (mmHg)|Blood Glucose (mg/dl)|Blood Cholesterol HDL (mg/dl)|Blood Cholesterol LDL (mg/dl)|Daily Energy Expenditure (Kcal/Day)|Evaluation of Activity of Daily Life|Salivary Cortisol (Nmol/l)|Number of Medications|Number of Patients Treated With Quetiapine|Number of Patients Treated With Citalopram|Number of Patients Treated With Donepezil|Number of Patients Treated With Memantine|Number of Patients Treated With Ticlopidin,"Universita di Verona|Mons. Mazzali Foundation (Mantua, Italy)",All,65 Years and older   (Older Adult),Not Applicable,163,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",18201,Jun-15,Oct-15,Dec-15,4-Jun-15,29-Feb-16,12-Oct-18,"Mons. Mazzali Foundation, Mantua Italy, Mantua, Italy",,https://ClinicalTrials.gov/show/NCT02462291
NCT02463084,Macronutrient Effects on Alzheimer's Disease (MEAL-2),MEAL-2,Completed,No Results Available,Prediabetic State|Insulin Resistance|Middle Age|Prehypertension|Mild Cognitive Impairment,Other: Low Diet|Other: High Diet,Change in cerebrospinal fluid levels of Alzheimer's disease biomarkers (CSF beta-amyloid 42)|Changes in brain structure|Changes in adipose tissue distribution (Change in dual energy x-ray absorptiometry (DEXA) scan and CT measures of central and subcutaneous body fat)|Changes in cognition (Change in delayed memory and executive function composites)|Change in brain function as measured by MRI|Change in brain perfusion,Wake Forest University Health Sciences,All,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",IRB 00022512,Mar-13,Jun-16,Jun-16,4-Jun-15,null,9-Aug-18,"Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02463084
NCT02462161,Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart,SNIFF-Quick,Recruiting,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Drug: Insulin aspart|Drug: Placebo,"Change in cognition|Cerebral spinal fluid (CSF) and blood amyloid-beta, tau protein, and inflammatory markers|MRI measure of cortical thickness in Alzheimer's disease (AD) -vulnerable regions",Wake Forest University Health Sciences|National Institute on Aging (NIA)|General Electric,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 1,30,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00026106|5P50AG005136-30,May-15,Sep-19,Sep-19,3-Jun-15,null,24-Sep-18,"Wake Forest Baptist Hospital, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02462161
NCT02460783,"Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function",,Recruiting,No Results Available,Alzheimer's Disease|Obesity|Diabetes Mellitus,Dietary Supplement: Boost A|Behavioral: Healthy Living Diet,"Exosomal p-S312-IRS-1/p-panY-IRS-1 ratio (index of brain insulin resistance)|Hormones (GLP-1, insulin) during a mixed|Anthropometric measures (weight, waist)|Measure: CSF, plasma BDNF|Cognitive performance (Examiner, Memory)|Mood, energy, concentration, etc. symptom|Si and HOMA-IR (indices of peripheral insulin resistance)|Lipid panel, uric acid|MRS metabolites|fMRI activation to food preference task|fMRI activation to Stroop|CSF, plasma AD biomarkers (A(SqrRoot) <=42,p181Tau)|Cytokines: IL-6, IL-8, IL-12, IL-23|Physical activity (Accelerometry)|DNA methylation|Measure: Exosomal proteins and mRNA|ROS, AGES|Resting fMRI|Gene expression",National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC),All,"55 Years to 70 Years   (Adult, Older Adult)",Phase 2,150,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,150123|15-AG-0123,22-Jun-15,1-Jul-19,1-Jul-19,2-Jun-15,null,10-May-19,"National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02460783
NCT02446132,"Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",,Recruiting,No Results Available,Agitation in Patients With Dementia of the Alzheimer's Type,Drug: AVP-786,"Number of Participants with any Treatment-Emergent Adverse Event|Number of Participants with any Treatment-Emergent Serious Adverse Event|Number of Participants with any abnormal, clinically significant Clinical Laboratory Value|Number of Participants with any abnormal, clinically significant 12-lead Electrocardiogram (ECG) value|Number of Participants with any abnormal, clinically significant Physical and Neurological Examination finding|Number of participants with any abnormal, clinically significant vital sign value|Change from Baseline to Week 64 in the Sheehan Suicidality Tracking Scale (S-STS) Score|Change from Baseline to Week 52 in the Mini-Mental State Examination (MMSE) Score|Change from Baseline to Week 52 in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Score|Change from Baseline to Week 52 in the Timed Up and Go (TUG) Test Score|Change from Baseline to Week 52 in the Epworth Sleepiness Scale (ESS) Score|Change from Baseline to Week 52 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score|Change from Baseline to Week 52 in the Neuropsychiatric Inventory (NPI) Total Score|Change from Baseline to Week 52 in the modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change-Agitation (mADCS-CGIC-Agitation) Score|Change from Baseline to Week 22 in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score|Change from Baseline to Week 52 in the ADCS-CGIC Overall Score|Change from Baseline to Week 52 in the Zarit Burden Interview (ZBI) Score|Change from Baseline to Week 52 in the Patient Global Impression of Change (PGIC) Score|Change from Baseline to Week 52 in the Dementia Quality of Life (DEMQOL) Score|Change from Baseline to Week 52 in the Cornell Scale for Depression in Dementia (CSDD) Score|Change from Baseline to Week 52 in the Resource Utilization in Dementia (RUD) Score|Change from Baseline to Week 52 in the General Medical Health Rating (GMHR) Score|Change from Baseline to Week 52 in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score",Avanir Pharmaceuticals,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,700,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-AVP-786-303,Dec-15,Jun-22,Jun-22,18-May-15,null,8-Feb-19,"Brain and Spine Center, Chandler, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|NoesisPharma, LLC, Phoenix, Arizona, United States|Health Initiatives Research, Fayetteville, Arkansas, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|University of California, Irvine, Irvine, California, United States|Omega Clinical Trials, LLC, La Habra, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|Shankle Clinic, Newport Beach, California, United States|NRC Research Institute, Orange, California, United States|California Neurological Services, Panorama City, California, United States|Pacific Research Network, Inc., San Diego, California, United States|VA San Diego Healthcare System, San Diego, California, United States|HB Clinical Trials Inc., Santa Ana, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Viking Clinical Research, Temecula, California, United States|New Foundation Medical Group Clinical Trials, Tustin, California, United States|Lytle and Weiss, PLLC dba Clinical Trials of the Rockies, Denver, Colorado, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Geriatric and Adult Psychiatry LLC, Hamden, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Neurology Offices of South Florida, Boca Raton, Florida, United States|Clinical Research Of Brandon, LLC, Brandon, Florida, United States|Meridien Research, Brooksville, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Moonshine Research Center, Inc, Doral, Florida, United States|University of Florida, Gainesville, Florida, United States|Direct Helpers Research Center, Hialeah, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|New Life Medical Research Center, Inc., Hialeah, Florida, United States|Reliable Clinical Research, LLC, Hialeah, Florida, United States|Research in Miami, Inc., Hialeah, Florida, United States|The Research Center, Inc., Hialeah, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|Maxblue Institute, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|SIH Research, LLC, Kissimmee, Florida, United States|Alzheimer's Research and Treatment Center Clinical Trial Site 1, Lake Worth, Florida, United States|Alzheimer's Research and Treatment Center Clinical Trial Site 2, Lake Worth, Florida, United States|Premier Clinical Research Institute, Inc. Clinical Trial Site 1, Miami, Florida, United States|Premier Clinical Research Institute, Inc. Clinical Trial Site 2, Miami, Florida, United States|Global Medical Institutes, LLC, Miami, Florida, United States|Project 4 Research, Miami, Florida, United States|BioMed Research Institute, Miami, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Advance Medical Research Center, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Miami Jewish Health Systems, Inc., Miami, Florida, United States|AMB Research Center, Inc., Miami, Florida, United States|United Health Research Corp., Miami, Florida, United States|Advanced Medical Center Group, Miami, Florida, United States|Coral Research Clinic Corp, Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Kendall Research Institute, Miami, Florida, United States|Collier Neurologic Specialists, LLC, Naples, Florida, United States|Naples Research, Inc., Naples, Florida, United States|Lazlo J. Mate, MD, PA, North Palm Beach, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|IMIC Inc., Palmetto Bay, Florida, United States|University of West Florida, Pensacola, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Compass Research North, LLC, The Villages, Florida, United States|Neurology Research Institute Palm Beach, LLC, West Palm Beach, Florida, United States|Florida Premier Research Institute, Winter Park, Florida, United States|Emory Brain Health Center, Atlanta, Georgia, United States|NeuroTrials Research Inc., Atlanta, Georgia, United States|Columbus Research & Wellness Institute, INC, Columbus, Georgia, United States|Medical Research & Health Education Foundation, Inc., Columbus, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Behavioral Health Care Associates, Schaumburg, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States|MidAmerica Neuroscience Research Foundation, Lenexa, Kansas, United States|Four Rivers Clinical Research Inc., Paducah, Kentucky, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|The Samuel & Alexia Bratton Memory Clinic, Easton, Maryland, United States|Bedford VA Hospital, Bedford, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Michigan State University Department of Neurology, East Lansing, Michigan, United States|Bronson Neurobehavioral Health, Paw Paw, Michigan, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|PsychCare Consultants Research, Saint Louis, Missouri, United States|Clinical Research Professionals, Saint Louis, Missouri, United States|Geriatric Solutions, LLC, Las Vegas, Nevada, United States|Flora Baker Center for Alzheimer's Disease and Related Disorders, Marmora, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Dent Neurologic Institute, Amherst, New York, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|Columbia University Medical Center, New York, New York, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Psychiatry and Alzheimer's Care of Rochester, PLLC, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Burke Rehabilitation Hospital, White Plains, New York, United States|Herbert Harris, MD, PHD, PA, Chapel Hill, North Carolina, United States|ANI Neurology PLLC dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Daystar Clinical Research Inc., Akron, Ohio, United States|Neurology and Neuroscience Associates, Inc., Akron, Ohio, United States|Insight Neuroscience, LLC, Bellevue, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Cleveland Clinic Lou Ruvo Center for Brain Health at Lakewood Hospital, Lakewood, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|The Birches at Newton / Family Medical Associates, Levittown, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, LTD, Willow Grove, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|RH Johnson VA Medical Center, Charleston, South Carolina, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Coastal Neurology, PA, Port Royal, South Carolina, United States|BG Neurology, Spartanburg, South Carolina, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Clinical Research Solutions, Franklin, Tennessee, United States|Texas Neurology, P.A., Dallas, Texas, United States|Neurology Consultants of Dallas, PA, Dallas, Texas, United States|University Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|Neurology Associates of Arlington, Mansfield, Texas, United States|Texas Medical Research Associates, L.L.C., San Antonio, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|Pharmaceuticals Research Associates, Inc., Salt Lake City, Utah, United States|Clinical Neuroscience Research Associates, Inc. dba The Memory Clinic, Bennington, Vermont, United States|Neuropsychiatric Associates, Woodstock, Vermont, United States|Sentara Neurosciences Institute, Norfolk, Virginia, United States|Veteran Affairs Medical Center, Salem Virginia, Salem, Virginia, United States|Frontier Institute, Spokane, Washington, United States|IPC Research, Waukesha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02446132
NCT02444078,Effects of Exercise on Functional Ability in People With Dementia in Nursing Homes:a Cluster Randomised Controlled Trial,LEDEN,Completed,No Results Available,Alzheimer Disease|Dementia,Other: Exercise|Other: Social Activity,Functional ability|Change of Functional ability|Physical function|Cost-effectiveness of the interventions|Falls and fractures|Cognitive function|Behavioural and psychological symptoms of dementia (BPSD)|Pain|Nutritional status,"University Hospital, Toulouse",All,65 Years and older   (Older Adult),Not Applicable,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,RC31/14/7292|2014-A01713-44,Aug-15,Sep-16,Sep-17,14-May-15,null,1-Jun-18,"Résidence d'Automne de Bruay sur Escaut, Bruay-sur-l'escaut, France|Korian Le Castelli, L'huisserie, France|Korian Pontlieue, Le Mans, France|Résidence Les Lauriers de Plaisance, Neuilly Plaisance, France|Korian Croix Périgourd, Saint Cyr Sur Loire, France|Résidence d'Automne de Notre Dame de Sanhilac, Sanilhac, France|Résidence Les Jardins de Sermaize, Sermaize-les-bains, France|Korian Vill'Alizé, Thise, France",,https://ClinicalTrials.gov/show/NCT02444078
NCT02444637,Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD,,Unknown status,No Results Available,Alzheimer Disease|CVA (Cerebrovascular Accident),Drug: Rivastigmine,Number of Participants with Demonstrated Benefit in Global and Cognitive Measures|Number of Participants with Adverse Events as a Measure of Safety and Tolerability,National Neuroscience Institute,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RACE_1.0,Apr-15,Apr-17,null,14-May-15,null,14-May-15,"National Neuroscience Institute, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT02444637
NCT02442765,"Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",,Completed,No Results Available,Agitation in Patients With Dementia of the Alzheimer's Type,Drug: AVP-786|Drug: Placebo,Change from Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score|Change from Baseline to Week 12 in the Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation (Global Clinical Status of Agitation on mADCS-CGIC Scale) Score|Change from Baseline to Week 12 in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score|Change from Baseline to Week 12 in the NPI Caregiver Distress Score|Change from Baseline to Week 12 in the NPI Aberrant Motor Behavior Domain Score|Change from Baseline to Week 12 in the Zarit Burden Interview (ZBI) Score|Change from Baseline to Week 12 in the NPI Irritability/Lability Domain Score|Change from Baseline to Week 12 in the NPI Total Score|Change from Baseline to Week 12 in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score|Change from Baseline to Week 12 in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Rating|Change from Baseline to Week 12 in the Patient Global Impression of Change (PGIC) Score|Change from Baseline to Week 12 in the Dementia Quality of Life (DEMQOL) Score|Change from Baseline to Week 12 in the Cornell Scale for Depression in Dementia (CSDD) Score|Change from Baseline to Week 12 in the General Medical Health Rating (GMHR) Score|Change from Baseline to Week 12 in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|Change from Baseline to Week 12 in the Resource Utilization in Dementia (RUD) Score,Avanir Pharmaceuticals,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,410,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-AVP-786-301,Sep-15,30-Jan-19,27-Feb-19,13-May-15,null,6-Mar-19,"NoesisPharma, LLC, Phoenix, Arizona, United States|Perseverance Research Center, LLC, Scottsdale, Arizona, United States|University of California, Irvine, Irvine, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|NRC Research Institute, Orange, California, United States|Pacific Research Network, Inc., San Diego, California, United States|VA San Diego Healthcare System, San Diego, California, United States|HB Clinical Trials Inc., Santa Ana, California, United States|New Foundation Medical Group Clinical Trials, Tustin, California, United States|Lytle and Weiss, PLLC dba Clinical Trials of the Rockies, Denver, Colorado, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Neurology Offices of South Florida, Boca Raton, Florida, United States|Coral Gables Clinical Research, Inc, Coral Gables, Florida, United States|Optimus U Corp, Coral Gables, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Direct Helpers Research Center, Hialeah, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|Care Research Center, Inc., Kendall, Florida, United States|SIH Research, LLC, Kissimmee, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Premier Clinical Research Institute, Inc., Miami, Florida, United States|Global Medical Institutes, LLC, Miami, Florida, United States|Project 4 Research, Miami, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Advance Medical Research Center, Miami, Florida, United States|Vitae Researrch Center LLC, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Miami Jewish Health Systems, Inc., Miami, Florida, United States|United Health Research Corp., Miami, Florida, United States|Advanced Medical Center Group, Miami, Florida, United States|Future Care Solution, LLC, Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Naples Research, Inc., Naples, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|Innovation Medical Research Center, Palmetto Bay, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|Compass Research North, LLC, The Villages, Florida, United States|Neurology Research Institute Palm Beach, LLC, West Palm Beach, Florida, United States|Florida Premier Research Institute, Winter Park, Florida, United States|NeuroTrials Research Inc., Atlanta, Georgia, United States|Medical Research & Health Education Foundation, Inc., Columbus, Georgia, United States|Behavioral Health Care Associates, Schaumburg, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|MidAmerica Neuroscience Research Foundation, Lenexa, Kansas, United States|Four Rivers Clinical Research Inc., Paducah, Kentucky, United States|Bedford VA Hospital, Bedford, Massachusetts, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Michigan Clinical Research Institute PC, Ann Arbor, Michigan, United States|Bronson Neurobehavioral Health, Paw Paw, Michigan, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|PsychCare Consultants Research, Saint Louis, Missouri, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Dent Neurologic Institute, Amherst, New York, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|Columbia University Medical Center, New York, New York, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Neurology and Neuroscience Associates, Inc., Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Abington Neurological Associates, LTD, Willow Grove, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Neurology Consultants of Dallas, PA, Dallas, Texas, United States|University Texas Southwestern Medical Center, Dallas, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|Neurology Associates of Arlington, Mansfield, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|Neuropsychiatric Associates, Woodstock, Vermont, United States",,https://ClinicalTrials.gov/show/NCT02442765
NCT02442778,"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",,Recruiting,No Results Available,Agitation in Patients With Dementia of the Alzheimer's Type,Drug: AVP-786|Drug: Placebo,Change from Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score|Change from Baseline to Week 12 in the Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation (Global Clinical Status of Agitation on mADCS-CGIC Scale) Score|Change from Baseline to Week 12 in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score|Change from Baseline to Week 12 in the NPI Caregiver Distress Score|Change from Baseline to Week 12 in the NPI Aberrant Motor Behavior Domain Score|Change from Baseline to Week 12 in the Zarit Burden Interview (ZBI) Score|Change from Baseline to Week 12 in the NPI Irritability/Lability Domain Score|Change from Baseline to Week 12 in the NPI Total Score|Change from Baseline to Week 12 in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score|Change from Baseline to Week 12 in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Overall Rating|Change from Baseline to Week 12 in the Patient Global Impression of Change (PGIC) Score|Change from Baseline to Week 12 in the Dementia Quality of Life (DEMQOL) Score|Change from Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score|Change from Baseline to Week 12 in the General Medical Health Rating (GMHR) Score|Change from Baseline to Week 12 in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|Change from Baseline in the Resource Utilization in Dementia (RUD) Score,Avanir Pharmaceuticals,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,470,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-AVP-786-302,Sep-15,Dec-19,Dec-19,13-May-15,null,8-Feb-19,"Brain and Spine Center, Chandler, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Health Initiatives Research, Fayetteville, Arkansas, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Omega Clinical Trials, LLC, La Habra, California, United States|California Neurological Services, Panorama City, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Viking Clinical Research, Temecula, California, United States|Denver Neurological Research, LLC, Denver, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Geriatric and Adult Psychiatry LLC, Hamden, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Clinical Research Of Brandon, LLC, Brandon, Florida, United States|Meridien Research, Brooksville, Florida, United States|Moonshine Research Center, Inc, Doral, Florida, United States|Science Connections, LLC, Doral, Florida, United States|University of Florida, Gainesville, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|New Life Medical Research Center, Inc., Hialeah, Florida, United States|Reliable Clinical Research, LLC, Hialeah, Florida, United States|Research in Miami, Inc., Hialeah, Florida, United States|The Research Center, Inc., Hialeah, Florida, United States|Maxblue Institute, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Premier Clinical Research Institute, Inc., Miami, Florida, United States|Project 4 Research, Miami, Florida, United States|BioMed Research Institute, Miami, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|DADE Research Center, LLC, Miami, Florida, United States|AMB Research Center, Inc., Miami, Florida, United States|Coral Research Clinic Corp., Miami, Florida, United States|P&S Reasearch, Miami, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|Kendall Research Institute, Miami, Florida, United States|Nuovida Research Center Corp., Miami, Florida, United States|Collier Neurologic Specialists, LLC, Naples, Florida, United States|Lazlo J. Mate, MD, PA, North Palm Beach, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|IMIC Inc., Palmetto Bay, Florida, United States|University of West Florida, Pensacola, Florida, United States|Emory Brain Health Center, Atlanta, Georgia, United States|Columbus Research & Wellness Institute, INC, Columbus, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States|Baptist Health Medical Group, Richmond, Kentucky, United States|The Samuel & Alexia Bratton Memory Clinic, Easton, Maryland, United States|Boston Center for Memory, Newton, Massachusetts, United States|AMAC Research Institute, North Dartmouth, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|Clinical Research Professionals, Saint Louis, Missouri, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Flora Baker Center for Alzheimer's Disease and Related Disorders, Marmora, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Psychiatry and Alzheimer's Care of Rochester, PLLC, Rochester, New York, United States|Burke Rehabilitation Hospital, White Plains, New York, United States|Herbert Harris, MD, PHD, PA, Chapel Hill, North Carolina, United States|ANI Neurology PLLC dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Daystar Clinical Research Inc., Akron, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Cleveland Clinic Lou Ruvo Center for Brain Health at Lakewood Hospital, Lakewood, Ohio, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|The Birches at Newton / Family Medical Associates, Levittown, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|RH Johnson VA Medical Center, Charleston, South Carolina, United States|Coastal Neurology, PA, Port Royal, South Carolina, United States|BG Neurology, Spartanburg, South Carolina, United States|Texas Neurology, P.A., Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|Texas Medical Research Associates, L.L.C., San Antonio, Texas, United States|Pharmaceuticals Research Associates, Inc., Salt Lake City, Utah, United States|Clinical Neuroscience Research Associates, Inc. dba The Memory Clinic, Bennington, Vermont, United States|Veteran Affairs Medical Center, Salem Virginia, Salem, Virginia, United States|Frontier Institute, Spokane, Washington, United States|IPC Research, Waukesha, Wisconsin, United States|Dr. Alexander McIntyre Inc., Calgary, Canada",,https://ClinicalTrials.gov/show/NCT02442778
NCT02434666,Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07,,Completed,No Results Available,Dementia of the Alzheimer's Type,Drug: CPC-201,safety and tolerability of the maximum tolerated dose (MTD) of CPC-201 (adverse events)|safety and tolerability of CPC-201 20mg/day (adverse events),"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,21,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPC-001-10,8-Jan-15,18-Oct-16,22-Nov-16,5-May-15,null,20-Sep-17,"Miami Jewish Health Systems, Miami, Florida, United States|Quantum Laboratories, Inc. Memory Disorder Center, Pompano Beach, Florida, United States|Premiere Research Institute Neuroscience, West Palm Beach, Florida, United States|IU School of Medicine IU Health Neuroscience Center, Indianapolis, Indiana, United States|Giles Cromwell, MD, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02434666
NCT02434718,Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease,PROPEL,Completed,No Results Available,Alzheimer's Disease,Drug: Aducanumab|Drug: Placebo,"Incidence and nature of adverse events (AE) / serious adverse events(SAE)|Clinically significant changes in vital signs and 12-lead electrocardiogram (ECG) data; abnormalities in neurological and physical examinations|Brain magnetic resonance imaging (MRI) findings to assess amyloid-related imaging abnormalities (ARIA), including incidence of ARIA-E (edema) or ARIA-H (hemosiderosis)|Area under the concentration-time curve (AUC) from time zero extrapolated to infinity (AUC0-∞)|AUC from time zero to time of the last measurable concentration (AUC0-last)|Maximum observed concentration (Cmax)|Time to Cmax (Tmax)|Elimination half-life (t1/2)|Volume of distribution at steady state (Vss)|Clearance (CL) after a single IV infusion of aducanumab|Incidence of anti-aducanumab antibodies in serum",Biogen,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,21,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",221AD104,30-Jun-15,9-Dec-16,9-Dec-16,5-May-15,null,10-Apr-17,"Research Site, Toon, Ehime, Japan|Research Site, Kobe, Hyogo, Japan|Research Site, Kamakura, Kanagawa, Japan|Research Site, Kanzaki, Saga, Japan|Research Site, Kodaira, Tokoyo, Japan|Research Site, Shinjuku, Tokoyo, Japan|Research Site, Kyoto, Japan",,https://ClinicalTrials.gov/show/NCT02434718
NCT02432222,Effects of Visual Arts Training on Dementia,,Completed,No Results Available,Dementia|Alzheimer Disease,Behavioral: Visual Arts Training|Behavioral: Music Training,"Montreal Cognitive Assessment (MOCA, change measure)|Working memory (change measure)|Rey-Osterreith test of long-term memory (change measure)|Trails test of set-shifting (change measure)|Dual task for visual and auditory search (change measure)|Behavioural psychiatric peformance (time-to-event measure)|Quality of Life (change measure)|Visual analog mood scale",York University,All,65 Years and older   (Older Adult),Not Applicable,23,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,YorkU-AD1,Apr-15,Dec-15,Dec-15,4-May-15,null,13-Jul-16,,,https://ClinicalTrials.gov/show/NCT02432222
NCT02431468,A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Bryostatin 1|Other: Placebo,Safety: Number of Subjects With Treatment-emergent Adverse Events and Serious Adverse Events|Efficacy: Change From Baseline in Severe Impairment Battery (SIB) in the Full Analysis Set (FAS)|Secondary Efficacy Endpoints,"Neurotrope Bioscience, Inc.",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,147,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NTRP-101-202,Nov-15,Feb-17,Feb-17,1-May-15,6-Jul-18,6-Jul-18,"Xenoscience, Inc/ 21st Century Neurology, Phoenix, Arizona, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Nader Pharmacology Research Institute, Los Alamitos, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|JEM Research, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of South Florida, Fort Myers, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health System, Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Compass Research, The Villages, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute Clinical Research, Elk Grove Village, Illinois, United States|University of Kansas Alzheimer's Disease Center, Fairway, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|J. Gary Booker, MD APMC Clinical Drug Trials, Shreveport, Louisiana, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|Atlantic Neuroscience Institute, Springfield, New Jersey, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Parker Jewish Institute for Health Care and Rehabilitation, New Hyde Park, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Neurobehavioral Clinical Research, Canton, Ohio, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Sunstone Clinical Research, Medford, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Neurology Clinic, PC, Cordova, Tennessee, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02431468/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02431468/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02431468
NCT02428387,"Evaluation of ""My Tools 4 Care"" for Family Caregivers of Persons With Dementia",,Completed,No Results Available,Family|Dementia,Behavioral: My Tools 4 Care,"Change from Baseline in Health Related Quality of Life at One, Three and Six Months|Change from Baseline in Hope at One, Three and Six Months|Change from Baseline in General Self Efficacy at One, Three and Six Months",University of Alberta|Canadian Institutes of Health Research (CIHR),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,199,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care",Pro00048721,Apr-15,12-Apr-17,12-Apr-17,28-Apr-15,null,31-May-17,"University of Alberta, Edmonton, Alberta, Canada|Jenny Ploeg, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02428387
NCT02423122,"A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)",,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Drug: VX-745,Percent change from Baseline in amyloid plaque burden by 11C-PiB PET|Number of adverse events,"EIP Pharma, LLC",All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,16,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EIP-VX00-745-302,Apr-15,Jul-16,Sep-16,22-Apr-15,null,17-Apr-17,"Alzheimer Research Center, VU Medical Center, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT02423122
NCT02423200,"Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD",,Completed,Has Results,Alzheimer's Disease,Drug: VX-745,Percent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines|Severe or Serious Adverse Events|Maximal CSF VX-745 Concentration|Episodic Memory Function,"EIP Pharma, LLC",All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,16,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EIP14-745-303,Apr-15,Sep-16,Nov-16,22-Apr-15,3-Apr-18,3-Apr-18,"Parexel International, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT02423200
NCT02420535,An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia,,Completed,No Results Available,Dementia,Behavioral: Immediately Receive Tool|Behavioral: One Month Delay,Effects of the WeCareAdvisor Tool on Caregiver Upset|Effect of the WeCareAdvisor Tool on Caregiver Confidence,University of Michigan|Johns Hopkins University,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,114,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HUM00066639,May-15,Oct-16,Oct-16,20-Apr-15,null,19-Dec-16,"Johns Hopkins School of Nursing, Baltimore, Maryland, United States|University of Michigan Department of Psychiatry, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02420535
NCT02418806,Group Therapy for Caregivers of Alzheimer's Disease Patients in Spanish Elderly Persons Centres,cuiDem,Completed,No Results Available,Alzheimer's Disease,Behavioral: Psychotherapy groups|Behavioral: Self-help groups,"Efficacy of group therapy in caregiver burden measured by Zarit Burden Interview.|Change in caregiver burden from baseline compared to the control and active arms measured by Zarit Burden Interview.|Change in anxiety and depression from baseline compared to the control and active arms measured by Goldberg Scale.|Descriptive analysis of the caregivers' characteristics (sociodemographics, relation wih the AD patient).|Descriptive analysis of the caregiver's cognition using DEM-DETECT Module 1.|Preliminary cost-effectiveness analysis related resources needed to caregivers and Alzheimer patients.|Change in quality of life from baseline compared to the control and active arms measured by Casp-19 and SF-36 questionnaires.|Change in resilience from baseline compared to the control and active arms measured by Connor-Davidson Resilience Scale.|Change in functional social support from baseline compared to the control and active arms using Duke-UNC questionnaire.","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,231,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,cuiDem/FBB-0113,Jan-14,Jul-14,Sep-15,16-Apr-15,null,20-Jan-16,"AFA Barcelona, Barcelona, Spain|Centro de día Vitalia, Barcelona, Spain|AFA Burgos, Burgos, Spain|AFA Castellón, Castellón, Spain|AGUAFA, Guadasuar, Spain|AFA Lleida, Lleida, Spain|Centro de envejecimiento saludable, Málaga, Spain|Fundació Ana Ribot, Pallejà, Spain|AVAN, Sabadell, Spain|AFATE, Tenerife, Spain|AFA Terres de l'Ebre, Tortosa, Spain",,https://ClinicalTrials.gov/show/NCT02418806
NCT02414282,"F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)",Protocol E,Enrolling by invitation,No Results Available,Alzheimer Disease|Progressive Posterior Cortical Dysfunction (PPCD),Drug: F 18 T807,"F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.",Washington University School of Medicine,All,"45 Years and older   (Adult, Older Adult)",Phase 2,25,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IND 123119 Protocol E,Mar-15,Mar-20,Sep-20,10-Apr-15,null,24-Jan-19,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02414282
NCT02414347,F 18 T807 Tau PET Imaging of Alzheimer's Disease,T807IND,Enrolling by invitation,No Results Available,Alzheimer Disease,Drug: F 18 T807,"F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.",Washington University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IND 123119 Protocol A,Oct-14,Oct-19,Dec-19,10-Apr-15,null,24-Jan-19,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02414347
NCT02406027,An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum,,Terminated,No Results Available,Alzheimer Disease,"Drug: JNJ-54861911, 10 mg|Drug: JNJ-54861911, 25 mg|Drug: Placebo|Drug: JNJ-54861911, 5 mg","Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels and Soluble Amyloid Precursor Protein (sAPP) Fragments (sAPP-alpha, sAPP-beta), Total sAPP Levels|Percent Change From Baseline in Plasma ABeta Levels 1-37, 1-38, 1-40, and 1-42|Maximum Plasma Concentration (Cmax) of JNJ-54861911|Area Under the Plasma/CSF Concentration-time Curve From Time 0 to tau Hours Post Dosing (AUCtau)|Relationship Between Changes in CSF and Plasma ABeta Species and sAPP Fragments With Safety","Janssen Research & Development, LLC",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,90,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR106978|54861911ALZ2004|2014-004274-41,2-Jul-15,28-Jun-18,28-Jun-18,1-Apr-15,null,14-Nov-18,"Gent, Belgium|Hoboken, Belgium|Montpellier Cedex 5, France|Paris, France|Toulouse, France|Essen, Germany|Homburg, Germany|Luebeck, Germany|Tübingen, Germany|Ulm, Germany|Amsterdam, Netherlands|Barcelona, Spain|Madrid, Spain|Terrasa Barcelona, Spain|Valencia, Spain|Mölndal, Sweden|Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02406027
NCT02403752,Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers (PairedPLIE),PairedPLIE,Completed,No Results Available,Dementia|Alzheimer's Disease,Behavioral: Paired PLIE Program,Change in Short Physical Performance Battery (SPPB) from Baseline to 4 months|Change in Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) from baseline to 4 months|Change in Quality of Life Scale in Alzheimer's Disease (QOL-AD) from baseline to 4 months|Change in Caregiver Burden Inventory (CBI) from baseline to 4 months,"University of California, San Francisco|Kaiser Permanente",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-14943,Mar-15,Jul-18,Jul-18,31-Mar-15,null,18-Dec-18,"UCaliforniaSF, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02403752
NCT02397980,Intervention Programs for Decreasing Caregiver Burden in Caregivers of Patients With Dementia,I-care,Unknown status,No Results Available,Alzheimer's Disease|Dementia,Behavioral: Behavioral intervention,Changes in Caregiver burden (Zaret's Burden Inventory (ZBI)|Changes in quality of life of caregivers as assessed by Philadelphia Geriatric Center for Moral Scale (PGCMS)|Changes in behavioral problems of patients with dementia as assessed by the Neuropsychiatry inventory|Changes in Depression of caregivers as assessed by the geriatric depression scale,Ewha Womans University Mokdong Hospital,All,"30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",EUMC2014-12-028,Mar-15,Dec-15,Dec-16,25-Mar-15,null,25-Mar-15,,,https://ClinicalTrials.gov/show/NCT02397980
NCT02392468,"Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers",,Completed,No Results Available,Schizophrenia|Alzheimer Disease,Drug: BI 409306 matching placebo|Drug: BI 409306,"The percentage of subjects with Adverse Events (AE), coded to the Medical Dictionary for Regulatory Activities, System Organ Class Eye disorders, as determined by the investigator at End of Study|The percentage of subjects with drug-related AEs as determined by the investigator at End of Study|Cmax,ss - maximum measured concentration of the analyte in plasma at steady-state|tmax,ss - time from dosing to maximum measured concentration of the analyte in plasma at steady-state.",Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 1,61,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1289.27,15-Apr-15,10-Aug-17,10-Aug-17,19-Mar-15,null,20-Dec-17,"Altman Clinical and Translational Research Institute, La Jolla, California, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Community Clinical Research, Inc., Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02392468
NCT02393027,"Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999",LBT 999,Terminated,No Results Available,Idiopathic Parkinson Disease,Drug: [18F] LBT-999 PET,Binding potential of [18F] LBT-999|DAT striatal density by estimating the LBT-999 distribution volume|presence of lipophilic metabolites,"University Hospital, Tours",All,"45 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PHAO14-MJR / LBT-999,Mar-15,Nov-16,May-17,19-Mar-15,null,30-May-17,"University Hospital, Tours, France",,https://ClinicalTrials.gov/show/NCT02393027
NCT02389413,Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease,SAPHIR,Completed,No Results Available,Alzheimer's Disease,Drug: PQ912 oral|Other: Placebo,Frequency of adverse events and serious adverse events (the study is a Phase II safety trial)|Exploratory clinical measures (measured by a questionnaire)|Change from baseline of a panel of concept and AD-related biomarkers in Cerebrospinal fluid (CSF) (measured by Analysis of several biochemical assays)|Change from baseline in brain functional connectivity (measured by Magnetic Resonance Imaging (MRI) analysis)|Change from baseline in functional connectivity and network Analysis in electroencephalography (EEG),"Probiodrug AG|Julius Clinical, The Netherlands|VU University Medical Center",All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,120,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBD01071|2014-001967-11,Mar-15,Apr-17,Apr-17,17-Mar-15,null,1-Jun-17,"Ziekenhuis Netwerk Antwerpen / Geheugenkliniek, Hoboken, Belgium|Kliininen tutkimuskeskus, Kuopio, Finland|Oulu University Hospital, Oulu, Finland|CRST Oy, Turku, Finland|CHU Bordeaux Pellegrin (CMRR), Bordeaux, France|CHU François Mitterand (Centre Mémoire Ressources Recherche (CMRR)), Dijon, France|CHRU de Lille / Hôpital Roger Salengro, Lille Cedex, France|Hôpital La Grave / Centre de Recherche Clinique, Toulouse Cedex 9, France|Charité - Universitätsmedizin Berlin, Berlin, Germany|Universitätsmedizin Göttingen / Klinik für Psychiatrie und Psychotherapie, Göttingen, Germany|Universitätsklinikum Halle (Saale) Klinik und Poliklinik für Psychiatrie, Psychotherapie und Psychosomatik, Halle (Saale), Germany|Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Universitätsklinikum Magdeburg / Institut für Kognitive Neurologie und Demenzforschung, Magdeburg, Germany|Klinikum rechts der Isar der TU München / Klinik für Psychiatrie und Psychotherapie, München, Germany|Universitätsklinikum Münster / Klinik für Allgemeine Neurologie, Münster, Germany|Universitätsmedizin Rostock / Zentrum für Nervenheilkunde/ Klinik für Psychosomatik und Psychotherapeutische Medizin, Rostock, Germany|Neurologische Universitätsklinik Ulm, Ulm, Germany|Alzheimer Research Center, Amsterdam, Netherlands|Hospital de la Santa Creu i Sant Pau, Neurology Department, Memory Unit, Barcelona, Spain|Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Spain|Complexo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Verksamheten för neuropsykiatri Sahlgrenska universitetssjukhuset, Mölndal, Sweden",,https://ClinicalTrials.gov/show/NCT02389413
NCT02388152,Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer Disease,"Drug: Lu AF20513, low dose|Drug: Lu AF20513, medium dose|Drug: Lu AF20513, high dose|Drug: Lu AF20513, double high dose","Safety and tolerability assessed by composite outcome measure consisting of absolute values and changes from baseline in: adverse events, clinical safety laboratory tests, vital signs|Antibody titre",H. Lundbeck A/S,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,50,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16026A|2014-001797-34,Mar-15,Oct-19,Dec-19,13-Mar-15,null,7-May-19,"AT001, Wien, Austria|FI001, Turku, Finland|SE002, Malmö, Sweden|SE003, Mölndal, Sweden|SE001, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02388152
NCT02386670,Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD),PACt-MD,Recruiting,No Results Available,"Mild Cognitive Impairment|Major Depressive Disorder, Recurrent, In Remission|Major Depressive Disorder, Single Episode, in Full Remission",Other: tDCS + CR|Other: sham tDCS + sham CR,Change in cognitive scores over time|Percentage of subjects who remain free of MCI or dementia over time,"Centre for Addiction and Mental Health|Brain Canada|Applied Health Research Centre|Queen's University|Baycrest Centre for Geriatric Care|St. Michael's Hospital, Toronto|Sunnybrook Health Sciences Centre|University Health Network, Toronto",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,375,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",041-2014,Jan-15,Dec-19,Feb-21,12-Mar-15,null,15-May-18,"Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Heath Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02386670
NCT02386306,"Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Drug: GC021109|Other: Placebo,"Assessment of the number and severity of treatment-emergent AEs (TEAEs) following single oral doses of GC021109 and placebo from Day 1 through Day 28|Estimate of the pharmacokinetic (PK) parameters of multiple, escalating dose levels of GC021109: AUC0-t, AUC0-24, AUC0-inf, AUC%extrap, CL/F, Cmax, Tmax, λz, and t1/2.|Determine the effect of multiple, escalating dose levels of GC021109 on potential biomarkers of activities.","GliaCure, Inc.",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,39,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GC-100-02,Feb-15,Oct-15,Oct-15,11-Mar-15,null,3-Feb-16,"Collaborative Neuroscience Network, Long Beach, California, United States|Quantum laboratories / Memory Disorder Center, Deerfield Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Compass Research, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT02386306
NCT02384993,aeRobic Exercise and Cognitive Health,REACH,Completed,No Results Available,Alzheimer's Disease|Aging,Behavioral: Enhanced Physical Activity,Cerebral Glucose Metabolism,"University of Wisconsin, Madison|Alzheimer's Association",All,"45 Years to 80 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2014-1434|2014-NIRGD-305257,Jan-15,Aug-16,Aug-16,10-Mar-15,null,30-Dec-16,"University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02384993
NCT02380573,"Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",MB2,Suspended,No Results Available,Mild Cognitive Impairment|MCI|Aging|Alzheimer's Disease|AD,Drug: Methylene Blue|Drug: FD&C Blue # 2|Drug: Phenazopyridine hydrochloride,Working memory task|Working memory task response|Episodic memory task|Episodic memory task response|Sustained attention task|Sustained attention task reaction time|Neuropsychological battery composite score|Cerebral blood flow measures,The University of Texas Health Science Center at San Antonio|Texas Alzheimer’s Research and Care Consortium (TARCC),All,"45 Years to 89 Years   (Adult, Older Adult)",Phase 2,117,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC20150410H,Jul-15,Jul-22,Jul-23,5-Mar-15,null,8-May-19,"Research Imaging Institute, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02380573
NCT02380703,Aggression Prevention Training for Caregivers of Persons With Dementia (APT),APT,Completed,No Results Available,Dementia|Pain|Alzheimer's Disease|Aggression|Depression|Interpersonal Relations,Behavioral: Aggression Prevention Training (APT)|Other: Enhanced Usual Primary Care (EU-PC),"Incidence of aggression (Cohen Mansfield Agitation Inventory, Aggression Subscale)|Nursing Home Placement|Caregiver Burden--Zarit Burden Interview|Positive Caregiving Attributes--Positive Aspects of Caregiving Scale|Behavior Problems--Revised Memory and Behavior Checklist|Pain--Philadelphia Geriatric Pain Intensity Scale|Depression--Geriatric Depression Screen (GDS), Caregiver Version|Caregiver-Patient Relationship Quality--Mutuality Scale|Pleasant Events--Pleasant Events and Activities Schedule Alzheimer's Disease (short version)",Baylor College of Medicine|National Institute of Nursing Research (NINR),All,"Child, Adult, Older Adult",Not Applicable,228,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,H-33720|R01NR014657-01A1,5-Feb-15,23-Oct-18,23-Oct-18,5-Mar-15,null,16-Jan-19,,,https://ClinicalTrials.gov/show/NCT02380703
NCT02377713,A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.,,Completed,No Results Available,Alzheimer's Disease,Drug: KHK6640|Drug: Placebo,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,"Kyowa Hakko Kirin Co., Ltd",All,"55 Years to 84 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",6640-002,Mar-15,Sep-16,Sep-16,4-Mar-15,null,7-Dec-16,"Tokyo, Sumida-ku, Japan",,https://ClinicalTrials.gov/show/NCT02377713
NCT02377206,Neuroinflammation and Cognitive Decline in Alzheimer Disease,NICAD,Unknown status,No Results Available,Alzheimer Disease,Other: ADAS-Cog evaluation,Change from baseline in ADAS-Cog score|Quantification of neuroinflammation by [18F]DPA-714 PET imaging,"University Hospital, Tours",All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,45,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PRTS13-CH / NICAD,Mar-15,Mar-17,Mar-17,3-Mar-15,null,23-Jun-15,"University hospital of Caen, Caen, France|university hospital of Nantes, Nantes, France|University Hospital of Rennes, Rennes, France|University Hospital of Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT02377206
NCT02370524,Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease (AD),Drug: [18F]T807,Quantitative evaluation of [18F]T807 as a potential PET radioligand for imaging Tau in patients with clinically characterized tauopathies,Molecular NeuroImaging|Institute for Neurodegenerative Disorders|Roche Pharma AG,All,"20 Years to 90 Years   (Adult, Older Adult)",Phase 1,16,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,[18F]T807,Jan-15,Jan-16,Jan-16,25-Feb-15,null,8-Mar-17,"Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02370524
NCT02365051,Translation of COPE for Publicly-Funded Home Care Clients and Their Families,COPECT,"Active, not recruiting",No Results Available,Dementia|Alzheimer's Disease,Behavioral: Care of Persons with Dementia in their Environments,Functional dependence,UConn Health,All,65 Years and older   (Older Adult),Not Applicable,582,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,15-014-3,May-15,31-Mar-19,31-Mar-20,18-Feb-15,null,10-Oct-18,"UConn Center on Aging, Farmington, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02365051
NCT02362880,Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study,,Recruiting,No Results Available,Alzheimer Disease,Radiation: Florbetaben,"Incidence of Adverse events of a single dose of FBB followed by PET scan in individuals at risk of genetic Alzheimer?s disease.|Proportion of FAD mutation carriers that present positive uptake after FBB-PET through visual examination|Proportion of FAD mutation carriers presenting standardized uptake value ratios (SUVRs) of FBB-PET higher than 1,4.|Areas of significant difference (p<0,05) in regional SUVR between FAD mutation carriers and non-carriers.|Earliest age of positive FBB-PET in FAD mutation carriers.|Individual cortical areas with positive amyloid deposition at visual or semi-quantitative assessment",Judit Pich Martínez|Fundacion Clinic per a la Recerca Biomédica,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,FBB-FAD-2014,Feb-15,Jan-19,Jan-19,13-Feb-15,null,8-Feb-18,"Hospital Clínic de Barcelona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02362880
NCT02361242,24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion,PLEODIAL-II,Completed,No Results Available,Alzheimer Disease,Drug: PXT00864,Change from Baseline in the total score of the 11-items Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Number of Treatment Emergent Adverse Events (TEAEs),Pharnext SA|Ascopharm Groupe Novasco,All,"60 Years and older   (Adult, Older Adult)",Phase 2,45,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLN-PXT00864-04,Jun-13,Dec-15,Dec-15,11-Feb-15,null,15-Feb-16,"CMRR, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT02361242
NCT02361424,Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD),PLEODIAL-I,Completed,No Results Available,Alzheimer Disease,Drug: PXT00864|Drug: placebo,Change From Baseline in the total score of the 11-item Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Number of Treatment Emergent Adverse Events (TEAEs)|Change From Baseline in the score of the Digit Symbol Substitution Test (DSST)|Change From Baseline in the speed to perform the Zazzo's Cancellation Test|Change From Baseline in the score of the Zazzo's Cancellation Test|Change From Baseline in the score of the 15-second Isaacs Set Test|Change From Baseline in the time score of the Trail Making Test - part A|Change From Baseline in the time score of the Trail Making Test - part B|Change From Baseline in the score of the Free and Cued Selective Reminding Test (FCSRT)|Change From Baseline in the score of the 4-item Instrumental Activities of Daily Living scale (IADL-PAQUID)|Change From Baseline in the score of the Clinical Dementia Rating (CDR) scale|Change From Baseline in the score of the Apathy Inventory (AI) scale,Pharnext SA|Ascopharm Groupe Novasco,All,"60 Years and older   (Adult, Older Adult)",Phase 2,47,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",CLN-PXT00864-03,Feb-13,Jun-15,Jun-15,11-Feb-15,null,15-Feb-16,"CMRR, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT02361424
NCT02359552,Rasagiline Rescue in Alzheimer's Disease Clinical Trial,R2,Completed,No Results Available,Alzheimer's Disease,Drug: Rasagiline|Drug: Placebo,The primary study endpoint is the change from baseline to Week 24 in regional glucose metabolism as measured by standard uptake units regional (SUVR) obtained through the 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET).,The Cleveland Clinic,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,27,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",14-519,May-15,29-Aug-18,4-Jan-19,10-Feb-15,null,8-May-19,"Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Cleveland Clinic Main Campus, Cleveland, Ohio, United States|Cleveland Clinic Lakewood Hospital, Lakewood, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02359552
NCT02360657,Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia,,Completed,No Results Available,Alzheimer's Disease,"Drug: JNJ-54861911, 10 mg|Drug: JNJ-54861911, 50 mg|Drug: Placebo","Levels of Amyloid (A)-beta1-40 in Cerebrospinal Fluid (CSF) After Treatment at the Intended Target Dose Range|Levels of A-beta1-40 in Plasma After Treatment at the Intended Target Dose Range|Maximum Observed Plasma Concentration (Cmax) of JNJ 54861911|Minimum Observed Plasma Concentration (Cmin) of JNJ 54861911|Time to Reach Maximum Observed Concentration (Tmax) of JNJ 54861911|Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau)|Cerebrospinal Fluid Exposure of JNJ-54861911|The Number of Participants who Experienced Adverse Events as a Measure of Safety and Tolerability of JNJ-54861911 After Multiple-Dose Administration in the Anticipated Target Dose Range|Levels of A-beta Fragments (A-beta1-37, A-beta1-38, and A-beta1-42) in CSF After Treatment at the Intended Target Dose Range|Levels of A-beta Fragments (A-beta1-37, A-beta1-38, and A-beta1-42) in Plasma After Treatment at the Intended Target Dose Range|Levels of Soluble Amyloid Precursor Protein (APP) Fragments in CSF (sAPP-alpha, sAPP-beta, totalAPP) After Treatment at the Intended Target Dose Range|Compare the Relationship of A-beta1-40 Levels in Plasma and CSF After Treatment at the Intended Dose Range",Janssen Pharmaceutical K.K.,All,65 Years to 85 Years   (Older Adult),Phase 1,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR106397|54861911ALZ1008,16-Feb-15,8-Sep-15,8-Sep-15,10-Feb-15,null,4-Feb-19,"Fukuoka, Japan|Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02360657
NCT02356055,Mass Practice of Activities of Daily Living in Dementia (STOMP),STOMP,Completed,No Results Available,Dementia|Alzheimer's Disease,Behavioral: STOMP (Skill-building through Task-Oriented Motor Practice),5 point Observation of Activities of Daily Living|Frequency of Behavioral Responses during the Trial|10 point Caregiver Perception of Activity of Daily Living Performance and Satisfaction with Performance|Change in 10 point Caregiver Perception of Activity of Daily Living Performance and Satisfaction with Performance|Retention of 10 point Caregiver Perception of Activity of Daily Living Performance and Satisfaction with Performance|Change in Observation of Activity of Daily Living|Retention of Observed Activity of Daily Living at 90 Days,University of Oklahoma|VA Office of Research and Development|OU Medical Center|Oklahoma Shared Clinical and Translational Resources|Alzheimer's Association,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,32,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,4648,Oct-14,Nov-16,Nov-16,5-Feb-15,null,21-Nov-16,,,https://ClinicalTrials.gov/show/NCT02356055
NCT02353598,A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease,,"Active, not recruiting",No Results Available,Alzheimer Disease,Drug: Crenezumab dose level 1|Drug: Crenezumab dose level 2|Drug: Crenezumb dose level 3|Drug: Placebo,"Number of participants with anti-crenezumab antibodies|Number of participants with suicidal ideation, suicidal behavior, and self-injurious behavior without suicidal intent, as determined using the columbia-cuicide severity rating scale (C-SSRS)|Number of participants with changes from baseline in vital signs, electrocardiogram (ECG) and clinical laboratory results|Number of participants with amyloid-related imaging abnormalities-hemorrhage (ARIA-H)|Number of participants with adverse events (AEs) and serious adverse events (SAEs) according to national cancer institute common terminology criteria for adverse events, version 4.0 (NCICTCAE v4.0)|Number of participants with of non-serious AEs of special interest|Number of participants with amyloid-related imaging abnormalities-edema/effusion (ARIA-E)|Serum concentration of crenezumab","Genentech, Inc.",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,77,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29632,26-Feb-15,30-Nov-16,26-Mar-19,3-Feb-15,null,6-Mar-19,"Mayo Clinic Scottsdale, Phoenix, Arizona, United States|UCSF - Memory and Aging Center, San Francisco, California, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Bioclinica Orlando, Orlando, Florida, United States|Bioclinica The Villages, The Villages, Florida, United States|Indiana University School Of Medicine; Department Of Neurology, Indianapolis, Indiana, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|UNiversity of Rochester, Rochester, New York, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Roper St. Francis Healthcare; Clinical Biotechnology Research Institute, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT02353598
NCT02353949,Investigating the Clinical Consequences of Flutemetamol-PET-scanning,,Recruiting,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease|Dementia,Drug: Flutemetamol (Vizamyl),Change of ADAS-cog 11 score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.|Change of ADCS-ADL score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.|Change of ADCS-CGIC score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.|Change of MMSE score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.,University of Zurich,All,"Child, Adult, Older Adult",Phase 3,110,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Flutemetamol 2,May-15,30-Sep-19,31-Dec-19,3-Feb-15,null,31-May-18,"University of Zurich, Institute for Regenerative Medicine, Center for Prevention and Dementia Therapy, Schlieren, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT02353949
NCT02350634,18F-AV-1451 High Resolution Autopsy Study,,Completed,No Results Available,Alzheimer's Disease,Drug: 18F-AV-1451,Relationship of 18F-AV-1451 scan and pathology,Avid Radiopharmaceuticals,All,"60 Years to 89 Years   (Adult, Older Adult)",Phase 1,3,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-1451-A13,Jun-15,18-May-18,18-May-18,30-Jan-15,null,24-Oct-18,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02350634
NCT02351388,Transcranial Direct Current Stimulation for Depression in Alzheimer's Disease Patient - Preliminary Research,ADAPT,Unknown status,No Results Available,Alzheimer Disease|Depression,Device: Transcranial Direct Current Stimulation|Other: Sham Stimulation,Attrition rate due to any adverse event|Rate of adverse events related to tDCS procedure|Geriatric Depression Scale|Cornell Scale for Depression in Dementia|Neuropsychiatric Inventory|Zarit Burden Interview|Clinical Global Impression of Improvement|Starkstein Apathy Scale,"National Center of Neurology and Psychiatry, Japan",All,65 Years to 90 Years   (Older Adult),Phase 1|Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2014-086,Dec-14,Dec-17,null,30-Jan-15,null,4-Jan-17,"National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02351388
NCT02351882,Safety and Efficacy of Nabilone in Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease|Agitation|Weight Loss|Pain|Oxidative Stress,Drug: Nabilone|Drug: Placebo,Change in agitation; Cohen-Mansfield Agitation Inventory (CMAI)|Change in neuropsychiatric symptoms; Neuropsychiatric Inventory (NPI)|Change in cognition; Standardized Mini-mental State Examination (sMMSE)|Change in cognition; Severe Impairment Battery (SIB)|Change in cognition; Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)|Change in clinical representation; Alzheimer's Disease Cooperative Study - The Clinician Global Impression (ADCS - CGIC),Sunnybrook Health Sciences Centre,All,"55 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,38,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",318-2013,Jan-15,Jan-18,Mar-19,30-Jan-15,null,10-Apr-19,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02351882
NCT02350127,Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia,PLIE-VA,Completed,No Results Available,Dementia|Alzheimer's Disease,Behavioral: Preventing Loss of Independence through Exercise (PLIE)|Behavioral: Usual Care Control,Short Physical Performance Battery (SPPB)-modified|Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)|Quality of Life Scale in Alzheimer's Disease (QOL-AD)|Disability Assessment for Dementia (DAD)|Geriatric Depression Scale (GDS)|Falls Efficacy Scale (FES)|Caregiver Burden Inventory (CBI)|Neuropsychiatric Inventory (NPI)|Positive Aspects of Caregiving (PAC),"VA Office of Research and Development|Marin Adult Day Health Center, Novato, CA|Institute on Aging, San Francisco, CA|Catholic Charities, Santa Rosa, CA|Alzheimer's Services of the East Bay|Bayview Hunters Point Adult Day Health Center|Primrose Alzheimer’s Living, Inc",All,"Child, Adult, Older Adult",Phase 2|Phase 3,88,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,D1507-I|5I01RX001507-02,4-May-15,13-Dec-18,31-Dec-18,29-Jan-15,null,31-Jan-19,"San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02350127
NCT02349191,Omental Transposition Surgery for Mild Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease,Procedure: Omental transposition for mild Alzheimers disease,Incidence of surgical complications from beginning of anesthesia to discharge from Intensive Care Unit.|Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 12 months.|Change in Montreal Cognitive Assessment (MoCA) score from baseline at 12 months|Change in General Practitioner Assessment of Cognition (GPCOG) score from baseline at 12 months|Change in Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) score from baseline at 12 months|Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 24 months|Change in Montreal Cognitive Assessment (MoCA) score from baseline at 24 months|Change in General Practitioner Assessment of Cognition (GPCOG) score from baseline at 24 months|Change in Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) score from baseline at 24 months,"Bariatric Medicine Institute, Salt Lake City, UT",All,65 Years to 85 Years   (Older Adult),Not Applicable,25,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Cottam - 1,Mar-16,Apr-17,May-19,28-Jan-15,null,22-Mar-16,,,https://ClinicalTrials.gov/show/NCT02349191
NCT02347202,Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention,,Recruiting,No Results Available,Alzheimer's Disease|Dementia,Other: Online counseling via Zoom teleconferencing|Other: Telephone support as needed,"Differences in depressive symptoms between groups (One-way analysis of variance, questionnaire)|Differences in reactions to problem behaviors between groups (questionnaire)|Differences in satisfaction with social support between groups (questionnaire)",New York University School of Medicine,All,"21 Years to 125 Years   (Adult, Older Adult)",Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,14-01185,Oct-15,Sep-19,Sep-19,27-Jan-15,null,29-Jan-19,"NYU School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02347202
NCT02346201,Apathy in Dementia Methylphenidate Trial 2,ADMET2,Recruiting,No Results Available,Apathy|Alzheimer's Disease,Drug: Methylphenidate|Drug: Placebo,Neuropsychiatric Inventory (NPI)|Clinical Global Impression of Change (CGIC),Johns Hopkins Bloomberg School of Public Health|National Institute on Aging (NIA),All,"Child, Adult, Older Adult",Phase 3,200,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADMET2|R01AG046543,Jan-16,Dec-19,Jun-20,26-Jan-15,null,1-Apr-19,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of Arkansas, Little Rock, Arkansas, United States|Yale Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Emory, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Rochester, Rochester, New York, United States|Wake Forest, Winston-Salem, North Carolina, United States|University Hospitals- Case Medical Center, Cleveland, Ohio, United States|Roper-St. Francis Healthcare, Charleston, South Carolina, United States|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02346201
NCT02343757,Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid,,Unknown status,No Results Available,Dementia|Alzheimer Disease,Device: PET/MRI,"To assess image quality and diagnostic performance of 18F-florbetapir (AMYVID) PET/MRI, including direct comparison to corresponding PET/CT images of the same patients.|To evaluate the incremental value of using 18F-florbetapir (AMYVID) in addition to 2-[F-18]-fluoro-2 deoxy-D-glucose (FDG) versus FDG alone.|To determine plaque burden quantitatively with 18F-florbetapir (AMYVID) in PET (form PET/CT and from PET/MR) using novel software developed specifically for these brain application;",University Hospitals Cleveland Medical Center,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,12/12/2013,Oct-13,Dec-16,Dec-16,22-Jan-15,null,22-Jan-15,"University Hospital Case Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02343757
NCT02340195,Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function,,Completed,No Results Available,Alzheimer Disease,Drug: Idalopirdine (Lu AE58054) 60 mg,Area under the LuAE58054 plasma concentration-time curve from time zero to 24h(AUC0-24)|Maximum observed concentration (Cmax) of Lu AE58054,H. Lundbeck A/S,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 1,16,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14916A|2012-005647-25,Jan-15,Sep-15,null,16-Jan-15,null,9-Nov-15,"DE801, Munchen, Germany",,https://ClinicalTrials.gov/show/NCT02340195
NCT02337907,BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,,Completed,Has Results,Alzheimer Disease,Drug: Placebo|Drug: BI 409306|Drug: Donepezil,"Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment.|Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Sister Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907)|Change From Baseline in Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Total Score After 12-week Treatment|Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment|Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment",Boehringer Ingelheim,All,"55 Years and older   (Adult, Older Adult)",Phase 2,329,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1289.7|2013-005040-28,21-Jan-15,15-Sep-17,10-Oct-17,14-Jan-15,14-Nov-18,14-Nov-18,"California Neuroscience Research, Sherman Oaks, California, United States|Bioclinica Research, Orlando, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Psychiatry And Alzheimer's Care of Rochester, PLLC, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|ANI Neurology, PLLC, dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|The Memory Clinic, Bennington, Vermont, United States|Private Practice for Psychiatry and Neurology, Wien, Austria|Brussels-UNIV Brugmann -Horta, Brussel, Belgium|AZ Sint-Blasius, Dendermonde, Belgium|UNIV UZ Gent, Gent, Belgium|Mons - UNIV Ambroise Paré, Mons, Belgium|University of Calgary, Calgary, Alberta, Canada|Dr. Alexander McIntyre Inc., Penticton, British Columbia, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada|Institut universitaire de geriatrie Sherbrooke, Quebec, Canada|HOP Pellegrin, Bordeaux, France|HOP Bocage, Dijon, France|HOP Timone, Marseille, France|HOP Gui de Chauliac, Montpellier, France|HOP Nord Laënnec, Nantes, France|HOP La Pitié Salpêtrière, Paris, France|HOP Jean Bernard, Géria, Poitiers, Poitiers, France|Praxis Dr. med. Volker Schumann, Berlin, Germany|emovis GmbH, Berlin, Germany|St. Josef- und St. Elisabeth-Hospital gGmbH, Bochum, Germany|Neuro Centrum Science GmbH, Erbach, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Zentralinstitut für seelische Gesundheit, Mannheim, Germany|Universitätsklinikum Ulm, Ulm, Germany|Neurologie und Psychiatrie / Psychotherapie, Westerstede, Germany|P.O. Bellaria IRCCS Istituto delle scienze Neurologiche di Bologna, Bologna, Italy|Azienda Ospedaliera Careggi, Firenze, Italy|Azienda Ospedaliera di Parma, Parma, Italy|Jeroen Bosch Ziekenhuis-Hertogenbosch, 's-HERTOGENBOSCH, Netherlands|Brain Research Center, Amsterdam, Netherlands|Podlassian Center of Psychogeriatry, Bialystok, Bialystok, Poland|Mental Health Center Biomed, Kielce, Poland|Non-Public Outpatient Clinic Neuromed M. i M. Nastaj, Lublin, Poland|Inst. of Rural Health, Spec. Outp. Clin. & Rural Occup. Dis., Lublin, Poland|Non-Public Outpatient Clinic Neuro-Kard Ilkowski & Partners, Poznan, Poland|Medical Center Senior, Sopot, Poland|EUROMEDIS Sp. z o.o., Szczecin, Szczecin, Poland|Reg. Specialist Hospital Wroclaw, Research & Develop. Center, Wroclaw, Poland|Hospital Fernando Fonseca, EPE, Amadora, Portugal|Hospital de Braga-Escala Braga, Braga, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|Hospital Senhora Oliveira Guimarães,EPE, Guimarães, Portugal|CHLO, EPE - Hospital Egas Moniz, Lisboa, Portugal|Hospital Beatriz Ângelo, Loures, Portugal|ULSM, EPE - Hospital Pedro Hispano, Matosinhos, Portugal|Centro Hospitalar de Entre o Douro e Vouga, E.P.E. - Hospital de São Sebastião, Santa Maria da Feira, Portugal|Royal United Hospital, Bath, United Kingdom|Ninewells Hospital & Medical School, Dundee, Scotland, United Kingdom|West Devon (Tavistock) CMHT & Memory Clinic (EDI), Ivybridge, United Kingdom|Re-Cognition Health, Plymouth, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02337907/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02337907/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02337907
NCT02336360,Augmenting 18F-AV-1451 Dosimetry Estimates,,Completed,No Results Available,Alzheimer's Disease,Drug: 18F-AV-1451,Urine Analysis - Total integrated radioactivity excreted in urine,Avid Radiopharmaceuticals,All,"Child, Adult, Older Adult",Phase 1,6,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-1451-A15,Jan-15,Jun-15,Jun-15,13-Jan-15,null,25-Jan-16,"Molecular NeuroImaging, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02336360
NCT02331784,Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease,PACR-AD,Completed,No Results Available,"Older Adults, Aging Brain",Behavioral: Computerized Plasticity-based Software|Behavioral: Commercially available Video Game,Changes in performance on global cognitive composite score|Changes in brain function|Changes in brain structure|Changes in task-related brain activation|Changes in performance on memory composite score|Changes in performance on executive function composite score|Changes in performance on processing speed composite score,Posit Science Corporation|University of Iowa,All,65 Years to 79 Years   (Older Adult),Not Applicable,68,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",PSC-PACR-AD-01,Apr-15,20-Apr-17,20-Apr-17,6-Jan-15,null,19-Apr-19,"University of Iowa, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT02331784
NCT02327182,Safety Study of MT-4666 in Subjects With Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: MT-4666,"Safety of 2 fixed doses of EVP-6124 in subjects with Alzheimer's disease. Criteria for evaluation include: adverse events, clinical laboratory tests, vital signs, body weight, 12-lead ECG, Columbia Suicide Severity Rating Scale (C-SSRS)|Change in Mini Mental State Examination (MMSE)|Change in Neuropsychiatric Inventory (NPI) total score",Mitsubishi Tanabe Pharma Corporation,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,117,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P211-05,Dec-14,Sep-15,Oct-15,30-Dec-14,null,13-Nov-15,"Investigational site, Osaka, Kansai, Japan",,https://ClinicalTrials.gov/show/NCT02327182
NCT02323217,I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers,I2PETHV,Completed,No Results Available,Healthy Volunteers|Alzheimer Disease|Molecular Imaging,Radiation: [11C]BU99008|Drug: Idazoxan|Drug: Isocarboxazid,"Density and distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP)|Intra- and Inter-Subject Variability in brain expression of Imidazoline 2 binding sites, measured using coefficient of variability (%COV), determined from either Total Volume of Distribution (VT) or Binding Potential (BP).|Peripheral distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP)",Imperial College London|GlaxoSmithKline,Male,"40 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,20,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14HH2250|MR/L01307X/1,Jan-15,Feb-16,Jul-16,23-Dec-14,null,18-Aug-16,"Centre for Neuropsychopharmacology; Division of Brain Sciences; Imperial College London; Burlington Danes Building; Hammersmith Hospital campus; 160 Du Cane Road, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02323217
NCT02323334,A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease,,Completed,No Results Available,Healthy Volunteers|Alzheimer Disease,"Drug: LY3202626|Drug: Placebo (Part A, B, C)|Drug: Itraconazole",Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3202626|Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3202626|Pharmacodynamic Biomarker: Plasma Minimum Amyloid-Beta Peptide (A-beta) 1-40 Concentration|Pharmacodynamic Biomarker: Cerebrospinal Fluid (CSF) Minimum Amyloid-beta Peptide (A-beta) 1-40 Concentration|Pharmacokinetics (PK): Cerebrospinal fluid (CSF) Concentration of LY3202626|Pharmacodynamic Biomarker: Change in Cerebrospinal Fluid (CSF) Amyloid-beta Peptide (A-beta) 1-40 Concentration,Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 1,136,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",15562|I7X-EW-LLCA,Dec-14,Feb-16,Feb-16,23-Dec-14,null,26-Feb-16,"California Clinical Trials Medical Group, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT02323334
NCT02322021,Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease,,"Active, not recruiting",No Results Available,"Alzheimer Disease|Dementia, Alzheimer Type",Drug: Elenbecestat (E2609)|Drug: Placebo,"Number of treatment emergent adverse event (TEAEs) and serious adverse events (SAEs)|Percentage change from baseline in cerebrospinal fluid (CSF) Abeta(1-x) and Abeta(1-42) after 4 weeks and 18 months of treatment in MCI/Prodromal participants and mild to moderate AD participants|Mean plasma concentration of elenbecestat, including the effect of intrinsic and extrinsic factors [including N-acetyltransferase 2 (NAT2) phenotype]|Mean CSF concentration of elenbecestat, including the effect of intrinsic and extrinsic factors [including N-acetyltransferase 2 (NAT2) phenotype]",Eisai Inc.|Biogen,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,71,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E2609-G000-202,26-Nov-14,27-Mar-18,31-Jul-22,22-Dec-14,null,4-Mar-19,"CITrials, Bellflower, California, United States|ATP Clinical Research, Costa Mesa, California, United States|Behavioral Research Specialists, Glendale, California, United States|Nervepro Research, Irvine, California, United States|JEM Research Institute, Atlantis, Florida, United States|Aventura Neurologic Associates, Aventura, Florida, United States|Elite Research and Clinical Trials LLC, Aventura, Florida, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton Inc, Boca Raton, Florida, United States|Bradenton Research Center Inc, Bradenton, Florida, United States|Quantum Labs Inc, Deerfield Beach, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|Alzheimers Research and Treatment Center, Lake Worth, Florida, United States|Compass Research, LLC, Melbourne, Florida, United States|Miami Jewish Health Systems Inc, Miami, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|Meridien Research, Spring Hill, Florida, United States|Neurology Clinical Research, Inc., Sunrise, Florida, United States|Infinity Clinical Research, Sunrise, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Neurostudies Inc, Decatur, Georgia, United States|RTR Medical Group LLC, Savannah, Georgia, United States|Southeastern Georgia Geriatrics, Savannah, Georgia, United States|Georgia Neurology and Sleep Medicine Associates, Suwanee, Georgia, United States|Heartland Research Associates LLC, Wichita, Kansas, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|Precise Research Centers, Flowood, Mississippi, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Cognitive Research Center of New Jersey, Springfield, New Jersey, United States|ANI Neurology, PLLC dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Ohio Clinical Research Partners LLC, Canton, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Alzheimers Research and Treatment Center, Willow Grove, Pennsylvania, United States|Abington Neurologic Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Coastal Neurology, Port Royal, South Carolina, United States|Neurology Consultants of Dallas, PA, Dallas, Texas, United States|Clinical Trials of Texas Incorporated, San Antonio, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Quorum Review, Inc., Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02322021
NCT02319681,"Reminiscence, Anxiety and Early Alzheimer's Disease",,Withdrawn,No Results Available,Alzheimer's Disease,Behavioral: Simple Reminiscence (SR)|Behavioral: Attention Control (AC),Acceptability of SR and AC|Number of times AC was used|Number of times SR was used|Change in Beck Depression Inventory-II (BDI-II) scale|Change in State-Trait Anxiety Inventory (STAI) scale|Change in Katz Instrumental Activities of Daily Living (IADL) scale|Change in Well-Being Picture Scale (WBPS) scale|Change in Short Psychological Well-Being Scale (SPWBS) scale|Change in Revised Memory and Behavior Problems Checklist (RMBPC) scale|Caregiver's mastery of SR intervention technique|Change in levels of cortisol,Emory University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB00075912,Jan-15,Dec-16,Jun-17,18-Dec-14,null,26-Jun-15,"Emory Alzheimer's Disease Research Center, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02319681
NCT02317523,Alzheimer's Caregiver Coping: Mental and Physical Health,,Recruiting,No Results Available,Alzheimer Disease|Alzheimer Dementia|Alzheimer's Disease|Dementia,Behavioral: Behavioral Activation|Behavioral: Information and Support,Endothelium-dependent Flow Mediated Dilation (FMD)|Center for Epidemiologic Studies - Depression (CES-D) scale|Interleukin-6|Baroreflex Sensitivity (BRS)|Arterial Compliance (AC)|Carotid Intima Media Thickness (IMT)|D-dimer|C-reactive Protein (CRP)|Tumor Necrosis Factor (TNF)- alpha|Plasminogen Activator Inhibitor (PAI)-1|von Willebrand Factor (vWF),"University of California, San Diego|National Institute on Aging (NIA)",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,200,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,BMausbach|RF1AG015301,Sep-14,Aug-19,Aug-19,16-Dec-14,null,1-Nov-18,"University of California San Diego, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT02317523
NCT02309723,Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.,,Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Device: Beta amyloid imaging,Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss|Likelihood of Recommending a Medication Indicated for Alzheimer's Disease|Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures,Tufts Medical Center|GE Healthcare,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,315,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CEVR-2013-001,Sep-13,Sep-13,Nov-13,5-Dec-14,10-Apr-17,10-Apr-17,"Tufts Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02309723
NCT02305836,Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease,,Recruiting,No Results Available,Cognitive Impairment,Procedure: acupuncture|Drug: donepezil,change of total ADAS-cog score from baseline|change of total MMSE score from baseline|change of total ADCS-ADL score score from baseline|change of total QoL-AD score score from baseline,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,334,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014S291,Jun-17,Jun-19,Dec-19,3-Dec-14,null,16-May-17,"Guang'an Men Hospotal Affiliated to China Academy of Chinese Medical Sciences, Beijing, China",,https://ClinicalTrials.gov/show/NCT02305836
NCT02302482,Predictive Factors and Autonomy Level Change,MEMORA,Recruiting,No Results Available,Memory Impairment,"Other: The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6",Functional autonomy level|Cognitive function level,Hospices Civils de Lyon,All,65 Years and older   (Older Adult),Not Applicable,6780,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2014.868,Nov-14,Nov-23,Nov-23,27-Nov-14,null,23-May-17,"Hôpital Dugoujon, Caluire-et-Cuire, France|Hospices Civils de Lyon - Hôpital des Charpennes, Lyon, France",,https://ClinicalTrials.gov/show/NCT02302482
NCT02300584,"Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program",,Completed,No Results Available,Dementia|Alzheimer's Disease|Depression,Behavioral: Tele-Savvy|Other: iPad,The number of participants who use at least half of the opportunities (half of the conferences and half of the daily lessons)|Change in Zarit Burden Interview Score|Change in Center for Epidemiological Studies-Depression Scale Score|Change in State Trait Anxiety Index (STAI) Score|Change in Connor Davidson Resilience Scale (CD-RISC)|Change in Perceived Stress Scale|Change in Caregiver Self-Efficacy Score|Change in Personal Mastery scale|Change in Revised Memory and Behavior Problem Checklist|Change in Lawton Activities of Daily Living (ADL) / Instrumental Activities of Daily Living (IADL) Scale,Emory University,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,42,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB00074715,Nov-14,Oct-15,Oct-15,25-Nov-14,null,8-Sep-16,"Emory Alzheimer's Disease Research Center, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02300584
NCT02299154,Memory Problems Perceptions Among Patients and Accompaniers During Diagnosis Process :,REMAD,Unknown status,No Results Available,Memory Disorders|Alzheimer Disease,Behavioral: Psychological questionnaires,"Memory problems perceptions of patients and next of kin during diagnosis process|Psychometric properties of the french adaptation of the Ilness Perceptions Questionnaire - Memory (IPQ-M, Hurt et al. 2010)|Impact of the memory problems perceptions on mood and well-being|Differences of memory problems perceptions and coping according to level of cognitive disorder at the Mini-Mental State Examination (MMSE)","Central Hospital, Nancy, France|Union des associations France Alzheimer et maladies apparentées, France|Laboratoire APEMAC :Maladies chroniques, santé perçue, processus d adaptation, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2014-A00156-41,Dec-14,Nov-17,Nov-17,24-Nov-14,null,8-Mar-16,"University Hospital of Nancy ,CHU Brabois, France, Vandoeuvre les Nancy, France",,https://ClinicalTrials.gov/show/NCT02299154
NCT02293915,An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease,,Completed,No Results Available,Mild to Moderate Alzheimer Disease|Cognitive Impairment,Drug: Sodium oligo-mannurarate 900mg|Drug: Placebo,Improvement of Alzheimer's Disease Assessment Scale-cognitive subscale(ADAS-cog)/12 of sodium oligo-mannurarate capsule|Improvement of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) of sodium oligo-mannurarate capsule|Improvement of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) of sodium oligo-mannurarate capsule|Improvement of Neuropsychiatric Inventory(NPI) of sodium oligo-mannurarate capsule|Glucose metabolism of bilateral temporoparietal cortex,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,818,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",971-III,1-Apr-14,29-Jun-18,28-Sep-18,19-Nov-14,null,10-Oct-18,"Beijing, Beijing, Beijing, China|Chongqing, Chongqing, Chongqing, China|Fujian, Fuzhou, Fujian, China|Guangzhou, Guangzhou, Guangdong, China|Wuhan, Wuhan, Hubei, China|Changsha, Changsha, Hunan, China|Nanjing, Nanjing, Jiangsu, China|Suzhou, Suzhou, Jiangsu, China|Yangzhou, Yangzhou, Jiangsu, China|Jinan, Jinan, Shandong, China|Shanghai, Shanghai, Shanghai, China|Xi'an, Xi'an, Shanxi, China|Sichuan, Chengdu, Sichuan, China|Tianjin, Tianjin, Tianjin, China|Hangzhou, Hangzhou, Zhejiang, China|Wenzhou, Wenzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT02293915
NCT02292238,Benfotiamine in Alzheimer's Disease: A Pilot Study,Benfotiamine,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: Benfotiamine,ADAS-cog as the primary clinical outcome|Brain glucose utilization|Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Neuropsychiatric Inventory (NPI).|Clinical Dementia Rating Scale (CDR).|Buschke Selective Reminding Test (SRT).,Burke Medical Research Institute|Burke Rehabilitation Hospital|Columbia University|National Institute on Aging (NIA)|Alzheimer’s Drug Discovery Foundation|Montefiore-Albert Einstein College of Medicine,All,"60 Years and older   (Adult, Older Adult)",Phase 2,76,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BRC-451|1R01AG043679-01A1,Nov-14,Nov-19,Nov-19,17-Nov-14,null,28-Feb-19,"Burke, White Plains, New York, United States",,https://ClinicalTrials.gov/show/NCT02292238
NCT02290912,Gray Matters Alzheimer's Disease Prevention Intervention,,Completed,No Results Available,Alzheimer's Disease,Behavioral: Health education program,Picture Vocabulary|Flanker Inhibitory Control and Attention Test|List Sorting Working Memory Test|Oral Symbol Digit Test|Montreal Cognitive Assessment|Rey Auditory Verbal Learning Test|Controlled Oral Word Association Test|Blood pressure|Body mass index|Insulin|Systemic inflammation|Skin carotenoid status|Triglycerides|HDL Cholesterol|LDL Cholesterol|Total cholesterol|Depression|Motivation|Sleep Quality|Stress|Emotional Support|Friendship|Hostility|Loneliness|Physical Activity - Moderate|Physical Activity - Vigorous|Nutrition|Readiness for Change|Metacognition,Utah State University,All,40 Years to 64 Years   (Adult),Not Applicable,146,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,5606,Apr-14,Dec-14,Dec-14,14-Nov-14,null,3-Dec-15,,,https://ClinicalTrials.gov/show/NCT02290912
NCT02291783,"Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment",,Completed,No Results Available,Alzheimer's Disease,Drug: HTL0009936|Drug: HTL0009936 placebo,"Number of participants with Adverse Events, as a measure of safety and tolerability|Changes in Safety Lab parameters as a measure of safety and tolerability|Changes in vital signs as a measure of safety and tolerability|Changes in 12-lead electrocardiograms as a measure of safety and tolerability|Pharmacokinetic measures in plasma as measured by Peak plasma concentration (Cmax)|Pharmacokinetic measures in cerebro spinal fluid (CSF) in young males as measured by max observed CSF (Cmax CSF)|Pharmacokinetic measures to assess the food effect as measured by ANOVA|Pharmacodynamic response as measured by pupillometry|Pharmacokinetic measures in urine in young males and elderly male and female subjects as measured by amount of urine excreted at collection intervals|Pharmacodynamic response as measured by Bond and Lader visual analogue scale|Pharmacodynamic response as measured by changes in qEEG and Event Related Potentials (ERP)",Heptares Therapeutics Limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1,108,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",9936-101|2013-002307-34,Nov-13,Jul-14,Jul-14,14-Nov-14,null,20-Jun-17,"Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom",,https://ClinicalTrials.gov/show/NCT02291783
NCT02288000,Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases,WP3_P002,Recruiting,No Results Available,Alzheimer Disease|Battery,Drug: Memantine|Drug: Placebo,Pharmacog battery,"University Hospital, Lille",Male,18 Years to 30 Years   (Adult),Phase 1,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2012_55|2013-001671-21,14-Sep-16,Jan-19,Feb-19,11-Nov-14,null,24-Apr-18,"CHRU de Lille/ Centre d'investigation Clinique, Lille, France|CIC Marseille, Marseille, France|CIC Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02288000
NCT02284906,AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease,,Terminated,No Results Available,Mild Cognitive Impairment Due to Alzheimer's Disease,Drug: Pioglitazone|Drug: Placebo,Change from Extension Study Baseline in Composite Score of a Broad Cognitive Test Battery|Time to Diagnosis of Alzheimer's Disease (AD) Dementia,Takeda,All,65 Years and older   (Older Adult),Phase 3,40,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AD-4833/TOMM40_303|U1111-1154-9637|2013-004984-30,17-Nov-14,8-May-18,8-May-18,6-Nov-14,null,21-May-18,"Phoenix, Arizona, United States|Sun City, Arizona, United States|San Diego, California, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Lake Worth, Florida, United States|Melbourne, Florida, United States|Merritt Island, Florida, United States|Port Orange, Florida, United States|Saint Petersburg, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Elk Grove, Illinois, United States|Iowa City, Iowa, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Marlton, New Jersey, United States|New York, New York, United States|Concord, North Carolina, United States|Durham, North Carolina, United States|Akron, Ohio, United States|Charleston, South Carolina, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Middleton, Wisconsin, United States|North Ryde, New South Wales, Australia|Southport, Queensland, Australia|Heidelberg West, Victoria, Australia|Nedlands, Western Australia, Australia|Basel, Switzerland|Bristol, Avon, United Kingdom|Exeter, Devon, United Kingdom|Plymouth, Devon, United Kingdom|Hammersmith, Greater London, United Kingdom|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Blackpool, Lancashire, United Kingdom|Isleworth, Middlesex, United Kingdom|Glasgow, Strathclyde, United Kingdom|Perth, Tayside Region, United Kingdom",,https://ClinicalTrials.gov/show/NCT02284906
NCT02279511,ATP in Alzheimer Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: ADENOSINE TRIPHOSPHATE|Drug: PLACEBO,Detection of brain metabolic changes after ATP infusion by spectroscopy techniques (H + MRS)|Changes in Cogstate results|Changes in test Mini-Mental State Examination|Changes in synaptic activity after treatment administration Neurological examination|Electrocardiogram results|adverse events,Sara Varea|Fundacion Clinic per a la Recerca Biomédica,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",ECA4A,Dec-14,Feb-16,Feb-16,31-Oct-14,null,29-Mar-17,"Fundació ACE, Barcelona, Spain|Hospital Sanitas CIMA, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02279511
NCT02278354,Tau Imaging in Professional Fighters,,Completed,No Results Available,Alzheimer's Disease,Drug: 18F-AV-1451,18F-AV-1451 Uptake,Avid Radiopharmaceuticals|The Cleveland Clinic,Male,"18 Years and older   (Adult, Older Adult)",Phase 1,30,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-1451-A11,Dec-14,3-Feb-17,3-Feb-17,30-Oct-14,null,14-Apr-17,"Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States",,https://ClinicalTrials.gov/show/NCT02278354
NCT02278367,Clinical Evaluation of 18F-AV-1451,,Recruiting,No Results Available,Alzheimer's Disease|Traumatic Brain Injury|Depression,Drug: 18F-AV-1451,Safety Assessment: Adverse event frequency related to 18F-AV-1451 administration|Efficacy Assessment: 18F-AV-1451 standard uptake value ratios (SUVRs),Avid Radiopharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,250,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-1451-A14,Dec-14,Apr-19,Apr-19,30-Oct-14,null,9-Jan-19,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Yale University, New Haven, Connecticut, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Center for Vital Longevity at the University of Texas at Dallas, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02278367
NCT02273895,"The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study",,Completed,No Results Available,AD,Drug: Scopolamine,Changes in EEG as a result of scopolamine administration,Mentis Cura|Landspitali University Hospital,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,29,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,MC-CT-001,Apr-04,Oct-04,Jan-10,24-Oct-14,null,24-Oct-14,,,https://ClinicalTrials.gov/show/NCT02273895
NCT02271685,Sound Estimation and Accuracy Task,,Completed,No Results Available,Parkinson's|Alzheimer Disease,Other: Instructions about Overestimates|Other: Instructions about Parkinson's|Other: Instructions about Underestimates|Other: Instructions about Alzheimers,Time Estimate|Time Generation|Perceived Risk of Disease,Carnegie Mellon University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Screening,HS14-553,Feb-15,May-15,May-15,22-Oct-14,null,21-May-15,"Carnegie Mellon University, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02271685
NCT02267057,Efficacy of Pain Treatment on Depression in Patients With Dementia,DEP-PAIN-DEM,Completed,No Results Available,Depression|Pain|Dementia,Drug: Paracetamol|Drug: Buprenorphine|Drug: Paracetamol placebo|Drug: Buprenorphine placebo,Change in the Cornell Scale for Depression in Dementia (CSDD)|Change in actigraphy recorded sleep patterns and circadian rhythm|Change in the Neuropsychiatric Inventory - Nursing Home Version (NPI-NH)|Change in the Mini-Mental State Examination (MMSE)|Change in the Mobilization- Observation - Behavior - Intensity - Dementia-2 (MOBID-2) Pain Scale|Change in the Numerical Rating Scale (NRS)|Change in the Quality of life in late-stage dementia (QUALID) scale|Change in the EuroQoL Quality of Life Scale (EQ-5D)|Adverse events (AE) and serious adverse event (SAE),University of Bergen,All,"60 Years and older   (Adult, Older Adult)",Phase 4,163,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NFR project nr 221951|2013-002226-23,Aug-14,21-Dec-16,21-Dec-16,17-Oct-14,null,4-Apr-17,"University of Bergen, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT02267057
NCT02265757,Behavioral Interventions to Prevent or Delay Dementia,,Completed,No Results Available,Mild Cognitive Impairment|Memory Disorders|Mild Dementia|Impaired Cognition|Mild Cognitive Disorder|Amnestic Disorder|Dementia and Amnestic Conditions|Poor Short-term Memory|Memory Impairment,Behavioral: Cognitive Rehabilitation|Behavioral: Computer Brain Fitness Training|Behavioral: Support Group (patient and partner)|Behavioral: Wellness Education|Behavioral: Physical Exercise,Improvement in patient quality of life|improvement in patient memory based everyday functioning|improvement in caregiver mood and sense of burden,Mayo Clinic|Patient-Centered Outcomes Research Institute,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,272,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",14-000885,Jun-14,31-Mar-18,31-Mar-18,16-Oct-14,null,22-Feb-19,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02265757/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02265757
NCT02264899,MEMENTO-VAScular COmponents of Dementia,VASCOD,Recruiting,No Results Available,Alzheimer's Disease (AD)|Alzheimer's Disease (AD) Related Disorders,Other: in Memento-VASCOD,"Change in cognitive performances over|Progression to clinical dementia of Alzheimer's type according to standardized criteria|Change in CSF and blood amyloid biomarkers of AD|Change in brain atrophy and hippocampal volumes|Progression of small vessels disease markers (white matter lesions, lacunar infarcts, microbleeds)","University Hospital, Bordeaux|Ministry for Health and Solidarity, France",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,350,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,CHUBX 2012/32,4-Nov-14,Dec-20,Dec-20,15-Oct-14,null,28-Feb-18,"CHU d'Amiens, Amiens, France|CHU de Bordeaux - Pellegrin, Bordeaux, France|CHU de Dijon, Dijon, France|CHU de Lille, Lille, France|Hospices civils de Lyon, Lyon, France|AP-HM, Marseille, France|CHU de Montpellier, Montpellier, France|AP-HP - Hôpital BROCA, Paris, France|AP-HP - Hôpital LARIBOISIERE, Paris, France|CHU de Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT02264899
NCT02263235,In Vivo Alzheimer Proteomics,PROMARA,Unknown status,No Results Available,Probable Alzheimer Disease|Parkinson Disease|Neurological Disease Without Cognitive Degradation|Brain Trauma|Acute Hydrocephaly,"Biological: administration of stable isotope-labelled leucine-|Other: collection of CSF, blood, urine, saliva","C13 Leucine incorporation in Amyloid peptides (1-40, 1-42) at different time points (in %)|C13 Leucine incorporation in detectable peptides generated after trypsin digestion of biological fluids from patients (CSF, blood, urine, saliva) (in %)","University Hospital, Montpellier|Assistance Publique - Hôpitaux de Paris|University Hospital, Clermont-Ferrand|International Atomic Energy Agency",All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,110,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,8652,Jun-13,Jun-17,Jun-17,13-Oct-14,null,3-May-16,"Laboratoire de Biochimie et Protéomique Clinique, CHU Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02263235
NCT02263287,"LESCOD: ""Lewy Body Screening in Cognitive Disorders""",LESCOD,Terminated,No Results Available,Alzheimer Disease|Lewy Body Disease,Other: LeSCoD scale,Construct validity of the LeSCoD scale with a factorial analysis|Diagnostic validity of the Lescod scale by measuring the sensitivity and the specificity|Intergroup variance will be used to assess the quality of the patient denomination|Concurrent validity will be assessed by the measurement of the striatal dopaminergic depletion and its correlation with the Lescod score,Nantes University Hospital,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,133,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,RC14_0007,Oct-14,Aug-17,Aug-17,13-Oct-14,null,7-Dec-17,"Nantes University Hospital, Nantes, France",,https://ClinicalTrials.gov/show/NCT02263287
NCT02260167,"Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol",MIND,Unknown status,No Results Available,Alzheimer's Disease|Dementia,Other: A mix of natural treatments and medications,Montreal Cognitive Assessment (MoCA)|Mini Mental Status Exam (MMSE)|Alzheimer's Disease Assessment Scale- Activities of Daily Living (ADAS-ADL),Practitioners Alliance Network,All,"Child, Adult, Older Adult",Phase 2,46,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PAN-ALZ002,Sep-14,Dec-15,null,9-Oct-14,null,15-Oct-14,"PAN, Kailua Kona, Hawaii, United States",,https://ClinicalTrials.gov/show/NCT02260167
NCT02260674,A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,"Drug: JNJ-54861911, 10 milligram (mg)|Drug: JNJ-54861911, 50 mg|Drug: Placebo","Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Relationship Between Dose and Exposure of JNJ-54861911 With Safety|Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels and Soluble Amyloid Precursor Protein (sAPP) Fragments (sAPP-alpha, sAPP-beta), Total sAPP Levels|Percent Change From Baseline in Plasma ABeta 1-40 Levels and sAPP Fragments (sAPP-alpha, sAPP-beta), Total sAPP Levels|Relationship Between Changes in CSF and Plasma ABeta Species and sAPP Fragments With Safety|Maximum Plasma Concentration (Cmax) of JNJ-54861911|Time to Reach the Maximum Plasma or CSF concentration (Tmax)|Area Under the Plasma/CSF Concentration-time Curve From Time 0 to tau Hours Post Dosing (AUCtau)","Janssen Research & Development, LLC",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,114,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",CR105240|54861911ALZ2002|2014-002159-24,Nov-14,Jun-16,Jun-16,9-Oct-14,null,3-Mar-17,"Gent, Belgium|Hoboken, Belgium|Montpellier Cedex 5, France|Paris, France|Toulouse, France|Essen, Germany|Halle, Germany|Hamburg N/A, Germany|Homburg, Germany|Luebeck, Germany|Tübingen, Germany|Ulm, Germany|Amsterdam, Netherlands|Barcelona, Spain|Madrid, Spain|Terrasa Barcelona N/A, Spain|Valencia, Spain|Mölndal, Sweden|Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02260674
NCT02260700,"A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants",,Completed,No Results Available,Healthy,Drug: JNJ-54861911 (Treatment A)|Drug: JNJ-54861911 (Treatment B)|Drug: JNJ-54861911 (Treatment C),Maximum Plasma Concentration (Cmax) of JNJ-54861911|Time to Reach the Maximum Plasma Concentration (Tmax) of JNJ-54861911|Area Under the Plasma Concentration-Time Curve From 0 to t Hours (AUC[0-t]) Post Dose of JNJ-54861911|Area Under the Plasma Concentration-Time Curve From 0 to Infinite Time (AUC[0-infinity]) Post Dose of JNJ-54861911|Elimination Rate Constant (Lambda [z]) of JNJ-54861911|Terminal Half-life (t[1/2]) of JNJ-54861911|Relative Bioavailability (F[rel]) of JNJ-54861911|Rate of Absorption of JNJ-54861911|Extent of Absorption of JNJ-54861911|Number of Participants with Adverse Events (AEs) and Serious AEs,"Janssen Research & Development, LLC",Male,"55 Years to 75 Years   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR102380|54861911ALZ1003|2013-002650-70,Sep-13,Nov-13,Nov-13,9-Oct-14,null,9-Oct-14,"Merksem, Belgium",,https://ClinicalTrials.gov/show/NCT02260700
NCT02256306,The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study,PLASMA,Completed,No Results Available,Mild-To-Moderate Alzheimer's Disease|Alzheimer's Disease,Other: Plasma,"Number of participants with adverse events as a measure of safety and tolerability, and number of subjects who comply with the research protocol as a measure of feasibility.|Change on the 13-item ADAS-Cog|Change on the Trail-Making Test|Change on the Clinical Dementia Rating scale Sum of Boxes (CDR-SB)|Change on the Functional Activities Questionnaire (FAQ)|Change on the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)|Change on the Geriatric Depression Scale|Change on the Neuropsychiatric Inventory Questionnaire (NPI-Q)","Stanford University|Alkahest, Inc.",All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,18,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30350,Sep-14,Feb-17,Feb-17,3-Oct-14,null,10-Oct-17,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02256306
NCT02253043,The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease,"Device: Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)","Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog)|Clinical Dementia Rating Scale","Beijing Pins Medical Co., Ltd|Beijing Tiantan Hospital",All,"40 Years to 80 Years   (Adult, Older Adult)",Not Applicable,10,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PINS-002,May-14,Dec-18,Dec-18,1-Oct-14,null,14-Oct-16,"Beijing Tiantan Hospital, Beijing, Beijing, China|301 Hospatl, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT02253043
NCT02253732,Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs,Brain-Muscle,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer Disease|Parkinson Disease|Healthy Volunteers,Behavioral: 3 months exercise intervention program,muscle microRNAs and myokines|whole body energy metabolism|cognitive function|motoric function|Muscle functional tests,Slovak Academy of Sciences|University Hospital Bratislava,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UEE-SAS,Sep-15,Sep-17,Mar-18,1-Oct-14,null,17-Apr-18,"Univeristy Hospital in Bratislava, Bratislava, Slovakia|Inst. Exp. Endocrinology Slovak Acad Sci, Bratislava, Slovakia",,https://ClinicalTrials.gov/show/NCT02253732
NCT02248636,Cholinesterase Inhibitor Discontinuation,CID,Recruiting,No Results Available,Dementia,Drug: Cholinesterase inhibitor|Drug: Sham discontinuation,Successful completion|Medical events|Caregiver burden|Veteran cognition|Veteran functioning|Behavioral symptoms|Post-study treatment choice,VA Office of Research and Development,All,"60 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,100,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLIN-014-13F,22-Jan-15,1-Oct-19,1-Oct-19,25-Sep-14,null,20-Dec-18,"Boise VA Medical Center, Boise, ID, Boise, Idaho, United States|Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02248636
NCT02247180,Cognitive Rehabilitation in Alzheimer`s Disease,,Unknown status,No Results Available,Alzheimer's Disease,Behavioral: cognitive rehabilitation|Behavioral: standardized cognitive training,"Change from baseline in activities of daily living measured by a test for action regulation and planning skills (HOTAP) to the end of intervention and to follow-up (6 months later)|Change from baseline in activities of daily living measured by an ADL-scale (Bayer-ADL) to the end of intervention and to follow-up (6 months later)|Change from baseline in behavioural memory abilities measured by a behavioural memory test (RBMT) to the end of intervention and to follow-up (6 months later)|Change from baseline in general cognitive state measured by the Consortium to Establish a Registry for Alzheimer´s Disease (CERAD) to the end of intervention and to follow-up (6 months later)|Change from baseline in structural and functional connectivity of the brain measured by MRI to the end of intervention and to follow-up (6 months later)|Change from baseline in depression and quality of life measured by two scales (GDS, DEMQoL) to the end of intervention and to follow-up (6 months later)",University of Rostock|German Center for Neurodegenerative Diseases (DZNE),All,"Child, Adult, Older Adult",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,A 2014-0113,Sep-14,May-15,Dec-15,23-Sep-14,null,23-Sep-14,"Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany",,https://ClinicalTrials.gov/show/NCT02247180
NCT02245737,An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease,AMARANTH,Terminated,No Results Available,Alzheimer´s Disease,Drug: Lanabecestat|Drug: Placebo,Change from Baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)|Change from Baseline on the Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-iADL) Instrumental Items|Change from Baseline on the Functional Activities Questionnaire (FAQ) Score|Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score|Change from Baseline on the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score|Time in Clinical Dementia Rating (CDR) Global Score Stage|Change from Baseline in Neuropsychiatric Inventory (NPI) Score|Change from Baseline on the Mini-Mental Status Examination (MMSE)|Pharmacodynamics (PD): Change from Baseline in Concentration of Cerebrospinal Fluid (CSF) Biomarker Aβ1-42|PD: Change from Baseline in Concentration of CSF Biomarker Aβ1-40|Change from Baseline in CSF Total Tau|Change from Baseline in CSF Phosphorylated Tau|Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET)|Change From Baseline in Tau PET|Change From Baseline in PET Using Fluorine-18 Fluorodeoxyglucose (18F-FDG)|Change from Baseline in Whole Brain Volume|Population Pharmacokinetics (PK): Apparent Oral Clearance of Lanabecestat|Population PK: Central Volume of Distribution of Lanabecestat,Eli Lilly and Company|AstraZeneca,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,7255,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",16023|I8D-MC-AZES|2014-002601-38|D5010C00009,30-Sep-14,4-Oct-18,4-Oct-18,22-Sep-14,null,26-Oct-18,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Positron Research International, Fremont, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Collaborative Neuroscience Network - CNS, Long Beach, California, United States|Pacific Research Network Inc, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Mile High Research Center, Denver, Colorado, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Brain Matters Research, Delray Beach, Florida, United States|Direct Helpers Medical Center, Hialeah, Florida, United States|Berma Research, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|MaxBlue Institute, Hialeah, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Medical Research Center, Miami, Florida, United States|Allied Biomedical Research Institute, Inc., Miami, Florida, United States|Advance Medical Research Institute, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|JDH Medical Group, LLC, Miami, Florida, United States|Compass Research, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|Compass Research, The Villages, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|The Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, LLV, Saint Louis, Missouri, United States|St. Louis Clinical Trials, LC, Saint Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|AdvanceMed Research, Lawrenceville, New Jersey, United States|Alzheimer's Research Company, Manchester, New Jersey, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|SPRI Clinical Trials, LLC., Brooklyn, New York, United States|Alzheimer's Disease and Memory Disorders Center, Buffalo, New York, United States|Empire Neurology, PC, Latham, New York, United States|Clinilabs, Inc (New York), New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Radiant Research, Greer, South Carolina, United States|Quillen College of Medicine, East TN State University, Johnson City, Tennessee, United States|Senior Adults Specialty Research Inc, Austin, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Medical Group of Texas, Fort Worth, Texas, United States|University of Texas Health Services Center - Houston, Houston, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|Southern Neurology, Kogarah, New South Wales, Australia|Griffith University, Goldcoast, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Delmont Private Hospital, Glen Iris, Victoria, Australia|Heidelberg Repatriation Hospital, Heidelberg, Victoria, Australia|The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|Neuro Trials Victoria Pty Ltd, Noble Park, Australia|Jessa Ziekenhuis, Hasselt, Limburg, Belgium|Hopital Universitaire Brugmann Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Hospital Universitaire Erasme Brussel, Brussel, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|Heilig Hartziekenhuis, Roeselare, Belgium|The Medical Arts Health Research Group, Kamloops, British Columbia, Canada|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|True North Clinical Research Halifax, LLC, Halifax, Nova Scotia, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|CSSS-Institut Universitaire Gériatric de Sherbrooke, Sherbrooke, Qubec, Canada|Clinique de la Memoire de l'Outaouais, Gatineau, Quebec, Canada|NeuroSearch Developements, Greenfield Park, Quebec, Canada|Hopital Maisonneure-Rosemount, Montreal, Quebec, Canada|Hopital de L'Enfant Jesus, Quebec City, Quebec, Canada|Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada|CHU de Toulouse Hopital Purpan, Toulouse, Cedex 9, France|Hopital Neuro Pierre Wertheimer, Bron Cedex, France|Chu de Nantes Hopital Laennec, Cedex 1, France|CHU Dijonon, Dijon Cedex, France|CHRU Lille - Hopital Roger Salengro, Lille Cedex, France|CHU Hopital de la Timone, Marseille Cedex 05, France|Hopital Broca, Paris, France|Hopital de la Pitie Salpetriere, Paris, France|Hopital Lariboisière, Paris, France|CHU de Toulouse, Toulouse, France|Hopital des Charpennes, Villeurbanne, France|Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany|Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Studien und Gedächtniszentrum München, München, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Institut fur Psychogerontologie, Nürnberg, Bayern, Germany|Neurozentrum Prien, Prien am Chiemsee, Bayern, Germany|Institut für Neuropsychiatrie INP3, Wenzenbach, Bayern, Germany|Studienzentrum Nord-West, Westerstede, Niedersachsen, Germany|Praxis Dr. Lauter, Bochum, Nordrhein-Westfalen, Germany|St Josef-Hospital Bochum, Bochum, Nordrhein-Westfalen, Germany|Universitätsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany|Gemeinschaftspraxis für Neurologie Prof. Gereon Nelles, Köln, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Neurologische Praxis Siegen, Siegen, Nordrhein-Westfalen, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Sachsen-Anhalt, Germany|Universitätsklinikum Otto-von-Guericke-Universität, Magdeburg, Sachsen-Anhalt, Germany|Pharmakologisches Studienzentrum Chemnitz, Mittweida, Sachsen, Germany|Arztpraxis Dr. Christian Oehlwein, Gera, Thüringen, Germany|Gemeinschaftspraxis Dr. R. Ehret & Dr. W. von Pannwitz, Berlin, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|PTE KK Pszichiatriai es Pszichoterapias Klinika, Pecs, Baranya, Hungary|Semmelweis Medical University, Budapest, Hungary|Del-pesti Centrumkorház - Orszagos Hematologiai és Infektologiai Intezet, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz, Debrecen, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Univerisity of Szeged, Szeged, Hungary|Ospedale Degli Infermi ASR USSL 12, Ponderano (BI), Biella, Italy|Azienda Ospedaliera San Gerardo, Monza, Milano, Italy|Fondazione San Raffaele Giglio di Cefalu, Cefalu, Palermo, Italy|Universita Di Pisa, Pisa, PI, Italy|Università Politecnica delle Marche Torrette, Ancona, Italy|IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy|Fondazione Universitaria degli Studi G D'Annunzio, Chieti, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Italy|Fondazione IRCCS Ca'Granda Ospedale Maggiore Policinico, Milano, Italy|Nuovo Ospedale Civile Sant'Agostino Estense, Modena, Italy|Policlinico Univ. Agostino Gemelli, Roma, Italy|Dip.to Med. Sperimentale -Polic.Umberto I -Univ. La Sapienza, Roma, Italy|Ospedale San Giovanni Calibita Fatebenefratelli, Roma, Italy|Policlinico Ospedale S. Andrea, Roma, Italy|Azienda Ospedaliera Citta della Salute della Scienza Torino, Torino, Italy|National Institute for Longevity Sciences NCGG, Obu, Aichi, Japan|National Chiba-East-Hospital, Chuo-ku, Chiba, Japan|National Hospital Organization Asahikawa Medical Center, Asahikawa, Hokkaido, Japan|Tsukuba University Hospital, Tsukuba, Ibaraki, Japan|Iwate Medical University Hospital, Morioka, Iwate, Japan|Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan|Nihon Kokan Hospital, Kawasaki, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Kyoto Prefectural University of Medicine, Kyoto-shi, Kyoto, Japan|Rakuwakai Otowarehabilitation Hospital, Kyoto-shi, Kyoto, Japan|Ina Central Hospital, Ina, Nagano, Japan|Matsumoto Medical Center, Matsumoto, Nagano, Japan|Katayama Medical Clinic, Kurashiki, Okayama, Japan|Shiroma Clinic, Urasoe, Okinawa, Japan|Koshokai aino hospital, Ibaragi, Osaka, Japan|Sakaguchi Clinic, Sakai, Osaka, Japan|National Sanatorium Toneyama Hospital, Toyonaka, Osaka, Japan|Saitama Medical University Hospital, Iruma-Gun, Saitama, Japan|Nippon Medical School Hospital, Bunkyo-Ku, Tokyo, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|Nozomi Memory Clinic, Mitaka-shi, Tokyo, Japan|Sangenjaya Nakamura Mental Clinic, Setagaya, Tokyo, Japan|Kanauchi Medical Clinic, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Memory Clinic Ochanomizu, Tsukuba, Tokyo, Japan|National Sanatorium Hokuriku Hospital, Nanto, Toyama, Japan|Fukuoka University Hospital, Fukuoka, Japan|Kyoto University Hospital, Kyoto, Japan|Kyoto Minami Hospital, Kyoto, Japan|Utano Hospital, Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|Dong-A University Medical Center, Seo-gu, Busan, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Geonggi-do, Korea, Republic of|The Catholic University of Korea-Bucheon St. Mary's Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggido, Korea, Republic of|Gachon University Gil Medical Center, Namdong-gu, Incheon, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|NZOZ Wroclawskie Centrum Alzheimerowskie, Wroclaw, Dolnoslaskie, Poland|Medycyna Milorzab, Lodz, Lódzkie, Poland|Podlaskie Centrum Psychogeriatrii, Białystok, Podlaskie, Poland|NZOZ Dom Sue Ryder - Pallmed Sp. z o.o., Bydgoszcz, Poland|NZOZ Wielospecjalistyczna Poradnia Lekarska, Katowice, Poland|Specjalistyczna Praktyka Lekarska prof. Grzegorz Opala, Katowice, Poland|Centrum Zdrowia Psychicznego, Kielce, Poland|Centrum Neurologii Klinicznej, Krakow, Poland|NZOZ Neuromed M. I M. Nastaj sp. P., Lublin, Poland|Instytut Medycyny Wsi, Lublin, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Centrum Medyczne, Warszawa, Poland|Centralny Szpital Kliniczny MSW, Warszawa, Poland|Santa Cruz Behavioral PSC, Bayamon, Puerto Rico|Ivonne Z. Jimenez-Velazquez, MD, Carolina, Puerto Rico|Instituto de Neurologia Dra. Ivonne Fraga, San Juan, Puerto Rico|Michel A. Woodbury-Farina, MD., San Juan, Puerto Rico|SC Med Life SA, Bucuresti, Romania|SC Centrul Medical Sana SRL, Bucuresti, Romania|Policlinica CCBR S.R.L., Bucuresti, Romania|SC Med Life SA, Timisoara, Romania|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital General de Catalunya, Sant Cugat del Valles, Barcelona, Spain|Hospital Virgen Del Puerto, Plasencia, Caceres, Spain|Hospital Universitario De Getafe, Madrid, Getafe, Spain|Hospital Puerta De Hierro, Majadahonda, Madrid, Spain|Centro de Atencion Especializada (CAE) OROITU, Getxo, Vizcaya, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Fundacion ACE-Institut Catala de Neurociences Aplicades, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital De La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Son Espases, Palma de Mallorca, Spain|Hospital Univ Sant Joan de Reus, S.A., Reus, Spain|Fundacion CITA Alzheimer, San Sebastian, Spain|Hospital Doctor Peset, Valencia, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Plymouth Hospitals NHS Trust, Plymouth, Devon, United Kingdom|Cognitive Treatment & Research Unit, Crowborough, East Sussex, United Kingdom|Glasgow Memory Clinic, Scotland, Glasgow, United Kingdom|Southern Health NHS, Southampton, Hampshire, United Kingdom|MAC UK Neuroscience Ltd, Lancashire, Lancs, United Kingdom|MAC Clinical Research, Stourton, Leeds, United Kingdom|Re-Cognition Health Ltd, Greater London, London, United Kingdom|MAC Clinical Research, Cannock, Staffordshire, United Kingdom|West London Mental Health NHS Trust, Brentford, United Kingdom|Hammersmith Hospital, London, United Kingdom|Guildford Nuffield Hospital, London, United Kingdom|MAC Clinical Research, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02245737
NCT02246075,Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine,,Withdrawn,No Results Available,Alzheimer's Disease|Dementia|Cognition,Drug: EVP-6124,Safety/Tolerability of EVP-6124 with concurrent memantine|Change from Baseline in the Mini-Mental State Examination (MMSE),"FORUM Pharmaceuticals Inc|Quintiles, Inc.",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EVP-6124-027,Jul-15,Oct-16,null,22-Sep-14,null,15-Oct-15,"Delray Beach, Florida, United States|Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT02246075
NCT02244541,"Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease",ANAVEX,Completed,No Results Available,Alzheimer's Disease,Drug: ANAVEX2-73 Oral|Drug: ANAVEX2-73 Intravenous,"To determine maximum tolerated dose of Anavex2-73.|PK sampling- blood test results|Mini-mental state examination score (MMSE)|Score from ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory)|Cogstate Brief Battery (CBB) Score and International Shopping List Task (ISLT) Score|Electroencephalographic activity, including event-related potentials (EEG/ERP)|Hamilton Psychiatric Rating Scale for Depression (HAM-D) Score|Rosen Modified Hachinski Ischemic Score (RM/HIS10)",Anavex Life Sciences Corp.,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,32,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANAVEX2-73-002,Dec-14,Nov-15,Nov-16,19-Sep-14,null,28-Nov-18,"Melbourne Health - The Royal Melbourne Hospital, Melbourne, Victoria, Australia|Austin Health - Heidelberg Repatriation Hospital, Melbourne, Victoria, Australia|Caulfield Hospital, Melbourne, Victoria, Australia|Nucleus Network- Centre for Clinical Studies, Melbourne, Victoria, Australia|St. Vincent's Hospital, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT02244541
NCT02245568,Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD),,Terminated,No Results Available,Alzheimer's Disease|Behavioral Variant Frontotemporal Dementia,Drug: TRx0237,Number of participants with serious and non-serious adverse events|Change from Baseline in laboratory test values|Change from Baseline in vital signs|Change from Baseline in electrocardiograms,TauRx Therapeutics Ltd,All,"Child, Adult, Older Adult",Phase 3,913,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TRx-237-020,Aug-14,May-17,May-17,19-Sep-14,null,18-May-18,"Xenoscience, Inc / 21st Century Neurology, Phoenix, Arizona, United States|Southern California Research, LLC, Fountain Valley, California, United States|Feldman, Robert MD, Laguna Hills, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|The Shankle Clinic, Newport Beach, California, United States|Neuro-Therapeutics, Inc., Pasadena, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Memory and Aging Centre, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Mile High Research Center, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|JEM Research, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|CNS Healthcare, Inc, Jacksonville, Florida, United States|Miami Research Associates, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|The Roskamp Institute, Inc., Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Compass Research, LLC - North Clinic, The Villages, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|Neurostudies.net, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute Clinical Research, Elk Grove Village, Illinois, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Mayo Clinic, Alzheimer's Disease Research Center, Rochester, Minnesota, United States|Neurological Research Center - Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|Memory Enhancement Center of America, Inc, Eatontown, New Jersey, United States|The Atlantic Neuroscience Institute, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ PC, Toms River, New Jersey, United States|Neurological Associates of Albany, P. C., Albany, New York, United States|SPRI, Brooklyn, New York, United States|Columbia University Taub Institute, New York, New York, United States|Research Foundation for Mental Hygiene, Inc., Orangeburg, New York, United States|UNC Department of Neurology, Physicians Office Building, Chapel Hill, North Carolina, United States|Clinical Trials of America, Inc, Winston-Salem, North Carolina, United States|Neurobehavioral Clinical Research, Canton, Ohio, United States|University Hospitals Case Medical Center, Neurology Clinical Trials Unit, Cleveland, Ohio, United States|Rivers Wellness and Research Institute, Oklahoma City, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Hospital of the University of Pennsylvania, Department of Neurology, Philadelphia, Pennsylvania, United States|RI Hospital, Providence, Rhode Island, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Clinical Neuroscience Solutions CNS Healthcare, Memphis, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Senior Adults Specialty Research, Inc., Austin, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Division of Rehabilitation and Aged Care, Hornsby, New South Wales, Australia|Southern Neurology Pty Limited, Kogarah, New South Wales, Australia|Neuroscience Research Australia, Randwick, New South Wales, Australia|Discipline of Psychiatry, University of Queensland, Herston, Queensland, Australia|Royal Adelaide Hospital Memory Trials Centre, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Medical and Cognitive Research Unit, Austin Health Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia|McCusker Alzheimer's Research Foundation Inc, Nedlands, Western Australia, Australia|Neurodegenerative Disorders Research Pty Ltd, Subiaco, Western Australia, Australia|Hospital Brussels Department of Neurology, Bruxelles, Belgium|University Hospital Ghent Department of Neurology, Ghent, Belgium|Jessa Hospital, Hasselt, Belgium|GZA Sint-Augustinus, Wilrijk, Belgium|Heritage Medical Research Clinic, Calgary, Alberta, Canada|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|University of British Columbia Hospital, Clinic for Alzheimer Disease and Related Disorders, Vancouver, British Columbia, Canada|Vancouver Island Health Authority, Victoria, British Columbia, Canada|True North Clinical Research, Halifax, Nova Scotia, Canada|True North Clinical Research Kentville Inc, Kentville, Nova Scotia, Canada|Geriatric Clinical Trials Group, St. Joseph's Health Care, Parkwood Hospital Site, London, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill Centre for Studies in Aging, Alzheimer Disease Research Unit, Verdun, Quebec, Canada|University Hospital Centre Zagreb, Department of Neurology, Zagreb, Croatia|University Psychiatric Hospital Vrapče, Zagreb, Croatia|University of Eastern Finland, Brain Research Unit Mediteknia, Kuopio, Finland|Clinical Research Services Turku (CRST), Turku, Finland|Hôpitaux Civils de Colmar, Colmar Cedex, France|Hôpital La Grave, Toulouse, France|Hôpital de Charpennes, Villeurbanne, France|Charité, University Medicine Berlin, CBF, Neurology, Berlin, Germany|Arzeneimittelforschung Leipzig GmbH, Leipzig, Germany|Dong-A Medical Center, Busan, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|University Kuala Lumpur Royal College of Medicine, Ipoh, Malaysia|Hospital Sultan Ismail, Johor Bahru, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Alzheimer Research Center Amsterdam, Amsterdam, Netherlands|Erasmus University Medical Center, Rotterdam, Netherlands|State Budgetary Healthcare Institution of Sverdlovsk region ""Sverdlovsk Regional Clinical Psychiatric Hospital"", Ekaterinburg, Russian Federation|Non-governmental Healthcare Institution ""Central Clinical Hospital #6 of the JSC ""Russian Railways"", Moscow, Russian Federation|Mental Health Research Center of the Russian Academy of Medical Sciences, Gerontopsychiatry department, Moscow, Russian Federation|Mental Health Research Center of the Russian Academy of Medical Sciences, Moscow, Russian Federation|City Clinical Hospital #34, City Scientific Practical Neurological Center, Novosibirsk, Russian Federation|City Geriatric Medical and Social Center, Saint Petersburg, Russian Federation|Saint Petersburg Psychoneurological Research Institute n. a. V.M. Bekhterev, Saint Petersburg, Russian Federation|National University Hospital (NUH), Singapore, Singapore|National Neuroscience Institute (NNI), Singapore, Singapore|Fundació ACE, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan|NHS Grampian, OAP Directorate, Aberdeen, United Kingdom|RICE - The Research Institute for the Care of Older People, Bath, United Kingdom|Belfast Health and Social Care Trust (BHSCT), Belfast, United Kingdom|The Barberry Centre, Birmingham, United Kingdom|MAC Clinical Research Ltd, Blackpool, United Kingdom|MAC Clinical Research Ltd, Cannock, United Kingdom|Sussex Partnership NHS Foundation Trust, Cognitive Treatment and Research Unit, Crowborough, United Kingdom|St Margaret's Hospital Mental Health Unit, Epping, United Kingdom|Cognition Health Ltd, Guildford, United Kingdom|MAC Clinical Research Ltd, Leeds, United Kingdom|Cognition Health Ltd., London, United Kingdom|Imperial College Healthcare NHS Trust - Charing Cross Hospital, London, United Kingdom|Leonard Watson Experimental Neurology Centre, London, United Kingdom|MAC Clinical Research Ltd, Manchester, United Kingdom|Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom|Redwoods Centre, Shrewsbury, United Kingdom|Wessex Neurological Centre, Southampton General Hospital, Southampton, United Kingdom|Memory Assessment and Research Centre (MARC), Southampton, United Kingdom|Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT02245568
NCT02240693,Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo,,Completed,Has Results,Alzheimer Disease,Drug: BI 409306|Drug: Placebo,"Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment.|Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907)|Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment|Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment|Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment",Boehringer Ingelheim,All,"55 Years and older   (Adult, Older Adult)",Phase 2,128,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1289.5|2013-005031-24,15-Jan-15,18-Sep-17,9-Oct-17,16-Sep-14,28-Nov-18,28-Nov-18,"Orange County Neuropsychiatric Research Center LLC, Orange, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Richmond Behavioral Associates, Staten Island, New York, United States|ANI Neurology, PLLC, dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Landeskrankenhaus Hall, Abt.f. Psychatrie & Psychotherapie A, Hall in Tirol, Austria|Private Practice for Psychiatry and Neurology, Wien, Austria|Brussels-UNIV Brugmann -Horta, Brussel, Belgium|University of Calgary, Calgary, Alberta, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|True North Clinical Research Halifax, Inc., Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Inc., Kentville, Nova Scotia, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Institut universitaire de geriatrie Sherbrooke, Quebec, Canada|HOP Pierre Wertheimer, Bron, France|HOP Gui de Chauliac, Montpellier, France|HOP Nord Laënnec, Nantes, France|HOP La Pitié Salpêtrière, Paris, France|HOP Jean Bernard, Géria, Poitiers, Poitiers, France|Praxis Dr. med. Volker Schumann, Berlin, Germany|emovis GmbH, Berlin, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Zentralinstitut für seelische Gesundheit, Mannheim, Germany|Universitätsklinikum Ulm, Ulm, Germany|Neurologie und Psychiatrie / Psychotherapie, Westerstede, Germany|A.O. Spedali Civili di Brescia, Brescia, Italy|Osp. S. Giovanni di Dio, Firenze, Italy|Policlinico Gemelli, Roma, Italy|Brain Research Center, Amsterdam, Netherlands|Podlassian Center of Psychogeriatry, Bialystok, Bialystok, Poland|Non-Public Outpat. Clinic ""Dom Sue Ryder"", PALLMED Sp. z o.o, Bydgoszcz, Poland|Non-Public Outpatient Clinic ""Synapsa"" Pawel Polrola, Kielce, Kielce, Poland|Mental Health Center Biomed, Kielce, Poland|Non-Public Outpatient Clinic Neuro-Kard Ilkowski & Partners, Poznan, Poland|Medical Center Senior, Sopot, Poland|EUROMEDIS Sp. z o.o., Szczecin, Szczecin, Poland|Reg. Specialist Hospital Wroclaw, Research & Develop. Center, Wroclaw, Poland|Hospital Fernando Fonseca, EPE, Amadora, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|CHLO, EPE - Hospital Egas Moniz, Lisboa, Portugal|CHLN, EPE - Hospital de Santa Maria, Lisboa, Portugal|Hospital Universitario Fundación Alcorcón, Alcorcon (Madrid), Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar (murcia), Spain|Hospital Universitari General de Catalunya, Sant Cugat del Vallès, Spain|Hospital Mútua Terrassa, Terrasa (Barcelona), Spain|Royal United Hospital, Bath, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Re-Cognition Health, Plymouth, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02240693/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02240693/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02240693
NCT02227953,A Pilot Study of tDCS for Mild to Moderate Alzhemier's Disease,,Unknown status,No Results Available,Alzheimer's Disease,Device: Yband (YDT-201N)|Device: sham-Yband (YDT-201N),Change in cognitive function|Change in questionnaire|Change in Korean version of Geriatric Depression Scale (K-GDS)|Change in activities of daily living|Change in behavioral symptoms|Change in Clinician's Interview-Based Impression of Change Plus (CIBIC plus)|Change in tDCS feedback,Samsung Medical Center|Ybrain Inc.,All,"45 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SMC 2014-04-025,Aug-14,Dec-14,Dec-14,28-Aug-14,null,3-Sep-14,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02227953
NCT02228187,Brain-Computer Interface System for Training Memory and Attention in Elderly,,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Cognitive Decline|Dementia,Device: Brain-Computer Interface,Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Sum of Scaled Score of the Rivermead Behavioral Memory Test-II|Number of Adverse Events/Serious Adverse Events Reported|Usability Measure of the Brain-Computer Interface training system,"Duke-NUS Graduate Medical School|Agency for Science, Technology and Research|National University, Singapore|Singapore Clinical Research Institute|Singapore General Hospital|Tan Tock Seng Hospital",All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 2,240,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,B-14-099,Jul-15,Jun-17,Jun-17,28-Aug-14,null,2-Aug-17,"Duke-NUS Medical School, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT02228187
NCT02221947,"Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease",,Terminated,Has Results,Alzheimer's Disease,Drug: Bryostatin 1|Drug: Placebo,Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Preliminary Efficacy of a Single Dose of Bryostatin in the Treatment of Patients With AD,"Neurotrope Bioscience, Inc.|Blanchette Rockefeller Neurosciences Insitute",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,9,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NTRP101-201,Jun-14,Dec-14,Dec-14,21-Aug-14,21-Apr-16,6-Nov-17,"California Clinical Trials Medical Center, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT02221947
NCT02222181,Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Other: Pharmacotherapy Management,Mini-mental State Examination (MMEE)|Clinical Dementia Rating (CDR)|Systolic Blood Pressure|Total Cholesterol|Triglycerides|Glycemia|Diastolic Blood Pressure,Universidade Estadual Paulista Júlio de Mesquita Filho|Fundação de Amparo à Pesquisa do Estado de São Paulo|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,55,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),24947914.5.0000.5426,Apr-14,Feb-16,Mar-16,21-Aug-14,6-May-16,6-May-16,"Centro de Referência do Idoso de Araraquara - CRIA, Araraquara, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02222181
NCT02220738,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",,Terminated,No Results Available,Alzheimer's Disease,Drug: ABT-957|Other: Placebo for ABT-957,Pharmacokinetic evaluation of the two ABT-957 diastereomers|Number of subjects with adverse events,AbbVie,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1,19,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M13-334,Sep-14,Mar-16,Mar-16,20-Aug-14,null,16-Jun-16,"Site Reference ID/Investigator# 129545, Glendale, California, United States|Site Reference ID/Investigator# 129435, Orlando, Florida, United States|Site Reference ID/Investigator# 129641, New York, New York, United States|Site Reference ID/Investigator# 144825, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02220738
NCT02221622,Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD,Allo,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer Disease,Drug: Allopregnanolone injection (intravenous solution)|Drug: Placebo injection (intravenous solution),Safety profile: Adverse events|Safety profile: Clinical laboratory measurements|Safety profile: ARIA|Safety profile: Physical and neurological examination|Tolerability - Maximum tolerated dose (MTD)|Pharmacokinetic profile after single and multiple doses: Maximum Concentration (Cmax)|Pharmacokinetic profile after single and multiple doses: time attain to Cmax (Tmax)|Pharmacokinetic profile after single and multiple doses: Area under the curve (AUC)|Pharmacokinetic profile after single and multiple doses: Drug Clearance (CL)|Pharmacokinetic profile after single and multiple doses: apparent volume of distribution at steady state (Vss)|Cognitive tests (ADAS-Cog; MMSE/MoCA; ADCS-CGIC; CogState)|Brain MRI volumetrics,University of Southern California|National Institute on Aging (NIA),All,"55 Years and older   (Adult, Older Adult)",Phase 1,24,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AlloPhase1|1UF1AG046148,Aug-14,Feb-18,Feb-18,20-Aug-14,null,4-Jun-18,"University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02221622
NCT02213458,Care Ecosystem: Navigating Patients and Families Through Stages of Care,,Completed,No Results Available,"Dementia|Alzheimer Disease|Dementia, Vascular|Lewy Body Disease|Frontotemporal Lobar Degeneration|Memory Disorders",Behavioral: Navigated Care,Quality of Life-AD|Health care utilization|Caregiver burden|Satisfaction with Dementia Care|Caregiver depression|Caregiver self-efficacy,"University of California, San Francisco|University of Nebraska|Centers for Medicare and Medicaid Services|National Institute on Aging (NIA)",All,"45 Years and older   (Adult, Older Adult)",Not Applicable,780,Other|U.S. Fed|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,1C12013003302|5R01AG056715|1C1CMS331346,20-Mar-15,8-Mar-18,8-Mar-18,11-Aug-14,null,15-Nov-18,"University of California, San Francisco, San Francisco, California, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT02213458
NCT02211079,"A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates",,Completed,No Results Available,Healthy,Drug: JNJ-54861911|Drug: Caffeine|Drug: Midazolam|Drug: Tolbutamide,Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Concentration (Tmax)|Time to Last Quantifiable Plasma Concentration (Tlast)|Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - infinity])|Area Under the Plasma Concentration-time Curve From Time Zero to Time 24 Hours (AUC [0-24])|Elimination Half-Life (t1/2)|Elimination Rate Constant (lambda[z])|Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs),"Janssen Research & Development, LLC",Male,18 Years to 55 Years   (Adult),Phase 1,16,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR105152|54861911ALZ1010|2014-001794-14,Sep-14,Nov-14,Nov-14,7-Aug-14,null,24-Nov-15,"Groningen, Netherlands",,https://ClinicalTrials.gov/show/NCT02211079
NCT02210286,Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia,,Completed,No Results Available,Dementia|Alzheimer's Disease,Dietary Supplement: Magtein,Cognitive Function|FDG-PET|RBC Magnesium chemistry,"Stanford University|Magceutics, Inc.",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,20,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,29329,Jul-14,Apr-16,Jul-16,6-Aug-14,null,13-Oct-16,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02210286
NCT02208193,"Alzheimer's Disease, Art and Garden",JAZ ART,Unknown status,No Results Available,Alzheimer Disease,Behavioral: Cognitive and psycho-behavioral effects of an artistic dimension,"Comparaison of the number of language acts in each category between AD and controls subjects|Scores obtained in standard neuropsychological tests, in particular to assess spatio-temporal orientation (Folstein MMSE),|Scores obtained with the "" MemoArtZ "" tool (MAZ) to evaluate the memorization of artistic elements of the garden,|Scores from the "" General Esthetic Preference "" (GEP) tool to evaluate the consistency of general esthetic appreciations,|obtained with the specific mood assessment scale (CSDD) for subjects in group A|Score obtained with the specific assessment of emotional events scale (AES) for all subjects.","Central Hospital, Nancy, France",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2014-A00139-38,Jul-14,Oct-16,Sep-17,4-Aug-14,null,30-Jul-15,"CHU Nancy, Nancy, France",,https://ClinicalTrials.gov/show/NCT02208193
NCT02204969,LIWA for Treatment of Alzheimer Patients,LIWA,Unknown status,No Results Available,Alzheimer Disease,Dietary Supplement: Lithia water|Device: Transcranial Magnetic stimulation,Cognitive functioning score by ADAS-COG,American Society Of Thermalism And Climatology Inc,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,822429989,Jan-15,Jun-15,Dec-15,31-Jul-14,null,6-Jan-15,"Gaviota Clinic, Newark, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT02204969
NCT02205710,Cognitive Training in Aging,,Unknown status,No Results Available,Mild Cognitive Impairment|Mild to Moderate Dementia|Alzheimer`s Disease,Other: Computerized cognitive training|Other: Computerized games,Change in ratings on cognitive training survey|Change in neural activity|Change in performance on neuropsychological tests|Change in ratings of psychological wellbeing,Bruyere Research Institute|University of Ottawa,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)",M16-14-018,Aug-16,Aug-17,null,31-Jul-14,null,25-Jul-16,"Bruyere Continuing Care, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02205710
NCT02197884,A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants,,Completed,No Results Available,Healthy,"Drug: JNJ-54861911, 25 mg|Drug: Itraconazole 200 mg|Drug: Clarithromycin 500 mg",Maximum Observed Plasma Concentration (Cmax) of JNJ-54861911 and diaminothiazine (DIAT)|Time to Reach Maximum Concentration (Tmax) of JNJ-54861911 and DIAT|Time to Last Quantifiable Plasma Concentration (Tlast) of JNJ-54861911 and DIAT|Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Time (AUC [0-last]) of JNJ-54861911 and DIAT|Area Under the Plasma Concentration-time Curve From Time Zero to Extrapolated Infinite Time (AUC [0-infinity]) of JNJ-54861911 and DIAT|Area Under the Plasma Concentration-time Curve From Time Zero to Time 24 Hours (AUC [0-24]) of JNJ-54861911 and DIAT|Elimination Half-Life (t1/2) of JNJ-54861911 and DIAT|Elimination Rate Constant (lambda[z]) of JNJ-54861911 and DIAT|Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs),"Janssen Research & Development, LLC",Male,18 Years to 55 Years   (Adult),Phase 1,13,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR104763|2014-001793-33|54861911ALZ1009,Jul-14,Sep-14,Sep-14,23-Jul-14,null,15-Oct-14,"Merksem, Belgium",,https://ClinicalTrials.gov/show/NCT02197884
NCT02196545,Physical Activity Training Program for Patients With Alzheimer's Dementia,MOTODEM,Completed,No Results Available,Dementia,Behavioral: Exercise,"activities of daily living|behavioral symptoms of dementia|cognition|executive function and language ability|caregiver burden|Reaction time, hand-eye quickness and attention",Technische Universität Dresden|RECK‑Technik GmbH & Co. KG,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MTDEM-001,Aug-11,Jul-13,Jul-13,22-Jul-14,null,22-Jul-14,"Technische Universität Dresden, Dresden, Saxony, Germany",,https://ClinicalTrials.gov/show/NCT02196545
NCT02195596,Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study.,EFA-P,Unknown status,No Results Available,Alzheimer Disease,Other: High intensity aerobic exercise+strength|Other: Low intensity aerobic exercise+strength,"Change in cognitive performance that is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12|Global cognitive performance",Basque Health Service,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,2011111100,Apr-13,Jan-15,Dec-15,21-Jul-14,null,21-Jul-14,"Galdakao Hospital/Galdakao C.S., Galdakao, Bilbao, Spain|Basauri C.S., Basauri, Bizkaia, Spain|Hospital Universitario de Basurto, Bilbao, Bizkaia, Spain",,https://ClinicalTrials.gov/show/NCT02195596
NCT02196116,Amyloïd Load in Elderly Population: Effect of Cognitive Reserve,EDUMA,Unknown status,No Results Available,"Plaque, Amyloid|Cognitive Deficits",Other: PET|Other: MRI|Other: neuropsychological tests,Amyloid load|Neuropsychological scores|Educational level|Memory complaint,"University Hospital, Bordeaux|Fondation Plan Alzheimer|General Electric",All,65 Years and older   (Older Adult),Not Applicable,120,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),CHUBX 2013/02,Jul-14,Jul-16,Jul-16,21-Jul-14,null,12-Feb-15,"CHU de Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT02196116
NCT02190084,Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia,,"Active, not recruiting",No Results Available,Apathy|Alzheimer's Dementia,Device: Neurostar repetitive transcranial magnetic stimulator,Apathy Evaluation Scale (AES)|Trials making test,Central Arkansas Veterans Healthcare System,All,"55 Years to 91 Years   (Adult, Older Adult)",Phase 4,20,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",547461,May-14,May-18,Jul-18,15-Jul-14,null,25-Jan-18,"Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT02190084
NCT02187627,"Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants",,Completed,No Results Available,"Alzheimer's Disease, Healthy Volunteer",Drug: [11C]RO6924963|Drug: [11C]RO6931643|Drug: [18F]RO6958948,"Part 1: Standard Uptake Value (SUV), as Assessed by Tau PET Brain Scan|Part 1: Standard Uptake Value Ratio (SUVR), as Assessed by Tau PET Brain Scan|Part 1: SUV, as Assessed by Tau PET Scan of Whole Body|Part 1: SUVR, as Assessed by Tau PET Scan of Whole Body|Mean Residence Times for Each Organ, as Assessed by Tau PET Scan of Whole Body|Part 1: Distribution Volume (VT), as Assessed by Tau PET Brain Scan|Part 2A: Absolute Percentage Difference Between Test and Retest of SUVR|Part 2A: Absolute Percentage Difference Between Test and Retest of VT|Part 2B: Effective dose (ED), as Assessed by Whole Body PET Scan|Part 2A: Absolute Percentage Difference Between Test and Retest of SUV|Percentage of Participants With Adverse Events (AEs)",Hoffmann-La Roche,All,"25 Years and older   (Adult, Older Adult)",Phase 1,52,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,BP29409,31-Aug-14,29-Feb-16,29-Feb-16,11-Jul-14,null,1-Jan-19,"Parexel International; Harbor Hospital Center, Baltimore, Maryland, United States|Johns Hopkins Universtiy; Radiology Dept, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02187627
NCT02185053,A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia,,Completed,No Results Available,Alzheimer's Disease,Drug: CPC-201,Donepezil Maximum tolerated dose (MTD) change,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",All,"50 Years to 79 Years   (Adult, Older Adult)",Phase 2,41,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPC-001-07,Jul-14,Jul-16,Jul-16,9-Jul-14,null,26-Jul-16,"CPC1, West Palm Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT02185053
NCT02180269,"A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants",,Completed,No Results Available,Healthy,Drug: JNJ-54861911 (25 mg)|Drug: JNJ-54861911 (50 mg)|Drug: JNJ-54861911 (100 mg)|Drug: Placebo,Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Maximum Plasma Concentration (Cmax)|Time to Reach Maximum Concentration (Tmax)|Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])|Apparent Clearance (CL/F)|Cerebrospinal Fluid (CSF) Amyloid-Beta Concentration|Plasma Amyloid-Beta Concentration,Janssen Pharmaceutical K.K.,Male,"55 Years to 75 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR104614|54861911ALZ1006,Jun-14,Aug-14,Aug-14,2-Jul-14,null,12-Sep-14,"Fukuoka, Japan",,https://ClinicalTrials.gov/show/NCT02180269
NCT02178124,"A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.",,Completed,No Results Available,Alzheimer Disease,Drug: Donepezil|Drug: placebo,safety and tolerability evaluation|pharmacokinetics characteristic evaluation,Icure Pharmaceutical Inc.,Male,20 Years to 45 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IPI-002,Jul-14,Dec-14,Dec-14,30-Jun-14,null,25-Mar-15,"ASAN Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02178124
NCT02176629,Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease,MeMO-RV2,Completed,No Results Available,MCI|Alzheimer's Disease,Other: Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|Other: Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR),"Evaluate the acceptability of the RV|Evaluate the motivation of subjects (interest, cognition) is greater in the virtual environment during the VR experience compared to a conventional cognitive stimulation activity (CSC).",Centre Hospitalier Universitaire de Nice,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),14-PP-03,Aug-14,Feb-15,Feb-15,27-Jun-14,null,1-Sep-15,"Institut Claude Pompidou, Nice, France",,https://ClinicalTrials.gov/show/NCT02176629
NCT02172612,A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the Elderly,,Completed,No Results Available,Alzheimer Disease,Other: Arm 1 Education Session,Change in appropriateness of anticholinergic medication prescribing practices.|Change in Anticholinergic Burden,Daniela Moga|University of Kentucky,All,65 Years and older   (Older Adult),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,14-0461-F3R,Sep-14,20-Nov-15,20-Nov-15,24-Jun-14,null,29-Mar-19,"Sander's BrownCenter on Aging, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT02172612
NCT02168920,Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,,Terminated,No Results Available,Agitation Associated With Dementia of the Alzheimer's Type,Drug: 2 mg/day|Drug: 3 mg/day|Drug: 6 mg/day|Drug: Placebo (0 mg/day),CMAI|Clinical Global Impression of Severity （CGI-S）|Clinical Global Impression-Improvement (CGI-I),"Otsuka Pharmaceutical Co., Ltd.",All,"55 Years to 89 Years   (Adult, Older Adult)",Phase 3,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",031-13-001,11-Jun-14,18-Mar-16,18-Mar-16,20-Jun-14,null,16-Oct-17,"Kanto Region, Japan",,https://ClinicalTrials.gov/show/NCT02168920
NCT02167256,"A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Drug: AZD0530 100mg daily|Drug: AZD0530 125mg daily|Drug: Placebo,"The effect of treatment with AZD0530 on 12-month reductions in 18F-FDG PET measurements of the cerebral metabolic rate for glucose (CMRgl) using statistical parametric mapping (SPM) statistical region of in|Safety and tolerability of treatment with AZD0530 over a 12-month period in subjects with mild AD as assessed by analysis of adverse events, including symptoms, and abnormal findings on physical and neurological examinations, and standard labs.|The effect of treatment with AZD0530 on cognitive and behavioral function in participants with mild AD.|To assess the effect of treatment with AZD0530 on the rate of brain atrophy using volumetric magnetic resonance imaging (MRI).|To assess the effect of treatment with AZD0530 on CSF biomarkers of AD (particularly CSF total Tau and CSF pTau).|To assess the influence of APOE genotype on the effects of treatment with AZD0530.",Yale University|Alzheimer's Therapeutic Research Institute,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,159,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1404013830|4UH3TR000967-02,Dec-14,27-Feb-18,27-Feb-18,19-Jun-14,null,27-Jun-18,"Barrow Neurological Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Los Angeles, Los Angeles, California, United States|Yale Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Wien Center for Clinical Research/Mount Sinai Medical Center, Miami Beach, Florida, United States|University of South Florida - Health Byrd Alzheimer Institute, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pittsburgh, Alzheimer's Disease Research Center, Pittsburgh, Pennsylvania, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|University of Washington, Seattle, Washington, United States|University of British Columbia, Clinic for AD & Related Disorders, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02167256
NCT02166827,"Effects of a NeuroAD System, for the Treatment of Alzheimer Disease",,Terminated,No Results Available,Alzheimer's Disease,Device: NeuroAD|Device: Sham TMS+Cog,Efficacy,Neuronix Ltd,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NRX-LT1,Nov-14,Nov-15,Nov-15,18-Jun-14,null,31-Mar-17,"Shaare Zedek, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT02166827
NCT02164643,Longitudinal Study of Brain Amyloid imaGing in MEMENTO,MEMENTOAmyGing,"Active, not recruiting",No Results Available,Alzheimer's Disease (AD) and Related Disorders,Drug: Flutemetamol (18F)|Drug: Florbetapir (18F),"Progression to clinical dementia stage according to standardized classifications (DSM-IV and NINCDS-ADRDA) as described in the MEMENTO protocol.|Longitudinal evolution of amyloid load measured through either Florbetapir (18F) or Flutemetamol (18F)|Speed of cognitive decline based on change in cognitive performances|Longitudinal evolution of biomarkers measured from blood, CSF, structural neuroimaging (MRI) and glucose metabolism molecular neuroimaging (18F-FDG PET).|Mortality|Loss of autonomy based on functional activity assessment|Institutionalization|Cardiovascular event (Stroke and Coronary events)|Quality of life|Prodromal AD (Pre-symptomatic dementia)|Etiology of dementia, when converted","University Hospital, Bordeaux|Fondation Plan Alzheimer|GE Healthcare|Avid Radiopharmaceuticals",All,"18 Years and older   (Adult, Older Adult)",Phase 3,448,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHUBX 2010/47 A,10-Jun-14,Dec-19,Dec-19,16-Jun-14,null,21-Jan-19,"CHU d'Angers, Angers, France|CHU de Besançon, Besancon, France|APHP - Avicenne, Bobigny, France|CHU de Bordeaux - Pellegrin, Bordeaux, France|CHU de Bordeaux - Hôpital Xavier-Arnozan, Bordeaux, France|CHU de Brest, Brest, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Lille, Lille, France|Hospices civils de Lyon, Lyon, France|AP-HM, Marseille, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nice, Nice, France|AP-HP - Hôpital BROCA, Paris, France|AP-HP - Hôpital LARIBOISIERE, Paris, France|Ap-Hp La Pitié-Salpêtrière, Paris, France|CHU de Poitiers, Poitiers, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-etienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse - Hôpital Purpan, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU de Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT02164643
NCT02155946,Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment,,Recruiting,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Device: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit,Functional MRI|Face-name memory test performance|Object Location Association memory test performance|fMRI|Objective memory test performance|Subjective memory test performance on the MMQ,VA Office of Research and Development,All,"50 Years to 88 Years   (Adult, Older Adult)",Not Applicable,100,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",N1534-R,1-Dec-14,31-Dec-19,31-Dec-19,4-Jun-14,null,11-Mar-19,"VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02155946
NCT02149017,Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F),,Terminated,No Results Available,Alzheimer Disease,Radiation: SNUBH-NM-333(18F),Distribution volume ratio (DVR)|Standardized uptake value ratio (SUVr),Seoul National University Hospital,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,SNUBH-NM-333(18F),Dec-10,May-11,Dec-12,29-May-14,null,29-May-14,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02149017
NCT02147652,Personalized Music Therapy and Agitation in Dementia,,Enrolling by invitation,No Results Available,Alzheimer's Disease|Vascular Dementia,Other: Personalized music,Changes in agitation,"University Health Network, Toronto",All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-7490-DE,May-14,Jun-19,Jun-19,28-May-14,null,11-Oct-18,,,https://ClinicalTrials.gov/show/NCT02147652
NCT02142777,S-Equol in Alzheimer's Disease (SEAD) Trial,SEAD,Completed,No Results Available,Alzheimer's Disease,Drug: S -Equol|Drug: Placebo,platelet mitochondria cytochrome oxidase (COX) activity|safety of S-equol,"Russell Swerdlow, MD|Ausio Pharmaceuticals, LLC|University of Kansas Medical Center",Female,"60 Years to 90 Years   (Adult, Older Adult)",Phase 1,15,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,STUDY00001228,Jul-14,Apr-16,Apr-16,20-May-14,null,16-Aug-16,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02142777
NCT02130661,Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers,,Withdrawn,No Results Available,Alzheimer's Disease,Drug: Rilapladib 25 mg|Drug: Rilapladib 250 mg|Drug: Itraconazole,"Maximum observed concentration (Cmax), time of occurrence of Cmax (Tmax), area under the concentration-time curve over the dosing interval (AUC(0-Tau)) of rilapladib parent compound after single and repeat dosing, in part A of the study.|Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)), and terminal phase half-life (T1/2) of rilapladib after repeat dosing, in part A of the study|Cmax, Tmax, AUC(0-tau), and area under the concentration-time curve from time zero (pre-dose) to time of last quantifiable concentration (AUC(0-t)) of SB-664601 and GSK1174379 after single and repeat dosing, in part A of the study|AUC(0-infinity) and T1/2 of SB-664601 and GSK1174379 after repeat dosing, as data permit, in part A of the study.|AUC(0 infinity), AUC(0 t), and Cmax of rilapladib alone and in the presence of itraconazole in part B of the study.|Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by adverse events (AEs), in part A of the study.|Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by 12-lead electrocardiogram (ECG) parameters, in part A of the study.|Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by measuring vital signs, in part A of the study.|Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by laboratory tests, in part A of the study.|Tmax and T1/2 of rilapladib alone and in the presence of itraconazole, in part B of the study.|AUC(0-infinity), AUC(0-t), Cmax, Tmax and T1/2 of rilapladib metabolites, SB-664601 and GSK1174379, alone and in the presence of itraconazole, in part B of the study.|Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed by AEs, in part B of the study.|Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed using ECG parameters, in part B of the study.|Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed as vital signs, in part B of the study.|Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed by laboratory tests, in part B of the study.",GlaxoSmithKline,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201274,Oct-17,Jan-18,Jan-18,5-May-14,null,13-Dec-16,,,https://ClinicalTrials.gov/show/NCT02130661
NCT02129348,Treatment of Psychosis and Agitation in Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer's Disease|Psychosis|Agitation,Drug: Lithium|Drug: Placebo,Change in Neuropsychiatric Inventory (NPI) Score|Clinical Global Impression (CGI) Global|Clinical Global Impression (CGI) Behavior|Young Mania Rating Scale|Treatment Emergent Signs and Symptoms (TESS)|Simpson-Angus Scale|Basic Activities of Daily Living (BADL)|Zarit Caregiver Burden Interview|Clinical Dementia Rating Scale (CDR),New York State Psychiatric Institute|National Institute on Aging (NIA),All,"Child, Adult, Older Adult",Phase 2,80,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",#6915|1R01AG047146-01,Jun-14,Apr-19,Apr-19,2-May-14,null,16-May-18,"University of Miami Miller School of Medicine, Miami, Florida, United States|McLean Hospital, Belmont, Massachusetts, United States|New York State Psychiatric Institute, New York, New York, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02129348
NCT02126514,"A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293",AZD3293hADME,Completed,No Results Available,Healthy Volunteers|Mass Balance Study,Drug: AZD3293,"PK parameters measured by assessment of AUC over time and Maximum observed concentration (Cmax)|Safety assessments including vital sign measurements, ECGs, physical examinations, clinical laboratory evaluations, and a record of adverse events (AEs).|The Columbia-Suicide Severity Rating Scale (C-SSRS)|Time to maximum observed concentration (tmax)|Area under the concentration-time curve|Area under the concentration-time curve extrapolated to infinity (AUC0-∞)|Apparent terminal elimination half-life (t1/2)|Apparent oral clearance (CL/F)|Apparent volume of distribution (Vz/F)|Ratios for AUC0-",AstraZeneca,Male,18 Years to 55 Years   (Adult),Phase 1,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,D5010C00007|AZD3293 hADME,May-14,May-14,May-14,30-Apr-14,null,16-Jun-14,"Research Site, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02126514
NCT02127476,A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: KHK6640|Drug: Matching Placebo,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,"Kyowa Hakko Kirin Pharma, Inc.|Kyowa Kirin Pharmaceutical Development, Inc.",All,"55 Years and older   (Adult, Older Adult)",Phase 1,57,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",6640-001|2013-002873-23,Jul-14,May-17,May-17,30-Apr-14,null,1-Jun-17,"UZ Gent, De Pintelaan 185, Gent, Belgium|Clinical Research Services Turku (CRST), Itäinen Pitkäkatu 4B,, Turku, Finland|Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, Netherlands|University Medical Centre Groningen (UMCG), Alzheimer Research Centre, Groningen, Netherlands|Clinical Centre of Serbia, Neurology Clinic, Dr Subotica Starijeg 6 ,, Belgrade, Serbia|Military Medical Academy, Crnotravska 17,, Belgrade, Serbia|Memory Clinic, Malmo Minneskliniken, Memory Research Unit, Hs 33,, Malmö, Sweden|Sahlgrenska Gothenburg, Minnesmottagningen, Wallinsgatan 6, Mölndal, Sweden|Karolinska Stockholm Karolinska University Hospital, Huddinge, Dept. of Geriatrics/Memory Disorders Unit, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02127476
NCT02120664,Florbetapir Calibration to the Centiloid Scale,,Completed,Has Results,Alzheimer's Disease,Drug: Florbetapir (18F)|Drug: 11C-PiB,Florbetapir SUVr Conversion to Centiloid Units|Correlation of Florbetapir (18F) Centiloid and 11C-PiB Centiloid|Variability of PET Images in Young Healthy Control Subjects.,Avid Radiopharmaceuticals,All,"21 Years and older   (Adult, Older Adult)",Phase 1,35,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-A22,Apr-14,Sep-15,Sep-15,23-Apr-14,9-Mar-17,9-Mar-17,"Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Heidelberg, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT02120664
NCT02119546,Effects of Exercise Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease,,Completed,No Results Available,Mild CognitIve Impairment|Alzheimer's Disease,Other: Aerobic exercise|Other: Stretch exercise,Change from baseline in Color Trails Test at week12 and Week24|Change from baseline in walking speed at week12 and Week24,National Taiwan University Hospital,All,"45 Years to 85 Years   (Adult, Older Adult)",Not Applicable,19,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,200912126R,May-10,Sep-12,Dec-12,21-Apr-14,null,21-Apr-14,"National Taiwan University Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02119546
NCT02108769,Yogic Breathing Changes Salivary Components,,Completed,No Results Available,Alzheimer Disease|Neurodegenerative Diseases|Cancer,Behavioral: Yogic Breathing|Behavioral: Attention Control,Nerve growth factor quantification|Measuring changes in salivary constituents,Medical University of South Carolina|National Institutes of Health (NIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Pro00024336,Oct-13,Nov-13,Nov-13,9-Apr-14,null,9-Apr-14,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT02108769
NCT02107599,The Feasibility of Florbetapir Quantitation in Europe,,Completed,Has Results,Alzheimer's Disease,Drug: Florbetapir (18F),Change in Reader Accuracy After Application of Quantitation Software|Change in Scan Interpretation Reliability After Application of Quantitation Software,Avid Radiopharmaceuticals,All,"Child, Adult, Older Adult",Phase 4,96,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-QP02,Mar-14,May-14,May-14,8-Apr-14,9-Jul-15,9-Jul-15,"Research Site, Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT02107599
NCT02103673,DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia,,Completed,No Results Available,Behavioral and Psychological Symptoms in Alzheimer's Disease|Behavioral and Psychological Symptoms in Vascular Dementia,Drug: DAOIB|Drug: Placebo,Behavioral Pathology in Alzheimer's Disease Rating Scale|Alzheimer's Disease Assessment Scale - cognitive subscale|Neuropsychiatirc Inventory|Instrumental Activities of Daily Living|Zarit Caregiver Burden Interview|Geriatric Geriatric Depression Scale|Mini-Mental Status Examination,Chang Gung Memorial Hospital,All,"50 Years to 100 Years   (Adult, Older Adult)",Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",102-0035C,Feb-14,Nov-17,Nov-17,4-Apr-14,null,24-Jan-18,"Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan",,https://ClinicalTrials.gov/show/NCT02103673
NCT02103894,Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects,,Completed,No Results Available,Alzheimer's Disease (AD)|Parkinson's Disease (PD)|Chronic Traumatic Encephalopathy (CTE)|Progressive Supranuclear Palsy (PSP)|Frontal Temporal Dementia (FTD)|Pick's Disease|Tauopathies,Drug: [18F]T807 ([18F]MNI-777),Brain uptake of [18F]T807 ([18F]MNI-777),Molecular NeuroImaging|Institute for Neurodegenerative Disorders,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,16,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),MNI-777,Feb-14,Aug-16,Sep-16,4-Apr-14,null,16-Dec-16,"Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02103894
NCT02097056,Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease,SAVE,Completed,Has Results,Alzheimer's Disease,Drug: Donepezil HCL,Overall Summary of Adverse Events (AEs)|Change From Baseline in the Mini-Mental State Examination (MMSE) Score|Change From Baseline in the Neuropsychiatric Inventory Questionnaire (NPI-Q) Severity and Distress Total Scores,Eisai Korea Inc.|Eisai Inc.,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 4,171,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ART-M082-401,Feb-14,May-15,May-15,26-Mar-14,27-Jun-16,27-Jun-16,"Chungju, Chungcheongbuk-do, Korea, Republic of|Ansan, Gyeonggi-do, Korea, Republic of|Buchoen, Gyeonggi-do, Korea, Republic of|Seongnam, Gyeonggi-do, Korea, Republic of|Jinju, Gyeongsangnam-do, Korea, Republic of|Iksan, Jeollabuk-do, Korea, Republic of|Hwasun, Jeollanam-do, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Incheon, Korea, Republic of|Jeju, Korea, Republic of|Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02097056
NCT02094729,"A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Drug: BAN2401 2.5 mg/kg|Drug: BAN2401 5 mg/kg|Drug: BAN2401 10 mg/kg|Drug: Placebo,"Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Pharmacokinetics of BAN2401: Maximum Concentration (Cmax)|Pharmacokinetics of BAN2401: time attain to Cmax (tmax)|Pharmacokinetics of BAN2401: Area under the curve (AUC)|Pharmacokinetics of BAN2401: Drug Clearance (CL)|Pharmacokinetics of BAN2401: apparent volume of distribution at steady state (Vss)|Investigation of the effect of repeated intravenous infusions of BAN2401 on the immunogenicity and CSF biomarkers|Investigation of the effect of apolipoprotein allele4 (ApoE4) on the safety, tolerability and pharmacodynamic (PD) response of repeated intravenous infusions of BAN2401","Eisai Co., Ltd.|Eisai Inc.",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,26,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BAN2401-J081-104,Sep-13,Mar-15,May-15,24-Mar-14,null,8-Jun-15,"Kobe, Hyogo, Japan|Sendai, Miyagi, Japan|Kurashiki, Okayama, Japan|Koto-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02094729
NCT02087865,Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease,,Recruiting,No Results Available,Genetic Risk for Alzheimer's Disease,Drug: donepezil HCL|Drug: Placebo,Change in BOLD response during functional magnetic resonance imaging|Neuropsychological testing scores,The Cleveland Clinic|National Institute on Aging (NIA),All,"60 Years to 75 Years   (Adult, Older Adult)",Phase 4,90,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Other",14-227,May-14,27-Feb-20,27-Feb-20,14-Mar-14,null,6-May-19,"Cleveland Clinic Center for Brain Health, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02087865
NCT02085265,Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients,SARTAN-AD,Recruiting,No Results Available,Alzheimer's Disease|Hypertension,Drug: Perindopril|Drug: Telmisartan,Ventricular enlargement|Safety - Blood pressure|Safety - Vital signs|Safety - Electrolytes|Safety - Adverse Events|Hippocampal volume|Grey/White matter volume|Cognitive and functional measures,Sunnybrook Health Sciences Centre|Alzheimer’s Drug Discovery Foundation|Weston Brain Institute,All,"50 Years and older   (Adult, Older Adult)",Phase 2,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,148-2013,Mar-14,Mar-20,Mar-21,12-Mar-14,null,27-Nov-17,"University of Calgary, Calgary, Alberta, Canada|University of Lethbridge, Lethbridge, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Parkwood Institute, London, Ontario, Canada|South East Toronto Family Health Team, Toronto, Ontario, Canada|Centre for Memory and Aging, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Baycrest Health Sciences, Toronto, Ontario, Canada|Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada|University of Waterloo, Waterloo, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02085265
NCT02079909,Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202),,Completed,Has Results,Alzheimer's Disease,Drug: T-817MA-H|Drug: T-817MA-L|Drug: Placebo,ADAS-cog Change From Baseline to Week 52|CGIC|ADCS-ADL Change From Baseline to Week 52,"FUJIFILM Toyama Chemical Co., Ltd.|Alzheimer's Disease Cooperative Study (ADCS)",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,482,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",T817MAUS202,Mar-14,5-May-17,5-May-17,6-Mar-14,9-Aug-18,26-Feb-19,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona Health Sciences Center, Tucson, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|UCSD Comprehensive Alzheimer's Program, La Jolla, California, United States|UC Irvine Medical Center, Orange, California, United States|Geriatric and Adult Psychiatry, LCC, Hamden, Connecticut, United States|Yale University, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Georgetown University Clinical Research Unit, Washington, District of Columbia, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|University of Miami Miller-School of Medicine, Miami, Florida, United States|Scientific Clinical Research, Inc, North Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Meridien Research, Tampa, Florida, United States|Neuro Trials Research, Inc, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|Indiana Medical Research, Elkhart, Indiana, United States|Indiana University Health Partners, Adult Neurology Clinic, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas/Clinical and Translational Science Unit, Fairway, Kansas, United States|University of Kentucky Sanders-Brown Center on Aging Clinic, Lexington, Kentucky, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Acadia Hospital, Bangor, Maine, United States|Boston University Alzheimer's Disease Center, Boston, Massachusetts, United States|University of Michigan Health System/ Michigan Clinical Research Unit, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Bronson Neurobehvioral Health, Paw Paw, Michigan, United States|University of Nebraska Medical Center(Geri Psych), Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Global Medical Institutes, LLC;Princeton Medical Institute, Princeton, New Jersey, United States|Dent Neurologic Institute, Amherst, New York, United States|Alzheimer's Disease Research Center of Mount Sinai, New York, New York, United States|Columbia University Medical Center Sergievsky Center Taub Institute, New York, New York, United States|The Nathan S. Kline Instituite for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Wake Forest University (WFU) School of Medicine, Winston-Salem, North Carolina, United States|Case Western Reserve University/ University Hospitals Case Medical Center, Beachwood, Ohio, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Hospital at the University of Pennsylvania, Penn Memory Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Alzheimer Disease Research Center, Pittsburgh, Pennsylvania, United States|Abington Neurological Associates, LTD., Willow Grove, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Vanderbilt University Medical Center -VUIIS, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Cary J. Kohlenberg MD., SC dba IPC Research, Waukesha, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02079909/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02079909
NCT02080364,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,STEADFAST,Terminated,No Results Available,Alzheimer's Disease,Drug: Azeliragon|Drug: Placebo,Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) total score|Change from Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)|Change from Baseline in Magnetic Resonance Imaging (MRI) brain volumetric measures|Change from Baseline in Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Scan|Change from Baseline in Neuropsychiatric Inventory (NPI)|Change from Baseline in Mini-Mental State Examination (MMSE)|Change from Baseline in Alzheimer's Disease Cooperative Study- Activities of Daily Living Inventory (ADCS-ADL)|Change from Baseline in Continuous Oral Word Association Task (COWAT)|Change from Baseline in Category Fluency Test (CFT)|Change from Baseline in Resource Utilization in Dementia (RUD)|Change from Baseline in Dementia Quality of Life (DEMQOL)|Change from Baseline in Plasma Amyloid Beta|Proportion of Responders based on ADAS-cog|Proportion of Responders based on CDR-SB|Adverse Events,vTv Therapeutics,All,"50 Years and older   (Adult, Older Adult)",Phase 3,880,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TTP488-301,Apr-15,1-Jun-18,1-Jun-18,6-Mar-14,null,17-May-19,"Phoenix, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Bellflower, California, United States|Costa Mesa, California, United States|Fullerton, California, United States|Glendale, California, United States|Imperial, California, United States|Irvine, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Long Beach, California, United States|Orange, California, United States|Riverside, California, United States|San Bernardino, California, United States|San Francisco, California, United States|Santa Ana, California, United States|Atlantis, Florida, United States|Brooksville, Florida, United States|Delray Beach, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Lake Worth, Florida, United States|Leesburg, Florida, United States|Miami Beach, Florida, United States|Miami Lakes, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pensacola, Florida, United States|Sarasota, Florida, United States|Sunrise, Florida, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Chicago, Illinois, United States|Fairway, Kansas, United States|Prairie Village, Kansas, United States|Lexington, Kentucky, United States|Baltimore, Maryland, United States|Newton, Massachusetts, United States|Plymouth, Massachusetts, United States|Quincy, Massachusetts, United States|Hattiesburg, Mississippi, United States|Creve Coeur, Missouri, United States|Princeton, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Lake Success, New York, United States|New York, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Shaker Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Portland, Oregon, United States|Media, Pennsylvania, United States|Norristown, Pennsylvania, United States|Plains, Pennsylvania, United States|East Providence, Rhode Island, United States|East Providence, Rhode Island, United States|Charleston, South Carolina, United States|Mount Pleasant, South Carolina, United States|Cordova, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Murray, Utah, United States|Kirkland, Washington, United States|Richland, Washington, United States|Southport, Queensland, Australia|Caulfield, Victoria, Australia|Geelong, Victoria, Australia|Heidelberg West, Victoria, Australia|Nedlands, Western Australia, Australia|West Perth, Western Australia, Australia|Calgary, Alberta, Canada|Medicine Hat, Alberta, Canada|Kentville, Nova Scotia, Canada|Chatham, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Gatineau, Quebec, Canada|Greenfield Park, Quebec, Canada|Cork, Ireland|Dublin 8, Ireland|Galway, Ireland|Christchurch, Canterbury, New Zealand|Christchurch, Canterbury, New Zealand|Cape Town, South Africa|Cape Town, South Africa|Johannesburg, South Africa|St. George, South Africa|Glasgow, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Northampton, United Kingdom|Oxford, United Kingdom|Penarth, United Kingdom|Preston, United Kingdom|Sheffield, United Kingdom|Southhampton, United Kingdom|Swindon, United Kingdom|Warrington, United Kingdom",,https://ClinicalTrials.gov/show/NCT02080364
NCT02078310,Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia,,Completed,No Results Available,Alzheimer's Disease,Drug: ITI-007|Drug: Placebo,Number of participants with adverse events|Area under the concentration-time curve (AUC),"Intra-Cellular Therapies, Inc.",All,65 Years and older   (Older Adult),Phase 1|Phase 2,35,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",ITI-007-200,Feb-14,Aug-14,Nov-14,5-Mar-14,null,17-Nov-17,"Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT02078310
NCT02079246,Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease,STAR Extension,Completed,Has Results,Alzheimer's Disease,Drug: Idalopirdine 60 mg,Number of Treatment Emergent Adverse Events (TEAEs) in the OLEX|Number of TEAEs in the OLEX-MEM|Change in Cognition|Clinical Global Impression Score|Change in Daily Functioning|Change in Behavioural Disturbance|Change in Cognitive Aspects of Mental Function,H. Lundbeck A/S,All,"50 Years and older   (Adult, Older Adult)",Phase 3,1463,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14861B|2013-000001-23,7-Apr-14,6-Jul-17,6-Jul-17,5-Mar-14,10-Aug-18,10-Aug-18,"US027, Birmingham, Alabama, United States|US012, Phoenix, Arizona, United States|US338, Phoenix, Arizona, United States|US024, Little Rock, Arkansas, United States|US351, Carlsbad, California, United States|US346, Costa Mesa, California, United States|US327, Fullerton, California, United States|US023, Imperial, California, United States|US045, Long Beach, California, United States|US307, Redlands, California, United States|US058, San Francisco, California, United States|US018, Santa Ana, California, United States|US301, Santa Rosa, California, United States|US021, Bradenton, Florida, United States|US050, Brooksville, Florida, United States|US308, Delray Beach, Florida, United States|US320, Hallandale Beach, Florida, United States|US347, Hialeah, Florida, United States|US340, Lake Worth, Florida, United States|US303, Miami, Florida, United States|US313, Miami, Florida, United States|US345, Orange City, Florida, United States|US019, Orlando, Florida, United States|US309, Palm Beach Gardens, Florida, United States|US038, Port Charlotte, Florida, United States|US302, Sunrise, Florida, United States|US304, Atlanta, Georgia, United States|US360, Augusta, Georgia, United States|US048, Kailua, Hawaii, United States|US030, Chicago, Illinois, United States|US040, Indianapolis, Indiana, United States|US334, Lake Charles, Louisiana, United States|US036, Freeport, Maine, United States|US344, Boston, Massachusetts, United States|US035, Kalamazoo, Michigan, United States|US310, Saint Paul, Minnesota, United States|US041, Flowood, Mississippi, United States|US321, Hattiesburg, Mississippi, United States|US339, Manchester, New Jersey, United States|US046, Princeton, New Jersey, United States|US028, Toms River, New Jersey, United States|US044, Toms River, New Jersey, United States|US014, Manhasset, New York, United States|US029, New York, New York, United States|US312, Staten Island, New York, United States|US316, Charlotte, North Carolina, United States|US336, Winston-Salem, North Carolina, United States|US007, Centerville, Ohio, United States|US323, Cincinnati, Ohio, United States|US006, Columbus, Ohio, United States|US306, Columbus, Ohio, United States|US352, Lakewood, Ohio, United States|US333, Oklahoma City, Oklahoma, United States|US026, Portland, Oregon, United States|US057, Jenkintown, Pennsylvania, United States|US324, Pittsburgh, Pennsylvania, United States|US341, Pittsburgh, Pennsylvania, United States|US319, Port Royal, South Carolina, United States|US356, Cordova, Tennessee, United States|US343, Fort Worth, Texas, United States|US354, Houston, Texas, United States|US047, Arlington, Virginia, United States|US025, Madison, Wisconsin, United States|US004, Milwaukee, Wisconsin, United States|AR303, Banfield, Argentina|AR007, Buenos Aires, Argentina|AR003, Ciudad Autonoma Buenos Aires, Argentina|AR304, Ciudad Autonoma Buenos Aires, Argentina|AR308, Ciudad Autonoma Buenos Aires, Argentina|AR311, Ciudad Autonoma Buenos Aires, Argentina|AR313, Ciudad Autonoma Buenos Aires, Argentina|AR314, Ciudad Autonoma Buenos Aires, Argentina|AR312, Ciudad Autonoma de Buenos Aires, Argentina|AR009, Cordoba, Argentina|AR307, Cordoba, Argentina|AR309, Cordoba, Argentina|AR305, Godoy Cruz, Argentina|AR004, Mar del Plata, Argentina|AR005, Mendoza, Argentina|AR008, Mendoza, Argentina|AR310, Mendoza, Argentina|AR010, Rosario, Argentina|AR302, Santa Fe, Argentina|AR306, Santiago del Estero, Argentina|BE003, Brugge, Belgium|BE002, Brussels, Belgium|BE004, Bruxelles, Belgium|BE005, Leuven, Belgium|BE001, Roeselare, Belgium|BR307, Curitiba, Brazil|BR309, Curitiba, Brazil|BR303, Porto Alegre, Brazil|BR301, Rio de Janeiro, Brazil|BR306, Rio de Janeiro, Brazil|BR302, Sao Paulo, Brazil|BR304, São Paulo, Brazil|BR308, São Paulo, Brazil|BG005, Plovdiv, Bulgaria|BG001, Sofia, Bulgaria|BG002, Sofia, Bulgaria|BG003, Sofia, Bulgaria|BG004, Sofia, Bulgaria|BG006, Sofia, Bulgaria|CA002, Gatineau, Canada|CA309, Gatineau, Canada|CA301, Halifax, Canada|CA302, Kelowna, Canada|CA006, London, Canada|CA306, Montreal, Canada|CA008, Newmarket, Canada|CA304, Qubec, Canada|CA001, Toronto, Canada|CA305, Toronto, Canada|CA308, Toronto, Canada|CA307, Verdun, Canada|CL004, Antofagasta, Chile|CL002, Santiago, Chile|CL003, Santiago, Chile|CL005, Santiago, Chile|CL001, Valdivia, Chile|HR304, Zabok, Croatia|HR301, Zagreb, Croatia|HR302, Zagreb, Croatia|CZ006, Brno, Czechia|CZ309, Chocen, Czechia|CZ306, Hradec Kralove, Czechia|CZ007, Kutna Hora, Czechia|CZ004, Pardubice, Czechia|CZ310, Praha 10 - Strasnice, Czechia|CZ003, Praha 10, Czechia|CZ304, Praha 10, Czechia|CZ001, Praha 2, Czechia|CZ002, Praha 6, Czechia|CZ301, Praha 6, Czechia|CZ303, Praha 6, Czechia|CZ005, Rychnov nad Kneznou, Czechia|DK003, Aarhus N, Denmark|DK001, Copenhagen, Denmark|EE301, Tallinn, Estonia|EE303, Tallin, Estonia|EE302, Tartu, Estonia|FI302, Kuopio, Finland|FI303, Oulu, Finland|FI301, Turku, Finland|FR006, Besancon Cedex, France|FR301, Bordeaux, France|FR308, Bron cedex, France|FR309, Elancourt, France|FR008, Limoges, France|FR302, Marseille cedex 5, France|FR003, Nantes Cedex, France|FR312, Nantes, France|FR303, Nice, France|FR005, Paris cedex 10, France|FR001, Paris, France|FR311, Paris, France|FR306, Reims, France|FR305, Rouen, France|FR004, Saint Priest en Jarez, France|FR313, Saint Priest en Jarez, France|FR002, Toulouse, France|DE002, Berlin, Germany|DE006, Ellwangen, Germany|DE005, Hannover, Germany|DE007, Heidelberg, Germany|DE009, Munchen, Germany|DE008, Ulm, Germany|DE004, Unterhaching, Germany|HU304, Budapest, Hungary|HU305, Budapest, Hungary|HU301, Esztergom, Hungary|HU302, Szeged, Hungary|IL302, Haifa, Israel|IL303, Holon, Israel|IL304, Ramat Gan, Israel|IT004, Ancona, Italy|IT006, Brescia, Italy|IT306, Brescia, Italy|IT309, Brescia, Italy|IT313, Cefalù, Italy|IT002, Firenze, Italy|IT311, Genova, Italy|IT003, Lamezia Terme, Italy|IT001, Milano, Italy|IT312, Monza, Italy|IT005, Palermo, Italy|IT007, Palermo, Italy|IT307, Perugia, Italy|IT301, Pisa, Italy|IT305, Roma, Italy|IT308, Roma, Italy|IT304, Torino, Italy|IT310, Torrette, Italy|KR303, Busan, Korea, Republic of|KR301, Incheon, Korea, Republic of|KR308, Seongnam-si, Korea, Republic of|KR302, Seoul, Korea, Republic of|KR304, Seoul, Korea, Republic of|KR305, Seoul, Korea, Republic of|KR306, Seoul, Korea, Republic of|KR307, Seoul, Korea, Republic of|KR309, Seoul, Korea, Republic of|LT302, Kaunas, Lithuania|LT303, Kaunas, Lithuania|LT301, Vilnius, Lithuania|LT304, Vilnius, Lithuania|PL301, Bialystok, Poland|PL304, Bydgoszcz, Poland|PL308, Gdynia, Poland|PL004, Gliwice, Poland|PL007, Katowice, Poland|PL309, Krakow, Poland|PL302, Lodz, Poland|PL310, Lubin, Poland|PL306, Lublin, Poland|PL307, Oswiecim, Poland|PL303, Poznan, Poland|PL005, Pozna, Poland|PL006, Sopot, Poland|PL002, Szczecin, Poland|PL311, Szczecin, Poland|PL003, Warszawa, Poland|PL008, Wroclaw, Poland|PT301, Amadora, Portugal|PT302, Coimbra, Portugal|RO002, Bucharest, Romania|RO001, Târgu-Mureş, Romania|ZA003, Bloemfontein, South Africa|ZA006, Cape Town, South Africa|ZA007, Cape Town, South Africa|ZA004, George, South Africa|ZA001, Pretoria, South Africa|ZA002, Rosebank, South Africa|ES006, Barcelona, Spain|ES005, Manresa, Spain|ES004, Salamanca, Spain|ES001, San Sebastian, Spain|ES002, San Vicente del Raspeig, Spain|ES003, Santiago de Compostela, Spain|TW301, Kaohsiung, Taiwan|TW302, Kaohsiung, Taiwan|TW303, Tainan, Taiwan|UA008, Dnipropetrovsk, Ukraine|UA006, Kherson, Ukraine|UA005, Kyiv, Ukraine|UA007, Kyiv, Ukraine|UA001, Lviv, Ukraine|GB307, Amersham, United Kingdom|GB301, Glasgow, United Kingdom|GB303, London, United Kingdom|GB308, London, United Kingdom|GB310, London, United Kingdom|GB306, Plymouth, United Kingdom|GB311, Plymouth, United Kingdom|GB309, Prescot, United Kingdom|GB305, Preston, United Kingdom|GB304, Southampton, United Kingdom|GB302, Swindon, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02079246/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02079246/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02079246
NCT02074215,Effect of Exercises Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Other: Aerobic exercises|Other: Stretch exercise,Changes of Memory and executive function related neuropsychological test|Changes of muscle strength of upper and lower extremity and walking speed,National Taiwan University Hospital,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,19,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,201012136RB,Mar-11,Dec-12,Dec-13,28-Feb-14,null,28-Feb-14,"National Taiwan University Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02074215
NCT02064920,Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318),,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Donepezil,One-card Learning (OCL) Measurement Over 12 Weeks of Treatment|Percentage of Correct Responses in the OCL Task Over 12 Weeks of Treatment,Merck Sharp & Dohme Corp.,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic",0000-318,22-Apr-14,13-Jul-16,13-Jul-16,17-Feb-14,1-Aug-17,12-Oct-18,,,https://ClinicalTrials.gov/show/NCT02064920
NCT02063269,Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles,,Unknown status,No Results Available,Alzheimer's Disease,Drug: Rivastigmine,the mean changes of Standardized Uptake Values (SUVmean) in PET imaging|the mean changes of serum BuChE activity between BuChE wild type and K-variant type|the mean changes of cortical thickness in brain MRI|the cognitive changes in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)|the cognitive changes in Mini-Mental State Exam (MMSE)|the daily function changes by Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|the behavioural changes by Caregiver-Administered Neuropsychiatric Inventory (NPI)|the disease severity changes by Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) between BuChE wild type and K-variant type,Seoul National University Hospital|Novartis Korea Ltd.,All,"55 Years to 80 Years   (Adult, Older Adult)",Not Applicable,70,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CENA713DKR15T,Feb-14,Jun-17,Jun-17,14-Feb-14,null,14-May-15,"Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02063269
NCT02063308,Oxaloacetate Pharmacokinetics and Safety,,Completed,No Results Available,Alzheimer's Disease,Dietary Supplement: Oxaloacetate (OAA),Correlation between oral OAA intake and plasma levels|safety of OAA in study participants,"Russell Swerdlow, MD|University of Kansas Medical Center",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,STUDY00000581,Feb-14,Jun-14,Jun-14,14-Feb-14,null,24-Jul-14,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02063308
NCT02061878,A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects,,Completed,No Results Available,Alzheimer's Disease,Drug: Bexarotene|Drug: Placebo,"Area under the effect curve for newly generated beta-Amyloid (clearance phase),|Fractional clearance rate of beta-Amyloid peptide in CNS","ReXceptor, Inc.",All,21 Years to 50 Years   (Adult),Phase 1,12,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)",REXCEPTOR-101,Aug-14,Nov-14,Nov-14,13-Feb-14,null,13-Aug-15,"Compass Research, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT02061878
NCT02062099,PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO),NIDeCo,Unknown status,No Results Available,Memory Complaint|Mild Cognitive Impairment|Alzheimer Disease,Drug: [18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment,"Fixation and distribution of [18F]DPA-714 (Binding Potential BP)|[18F]AV-45 Standard Uptake Values ratio|Relationship between [18F]DPA-714 uptake and cognitive, affective symptoms at baseline.","University Hospital, Tours",All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1,36,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PHAO13-CH/ NIDeCo,Jan-14,Jan-16,Jan-18,13-Feb-14,null,13-Feb-14,"University Hospital of Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT02062099
NCT02054208,Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer's Disease,Biological: human umbilical cord blood derived mesenchymal stem cells|Other: Normal saline 2mL,Number of subjects with adverse events|Change from the baseline in ADAS-Cog|Change from the baseline in S-IADL|Change from the baseline in K-MMSE|Change from the baseline in CGA-NPI|ADAS-Cog Response Rate|Change in CDR-SOB|Change in Florbetaben-PET|Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)|Change in CIBIC-plus|Change from baseline in MRI (DTI mapping)|Change from the baseline in CSF biomarkers,Medipost Co Ltd.,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP-CR-010,Feb-14,Jul-19,Jul-19,4-Feb-14,null,17-Aug-18,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02054208
NCT02052947,Co-LEsions in Alzheimer Disease and Related Disorders,CLEM,Recruiting,No Results Available,Alzheimer's Disease|Cerebrovascular Disease|Lewy Body Disease,Radiation: SPECT-DaTscan,Disability progression|Neuropsychological inventory|NeuroPsychiatric inventory|Clinical/serum markers,Hospices Civils de Lyon,All,70 Years and older   (Older Adult),Not Applicable,214,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2013.795,Jan-14,Jul-18,Oct-20,3-Feb-14,null,23-Aug-17,"Hopital Charpennes, Villeurbanne, France",,https://ClinicalTrials.gov/show/NCT02052947
NCT02051335,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,,Completed,Has Results,Memory Impairment|Alzheimer's Disease,Drug: Roflumilast|Drug: Roflumilast placebo|Drug: Donepezil|Drug: Donepezil placebo|Drug: Scopolamine,Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Delayed Recall at 1 Hour After Scopolamine Administration|Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Immediate Recall at 1 Hour After Scopolamine Administration|Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Immediate and Delayed Recall at 2 and 4 Hours After Scopolamine Administration|Change From Baseline in the Paired Associates Learning (PAL) Total Number of Errors Adjusted at All Time-points Assessed After Scopolamine Administration|Change From Baseline in the Rapid Visual Information Processing (RVP) A Prime Signal Detection at All Time-points Assessed After Scopolamine Administration|Change From Baseline in the Rapid Visual Information Processing (RVP) Median Latency at All Time-points Assessed After Scopolamine Administration|Change From Baseline in the Spatial Working Memory (SWM) Total Number of Between Errors at the 10-Box Stage and the 12-Box Stage at All Time-points Assessed After Scopolamine Administration|Percentage of Participants Who Experience at Least 1 Treatment Emergent Adverse Event (TEAE)|Percentage of Participants With Markedly Abnormal Safety Laboratory Tests|Percentage of Participants With Markedly Abnormal Vital Sign Measurements at Least Once Post-dose|Percentage of Participants With Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-Dose,AstraZeneca,Male,18 Years to 45 Years   (Adult),Phase 1,27,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ROF-ALZ_102|2012-002089-11|U1111-1151-7178,Jan-14,May-14,May-14,31-Jan-14,17-Aug-15,1-Feb-17,"London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02051335
NCT02051608,A Study of Gantenerumab in Participants With Mild Alzheimer Disease,,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: Gantenerumab|Drug: Placebo,"Mean Change From Baseline in Alzheimer's Disease Activity Scale-Cognitive subscale 13 (ADAS-Cog13) scores at Week 104|Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scores at week 104|Part 2: Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Total Tau (t-tau) in CSF at Week 104|Change From Baseline in phosphorylated tau [p-tau]in CSF at Week 104|Change From Baseline in Abeta 1-42 levels in CSF at Week 104|Change From Baseline in Hippocampal Volume, as Assessed by Magnetic Resonance Image (MRI) at Week 104|Change From Baseline in Whole Brain Volume, as assessed by MRI at Week 104|Change From Baseline in Cortical thickness, as assessed by MRI at Week 104|Change From Baseline in Ventricular Volume, as Assessed by MRI at Week 104|Change From Baseline in Clinical Dementia Rating Global Score (CDR-GS) at Week 104|Change From Baseline in CDR Sum of Boxes (SB) at Week 104|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Week 104|Change From Baseline in NPI Domain Score at Week 104|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Week 104|Safety: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs)|Percentage of Participants with anti-gantenerumab antibodies|Change From Baseline in Columbia - Suicide Severity Rating Scale (C-SSRS) Over Week 152|Pharmacokinetics: Apparent Total Clearance (CL/F) of gantenerumab|Pharmacokinetics: Apparent Volume of Distribution (V/F) of gantenerumab|Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of gantenerumab|Pharmacokinetics: Time to Reach Maximum Plasma Concentrations (Tmax) of gantenerumab|Pharmacokinetics: Minimum Observed Plasma Concentration (Cmin) of gantenerumab|Pharmacokinetics: Area Under Plasma Concentration (AUC) -Time Curve of gantenerumab|Quality of Life - Change From Baseline in Alzheimer's Dementia (QoL-AD) Global Score at Week 104|Efficacy: Change From Baseline in Symptom Guide Facilitated (GAS) at Week 104|Efficacy: Change from Baseline in Dependence Scale (DS) at Week 104|Efficacy: Change From Baseline in Resource Utilization Dementia-Lite (RUD - Life) Scale at Week 104|Change From Baseline in Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) at Week 104|Time to Clinical Decline (as measured by Confirmed greater than or equal to [>=] 2-point decline on MMSE, Loss of >= 1 or 2 points on one or more ADL and I ADL, respectively)|Change from Baseline in Clinical Composite Score (Prespecified Items From The ADAS-Cog, MMSE, and CDR) at Week 104",Hoffmann-La Roche,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,389,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WN28745|2013-003390-95,27-Mar-14,20-Nov-20,20-Nov-20,31-Jan-14,null,8-May-19,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|Territory Neurology and Research Institute, Tucson, Arizona, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Neuropsychiatric Research Center of Orange County, Orange, California, United States|Pacific Research Network - PRN, San Diego, California, United States|California Neuroscience Research Medical Group, Inc, Sherman Oaks, California, United States|Radiant Research, Inc., Denver, Colorado, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems; Clinical Research, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|University of South Florida, Tampa, Florida, United States|Bioclinica The Villages, The Villages, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research, Kalamazoo, Michigan, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Ocean Rheumatology, Toms River, New Jersey, United States|Nathan Kline Institute, Orangeburg, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Richard H Weisler, MD, Raleigh, North Carolina, United States|Tulsa Clinical Research LLC, Tulsa, Oklahoma, United States|Northeastern Pennsylvania Memory, Plains, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Neurology Clinic PC, Cordova, Tennessee, United States|Senior Adults Specialty Research, Austin, Texas, United States|University of Utah, Center for Alzheimer's Care Imaging & Research, Salt Lake City, Utah, United States|Instituto Neurologia Bs As, Ciudad Autonoma de Bs As, Argentina|Instituto de Neurología y Neurorehabilitación del Litoral (INNEL), Santa Fé, Argentina|Hornsby Ku-ring-gai Hospital; Division of Rehabilitation & Aged Care, Hornsby, New South Wales, Australia|Royal Adelaide Hospital; Memory Trials Centre, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Shat Np Sveti Naum; 3Rd Clinic of Neurology, Sofia, Bulgaria|MBAL St. Marina; First Neurology Department, Varna, Bulgaria|University of Calgary; Heritage Medical Research Clinic, Calgary, Alberta, Canada|The Medical Arts Health Research Group, Powell River, British Columbia, Canada|True North Clinical Research-Halifax, Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|Jbn Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Queens University - Hotel Dieu Hospital, Kingston, Ontario, Canada|Parkwood Hospital; Geriatric Medicine, London, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Recherches Neuro-Hippocame, Gatineau, Quebec, Canada|NeuroSearch Developpements inc, Greenfield Park, Quebec, Canada|Jewish General Hospital / McGill University, Montreal, Quebec, Canada|CHAUQ Hopital Enfant-Jesus, Quebec City, Quebec, Canada|McGill Univeristy; Douglas Mental Health University Institute; Neurological and Psychiatric, Verdun, Quebec, Canada|ALPHA Recherche Clinique, Quebec, Canada|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus N, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|University of Eastern Finland, Kuopio, Finland|CRST Oy, Turku, Finland|Hopital Pellegrin; Cmrr Aquitaine, Bordeaux, France|Hopital Pierre Wertheimer; Laboratoire De Neuro Psychologie, Bron, France|CHU de Limoges Hopital Dupuytren; Service de Medecine Geriatrique, Limoges, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France|CHU Rennes - hopital Hotel Dieu; Consultation Memoire - Gerontologie, Rennes, France|Hop Guillaume Et Rene Laennec; Cmrr St Herblain, St Herblain, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|Hopital la Grave; Gerontopole - Centre de Recherche Clinique, Toulouse, France|ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic, Berlin, Germany|Universitätsklinik Göttingen; Klinik für Psychiatrie und Psychotherapie; Gedächtnisambulanz, Göttingen, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Pharmakologisches Studienzentrum, Mittweida, Germany|Klinikum rechts der Isar der TU München; Klinikapotheke, Muenchen, Germany|Neurologische Praxis Dr. Andrej Pauls, München, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, Germany|Clinica Humanamente, Ciudad de Guatemala, Guatemala|Edificio Multimédica, Ciudad De Guatemlala, Guatemala|Semmelweis University; Department of Neurology, Budapest, Hungary|University of Szeged; Department of Psychiatry, Szeged, Hungary|Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica - Dipartimento di Neuroscienze, Modena, Emilia-Romagna, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata; Neurologia, Roma, Lazio, Italy|Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy|IRCCS ""Centro S. Giovanni di Dio"" Fatebenefratelli -UO Alzheimer, Brescia, Lombardia, Italy|Irccs Multimedica Santa Maria; Unita' Di Neurologia, Castellanza, Lombardia, Italy|Fondazione San Raffaele Del Monte Tabor; Dipartimento Di Neurologia, Milano, Lombardia, Italy|ASST DI MONZA; Neurologia, Monza, Lombardia, Italy|A.O. Universitaria Pisana; Neurologia, Pisa, Toscana, Italy|Medical Corporation Hakuyokai Kashiwado Hospital, Chiba, Japan|National Hospital Organization Chiba-east Hospital; Neurology, Chiba, Japan|Juntendo University Urayasu Hospital; Neurology, Chiba, Japan|Fukuoka University Hospital; Neurology and Health Care, Fukuoka, Japan|Maebashi Red Cross Hospital; Neurology, Gunma, Japan|National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan|Hyogo Brain and Heart Center at Himeji; Department of Aging Brain and Cognitive Disorders, Hyogo, Japan|Shonan Kamakura General Hospital; Neurology, Kanagawa, Japan|National Hospital Organization Utano National Hospital; Neurology, Kyoto, Japan|Nagasaki kita Hospital; Neurology, Nagasaki, Japan|Mishima Hospital; psychiatry, Niigata, Japan|Oita University Hospital; Neurology, Oita, Japan|Kurashiki Heisei Hospital; Neurology, Okayama, Japan|Osaka City University Hospital; Geriatric Medicine and Neurology, Osaka, Japan|Shizuoka City Shimizu Hospital; Neurology, Shizuoka, Japan|Dong-A University Medical Center, Busan, Korea, Republic of|Seoul National University Bundang Hospital; Neurology Department, Gyeonggi-do, Korea, Republic of|Inha University Hospital; Neurology Department, Incheon, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital; Dept of Neurology, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Brain Research Center B.V, Amsterdam, Netherlands|Erasmus Mc - Locatie Centrum; Dept of Neurology, Rotterdam, Netherlands|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, Portugal|Republican clinical hospital of regenerative treatment of Ministry of Health of Tatarstan republic, Kazan, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Institution of RAMS (Mental Health Research Center of RAMS), Moscow, Russian Federation|SBEI of HPI The 1st Moscow State Medical University n.a. I.M. Sechenov of MOH of RF, Moscow, Russian Federation|Saint Petersburg State Institution of Healthcare City Geriatric Medico-Social Center, Saint Petersburg, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|St. Petersburg GUZ City Psychiatric Hospital #6, St Petersburg, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|Hospital General Universitario de Elche; Servicio de Neurología, Elche, Alicante, Spain|Fundació ACE, BArcelon, Barcelona, Spain|Policlínica Guipuzkoa; Servicio de Neurología, Donosti-San Sebastián, Guipuzcoa, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmoe, Sweden|Karolinska Uni Hospital, Huddinge; Dept. of Geriatric Med, Stockholm, Sweden|Universitäres Zentrum für Altersmedizin und Rehabilitation, Basel, Switzerland|CHUV; Centre Leenaards de la Mémoire, Lausanne, Switzerland|Akdeniz University School of Medicine, Neurology Department, Antalya, Turkey|Osmangazi University School of Medicine,Neurology Department, Eskişehir, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Dokuz Eylul University Medicine Faculty; Noroloji Departmani, Izmir, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, Turkey|Sussex Partnership NHS Foundation Trust; Cognitive Treatment and Research unit, Crowborough, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Charing Cross Hospital; Dept of Neurosciences, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Royal Preston Hosptial, Preston, United Kingdom|Memory Service North, Sheffield, United Kingdom|Memory Assesment and Research Centre (MARC), Southampton, United Kingdom|Victoria Centre; Kingshill Research Centre, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT02051608
NCT02051764,Imaging Characteristics of a Follow-up 18F-AV-1451 Scan,,Completed,No Results Available,Alzheimer's Disease,Drug: 18F-AV-1451|Drug: Florbetapir F 18,Change in Tau deposition,Avid Radiopharmaceuticals,All,"50 Years and older   (Adult, Older Adult)",Phase 2,38,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-1451-A04,May-14,Dec-16,Dec-16,31-Jan-14,null,9-Feb-17,"Hoag Memorial Hospital, Newport Beach, California, United States|UC Irvine Medical Center, Orange, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Center for Clinical Imaging Research, Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02051764
NCT02051790,Evaluation of Reader Training Processes,,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Agreement Between Expert Panel and Clinical Practice Reads,Avid Radiopharmaceuticals,All,"Child, Adult, Older Adult",Phase 4,241,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-RTP01,Mar-14,Aug-14,Aug-14,31-Jan-14,28-Sep-15,28-Sep-15,"Research Site, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02051790
NCT02045056,Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease,,"Active, not recruiting",No Results Available,Preclinical Alzheimer's Disease,Drug: Gemfibrozil|Drug: Placebo,Safety|microRNA-107 levels|beta-amyloid levels|Free and cued selective reminding test (FCSRT)|Paired associates learning (PAL),"Gregory Jicha, 323-5550|University of Kentucky",All,65 Years to 90 Years   (Older Adult),Early Phase 1,72,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",R01AG042419,May-14,30-Jun-18,Jun-19,24-Jan-14,null,16-Oct-18,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT02045056
NCT02040987,AZD3293 Thorough QT Study in Healthy Male Volunteers,AZD3293TQT,Completed,No Results Available,Alzheimer's Disease,Drug: AZD3293|Drug: Placebo|Drug: Moxifloxacin,"The effect of a single dose of AZD3293 low dose and high dose on the change in time-matched QTcF intervals compared with placebo.|The effect of a single oral dose of moxifloxacin on the changes in time-matched QTcF intervals compared with placebo.|The safety and tolerability of AZD3293 in healthy male subjects by assessing a panel of adverse events measures|Plasma concentrations, AUC, Cmax and tmax of single dose AZD3293 and moxifloxacin in healthy male subjects|The effect of AZD3293 on additional electrocardiogram (ECG) variables (heart rate, RR, PR, QRS, QT and QTcB)",AstraZeneca|Parexel,Male,18 Years to 55 Years   (Adult),Phase 1,52,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",D5010C00008,Jan-14,May-14,May-14,20-Jan-14,null,3-Jul-14,"Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02040987
NCT02036645,"SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.",,Completed,No Results Available,Mild-Moderate Alzheimer's Disease|Healthy Elderly,Biological: MEDI1814 for IV injection|Biological: MEDI1814 for Subcutaneous Injection|Biological: IV Placebo|Biological: Placebo for Subcutaneous Injection,"To Assess Safety & Tolerability of MEDI1814 by a panel of adverse event measures: Physical exam, Vital signs, ECG, clinical laboratory testing, MRI, Columbia Suicide Severity Rating Scale|To Assess Pharmacokinetics of MEDI1814 in terms of: ﻿Cmax, Cmin, tmax, AUC, t1/2, CL and Vz for SAD and for MAD First dose: Cmax, Cmin, tmax, AUC and Third Dose: Cmax, Cmin, tmax, AUC, t1/2, CL, Vz, Vss and accumulation rations|To Assess Pharmacodynamics of MEDI1814 in terms of a) blood biomarkers: total amyloid beta 1-42 and b) CSF biomarkers: total and free amyloid beta 1-42 and total amyloid beta 1-40|To Assess Immunogenicity of MED1814 in terms of anti drug antibody detection",AstraZeneca,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,219,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",D4750C00001,Feb-14,Sep-16,Sep-16,15-Jan-14,null,27-Sep-16,"Research Site, Glendale, California, United States|Research Site, Long Beach, California, United States|Research Site, Panorama City, California, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Baltimore, Maryland, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02036645
NCT02035553,A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis,,Completed,Has Results,Alzheimer's Disease Psychosis,Drug: Pimavanserin tartrate|Drug: Placebo,Antipsychotic Efficacy,ACADIA Pharmaceuticals Inc.,All,"50 Years and older   (Adult, Older Adult)",Phase 2,181,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ACP-103-019,Nov-13,28-Sep-16,27-Oct-16,14-Jan-14,25-Oct-17,25-Oct-17,"London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02035553
NCT02035982,Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Dementia,Drug: Cholinesterase Inhibitor|Drug: Placebo,Clinician's Global Impression of Change (CGIC)|Number of total adverse events,Sunnybrook Health Sciences Centre,All,"55 Years and older   (Adult, Older Adult)",Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",107-2010|Grant #12-74,Jul-10,May-14,Sep-15,14-Jan-14,null,28-Apr-17,"North York General Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02035982
NCT02033941,Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD),,Recruiting,No Results Available,Alzheimer's Disease,Drug: Meganatural-Az Grapeseed Extract|Drug: Placebo,pharmacokinetic analysis|primary safety evaluations|AD Biomarkers|cognitive and functional assessments,Hillel Grossman|National Center for Complementary and Integrative Health (NCCIH)|Icahn School of Medicine at Mount Sinai,All,"Child, Adult, Older Adult",Phase 2,20,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GCO 09-0307|5R21AT005510,Nov-14,Sep-20,Sep-20,13-Jan-14,null,13-Mar-19,"Mount Sinai Alzheimer's Disease Research Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02033941
NCT02031198,"18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease",FUNDAMANT,Completed,No Results Available,Alzheimer's Disease,Drug: AADvac1,Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease|Immunogenicity of AADvac1|Patient cognition,Axon Neuroscience SE,All,"50 Years to 86 Years   (Adult, Older Adult)",Phase 1,25,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AC-AD-002|2013-004499-36,Jan-14,Aug-16,Dec-16,9-Jan-14,null,17-Mar-17,"Medizinische Universitat Graz, Graz, Steiermark, Austria|Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik, Salzburg, Austria|Medizinische Universitat Wien, Wien, Austria|Sozialmedizinisches Zentrum Ost (SMZ Ost) /Donauspital, Memory Clinic and Karl Landsteiner Institut for Amnestic disorders, Wien, Austria",,https://ClinicalTrials.gov/show/NCT02031198
NCT02029547,Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians,,Withdrawn,No Results Available,Alzheimer's Disease,Drug: Florbetapir (18F),Inter Rater Reliability|Percent Agreement with Expert Panel|Change in inter reader reliability after application of quantitation software|Change in agreement with expert panel,Avid Radiopharmaceuticals,All,"Child, Adult, Older Adult",Not Applicable,0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-JPT01,Oct-14,May-15,May-15,8-Jan-14,null,23-Oct-14,"Research Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02029547
NCT02020356,Music Therapy in Alzheimer's Disease,PRE-MUSICAL,Terminated,No Results Available,Alzheimer's Type Dementia,Behavioral: Music therapy|Behavioral: Placebo,Neuroleptic reduction dose|Durability of treatment effect,"University Hospital, Toulouse",All,65 Years to 100 Years   (Older Adult),Not Applicable,35,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,RC31/12/0385|AOL 2012,Apr-13,Jun-15,Jun-15,24-Dec-13,null,6-Feb-18,"University Hospital Toulouse, Toulouse, Midi-Pyrenees, France|EHPAD La Villegiale, Castres, Tarn, France|Residence Christian Bressole, Castres, Tarn, France|EHPAD L'Oustal d'en Thibaud, Labruguiere, Tarn, France|EHPAD Les Quietudes, Lautrec, Tarn, France|EHPAD KORIAN Grand Maison, L'Union, France|Centre Hospitalier Gérard Marchant, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02020356
NCT02016560,"Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects",,Completed,No Results Available,Alzheimer's Disease,Drug: florbetapir F 18|Drug: 18F-AV-1451,Cross-sectional 18F-AV-1451 Imaging Results|Change in tau deposition over time|18F-AV-1451 imaging in healthy individuals,Avid Radiopharmaceuticals,All,"20 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,383,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-1451-A05,Dec-13,28-Jul-17,28-Jul-17,20-Dec-13,null,25-Oct-18,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Four Peaks Neurology, Scottsdale, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|UC Irvine, Irvine, California, United States|Hoag Memorial, Newport Beach, California, United States|Norther California PET Imaging Center, Sacramento, California, United States|UC Davis, Sacramento, California, United States|UC San Francisco, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Molecular NeuroImaging, New Haven, Connecticut, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|21st Century Oncology, Fort Myers, Florida, United States|Sandlake Imaging, Orlando, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|USF Health Byrd Alzheimer's Center, Tampa, Florida, United States|Independent Imaging, West Palm Beach, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Center for Clinical Imaging Research, Saint Louis, Missouri, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|Center for Brain Health - NYU Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02016560
NCT02017340,A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease,NILVAD,Completed,No Results Available,Alzheimer's Disease,Drug: Nilvadipine|Drug: Placebo,Alzheimer's Disease Assessment Scale (ADAS) Cog|Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)|Disability Assessment for Dementia (DAD),"Prof Brian Lawlor|University of Dublin, Trinity College|Molecular Medicine Ireland LBG|Alzheimer Europe|Archer Pharmaceuticals, Inc.|E-Search Limited|University College Dublin|King's College London|Istituto Di Ricerche Farmacologiche Mario Negri|University Hospital, Lille|University of Ulm|Szeged University|Göteborg University|University College Cork|Aristotle University Of Thessaloniki|Stichting Katholieke Universiteit|St. James's Hospital, Ireland",All,"50 Years and older   (Adult, Older Adult)",Phase 3,511,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NILVAD2012|2012-002764-27|279093,24-Apr-13,16-Dec-16,16-Dec-16,20-Dec-13,null,6-Mar-17,"Centre Hospitalier Universitaire d'Amiens (CHU Amiens), Amiens, France|Centre Hospitalier Universitaire de Bethune (CH Bethune), Bethune, France|Centre Hospitalier Universitaire de Caen (CHU Caen), Caen, France|Centre Hospitalier Universitaire de Calais (CHU Calais), Calais, France|Centre Hospitalier Universitaire de Lens (CHU Lens), Lens, France|Centre Hospitalier Regional et Universitaire de Lille (CHRU Lille), Lille, France|Centre Hospitalier Universitaire de Saint Philibert (GHICL), Lille, France|University of Ulm, Ulm, Germany|""G. Papanicolaou"" Hospital, Athens, Greece|""G.Papageorgiou"" Hospital, Athens, Greece|AXEPA Hospital, Athens, Greece|Szeged University, Szeged, Hungary|University College Cork, Cork, Ireland|St James Hospital, Dublin, Ireland|Hospital of Brescia, Brescia, Italy|Hospital Castellanza, Castellanza, Italy|Hospital of Genoa, Genoa, Italy|Hospital of Milan, Milan, Italy|Hospital of Arnhem, Arnhem, Netherlands|Hospital of Maastricht, Maastricht, Netherlands|Hospital of Nijmegen, Nijmegen, Netherlands|Gothenburg Univeristy, Gothenburg, Sweden|Kings College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02017340
NCT02013518,Cognitive Behavioural Therapy for Persons With MCI or Mild Dementia,,Unknown status,No Results Available,Alzheimers' Disease,Behavioral: Cognitive Behavioural Therapy,Number of participants reporting decrease in depression scores|Number of participants reporting increased Self-efficacy|Number of participants reporting increased Quality of Life|Number of participants reporting change in cognitive function|Number of participating caregivers reporting decreased burden of care,Oslo University Hospital|Sykehuset i Vestfold HF|Sykehuset Innlandet HF,All,"Child, Adult, Older Adult",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2012/1943|12345,Sep-13,Dec-15,Dec-16,17-Dec-13,null,17-Dec-13,"Oslo University Hospital, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT02013518
NCT02008357,Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss,A4,"Active, not recruiting",No Results Available,Cognition Disorders,Drug: Placebo|Drug: Solanezumab,Change from Baseline of the Preclinical Alzheimer Cognitive Composite (PACC)|Change from Baseline in Cognitive Function Index (CFI)|Change from Baseline in Alzheimer's Disease Cooperative Study—Activities Daily Living—Prevention Questionnaire (ADCS-ADL-Prevention Questionnaire) Score|Change from Baseline in Mean Composite Standardized Uptake Value Ratio (SUVr)|Change from Baseline in Cerebrospinal Fluid (CSF) Tau Biomarkers|Change from Baseline of CSF Concentrations of Amyloid Beta (Abeta)|Change from Baseline of Volumetric Magnetic Resonance Imaging (vMRI)|Change from Baseline on the Clinical Dementia Rating—Sum of Boxes score (CDR-SB)|Change from Baseline on the Computerized Cognitive Composite (C3),Eli Lilly and Company|Alzheimer's Therapeutic Research Institute,All,65 Years to 85 Years   (Older Adult),Phase 3,1150,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15275|H8A-MC-LZAZ,28-Feb-14,22-Jul-22,22-Jul-22,11-Dec-13,null,4-Dec-18,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner Health Research Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Institute for Memory Impairment & Neurological Disorders, Irvine, California, United States|University of California - San Diego, La Jolla, California, United States|University of Southern California School of Medicine, Los Angeles, California, United States|University of California - Los Angeles, Los Angeles, California, United States|Univ of California Irvine College of Medicine, Orange, California, United States|Veterans Affairs Medical Center Palo Alto, Palo Alto, California, United States|Sutter Medical Group, Sacramento, California, United States|Univ of California San Francisco, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|University of California, Davis - Health Systems, Walnut Creek, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Howard University Hospital, Washington, District of Columbia, United States|Brain Matters Research, Delray Beach, Florida, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, United States|Wien Center for Clinical Research, Miami Beach, Florida, United States|Compass Research - Orlando, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Compass Research -The Villages, The Villages, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Hospital, Fairway, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Univ of Nebraska Med Center, Omaha, Nebraska, United States|Cleveland Clinic of Las Vegas, Las Vegas, Nevada, United States|Dent Neurological Institute, Amherst, New York, United States|New York University Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Tulsa Clinical Research LLC, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Drexel University College of Medicine at EPPI, Philadelphia, Pennsylvania, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Roper Hospital, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Washington School of Medicine, Seattle, Washington, United States|University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parkville, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., London, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Vancouver, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bunkyo-ku, Japan",,https://ClinicalTrials.gov/show/NCT02008357
NCT02008513,Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006,,Terminated,No Results Available,Alzheimer´s Disease,Biological: AFFITOPE® AD02|Biological: Placebo,Composite Measures of Primary Safety and Tolerability Endpoints|Composite Measures of Secondary Efficacy Endpoints,Affiris AG,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,194,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AFF006A|2012-005280-27,Jun-13,Sep-14,Sep-14,11-Dec-13,null,24-Jun-15,"Landeskrankenhaus Hall Gedächtnisambulanz, Hall in Tirol, Austria|LNK Wagner-Jauregg, Dept. of geriatrics, Linz, Austria|Christian Doppler Klinik, Univ. Klinik f. Neurologie, Salzburg, Austria|MUW Klin. Pharmakologie und Klinik für Neurologie, Vienna, Austria|MUW, Klin.Abt.f. Biolog. Psychiatrie, Vienna, Austria|SMZ-Ost, Psychiatric Dep., Vienna, Austria|Klinčki Bolnički Centar Rijeka, Klinika za Psihijatriju, Rijeka, Croatia|Opća bolnica Varaždin, Klinika za Neurologiju, Varaždin, Croatia|""BONIFARM"" Poliklinika za kliničku farmakologiju i toksikologiju, Zagreb, Croatia|Psihijatrijska Bolnica Vrapče, Zagreb, Croatia|University Thomayer Hospital, Praha, Czech Republic|University Hospital Motol, Clinic of Neurology, Praha, Czech Republic|CMRR Hôpital Pellegrin, Bâtiment USN Tastet Girard, Bordeaux Cedex, France|Hôpital Neurologique Pierre Wertheimer, Bron, France|Centre Hospitalier Universitaire (CHU) de Dijon, Dijon, France|Centre Mémoire de Ressources et de Recherche, Service de Neurologie, Montpellier Cedex, France|Hôpital de la Pitié-Salpêtrière, Paris, France|CHU de Rennes Site Hôtel Dieu, Rennes Cedex, France|Hopital La Grave, Toulouse, France|Charite Universitätsmedizin Berlin, Klinik u. Hochschulambulanz f. Psychiatrie u. Psychotherapie, Berlin, Germany|Universitätsklinikum Hamburg-Eppendorf, Klinik für Psychiatrie und Psychotherapie, Hamburg, Germany|Arzneimittelforschung Leipzig GmbH, Studienzentrum, Leipzig, Germany|Zentralinstitut für Seelische Gesundheit, Abt. Gerontopsychiatrie, Mannheim, Germany|Klinik u. Poliklinik f. Psychiatrie u. Psychotherapie der TU München, Munich, Germany|Studienzentrum PD Dr. Steinwachs, Nürnberg, Germany|NeuroPoint GmbH, Ulm/Donau, Germany|EPAMED, s.r.o., Kosice, Slovakia",,https://ClinicalTrials.gov/show/NCT02008513
NCT02006641,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,STARBEAM,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,Change in Cognition|Change in Daily Functioning|Change in Global Impression|Change in Behavioural Disturbance|Change in Individual Behavioural Disturbance Items|Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline|Number of Participants With Clinical Improvement|Number of Participants With Clinical Worsening|Change in Cognitive Aspects of Mental Function|Change in Health-related Quality of Life (EQ-5D) Utility Score|Change in Health-related Quality of Life (EQ-5D VAS),"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,858,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14862A|2012-004764-22,Feb-14,Dec-16,Dec-16,10-Dec-13,20-Feb-18,20-Feb-18,"US338, Phoenix, Arizona, United States|US342, Fayetteville, Arkansas, United States|US322, Anaheim, California, United States|US305, Carson, California, United States|US346, Costa Mesa, California, United States|US327, Fullerton, California, United States|US315, Lomita, California, United States|US351, Oceanside, California, United States|US307, Redlands, California, United States|US301, Santa Rosa, California, United States|US337, New London, Connecticut, United States|US332, Stamford, Connecticut, United States|US308, Delray Beach, Florida, United States|US320, Hallandale Beach, Florida, United States|US347, Hialeah, Florida, United States|US340, Lake Worth, Florida, United States|US303, Miami, Florida, United States|US313, Miami, Florida, United States|US335, Naples, Florida, United States|US345, Orange City, Florida, United States|US309, Palm Beach Gardens, Florida, United States|US302, Sunrise, Florida, United States|US304, Atlanta, Georgia, United States|US360, Augusta, Georgia, United States|US318, Decatur, Georgia, United States|US334, Lake Charles, Louisiana, United States|US350, Belmont, Massachusetts, United States|US344, Boston, Massachusetts, United States|US310, Saint Paul, Minnesota, United States|US321, Hattiesburg, Mississippi, United States|US330, Creve Coeur, Missouri, United States|US339, Manchester, New Jersey, United States|US312, Staten Island, New York, United States|US316, Charlotte, North Carolina, United States|US336, Winston-Salem, North Carolina, United States|US323, Cincinnati, Ohio, United States|US349, Cleveland, Ohio, United States|US306, Columbus, Ohio, United States|US352, Lakewood, Ohio, United States|US333, Oklahoma City, Oklahoma, United States|US314, Allentown, Pennsylvania, United States|US324, Pittsburgh, Pennsylvania, United States|US341, Pittsburgh, Pennsylvania, United States|US325, Reading, Pennsylvania, United States|US319, Port Royal, South Carolina, United States|US356, Cordova, Tennessee, United States|US343, Fort Worth, Texas, United States|US354, Houston, Texas, United States|AR303, Banfield, Argentina|AR301, Ciudad Autonoma Buenos Aires, Argentina|AR304, Ciudad Autonoma Buenos Aires, Argentina|AR308, Ciudad Autonoma Buenos Aires, Argentina|AR311, Ciudad Autonoma Buenos Aires, Argentina|AR313, Ciudad Autonoma Buenos Aires, Argentina|AR314, Ciudad Autonoma Buenos Aires, Argentina|AR315, Ciudad Autonoma Buenos Aires, Argentina|AR312, Ciudad Autonoma de Buenos Aires, Argentina|AR309, Cordoba, Argentina|AR307, Córdoba, Argentina|AR305, Godoy Cruz, Argentina|AR310, Mendoza, Argentina|AR302, Santa Fe, Argentina|AR306, Santiago del Estero, Argentina|BR307, Curitiba, Brazil|BR309, Curitiba, Brazil|BR301, Rio de Janeiro, Brazil|BR306, Rio de Janeiro, Brazil|BR308, San Paolo, Brazil|CA301, Halifax, Canada|CA302, Kelowna, Canada|CA306, Montreal, Canada|CA304, Qubec, Canada|CA303, Sherbrooke, Canada|CA305, Toronto, Canada|HR304, Zabok, Croatia|HR301, Zagreb, Croatia|HR302, Zagreb, Croatia|HR303, Zagreb, Croatia|CZ305, Brno, Czechia|CZ306, Chocen, Czechia|CZ309, Chocen, Czechia|CZ308, Pardubice, Czechia|CZ310, Praha 10 - Strasnice, Czechia|CZ304, Praha 10, Czechia|CZ307, Praha 2, Czechia|CZ301, Praha 6, Czechia|CZ303, Praha 6, Czechia|CZ302, Rychnov nad Kneznou, Czechia|EE301, Tallinn, Estonia|EE303, Tallin, Estonia|EE302, Tartu, Estonia|FI302, Kuopio, Finland|FI303, Oulu, Finland|FI301, Turku, Finland|FR301, Bordeaux, France|FR308, Bron, France|FR307, Colmar cedex, France|FR304, Dijon, France|FR309, Elancourt, France|FR302, Marseille cedex 5, France|FR303, Nice Cedex 1, France|FR306, Reims, France|FR305, Rouen, France|HU304, Budapest, Hungary|HU305, Budapest, Hungary|HU301, Esztergom, Hungary|HU303, Gyor, Hungary|HU302, Szeged, Hungary|IE301, Cork, Ireland|IL302, Haifa, Israel|IL303, Holon, Israel|IL304, Ramat Gan, Israel|IT306, Brescia, Italy|IT309, Brescia, Italy|IT311, Genova, Italy|IT312, Monza, Italy|IT302, Naples, Italy|IT313, Palermo, Italy|IT307, Perugia, Italy|IT301, Pisa, Italy|IT305, Roma, Italy|IT308, Roma, Italy|IT304, Torino, Italy|IT310, Torrette, Italy|KR303, Busan, Korea, Republic of|KR301, Incheon, Korea, Republic of|KR308, Seongnam-si, Korea, Republic of|KR302, Seoul, Korea, Republic of|KR304, Seoul, Korea, Republic of|KR305, Seoul, Korea, Republic of|KR306, Seoul, Korea, Republic of|KR307, Seoul, Korea, Republic of|KR309, Seoul, Korea, Republic of|LT302, Kaunas, Lithuania|LT303, Kaunas, Lithuania|LT301, Vilnius, Lithuania|LT304, Vilnius, Lithuania|PL301, Bialystok, Poland|PL304, Bydgoszcz, Poland|PL308, Gdynia, Poland|PL309, Krakow, Poland|PL302, Lodz, Poland|PL310, Lubin, Poland|PL306, Lublin, Poland|PL307, Oswiecim, Poland|PL303, Poznan, Poland|PT301, Amadora, Portugal|PT302, Coimbra, Portugal|TW301, Kaohsiung, Taiwan|TW302, Kaohsiung, Taiwan|TW303, Taichung, Taiwan|TW304, Taipei, Taiwan|TW305, Taipei, Taiwan|GB307, Amersham, United Kingdom|GB301, Glasgow, United Kingdom|GB303, London, United Kingdom|GB308, London, United Kingdom|GB306, Plymouth, United Kingdom|GB305, Preston, United Kingdom|GB304, Southampton, United Kingdom|GB302, Swindon, United Kingdom|GB309, Warrington, United Kingdom",,https://ClinicalTrials.gov/show/NCT02006641
NCT02006654,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,STARBRIGHT,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,Change in Cognition|Change in Global Impression|Change in Daily Functioning|Change in Behavioural Disturbance|Change in Individual Behavioural Disturbance Items|Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline|Clinical Improvement|Clinical Worsening|Change in Cognitive Aspects of Mental Function|Change in Health-related Quality of Life (EQ-5D) Utility Score|Change in Health-related Quality of Life (EQ-5D VAS),"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,734,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14863A|2012-004765-40,Mar-14,Jan-17,Jan-17,10-Dec-13,7-Feb-18,7-Feb-18,"US612, Mesa, Arizona, United States|US625, Bellflower, California, United States|US626, Costa Mesa, California, United States|US604, Oxnard, California, United States|US627, Santa Ana, California, United States|US609, Danbury, Connecticut, United States|US614, Norwalk, Connecticut, United States|US608, Deerfield Beach, Florida, United States|US616, Hialeah, Florida, United States|US620, Miami, Florida, United States|US603, North Palm Beach, Florida, United States|US631, Port Charlotte, Florida, United States|US622, Elk Grove Village, Illinois, United States|US611, Elkhart, Indiana, United States|US606, Prairie Village, Kansas, United States|US601, Farmington Hills, Michigan, United States|US607, Saint Louis, Missouri, United States|US613, Lawrenceville, New Jersey, United States|US635, Manchester, New Jersey, United States|US630, Toms River, New Jersey, United States|US621, Albany, New York, United States|US632, Staten Island, New York, United States|US633, Charlotte, North Carolina, United States|US623, Oklahoma City, Oklahoma, United States|US618, Norristown, Pennsylvania, United States|US619, Houston, Texas, United States|AU603, Caulfield, Australia|AU609, Glen Iris, Australia|AU602, Heidelberg West, Australia|AU604, Kanwal, Australia|AU606, Newcastle, Australia|AU601, West Perth, Australia|AU610, Woodville south, Australia|BR608, Belo Horizonte, Brazil|BR609, Itapira, Brazil|BR607, Rio de Janeiro, Brazil|CZ602, Chocen, Czechia|CZ608, Chocen, Czechia|CZ605, Havlickuv Brod, Czechia|CZ606, Kladno, Czechia|CZ603, Plzen, Czechia|CZ601, Prague, Czechia|CZ607, Praha 10 - Strasnice, Czechia|CZ604, Praha 6, Czechia|DE612, Bad Homburg, Germany|DE610, Bad Honnef, Germany|DE609, Berlin, Germany|DE617, Berlin, Germany|DE604, Erbach, Germany|DE611, Freiburg, Germany|DE607, Gelsenkirchen, Germany|DE605, Homburg, Germany|DE608, Karlstadt, Germany|DE602, Mittweida, Germany|DE601, Munich, Germany|DE606, Rostock, Germany|DE603, Ulm, Germany|DE616, Unterhaching, Germany|IL605, Bat Yam, Israel|IL601, Haifa, Israel|IL604, Holon, Israel|IL602, Ramat Gan, Israel|IL603, Tel Aviv, Israel|KR601, Seongnam-si, Korea, Republic of|KR602, Seoul, Korea, Republic of|KR603, Seoul, Korea, Republic of|KR604, Seoul, Korea, Republic of|MX602, Mexico, Mexico|MX601, Monterrey, Mexico|MX603, Monterrey, Mexico|MX604, Monterrey, Mexico|MX605, Monterrey, Mexico|MX606, Saltillo, Mexico|RS602, Belgrade, Serbia|RS603, Kragujevac, Serbia|RS601, Novi Sad, Serbia|SG601, Singapore, Singapore|SG602, Singapore, Singapore|SK601, Banska Bystrica, Slovakia|SK603, Bratislava, Slovakia|SK605, Bratislava, Slovakia|SK604, Rimavska Sobota, Slovakia|SK602, Svidnik, Slovakia|ES601, Barcelona, Spain|ES603, Barcelona, Spain|ES604, Barcelona, Spain|ES608, Barcelona, Spain|ES611, Bilbao, Spain|ES612, Burgos, Spain|ES602, Lleida, Spain|ES613, Madrid, Spain|ES610, Sant Cugat del Vallès, Spain|ES606, Sevilla, Spain|ES605, Terrassa, Spain|ES607, Valencia, Spain|CH603, Biel, Switzerland|CH605, Lausanne, Switzerland|CH602, Les Acacias, Switzerland|CH601, Schlieren, Switzerland|TR602, Balova, Turkey|TR601, Istanbul, Turkey|TR603, İstanbul, Turkey|TR605, Istanbul, Turkey|TR606, Izmir, Turkey|TR607, Samsun, Turkey|GB601, Brentford, United Kingdom|GB603, Northampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT02006654
NCT02004392,Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025,,Terminated,No Results Available,Alzheimer's Disease|Dementia,Drug: EVP-6124,Safety of 2 fixed doses of EVP-6124 for up to 52 weeks in subjects with Alzheimer's disease who complete study EVP-6124-024 or EVP-6124-025|Change from Baseline in cognition using the Mini-Mental State Examination (MMSE)|Change from Baseline in psychiatric and behavioral symptoms using the Neuropsychiatric Inventory (NPI)|Change from Baseline in quality of life using the EuroQol-5D (EQ-5D)|Pharmacoeconomic outcomes using the Resource Utilization in Dementia (RUD-Lite 3.3)|Caregiver perceived burden using the Zarit Burden Interview (ZBI),FORUM Pharmaceuticals Inc,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,348,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EVP-6124-026|2013-002654-75,Jun-14,Aug-17,Aug-17,9-Dec-13,null,3-May-16,"Phoenix, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Costa Mesa, California, United States|Culver City, California, United States|Encino, California, United States|Glendale, California, United States|Long Beach, California, United States|Los Alamitos, California, United States|Orange, California, United States|Redding, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Norwich, Connecticut, United States|Atlantis, Florida, United States|Brooksville, Florida, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Leesburg, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Sunrise, Florida, United States|West Palm Beach, Florida, United States|Columbus, Georgia, United States|Park Ridge, Illinois, United States|Wichita, Kansas, United States|Baton Rouge, Louisiana, United States|Bangor, Maine, United States|Newton, Massachusetts, United States|Plymouth, Massachusetts, United States|Flowood, Mississippi, United States|Hattiesburg, Mississippi, United States|Creve Coeur, Missouri, United States|Princeton, New Jersey, United States|Springfield, New Jersey, United States|Albuquerque, New Mexico, United States|Brooklyn, New York, United States|Cedarhurst, New York, United States|Latham, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Wilmington, North Carolina, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Norristown, Pennsylvania, United States|Plains, Pennsylvania, United States|East Providence, Rhode Island, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Charlottesville, Virginia, United States|Williamsburg, Virginia, United States|Richland, Washington, United States|Geelong, Victoria, Australia|Leuven, Belgium|Kelowna, British Columbia, Canada|Halifax, Nova Scotia, Canada|Chatham, Ontario, Canada|Toronto, Ontario, Canada|Praha, Czech Republic|Rychnov nad Kneznou, Czech Republic|Milano, Lombardia, Italy|Busan, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Bialystok, Poland|Warszawa, Poland|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Durban, Kwa-Zulu Natal, South Africa|Bellville, Western Cape, South Africa|George, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Terrassa, Barcelona, Spain|Burgos, Spain|Madrid, Spain|Salamanca, Spain|Glasgow, United Kingdom|Isleworth, United Kingdom|Northampton, United Kingdom|Penarth, United Kingdom|Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT02004392
NCT02005991,A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377,,Completed,No Results Available,Healthy,Drug: PF-05212377,5-HT2a receptor occupancy of PF-05212377 in the frontal cortex using PET|Plasma PF-05212377 exposure associated with PF-05212377 5-HT2a receptor occupancy|5-HT2a receptor occupancy of PF-05212377 in other cortical regions,Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,4,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B2081015,Nov-13,Jan-14,Jan-14,9-Dec-13,null,16-Apr-14,"Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02005991
NCT02002819,Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability,LEV-AD,Recruiting,No Results Available,Alzheimer's Disease,Drug: levetiracetam,Changes in Executive Function as Measured by the E.X.A.M.I.N.E.R. Computer Battery|Changes in Epileptiform Activity Frequency|Changes in Cognitive Function|Changes in Behavior and Level of Disability,University of Minnesota - Clinical and Translational Science Institute,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 2,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",LEV-AD|PCTRB-13-288476,Jun-14,Dec-19,Dec-19,6-Dec-13,null,22-Apr-19,"UCSF, San Francisco, California, United States|University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02002819
NCT02000583,Alzheimer's Prevention Through Exercise,APEx,"Active, not recruiting",No Results Available,Alzheimer's Disease,Other: Aerobic Exercise|Other: Standard of Care,Change in amyloid burden|Amount of reduction in structural brain changes in preclinical AD|Change in cognitive function,University of Kansas Medical Center|National Institute on Aging (NIA),All,65 Years and older   (Older Adult),Not Applicable,100,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,13376|R01AG043962-01,Nov-13,Dec-19,Dec-19,4-Dec-13,null,21-Nov-18,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02000583
NCT01998711,Impact of a Memory Group for Older Adults Reporting Memory Difficulties,,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Behavioral: Memory group,Neuropsychological measures of memory and attention|Self-report on memory performance in everyday activities|Self-report on use of memory strategies|Informant report on memory performance in everyday activities|Informant report on use of strategies|Assessment of psychological wellbeing,Bayside Health,All,"Child, Adult, Older Adult",Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator),156/04,Oct-04,Nov-07,Nov-07,2-Dec-13,null,2-Dec-13,"Caulfield General Medical Centre, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT01998711
NCT01998841,"A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort",,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: Crenezumab|Drug: Placebo,Change From Baseline in Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Composite Cognitive Test Total Score at Week 260|Time to Progression to Mild Cognitive Impairment (MCI) due to AD or to Dementia due to AD|Time to Clinical Dementia Rating (CDR) Scale Global Score of Greater Than (>) Zero|Change From Baseline in CDR Scale - Sum of Boxes at Week 260|Change From Baseline in Episodic Memory Measure: Free and Cued Selective Reminding Task (FCSRT) at Week 260|Change From Baseline in Measure of Overall Neurocognitive Functioning: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at Week 260|Change From Baseline in Mean Cerebral Fibrillar Amyloid Accumulation Standard Uptake Value Ratio (SUVR) as Assessed by Positron Emission Tomography (PET) at Week 260|Change From Baseline in Regional Cerebral Metabolic Rate of Glucose (CMRgI) Using Fluorine-18-Labeled 2-Deoxyglucose (FDG)-PET at Week 260|Change From Baseline in Brain Atrophy Measured by Volumetric Measurements Using Magnetic Resonance Imaging (MRI) at Week 260|Change From Baseline in a tau-Based Cerebral Spinal Fluid (CSF) Biomarker at Week 260|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Anti-Crenezumab Antibodies|CSF Crenezumab Concentration|Serum Crenezumab Concentration,"Genentech, Inc.|Banner Alzheimer's Institute|National Institute on Aging (NIA)",All,30 Years to 60 Years   (Adult),Phase 2,252,Industry|Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN28352,20-Dec-13,25-Feb-22,25-Feb-22,2-Dec-13,null,26-Feb-19,"Fundacion Cardiomet, Armenia, Colombia|Clínica de Marly, Bogota, Colombia|Grupo Neurociencias de Antioquia, Medellin, Colombia|Hospital San Juan de Dios, Yarumal, Colombia",,https://ClinicalTrials.gov/show/NCT01998841
NCT01992380,A Study of 18F-AV-1451 in Healthy Volunteers and Cognitively Impaired Subjects,,Completed,No Results Available,Alzheimer's Disease,Drug: 18F-AV-1451,Test-Retest Reproducibility,Avid Radiopharmaceuticals,All,"50 Years and older   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-1451-A03,Nov-13,May-14,May-14,25-Nov-13,null,9-Jun-14,"Research Site, Newport Beach, California, United States|Research Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01992380
NCT01993628,Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)),,Unknown status,No Results Available,Alzheimer's Disease|Lewy Body's Dementia,Other: Rey figure test|Other: MRI,Score obtained at the Rey figure test with a planning strategy help by LBD patients compared to the score obtained by AD patients.,"University Hospital, Strasbourg, France",All,"45 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,5565,Oct-13,Nov-16,Nov-16,25-Nov-13,null,25-Nov-13,"Hôpitaux Universitaires de Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT01993628
NCT01993836,Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care,MADCO-PC,"Active, not recruiting",No Results Available,Alzheimers Disease|Postoperative Delirium|Post Operative Cognitive Dysfunction,Drug: Total intravenous anesthesia with propofol|Drug: General anesthesia with isoflurane,Assess the correlation between perioperative change in CSF Markers of Alzheimers Disease and perioperative cognitive change.|Continuous cognitive index score change|Assess CSF Markers of Alzheimers Disease|Perioperative CSF Tau/Abeta ratio change,Duke University,All,"60 Years and older   (Adult, Older Adult)",Phase 4,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic",Pro00045180,Nov-13,Feb-19,Feb-19,25-Nov-13,null,24-Dec-18,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01993836
NCT01982578,Genistein as a Possible Treatment for Alzheimer's Disease.,GENISTEÍNA_2,Unknown status,No Results Available,Alzheimer's Disease,Dietary Supplement: Genistein|Other: Placebo,"Amyloid beta concentration in cerebrospinal fluid (CSF). The primary study endpoint is the change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.|MMSE. Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.|Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.|Memory alteration test (M@t). Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.|Neuropsychiatric Inventory (NPI). Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.|Barthel index. Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.|P-TAU concentration in CSF. Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.",Fundación para la Investigación del Hospital Clínico de Valencia|University of Valencia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",INC-GEN-2013-01|U1111-1150-4063,Nov-13,Sep-17,Sep-18,13-Nov-13,null,3-Aug-15,"Hospital de La Ribera, Alzira, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Universitat de València, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT01982578
NCT01978327,"GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers",,Terminated,No Results Available,Alzheimer's Disease,Drug: GSK2647544|Drug: drug-drug interaction,Safety and tolerability of GSK2647544 as assessed by number of subjects with adverse events (AE)s|Safety and tolerability of GSK2647544 as assessed by change from Baseline in laboratory values|Safety and tolerability of GSK2647544 as assessed by change from Baseline in ECG readings|Safety and tolerability of GSK2647544 as assessed by change from Baseline in Telemetry ECG parameters|Safety and tolerability of GSK2647544 as assessed by change from Baseline in vital signs|Safety and tolerability of GSK2647544 as assessed by Columbia Suicide Severity Rating Scale (C-SSRS)|Peak plasma concentration (Cmax) of GSK2647544|Time of peak plasma concentration (tmax) of GSK2647544|Area under the time concentration curve (AUC) of GSK2647544|Terminal half-life (t½ ) of GSK2647544|Time of peak plasma concentration (tmax) of simvastatin|Area under the time concentration curve (AUC) of simvastatin|Predose plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and postdose Lp-PLA2 activity,GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,200592,22-Nov-13,3-Mar-14,3-Mar-14,7-Nov-13,null,8-Jun-17,"GSK Investigational Site, Harrow, Middlesex, United Kingdom",,https://ClinicalTrials.gov/show/NCT01978327
NCT01978353,Memory Training in Patients With Amnestic Mild Cognitive Impairment,,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Memory Training|Behavioral: Psychoeducation,Changes in memory measures|Changes in functional magnetic resonance imaging (fMRI)|Changes in perception of memory performance and mood|Changes in memory performance and perception of memory performance over time - follow up,University of Sao Paulo General Hospital,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CAAE: 08223513.3.0000.0068|12/51699-1,Nov-12,Oct-15,Oct-15,7-Nov-13,null,26-Oct-15,"University of São Paulo, Faculty of Medicine, Institute and Department of Psychiatry, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01978353
NCT01978548,A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Drug: JNJ-54861911 10 mg|Drug: JNJ-54861911 50 mg|Drug: Placebo,"Levels of amyloid beta 1-40 in cerebrospinal (CSF) after treatment at the intended target dose range|Levels of amyloid beta 1-40 in plasma after treatment at the intended target dose range|Maximum observed plasma concentration (Cmax) of JNJ-54861911|Time to reach maximum observed plasma concentration of JNJ-54861911|Area under the plasma concentration time curve (AUC) from 0 to t hours of JNJ-54861911|Half-life of JNJ-54861911|Cerebrospinal fluid exposure of JNJ-54861911|The number of volunteers who experience adverse events as a measure of safety and tolerability of JNJ-54861911 after multiple-dose administration in the anticipated target dose range|Levels of amyloid beta fragments (amyloid beta 1-37, 1-38, and 1-42) in cerebrospinal fluid after treatment at the intended target dose range|Levels of amyloid beta fragments (amyloid beta 1-37, 1-38, and 1-42) in plasma after treatment at the intended target dose range|Levels of amyloid precursor protein (APP) fragments (soluble amyloid precursor protein α [sAPPalpha], sAPPbeta, totalAPP) in CSF after treatment at the intended target dose range|Compare the relationship of amyloid beta 1-40 levels in plasma and cerebrospinal fluid after treatment at the intended target dose range","Janssen Research & Development, LLC",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR103012|54861911ALZ1005|2013-003036-69,Dec-13,Apr-15,Apr-15,7-Nov-13,null,25-Jun-15,"Antwerp, Belgium|Gent, Belgium|Hoboken, Belgium|Amsterdam, Netherlands|Barcelona, Spain|Madrid N/A, Spain|Madrid, Spain|Terrassa, Spain|Valencia, Spain|Mölndal, Sweden|Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01978548
NCT01972204,Intensive Instruction on the Use of Aricept,,Unknown status,No Results Available,Alzheimer's Type Dementia,Behavioral: Intensive adherence instruction|Behavioral: Control,Medication persistence rate|Reasons for discontinuation|Factor analysis for medication persistence|Adverse Events,"Mirai Iryo Research Center, Inc.",All,"Child, Adult, Older Adult",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ART-2013-01,Sep-13,Mar-15,null,30-Oct-13,null,30-Oct-13,"Shonan Fujisawa Tokushukai Hospital, Tsujidoukandai 1-5-1, Fujisawa-City, Kanagawa, Japan",,https://ClinicalTrials.gov/show/NCT01972204
NCT01969123,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease|Dementia,Drug: Drug: EVP-6124|Drug: Placebo,Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog-13) to Day 182|Change from Baseline in the Clinical Dementia Rating Sum of the Boxes (CDR-SB) to Day 182|Safety and tolerability of EVP-6124 or Placebo in Subjects with AD|Change from Baseline in activities of daily living using the Disability Assessment for Dementia (DAD)|Change from Baseline in psychiatric and behavioral symptoms using the Neuropsychiatric Inventory (NPI)|Change from Baseline in the Mini-Mental State Examination (MMSE)|Change from Baseline in the Controlled Oral Word Association Test (COWAT),FORUM Pharmaceuticals Inc,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,474,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EVP-6124-024|2013-002618-10,Oct-13,Jan-17,Jan-17,25-Oct-13,null,3-May-16,"Phoenix, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Encino, California, United States|Glendale, California, United States|Long Beach, California, United States|Redding, California, United States|San Diego, California, United States|Atlantis, Florida, United States|Brooksville, Florida, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Lake Worth, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|St. Petersburg, Florida, United States|Weston, Florida, United States|Columbus, Georgia, United States|Douglasville, Georgia, United States|Chicago, Illinois, United States|Park Ridge, Illinois, United States|Baton Rouge, Louisiana, United States|Bangor, Maine, United States|Chestnut Hill, Massachusetts, United States|Plymouth, Massachusetts, United States|Flowood, Mississippi, United States|Creve Coeur, Missouri, United States|Princeton, New Jersey, United States|Springfield, New Jersey, United States|Brooklyn, New York, United States|Latham, New York, United States|New York, New York, United States|Staten Island, New York, United States|Wilmington, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Norristown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Williamsburg, Virginia, United States|Hornsby, New South Wales, Australia|Geelong, Victoria, Australia|West Heidelberg, Victoria, Australia|Brussels, Belgium|Leuven, Belgium|St. Truiden, Belgium|Kelowna, British Columbia, Canada|Chatham, Ontario, Canada|Toronto, Ontario, Canada|Gatineau, Quebec, Canada|Nice, France|Paris, France|Rouen, France|Toulouse cedex 9, France|Achim, Germany|Köln, Germany|Munchen, Germany|Nurnberg, Germany|Brescia, Italy|Milano, Italy|Seongnam-si, Gyenggi-go, Korea, Republic of|Busan, Korea, Republic of|Seoul, Korea, Republic of|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Bialystok, Poland|Bydgoszcz, Poland|Poznan, Poland|Warszawa, Poland|Bellville, South Africa|Johannesburg, South Africa|Pretoria, South Africa|Somerset West, South Africa|Elche, Altcante, Spain|Terrassa, Barcelona, Spain|Barcelona, Spain|Burgos, Spain|Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01969123
NCT01969136,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease|Dementia,Drug: Drug: EVP-6124|Drug: Placebo,Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog-13) to Day 182|Change from Baseline in the Clinical Dementia Rating Sum of the Boxes (CDR-SB) to Day 182|Safety and tolerability of EVP-6124 or Placebo in Subjects with AD|Change from Baseline in activities of daily living using the Disability Assessment for Dementia (DAD)|Change from Baseline in psychiatric and behavioral symptoms using the Neuropsychiatric Inventory (NPI)|Change from Baseline in the Mini-Mental State Examination (MMSE)|Change from Baseline in the Controlled Oral Word Association Test (COWAT),FORUM Pharmaceuticals Inc,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,403,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EVP-6124-025|2013-002653-30,Oct-13,Jan-17,Jan-17,25-Oct-13,null,3-May-16,"Tucson, Arizona, United States|Little Rock, Arkansas, United States|Culver City, California, United States|Downey, California, United States|Los Alamitos, California, United States|Los Angeles, California, United States|Oceanside, California, United States|Orange, California, United States|Norwich, Connecticut, United States|Bradenton, Florida, United States|Gainesville, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Leesburg, Florida, United States|Miami, Florida, United States|Sarasota, Florida, United States|Sunrise, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Elk Grove Village, Illinois, United States|Springfield, Illinois, United States|Newton, Massachusetts, United States|Hattiesburg, Mississippi, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Cedarhurst, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Shaker Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Abington, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|Plains, Pennsylvania, United States|East Providence, Rhode Island, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Richland, Washington, United States|Rosario, Santa Fe, Argentina|Buenos Aires, Argentina|Santa Fe, Argentina|Box Hill, Victoria, Australia|Caulfield South, Victoria, Australia|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Quebec, Canada|Brno, Czech Republic|Chocen, Czech Republic|Hradec Kralove, Czech Republic|Praha 6, Czech Republic|Richnov nad Kneznou, Czech Republic|Bordeaux, France|Caen, France|Paris, France|Homburg, Germany|Mittweida, Germany|Munchen, Germany|Westerstede, Germany|Ancona, Italy|Milano, Italy|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Saltillo, Coahuila, Mexico|Amsterdam, Netherlands|Den Haag, Netherlands|S'Hertogenbosch, Netherlands|Durban, Kwa-Zulu Natal, South Africa|Bellville, Western Cape, South Africa|George, Western Cape, South Africa|Madrid, Spain|Salamanca, Spain|West End, Southampton, United Kingdom|Bath, United Kingdom|Glasgow, United Kingdom|Isleworth, United Kingdom|Northampton, United Kingdom|Penarth, United Kingdom",,https://ClinicalTrials.gov/show/NCT01969136
NCT01970150,The Effect of Repeated Transcranial Magnetic Stimulation on Off-line Resting Electroencephalographic Signal in Alzheimer's Disease,,Terminated,No Results Available,Alzheimer Disease,Device: rTMS real,"A change in the quantitative EEG spectra in the frontal lobe, i.e. a change in percentage of theta waves, alpha and beta waves|Improvement on memory and attention",Lawson Health Research Institute,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,104382,Feb-14,Apr-15,Apr-15,25-Oct-13,null,7-Sep-16,"Regional Mental Health Care London, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01970150
NCT01966666,"A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease",,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: TPI-287 2 mg/m2|Drug: TPI-287 6.3 mg/m2|Drug: TPI-287 20 mg/m2|Drug: Placebo,Maximum tolerated dose of TPI-287|TPI-287 levels in blood plasma and cerebrospinal fluid,"University of California, San Francisco",All,"50 Years to 82 Years   (Adult, Older Adult)",Phase 1,33,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",TPI287-AD-001,Nov-13,Aug-19,Nov-19,21-Oct-13,null,5-Apr-19,"UCSF Memory and Aging Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01966666
NCT01965756,Effect of Insulin Sensitizer Metformin on AD Biomarkers,,Completed,Has Results,Alzheimer's Disease|Vascular Dementia|Dementia|Memory Impairment,Drug: Metformin|Drug: Placebos,Word List Memory Total - ADAS-cog|Trails-B,University of Pennsylvania,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UPenn-AHAF_A2012116,Jan-13,22-Dec-15,Apr-17,18-Oct-13,21-Sep-17,21-Sep-17,"University of Pennsylvania, Penn Memory Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01965756
NCT01962779,"Sleep, Aging and Risk for Alzheimer's Disease",SARA,"Active, not recruiting",No Results Available,Sleep Disordered Breathing|Alzheimer's Disease,Device: Continuous positive airway pressure (CPAP),"Observational. Cerebrospinal fluid (CSF) biomarkers of risk for Alzheimer's disease (AD) in sleep disordered breathing (SDB) subjects.|Observational. Structural MRI hippocampal volume in SDB subjects.|Observational. MRI-ASL vasoreactivity response to CO2 challenge in subjects with SDB|Interventional CPAP Clinical Trial, memory changes after CPAP treatment|Interventional CPAP Clinical Trial, CSF biomarker changes after CPAP treatment|Interventional CPAP Clinical Trial, MRI biomarker changes","New York University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,224,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,12-03068|R01HL118624,31-Jul-13,30-Apr-17,30-May-19,14-Oct-13,null,22-Apr-19,"NYU Sleep Disorders Center, New York, New York, United States|NYU Center for Brain Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01962779
NCT01958437,Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation,,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease,Device: Transcranial direct current stimulation (tDCS),Accuracy in Centimeters From Target Location for Allocentric|Hippocampal BOLD Signal During Task-based fMRI|Dorsal Attention Network Connectivity During Resting-state fMRI|Egocentric,VA Office of Research and Development,All,"50 Years to 88 Years   (Adult, Older Adult)",Not Applicable,44,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C1381-P,1-Oct-13,23-Mar-17,24-Mar-17,9-Oct-13,31-Aug-18,31-Aug-18,"Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT01958437/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01958437
NCT01955161,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,STARSHINE,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,Change in Cognition|Change in Daily Functioning|Change in Global Impression|Change in Behavioural Disturbance|Change in Individual Behavioural Disturbance Items|Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline|Clinical Improvement|Clinical Worsening|Change in Cognitive Aspects of Mental Function|Change in Health-related Quality of Life (EQ-5D) Utility Score|Change in Health-related Quality of Life (EQ-5D VAS),"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,933,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14861A|2012-004763-45,Oct-13,Jul-16,Jul-16,7-Oct-13,19-Sep-17,19-Sep-17,"US027, Birmingham, Alabama, United States|US012, Phoenix, Arizona, United States|US024, Little Rock, Arkansas, United States|US053, Glendale, California, United States|US023, Imperial, California, United States|US015, La Jolla, California, United States|US045, Long Beach, California, United States|US002, Los Angeles, California, United States|US058, San Francisco, California, United States|US018, Santa Ana, California, United States|US060, Denver, Colorado, United States|US042, Boca Raton, Florida, United States|US021, Bradenton, Florida, United States|US050, Brooksville, Florida, United States|US019, Orlando, Florida, United States|US038, Port Charlotte, Florida, United States|US001, West Palm Beach, Florida, United States|US020, Atlanta, Georgia, United States|US048, Kailua, Hawaii, United States|US030, Chicago, Illinois, United States|US051, Joliet, Illinois, United States|US040, Indianapolis, Indiana, United States|US036, Freeport, Maine, United States|US032, Newton, Massachusetts, United States|US035, Kalamazoo, Michigan, United States|US041, Flowood, Mississippi, United States|US054, Saint Louis, Missouri, United States|US046, Princeton, New Jersey, United States|US028, Toms River, New Jersey, United States|US044, Toms River, New Jersey, United States|US049, Albany, New York, United States|US010, Amherst, New York, United States|US014, Manhasset, New York, United States|US008, New York, New York, United States|US029, New York, New York, United States|US056, New York, New York, United States|US037, Orangeburg, New York, United States|US043, Staten Island, New York, United States|US007, Centerville, Ohio, United States|US006, Columbus, Ohio, United States|US052, Edmond, Oklahoma, United States|US026, Portland, Oregon, United States|US057, Jenkintown, Pennsylvania, United States|US047, Arlington, Virginia, United States|US025, Madison, Wisconsin, United States|US004, Milwaukee, Wisconsin, United States|AR002, Buenos Aires, Argentina|AR003, Buenos Aires, Argentina|AR006, Buenos Aires, Argentina|AR007, Buenos Aires, Argentina|AR009, Cordoba, Argentina|AR004, Mar del Plata, Argentina|AR005, Mendoza, Argentina|AR008, Mendoza, Argentina|AR010, Rosario, Argentina|BE003, Brugge, Belgium|BE002, Brussels, Belgium|BE004, Bruxelles, Belgium|BE005, Leuven, Belgium|BE001, Roeselare, Belgium|BE006, Thuin, Belgium|BG005, Plovdiv, Bulgaria|BG001, Sofia, Bulgaria|BG002, Sofia, Bulgaria|BG003, Sofia, Bulgaria|BG004, Sofia, Bulgaria|BG006, Sofia, Bulgaria|BG007, Varna, Bulgaria|CA002, Gatineau, Canada|CA006, London, Canada|CA008, Newmarket, Canada|CA001, Toronto, Canada|CA004, Toronto, Canada|CL004, Antofagasta, Chile|CL002, Santiago, Chile|CL003, Santiago, Chile|CL005, Santiago, Chile|CL001, Valdivia, Chile|CZ006, Brno, Czechia|CZ007, Kutna Hora, Czechia|CZ004, Pardubice, Czechia|CZ003, Praha 10, Czechia|CZ001, Praha 2, Czechia|CZ002, Praha 6, Czechia|CZ005, Rychnov nad Kneznou, Czechia|DK003, Aarhus N, Denmark|DK001, Copenhagen, Denmark|DK002, Odense C, Denmark|FR006, Besancon Cedex, France|FR008, Limoges Cedex1, France|FR003, Nantes Cedex, France|FR005, Paris cedex 10, France|FR001, Paris, France|FR004, Saint Etienne Cedex 2, France|FR002, Toulouse, France|DE002, Berlin, Germany|DE006, Ellwangen, Germany|DE010, Günzburg, Germany|DE005, Hannover, Germany|DE007, Heidelberg, Germany|DE009, Munchen, Germany|DE008, Ulm, Germany|DE004, Unterhaching, Germany|IT004, Ancona, Italy|IT006, Brescia, Italy|IT002, Firenze, Italy|IT005, Genoa, Italy|IT003, Lamezia Terme, Italy|IT001, Milano, Italy|IT007, Palermo, Italy|PL004, Gliwice, Poland|PL007, Katowice, Poland|PL005, Poznan, Poland|PL006, Sopot, Poland|PL002, Szczecin, Poland|PL003, Warszawa, Poland|PL008, Wroclaw, Poland|RO002, Bucharest, Romania|RO001, Tirgu Mures, Romania|ZA003, Bloemfontein, South Africa|ZA006, Cape Town, South Africa|ZA007, Cape Town, South Africa|ZA004, George, South Africa|ZA005, Port Elizabeth, South Africa|ZA001, Pretoria, South Africa|ZA002, Rosebank, South Africa|ES002, Alicante, Spain|ES006, Barcelona, Spain|ES005, Manresa, Spain|ES004, Salamanca, Spain|ES001, San Sebastian, Spain|ES003, Santiago de Compostela, Spain|UA008, Dnipropetrovsk, Ukraine|UA006, Kherson,Vil. Stepanivka, Ukraine|UA005, Kyiv, Ukraine|UA007, Kyiv, Ukraine|UA001, Lviv, Ukraine",,https://ClinicalTrials.gov/show/NCT01955161
NCT01953601,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),APECS,Terminated,Has Results,Amnestic Mild Cognitive Impairment|Alzheimer's Disease|Prodromal Alzheimer's Disease,Drug: Verubecestat 12 mg (Parts 1 and 2)|Drug: Verubecestat 40 mg (Parts 1 and 2)|Other: Placebo (Part 1),Part 1 (Base Study). Least Squares Mean (LSM) Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 104|Part 2 (Extension Study). Mean Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 130|Part 1 (Base Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)|Part 1 (Base Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)|Part 2 (Extension Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)|Part 2 (Extension Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)|Part 1 (Base Study). Event-Rate Per 100 Participant Years for Progression to a Clinical Diagnosis of Probable AD Dementia|Part 1 (Base Study). Estimated Least Squares Mean Difference Between the Last (Week 104) and First (Week 13) Post-dose CDR-SB Assessment|Part 1 (Base Study). Least Squares Mean Change From Baseline in the 3-Domain Composite Cognition Score (CCS-3D) at Week 104|Part 1 (Base Study). Least Squares Mean Percent Change From Baseline in Total Hippocampal Volume (THV) at Week 104|Part 1 (Base Study). Least Squares Mean Change From Baseline in Composite Cortical Amyloid Standard Uptake Value Ratio (SUVR) Assessed With Amyloid Tracer [18F]Flutemetamol Using Positron Emission Tomography (PET) Imaging at Week 104|Part 1 (Base Study). Least Squares Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment Version) (ADCS-ADL MCI) Score at Week 104|Part 1 (Base Study). Mean Percent Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau Concentration at Week 104,Merck Sharp & Dohme Corp.,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1454,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",8931-019|2012-005542-38|142502|MK-8931-019,5-Nov-13,17-Apr-18,17-Apr-18,1-Oct-13,17-May-19,17-May-19,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT01953601/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01953601
NCT01953705,n-3 PUFA for Vascular Cognitive Aging,,"Active, not recruiting",No Results Available,Age Related Cognitive Decline|Alzheimer's Disease|Vascular Dementia|Endothelial Dysfunction|Executive Dysfunction,Drug: Omega 3 PUFA|Drug: Placebo,total cerebral white matter hyperintensity volume|biomarkers of endothelial health|total brain atrophy|medial temporal lobe atrophy|ventricular expansion,Oregon Health and Science University|National Institute on Aging (NIA),All,75 Years and older   (Older Adult),Phase 2,150,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",R01AG043398|R01AG043398-01A1,May-14,Jul-19,Sep-19,1-Oct-13,null,20-Dec-17,"Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01953705
NCT01954550,Effects of Aerobic Exercise for Treating Alzheimer's Disease,FIT-AD,"Active, not recruiting",No Results Available,"Alzheimer's Disease, Late Onset",Behavioral: Cycling exercise|Behavioral: Range of motion/stretching exercise,Change in cognition from baseline to 6 months as measured by the Alzheimer's Disease Assessment Scale - Cognitive Subscale|Change in hippocampal volume as measured by Magnetic Resonance Imaging (MRI),University of Minnesota - Clinical and Translational Science Institute|Mayo Clinic|University of St Thomas,All,66 Years and older   (Older Adult),Not Applicable,96,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1R01AG043392-01A1,Mar-14,Dec-19,Dec-20,1-Oct-13,null,13-May-19,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01954550
NCT01951118,Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly,,"Active, not recruiting",No Results Available,"Alzheimer Disease|Mild Cognitive Impairment|Delirium, Dementia, Amnestic, Cognitive Disorders",Drug: Donepezil,Change over time in Selective Reminding Test (SRT) Scores|Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)|Clinician's Interview Based Impression (CIBIC-plus)|Pfeffer Functional Activities Questionnaire (FAQ)|Measurement of Everyday Cognition (Ecog),New York State Psychiatric Institute|National Institutes of Health (NIH)|National Institute on Aging (NIA),All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 4,170,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,6655|1R01AG041795,Oct-13,May-19,May-19,26-Sep-13,null,13-Jun-18,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01951118
NCT01948791,16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients,INSTINCT,Completed,Has Results,Alzheimer's Disease,Drug: ENA713,Mean Change From Baseline in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)|Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score|Change From Baseline in Mini-Mental State Examination (MMSE)|Mean Change From Baseline in Neuropsychiatric Inventory (NPI) Score|Change From Baseline in Caregiver Burden Inventory (CBI) Score,Novartis Pharmaceuticals|Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,222,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713BCN05,Aug-14,Sep-15,Sep-15,24-Sep-13,13-Feb-17,13-Feb-17,"Novartis Investigative Site, Beijing, China",,https://ClinicalTrials.gov/show/NCT01948791
NCT01946243,The Feasibility of Florbetapir Quantitation,,Completed,Has Results,Alzheimers Disease,Drug: Florbetapir F18,"Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers)|Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm Low Accuracy Readers)|Change in Total Accuracy (MIMNeuro Software, All Readers)|Change in Reliability (MIMNeuro Software)|Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm All Readers)|Change in Reliability (Siemens Syngo.PET Software)",Avid Radiopharmaceuticals,All,"Child, Adult, Older Adult",Phase 4,96,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-QP01,Aug-13,Apr-14,Apr-14,19-Sep-13,1-Jun-15,29-Jun-15,"Research Site, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01946243
NCT01940952,Zydena on Cognitive Function of Alzheimer's Disease Patients,,Unknown status,No Results Available,Alzheimer's Disease,Drug: Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg|Drug: Placebo + Donepezil 5mg or 10mg|Drug: Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg,Change in cognitive function|Change in behavioral symptoms|Change in brain function,"Samsung Medical Center|Dong-A Pharmaceutical Co., Ltd.",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,210,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2012-03-065,Sep-13,Aug-15,null,12-Sep-13,null,12-Sep-13,"Samguns Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01940952
NCT01935024,Benefits of Exercise in Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer's Disease,Other: Personalized Exercise Regimen,Neuropsychological Test Battery,"University Health Network, Toronto",All,"60 Years to 95 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-5749-AE,Aug-13,Apr-19,Apr-19,4-Sep-13,null,11-Oct-18,"Toronto Western Hospital, WW5-449, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01935024
NCT01931566,Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset,TOMMORROW,Terminated,No Results Available,Mild Cognitive Impairment Due to Alzheimer's Disease,Drug: Pioglitazone|Drug: Pioglitazone placebo,"Time to diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD) for placebo-treated, high-risk, non-Hispanic/Latino Caucasian subjects versus placebo-treated, low-risk, non-Hispanic/Latino Caucasian subjects|Time to diagnosis of MCI due to AD for pioglitazone-treated, non-Hispanic/Latino Caucasian subjects versus placebo-treated non-Hispanic/Latino, Caucasian subjects in the high-risk stratum|Change from baseline for cognitive decline on composite score on the cognitive test battery for pioglitazone-treated subjects versus placebo-treated subjects in the high-risk stratum|Change from baseline in instrumental activities of daily living (Alzheimer's Disease Cooperative Study Activities of Daily Living - Prevention Instrument [ADCS ADL-PI]) between pioglitazone-treated and placebo-treated groups of the high-risk stratum",Takeda|Zinfandel Pharmaceuticals Inc.,All,65 Years to 83 Years   (Older Adult),Phase 3,3494,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AD-4833/TOMM40_301|2012-003111-58|U1111-1139-0355,28-Aug-13,7-Aug-18,7-Aug-18,29-Aug-13,null,14-Aug-18,"Phoenix, Arizona, United States|Sun City, Arizona, United States|Long Beach, California, United States|San Diego, California, United States|San Francisco, California, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Lady Lake, Florida, United States|Lake Worth, Florida, United States|Merritt Island, Florida, United States|Orlando, Florida, United States|Port Orange, Florida, United States|Saint Petersburg, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Elk Grove, Illinois, United States|Iowa City, Iowa, United States|Farmington Hills, Michigan, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Marlton, New Jersey, United States|New York, New York, United States|Concord, North Carolina, United States|Durham, North Carolina, United States|Akron, Ohio, United States|Portland, Oregon, United States|Charleston, South Carolina, United States|Cordova, Tennessee, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Middleton, Wisconsin, United States|North Ryde, New South Wales, Australia|Southport, Queensland, Australia|West Heidelberg, Victoria, Australia|Nedlands, Western Australia, Australia|Stuttgart, Baden Wuerttemberg, Germany|Siegen, Nordrhein Westfalen, Germany|Halle, Sachsen Anhalt, Germany|Berlin, Germany|Basel, Switzerland|Exeter, Devon, United Kingdom|Plymouth, Devon, United Kingdom|Hammersmith, Greater London, United Kingdom|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Salford, Greater Manchester, United Kingdom|Blackpool, Lancashire, United Kingdom|Isleworth, Middlesex, United Kingdom|Glasgow, Strathclyde, United Kingdom|Dundee, Tayside Region, United Kingdom|Perth, Tayside Region, United Kingdom|Bristol, United Kingdom",,https://ClinicalTrials.gov/show/NCT01931566
NCT01928420,"A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease|Dementia,Drug: Drug: NIC5-15|Drug: Placebo,Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score|Change in Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) Score|Change in Mini-Mental State Examination (MMSE) Score|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score|Change in Neuropsychiatric Inventory (NPI) Score|Changes in AD Biomarkers|APO-E genotyping,Humanetics Corporation|National Center for Complementary and Integrative Health (NCCIH)|James J. Peters Veterans Affairs Medical Center,All,"40 Years to 95 Years   (Adult, Older Adult)",Phase 2,30,Industry|NIH|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R21AT003302-01A1|MHBB-009-06S,Apr-07,Jun-14,Jun-14,26-Aug-13,null,17-Oct-16,"James J Peters Veterans Affairs Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01928420
NCT01924858,A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.,,Terminated,No Results Available,Alzheimer's Disease,Drug: GSK2647544 oral|Drug: [18F]GSK2647544 IV bolus,Whole brain PET VT of [18F]-GSK2647544|Safety and tolerability assessment following oral administration of GSK2647544|GSK2647544 PK assessment,GlaxoSmithKline,Male,30 Years to 55 Years   (Adult),Phase 1,4,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,117155,19-Aug-13,3-Mar-14,3-Mar-14,19-Aug-13,null,19-Oct-17,"GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01924858
NCT01921972,The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease,AD-Combi,Completed,No Results Available,Alzheimer's Disease,Drug: Galantamine CR|Drug: Memantine|Drug: Placebo,ADAScog/11|ADCS-ADL|Clinical Dementia Rating|Neuropsychiatric Inventory NPI|Resource Utilization of Dementia Scale (RUD)|Burden Interview (BI)|Adverse Event Reports|Rate of brain atrophy,"Charite University, Berlin, Germany|German Federal Ministry of Education and Research",All,"50 Years and older   (Adult, Older Adult)",Phase 4,232,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Modul E.2 II,Nov-04,Nov-08,May-09,14-Aug-13,null,14-Aug-13,,,https://ClinicalTrials.gov/show/NCT01921972
NCT01922258,Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,,Completed,No Results Available,Agitation Associated With|Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases,"Drug: Brexpiprazole, OPC-34712","Change in the Cohen-Mansfield Agitation Inventory (CMAI) total score|Change in the Clinical Global Impression Severity of Illness (CGI-S) score, as related to symptoms of agitation","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,270,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",331-12-284,Sep-13,Mar-17,Mar-17,14-Aug-13,null,17-May-18,"Imperial, California, United States|Lakewood, California, United States|Long Beach, California, United States|Long Beach, California, United States|Panorama City, California, United States|Universal City, California, United States|Denver, Colorado, United States|Bradenton, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orange City, Florida, United States|Atlanta, Georgia, United States|Smyrna, Georgia, United States|Honolulu, Hawaii, United States|Indianapolis, Indiana, United States|Quincy, Massachusetts, United States|South Dartmouth, Massachusetts, United States|Ann Arbor, Michigan, United States|Brooklyn, New York, United States|Buffalo, New York, United States|New Hyde Park, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Austin, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Woodstock, Vermont, United States|Burgas, Bulgaria|Kardzhali, Bulgaria|Pazardzhik, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Penticton, British Columbia, Canada|Kentville, Canada|Kuopio, Finland|Turku, Finland|Bourg en Bresse, France|Douai, France|Elancourt, France|Limoges, France|Nice, France|Toulouse, France|Tonnelniy, Stavropol Region, Russian Federation|Ekaterinburg, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Ljubljana, Slovenia|Maribor, Slovenia|Sempeter pri Gorici, Slovenia|Donetsk, Ukraine|Kharkiv, Ukraine|Kharkov, Ukraine|Kherson, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Poltava, Ukraine|Simferopol, Ukraine|Vinnytsia, Ukraine|Crewe, United Kingdom|Manchester, United Kingdom|Margate, United Kingdom|Torpoint, United Kingdom",,https://ClinicalTrials.gov/show/NCT01922258
NCT01920672,"Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD",,Completed,No Results Available,Alzheimer's Disease,Behavioral: Timed Planned Activity|Behavioral: Home Safety and Education Program,total sleep time|Wake after sleep onset,Johns Hopkins University|National Institute of Nursing Research (NINR),All,"60 Years to 100 Years   (Adult, Older Adult)",Not Applicable,82,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",NA_00088139|P30NR014131,Sep-13,Jun-15,Jun-15,12-Aug-13,null,12-Dec-17,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01920672
NCT01908010,"Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",,Completed,No Results Available,Alzheimer's Disease,Drug: ABT-354|Drug: Placebo,Vital signs|ECG (electrocardiogram)|Neurological exam|Laboratory tests|Number of subject with adverse events|C-SSRS (Columbia-Suicide Severity Rating Scale)|Pharmacokinetic parameters,AbbVie,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",M13-080,Jul-13,Nov-13,Nov-13,25-Jul-13,null,11-Dec-13,"Site Reference ID/Investigator# 106999, Miami, Florida, United States|Site Reference ID/Investigator# 106998, Orlando, Florida, United States|Site Reference ID/Investigator# 107000, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01908010
NCT01903421,Inhalational Anesthesia and Precipitation of Dementia: is There a Link?,,"Active, not recruiting",No Results Available,Alzheimer's Disease|Dementia,"Drug: Spinal anesthesia group: bupivacaine 10-15mg|Drug: General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane|Genetic: Blood test|Other: Lumbar spinal tap|Behavioral: Montreal Cognitive Assessment (MOCA) and MMSE",Assessing the incidence of early dementia,"University Health Network, Toronto",All,65 Years and older   (Older Adult),Not Applicable,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,13-6122-A,Mar-14,Dec-18,Dec-19,19-Jul-13,null,20-May-19,"Toronto General Hospital, University Health Network, Toronto, Ontario, Canada|William Osler Health Centre, Toronto, Ontario, Canada|Pauls Stradins Clinical University Hospital, Riga, Latvia",,https://ClinicalTrials.gov/show/NCT01903421
NCT01900665,Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo,EXPEDITION 3,Terminated,Has Results,Alzheimer's Disease,Drug: Solanezumab|Drug: Placebo,Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 14 Item Subscore (ADAS-Cog14)|Change From Baseline in Alzheimer's Disease Cooperative Study- Instrumental Activities of Daily Living (ADCS-iADL)|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 11 Item Subscore (ADAS-Cog11)|Change From Baseline in Mini-Mental State Examination (MMSE)|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)|Change From Baseline in Functional Activities Questionnaire (FAQ)|Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Change From Baseline in Neuropsychiatric Inventory (NPI)|Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite)|Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)|Change From Baseline in 5-Dimensional EuroQol Quality of Life Scale Proxy Version (EQ-5D Proxy)|Change From Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)|Percentage of Participants of Cognitive and Functional Responders|Change From Baseline in Plasma Amyloid-Beta (Aβ) Species|Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI)|Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Solanezumab (LY2062430)|Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan|Change From Baseline in Cerebrospinal Fluid (CSF) Aβ Levels,Eli Lilly and Company,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,2129,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15136|H8A-MC-LZAX,Jul-13,Oct-16,Feb-17,16-Jul-13,14-Mar-18,3-May-18,"Xenoscience, Phoenix, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|ANI Arizona Neurological Institute Research, PC, Sun City, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|Arizona Health Sciences Center, Tucson, Arizona, United States|American Neuropsychiatric Research Institute, Inc, Carson, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Institute for Memory Impairment & Neurological Disorders, Irvine, California, United States|University of California - San Diego, La Jolla, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Torrance Clinical Research, Lomita, California, United States|Collaborative Neuroscience Network - CNS, Long Beach, California, United States|Apostle Clinical Trials, Inc, Long Beach, California, United States|Univ of Southern California Medical Center, Los Angeles, California, United States|University of California Los Angeles School of Medicine, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Anderson Clinical Research, Redlands, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Pacific Research Network Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|Apex Research Institute, Santa Ana, California, United States|St. Joseph Health, Santa Rosa, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Radiant Research, Denver, Colorado, United States|Associated Neurologists of Southern Connecticut, Fairfield, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Norwalk, Connecticut, United States|Christiana Care Research Institute, Newark, Delaware, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Parkinson's Disease and Movement Disorders, Boca Raton, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Cohen Medical Associates P.A., Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Galiz Research, Hialeah, Florida, United States|Infinity Clinical Research . LLC, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Mayo Clinic of Jacksonville, Jacksonville, Florida, United States|Miami Jewish Home and Hospital for the Aged, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, Orlando, Florida, United States|Neurology Clinical Research, Inc, Sunrise, Florida, United States|Axiom Research, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|CTT Consultants, Prairie Village, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Baptist Physician's Lexington, Lexington, Kentucky, United States|Private Office: J. Gary Booker, Shreveport, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Maine Neurology, Scarborough, Maine, United States|PharmaSite Research Inc, Baltimore, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Univ of Nebraska Med Center, Omaha, Nebraska, United States|Cleveland Clinic of Las Vegas, Las Vegas, Nevada, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|AdvanceMed Research, Lawrenceville, New Jersey, United States|Albuquerque Neurosciences, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|SPRI Clinical Trials, LLC., Brooklyn, New York, United States|New York University Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Richmond Behavorial Associates, Staten Island, New York, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|Behavioral Health Center Research, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Valley Medical Research, Centerville, Ohio, United States|Ohio State Univ College Of Medicine, Columbus, Ohio, United States|Neurology Specialists Inc., Dayton, Ohio, United States|Insight Clinical Trials, Shaker Heights, Ohio, United States|Red River Medical Center, LLC, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Summit Research Network Inc, Portland, Oregon, United States|Drexel University College of Medicine at EPPI, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Radiant Research, Greer, South Carolina, United States|University Psychiatry Associates Avera Health, Sioux Falls, South Dakota, United States|Quillen College of Medicine, East TN State University, Johnson City, Tennessee, United States|Vanderbilt Univeristy School of Medicine, Nashville, Tennessee, United States|Texas Neurology, PA, Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Diagnostic Research Group, San Antonio, Texas, United States|Radiant Research, Murray, Utah, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|National Clinical Research - Norfolk Inc, Norfolk, Virginia, United States|National Clinical Research - Richmond, Richmond, Virginia, United States|Blue Ridge Research Center, Roanoke, Virginia, United States|Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Darlinghurst, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Gosford, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caulfield, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fitzroy, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Subiaco, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peterborough, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gatineau, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenfield Park, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bron, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reims, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villeurbanne, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boeblingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Westerstede, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponderano (BI), Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ibaraki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobe, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bydgoszcz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sopot, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barakaldo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getafe, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guipuzcoa, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt-Girona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jönköping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Molndal, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umea, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bath, Avon, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, Devon, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Crowborough, East Sussex, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scotland, Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greater London, London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salford, Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swindon, Wiltshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle, United Kingdom",,https://ClinicalTrials.gov/show/NCT01900665
NCT01894620,The Effect of rTMS Treatment on Alzheimer's and Sleep Quality,rTMS,Completed,Has Results,Alzheimer's Disease,Device: rTMS real-sham|Device: rTMS sham-real,Cognitive Improvement Measured Using Montreal Cognitive Assessment (MoCA)|Improvement in Sleep Quality,Dr. Zahra Kazem-Moussavi|University of Manitoba,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,11,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",B2012:76,May-13,May-14,Oct-14,10-Jul-13,12-Feb-18,12-Feb-18,"Misericordia Health Center, Winnipeg, Manitoba, Canada|Riverview Health Center, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT01894620
NCT01893398,Multistimulation Group Therapy for Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Other: Multidimensional stimulation group therapy,Change from baseline in behavioral level|Change from baseline in cognitive level|Change from baseline in quality of life,Fondazione Don Carlo Gnocchi Onlus,All,65 Years to 85 Years   (Older Adult),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),FdG_AD_01,Jan-10,Dec-12,null,9-Jul-13,null,9-Jul-13,"IRCCS, S Maria Nascente, FOndazione don Gnocchi, Milan, Italy",,https://ClinicalTrials.gov/show/NCT01893398
NCT01892579,Reducing Agitation in People With Dementia: the Customized Activity Trial,TAP,"Active, not recruiting",No Results Available,Dementia,Behavioral: Tailored Activity Program|Other: Home Safety and Education Program,Frequency by severity of Agitated and Aggressive Behavior in person with dementia|Frequency of behavioral symptoms in person with dementia|Quality of life in person with dementia rated by caregiver|Quality of life in person with dementia rated by person with dementia|Caregiver wellbeing|Time spent caregiving|Cost effectiveness by intervention cost|Cost effectiveness by medical costs|Cost effectiveness by quality of life,Johns Hopkins University|National Institute on Aging (NIA),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,250,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,NA_00067873|R01AG041781,Nov-13,23-Aug-17,Aug-19,4-Jul-13,null,21-Mar-19,"Johns Hopkins University School of Nursing, Center for Innovative Care in Aging, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01892579
NCT01890343,"Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.",,Completed,Has Results,Alzheimer's Disease|Frontotemporal Dementia,Drug: florbetapir 18F|Drug: 18F-FDG,Qualitative Amyloid Image Assessment|Quantitative Amyloid Image Assessment,Avid Radiopharmaceuticals,All,"45 Years and older   (Adult, Older Adult)",Phase 2,34,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-010,Sep-09,Dec-12,Apr-13,1-Jul-13,17-Sep-14,29-Sep-14,"Research Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01890343
NCT01887535,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants",,Completed,No Results Available,Healthy,Drug: JNJ-54861911 3 mg|Drug: JNJ-54861911 10 mg|Drug: JNJ-54861911 30 mg|Drug: JNJ-54861911 80 mg|Drug: JNJ-54861911 25 mg|Drug: Placebo,"The number of volunteers who experience adverse events as a measure of safety and tolerability of JNJ-54861911 after multiple dose administration in the target dose range and above|Maximal tolerated dose (MTD) or maximal feasible exposure level of JNJ-54861911 after multiple dose administration|Maximum observed plasma/cerebrospinal fluid (CSF) concentration (Cmax) of JNJ-54861911|Levels of amyloid beta (Aβ) fragments (Aβ1-37, Aβ1-38, Aβ1-40 and Aβ1-42) in CSF after multiple dose administration|Time to reach maximum observed plasma/CSF concentration of JNJ-54861911|Area under the plasma/CSF concentration-time curve (AUC) from time 0 to t hours of JNJ-54861911|Half-life of JNJ-54861911","Janssen Research & Development, LLC",All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 1,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR101620|2013-000217-21,May-13,Dec-13,Dec-13,27-Jun-13,null,14-Jan-14,"Antwerp, Belgium",,https://ClinicalTrials.gov/show/NCT01887535
NCT01887899,Influence of tDCS on Cortical Plasticity in Patients With Dementia of the Alzheimer Type,,Unknown status,No Results Available,Dementia of Type Alzheimer,Device: transcranial direct current stimulation|Device: sham stimulation,"the anodal transcranial direct current stimulation over the primary motor cortex (M1) in patients with dementia of Alzheimer type (DAT)|tDCS effects on central cholinergic activity in patients with DAT|tDCS effects on learning|MR elastography|genetic polymorphism, ApoE4","Charite University, Berlin, Germany",All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Plasticity in Alzheimer's,May-13,Oct-17,Dec-17,27-Jun-13,null,22-Dec-16,"Klinik und Poliklinik für Neurologie, Charité Universitätsmedizin Berlin, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01887899
NCT01886820,A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology,,"Active, not recruiting",No Results Available,Dementia|Alzheimer's Disease,Drug: [18F]NAV4694,Incidence of [18F]NAV4694 Brain PET scan positivity compared to histopathology|Quantification of [18F]NAV4694 brain PET Scan positivity compared to histopathology|Incidence of [18F]NAV4694 PET Scan positivity in 6 pre-specified brain regions compared to histopathology|Quantification of [18F]NAV4694 PET Scan positivity in 6 pre-specified brain regions compared to histopathology|Incidence of adverse events,Navidea Biopharmaceuticals,All,"21 Years and older   (Adult, Older Adult)",Phase 3,290,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NAV4-02,Jun-13,Jun-18,Sep-18,26-Jun-13,null,26-Jul-17,"Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California San Diego, La Jolla, California, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Mount Sinai Medical Center of Florida, Miami Beach, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Compass Research, Orlando, Florida, United States|Physicians Care Clinical Research, Sarasota, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Biomedical Research Foundation, Shreveport, Louisiana, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|Albert Einstein College of Medicine, The Bronx, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health-Gerontology, Winston-Salem, North Carolina, United States|Valley Medical Center, Centerville, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01886820
NCT01885806,Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease|Apathy,Device: Magnetic Stimulator Magstim Rapid 2|Device: Sham Magnetic Stimulator,Change in apathy symptoms|Change in ADAS-Cog scores|Change in the Zarit Burden Scale,Federal University of Minas Gerais,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",CAAE: 15388913.6.0000.5149,Jun-13,Dec-14,Dec-15,25-Jun-13,null,25-Jun-13,"Federal University of Minas Gerais, Belo Horizonte, Outside of U.S., Brazil|Federal University of Minas Gerais, Belo Horizonte, Outside of U.S., Brazil",,https://ClinicalTrials.gov/show/NCT01885806
NCT01883648,Study to Evaluate Coconut Oil for Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: Coconut Oil Beverage|Other: Placebo Beverage,"Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in cognitive testing (ADAS-cog, MMSE, Category/Letter Fluency)|Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in Trails A & B cognitive testing|Change from baseline to Month 3 of each treatment phase (a 3 month period of time) on Geriatric Depression Scale|Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in behaviors measured by Neuropsychiatric Inventory|Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in functional ability measured by Activities of Daily Living (ADCS-ADLs)|Measure changes in Ketone & C-Reactive Protein assays from research blood samples throughout study during the 2 treatment periods from Baseline to Month 6 (change during a total 6 month period of time).|Adverse events related to coconut oil usage during 6 months of treatment periods (change during a total 6 month period of time).",University of South Florida,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,21,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Byrd AD-001,Jun-13,1-Feb-17,1-Feb-17,21-Jun-13,null,28-Apr-17,"USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT01883648
NCT01880151,Neuroelectrical Biomarkers for Alzheimer's Disease Stages,ESTIMATE,Unknown status,No Results Available,Alzheimer Disease,Device: EEG,Frequency band charactersitics of the electrophysiological brain response,"Institut National de la Santé Et de la Recherche Médicale, France",All,70 Years to 85 Years   (Older Adult),Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,C12-71|2013-A00344-41,Jun-13,Mar-17,Jul-17,18-Jun-13,null,31-Aug-16,"Institute of Memory and Alzheimer's Disease, Pitie-Salpetriere Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01880151
NCT01876823,Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment,,Completed,Has Results,Mild Cognitive Impairment|Major Depressive Disorder|Alzheimer's Disease,Drug: es-citalopram|Drug: Memantine,Change in Selective Reminding Test - Total Immediate Recall (SRT-IR)|Change in Wechsler Memory Scale-III (WMS-III)|Change in Selective Reminding Test - Delayed Recall (SRT-DR)|Change in Trails B|Change in Trails A,New York State Psychiatric Institute,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,60,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6277R,Apr-06,Mar-10,Mar-10,13-Jun-13,24-Oct-14,24-Oct-14,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01876823
NCT01876459,Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.,AlphaLewyMa,Unknown status,No Results Available,"""Alzheimer's Disease"" and ""Lewy Body Disease""",Other: MRI|Procedure: lumbar puncture|Behavioral: neuropsychological tests,rate of alpha-synuclein in cerebrospinal fluid,"University Hospital, Strasbourg, France",All,"45 Years and older   (Adult, Older Adult)",Not Applicable,265,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,5330|N° IDRCB 2012-A00992-41,Apr-13,Apr-15,Apr-15,12-Jun-13,null,18-Jun-13,"Hôpitaux Universitaires de Strasbourg, Strasbourg, Hôpital de Hautepierre, France",,https://ClinicalTrials.gov/show/NCT01876459
NCT01874418,Biomarker Study to Diagnose Alzheimer's Disease,ADAM,Unknown status,No Results Available,Alzheimer Disease|Mild Cognitive Impairment,Other: Biomarker,Oligomeric beta-amyloid 42 in serum|Total tau concentration in CSF|Phosphorylated tau concentration in CSF|Monomeric beta-amyloid 42 in CSF,Seoul National University Hospital,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,ADAM,Mar-12,Feb-15,Feb-15,11-Jun-13,null,11-Jun-13,"Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01874418
NCT01871610,Amyloid Accumulation After Mild Traumatic Brain Injury,,Unknown status,No Results Available,Traumatic Brain Injury,Drug: [18F]AV-45 PET amyloid binding imaging,The amyloids load in brain among mild traumatic brain injury and controls in a temporal manner.|F-18-AV-45 binding changes and cognitive function among mild traumatic brain injury and controls,Chang Gung Memorial Hospital,All,"30 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,100-4313A,Nov-12,Nov-12,Oct-13,7-Jun-13,null,7-Jun-13,,,https://ClinicalTrials.gov/show/NCT01871610
NCT01872598,Masitinib in Patients With Mild to Moderate Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer Disease,Drug: Masitinib|Drug: Placebo,ADCS-ADL|ADAS-Cog|MMSE|CIBIC-plus,AB Science,All,"50 Years and older   (Adult, Older Adult)",Phase 3,721,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AB09004,Jan-12,Apr-19,Oct-19,7-Jun-13,null,6-Feb-19,"MHAT Sveta Marina, Varna, Bulgaria|General Hospital of Thessaloniki, Thessaloniki, Greece|Centrum Zdrowia Stołeczna 7, Białystok, Poland|Spitalul Universitar de Urgenta Elias, Bucuresti, Romania|Hospital Universitario Ramón y Cajal, Madrid, Spain|Municipal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov, Dnipropetrovsk, Ukraine",,https://ClinicalTrials.gov/show/NCT01872598
NCT01867775,Mirtazapine for Sleep Disorders in Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease|Sleep Disorders,Drug: Mirtazapine,Change From Baseline in Nighttime Total Sleep Time|Change From Baseline in Nighttime Number Of Awakenings|Change From Baseline in Nighttime Wake After Sleep Onset|Change From Baseline in in Daytime Total Sleep Time|Change From Baseline in Number of Daytime Naps|Change in Cognitive Function (as Measured by the Mini-Mental State Examination)|Change in Activities of Daily Living (The Index of ADL - Katz)|Change of Baseline in Behavioral Variables (BAHAVE-AD Scale)|Change From Baseline in Cognitive Function (Digit Symbol Substitution Test),Brasilia University Hospital,All,"55 Years and older   (Adult, Older Adult)",Phase 3,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",052/2012,May-12,Dec-13,May-14,4-Jun-13,null,4-Jun-13,"Brasilia University, Brasilia, Distrito Federal, Brazil",,https://ClinicalTrials.gov/show/NCT01867775
NCT01864655,Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: saracatinib|Drug: Placebo,Number of Participants with Adverse Events on AZD0530|CNS availability of AZD0530 after oral dosing|Effects of AZD0530 on cognitive function in patients with Alzheimer's disease|Effect of AZD0530 on brain glucose metabolism in patients with Alzheimer's disease,Stephen M. Strittmatter|Yale University,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1UH2TR000967-01,Jul-13,Mar-14,null,29-May-13,null,13-Jun-14,"Yale Alzheimer's Disease Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01864655
NCT01862640,Safety and Tolerability Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,,Completed,No Results Available,Agitation Associated With|Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases,"Drug: Brexpiprazole, OPC-34712|Drug: Placebo Oral Tablet","The primary outcome is the change in the Cohen-Mansfield Agitation Inventory (CMAI) total score|The secondary outcome is the change in the Clinical Global Impression-Severity of Illness (CGI-S) score, as related to symptoms of agitation","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,433,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",331-12-283,Jul-13,Mar-17,Mar-17,24-May-13,null,14-Mar-19,"Tuscaloosa, Alabama, United States|Phoenix, Arizona, United States|Bellflower, California, United States|Costa Mesa, California, United States|Downey, California, United States|Orange, California, United States|Redlands, California, United States|Yorba Linda, California, United States|Norwalk, Connecticut, United States|Coconut Creek, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Lauderhill, Florida, United States|Miami Springs, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Sarasota, Florida, United States|Decatur, Georgia, United States|Suwanee, Georgia, United States|Weymouth, Massachusetts, United States|Saint Louis, Missouri, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Manchester, New Jersey, United States|Mount Arlington, New Jersey, United States|Toms River, New Jersey, United States|Hickory, North Carolina, United States|Oklahoma City, Oklahoma, United States|Franklin, Tennessee, United States|Bedford, Texas, United States|Waukesha, Wisconsin, United States|Rijeka, Croatia|Zadar, Croatia|Zagreb, Croatia|Zagreb, Croatia|Mittweida, Saxony, Germany|Achim, Germany|Berlin, Germany|Bielefeld, Germany|Bochum, Germany|Hambrg, Germany|Koln, Germany|Ostfildern, Germany|Westerstede, Germany|Ekaterinburg, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tonnelniy, Russian Federation|Belgrade, Serbia|Kovin, Serbia|Kragujevac, Serbia|Nis, Serbia|Novi Knezevac, Serbia|Novi Sad, Serbia|Vrsac, Serbia|Barcelona, Spain|Getafe, Spain|Girona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pamplona, Spain|Salamanca, Spain|Valencia, Spain|Valencia, Spain|Zamora, Spain|Kharkiv, Ukraine|Kherson, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Odessa, Ukraine|Poltava, Ukraine",,https://ClinicalTrials.gov/show/NCT01862640
NCT01860625,"A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects",,Completed,No Results Available,Alzheimer Disease,Drug: Donepezil patch|Drug: placebo,safety and tolerability evaluation|pharmacokinetics characteristic evaluation,Icure Pharmaceutical Inc.,Male,20 Years to 45 Years   (Adult),Phase 1,36,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IPI-001,Apr-13,Dec-13,Feb-14,23-May-13,null,30-Jun-14,"ASAN Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01860625
NCT01859767,Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.,,Completed,No Results Available,Alzheimer's Disease,Drug: [123I]MNI-672 SPECT,Number of subjects with adverse events|Clinically significant changes in vital signs|Total I-123 radioactivity in plasma|Standard uptake values (SUV)|Visual analysis,Molecular NeuroImaging,All,"20 Years and older   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),MNI-672-01,Apr-13,Mar-15,Apr-15,22-May-13,null,16-Dec-16,"Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01859767
NCT01852110,Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012),,Terminated,Has Results,Alzheimer's Disease,Drug: MK-7622|Drug: Placebo|Drug: AChEI,"Change From Baseline in the 11-item Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at Week 12 (Stage 1, MK-7622 45 mg Versus Placebo)|Change From Baseline in ADAS-Cog11 Score at Week 12 (Stage 2, MK-7622 45 mg and 15 mg Versus Placebo)|Number of Participants Experiencing an Adverse Event (AE)|Number of Participants Who Discontinued Study Drug Due to an AE|Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) at Week 24 (Combining Stage 1 and 2, MK-7622 45 mg Versus Placebo)|Change From Baseline in Composite Cognition Score-3 Domain (CCS-3D) at Week 12 (Stage 1, MK-7622 45 mg Versus Placebo)|Change From Baseline in CCS-3D at Week 12 (Stage 2, MK-7622 45 mg and 15 mg Versus Placebo)",Merck Sharp & Dohme Corp.,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,240,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",7622-012|2013-000937-11|MK-7622-012,22-Oct-13,11-Apr-16,11-Apr-16,13-May-13,7-Feb-18,18-Sep-18,,,https://ClinicalTrials.gov/show/NCT01852110
NCT01850238,"Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease",,Completed,No Results Available,Alzheimer Disease,Biological: AADvac1|Other: Placebo,Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease|Immunogenicity of AADvac1,Axon Neuroscience SE,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AXON CO 18700|2012-003916-29,May-13,Mar-15,Mar-15,9-May-13,null,12-Oct-15,"Medizinische Universitat Graz, Graz, Steiermark, Austria|Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik, Salzburg, Austria|Medizinische Universitat Wien, Wien, Austria",,https://ClinicalTrials.gov/show/NCT01850238
NCT01849042,Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease,ROMEO-AD,Unknown status,No Results Available,Alzheimer's Disease|Dementia,Drug: Ebixa|Drug: donepezil,AQ-WAB(Western aphasia battery)|ROSA (Relevant Outcome Scale for Alzheimer's Disease),Konkuk University Medical Center,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,188,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ROMEO-AD 14394A,Jan-13,Aug-14,Aug-15,8-May-13,null,13-Aug-14,"Konkuk university medical center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01849042
NCT01847586,Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease,TMS-AD,Completed,No Results Available,Alzheimer's Disease,Procedure: Paired Associative Stimulation|Procedure: Paired Associative Stimulation-Control,Paired Associated Stimulation induced Long-term potentiation as a measure of neuroplasticity in the dorsolateral prefrontal cortex|N-back Task,Centre for Addiction and Mental Health,All,65 Years and older   (Older Adult),Not Applicable,49,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",215/2012,Apr-13,Oct-16,Oct-17,7-May-13,null,24-Jan-18,"Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01847586
NCT01845636,Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil,,Completed,Has Results,Mild Cognitive Impairment,Drug: Donepezil|Drug: Atropine,Selective Reminding Test (SRT)|Total Number of Errors Measured Using the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)|Pfeffer Functional Activities Questionnaire (FAQ)|Measurement of Everyday Cognition (Ecog)|Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-plus),New York State Psychiatric Institute|United States Department of Defense,All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 4,41,Other|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6577|W81XWH-12-0142,Aug-12,Mar-16,Mar-16,3-May-13,13-Mar-18,9-Jul-18,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01845636
NCT01843075,Evaluating Liraglutide in Alzheimer's Disease,ELAD,Unknown status,No Results Available,Alzheimer's Disease,Drug: Liraglutide|Drug: Placebo,"The change in cerebral glucose metabolic rate|The change in z-scores for the ADAS Exec, MRI changes, microglial activation, and CSF markers|The incidence and severity of treatment emergent adverse events|The change in microglial activation|The change in tau deposition|The change in cortical amyloid",Imperial College London|King's College Hospital NHS Trust|University of Oxford|University of Southampton|Avon and Wiltshire Mental Health Partnership NHS Trust,All,"50 Years and older   (Adult, Older Adult)",Phase 2,206,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U1111-1131-9252,Jan-14,Mar-19,Mar-19,30-Apr-13,null,27-Mar-17,"Imperial College, Hammersmith Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01843075
NCT01841125,Escitalopram for the Treatment of Depression in Alzheimer's Disease,Escitalopram,Completed,No Results Available,Alzheimer's Disease,Drug: escitalopram|Drug: Placebo,"Change in CSDD(Cornell scale for depression in dementia) from baseline after 12 weeks of between treatment groups|Change from baseline in CSDD(Cornell scale for depression in dementia) at week 4, 8, 16 and 24.|Change from baseline in K-MMSE at week 12 and 24.|Change from baseline in ADAS-Cog at week 12 and 24.|Change from baseline in NPIQ at week 12 and 24.|Change from baseline in S-IADL at week 12 and 24.|Change from baseline in GDS-15 at week 4, 8, 12, 16 and 24.|Change from baseline in CDR at week 12 and 24.|Change from baseline in CDR sum of box at week 12 and 24.|Change from baseline in Pittsburgh Sleep Quality Index at week 12 and 24.",Konkuk University Medical Center,All,"50 Years and older   (Adult, Older Adult)",Phase 4,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ADD_E_2010,Nov-11,Jul-14,Jul-14,26-Apr-13,null,13-Aug-14,"MedicalExcellence, Seoul, Secho-gu banpo-dong, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01841125
NCT01839422,Imaging of New Learning in Severe Alzheimer's Disease Patients,INCAS,Unknown status,No Results Available,Alzheimer Disease,Behavioral: Memory assessment|Other: Brain imaging examination MRI,"Succesful learning of new songs and paintings, succesful MRI acquisitions.","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France|National Research Agency, France",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2011-A00351-40,Jan-12,Dec-15,null,24-Apr-13,null,9-Apr-14,"GIP Cyceron, Caen, France",,https://ClinicalTrials.gov/show/NCT01839422
NCT01837641,A Study of LY3002813 in Participants With Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Biological: LY3002813-IV|Biological: LY3002183-SC|Drug: Placebo-IV,Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics: Maximum Concentration (Cmax) of LY3002813|Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3002813,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 1,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",15082|I5T-MC-AACC,3-May-13,24-Aug-16,24-Aug-16,23-Apr-13,null,26-Dec-17,"Collaborative Neuroscience Network - CNS, Long Beach, California, United States|Compass Research, Orlando, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|PRAHealthSciences, Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sumida-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01837641
NCT01834716,Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study,,Completed,Has Results,Alzheimer's Disease Prevention,Behavioral: Aerobic vs. Non-Aerobic exercise,Number of Subjects Retained at 6 Months,Mayo Clinic,All,65 Years and older   (Older Adult),Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,12-002817,Apr-13,Dec-14,Dec-14,18-Apr-13,29-Mar-19,29-Mar-19,"Mayo Clinic in Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT01834716
NCT01832350,Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer's Disease|Pseudobulbar Affect (PBA),Drug: Nuedexta (20/10),reduction of PBA frequency|reduction of PBA severity,"St. Joseph's Hospital and Medical Center, Phoenix|Avanir Pharmaceuticals",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 4,60,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,AVP923,Dec-12,Nov-17,Dec-17,16-Apr-13,null,12-Jul-17,"Barrow Neurological Institute, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT01832350
NCT01827982,"A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo",,Completed,No Results Available,Healthy,Drug: JNJ-54861911 1mg|Drug: JNJ-54861911 3 mg|Drug: JNJ-54861911 9 mg|Drug: JNJ-54861911 27 mg|Drug: JNJ-54861911 81 mg|Drug: JNJ-54861911 160 mg|Drug: JNJ-54861911 tbd|Drug: Placebo,Maximum Tolerated Dose (MTD) of JNJ-54861911|Maximum observed plasma/cerebrospinal fluid (CSF) concentration (Cmax) of JNJ-54861911|Time to reach maximum observed plasma/CSF concentration of JNJ-54861911|Area under the plasma/CSF concentration-time curve (AUC) from time 0 to t hours of JNJ-54861911|Half-life of JNJ-54861911|Amyloid Beta profile in cerebrospinal fluid (CSF)|Elimination rate constant|Area under the plasma/CSF concentration-time curve from time 0 to infinity of JNJ-54861911,"Janssen Research & Development, LLC",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR101083|2013-000215-24,Mar-13,Jul-13,Jul-13,10-Apr-13,null,10-Nov-14,"Antwerpen, Belgium",,https://ClinicalTrials.gov/show/NCT01827982
NCT01826110,PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers,,Completed,No Results Available,Alzheimer's Disease,Drug: [11C]PIB,Distribution Volumes of 11C-PIB,Johns Hopkins University|National Institute on Aging (NIA),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,21,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NA_00033154|1R21AG056142-01,Sep-13,Jul-18,Jul-18,8-Apr-13,null,5-Mar-19,"Johns Hopkins Medical Institution- Dept of Radiology , Division of Nuclear Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01826110
NCT01825317,Effect of NeuroAD on Alzheimer Patients,,Completed,No Results Available,Alzheimer's Disease,Device: NeuroAD|Device: Sham device,ADAS-Cog,Neuronix Ltd|company: K The Power|Chungnam National University Hospital,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,32,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",NRX-KOR1,Mar-13,Dec-13,Dec-13,5-Apr-13,null,21-Apr-14,"Chungnam national university hospital, Daejeon Geriatric Medical Center, Daejeon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01825317
NCT01825330,Effect of NeuroAD on the Cognitive Function of Alzheimer Patients,,Completed,No Results Available,Alzheimer's Disease,Device: TMS and cognitive stimulation|Device: sham,Efficacy,Neuronix Ltd,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,131,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NRX - US4,Oct-13,Jan-16,Mar-16,5-Apr-13,null,31-Mar-16,"Banner Sun Health Research Institute, Sun City, Arizona, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Miami Jewish Health Systems, Miami, Florida, United States|Roskamp Institute Clinic, Sarasota, Florida, United States|Palm Beach Neurology and Premiere Research Institute, West Palm Beach, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Cleveland Clinic Lou Ruvo Brain Center, Las Vegas, Nevada, United States|NYU Langone Medical Center, New York, New York, United States|Cleveland Clinic Center for Brain Health Lakewood Hospital, Cleveland, Ohio, United States|Assaf Harofe Medical Center, Beer Yaakov, Israel",,https://ClinicalTrials.gov/show/NCT01825330
NCT01825577,Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.,,Terminated,Has Results,Dementia|Accidental Falls|Apathy,Drug: Transdermal Methylphenidate,Timed Get Up and Go Test - Measure of Mobility|POMA -Performance Oriented Mobility Assessment - Measure of Gait and Balance.,St. Louis University,All,65 Years to 95 Years   (Older Adult),Phase 4,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,23014,Nov-12,Feb-15,Feb-15,5-Apr-13,19-Aug-16,24-Jul-18,"Delmar Gardens, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01825577
NCT01819714,Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease,SensiCare,Completed,No Results Available,Alzheimer Disease,Other: Multi-sensory supportive care,"Change from baseline in NPI-Q scores|Change from baseline in the Quality-of-life-Alzheimer's Disease questionnaire (QOL-AD)|Change from baseline in the ""aggressive behavior"" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire|Change in drug consumption from baseline",Centre Hospitalier Universitaire de Nīmes,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,31,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PHRIP/2012/JD|2013-A00005-40,Jun-13,May-14,Feb-15,28-Mar-13,null,29-Apr-15,"CHU de Nîmes - Centre de Gérontologie de Serre Cavalier, Nîmes, France",,https://ClinicalTrials.gov/show/NCT01819714
NCT01815112,Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging,,Terminated,No Results Available,Alzheimer Disease|Mild Cognitive Impairment|Vascular Dementia,Other: Magnetic resonance imaging|Other: Positron emission tomography,Dynamic FDG (fluoro-deoxyglucose) PET|Aqueductal CSF flow|Follow-up MRI|Follow-up PET,"Centre Hospitalier Universitaire, Amiens",All,65 Years and older   (Older Adult),Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,PI07-PR-MEYER1|2007-A01009-44,Feb-08,Apr-13,Apr-14,20-Mar-13,null,10-Mar-15,"CHU Rouen, Rouen, Haute Normandie, France|CHU Amiens, Amiens, Picardie, France",,https://ClinicalTrials.gov/show/NCT01815112
NCT01812213,Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI),NAV4-04,"Active, not recruiting",No Results Available,Mild Cognitive Impairment,Drug: [18F]NAV4694,Incidence of Mild Cognitive Impairment Progression to Alzheimer's Disease|Incidence of [18F]NAV4694 PET Positive scans at 18 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 6 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 12 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 18 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 24 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 30 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 36 months compared to baseline|Change in SUVR scores at 18 months compared to baseline|Incidence of Adverse Events post baseline,Navidea Biopharmaceuticals,All,"55 Years to 99 Years   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NAV4-04,Mar-13,Jun-18,Aug-18,18-Mar-13,null,26-Jul-17,"Banner Sun Health Research Institute, Sun City, Arizona, United States|Galiz Research, Hialeah, Florida, United States|Mt. Sinai Wien Center for Alzheimer's Disease, Miami Beach, Florida, United States|Compass Research, Orlando, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|McLean Hospital, Belmont, Massachusetts, United States|Qunicy Medical Center, Alzheimer's Disease Center, Quincy, Massachusetts, United States|Neurological Associates of Albany, Albany, New York, United States|Albert Einstein College of Medicine, The Bronx, New York, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01812213
NCT01811381,Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease,,Recruiting,No Results Available,Mild Cognitive Impairment,Drug: Curcumin|Behavioral: aerobic yoga|Behavioral: non aerobic yoga|Dietary Supplement: Placebo,"Curcumin effects (first six month period) or curcumin and aerobic yoga effects (second six month period) on the changes in the levels of blood biomarkers for Mild Cognitive Impairment relative to baseline or relative to placebo or non-aerobic yoga.|Changes in 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) glucose metabolism neuroimaging after supplementation compared to baseline and compared to placebo|Curcumin effects on changes in Neuropsychological parameters compared to baseline and to placebo (first six month period) and in combination with aerobic yoga, compared to baseline and to non-aerobic yoga with curcumin or aerobic yoga with supplement|Number of Participants with Adverse Events",VA Office of Research and Development|heather.d'adamo@va.gov,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,80,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",E0669-I|VA_RX00069,20-Jan-14,1-Jun-19,31-Dec-19,14-Mar-13,null,18-Sep-18,"VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01811381
NCT01807026,A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease|Healthy Volunteers,Drug: LY2886721|Drug: Placebo,Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Plasma LY2886721|Pharmacokinetics: Maximum Concentration (Cmax) of Plasma LY2886721|Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Cerebrospinal Fluid (CSF) LY2886721|Pharmacokinetics: Maximum Concentration (Cmax) of CSF LY2886721|Pharmacodynamics (PD): Cnadir of Plasma Amyloid β (Aβ)1-40|PD: Cnadir of CSF Aβ 1-40|Cohort C: Mean QTcF Value at Cmax,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",15107|I4O-EW-BACX,Mar-13,May-13,May-13,8-Mar-13,null,3-Jun-13,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01807026
NCT01802554,Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention,,Completed,Has Results,Depressive Symptoms|Inflammation,Behavioral: Pleasant Events Program (PEP)|Behavioral: Information Support (IS),Brief Center for Epidemiologic Studies Depression Scale (CESD)|D-dimer|Interleukin-6 (IL-6)|Positive and Negative Affect Schedule,"University of California, San Diego",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01AG031090,Apr-08,Feb-13,Feb-13,1-Mar-13,3-Apr-14,13-Jun-16,"University of California San Diego, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT01802554
NCT01798199,Vanquishing Apathy Through E-inclusion Using Realistic Virtual Environment Project,VERVE,Completed,No Results Available,Alzheimer's Disease,Other: The training by Verve System,"the participants and careers acceptability|To assess the impact of behavioral disturbances over the use of the VR using the NPI and the Apathy Inventory|To describe the parameters those facilitate engagement within the designs of VERVE VR setting using the engagement scale OME|To assess the potential acceptability and preventive effectiveness of such setting in home setting using visual analogic scale and EQ-D6|To assess cognitive impact of the light VERVE setting. Using Stroop, TMT, VAT and functional task (IADL)",Centre Hospitalier Universitaire de Nice,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,12-PP-04,May-13,Sep-14,Sep-14,25-Feb-13,null,1-Sep-15,"CHU de Nice, Nice, France|EHPAD Valrose, Nice, France|EHPAD Villa Hélios Saint Jean, Nice, France",,https://ClinicalTrials.gov/show/NCT01798199
NCT01796314,Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life,THERAD,Completed,No Results Available,Alzheimer Disease,Behavioral: Therapeutic Educational Program,Quality of life|Caregiver quality of life,"University Hospital, Toulouse",All,"50 Years to 100 Years   (Adult, Older Adult)",Not Applicable,170,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,RC31/11/255|PREQHOS n°11 255 07,Jan-13,Feb-17,Feb-17,21-Feb-13,null,1-Jun-18,"CHU de Toulouse, Hôtel-Dieu, 2 rue Viguerie, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01796314
NCT01795339,A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients,,Completed,No Results Available,Healthy Elderly Volunteers|Mild-to-moderate Alzheimer's Disease Patients,Drug: AZD3293|Drug: Placebo,"Adverse event monitoring|Assessment of vital signs (blood pressure, pulse and body temperature) and physical exams|Clinical laboratory tests (chemistry, hematology, urinalysis, renal safety)|Assessment of 12-lead digital electrocardiograms to measure rhythm, rate, morphology, QT/QTc interval|Assessment of telemetry, as reported by Investigator Columbia-Suicide Severity Rating Scale (C-SSRS)|Investigation of the effect of AZD3293 on plasma and cerebrospinal fluid (CSF) biomarkers relevant for Alzheimer Disease (AD)|Investigation of the effect of AZD3293 on plasma and cerebrospinal fluid (CSF) biomarkers relevant for Alzheimer Disease (AD) in mild-moderate AD patients in comparison to elderly healthy volunteers|Investigation of the multiple dose Pharmacokinetics for AZD3293 and its metabolite AZ13569724, including dose proportionality for AZD3293 following oral administration|Investigation of the Pharmacokinetics/Pharmacodynamics relationship of the effect of AZD3293 on biomarkers relevant for Alzheimer Disease (AD) in plasma",AstraZeneca,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1,47,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",D5010C00002,Mar-13,Mar-14,Mar-14,20-Feb-13,null,3-Apr-14,"Research Site, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT01795339
NCT01782742,Bexarotene Amyloid Treatment for Alzheimer's Disease,BEAT-AD,Completed,Has Results,Alzheimer's Disease,Drug: Bexarotene|Drug: Placebo,Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain|Primary Outcome by Genotype (ALL SUBJECTS)|Primary Outcome by Genotype (NON ApoE4 CARRIERS)|Primary Outcome by Genotype (ApoE4 CARRIERS)|Primary Outcome by Genotype (HETEROZYGOTE ApoE4 CARRIERS)|Primary Outcome by Genotype (HOMOZYGOTE ApoE4 CARRIERS)|Change in MMSE Score in ALL Subjects From Baseline to Week 4|Change in ADAS-Cog Score in ALL Subjects From Baseline to Week 4|Change in the Global Clinical Dementia Rating Score in ALL Subjects From Baseline to Week 4|Change in NPI Scores in ALL Subjects From Baseline to Week 4|Change in the Activities of Daily Living (ADCS-ADL) Score in ALL Subjects From Baseline to Week 4|Secondary Outcome Measuring Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (ALL SUBJECTS)|Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (Non ApoE4 Carriers)|Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in All Subjects|Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in Non ApoE4 Carriers,The Cleveland Clinic,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CCF-IRB 12-783,Feb-13,Aug-14,Dec-14,4-Feb-13,12-Feb-16,12-Feb-16,"Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States",,https://ClinicalTrials.gov/show/NCT01782742
NCT01782248,Self-consciousness in Dementia,,Unknown status,No Results Available,Alzheimer Disease|Fronto-temporal Lobar Dementia,Other: Questionnary and IRM,"Characterize the deficit in critical components of personal identity in patients with Alzheimer's disease (AD) and fronto-temporal lobar dementia (FTLD), compared to healthy elderly, combining a neuropsychology and multi-podal neuroimaging study.","University Hospital, Strasbourg, France",All,"45 Years to 85 Years   (Adult, Older Adult)",Early Phase 1,65,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),5289,Feb-13,Oct-15,Oct-15,1-Feb-13,null,1-Feb-13,"Hôpitaux Universitaires de Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT01782248
NCT01780519,The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms,,Completed,No Results Available,Alzheimer's Disease (AD),Drug: lorazepam,Groton Maze Learning Test (GMLT) score|Auditory Verbal Learning Test (AVLT) Long-term memory score|Two Back Test (TBK),Mayo Clinic,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,57,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,12-006469,Jan-13,Sep-16,Sep-16,31-Jan-13,null,10-Nov-16,"Mayo Clinic, Scottsdale, Arizona, United States",,https://ClinicalTrials.gov/show/NCT01780519
NCT01780974,Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention,,Completed,Has Results,Treated Hypertension,Drug: Lipoic Acid plus Omega-3 Fatty Acids|Drug: Placebo,Trails Making Test Part B (Executive Function)|White Matter Hyperintensity Volume (Brain MRI),Oregon Health and Science University,All,"55 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,42,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",SFF01,Apr-13,Oct-15,Oct-15,31-Jan-13,7-Apr-17,7-Apr-17,"Lynne Shinto, ND, MPH, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01780974
NCT01778946,Nicotine Treatment of Cognitive Decline in Down Syndrome,,Recruiting,No Results Available,Down Syndrome|Mild Cognitive Impairment,Drug: Low Dose Nicotine (7mg)|Drug: Moderate Dose Nicotine (14mg),Safety of Nicotine Intervention|Cognitive Improvement|Exploratory,Vanderbilt University Medical Center,All,"25 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,121759,Apr-13,Dec-19,Dec-19,29-Jan-13,null,20-May-19,"Vanderbilt Psychiatric Hospital, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01778946
NCT01772537,The Effects of Anesthesia on Patients Undergoing Surgery for Repair of a Thoracoabdominal Aneurysm.,,Terminated,Has Results,Thoracic Aneurysm|Aneurysm Stent|Cardiopulmonary Bypass|Abdominal Aneurysm,Drug: Propofol|Drug: isoflurane,Changes in Cerebrospinal Fluid (CSF) Levels of Tau|Changes in CSF Levels of Amyloid|Number of Participants With Delirium as Assessed by the Confusion Assessment Method (CAM),Johns Hopkins University|National Center for Research Resources (NCRR),All,"21 Years to 100 Years   (Adult, Older Adult)",Not Applicable,14,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other",NA_00067716|5KL2RR025006,May-12,Feb-14,Feb-14,21-Jan-13,24-Feb-17,31-Mar-17,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01772537
NCT01767909,The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF),,Completed,No Results Available,Amnestic Mild Cognitive Impairment|Alzheimer's Disease,Drug: Insulin (Humulin® R U-100)|Drug: Placebo,Change in global measure of cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12)|Change in Memory Composite as measured by Story Recall and Buschke Selective Reminding Test|Change in daily functioning as measured by the ADCS-MCI Activities of Daily Living (ADCS-ADL-MCI)|Change from screen in magnetic resonance imaging (MRI)|Rate of change over time on CSF Abeta|Rate of change over time on CSF Abeta/tau ratio|Comparison of the response to treatment of INI based on baseline AD biomarker profile|Comparison of the response to treatment of INI based on gender|Comparison of the response to treatment of INI based on APOE-ε4 genotype|Examine whether further improvement occurs after 18 months of treatment,University of Southern California|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute|Wake Forest University Health Sciences,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,239,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADC-046-INI|RF1AG041845,8-Jan-14,11-Dec-18,11-Dec-18,15-Jan-13,null,18-Jan-19,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|University of California, Irvine, Irvine, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|Baylor College of Medicine, Houston, Texas, United States|U of WA / VA Puget Sound Alzheimer's Disease Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01767909
NCT01767311,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: BAN2401 2.5 mg/kg|Drug: BAN2401 5.0 mg/kg|Drug: BAN2401 10 mg/kg|Drug: Placebo,"Core Study: Change from Baseline in the Alzheimer's Disease Composite Score (ADCOMS) at 12 months|Core Study and Extension Phase: Safety will be assessed by monitoring and recording all adverse events (AEs) and serious adverse events (SAEs)|Core Study: Change from Baseline at 18 Months in Brain Amyloid Pathophysiology as Measured by Amyloid Positron Emission Tomography (PET)|Core Study: Change from Baseline in the ADCOMS at 18 Months|Core Study: Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) at 18 Months|Core Study: Change from Baseline in Alzheimer Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 18 Months|Core Study: Change from Baseline in Cerebrospinal fluid (CSF) Biomarkers (Aβ[1-42], t-tau, and p-tau) at 18 Months|Core Study: Change from Baseline in Total Hippocampal Volume at 18 Months as Measured by Volumetric Magnetic Resonance Imaging (vMRI)|Core Study: Change from Baseline at 12 Months in Brain Amyloid Pathophysiology as Measured by Amyloid PET|Core Study: Change from baseline at 12 months on clinical status for the following assessments: ADCOMS, CDR-SB, and ADAS-cog|Core Study: Change from Baseline in CSF Biomarkers (Aβ[1-42], t-tau, and p-tau) at 12 Months|Core Study: Change from Baseline in Total Hippocampal Volume at 6 and 12 Months as Measured by vMRI|Core Study: Change from Baseline in Left and Right Hippocampal Volume at 6, 12, and 18 Months as Measured by vMRI|Core Study: Change from Baseline in Whole Brain Volume at 6, 12, and 18 Months as Measured by vMRI|Core Study: Change from Baseline in Total Ventricular Volume at 6, 12, and 18 Months as Measured by vMRI|Extension Phase: Change from Baseline in Brain Amyloid Levels as Measured by Amyloid PET at at 3 months (Cohort 1) or 6 months (Cohort 2), and 12 and 24 months|Extension Phase: Change from end of Core Study in Brain Amyloid Levels as Measured by Amyloid PET at the Baseline of Extension Phase|Extension Phase: Percentage of Amyloid Positive Participants Over Time",Eisai Inc.,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,800,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BAN2401-G000-201|2012-002843-11,20-Dec-12,Aug-21,Aug-21,14-Jan-13,null,2-Apr-19,"Facility #1, Birmingham, Alabama, United States|Facility #1, Phoenix, Arizona, United States|Facility #1, Tucson, Arizona, United States|Facility #1, Carson, California, United States|Facility #1, Lomita, California, United States|Facility #1, Long Beach, California, United States|Facility #1, Los Alamitos, California, United States|Facility #1, Los Angeles, California, United States|Facility #2, Los Angeles, California, United States|Facility #3, Los Angeles, California, United States|Facility #1, Orange, California, United States|Facility #1, Oxnard, California, United States|Facility #1, San Diego, California, United States|Facility #1, Denver, Colorado, United States|Facility #1, New Haven, Connecticut, United States|Facility #2, New Haven, Connecticut, United States|Facility #1, Atlantis, Florida, United States|Facility #1, Boca Raton, Florida, United States|Facility #2, Boca Raton, Florida, United States|Facility #1, Bradenton, Florida, United States|Facility #1, Deerfield Beach, Florida, United States|Facility #1, Delray Beach, Florida, United States|Facility #1, Fort Myers, Florida, United States|Facility #1, Hallandale Beach, Florida, United States|Facility #1, Hialeah, Florida, United States|Facility #1, Lake Worth, Florida, United States|Facility #1, Leesburg, Florida, United States|Facility #2, Leesburg, Florida, United States|Facility #1, Miami Springs, Florida, United States|Facility #1, Miami, Florida, United States|Facility #2, Miami, Florida, United States|Facility #3, Miami, Florida, United States|Facility #1, Naples, Florida, United States|Facility #1, Ocala, Florida, United States|Facility #1, Orlando, Florida, United States|Facility #1, Palm Beach Gardens, Florida, United States|Facility #1, Saint Petersburg, Florida, United States|Facility #1, Sunrise, Florida, United States|Facility #3, Tampa, Florida, United States|Facility #1, Tampa, Florida, United States|Facility #2, Tampa, Florida, United States|Facility #1, The Villages, Florida, United States|Facility #2, Atlanta, Georgia, United States|Facility #1, Atlanta, Georgia, United States|Facility #1, Columbus, Georgia, United States|Facility #1, Decatur, Georgia, United States|Facility #1, Chicago, Illinois, United States|Facility #1, Elk Grove Village, Illinois, United States|Facility #1, Elkhart, Indiana, United States|Facility #1, Indianapolis, Indiana, United States|Facility #1, Wichita, Kansas, United States|Facility #1, Lexington, Kentucky, United States|Facility #1, Boston, Massachusetts, United States|Facility #2, Boston, Massachusetts, United States|Facility #1, Burlington, Massachusetts, United States|Facility #1, Newton, Massachusetts, United States|Facility #1, Ann Arbor, Michigan, United States|Facility #1, East Lansing, Michigan, United States|Facility #1, Farmington Hills, Michigan, United States|Facility #1, Lansing, Michigan, United States|Facility #1, West Bloomfield, Michigan, United States|Facility #1, Saint Louis, Missouri, United States|Facility #1, Eatontown, New Jersey, United States|Facility #1, Toms River, New Jersey, United States|Facility #1, Albany, New York, United States|Facility #1, Amherst, New York, United States|Facility #1, Latham, New York, United States|Facility #1, New York, New York, United States|Facility #2, New York, New York, United States|Facility #1, Rochester, New York, United States|Facility #2, Rochester, New York, United States|Facility #1, Charlotte, North Carolina, United States|Facility #1, Centerville, Ohio, United States|Facility #1, Oklahoma City, Oklahoma, United States|Facility #2, Oklahoma City, Oklahoma, United States|Facility #2, Portland, Oregon, United States|Facility #1, Portland, Oregon, United States|Facility #1, Abington, Pennsylvania, United States|Facility #1, Jenkintown, Pennsylvania, United States|Facility #1, East Providence, Rhode Island, United States|Facility #1, Knoxville, Tennessee, United States|Facility #1, Austin, Texas, United States|Facility #1, Dallas, Texas, United States|Facility #2, Dallas, Texas, United States|Facility #1, Houston, Texas, United States|Facility #1, San Antonio, Texas, United States|Facility #2, San Antonio, Texas, United States|Facility #3, San Antonio, Texas, United States|Facility #1, Bennington, Vermont, United States|Facility #1, Richmond, Virginia, United States|Facility #1, Milwaukee, Wisconsin, United States|Facility #1, Kentville, Nova Scotia, Canada|Facility #1, Kingston, Ontario, Canada|Facility #2, London, Ontario, Canada|Facility #1, Ottawa, Ontario, Canada|Facility #1, Peterborough, Ontario, Canada|Facility #1, Toronto, Ontario, Canada|Facility #1, Greenfield Park, Quebec, Canada|Facility #1, Montreal, Quebec, Canada|Facility #1, Verdun, Quebec, Canada|Facility #1, Québec city, Canada|Facility #1, Strasbourg Cedex, Bas Rhin, France|Facility #1, Toulouse, Haute Garonne, France|Facility #1, Paris Cedex 10, Paris, France|Facility #1, Bron Cedex, France|Facility #1, Paris, France|Facility #1, Rennes Cedex 9, France|Facility #1, Villeurbanne, France|Facility #1, Gunzburg, Baden Wuerttemberg, Germany|Facility #1, Karlstadt Am Main, Bayern, Germany|Facility #1, Hoppegarten, Berlin, Germany|Facility #1, Hannover, Niedersachsen, Germany|Facility #1, Mittweida, Sachsen, Germany|Facility #1, Berlin, Germany|Facility #2, Berlin, Germany|Facility #3, Berlin, Germany|Facility #1, Guenzburg, Germany|Facility #1, Hamburg, Germany|Facility #1, Heidelberg, Germany|Facility #1, Leipzig, Germany|Facility #1, Mannheim, Germany|Facility #1, Muenchen, Germany|Facility #1, Tuebingen, Germany|Facility #1, Brescia, Italy|Facility #1, Genova, Italy|Facility #1, Milano, Italy|Facility #1, Parma, Italy|Facility #1, Perugia, Italy|Facility #1, Pisa, Italy|Facility #1, Roma, Italy|Facility #2, Roma, Italy|Facility #3, Roma, Italy|Eisai Trial Site #1, Otake-shi, Hiroshima-Ken, Japan|Eisai Trial Site #1, Himeji-shi, Hyogo-Ken, Japan|Eisai Trial Site #2, Himeji-shi, Hyogo-Ken, Japan|Eisai Trial Site #3, Himeji-shi, Hyogo-Ken, Japan|Eisai Trial Site #1, Kobe-shi, Hyogo-Ken, Japan|Eisai Trial Site #1, Nishinomiya-shi, Hyogo-Ken, Japan|Eisai Trial Site #1, Kyoto-shi, Kyoto-Fu, Japan|Eisai Trial Site #1, Kurashiki-shi, Okayama-Ken, Japan|Eisai Trial Site #1, Osaka-shi, Osaka-Fu, Japan|Eisai Trial Site #1, Saitama-shi, Saitama-Ken, Japan|Eisai Trial Site #1, Itabashi-ku, Tokyo-To, Japan|Eisai Trial Site #1, Shinjuku-ku, Tokyo-To, Japan|Eisai Trial Site #2, Shinjuku-ku, Tokyo-To, Japan|Facility #1, Seongnam-si, Gyeonggi-do, Korea, Republic of|Facility #1, Busan, Gyeongsangnam-do, Korea, Republic of|Facility #2, Seoul, Korea, Republic of|Facility #3, Seoul, Korea, Republic of|Facility #4, Seoul, Korea, Republic of|Facility #1, Amsterdam, Netherlands|Facility #1, Sant Cugat Del Vallés, Barcelona, Spain|Facility #1, San Sebastian, Guipuzcoa, Spain|Facility #1, Barakaldo, Vizcaya, Spain|Facility #1, Alicante, Spain|Facility #1, Barcelona, Spain|Facility #1, Madrid, Spain|Facility #2, Madrid, Spain|Facility #1, Sevilla, Spain|Facility #1, Malmö, Sweden|Facility #1, Mölndal, Sweden|Facility #1, Stockholm, Sweden|Facility #1, Uppsala, Sweden|Facility #1, London, Greater London, United Kingdom|Facility #1, Isleworth, Middlesex, United Kingdom|Facility #1, Glasgow, Renfrewshire, United Kingdom|Facility #1, Bath, United Kingdom|Facility #2, London, United Kingdom|Facility #1, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT01767311
NCT01766336,A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,,Terminated,Has Results,Alzheimer's Disease,Drug: Group 1 ELND005|Drug: Group 2 ELND005,Number of Participants Experiencing Treatment Emergent Adverse Events,Transition Therapeutics Ireland Limited|Elan Pharmaceuticals,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 2,296,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ELND005-AG251|2012-005524-15,Jan-13,Aug-15,Aug-15,11-Jan-13,13-May-16,22-Jun-16,"TransitionTIL Investigational Site, Birmingham, Alabama, United States|TransitionTIL Investigational Site, Phoenix, Arizona, United States|TransitionTIL Investigational Site, Phoenix, Arizona, United States|TransitionTIL Investigational Site, Encino, California, United States|TransitionTIL Investigational Site, Escondido, California, United States|TransitionTIL Investigational Site, Fresno, California, United States|TransitionTIL Investigational Site, Long Beach, California, United States|TransitionTIL Investigational Site, Newport Beach, California, United States|TransitionTIL Investigational Site, Orange, California, United States|TransitionTIL Investigational Site, Norwalk, Connecticut, United States|TransitionTIL Investigational Site, Washington, District of Columbia, United States|TransitionTIL Investigational Site, Atlantis, Florida, United States|TransitionTIL Investigational Site, Deerfield Beach, Florida, United States|TransitionTIL Investigational Site, Delray Beach, Florida, United States|TransitionTIL Investigational Site, Lake Worth, Florida, United States|TransitionTIL Investigational Site, Oakland Park, Florida, United States|TransitionTIL Investigational Site, Orlando, Florida, United States|TransitionTIL Investigational Site, Port Charlotte, Florida, United States|TransitionTIL Investigational Site, Sarasota, Florida, United States|TransitionTIL Investigational Site, Columbus, Georgia, United States|TransitionTIL Investigational Site, Savannah, Georgia, United States|TransitionTIL Investigational Site, Springfield, Illinois, United States|TransitionTIL Investigational Site, Easton, Maryland, United States|TransitionTIL Investigational Site, Winchester, Massachusetts, United States|TransitionTIL Investigational Site, St. Paul, Minnesota, United States|TransitionTIL Investigational Site, Rochester, New York, United States|TransitionTIL Investigational Site, Rochester, New York, United States|TransitionTIL Investigational Site, Charlotte, North Carolina, United States|TransitionTIL Investigational Site, Durham, North Carolina, United States|TransitionTIL Investigational Site, Wilmington, North Carolina, United States|TransitionTIL Investigational Site, Winston Salem, North Carolina, United States|TransitionTIL Investigational Site, Oklahoma City, Oklahoma, United States|TransitionTIL Investigational Site, Portland, Oregon, United States|TransitionTIL Investigational Site, Abington, Pennsylvania, United States|TransitionTIL Investigational Site, Jenkintown, Pennsylvania, United States|TransitionTIL Investigational Site, Norristown, Pennsylvania, United States|TransitionTIL Investigational Site, Pittsburgh, Pennsylvania, United States|TransitionTIL Investigational Site, Port Royal, South Carolina, United States|TransitionTIL Investigational Site, DeSoto, Texas, United States|TransitionTIL Investigational Site, Bellevue, Washington, United States|TransitionTIL Investigational Site, Toronto, Ontario, Canada|TransitionTIL Investigational Site, Elche, Alicante, Spain|TransitionTIL Investigational Site, Terrassa, Barcelona, Spain|TransitionTIL Investigational Site, Barcelona, Spain|TransitionTIL Investigational Site, Madrid, Spain|TransitionTIL Investigational Site, Swindon, Wiltshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01766336
NCT01764243,Safety and Efficacy of MT-4666,,Completed,No Results Available,Alzheimer's Disease,Drug: MT-4666|Drug: Placebo,Change from baseline in ADAS-cog-13|Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)|Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Change from baseline in Alzheimers Disease Assessment Scale-cognitive subscale 11-item (ADAS-cog-11)|Change from baseline in Mini-Mental State Examination (MMSE)|Change from baseline in Neuropsychiatric Inventory (NPI)|Change from baseline in Modified Crichton Scale,Mitsubishi Tanabe Pharma Corporation,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P211-03,Nov-12,Jun-15,Jul-15,9-Jan-13,null,28-Sep-15,"Kanto, Japan",,https://ClinicalTrials.gov/show/NCT01764243
NCT01762618,Experimental Study of the Impact of a Group Therapy Psychological Intervention for Caregivers of Alzheimer's Disease Patients,EMOCUIDA,Completed,No Results Available,Psychological Support to Caregivers of Azlheimer's Patients,Behavioral: Cognitive Behavioral Therapy Group,"Change from baseline in POMS Scale (""Profile of Mood States"")|Change from baseline compared to the control and active arms using the Martin and cols. scale to assess the overload level of the family caregivers of patients with probable or possible Alzheimer's disease or other advanced stage dementia.","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation",All,"18 Years to 95 Years   (Adult, Older Adult)",Not Applicable,83,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,EMOCUIDA/FPM-0211,Jan-12,Apr-13,Jul-13,8-Jan-13,null,9-Jul-14,"Hospital del Carme, Badalona, Barcelona, Spain|Primary Assistant Center Les Corts, Barcelona, Catalonia, Spain|Primary Assistant Center Sarrià, Barcelona, Catalonia, Spain",,https://ClinicalTrials.gov/show/NCT01762618
NCT01760005,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,DIAN-TU,"Active, not recruiting",No Results Available,"Alzheimers Disease|Dementia|Alzheimers Disease, Familial",Drug: Gantenerumab|Drug: Solanezumab|Drug: Matching Placebo (Gantenerumab)|Drug: Matching Placebo (Solanezumab),Assess cognitive efficacy in individuals with mutations causing dominantly inherited AD as measured by change in the DIAN-TU cognitive composite score.|Gantenerumab: Cerebral amyloid imaging using [11C]PiB-PET.|Solanezumab: Total Abeta 1-42 (Aβ42) in CSF.|Change from Baseline in Clinical Measures|Change from Baseline in Cognitive Measures,"Washington University School of Medicine|Eli Lilly and Company|Hoffmann-La Roche|Alzheimer's Association|National Institute on Aging (NIA)|Avid Radiopharmaceuticals|Accelerating Medicines Partnership (AMP)|Janssen, LP",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,490,Other|Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DIAN-TU-001|The Alzheimer's Association|U01AG042791|2013-000307-17|R01AG046179|REec-2014-0817|R56AG053267|GHR Foundation|Alzheimer's Association|U01AG059798|R01AG053267,Dec-12,Dec-20,Mar-21,3-Jan-13,null,28-Feb-19,"University of Alabama in Birmingham, Birmingham, Alabama, United States|University of California San Diego Medical Center, La Jolla, California, United States|USC Keck School of Medicine, Los Angeles, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Columbia University, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|Texas Health Hospital, Arlington, Texas, United States|University of Washington, Seattle, Washington, United States|Instituto de Investigaciones Neurologicas Raul Carrea, FLENI, Ciudad Autonoma de Buenos Aire, Argentina|Neuroscience Research Australia, Randwick, New South Wales, Australia|Mental Health Research Institute, Melbourne, Victoria, Australia|The McCuster Foundation of Alzheimer's Disease Research, Nedlands, Western Australia, Australia|Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil|UBC Hospital, Vancouver, British Columbia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|McGill Center for Studies in Aging, Verdun, Quebec, Canada|CHU de Quebec - Hôpital de l' Enfant Jésus, Québec, Canada|Beijing Xuan Wu Hospital Affiliated Capital Medical University, Beijing, Beining, China|Ruijin Hospital, Shanghai Jiaotong Uni. School of Med., Shanghai, Shanghai, China|Grupo de Neurociencias Sede de la Universidad de Antioquia, Medellín, Medellin, Colombia|CHU de Toulouse - Hôpital Purpan, Toulouse, Haute Garonne, France|Hopital Roger Salengro - CHU Lille, Lille, Nord, France|Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, Paris, France|Hopital Neurologique Pierre Wertheimer, Bron cedex, Rhone, France|CHU de Rouen - Hôpital Charles Nicolle, Rouen, Seine Maritime, France|Universitaetsklinikum Tubingen, Tübingen, Baden Wuerttemberg, Germany|LMU-Campus Grosshadern, Muenchen, Bayern, Germany|St Vincent's University Hospital, Dublin, Ireland|IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|University of Tokyo Hospital, Bunkyō-Ku, Tokyo-To, Japan|Osaka City University Hospital, Osaka-Fu, Japan|Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico, Distrito Federal, Mexico|Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V., Zapopan, Jalisco, Mexico|Brain Research Center, Amsterdam, Netherlands|University of Puerto Rico, School of Medicine, San Juan, Puerto Rico|Hospital Clínic I Provincial de Barcelona, Barcelona, Spain|The National Hospital for Neurology and Neurosurgery, London, Greater London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01760005
NCT01746498,Therapeutic Effect of Direct Current Stimulation on Cognitive Function of Mild to Moderate Alzheimer Patients,,Completed,No Results Available,Alzheimer Disease,Procedure: Direct current stimulation using Anodal electrode|Procedure: direct current stimulation using cathodal electrode|Procedure: Sham direct current stimulation,Minimental state Examination|changes in cortical excitability|Wechsler memory scale|Intelligent questant ( IQ),Assiut University,All,"45 Years to 79 Years   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Direct current in Alzheimer's,Jun-11,Nov-12,Nov-12,11-Dec-12,null,17-Dec-12,"Eman Khedr, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT01746498
NCT01746706,Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease? A Validation Study Using PET With Florbetapir (AV-45).,,Unknown status,No Results Available,Alzheimer's Disease,Device: PET amyloid tracer (Florbetapir F18 AV45 F18,the assessment of subhippocampal dysfunction,Assistance Publique Hopitaux De Marseille,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2011 A00383-38,Oct-11,Nov-15,Nov-17,11-Dec-12,null,14-Apr-17,"Assistance Publique Hopitaux de Marseille, Marseille, France",,https://ClinicalTrials.gov/show/NCT01746706
NCT01747213,Bisnorcymserine in Healthy Adult Volunteers,,Completed,No Results Available,Alzheimer's Disease|Healthy Volunteers,Drug: BNC|Other: Placebo,"Safety and tolerability|AUC, Tmax, Cmax, elimination rate constant, T1/2, clearance and volume of distribution of BNC",National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC),All,"55 Years and older   (Adult, Older Adult)",Phase 1,75,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",130034|13-AG-0034,1-Jan-13,8-Jan-19,8-Jan-19,11-Dec-12,null,16-May-19,"National Institute on Aging, Clinical Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01747213
NCT01741194,AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext,NOURISH-AD,Completed,No Results Available,Alzheimer's Disease,Drug: AC-1204|Drug: Placebo,Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Clock Draw Interpretation Scale (CDIS)|Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change (ADCS-CGIC)|Alzheimer's Disease Co-operative Study - Activities of Daily Living (ADCS-ADL)|Quality of Life - Alzheimer's Disease (QoL-AD)|Resource Utilization in Dementia (RUD-Lite)|Incidence of treatment-emergent adverse events,"Accera, Inc.",All,66 Years to 90 Years   (Older Adult),Phase 2|Phase 3,418,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",AC-12-010,Mar-13,24-Oct-16,14-Apr-17,4-Dec-12,null,17-May-17,"University of Alabama at Birmingham, Department of Neurology, Memory Disorders Division, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Principals Research Group, Hot Springs, Arkansas, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|CITrials, Inc., Bellflower, California, United States|Southern Research LLC, Beverly Hills, California, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Diligent Clinical Trials, Downey, California, United States|UCSD Comprehensive Alzheimer's Program, La Jolla, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Alliance for Research, Long Beach, California, United States|Renew Behavioral Health, Long Beach, California, United States|Pacific Research Network, San Diego, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Research Across America, Santa Ana, California, United States|Neurological Research Institute, Santa Monica, California, United States|Redwood Research Medical Group, Santa Rosa, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|IMMUNOe Research Centers, Centennial, Colorado, United States|The Mile High Research Center, Denver, Colorado, United States|Chase Medical Research of Greater New Haven, Hamden, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Meridian Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States|The Roskamp Institute, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|NeuroTrials Research, Inc, Atlanta, Georgia, United States|IU Health Partners Adult Neurology Clinic, Indianapolis, Indiana, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Alzheimers Disease Center, Quincy Medical Center, Somerville, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|Saint Louis University Medical School /Department of Neurology & Psychiatry, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Alzheimer's Research Corporation, Manchester Township, New Jersey, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|The Cognitive Research Center of New Jersey, Springfield, New Jersey, United States|Memory Enhancement Center of NJ, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|The Litwin-Zucker Research Center, Manhasset, New York, United States|Parker Jewish Institute For Health Care & Rehabilitation, New Hyde Park, New York, United States|NYU Langone Medical Center Comprehensive Center on Brain Aging, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Nathan S. Kline Institute Geriatric Psychiatry Program, Orangeburg, New York, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|Ani Neurology, PLLC dba Alzheimer's Memory Ctr, Charlotte, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Insight Clinical Trials LLC, Shaker Heights, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Drexel Neurological Associates, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Clinical Research Solutions, Franklin, Tennessee, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Senior Adults Specialty Research, Inc, Austin, Texas, United States|Texas Neurology, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|VA Puget Sound-Alzhemier's Disease Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01741194
NCT01739348,An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738),EPOCH,Terminated,Has Results,Alzheimer's Disease,Drug: Verubecestat (Part I and Part II)|Drug: Placebo (Part I)|Drug: Verubecestat (Part II),[Part I (Base Study)] Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|[Part I (Base Study)] Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score|[Part II (Extension Study)] Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|[Part II (Extension Study)] Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score|[Part I (Base Study)] Number of Participants Who Experienced an Adverse Event|[Part II (Extension Study)] Number of Participants Who Experienced an Adverse Event|[Part I (Base Study)] Number of Participants Who Discontinued From Study Drug Due to an Adverse Event|[Part II (Extension Study)] Number of Participants Who Discontinued From Study Drug Due to an Adverse Event|[Part I (Base Study)] Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score|[Part I (Base Study)] Percent Change From Baseline in Total Hippocampal Volume (THV)|[Part I (Base Study)] Fold Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau|[Part I (Base Study)] Change From Baseline in Cortical Amyloid Load Assessed by [18F]Flutemetamol PET Standard Uptake Value Ratio (SUVR)|[Part I (Base Study)] Percentage of Participants Achieving Responder Status|[Part I (Base Study)] Change From Baseline in Neuropsychiatric Inventory (NPI) Score|[Part I (Base Study)] Change From Baseline in Mini-Mental State Examination (MMSE) Score,Merck Sharp & Dohme Corp.,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,2211,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P07738|MK-8931-017|2011-003151-20|132229,30-Nov-12,14-Apr-17,14-Apr-17,3-Dec-12,16-May-18,24-Oct-18,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT01739348/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01739348
NCT01736579,"Long-Term Study of IGIV, 10% in Alzheimer´s Disease",,Terminated,Has Results,Alzheimer´s Disease,"Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)","Number and Severity of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Infusions Temporally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Infusions Causally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Infusions Discontinued, Slowed or Interrupted Due to an Adverse Event (AE) or Serious Adverse Event (SAE)|Total Score of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog)|Total Score of the Cognitive Subscale of the Severe Impairment Battery (SIB)|Alzheimer's Disease Cooperative Study (ADCS) - Activities of Daily Living (ADL) Inventory (ADCS-ADL/ ADCS-ADL-severe)|Mini Mental State Examination (MMSE)|Neuropsychiatric Inventory (NPI) Score|Logsdon Quality of Life in Alzheimer's Disease (QOL-AD)|EQ-5D Questionnaire (Proxy Version)|Healthcare Resource Utilization Questionnaire (HRUQ)|Caregiver Burden Questionnaire|Time to Skilled Nursing Facility Placement|Volumetric MRI",Baxalta now part of Shire|Shire,All,"51 Years and older   (Adult, Older Adult)",Phase 3,6,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,161202,Nov-12,Jun-13,Jun-13,29-Nov-12,23-Aug-16,23-Oct-17,"Rochester, New York, United States",,https://ClinicalTrials.gov/show/NCT01736579
NCT01735630,Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: ELND005|Drug: Placebo,Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A).|Change From Baseline in Modified-ADCS-CGIC Agitation Scores|Change From Baseline in NPI Total Scores|Change From Baseline in MMSE Scores|Change From Baseline in ADCS-ADL Scores,Transition Therapeutics Ireland Limited|Elan Pharmaceuticals,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 2,350,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ELND005-AG201|2012-004299-20,Nov-12,May-15,May-15,28-Nov-12,15-Aug-16,15-Aug-16,"TransitionTIL Investigational Site, Birmingham, Alabama, United States|TransitionTIL Investigational Site, Phoenix, Arizona, United States|TransitionTIL Investigational Site, Phoenix, Arizona, United States|TransitionTIL Investigational Site, Encino, California, United States|TransitionTIL Investigational Site, Escondido, California, United States|TransitionTIL Investigational Site, Fresno, California, United States|TransitionTIL Investigational Site, Irvine, California, United States|TransitionTIL Investigational Site, Long Beach, California, United States|TransitionTIL Investigational Site, Los Alamitos, California, United States|TransitionTIL Investigational Site, Los Angeles, California, United States|TransitionTIL Investigational Site, Newport Beach, California, United States|TransitionTIL Investigational Site, Santa Ana, California, United States|TransitionTIL Investigational Site, Norwalk, Connecticut, United States|TransitionTIL Investigational Site, Washington, District of Columbia, United States|TransitionTIL Investigational Site, Atlantis, Florida, United States|TransitionTIL Investigational Site, Deerfield Beach, Florida, United States|TransitionTIL Investigational Site, Delray Beach, Florida, United States|TransitionTIL Investigational Site, Lake Worth, Florida, United States|TransitionTIL Investigational Site, Miami, Florida, United States|TransitionTIL Investigational Site, Oakland Park, Florida, United States|TransitionTIL Investigational Site, Orlando, Florida, United States|TransitionTIL Investigational Site, Ormond Beach, Florida, United States|TransitionTIL Investigational Site, Port Charlotte, Florida, United States|TransitionTIL Investigational Site, Sarasota, Florida, United States|TransitionTIL Investigational Site, Sunrise, Florida, United States|TransitionTIL Investigational Site, Columbus, Georgia, United States|TransitionTIL Investigational Site, Savannah, Georgia, United States|TransitionTIL Investigational Site, Springfield, Illinois, United States|TransitionTIL Investigational Site, Bangor, Maine, United States|TransitionTIL Investigational Site, Easton, Maryland, United States|TransitionTIL Investigational Site, Winchester, Massachusetts, United States|TransitionTIL Investigational Site, Ann Arbor, Michigan, United States|TransitionTIL Investigational Site, Paw Paw, Michigan, United States|TransitionTIL Investigational Site, St. Paul, Minnesota, United States|TransitionTIL Investigational Site, Hattiesburg, Mississippi, United States|TransitionTIL Investigational Site, Stratford, New Jersey, United States|TransitionTIL Investigational Site, Rochester, New York, United States|TransitionTIL Investigational Site, Rochester, New York, United States|TransitionTIL Investigational Site, Charlotte, North Carolina, United States|TransitionTIL Investigational Site, Charlotte, North Carolina, United States|TransitionTIL Investigational Site, Durham, North Carolina, United States|TransitionTIL Investigational Site, Wilmington, North Carolina, United States|TransitionTIL Investigational Site, Winston-Salem, North Carolina, United States|TransitionTIL Investigational Site, Oklahoma City, Oklahoma, United States|TransitionTIL Investigational Site, Portland, Oregon, United States|TransitionTIL Investigational Site, Abington, Pennsylvania, United States|TransitionTIL Investigational Site, Jenkintown, Pennsylvania, United States|TransitionTIL Investigational Site, Norristown, Pennsylvania, United States|TransitionTIL Investigational Site, Philadelphia, Pennsylvania, United States|TransitionTIL Investigational Site, Philadelphia, Pennsylvania, United States|TransitionTIL Investigational Site, Pittsburgh, Pennsylvania, United States|TransitionTIL Investigational Site, North Charleston, South Carolina, United States|TransitionTIL Investigational Site, Port Royal, South Carolina, United States|TransitionTIL Investigational Site, Nashville, Tennessee, United States|TransitionTIL Investigational Site, DeSoto, Texas, United States|TransitionTIL Investigational Site, Richmond, Virginia, United States|TransitionTIL Investigational Site, Bellevue, Washington, United States|TransitionTIL Investigational Site, Calgary, Alberta, Canada|TransitionTIL Investigational Site, Kelowna, British Columbia, Canada|TransitionTIL Investigational Site, Toronto, Ontario, Canada|TransitionTIL Investigational Site, Toronto, Ontario, Canada|TransitionTIL Investigational Site, Regina, Saskatchewan, Canada|TransitionTIL Investigational Site, Elche, Alicante, Spain|TransitionTIL Investigational Site, Getxo, Biscay, Spain|TransitionTIL Investigational Site, Barcelona, Spain|TransitionTIL Investigational Site, Barcelona, Spain|TransitionTIL Investigational Site, Burgos, Spain|TransitionTIL Investigational Site, Madrid, Spain|TransitionTIL Investigational Site, Bath, United Kingdom|TransitionTIL Investigational Site, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT01735630
NCT01733355,"A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807",,Terminated,No Results Available,Alzheimers Disease|AD,Radiation: [F18] T807,To evaluate the bio-distribution and radiation dosimetry of [F-18]T807 in participants with low probability of Alzheimer's disease (AD) using PET/CT whole body imaging|To evaluate the metabolism of [F-18]T807 in participants with low probability of AD using serial blood samples collected pre- and post-IP administration|To evaluate [F-18]T807 uptake and signal/background information in brain PET/CT imaging of participants with a high probability of currently being positive for AD and age-matched participants with a low probability of currently being positive for AD|To assess the safety of IV administration of [F-18]T807|To begin collection of baseline [F-18]T807 PET/CT imaging data|To gain information to improve the study design for the conduct of future trials,Avid Radiopharmaceuticals,All,"55 Years and older   (Adult, Older Adult)",Early Phase 1,11,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),T807000,Jul-12,Mar-13,Mar-13,27-Nov-12,null,19-Jul-13,"Research Site, Irvine, California, United States|Research Site, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01733355
NCT01729598,Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study,VPA,Completed,No Results Available,Alzheimer's Disease,Drug: Valproic Acid|Drug: Placebo,Frequency of adverse events|Change in cerebrospinal fluid amyloid levels|Change in cerebrospinal fluid tau levels|Cognitive tests|Change in cerebrospinal fluid clusterin levels,University of Kentucky|Kentucky Alzheimer's Center,All,65 Years to 90 Years   (Older Adult),Early Phase 1,14,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",12-0068-F6A,Apr-12,Oct-14,Oct-14,20-Nov-12,null,18-Feb-15,"Sander's Brown Center on Aging, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT01729598
NCT01723488,"A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808",T808,Terminated,No Results Available,Alzheimers Disease,Radiation: [F18] T808,To monitor and assess the safety of IV administration of [F-18]T808|To begin collection of baseline [F-18]T808 PET/CT imaging data,Avid Radiopharmaceuticals,All,"55 Years and older   (Adult, Older Adult)",Early Phase 1,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),T808000,Jul-12,Mar-13,Mar-13,8-Nov-12,null,19-Jul-13,"Research Site, Irvine, California, United States|Research Site, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01723488
NCT01723553,Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD,,Completed,No Results Available,Atypical Alzheimers Disease|Logopenic Variant of Primary Progressive Aphasia (LPA)|Posterior Cortical Atrophy (PCA),Drug: C-11 PiB,Proportion of subjects with and without microbleeds|Percentage of white matter hyperintensity burden on MRI and ratio of amyloid burden on PiB PET scan|Number of microbleeds per subject,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1,27,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,12-007139,Nov-12,Mar-15,Mar-15,8-Nov-12,null,21-Dec-15,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01723553
NCT01723670,Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment,CT05,Withdrawn,No Results Available,Alzheimer's Disease,Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: Placebo,To determine the effects on change from baseline on brain atrophy|To determine the presence of other biomarkers of neuronal degeneration,CERESPIR,All,45 Years to 64 Years   (Adult),Phase 2,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CCD-1109-PR-0072,Dec-12,Mar-16,Mar-16,8-Nov-12,null,10-Feb-15,,,https://ClinicalTrials.gov/show/NCT01723670
NCT01723826,A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab,,Completed,No Results Available,Alzheimer's Disease,Drug: Crenezumab,Percentage of Participants with Adverse Events|Percentage of Participants by Nature of Adverse Events|Percentage of Participants by Severity of Adverse Events|Percentage of Participants with Human Anti-Therapeutic Antibody (ATA) Formation|Percentage of Participants with Amyloid-Related Imaging Abnormalities-Edema/Effusions (ARIA-E)|Percentage of Participants with Amyloid-Related Imaging Abnormalities-Hemorrhage (ARIA-H),"Genentech, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 2,360,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GN28525|2012-003242-33,7-Dec-12,8-Feb-17,8-Feb-17,8-Nov-12,null,22-Feb-19,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|Pharmacology Research Inst, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Univ of CA San Diego; Neurosciences Comp.Alzheimer's, La Jolla, California, United States|USC School of Medicine, Los Angeles, California, United States|University of California Los Angeles (UCLA), Los Angeles, California, United States|Pharmacology Research Inst, Newport Beach, California, United States|Pacific Neuroscience Med Grp, Oxnard, California, United States|Stanford Univ Medical Center, Palo Alto, California, United States|University of California Davis Medical System, Sacramento, California, United States|Pacific Research Network - PRN, San Diego, California, United States|Uni of California San Francisco, San Francisco, California, United States|Redwood Regional Medical Group, Santa Rosa, California, United States|Yale University, New Haven, Connecticut, United States|Florida Atlantic University; College of Medicine, Boca Raton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Miami Jewish Health Systems; Clinical Research, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Dekalb Neurology Associates, Decatur, Georgia, United States|Rush Alzheimer's Disease Cntr., Chicago, Illinois, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Indiana Univ School of Med, Indianapolis, Indiana, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Empire Neurology, PC, Latham, New York, United States|Litwin Zucker Research Ctr.; Feinstein Inst. Med. Rsch., Manhasset, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center; Monroe Community Hospital, Rochester, New York, United States|Investigational Drug Service; Univ of Rochester Medical Ctr, Rochester, New York, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Summit Research Network Inc., Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical Uni of South Carolina, North Charleston, South Carolina, United States|Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine, Houston, Texas, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|The Med Arts Health Rsrch Grp, Kelowna, British Columbia, Canada|University of British Columbia Hospital; Division of Neurology, Vancouver, British Columbia, Canada|Capitol District Health Authority, Halilfax, Nova Scotia, Canada|Jbn Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Hotel Dieu Hospital, Kingston, Ontario, Canada|St. Joseph's HC-Parkwood Hosp, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|Hôpital Maisonneuve-Rosemont/Polyclinique;Recherche Clinique, Montreal, Quebec, Canada|CHAUQ Hopital Enfant-Jesus, Quebec City, Quebec, Canada|McGill Univeristy; Douglas Mental Health University Institute; Neurological and Psychiatric, Verdun, Quebec, Canada|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|CHU de Limoges Hopital Dupuytren; Service de Medecine Geriatrique, Limoges, France|Hopital Central; Neurologie, Nancy, France|Hopital Nord Laennec, Nantes, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, France|Hôpital Civil de Strasbourg, Strasbourg, France|Univ Berlin; Klin fur Psychi & Psycho Charite, Berlin, Germany|Bezirkskrankenhaus Günzburg, Günzburg, Germany|Zentralinstitut fuer Seelische Gesundheit, Mannheim, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, Germany|Universitätsklinik Tübingen; Psychiatrie und Psychotherapie, Tubingen, Germany|Fundació ACE, BArcelon, Barcelona, Spain|Hospital General de Catalunya, San Cugat Del Valles, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Clinica Ruber, 4 planta; Servicio de Neurologia, Madrid, Spain|The Rice Centre; Royal United Hospital, Bath, United Kingdom|West London Research Unit; Brentford Lodge, Brentford, United Kingdom|Royal Sussex County Hospital, CIRU Level 5, Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|The National Hospital for Neurology & Neurosurgery; Dementia Research Center, London, GT LON, United Kingdom|Southampton General Hospital; Pharmacy, Southampton, United Kingdom|Moorgreen Hospital; Memory Assessment & Rsch Ctr, Southampton, United Kingdom|Great Western Hosp.; Kingshill Research Ctr, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT01723826
NCT01716637,Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,"Biological: Etanercept|Dietary Supplement: Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.",Difference in effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Mini-Mental Status Examination (MMSE) score.|Difference in the effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) score.|Difference in the effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Montreal Cognitive Assessment (MoCA) score.,Life Extension Foundation Inc.,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,CL025,Feb-10,Oct-15,May-16,30-Oct-12,null,12-May-16,"Paul H. Wand M.D., P.A., Coral Springs, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT01716637
NCT01716897,An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption,,Completed,No Results Available,Alzheimer's Disease,Drug: E2609,"AUC(0-inf) ratio, new tablet vs. capsule|AUC(0-inf) ratio, fed state vs. fasted state, both after administration of new tablet|Cmax ratio, new tablet vs. capsule|Cmax ratio, fed state vs. fasted state, both after administration of new tablet|incidence of Adverse events",Eisai Inc.,Male,30 Years to 55 Years   (Adult),Phase 1,18,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E2609-A001-007,Oct-12,Dec-12,Feb-13,30-Oct-12,null,22-May-13,"California Clinical Trials/Parexel, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT01716897
NCT01715181,Volunteers Adding Life in Dementia: VALID,VALID,Completed,No Results Available,Dementia|Alzheimer's Disease,Other: Volunteer visits,Change in neuropsychiatric symptoms (measured by the Cohen-Mansfield Agitation Inventory)|Change in Neuropsychiatric Inventory score|Change in Cornell Depression in Dementia Rating Scale score|Change in Dementia Quality of Life Scale (DEMQoL) score|Change in Clinical Global Impression of Change (CGI-C)score,Queen's University|Alzheimer's Association,All,65 Years and older   (Older Adult),Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,VALIDII|NIRG-12-236827,Jan-13,Jun-15,Mar-16,26-Oct-12,null,14-Apr-17,"Queen's University, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01715181
NCT01715350,Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease,ADD,Completed,No Results Available,Alzheimer's Disease,Drug: PM012|Drug: Placebo,ADAS-cog|CDR|K-IADL|NPI|K-MMSE|VAS|AE,"GMP BIO Co., LTD.|ADM Korea Inc",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,151,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PM012-P2,May-12,Sep-14,Jun-15,26-Oct-12,null,18-Apr-16,"Kyung Hee University Oriental Medicine Hospital, Seoul, Dongdaemun-gu, Korea, Republic of|National Health Insurance Corporation Ilsan Hospital, Goyang, Ilsandong-gu, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon, Paldal-gu, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01715350
NCT01712074,Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil,,Terminated,Has Results,Alzheimer's Disease,Drug: PF-05212377 (SAM-760)|Other: Placebo,Change From Baseline in ADAS-cog13 Total Score at Week 16|Change From Baseline in the Neuropsychiatric Inventory (NPI) Total Score at Week 16 (Visit 5),Pfizer,All,"60 Years and older   (Adult, Older Adult)",Phase 2,186,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B2081011|2014-000830-42,Nov-12,Sep-15,Sep-15,23-Oct-12,20-Mar-17,20-Mar-17,"ATP Clinical Research, Inc, Costa Mesa, California, United States|Sun Valley Research Center, Imperial, California, United States|Desert Valley Research, Rancho Mirage, California, United States|RAA - Apex Aquisition, LLC, Santa Ana, California, United States|Geriatric and Adult Psychiatry LLC, Hamden, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital, Temple Radiology, New Haven, Connecticut, United States|Yale University School of Medicine, MRI Research Center (MRI), New Haven, Connecticut, United States|Diagnostic Centers of America, Boynton Beach, Florida, United States|Meridien Research, Brooksville, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Brain Matters Research Inc, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Compass Research LLC-North Clinic, Leesburg, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Columbus Research & Wellness Institute, Inc., Columbus, Georgia, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Michigan State University, East Lansing, Michigan, United States|Metro Imaging (Imaging only), Creve Coeur, Missouri, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|University of Rochester Medical Center AD-CARE Program   University of Rochester Medical Center, Rochester, New York, United States|University of Rochester Medical Center (MRI Imaging Only), Rochester, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|The Ohio State University (administrative offices only), Columbus, Ohio, United States|The Ohio State University - 2050, Columbus, Ohio, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|Roper Hospital (Imaging Only), Charleston, South Carolina, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Roper St. Francis Pharmacy (IP Shipment/Storage), Charleston, South Carolina, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Senior Adults Speciality Research Inc., Austin, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Clinical Neuroscience Research Assoc. d/b/a The Memory Clinic, Bennington, Vermont, United States|Dean Foundation for Health, Research and Education, Middleton, Wisconsin, United States|Cary J. Kohlenberg, MD, dba, IPC Research, Waukesha, Wisconsin, United States|Merrill Hills Manor, Waukesha, Wisconsin, United States|True North Clinical Research Halifax, Inc., Halifax, Nova Scotia, Canada|Chatham-kent Clinical Trials Research Centre, Chatham, Ontario, Canada|Chatham-Kent Clinical Trials Research Centre, Chatham, Ontario, Canada|Recherches Neuro-Hippocampe Inc., Gatineau, Quebec, Canada|Psicomed Estudios Medicos CIA. LTDA, Antofagasta, Ii Region, Chile|Biomedica Research Group, Santiago, Metropolitana, Chile|Especialidades Medicas L Y S, Santiago, Metropolitana, Chile|Espace Sante 2, La Seyne Sur Mer, France|Dr. med. Volker Schumann, Arzt fuer Nervenheilkunde, Berlin, Germany|Praxis Dr. Franz- Arztehaus am KEH mit Epilepsie-Zentrum, Berlin, Germany|Praxis Dr. sc. med. Alexander Schulze, Berlin, Germany|Arzneimittelforschung Leipzig Gmbh, Leipzig, Germany|Praxis fuer Neurologie / Psychiatrie Prof. Dr. Steinwachs, Nuernberg, Germany|Hospital General Universitario De Elche, Elche, Alicante, Spain|Hospital de Cantoblanco, Madrid, Spain|The Research Institute for the Care of Older People Centre, Bath, United Kingdom|Fulbourn Hospital, Cambridge, United Kingdom|Surrey and Borders Partnership NHS Foundation Trust, Chertsey, United Kingdom|Berrywood Hospital, Northampton, United Kingdom|Covance Laboratories, Switzerland, United Kingdom",,https://ClinicalTrials.gov/show/NCT01712074
NCT01708304,Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs),RDAD,Completed,No Results Available,Alzheimer's Disease|Dementia|Memory Impairment|Cognitive Impairment,Behavioral: RDAD,Minutes of exercise per week|Restricted Activity Days|Restricted Days of Activity|Independence/Residential Status|Revised Memory and Behavior Problem Checklist (RMBPC)|Quality of Life-AD|CES-D,University of Washington,All,65 Years and older   (Older Adult),Not Applicable,510,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,41906,Nov-12,Jun-17,Jun-17,16-Oct-12,null,15-Sep-17,"University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01708304
NCT01703117,Riluzole in Mild Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer's Disease,Drug: Riluzole|Drug: Placebo,Imaging Biomarkers N-acetylaspartate (NAA) and FDG-PET values in regions of interest|Cognitive function (neuropsychological tests); Glutamate levels obtained through MRS,Icahn School of Medicine at Mount Sinai|Rockefeller University,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 2,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GCO 18-0623|APE-0792,Nov-13,Nov-20,Nov-20,10-Oct-12,null,18-Mar-19,"Icahn School of Medicine at Mount Sinai, New York, New York, United States|The Rockefeller University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01703117
NCT01703702,Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline,,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir (18F),Clinical and Diagnostic Change in Patient Management|Change in ADAS-Cog 11 Total Score|Change in Patient's Clinical Diagnosis|Change in Diagnostic Confidence|Change in Patient Management: Advice/Counseling|Change in Caregiver Self-efficacy|Change in Patient Management: Individual Categories,Avid Radiopharmaceuticals|Eli Lilly and Company,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,641,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-45-A18,Oct-12,Apr-15,Apr-15,10-Oct-12,17-Aug-16,17-Aug-16,"Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Sun City, Arizona, United States|Research Site, Clearwater, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Chestnut Hill, Massachusetts, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Patchogue, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Bennington, Vermont, United States|Research Site, Amiens, France|Research Site, Bordeaux, France|Research Site, Bron, France|Research Site, Dijon, France|Research Site, Lille, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nancy, France|Research Site, Nantes, France|Research Site, Nice, France|Research Site, Paris, France|Research Site, Pessac, France|Research Site, Reims, France|Research Site, Rouen, France|Research Site, Strasbourg, France|Research Site, Toulouse, France|Research Site, Tours, France|Research Site, Villeurbanne, France|Research Site, Bergamo, Italy|Research Site, Brescia, Italy|Research Site, Brescia, Italy|Research Site, Florence, Italy|Research Site, Genoa, Italy|Research Site, Genoa, Italy|Research Site, Milan, Italy|Research Site, Milan, Italy|Research Site, Milan, Italy|Research Site, Milan, Italy|Research Site, Modena, Italy|Research Site, Monza, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Rome, Italy|Research Site, Rome, Italy",,https://ClinicalTrials.gov/show/NCT01703702
NCT01702467,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers",,Completed,No Results Available,Alzheimer's Disease,Drug: GSK2647544|Drug: Placebo,Safety and tolerability of GSK2647544 as assessed by number of subjects with adverse events (AE)s|Safety and tolerability of GSK2647544 as assessed by change from Baseline in laboratory values|Safety and tolerability of GSK2647544 as assessed by change from Baseline in ECG readings|Safety and tolerability of GSK2647544 as assessed by change from Baseline in Telemetry ECG parameters|Safety and tolerability of GSK2647544 as assessed by change from Baseline in vital signs|Safety and tolerability of GSK2647544 as assessed by using the Columbia Suicide Severity Rating Scale (C-SSRS)|Peak plasma concentration (Cmax) of GSK2647544|Time of peak plasma concentration (tmax) of GSK2647544|Area under the time concentration curve (AUC) of GSK2647544|Terminal half-life (t½ ) of GSK2647544|Apparent oral clearance (CL/F) of GSK2647544|Predose plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and postdose Lp-PLA2 activity,GlaxoSmithKline,Male,18 Years to 55 Years   (Adult),Phase 1,27,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,116698,19-Oct-12,15-May-13,15-May-13,8-Oct-12,null,18-Oct-17,"GSK Investigational Site, Randwick, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT01702467
NCT01702480,Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects,,Completed,No Results Available,Alzheimer's Disease,Drug: GSK2981710|Drug: Placebo,Part 1: Plasma BHB elevation time course of GSK2981710|Part 1: Area under the time concentration curve (AUC) of GSK2981710|Part 1: Maximum concentration (Cmax) of GSK2981710|Part 2: Change from Baseline in performance on CANTAB Paired Associates Learning task|Part 2: Change from Baseline in performance on CANTAB Verbal Recognition Memory task|Part 2: Change from Baseline in performance on CANTAB Spatial Working Memory (SWM) task|Part 2: Change from Baseline in performance on CANTAB Rapid Visual Processing task|Part 2: Change from Baseline in performance on CANTAB Reaction Time task|Part 2: Change from Baseline in performance on Source Memory Task|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by number of subjects with adverse events (AE)s|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in ECG readings|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in laboratory values|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in vital signs|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by Gastrointestinal (GI) Symptom and stool diary|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by Liking Assessment|Part 2: Change from Baseline in P300 EEG measurement|Part 2: Resting EEG measurement|Part 2: EEG measurement during Source Memory Task|Part 2: Correlation between systemic exposure of BHB and selected PD measurements,GlaxoSmithKline,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1,116,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",116713,5-Nov-12,3-Jul-15,3-Jul-15,8-Oct-12,null,9-May-17,"GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01702480
NCT01699711,Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool,,Completed,No Results Available,Down Syndrome (DS),Dietary Supplement: Epigallocatechin-3-gallate (EGCG),"Change in Cognitive Evaluation|Change in Amyloidosis Biomarkers|Treatment compliance|Change in Biomarkers of lipid oxidation|Change in DYRK1A activity biomarkers|COMT val158met genetic polymorphism (catechol methyl transferase) (Taqman)|Change in AST (SGOT -serum glutamic oxaloacetic transaminase-) and ALT (SGPT- Serum Glutamic Pyruvate Transaminase-) (Pentra Autoanalyzer, and ELISA Mercodia for LDLox)|Change in Body Composition by electrical impedance (TANITA-MC-180)|Changes in Neurophysiology|Changes in Neuroimaging",Parc de Salut Mar,All,"14 Years to 29 Years   (Child, Adult)",Phase 2,87,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TESDAD,Feb-12,Jun-14,Mar-15,4-Oct-12,null,11-Feb-16,"IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT01699711
NCT01700556,A Trial to Support Caregivers of Patients With Dementia in Italy: the UP-TECH Project,UP-TECH,Unknown status,No Results Available,Alzheimer Disease,Other: Case Manager|Other: Assistive Technologies|Other: light support|Other: 3 preventive home visits by a nurse,"Caregiver Burden Inventory|Proportion of days spent at home by the AD patient in the past year|Quality of Life Questionnaire, SF12|Analysis of resource consumption","Istituto Nazionale di Ricovero e Cura per Anziani|Regione Marche|REGIONAL HEALTH UNIT - MARCHE REGION - AREA 5 (ASUR Marche, Area Vasta 5, Distretto Sanitario San Benedetto), Italy",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,900,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,INRCA-01-2012,Nov-12,Jan-14,Jan-15,4-Oct-12,null,29-Jan-13,"REGIONAL HEALTH UNIT - MARCHE REGION - AREA 2 (ASUR Marche, Area Vasta 2, Distretto Sanitario Centro Ancona), Italy, Ancona, Italy|REGIONAL HEALTH UNIT-MARCHE REGION-AREA 3 (ASUR Marche, Area Vasta 3, Distretto Sanitario Macerata), Italy, Macerata, Italy|REGIONAL HEALTH UNIT - MARCHE REGION - AREA 1 (ASUR Marche, Area Vasta 1, Distretto Sanitario Pesaro), Italy, Pesaro, Italy|REGIONAL HEALTH UNIT - MARCHE REGION - AREA 4 (ASUR Marche, Area Vasta 4, Distretto Sanitario Fermo), Italy, Porto San Giorgio, Italy|REGIONAL HEALTH UNIT - MARCHE REGION - AREA 5 (ASUR Marche, Area Vasta 5, Distretto Sanitario San Benedetto), Italy, San Benedetto del Tronto, Italy",,https://ClinicalTrials.gov/show/NCT01700556
NCT01701089,A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers,,Completed,No Results Available,"Healthy Volunteer, Alzheimer's Disease",Drug: 11C-L-deprenyl-D2|Drug: RO4602522,Change in monoamine oxidase (MAO-B) enzyme activity as measured by in vivo positron emission tomography (PET)|Pharmacokinetics: Plasma concentration of RO4602522|Reduction of 11C-L-deprenyl-D2 tracer uptake by in vivo positron emission tomography (PET)|Safety: incidence of adverse events,Hoffmann-La Roche,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,17,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP28253,Sep-12,May-13,May-13,4-Oct-12,null,2-Nov-16,"Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01701089
NCT01699503,Indiana University Dementia Screening Trial,IU-CHOICE,Completed,Has Results,Dementia|Alzheimer's Disease|Mild Cognitive Impairment,Behavioral: Collaborative Dementia Care Program,Health Related Quality of Life (HRQOL)|Patient Health Questionnaire (PHQ-9)|Generalized Anxiety Disorder Scale (GAD-7)|Number of Participants With Health Care Utilization|Number of Participants With an Advance Directive at 12 Months,Indiana University|National Institutes of Health (NIH)|National Institute on Aging (NIA),All,65 Years and older   (Older Adult),Not Applicable,4005,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening,R01AG040220-01A1|1R01AG040220-01A1,Oct-12,22-Nov-17,22-Nov-17,3-Oct-12,23-Jan-19,23-Jan-19,"IU Health-Primary Care Clinics, Indianapolis, Indiana, United States|Wishard Health Services-Primary Care Clinics, Indianapolis, Indiana, United States|IU Health Arnett Primary Care Clinics, West Lafayette, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT01699503/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01699503
NCT01696019,Randomized Trial of Exercise and Social Interaction in a Community-Based Sample of Non-Demented Chinese Elders,SCIBHI,Completed,No Results Available,Cognitive Impairment|Dementia|Mild Cognitive Impairment|Alzheimer Disease,Other: Fast walking|Other: Tai Chi|Other: Intellectual stimulation|Other: Contact and testing only,Change in cognitive performance on battery of neuropsychological tests|Change in whole brain volume,University of South Florida|Fudan University,All,"60 Years to 79 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,Byrd-ARG2007,Jul-08,Sep-09,Sep-09,28-Sep-12,null,28-Sep-12,"Huashan Hospital, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01696019
NCT01696123,Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine,,Completed,No Results Available,Alzheimer Disease,Drug: MLC601,changes in the Mini-Mental State Examination (MMSE) relative to baseline measurements|changes in the cognitive subscale of the AD Assessment Scale (ADAS-cog) relative to baseline measurements|to measure included adverse events (AEs)|measuring withdrawal rate,Shahid Beheshti University of Medical Sciences,All,"50 Years and older   (Adult, Older Adult)",Phase 2,125,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SBMU-1391,Jan-11,Jan-12,Aug-12,28-Sep-12,null,28-Sep-12,"Loghman Hospital, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01696123
NCT01692977,What Elements of the Design of a Healing Garden Are Used as Landmarks by Patients With Alzheimer's Disease to Locate?,JAZ-TOP,Completed,No Results Available,Alzheimer Disease,Other: neuropsychological assessment,"Analyze nature and frequency of elements of the "" art, memory and life "" garden used as landmarks by Alzheimer's disease patients|Study the characteristics of the elements that contributed to decision-making regarding spatial orientation, the cognitive map, correlations between success in experimental, neuropsychological assessment in Alzheimer disease and healthy control subjects.","Central Hospital, Nancy, France",All,65 Years to 90 Years   (Older Adult),Not Applicable,77,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2011-A00993-38,Aug-12,Oct-14,Oct-14,26-Sep-12,null,30-Jul-15,"University Hospital of Nancy , Saint Julien Hospital, France, Nancy, France",,https://ClinicalTrials.gov/show/NCT01692977
NCT01689233,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: TRx0237 200 mg/day|Drug: Placebo,Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)|Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)|Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes|Change from Baseline in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)|Change from Baseline in Mini-Mental Status Examination (MMSE)|Change from Baseline in Neuropsychiatric Inventory (NPI)|Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in expected decline of whole brain volume as measured by brain MRI,TauRx Therapeutics Ltd,All,"up to 89 Years   (Child, Adult, Older Adult)",Phase 3,800,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TRx-237-005,Oct-12,May-16,May-16,21-Sep-12,null,14-Mar-18,"Xenoscience, Inc / 21st Century Neurology, Phoenix, Arizona, United States|NoesisPharma Clinical Trials, Phoenix, Arizona, United States|CITrials, Bellflower, California, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Southern California Research, LLC, Fountain Valley, California, United States|Feldman, Robert MD, Laguna Hills, California, United States|Synergy East, Lemon Grove, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Neuro-Therapeutics, Inc., Pasadena, California, United States|Anderson Clinical Research, Redlands, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Mile High Research Center, Denver, Colorado, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States|JEM Research, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|The Roskamp Institute, Inc., Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Compass Research, LLC - North Clinic, The Villages, Florida, United States|Premiere Research Institute (Palm Beach Neurology), West Palm Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Neurostudies.net, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove, Illinois, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|CBH Health, LLC, Rockville, Maryland, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Neurological Research Center - Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Olive Branch Family Medical, Olive Branch, Mississippi, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|Memory Enhancement Centers of America, Inc, Eatontown, New Jersey, United States|Advanced Memory Research Institute of NJ PC, Toms River, New Jersey, United States|Albuquerque Neuroscience, Albuquerque, New Mexico, United States|Neurological Associates of Albany, P. C., Albany, New York, United States|MedicalPsych Care, PLLC, Elmsford, New York, United States|Columbia University Taub Institute, New York, New York, United States|Research Foundation for Mental Hygiene, Inc., Orangeburg, New York, United States|Wake Research Associates, Raleigh, North Carolina, United States|Clinical Trials of America, Inc, Winston-Salem, North Carolina, United States|Neurobehavorial Clinical Research, Canton, Ohio, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|RI Hospital, Providence, Rhode Island, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Clinical Neuroscience Solutions CNS Healthcare, Memphis, Tennessee, United States|Senior Adults Specialty Research, Inc., Austin, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|PRA Health Sciences, Salt Lake City, Utah, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Discipline of Psychiatry, University of Queensland, Herston, Queensland, Australia|University Hospital Brussels Department of Neurology, Bruxelles, Belgium|University Hospital Gent Department of Neurology, Gent, Belgium|Jessa Hospital, Hasselt, Belgium|Regional Hospital Sint-Trudo, Sint-Truiden, Belgium|GasthuisZusters Antwerpen Sint-Augustinus, Wilrijk, Belgium|University of British Columbia Hospital, Clinic for Alzheimer Disease and Related Disorders, Vancouver, British Columbia, Canada|Parkwood Institute, London, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|University Hospital Centre Zagreb, Department of Neurology, Zagreb, Croatia|University Psychiatric Hospital Vrapče, Zagreb, Croatia|University of Eastern Finland, Brain Research Unit Mediteknia, Kuopio, Finland|Clinical Research Services Turku (CRST), Turku, Finland|Hôpitaux Civils de Colmar, Colmar Cedex, France|Hôpital La Grave, Toulouse, France|Hôpital de Charpennes, Villeurbanne, France|Neurozentrum Achim Dr. med. Andreas Mahler, Achim, Germany|University Medicine Berlin - Charité, CBF, Neurology, Berlin, Germany|Memory Clinic, ECRC, Berlin, Germany|Arzeneimittelforschung Leipzig GmbH, Leipzig, Germany|Klinik und Poliklinik für Psychiatrie und Psychotherapie Zentrum für Nervenheilkunde - Universitätsklinikum Rostock, Rostock, Germany|A.O.U. Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Ancona, Italy|IRCCS San Giovanni di Dio - Fatebenefratelli, Brescia, Italy|Fondazione Universita 'G. D'Annunzio di Chieti, Chieti Scalo, Italy|Clinical Neurology Department of Neuroscience (DINOGMI) - University of Genoa, Genova, Italy|Azienda Ospedaliera Universitaria Sant'Andrea di Roma - Unita' di Neurologia, Roma, Italy|Alzheimer Center Southwest Netherlands, Erasmus MC, Rotterdam, Netherlands|Fundacio ACE, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitari Mútua de Terrassa, Terrassa, Spain|Grampian NHS, Royal Cornhill Hospital, Aberdeen, United Kingdom|Sussex Partnership NHS Foundation Trust, Cognitive Treatment and Research Unit, Crowborough, United Kingdom|Re:Cogniton Health, London, United Kingdom|Memory Assessment and Research Centre (MARC), Southampton, United Kingdom|Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT01689233
NCT01689246,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: TRx0237 150 mg/day|Drug: TRx0237 250 mg/day|Drug: Placebo,Change from Baseline on Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)|Change from Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)|Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes|Change from Baseline on Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)|Change from Baseline on Mini-Mental Status Examination (MMSE)|Change in expected decline of whole brain volume as measured by brain MRI,TauRx Therapeutics Ltd,All,"up to 89 Years   (Child, Adult, Older Adult)",Phase 3,891,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TRx-237-015,Jan-13,Nov-15,Nov-15,21-Sep-12,null,14-Mar-18,"Xenoscience, Inc/ 21st Century Neurology, Phoenix, Arizona, United States|Feldman, Robert MD, Laguna Hills, California, United States|University of Southern California, Los Angeles, California, United States|Shankle Clinic and Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|JEM Research, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|CNS Healthcare, Inc, Jacksonville, Florida, United States|Compass Research, LLC-North Clinic, Leesburg, Florida, United States|Miami Research Associates, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove, Illinois, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Olive Branch Family Medical, Olive Branch, Mississippi, United States|Memory Enhancement Centers of America, Inc, Eatontown, New Jersey, United States|CRI Worldwide, Marlton, New Jersey, United States|The Cognitive Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ PC, Toms River, New Jersey, United States|Neurological Associates of Albany, P. C., Albany, New York, United States|SPRI, Brooklyn, New York, United States|Neurobehavioral Clinical Research, Canton, Ohio, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Division of Rehabilitation and Aged Care, Hornsby, New South Wales, Australia|Southern Neurology Pty Limited, Kogarah, New South Wales, Australia|Academic Department for Old Age Psychiatry, Prince of Wales Hospital, Randwick, New South Wales, Australia|Discipline of Psychiatry, University of Qld, Herston, Queensland, Australia|Royal Adelaide Hospital Memory Trials Centre, Adelaide, South Australia, Australia|Memory Unit, Neurology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Medical and Cognitive Research Unit, Austin Health Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia|McCusker Alzheimer's Research Foundation Inc, Nedlands, Western Australia, Australia|Neurodegenerative Disorders Research Pty Ltd, Perth, Western Australia, Australia|UMHAT ""Alexandrovska"" Clinic of Neurology Diseases Department of Neurodegenerative and Immune and Infectious Diseases of Central Nervous System with Sector for Treatment of Neuroinfections, Sofia, Bulgaria|UMHAT ""Alexandrovska"" Clinic of Psychiatry First Department of Psychiatry, Sofia, Bulgaria|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|True North Clinical Research Kentville Inc, Kentville, Nova Scotia, Canada|Toronto Memory Program, North York, Ontario, Canada|University Hospital Centre Zagreb, Zagreb, Croatia|University Psychiatric Hospital Vrapce, Zagreb, Croatia|Neurozentrum Achim Dr. med. Andreas Mahler, Achim, Germany|Charité, University Medicine Berlin, CBF, Neurology, Berlin, Germany|Memory Clinic, ECRC, Berlin, Germany|Neurologia Ospedale Maggiore Policlinico, Milano, Italy|Istituto Neurologico Carlo Besta, Milano, Italy|IRCCS Istituto neurologico Casimiro Mondino, Pavia, Italy|Clinica Neurologica, Università di Perugia-Ospedale S. Maria della Misericordia, Perugia, Italy|Universita' Cattolica del Sacro Cuore, Roma, Italy|Azienda Ospedaliera Universitaria Sant'Andrea di Roma- Unita' di Neurologia, Roma, Italy|Dipartimento di Neuroscienze Universita' di Torino, Torino, Italy|Azienda Ospedaliera S.maria Della Misericordia, Udine, Italy|U.O. Di Neurologia Ospedale di Circolo e Fondazione Macchi, Varese, Italy|Dong-A Medical Center, Busan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|University Kuala Lumpur Royal College of Medicine, Ipoh, Malaysia|Hospital Sultan Ismail, Johor Bahru, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Taiping Hospital, Taiping, Malaysia|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|Pallmed sp zoo prowadząca NZOZ Dom Sue Ryder; Centrum Psychoneurologii Wieku Podeszłego, Bydgoszcz, Poland|NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS, Katowice, Poland|Gabinet Neurologiczny, Indywidualna Specjalistyczna Praktyka Lekarska, Mosina, Poland|NZOZ Neuro-Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy, Poznań, Poland|Euromedis Sp. z o.o., Szczecin, Poland|Usługi Lekarskie Sp.c Palasik, Żabierek, Warszawa, Poland|mMED, Warszawa, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|County Emergency Clinical Hospital Arad, Psychiatry Department, Arad, Romania|CMDTA ""Neomed"", Brasov, Romania|University Emergency Central Military Hospital ""Dr.Carol Davila"", Psychiatry Department, Bucharest, Romania|Psychomedical Consult, Bucharest, Romania|Clinical Municipal Hospital ""Dr. Gavril Curteanu"", Psychiatry Department, Oradea, Romania|Psychiatry Hospital ""Dr. Gheorghe Preda"", Center of Mental Health, Sibiu, Romania|Psychiatry Hospital ""Dr. Gheorghe Preda"", Department of Psychiatry III, Sibiu, Romania|Emergency Clinical County Hospital Sibiu, Neurology Department, Sibiu, Romania|State Budgetary Healthcare Institution of Sverdlovsk region ""Sverdlovsk Regional Clinical Psychiatric Hospital"", Ekaterinburg, Russian Federation|Non-governmental Healthcare Institution ""Central Clinical Hospital #6 of the JSC ""Russian Railways"", Moscow, Russian Federation|Mental Health Research Center of the Russian Academy of Medical Sciences, Gerontopsychiatry department, Moscow, Russian Federation|Mental Health Research Center of the Russian Academy of Medical Sciences, Moscow, Russian Federation|CityClinical Hospital #34, City Scientific Practical Neurological Center, Novosibirsk, Russian Federation|City Geriatric Medical and Social Center, Saint Petersburg, Russian Federation|Saint Nicholas Psychiatric Hospital, Saint Petersburg, Russian Federation|Saint Petersburg Psychoneurological Research Institute n. a. V.M. Bekhterev, Saint Petersburg, Russian Federation|National University Hospital (NUH), Singapore, Singapore|National Neuroscience Institute (NNI), Singapore, Singapore|Tan Tock Seng Hospital (TTSH), Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Hospital Universitario de Ceuta, Ceuta, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|Changhua Christian Hospital, Changhua, Taiwan|Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|En Chu Kong Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|National Yang-Ming University School of Medicine, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan|NHS Grampian, Department of Old Age Psychiatry Royal Cornhill Hospital, Aberdeen, United Kingdom|RICE - The Research Institute for the Care of Older People, Bath, United Kingdom|Belfast Health and Social Care Trust (BHSCT), Belfast, United Kingdom|The Barberry Centre, Birmingham, United Kingdom|MAC Clinical Research Ltd, Blackpool, United Kingdom|MAC Clinical Research Ltd, Bradford, United Kingdom|MAC Clinical Research Ltd, Cannock, United Kingdom|MAC Clinical Research Ltd, Leeds, United Kingdom|Re: Cognition Health Ltd., London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Dementia Research Centre, London, United Kingdom|MAC Clinical Research Ltd, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT01689246
NCT01689948,Alzheimer Disease : Rehabilitation's Intervention at Home,pré MATAPA,Terminated,No Results Available,Alzheimer's Disease,Behavioral: Home rehabilitation therapy,Evaluation of the mean scores of Instrumental Activities of Daily Living (IADL)|Evaluation of the mean scores of Neuro Psychiatric Inventory (NPI)|Evaluation of the mean scores of Zarit's scale (caregiver burden)|Alcohol consumption for the patient and the caregiver|Evaluation of the mean scores of Mini Mental State Examination (MMSE)(meaning evaluation of patient's cognitive impairment)|Evaluation of the mean scores of Goal Attainment scales (GAS) (meaning evaluation of the satisfaction of the patient and of her/his caregiver),Nantes University Hospital,All,65 Years and older   (Older Adult),Not Applicable,17,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,RC12_0080,Oct-12,May-14,Sep-14,21-Sep-12,null,15-Oct-14,"Bellier Hospital, CHU of Nantes, Nantes, France",,https://ClinicalTrials.gov/show/NCT01689948
NCT01690195,Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: ABT-126,Adverse Events|Laboratory Data|Vital Signs|Physical examinations|Brief Neurological examination|Brief Psychiatric assessments|Columbia-Suicide Severity Rating Scale|Cornell Scale for Depression in Dementia|Electrocardiogram,"AbbVie (prior sponsor, Abbott)|AbbVie",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,343,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M11-428|2012-000537-39,Sep-12,Feb-14,Feb-14,21-Sep-12,null,26-Mar-14,"Site Reference ID/Investigator# 84185, Long Beach, California, United States|Site Reference ID/Investigator# 84183, San Francisco, California, United States|Site Reference ID/Investigator# 84187, Hamden, Connecticut, United States|Site Reference ID/Investigator# 84178, Delray Beach, Florida, United States|Site Reference ID/Investigator# 84180, Orlando, Florida, United States|Site Reference ID/Investigator# 84186, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 84182, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 84181, Staten Island, New York, United States|Site Reference ID/Investigator# 84179, Bennington, Vermont, United States|Site Reference ID/Investigator# 84173, Gatineau, Canada|Site Reference ID/Investigator# 84174, Montreal, Canada|Site Reference ID/Investigator# 84177, Peterborough, Canada|Site Reference ID/Investigator# 84175, Toronto, Canada|Site Reference ID/Investigator# 84176, Verdun, Canada|Site Reference ID/Investigator# 84376, Dijon Cedex, France|Site Reference ID/Investigator# 84373, Limoges Cedex, France|Site Reference ID/Investigator# 84374, Paris Cedex 10, France|Site Reference ID/Investigator# 84377, Paris, France|Site Reference ID/Investigator# 84375, Toulouse Cedex 9, France|Site Reference ID/Investigator# 84382, Berlin, Germany|Site Reference ID/Investigator# 84380, Freiburg, Germany|Site Reference ID/Investigator# 84383, Huettenberg, Germany|Site Reference ID/Investigator# 84379, Mittweida, Germany|Site Reference ID/Investigator# 84381, Munich, Germany|Site Reference ID/Investigator# 84378, Schwerin, Germany|Site Reference ID/Investigator# 84385, Athens, Greece|Site Reference ID/Investigator# 84388, Athens, Greece|Site Reference ID/Investigator# 84389, Athens, Greece|Site Reference ID/Investigator# 84386, Haidari, Athens, Greece|Site Reference ID/Investigator# 84390, Thessaloniki, Greece|Site Reference ID/Investigator# 84395, Belville, South Africa|Site Reference ID/Investigator# 84391, Cape Town, South Africa|Site Reference ID/Investigator# 84393, George, South Africa|Site Reference ID/Investigator# 84394, Johannesburg, South Africa|Site Reference ID/Investigator# 84392, Rosebank, South Africa|Site Reference ID/Investigator# 84398, Bath, United Kingdom|Site Reference ID/Investigator# 84397, Glasgow, United Kingdom|Site Reference ID/Investigator# 84400, London, United Kingdom|Site Reference ID/Investigator# 84399, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01690195
NCT01688128,Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART),U-SMART,Completed,No Results Available,Mild Cognitive Impairment,Device: Phase I U-SMART (4 wks)|Other: Washout (2 wks)|Device: Phase II U-SMART (4 wks),"Change in the Word List Test (memory, recall, recognition) of the CERAD Neuropsychological Assessment Battery before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Subjective Memory Complaints Questionnaire (SMCQ) before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Geriatric Depression Scale (GDS) before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Mini-Mental State Examination before and after phase I intervention and before and after phase II intervention (crossover part of the study)",Seoul National University Bundang Hospital|KT Corporation,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E-1207/162-001,Aug-12,Dec-15,Dec-15,19-Sep-12,null,20-Apr-16,"Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01688128
NCT01681602,Effect of Physical Exercise in Alzheimer Patients,ADEX,Completed,No Results Available,Alzheimer Disease,Other: Aerobic exercise,Symbol Digit Modalities Test|NPI (psychological symptoms.)|Astrand submaximal bicycle test for estimating VO2 max|Euro-qol-5D-5L (health related quality of life)|Alzheimer's disease Assessment Scale - Cognitive section (ADAS-cog).|Changes in physical fitness|Self-efficacy scale|Verbal fluency|Stroop|MMSE (Mini Mental State Examination),"Rigshospitalet, Denmark",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,H-3-2011-128,Jan-12,Jan-14,Jun-14,10-Sep-12,null,2-Dec-14,"Danish Dementia Research Centre, Department of Neurology, Rigshospitalet., Copenhagen, Copenhagen Ø, Denmark",,https://ClinicalTrials.gov/show/NCT01681602
NCT01680588,Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer Disease,Drug: [18F]NAV4694,[18F]NAV4694 PET visual assessment by centralized readers|Assess the incidence of adverse events after a single dose of [18F]NAV4694|Evaluate [18F]NAV4694 PET quantitative assessment|Determine correlation of neuro-psychiatric tests with [18F]NAV4694 imaging|Assess changes in laboratory values after a single dose of [18F]NAV4694,Navidea Biopharmaceuticals,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,70,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NAV4-01,Aug-12,Dec-18,Dec-18,7-Sep-12,null,30-Mar-16,"Molecular NeuroImaging, LLC, New Haven, Connecticut, United States|Rush University Medical Center, Chicago, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Indiana Medical Research, Indianapolis, Indiana, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Alzheimer's Disease Center, Quincy Medical Center, Quincy, Massachusetts, United States|Neurological Associates of Albany, Albany, New York, United States",,https://ClinicalTrials.gov/show/NCT01680588
NCT01677572,"Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease",PRIME,"Active, not recruiting",No Results Available,Alzheimer's Disease,"Drug: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)|Drug: Placebo",Number of Participants with Adverse Events|Change from baseline in florbetapir-fluorine-18 (18F-AV-45F-AV-45) positron emission tomography (PET) imaging in certain brain areas.|Multiple dose pharmacokinetic (PK) serum concentrations of Aducanumab|Change from Baseline in Incidence of Anti-Aducanumab Antibodies in Serum.,Biogen,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,197,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",221AD103|2012-000349-10,5-Oct-12,21-Oct-21,21-Oct-21,3-Sep-12,null,16-Apr-19,"NNS Clinical Research, LLC, Tucson, Arizona, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Pacific Research Network, Inc., San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Alzheimer's Disease Research Unit, Yale University, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical Trials, Inc., Hallandale Beach, Florida, United States|Galiz Research, LLC, Miami Springs, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Infinity Clinical Research, Inc., Sunrise, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Neurostudies.net, LLC, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|St. Louis Clinical Trials, LLC, Saint Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|CRI Lifetree, Marlton, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Empire Neurology, PC, Latham, New York, United States|Insight Clinical Trials LLC, Beachwood, Ohio, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Brown Hospital, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01677572
NCT01677754,A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy,MAyflOwer RoAD,Completed,No Results Available,Alzheimer's Disease,Drug: RO4602522|Drug: Placebo|Drug: Donepezil|Drug: Memantine|Drug: Rivastigmine|Drug: Galantamine,"Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Behavior Subscale (ADAS-Cog-11) Score at Month 12|Percentage of Participants Achieving Response, Defined as an Increase From Baseline of Less Than or Equal to (<=) 4 Points in ADAS-Cog-11|Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Scale Score at Month 12|Change From Baseline in Behavioral Pathology in Alzheimer's Disease Frequency-Weighted Severity Scale (BEHAVE-AD-FW) Score at Month 12|Percentage of Participants With Worsening in BEHAVE-AD-FW Score|Change From Baseline in Apathy Evaluation Scale (AES) Score at 12 months|Change From Baseline in Alzheimer's Disease Cooperative Study Clinician Global Impression of Change (ADCS-CGIC) Scale Score at 12 months|Percentage of Participants With Worsening in ADCS-CGIC Score|Change From Baseline in Global Deterioration Scale (GDS) Score at 12 months|Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score at 12 months|Percentage of Participants with Adverse Events|Percentage of Participants with Change in Lens Opacity Grading|Percentage of Participants with Abnormal Visual Acuity Test Results|Change From Baseline in Michigan Neuropathy Screening Instrument Score|Percentage of Participants Receiving Concomitant Medications|Apparent Total Clearance of the Drug From Plasma After Administration of RO4602522|Apparent Volume of Distribution at Steady State after Administration of RO4602522|Area Under the Plasma Concentration-Time Curve of RO4602522|Maximum Plasma Concentration of RO4602522",Hoffmann-La Roche,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,542,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP28248|2012-000943-29,24-Oct-12,12-Jun-15,12-Jun-15,3-Sep-12,null,30-May-17,"Advanced Research Center, Inc.;In-Patient Unit, Anaheim, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Torrance Clinical Research, Lomita, California, United States|Artemis Institute for Clinical Research, LLC, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Neurological Research Inst, Santa Monica, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|Galiz Research, LLC, Hialeah, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Compass Research East, LLC, Orlando, Florida, United States|Comprehensive Clinical Development, Inc.- St. Petersburg, FL, Saint Petersburg, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Booker, J. Gary, MD, APMC, Shreveport, Louisiana, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Albuquerque Neuroscience Inc., Albuquerque, New Mexico, United States|New York University Medical Center;Child Study Center, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Radiant Research, Inc., Wyomissing, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Alzheimer's Research & Clinical Programs, Charleston, South Carolina, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Central Coast Neurosciences Research, Erina, New South Wales, Australia|Southern Neurology, Kogarah, New South Wales, Australia|Queen Elizabeth Hospital, Woodville, South Australia, Australia|Box Hill Hospital; Eastern Clinical Research Unit, Box Hill, Victoria, Australia|A.G.Mander Pty Ltd, Geelong, Victoria, Australia|Heidelberg Repatriation Hospital, Heidelberg, Victoria, Australia|Hollywood Specialist Centre, Nedlands, Western Australia, Australia|Neurodegenerative Disorders Research, Subiaco, Western Australia, Australia|The Medical Arts Health Research Group, Powell River, British Columbia, Canada|Vancouver Hospital - UBC Hospital Site, Vancouver, British Columbia, Canada|Vancouver Island Health Authority, Victoria, British Columbia, Canada|Capitol District Health Authority, Halilfax, Nova Scotia, Canada|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|Jbn Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Ingram, Jennifer MD, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, Canada|Recherches Neuro-Hippocame, Gatineau, Quebec, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|Institut Universitaire de gériatrie de Sherbrooke; Service de gériatrie/pavillon Argyll, Sherbrooke, Quebec, Canada|McGill Univeristy; Douglas Mental Health University Institute; Neurological and Psychiatric, Verdun, Quebec, Canada|CHU de Quebec - Hôpital de l' Enfant Jésus, Quebec, Canada|NEUROHK s.r.o., Chocen, Czechia|P-P Klinika, Kladno, Czechia|Supervize s.r.o., Kutna Hora - Vnitrni Mesto, Czechia|Nemocnice Na Bulovce, Prague, Czechia|Clintrial,s.r.o., Praha 10, Czechia|AD71 s.r.o., Praha 10, Czechia|Thomayerova nemocnice, Praha 4 - Krc, Czechia|Psychiatry Trial s.r.o., Praha 5, Czechia|Neurologicka ambulance, Praha 6, Czechia|FORBELI s.r.o., Praha 6, Czechia|Centre Hospitalier de la côte Basque, Bayonne, France|Hopital Neurologique Pierre Wertheimer, Bron, France|Hopital Nord Laënnec - CHU Nantes, Nantes, France|Hopital Cimiez; CMRR, Nice, France|Hôpital Lariboisière, Paris, France|Groupe Hospitalier Sud - Hôpital Xavier Arnozan, Pessac, France|Hôpital Maison Blanche, Reims, France|CHU Rennes - Hopital Hôtel Dieu, Rennes, France|CHU Toulouse - La Grave, Toulouse, France|CHU Tours - Hôpital Bretonneau, Tours, France|Hôpital de Brabois Adultes, Vandoeuvre-les-nancy, France|Hopital des Charpennes, Villeurbanne, France|Gemeinschaftspraxis, Ellwangen, Germany|Henriettenstiftung Hannover, Hannover, Germany|ISPG - Institut fuer Studien zur Psychischen Gesundheit, Mannheim, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, Germany|Zentrum f. Neurologisch- Psychiatrische Studien und Begutachtung, Siegen, Germany|Nuovo Ospedale Civile S.Agostino - Estense, Modena, Emilia-Romagna, Italy|Policlinico Universitario Agostino Gemelli; Farmacia, Roma, Lazio, Italy|Fondazione Santa Lucia IRCCS, Roma, Lazio, Italy|Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Liguria, Italy|Università degli Studi di Genova, Genova, Liguria, Italy|Azienda Ospedaliero Universitaria Pisana; Uff. Sperim. Clin. U.O. Farmaceutica, Pisa, Toscana, Italy|Università degli studi di Perugia, Perugia, Umbria, Italy|Dong-A University Hospital, Busan, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Gyeonggi-do, Korea, Republic of|Inha University Hospital; Pulmonary Medicine, Incheon, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Specjal. Praktyka Lekarska; Prof. Grzegorz Opala, Katowice, Poland|Centrum Medyczne Dendryt, Katowice, Poland|NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek, Poznan, Poland|NZOZ Syntonia, Pruszcz Gdanski, Poland|NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog, Sopot, Poland|mMED Maciej Czarnecki, Warszawa, Poland|Instytut Psychiatrii i Neurologii, Warszawa, Poland|Hospital General Universitario de Elche; Servicio de Farmacia, Elche, Alicante, Spain|Fundació ACE, BArcelon, Barcelona, Spain|Hospital General De Catalunya; Servicio de Neurologia, Sant Cugat del Valles, Barcelona, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Virgen del Puerto, Plasencia, Palencia, Spain|Hospital Universitario Virgen Macarena, Seville, Sevilla, Spain|CAE Oroitu, BaraKaldo, Vizcaya, Spain|Hospital Perpetuo Socorro, Servicio de Geriatria, Albacete, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos, Madrid, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Skanes Universitetssjukhus, Malmo Skanes Universitetssjukhus, Malmo, Malmö, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Cognitive Treatment & Research Unit, Crowborough, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|West London Cognitive Disorders Treatment and Research Unit; Lakeside Metal Health Unit, Isleworth, United Kingdom|Institute of Psychiatry, London, United Kingdom|Norwich Medical School, Norwich, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Memory Service North, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT01677754
NCT01676935,This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: ABT-126,Adverse Events|Laboratory Data|Vital Signs|Physical examinations|Brief Neurological examination|Brief Psychiatric assessments|Columbia-Suicide Severity Rating Scale|Cornell Scale for Depression in Dementia|Electrocardiogram,"AbbVie (prior sponsor, Abbott)|AbbVie",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,349,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M11-427|2011-004780-75,Aug-12,Mar-14,Mar-14,31-Aug-12,null,26-Mar-14,"Site Reference ID/Investigator# 73493, Delray Beach, Florida, United States|Site Reference ID/Investigator# 73496, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 73495, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 73494, Staten Island, New York, United States|Site Reference ID/Investigator# 97035, Wichita Falls, Texas, United States|Site Reference ID/Investigator# 73514, Poznan, Poland|Site Reference ID/Investigator# 73515, Szczecin, Poland|Site Reference ID/Investigator# 73516, Kazan, Russian Federation|Site Reference ID/Investigator# 73525, Kazan, Russian Federation|Site Reference ID/Investigator# 73523, Kirov, Russian Federation|Site Reference ID/Investigator# 73521, Moscow, Russian Federation|Site Reference ID/Investigator# 73519, Moscow, Russian Federation|Site Reference ID/Investigator# 73517, Novosibirsk, Russian Federation|Site Reference ID/Investigator# 73520, Saratov, Russian Federation|Site Reference ID/Investigator# 73518, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 73524, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 84615, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 73522, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 73507, Belville, South Africa|Site Reference ID/Investigator# 84614, Cape Town, South Africa|Site Reference ID/Investigator# 73505, George, South Africa|Site Reference ID/Investigator# 73506, Johannesburg, South Africa|Site Reference ID/Investigator# 73533, Donetsk, Ukraine|Site Reference ID/Investigator# 73534, Kiev, Ukraine|Site Reference ID/Investigator# 73535, Poltava, Ukraine|Site Reference ID/Investigator# 73502, Bath, United Kingdom|Site Reference ID/Investigator# 73503, Blackburn, United Kingdom|Site Reference ID/Investigator# 73501, Glasgow, United Kingdom|Site Reference ID/Investigator# 73504, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01676935
NCT01672827,Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images,,Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: [18F]Flutemetamol,Summary of Sensitivity of the Blinded Visual PET Image Interpretations Without Anatomic Images.|Summary of Specificity of Blinded Visual PET Image Interpretations Without Anatomic Images.|Inter-Reader Agreement of PET Images Without Anatomic Images,GE Healthcare,All,"18 Years and older   (Adult, Older Adult)",Phase 3,276,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,GE-067-021,Jul-12,Aug-12,Aug-12,27-Aug-12,19-Dec-13,24-Jan-14,,,https://ClinicalTrials.gov/show/NCT01672827
NCT01669876,Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease,ASAP,Terminated,No Results Available,Alzheimer Disease,Dietary Supplement: Anatabloc(R)|Dietary Supplement: Placebo,Number of subjects experiencing adverse effects when using the supplement|Measured changes in blood markers of AD|Changes in global or functional measures of AD in subjects during the course of the study,"Rock Creek Pharmaceuticals, Inc.|Roskamp Institute Inc.",All,65 Years to 90 Years   (Older Adult),Phase 2,85,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RCP-009,Aug-12,Dec-14,Feb-15,21-Aug-12,null,30-Apr-15,"Roskamp Institute, Sarasota, Florida, United States",,https://ClinicalTrials.gov/show/NCT01669876
NCT01662882,"A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",,Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: florbetapir (18F),Qualitative Amyloid Image Assessment|Mean Cortical to Cerebellum SUVR,Avid Radiopharmaceuticals|Eli Lilly and Company,All,"50 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-45-J05|I6E-AV-AVBB,Oct-12,Feb-13,Feb-13,13-Aug-12,19-Sep-13,19-Sep-13,"Research Site, Kobe, Japan|Research Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01662882
NCT01661894,Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly,3ECog,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Cognitive Decline|Dementia,Device: BrainPalTM,Total Score on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Number of Adverse Events reported by participants on the Safety Measurement Form|Usability Measurement,"Duke-NUS Graduate Medical School|Agency for Science, Technology and Research|National University, Singapore|Singapore Clinical Research Institute|Singapore General Hospital",All,"60 Years to 70 Years   (Adult, Older Adult)",Phase 1,82,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-363,Apr-12,Apr-14,Apr-14,10-Aug-12,null,25-Jul-14,"Duke-NUS Graduate Medical School, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01661894
NCT01660815,A Study of Florbetapir (18F) in Japanese Healthy Volunteers,,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir (18F),Whole Body Radiation Dosimetry,Avid Radiopharmaceuticals|Eli Lilly and Company,All,"45 Years and older   (Adult, Older Adult)",Phase 1,7,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-45-J02|I6E-AV-AVBA,Aug-12,Jan-13,Jan-13,9-Aug-12,19-Sep-13,19-Sep-13,"Research Site, Kobe, Japan",,https://ClinicalTrials.gov/show/NCT01660815
NCT01661673,"Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease",,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Drug: EVP-0962|Drug: Placebo,"The number of adverse experiences reported by subjects and/or observed by investigator and repeated clinical evaluations of physical examinations, vital signs, 12-lead ECG (electrocardiogram), and lab tests (hematology, chemistry, urinalysis)|To measure the rate of synthesis of Amyloid Beta in cerebral spinal fluid of healthy subjects|To measure the concentration of Amyloid Beta in cerebral spinal fluid|To measure the rate of synthesis of Amyloid Beta and steady-state levels in the cerebral spinal fluid in MCI or early Alzheimer's disease patients|To determine single-and repeat-dose EVP-0962 pharmacokinetics in cerebral spinal fluid and plasma",FORUM Pharmaceuticals Inc|Parexel,All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 2,52,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EVP-0962-002,Nov-12,Oct-13,null,9-Aug-12,null,13-Jan-14,"Glendale Adventist Medical Center, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT01661673
NCT01659398,Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients,,Completed,No Results Available,Mild Cognitive Impairment,Device: External Counterpulsation (EECP),Change in Cognitive Function|Change in Ophthalmic blood flow (OBF)|Change in Blood Viscosity|Cholesterol composition of the blood,"Patrick Moriarty, MD, FACP, FACC|University of Kansas Medical Center",All,"18 Years to 85 Years   (Adult, Older Adult)",Early Phase 1,8,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13106,Jun-12,Oct-14,Oct-14,7-Aug-12,null,13-Jan-16,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01659398
NCT01656525,A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients,,Completed,No Results Available,Alzheimer's Disease,Drug: Gantenerumab|Drug: Placebo,Number of participants with Adverse Events|Pharmacokinetic parameters of Gantenerumab in plasma|CSF/plasma ratios of Gantenerumab.|Change from baseline in plasma Abeta|Change from baseline in plasma and CSF tau|Change from baseline in Mini-Mental State Examination (MMSE) and Alzheimer's disease assessment scale cognitive behaviors (ADAS-Cog).,Chugai Pharmaceutical,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,28,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",JP22431|JapicCTI-121849,Jun-12,Mar-14,Jun-14,3-Aug-12,null,19-Sep-14,"Kansai region, Kansai, Japan|Kanto region,, Kanto, Japan|Kyushu region, Kyushu, Japan|Tokai region, Toakai, Japan|Tohoku region, Tohoku, Japan",,https://ClinicalTrials.gov/show/NCT01656525
NCT01652222,"Experimental Study to Validate the ""Therapeutic Game"" CONEM-BETA",,Completed,No Results Available,Alzheimer's Disease|Dementia,Other: CONEM-BETA + socio-educational training|Other: Socio-educational training only,change from baseline compared to the control and active arms using the EBP questionnaire (subjective welfare of family caregivers of patients with possible or probable Alzheimer or other advanced stage dementia)|change from baseline compared to the control and active arms using the Cornell scale and NPI-Q to assess behaviour of the patients with probable or possible Alzheimer's disease or other advanced stage dementia|change from baseline compared to the control and active arms using the Martin and cols. scale to assess the overload level of the family caregivers of patients with probable or possible Alzheimer's disease or other advanced stage dementia|change from baseline compared to the control and active arms using the Goldberg's scale to assess anxiety and depression of the family caregivers of patients with probable or possible Alzheimer's disease or other advanced stage dementia|change from baseline compared to the control and active arms using the DUKE-UNC scale to assess the perceived social support of the family caregivers of patients with probable or possible Alzheimer's disease or other advanced stage dementia|change from baseline compared to the control and active arms using the PANAS scale to assess the changes in positive and negative affect of the caregivers of patients with probable or possible Alzheimer's disease or other advanced stage dementia,"Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|Fundacion SARquavitae",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,101,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CONEM-BETA-FPM/SAR-0111,Jan-12,Jul-12,Aug-12,27-Jul-12,null,9-Jul-14,"Hospital de Santa Maria, Lleida, Catalonia, Spain|Hospital de Salt, Salt, Catalonia, Spain|Hospital Universitari Mutua de Terrassa, Terrassa, Catalonia, Spain",,https://ClinicalTrials.gov/show/NCT01652222
NCT01646723,Volunteers Adding Life in Dementia,VALID,Completed,No Results Available,Dementia|Alzheimer Disease|Behavior,Behavioral: Volunteers Adding Life in Dementia (VALID) Program,Change in Cohen-Mansfield Agitation Inventory (CMAI) score|Clinically significant reduction in agitation|Remission of neuropsychiatric symptoms|Change in Neuropsychiatric Inventory (NPI) score|Change in depression symptoms (Cornell Depression in Dementia Rating Scale)|Dementia Quality of Life (DemQoL) Scale|Clinical Global Impression of Change (CGI-C)|Use and dose of required medication|Short form health survey|Change in Modified Nursing Care Assessment Scale score,Queen's University,All,65 Years and older   (Older Adult),Not Applicable,75,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,VALID1,Jun-12,Dec-15,Mar-16,20-Jul-12,null,14-Apr-17,"Extendicare Kingston, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01646723
NCT01640275,Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia,MAD-PIA,Completed,No Results Available,General Anesthesia,Drug: Propofol|Drug: Isoflurane,"Ratio of cerebrospinal fluid tau to amyloid beta|the relationship between anesthetic exposure and CSF biomarker changes|the relationship between anesthetic exposure and CSF biomarker changes, and demographics (age, gender, and race)|the relationship between CSF biomarker changes and serum markers of metabolic and/or inflammatory status|the relationship between anesthetic exposure and biomarker changes and serum markers of metabolic and/or inflammatory status|the relationship between anesthetic exposure and biomarker changes and neuroimaging results obtained as dictated by routine standard of care|the relationship between anesthetic exposure and biomarker changes and depth of anesthesia, based on average BIS (bispectral index) monitoring signal|the relationship between anesthetic exposure and biomarker changes and the time of day that surgery is performed|the relationship between anesthetic exposure and biomarker changes with genetic polymorphisms in ApoE (apolipoprotein E) and other genes related to inflammation, metabolism, brain function and/or Alzheimer's disease",Duke University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,105,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,Pro00030861,Mar-12,Mar-15,Mar-15,13-Jul-12,null,4-Aug-15,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01640275
NCT01638884,Prospective Memory Imaging,IMPRO,Unknown status,No Results Available,Alzheimer Disease,Behavioral: Memory assessment|Other: Structural MRI|Other: Functional MRI|Other: Virtual reality / Memory assessment,Rate of volume change of whole brain and other structural MRI measures|Cerebral regions implicated in prospective memory observed by functional MRI|Episodic memory as measured by Cognitive Tests|Virtual reality evaluation of prospective memory|Group differences for each imaging and neuropsychological measurement,"University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,118,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2010-A00031-38,Sep-10,Jun-15,Jun-15,12-Jul-12,null,9-Apr-14,"GIP Cyceron, Caen, Calvados, France|MRSH - University of Caen, Caen, Calvados, France|University Hospital Côte de Nacre, Caen, France",,https://ClinicalTrials.gov/show/NCT01638884
NCT01638949,Multi-modal Neuroimaging in Alzheimer's Disease,IMAP+,Recruiting,No Results Available,Alzheimer's Disease,Behavioral: Memory assessment|Biological: Circulating biomarkers measure|Genetic: ApoE4|Other: Brain imaging examination MRI and PET examinations,"Rate of volume change of whole brain, hippocampus and other structural MRI measures|Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by 18F-AV45|Group differences for each imaging and biomarker measurement|APOE genotype","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,295,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2011-A01493-38,May-12,Dec-21,null,12-Jul-12,null,9-Apr-14,"GIP Cyceron, Caen, Calvados, France|Inserm - EPHE - University of Caen U1077, Caen, France|University Hospital Côte de Nacre, Caen, France|University Hospital Roger Salengro, Lille, France|University Hospital Pontchaillou, Rennes, France|University Hospital Rouen, Rouen, France|University Hospital Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01638949
NCT01639586,Comparison for the Patient With Alzheimer Disease the Impact of Three Different Groups of Patient Care,COMPARSE,Unknown status,No Results Available,Alzheimer Disease,Behavioral: respite platform|Behavioral: Day care|Behavioral: No access to a respite structure,Analysis of the perceived and diagnosed health evolution of the patient|Efficacity of the different structures,Department of Clinical Research and Innovation|Centre Hospitalier Universitaire de Nice,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,360,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2011-A00167-34,Aug-11,Oct-12,Apr-13,12-Jul-12,null,12-Jul-12,"Le Duff, Nice, France",,https://ClinicalTrials.gov/show/NCT01639586
NCT01636596,Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease,,Withdrawn,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Drug: Insulin LISPRO,cerebral glucose metabolism|cognition|general clinical improvement|basal metabolism,Louisiana State University Health Sciences Center Shreveport|Acuity Center,All,"50 Years to 95 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H12-166,Sep-13,Jan-15,Jan-15,10-Jul-12,null,13-Mar-14,"LSUHSC Shrevport Psychopharmacology Research Clinic, Shreveport, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT01636596
NCT01628653,Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training,U-SMART,Completed,No Results Available,Mild Cognitive Impairment,Device: U-SMART,the five-point Likert scales for satisfaction and compliance|Word List Memory Test of the CERAD Neuropsychological Assessment Battery|Mini-Mental State Examination (MMSE),Seoul National University Bundang Hospital|KT Corporation,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1,10,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06-2011-084,Jun-11,Feb-12,Feb-12,27-Jun-12,null,27-Jun-12,"Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01628653
NCT01626391,Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease,,Terminated,Has Results,Alzheimer's Disease,Drug: TRx0237|Drug: Placebo,Safety and Tolerability of TRx0237 When Coadministered With an Acetylcholinesterase Inhibitor (AChEI) and/or Memantine,TauRx Therapeutics Ltd,All,"up to 90 Years   (Child, Adult, Older Adult)",Phase 2,9,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TRx-237-008,Sep-12,Mar-13,Mar-13,22-Jun-12,11-Jul-14,11-Jul-14,"Achim, Germany|Berlin, Germany|Leipzig, Germany|München, Germany|Birmingham, United Kingdom|Bradford, United Kingdom|Crowborough, United Kingdom|Duston, United Kingdom|Oxford, United Kingdom|Sheffield, United Kingdom|St Leonards on Sea, United Kingdom|Staffordshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01626391
NCT01624389,Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study,Alzheimer's,Unknown status,No Results Available,Alzheimer's Disease,Drug: F18-AV45,"Rate of conversion from NC, EMCI, LMCI to AD.",Chang Gung Memorial Hospital,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,101-1074A1,Jan-12,Jan-15,Jan-15,20-Jun-12,null,20-Jun-12,"Tzu-Chen-Yen, Taoyuan, Taiwan",,https://ClinicalTrials.gov/show/NCT01624389
NCT01617577,Efficacy and Safety of Filgrastim in Alzheimer's Disease,FFAD,Completed,Has Results,Alzheimer's Disease,Drug: G-CSF; filgrastim|Drug: Placebo,"Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL )",University of South Florida,All,"55 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,8,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADDF-GCSF,Jun-09,Feb-12,Feb-12,12-Jun-12,27-Dec-12,27-Dec-12,"USF/Byrd Alzheimer's Center, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT01617577
NCT01614886,"Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)",,Completed,Has Results,Alzheimer's Disease,Drug: Active Comparator|Drug: ENA713,"Percentage of Patients With Adverse Events Leading to Study Drug Discontinuation|Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)|Change From Baseline in Mini-Mental State Examination (MMSE)|Number of Participants With Improvement in Japanese Clinical Global Impression of Change (J-CGIC). Patients With ""Improvement"": a Total of 1. Markedly Improved, 2. Improved, and 3. Slightly|The Percentage of Treatment Retention.",Novartis Pharmaceuticals|Ono Pharmaceutical Co. Ltd|Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,216,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CENA713D1303,Jul-12,May-14,May-14,8-Jun-12,12-May-15,1-Aug-16,"Novartis Investigative Site, Anjo-city, Aichi, Japan|Novartis Investigative Site, Obu-city, Aichi, Japan|Novartis Investigative Site, Seto-city, Aichi, Japan|Novartis Investigative Site, Toyoake-city, Aichi, Japan|Novartis Investigative Site, Akita-city, Akita, Japan|Novartis Investigative Site, Chiba-city, Chiba, Japan|Novartis Investigative Site, Toon-city, Ehime, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Fujioka-city, Gumma, Japan|Novartis Investigative Site, Hiroshima-city, Hiroshima, Japan|Novartis Investigative Site, Miyoshi-city, Hiroshima, Japan|Novartis Investigative Site, Kasama-city, Ibaraki, Japan|Novartis Investigative Site, Kamakura-city, Kanagawa, Japan|Novartis Investigative Site, Kawasaki-city, Kanagawa, Japan|Novartis Investigative Site, Kawasaki-city, Kanagawa, Japan|Novartis Investigative Site, Sagamihara-city, Kanagawa, Japan|Novartis Investigative Site, Yokohama, Kanagawa, Japan|Novartis Investigative Site, Kochi-city, Kochi, Japan|Novartis Investigative Site, Kochi-city, Kochi, Japan|Novartis Investigative Site, Koshi-city, Kumamoto, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Kumamoto-city, Kumamoto, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Kitamorokata-gun, Miyazaki, Japan|Novartis Investigative Site, Azumino-city, Nagano, Japan|Novartis Investigative Site, Matsumoto-city, Nagano, Japan|Novartis Investigative Site, Nagaoka-city, Niigata, Japan|Novartis Investigative Site, Kurashiki-city, Okayama, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Sakai-city, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Kanzaki-gun, Saga, Japan|Novartis Investigative Site, Kasukabe-city, Saitama, Japan|Novartis Investigative Site, Kawaguchi-city, Saitama, Japan|Novartis Investigative Site, Koshigaya-city, Saitama, Japan|Novartis Investigative Site, Saitama-city, Saitama, Japan|Novartis Investigative Site, Shizuoka-city, Shizuoka, Japan|Novartis Investigative Site, Shizuoka-city, Shizuoka, Japan|Novartis Investigative Site, Tokushima-city, Tokushima, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Hachioji-city, Tokyo, Japan|Novartis Investigative Site, Koto-ku, Tokyo, Japan|Novartis Investigative Site, Musashino-city, Tokyo, Japan|Novartis Investigative Site, Ota-ku, Tokyo, Japan|Novartis Investigative Site, Tachikawa-city, Tokyo, Japan|Novartis Investigative Site, Shimonoseki-city, Yamaguchi, Japan",,https://ClinicalTrials.gov/show/NCT01614886
NCT01609348,Venlafaxine for Depression in Alzheimer's Disease (DIADs-3),DIADs-3,Completed,Has Results,Alzheimer's Disease|Depression,Drug: Placebo|Drug: Venlafaxine,Changes in Dose Response Using the Modified Alzheimer's Disease (AD) Cooperative Study-Clinical Global Impression of Change.,Johns Hopkins University,All,"Child, Adult, Older Adult",Not Applicable,5,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NA_00066043,Apr-12,Dec-16,Jan-17,1-Jun-12,31-Jan-18,31-Jan-18,"Johns Hopkins at Bayview, Baltimore, Maryland, United States|Reading Hospital, West Reading, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01609348
NCT01608217,Delta-THC in Dementia,,Completed,No Results Available,Behavioural Disturbances|Pain|Dementia|Alzheimer's Dementia|Vascular Dementia,Drug: delta-9-tetrahydrocannabinol (delta-THC)|Drug: Placebo|Drug: Acetaminophen,Neuropsychiatric Inventory (NPI)|Pain Assessment Checklist for Seniors with Limited Ability to Communicate Dutch version (PACSLAC-D)|Caregiver Clinical Global Impression of Change (CCGIC)|Cohen-Mansfield Agitation Inventory (CMAI)|Quality of Life-Alzheimer's Disease Scale (QoL-AD)|Barthel Index|Paired Associates Learning test Wechsler Memory Scale Revised(PAL WMS-R)|Safety assessments|Verbal Rating Scale (VRS),"Radboud University|Health Valley, Netherlands",All,"40 Years and older   (Adult, Older Adult)",Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GER001-02-02|2011-005289-39|NL38617.091.12,Jun-12,Jun-14,Jun-14,31-May-12,null,30-Jun-14,"Radboud university medical center, department of Geriatrics, Nijmegen, Gelderland, Netherlands|Vincent van Gogh Institute for Psychiatry, department of Elderly, Venlo, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT01608217
NCT01609335,Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults,,Completed,No Results Available,Alzheimer's Disease,Drug: F-18 FDG|Drug: C-11 PiB,"Normal values for amyloid PET, FDG and Magnetic Resonance Imaging",Mayo Clinic,All,30 Years to 49 Years   (Adult),Phase 1,41,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11-006972,Jul-12,Aug-13,Aug-13,31-May-12,null,8-Aug-14,"Mayo Clinic Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01609335
NCT01607476,Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET),,Completed,Has Results,Alzheimer's Disease,Drug: C11 PiB|Drug: F18 Flutametamol,Global Distribution of C11 PiB in the Brain|Global Distribution of F18 Flutemetamol in the Brain,Mayo Clinic,All,"30 Years and older   (Adult, Older Adult)",Phase 2,89,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,12-000118,Jul-12,Dec-14,Mar-16,30-May-12,1-Nov-16,18-Apr-17,"Mayo Clinic Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01607476
NCT01608061,ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease,ADvance,Unknown status,No Results Available,Alzheimer Disease,Device: DBS-f on|Device: DBS-f off,"The study will assess the acute and long-term safety of the system. A detailed assessment of all device and/or therapy related adverse events will be conducted.|Efficacy outcomes include: improvement in ADAS-cog 13 at twelve months, improvement in the CDR and changes in glucose metabolism measured by FDG-PET at twelve months",Functional Neuromodulation Ltd,All,"45 Years to 85 Years   (Adult, Older Adult)",Not Applicable,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FNMI-001,May-12,Jun-15,Sep-18,30-May-12,null,16-Feb-17,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Research Institute at Sun City, Sun City, Arizona, United States|University of Florida at Gainesville, Gainesville, Florida, United States|Johns Hopkins Bayview, Baltimore, Maryland, United States|Hospital of the University of Pennsylvania: Penn Memory Clinic, Philadelphia, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|Toronto Western Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01608061
NCT01606488,Effects of Brain Beta-Amyloid on Postoperative Cognition,,Recruiting,No Results Available,Postoperative Cognitive Dysfunction,Drug: Florbetapir F 18 (18F-AV-45)|Other: no intervention,Cognitive Decline|Genetic Polymorphisms|Vagus nerve tone assessment|Inflammatory Markers|Perioperative Complications|Delirium|Coma Assessment|Hospital Length of Stay|Postoperative Complications|Change in Cognition|Quality of Life|Mortality|Pain intensity|Pain unpleasantness|Post-traumatic Stress Disorder symptomatology,"University of California, San Francisco|Alzheimer’s Drug Discovery Foundation|Avid Radiopharmaceuticals",All,65 Years and older   (Older Adult),Phase 4,100,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,20110506|18F-AV-45-A14,May-12,Jun-19,Jun-19,25-May-12,null,17-May-18,"San Francisco VA Medical Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01606488
NCT01605448,Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment,,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Mindfulness Based Stress Reduction (MBSR),"Number of participants with adverse events|Feasibility: 85% completion|Change in fMRI Resting state|Change in Cognition|Change in Measures of ""well-being""|Qualitative Improvements",Beth Israel Deaconess Medical Center,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009P-000411,Jan-10,May-11,Jan-12,24-May-12,null,24-May-12,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01605448
NCT01602393,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase,CT04 POLEP,Completed,No Results Available,Alzheimer's Disease,Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x,Determine maximum tolerated dose of CHF 5074 after multiple oral once daily administration to patients with mild cognitive impairment,Chiesi USA,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,51,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCD-1014-PR-0053 POLEP|2010-024270-19,May-12,Oct-13,Oct-13,21-May-12,null,6-Feb-14,"Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Memory Center of New Jersey, Inc., Monroe Twp, New Jersey, United States|Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States|Senior Adults Specialty Research, Austin, Texas, United States|Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milano, Italy",,https://ClinicalTrials.gov/show/NCT01602393
NCT01600469,NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Drug: DAOI-B|Other: Placebo,"Change from baseline in Alzheimer's disease assessment scale-cognitive subscale in week 8, 16 and 24|Change from baseline in Mini Mental Status Examination at week 8, 16 and 24|Change from baseline in Instrumental Activities of Daily Living at week 8, 16 and 24|Change from baseline in Verbal learning and memory at week 24|Change from baseline in Digit Span subtest of the Wechsler Memory Scale at week 24",Chang Gung Memorial Hospital,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,86,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",99-2452A3,Jan-12,May-13,May-13,17-May-12,null,4-Jun-13,"Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",,https://ClinicalTrials.gov/show/NCT01600469
NCT01600859,Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02),,Completed,No Results Available,Alzheimer's Disease,Drug: E2609|Drug: Placebo for E2609,Percent change from baseline in cerebrospinal fluid amyloid-beta levels|Incidence of adverse events,Eisai Inc.,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,65,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",E2609-A001-101,Jul-12,Sep-13,Oct-13,17-May-12,null,30-Dec-16,"Glendale, California, United States|Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01600859
NCT01595646,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),SL120,Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: Saline|Drug: Insulin detemir|Drug: Insulin,Verbal Memory Composite|Cerebral Spinal Fluid (CSF) Biomarkers of AD|Cerebral Spinal Fluid (CSF) Biomarkers of AD TTau-P181/Abeta42 Ratio|Functional Ability|The Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog/Alzheimer's Disease Cooperative Study (ADCS)] - MCI Revision,Wake Forest University Health Sciences|Alzheimer's Association,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,37,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00023230|ZEN-10-173646US,Nov-11,12-Mar-15,12-Mar-15,10-May-12,1-Feb-18,22-May-18,"Wake Forest Baptist Hospital, Winston-Salem, North Carolina, United States|VA Puget Sound Health Care System - American Lake Division, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT01595646
NCT01594346,Multicenter Vitamin E Trial in Aging Persons With Down Syndrome,,Completed,No Results Available,Alzheimer's Disease|Down Syndrome,Drug: Alpha-Tocopherol|Drug: Sugar Pill,The Brief Praxis Test|The Fuld Object Memory Test|New Dot Test|Orientation Test|Vocabulary Test|Behavior and Function|Clinical Global Impression|Incident Dementia,"New York State Institute for Basic Research|National Institute on Aging (NIA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Complementary and Integrative Health (NCCIH)|New York State Psychiatric Institute|University of California, San Diego|Columbia University|Bronx Veterans Medical Research Foundation, Inc",All,"50 Years and older   (Adult, Older Adult)",Phase 3,349,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",R01AG016381,Sep-00,Apr-10,Apr-10,9-May-12,null,9-May-12,,,https://ClinicalTrials.gov/show/NCT01594346
NCT01584440,"Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients",,Completed,No Results Available,Agitation|Alzheimer's Disease,Drug: AVP-923 (dextromethorphan/quinidine)|Drug: Placebo,Neuropsychiatric Inventory (NPI)|Safety and Tolerability|ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change Rating)|PGIC Patient Global Impression of Change (PGI-C)|QoL-AD (Quality of Life - Alzheimer's Disease measure)|ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory)|CSI (Caregiver Strain Index)|CSDD (Cornell Scale for Depression in Dementia)|(MMSE) Mini-Mental State Examination,Avanir Pharmaceuticals,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,220,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12-AVR-131,Jun-12,Jul-14,Sep-14,25-Apr-12,null,11-Jan-18,"Phoenix, Arizona, United States|Sun City, Arizona, United States|Fresno, California, United States|Fullerton, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Diego, California, United States|San Francisco, California, United States|Sherman Oaks, California, United States|Temecula, California, United States|Boynton Beach, Florida, United States|Deerfield Beach, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Sunrise, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|West Palm Beach, Florida, United States|Weston, Florida, United States|Elk Grove Village, Illinois, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Summit, New Jersey, United States|Toms River, New Jersey, United States|Orangeburg, New York, United States|Rochester, New York, United States|White Plains, New York, United States|Centerville, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Lakewood, Ohio, United States|Allentown, Pennsylvania, United States|Reading, Pennsylvania, United States|Charleston, South Carolina, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT01584440
NCT01585272,Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia,,Completed,Has Results,Alzheimer's Dementia,Drug: ENA713,"Number of Patients With Adverse Events, Serious Adverse Events, and Death|Change From Baseline in Mini-Mental Status Examination (MMSE)|Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)|The Discontinuation Rate Due to the Treatment Switching From Oral Capsule to Rivastigmine Patch Treatment|Percentage of Patients Successfully Titrated to Rivastigmine Patch 10 cm^2",Novartis Pharmaceuticals|Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,121,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713DTW04,Aug-12,Jun-15,Jun-15,25-Apr-12,10-Nov-16,18-Apr-18,"Novartis Investigative Site, Taichung, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01585272
NCT01582919,Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study,AMIMAGE 2,Completed,No Results Available,Dementia|Alzheimer Disease,Other: Neuroimaging,Measures of volume and diffusion parameters in the gray matter (hippocampus and cingular posterior cortex)|Performance on neuropsychological and daily life cognitive tests,"University Hospital, Bordeaux",All,65 Years and older   (Older Adult),Not Applicable,304,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHUBX 2011/15,Sep-12,Jun-15,Jun-15,23-Apr-12,null,4-Apr-17,"Groupe Hospitalier Pellegrin - C.H.U. de Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT01582919
NCT01577394,Oculomotor Testing in the Differential Diagnosis of Dementia,OculoMacl,Completed,No Results Available,Lewy Body Disease|Alzheimer's Disease,Other: oculomotor measurements,Variability of reflexive saccades latencies|Correlations between oculomotor records and neuropsychological examination assessing attention abilities and their fluctuations|Potential correlations between hippocampal volume and neuropsychological examination in DLB cases|Cerebral atrophy differences between DLB and AD using SVM (Support Vector Machine) method|Percentage of alpha synuclein in CSF to discriminate DLB from AD|Variations at one year in oculomotor test scores and neuropsychological test scores|Mean reflexive saccades latency|Percentage of express saccades|Correlations between neuropsychological tests scores assessing attention abilities and variability of reflexive saccades latencies,Assistance Publique - Hôpitaux de Paris,All,65 Years and older   (Older Adult),Phase 3,65,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AOM 09158,Jun-11,Feb-16,Apr-16,13-Apr-12,null,23-May-16,"Assistance Publique Hôpitaux de Paris - Pitié-Salpetriere hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01577394
NCT01571427,Conversations as a Means to Delay the Onset of Alzheimer's Disease,conversation,Completed,Has Results,Mild Cognitive Impairment|Cognitive Change,Behavioral: Active social engagement group|Behavioral: Control group,Changes in Global Cognitive Function Using Mini Mental State Examination Score (Post-study Test Score - Baseline Test Score)|Changes in Category Fluency (Animals) Test Scores (Post-study Test Score - Baseline Test Score)|Changes in Verbal Fluency Letter Test Scores (Post-study Test Score - Baseline Test Score)|Changes in the Consortium to Establish a Registry for Alzheimer's Disease Word List Immediate Recall (Post-study Test Score - Baseline Test Score)|Changes in the Consortium to Establish a Registry for Alzheimer's Disease Word List Delayed Recall (Post-study Test Score - Baseline Test Score)|Changes in Trail Making Test A Scores (Post-study Test Score - Baseline Test Score)|Changes in Trail Making Test B Scores (Post-study Test Score - Baseline Test Score)|Changes in the Stroop Color and Word Test (Stroop Test C) Scores (Post-study Test Scores - Baseline Test Scores)|Changes in Cogstate Computerized Test: Detection Test (Post-study Test Score - Baseline Test Score)|Changes in Cogstate One Back Accuracy (Post-study Test Score - Baseline Test Score)|Changes in Cogstate Two Back Accuracy (Post-study Test Score - Baseline Test Score)|Changes in CAMCI Total Score (Post-study Test Score - Baseline Test Score),Oregon Health and Science University|National Institute on Aging (NIA),All,70 Years and older   (Older Adult),Early Phase 1,83,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,socialengagementR01|R01AG033581,Feb-12,Sep-13,Sep-13,5-Apr-12,24-Apr-19,7-May-19,"Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01571427
NCT01569997,Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units,IDEM,Completed,No Results Available,Dementia in Nursing Home,Other: MultiDisciplinary Team Meetings (MDTM),Incidence of hospitalizations in emergency care units|Prevalence of antipsychotic prescription|Incidence of inappropriate hospitalizations|Prevalence of neuropsychiatric symptoms evaluated by NPI-nursing staff version|Dependency evaluated by AGGIR and IADL-4 items|Quality of life evaluated by QOL-AD|Number of nursing staff's time off work|Number of days off work by nursing staff|Presence of advanced care planning in patients medical records|Overall healthcare costs,"University Hospital, Toulouse",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,1428,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,0910701|2009-A01062-55,May-10,Sep-13,Sep-13,4-Apr-12,null,24-Aug-15,"Centre de Gerontologie Pompeyrie Chu Agen, Agen, France|Ehpad Maison de Retraite Louise Anceau, Albi, France|Ehpad Maison de Retraite Olga Ducoudray, Albi, France|Ehpad Mr ""Les Jardins de Jouvence"", Albi, France|Mapad La Renaudie Ch Albi, Albi, France|Ehpad Les Ajoncs D'Or, Allaire, France|Ehpad Maison de Retraite Hl Ax Les Thermes, Ax Les Termes, France|Ehpad Marie Lehman, Balma, France|Ehpad Kerdigemer, Brest, France|Ehpad Residence Ker-Heol, Brest, France|Ehpad Residence Saint Astier, Catus, France|Mapa de L'Hopital Local de Caussade, Caussade, France|Ehpad Maison de Retraite Ste Marthe, Ceignac, France|EHPAD Résidence Castelgirou, Cepet, France|Ehpad Leon Ronzier Joly, Clermont L'herault, France|Ehpad Themis Lasplanes, Colomiers, France|Ehpad Maison de Retraite Joseph Sauvy, ERR, France|Ehpad Residence Borde Haute Promo-Accueil, Escalquens, France|Mapad ""Firmi"", Firmi, France|Ehpad Hopital Local Fleurance, Fleurance, France|Ehpad Mr Bellissen Chi Du Val D'Ariege, Foix, France|Ehpad Dr Robert, Guer, France|Ehpad Residence Grand'Maison, L'union, France|Ehpad Residence Provencale Medicafrance, La Roquebrussanne, France|Ehpad Residence Clairefontaine, Lamorlaye, France|Mapad Ch Lavaur, Lavaur, France|Ehpad Saint Reah Hir, Le Conquet, France|Ehpad Residence D'Automne de La Ferme, Le Mee Sur Seine, France|Ehpad Maison de Retraite ""Les Charmilles"", Lescure d'Albigeois, France|Residence Le Parc, Lezat Sur Leze, France|Ehpad La Cheneraie, Lherm, France|Ehpad Mr Lagrange, Lisle Sur Tarn, France|Mapad Labastide Ch Lourdes, Lourdes, France|Ehpad Emile Dubois, Marchiennes, France|Ehpad Les Mille Soleils, Marciac, France|Ehpad Et. Public Gerontologie de Marines, Marines, France|AP-HM Hôptal La Timone Service de Pédiatrie Mutidisciplinaire, Marseille, France|Ehpad Maison Retraite Hl Mauvezin, Mauvezin, France|Ehpad Maison de Retraite Saint Joseph, Mazamet, France|Ehpad Maison de Retraite Privee de Mazeres, Mazeres, France|Ehpad-Maison Retraite Hl Mirande, Mirande, France|Ehpad Chis Castelsarrasin-Moissac, Moissac, France|Ehpad Era Caso, Montauban de Luchon, France|Ehpad Maison Retraite Ch Montauban, Montauban, France|Ehpad Ma Maison, Montpellier, France|Ehpad Maison de Retraite Sainte Agnes, Montredon Labessonnie, France|Ehpad L'Ecrin Des Sages, Mèze, France|Ehpad L'Acacia, Nailloux, France|Logements Foyer La Fontanelle, Naucelle, France|Ehpad Fondation Pauliani, Nice, France|Ehpad Les Noisetiers, Nice, France|Ehpad Residence Ancilla, Nice, France|Ehpad Mais de Retraite Saint-Joseph, Ossun, France|Ehpad Mr Bariol Chi Du Val D'Ariege, Pamiers, France|Ehpad Residence Le Parc, Panazol, France|AP-HP Hôpital Necker Enfants Malades Service d'endocrinologie pédiatrique - 149 route de Sèvres, Paris, France|Ehpad Furtado Heine, Paris, France|Ehpad Julie Siegfried, Paris, France|Ehpad La Pirandelle, Paris, France|Ehpad Residence Anselme, Paris, France|Ehpad Residence Belleville, Paris, France|Ehpad Residence Herold, Paris, France|Ehpad Residence Oceane, Paris, France|Ehpad Tiers Temps Paris, Paris, France|Ehpad Residence Adeline, Pierre Buffiere, France|Ehpad Residence D'Automne Medica-France, Reims, France|Ehpad L'Oree Du Bois, Rieux Volvestre, France|Ehpad Residence Saint-Amans, Rodez, France|Ehpad Le Jardin Des Loges, Saint Bonnet, France|Ehpad Residence Themis La Joie de Vivre, Saint Lys, France|Ehpad A Labouilhe, Saint Orens de Gameville, France|Ehpad Public de Saint-Remy de Provence, Saint Remy de Provence, France|Ehpad Les Bruyeres, Sousceyrac, France|Ehpad Maison Retraite Orelia Ch St Gaudens, St Gaudens, France|Ehpad Genevriers, St Martory, France|Ehpad Maison de Retraite Chic Tarbes Vic, Tarbes, France|Ehpad Residence ""Le Doyenne Du Carmel"", Tarbes, France|Ehpad Sainte Anne, Tinteniac, France|Ehpad de La Cote Pavee, Toulouse, France|Ehpad Gaubert, Toulouse, France|Ehpad Mr Henri Iv, Toulouse, France|Ehpad Pierre Ducis, Toulouse, France|Ehpad Residence La Cotonniere, Toulouse, France|Ehpad Residence Le Clos Des Carmes, Toulouse, France|Ehpad Residence Marguerite, Toulouse, France|Ehpad Residence Saint-Simon, Toulouse, France|Usld Domaine de La Cadene, Toulouse, France|Ehpad Umt, Valence-d'albigeois, France|Ehpad Maisonneuve, Villefranche de Lauragais, France|Ehpad Saint-Jacques, Villemur Sur Tarn, France",,https://ClinicalTrials.gov/show/NCT01569997
NCT01569516,Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease,Drug: Octohydroaminoacridine Succinate Tablets|Drug: Octohydroaminoacridine succinate Tablets|Drug: Placebo,"Alzheimer's Disease Assessment Scale - Cognitive Subscale|Clinician's Interview Based Impression of Change, plus caregiver input|Activities of Daily Living:Activities of Daily Living Scale（ADL)|Mental behavior: neuropsychiatric questionnaire (NPI)","Changchun Huayang High-tech Co., Ltd|Beijing Bionovo Medicine Development Co., Ltd.",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,288,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCHY2010L00161-HPAD2,Jun-11,Jul-12,Oct-12,3-Apr-12,null,9-Apr-12,"Guangzhou Brain Hospital, Guangzhou, Guangdong, China|Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China|Hebei mental health center, Baoding, Hebei, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The first Affiliated Hospital of Jilin University, Changchun, Jilin, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China|Beijing HuiLongGuan Hospital, Beijing, China|Beijing Shijitan Hospital, EMU, Beijing, China|Shanghai Changzheng Hospital, Shanghai, China|Shanghai First People's Hospital, Shanghai, China|Shanghai Tenth People's hospital, Shanghai, China|Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01569516
NCT01566071,Ability to Drive of Early Stage Alzheimer Disease,DRIVE COG,Completed,No Results Available,Alzheimer Disease,Other: Assessment of drive abilities,,CHU de Reims,All,70 Years and older   (Older Adult),Not Applicable,60,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic,PN11009,Jul-12,null,Jul-15,29-Mar-12,null,9-Jun-16,"CHU de REIMS, Reims, France",,https://ClinicalTrials.gov/show/NCT01566071
NCT01564706,A Study of 18F-AV-45 in Healthy Volunteers,,Completed,Has Results,Alzheimer Disease,Drug: florbetapir F 18,Whole Body Radiation Dosimetry,Avid Radiopharmaceuticals,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-45-A02,Oct-07,Jan-08,Jan-08,28-Mar-12,30-Apr-12,18-May-12,"Research Site, Jenkintown, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01564706
NCT01565291,A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers,,Completed,Has Results,Alzheimer Disease,Drug: florbetapir F 18,Mean Cortical to Cerebellum SUVR|Precuneus to Cerebellum SUVR,Avid Radiopharmaceuticals,All,"50 Years and older   (Adult, Older Adult)",Early Phase 1,32,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-45-A01,Jun-07,Jan-08,Jan-08,28-Mar-12,3-May-12,18-May-12,"Research Site, Baltimore, Maryland, United States|Research Site, North East, Maryland, United States|Research Site, Long Branch, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01565291
NCT01565330,A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers,,Completed,Has Results,Alzheimer Disease,Drug: florbetapir F 18,Florbetapir-PET Scan Quality|Mean Cortical to Cerebellum SUVR,Avid Radiopharmaceuticals,All,"35 Years and older   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-A03,Mar-08,Aug-08,Aug-08,28-Mar-12,2-May-12,18-Jun-12,"Research Site, West Palm Beach, Florida, United States|Research Site, North East, Maryland, United States|Research Site, Clementon, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01565330
NCT01565343,A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers,,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Mean Cortical to Cerebellum SUVR,Avid Radiopharmaceuticals,All,"35 Years and older   (Adult, Older Adult)",Phase 1,25,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-A04,Apr-08,Apr-09,Apr-09,28-Mar-12,2-May-12,10-May-12,"Research Site, New Haven, Connecticut, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, North East, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01565343
NCT01565356,Evaluation of PET Scan Timing Relative to AV-45 Injection Time,,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Percent Agreement of Interpretation Between 30-40 and 50-60 Min Reads - Qualitative Evaluation|Agreement of Interpretation Between 30-40 and 50-60 Min Reads - Semi-quantitative Evaluation,Avid Radiopharmaceuticals,All,"35 Years and older   (Adult, Older Adult)",Not Applicable,41,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-A06,Mar-10,May-10,May-10,28-Mar-12,7-Jun-12,7-Jun-12,,,https://ClinicalTrials.gov/show/NCT01565356
NCT01565369,Evaluation of Physician Training Methods to Read Florbetapir-PET Scans,,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Sensitivity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque|Specificity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque|Inter-reader Agreement,Avid Radiopharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-A08,Jan-11,Jan-11,Jan-11,28-Mar-12,7-Jun-12,7-Jun-12,,,https://ClinicalTrials.gov/show/NCT01565369
NCT01565382,Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI),,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Inter-reader Agreement - Median Kappa Statistic|Overall Inter-reader Agreement - Fleiss' Kappa,Avid Radiopharmaceuticals,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,40,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-A09,Feb-11,Feb-11,Feb-11,28-Mar-12,27-Jun-12,27-Jun-12,,,https://ClinicalTrials.gov/show/NCT01565382
NCT01565434,Erythrocyte Complement Receptor 1 and Alzheimer Disease,,Completed,No Results Available,Alzheimer Disease,Other: CR1 impact,,CHU de Reims,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Primary Purpose: Screening,PA11014,Feb-12,null,Apr-15,28-Mar-12,null,9-Jun-16,"CHU de REIMS, Reims, France",,https://ClinicalTrials.gov/show/NCT01565434
NCT01561430,Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease,,Terminated,Has Results,Alzheimer's Disease,Drug: LY2886721|Drug: Placebo,Change From Baseline to 12 Weeks in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations|Change From Baseline to 26 Weeks in CSF Aβ1-40 and Aβ1-42 Concentrations|Change From Baseline in Plasma Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations|Change From Baseline to 26 Weeks in Neuropsychological Test Battery (NTB)|Change From Baseline to 26 Weeks in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Change From Baseline to 26 Weeks in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Change From Baseline to 26 Weeks in Mini Mental State Examination (MMSE)|Change From Baseline in Cerebrospinal Fluid (CSF) Tau and Phosphorylated Tau (Ptau)-181 Concentrations,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",13735|I4O-MC-BACC|2011-005217-37,Mar-12,Aug-13,Aug-13,23-Mar-12,18-May-18,18-May-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Long Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Delray Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ocala, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Decatur, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quincy, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monroe, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dayton, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Biella, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getafe, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sant Cugal Del Valles, Spain",,https://ClinicalTrials.gov/show/NCT01561430
NCT01560585,Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: Isotretinoin,Change from Baseline to Six month timepoint in the score on the Alzheimer's disease Assessment Scale- Cognitive subscale|Number and types of adverse effects,University Hospitals Cleveland Medical Center,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISOTRT-01,Apr-12,Aug-14,Aug-14,22-Mar-12,null,28-Aug-14,"Parkway Medical Building, Beachwood, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01560585
NCT01561053,A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease,AMBAR,"Active, not recruiting",No Results Available,Alzheimer's Disease,Biological: Albumin|Biological: Immune globulin,"Cognitive scores (as a change from baseline measurement), measured by ADAS-Cog (Cognitive subscale of the Alzheimer's Disease Assessment Scale) and ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living).|Cognitive, functional and neuropsychiatric scores and overall development as measured by MMSE, NPS battery, ADCS-ADL, NPICDR-Sb, ADCS-CGIC, CSDD, C-SSRS and QoL-AD, RUD-lite.|Levels of AB1-40 and AB1-42, T-tau and P-tau in CSF|Levels of AB1-40 and AB1-42 in plasma|Evaluate the structural changes in volume of the hippocampus, posterior cingulate area, and other associated areas based on neuroimaging study with magnetic resonance imaging (MRI) variation versus baseline.|Variation in FDG-PET patterns (flurodeoxyglucose-PET)","Instituto Grifols, S.A.|Grifols Biologicals, LLC",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,350,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",IG1002,Mar-12,Dec-17,Dec-17,22-Mar-12,null,2-Aug-17,"Northern California Research, Sacramento, California, United States|Mountain View Clinical Research, Inc, Denver, Colorado, United States|Howard University, Washington, D.C., District of Columbia, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Galiz Research, LLC, Hialeah, Florida, United States|L&L Research Choices, Inc, Miami, Florida, United States|Allied Biomedical Research Institute, Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|PharmaSeek LLC (DMI Research), Pinellas Park, Florida, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|RTR Medical Group, Savannah, Georgia, United States|Mid-Atlantic Geriatric/ARC, Manchester Township, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Wesley Neurology Clinic, Cordova, Tennessee, United States|Hospital General de Elche, Elche, Alicante, Spain|Hospital de Vinalopó, Elche, Alicante, Spain|Hospital de Torrevieja, Torrevieja, Alicante, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital General de Catalunya, San Cugat del Valles, Barcelona, Spain|Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital Ntra. Sra. de la Candelaria, Santa Cruz de Tenerife, Canary Islands, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Funcació ACE, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario De Burgos, Burgos, Spain|Parc Hospitalari Marti i Julia, Girona, Spain|Hospital de Santa María, Lleida, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain|Hospital Montecanal, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT01561053
NCT01559220,Deep Brain Stimulation for the Treatment of Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Device: Deep Brain Stimulation,Clinical Dementia Rating Scale,"Ali Rezai, MD|Ohio State University",All,"45 Years to 85 Years   (Adult, Older Adult)",Not Applicable,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,2011H0362,Mar-12,Jan-16,Jan-16,21-Mar-12,null,30-Mar-17,"Wexner Medical Center at the Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01559220
NCT01554683,Seizure Activity in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Seizures,Drug: Low/High/Placebo Dose Keppra (Levetiracetam),Brain Perfusion Blood Flow fMRI|Free and Cued Selective Reminding Test|Mini Mental Status Exam (MMSE)|Trial Making Test Parts A & B|Phonemic & Category Fluency Test|Boston Naming Test 15-item version,Beth Israel Deaconess Medical Center,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",2011P000303,Feb-12,1-Jul-17,1-Jul-17,15-Mar-12,null,23-Feb-18,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01554683
NCT01555827,Retinal Neurodegenerative Signs in Alzheimer's Diseases,SIGNAL,Completed,No Results Available,Alzheimer's Disease,Other: Ophthalmological examination & Questionnaire,"RNFL thickness measured on a peri-papillary scan of SD-OCT examination.|Glaucomatous optic nerve damage observed on colour photographs (cup/disc ratio)|Retinal microvascular abnormalities (microaneurysms, micro-hemorrhage, cotton wool spots, arteriovenous nicking), observed on retinal colour photography|Macular abnormalities observed on retinal colour photographs (drusen, pigmentary abnormalities, neovascular AMD, atrophic AMD, other retinal diseases)|Macular abnormalities observed on macular scans in SD-OCT (drusen, pigmentary abnormalities, neovascular AMD, atrophic AMD, epiretinal membranes, other retinal diseases).|Macular abnormalities observed in autofluorescence imaging (increased autofluorescence, decreased autofluorescence, reticular drusen, atrophic AMD, other abnormalities)|Macular and peripheral abnormalities diagnosed in wide-field retinal imaging|Retinal blood flow velocity (RFI)|Intraocular pressure|axial length","University Hospital, Bordeaux",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHUBX2011/19,12-Mar-12,7-Jun-14,7-Jun-14,15-Mar-12,null,13-Nov-17,"CHU Bordeaux - hôpital Pellegrin, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT01555827
NCT01553929,Physical Training and Cognitive Activity on the Mild Cognitive Impairment (MCI) Patient,EPAC-M,Terminated,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Other: Physical Training and cognitive activity (EPC group)|Other: Physical training (EP group)|Other: control group,effectiveness of physical training|Cognitive improvement,Centre Hospitalier Universitaire de Nice,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,5,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,11-AOI-03,Mar-12,Mar-12,Jan-15,14-Mar-12,null,14-Aug-15,"CHU de Nice, Nice, France",,https://ClinicalTrials.gov/show/NCT01553929
NCT01554202,Multi-modal Neuroimaging in Alzheimer's Disease,IMAP,"Active, not recruiting",No Results Available,Alzheimer's Disease,Behavioral: assessment of memory|Biological: circulating tPA dosage|Genetic: ApoE4|Other: Brain imaging examination MRI and PET examinations,"Rate of volume change of whole brain, hippocampus and other structural MRI measures|Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by 18F-AV45|Group differences for each imaging and biomarker measurement|APOE genotype","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,295,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2007-A00414-49,Jan-08,Dec-21,null,14-Mar-12,null,6-Mar-13,"University Hospital Côte de Nacre, Caen, France|University Hospital Roger Salengro, Lille, France|University Hospital Pontchaillou, Rennes, France|University Hospital Rouen, Rouen, France|University Hospital Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01554202
NCT01550549,Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans,,Completed,Has Results,Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases,Drug: florbetapir F 18,Inter-rater Reliability|Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)|Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease),Avid Radiopharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,151,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-PT01,Aug-11,Sep-11,Sep-11,12-Mar-12,7-Jun-12,7-Jun-12,,,https://ClinicalTrials.gov/show/NCT01550549
NCT01550718,Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial,,Completed,No Results Available,Dementia,Behavioral: ESML-EX (Physical Activity Program)|Behavioral: ESML-Social (Social Activity Program),Change from Baseline in Social Activity at post-treatment (1 month)|Change from Baseline in Physical Activity at post-treatment (1 month)|Change from Baseline in Quality of Life at post-treatment (1 month)|Change from Baseline in Social Activity at 4 month follow-up|Change from Baseline in Physical Activity at 4 month follow-up|Change from Baseline in Quality of Life at 4 month follow-up|Change from Baseline in Communication at post-treatment (1 month)|Change from Baseline in Physical Function at post-treatment (1 month)|Change from Baseline in Mood at post-treatment (1 month)|Change from Baseline in Physical Functioning at post-treatment (1 month)|Change from Baseline in Mood at 4 month follow-up.,University of Washington,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,152,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,41577-G,Feb-12,Feb-15,Feb-15,12-Mar-12,null,10-Jun-15,"UWashington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01550718
NCT01549834,Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors,,Completed,No Results Available,Alzheimer's Disease,Drug: ABT-126|Drug: placebo,Alzheimer's Disease Assessment Scale - cognitive subscale|Mini Mental Status Exam|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|DEMentia Quality of Life (DEMQOL)|Clinician Interview-Based Impression of Change - plus (CIBIC-plus)|Neuropsychiatry Inventory (NPI)|Partner-Patient Questionnaire for Shared Activities (PPQSA)|Resource Use in Dementia (RUD-Lite)|EuroQol-5D Questionnaires|Wechsler Memory Scale-III (WMS-III) Working Memory Index,"AbbVie (prior sponsor, Abbott)|AbbVie",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,434,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",M11-793|2011-004849-40,Mar-12,Oct-13,Oct-13,9-Mar-12,null,31-Oct-14,"Site Reference ID/Investigator# 66528, Fresno, California, United States|Site Reference ID/Investigator# 69602, Long Beach, California, United States|Site Reference ID/Investigator# 66527, San Francisco, California, United States|Site Reference ID/Investigator# 66530, Hamden, Connecticut, United States|Site Reference ID/Investigator# 66522, Delray Beach, Florida, United States|Site Reference ID/Investigator# 66524, Orlando, Florida, United States|Site Reference ID/Investigator# 66531, Tampa, Florida, United States|Site Reference ID/Investigator# 66529, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 66526, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 66525, Staten Island, New York, United States|Site Reference ID/Investigator# 66523, Bennington, Vermont, United States|Site Reference ID/Investigator# 71793, Gatineau, Canada|Site Reference ID/Investigator# 71794, Montreal, Canada|Site Reference ID/Investigator# 71798, Peterborough, Canada|Site Reference ID/Investigator# 71795, Toronto, Canada|Site Reference ID/Investigator# 71796, Verdun, Canada|Site Reference ID/Investigator# 71573, Dijon Cedex, France|Site Reference ID/Investigator# 77833, Limoges Cedex, France|Site Reference ID/Investigator# 68704, Paris Cedex 10, France|Site Reference ID/Investigator# 68706, Paris, France|Site Reference ID/Investigator# 68705, Toulouse Cedex 9, France|Site Reference ID/Investigator# 68768, Berlin, Germany|Site Reference ID/Investigator# 68764, Freiburg, Germany|Site Reference ID/Investigator# 68767, Huettenberg, Germany|Site Reference ID/Investigator# 69960, Mittweida, Germany|Site Reference ID/Investigator# 68765, Munich, Germany|Site Reference ID/Investigator# 69959, Schwerin, Germany|Site Reference ID/Investigator# 68730, Athens, Greece|Site Reference ID/Investigator# 68732, Athens, Greece|Site Reference ID/Investigator# 68733, Athens, Greece|Site Reference ID/Investigator# 68731, Haidari, Athens, Greece|Site Reference ID/Investigator# 68729, Thessaloniki, Greece|Site Reference ID/Investigator# 68735, Thessaloniki, Greece|Site Reference ID/Investigator# 67586, Belville, South Africa|Site Reference ID/Investigator# 67582, Cape Town, South Africa|Site Reference ID/Investigator# 67584, George, South Africa|Site Reference ID/Investigator# 67585, Johannesburg, South Africa|Site Reference ID/Investigator# 67583, Rosebank, South Africa|Site Reference ID/Investigator# 67787, Bath, United Kingdom|Site Reference ID/Investigator# 67784, Glasgow, United Kingdom|Site Reference ID/Investigator# 67786, London, United Kingdom|Site Reference ID/Investigator# 67785, Manchester, United Kingdom|Site Reference ID/Investigator# 67783, Warrington, United Kingdom",,https://ClinicalTrials.gov/show/NCT01549834
NCT01550172,Improving Dementia Caregiver Sleep & the Effect on Heart Disease Biomarkers,,Completed,No Results Available,Caregivers of Persons With Dementia,Behavioral: Sleep Behavioral Therapy A and NHMS|Behavioral: Sleep Behavioral Therapy B and NHMS,"Total Wake Time (TWT)|Sleep Efficiency (SE)|Nighttime Injuries|D-Dimer Levels|Tissue Plasminogen Activator Levels|C-reactive Protein (CRP) Levels|Intercellular Adhesion Molecule-1 (ICAM-1)|IL-6, and TNFα Levels",University of South Florida|National Institute on Aging (NIA),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,80,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",6201111800|1R01AG039495-01,Apr-12,Jul-16,Jul-16,9-Mar-12,null,26-Oct-16,"University of South Florida, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT01550172
NCT01547689,Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells(UC-MSC) in Patients With Alzheimer's Disease,SEMAD,Unknown status,No Results Available,Alzheimer's Disease,Biological: Human Umbilical Cord Derived MSC,Number of participants with adverse event|Changes from the baseline in Alzheimer' s Disease Assessment Scale-cognitive subscale(ADAS-Cog) at 10 weeks post-dose,Affiliated Hospital to Academy of Military Medical Sciences|Peking University Third Hospital,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,307-CTC-MSC-001|2011AA020114,Mar-12,Dec-16,Dec-16,8-Mar-12,null,22-Feb-16,"Department of Hematopoietic Stem Cell Transplantation, Beijing, China",,https://ClinicalTrials.gov/show/NCT01547689
NCT01548053,The Primary Care - Dementia Assessment and Treatment Algorithm,PC-DATA,Completed,No Results Available,Dementia|Alzheimer's Disease,Other: PC-DATA tool,Change in number of dementia care process quality indicators achieved.|Impact on learning and knowledge application|Client-centred care,Queen's University|Canadian Institutes of Health Research (CIHR),All,"60 Years and older   (Adult, Older Adult)",Not Applicable,55,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,PC-DATA1,Mar-12,Dec-15,May-16,8-Mar-12,null,14-Apr-17,"Queen's University, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01548053
NCT01548287,A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment,,Completed,Has Results,Mild Cognitive Impairment|Mild Alzheimer's Disease,Drug: AZD5213|Other: Placebo,"Change From Baseline in Total Sleep Time (TST) After 4 Weeks of Treatment, Based on PSG Measurement.|Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on PSG Measurements.|Change From Baseline in Latency to Persistent Sleep After 4 Weeks of Treatment, Based on PSG Measurements.|Change From Baseline in Night Total Sleep Time After 4 Weeks of Treatment, Based on Actigraphy Recording.|Change From Baseline in Latency of Persistent Sleep After 4 Weeks of Treatment, Based on Actigraphy Recording.|Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on Actigraphy Recording.",AstraZeneca,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,164,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3030C00005,Apr-12,Jan-13,Jan-13,8-Mar-12,5-Dec-16,7-Feb-17,"Research Site, Phoenix, Arizona, United States|Research Site, Indio, California, United States|Research Site, Lomita, California, United States|Research Site, San Francisco, California, United States|Research Site, Delray Beach, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, New York, New York, United States|Research Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01548287
NCT01548430,A Safety Study of TTP4000 in Subjects With Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: TTP4000|Drug: Placebo,Number of participant with adverse events|Evaluation of participant plasma TTP4000 concentrations,vTv Therapeutics,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,8,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)",TTP4000-101,Oct-11,Feb-13,Feb-13,8-Mar-12,null,12-Feb-15,"Miami, Florida, United States|Durham, North Carolina, United States|High Point, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01548430
NCT01547169,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days,SNIFF-LONG 21,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Drug: Placebo Comparator|Drug: insulin detemir,Verbal Memory Composite|Neuropsychological Test of Executive Function 1|Glucose Tolerance|Functional Ability|Plasma biomarkers of AD|Neuropsychological Test of Executive Functioning 2|Neuropsychological Tests of Visual Working Memory,University of Washington|National Institute on Aging (NIA),All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",39683-A|2P50AG005136-27,Mar-11,Dec-12,Dec-12,7-Mar-12,null,18-Dec-12,"VA Puget Sound Health Care System, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01547169
NCT01539031,Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Type Dementia,Drug: E2020,"The Severe Impairment Battery (SIB)|The Clinician's Interview-Based Impression of Change, Plus Caregiver Input Version (CIBIC+)","Eisai Co., Ltd.|Eisai Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,351,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E2020-J081-343,Mar-12,Jan-15,Mar-15,27-Feb-12,null,17-Sep-15,"Anjo, Aichi, Japan|Obu, Aichi, Japan|Toyoake, Aichi, Japan|Chikushi, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Fukuoka, Gunma, Japan|Miyoshi, Hiroshima, Japan|Otake, Hiroshima, Japan|Amagasaki, Hyogo, Japan|Himeji, Hyogo, Japan|Morioka, Iwate, Japan|Kida, Kagawa, Japan|Takamatsu, Kagawa, Japan|Kawasaki, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Maizuru, Kyoto, Japan|Nagasaki, Kyushu, Japan|Sendai, Miyagi, Japan|Kitamorokata, Miyazaki, Japan|Ina, Nagano, Japan|Nagaoka, Niigata, Japan|Kurashiki, Okayama, Japan|Ibaraki, Osaka, Japan|Ikeda, Osaka, Japan|Sakai, Osaka, Japan|Sennan, Osaka, Japan|Takatsuki, Osaka, Japan|Age, Saitama, Japan|Iruma, Saitama, Japan|Kasukabe, Saitama, Japan|Tokorozawa, Saitama, Japan|Fuji, Shizuoka, Japan|Izunokuni, Shizuoka, Japan|Anan, Tokushima, Japan|Bunkyo-ku, Tokyo, Japan|Kodaira, Tokyo, Japan|Koto, Tokyo, Japan|Ota-ku, Tokyo, Japan|Setagaya, Tokyo, Japan|Suginami, Tokyo, Japan|Akita, Japan|Chiba, Japan|Fukuoka, Japan|Hiroshima, Japan|Iwate, Japan|Kagoshima, Japan|Kochi, Japan|Kyoto, Japan|Nara, Japan|Osaka, Japan|Saitama, Japan|Tokushima, Japan",,https://ClinicalTrials.gov/show/NCT01539031
NCT01537757,"A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])",,Completed,No Results Available,Alzheimer's Disease,Drug: MK-8931,Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of MK-8931|Renal clearance (CLr) of MK-8931|Fraction of MK-8931 dose excreted in urine (fe),Merck Sharp & Dohme Corp.,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P08535|MK-8931-009,Mar-12,May-12,May-12,23-Feb-12,null,26-Jan-15,,,https://ClinicalTrials.gov/show/NCT01537757
NCT01529619,"Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors",,Completed,No Results Available,Alzheimer's Disease,Drug: Rivastigmine transdermal patch,"Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J cog)|Adverse Events, Serious Adverse Events, Adverse event leading to discontinuation of study drug|Change From Baseline in Disability Assessment for Dementia (DAD)|Change From Baseline in Mini-Mental State Examination (MMSE)|Change From Baseline in Japanese version of the Clinical global impression of change (J-CGIC)|Change From Baseline in Modified Crichton Scale|Formulation usability questionnaire",Novartis Pharmaceuticals|Ono Pharmaceutical Co. Ltd|Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,52,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713D1403,Mar-12,Dec-13,Dec-13,9-Feb-12,null,18-Nov-16,"Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Miyoshi-city, Hiroshima, Japan|Novartis Investigative Site, Ohtake, Hiroshima, Japan|Novartis Investigative Site, Kita-gun, Kagawa, Japan|Novartis Investigative Site, Kamakura-city, Kanagawa, Japan|Novartis Investigative Site, Kawasaki-city, Kanagawa, Japan|Novartis Investigative Site, Yokohama, Kanagawa, Japan|Novartis Investigative Site, Koshi-city, Kumamoto, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Kyoto, Japan",,https://ClinicalTrials.gov/show/NCT01529619
NCT01527916,Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: placebo|Drug: donepezil|Drug: ABT-126,Alzheimer's Disease Assessment Scale - cognitive subscale|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Mini Mental Status Exam (MMSE)|DEMentia Quality of Life (DEMQOL)|Clinician Interview-Based Impression of Change - plus (CIBIC-plus)|Neuropsychiatry Inventory (NPI)|Partner-Patient Questionnaire for Shared Activities (PPQSA)|Resource Use in Dementia (RUD-Lite)|EuroQol-5D Questionnaires|Wechsler Memory Scale-III (WMS-III) Working Memory Index,"AbbVie (prior sponsor, Abbott)|AbbVie",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,438,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",M10-985|2011-002004-32,Feb-12,Nov-13,Nov-13,7-Feb-12,null,19-Nov-14,"Site Reference ID/Investigator# 56503, Delray Beach, Florida, United States|Site Reference ID/Investigator# 56518, Tampa, Florida, United States|Site Reference ID/Investigator# 56514, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 62611, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 56506, Staten Island, New York, United States|Site Reference ID/Investigator# 82994, Jenkintown, Pennsylvania, United States|Site Reference ID/Investigator# 77636, Wichita Falls, Texas, United States|Site Reference ID/Investigator# 56504, Bennington, Vermont, United States|Site Reference ID/Investigator# 62565, Gdynia, Poland|Site Reference ID/Investigator# 62563, Poznan, Poland|Site Reference ID/Investigator# 62562, Szczecin, Poland|Site Reference ID/Investigator# 60945, Kazan, Russian Federation|Site Reference ID/Investigator# 60955, Kazan, Russian Federation|Site Reference ID/Investigator# 60954, Kirov, Russian Federation|Site Reference ID/Investigator# 60951, Moscow, Russian Federation|Site Reference ID/Investigator# 60959, Moscow, Russian Federation|Site Reference ID/Investigator# 60946, Novosibirsk, Russian Federation|Site Reference ID/Investigator# 60950, Saratov, Russian Federation|Site Reference ID/Investigator# 60947, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60958, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60949, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60952, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60911, Belville, South Africa|Site Reference ID/Investigator# 76073, Cape Town, South Africa|Site Reference ID/Investigator# 60912, George, South Africa|Site Reference ID/Investigator# 60910, Johannesburg, South Africa|Site Reference ID/Investigator# 60909, Donetsk, Ukraine|Site Reference ID/Investigator# 60906, Kiev, Ukraine|Site Reference ID/Investigator# 60905, Poltava, Ukraine|Site Reference ID/Investigator# 60960, Bath, United Kingdom|Site Reference ID/Investigator# 60963, Blackburn, United Kingdom|Site Reference ID/Investigator# 60962, Glasgow, United Kingdom|Site Reference ID/Investigator# 60961, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01527916
NCT01524887,"Phase 3 IGIV, 10% in Alzheimer´s Disease",,Terminated,Has Results,Alzheimer´s Disease,"Biological: Immune Globulin Intravenous (Human), 10% Solution|Biological: Human albumin 0.25%","Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)|Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory|ADCS-Clinical Global Impression of Change (CGIC) at 18 Months|Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)|Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement|Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)|Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)|Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)|Number of Participants Experiencing Any AEs and/or SAEs|Number of Infusions Temporally Associated With AEs and/or SAEs|Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion|Number of Infusions Causally Associated With AEs and/or SAEs|Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE",Baxalta now part of Shire|Shire,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 3,508,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",161003|2011-000914-21,Jan-12,Jul-13,Jul-13,2-Feb-12,31-Mar-15,24-Nov-17,"Birmingham, Alabama, United States|Phoenix, Arizona, United States|Long Beach, California, United States|San Diego, California, United States|Santa Ana, California, United States|Boca Raton, Florida, United States|Delray Beach, Florida, United States|Edgewater, Florida, United States|Orlando, Florida, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Springfield, Illinois, United States|Paducah, Kentucky, United States|Saint Paul, Minnesota, United States|Olive Branch, Mississippi, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Chester, New Jersey, United States|Eatontown, New Jersey, United States|Summit, New Jersey, United States|Toms River, New Jersey, United States|Albany, New York, United States|Brooklyn, New York, United States|Latham, New York, United States|Manhasset, New York, United States|New Hyde Park, New York, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Providence, Rhode Island, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Bennington, Vermont, United States|Charlottesville, Virginia, United States|Milwaukee, Wisconsin, United States|Woodville South, South Australia, Australia|Edegem, Belgium|Gent, Belgium|Hasselt, Belgium|Leuven, Belgium|Roeselare, Belgium|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Sherbrooke, Quebec, Canada|Akashi, Japan|Akita, Japan|Azumino, Japan|Chiba, Japan|Fukui, Japan|Kyoto, Japan|Niigata, Japan|Osaka, Japan|Saga, Japan|Tokushima, Japan|Tokyo, Japan|Lublin, Poland|Scinawa, Poland|Warszawa, Poland|Cruces-Barakaldo, Vizcaya, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Uckfield, East Sussex, United Kingdom|Bath, United Kingdom|Brentford, United Kingdom|Brighton, United Kingdom|Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT01524887
NCT01522404,Effects of Atomoxetine in Mild Cognitive Impairment,ATX-001,Completed,Has Results,Mild Cognitive Impairment,Drug: Atomoxetine|Drug: Placebo,Change in Interleukin 1 (IL 1-alpha) in Cerebrospinal Fluid (CSF) in Subjects With Mild Cognitive Impairment (MCI) Treated With Atomoxetine/Inactive Compound Compared to Subjects Treated With Inactive Compound / Atomoxetine|Change in Mean Level of Thymus-Expressed Chemokine (TECK) in Cerebrospinal Fluid (CSF) in Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine|Number of All Adverse Events Among the Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine Compared to the Participants Treated With Placebo/Inactive Compound|Number of Participants That Drop Out of the Study Among the Participants Treated With Atomoxetine When Compared to the Participants Treated With Inactive Compound (Placebo)|Change in Rate of Cerebral Blood Flow in Subjects With Mild Cognitive Impairment MCI Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine|Change in FluoroDeoxyGlucose (FDG) Uptake in Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine,Emory University|National Institute on Aging (NIA),All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,39,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",IRB00054397|5U01AG010483|ATX-001,Mar-12,31-Oct-17,30-Jun-18,31-Jan-12,5-Dec-18,5-Dec-18,"Emory University School of Medicine, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01522404/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01522404
NCT01518374,Clinical Evaluation of Florbetapir F 18 (18F-AV-45),,Completed,Has Results,Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases,Drug: Florbetapir F 18,Number of Participants Experiencing Treatment-emergent Adverse Events Considered Related to Florbetapir Administration,Avid Radiopharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1768,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-45-A14,Dec-09,3-May-17,3-May-17,26-Jan-12,14-Jun-18,18-Jul-18,"Banner Health, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|UC Davis, Davis, California, United States|UC Irvine, Irvine, California, United States|University of Southern California, Los Angeles, California, United States|UC Irvine, Orange, California, United States|UC San Francisco, San Francisco, California, United States|UC San Francisco Memory Center, San Francisco, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Mt. Sinai Medical Center, Miami Beach, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas, Kansas City, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Jefferson, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|University of Tennessee, Knoxville, Tennessee, United States|Vanderbilt, Nashville, Tennessee, United States|UTSW, Dallas, Texas, United States|UTSW, Dallas, Texas, United States|UTSW, Dallas, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01518374/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01518374/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01518374
NCT01515982,Physical Exercise as an Additional Treatment for Alzheimer Disease,,Completed,No Results Available,Alzheimer Disease,Behavioral: Aerobic Exercise|Behavioral: Control Group,Change from baseline in CAMCOG scale at 16 weeks|Change from baseline in Time to Up and Go Test at 16 weeks|Change from baseline in Sit-to-Stand test at 16 weeks|Change from baseline in Berg Balance Scale at 16 weeks|Change from baseline in Trail Making Test at 16 weeks,Universidade Federal do Rio de Janeiro|Rio de Janeiro State Research Supporting Foundation (FAPERJ)|Conselho Nacional de Desenvolvimento Científico e Tecnológico,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,60liv02-09B,Feb-10,Jun-13,Dec-13,24-Jan-12,null,3-Dec-14,"Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT01515982
NCT01513967,A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease,,Completed,No Results Available,Moderate to Severe Alzheimer|Alzheimer Disease,"Drug: RPh201, botanical drug product|Drug: Placebo|Drug: RPh201, botanical extract product",The primary objective: to evaluate the safety and tolerability of RPh201 after single and multiple rising doses.|To evaluate efficacy of RPh201 in subjects with AD,Regenera Pharma Ltd|Syneos Health,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,36,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",RGN-ADC-001,Jan-12,Jun-15,Jun-15,20-Jan-12,null,6-Dec-16,"Toronto Memory Program, Toronto, Ontario, Canada|Kendle Early Stage - Toronto, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01513967
NCT01504854,Resveratrol for Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Resveratrol|Drug: Placebo,Number of Adverse Events|Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)|Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Comparison of the Response to Treatment of Resveratrol Based on ApoE Genotype,Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA),All,"50 Years and older   (Adult, Older Adult)",Phase 2,119,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADC-037-RES,May-12,Mar-14,Mar-14,6-Jan-12,14-Jun-16,14-Jun-16,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego - Comprehensive Alzheimer's Program, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|New York University, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Case Western Reserve University, Beachwood, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, N. Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|U of WA / VA Puget Sound Alzheimer's Disease Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01504854
NCT01504958,Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients,,Completed,Has Results,Alzheimer's Disease,Device: Repetitive Transcranial Magnetic Stimulation (rTMS)|Behavioral: NICE Cognitive Training,Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Clinical Global Impression of Change (CGIC)|Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL),Beth Israel Deaconess Medical Center|Neuronix Ltd,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,22,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",2010P000325,Dec-10,May-15,May-15,6-Jan-12,5-Jun-17,2-Jul-17,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01504958
NCT01503944,A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET),,Completed,No Results Available,Dementia With Lewy Bodies|Alzheimer's Disease|Parkinson's Disease,Drug: 18F-AV-133|Drug: 18F-AV-45,18F-AV-133 striatal to occipital standard uptake value ratio|18F-AV-45 cortical to cerebellar standard uptake value ratio,Avid Radiopharmaceuticals,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-133-B03,Mar-10,Jul-11,Jul-11,4-Jan-12,null,14-Aug-12,"Research Site, Sun City, Arizona, United States|Research Site, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01503944
NCT01496170,"A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])",,Completed,No Results Available,Alzheimer's Disease,Drug: MK-8931|Drug: Placebo,Mean population Inhibitory Concentration for 50% Effect (IC50) in cerebral spinal fluid (CSF) ß-amyloid peptide 40 (Aß40)|Change in CSF Aß40 concentration determined by time-weighted average from 0 to 24 hours (TWA0-24)|Change in CSF soluble amyloid precursor protein ß (sAPPß ) concentration determined by TWA0-24,Merck Sharp & Dohme Corp.,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P07820|MK-8931-010,Dec-11,Jun-12,Jun-12,21-Dec-11,null,23-Oct-15,,,https://ClinicalTrials.gov/show/NCT01496170
NCT01492374,"Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Drug: BMS-241027|Drug: Placebo matching BMS-241027,"Safety assessments: based on frequency of Serious Adverse Events (SAEs), frequency of Adverse events (AEs), discontinuation due to AEs and dose reduction|Biomarker Measures: CSF levels of Tau N-terminal domain fragments|Effects of BMS-241027 on CSF levels of the mid-domain Tau fragment|Effects of BMS-241027 on cognitive performance using computerized cognitive tests|Effects of BMS-241027 on connectivity MRI|Maximal observed plasma concentration (Cmax) of BMS-241027 in subjects with mild Alzheimer's disease|Observed plasma concentration at 24 hours post dose (C24) of BMS-241027 in subjects with mild Alzheimer's disease|Time of maximal observed plasma concentration (Tmax) of BMS-241027 in subjects with mild Alzheimer's disease|Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-241027 in subjects with mild Alzheimer's disease|Safety assessments: based on vital sign measurements, ECGs and clinical laboratory tests|Effects of BMS-241027 on CSF levels of neurofilaments",Bristol-Myers Squibb,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CN167-003|2011-004065-33,Feb-12,Oct-13,Oct-13,15-Dec-11,null,24-Jul-14,"Anaheim Clinical Trials Llc, Anaheim, California, United States|Long Beach, California, United States|Ucsf Memory And Aging Center, San Francisco, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Associated Neurologists Of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Compass Research, Llc, Orlando, Florida, United States|Palm Beach Neurological Center Advanced Research Consultants, Palm Beach Gardens, Florida, United States|Alexian Brothers Neurosciences Institute Clinical Research, Elk Grove Village, Illinois, United States|Brigham And Women'S Hospital, Boston, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|The Ohio State University, Columbus, Ohio, United States|The Clinical Trial Center, Llc, Jenkintown, Pennsylvania, United States|Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Local Institution, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Toulouse, Cedex 9, France|Local Institution, Lille Cedex, France|Local Institution, Paris, France|Local Institution, Berlin, Germany|Local Institution, Heidelberg, Germany|Local Institution, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01492374
NCT01487395,Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development,PharmacogWP3,Completed,No Results Available,Alzheimer Disease|Battery,Drug: Donepezil .|Drug: Placebo,Pharmacog battery,"University Hospital, Lille|Innovative Medicines Initiative",Male,18 Years to 30 Years   (Adult),Phase 1,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2010_41|2010-023989-51,Dec-11,Dec-12,Dec-13,7-Dec-11,null,9-Apr-15,"CHRU de Lille/ Centre d'investigation Clinique, Lille, France|CIC Marseille, Marseille, France|CIC Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01487395
NCT01485302,Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients,,Completed,No Results Available,Alzheimer's Disease,Drug: SAR228810,"number of patients with adverse events|AUC|Cmax|t1/2z|brain magnetic resonance imaging|hematology, biochemistry, coagulation|vital signs, ECG",Sanofi,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TDR12399|2011-002910-35|U1111-1120-0550,Jan-12,Feb-15,Feb-15,5-Dec-11,null,25-Mar-15,"Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 250001, Pierre Bénite, France|Investigational Site Number 250002, Toulouse Cedex 3, France|Investigational Site Number 528001, Leiden, Netherlands|Investigational Site Number 710001, Bloemfontein, South Africa|Investigational Site Number 752003, Malmö, Sweden|Investigational Site Number 752002, Mölndal, Sweden|Investigational Site Number 752001, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01485302
NCT01482845,"A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Drug: ABT-126|Drug: Placebo,Safety and tolerability assessments|Pharmacokinetic evaluation profile,Abbott,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)",M12-970,Nov-11,Mar-12,Mar-12,1-Dec-11,null,2-May-12,"Site Reference ID/Investigator# 62908, Glendale, California, United States|Site Reference ID/Investigator# 62904, Hallandale Beach, Florida, United States|Site Reference ID/Investigator# 62903, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT01482845
NCT01481961,Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease,ALSTIMAG,Completed,No Results Available,Alzheimer's Disease|Cognition Disorders,Procedure: repetitive Transcranial Magnetic Stimulation (rTMS),changes in MMSE (Mini Mental State Examination)|changes in HDRS (Hamilton Depression Rating Scale)|changes in STAI (State-Trait Anxiety Inventory)|changes in BDI (Beck Depression Inventory)|changes in HAMA (Hamilton Anxiety Scale)|changes in Mattis DRS (Dementia Rating Scale)|changes in CDR (Clinical Dementia Rate)|changes in Grober Free and Cued Selective Reminding Test|changes in TMT (Trail Making Test)|changes in COT (Crossing Of Test)|changes in IST (Isaacs Set Test)|changes in CDT (Clock-Drawing Test)|changes in Signoret's Battery of Cognitive Efficacy (BEC96)|changes in Rey-complex figure test-copy|changes in Picture naming 80 items test (DO80)|changes in RUD (Resource Utilisation Dementia)|changes in AI (Apathy Inventory)|changes in ADL (Activities of Daily Living)|changes in IADL (Instrumental Activities of Daily Living)|changes in QoL-AD (Quality of Life in Alzheimer's Disease)|changes in CP6 (Questionnaire of recent change in personnality),"Pierre Vandel, MD PhD|Neurology department of CHU Besancon (Dr Rumbach L, Dr Berger E, Dr Galmiche J)|Memory Center of Research and Resources (MCRR) of Besancon (Dr Magnin E)|Rapid-fr network (Dr Galmiche J)|Clinical Investigation Centre for Innovative Technology Network|Funding by French Internal Project Call for Clinical Research(2010-A00659-30)|Centre Hospitalier Universitaire de Besancon",All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALSTIMAG,Nov-10,May-12,May-12,30-Nov-11,null,3-Mar-15,"Psychiatric Department of CHU of Besancon, Besancon, France",,https://ClinicalTrials.gov/show/NCT01481961
NCT01482013,Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease,,Terminated,No Results Available,Mild Alzheimer's Disease|Mild Cognitive Impairment,Drug: HPP854|Drug: Placebo,Number of Participant Adverse Events|Evaluation of participant plasma HPP854 concentrations|Change in cerebrospinal fluid concentration of Amyloid-Beta,"High Point Pharmaceuticals, LLC.",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,7,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HPP854-104,Oct-11,Mar-12,Mar-12,30-Nov-11,null,30-Aug-12,"Elite Research Institute, Miami, Florida, United States|Duke Clinical Research Unit, Durham, North Carolina, United States|High Point Clinical Trials Center, High Point, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01482013
NCT01482351,Mild Cognitive Impairment and Obstructive Sleep Apnea,MEMORIES,Completed,Has Results,Obstructive Sleep Apnea|Mild Cognitive Impairment,Behavioral: CPAP adherence intervention|Behavioral: Attention control intervention,Hopkins Verbal Learning Test-Revised (HVLT-R)|Digit Symbol Subtest (DS)|Mini Mental State Evaluation Exam (MMSE)|Stroop Color and Word Test (SCW)|The Psychomotor Vigilance Task (PVT)|Epworth Sleepiness Scale [ESS]|Functional Outcomes Sleep Questionnaire (FOSQ)|Everyday Function Outcome: Everyday Cognition (E-Cog)|Alzheimer's Disease Cooperative Study - Clinicians' Global Impression of Change Scale (ADCS-CGIC)|Clinical Dementia Rating Scale (CDR),George Mason University|National Institute on Aging (NIA)|University of Pennsylvania,All,"55 Years to 89 Years   (Adult, Older Adult)",Not Applicable,54,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,7584|R01AG034682-01A2,Sep-12,Dec-14,Dec-14,30-Nov-11,29-Jan-19,6-Mar-19,"Abington Memorial Hospital, Abington, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|George Mason University, Fairfax, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01482351
NCT01481558,Effects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's Disease,,Completed,Has Results,Apathy|Alzheimer's Disease,Device: Transcranial direct current stimulation,Apathy Symptoms,University of Sao Paulo,All,"50 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",0679/11,Jan-12,May-12,May-12,29-Nov-11,9-Jan-14,9-Jan-14,"University of São Paulo Medical School, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01481558
NCT01478633,Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil,,Completed,No Results Available,Alzheimer's Disease,Drug: Galantamine,The Change from Baseline in Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) Score at Week 24|The Clinical Global Impression of Change (CGI-C) at Week 24|Proportion of Responders at Week 24,Janssen Pharmaceutical K.K.,All,"40 Years and older   (Adult, Older Adult)",Phase 4,102,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR018649|JNS023-JPN-02,Sep-11,Jun-13,Jun-13,23-Nov-11,null,26-Mar-14,"Akita, Japan|Izunokuni, Japan|Kochi N/A, Japan|Kumamoto, Japan|Osaka, Japan|Saitama N/A, Japan|Takatsuki, Japan|Tokyo, Japan|Uji, Japan|Urayasu, Japan|Yokohama, Japan",,https://ClinicalTrials.gov/show/NCT01478633
NCT01476228,EEG Objectification in Neuropsychiatry,,Unknown status,No Results Available,Personality Disorder|Depression|Neurodegeneration|Alzheimer's Disease|Epilepsy,Device: EEG recording,"percentage of fitting (0-100%) of EEG pattern to a previously identified electrophysiological ""key""",Hadassah Medical Organization,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Not Applicable,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,0394-11-HMO-CTIL,Nov-11,Nov-13,Dec-15,22-Nov-11,null,22-Nov-11,"HMO, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01476228
NCT01469351,Identifying Potential Effects of Liraglutide on Degenerative Changes,,Completed,No Results Available,Alzheimers Disease,Drug: Liraglutide|Drug: non-active study drug,PIB PET scan|Neuro-psychological tests|FDG PET Scan,University of Aarhus,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,34,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2011-000794-31,Jan-12,Apr-13,Apr-13,10-Nov-11,null,19-Apr-13,"Aarhus University, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT01469351
NCT01467726,"Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects",,Completed,No Results Available,Alzheimer's Disease,Drug: Velusetrag|Drug: Placebo,Tolerability of repeat dosing of velusetrag|Profile of Plasma Pharmacokinetics (PK) of velusetrag and metabolite|Profile of urine PK of velusetrag and metabolite|Pharmacodynamic effects of velusetrag,Theravance Biopharma,All,65 Years to 85 Years   (Older Adult),Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",48,Nov-11,Jan-12,Jan-12,9-Nov-11,null,3-Dec-14,"Comprehensive Clinical Development, Miramar, Florida, United States",,https://ClinicalTrials.gov/show/NCT01467726
NCT01466088,"Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)",,Completed,No Results Available,Alzheimer's Disease,Drug: Donepezil|Drug: AZD3480,Change from baseline in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)|Change from baseline in the Clinician Interview-Based Impression of Change plus carer interview [CIBIC-(+)]|Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Change from baseline in the Neuropsychiatric Inventory (NPI)|Change from baseline in the Mini-Mental State Examination (MMSE)|Change from baseline in the Alzheimer's Disease Related Quality of Life (ADRQL),Targacept Inc.,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,386,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TC-1734-226-CRD-006,Oct-11,May-14,May-14,7-Nov-11,null,3-Jun-15,"Banner Alzheimer Institute, Phoenix, Arizona, United States|Meridien Research, Brooksville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Policlinic, Chocen, Czech Republic|BRAIN-SOULTHERAPY s.r.o., Kladno, Czech Republic|Bialbi.s.r.o. Psychiatrické oddělení, Litoměřice, Czech Republic|Psychiatricka Ambulance, Olomouc, Czech Republic|Vojenska Nemocnice Psychiatricke oddeleni, Olomouc, Czech Republic|Clintrial, Praha, Czech Republic|PRAGTIS s.r.o., Praha, Czech Republic|Psychosocialni centrum, Prerov, Czech Republic|Crucea Alba - Dr. Oros si Asociatii - Societate Civila Medicala, Oradea, Romania|Spitalul de Psihiatrie Sibiu, Sibiu, Romania|Spitalul Clinic Judetean de Urgenta SIBIU, Sibiu, Romania|Spitalul Clinic Judetean de Urgenta, Clinica Psihiatrie, Timisoara, Romania|Spitalul Clinic Judetean de Urgenta, Clinica Neurologie 2, Timisoara, Romania|Neurologicka Ambulancia, s.r.o., Banska Bystrica, Slovakia|Univerzitna nemocnica Bratislava, Geronto-psychiatrické oddelenie, Bratislava, Slovakia|KONZILIUM s.r.o., Dubnica nad Váhom, Slovakia|Neurologická ambulancia, Krompachy, Slovakia|Dnipropetrovsk Regional Clinical Hospital, Dnipropetrovsk, Ukraine|Donetsk National Medical University of M. Gorky, Donetsk, Ukraine|Donetsk Regional Clinical Psychiatric Hospital, Donetsk, Ukraine|Crimean Republican Institution Psychoneurological Dispensary, Kerch, Ukraine|Central Clinical Hospital Ukrzaliznytsi, Kharkiv, Ukraine|Department of Age Physiology and Pathology of Nervous System; Institute of Gerontology NAMS, Kyiv, Ukraine|Lugansk Regional Clinical Psychoneurological Hospital, Lugansk, Ukraine|Lviv National Medical University named after Galytskyy, Lviv, Ukraine|Lviv Regional Clinical Psychiatric Hospital, Lviv, Ukraine|Odessa Regional Psychoneurology Dispensary, Odessa, Ukraine|Odessa Regional Psychiatric Hospital # 2, Oleksandrivka, Ukraine|Ukrainian Medical Stomatological Academy, Poltava, Ukraine|Department #3 of the Kherson Regional Psychiatric Hospital, Stepanovka, Ukraine",,https://ClinicalTrials.gov/show/NCT01466088
NCT01463384,Minocycline in Patients With Alzheimer's Disease,,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease,Drug: Minocycline,"Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).|Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)",Huntington Medical Research Institutes,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,13,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LKW-AB34,Sep-11,Oct-12,Oct-12,1-Nov-11,25-Sep-14,25-Sep-14,"Huntington Medical Research Institutes, Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT01463384
NCT01461109,"Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls",,Completed,No Results Available,Parkinson Disease|Alzheimer Disease,Drug: [18F] CFPyPB,To assess the dynamic uptake and washout of [18F] CFPyPB|Perform blood metabolite characterization of [18F] CFPyPB|To obtain safety data|Obtain test/retest reproductibility,Institute for Neurodegenerative Disorders,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),GlyT1-01,Aug-11,Sep-12,May-14,27-Oct-11,null,4-Jun-14,"Institute_Neurodegenerative_Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01461109
NCT01459016,A Non-drug Methods Study in Participants With Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Other: PET scan using florbetapir|Other: MRI Scan,Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI)|Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg)|Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI)|Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA)|Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD)|Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir|Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T)|Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T|Change From Baseline in the Mini Mental State Examination (MMSE) Total Score|Change From Baseline in the Alzheimer's Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score|Change From Baseline in the Clinical Dementia Rating (CDR) Total Score,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14162|I4O-MC-BACH,Dec-11,Dec-14,Dec-14,25-Oct-11,13-Feb-17,28-Jun-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cahors, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Castres, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Foix Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lavaur, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Limoges, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Léon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montauban Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vic-En-Bigorre, France",,https://ClinicalTrials.gov/show/NCT01459016
NCT01454453,Optimisation of Antipsychotic Drug Use in Older People,,Terminated,No Results Available,Alzheimer's Disease|Schizophrenia,Drug: Patients- dose titration,dose titration,"Institute of Psychiatry, London",All,"60 Years to 95 Years   (Adult, Older Adult)",Phase 4,64,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2167SR,May-12,Jul-15,Jul-15,19-Oct-11,null,19-Apr-17,"Institute of Psychiatry, Kings College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01454453
NCT01453569,"Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease",,Completed,Has Results,Alzheimer Disease|Cognitive Impairment,Drug: Sodium oligo-mannurarate 600mg|Drug: Sodium oligo-mannurarate 900mg|Drug: Placebo,Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule,"Shanghai Greenvalley Pharmaceutical Co., Ltd.|Shanghai Mental Health Center",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,255,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",9712011-1,Oct-11,Aug-13,Aug-13,18-Oct-11,27-Jan-15,27-Jan-15,"Beijing Hospital, Beijing, Beijing, China|Chongqing Medical University Second Affiliated Hospital, Chongqing, Chongqing, China|The First Affliated Hospital of Third Military Medical University, Chongqing, Chongqing, China|The Third Affliated Hospital of Third Military Medical University, Chongqing, Chongqing, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Guangzhou Brain Hospital, Guangzho, Guangdong, China|The 251 Hospital of People's Liberation Army, Zhangjiakou, Hebei, China|The First Affliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|Wuhan General Hospital of Guangzhou Military of People's Military Army, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|The Central Hospital of Baotou, Baotou, Inner Mongolia, China|The Affliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Wuxi Mental Health Center, Wuxi, Jiangsu, China|The First Affliated Hospital of Chinese Medical University, Shenyang, Liaoning, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Shandong Provincial Hospital, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|The Ninth Hospital, Shanghai Jiao Tong University school of Medicine, Shanghai, Shanghai, China|Shanghai Mental Health Center , Shanghai Jiao Tong University school of Medicine, Shanghai, Shanghai, China|Tangdu Hospital of The Forth Military Medical University of PLA, Xi'an, Shanxi, China|West China Hospital, West China School of Medicine Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|Sir Run Run Shaw Hospital, Medical college of Zhejiang University, Hangzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT01453569
NCT01454115,"Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163",,Completed,No Results Available,Alzheimer's Disease,Drug: BMS-708163 (Gamma-Secretase Inhibitor)|Drug: Placebo matching BMS-708163,"Safety and tolerability of Single doses of BMS-708163 in the range of 0.3 to 800 mg in the healthy subjects|Effects of BMS-708163 on cortisol and QT interval corrected for heart rate|Effect of BMS-708163 on thyroid stimulating hormone (TSH), free triiodothyronine (T3), free thyroxine (T4), and lymphocyte subsets|Bioavailability of BMS-708163 from a capsule formulation relative to a solution formulation|Effect of food on the PK of BMS-708163 administered as a capsule formulation|Maximum observed plasma concentration (Cmax) of BMS-708163|Time of maximum observed plasma concentration (Tmax) of BMS-708163|Area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration [AUC(0-T)] of BMS-708163|Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-708163|Plasma half-life (T-HALF) of BMS-708163",Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1,116,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",CN156-001,Jun-07,Mar-09,Mar-09,18-Oct-11,null,21-Nov-11,,,https://ClinicalTrials.gov/show/NCT01454115
NCT01447719,Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07,,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Sensitivity Analysis in All Autopsy Population|Specificity Analysis in All Autopsy Population|Correlation of Florbetapir-PET Image and Amyloid Plaque Density|Sensitivity Analysis in Subjects With Autopsy Within 1 Year of Scan|Specificity Analysis in Subjects With Autopsy Within 1 Year of Scan,Avid Radiopharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,110,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-45-A16,Mar-10,Mar-11,Jul-11,6-Oct-11,7-May-12,22-May-12,"Research Site, Phoeniz, Arizona, United States|Research Site, Sun City, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Irvine, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Baltimore, Maryland, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Albany, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Centerville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Charleston, South Carolina, United States|Research Site, Johnson City, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01447719
NCT01439555,Endothelial Facilitation in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Simvastatin|Drug: L-Arginine|Drug: Tetrahydrobiopterin,Change in regional cerebral blood flow|Psychometric evaluation|Mini Mental State Examination (MMSE) scores|Cognitive Assessment Screening Test (CAST)|Clinical Dementia Rating Scale (CDR)|Alzheimer's Disease Assessment Scale: Cognitive and Modified Version (ADAS-COG)|Clinical Interview Based Impression of Change + Caregiver Input (CIBIC Plus),"University of Massachusetts, Worcester|The Glass Foundation",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13748,Nov-11,Nov-17,Nov-17,23-Sep-11,null,3-Apr-19,"UMass Medical School/ UMass Memorial Medical Center, Worcester, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT01439555/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01439555
NCT01438060,Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type,,Completed,Has Results,"Dementia, Alzheimer Type",Drug: Aripiprazole (BMS-337039)|Drug: Placebo,"Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase|Change From Baseline in NPI Psychosis Subscale Score Through Week 8 in Acute Phase|Change From Baseline in NPI Total Score in Acute Phase|Participants Who Demonstrated a ≥ 50% Decrease From Baseline to Endpoint in the NPI Psychosis Subscale Score in Acute Phase|Participants Who Demonstrated a ≥ 50% Decrease From Baseline in the Total NPI Score in Acute Phase|Change From Baseline in NPI Psychosis Subscale Caregiver Distress Score in Acute Phase|Change From Baseline in NPI Total Caregiver Distress Score in Acute Phase|Change From Baseline in Clinical Global Impression (CGI) Severity of Illness Score in Acute Phase|CGI Improvement Score in Acute Phase|Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Score in Acute Phase|Change From Baseline in Mini Mental State Examination (MMSE) Total Score in Acute Phase|Change From Baseline in NPI Individual Item Scores in Acute Phase: Delusions|Change From Baseline in NPI Individual Item Scores in Acute Phase: Hallucinations|Change From Baseline in NPI Individual Item Scores in Acute Phase: Agitation/Aggression|Change From Baseline in NPI Individual Item Scores in Acute Phase: Depression/Dysphoria|Change From Baseline in NPI Individual Item Scores in Acute Phase: Anxiety|Change From Baseline in NPI Individual Item Scores in Acute Phase: Apathy/Indifference|Change From Baseline in NPI Individual Item Scores in Acute Phase: Elation/Euphoria|Change From Baseline in NPI Individual Item Scores in Acute Phase: Disinhibition|Change From Baseline in NPI Individual Item Scores in Acute Phase: Irritability/Lability|Change From Baseline in NPI Individual Item Scores in Acute Phase: Aberrant Motor Behavior|Change From Baseline in NPI Individual Item Scores in Acute Phase: Appetite/Eating Behaviors|Change From Baseline in NPI Individual Item Scores in Acute Phase: Sleep|Change From Baseline in Simpson-Angus Scale (SAS) Total Score in Acute Phase|Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score in Acute Phase|Change From Baseline in Barnes Global Clinical Assessment of Akathisia in Acute Phase|Participants With Extrapyramidal Symptoms (EPS) Related Adverse Events in Acute Phase|Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AEs in Acute Phase|Participants With Potentially Clinically Significant Laboratory Abnormalities in Acute Phase|Participants With Potentially Clinically Significant (PCS) Vital Sign Abnormalities in Acute Phase|Participants With Potentially Clinically Significant Electrocardiogram Abnormalities in Acute Phase|Change in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score From Baseline During Extension Phase|Clinical Global Impression (CGI) Improvement Score During Extension Phase|Change in Abnormal Involuntary Movement Scale (AIMS) Total Score During Extension Phase|Change in Simpson-Angus Scale (SAS) Total Score During Extension Phase|Change in Barnes Global Clinical Assessment of Akathisia Score During Extension Phase|Participants With Extrapyramidal Symptoms (EPS) Related Adverse Events During Extension Phase|Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AE During Extension Phase|Participants With a Potentially Clinically Significant Vital Sign Abnormality During Extension Phase|Participants With a Potentially Clinically Significant Electrocardiogram Abnormalities During Extension Phase|Participants With Potentially Clinically Significant Laboratory Abnormalities During Extension Phase|Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AE During Treatment Beyond 140 Weeks","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical",All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 3,232,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CN138-006,Aug-00,Jul-10,Jul-10,21-Sep-11,5-Mar-12,2-Dec-13,,,https://ClinicalTrials.gov/show/NCT01438060
NCT01436045,Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.,,Completed,Has Results,Alzheimer's Disease,Drug: Insulin glulisine|Drug: Saline,Cognitive Performance|Trails B - Seconds|Trails B - Errors|Olfactory Function,HealthPartners Institute,All,65 Years to 85 Years   (Older Adult),Phase 2,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-111,Sep-11,Jun-13,Jun-13,19-Sep-11,19-Oct-15,19-Oct-15,"HealthPartners Specialty Center - Center for Dementia & Alzheimer's Care, St. Paul, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01436045
NCT01436188,A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease,,Completed,No Results Available,Healthy|Alzheimer Disease,Procedure: Standard CSR sampling procedure|Procedure: Alternate frequency CSR sampling procedure|Procedure: Standard frequent CSR sampling procedure with 800 mg ibuprofen|Procedure: Alternative lower frequency CSR sampling procedure,Measurement of CSF proteins|The number of volunteers with adverse events,"Janssen Research & Development, LLC",All,"50 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,5,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),CR100658|NOCOMPOUNDEDI0001|2011-003525-94,Sep-11,null,Jun-13,19-Sep-11,null,18-Mar-14,"Antwerp, Belgium|Groningen, Netherlands|Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT01436188
NCT01434667,Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV,,Completed,Has Results,Mild Cognitive Impairment,Behavioral: APOE genotype and Alzheimer's disease risk disclosure|Behavioral: Alzheimer's disease risk disclosure,Geriatric Depression Scale|Mini State Trait Anxiety Inventory|Impact of Event Scale (IES)|Psychological Impact of Test Disclosure (IGT-AD)|Recall and Comprehension of Risk Information|Participant Satisfaction|User Ratings of Risk Assessment Experience|Health Behavior and Insurance Changes|Insurance and Advance Planning Changes|Participation in Alzheimer's Disease-related Research After Receiving the Alzheimer's Disease Risk Estimate.,Brigham and Women's Hospital|National Human Genome Research Institute (NHGRI)|University of Michigan|University of Pennsylvania|Howard University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,146,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,R01HG002213,Jan-10,Jul-14,Jul-14,15-Sep-11,23-Oct-18,23-Oct-18,"Howard University, Washington, District of Columbia, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01434667
NCT01434940,Eye Movement Recording as an Early Differential Diagnostic Tool for Alzheimer/Depression,MOMAD,Recruiting,No Results Available,Alzheimer Disease|Depression,Other: Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam,pro-saccade task|anti-saccade task|predictive saccade task|scan of images pair with emotional connotation|portrait analysis,Centre Hospitalier Universitaire de Besancon|Laboratoire de psychologie EA 3188|Centre Hospitalier Universitaire Dijon|Centre Hospitalier de Novillars,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,288,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,N/2009/55,Apr-10,Jan-18,Jul-18,15-Sep-11,null,31-Jul-17,"Univserity Hospital of Besançon - Psychiatry Department, Besançon, France",,https://ClinicalTrials.gov/show/NCT01434940
NCT01430286,Web-based Psycho-Educational Program to Support Carers of Alzheimer's Patients,DIAPASON,Completed,No Results Available,Alzheimer Disease,"Behavioral: psycho-social intervention based on a web-based psycho-educational program, called Diapason.|Behavioral: Consultation in memory clinic",Perceived stress|Nottingham Health Profile (NPH)|ZARIT Burden Interview (BI)|Revised Memory and Behavior Problems Checklist (RMBPC)|Beck Depression Inventory (BDI-2)|Revised Scale for Caregiving Self-Efficacy (RCSE),Assistance Publique - Hôpitaux de Paris|Direction de l’Hospitalisation et de l’Organisation des Soins (PREQHOS)|Fondation Médéric Alzheimer,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,49,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,P081002,Oct-11,May-14,Jul-14,8-Sep-11,null,19-Mar-18,"Hôpital Broca - la Collégiale, Geriatric Unit, Memory Clinic, Paris, France",,https://ClinicalTrials.gov/show/NCT01430286
NCT01429623,A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment,,Completed,Has Results,Mild Cognitive Impairment|Dementia,Drug: ladostigil hemitartrate|Drug: Placebo,Conversion From Mild Cognitive Impairment to Alzheimer's Disease Compared to Placebo|Change in Geriatric Depression Scale for Ladostigil Versus Placebo Population|Change in Neuropsychiatric Test Battery for Ladostigil Versus Placebo Population|Change in Disability Assessment in Dementia for Ladostigil Versus Placebo Population,Avraham Pharmaceuticals Ltd,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,210,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CO17730|2011-004187-30,Feb-12,Jul-16,Sep-16,7-Sep-11,15-Jun-17,15-Jun-17,"Medizinische Universitat Graz, Abteilung fur Neurologie, Graz, Austria|Landeskrankenhaus Hall, Memory Klinik, Hall in Tirol, Austria|Privatordination Rainer, Wien, Austria|Studienambulanz St. Joseph Krankenhaus Berlin, Emovis GmbH, Berlin, Germany|Otto-von-Guericke-Universitat, Universitatsklinik fur Neurologie und fur Stereotaktische, Magdeburg, Germany|Studienzentrum Nordwest, Westerstede, Germany|Department of Geriatrics and Memory Clinic, Mental Health Center, Israel, Beersheva, Israel|Cognitive Neurology Unit, Rambam Health Care Campus, Haifa, Israel|Cognitive Clinic, Department of Geriatrics, Carmel Medical Center, Haifa, Israel|Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, PO Box 24035, Jerusalem, Israel|Memory Clinic, Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel|Center for Memory and Attention Disorders, Department of Neurology, Sourasky Medical Center, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01429623
NCT01428362,VI-1121 for the Treatment Alzheimer's Disease,AD-201,Completed,No Results Available,Alzheimer's Disease,Drug: VI-1121|Drug: Placebo,"The primary efficacy variable is the change in Alzheimer's Disease Assessment-Cognitive Subscale (ADAS-Cog) score from baseline to Week 12 of each treatment period.|The secondary efficacy endpoint is the mean change in Mini-Mental State Examination (MMSE) score from baseline to Week 12 of each treatment period.|Percentage of subjects who achieve 3-point improvement in ADAS-Cog score from baseline to Week 12 of each treatment period.|Change in Clinician's Interview Based Impression of Change Plus Caregiver's Input (CIBIC-plus) score from baseline to Week 12 of each treatment period|Mean change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) score from baseline to Weeks 4, 8, and 12 of each treatment period","VIVUS, Inc.|Medpace, Inc.",All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,61,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AD-201,Aug-11,Aug-13,Aug-13,5-Sep-11,null,11-Dec-13,"San Francisco, California, United States|Santa Monica, California, United States|Sunrise, Florida, United States|Louisville, Kentucky, United States|Las Vegas, Nevada, United States|Toms River, New Jersey, United States|New Windsor, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Toledo, Ohio, United States|Plano, Texas, United States",,https://ClinicalTrials.gov/show/NCT01428362
NCT01428453,A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: 250mg rilapladib|Drug: placebo,Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24|Change From Baseline (Day 0) in CSF Abeta42/ Abeta40 Ratio at Week 24|Change From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24|Change From Baseline (Day 0) in the Computerized Test Battery for Cognition (CogState) Battery Working Memory/Executive Function (WM/EF) Composite Score at Week 24|Change From Baseline (Day 0) in CSF Albumin Quotients at Week 24|Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24|Change From Baseline (Day 0) in Plasma Levels of Abeta42/Abeta40 Ratio at Week 24|Percentage Inhibition in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity at Week 24|Change From Baseline (Day 0) in CogState Battery Overall Composite Score|Change From Baseline (Day 0) in CogState Battery Attention Composite Score,GlaxoSmithKline,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,124,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",114458,1-Oct-11,4-Feb-13,18-Feb-13,5-Sep-11,24-Sep-18,24-Sep-18,"GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Gatineau, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Alzenau, Bayern, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Oldenburg, Schleswig-Holstein, Germany|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Brescia, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Verona, Veneto, Italy|GSK Investigational Site, Lørenskog, Norway|GSK Investigational Site, Baracaldo/Vizcaya, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Castellón de La Plana, Spain|GSK Investigational Site, Getafe/Madrid, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01428453
NCT01425957,Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment,,Completed,No Results Available,MILD COGNITIVE IMPAIRMENT,Procedure: Lumbar puncture,Part A: Magnetic Resonance Imagery protocol|Part B: Changes of the hippocampal volume|Part B: Clinical assessment|Part B: Neuropsychology|Part B: Neurophysiology|Part B: Magnetic Resonance Imagery and functional MRI|Part B: Blood drawing|Part B: Actigraphy|Adverse events,Qualissima|European Union,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,229,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,WP5P001|2011-A00985-36,Dec-11,Aug-15,Oct-15,30-Aug-11,null,2-Nov-15,"Université Lille 2, UL2 - Centre d'investigation clinique / Centre de Ressources biologiques 9301 - INSERM - Centre Hospitalier Régional et Universitaire de LILLE, Lille, France|APHM, Hopital de la Timone, Service de Neurologie et Neuropsychologie, Marseille, France|INSERM - CHU Purpan, Toulouse, France|Hospital and Institute of the University of Duisburg and Essen - Department for Psychiatry and Psychotherapy, LVR Hospital Essen, Essen, Germany|University Hospital of Leipzig - Department of Psychiatry, Leipzig, Germany|Aristotle University of Thessaloniki, Greek Association of Alzheimer's disease and related disorders, Thessaloniki, Greece, Thessaloniki, Greece|IRCCS-FBF - Ordine Ospedaliero San Giovanni di Dio, Fatebenefratelli, Istituto di Ricovero e Cura a Carattere Scientifico, Brescia, Provincia Lombardo-Veneta, Italy|Neurofisiologia Clinica IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Padiglione Specialita' piano Fondi, Genoa, Italy|IRCCS Fondazione SDN per la Ricerca e l'Alta Formazione in Diagnostica Nucleare di Napoli, Napoli, Italy|Dipartimento di Specialità medico-chirurgiche e Sanità Pubblica, Sezione di Clinica Neurologica, Centro Disturbi della Memoria, Perugia, Italy, Perugia, Italy|Università Cattolica del Sacro Cuore - Policlinico Agostino Gemelli Istituto di Neurologia - Neuropsychological and Neurorehabilitation Unit, Roma, Italy|VUmc Alzheimercentrum, Amsterdam, Netherlands|Institut d'Investigacions Biomèdiques August Pi I Sunyer, IDIBAPS, Barcelona, Catalunya, Spain",,https://ClinicalTrials.gov/show/NCT01425957
NCT01424436,Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient,,Completed,No Results Available,Alzheimer's Disease,Biological: GSK933776,"The temporal changes of amyloid beta levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|The temporal changes of total and free amyloid beta levels in plasma after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|The temporal changes of Tau and phosphor Tau - 181 levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|Estimated pharmacokinetic parameters of AUC, Cmax and Tmax in CSF and plasma at multiple time points with various intervals.|To assess the safety and tolerability after single dose of GSK933776 administration.",GlaxoSmithKline,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,19,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,113043,19-May-10,8-Dec-11,8-Dec-11,29-Aug-11,null,14-Jun-17,"GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01424436
NCT01423396,Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease,COVARAD,Recruiting,No Results Available,Alzheimer's Disease|Cardiovascular Risk Factors,Other: optimal care of VRF|Other: standard care,ADAS-Cog|MMSE|MoCA|VADAS-Cog|Trail Making Test|ADL-ADCS|IADL|MADRS|NPI|Zarit Inventory of Burden,"University Hospital, Lille|Ministry of Health, France",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,406,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2008_28/0914|2009-A00269-48|PHRC 2008/1925|B90419-40,15-Mar-10,Mar-21,Mar-21,25-Aug-11,null,15-Feb-19,"CMRR Lille hopital Roger Salengro, Lille, France",,https://ClinicalTrials.gov/show/NCT01423396
NCT01421056,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP),,Completed,No Results Available,Alzheimer's Disease,Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x,Determine maximum tolerated dose of CHF 5074 after multiple oral once daily administration to patients with mild cognitive impairment,Chiesi USA,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,74,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCD-1014-PR-0053 OLEP|2010-024270-19,Jul-11,Nov-12,Nov-12,22-Aug-11,null,6-Feb-14,"Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Memory Center of New Jersey, Inc., Monroe Twp, New Jersey, United States|Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States|Senior Adults Specialty Research, Austin, Texas, United States|Clinica Santa Maria, Div Neurologia, Castellanza, Italy|Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milano, Italy",,https://ClinicalTrials.gov/show/NCT01421056
NCT01416012,Health Related Quality of Life Effects of Off-the-shelf Computer Gaming in Alzheimer and Related Disorders Populations,,Unknown status,No Results Available,Disease Alzheimer,Behavioral: Physical Therapy (standard)|Behavioral: Balance and Gait training in Individualized sessions|Behavioral: Kinect|Behavioral: Group Xbox Kinect,questionnaires on quality of life|tests on health,Centre Hospitalier Universitaire de Nice,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),11-PP-06,Oct-11,Oct-11,Sep-13,12-Aug-11,null,24-Apr-13,"The University of Queensland, St Lucia, Australia|CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez, Nice, Alpes-Maritimes, France|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT01416012
NCT01409564,Cilostazol Augmentation Study in Dementia,,Completed,Has Results,Alzheimer's Dementia,Drug: Cilostazol|Drug: Placebo,Regionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method|Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog)|Mini-Mental State Examination (MMSE) in the Korean Version of the CERAD Assessment Packet)|Activities of Daily Living (ADCS-ADL)|Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)|Fazekas Scale,Seoul National University Hospital|Korea OIAA,All,"60 Years and older   (Adult, Older Adult)",Phase 4,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",06-2009-145,May-10,Jun-12,Jul-13,4-Aug-11,13-May-14,13-May-14,"SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01409564
NCT01409694,Alzheimer's Disease - Input of Vitamin D With mEmantine Assay,AD-IDEA,Completed,No Results Available,Alzheimer Disease,Drug: Memantine|Drug: Vitamin D|Drug: Vitamin D placebo,Change in cognitive performance|Change in other cognitive scores|Change in functional performance|Change in posture and gait|Between-group comparison of compliance to treatment and tolerance,"University Hospital, Angers",All,"60 Years and older   (Adult, Older Adult)",Phase 3,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2010-024506-35,Sep-11,Jan-16,Jan-16,4-Aug-11,null,22-Sep-16,"University Hospital, Angers, France",,https://ClinicalTrials.gov/show/NCT01409694
NCT01409915,Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: Sagramostim|Drug: Saline -- placebo comparator,Ability of Alzheimer's Disease subjects to tolerate Leukine treatment will be assessed|Ability of Leukine treatment to improve cognition of Alzheimer's Disease subjects,"University of Colorado, Denver|The Dana Foundation",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12-1273,Mar-11,1-May-20,30-May-20,4-Aug-11,null,17-Apr-19,"University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01409915
NCT01406145,A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil,,Completed,No Results Available,Alzheimer's Disease,Drug: ASP0777|Drug: Placebo,"Number and percentage of subjects with adverse events|Pharmacokinetic assessment of AUC, maximum concentration (Cmax), minimum concentration (Cmin) and time to maximum concentration (tmax) through analysis of blood samples",Astellas Pharma Inc,All,"50 Years and older   (Adult, Older Adult)",Phase 1,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0777-CL-0030,16-Jun-11,4-Nov-11,4-Nov-11,1-Aug-11,null,30-Jan-19,"Pacific Research Network, Inc., San Diego, California, United States|MD Clinical, Hallandale Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT01406145
NCT01404169,"A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Type Dementia,Drug: E2020|Drug: Placebo,The change in the total Severe Impairment Battery (SIB) score at Week 24|Clinician Interview-Based Impression of Severity (CIBIC)+ overall score at Week 24,Eisai Limited|Eisai Inc.,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,260,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E2020-C086-339,Sep-11,Jul-14,Sep-14,27-Jul-11,null,8-Mar-17,"Beijing Anding Hospital, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Beijing Huilongguan Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Xuanwu Hospital Capital Medical University, Beijing, Beijing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Guangzhou Brain Hospital, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China|Union Hospital, Tongji Medical college Huazhong University of Science and Technology, Wuhan, Hubei, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|The First People's Hospital of YueYang, Yueyang, Hunan, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|The Affiliated Hospital of Medical College Qingdao University, Qingdao, Shandong, China|Hushan Hospital affliated to Fudan University, Shanghai, Shanghai, China|Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Shanghai Ruijin Hospital, Shanghai, Shanghai, China|Tangdu Hospital, The Fourth Military Medical University, Xi'An, Shanxi, China|Xi'An Mental Health Center, Xi'An, Shanxi, China|Xijing Hospital, The Fourth Military Medical University, Xi'An, Shanxi, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|The Second Affiliated Hospital to Nanchang University, Nanchang, China|Nanjing Brain Hospital, Nanjing Jiangsu, China|Tianjin Anding Hospital, Tianjin, China|Tianjin People's Hospital, Tianjin, China",,https://ClinicalTrials.gov/show/NCT01404169
NCT01399125,"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease",,Completed,Has Results,Alzheimer's Disease,Drug: Rivastigmine Patch|Drug: Rivastigmine Capsules|Drug: Placebo to Rivastigmine patch|Drug: Placebo to Rivastigmine capsules,"Change From Baseline on Cognition, Assessed by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)|Change From Baseline in Global Functioning, Assessed by the Alzheimer's Disease Assessment Scale Clinical Impression of Change (ADCS-CGIC)|Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Total Score|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score|Change From Baseline in Mini-Mental State Examination (MMSE) Total Score",Novartis Pharmaceuticals|Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,501,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CENA713D2344,Jul-11,May-13,May-13,21-Jul-11,4-Aug-14,4-Aug-14,"Novartis Investigative Site, Fuzhou, Fujian, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Suzhou, Jiangsu, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01399125
NCT01397539,Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: BIIB037|Other: Placebo,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Area Under the Curve from Time Zero Extrapolated to Infinity [AUC0-∞]|Area Under the Curve from Time 0 to Time of the Last Measurable Concentration [AUC0-tlast]|Maximum Concentration [Cmax] of BIIB037|Time to Cmax [Tmax]|Elimination Half-life [t1/2]|Clearance [Cl]|Incidence of Anti-BIIB037 Antibodies in Serum,Biogen,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,53,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",221AD101,Jun-11,Aug-13,Aug-13,19-Jul-11,null,23-Mar-15,"Brain Matters Research, Delray Beach, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Insight Clinical Trials, LLC, Beachwood, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01397539
NCT01397578,A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: MABT5102A|Drug: placebo,Change in brain amyloid load as assessed by amyloid PET imaging|Changes in cerebrospinal fluid (CSF) biomarkers relevant to Alzheimer's disease|Change in brain metabolism as assessed by 18F-fluorodeoxyglucose positron emission tomography (FDG PET) imaging|Change in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS Cog) score,"Genentech, Inc.",All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,91,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ABE4955g|GN00762,31-Aug-11,30-Apr-14,30-Apr-14,19-Jul-11,null,12-Jul-17,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|NNS Clinical Research LLC, Tucson, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|University of California Los Angeles (UCLA), Los Angeles, California, United States|Pacific Neuroscience Med Grp, Oxnard, California, United States|Stanford Univ Medical Center, Palo Alto, California, United States|Redwood Regional Medical Group, Santa Rosa, California, United States|Internal Med Assoc of Lee Cty, Fort Myers, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Compass Research, Orlando, Florida, United States|Dekalb Neurology Associates, Decatur, Georgia, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Litwin Zucker Research Ctr.; Feinstein Inst. Med. Rsch., Manhasset, New York, United States|Neurology & Neuroscience Ctr of Ohio, Toledo, Ohio, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Hopital Central-CHU de Nancy; Pharmacie, Nancy, France|Hôpital Casselardit; Cons memoire, Toulouse, France|Clinique Psychiatrique Univ, Tours Cedex 9, France|Fundació ACE, BArcelon, Barcelona, Spain|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Mutua De Terrasa, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT01397578
NCT01388478,Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: R-pramipexole,Number of Patients with Adverse Events|Reduction of Oxidative Stress|Changes in cerebral glucose metabolism|Effects on Cognitive Performance,Virginia Commonwealth University|University of Kansas Medical Center|Alzheimer’s Drug Discovery Foundation,All,"55 Years and older   (Adult, Older Adult)",Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VCU-KU-ADDF-2011|20101202,Jul-11,Jan-14,Apr-14,6-Jul-11,null,25-Apr-16,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01388478
NCT01384344,Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Video Recognition and Actigraphy,,Completed,No Results Available,Alzheimer Disease,Other: observational,"stride and speed walking|For comparison between Alzheimer disease patients with (n=20) or without apathy, we use again stride and speed walking|For reproducibility, we use stride and speed walking|Reliability is the sum of posture's concordance|Relation between LF/HF variations and activity index",Centre Hospitalier Universitaire de Nice,All,65 Years and older   (Older Adult),Not Applicable,82,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11-PP-03,Jun-11,Dec-11,Jun-12,29-Jun-11,null,18-Dec-12,"Hôpital de Cimiez, Nice, France",,https://ClinicalTrials.gov/show/NCT01384344
NCT01385033,[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002),,Terminated,Has Results,Alzheimer's Disease,Drug: [18F]MK-3328,Area Under the Receiver Operating Curve (AUC of ROC) for Distinguishing Between AD and HE Participants Based on Brain Cortical [18F]MK-3328 Standard Uptake Value Ratio (SUVR)|Brain Cortical [18F]MK-3328 SUVR in AD Participants and HE Participants|Amyloid Plaque Burden Threshold Determined by the Trimmed HE Sample Mean and SD Brain Cortical [18F]MK-3328 SUVR,Merck Sharp & Dohme Corp.,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,3328-002,19-Aug-11,15-May-12,15-May-12,29-Jun-11,20-Feb-14,8-Nov-18,,,https://ClinicalTrials.gov/show/NCT01385033
NCT01380288,Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine,CAREER,Completed,No Results Available,Alzheimer's Disease,Drug: rivastigmine patch,The changes of cognitive function as measured by ADAS-Cog|MMSE (Mini-Mental State Examination)|Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI)|Caregiver burden scale|Adverse events,Dong-A University|Novartis Korea Ltd.,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,300,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,neuropark,Jun-11,Dec-16,31-Dec-17,27-Jun-11,null,5-Feb-18,"Holy Family Hospital, The Catholic Univerisy of Korea, School of Medicine, Bucheon, Korea, Republic of|Busan National University Hospital, Busan, Korea, Republic of|Busan Paik Hospital, Inje University College of Medicine, Busan, Korea, Republic of|Changwon Fatima Hospital, Changwon, Korea, Republic of|Daegu Fatima Hospital, Daegu, Korea, Republic of|Keimyung University School of Medicine, Daegu, Korea, Republic of|Kyungpook National University School of Medicine, Daegu, Korea, Republic of|Myongji Hospital, Kwandong University College of Medicine, Goyang, Korea, Republic of|Dongguk University International Hospital, Ilsan, Korea, Republic of|National Health Insurance Corporation Ilsan Hospital, Ilsan, Korea, Republic of|Inha University College of Medicine, Incheon, Korea, Republic of|Gyeongsang National University College of Medicine, Jinju, Korea, Republic of|Chonnam National University, Medical School, Kwangju, Korea, Republic of|Seoul National Unviersity College of Medicine, Clinical neuroscience center, Seoul National Unviersity Bundang Hospital, Seongnam, Korea, Republic of|The Catholic Univerisy of Korea, School of Medicine, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01380288
NCT01378195,iCare Stress Management e-Training for Dementia Family Caregivers,iCare,Completed,Has Results,Alzheimer's Disease|Dementia,Behavioral: CBT-based program for dementia caregivers|Behavioral: Educational/Resources program,Perceived Stress Scale|Revised Memory and Behavior Problems Checklist|Perceived Quality of Life,"Photozig, Inc.|Stanford University|National Institute on Aging (NIA)",All,"21 Years and older   (Adult, Older Adult)",Phase 2,150,Industry|Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pz-A103a|R44AG032762,May-11,Jul-12,Jul-12,22-Jun-11,8-Jan-13,28-Feb-13,"Photozig, Inc., Moffett Field, California, United States",,https://ClinicalTrials.gov/show/NCT01378195
NCT01374438,"3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease",,Completed,Has Results,Alzheimer's Disease,Drug: MSDC-0160|Drug: Placebo,Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum|Change From Baseline in Global Cognitive Function Tests|Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale|Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale|Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks,Metabolic Solutions Development Company,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,29,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSDC-0160-C006,Jul-11,Mar-13,May-13,16-Jun-11,5-Nov-14,18-Nov-14,"Rush Memorial University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01374438
NCT01371214,Preventing Loss of Independence Through Exercise (PLIÉ) - Pilot,PLIÉ-pilot,Completed,No Results Available,Dementia,Behavioral: PLIÉ (Preventing Loss of Independence through Exercise),Change in physical function (participant)|Change in quality of life (participant)|Change in functional health and well-being (participant)|Change in number of falls (participant)|Change in fall-related self-efficacy (participant)|Change in physical performance (participant)|Change in cognitive function (participant)|Compliance (participant)|Adverse events (participant)|Change in dementia-related behaviors (participant)|Change in functional health and well-being (caregiver)|Change in burden (caregiver),"University of California, San Francisco",All,"Child, Adult, Older Adult",Phase 1,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,10-04080-023906,Jun-11,Sep-12,Sep-12,10-Jun-11,null,3-Jun-15,"Irene Swindells Center for Adult Day Services, Institute on Aging, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01371214
NCT01369225,Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: AAB-003 (PF-05236812),Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern|Number of Participants With Potentially Clinically Important Vital Sign Findings|Number of Participants With Potentially Clinically Important Electrocardiogram (ECG) Findings|Number of Participants With Abnormal Physical Examination Findings|Number of Participants With Abnormal Neurological Examination Findings|Number of Participants With Suicidal Ideation or Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Number of Participants With Any New Magnetic Resonance Imaging (MRI) Findings,"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,52,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B2601003,Jul-11,Aug-14,Aug-14,8-Jun-11,10-Mar-17,10-Mar-17,"MD Clinical, Hallandale Beach, Florida, United States|Munroe Regional Medical Center, Ocala, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Trinity Care Solutions, Ocala, Florida, United States|Advanced Imaging of Ocala, Ocala, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Foers Medical Arts Pharmacy, Bethesda, Maryland, United States|CBH Health, LLC, Rockville, Maryland, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|KNI Southwest Michigan Imaging Center, LLC, Kalamazoo, Michigan, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|DePaul Health Center-MRI Department, St. Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Central Jersey Radiology, Oakhurst, New Jersey, United States|Seoul National University Hospital, Department Neurology, Seongnam-si, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Department of Neurology, Incheon, Korea, Republic of|Samsung Medical Center, Department of Neurology, Seoul, Korea, Republic of|Korea University Anam Hospital IRB, Seoul, Korea, Republic of|ASAN Medical Center, Seoul, Korea, Republic of|Konkuk University Medical Center, Department of Neurology, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01369225
NCT01362686,Comparative Research of Alzheimer's Disease Drugs,COMET-AD,Terminated,Has Results,Dementia|Alzheimer's Disease,Drug: Donepezil|Drug: Galantamine|Drug: Rivastigmine,Discontinuation Rates|Neuropsychiatric Inventory (NPI)|Healthy Aging Brain Care (HABC)-Monitor,Indiana University|Agency for Healthcare Research and Quality (AHRQ),All,65 Years and older   (Older Adult),Not Applicable,200,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01HS019818-01,Apr-11,Oct-15,Oct-15,30-May-11,27-Feb-17,27-Feb-17,"Touchpoint, Fishers, Indiana, United States|Methodist Center for Geriatric Medicine, Indianapolis, Indiana, United States|University Clinical Neurology, Indianapolis, Indiana, United States|Wishard Health Services, Indianapolis, Indiana, United States|St. Vincent Center for Healthy Aging, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT01362686
NCT01354691,Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Dementia|Memory Loss|Cognitive Impairment,Drug: ladostigil hemitartrate,ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale|Safety Evaluation|Neuropsychiatric Inventory (NPI)|Cornell Scale for Depression in Dementia (CSDD)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Mini-Mental State Examination (MMSE)|ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive Subscale,Avraham Pharmaceuticals Ltd,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,201,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR100101/CO15570,Feb-11,Sep-12,Mar-13,17-May-11,null,23-Jul-13,"Medizinische Univeritat Graz, Universitatsklinik fur Neurologie, Auenbruggerplatz 22, Graz, Austria|Privatordination Horn, HamerlingstraBe 15, Horn, Austria|Allgemeines Krankenhaus der Stadt Linz, KrankenhausstraBe 9, Linz, Austria|Privatordination, Lainzerstrasse 20, Wein, Austria|General Hospital Pula, Negrijeva 6, Pula, Croatia|General Hospital Zabok, Bracak 8, Zabok, Croatia|Clinical Hospital Center Zagreb, Kispaticeva 12, Zagreb, Croatia|Clinical Hospital Dubrava, Avenija Gojka Suska 6, Zagreb, Croatia|Polyclinic Neuron, Salata 12, Zagreb, Croatia|Psychiatric Hospital Vrapce, Bolnicka cesta 32, Zagreb, Croatia|Klinische Forschung Hamburg GmbH, Hoheluftaussee 18, Hanburg, Germany|Klinische Forschung Schwerin GmbH, FriedrichstraBe 1, Schwerin, Germany|Studienzentrum Nordwest, Lange StraBe 23-25, Westerstede, Germany|Clinical Centre of Serbia, Dr. Subotica 6, Beograd, Serbia|Military Medical Academy, Crnotravska 17, Beograd, Serbia|CAE Oroitu Centro Atencion Especializada C/Jata, 9, Algorta (Vizcaya), Spain|Centro Geroinnova Barcelona, Calle Mandoni n 17, Barcelona, Spain|Fundacio ACE, Institut Catala de Neurosciencies Aplicadas, C/Margues de Sentmenat 35-37, Barcelona, Spain|Institud d' Assistencia Sanitaria de Girona, Edifici La Republica - C/Dr. Castany, s/n, SALT (Girona), Spain",,https://ClinicalTrials.gov/show/NCT01354691
NCT01354444,Trial of Carvedilol in Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Carvedilol|Drug: Placebo,"Hopkins Verbal Learning Test (HVLT) Scores at Baseline, 3, and 6 Months|Effect of Carvedilol Treatment in Cerebrospinal Fluid (CSF) Levels of Amyloid-beta Oligomers",Johns Hopkins University|Icahn School of Medicine at Mount Sinai,All,"up to 100 Years   (Child, Adult, Older Adult)",Phase 4,29,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NA_00035546,Jun-11,Dec-16,Jan-17,16-May-11,6-Feb-18,6-Feb-18,"Johns Hopkins School of Medicine Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01354444
NCT01351142,Cytokines and Cognitive Decline in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Other: blood test and cognitive tests,,Poitiers University Hospital,All,"Child, Adult, Older Adult",Not Applicable,133,Other,Interventional,Intervention Model: Single Group Assignment,CYTOCOGMA,Nov-09,Nov-13,null,10-May-11,null,11-Oct-16,"CHU Angers - service Gérontologie clinique, Angers, France|Hôpital Dupuytren - CHU de Limoges, Limoges, France|CHU de NANTES - service Gériatrie, Nantes, France|CHU DE NANTES - Centre ambulatoire de Gérontologie clinique, Nantes, France|Hôpital Broca - service de Gériatrie, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Chu de Poitiers -, Poitiers, France|Chu Strasbourg, Strasbourg, France|CHU de TOURS - service de Gériatrie, Tours, France|Hôpital gériatrique des Charpennes, Villeurbanne, France",,https://ClinicalTrials.gov/show/NCT01351142
NCT01350362,"Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients",ARGO,Completed,No Results Available,Alzheimer's Disease,Drug: tideglusib|Drug: Placebo,"ADAS-Cog+|Adverse events (AEs): Number of AEs and patients with an incidence rate of ≥ 5% AEs|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Alzheimer's Disease Cooperative Study Unit Activities of Daily Living (ADCS-ADL).|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Mini Mental State Examination (MMSE)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Word Fluency test|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Neuropsychiatric Inventory (NPI)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Geriatric Depression Scale (GDS)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Clinical Global Impression of Change (CGIC)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the European Quality of life Instrument (EQ-5D)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Caregiver time (RUD Lite)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Questionnaire on urinary incontinence|Exploratory Endpoints (only in a subgroup of patients at predefined sites): Change from Baseline of the 3 active study medication groups will be compared with the placebo group in levels of τ, phospho-τ, and β−amyloid in CSF and change in MRI measures.",Noscira SA|ICON Clinical Research,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,306,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP031112-10B04,Apr-11,Jul-12,Oct-12,9-May-11,null,2-Oct-12,"Leuven and 4 additional cities, Belgium|Turku and 3 additional cities, Finland|Paris and 10 additional cities, France|Freiburg and 5 additional cities, Germany|Madrid and 7 additional cities, Spain|London and 11 additional cities, United Kingdom",,https://ClinicalTrials.gov/show/NCT01350362
NCT01348737,"Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers",,Completed,No Results Available,Alzheimer's Disease|Safety|Tolerability|Blood Concentration|Healthy Volunteers,Drug: AZD3839|Drug: AZD3839 Placebo,Number of Adverse Event as a measure of safety and tolerability of AZD3839 (Part 1)|Number of Adverse Events as a measure of Safety and tolerability of AZD3839 (Part 2)|Time at which maximum concentration occurs in AZD3839 (Part 1)|Maximum observed concentration of AZD3839 in plasma (Part 1)|Time at which maximum concentration occurs in AZD3839 (Part 2)|Maximum observed concentration of AZD3839 in plasma (Part 2),AstraZeneca,All,18 Years to 55 Years   (Adult),Phase 1,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",D4080C00001|2011-001337-16,Jun-11,Nov-11,Nov-11,5-May-11,null,6-Apr-12,"Research Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01348737
NCT01343966,A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY),,Completed,No Results Available,Alzheimer's Disease,Drug: MABT5102A|Drug: placebo,"Change in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score|Change in Clinical Dementia Rating, Sum of Boxes (CDR-SOB) score|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score","Genentech, Inc.",All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,448,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ABE4869g|ABBY|GN00761,30-Apr-11,28-Feb-14,28-Feb-14,28-Apr-11,null,12-Jul-17,"Hope Research Institute, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Pharmacology Research Inst, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Univ of CA San Diego; Neurosciences Comp.Alzheimer's, La Jolla, California, United States|USC School of Medicine, Los Angeles, California, United States|Pharmacology Research Inst, Newport Beach, California, United States|University of California Davis Medical System, Sacramento, California, United States|Pacific Research Network - PRN, San Diego, California, United States|Uni of California San Francisco, San Francisco, California, United States|Neurological Research Inst, Santa Monica, California, United States|Yale University, New Haven, Connecticut, United States|Florida Atlantic University; College of Medicine, Boca Raton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Miami Jewish Health Systems; Clinical Research, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Compass Research, Orlando, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Rush Alzheimer's Disease Cntr., Chicago, Illinois, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|IU Healthy Partners Adult Neurology Clinic, Indianapolis, Indiana, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|Empire Neurology, PC, Latham, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center; Monroe Community Hospital, Rochester, New York, United States|Investigational Drug Service; Univ of Rochester Medical Ctr, Rochester, New York, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Neurology & Neuroscience Ctr of Ohio, Toledo, Ohio, United States|Clinical Trials of America, Inc., Eugene, Oregon, United States|Summit Research Network Inc., Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Medical Uni of South Carolina, North Charleston, South Carolina, United States|Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine, Houston, Texas, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|Saibal Nandy Professional Corporation, Medicine Hat, Alberta, Canada|The Med Arts Health Rsrch Grp, Kelowna, British Columbia, Canada|The Med Arts Health Rsrch Grp, Penticton, British Columbia, Canada|University of British Columbia Hospital; Division of Neurology, Vancouver, British Columbia, Canada|Capitol District Health Authority, Halilfax, Nova Scotia, Canada|Jbn Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Hotel Dieu Hospital, Kingston, Ontario, Canada|Providence Care Centre; Mental Health Site, Kingston, Ontario, Canada|St. Joseph's HC-Parkwood Hosp, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|Hôpital Maisonneuve-Rosemont/Polyclinique;Recherche Clinique, Montreal, Quebec, Canada|CHAUQ Hopital Enfant-Jesus, Quebec City, Quebec, Canada|McGill Univeristy; Douglas Mental Health University Institute; Neurological and Psychiatric, Verdun, Quebec, Canada|Groupe Hospitalier Pellegrin, Bordeaux, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|Chu Limoges, Limoges, France|Hopital Nord Laennec, Nantes, France|Hopital de Cimiez, Nice, France|Hopital Broca, Paris, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|Hôpital Casselardit; Cons memoire, Toulouse, France|Studienambulanz emovis GmbH; St. Joseph Krankenhaus, Berlin, Germany|Univ Berlin; Klin fur Psychi & Psycho Charite, Berlin, Germany|Universitätsklinikum Erlangen; Augenklinik, Erlangen, Germany|Bezirkskrankenhaus Günzburg, Günzburg, Germany|Zentralinstitut fuer Seelische Gesundheit, Mannheim, Germany|Inst fur Stedien zur Psych Ges, Mannheim, Germany|Psych Klin der LMU Muenchen, Muenchen, Germany|Ludwig-Maximilians-Univ., Munchen, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, Germany|Villa Sauer, Praxis für; Neurologie und Psychiatrie, Siegen, Germany|Universitätsklinik Tübingen; Psychiatrie und Psychotherapie, Tubingen, Germany|Hospital General de Catalunya, San Cugat del Valles, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital Perpetuo Socorro, Albacete, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Clinica Ruber, 4 planta; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Virgen de la Macarena;, Sevilla, Spain|The Rice Centre; Royal United Hospital, Bath, United Kingdom|West London Research Unit; Brentford Lodge, Brentford, United Kingdom|Royal Sussex County Hospital, CIRU Level 5, Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|The National Hospital for Neurology & Neurosurgery; Dementia Research Center, London, GT LON, United Kingdom|Camden Mews Day Hospital; Camden and Islington, London, United Kingdom|Southampton General Hospital; Pharmacy, Southampton, United Kingdom|Moorgreen Hospital; Memory Assessment & Rsch Ctr, Southampton, United Kingdom|Great Western Hosp.; Kingshill Research Ctr, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT01343966
NCT01339130,Assessment of Social-emotional Functioning in Neurological Diseases,Emotion,Completed,No Results Available,Alzheimer Disease|Stroke|Parkinson's Disease|Lewy Body Dementia|Huntington Disease,Behavioral: Computerized tests and Electrophysiological measurements,"Empathy ability|Empathy for pain|pattern of empathy disorders according to the disease (stroke, Mild cognitive impairment, Alzheimer disease and Parkinson disease","Centre Hospitalier Universitaire, Amiens",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,177,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PI09-PR-GODEFROY|2009-A00596-51,Jun-09,Jun-13,Jun-13,20-Apr-11,null,7-Sep-15,"CHU Amiens, Amiens, Picardie, France",,https://ClinicalTrials.gov/show/NCT01339130
NCT01339195,Post-stroke Cognitive Impairment and Dementia,GRECogVASC,Completed,No Results Available,Stroke|Cognitive Disorders|Behavioral Disorders,Behavioral: French adaptation of NINDS-Canadian Stroke Network battery,determine the frequency of cognitive and behavioral disorders 6 months post-stroke assessed with this new NINDS-Canadian Stroke Network battery|determine the proportion of patients with dementia|determine the value of cognitive screening tests,"Centre Hospitalier Universitaire, Amiens",All,"40 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1635,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AOL10-PR-GODEFROY|2010-A00657-32,Aug-10,Dec-16,Dec-16,20-Apr-11,null,31-Jan-17,"CHRU Lille, Lille, Pas-de-calais, France|CHU Amiens, Amiens, Picardie, France|CHU Brest, Brest, France|CHU Dijon, Dijon, France|CH La Rochelle, La rochelle, France|HIA Val de Grâce, Paris, France|CHU Saint Etienne, Saint Etienne, France",,https://ClinicalTrials.gov/show/NCT01339195
NCT01334450,Transcranial Magnetic Stimulation (TMS) Treatment for Alzheimer Patients,,Unknown status,No Results Available,Alzheimer Disease,"Device: TMS , H2-coil",cognitive functioning score by ADAS-COG,Hadassah Medical Organization,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,42,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",316,Jun-11,Jun-12,Jun-13,13-Apr-11,null,28-Apr-11,"Hadassah Medical Center, Jerusalem District, Israel",,https://ClinicalTrials.gov/show/NCT01334450
NCT01329484,Computerized Personal Interventions for Alzheimer's Patients,,Unknown status,No Results Available,Alzheimer's Disease,Behavioral: Reminiscence therapy|Behavioral: Cognitive training|Other: No treatment,"Cognitive function measured by Mindstreams (NeuroTrax Corp., NJ) computerized neuropsychological assessment instrument.",Shaare Zedek Medical Center,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,159,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPI-AD-TD-CTIL,Mar-11,Sep-12,Sep-12,6-Apr-11,null,6-Apr-11,"Mental Health Center, Beer Sheva, Israel|Memory Clinic, Shaare Zedek Medical Center, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01329484
NCT01329601,Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI,ECIF,Unknown status,No Results Available,Dementia of the Alzheimer Type,"Behavioral: StaCog, stage specific cognitive Intervention|Behavioral: booklet based training",California Verbal Learning Test|functional cortical activity in fMRI,"University of Rostock|DZNE, German Center for Neurodegenerative Disorders, Germany",All,"55 Years and older   (Adult, Older Adult)",Phase 4,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Int_HRO_1,Jan-11,Oct-11,Dec-11,6-Apr-11,null,6-Apr-11,"Department of Psychiatry, University of Rostock, Rostock, Mecklenburg-Western Pomerania, Germany",,https://ClinicalTrials.gov/show/NCT01329601
NCT01324518,Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease,ALPO,Completed,No Results Available,Alzheimer's Disease,Drug: ORM-12741|Drug: Placebo for ORM-12741,"Safety measures, i.e. assessing adverse events, vital signs, ECG,safety laboratory values|Efficacy measures on cognitive symptoms, i.e. CDR computerised cognitive test battery, COWAT and CFT|Scores on Neuropsychiatric Inventory NPI assessment scale|Pharmacokinetics of ORM-12741, metabolites and AChE inhibitor|Scores on Cornell Scale for Depression in Dementia CSDD|Scores on Cognitive Failures Questionnaire CFQ|Scores on Clinical Global Impression of Change CGI-C","Orion Corporation, Orion Pharma",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3098006,Apr-11,Sep-12,Oct-12,29-Mar-11,null,21-Oct-14,"Clinical Research Services Turku (CRST), Turku, Finland",,https://ClinicalTrials.gov/show/NCT01324518
NCT01325259,FluoroAv45 Imaging Research-in Alzheimer's Disease,FAIR-AD,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Other: neuropsychologic assessment|Radiation: [18F]AV-45 PET|Radiation: 18-FDG PET|Other: MRI,Standard Uptake Value Ratios (SUVr),"University Hospital, Tours",All,"60 Years and older   (Adult, Older Adult)",Phase 2,54,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,PHRN08-VC / FAIR AD,Apr-09,Dec-11,Dec-13,29-Mar-11,null,8-Feb-16,"university hospital of CAEN, Caen, France|University Hospital of Lille, Lille, France|University Hospital of Toulouse, Toulouse, France|University Hospital of Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01325259
NCT01325402,An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease,,Completed,No Results Available,Maximum Diagnostic Mass of [18Fluor]AZD4694,Other: [18Fluor]AZD4694,The Maximum Diagnostic Mass by assessing the visual read out of amyloid status according to and quantification of an [18F]AZD4694 PET image in a high mass experiment compared to the image in a low mass experiment in the same subject.|Number of Adverse Events as a measure of Safety and tolerability of [18F]AZD4694|Correlation between early uptake of [18F]AZD4694 images and cerebral blood flow images as measured by Arterial Spin Labeling Magnetic resonance imaging|Correlation between estimates of β-amyloid load in brain obtained using [18F]AZD4694 Position Emission Tomography imaging and concentrations of β-amyloid in Cerebrospinal fluid,AstraZeneca,Male,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,16,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D2750C00002|EudraCT # 2011-000095-34,Aug-11,Nov-12,Nov-12,29-Mar-11,null,10-Dec-12,"Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT01325402
NCT01320527,A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Dietary Supplement: Nutriceutical formulation|Other: Placebo,cognitive improvement or maintenance of cognitive performance|behavioral/psychotic symptoms,"University of Massachusetts, Worcester|University of Massachusetts, Lowell|Alzheimer's Association",All,"40 Years and older   (Adult, Older Adult)",Phase 2,135,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",05-1350|IIRG-08-91737,Aug-08,Apr-12,Apr-12,22-Mar-11,null,3-Mar-16,"Naples Medical Center, Naples, Florida, United States|University of Maryland, Baltimore, Maryland, United States|Primary Care Cardiology Research, Ayer, Massachusetts, United States|Rivercourt Residences, Groton, Massachusetts, United States|Mary Immaculate Residential, Lawrence, Massachusetts, United States|D'Youville Senior Care, Lowell, Massachusetts, United States|Neurocognitive Institute, Mt. Arlington, New Jersey, United States|Advanced Memory Dynamics, Layton, Utah, United States",,https://ClinicalTrials.gov/show/NCT01320527
NCT01314950,Alzheimer's Disease Multiple Intervention Trial,ADMIT,Completed,No Results Available,Alzheimer's Disease,Behavioral: Home based occupational therapy|Behavioral: Best practices primary care,"Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS - ADLI)|Short Physical Performance Battery (SPPB)|Tandem Stand, eyes closed|One Leg Stand, eyes open|Mini Mental State Examination|Word List Learning|Delayed Word List Recall|Grip Strength|Neuropsychiatric Inventory (NPI)|Alzheimer's Disease Cooperative Studies Resource Use Scale|PHQ - 9|GAD - 7|Comorbid Conditions|Adverse Events","Indiana University|National Institute on Aging (NIA)|Regenstrief Institute, Inc.",All,"45 Years and older   (Adult, Older Adult)",Not Applicable,180,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01AG034946-01A1,Jul-10,Dec-15,Dec-15,15-Mar-11,null,8-Mar-16,"Wishard Health Services, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT01314950
NCT01315639,New Biomarker for Alzheimer's Disease Diagnostic,BALTAZAR,"Active, not recruiting",No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,"Biological: biomarkers, MRI and CSF",Mean concentration of plasma AB peptides|plasma levels of Tau protein|Mean concentration of biomarker|MRI|Transcriptomics biomarkers|Bace peptide|TACE/ADAM17|Cathepsin|sAPPβ|Ratio of CSF sAPPβ and CSF sAPPα|Ratio of plasma Aβ and plasma Tau|Plasma Tau|MRI biomarkers,Assistance Publique - Hôpitaux de Paris,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,1067,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P081205,3-Sep-10,Sep-18,Feb-19,15-Mar-11,null,19-Mar-18,"APHP, Hôpital Broca, Paris, France",,https://ClinicalTrials.gov/show/NCT01315639
NCT01313806,Study of Magnetic Fields to Treat Alzheimer's Disease,,Withdrawn,No Results Available,Alzheimer's Disease,Device: Resonator|Device: Placebo,"Alzheimer's Disease Assessment Scale-Cog (ADAS-cog)|Mini-Mental Status Exam (MMSE), Neuropsychiatric Inventory Questionnaire (NPI-Q), Clinical Dementia Scale","pico-tesla Magnetic Therapies, LLC",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WIRB 1123661,Sep-11,Sep-12,Sep-12,14-Mar-11,null,30-May-11,"Mile High Research Center, Denver, Colorado, United States|Innovative Research of West Florida, Clearwater, Florida, United States",,https://ClinicalTrials.gov/show/NCT01313806
NCT01314131,Use of Autobiographical and Interest Assessment for a Better Stimulation of Patients in Nursing Home,,Unknown status,No Results Available,Alzheimer's Disease,Behavioral: Stimulation group,"The primary outcome is the engagement duration for an activity, measured by the OME (Observational Measurement of Engagement) scale.",Association Recherche Méthodologie Evaluation Psychiatrique,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),ARMEP-01,Mar-11,Sep-11,Jun-12,14-Mar-11,null,29-Apr-11,"Centre Mémoire de Ressources et de Recherche, Nice, France",,https://ClinicalTrials.gov/show/NCT01314131
NCT01311492,Exercise Trial for Alzheimer's Disease,EXTRA,Completed,No Results Available,Alzheimer's Disease,Behavioral: Healthy Lifestyle Program|Behavioral: Physical Activity Intervention,"Effect of exercise on cognitive decline|Measuring the effects of exercise on depression, metabolic indices, and changes in overall function.|Evidence based feasibility for conducting exercise interventions in the Alzheimer's Disease population.",Pennington Biomedical Research Center|St. James Place of Baton Rouge,All,65 Years and older   (Older Adult),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,PBRC10035,Mar-11,Apr-13,Apr-13,9-Mar-11,null,27-May-13,"Programs of All-Inclusive Care for the Elderly (PACE), Baton Rouge, Louisiana, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT01311492
NCT01309763,Safety and Tolerability of AFFITOPE AD03,MimoVax,Completed,No Results Available,Alzheimer's Disease,Biological: AFFITOPE AD03|Biological: AFFITOPE AD03 + Alum,change in ADAS-Cog score as a measure of cognition,Affiris AG,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,28,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,AFF005A,Oct-10,Sep-11,Nov-11,7-Mar-11,null,20-Dec-11,"MUW Wien, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT01309763
NCT01303744,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,CT04,Completed,Has Results,Alzheimer's Disease,Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x|Drug: Placebo,Differences in ∆sCD40L Levels Between CHF 5074 Doses and Placebo at Any Specific Time Point|Measurement of Trough CHF 5074 Plasma Levels|Changes in Plasma ΔTNFα Concentrations,CERESPIR,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,96,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCD-1014-PR-0053|2010-024270-19,Mar-11,Apr-12,Apr-12,25-Feb-11,11-Jan-16,11-Jan-16,"Comprehensive NeuroScience, Inc., St. Petersburg, Florida, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Memory Center of New Jersey, Inc., Monroe Twp, New Jersey, United States|Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States|Senior Adults Specialty Research, Austin, Texas, United States|Clinica Santa Maria, Div Neurologia, Castellanza, Italy|Osp. Maggiore Policlinico, Clin. Neurol, Milano, Italy|Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milano, Italy|Nuovo Osp Civ S. Agostino Estense, Dip di Neuroscienze, Modena, Italy",,https://ClinicalTrials.gov/show/NCT01303744
NCT01300728,Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment,MCI,"Active, not recruiting",Has Results,Mild Cognitive Impairment,Drug: NewGam 10% IVIG|Other: Placebo,Annualized Percent Change in Ventricular Volume (APCV) as Measured by MRI|Number of Participants Who Converted From Amnestic Mild Cognitive Impairment (a-MCI) to Alzheimer Disease (AD)|Change in Ventricular Volume in Patients With Positive Cerebrospinal Fluid (CSF) Aβ1-42/CSF P-Tau181P Alzheimer Signature|Mean Cognitive Performance at 12 Months|Mean Cognitive Performance at 24 Months,Sutter Health,All,"50 Years to 84 Years   (Adult, Older Adult)",Phase 2,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IVIG-KILE-032010,Jan-11,Nov-14,Dec-18,23-Feb-11,31-Mar-16,2-Oct-18,"Sutter Neuroscience Medical Group, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT01300728
NCT01297036,Pharmacokinetic Comparisons of Two Donepezil Formulations,,Completed,No Results Available,Alzheimer Disease,"Drug: Donepezil, ODT 10 mg|Drug: Donepezil, 10 mg tablet",donepezil pharmacokinetics: peak plasma concentrations (Cmax)|donepezil pharmacokinetics: Area under the time vs. plasma concentration curve from 0 to 240 hr(AUCall)|donepezil pharmacokinetics: Area under the time vs. plasma concentration curve from 0 to infinity(AUCinf),Korea University Anam Hospital|Chong Kun Dang Pharmaceutical Corp.,Male,20 Years to 45 Years   (Adult),Phase 1,22,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),121HPS07D_03,Jan-08,Mar-08,May-08,16-Feb-11,null,16-Feb-11,"Dept. of Clinical Pharmacology & Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01297036
NCT01297140,"The PACO Study (""Personnalité Alzheimer COmportement"")",PACO,Unknown status,No Results Available,Alzheimer Disease,Behavioral: questioning,Behavioural and psychological symptoms of dementia (BPSD)|social cognition tests|connection between social cognitive tests and BPSD|connection between cerebral atrophy and BPSD,Hospices Civils de Lyon,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,252,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),2008.508,Jan-09,Jul-15,Nov-15,16-Feb-11,null,3-Oct-14,"Service de Gériatrie - Hôpital des Charpennes - Hospices Civils de Lyon, Villeurbanne, France",,https://ClinicalTrials.gov/show/NCT01297140
NCT01297218,The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease,,Completed,No Results Available,Dementia of the Alzheimer's Type,Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells,Number of participants with Adverse event|Changes from the baseline in ADAS-cog at 12 weeks post-dose,Medipost Co Ltd.,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MP-CR-007,Feb-11,Sep-11,Dec-11,16-Feb-11,null,23-Apr-12,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01297218
NCT01295957,Alzheimer's Disease Reminiscence Quality of Life,,Completed,No Results Available,Alzheimer's Disease,Behavioral: reminiscence therapy|Behavioral: comparison group|Other: control,self rated quality of life|Social engagement scale,Universidad Nacional de Rosario,All,65 Years to 87 Years   (Older Adult),Phase 4,135,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PSI851,Jan-10,Aug-10,Nov-10,15-Feb-11,null,15-Feb-11,"Faculty of Psychology, Rosario, Santa Fe, Argentina",,https://ClinicalTrials.gov/show/NCT01295957
NCT01294540,"Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort",,Completed,No Results Available,Alzheimer's Disease,Drug: Drug: E2609|Drug: Placebo,Safety and tolerability as evidenced by the number of subjects with adverse events|To assess the pharmacokinetics (PK) of E2609 in plasma and urine following administration of single oral doses,Eisai Inc.,All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 1,73,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E2609-A001-001,Dec-10,Oct-11,Dec-11,11-Feb-11,null,29-Aug-13,"Glendale Adventist Medical Center, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT01294540
NCT01284387,Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease,ACCTION,Completed,No Results Available,Alzheimer's Disease,Biological: ACC-001 (vanutide cridificar),"To evaluate the effect of ACC-001 in combination with an adjuvant immunostimulatory agent (QS-21), administered intramuscularly compared to placebo on cerebral amyloid burden in subjects with mild to moderate Alzheimer's disease.|To evaluate the safety and tolerability of 2 dosage levels of ACC-001 plus QS-21 vs. placebo in subjects with mild to moderate AD.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in disease biomarkers.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in measurements of immunogenicity.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in cognitive and functional scales.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in health outcome measures.","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer",All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,126,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ACC-001-ALZ-2001,Jan-11,Jan-14,Feb-14,27-Jan-11,null,5-Jan-15,"Janssen AI Investigational Site, Sun City, Arizona, United States|Janssen AI Investigational Site, La Jolla, California, United States|Janssen AI Investigational Site, Long Beach, California, United States|Janssen AI Investigational Site, Los Angeles, California, United States|Janssen AI Investigational Site, Oxnard, California, United States|Janssen AI Investigational Site, San Diego, California, United States|Janssen AI Investigational Site, San Francisco, California, United States|Janssen AI Investigational Site, Washington, District of Columbia, United States|Janssen AI Investigational Site, Miami, Florida, United States|Janssen AI Investigational Site, Miami, Florida, United States|Janssen AI Investigational Site, Ocala, Florida, United States|Janssen AI Investigational Site, Orlando, Florida, United States|Janssen AI Investigational Site, Sunrise, Florida, United States|Janssen AI Investigational Site, Tampa, Florida, United States|Janssen AI Investigational Site, Tampa, Florida, United States|Janssen AI Investigational Site, West Palm Beach, Florida, United States|Janssen AI Investigational Site, Scarborough, Maine, United States|Janssen AI Investigational Site, Boston, Massachusetts, United States|Janssen AI Investigational Site, Kansas City, Missouri, United States|Janssen AI Investigational Site, Las Vegas, Nevada, United States|Janssen AI Investigational Site, Princeton, New Jersey, United States|Janssen AI Investigational Site, Albany, New York, United States|Janssen AI Investigational Site, New York, New York, United States|Janssen AI Investigational Site, Centerville, Ohio, United States|Janssen AI Investigational Site, Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT01284387
NCT01282619,Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease,Drug: Huperzine A|Drug: huperzine A|Drug: Placebo,"Alzheimer's Disease Assessment Scale - Cognitive Subscale|Clinician's Interview Based Impression of Change, plus caregiver input|Activities of Daily Living|Neuropsychiatric Inventory","Shandong Luye Pharmaceutical Co., Ltd.",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,390,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",LY200901-04,May-10,Jun-12,Jun-12,25-Jan-11,null,25-Jan-11,"Shanghai Mental Health Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01282619
NCT01276353,A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia,,Completed,Has Results,Alzheimer's Type Dementia,Drug: E2020,Maximum Observed Plasma Concentration (Cmax) of E2020 on Visits 2 and 3|Cmax of E2020 on Visits 2 and 3 According to Cytochrome P450 2D6 (CYP2D6) Phenotype Status,Eisai Inc.,All,"50 Years and older   (Adult, Older Adult)",Phase 2,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E2020-J081-221,Jan-11,Apr-12,Apr-12,13-Jan-11,1-Aug-14,8-Aug-14,"Kitakyushu, Fukuoka, Japan|Mizunami, Gifu, Japan|Yokosuka, Kanagawa, Japan|Sanjo, Niigata, Japan|Kurashiki, Okayama, Japan|Fuji, Shizuoka, Japan|Hachioji, Tokyo, Japan|Kodaira, Tokyo, Japan|Akita, Japan|Fukuoka, Japan|Saitama, Japan",,https://ClinicalTrials.gov/show/NCT01276353
NCT01273272,Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers,CBTAC,Completed,No Results Available,Alzheimer Disease,"Behavioral: Comprehensive, CBT-based, multi-component treatment|Behavioral: Treatment as usual",Change from baseline in Geriatric Depression Scale (GDS)|Change from baseline in Neuropsychiatric Inventory (NPI)|Change from baseline in Bayer-Activities of Daily Living (B-ADL)|Change from baseline in Stress Coping Inventory (SCI)|Change from baseline in Apathy Evaluation Scale (AES)|Caregiver: Change from baseline in Center for Epidemiologic Studies Depression Scale (CES-D)|Caregiver: Change from baseline in Trait scale of the State Trait Anxiety Inventory (STAI)|Caregiver: Change from baseline in Anger-in and anger-out scales of the State Trait Anger Expression Inventory (STAXI)|Caregiver: Change from baseline in Short-Form Health Survey (SF-12)|Caregiver: Change from baseline in Zarit Burden Interview (ZBI)|Caregiver: Change from baseline in Stress Coping Inventory (SCI),"University of Zurich|Psychiatric University Hospital, Zurich",All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 2,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,10-130034/1a,Feb-11,Sep-17,Sep-17,10-Jan-11,null,6-Nov-17,"Psychiatric University Hospital, Clinic for Geriatric Medicine, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT01273272
NCT01268020,Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC,FMH3,Completed,No Results Available,Alzheimer Disease,Drug: [18F]-FMH3,To assess the dynamic uptake and washout of 18F-FMH3,Institute for Neurodegenerative Disorders,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,FMH3-01,Dec-10,Oct-12,Oct-12,29-Dec-10,null,11-Nov-13,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01268020
NCT01266525,Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,,Completed,No Results Available,Dementia Alzheimer's Type,Drug: SAR110894|Drug: placebo (for SAR110894)|Drug: Donepezil,"Change from baseline to Week 24 in the standard 11-item total score from the 13-item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog).|Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) global score|Change from baseline in each of the two remaining items of the ADAS-Cog (namely ""delayed word recall"" and ""concentration/distractibility"")|Change from baseline in each of the five factors from the Cognitive Drug Research System (CDR-S) computerized assessment|Change from baseline in the Mini Mental State Examination (MMSE) total score",Sanofi,All,"55 Years and older   (Adult, Older Adult)",Phase 2,291,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DRI10734|2010-022596-64|U1111-1115-7535,Feb-11,Jan-13,Jan-13,24-Dec-10,null,14-Mar-16,"Investigational Site Number 840041, Gilbert, Arizona, United States|Investigational Site Number 840032, Phoenix, Arizona, United States|Investigational Site Number 840024, Costa Mesa, California, United States|Investigational Site Number 840013, Fresno, California, United States|Investigational Site Number 840030, La Jolla, California, United States|Investigational Site Number 840001, Redlands, California, United States|Investigational Site Number 840002, Santa Ana, California, United States|Investigational Site Number 840026, Sherman Oaks, California, United States|Investigational Site Number 840034, Darien, Connecticut, United States|Investigational Site Number 840003, Delray Beach, Florida, United States|Investigational Site Number 840015, Hialeah, Florida, United States|Investigational Site Number 840004, Jacksonville, Florida, United States|Investigational Site Number 840006, Miami, Florida, United States|Investigational Site Number 840012, Orlando, Florida, United States|Investigational Site Number 840011, Tampa, Florida, United States|Investigational Site Number 840005, W Palm Beach, Florida, United States|Investigational Site Number 840008, Baton Rouge, Louisiana, United States|Investigational Site Number 840025, Quincy, Massachusetts, United States|Investigational Site Number 840009, Hattiesburg, Mississippi, United States|Investigational Site Number 840040, Eatontown, New Jersey, United States|Investigational Site Number 840018, Cedarhurst, New York, United States|Investigational Site Number 840039, Charlotte, North Carolina, United States|Investigational Site Number 840037, Tulsa, Oklahoma, United States|Investigational Site Number 840014, Franklin, Tennessee, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840021, Bennington, Vermont, United States|Investigational Site Number 840031, Williamsburg, Virginia, United States|Investigational Site Number 036002, Adelaide, Australia|Investigational Site Number 036007, Chermside, Australia|Investigational Site Number 036008, Heidelberg West, Australia|Investigational Site Number 036006, Herston, Australia|Investigational Site Number 036001, Nedlands, Australia|Investigational Site Number 036004, Randwick, Australia|Investigational Site Number 036009, Toowoomba, Australia|Investigational Site Number 036005, Waratah, Australia|Investigational Site Number 036003, Woodville, Australia|Investigational Site Number 124010, Calgary, Canada|Investigational Site Number 124015, Gatineau, Canada|Investigational Site Number 124009, Greenfield Park, Canada|Investigational Site Number 124014, Halifax, Canada|Investigational Site Number 124001, London, Canada|Investigational Site Number 124011, Montreal, Canada|Investigational Site Number 124008, Ottawa, Canada|Investigational Site Number 124013, Regina, Canada|Investigational Site Number 124003, Sherbrooke, Canada|Investigational Site Number 124006, St. John, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 124004, Toronto, Canada|Investigational Site Number 250004, Bordeaux, France|Investigational Site Number 250001, Lille Cedex, France|Investigational Site Number 250009, Limoges, France|Investigational Site Number 250007, Marseille, France|Investigational Site Number 250003, Nantes, France|Investigational Site Number 250005, Nice, France|Investigational Site Number 250006, Paris, France|Investigational Site Number 250008, Strasbourg Cedex, France|Investigational Site Number 250002, Toulouse Cedex 3, France|Investigational Site Number 276011, Berlin, Germany|Investigational Site Number 276012, Dresden, Germany|Investigational Site Number 276007, München, Germany|Investigational Site Number 276008, München, Germany|Investigational Site Number 276001, Schwerin, Germany|Investigational Site Number 276009, Würzburg, Germany|Investigational Site Number 380006, Ancona, Italy|Investigational Site Number 380004, Castellanza, Italy|Investigational Site Number 380005, Cefalù, Italy|Investigational Site Number 380002, Milano, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 616004, Bydgoszcz, Poland|Investigational Site Number 616003, Gdansk, Poland|Investigational Site Number 616001, Gdynia, Poland|Investigational Site Number 616002, Poznan, Poland|Investigational Site Number 616006, Szczecin, Poland|Investigational Site Number 616005, Warszawa, Poland|Investigational Site Number 620002, Amadora, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 724002, Algorta, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724008, Madrid, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 724003, Terrassa, Spain",,https://ClinicalTrials.gov/show/NCT01266525
NCT01264614,Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults,,Completed,Has Results,Cognitive Decline|Dementia|Alzheimer's Disease|Mild Cognitive Impairment,Behavioral: Strengthening exercise,Stroop Test Performance From Pre- to Post-intervention|Digits Backwards Test Performance From Pre- to Post-intervention|Color Trails Test Performance From Pre- to Post-intervention|Fuld Test Performance From Pre- to Post-intervention|Figure Copy & Delayed Test Performance From Pre- to Post-intervention|Neurophysiological Function Pre- & Post- Intervention,"Union College, New York|US Department of Veterans Affairs",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,22,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MIRB#00663,Dec-10,Apr-11,Apr-11,22-Dec-10,11-Mar-15,11-Mar-15,"Stratton VA Medical Center, Albany, New York, United States",,https://ClinicalTrials.gov/show/NCT01264614
NCT01258452,Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects,CT03,Completed,No Results Available,Alzheimer's Disease,Drug: CHF 5074|Drug: CHF 5974,area under the curve of plasma CHF 5074 levels from 0 to 96 hours (AUC 0-96)|peak CHF 5074 plasma concentration (Cmax)|the time of occurrence of Cmax (Tmax),CERESPIR,Male,18 Years to 45 Years   (Adult),Phase 1,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCD-1013-PR-0052,Feb-11,Mar-11,Mar-11,13-Dec-10,null,10-Feb-15,"Iberica Clinical Research Center, Eatontown, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01258452
NCT01254773,Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease,SUMMIT AD,Completed,No Results Available,Alzheimer's Disease,Drug: Experimental Bapineuzumab,To evaluate the effect of bapineuzumab administered subcutaneously (SC) at monthly intervals compared to placebo on cerebral amyloid burden in subjects with mild to moderate AD.|To assess the safety of bapineuzumab administered SC at monthly intervals compared to placebo in subjects with mild to moderate AD|To assess the effect of bapineuzumab administered SC at monthly intervals compared to placebo on cognitive and functional endpoints.,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer",All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,146,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAB-001-SC-ALZ-2003,Dec-10,Jan-13,Mar-13,7-Dec-10,null,9-May-14,"Janssen AI Investigational Site, Tucson, Arizona, United States|Janssen AI Investigational Site, Tucson, Arizona, United States|Janssen AI Investigational Site, La Habra, California, United States|Janssen AI Investigational Site, Lomita, California, United States|Janssen AI Investigational Site, Long Beach, California, United States|Janssen AI Investigational Site, Oceanside, California, United States|Janssen AI Investigational Site, Pasadena, California, United States|Janssen AI Investigational Site, Santa Monica, California, United States|Janssen AI Investigational Site, Sherman Oaks, California, United States|Janssen AI Investigational Site, Deerfield Beach, Florida, United States|Janssen AI Investigational Site, Delray Beach, Florida, United States|Janssen AI Investigational Site, Fort Meyers, Florida, United States|Janssen AI Investigational Site, Miami Springs, Florida, United States|Janssen AI Investigational Site, South Miami, Florida, United States|Janssen AI Investigational Site, Atlanta, Georgia, United States|Janssen AI Investigational Site, Indianapolis, Indiana, United States|Janssen AI Investigational Site, Kansas City, Kansas, United States|Janssen AI Investigational Site, Lexington, Kentucky, United States|Janssen AI Investigational Site, Plymouth, Massachusetts, United States|Janssen AI Investigational Site, Farmington Hills, Michigan, United States|Janssen AI Investigational Site, Creve Coeur, Missouri, United States|Janssen AI Investigational Site, St. Louis, Missouri, United States|Janssen AI Investigational Site, Latham, New York, United States|Janssen AI Investigational Site, Winston-Salem, North Carolina, United States|Janssen AI Investigational Site, Dayton, Ohio, United States|Janssen AI Investigational Site, Portland, Oregon, United States|Janssen AI Investigational Site, Philadelphia, Pennsylvania, United States|Janssen AI Investigational Site, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01254773
NCT01255046,Study of STA-1 as an Add-on Treatment to Donepezil,,Unknown status,No Results Available,Alzheimer Disease,"Drug: Donepezil,|Drug: STA-1|Drug: placebo",Change from baseline in ADAS-cog at Week 72|Change from baseline in Mini-Mental State Examination Scale Score (MMSE) at 72 week,"Sinphar Pharmaceutical Co., Ltd",All,"50 Years and older   (Adult, Older Adult)",Phase 2,136,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCCD09009A,Dec-15,Dec-18,null,7-Dec-10,null,20-Aug-14,"Tri-Service General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01255046
NCT01255163,A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease,,Terminated,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: Exendin-4 SC|Drug: Placebo SC,Number of Participants With Incidence of Nausea|Mini Mental State Examination (MMSE)|Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog70)|Clinical Dementia Rating (CDR) Global Score|Clinical Dementia Rating (CDR) Sum of Boxes|Cerebrospinal Fluid (CSF) Total Tau|Cerebrospinal Fluid phospho181-tau (CSF p181-tau)|Cerebrospinal Fluid Amyloid-beta 42 (CSF Abeta42)|Body Mass Index (BMI),National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC),All,"60 Years and older   (Adult, Older Adult)",Phase 2,57,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",100423|10-AG-0423,21-Nov-10,18-Nov-16,18-Nov-16,7-Dec-10,21-Feb-18,21-Feb-18,"National Institute on Aging, Clinical Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01255163
NCT01254448,Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: TC-5619|Drug: Placebo,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Pharmacokinetic profiles|Markers of inflammation in cerebrospinal fluid|Markers of inflammation in plasma,Targacept Inc.,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic",TC-5619-238-CLP-003,Sep-10,Mar-11,May-11,6-Dec-10,null,4-Sep-13,"Collaborative Neuroscience Network, Long Beach, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Comprehensive Phase One, Miramar, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Atlanta Center For Clinical Research, Atlanta, Georgia, United States|Princeton Medical Institutes, Princeton, New Jersey, United States|Community Clinical Research, Austin, Texas, United States|Aspen Clinical Research, Orem, Utah, United States",,https://ClinicalTrials.gov/show/NCT01254448
NCT01253122,Comparative Bioavailability in Healthy Elderly Volunteers,,Completed,No Results Available,Alzheimer's Disease,Drug: TRx0037,"Relative bioavailability|Safety, tolerability and pharmacokinetics",TauRx Therapeutics Ltd|Quotient Clinical,All,"55 Years and older   (Adult, Older Adult)",Phase 1,24,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,TRx-037-002,Feb-10,Apr-10,Apr-10,3-Dec-10,null,3-Dec-10,,,https://ClinicalTrials.gov/show/NCT01253122
NCT01253499,Multiple Dose Study of TRx0037,,Completed,No Results Available,Alzheimer's Disease,Drug: TRx0037,Bioavailability|Pharmacokinetics|Safety and tolerability,TauRx Therapeutics Ltd|Quotient Clinical,All,"55 Years and older   (Adult, Older Adult)",Phase 1,31,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",TRx-037-003,Mar-10,May-10,May-10,3-Dec-10,null,17-Dec-10,,,https://ClinicalTrials.gov/show/NCT01253499
NCT01249196,A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: SK-PC-B70M,ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale)|CIBIC-Plus (Clinician's Interview-Based Impression of Change-Plus caregiver input)|MMSE (Mini Mental State Examination)|CDR-SB (Clinical Dementia Rating Sum of Box),"SK Chemicals Co., Ltd.",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,256,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SMART_AD_III_2009,May-10,Aug-13,null,29-Nov-10,null,26-Nov-13,"SKChemicals invetigational site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01249196
NCT01245530,An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia,,Completed,No Results Available,Alzheimer Type Dementia,Drug: Aricept|Drug: INM-176,Change in cognition as assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) total score|Change from baseline to endpoint in Mini-Mental State Examination (MMSE)|Change from baseline to endpoint in Clinical Dementia Rating|Change from baseline to endpoint in Global Deterioration Scale(GDS)|Change from baseline to endpoint in Korean Activity of Living(K-IADL)|Change from baseline to endpoint in Korean Neuropsychiatric Inventory (NPI),Whanin Pharmaceutical Company,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 3,280,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",INM-176,Jun-08,Feb-11,Mar-11,22-Nov-10,null,13-Jun-11,"Whanin Pharm.Co.,Ltd., Seoul, Moonjung, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01245530
NCT01238991,"Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease",,Terminated,Has Results,Alzheimer's Disease,Biological: ACC-001,Number of Treatment Emergent Adverse Events (AEs) by Severity|Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data|Number of Participants With Abnormalities in Neurological Examination,"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",All,"52 Years to 87 Years   (Adult, Older Adult)",Phase 2,53,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B2571001|3134K1-2207,Dec-10,Dec-13,Dec-13,11-Nov-10,22-Dec-14,22-Dec-14,"Meitetsu Hospital, Nagoya, Aichi, Japan|Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, Japan|Shonan Atsugi Hospital, Atsugi, Kanagawa, Japan|Kitasato University East Hospital, Sagamihara-shi, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Koto-ku, Tokyo, Japan|The Tokyo Jikei University School of Medicine, Minato-ku, Tokyo, Japan|Kanto Central Hospital of the Mutual Aid Association of Public School Teachers, Setagaya-ku, Tokyo, Japan|Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT01238991
NCT01238458,"Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers",[18F]AV-45,Unknown status,No Results Available,Alzheimer's Disease,Drug: [18F]AV-45 PET amyloid binding imaging,To expand the safety database of [18F]AV-45 PET imaging,Chang Gung Memorial Hospital,All,"50 Years and older   (Adult, Older Adult)",Phase 2,150,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,98-1852A,Nov-09,Nov-11,Jun-13,10-Nov-10,null,28-Sep-12,,,https://ClinicalTrials.gov/show/NCT01238458
NCT01230853,"A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study",,Completed,No Results Available,Alzheimer's Disease,Drug: Active Comparator: A|Drug: Placebo Comparator B|Drug: Active Comparator B|Drug: Placebo Comparator A,Single Ascending Dose (SAD)|Multiple Ascending Dose(MAD),Eisai Inc.,All,"50 Years and older   (Adult, Older Adult)",Phase 1,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BAN2401-A001-101,Aug-10,Oct-12,Feb-13,29-Oct-10,null,22-May-13,"Garden Grove, California, United States|San Francisco, California, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Indianapolis, Indiana, United States|Eatontown, New Jersey, United States|Princeton, New Jersey, United States|Salt Lake City, UT, Utah, United States",,https://ClinicalTrials.gov/show/NCT01230853
NCT01227252,A Safety Study of LY2886721 Multiple Doses in Healthy Subjects,,Completed,No Results Available,Alzheimer's Disease,Drug: LY2886721|Drug: Placebo,"Number of participants with Clinically Significant Effects|Plasma maximum observed drug concentration at steady state (Cmax,ss) of LY2886721|Plasma area under the concentration versus time curve (AUC) of LY2886721|Plasma Abeta 1-40 concentration|Cerebrospinal fluid (CSF) concentration of LY2886721|Change from baseline to Day 15 endpoint in cerebrospinal fluid (CSF) Abeta 1-40 concentration",Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 1,42,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",13734|I4O-MC-BACB,Dec-10,Apr-11,Apr-11,25-Oct-10,null,10-May-11,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT01227252
NCT01227564,Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Biological: ACC-001 3 μg/ QS-21 50 μg|Biological: ACC-001 10 μg/ QS-21 50 μg|Other: Placebo- Phosphate buffered saline (PBS),Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ) at Week 104 as Measured by Standard Uptake Value Ratios (SUVRs) Over the Composite Regions of Interest (ROIs),"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,63,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B2571010|3134K1-2208,Feb-11,Feb-14,Feb-14,25-Oct-10,25-Feb-16,25-Feb-16,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|Banner Boswell Medical Center, Sun City, Arizona, United States|Banner Lakes Imaging Center, Sun City, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Southwest PET Institute, Tucson, Arizona, United States|University of Arizona, Health Sciences Center - Department of Neurology, Tucson, Arizona, United States|Universal Medical Center, Tucson, Arizona, United States|Northwest NeuroSpecialists, LLC, Tucson, Arizona, United States|Radiology Limited, Tucson, Arizona, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|GCRC (Drug administered), New Haven, Connecticut, United States|Yale University School of Medicine, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Investigational Drug Service, New Haven, Connecticut, United States|Norman S. Werdiger, MD, New Haven, Connecticut, United States|Clinical Research Unit, Washington, District of Columbia, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Georgetown University Medical Center Department of Neurology, Washington, District of Columbia, United States|Meridien Research, Brooksville, Florida, United States|Florida Neurology Group PL, Fort Myers, Florida, United States|Internal Medicine Associates of Lee County, MD, PA, Fort Myers, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Florida Radiology Leasing, Limited Liability Corporation, Fort Myers, Florida, United States|Radiology Regional Center, Fort Myers, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Premiere Research Institute (Palm Beach Neurology), West Palm Beach, Florida, United States|Massachusetts General Hospital (For PET only), Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Steinberg Diagnostic Imaging, Las Vegas, Nevada, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Incorporated, Eatontown, New Jersey, United States|Satatoga PET Associates, Clifton Park, New York, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Baylor College of Medicine, Department of Neurology, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|The Pharmacy Inc., Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT01227564
NCT01224106,A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease,,"Active, not recruiting",No Results Available,Alzheimer's Disease,Drug: Gantenerumab|Drug: Placebo,"Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 104|Part 3: Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs)|Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 104|Time to Onset of Dementia|Mean Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Composite Score at Week 104|Mean Change from Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 104|Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 104|Mean Change From Baseline in CDR-Global Score at Week 104|Mean Change from Baseline in Neuropsychiatric Inventory (NPI) Questionnaire Score at Week 104|Percent Change from Baseline in Cerebrospinal Fluid Biomarkers (Phosphorylated-tau [p-tau], Amyloid Beta 1-42 [Abeta 1-42], Total tau [t-tau]) at Week 104|Percent Change from Baseline in Hippocampal Volume at Week 104|Percent Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 104|Gantenerumab Plasma Concentration at Different Time Points|Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 104",Hoffmann-La Roche,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,799,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WN25203|2010-019895-66,30-Nov-10,28-Aug-20,28-Aug-20,19-Oct-10,null,23-Apr-19,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Pacific Neuroscience Med Grp, Oxnard, California, United States|Yale University ADRU, New Haven, Connecticut, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Roskamp Institute, Inc., Sarasota, Florida, United States|Compass Research, The Villages, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Atlanta Center For Medical Research, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Boston Center for Memory, Newton, Massachusetts, United States|Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research, Kalamazoo, Michigan, United States|Neurological Research Center, Hattiesburg, Mississippi, United States|CRI Lifetree Marlton, Marlton, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Nathan Kline Institute, Orangeburg, New York, United States|University of Rochester Medical Center; Monroe Community Hospital, Rochester, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Oregon Health and Science University, Layton Aging and Alzheimer's Disease Center, Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Northeastern Pennsylvania Memory, Plains, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Senior Adults Specialty Research, Austin, Texas, United States|Texas Neurology PA, Dallas, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|Hospital Italiano, Buenos Aires, Argentina|IME - Instituto Médico Especializado; Ensayos Clínicos, Buenos Aires, Argentina|ALPI-Inst. de Rehabilitacion Marcelo Fitte, Buenos Aires, Argentina|CEMIC, Buenos Aires, Argentina|Mulieris, Caba, Argentina|Instituto De Neurología Cognitiva - INECO, Caba, Argentina|FLENI, Caba, Argentina|Instituto Kremer, Córdoba, Argentina|CENPIA; Neurología - Psicología, La Plata, Argentina|Hornsby Ku-ring-gai Hospital; Division of Rehabilitation & Aged Care, Hornsby, New South Wales, Australia|Prince of Wales Hospital, Academic Department for Old Age Psychiatry, Randwick, New South Wales, Australia|Royal Adelaide Hospital; Memory Trials Centre, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Hospital das Clinicas - UFPR; Ciencias da Saude, Curitiba, PR, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital Mae de Deus, Porto Alegre, RS, Brazil|Universidade Federal de Sao Paulo - UNIFESP; Neurologia, Sao Paulo, SP, Brazil|Hospital das Clinicas - FMUSP; Psiquiatria, Sao Paulo, SP, Brazil|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|NeuroSearch Developpements inc, Greenfield Park, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Neurological and Psychiatric, Montreal, Quebec, Canada|CHAUQ - Hôpital Enfant-Jésus, Quebec City, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada|Biomedica Research Group, Santiago, Chile|Especialidades Medicas LYS, Santiago, Chile|CIMN Centro de Investigaciones Medicas Neurologicas, Viña De Mar, Chile|St. Anne´s University Hospital; Clinical Trials Department, Brno, Czechia|Fakultní Nemocnice Olomouc; Neurologicka Klinika, Olomouc, Czechia|Vestra Clinics s.r.o., Rychnov nad Kneznou, Czechia|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus N, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|Turku Hospital; PET (Positron Emission Tomography) Center, Turku, Finland|Hopital Avicenne; Neurologie, Bobigny, France|Hopital Pellegrin; Cmrr Aquitaine, Bordeaux, France|Hopital Pierre Wertheimer; Laboratoire De Neuro Psychologie, Bron, France|CHU De Caen; Service De Neurologie Dejerine, Caen, France|Hopital B Roger Salengro; Cmrr Lille, Lille, France|Ch Pitie Salpetriere; Cmrr Ile De France Salpetriere, Paris, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, France|Hop Guillaume Et Rene Laennec; Cmrr St Herblain, St Herblain, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|Hopital de La Grave, Toulouse, France|Univ Berlin; Klin fur Psychi & Psycho Charite, Berlin, Germany|Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin, Bonn, Germany|Klinikum Joh.Wolfg.Goethe-UNI Zentrum d. Psychiatrie Klinik f. Psychiatrie Psychosomatik, Frankfurt, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Zentralinstitut für Seelische Gesundheit Abt.Gerontopsychiatrie, Mannheim, Germany|Pharmakologisches Studienzentrum, Mittweida, Germany|Neurologische Praxis Dr. Andrej Pauls, München, Germany|Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie, München, Germany|Office of Dr Klaus Steinwachs Neurology & Psychiatry, Nürnberg, Germany|Universitätsklinikum Rostock Zentrum für Nervenheilkunde, Rostock, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Rambam Medical Center, Halfa, Israel|Sheba Medical Center; Psychiatry Department, Ramat Gan, Israel|Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica - Dipartimento di Neuroscienze, Modena, Emilia-Romagna, Italy|Universita' Di Parma Istituto Neurologia, Parma, Emilia-Romagna, Italy|Azienda Ospedaliera Spedali Civili; Scienze Neurologiche, Brescia, Lombardia, Italy|IRCCS ""Centro S. Giovanni di Dio"" Fatebenefratelli -UO Alzheimer, Brescia, Lombardia, Italy|Irccs Multimedica Santa Maria; Unita' Di Neurologia, Castellanza, Lombardia, Italy|Irccs Ospedale Maggiore Policlinico Di Milano; Scienze Neurologiche, Milano, Lombardia, Italy|Fondazione San Raffaele Del Monte Tabor; Dipartimento Di Neurologia, Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi Di Ancona, Torrette - Ancona, Marche, Italy|Uni Di Firenze Dip. Scienze Neurol Psic Sod Neurologia 1, Firenze, Toscana, Italy|Azienda Ospedaliera Universitaria Integrata; Neuroscienze Centro Alzheimer e Disturbi Cognitivi, Verona, Veneto, Italy|Seoul National University Bundang Hospital; Neurology Department, Gyeonggi-do, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC, Culiacan, Mexico|Hospital Mexico Americano, Guadalajara, Mexico|Unidad de Investigacion en Enfermedades Cronico-Degenerativa; Reumatologia, Guadalajara, Mexico|Estimulacion Magnetica Trnscraneal de Mexico SC., Mexico City, Mexico|Hospital Uni; Dr. Jose E. Gonzalez, Monterrey, Mexico|Centro Medico San Francisco; Geriatrics, Monterrey, Mexico|Hospital Universitario de Saltillo, Saltillo, Mexico|Jeroen Bosch Ziekenhuis; Polikliniek Geriatrie, 'S Hertogenbosch, Netherlands|Brain Research Center B.V, Amsterdam, Netherlands|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|Szpital Uniwersytecki nr 1 im. dr Antoniego Jurasza w Bydgoszczy Klinika Psychiatrii, Bydgoszcz, Poland|PALLMED Sp. z o.o. prowadząca NZOZ DOM SUE RYDER, Bydgoszcz, Poland|NEURO - KARD Ośrodek Badań Klinicznych, Poznań, Poland|Przychodnia Specjalistyczna PROSEN, Warszawa, Poland|mMED Maciej Czarnecki, Warszawa, Poland|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, Portugal|Sverdlovsk Regional Clinical Psychoneurological War Veteran Hospital, Ekaterinburg, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Saint Petersburg State Institution of Healthcare City Geriatric Medico-Social Center, Saint Petersburg, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|Fundació ACE, BArcelon, Barcelona, Spain|Hospital Mutua De Terrasa; Servicio de Neurologia, Terrassa, Barcelona, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Hospital Clinic i Provincial; Servicio de Neurologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, Spain|Hospital Clinico Universitario San Carlos; Servicio de Geriatria, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Dr. Peset; Servicio de Neurologia, Valencia, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmoe, Sweden|Universitäres Zentrum für Altersmedizin und Rehabilitation, Basel, Switzerland|HUG; Département de santé mentale et de psychiatrie Unité de psychiatrie gériatrique, Chêne-Bourg, Switzerland|Akdeniz University School of Medicine, Neurology Department, Antalya, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, Turkey|Addenbrooke's Hospital, Cambridge, United Kingdom|Llandough Hospital; Llandough Hospital Memory Team 3rd Floor Academic Building, Cardiff, United Kingdom|St Margaret's Hospital, Epping, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Charing Cross Hospital; Dept of Neurosciences, London, United Kingdom|Campus for Ageing & Vitality; Clincal Ageing Research Unit, Newcastle, United Kingdom|John Radcliffe Hospital; Nuffield dept. Of medicine, Oxford, United Kingdom|Moorgreen Hospital; Memory Assessment & Rsch Ctr, Southampton, United Kingdom|Victoria Centre; Kingshill Research Centre, Swindon, United Kingdom|Hollins Park Hospital, Warrington, United Kingdom",,https://ClinicalTrials.gov/show/NCT01224106
NCT01222351,Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172,,"Active, not recruiting",No Results Available,Late Onset Alzheimer Disease,Drug: BAY 94-9172 (Florbetaben),Changes in amyloid plaque load in the brain of the course of 3 years,New York State Psychiatric Institute|Bayer|National Institute on Aging (NIA),All,65 Years and older   (Older Adult),Not Applicable,161,Other|Industry|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,6045/7130R (Bayer)|IND 78868|R01AG037212-01,Dec-10,Jan-20,Jan-29,18-Oct-10,null,21-May-18,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01222351
NCT01221259,"A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects",,Completed,No Results Available,Alzheimer's Disease,Drug: E2212|Drug: placebo,To evaluate the safety and tolerability of single ascending oral doses of E2212 in healthy subjects.,Eisai Inc.,All,18 Years to 55 Years   (Adult),Phase 1,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E2212-A001-001,Jan-10,Oct-11,Nov-12,14-Oct-10,null,22-May-13,"Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01221259
NCT01217021,Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558,MNI-558,Completed,No Results Available,Alzheimer Disease,Drug: [18F] MNI-558,"To evaluate the efficacy safety of MNI-558 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer disease (AD) compared to healthy volunteers (HV)|To assess the dynamic uptake of MNI-558, a potential imaging biomarker for B-amyloid burden in brain, using positron emission tomography (PET) in similarly aged Alzheimer (AD) subjects and healthy volunteers (HV|To determine pharmacokinetics pattern of MNI-558 in venous plasma of healthy and AD subjects.|To determine metabolite pattern of MNI-558 in venous plasma of healthy and AD subjects.",Institute for Neurodegenerative Disorders|Molecular NeuroImaging,All,"55 Years and older   (Adult, Older Adult)",Early Phase 1,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,MNI-558-01,Sep-10,Mar-11,Mar-11,8-Oct-10,null,25-Jul-11,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01217021
NCT01217541,Collaboration Between Department of Old Age Psychiatry and Nursing Homes,SAM-AKS,Completed,No Results Available,Dementia|Alzheimer's Disease|Behavioral Symptoms|Agitation,Other: Education and Supervision|Other: Control,"Quality of Life in Severe Dementia (QUALID), Person-Centred Care Assessment Tool (P-CAT, 2010)|Neuropsychiatric Inventory - Nursing Home version, Cornell Scale of Depression in Dementia, Registration of Constraints (Kirkevold, 2004)",Sykehuset Innlandet HF|Helse Sor-Ost|Norwegian Department of Health and Social Affairs,All,"Child, Adult, Older Adult",Not Applicable,700,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,50022,Sep-10,Mar-12,Mar-12,8-Oct-10,null,12-Dec-14,"Lillehammer sykehjem, Lillehammer, Oppland, Norway",,https://ClinicalTrials.gov/show/NCT01217541
NCT01209156,Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions,PBR111,Completed,No Results Available,Alzheimer Disease,Drug: [18F] PBR111,"To evaluate the cerebral distribution of [18F]PBR-111 positron emission tomography (PET) for detection/exclusion of microglial activation in patients with Alzheimer Disease compared to healthy volunteers.|To assess the dynamic uptake and washout of [18F]PBR-111, a potential imaging biomarker for inflammatory changes in brain, using positron emission tomography (PET) in Alzheimer disease subjects compared to healthy volunteers.|To perform blood metabolite characterization of [18F]PBR-111 in AD subjects compared to Healthy volunteers to determine the nature of metabolites in assessment of [18F]PBR-111 as a single positron computed tomography (PET) brain imaging agent.",Institute for Neurodegenerative Disorders,All,"18 Years and older   (Adult, Older Adult)",Phase 1,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PBR111 001,Mar-10,Jun-13,Jun-13,27-Sep-10,null,11-Nov-13,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01209156
NCT01202994,Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET,,"Active, not recruiting",Has Results,Alzheimer's Disease,Drug: 18F-Flutemetamol,Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan.|Change in Participant Z-score,University of Utah,All,65 Years and older   (Older Adult),Phase 2,27,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,43306,May-11,May-16,Dec-18,16-Sep-10,11-Jan-18,7-Feb-18,"University of Utah Center for Alzheimer's Care, Imaging and Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01202994
NCT01203384,"Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects",CT02,Completed,No Results Available,Alzheimer's Disease,Drug: CHF5074 1x|Drug: CHF5074 2x|Drug: CHF5074 3x|Drug: Placebo,Adverse Events|Dose linearity of CHF5074 plasma levels (Cmax)|Dose linearity of CHF5074 plasma levels (AUC 0-t),CERESPIR,Male,18 Years to 45 Years   (Adult),Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCD-0913-PR-0038,Sep-10,Dec-10,Dec-10,16-Sep-10,null,10-Feb-15,"Iberica Clinical Research Center, Eatontown, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01203384
NCT01195389,Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Dementia,Device: Resonator,Alzheimer's Disease Assessment Scale-Cog (ADAS-cog),"pico-tesla Magnetic Therapies, LLC",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,USF #6178-P67865,Dec-10,Oct-11,Oct-11,6-Sep-10,null,8-Jul-11,"USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT01195389
NCT01194713,Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics,AWAKE,Completed,No Results Available,Alzheimer Disease,Behavioral: Sleep deprivation,Amyloid beta,University Medical Center Nijmegen,Male,40 Years to 60 Years   (Adult),Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,AWAKE32920,Mar-11,Sep-13,Sep-13,3-Sep-10,null,13-May-14,"Clinical Research Centre Nijmegen, Nijmegen, Gelderland, Netherlands",,https://ClinicalTrials.gov/show/NCT01194713
NCT01193608,Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: AAB-003 (PF-05236812)|Other: Placebo,Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Laboratory Abnormalities|Number of Participants With Vital Signs of Potential Clinical Concern|Number of Participants With Abnormal Physical Examination Findings|Number of Participants With Abnormal Neurological Examination Findings|Maximum Observed Serum Concentration (Cmax) for AAB-003 at Day 1|Maximum Observed Serum Concentration (Cmax) for AAB-003 at at Week 26|Average Concentration (Cavg) for AAB-003 in Serum at Day 1|Average Concentration (Cavg) for AAB-003 in Serum at Week 26|Time to Reach Maximum Observed Serum Concentration (Tmax) for AAB-003 at Day 1|Time to Reach Maximum Observed Serum Concentration (Tmax) for AAB-003 at Week 26|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for AAB-003 in Serum at Day 1|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for AAB-003 in Serum at Day 1|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for AAB-003 in Serum at Day 1|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for AAB-003 in Serum at Week 26|Systemic Clearance (CL) for AAB-003 in Serum at Day 1|Systemic Clearance (CL) for AAB-003 in Serum at Week 26|Volume of Distribution at Steady State (Vss) for AAB-003 in Serum at Day 1|Volume of Distribution at Steady State (Vss) for AAB-003 in Serum at Week 26|Serum Decay Half-Life (t1/2) for AAB-003 at Day 1|Serum Decay Half-Life (t1/2) for AAB-003 at Week 26|Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)|Number of Participants With New Occurrence of Brain Magnetic Resonance Imaging (MRI) Finding|Number of Participants With Vasogenic Edema of All Severity After Each Infusion Visit|Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarization Criteria,"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 1,88,Industry,Interventional,"Allocation: Randomized|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B2601001|3245K1-1000,Sep-10,Oct-13,Oct-13,2-Sep-10,23-Feb-17,23-Feb-17,"Early Phase Investigational Center, Escondido, California, United States|Synergy Clinical Research Center of Escondido, Escondido, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Franck's Pharmacy, Ocala, Florida, United States|Munroe Regional Medical Center, Ocala, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Advanced Imaging of Ocala, Ocala, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Foers Medical Arts Pharmacy, Bethesda, Maryland, United States|CBH Health, LLC, Rockville, Maryland, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|KNI/Southwest Michigan Imaging Center, LLC, Kalamazoo, Michigan, United States|Brentwood Behavioral Healthcare, Flowood, Mississippi, United States|Marty's Pharmacy, Flowood, Mississippi, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|DePaul Health Center, St. Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pharmacare USA, Edison, New Jersey, United States|Central Jersey Radiology, Oakhurst, New Jersey, United States|Belmont Center for Comprehensive Treatment, Philadelphia, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Seoul National University Bundang Hospital, Department of Neurology, Seongnam-si, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Department of Neurology, Incheon, Korea, Republic of|Samsung Medical Center, Department of Neurology, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|ASAN Medical Center, Seoul, Korea, Republic of|Konkuk University Medical Center, Department of Neurology, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01193608
NCT01192529,Evaluation of a Diet in Patients With Senile Dementia,SUPRESSI,Unknown status,No Results Available,Alzheimer's Disease|Parkinson's Disease|Senile Dementia,Dietary Supplement: Supressi. T-Diet plus Range|Dietary Supplement: High Protein. T-Diet plus Range,Nutritional and cognitive status in elderly people|Biochemical parameters measure,"Vegenat, S.A.",All,70 Years and older   (Older Adult),Not Applicable,184,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care",VEGENAT-SUPR|SUPRESSI2010-PROYECTO CDTI,Oct-10,Sep-12,Dec-12,1-Sep-10,null,22-Jun-12,"Clinical Nutrition and Dietetic Unit, University Hospital Virgen de las Nieves, Granada, Spain|Department of Biochemistry and Molecular Biology II. University of Granada, Granada, Spain|Neurological Unit, Complejo Asistencial de León, León, Spain",,https://ClinicalTrials.gov/show/NCT01192529
NCT01188070,Caregiver Stress: Interventions to Promote Health and Wellbeing,,Completed,No Results Available,Health Promotion,Behavioral: Usual Care|Behavioral: Psycho-education|Behavioral: Psycho-education plus physical exercise,Emotional outcomes|Behavioral Outcomes|Health Status|Neuroendocrine|Cardiovascular Risk Outcomes,Emory University|National Institute of Nursing Research (NINR),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,354,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB00032005|P01NR011587,Jan-10,Apr-14,May-14,25-Aug-10,null,23-Feb-17,"Emory Universtiy, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01188070
NCT01183806,Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients,,Completed,No Results Available,Alzheimer Disease,Drug: Rivastigmine|Other: Exercise training program,Patients' Quality of life|Cognition|Caregivers' Quality of life|Activities of daily living|Functional mobility,Federal University of Bahia,All,"55 Years and older   (Adult, Older Adult)",Phase 3,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PA-01,Jul-10,Jan-12,Mar-12,18-Aug-10,null,20-Mar-12,"Ferderal University of Bahia - DINEP, Salvador, Bahia, Brazil|Federal University of Bahia, Salvador, Bahia, Brazil",,https://ClinicalTrials.gov/show/NCT01183806
NCT01181921,The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease,,Terminated,Has Results,Alzheimer Disease,Drug: Galantamine,Change From Baseline in Sleep/Wake Patterns as Measured by Actigraph at 12 Weeks,"Janssen-Cilag, S.A.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,1,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CR015586|GALALZ4041|2009-013689-18,May-11,Jun-11,Jun-11,13-Aug-10,14-Aug-12,1-May-14,"Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT01181921
NCT01179373,Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,"Device: TMS, H coil",cognitive functioning score by ADAS-COG|Global advancement score by CGI-C|Frontal lobe functioning score by FAB|Daily activity score by ADL,Brainsway,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",10003,Aug-10,Jan-15,Jun-15,11-Aug-10,null,25-Jan-18,"Merchav Clinics, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01179373
NCT01172145,Treatment of Apathy in Alzheimer's Disease With Modafinil,,Completed,Has Results,Apathy|Alzheimer's Disease,Drug: Modafinil|Drug: Placebo,Apathy|Lawton Brody Activities of Daily Living Questionnaire|The Direct Assessment of Functional Status Scale|Zarit Burden Inventory,Brown University|National Institute of Mental Health (NIMH)|Cephalon,All,65 Years to 95 Years   (Older Adult),Phase 3,22,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1F32MH075583-01,Jul-05,null,Sep-07,29-Jul-10,4-Mar-11,4-Mar-11,"Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01172145
NCT01168245,TMS Stimulation and Cognitive Training in Alzheimer Patients,,Completed,No Results Available,Alzheimer Disease|Mild to Moderate,Device: Sham-NICE-System|Device: NICE-System,A significant improvement and/or improvement of at least 2 points on ADAS-COG of the Treatment Group in comparison with the Placebo Group after 6 weeks of treatment.|Safety profile: rate of device and/or procedure related adverse events.,Neuronix Ltd|Assaf-Harofeh Medical Center,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,15,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NRX-NICE-PLA02,Jan-10,Sep-11,Sep-11,23-Jul-10,null,28-Mar-13,"Assaf-Harofeh Medical Center, Beer Yaakov, Israel",,https://ClinicalTrials.gov/show/NCT01168245
NCT01163825,Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients,NsG0202,Unknown status,No Results Available,Alzheimer's Disease,Drug: Nerve Growth Factor,Adverse events|Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog),"NsGene A/S|Karolinska Institutet|Stockholm County Council, Sweden",All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,6,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NsG0202-001,Jan-08,Dec-11,null,16-Jul-10,null,16-Jul-10,"Karolinska University Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01163825
NCT01153607,Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers,,Completed,No Results Available,Diagnostic Imaging,Drug: BAY1006578,Discrimination of probable Alzheimer's Disease patients from healthy volunteers by BAY1006578 brain Positron Emission Tomography (PET) imaging as evaluated by different quantification approaches|Discrimination of probable Alzheimer's Disease patients from healthy volunteers by BAY1006578 brain Positron Emission Tomography (PET) imaging as evaluated by visual analysis and by standard parameters (e.g. Standardized Uptake Values=SUV)|Electrocardiogram (ECG)|Blood pressure|Adverse events collection,Life Molecular Imaging SA,All,"50 Years and older   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,14708|2009-017166-24,Jun-10,Oct-11,Oct-11,30-Jun-10,null,21-Jan-13,"Turku, Finland|Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01153607
NCT01153802,"An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands",,Completed,No Results Available,Depressive Disorder,"Drug: GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin",To estimate the degree of DAT occupancy in brain regions of interest (ROIs)following oral doses of GSK1360707 in healthy male subjects-To estimate the degree of SERT occupancy in brain ROIs following total oral doses of GSK1360707 in healthy male subject|To evaluate the relationship between the plasma concentration and the resultant DAT occupancy by GSK1360707.To evaluate the relationship between the plasma concentration and the resultant SERT occupancy by GSK1360707.|To further assess the safety and tolerability of total oral doses of GSK1360707 including the maximal tolerated dose in the FTIH study (150 mg PO)-To further assess the pharmacokinetics of GSK1360707 in healthy male subjects,GlaxoSmithKline,Male,35 Years to 55 Years   (Adult),Phase 1,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,112773,3-Apr-09,12-Oct-09,12-Oct-09,30-Jun-10,null,27-Jun-17,"GSK Investigational Site, Harrow, Middlesex, United Kingdom",,https://ClinicalTrials.gov/show/NCT01153802
NCT01152216,An Extension of the CONCERT Protocol (DIM18),CONCERT PLUS,Terminated,No Results Available,Alzheimer's Disease,Drug: Dimebon,Safety,"Medivation, Inc.|Pfizer",All,"50 Years and older   (Adult, Older Adult)",Phase 3,672,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIM18EXT,Apr-10,May-12,null,29-Jun-10,null,27-Sep-16,,,https://ClinicalTrials.gov/show/NCT01152216
NCT01148498,A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's,,Completed,No Results Available,Alzheimer's Disease,Drug: solanezumab,Mean change from baseline up to 112 days post drug administration in plasma levels of Aβ fragment-2 in (Group 1) and (Group 3)|Mean change in plasma levels of Aβ1-42 after solanezumab infusion|Mean change in plasma levels of Aβ1-40 species after solanezumab infusion|Mean change in plasma levels of modified Aβ species after solanezumab infusion,Eli Lilly and Company,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,55,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,13572|H8A-MC-LZAT,Aug-10,Aug-12,Aug-12,22-Jun-10,null,25-Sep-12,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01148498
NCT01145482,Mechanisms of Insulin Facilitation of Memory,,Completed,Has Results,Memory Disorders,Drug: Insulin|Other: Saline,Cerebral Glutamate Concentration|Memory,University of Texas at Austin,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2010-05-0007,Jul-10,Apr-14,Apr-14,16-Jun-10,3-Nov-14,3-Nov-14,"University of texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT01145482
NCT01143350,Non Pharmacological Treatment in Alzheimer's Disease and Associated Disorders,,Terminated,No Results Available,Alzheimer's Disease,Other: Bras A (EHPAD Training and stimulation)|Other: EHPAD Control,"Identification of yet unknown enzymes involved in the processing of Ab, especially on those responsible for the exoproteasic truncation of Ab at its N-terminus.|Secondary efficacy criteria: Apathy Inventory patient and caregiver version changes, Observation scale changes, frequency and severity of the other BPSD using the NPI, qualitative analysis of the nursing home staff behavioural changes",Centre Hospitalier Universitaire de Nice,All,65 Years and older   (Older Adult),Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,09-PP-09,Mar-10,Mar-10,Mar-11,14-Jun-10,null,1-Jun-11,"Robert, Nice, Alpes-Maritimes, France",,https://ClinicalTrials.gov/show/NCT01143350
NCT01142258,Trazodone for Sleep Disorders in Alzheimer's Disease,,Completed,No Results Available,Sleep|Sleep Disorders|Insomnia|Alzheimer's Disease,Drug: Trazodone|Drug: Placebo,Change from Baseline in Nighttime Total Sleep Time|Change from Baseline in Nighttime Wake After Sleep Onset|Change from Baseline in Nighttime Number Of Awakenings|Change from Baseline in Daytime Total Sleep Time|Change from Baseline in Number of Daytime Naps|change in cognitive function (as measured by the Mini-Mental State Examination)|Change in activities of daily living (The index of ADL - Katz)|Change of baseline in behavioral variables (BAHAVE-AD scale)|Proportion of subjects who gained at least 30 minutes in total nighttime sleep|Change from Baseline in Clinical Dementia Rating|Change from Baseline in cognitive function (Digit Symbol Substitution Test),Brasilia University Hospital|Universidade Federal do Paraná,All,"55 Years and older   (Adult, Older Adult)",Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",TZD-001,Mar-10,Apr-12,Aug-12,11-Jun-10,null,15-Oct-12,"Geriatric Medical Centre, Brasilia, Distrito Federal, Brazil",,https://ClinicalTrials.gov/show/NCT01142258
NCT01142336,Effects of Simvastatin on Biomarkers,SimBio,Completed,Has Results,Alzheimer's Disease,Drug: Simvastatin|Drug: Placebo,Change From Baseline in Aβ42 in Cerebrospinal Fluid (CSF) at 1 Year|Change From Baseline in CSF Total Tau at 1 Year|Change From Baseline in CSF ptau181 at 1 Year,University of Washington|Seattle Institute for Biomedical and Clinical Research|VA Puget Sound Health Care System,All,45 Years to 64 Years   (Adult),Phase 4,49,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",37373|00183,Jun-10,Oct-15,Oct-15,11-Jun-10,28-Jul-17,28-Jul-17,"VA Puget Sound Health Care System, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01142336
NCT01138111,Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients,,Completed,Has Results,Alzheimer Disease|Amyloid Beta-Protein,Drug: Florbetaben (BAY94-9172),"Quantitative Assessment of Neocortical SUVRs (Mean Standard Uptake Value Ratios) as a Measure of Florbetaben Uptake|Number of Normal and Abnormal Scans in Patients With MCI Progressing to AD and Those Who do Not Progress Based on a Threshold of Neocortical SUVR=1.4|Number and Proportion of Normal and Abnormal Scans Based on Brain ß-amyloid Plaque Load (BAPL) in Subjects With MCI Converting to AD and Those Who do Not Progress|Sensitivity/Specificity/Negative Predictive Value (NPV)/Positive Predictive Value (PPV) at Baseline, 12, and 24 Months in the Detection of Significant Brain ß-amyloid Plaque Load in Patients With MCI Progressing to AD Compared to Those Who do Not Progress",Life Molecular Imaging SA,All,"60 Years and older   (Adult, Older Adult)",Phase 1,45,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,312043,Jun-08,Dec-11,Dec-11,7-Jun-10,25-Jun-14,25-Jun-14,"Heidelberg, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT01138111
NCT01137526,Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: ABT-384|Drug: donepezil|Drug: placebo,"Change from baseline to final observation in the Alzheimer's Disease Assessment Scale-Cognition portion (ADAS-cog) total score|Mini Mental Status Examination (MMSE) score at Baseline, Weeks 4, 8, and 12|Clinician's Interview Based Impression of Change-plus (CIBIC-plus) score at Baseline, Weeks 4, 8, and 12|Neuropsychiatric Inventory (NPI) score at Baseline, Weeks 4, 8, and 12|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) score at Baseline, Weeks 4, 8, and 12","AbbVie (prior sponsor, Abbott)|AbbVie",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,267,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",M12-033|2009 017801-12,May-10,Jul-11,Jul-11,4-Jun-10,null,29-Jan-13,"Site Reference ID/Investigator# 40834, Ekaterinburg, Russian Federation|Site Reference ID/Investigator# 36304, Kazan, Russian Federation|Site Reference ID/Investigator# 36306, Kirov, Russian Federation|Site Reference ID/Investigator# 37944, Moscow, Russian Federation|Site Reference ID/Investigator# 26909, Saratov, Russian Federation|Site Reference ID/Investigator# 26904, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 26902, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 36305, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 38383, Yaroslavl, Russian Federation|Site Reference ID/Investigator# 45584, Belville, South Africa|Site Reference ID/Investigator# 47102, George, South Africa|Site Reference ID/Investigator# 45583, Johannesburg, South Africa|Site Reference ID/Investigator# 39855, Donetsk, Ukraine|Site Reference ID/Investigator# 26914, Kharkiv, Ukraine|Site Reference ID/Investigator# 26912, Kiev, Ukraine|Site Reference ID/Investigator# 40484, Lviv, Ukraine|Site Reference ID/Investigator# 27002, Poltava, Ukraine|Site Reference ID/Investigator# 39856, Poltava, Ukraine|Site Reference ID/Investigator# 40482, Simferopil, Ukraine|Site Reference ID/Investigator# 40483, Ternopil, Ukraine|Site Reference ID/Investigator# 35660, Vinnytsia, Ukraine|Site Reference ID/Investigator# 36327, Bath, United Kingdom|Site Reference ID/Investigator# 35657, Blackburn, United Kingdom|Site Reference ID/Investigator# 36330, Crowborough, United Kingdom|Site Reference ID/Investigator# 36326, Glasgow, United Kingdom|Site Reference ID/Investigator# 44123, Ivybridge, Devon, United Kingdom|Site Reference ID/Investigator# 35658, London, United Kingdom|Site Reference ID/Investigator# 35902, Northampton, United Kingdom|Site Reference ID/Investigator# 36328, Oxford, United Kingdom|Site Reference ID/Investigator# 36329, Peterborough, United Kingdom",,https://ClinicalTrials.gov/show/NCT01137526
NCT01137799,The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients,,Terminated,No Results Available,Schizophrenia|Alzheimer's Disease|Cognition Disorders,Drug: JNJ-39393406|Drug: placebo,Improvement of deficits (i.e. sensory gating deficits) in event related potentials like Auditory Evoked Potentials P50 and P300 and Mismatch Negativity.|Improvement in continuous performance testing|Plasma concentrations of JNJ-39393406 (PK blood samples)|Number of patients with clinical significant changes in vitals signs|Number of patients with clinical significant changes in ECG parameters|Number of patients with clinical clinical significant changes in clinical laboratory parameters,"Janssen Pharmaceutica N.V., Belgium",Male,18 Years to 55 Years   (Adult),Phase 1,47,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR016762,Aug-09,null,Mar-11,4-Jun-10,null,8-Nov-12,"Berlin, Germany|Erlangen, Germany|München, Germany|Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01137799
NCT01133405,A Safety Study of LY2886721 Single Doses in Healthy Subjects,,Completed,No Results Available,Alzheimer's Disease,Drug: LY2886721|Drug: Placebo,Number of participants with Clinically Significant Effects|Plasma concentrations of LY2886721 (Cmax)|Plasma concentration of LY2886721 (AUC)|Pharmacodynamic biomarker plasma Abeta 1-40 concentration|Cerebrospinal fluid (CSF) concentration of LY2886721 (Cmax) (Part 2 only)|Cerebrospinal fluid (CSF) Pharmacodynamic biomarker Abeta 1-40 concentration (Part 2 only)|Cerebrospinal fluid (CSF) concentration of LY2886721 (AUC) (Part 2 only),Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 1,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",13733|I4O-MC-BACA,Jun-10,Oct-10,Oct-10,28-May-10,null,5-Nov-10,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beverly Hills, California, United States",,https://ClinicalTrials.gov/show/NCT01133405
NCT01128725,"Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers",,Unknown status,No Results Available,Alzheimer Disease,Other: Alzhamyd,"Identification of yet unknown enzymes involved in the processing of Ab, especially on those responsible for the exoproteasic truncation of Ab at its N-terminus.|The availability of truncated fragments designed to set up monoclonal antibodies will allow us to estimate their associated toxicity in various cellular models.",Centre Hospitalier Universitaire de Nice,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,10-PP-01,Sep-10,Sep-10,Dec-12,24-May-10,null,26-Mar-12,"Robert, Nice, Alpes-Maritimes, France",,https://ClinicalTrials.gov/show/NCT01128725
NCT01129115,Dose Response Study of Aerobic Exercise in Older Adults,,Completed,Has Results,Alzheimer's Disease,Behavioral: Nonexercise control group|Behavioral: Aerobic Exercise Group 1|Behavioral: Aerobic Exercise Group 2|Behavioral: Aerobic Exercise Group 3,Visuospatial Processing|Change in Maximal Oxygen Consumption|Change in Physical Performance Test|Verbal Memory|Simple Attention|Set Maintenance & Shifting|Reasoning,"Jeff Burns, MD|University of Kansas Medical Center",All,65 Years and older   (Older Adult),Early Phase 1,101,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11883,May-10,Feb-14,Apr-14,24-May-10,15-Feb-16,15-Feb-16,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01129115
NCT01127633,Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease,EXPEDITION EXT,Terminated,Has Results,Alzheimer's Disease,Drug: Solanezumab|Drug: Placebo,Assess the Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs)|Change From Baseline to 104-week Endpoint in Alzheimer's Disease Assessment Scale - Cognitive 14-Item Scale (ADAS-Cog14)|Change From Baseline to 104-week Endpoint in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL)|Change From Baseline to 104-week Endpoint in Clinical Dementia Rating - Sum of Boxes (CDR-SB)|Change From Baseline to 104-week Endpoint in Neuropsychiatric Inventory (NPI)|Change From Baseline to 104-week Endpoint in Resource Utilization in Dementia - Lite (RUD-Lite) Caregiver Hours|Change From Baseline to 104-week Endpoint in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy)|Change From Baseline to 104-week Endpoint in Quality of Life in Alzheimer's Disease (QoL-AD)|Change From Baseline to 104-week Endpoint in Mini-Mental State Examination (MMSE)|Change From Baseline to 52-week Endpoint in Plasma Amyloid Beta (Aβ) Levels|Change From Baseline to 104-week Endpoint in Volumetric Magnetic Resonance Imaging (vMRI)|Change From Baseline to 104-week Endpoint in Alzheimer's Disease Assessment Scale - Cognitive Subscore 11-Item Scale (ADAS-Cog11)|Mean Change From Baseline to Endpoint in Amyloid Imaging Parameters in Subjects With Mild Alzheimer's Disease,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1457,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11935|H8A-MC-LZAO,Dec-10,Jul-14,Feb-17,21-May-10,3-May-18,5-Jun-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Carson, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laguna Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lomita, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxnard, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Ana, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fairfield, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norwalk, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newark, Delaware, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange City, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunrise, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Canton, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Decatur, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Traverse City, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Creve Coeur, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amherst, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooklyn, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Latham, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beachwood, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Providence, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norfolk, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roanoke, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Automona De Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mendoza, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gosford, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chermside, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toowoomba, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Iris, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg Heights, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melbourne, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Subiaco, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Curitiba, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Itapira, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Medicine Hat, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Penticton, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenfield Park, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baggiovara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Biella, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chieti, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lido Di Camaiore, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seongnam-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bydgoszcz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gliwice, Poland|For additio",,
NCT01128361,Pilot Study of Aerobic Exercise in Early Alzheimer's Disease(AD),,Completed,Has Results,Alzheimer's Disease,Behavioral: Aerobic Exercise|Behavioral: Stretching,Memory Composite|Executive Function Composite|Disability Assessment for Dementia|Cornell Scale for Depression in Dementia,"Jeff Burns, MD|University of Kansas Medical Center",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,76,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11969,May-10,Apr-15,Apr-15,21-May-10,13-Mar-17,13-Mar-17,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01128361
NCT01126099,Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Prazosin|Drug: Placebo,Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change|Change in Neuropsychiatric Inventory Score|Change in Brief Psychiatric Rating Scale Total Score|Days in Study,Seattle Institute for Biomedical and Clinical Research|National Institute on Aging (NIA)|VA Puget Sound Health Care System,All,"Child, Adult, Older Adult",Not Applicable,20,Other|NIH|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1R01AG033133-01A1|5R01AG033133,Mar-10,Mar-14,Mar-14,19-May-10,21-May-15,21-May-15,"Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01126099
NCT01125631,Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Biological: PF-04360365 8.5 mg/kg|Drug: Placebo,"Safety of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's disease dosed for 6 months. (adverse events, physical/neurologic exams, vital signs, 12-lead ECG, clinical labs, brain MRI, immunogenicity and cognitive assessments)|Pharmacokinetics of PF-04360365 following administration of multiple doses in Japanese subjects with mild to moderate Alzheimer's disease. (plasma PF-04360365 concentrations)|Plasma concentration of Aβ species following administration of multiple doses of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's disease.",Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 1,8,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A9951016,May-10,Aug-11,Aug-11,18-May-10,null,12-Aug-11,"Pfizer Investigational Site, Hirosaki, Aomori, Japan|Pfizer Investigational Site, Fukuoka-shi, Fukuoka, Japan|Pfizer Investigational Site, Fukuyama city, Hiroshima, Japan|Pfizer Investigational Site, Kanazawa, Ishikawa, Japan",,https://ClinicalTrials.gov/show/NCT01125631
NCT01125683,"To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease",,Terminated,No Results Available,Alzheimer´s Disease,Drug: AZD1446|Drug: Donepezil|Drug: Placebo,"To evaluate the effect of single and multiple dosing of AZD1446 and a single dose of donepezil on Quantified electroencephalography (qEEG) and Event-related potentials (ERP) in patients with mild-to-moderate AD.|To measure the relationship between plasma concentration of AZD1446/donepezil and qEEG and ERP.|To evaluate the correlation between changes in qEEG/ERP and changes in cognition, if applicable|Safety as measured by Adverse Events, Vital Signs, ECGs, Clinical Chemistry, Haematology, Urinalysis and Physical Examination.",AstraZeneca,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",D1950C00011|2010-018273-38,Jun-10,Mar-11,Mar-11,18-May-10,null,13-May-11,"Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lugansk, Ukraine|Research Site, Vinnytsia, Ukraine",,https://ClinicalTrials.gov/show/NCT01125683
NCT01122329,A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease,AD,Completed,No Results Available,Alzheimer Disease,Dietary Supplement: caprylidene|Dietary Supplement: Placebo,Regional cerebral blood flow (rCBF)|Examine differences between ApoE ε4 carriers and noncarriers in changes on rCBF and cognition|To examine the effect of AC-1202 on cognition,"University of California, Los Angeles|John Douglas French Foundation",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,17,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",GG-AC-1202,Oct-10,Jan-15,Jan-15,13-May-10,null,23-Mar-15,"200 Medical Plaza, UCLA Medical Center, Los Angeles, California, United States|Center for Neurotherapeutics at UCLA, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01122329
NCT01120002,Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease,Drug: Tamibarotene|Drug: Placebo,Changes in Alzheimer's Disease Assessment Scale (ADAS-JCog)|Changes in Mini-Mental State Examination (MMSE)|Changes in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Changes in Clinician Interview-Based Assessment of Change Plus Caregiver Information (CIBIC-Plus),Osaka City University,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OAM80-01,May-10,Dec-12,Dec-12,10-May-10,null,22-Jul-11,"Osaka City University Hospital, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT01120002
NCT01119638,Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone,EscBPSD,Completed,No Results Available,Agitation|Psychosis|Alzheimer's Disease,Drug: Escitalopram|Drug: Risperidone,Change in total score on the NPI.|Time from initial treatment to the discontinuation of treatment for any reason.,Abarbanel Mental Health Center,All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 4,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ABR-BPSD-001|CO01ABR01022008,Apr-08,Apr-10,May-10,7-May-10,null,24-Jun-15,"Abarbanel MHC, Bat-Yam, Israel",,https://ClinicalTrials.gov/show/NCT01119638
NCT01117818,"Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Biological: active: AFFITOPE AD02|Biological: control: Placebo,"cognitive(ADAS-cog modified) and functional(ADCS-ADL modified)|cognitive(computerised test battery), global(CDR-sb), behavioral(NPI), biomarker (volumetric MRI)",Affiris AG,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,335,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AFF006|2009-016504-22,Sep-10,Dec-13,Dec-13,6-May-10,null,11-Dec-13,"Landeskrankenhaus Hall Gedächtnisambulanz, Hall in Tirol, Austria|LNK Wagner-Jauregg, Dept. of geriatrics, Linz, Austria|Christian Doppler Klinik, Univ. Klinik f. Neurologie, Salzburg, Austria|Studienzentrum der PROSENEX, Ambulatoriumbetriebsges.m.b.H an der Confraternität - Privatklinik Josefstadt, Vienna, Austria|MUW Klin. Pharmakologie und Klinik für Neurologie, Vienna, Austria|MUW, Klin.Abt.f. Biolog. Psychiatrie, Vienna, Austria|SMZ-Ost, Psychiatric Dep., Vienna, Austria|Klinčki Bolnički Centar Rijeka, Klinika za Psihijatriju, Rijeka, Croatia|Opća bolnica Varaždin, Klinika za Neurologiju, Varaždin, Croatia|""BONIFARM"" Poliklinika za kliničku farmakologiju i toksikologiju, Zagreb, Croatia|Klinčki Bolnički Centar Zagreb (REBRO), Klinika za Neurologiju, Zagreb, Croatia|Psihijatrijska Bolnica Vrapče, Zagreb, Croatia|University Thomayer Hospital, Praha 4, Czech Republic|University Hospital Motol, Clinic of Neurology, Praha 5, Czech Republic|CMRR Hôpital Pellegrin, Bâtiment USN Tastet Girard, Bordeaux Cedex, France|Hôpital Neurologique Pierre Wertheimer, Bron, France|Centre Hospitalier Universitaire (CHU) de Dijon, Dijon, France|Centre Mémoire de Ressources et de Recherche, Service de Neurologie, Montpellier Cedex 05, France|Hôpital de la Pitié-Salpêtrière, Paris, France|CHU de rennes Site Hôtel Dieu, RENNES Cedex, France|Hopital La Grave, Toulouse, France|Charite Universitätsmedizin Berlin, Klinik u. Hochschulambulanz f. Psychiatrie u. Psychotherapie, Berlin, Germany|Universitätsklinikum Hamburg-Eppendorf, Klinik für Psychiatrie und Psychotherapie, Hamburg, Germany|Arzneimittelforschung Leipzig GmbH, Studienzentrum, Leipzig, Germany|Zentralinstitut für Seelische Gesundheit, Abt. Gerontopsychiatrie, Mannheim, Germany|Klinik u. Poliklinik f. Psychiatrie u. Psychotherapie der TU München, Munich, Germany|Studienzentrum PD Dr. Steinwachs, Nürnberg, Germany|Klinikum Nürnberg Nord, Klinik f. Psychiatrie u. Psychotherapie, Nürnberg, Germany|NeuroPoint GmbH, Ulm/Donau, Germany|EPAMED, s.r.o., Kosice, Slovakia|Psychiatric Hospital Michalovce, Michalovce, Slovakia",,https://ClinicalTrials.gov/show/NCT01117818
NCT01117948,Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.,,Terminated,Has Results,Alzheimer´s Disease,Drug: Lornoxicam|Drug: Placebo,Cognitive Performance - ADAS-cog+|Activities of Daily Living - ADCS-ADL; Behavioral/Psychiatric Symptoms - NPI,JSW Lifesciences,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,219,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CR081101/CO14950,Sep-09,Apr-11,Apr-11,6-May-10,29-Nov-12,6-Feb-13,,,https://ClinicalTrials.gov/show/NCT01117948
NCT01117181,Apathy in Dementia Methylphenidate Trial (ADMET),ADMET,Completed,Has Results,Apathy|Alzheimer's Disease,Drug: Methylphenidate|Drug: placebo|Other: Psychosocial intervention,Apathy Evaluation Scale (AES)|Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change|Digit Span|Mini-Mental State Exam (MMSE)|Neuropsychiatric Inventory (NPI): Apathy Subscale|Vital Status|Electrolytes|Electrocardiogram (ECG),Johns Hopkins Bloomberg School of Public Health|National Institute on Aging (NIA)|Medical University of South Carolina|Johns Hopkins University|University of Toronto,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01AG033032-01,Jun-10,Aug-12,Aug-12,5-May-10,10-May-13,12-Jun-18,"Johns Hopkins University, Baltimore, Maryland, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01117181
NCT01099332,Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Other: Gastro-retentive zinc cysteine tablet|Other: Tablet identical physically to active comparator containing some lactose,"Biometal levels will be measured in serum by atomic absorption spectrometry|Serum zinc levels after oral administration of two different zinc-containing compounds and placebo will be determined by atomic absorption spectrometry|Comparison of mental status functions at baseline, 3 and 6 months in active comparator versus placebo groups.",Adeona Pharmaceuticals,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CopperProof-2,Nov-09,Jan-11,Jan-11,7-Apr-10,null,28-Jan-11,"Neuroscience Research Unit, Clearwater, Florida, United States|ATIT Neurology, Holiday, Florida, United States|The Cottages, Port Richey, Florida, United States",,https://ClinicalTrials.gov/show/NCT01099332
NCT01097096,"Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients",,Completed,No Results Available,Alzheimer's Disease,Biological: CAD106,"Safety and tolerability assessments (physical/neurological examinations, electrocardiogram (ECG), vital signs, standard and special laboratory evaluations, Magnetic Resonance Imaging (MRIs), Adverse events / Serious adverse events (AE/SAE) monitoring).|Amyloid beta (Aβ)-specific and Qβ carrier-specific antibody response to CAD106 (with either adjuvant) in serum and cerebrospinal fluid (CSF)|Amyloid beta (Aβ)-specific and Qβ carrier-specific T-cell response to CAD106 (with either adjuvant) using peripheral blood mononuclear cells (PBMCs)|Changes over time of the concentrations of disease related markers (Aβ1-40 and Aβ1-42 in plasma; Aβ1-40, Aβ1-42, total-tau, phospho-tau in CSF, or other markers) in patients with mild AD receiving CAD106 (with either adjuvant) compared to placebo",Novartis Pharmaceuticals|Novartis,All,"up to 85 Years   (Child, Adult, Older Adult)",Phase 2,177,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCAD106A2203|2009-012394-35,Mar-10,Dec-12,Dec-12,1-Apr-10,null,25-Apr-16,"Novartis Investigative Site, Costa Mesa, California, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Eatontown, New Jersey, United States|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Sant Cugat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Barakaldo, País Vasco, Spain|Novartis Investigative Site, Mölndal, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Biel, Switzerland|Novartis Investigative Site, Lausanne, Switzerland",,https://ClinicalTrials.gov/show/NCT01097096
NCT01095718,Comparison of 3 Learning Methods to Improve Independent Activities of Daily Living (IADLs) in Alzheimer Disease,C3LM-ILAD,Unknown status,No Results Available,Alzheimer Disease,Behavioral: Errorless Learning|Behavioral: Modeling|Behavioral: Trial and Error,The primary outcome of the intervention will be the performance and errors of participants. Each task is comparable as the assessment procedure remains the same across disease stages.|Baseline neuropsychological assessments. Premorbid intelligence level will be estimated by the National Adult Reading Test (NART). The Mini Mental State Examination (MMSE) will be used to assessed cognitive status.,"Department of Clinical Research and Innovation|Institut National de la Santé Et de la Recherche Médicale, France|Fondation Médéric Alzheimer|Centre Hospitalier Universitaire de Nice",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ID RCB 2009-A01303-54,Mar-10,Mar-12,null,30-Mar-10,null,26-Mar-12,"CHU de Nice Centre Mémoire, Nice, France",,https://ClinicalTrials.gov/show/NCT01095718
NCT01093664,"Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02",,Completed,No Results Available,Alzheimer's Disease,Biological: AFFITOPE AD02,Safety and Tolerability|Immunological and clinical activity,Affiris AG,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AFF004A,Oct-09,Jul-10,Jul-10,26-Mar-10,null,19-Oct-10,"Ordination Schmitz, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT01093664
NCT01094145,Deep Brain Stimulation (DBS) of the Nucleus Basalis Meynert (NBM) to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease,MeynD-DBS,Completed,No Results Available,Alzheimer Disease,Other: Deep brain stimulation,cognitive improvement|determination of the optimal stimulation parameter,University of Cologne,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,6,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",UK-09157,Jan-10,Jan-13,Jan-13,26-Mar-10,null,7-Jun-13,"Uni-Klinik Köln AöR, Cologne, North Rhine Westphalia, Germany",,https://ClinicalTrials.gov/show/NCT01094145
NCT01094340,Thalidomide for Patients With Mild to Moderate Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease,Drug: Thalidomide,Improve cognition,Banner Health,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1R01AG034155-01,Mar-10,Dec-12,Jan-13,26-Mar-10,null,8-Aug-12,"Banner Sun Health Research Institute, Sun City, Arizona, United States",,https://ClinicalTrials.gov/show/NCT01094340
NCT01082965,Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease,,Terminated,Has Results,Alzheimer's Disease,Drug: Donepezil|Drug: Placebo,"Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 1|Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 0 on Day 8|Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 8|Change From Baseline in Arterial Spin Label (ASL) Perfusion at Hour 4 on Day 1 and at Hour 0, 4 on Day 8|Change From Baseline in CogState Continuous Paired Associate Learning (CPAL) at Hour 5 on Day 1 and at Hour 1, 5 on Day 8|Change From Baseline in Rey Auditory Verbal Learning Test (RAVLT): Immediate and Delayed Recall at Hour 5 on Day 8|Change From Baseline in CogState Test Battery at Hour 5 on Day 1 and at Hour 0, 5 on Day 8",Pfizer,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",A9001437,Jul-10,Jul-12,Jul-12,9-Mar-10,12-Sep-13,12-Sep-13,"Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01082965
NCT01081743,Effectiveness of Care Management in Alzheimer Patients,AIDALZ,Completed,No Results Available,Alzheimer Disease or Associated Disorder|Mild to Moderately Severe Dementia,Other: Intervention of the social worker,NeuroPsychiatric Inventory (NPI)|Cohen-Mansfield Agitation Inventory (CMAI)|Apathy Inventory|Disablement Assessment for Dementia (DAD)|Mini Mental State Examination (MMSE)|Global Deterioration Scale (GDS)|Montgomery-Asberg Depression Rating Scale (MADRS)|Questionnaire Quality of Life - Alzheimer's Disease (QoL-AD)|Burden Interview of Zarit|Resource utilization in dementia scale (RUD Lite)|Medical Outcome Study Short Form 36-item health survey (MOS SF-36)|Institutionalization|Tiredness scale,"Institut de Sante Publique, d'Epidemiologie et de Developpement",All,"Child, Adult, Older Adult",Not Applicable,270,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,RCB : 2009-A00326-51,24-Nov-09,2-Oct-13,2-Oct-13,5-Mar-10,null,28-Aug-17,"ISPED (Institut de Santé Publique, d'Epidémiologie et de Développement), Bordeaux, France",,https://ClinicalTrials.gov/show/NCT01081743
NCT01079819,"Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163",,Completed,No Results Available,Alzheimer's Disease,Drug: BMS-708163|Drug: Placebo,"Safety assessments will be based on adverse event reports and the results of vital sign measurements, ECGs, physical exams and clinical laboratory tests. Adverse events will be tabulated and reviewed for potential significance and clinical importance|Single-dose pharmacokinetic parameters (Cmax, Tmax, AUC(0-T), AUC(INF), T-HALF and multiple-dose pk parameters (Cmax, Tmax, Cmin, AUC(TAU), T-HALF, and accumulation index will be derived from plasma concentration versus time data",Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",CN156-029,Apr-10,Dec-10,Dec-10,3-Mar-10,null,7-Feb-11,"West Coast Clinical Trials, Llc, Cypress, California, United States|California Clinical Trials Medical Group, Glendale, California, United States|Iberica Clinical Research Center, Eatontown, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01079819
NCT01078168,Alzheimer`s Disease Acitretin Medication,ADAM,Completed,Has Results,Alzheimer Disease,Drug: Acitretin|Drug: Placebo,Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline,K. Lieb|Alzheimer Forschungsinitiative e.V. (AFI)|Johannes Gutenberg University Mainz,All,"18 Years and older   (Adult, Older Adult)",Phase 2,22,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ADAM|2009-011881-27,Mar-10,Jan-13,May-13,2-Mar-10,2-Feb-18,2-Feb-18,"Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz, Mainz, Rheinland-Pfalz, Germany|Universität Rostock, Rostock, Germany",,https://ClinicalTrials.gov/show/NCT01078168
NCT01075763,A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease,REAL,Completed,Has Results,Alzheimer's Disease,Drug: Interferon beta-1a|Drug: Placebo,"Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score|Mini Mental Status Examination (MMSE) Score|Alzheimer's Disease Assessment Scale, Non-cognitive Subscale (ADAS-NonCog) Score|Instrumental Activities of Daily Living (IADL) Score|Physical Self-Maintenance Scale (PSMS) Score|Clinician's Interview Based Impression of Change (CIBIC-PLUS) Score|Geriatric Depression Scale (GDS) Score|Global Deterioration Scale Score","Merck KGaA, Darmstadt, Germany|Merck Serono S.P.A., Italy",All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 2,42,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",24386,Nov-04,May-08,May-08,25-Feb-10,4-Apr-12,13-Feb-14,"U.VA. Neurologia - Azienda Ospedaliera Garibaldi Nesina, Catania, CT, Italy",,https://ClinicalTrials.gov/show/NCT01075763
NCT01073228,Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Central Nervous System Diseases|Cognition,Drug: EVP-6124|Drug: Placebo,Alzheimer's Disease Assessment Scale-Cognitive subscale-13 (ADAS-cog-13)|Alzheimer's Disease Assessment Scale-Cognitive subscale-11|Controlled Oral Word Association Test|Category Fluency Test|Clinical Dementia Rating Scale Sum of Boxes|Alzheimer's Disease Cooperative Study-Activities of Daily Living|Neuropsychiatric Inventory|Mini-Mental State Exam,FORUM Pharmaceuticals Inc|INC Research Limited,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,409,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EVP-6124-010,Apr-10,Nov-11,Feb-12,23-Feb-10,null,25-Apr-14,"HOPE Research Institute, Phoenix, Arizona, United States|Catalina Research Institute, Chino, California, United States|ATP Clinical Research, Costa Mesa, California, United States|University of California, Irvine, Orange, California, United States|Radiant Research, Santa Rosa, California, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Memory Enhancement Center of NJ, Toms River, New Jersey, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Advanced Bio Behavioral Sciences Inc., Elmsford, New York, United States|University of Rochester Medical Center at MCH, Rochester, New York, United States|Columbus Research and Wellness Institute, Columbus, Ohio, United States|Summit Research Network, Portland, Oregon, United States|FutureSearch Trials of Dallas, L.P., Dallas, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States|Clinical Site 1, Bucharest, Romania|Clinical Site 2, Bucharest, Romania|Clinical Site 3, Bucharest, Romania|Clinical Site 4, Bucharest, Romania|Clinical Site 5, Bucharest, Romania|Iasi, Romania|Oradea, Romania|Tirgu Mures, Romania|Kazan, Russian Federation|Clinical Site 1, Moscow, Russian Federation|Clinical Site 2, Moscow, Russian Federation|Saratov, Russian Federation|Clinical Site 3, St Petersburg, Russian Federation|Clinical Site 4, St Petersburg, Russian Federation|Clinical Site 1, St. Petersburg, Russian Federation|Clinical Site 2, St. Petersburg, Russian Federation|Voronezh, Russian Federation|Yekaterinburg, Russian Federation|Clinical site 1, Belgrade, Serbia|Clinical Site 2, Belgrade, Serbia|Kragujevac, Serbia|Nis, Serbia|Dnipropetrovs'k, Ukraine|Donets'k, Ukraine|(1), Kyiv, Ukraine|(2), Kyiv, Ukraine|Odesa, Ukraine|Simferopol, Ukraine|Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT01073228
NCT01072812,Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment,,Terminated,No Results Available,Alzheimer's Disease|Amnestic Mild Cognitive Impairment,Drug: Posiphen® tartrate capsules,Pharmacokinetics|Pharmacodynamics|Biomarkers|Safety,QR Pharma Inc.,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1,5,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QR 12001,Feb-10,Jul-10,Jul-10,22-Feb-10,null,22-Apr-15,"CEDRA Clinical Research, LLC, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01072812
NCT01068353,Safety and Tolerability of Etanercept in Alzheimer's Disease,STEADI-09,Completed,No Results Available,Alzheimer's Disease,Biological: Etanercept|Other: Placebo,"Frequency of adverse events and serious adverse events (the study is a Phase II safety trial)|Difference in change in Alzheimer's Disease Assessment Scale - Cognitive Section (ADAS-cog) total score between treated and placebo groups from baseline to end point at 6 months|Difference in change in Neuropsychiatric Inventory (NPI) total score between treated and placebo groups from baseline to end point at 6 months|Difference in change in Clinician's Global Impression of Change (CGIC) and Carer's Impression of Change (Carer-IC) total score between treated and placebo groups from baseline to end point at 6 months|Difference in change in Mini-Mental State Examination (MMSE) total score between treated and placebo groups from baseline to end point at 6 months|Difference in change in Sickness Behaviour Scale between treated and placebo groups from baseline to end point at 6 months|To establish whether a pro-inflammatory baseline cytokine profile predicts better response to treatment with etanercept|To examine the effects of etanercept on inflammatory markers in the cerebrospinal fluid (CSF) of patients with Alzheimer's disease, and the relationship of these factors with clinical outcome",University of Southampton|Hampshire Hospitals NHS Foundation Trust|Wyeth is now a wholly owned subsidiary of Pfizer,All,"55 Years and older   (Adult, Older Adult)",Phase 2,41,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",STEADI-09|2009-013400-31,Jan-11,Dec-13,null,12-Feb-10,null,23-Apr-14,"Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, Hampshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01068353
NCT01066481,A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease,,Withdrawn,No Results Available,Alzheimer's Disease|Dementia|Dimebon|Investigational Drug,Drug: PF-01913539 5 mg|Drug: Placebo,"Mean change in the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog) score from baseline.|Distribution of Clinician's Interview-Based Impression of Change plus Caregiver (CIBIC-plus) Input|Mean change in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADAS-ADL) score from baseline.|Mean change in Neuropsychiatric Inventory (NPI) score from baseline.|Mean change in Mini-Mental State Examination (MMSE) score from baseline.|Mean change in each item of Resource Utilization In Dementia(RUD) Lite from baseline.|Adverse events, physical examination, vital signs (blood pressure, temperature, and heart rate), 12-lead ECG, and laboratory tests (hematology, blood chemistry and urinalysis).|Population PK parameters (CL/F, V/F, etc.)",Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 2,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B1451010,Apr-10,Mar-12,Apr-12,10-Feb-10,null,29-Jun-10,,,https://ClinicalTrials.gov/show/NCT01066481
NCT01066546,An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease,,Terminated,Has Results,Alzheimer's Disease,Drug: Dimebon tablet for oral administration,"Number of Participants With Adverse Events (AEs)|Change From Baseline in Severe Impairment Battery (SIB) at Week 6, 12 and 26|Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Version (ADCS-ADLsev) at Week 6, 12 and 26|Change From Baseline in Mini-Mental State Examination (MMSE) at Week 12 and 26|Change From Baseline in Neuropsychiatric Inventory (NPI) at Week 6, 12 and 26|Sum of Delusions and Hallucinations Sub-domain Scores of Neuropsychiatric Inventory (NPI) at Week 26|Change From Baseline in Resource Utilization in Dementia - Lite Version (RUD-Lite) at Week 12 and 26|Change From Baseline in European Quality of Life 5 Domain Scale (EQ-5D) at Week 12 and 16","Pfizer|Medivation, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,5,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B1451030,Apr-10,Jul-10,Jul-10,10-Feb-10,2-Oct-12,2-Oct-12,"Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, Los Alamitos, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Delray Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT01066546
NCT01061489,Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment,,Completed,No Results Available,Mild Cognitive Impairment (MCI)|Mild Alzheimer's Disease,Other: auditory discrimination training|Other: physical movement training,"Change in global cognition|electrophysiological, MRI, blood and liquor correlates",University of Konstanz|University of Ulm,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,65,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,WIN-Kol-09,Aug-09,Mar-13,Mar-13,3-Feb-10,null,14-Jul-16,"University of Konstanz, Konstanz, Germany|University of Ulm, Memory Clinic, Ulm, Germany",,https://ClinicalTrials.gov/show/NCT01061489
NCT01059877,Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia,,Completed,Has Results,Dementia,Device: 1072nm infrared Photobiomodulation|Device: Photobiomodulation SIMULATED,Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) Delayed Word Recall.,Quietmind Foundation|Maculume Limited,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,11,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",QMF-MID12610,Jan-10,Feb-12,Feb-12,1-Feb-10,27-Sep-18,27-Sep-18,"Quietmind Foundation, Plymouth Meeting, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01059877
NCT01058941,Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Lipoic acid and fish oil concentrate|Drug: Placebo,Change From Baseline in Activities of Daily Living (ADL) at 18 Months|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 18 Months,Oregon Health and Science University,All,"55 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,67,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01AG033613-01A1,Sep-10,Dec-14,Dec-14,29-Jan-10,13-Apr-17,13-Apr-17,"Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01058941
NCT01057030,Multiple Dose Japanese Bridging Study,,Completed,No Results Available,Alzheimer Disease,Drug: BMS-708163|Drug: Placebo,"BMS-708163 or placebo in Japanese and non-Japanese: Safety and tolerability (AE's, ECG, vital signs, safety labs)|BMS-708163 pharmacokinetic parameters (Cmax, Cmin, Ctrough, Tmax, AUC(TAU), AI, and CLT/F and T-HALF (only following Day 14 dose))",Bristol-Myers Squibb,Male,20 Years to 45 Years   (Adult),Phase 1,22,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",CN156-038,Mar-10,Jun-10,Jun-10,27-Jan-10,null,25-Jan-11,"California Clinical Trials Medical Group, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT01057030
NCT01055392,Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease,,Unknown status,No Results Available,Cognitive Impairment|Alzheimer Disease,Drug: Lithium Carbonate|Drug: Placebo,"effect of lithium to delay progression of cognitive deficits in patients with amnestic MCI|effect of lithium on CSF levels of Total Tau, Phosphorylated Tau and Amyloid-beta42|the effect of lithium on the activity of GSK3β in platelets and leukocytes drawn from peripheral blood.",University of Sao Paulo,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 2,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",OVForlenza-Lithium|554535/2005-0,Mar-07,Mar-09,null,25-Jan-10,null,25-Jan-10,"Institute of Psychiatry, Faculty of Medicine - University of Sao Paulo, Sao Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT01055392
NCT01055561,A Study of Acupuncture for Patients With Behavioural and Psychological Symptoms of Dementia,,Completed,No Results Available,Alzheimer's Disease|Dementia,Other: Acupuncture,"The Questionnaire of Acupuncture Events|Change from baseline on Mini-Mental State-Examination（MMSE）,The Behavioral Pathology in Alzheimer's Disease Rating Scale（BEHAVE-AD）and Activity of Daily Living Scale（ADL）|Treatment Emergent Symptom Scale (TESS)",Chengdu University of Traditional Chinese Medicine,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008SZ0135,Jan-10,Feb-11,Mar-11,25-Jan-10,null,30-May-16,"Yong Tang, Chengdu, Sichuan, China",,https://ClinicalTrials.gov/show/NCT01055561
NCT01054976,The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Galantamine,Change From Baseline in Simple Reaction Time|Change From Baseline in Choice Reaction Time|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Change From Baseline in Korean Version of Disability Assessment for Demential Scale (DAD-K)|Change From Baseline in Seoul-Instrumental Activities of Daily Livings (S-IADL),"Janssen Korea, Ltd., Korea",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,99,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR015850|GAL-KOR-21|GALALZ4039,Oct-06,Feb-09,Feb-09,22-Jan-10,24-Dec-12,24-Dec-12,,,https://ClinicalTrials.gov/show/NCT01054976
NCT01049555,Contribution of Actigraphy and Recognition Video in Apathy Assessment of Alzheimer's Disease : Experimental Research,09-PP-06,Completed,No Results Available,Alzheimer's Disease,Other: Actigraphy and video recording signal,assessment of motricity|video recording,Centre Hospitalier Universitaire de Nice,All,65 Years and older   (Older Adult),Not Applicable,42,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,09-PP-06,Sep-11,Sep-12,Dec-12,14-Jan-10,null,30-Sep-15,"Nice University Hospital, Nice, France",,https://ClinicalTrials.gov/show/NCT01049555
NCT01047579,"A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease",BETTER,Completed,No Results Available,Alzheimer's Disease,Drug: Rivastigmine transdermal,Caregiver questionnaire|Safety and Tolerability. Safety assessments include vital signs and adverse events (AEs),Novartis Pharmaceuticals|Novartis,All,"50 Years and older   (Adult, Older Adult)",Phase 4,51,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,CENA713DIL01,Apr-10,Jan-12,Jan-12,13-Jan-10,null,24-Feb-17,"Novartis Investigative Site, Ashkelon, Israel|Novartis Investigational Site, Haifa, Israel|Novartis Investigative Site, Holon, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01047579
NCT01047254,Bupropion for the Treatment of Apathy in Alzheimer's Dementia,APA-AD,Completed,No Results Available,Apathy in Dementia,Drug: Elontril|Drug: placebo,Change in Apathy Evaluation Scale (AES) score|NPI total score;NPI caregivers' distress total score;ADCS-ADL; QoL-AD; RUD;ADAScog;MMSE,"University Hospital, Bonn|University of Cologne|Physician of neurology, psychiatry and psychotherapy Horn, MD; Bad Honnef|Charite University, Berlin, Germany|Universität Duisburg-Essen|University of Erlangen-Nürnberg|University of Freiburg|University Medical Center Goettingen|Saarland University|Johannes Gutenberg University Mainz|Heidelberg University|Philipps University Marburg Medical Center|Ludwig-Maximilians - University of Munich|University of Rostock|University Hospital Tuebingen|University of Ulm",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,110,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2007-005352-17,Jan-10,Jul-14,Jul-14,12-Jan-10,null,9-May-17,"Department of Psychiatry, University Bonn, Bonn, Germany",,https://ClinicalTrials.gov/show/NCT01047254
NCT01044758,Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI),,Completed,Has Results,Mild Cognitive Impairment (MCI),Drug: Levetiracetam 62.5mg|Drug: Levetiracetam 125mg|Drug: Levetiracetam 250mg|Drug: Placebo,Brain Activity in the Dentate Gyrus / CA3 Subregion of the Hippocampus Measured With Blood Oxygenation Level Dependent (BOLD) Functional MRI|Behavioral Performance as Assessed in the Functional Magnetic Resonance Imaging (fMRI) Memory Task,Johns Hopkins University|National Institute on Aging (NIA),All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,96,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",NA_00030573|RC2AG036419,Dec-09,Jul-12,Jul-12,8-Jan-10,21-Aug-17,21-Aug-17,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01044758
NCT01042314,Drug-Drug Interaction Study With Aricept® (Donepezil),,Completed,No Results Available,Alzheimer Disease,Drug: Donepezil|Drug: BMS-708163,"Aricept® alone and with BMS-708163: Aricept® Multiple-dose pharmacokinetic parameters (Cmax, Tmax, AUC (TAU), and Ctrough) will be assessed without BMS-708163 on Day 14 and with BMS-708163 (Ctrough) on Day 28|Aricept® alone and with BMS-708163: Safety and tolerability based on adverse events, ECG, vital signs and safety labs",Bristol-Myers Squibb,All,18 Years to 55 Years   (Adult),Phase 1,18,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),CN156-008,Jan-10,Apr-10,Apr-10,5-Jan-10,null,25-Jan-11,"Parexel International - Baltimore Epcu, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01042314
NCT01039701,"4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease",ROBIN,Completed,No Results Available,Mild to Moderate Alzheimer's Disease,Drug: AZD1446|Drug: Placebo,Nature and incidence of adverse events|To evaluate any effects PK of AZD1446 as an add-on treatment to donepezil on the PK of donepezil|To characterize the PK of AZD1446 as an add-on treatment to donepezil in AD patients|To explore the effects of 3 dose regimens of AZD1446 compared to placebo as an add-on treatment to donepezil on changes in global functioning using ADCS-CGIC,AstraZeneca,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,99,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",D1950C00006,Dec-09,Jul-10,Jul-10,25-Dec-09,null,11-Aug-10,"Research Site, Litomerice, Czech Republic|Research Site, Praha 10 - Strasnice, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Miskolc, Hungary|Research Site, Nagykallo, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Bratislava, Slovakia|Research Site, Roznava, Slovakia|Research Site, Zlate Moravce, Slovakia",,https://ClinicalTrials.gov/show/NCT01039701
NCT01038726,Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults,,Completed,No Results Available,Aging|Alzheimer's Disease,Other: Exercise Training|Other: Cognitive Training|Other: Flexibility Training|Other: Educational Sessions,Brain activation patterns measured by functional MRI|Neuropsychological Testing|Exercise assessment,The Cleveland Clinic|National Institutes of Health (NIH),All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,108,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,NIH AG035775-01,Dec-09,Sep-12,Sep-12,24-Dec-09,null,18-Sep-13,"The Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01038726
NCT01039194,Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER),,Completed,No Results Available,Alzheimer Disease,Drug: galantamine|Drug: BMS-708163,"Galantamine alone and with BMS-708163: Galantamine PK parameters (Cmax, Tmax, AUC(TAU) and Ctrough rations will be assessed without BMS-708163 Day 14) and with BMS708-163 (Ctrough Day 24)|Galantamine alone and with BMS 708163: Safety and tolerability (AE's, ECG, vital signs, safety labs)",Bristol-Myers Squibb,All,18 Years to 55 Years   (Adult),Phase 1,18,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),CN156-009,Jan-10,Apr-10,Apr-10,24-Dec-09,null,25-Jan-11,"Parexel International - Baltimore Epcu, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01039194
NCT01035138,A Study of Semagacestat for Alzheimer's Patients,Identity XT,Completed,Has Results,Alzheimer's Disease,Drug: semagacestat,Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog11) at Week 16 After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at Week 16 After Cessation of Study Drug|Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at Week 12|Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) at Week 12|Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45-PET) at Week 12|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog11) at Week 12|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12) at Week 12|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog14) at Week 12|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at Week 12|Mean Concentration of LY450139|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12) at Week 16 After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog14) at Week 16 After Cessation of Study Drug|Change From Baseline in Clinical Dementia Rating Scale (Sum of Boxes) (CDR-SB) at Week 24|Change From Baseline in Mini-Mental State Examination (MMSE) at Week 24|Change From Baseline in Neuropsychiatric Inventory (NPI) at Week 24|Change From Baseline in EuroQol-5D (EQ-5D) at Week 24|Change From Baseline in Resource Utilization in Dementia-Lite Questionnaire (RUD-Lite) at Week 12,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 3,180,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5930|H6L-MC-LFBF,Dec-09,Apr-11,Apr-11,18-Dec-09,25-Sep-14,25-Sep-14,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Costa Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laguna Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lomita, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooksville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Deerfield Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Lauderdale, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Petersburg, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa Bay, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Orleans, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyannis, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jenkintown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Providence, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Geelong, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg West, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Penticton, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antofagasta, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valdivia, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuopio, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muenchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashkelon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukui, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellville, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01035138
NCT01035164,Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers,,Completed,No Results Available,Positron-Emission Tomography|Alzheimer's Disease,Drug: F-18 FEDAA1106 (BAY85-8101),Visual analysis/description of the uptake and description of brain PET scans|Standardized uptake value (SUV) in various cerebral regions/volumes of interest (ROI/VOI) assumed and found to be involved in the pathophysiology of Alzheimer's disease.|Standard quantification variables derived from 3D PET imaging and brain modeling|Standard Safety Measurement:adverse event collection|Standard Safety Measurement:electrocardiogram|Standard Safety Measurement:safety laboratory|Standard Safety Measurement: vital signs,Bayer,All,"50 Years and older   (Adult, Older Adult)",Phase 1,25,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,91683|2006-006045-14|311401,Jun-07,Jan-10,Jan-10,18-Dec-09,null,8-Jan-15,"Amsterdam, Netherlands|Stockholm, Sweden|Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01035164
NCT01028053,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease,Drug: Flutemetamol (18F) Injection,Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.|The of Normal and Abnormal Subjects Who Convert to Probable Alzheimer's Disease (pAD) Within the Follow up Period.,"GE Healthcare|Medpace, Inc.|i3 Statprobe|i3 Research|Quintiles, Inc.",All,"60 Years and older   (Adult, Older Adult)",Phase 3,365,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,GE-067-005,Dec-09,Jan-14,Jan-14,9-Dec-09,11-Sep-14,11-Sep-14,"GE Healthcare, Princeton, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01028053
NCT01028209,Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions,PBR06,Terminated,No Results Available,Alzheimer Disease|Parkinson Disease|Multiple Sclerosis,Drug: [18F] PBR06,"To evaluate [18F] PBR06 PET imaging as a tool to detect microglial activation in the brain of AD, PD and MS research participants.",Institute for Neurodegenerative Disorders,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PBR06 001,Nov-09,22-Sep-10,22-Sep-10,9-Dec-09,null,3-Apr-19,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01028209
NCT01028911,"A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease",,Terminated,Has Results,Alzheimer's Disease,Drug: PF-03654746|Drug: Placebo,Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Number of Participants With Clinically Significant Laboratory Test Abnormalities|Number of Participants With Clinically Significant Change From Baseline in Physical Examination|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Baseline|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 5|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 10|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 15|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 20|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 25|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 30|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Follow-up|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 5|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 10|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 15|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 20|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 25|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 30|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Follow-up|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 5|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 10|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 15|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 20|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 25|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 30|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Follow-up|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for PF-03654746|Maximum Serum Concentration (Cmax) for PF-03654746|Time to Reach Maximum Observed Serum Concentration (Tmax) for PF-03654746|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for Donepezil|Maximum Plasma Concentration (Cmax) for Donepezil|Time to Reach Maximum Observed Plasma Concentration (Tmax) for Donepezil,Pfizer,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A8801016,Dec-09,May-10,May-10,9-Dec-09,4-Jun-14,4-Jun-14,"Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Wichita, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01028911
NCT01029132,Characteristics of Treatment Responders to Galantamine,,Completed,No Results Available,Dementia,Drug: galantamine,Alzheimer's Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K)|Seoul-Activities of Daily Living (S-ADL) Seoul-Instrumental Activities of Daily Living (S-IADL) Korean version Neuropsychiatric Inventory (K-NPI),"Samsung Medical Center|Janssen Korea, Ltd., Korea",All,"Child, Adult, Older Adult",Not Applicable,66,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007-04-021,Apr-07,Oct-09,Oct-09,9-Dec-09,null,6-Jan-16,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01029132
NCT01024660,The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil,,Completed,No Results Available,Alzheimer's Disease,Drug: Donepezil|Drug: Placebo to match Aricept,CogState Computerized Neurological Test Battery|Neuropsychological Test Battery (NTB)|Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog)|Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC),AstraZeneca,All,"55 Years to 85 Years   (Adult, Older Adult)",Early Phase 1,155,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",D2285M00010,Dec-09,Jan-11,Jan-11,3-Dec-09,null,8-Feb-11,"Research Site, Ottawa, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Reearch Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Callao, Lima, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Chojnice, Poland|Research Site, Gdansk, Poland|Research Site, Kalisz, Poland|Research Site, Pila, Poland|Research Site, Poznan, Poland|Research Site, Scinawa, Poland|Research Site, Sopot, Poland|Research Site, Warszawa, Poland|Research Site, Cape Town, Western Cape, South Africa|Research Site, Roodepoort, South Africa",,https://ClinicalTrials.gov/show/NCT01024660
NCT01025466,Exelon Patch and Combination With Memantine Comparative Trial,EXPECT,Completed,No Results Available,Alzheimer's Disease,"Drug: Rivastigmine transdermal patch (Exelon patch), memantine|Drug: Rivastigmine transdermal patch",Retention rate at week 16 after randomization|Change from baseline at week 16 in Alzheimer's Disease Assessment Scale-Cognitive subscale|Change from baseline at week 16 in Mini-Mental State Examination|Change from baseline at week 16 in Frontal Assessment Battery|Change from baseline at week 16 in Alzheimer's Disease Cooperative Study - Activities of Daily Living|Change from baseline at week 16 in Caregiver-Administered Neuropsychiatric Inventory|Change from baseline at week 16 in Cohen Mansfield Agitation Inventory|Change from baseline at week 16 in Clinical Dementia Rating Scale-Sum of Boxes|Safety,Inha University Hospital,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,206,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EXPECT,Dec-08,Nov-09,Apr-10,3-Dec-09,null,19-May-10,"Soonchunhyang University Hospital, Bucheon, Korea, Republic of|The Catholic University of Korea Hospital, Bucheon, Korea, Republic of|Donga University Hospital, Busan, Korea, Republic of|Changwon Fatima Hospital, Changwon, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Daejun Eulji University Hopistal, Daejun, Korea, Republic of|Dongguk University Medical Center, Goyang, Korea, Republic of|Myongji Hospital, Goyang, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Wonkwang University Hospital, Iksan, Korea, Republic of|Inha Univeristy Hospital, Incheon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, Republic of|Maryknoll Hospital, Pusan, Korea, Republic of|Bobath Memorial Hospital, Seongnam, Korea, Republic of|Kyughee University Medical Center, Seoul, Korea, Republic of|Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|Sungkyunkwan University, Samsung Seoul Hospital, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Hallym University Hospital, Seoul, Korea, Republic of|Ewha Womans University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul Eulji Hospital, Seoul, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|Seoul National University Boramae Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01025466
NCT01023425,Clinical Trial of Donepezil Between the Naive Group and the Switching Group,,Completed,No Results Available,Alzheimer's Disease|Dementia,Drug: donepezil,"Alzheimer's Disease Assessment Scale-Cognitive, Korean version (ADAS-Cog-K)|Seoul Activities of Daily Living (S-ADL)|Seoul-Instrumental Activities of Daily Living (S-IADL)|Korean Neuropsychiatric Inventory (K-NPI)",Samsung Medical Center|Eisai Korea Inc.,All,"Child, Adult, Older Adult",Not Applicable,72,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008-02-072,Feb-08,Apr-09,Apr-09,2-Dec-09,null,6-Jan-16,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01023425
NCT01023685,To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients,,Completed,No Results Available,Alzheimer Disease,Biological: CAD106,"Safety/tolerability assessments at multiple time points including but not limited to screening, and through to the end of the study to week 66.|Collect long-term safety information through SAE's collection for two years after completion of the extension study.|Immune response, cognitive and functional assessments at multiple time points including but not limited to baseline, and through to the end of the study to week 66.|Evaluate the antibody response after 4 additional injections in the Extension study, in patients initially treated with CAD106 in the Core study.",Novartis,All,"Child, Adult, Older Adult",Phase 2,24,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCAD106A2202E1,Dec-09,Feb-12,Feb-12,2-Dec-09,null,26-Jun-13,"ATP Clinical Research, Inc., Costa Mesa, California, United States|Alpin Research Center, Boulder, Colorado, United States|Sunrise Clinical Research, Inc., Hollywood, Florida, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Volunteer Research Group, Knoxville, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01023685
NCT01023867,Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia,,Completed,No Results Available,Alzheimer's Disease|Dementia,Drug: donepezil,"Alzheimer's Disease Assessment Scale-Cognitive, Korean version (ADAS-Cog-K)|Seoul Activities of Daily Living (S-ADL)|Seoul-Instrumental Activities of Daily Living (S-IADL)|Korean Neuropsychiatric Inventory (K-NPI)",Samsung Medical Center|Eisai Korea Inc.,All,"Child, Adult, Older Adult",Not Applicable,88,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007-03-039,Mar-07,Jun-10,Jun-10,2-Dec-09,null,6-Jan-16,"Samsung Medical Center, Seoul City, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01023867
NCT01021644,"Genes, Exercise, Memory and Neurodegeneration",,Completed,No Results Available,Alzheimer's Disease,Behavioral: aerobic exercise-training|Behavioral: stretch exercise,AD Assessment Scale-Cognitive (ADAS-COG)|Mini-Mental State Exam (MMSE)|CDR (Clinical Dementia Rating) Scale|Logical Memory Test (Delayed Paragraph Recall)|Visuospatial and Visuographic: Clock Drawing Test|American National Adult Reading Test (ANART)|Neuropsychiatric Inventory Q (NPIQ)|Geriatric Depression Scale|Activities of Daily Living (ADCS-ADL)|PET imaging to measure cerebral glucose homeostasis/metabolism,Howard University,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,73,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IA0172|1R01AG031517-01A209|1R01AG031517-01,Oct-09,Dec-13,Dec-13,30-Nov-09,null,14-Feb-14,"Howard University General Clinical Research Center (GCRC), Washington, District of Columbia, United States|Temple University Exercise Physiology Laboratory, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01021644
NCT01020838,Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology,,Completed,Has Results,Alzheimer Disease,Drug: Florbetaben (BAY94-9172),"Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral Beta-amyloid in Postmortem Specimens|Sensitivity and Specificity of the Majority Read ""Whole Brain"" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification With Bielschowsky Silver Staining (SOT 1).|Sensitivity and Specificity of the Majority Read ""Whole Brain"" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With Histopathological Verification With Bielschowsky Silver Staining and Immunohistochemistry (SOT 2).|Sensitivity and Specificity of the Majority Read ""Whole Brain"" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification According to CERAD Criteria (SOT 3).|Sensitivity and Specificity of the Subject Level Composite SUVR Calculated Based on Pathology Results.|Subject Level Composite SUVRs by SOT for Baseline and Available Follow-Up Scans",Life Molecular Imaging SA,All,"21 Years and older   (Adult, Older Adult)",Phase 3,218,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,14595|2009-012569-79,Nov-09,Sep-11,Dec-13,26-Nov-09,25-Mar-15,27-May-16,"Sun City, Arizona, United States|Stanford, California, United States|Tampa, Florida, United States|Teaneck, New Jersey, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Heidelberg, Victoria, Australia|Lille, France|Strasbourg, France|Jülich, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Toyohashi, Aichi, Japan|Toyohashi, Aichi, Japan|Toyohashi, Aichi, Japan|Isezaki, Gunma, Japan|Hamamatsu, Shizuoka, Japan|Itabashi-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01020838
NCT01019421,Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Lu AE58054|Drug: Placebo,"Change in cognition after 24 weeks|Change in global function, activities of daily living, safety and tolerability, pharmacokinetics/pharmacodynamics",H. Lundbeck A/S,All,"50 Years and older   (Adult, Older Adult)",Phase 2,278,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",12936A|EudraCT 2009-011845-24,Dec-09,Dec-11,null,25-Nov-09,null,6-Jan-12,"AU004, East Gosford, Australia|AU002, Heidelberg West, Australia|AU005, Kew, Australia|AU001, Nedlands, Australia|AU003, Woodville South, Australia|CA005, Toronto, Ontario, Canada|CA007, Burlington, Canada|CA006, Calgary, Canada|CA008, Gatineau, Canada|CA011, Kamloops, Canada|CA002, Kingston, Canada|CA010, Penticton, Canada|CA004, Sherbrooke, Canada|CA001, Toronto, Canada|CZ001, Kladno, Czech Republic|CZ002, Kutna Hora, Czech Republic|CZ007, Litomerice, Czech Republic|CZ004, Praha 8, Czech Republic|CZ005, Praha, Czech Republic|CZ008, Praha, Czech Republic|CZ006, Praha, Czech Republic|CZ003, Rychnov nad Kneznou, Czech Republic|DE004, Ellwangen, Germany|DE003, Erbach, Germany|DE005, Frankfurt am Main, Germany|DE002, Gunzburg, Germany|DE001, Homburg, Germany|DE006, Leipzig, Germany|DE009, Munich, Germany|DE007, Unterhaching, Germany|IT001, Brescia, Italy|IT005, Brescia, Italy|IT008, Firenze, Italy|IT003, Genova, Italy|IT004, Lamezia Terme, Italy|IT007, Milano, Italy|IT002, Roma, Italy|PL002, Bydgoszcz, Poland|PL001, Krakow, Poland|PL007, Lublin, Poland|PL003, Sopot, Poland|PL009, Szczecin, Poland|PL005, Warszawa, Poland|PL004, Warszaw, Poland|PL008, Warszaw, Poland|ES002, Barcelona, Spain|ES003, Elche, Spain|ES004, Madrid, Spain|ES005, Madrid, Spain|ES006, Majadahonda, Spain|ES001, Terrassa, Spain",,https://ClinicalTrials.gov/show/NCT01019421
NCT01018875,Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: ABT-288|Drug: donepezil|Drug: placebo,ADAS-cog: Alzheimer's Disease Assessment Scale - Cognition portion|MMSE: Mini Mental Status Exam|NPI: Neuropsychiatric Inventory|ADCS-ADL: Alzheimer's Disease Cooperative Study|CIBIC-Plus: Clinician Interview-Baed Impression of Change - plus,"AbbVie (prior sponsor, Abbott)|AbbVie",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,242,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M10-822|2009-010704-29,Dec-09,Feb-11,Feb-11,24-Nov-09,null,5-Jun-18,"Site Reference ID/Investigator# 22687, Kazan, Russian Federation|Site Reference ID/Investigator# 22636, Moscow, Russian Federation|Site Reference ID/Investigator# 23702, Moscow, Russian Federation|Site Reference ID/Investigator# 22689, Saratov, Russian Federation|Site Reference ID/Investigator# 22635, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22633, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22637, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22632, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22634, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 24563, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22630, Dnipropetrovs'k, Ukraine|Site Reference ID/Investigator# 22625, Donetsk, Ukraine|Site Reference ID/Investigator# 22624, Glevakha, Ukraine|Site Reference ID/Investigator# 22629, Kharkiv, Ukraine|Site Reference ID/Investigator# 24565, Kherson, Ukraine|Site Reference ID/Investigator# 24566, Kiev, Ukraine|Site Reference ID/Investigator# 22622, Kiev, Ukraine|Site Reference ID/Investigator# 22623, Kiev, Ukraine|Site Reference ID/Investigator# 22628, Lugansk, Ukraine|Site Reference ID/Investigator# 43143, Odessa, Ukraine|Site Reference ID/Investigator# 22627, Poltava, Ukraine",,https://ClinicalTrials.gov/show/NCT01018875
NCT01013610,"An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease",,Completed,No Results Available,Mild Alzheimer's Disease,Drug: LNK-754|Drug: Placebo,"Safety assessments to include pharmacokinetics, and adverse events",Link Medicine Corporation,All,"55 Years and older   (Adult, Older Adult)",Phase 1,110,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",LNK754-0902-1AB,Nov-09,Mar-11,Mar-11,16-Nov-09,null,15-Mar-11,"Dedicated Phase I, Phoenix, Arizona, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Elite Research Insitute, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|St. Louis Clinical Trials, LC, St. Louis, Missouri, United States|Clinical Trial Network, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01013610
NCT01009255,Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: GSK239512|Drug: Placebo,"Change from Baseline (Day 1) in the executive function/working memory composite score in the Cog State battery at Week 16|Change from Baseline (Day 1) in the episodic memory composite score in the CogState battery at Week 16|Change from Baseline (Day 1) in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) total score at Weeks 8 and 16|Change from Baseline (Day 1) in the attention composite score in the CogState battery at Week 16.|Clinician's Interview-Based Impression of Change-plus (CIBIC+) score at Weeks 8 and 16.|Change from Baseline (Day 1) to Weeks 8 and 16 of the Disability Assessment for Dementia scale (DAD) total score|Participant's Global Impression of Change (PGIC) score, Carer's Global Impression of Change (CrGIC) score, and Clinician Global Impression of Change (CGIC) at Week 8 and 16|Change from baseline in the Neuropsychiatric Inventory (NPI) at Weeks 8 and 16|Change from Baseline (Day 1) in Mini Mental State Examination (MMSE) total score at Week 16|Change from baseline during the titration phase, and to Weeks 8 and 16 of the Pittsburgh Sleep Quality Inventory (PSQI) and Epworth Sleepiness Scale (ESS)|Change from Baseline for Bilateral Score from Olfaction Test at Week 16|Plasma concentrations of GSK239512 over period|Number of participants with adverse events (AEs) and serious adverse events (SAEs)|Number of participants with vital signs outside clinical concern range (Systolic blood pressure [SBP], diastolic blood pressure [DBP], and heart rate [HR])|Number of participants with hematological and clinical chemistry parameters outside the reference range up to 16 weeks|Number of participants with abnormal electrocardiogram (ECG) over period",GlaxoSmithKline,All,"50 Years and older   (Adult, Older Adult)",Phase 2,196,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",110651,2-Nov-09,10-Nov-10,10-Nov-10,6-Nov-09,null,13-Apr-17,"GSK Investigational Site, Ruse, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Pardubice, Czech Republic|GSK Investigational Site, Praha 10, Czech Republic|GSK Investigational Site, Praha 2, Czech Republic|GSK Investigational Site, Praha 5, Czech Republic|GSK Investigational Site, Trutnov, Czech Republic|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Seongnam-si,, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Rostov-on-Don, Russian Federation|GSK Investigational Site, Saratov, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, Voronezh, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Levoca, Slovakia|GSK Investigational Site, Michalovce, Slovakia|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT01009255
NCT01009359,"Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers",,Completed,No Results Available,Diagnostic Imaging,Drug: F-18 DPA-714 (BAY85-8102),"Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by different quantification approaches|Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by visual analysis and standard parameters(e.g. Standardized Uptake Values = SUV)|Electrocardiogram (ECG)|Blood pressure|Serum protein|Serum creatinine|Serum GOT (Glutamat-Oxalacetate-Transaminase)|Adverse events collection",Bayer,All,"50 Years and older   (Adult, Older Adult)",Phase 1,22,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,13150|2009-009358-26,Oct-09,Jul-10,Oct-10,6-Nov-09,null,31-Jul-13,"Turku, Finland|Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01009359
NCT01005862,Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers,,Completed,No Results Available,Alzheimer's Disease,Biological: PF-04360365|Drug: Placebo,"Fractional Clearance rate of ABeta peptide in CSF|Area under the ratio of CSF labeled/unlabeled ABETA time curve from onset of clearance to 36h following start of infusion|PF-04360365 concentrations and ABETA concentrations in plasma and CSF|Ratio of labeled/unlabeled leucine in plasma and CSF post labeled leucine administration|Adverse events, vital signs, clinical labs, electrocardiograms, physical / neurologic examinations, Columbia Suicide Severity Rating Scale, MRI",Pfizer,All,"21 Years and older   (Adult, Older Adult)",Phase 1,17,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",A9951011,Mar-10,Sep-12,Sep-12,2-Nov-09,null,26-Sep-12,"Pfizer Investigational Site, Glendale, California, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01005862
NCT01002079,Drug-Drug Interaction Study With Rifampin,,Completed,No Results Available,Alzheimer Disease,Drug: BMS-708163|Drug: Rifampin,"BMS-708163 alone and with rifampin: BMS-708163 single dose PK parameters (Cmax, Tmax, T-HALF, AUC(0-T), AUC(INF), CLT/F and molar AUCmet/AUCparent ratios will be assessed without rifampin (Day 1) and with rifampin (Day 13)|BMS-708163 alone and with rifampin: Safety and tolerability (AE's, ECG, vital signs, safety labs)",Bristol-Myers Squibb|PRA Health Sciences,All,18 Years to 55 Years   (Adult),Phase 1,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CN156-028,Aug-10,Oct-10,Oct-10,27-Oct-09,null,25-Jan-11,"Local Institution, Bangalore, India",,https://ClinicalTrials.gov/show/NCT01002079
NCT01002586,"Wii-Fit For Improving Activity, Gait And Balance In Alzheimer's Dementia",,Completed,No Results Available,Alzheimer's Dementia|Falls|Gait Impairment|Balance Impairment,Other: Wii-Fit intervention|Other: Walking exercise program,"Berg Balance Test|Biomechanical assessment of balance, gait and dual tasking|Activities of daily living (ADL)|Instrumental activities of daily living (IADL)|Quality Of Life-AD (QOL-AD)|Mini mental state exam (MMSE)|Falls Efficacy Scale (FES)|Activities-specific Balance Confidence Scale (ABC)|Exit-25",University of Nebraska,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",361-09-EP,Nov-09,Oct-12,Oct-12,27-Oct-09,null,6-Sep-17,"University of Nebrasaka Medical Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT01002586
NCT01001637,Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer Disease,Dietary Supplement: Curcumin Formulation|Dietary Supplement: Placebo,To determine if curcumin formulation affects mental capacity in Alzheimer's patients based on mental exams|To determine if curcumin formulation changes blood concentrations of amyloid-beta,"Jaslok Hospital and Research Centre|Pharmanza Herbal Pvt Ltd|Verdure Sciences|University of California, Los Angeles",All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Longvida|919820711140,Oct-09,Jun-10,Nov-10,26-Oct-09,null,26-Oct-09,"Jaslok Hospital and research centre, Mumbai, Maharashtra, India",,https://ClinicalTrials.gov/show/NCT01001637
NCT01000870,Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513,,Terminated,No Results Available,Alzheimer Disease,Drug: MNI-513-01,To evaluate the efficacy and safety of MNI-513 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers,Institute for Neurodegenerative Disorders,All,"55 Years and older   (Adult, Older Adult)",Early Phase 1,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,MNI-513-01,Oct-09,Sep-10,Sep-10,23-Oct-09,null,6-Oct-10,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01000870
NCT01000038,"Wii-fit for Activity, Balance and Gait in Assisted Living",,Completed,No Results Available,Falls|Alzheimer's Disease,Other: Wii-Fit intervention|Other: Walking,Berg Balance Scale|Activities of Daily Living|Instrumental Activities of Daily Living|Timed Up and Go|Quality of Life-AD|Mini Mental State Exam|Actigraphy|Trails A and B,University of Nebraska,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,085-09-FB,Mar-09,Jul-11,Jul-11,22-Oct-09,null,27-Aug-18,"Parson's House Assisted Living, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT01000038
NCT00998764,A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients,,Terminated,Has Results,Alzheimer Disease,Drug: Bapineuzumab 0.5 mg/kg,"Number of Participants Reporting a Serious Adverse Event|Change From Base Study Baseline in Alzheimer's Disease Assesment Scale-Cognitive Subscale (ADAS-Cog/11) at Weeks 13, 26, 39, 52 and 78|Change From Extension Study Baseline in ADAS-Cog/11 at Weeks 13, 26, 39, 52 and 78.|Change From Base Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.|Change From Extension Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.|Change From Base Study Baseline in Neuropsychiatric Inventory (NPI) Score at Weeks 26, 52 and 78.|Change From Extension Study Baseline in NPI Score at Weeks 26, 52 and 78.|Change From Base Study Baseline in Mini-mental State Examination (MMSE) Score at Weeks 6, 19, 32, 45 and 78.|Change From Extension Study Baseline in MMSE Score at Weeks 6, 19, 32, 45 and 78.",Pfizer,All,"51 Years to 90 Years   (Adult, Older Adult)",Phase 3,494,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3133K1-3003|B2521004|2009-015080-13,Dec-09,Oct-12,Nov-12,20-Oct-09,1-Jan-16,1-Jan-16,"University Of Alabama at Birmingham, Birmingham, Alabama, United States|UAB Center for Psychiatric Medicine, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama-Birmingham, Birmingham, Alabama, United States|Dedicated Clinical Research, Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Good Samaritan Medical Center (Imaging, Phoenix, Arizona, United States|Jeffrey S. Gitt, Phoenix, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Associated Neurologist, PC, Boulder, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Bendheim Infusion Center, Greenwich Hospital, Greenwich, Connecticut, United States|Center for Healthy Aging, Greenwich Hospital, Greenwich, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|JEM Research LLC, Atlantis, Florida, United States|Medical Specialists of the Palm Beaches, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center, Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|Southwest Florida Infusion Care, Inc., Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Neuroscience Research Institute, LLC, Lawrenceville, Georgia, United States|Neurostudies.net, Lawrenceville, Georgia, United States|Alexian Brothers Neurosciences Institute Clinical Research, Elk Grove Village, Illinois, United States|Southern Illinois University School of Medicine Department, Springfield, Illinois, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Neurological Research Center of Hattiesburg Clinic, Hattiesburg, Mississippi, United States|The Center for Pharmaceutical Research, P.C., Kansas City, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corp./Merician Institute for Aging, Manchester, New Jersey, United States|Toms River X-Ray, CT & MRI, Toms River, New Jersey, United States|MDR, LiverPool, New York, United States|Neurological Care of Central New York, Liverpool, New York, United States|Carolina Neuropsychological Services, Inc., Raleigh, North Carolina, United States|Healthsouth Blue Ridge Surgery Center, Raleigh, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Radiology Associates, Raleigh, North Carolina, United States|Ohio State Unviersity, Columbus, Ohio, United States|Summit Research Network(Oregon) Inc., Portland, Oregon, United States|Providence Brain Institute-Cognitive Assessment Clinic, Portland, Oregon, United States|Providence Brain Institute, Portland, Oregon, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Abington Neurological Assoc, Abington, Pennsylvania, United States|Bington Memorial Hospital, Abington, Pennsylvania, United States|Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Medical University of South Carolina Hospitals and Clinics, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Texas Neurology, P.A., Dallas, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Vista Infusions, San Antonio, Texas, United States|Inventive Infusion Solutions, San Antonio, Texas, United States|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Gosford Hospital; Pharmacy Dept, Gosford, New South Wales, Australia|Hornsby Hospital, Hornsby, New South Wales, Australia|Royal Adelaide Memory Trials Centre, Adelaide, South Australia, Australia|Memory Unit 5C, Department of Neurology, Woodville South, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia|Hollywood Hospital; Pharmacy Dept, Nedlands, Western Australia, Australia|The McCusker Foundation for Alzheimer's Disease Research, Nedlands, Western Australia, Australia|ZNA Middelheim, Antwerpen, Belgium|AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium|Cliniques Universitaires St Luc, Brussels, Belgium|Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|Psicomedica Research Group, Santiago, Chile|Ita-Suomen Yliopisto, Kuopio, Finland|University of Turku/CRST, Turku, Finland|CHU Hôpital Pellegrin-Tripode, Bordeaux, France|Hopital Neurologique, Bron, France|CHU de Caen, Caen, France|Hôpitaux Civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|Hôpital Roger Salengro, Lille, France|Hôpital la Timone, Marseille cedex 5, France|Hôpital la Timone, Marseille, France|CHU Hôpital Gui de Chaulliac, Montpellier, France|CHU Nord - Hôpital Guillaume et René Laënnec, Nantes - Saint Herblain, France|Hôpital Cimiez, Nice, France|Hôpital Pitié-Salpétrière, Paris, France|CHU La Milétrie, Poitiers, France|C.H.U de Reims, Reims, France|Department de Radiologie et d'Imagerie Medicale, Hopital Pontchaillou, Rennes Cedex 9, France|CHRU Hôtel Dieu, Rennes, France|Centre Hospitalier Universitaire Charles Nicolle, Rouen Cedex, France|Hôpital Purpan, Toulouse, France|CHU Purpan - Hôpital Casselardit, Toulouse, France|Sezione di Neurologia - Dipartimento di Neuroscienze, Ancona, Italy|Dipartimento di Neuroscienze,, Catania, Italy|Fondazione IRCCS- Istituto Neurologico Carlo Besta, Milano, Italy|Unita' Operativa C - Riabilitazione Neurologica, Roma, Italy|Nagoya City University Hospital, Nagoya, Aichi,, Japan|Yachiyo Hospital, Aichi, Japan|National Hospital Organization Chiba-East Hospital, Chiba-shi, Japan|Kashiwado Hospital, Chiba, Japan|Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan|National Hospital Organization Kokura Medical Center, Fukuoka, Japan|Maebashi Red Cross Hospital, Gunma, Japan|Gunma University Hospital, Gunma, Japan|Shinozuka Hospital, Gunma, Japan|National Hospital Organization Hiroshima-nishi Medical Ctr., Hiroshima, Japan|Kobe University Hospital, Hyogo, Japan|Kagawa University Hospital, Kagawa, Japan|Nippon Medical School Musashi Kosugi Hospital, Kanagawa, Japan|Rakuwakai Otowa Hospital, Kyoto, Japan|National Hospital Organization Minami-Kyoto Hospital, Kyoto, Japan|National Hospital Organization Maizuru Medical Center, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|National Hospital Organization Niigata National Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Kansai Medical University Takii Hospital, Osaka, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Tokyo Metropolitan Health and Med. Treatment Co. Ebara Hosp, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|National Hospital Organization Tokyo National Hospital, Tokyo, Japan|Geriatry, 's-HERTOGENBOSCH, Netherlands|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|The Memory Clinic Limited, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Signet Research, Christchurch, New Zealand|Pallmed Spolka z o.o., Bydgoszcz, Poland|MCD Voxel, Poznan, Poland|NZOZ Neuro-kard, Poznan, Poland|Pracownia Rezonansu Magnetycznego, Warszawa, Poland|SP ZOZ Szpital Wolski, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Warszawa, Poland|Hospital Fernando da Fonseca, Amadora, Lisboa, Portugal|Hospitais Da Universidade De Coimbra, Coimbra, Portugal|Hospital Santa Maria, Lisboa, Portugal|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Vseobecna nemocnica Rimavska Sobota, Rimavska Sobota, Slovakia|Boithuso Caregivers, Johannesburg, Gauteng, South Africa|The Osteoporosis and Memory Centre, Johannesburg, Gauteng, South Africa|St Augustine's Medical Centre 2, Durban, Kwa Zulu Natal, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Mutua de Terrasa, Terrasa, Barcelona, Spain|Hospital Virgen del Puerto, Plasencia, Caceres, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain|CLONUS, Palma de Mallorca, Islas Baleares, Spain|Hospital del Mar, Barcelona, Spain|Fundacio ACE Institut Catala de Neurociences Aplicades, Barcelona, Spain|Clinica CIMA, Barcelona, Spain|Hospital Divino Valles, Burgos, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Malmo University Hospital, Malmo, Sweden|Minnes- och geriatrikmottagningen, Uppsala, Sweden|Memory Clinic Neuro-Psychologie Zentrum, Basel, BS, Switzerland|Memory Service North, Grenoside Grange Hospital, Grenoside, Sheffield, United Kingdom|Llandough Hospital, Universtity Hospital of Wales, Cardiff, Wales, United Kingdom|MAC UK Neuroscience Ltd., Bradford, United Kingdom|Clinical Investigation and Research Unit (CIRU), Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Dept. of Neurosciences Charing Cross Hospital, London, United Kingdom|The Doctors Laboratory Ltd., London, United Kingdom|Newcastle General Hospital, Newcastle upon Tyne, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Victoria Hospital, Swindon, United Kingdom|Alliance Medical, Wakefield, United Kingdom",,https://ClinicalTrials.gov/show/NCT00998764
NCT00997425,Home Evaluation of Exit Barriers in Wandering,HEEBW,Completed,Has Results,"Dementia, Alzheimer Type|Problem Behavior",Device: Door cover/Floor cover,Number and Means of Exit Seeking (Door Approach Behaviors) and Exit Door Pass Through Behaviors (Eloping),US Department of Veterans Affairs|VA Office of Research and Development,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,19,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,E6275-R|107401 I,Oct-09,Oct-10,Dec-12,19-Oct-09,21-Nov-14,21-Nov-14,"James A Haley Veterans' Hospital, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT00997425
NCT00996918,A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients,,Terminated,Has Results,Alzheimer Disease,Drug: Bapineuzumab 0.5 mg/kg|Drug: Bapineuzumab 1.0 m/kg,"Number of Participants Reporting a Serious Adverse Event.|Change From Base Study Baseline in Alzheimer's Disease Assesment Scale-Cognitive Subscale (ADAS-Cog/11) at Weeks 13, 26, 39, 52 and 78.|Change From Extension Study Baseline in ADAS-Cog/11 at Weeks 13, 26, 39, 52 and 78.|Change From Base Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.|Change From Extension Study Baseline in DAD Score at Weeks 13, 26, 39, 52 and 78|Change From Base Study Baseline in Neuropsychiatric Inventory (NPI) Score at Weeks 26, 52 and 78.|Change From Extension Study Baseline in NPI Score at Weeks 26, 52 and 78.|Change From Base Study Baseline in Mini-mental State Examination (MMSE) Score at Weeks 6, 19, 32, 45 and 78.|Change From Extension Study Baseline in MMSE Score at Weeks 6, 19, 32, 45 and 78.",Pfizer,All,"51 Years and older   (Adult, Older Adult)",Phase 3,198,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3133K1-3002|B2521003,Dec-09,Nov-12,Nov-12,16-Oct-09,1-Jan-14,1-Jan-14,"Pfizer Investigational Site, Hornsby, New South Wales, Australia|Pfizer Investigational Site, Adelaide, South Australia, Australia|Pfizer Investigational Site, Woodville South, South Australia, Australia|Pfizer Investigational Site, Heidelberg Heights, Victoria, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, Antwerpen, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Edegem, Belgium|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Turku, Finland|Pfizer Investigational Site, Caen, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Lille, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Montpellier, France|Pfizer Investigational Site, Nantes - Saint Herblain, France|Pfizer Investigational Site, Nice, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Poitiers, France|Pfizer Investigational Site, Rennes, France|Pfizer Investigational Site, Rouen, France|Pfizer Investigational Site, Toulouse, France|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Aichi, Japan|Pfizer Investigational Site, Chiba, Japan|Pfizer Investigational Site, Fukuoka, Japan|Pfizer Investigational Site, Hiroshima, Japan|Pfizer Investigational Site, Hyogo, Japan|Pfizer Investigational Site, Kagawa, Japan|Pfizer Investigational Site, Kanagawa, Japan|Pfizer Investigational Site, Kyoto, Japan|Pfizer Investigational Site, Nagano, Japan|Pfizer Investigational Site, Okayama, Japan|Pfizer Investigational Site, Osaka, Japan|Pfizer Investigational Site, Shizuoka, Japan|Pfizer Investigational Site, Tokyo, Japan|Pfizer Investigational Site, 's-Hertogenbosch, Netherlands|Pfizer Investigational Site, Leeuwarden, Netherlands|Pfizer Investigational Site, North Shore, NZ, New Zealand|Pfizer Investigational Site, Bydgoszcz, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Poznan, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Amadora, Portugal|Pfizer Investigational Site, Coimbra, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Rimavska Sobota, Slovakia|Pfizer Investigational Site, Johannesburg, Gauteng, South Africa|Pfizer Investigational Site, Pretoria, Gauteng, South Africa|Pfizer Investigational Site, Elche, Alicante, Spain|Pfizer Investigational Site, Terrasa, Barcelona, Spain|Pfizer Investigational Site, Plasencia, Caceres, Spain|Pfizer Investigational Site, Palma de Mallorca, Islas Baleares, Spain|Pfizer Investigational Site, Palma de Mallorca, Islas Baleares, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Burgos, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Malmo, Sweden|Pfizer Investigational Site, Basel, BS, Switzerland|Pfizer Investigational Site, Brighton, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Newcastle upon Tyne, United Kingdom|Pfizer Investigational Site, Penarth, United Kingdom|Pfizer Investigational Site, Sheffield, United Kingdom|Pfizer Investigational Site, Sheffield, United Kingdom|Pfizer Investigational Site, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00996918
NCT00991419,To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden,,Completed,No Results Available,Alzheimer's Disease,Drug: [18F]AZD4694,PET Measurements,AstraZeneca,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,25,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,D2750N00006,Feb-10,Aug-11,Aug-11,8-Oct-09,null,30-Jan-13,"Research Site, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00991419
NCT00990613,A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin,,Completed,No Results Available,Alzheimer's Disease|Huntington's Disease,Drug: Dimebon IR|Drug: Dimebon Transdermal,"Pharmacokinetic endpoints include dimebon area under the curve from 0 to the last quantifiable concentration (AUClast) and dimebon area under the curve from 0 to infinity (AUCinf) as permitted by data|Safety endpoints include subjective symptoms/objective findings (including skin irritation), clinical safety laboratory assessments, 12 lead ECGs, and supine vital signs.","Pfizer|Medivation, Inc.",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,19,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",B1451038,Oct-09,Jan-10,Jan-10,7-Oct-09,null,3-Feb-10,"Pfizer Investigational Site, Kalamazoo, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00990613
NCT00988598,"A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Drug: PF-04447943|Drug: Placebo,vital signs|ECGs|Physical and Neurological examinations|Laboratory tests|adverse events|Plasma concentrations of PF 04447943 over time|Plasma concentrations of donepezil over time,Pfizer,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,15,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B0401008,Oct-09,Jul-10,Jul-10,2-Oct-09,null,9-Aug-10,"Pfizer Investigational Site, Glendale, California, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Hallandale Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT00988598
NCT00988624,A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine),,Completed,No Results Available,Alzheimer's Disease|Huntington Disease,Drug: Dimebon IR Tablet|Drug: Dimebon MR1|Drug: Dimebon MR2|Drug: Dimebon MR3|Drug: Dimebon MR4,"PK endpoints for dimebon and M7 (where appropriate) for each formulation: AUC0-24, AUC0-24(dn), AUCinf (as data permit) AUCinf(dn), AUClast, AUClast(dn), Tlag, Cmax, Tmax, and t1/2 (as data permit).|Safety and tolerability for each formulation (AEs, ECG, vital signs, safety labs)","Pfizer|Medivation, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),B1451023,Oct-09,Dec-09,Dec-09,2-Oct-09,null,12-Jan-10,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00988624
NCT00987090,Early-onset and Late-onset Sporadic Alzheimer's Disease (AD),,Unknown status,No Results Available,Alzheimer's Disease,Biological: Clinic and neuropsychologic evaluation|Radiation: MRI|Procedure: PET|Biological: Apolipoprotein E genotyping|Biological: Study of cerebrospinal fluid,"to establish the impact of age on the clinical and neuroimaging picture of sporadic Alzheimer Disease in a multicentric setting.|to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.",Assistance Publique Hopitaux De Marseille,All,"45 Years to 90 Years   (Adult, Older Adult)",Not Applicable,240,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2008/24|2008-A01213-52,Oct-09,Sep-16,null,30-Sep-09,null,23-Oct-15,"Assistance Publique - Hôpitaux de Marseille, Marseille, France",,https://ClinicalTrials.gov/show/NCT00987090
NCT00982202,Pioglitazone in Alzheimer Disease,,Completed,No Results Available,Alzheimer Disease,Drug: pioglitazone|Drug: Placebo,Frequency of adverse events|Laboratory abnormalities|Cognition|Activities of Daily Living (ADL)|Behavior|Global function,"National Institute on Aging (NIA)|Takeda Pharmaceuticals North America, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 2,25,NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IA0168|1R01AG018905,Jan-02,Jan-05,Jan-05,23-Sep-09,null,23-Sep-09,"University Hospitals of Cleveland, Cleveland, Ohio, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00982202
NCT00980785,Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's,SEAIRA,Completed,No Results Available,Alzheimer's Disease|Hypertension,Drug: Ramipril|Drug: Placebo,"To determine the effects of 4 months of ramipril therapy on CSF Aβ levels in mildly hypertensive, non-demented adult children of persons with AD when compared to subjects taking placebo.|To evaluate the effects of 4 months of ramipril on CSF ACE levels in mildly hypertensive, non-demented adult children of persons with AD when compared to subjects taking placebo.|To determine the effects of 4 months of ramipril therapy on the cardiovascular outcome variables of brachial reactivity and aortic augmentation index in non-demented adult children of persons with AD when compared to subjects taking placebo.","University of Wisconsin, Madison",All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 4,14,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",H-2014-1353|H-2009-0036,Apr-09,Jul-11,Jul-11,21-Sep-09,null,29-Mar-17,"Wisconisn Alzheimer's Disease Research Center, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00980785
NCT00979316,Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects,,Completed,No Results Available,Alzheimer Disease,Drug: BMS-708163|Drug: Placebo|Drug: Moxifloxacin,"Effect on the electrocardiographic QT interval corrected for heart rate (QTc) in healthy subjects|To assess the effects of BMS-708163 on other ECG endpoints (heart rate [HR], QRS and PR intervals), and changes in waveform morphology",Bristol-Myers Squibb,All,18 Years to 55 Years   (Adult),Phase 1,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",CN156-020,Sep-09,Feb-10,Feb-10,18-Sep-09,null,7-Jan-11,"Mds Pharma Services (Us), Inc, Tempe, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00979316
NCT00979446,Passport to Brain Wellness in Sedentary Adults,,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Behavioral: Guided|Behavioral: Self-directed,We will use this pilot to determine the feasibility of carrying out a full-scale randomized trial to test the efficacy of our intervention.,HealthPartners Institute,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,63,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,03-024S2|3R01AG023410-05S2,Jun-08,May-09,Aug-09,18-Sep-09,null,18-Sep-09,"HealthPartners Research Foundation, Bloomington, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00979446
NCT00978536,"A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).",BioCogS,Terminated,No Results Available,Disseminated Sclerosis,Other: Cognitive impairment of multiple sclerosis,"The aim of this pilot study is to measure the level of total tau, phosphorylated tau and amyloid peptide in the CSF in order to establish correlations between a profile ofCSF biomarkers and a type of cognitive impairment, cortical or subcortical.|To compare each biomarker individually between the three groups.|To define clinical and paraclinical characteristics of MS patients with cortical cognitive dysfunction by a clinical and neuropsychological evaluation, a morphological (cerebral MRI) and a functional exam (cerebral scintigraphy).",Nantes University Hospital,All,"17 Years to 66 Years   (Child, Adult, Older Adult)",Not Applicable,29,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),08/11-K,Feb-09,Nov-11,Nov-11,17-Sep-09,null,30-Sep-13,"CHU de Nantes, Nantes, France",,https://ClinicalTrials.gov/show/NCT00978536
NCT00976118,Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: masitinib (AB1010)|Drug: placebo,change from baseline in ADAS-Cog|change from baseline in CIBIC-plus|change from baseline in CDR|change from baseline in MMSE,AB Science,All,"50 Years and older   (Adult, Older Adult)",Phase 2,34,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AB04024,Feb-06,Jul-08,Feb-09,14-Sep-09,null,13-Dec-18,,,https://ClinicalTrials.gov/show/NCT00976118
NCT00975481,A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users,,Completed,Has Results,Alzheimer's Disease|Huntington's Disease,Drug: dimebon|Drug: placebo|Drug: alprazolam,Balance of Effects- Drug Liking VAS: Peak Effect (Maximum Effect [Emax]) and Minimum Effect (Emin)|Balance of Effects- Overall Drug Liking VAS: Peak Effect (Maximum Effect [Emax]) and Minimum Effect (Emin)|Balance of Effects- Take Drug Again VAS: Peak Effect (Maximum Effect [Emax])|Balance of Effects- Good and Bad Effects VAS: Peak Effect (Maximum Effect [Emax]) and Minimum Effect (Emin)|Balance of Effects- Subjective Drug Value (SDV): Maximum Effect (Emax)|Positive Effects- Addiction Research Center Inventory (ARCI) Morphine Benzedrine Group (MBG): Maximum Effect (Emax)|Positive Effects- Good Drug Effects: Peak Effect (Maximum Effect [Emax])|Positive Effects- High VAS: Peak Effect (Maximum Effect [Emax])|Negative Effects- Bad Drug Effects: Peak Effect (Maximum Effect [Emax])|Negative Effects- Addiction Research Center Inventory (ARCI) Lysergic Acid Diethylamide (LSD): Maximum Effect (Emax)|Sedative Effects- Addiction Research Center Inventory (ARCI) Pentobarbital Chlorpromazine Group (PCAG): Maximum Effect (Emax)|Sedative Effects- Alertness/Drowsiness: Minimum Effect (Emin)|Other Subjective Effects- Any Drug Effects: Peak Effect (Maximum Effect [Emax])|Other Subjective Effects- Drug Similarity|Other Subjective Effects- Addiction Research Center Inventory (ARCI) Benzedrine Group (BG): Maximum Effect (Emax) and Minimum Effect (Emin),"Pfizer|Medivation, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",B1451037,Oct-09,Feb-10,Feb-10,11-Sep-09,2-Apr-13,2-Apr-13,,,https://ClinicalTrials.gov/show/NCT00975481
NCT00970333,Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions,,Completed,No Results Available,Alzheimer Disease|Parkinson Disease|Multiple Sclerosis,Drug: [18F]-FEPPA,"The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, [18F]-FEPPA.",Institute for Neurodegenerative Disorders,All,"18 Years and older   (Adult, Older Adult)",Phase 1,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,FEPPA 001,Aug-09,Oct-10,Oct-10,2-Sep-09,null,8-Feb-12,"Instiute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00970333
NCT00968097,Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition,,Terminated,No Results Available,Alzheimer's Disease,Drug: 123-I MNI-340,"The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, 123-I MNI-340.",Institute for Neurodegenerative Disorders,All,"50 Years and older   (Adult, Older Adult)",Phase 1,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,MNI-340-01,Apr-08,Jul-08,Jul-08,28-Aug-09,null,3-Apr-19,"The Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00968097
NCT00966966,Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered,,Completed,No Results Available,Healthy,Drug: SAM-531 and gemfibrozil,"Maximum plasma concentration (Cmax)|Time to maximum plasma concentration (tmax)|Area under the concentration-time curve (AUC)|Safety as measured by adverse event monitoring, ECG, vital signs, and laboratory tests",Wyeth is now a wholly owned subsidiary of Pfizer|Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,17,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3193A1-1109|B1961001,Sep-09,Dec-09,Dec-09,27-Aug-09,null,20-Aug-10,"Pfizer Investigational Site, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT00966966
NCT00965588,"Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Biological: UB 311,To evaluate safety and tolerability of the vaccine (UB 311).|To evaluate immunogenicity [and efficacy] of the vaccine (UB 311).,"United Biomedical|Taipei Veterans General Hospital, Taiwan|National Taiwan University Hospital",All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,19,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UBI Protocol V118|Protocol V118-AD,Feb-09,Apr-11,Apr-11,25-Aug-09,null,23-Aug-11,"National Taiwan University Hospital (NTUH), Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00965588
NCT00959803,Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.,,Completed,No Results Available,Healthy,Drug: PF-04447943|Drug: Placebo,"AEs (spontaneous and solicited). Change from baseline in vital signs.|ECG and clinical safety laboratory endpoints, including a complete blood count, a full chemistry panel (including electrolytes and hepatic transaminases) and urinalysis.|Pharmacokinetic (single): AUClast, Cmax, Tmax|Pharmacokinetic(multiple): AUCt, Cmax and Tmax on Days 1 and 7, and Ctrough on Days 2, 3, 4 and 7.",Pfizer,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,17,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B0401004,Aug-09,Nov-09,Nov-09,17-Aug-09,null,7-Dec-09,"Pfizer Investigational Site, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT00959803
NCT00959881,Study Evaluating The Coadministration of Begacestat And Donepezil,,Completed,No Results Available,Healthy Subjects,Drug: Donepezil plus placebo|Drug: Donepezil|Drug: Begacestat,"Pharmacodynamic interaction of multiple doses of begacestat and donepezil coadministered to healthy subjects as assessed by 12-lead electrocardiogram (ECG).|Pharmacokinetic parameters including Cmax, AUC, and t 1/2|Safety and tolerability as assessed by results of 12-lead ECGs, cardiac telemetry, laboratory tests, vital signs, physical examinations and reported adverse events.",Wyeth is now a wholly owned subsidiary of Pfizer|Pfizer,All,18 Years to 50 Years   (Adult),Phase 1,47,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",3183A1-1106|B1941005,Aug-09,Nov-09,Nov-09,17-Aug-09,null,4-Apr-11,"Pfizer Investigational Site, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00959881
NCT00960531,A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease,,Terminated,Has Results,Alzheimer Disease,Biological: ACC-001+ QS21 (3mcg)|Biological: ACC-001 (10 mcg) + QS-21|Biological: ACC-001+QS-21 (30mcg),Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs),"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,160,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3134K1-2205|B2571008,Jul-09,Dec-13,Dec-13,17-Aug-09,1-Apr-16,1-Apr-16,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Boswell Medical Center, Sun City, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California San Francisco, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|University of California - San Francisco, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|General Clinical Research Unit, Washington, District of Columbia, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|MD Clinical, Hallandale Beach, Florida, United States|Palm Beach Neurology - Premiere Research Institute, West Palm Beach, Florida, United States|Brigham and Woman's Hospital, Boston, Massachusetts, United States|Center for Alzheimer Research and Treatment, Boston, Massachusetts, United States|Barnes Jewish Hospital, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Barnes Jewish Hospital at Washington University, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Columbia University/Taub Institute, New York, New York, United States|CUMC Research Pharmacy, New York, New York, United States|Butler Hospital, Providence, Rhode Island, United States|Southwestern Vermont Healthcare, Bennington, Vermont, United States|The Memory Clinic, Bennington, Vermont, United States|The Pharmacy, Inc, Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00960531
NCT00959192,"Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease",,Completed,Has Results,Alzheimer's Disease,Biological: ACC-001|Other: QS-21,Incidence of Treatment-emergent Adverse Events (AEs) by Severity|Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data|Number of Participants With Abnormalities in Neurological Examination|Anti-a-beta IgG Titer at Specified Visits|Anti-a-beta IgM Titer at Specified Visits,"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3134K1-2206|B2571009,Aug-09,Jan-13,Jan-13,14-Aug-09,1-Jan-16,1-Jan-16,"Meitetsu Hospital, Aichi, Japan|Ibaraki Prefectural Central Hospital, Ibaraki, Japan|Shonan Atsugi Hospital, Kanagawa, Japan|Kitasato University East Hospital, Kanagawa, Japan|Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan|The Jikei University School of medicine, Tokyo, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Kanto Ctrl Hp of the Mutual Aid Asso of Public school Teache, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00959192
NCT00956410,To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients,,Completed,No Results Available,Alzheimer Disease,Biological: CAD106,"Safety/tolerability assessments at multiple timepoints including but not limited to screening, and through to the end of the study to week 66.|Immune response, cognitive and functional assessments at multiple timepoints including but not limited to baseline and through to the end of the study to week 66.|Evaluate the antibody response after 4 additional injections in the Extension study in patients initially treated with CAD106 in the Core study.|Collect long-term safety information through SAEs collection for two years after completion of the core study, CAD106A2201, or extension study, CAD106A2201E1.",Novartis,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,21,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCAD106A2201E1,Sep-09,Jun-11,Jun-11,11-Aug-09,null,17-Nov-11,"Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00956410
NCT00955409,"Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease",,Completed,No Results Available,Alzheimer Disease,Drug: ACC-001+ QS21|Drug: ACC-001|Drug: ACC-001 + QS21,"Incidence and severity of treatment emergent adverse events; clinically important changes in safety assessment results including adverse events , vital signs, weight, clinical laboratory tests, ECGs, MRI scans, and physical and neurological examinations.|Change from baseline levels of anti-A-beta IgG, Anti-A-beta IgM and IgG subclass antibody levels at selected time points.","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",All,"Child, Adult, Older Adult",Phase 2,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3134K1-2203|B2571007,Nov-09,Dec-13,Dec-13,10-Aug-09,null,31-Jan-14,"Pfizer Investigational Site, Bordeaux, France|Pfizer Investigational Site, Lille, France|Pfizer Investigational Site, Marseille cedex 5, France|Pfizer Investigational Site, Paris Cedex 13, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Toulouse cedex 9, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bonn, Germany|Pfizer Investigational Site, Bonn, Germany|Pfizer Investigational Site, Freiburg, Germany|Pfizer Investigational Site, Goettingen, Germany|Pfizer Investigational Site, Mannheim, Germany|Pfizer Investigational Site, Munich, Germany|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00955409
NCT00954252,"Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects",CT01,Completed,No Results Available,Alzheimer's Disease,Drug: CHF 5074|Drug: placebo,Adverse Events|Dose linearity of CHF5074 plasma levels (Cmax and AUC0-t),CERESPIR,Male,18 Years to 45 Years   (Adult),Phase 1,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",CCD-0814-PR-0008,Oct-09,May-10,May-10,7-Aug-09,null,10-Feb-15,"Iberica Clinical Research Center, Eatontown, NJ 07724, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00954252
NCT00954369,Exploratory and Safety Study of [F-18]W372,,Completed,No Results Available,Alzheimer's Disease,Drug: [F-18]W372,Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.,Siemens Molecular Imaging,All,"55 Years and older   (Adult, Older Adult)",Early Phase 1,24,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),W372000,Aug-09,Feb-10,Feb-10,7-Aug-09,null,22-Aug-12,"University of California, Irvine, Irvine, California, United States",,https://ClinicalTrials.gov/show/NCT00954369
NCT00954538,"Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)",,Completed,Has Results,Alzheimer's Disease,Drug: [18F]MK-3328,Number of Participants With an Adverse Event (AE)|Number of Participants Who Discontinued Study Due to an AE|Effective Dose of [18F]MK-3328|Organ Effective Dose of [18F]MK-3328|Mean Brain Cortical [18F]MK-3328 Standard Uptake Value Ratio (SUVR) in AD Participants and HE Participants|Least Squares (LS) Mean [18F]MK-3328 SUVR in Brain Posterior Cingulate Gyrus in AD Participants and HE Participants,Merck Sharp & Dohme Corp.,All,"50 Years and older   (Adult, Older Adult)",Phase 1,19,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,3328-001|2009_630,Aug-09,May-11,May-11,7-Aug-09,5-Feb-14,3-Nov-15,,,https://ClinicalTrials.gov/show/NCT00954538
NCT00954590,A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease,CONTACT,Terminated,No Results Available,Moderate to Severe Alzheimer,Drug: Dimebon (latrepirdine)|Drug: Placebo,Neuropsychiatric Inventory (NPI)|Activities of Daily Living (severe) (ADCS ADLsev),"Medivation, Inc.|Pfizer",All,"50 Years and older   (Adult, Older Adult)",Phase 3,89,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DIM19,Oct-09,Aug-10,null,7-Aug-09,null,27-Sep-16,"Santiago, Chile|Glasgow, Scotland, United Kingdom",,https://ClinicalTrials.gov/show/NCT00954590
NCT00951834,Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease,SUN-AK,Completed,No Results Available,Alzheimer's Disease,Drug: Epigallocatechin-Gallate|Drug: Placebo,ADAS-COG (Score 0-70) (Baseline to treatment)|Safety and tolerability of the verum|MMSE (Score 0-30) after 18 months compared to baseline|Time to hospitalisation and Time to death related to AD|Brain atrophy assessed by brain MRI|Baseline-ADAS-COG and Baseline-MMSE as covariates|CIBIC+ and WHO-QOL-Bref|Trail Making Test and MVGT,"Charite University, Berlin, Germany",All,"60 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,21,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SUN-AK,Oct-09,Feb-15,Feb-15,4-Aug-09,null,29-Nov-18,"Charite University Medicine Berlin, Berlin, Germany|Charité Universitätsmedizin Berlin Klinik für Psychiatrie und Psychotherapie, Berlin, Germany|Klinik für Neurologie, Ulm, Germany",,https://ClinicalTrials.gov/show/NCT00951834
NCT00950430,Imaging of Brain Amyloid Plaques in the Aging Population,,Enrolling by invitation,No Results Available,Alzheimer's Disease|Dementia With Lewy Bodies|Frontotemporal Dementia|Vascular Dementia,Drug: Pittsburgh Compound B (C-11 PiB)|Drug: F-18 FDG|Drug: Tau (18-F-AV-1451),"To understand the predictive ability of PiB PET imaging for neurodegenerative diseases.|Using PiB-PET, to ascertain cross-sectionally the magnitude and the spatial distribution of amyloid deposition in the brain in subjects who are clinically classified as CN, MCI, and demented.|To identify the relationship between amyloid burden and the risk of progression from CN at baseline to MCI.|To identify the relationship between amyloid burden and the risk of progression from MCI at baseline to dementia.|To measure longitudinal change in amyloid burden and cognition and characterize the correlation between change on serial PiB-PET measures vs. FDG measures and concurrent change on continuous measures of cognitive performance.",Mayo Clinic|National Institute on Aging (NIA),All,"30 Years to 100 Years   (Adult, Older Adult)",Phase 4,2500,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,08-005553|U01AG006786|R01AG011378,Apr-08,Apr-23,Apr-23,31-Jul-09,null,14-Aug-18,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00950430
NCT00948259,Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease,,Completed,No Results Available,Alzheimer´s Disease,Drug: NP031112|Drug: Placebo,Incidence rates and severity of clinical adverse events and lab abnormalities for each dose level and placebo|Effect of treatment with four doses of NP031112 on cognition and depressive mood,Noscira SA,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP031112-08B03 (CR080901),Dec-08,Nov-09,Nov-09,29-Jul-09,null,11-Nov-09,"Pharmacologische Studiecentrum Chemnitz, Chemnitz, Germany|Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Studienzentrum PD Dr. Steinwachs, Nürnberg, Germany",,https://ClinicalTrials.gov/show/NCT00948259
NCT00948766,"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44",ACTION,Completed,Has Results,Alzheimer's Disease,Drug: Rivastigmine 4.6 mg/24 h (5 cm^2)|Drug: Rivastigmine 9.5 mg/24 h (10 cm^2)|Drug: Rivastigmine 13.3 mg/24 h (15 cm^2)|Drug: Placebo,Core Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24|Core Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24|Core Study: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24|Core Study: Change From Baseline in the Neuropsychiatric Inventory (NPI-12) Score at Week 24|Extension Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24|Extension Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24|Extension Study: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24,Novartis,All,"50 Years and older   (Adult, Older Adult)",Phase 4,716,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CENA713DUS44,Jul-09,Jan-12,Jun-12,29-Jul-09,11-Feb-13,28-Aug-13,"Clinical Research Advantage Inc./Neurological. Physicians of Arizona, Inc, Tempe, Arizona, United States|Northwest Neuro Specialist, PLLC, Tucson, Arizona, United States|IHS Research Center Inc., Conway, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Neuro Pain Medical Center, Fresno, California, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative Neuroscience Network Inc., Garden Grove, California, United States|PCND Neuroscience Research Institute Inc./The Center for Memory and Aging, Poway, California, United States|Anderson Clinical Research, Redlands, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Viking Clinical Research Center, Temecula, California, United States|Collaborative Neuroscience Network, Inc, Torrance, California, United States|Senior Care of Colorado, Aurora, Colorado, United States|Clinical Research Studies Dept. of Clinical Science and Medical Education, Boca Raton, Florida, United States|Quantum Laboratories Memory Disorder Center, Deerfield Beach, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neurologic Consultants, PA, Fort Lauderdale, Florida, United States|White-Wilson Medical Center, Fort Walton Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Sunrise Clinical Research, Inc, Hollywood, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Integrity Research, LLC, Pensacola, Florida, United States|Neurostudies, Inc., Port Charlotte, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Center for Clinical Trials, Venice, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|MidAmerica Neuroscience Reseach Institute, Lenexa, Kansas, United States|Precise Clinical Research Solutions, Manhattan, Kansas, United States|LSU Health Sciences Center/Department of Psychiatry Psychopharmacology Research Clinic, Shreveport, Louisiana, United States|J. Gary Booker, MD APMC, Shreveport, Louisiana, United States|Pharmasite Research, Baltimore, Maryland, United States|The Samuel and Alexia Bratton Memory Clinic, William Hill Inc, Easton, Maryland, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Michigan Neurology Associates, P.C., Clinton Township, Michigan, United States|Wayne State University/Detroit Medical center, Detroit, Michigan, United States|West Michigan Clinical Research, Muskegon, Michigan, United States|Orr & Associates Memory and Geriatric Behavioral Health Clinic, St. Paul, Minnesota, United States|Neurological Research Clinic, Hattiesburg Clinic, Hattiesburg, Mississippi, United States|The Neuroscience Center, Ocean Springs, Mississippi, United States|Sky, LLC., St Louis, Missouri, United States|St. Louis University, St. Louis, Missouri, United States|Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|NeuroCognitive Institute, Mt. Arlington, New Jersey, United States|UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States|UMDNJ-School of Osteopathic Medicine Center, Stratford, New Jersey, United States|Memory Enhancement Center of NJ, Toms River, New Jersey, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|Neurological Care of Central NY, Liverpool, New York, United States|Eastside Comprehensive medical Center, LLC, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|The Burke Rehabilitation Hospital, White Plains, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Inc., Winston Salem, North Carolina, United States|Valley Medical Research, Centerville, Ohio, United States|University Neurology, Inc., Cincinnati, Ohio, United States|Cognitive Assessment Clinic, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Paramount Clinical Research, Bridgeville, Pennsylvania, United States|Department of Veterans Affairs Medical Center, Coatesville, Pennsylvania, United States|Westmoreland Neurology associates, Inc., Greensburg, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Research Protocol Management Specialists, Pittsburg, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Jacinto Medical Group, PA, Baytown, Texas, United States|Future Search Trials, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Radiant Research Inc., San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|TLC Neurology, P.L.L.C, Arlington, Virginia, United States|UVA Neurology, Charlottesville, Virginia, United States|Neurological Associates, Inc., Richmond, Virginia, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States|Internal Medicine Northwest, Tacoma, Washington, United States|Independent Psychiatric Consultants, SC, Waukesha, Wisconsin, United States|Metro Medical Center, Bayamon, Puerto Rico|INSPIRA Clinical Research, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00948766
NCT00948909,Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Placebo|Drug: ABT-126|Drug: donepezil,"ADAS-Cog - Alzheimer's Disease Assessment Scale Cognition portion|MMSE, QoL-AD, CIBIC-plus, NPI, CSDD, ADAS-Cog (13 item) and ADCS-ADL. Note: Acronyms are fully defined in the area titled Detailed Description.","AbbVie (prior sponsor, Abbott)|AbbVie",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,274,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",M10-984|2009-011424-64,Oct-09,Nov-10,Nov-10,29-Jul-09,null,31-Jan-13,"Site Reference ID/Investigator# 19904, Fresno, California, United States|Site Reference ID/Investigator# 23025, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 19905, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 22944, Pleven, Bulgaria|Site Reference ID/Investigator# 22942, Plovdiv, Bulgaria|Site Reference ID/Investigator# 22945, Sofia, Bulgaria|Site Reference ID/Investigator# 22946, Sofia, Bulgaria|Site Reference ID/Investigator# 20276, Litomerice, Czech Republic|Site Reference ID/Investigator# 20273, Plzen, Czech Republic|Site Reference ID/Investigator# 20274, Prague 10, Czech Republic|Site Reference ID/Investigator# 20272, Prague 2, Czech Republic|Site Reference ID/Investigator# 20701, Prague 5, Czech Republic|Site Reference ID/Investigator# 23625, Bratislava, Slovakia|Site Reference ID/Investigator# 23624, Bratislava, Slovakia|Site Reference ID/Investigator# 23622, Michalovce, Slovakia|Site Reference ID/Investigator# 23942, Rimavska Sobota, Slovakia|Site Reference ID/Investigator# 20267, Belville, South Africa|Site Reference ID/Investigator# 20266, Cape Town, South Africa|Site Reference ID/Investigator# 20261, Durban, South Africa|Site Reference ID/Investigator# 21682, George, South Africa|Site Reference ID/Investigator# 20265, Johannesburg, South Africa|Site Reference ID/Investigator# 20271, Port Elizabeth, South Africa|Site Reference ID/Investigator# 20263, Richards Bay, South Africa|Site Reference ID/Investigator# 20187, Blackburn, United Kingdom|Site Reference ID/Investigator# 20183, Bradford, United Kingdom|Site Reference ID/Investigator# 20191, Crowborough, United Kingdom|Site Reference ID/Investigator# 20184, Glasgow, United Kingdom|Site Reference ID/Investigator# 20190, London, United Kingdom|Site Reference ID/Investigator# 20192, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00948909
NCT00947934,Study of the Brain Stimulation Effect on Memory Impairment in Alzheimer Disease,,Unknown status,No Results Available,Memory Disorders,Device: Deep brain stimulation,"Evaluation criteria for feasibility will be the proportion of patients undergoing the procedure, chronic stimulation and evaluation process without adverse event.|- Efficacy : evaluated using cognitive and memory testing. - Global improvement : CGI and IADL - Neuro-imaging : MRI and functional imaging - Safety/tolerance : Changes in behavioral,in hypothalamic functions and assessment of adverse events",Centre Hospitalier Universitaire de Nice,All,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09 - APN - 04|AFSSAPS2009-A00318-49,Aug-09,Aug-10,Aug-12,28-Jul-09,null,8-Dec-11,"CMR2 Hôpital de Cimiez, Nice, France|Service de Neurochirurgie Hôpital Universitaire de Pasteur, Nice, France",,https://ClinicalTrials.gov/show/NCT00947934
NCT00946530,Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease,,Completed,Has Results,Sleep Initiation and Maintenance Disorders,Device: Bright light|Device: Control,Total Sleep Time|WASO (Wake After Sleep Onset),Stanford University|Palo Alto Veterans Institute for Research,All,"55 Years to 100 Years   (Adult, Older Adult)",Not Applicable,118,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",SU-06302009-2840|1677,Sep-04,Dec-10,Dec-10,27-Jul-09,29-Mar-17,3-Oct-18,"VA Palo Alto Health Care System, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT00946530
NCT00945672,A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Biological: PF-04360365 10 mg/kg|Biological: PF-04360365 7.5 mg/kg|Drug: placebo,"Safety/tolerability/PK of multiple doses of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 1 year (adverse events, physical/neurological exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)|Brain amyloid burden|CSF abeta|Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma abeta, CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; immunogenicity (anti-drug antibodies)",Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 2,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",A9951007,Aug-09,Jun-11,Jun-11,24-Jul-09,null,5-May-16,"Pfizer Investigational Site, Göteborg, Sweden|Pfizer Investigational Site, Malmo, Sweden|Pfizer Investigational Site, Molndal, Sweden|Pfizer Investigational Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00945672
NCT00940589,Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor,,Completed,Has Results,Alzheimer's Disease|Sleep Disorder,Drug: Circadin|Drug: Placebo,Change From Baseline to 24 Weeks in ADAS-cog|Change From Baseline to 24 Weeks in iADL|Change From Baseline to 24 Weeks in MMSE,Neurim Pharmaceuticals Ltd.,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,73,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NEU AZ1,Sep-09,Feb-13,May-13,16-Jul-09,1-Jun-18,1-Jun-18,"Meridien Research, Brooksville, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Exodon LLC, Mount Arlington, New Jersey, United States|Scranton Medical Institute, Scranton, Pennsylvania, United States|Merchav clinics, Tel-Aviv, Israel|CPS Research, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT00940589
NCT00939783,An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease,,Terminated,Has Results,Alzheimer's Disease,Drug: Dimebon,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Abnormal Clinically Significant Vital Signs|Percentage of Participants With Abnormal Clinically Significant Laboratory Values|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Findings,"Pfizer|Medivation, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,649,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B1451029,Sep-09,Aug-10,Aug-10,15-Jul-09,14-Nov-12,14-Nov-12,"Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Northport, Alabama, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, Oceanside, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Santa Rosa, California, United States|Pfizer Investigational Site, Pueblo, Colorado, United States|Pfizer Investigational Site, Hockessin, Delaware, United States|Pfizer Investigational Site, Bradenton, Florida, United States|Pfizer Investigational Site, Brooksville, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Fort Walton Beach, Florida, United States|Pfizer Investigational Site, Maitland, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Naples, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Plant City, Florida, United States|Pfizer Investigational Site, Port Charlotte, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Burr Ridge, Illinois, United States|Pfizer Investigational Site, Elk Grove Village, Illinois, United States|Pfizer Investigational Site, Elkhart, Indiana, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Fort Wayne, Indiana, United States|Pfizer Investigational Site, Greenfield, Indiana, United States|Pfizer Investigational Site, Prairie Village, Kansas, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Lake Charles, Louisiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Hyannis, Massachusetts, United States|Pfizer Investigational Site, Flowood, Mississippi, United States|Pfizer Investigational Site, Olive Branch, Mississippi, United States|Pfizer Investigational Site, Springfield, Missouri, United States|Pfizer Investigational Site, Great Falls, Montana, United States|Pfizer Investigational Site, Eatontown, New Jersey, United States|Pfizer Investigational Site, Oakhurst, New Jersey, United States|Pfizer Investigational Site, Toms River, New Jersey, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Amherst, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Orchard Park, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Winston Salem, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Altoona, Pennsylvania, United States|Pfizer Investigational Site, Beaver, Pennsylvania, United States|Pfizer Investigational Site, Bridgeville, Pennsylvania, United States|Pfizer Investigational Site, Grove City, Pennsylvania, United States|Pfizer Investigational Site, Indiana, Pennsylvania, United States|Pfizer Investigational Site, Norristown, Pennsylvania, United States|Pfizer Investigational Site, Scotland, Pennsylvania, United States|Pfizer Investigational Site, Upper St. Clair, Pennsylvania, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Greer, South Carolina, United States|Pfizer Investigational Site, Murrells Inlet, South Carolina, United States|Pfizer Investigational Site, North Charleston, South Carolina, United States|Pfizer Investigational Site, Orangeburg, South Carolina, United States|Pfizer Investigational Site, Sioux Falls, South Dakota, United States|Pfizer Investigational Site, Franklin, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Carrollton, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Grand Prairie, Texas, United States|Pfizer Investigational Site, Lake Jackson, Texas, United States|Pfizer Investigational Site, Williamsburg, Virginia, United States|Pfizer Investigational Site, Kirkland, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Charleston, West Virginia, United States|Pfizer Investigational Site, La Crosse, Wisconsin, United States|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Medicine Hat, Alberta, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Saint John, New Brunswick, Canada|Pfizer Investigational Site, Bay Roberts, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Kentville, Nova Scotia, Canada|Pfizer Investigational Site, Pictou, Nova Scotia, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, L'Ancienne-Lorette, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, St-Jean-sur-Richelieu, Quebec, Canada|Pfizer Investigational Site, St. Leonard, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Cayey, Puerto Rico|Pfizer Investigational Site, Cidra, Puerto Rico|Pfizer Investigational Site, San Juan, Puerto Rico|Pfizer Investigational Site, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00939783
NCT00939822,Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease,SHARP,Unknown status,No Results Available,Alzheimer's Disease,Drug: Simvastatin|Drug: Placebo,Changes in cerebrospinal fluid (CSF) beta-amyloid-42 levels as measured by xMAP|Changes in CSF beta-amyloid-40 levels as measured by xMAP|Changes in CSF soluble alpha precursor proteins (sAPP-alpha) and soluble beta precursor proteins (sAPP-beta) as measured by Duplex|Changes in cerebrospinal fluid CSF beta-amyloid-42 levels as measured by Triplex|Changes in CSF total tau (t-tau) and phosphorylated tau (p-tau) as measured by xMAP|Changes in beta-amyloid peptides as measured by surface-enhanced laser desorption ionization - time of flight (SELDI-TOF),"University of Wisconsin, Madison|National Institute on Aging (NIA)",All,"40 Years to 72 Years   (Adult, Older Adult)",Phase 2,88,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2015-0038|R01AG031790-01A1|H-2009-0030|H-2008-0275,Mar-09,Sep-13,Sep-17,15-Jul-09,null,29-Mar-17,"University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00939822
NCT00937352,A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: Bapineuzumab,"Clinically important changes in safety assessment results including vital signs, weight, clinical laboratory tests, electrocardiograms (ECGs), brain magnetic resonance imaging (MRI), physical and neurological examinations, and infusion site assessments.|To evaluate the efficacy of long term treatment of IV administered bapineuzumab in subjects with AD.","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer",All,"51 Years and older   (Adult, Older Adult)",Phase 3,896,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ELN115727-351,Jul-09,Sep-12,Sep-12,13-Jul-09,null,20-Dec-13,"University of Alabama Hospital, Birmingham, Alabama, United States|Dedicated Clinical Research, Inc., Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|HOPE Research Institute, LLC, Phoenix, Arizona, United States|Banner Research Institute, Sun City, Arizona, United States|University of Arizona College of Medicine, Health Sciences Center, Tucson, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|AVI Clinical Research, Carson, California, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Coordinated Clinical Research, La Jolla, California, United States|University of California San Diego, La Jolla, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Collaborative NeuroScience Network, Inc., Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|UCLA Department of Neurology, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Neurology Center, Oceanside, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Neuro-Therapeutics, Inc., Pasadena, California, United States|Sutter Neuroscience Medical Group, Sacramento, California, United States|University of California at Davis, Alzheimer's Disease Research Center, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Diablo Clinical Research, Inc, Walnut Creek, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Christiana Care Neurology Specialists, Newark, Delaware, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|JEM Research, LLC, Atlantis, Florida, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neurologic Consultants, PA, Fort Lauderdale, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Clinical Physiology Associates, Inc, Fort Myers, Florida, United States|Emerald Coast Mood and Memory, PA., Fort Walton Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Mayo Clinic College of Medicine, Jacksonville, Florida, United States|Neurology Associates, Maitland, Florida, United States|Melbourne Internal Medicine Associates, Melbourne, Florida, United States|Pharmax Research Clinic, LLC, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Allied Clinical Trials Inc., Miami, Florida, United States|Miami Research Associates, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center, Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States|Neurostudies, Inc., Port Charlotte, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|The Roskamp Institute, Inc, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, School of Medicine, Atlanta, Georgia, United States|Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Medical Research and Health Education Foundation, Inc., Columbus, Georgia, United States|Medical Research and Health Education Foundation, Inc, Columbus, Georgia, United States|DeKalb Neurology Associates, LLC, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Four Rivers Clinical Research, Inc., Paducah, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Maine Medical Partners Neurology, Scarborough, Maine, United States|CBH Health, LLC, Rockville, Maryland, United States|Brigham and Women's Hospital, Dept. of Neurology, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|ActivMed Practices and Research, Inc., Haverhill, Massachusetts, United States|Neurocare, Inc., Newton, Massachusetts, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Donald S. Marks, MD, PC, Plymouth, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Borgess Medical Center/Borgess Research Institute, Kalamazoo, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Center for Pharmaceutical Research, Kansas City, Missouri, United States|Saint Louis University School of Medicine, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Lous, Missouri, United States|Deaconess Billings Clinical Research Center, Billings, Montana, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Global Medical Institutes, LLC, Princeton, New Jersey, United States|Shore Neurology, PA, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Neuroscience Research Center at Albany Medical Center, Albany, New York, United States|Advanced BioBehavioral Sciences, Elmsford, New York, United States|Empire Neurology, PC, Latham, New York, United States|Neurological Care of Central New York, Liverpool, New York, United States|Parker Jewish Institute for Health Care and Rehabilitation, New Hyde Park, New York, United States|New York University School of Medicine/Psychiarty, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Monroe Community Hospital, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Inc, Hickory, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Ohio State University, Dept. of Neurology, Columbus, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Providence Medical Group-Medford Neurology, Medford, Oregon, United States|Summit Research Group, LLC, Portland, Oregon, United States|Providence Health Service System, AD Center, Brain Institute, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Abington Neurological Associates, Ltd., Abington, Pennsylvania, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|East Tennessee State University, Johnson City, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Psychiatric Consultants, PC, Nashville, Tennessee, United States|Senior Adults Specialty Research (SASR), Austin, Texas, United States|Texas Neurology, PA, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dept. of Neurology, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|University of North Texas Health Science Center at Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|University of Utah, Dept. of Neurology, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|University of Washington Veterans Affairs, Seattle, Washington, United States|Pacific Medical Centers, Seattle, Washington, United States|Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Landeskrankenhaus- Universitätsklinikum Graz, Graz, Styria, Austria|University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada|Medical Arts Health Research Group, Kamloops, British Columbia, Canada|Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Queens University Memorial Clinics, Kingston, Ontario, Canada|Parkwood Hospital, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Neurology Research Inc, Toronto, Ontario, Canada|Toronto Centre for Memory and Aging, Toronto, Ontario, Canada|Ontario Shores Centre for Mental Health Sciences, Whitby, Ontario, Canada|Neuro Rive-Sud Memory Clinic, Greenfield Park, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Sir Mortimer B. Davis, Jewish General Hospital, Montréal, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Douglas Mental Health University Institute, Verdun, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00937352
NCT00937846,Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study,,Completed,No Results Available,Cognitive Disorders,Drug: GSK1034702,Volume of distribution of [11C]GSK1034702 at tracer and pharmacological doses.|The kinetic rate constants at tracer and pharmacological doses.|GSK1034702 PK parameters: Cmax; tmax; AUC(0-t).|Safety and tolerability endpoints consisting of: AEs; 12-lead ECG; 12 lead digital Holter and lead II telemetry; vital signs; clinical laboratory evaluations.,GlaxoSmithKline,Male,35 Years to 55 Years   (Adult),Phase 1,4,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,110771,15-Jul-09,28-Aug-09,28-Aug-09,13-Jul-09,null,27-Jun-17,"GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00937846
NCT00934050,ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: ELND005 (scyllo-inositol),Treatment Emergent Adverse Events (TEAEs),Transition Therapeutics Ireland Limited|Transition Therapeutics,All,"Child, Adult, Older Adult",Phase 2,103,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ELND005-AD251,Jun-09,Jun-11,Jun-11,8-Jul-09,13-May-15,13-May-15,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona, Health Sciences Center, Dept. of Neurology, Tucson, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative NeuroScience Network, Inc., Garden Grove, California, United States|Yale University School of Medicine, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Brain Matters Research, Delray Beach, Florida, United States|Sunrise Clinical Research, Inc, Hollywood, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Dept. of Neurology, Atlanta, Georgia, United States|Dekalb Neurology Associates, LLC, Decatur, Georgia, United States|Department of Neurology - Indiana University Medical Center, Indianapolis, Indiana, United States|University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, United States|Innovative Clinical Concepts, Paducah, Kentucky, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Global Medical Institutes, Princeton, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Columbia University Sergievsky Center, New York, New York, United States|AD-CARE, Monroe Community Hospital, Rochester, New York, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|Medford Neurological and Spine Clinic, Medford, Oregon, United States|Summit Research Newtwork, Inc., Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|University of Pittsburgh Alzheimer Disease Research Clinic, Pittsburgh, Pennsylvania, United States|Butler Hospital, Memory and Aging Center, Providence, Rhode Island, United States|Alliance for Neuro Research, LLC dba Absher Neurology, PA, Greenville, South Carolina, United States|Clinical Neuroscience Research Associates, Inc-The Memory Clinic, Bennington, Vermont, United States|Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada|University of British Columbia Hospital, Division of Neurology, Vancouver, British Columbia, Canada|Parkwood Hospital, London, Ontario, Canada|Sisters of Charity of Ottawa Health Service, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Whitby Mental Health Memory Clinic, Toronto, Ontario, Canada|Gerontion Research, Inc., Toronto, Ontario, Canada|Recherche Clinique de Neurologie (Hospital Maisonneuve Rosemont), Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00934050
NCT00933608,Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: memantine|Drug: Placebo,N-acetylaspartate,New York University School of Medicine|Forest Laboratories,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 4,17,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",NAM-MD-68,Jul-09,Sep-11,Sep-11,7-Jul-09,21-Oct-14,21-Oct-14,"NYU School of Medicine, Dept. of Psychiatry, Center for Brain Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00933608
NCT00931073,A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers,,Completed,No Results Available,Alzheimer's Disease|Huntington's Disease,Drug: Dimebon alone|Drug: Dimebon + Ketoconazole|Drug: Dimebon + Omeprazole,"Dimebon alone: Dimebon PK in CYP2D6 EMs and PMs (Cmax, Tmax, AUCinf (as data permit), AUClast, and t1/2 (as data permit), CL/F (as data permit) and V/F (as data permit))|Dimebon + keto: Dimebon PK in CYP2D6 EMs and PMs (Cmax, Tmax, AUCinf (as data permit), AUClast, and t1/2 (as data permit), CL/F (as data permit) and V/F (as data permit))|Dimebon + omeprazole: Dimebon PK in CYP2D6 EMs and PMs (Cmax, Tmax, AUCinf (as data permit), AUClast, and t1/2 (as data permit), CL/F (as data permit) and V/F (as data permit))|Dimebon alone: Safety and tolerability (AE's, ECG, vital signs, safety labs)|Dimebon + keto: Safety and tolerability (AE's, ECG, vital signs, safety labs)|Dimebon + omeprazole: Safety and tolerability (AE's, ECG, vital signs, safety labs)","Pfizer|Medivation, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),B1451017,Jul-09,Oct-09,Oct-09,2-Jul-09,null,18-Nov-09,"Pfizer Investigational Site, Kalamazoo, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00931073
NCT00930059,A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: PF-04447943|Drug: Placebo,"Change from baseline on Alzheimer's Disease Assessment Scale (Cognitive Subscale)|Change from baseline on Neuropsychiatric Inventory|Clinical Global Impression - Improvement|Safety Assessments (including adverse events, vital signs, electrocardiograms, laboratory tests)|Plasma Concentrations of PF-04447943",Pfizer,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,198,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B0401005,Sep-09,Sep-10,Sep-10,30-Jun-09,null,16-Apr-13,"Pfizer Investigational Site, Northport, Alabama, United States|Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Glendale, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Rancho Mirage, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Vista, California, United States|Pfizer Investigational Site, Hallandale Beach, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Plantation, Florida, United States|Pfizer Investigational Site, Joliet, Illinois, United States|Pfizer Investigational Site, Fort Wayne, Indiana, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Paducah, Kentucky, United States|Pfizer Investigational Site, Lake Charles, Louisiana, United States|Pfizer Investigational Site, Newton, Massachusetts, United States|Pfizer Investigational Site, Cedarhurst, New York, United States|Pfizer Investigational Site, Staten Island, New York, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Cordova, Tennessee, United States|Pfizer Investigational Site, Kelowna, British Columbia, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Peterborough, Ontario, Canada|Pfizer Investigational Site, Greenfield Park, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Antofagasta, II Region, Chile|Pfizer Investigational Site, Providencia, RM, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, La Florida, Santiago, Chile|Pfizer Investigational Site, Valdivia, XIV Region, Chile|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Pardubice, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Praha 8, Czech Republic|Pfizer Investigational Site, Praha 8, Czech Republic|Pfizer Investigational Site, Rychnov nad Kneznou, Czech Republic|Pfizer Investigational Site, Strakonice, Czech Republic",,https://ClinicalTrials.gov/show/NCT00930059
NCT00927108,Rajavtihi Neuronal Adult Stem Cells Project,RNASc,Unknown status,No Results Available,Alzheimer's Disease|Parkinson's Disease|Multiple Sclerosis,Other: Progenitor Stem Cell Culture,,Rajavithi Hospital|Rajavithi Biomolecular Research Center,All,"20 Years and older   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RH-CMR-005,Jul-09,Dec-11,null,24-Jun-09,null,24-Jun-09,"Rajavithi Hospital, Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT00927108
NCT00921297,Cataract Removal and Alzheimer's Disease,,Completed,No Results Available,Cataracts|Alzheimer's Disease,Procedure: Immediate Cataract Surgery,"Visual acuity, spatial contrast sensitivity, visual perception and cognition|Independent function|Quality of Life|Retinal Nerve Fiber Layer",University Hospitals Cleveland Medical Center|Case Western Reserve University|MetroHealth Medical Center|National Institute on Aging (NIA),All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,122,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,04-09-21|1R01AG030114,Jun-09,30-Mar-17,30-Mar-17,16-Jun-09,null,9-Nov-17,"University Hospitals Case Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00921297
NCT00916617,Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab,,Terminated,Has Results,Alzheimer Disease,Drug: bapineuzumab,"Number of Participants Reporting Clinically Significant Magnetic Resonance Imaging (MRI) Findings|Pharmacokinetic Parameters Including Maximal Serum Drug Concentration, Time to Maximal Serum Drug Concentration, and Terminal Half-life of Elimination","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,62,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3133L1-2204|B2521009,Jun-09,Sep-12,Sep-12,9-Jun-09,1-Jun-17,1-Jun-17,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Pharmacology Research Institute, Encino, California, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Palm Beach Neurology - Premiere Research Institute, West Palm Beach, Florida, United States|Neurostudies.net, Decatur, Georgia, United States|Dekalb Neurology Associates, LLC, Lawrenceville, Georgia, United States|NeuroStudies.net, Lawrenceville, Georgia, United States|Clinical Research Institute, Wichita, Kansas, United States|Monroe Community Hospital, Rochester, New York, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Texas Neurology, P.A., Dallas, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|University of Wisconsin, Department of Surgery, Madison, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00916617
NCT00912288,A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease,,Terminated,Has Results,Alzheimer Disease,Drug: Dimebon 20 mg po TID|Drug: Placebo po TID,Change From Baseline in the Severe Impairment Battery (SIB) Score at Week 26|Change From Baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (Severe) (ADCS-ADLsev) Score at Week 26|Change From Baseline in the Neuropsychiatric Inventory (NPI) Total Score at Week 26|Sum of the Delusions and Hallucinations Sub-domain Scores of the NPI|Change From Baseline in the Mini-Mental State Examination (MMSE) Score at Week 26|Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) Scores|Resource Utilization in Dementia-Lite Version (RUD-Lite)|Euro Quality of Life - 5 Domain (EQ-5D) Assessment|Population Pharmacokinetic (PK) Analysis|Number of Participants With Adverse Events (AEs),"Pfizer|Medivation, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,86,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B1451006,Sep-09,Aug-10,Aug-10,3-Jun-09,2-Oct-12,2-Oct-12,"Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, Los Alamitos, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Brooksville, Florida, United States|Pfizer Investigational Site, Delray Beach, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Pittsfield, Massachusetts, United States|Pfizer Investigational Site, Princeton, New Jersey, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Norristown, Pennsylvania, United States|Pfizer Investigational Site, East Providence, Rhode Island, United States|Pfizer Investigational Site, Cordova, Tennessee, United States|Pfizer Investigational Site, Middleton, Wisconsin, United States|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bochum, Germany|Pfizer Investigational Site, Guenzburg, Germany|Pfizer Investigational Site, Leipzig, Germany|Pfizer Investigational Site, Mainz, Germany|Pfizer Investigational Site, Mittweida, Germany|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Gyula, Hungary|Pfizer Investigational Site, Szekesfehervar, Hungary|Pfizer Investigational Site, Amadora, Portugal|Pfizer Investigational Site, Coimbra, Portugal|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Michalovce, Slovakia|Pfizer Investigational Site, Roznava, Slovakia|Pfizer Investigational Site, Zilina, Slovakia|Pfizer Investigational Site, Algorta, Getxo, Bilbao, Spain|Pfizer Investigational Site, Salt, Girona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Kocaeli, Turkey|Pfizer Investigational Site, Samsun, Turkey",,https://ClinicalTrials.gov/show/NCT00912288
NCT00911807,Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease,Combi,Completed,Has Results,Alzheimer Disease,Drug: Cerebrolysin + donepezil|Drug: Cerebrolysin + placebo|Drug: Donepezil + placebo,"Change From Baseline in Alzheimer's Disease Assessment Scale Cognitive Subpart (Extended Version) (ADAS-COG+) at Week 28|Clinical Interview-Based Impression of Change (CIBIC+) Score|Change From Baseline for ADAS-COG+|ADAS-COG+ Responders|Change From Baseline for Original ADAS-COG|CIBIC+ Score|CIBIC+ Responders|Clinical Interview-Based Impression of Severity (CIBIS+) Score|Change From Baseline for Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL)|Change From Baseline in Total Score for Neuropsychiatric Inventory (NPI)|Combined Responders, i.e. Response in ADAS-COG+ and CIBIC+|Adverse Experiences, Vital Signs, Physical and Neurological Examinations, Laboratory Tests (Hematology, Clinical Chemistry , Urinalysis, Electrocardiogram [ECG])",Ever Neuro Pharma GmbH|acromion GmbH,All,"51 Years and older   (Adult, Older Adult)",Phase 2,217,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EBE-031010,Oct-04,Apr-08,Apr-08,2-Jun-09,2-Jun-09,10-Jun-09,"Centro Geriátrico Fuente Salinas, Granada, Spain|EuroEspes Biomedical Research Centre, La Coruna, Spain|Clínica de Memoria, Málaga, Spain",,https://ClinicalTrials.gov/show/NCT00911807
NCT00908492,Supporting Caregivers of Persons With Dementia: A Pilot Study,,Completed,No Results Available,Alzheimer Disease|Dementia,Behavioral: Education Control|Behavioral: Environmental Skill Building,Revised Memory and Behavior Problem Checklist|Disability Assessment for Dementia|Number of caregiving assistance hours|Short Zarit Burden Interview|Task Management Strategy Index|Perceived Change Scale,McMaster University|Alzheimer Society of Canada,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,38,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ASC1050,Nov-09,Aug-11,Sep-11,27-May-09,null,7-Apr-15,"McMaster University, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00908492
NCT00909285,Effects of Transcranial Magnetic Stimulation (TMS) and Cognitive Training for Alzheimer Patients,,Completed,No Results Available,"Alzheimer Disease, Early Onset",Device: TMS stimulation|Device: Sham comparator|Behavioral: Cognitive training,Evaluation of the efficacy of the TMS stimulation with cognitive training in treatment of early- to mid- stage Alzheimer's patients will be established by improvement of at least 4 points on ADAS-COG.|Safety will be established by paucity of related adverse events.,Assaf-Harofeh Medical Center,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NRX -NC-01,Jul-09,Jul-10,Jul-10,27-May-09,null,13-Jul-10,"Assaf-Harofeh MC, Beer-Yaakov, Israel",,https://ClinicalTrials.gov/show/NCT00909285
NCT00906191,Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects,,Completed,No Results Available,Alzheimer Disease,Drug: SAM-531,"Radioactivity measurements in blood, urine and feces and pharmacokinetic parameters (Cmax, AUC, terminal elimination half life, total clearance and volume of distribution in the plasma ; urine clearance ; metabolite profiling in plasma, urine and feces.)",Wyeth is now a wholly owned subsidiary of Pfizer,Male,18 Years to 50 Years   (Adult),Phase 1,6,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,3193A1-1114,May-09,Aug-09,Aug-09,21-May-09,null,26-Aug-09,"Zuidlaren, Netherlands",,https://ClinicalTrials.gov/show/NCT00906191
NCT00904683,Effect of LY2062430 on the Progression of Alzheimer's Disease,EXPEDITION2,Completed,No Results Available,Alzheimer's Disease,Drug: LY2062430|Drug: Placebo,Change from Baseline to Week 80 in Alzheimer's Disease Assessment Scale - Cognitive Subscore 14-Item Scale (ADAS-Cog14)|Change from Baseline to Week 80 in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score|Change from Baseline to Week 80 in Neuropsychiatric Inventory (NPI) Score|Change from Baseline to Week 80 in volumetric Magnetic Resonance Imaging (vMRI)|Change from Baseline to Week 80 in Mini-Mental State Examination (MMSE) Score|Change from Baseline to Week 80 in Resource Utilization in Dementia - Lite (RUD-Lite) Score|Change from Baseline to Week 80 in EuroQol 5-Dimensional Health-related Quality of Life Scale Proxy version (EQ-5D Proxy) Score|Change from Baseline to Week 80 in Quality of Life in Alzheimer's Disease (QoL-AD) Score|Change from Baseline to Week 80 in Plasma Amyloid Beta Levels|Change from Baseline to Week 80 in Alzheimer's Disease Assessment Scale - Cognitive Subscore 11-Item and 12-Item Scale (ADAS-Cog11 and ADAS-Cog12)|Change from Baseline to Week 80 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Score,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1040,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11934|H8A-MC-LZAN,May-09,Jun-12,Jun-12,20-May-09,null,13-Dec-12,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa Bay, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hattiesburg, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Creve Coeur, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amherst, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bankstown, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Darlinghurst, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gosford, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chermside, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toowoomba, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Iris, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg Heights, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melbourne, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Subiaco, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aix En Provence, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., München, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Biella, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boggiovara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cassino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chieti, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lido Di Camaiore, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seongnam-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bydgoszcz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gliwice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelyabinsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ekaterinburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rostov-On-Don, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getafe, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terrassa, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Joenkoeping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kalmar, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Molndal, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umea, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niao Sung Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uckfield, E Susx, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scotland, Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Greater London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camberwell, London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, Syorks, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swindon, Wiltshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00904683
NCT00905372,Effect of LY2062430 on the Progression of Alzheimer's Disease,EXPEDITION,Completed,No Results Available,Alzheimer's Disease,Drug: LY2062430|Drug: Placebo,Change from baseline to endpoint in Alzheimer's Disease Assessment Scale—Cognitive subscore (ADAS-Cog11)|Change from baseline to endpoint in Alzheimer's Disease Cooperative Study—Activities of Daily Living Inventory (ADCS-ADL)|Change from baseline to endpoint in Clinical Dementia Rating—Sum of Boxes (CDR-SB)|Change from baseline to endpoint in Neuropsychiatric Inventory (NPI)|Change from baseline to endpoint in volumetric magnetic resonance imaging (vMRI)|Change from baseline to endpoint in Mini-Mental State Examination (MMSE)|Change from baseline to endpoint in Resource Utilization in Dementia—Lite (RUD-Lite)|Change from baseline to endpoint in EuroQol 5-Dimensional Health-related Quality of Life Scale Proxy version (EQ-5D Proxy)|Change from baseline to endpoint in Quality of Life in Alzheimer's Disease (QoL-AD)|Change from baseline to endpoint in plasma LY2062430 to investigate a relationship between plasma LY2062430 and plasma A Beta levels.|Change from baseline to endpoint in plasma A Beta,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",6747|H8A-MC-LZAM,May-09,Apr-12,Apr-12,20-May-09,null,25-Sep-12,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tuscon, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Carson, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Irvine, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laguna Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lomita, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxnard, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Ana, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fairfield, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norwalk, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newark, Delaware, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange City, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunrise, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Canton, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Decatur, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grand Rapids, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Traverse City, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Latham, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orangeburg, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beachwood, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Providence, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norfolk, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roanoke, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mendoza, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pueyrredon Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Curitiba, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Itapira, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Medicine Hat, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Penticton, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenfield Park, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00905372
NCT00901498,Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Healthy,Drug: BMS-708163,To assess the bioavailability of 4 experimental formulations relative to the current reference formulation|Safety: Adverse Events|Safety: Vital Signs|Safety: ECGs|Safety: Clinical Lab Tests,Bristol-Myers Squibb,Male,18 Years to 45 Years   (Adult),Phase 1,36,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),CN156-004,May-09,Jul-09,Jul-09,13-May-09,null,7-Jan-11,"Mds Pharma Services (Us) Inc., Neptune, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00901498
NCT00898807,Citalopram for Agitation in Alzheimer's Disease,CitAD,Completed,Has Results,Alzheimer's Disease|Agitation,Drug: citalopram|Drug: placebo,NeuroBehavior Rating Scale-- Agitation|Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in Agitation(CGIC)|Cohen-Mansfield Agitation Inventory (CMAI)|Neuropsychiatric Inventory (NPI)-- Agitation Subscore,JHSPH Center for Clinical Trials|National Institute on Aging (NIA)|National Institute of Mental Health (NIMH),All,"Child, Adult, Older Adult",Phase 3,186,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IA0155|R01AG031348,Jul-09,Sep-13,Sep-13,12-May-09,27-Jun-14,27-Jun-14,"University of Southern California Keck School of Medicine Memory and Aging Center, Los Angeles, California, United States|VA Palo Alto Health Care System, Palo Alto, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|Columbia University, New York, New York, United States|Monroe Community Hospital, Rochester, New York, United States|University of Pennsylvania, Section of Geriatric Psychiatry, Ralston House, Philadelphia, Pennsylvania, United States|Medical University of South Carolina Alzheimer's Research and Clinical Programs, Charleston, South Carolina, United States|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00898807
NCT00895895,Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease,,Terminated,Has Results,Alzheimer Disease,Drug: Placebo|Drug: SAM-531 1.5 mg|Drug: SAM-531 3.0 mg|Drug: SAM-531 5.0 mg|Drug: Donepezil,"Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) Total Score at Week 24|Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 24|Change From Baseline in Neuropsychiatry Inventory (NPI) at Week 24|Number of Participants With Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) Scores at Week 24|Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associate Learning (PAL)Total Errors (N, Shapes, Adjusted) at Week 24|Change From Baseline in CANTAB PAL - Number of Patterns Reached at Week 24|Change From Baseline in CANTAB PAL - First Trial Memory Score, Patterns at Week 24|Change From Baseline in CANTAB Spatial Working Memory (SWM) - Between Errors (4 Boxes) at Week 24|Change From Baseline in CANTAB-SWM - Between Errors (6 Boxes) at Week 24|Change From Baseline in CANTAB SWM - Between Errors (8 Boxes) at Week 24|Change From Baseline in CANTAB SWM - Between Errors (N Boxes) at Week 24|Change From Baseline in CANTAB SWM Strategy at Week 24|Change From Baseline in CANTAB Pattern Recognition Memory (PRM)-Mean Correct Latency at Week 24|Change From Baseline in CANTAB PRM-Percentage Correct at Week 24|Change From Baseline in CANTAB Reaction Time (RTI) Five-Choice Accuracy at Week 24|Change From Baseline in CANTAB RTI Five-Choice Movement Time at Week 24|Change From Baseline in CANTAB RTI Five-Choice Reaction Time at Week 24|Change From Baseline in CANTAB RTI Simple Movement Time at Week 24|Change From Baseline in CANTAB RTI Simple Reaction Time at Week 24|Percentage of Participants Who Were Responders at Week 24",Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 2,526,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",3193A1-2005|B1961007,May-09,May-11,May-11,8-May-09,31-Jan-13,31-Jan-13,"Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Garden Grove, California, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Oxnard, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, aTLANTIS, Florida, United States|Pfizer Investigational Site, Brooksville, Florida, United States|Pfizer Investigational Site, Hallandale Beach, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Naples, Florida, United States|Pfizer Investigational Site, Plantation, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, Sunrise, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Elk Grove Village, Illinois, United States|Pfizer Investigational Site, Park Ridge, Illinois, United States|Pfizer Investigational Site, Saint Louis, Missouri, United States|Pfizer Investigational Site, Saint Louis, Missouri, United States|Pfizer Investigational Site, Cedarhurst, New York, United States|Pfizer Investigational Site, Staten Island, New York, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Franklin, Tennessee, United States|Pfizer Investigational Site, Bennington, Vermont, United States|Pfizer Investigational Site, Middleton, Wisconsin, United States|Pfizer Investigational Site, C.a.b.a., Buenos Aires, Argentina|Pfizer Investigational Site, Caba, Buenos Aires, Argentina|Pfizer Investigational Site, Ciudad de Buenos Aires, Argentina|Pfizer Investigational Site, Ciudad de Buenos Aires, Argentina|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Vina del Mar, Chile|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Pereira, Risaralda, Colombia|Pfizer Investigational Site, Bucamaranga, Santander, Colombia|Pfizer Investigational Site, Cali, Valle, Colombia|Pfizer Investigational Site, Valle del Cauca, Colombia|Pfizer Investigational Site, Shatin, N.T., Hong Kong SAR, China, Hong Kong|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Hachioji, Tokyo, Japan|Pfizer Investigational Site, Chiba, Japan|Pfizer Investigational Site, Fukuoka, Japan|Pfizer Investigational Site, Hiroshima, Japan|Pfizer Investigational Site, Kanagawa, Japan|Pfizer Investigational Site, Kumamoto, Japan|Pfizer Investigational Site, Kyoto, Japan|Pfizer Investigational Site, Nagano, Japan|Pfizer Investigational Site, Nagasaki, Japan|Pfizer Investigational Site, Shizuoka, Japan|Pfizer Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Saltillo, Coahuila, Mexico|Pfizer Investigational Site, Aguascalientes, Mexico|Pfizer Investigational Site, Auckland, New Zealand|Pfizer Investigational Site, Hamilton, New Zealand|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Poznan, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Craiova, Dolj, Romania|Pfizer Investigational Site, Timisoara, Timis, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Nikolskoe village, Gatchina district, Leningrad region, Russian Federation|Pfizer Investigational Site, Kazan, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Novosibirsk, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, Yaroslavl, Russian Federation|Pfizer Investigational Site, Bloemfontein, Free State, South Africa|Pfizer Investigational Site, Johannesburg, Gauteng, South Africa|Pfizer Investigational Site, Pretoria, Gauteng, South Africa|Pfizer Investigational Site, Bellville, Western Cape, South Africa|Pfizer Investigational Site, Cape Town, South Africa",,https://ClinicalTrials.gov/show/NCT00895895
NCT00890890,"A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease",,Terminated,No Results Available,Alzheimer's Disease,Drug: Avagacestat|Drug: Placebo,"Safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease as measured by adverse events, vital signs, laboratory assessments, electrocardiograms (ECGs) and Safety Head Magnetic resonance imaging (MRI) findings|Predictive value of Cerebral Spinal Fluid (CSF) biomarkers (Aβ40, and Aβ42, total Tau, total Tau/Aβ42 ratio, phosphorylated Tau) on progression to dementia",Bristol-Myers Squibb,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 2,263,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CN156-018|2009-010067-16,May-09,Jul-13,Jul-13,30-Apr-09,null,12-Oct-15,"University Of Alabama At Birmingham, Birmingham, Alabama, United States|Pivotal Research Centers, Peoria, Arizona, United States|21st Century Neurology, Phoenix, Arizona, United States|Banner Alzheimer'S Institute, Phoenix, Arizona, United States|Sun Health Research Institue, Sun City, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative Neuroscience Network, Inc., Long Beach, California, United States|Mary S. Easton Center, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Uc Irvine Medical Center, Orange, California, United States|Pacific Research Network, San Diego, California, United States|Affiliated Research Institute, San Diego, California, United States|University Of California, San Diego, San Diego, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Radiant Research, Inc., Denver, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Md Clinical, Hallandale Beach, Florida, United States|Compass Research, Llc, Orlando, Florida, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Four Rivers Clinical Research, Inc, Paducah, Kentucky, United States|Brigham & Women'S Hospital, Boston, Massachusetts, United States|St Louis University, Saint Louis, Missouri, United States|Washington University School Of Medicine, St. Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center For Brain Health, Las Vegas, Nevada, United States|Memory Enhancement Center Of Amercia, Inc., Eatontown, New Jersey, United States|Robert Wood Johnson Medical School, Umdnj, New Brunswick, New Jersey, United States|Global Medical Institutes, Llc, Princeton, New Jersey, United States|Memory Enhancement Center Of Nj, Inc., Toms River, New Jersey, United States|Spri Clinical Trials, Llc, Brooklyn, New York, United States|Nyu Langone Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|University Of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Raleigh Neurology Associates, Pa, Raleigh, North Carolina, United States|Richard H. Weisler, Md, Pa & Assoc., Raleigh, North Carolina, United States|Clinical Trials Of America, Inc., Winston Salem, North Carolina, United States|Wake Forest University School Of Medicine, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Neurology & Neuroscience Center Of Ohio, Toledo, Ohio, United States|Tulsa Clinical Research, Llc, Tulsa, Oklahoma, United States|Providence Cognitive Assessment Clinic, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Butler Hospital, Providence, Rhode Island, United States|Senior Adults Specialty Research (Sasr), Austin, Texas, United States|The University Of Texas, Dallas, Texas, United States|Dean Foundation For Health Research & Education, Middleton, Wisconsin, United States|Mcw Clinics At Froedtert Hospital, Milwaukee, Wisconsin, United States|Local Institution, Calgary, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Turku, Finland|Local Institution, Toulouse, Cedex 9, France|Local Institution, Bordeaux Cedex, France|Local Institution, Dijon, France|Local Institution, Nantes, France|Local Institution, Rennes Cedex 9, France|Local Institution, Molndal, Sweden|Local Institution, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00890890
NCT00888056,Chronic Electrical Stimulation of Hypothalamus/Fornix in Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease,Procedure: Bilateral chronic electrical stimulation of the hypothalamus/fornix,"Evaluation criteria for feasibility will be the proportion of patients undergoing the procedure, chronic stimulation and evaluation process without adverse event.|Efficacy will be evaluated using numerous cognitive and memory testing. Neuro-imaging changes after stimulation will be evaluate by morphological MRI and functional imaging (PET). Changes in behavioral and mood scales: evaluate safety",Centre Hospitalier Universitaire de Nice,All,"50 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-PP-01,Jun-09,null,null,24-Apr-09,null,27-Jun-12,"CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez, Nice, Alpes-Maritimes, France",,https://ClinicalTrials.gov/show/NCT00888056
NCT00886951,Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: I123MNI388/I123MNI390,To determine the reliability of MNI 388/390 as a potential imaging biomarker for amyloid imaging in the brain,Institute for Neurodegenerative Disorders,All,"50 Years and older   (Adult, Older Adult)",Phase 1,2,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,MNI-388/390-01,Mar-09,Mar-09,Mar-09,23-Apr-09,null,3-Apr-19,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00886951
NCT00884507,A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Placebo|Drug: RO5313534,"Change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score|CANTAB tests, MMSE total score, ADCS CGIC, Behave-AD-FW, ADCS-ADL, Zarit Burden interview|AEs, lab parameters, suicidal risk, concomitant medications, physical and neurological examinations.",Hoffmann-La Roche,All,"50 Years and older   (Adult, Older Adult)",Phase 2,389,Industry,Interventional,"Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WN22018|2008-004012-13,May-09,Nov-10,Nov-10,20-Apr-09,null,2-Nov-16,"Orange, California, United States|Torrance, California, United States|Norwalk, Connecticut, United States|Delray Beach, Florida, United States|Ft Myers, Florida, United States|Maitland, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Paducah, Kentucky, United States|Kalamazoo, Michigan, United States|Creve Coeur, Missouri, United States|Eatontown, New Jersey, United States|Albuquerque, New Mexico, United States|White Plains, New York, United States|Portland, Oregon, United States|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Caba, Argentina|Hornsby, New South Wales, Australia|Chermside, Queensland, Australia|Woodville, South Australia, Australia|Medicine Hat, Alberta, Canada|Vancouver, British Columbia, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Verdun, Quebec, Canada|Regina, Saskatchewan, Canada|Montpellier, France|Nice, France|St Herblain, France|Toulouse, France|Günzburg, Germany|Leipzig, Germany|München, Germany|Nürnberg, Germany|Napoli, Campania, Italy|Castellanza, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Aguascalientes, Mexico|Guadalajara, Mexico|Monterrey, Mexico|Saltillo, Mexico|Gdansk, Poland|Leszno, Poland|Torun, Poland|Warszawa, Poland|Bucharest, Romania|Bucharest, Romania|Bratislava, Slovakia|Michalovce, Slovakia|BArcelon, Barcelona, Spain|Salt, Girona, Spain|Barakaldo, Vizcaya, Spain|Barcelona, Spain|Madrid, Spain|Malaga, Spain|Blackpool, United Kingdom|Bradford, United Kingdom|Glasgow, United Kingdom|Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00884507
NCT00884533,QTc Study of Rosi XR in Healthy Volunteers,Rosi XR,Withdrawn,No Results Available,Alzheimer's Disease,Drug: Rosi XR|Other: Placebo|Drug: Moxifloxacin,"Day 20 time-matched change from baseline in QTcI for RSG- XR 8mg and placebo|Day 21 time-matched change from baseline in QTcI for RSG- XR 20mg, placebo and moxifloxacin 400mg|Day 20 time-matched change from baseline in QTcF and QTcB for RSG XR 8mg and placebo.|Day 21 time-matched change from baseline in QTcF and QTcB for RSG XR 20mg, placebo and moxifloxacin 400mg|Tolerability of repeat doses of RSG- XR at 8 mg and a single oral dose of RSG- XR at 20 mg as assessed by 12-lead ECGs, vital signs, adverse events, and clinical laboratory tests.",GlaxoSmithKline,All,18 Years to 45 Years   (Adult),Phase 1,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,111802,Jun-09,Aug-09,Aug-09,20-Apr-09,null,17-Apr-15,"GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00884533
NCT00880347,Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia,,Completed,No Results Available,Alzheimer's Disease|Dementia,Device: Blood sampling,"To define the test performance of the blood expression signatures in the intended use population of demented patients to differentiate AD patients from non-AD demented patients.|Performance of blood signatures (AD versus control, AD vs each individual type of non-AD dementia,...). Specificity of the blood signatures versus NINCDS-ADRDA criteria. Exploratory assessment of clinical parameters that may influence blood signature.",Exonhit,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,550,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,EHTAD/002,Feb-08,Feb-11,Feb-11,13-Apr-09,null,31-Mar-11,"Hôpital Privé Les Magnolias, Ballainvilliers, France|Cabinet Médical, Bergerac, France|Centre Médical, Dijon, France|Cabinet Médical, La Seyne sur Mer, France|Cabinet Médical, Le Vesinet, France|Clinique Léopold Bellan, Magnanville, France|Cabinet Médical, Marseille, France|Centre Médical, Montpellier, France|Cabinet Médical, Montpellier, France|CMRR Gui de Chauliac Hospital, Montpellier, France|CHU Nantes Hôpital Laennec, Nantes, France|ClinOuest network, Nantes, France|Cabinet Médical 2, Nice, France|Cabinet Médical, Nice, France|Cabinet Médical, Paris, France|Centre Médical, Rambouillet, France|Cabinet Médical, Rodez, France|Cabinet Médical, Rueil Malmaison, France|Cabinet Médical, Saint Brieuc, France|Purpan-Casselardit Hospital - University of Toulouse, Toulouse, France|CDPRV Le Capitole, Valence, France",,https://ClinicalTrials.gov/show/NCT00880347
NCT00880412,A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease,EHT0202/002,Completed,No Results Available,Alzheimer's Disease,Drug: EHT 0202 etazolate|Drug: Placebo,"incidence/frequency and severity of adverse events, relation to treatment start and drug exposure, drop-out rate, including reason for withdrawal, clinical examination, change from screening of biological safety parameters, vital signs, ECG and weight.|Assessment of cognition (ADAS-Cog, Neuropsychological Test Battery, MMSE), patient's global functioning (CDR-SB,CGI), patient's behaviour (NPI), daily living activities (ADCS-ADL) and caregiver's burden. Population PK of EHT 0202 and PK/PD profile.",Exonhit,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,197,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EHT0202/002,Apr-08,Jun-09,Aug-09,13-Apr-09,null,21-Sep-09,"Hôpital Privé Les Magnolias, Ballainvilliers, France|Cabinet Médical, Bergerac, France|Fleyriat Hospital, Bourg en Bresse, France|Cabinet Médical, Dijon, France|Charles Foix Hospital, Ivry sur Seine, France|Cabinet Médical, La Seyne sur Mer, France|Roger Salengro Hospital, Lille, France|Dupuytren Hospital, Limoges, France|Clinique Léopold Bellan, Magnanville, France|Cabinet Médical, Montpellier, France|Cabinet Médical 2, Montpellier, France|CHU Nantes Hôpital Laennec, Nantes, France|Cabinet Médical 2, Nice, France|Cabinet Médical, Nice, France|CHU Cochin Broca, Paris, France|Cabinet Médical, Rambouillet, France|CHU Rennes, Rennes, France|Cabinet Médical, Rodez, France|Cabinet Médical, Rueil Malmaison, France|Cabinet Médical, Saint Brieuc, France|Cabinet Médical, Toulon, France|Purpan-Casselardit Hospital - University of Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00880412
NCT00876863,"Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease",,"Active, not recruiting",No Results Available,Alzheimer's Disease,Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF|Procedure: Placebo Surgery,Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Neuropsychological Test Battery|Mini-Mental State Examination (MMSE)|Neuropsychiatric Inventory (NPI)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL),Sangamo Therapeutics|Alzheimer's Disease Cooperative Study (ADCS),All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2,50,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CERE-110-03|NIH Grant 1R01AG030048-01A1,Sep-09,Dec-19,Mar-20,7-Apr-09,null,10-Jan-17,"University of Alabama, Birmingham, Alabama, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|Georgetown University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Mount Sinai School of Medicine, New York, New York, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00876863
NCT00874939,A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023),,Terminated,Has Results,Alzheimer's Disease|Dementia,Drug: MK-0249 7.5 mg|Drug: MK-0249 25 mg|Drug: Donepezil 5mg|Drug: Placebo to MK-0249|Drug: Placebo to Donepezil,"Time Weighted Average of the Change From Baseline After Single Dose Administration of Donepezil 5 mg or Placebo, Measured by Groton Maze Learning Test (GMLT) in Participants With Alzheimer's Disease|Time Weighted Average of the Change From Baseline After Single Dose Administration of Donepezil 5 mg or Placebo, Measured by Groton Maze Learning Test (GMLT) in Healthy Participants|Time Weighted Average of the Change From Baseline After Single Dose Administration of MK-0249, Measured by GMLT in Participants With Alzheimer's Disease.|Time Weighted Average of the Change From Baseline After Single Dose Administration of MK-0249, Measured by GMLT in Healthy Participants.",Merck Sharp & Dohme Corp.,All,65 Years and older   (Older Adult),Phase 1,4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0249-023|MK-0249-023|2009_572,6-Apr-09,20-Apr-09,20-Apr-09,3-Apr-09,8-Jun-15,17-Oct-18,,,https://ClinicalTrials.gov/show/NCT00874939
NCT00870519,Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects,,Terminated,No Results Available,Alzheimer's Disease,Drug: I-123-MNI-168|Drug: 123-I MNI-168,"To assess the uptake and washout of {I123}MNI-168, a potential imaging biomarker for β-amyloid burden in brain,|To acquire initial safety data following injection of (123I) MNI-168.",Institute for Neurodegenerative Disorders,All,"50 Years and older   (Adult, Older Adult)",Phase 1,2,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,MNI-168-01,Jan-09,Dec-10,Dec-10,27-Mar-09,null,3-Apr-19,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00870519
NCT00870974,A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions,FPEB,Completed,No Results Available,Parkinson Disease|Huntington Disease|Autistic Spectrum Disorders|Fragile X Syndrome|Alzheimer Disease|Mild Cognitive Impairment,Drug: [18F]FPEB,Does FPEB reliably represent the known distribution of MGLUR5 in the brain?,Institute for Neurodegenerative Disorders,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,48,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),FPEB,Mar-09,Oct-16,Nov-16,27-Mar-09,null,6-Jan-17,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00870974
NCT00867828,Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE),MNEMOSYNE,Completed,No Results Available,Early Onset Alzheimer Disease,Dietary Supplement: Neptune Krill Oil|Dietary Supplement: Fish Oil|Dietary Supplement: Placebo (soy oil),"The primary outcome measure will be the change in Neurological Test Battery between baseline and 24 weeks of treatment.|Secondary outcome measures will include the change in DAD at 24 weeks of treatment, the change in NTB, GDS, DAD, and MMSE at 12 weeks.Safety and tolerability will be assessed by the incidence of treatment emergent adverse events.",NeuroBioPharm Inc.|Neptune Technologies and Bioressources Inc.,All,"50 Years and older   (Adult, Older Adult)",Phase 4,175,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NBP-4209AD,May-09,Jul-10,Jan-11,24-Mar-09,null,3-Oct-11,"Surrey, British Columbia, Canada|Deer Lake, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Cornwall, Ontario, Canada|Hamilton, Ontario, Canada|Hawkesbury, Ontario, Canada|Newmarket, Ontario, Canada|Ottawa, Ontario, Canada|Sarnia, Ontario, Canada|Thornhill, Ontario, Canada|Thunder Bay, Ontario, Canada|Dollard Des Ormeaux, Quebec, Canada|Grand-Mere, Quebec, Canada|Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00867828
NCT00867399,A Safety and Tolerability Study of ABT-126 in Elderly,,Completed,No Results Available,Alzheimer's Disease,Drug: ABT-126,"Safety and Tolerability Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)|Assess the Pharmacokinetics",Abbott,All,65 Years and older   (Older Adult),Phase 1,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",M10-717,Mar-09,May-09,null,23-Mar-09,null,2-Nov-10,"Site Reference ID/Investigator# 17283, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT00867399
NCT00866060,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,DOMINO-AD,Unknown status,No Results Available,Moderate to Severe Alzheimer's Disease,Drug: Memantine|Drug: Donepezil|Drug: Placebo donepezil|Drug: Placebo memantine,"Cognitive Function measured with the Standardised MMSE (SMMSE).|Activities of Daily Living measured with the Bristol Activities of Daily Living scale (BADLS).|Non−cognitive dementia symptoms measured with the Neuropsychiatric Inventory (NPI) and the Cohen−Mansfield Agitation Inventory.|Health−related quality of life measured with the EQ−5D (Euroqol Group 1990) and the DEMQOL−Proxy (Smith et al 2004) − a carer−rated and disease−specific measure of quality of life in dementia.|Care−giver burden measured with the General Health Questionnaire.|Cost effectiveness assessed through consideration of the combination of costs generated from the Client Service Receipt Inventory (CSRI) and the assessments of function and quality of life (BADLS, DEMQOL, EQ−5D).|Institutionalisation defined as permanent transition from living in an independent household to a care home, NHS continuing care unit or hospital and measured with questions taken from the CSRI and telephone interviews.",King's College London,All,"Child, Adult, Older Adult",Phase 4,800,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2006/123|ISRCTN49545035|Eudract 2007-001172-36,Feb-08,Feb-12,Jun-13,20-Mar-09,null,20-Mar-09,"Institute of Psychiatry, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00866060
NCT00862940,A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Memantine|Drug: Placebo,Total Brain Atrophy Rate Estimated Using Brain Boundary Shift Integral (BBSI)|Changes in Total Hippocampal Volume (HCV)|Cognitive and Behavioural Outcomes: Controlled Oral Word Association Test (COWAT) Total Score|Cognitive and Behavioural Outcomes: Mini Mental State Examination (MMSE) Total Score,H. Lundbeck A/S,All,"50 Years and older   (Adult, Older Adult)",Phase 4,277,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",10112|2004-002614-10,Sep-05,Feb-09,Apr-09,17-Mar-09,3-Jun-11,3-Sep-12,,,https://ClinicalTrials.gov/show/NCT00862940
NCT00860275,Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole,,Completed,No Results Available,Alzheimer Disease,Drug: BMS-708163|Drug: BMS-708163 + Ketoconazole|Drug: Ketoconazole|Drug: Fluconazole|Drug: BMS-708163 + Fluconazole,PK profile of BMS-708163|Safety and tolerability of BMS-708163 when administered alone and with either ketoconazole or fluconazole,Bristol-Myers Squibb,All,18 Years to 55 Years   (Adult),Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CN156-019,Apr-09,Jun-09,Jun-09,12-Mar-09,null,25-Jan-11,"Ppd Development, Lp, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT00860275
NCT00857233,Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease,,Terminated,Has Results,Alzheimer's Disease,Drug: Memantine,Number of Patients With Adverse Events (AEs)|Percentage of Patients Who Withdrew Due to Intolerance to Treatment|Long-term Efficacy of Memantine on Behavioural Symptoms Using the Neuropsychiatric Inventory (NPI) - 12 Items Version Total Score.|Long-term Efficacy of Memantine on Cognition Using the Severe Impairment Battery (SIB) Total Score.|Long-term Efficacy of Memantine on Global Condition Using the Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-plus).|Long-term Efficacy of Memantine on Functioning Using the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) 19-item Version Total Score,H. Lundbeck A/S,All,"50 Years and older   (Adult, Older Adult)",Phase 3,297,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10252,Jun-04,Jul-10,Oct-10,6-Mar-09,29-Aug-12,29-Aug-12,"CA019, Edmonton, Alberta, Canada|CA033, Kelowna, British Columbia, Canada|CA043, Kelowna, British Columbia, Canada|CA042, Penticton, British Columbia, Canada|CA034, Winnipeg, Manitoba, Canada|CA022, St. John, New Brunswick, Canada|CA045, Pictou, Nova Scotia, Canada|CA032, Burlington, Ontario, Canada|CA029, Orangeville, Ontario, Canada|CA004, Ottawa, Ontario, Canada|CA038, Peterborough, Ontario, Canada|CA009, Toronto, Ontario, Canada|CA005, Beauport, Quebec, Canada|CA023, Greenfield Park, Quebec, Canada|CA013, Montreal, Quebec, Canada|CA012, Sherbrooke, Quebec, Canada|CA030, Vanier, Quebec, Canada|CA017, Verdun, Quebec, Canada|CA015, Regina, Saskatchewan, Canada|CA040, Saskatoon, Saskatchewan, Canada|CA044, Chatham, Canada|CA007, Kentville, Canada|CA046, Kentville, Canada|CA001, Kingston, Canada|CA003, London, Canada|CA002, London, Canada|CA016, Moncton, Canada|CA024, Montreal, Canada|CA014, Montreal, Canada|CA011, Montreal, Canada|CA031, Sherbrooke, Canada|CA006, Toronto, Canada|CA037, Windsor, Canada",,https://ClinicalTrials.gov/show/NCT00857233
NCT00857415,Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain,,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Correlation of Florbetapir-PET Image and Amyloid Plaque Density|Specificity Analysis|Regional Correlation Analysis,Avid Radiopharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,226,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-A07,Dec-08,Mar-10,May-10,6-Mar-09,7-May-12,22-May-12,"Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Sun City, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Irvine, California, United States|Research Site, San Francisco, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Baltimore, Maryland, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Albany, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Centerville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Charleston, South Carolina, United States|Research Site, Johnson City, Tennessee, United States|Research Site, Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00857415
NCT00857506,Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45),,Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: florbetapir F 18,Change in ADAS-Cog for MCI Subjects|Cognitive Decline in MCI Subjects|Change in ADAS-Cog in CN and AD Subjects|Cognitive Decline in CN and AD Subjects|Covariate Adjusted Psychometric Score Change|Correlation of Change in ADAS-Cog and SUVR,Avid Radiopharmaceuticals,All,"50 Years and older   (Adult, Older Adult)",Phase 2,152,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-A11,Jan-09,Dec-11,Dec-11,6-Mar-09,28-Mar-13,28-Mar-13,"Research Site, Scottsdale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Costa Mesa, California, United States|Research Site, Brooksville, Florida, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Albany, New York, United States|Research Site, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00857506
NCT00857649,Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease,,Terminated,Has Results,Alzheimer's Disease,Drug: Memantine|Drug: Placebo,Efficacy of Memantine on Behavioural Symptoms in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the NPI - 12 Items Version Total Score.|Efficacy of Memantine on Cognition in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the SIB Total Score.|Efficacy of Memantine on Global Condition Using CIBIC-plus.|Efficacy of Memantine on Functioning Using ADCS-ADL - 19 Items Total Score.|Efficacy of Memantine on Functioning Using CMAI - Long Form Total Score.,H. Lundbeck A/S,All,"50 Years and older   (Adult, Older Adult)",Phase 3,369,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",10158,Dec-03,Apr-10,Sep-10,6-Mar-09,9-Jan-12,5-Dec-13,"CA019, Edmonton, Alberta, Canada|CA033, Kelowna, British Columbia, Canada|CA034, Winnipeg, Manitoba, Canada|CA022, St. John, New Brunswick, Canada|CA046, Kentville, Nova Scotia, Canada|CA045, Pictou, Nova Scotia, Canada|CA032, Burlington, Ontario, Canada|CA029, Orangeville, Ontario, Canada|CA004, Ottawa, Ontario, Canada|CA038, Peterborough, Ontario, Canada|CA009, Toronto, Ontario, Canada|CA037, Windsor, Ontario, Canada|CA005, Beauport, Quebec, Canada|CA023, Greenfield Park, Quebec, Canada|CA013, Montreal, Quebec, Canada|CA031, Sherbrooke, Quebec, Canada|CA012, Sherbrooke, Quebec, Canada|CA030, Vanier, Quebec, Canada|CA017, Verdun, Quebec, Canada|CA015, Regina, Saskatchewan, Canada|CA040, Saskatoon, Saskatchewan, Canada|CA043, Kelowna, Canada|CA042, Penticton, Canada",,https://ClinicalTrials.gov/show/NCT00857649
NCT00855868,Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals,,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18|Drug: [11C]-PIB,Differences in Standard Uptake Value Ratio (SUVR) for Frontal Cortex/Cerebellum and Whole Brain/Cerebellum of the Positron Emission Tomography (PET) Scan With [18F]-AV-45 for Probable Alzheimer's Disease (AD) Versus Cognitively Normal Subjects.,Avid Radiopharmaceuticals|American College of Radiology Imaging Network|General Electric,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,28,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,ACRIN PA 4003,Mar-09,Jan-11,Jan-11,5-Mar-09,26-Jul-12,26-Jul-12,"Research Site, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00855868
NCT00855686,Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies,,Completed,No Results Available,Parkinson's Disease Dementia|Dementia With Lewy Bodies,Drug: Memantine|Drug: Placebo,No primary or secondary outcome measures are defined. This study is exploratory (see above under detailed description).,H. Lundbeck A/S,All,"50 Years and older   (Adult, Older Adult)",Phase 4,199,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",11018|2005-002038-36,Jan-07,Dec-08,Jan-09,4-Mar-09,null,20-Sep-13,"DE001, Munich, Germany",,https://ClinicalTrials.gov/show/NCT00855686
NCT00843518,Treatment for Aggression and Agitation in Patients With Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: LY451395|Drug: Placebo,"Mean Change From Baseline in the 4-Item Agitation/Aggression Subscale of the Neuropsychiatric Inventory (NPI-4 A/A) at Week 12|Mean Change From Baseline in 10-Item Version of Neuropsychiatric Inventory (NPI-10) at Week 12|Mean Change From Baseline in the Neuropsychiatric Inventory (NPI) Depression Domain at Week 12|Mean Change From Baseline in the Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 12|Mean Change From Baseline in Cohen-Mansfield Agitation Inventory-Community Version (CMAI-C) at Week 12|Mean Change From Baseline in Cornell Scale for Depression in Dementia (CSDD) at Week 12|Mean Change From Baseline in Total T-Score in the Frontal System Behaviors Scale (FrSBe) at Week 12|Mean Change From Baseline in Clinical Global Impression-Severity-Agitation/Aggression (CGI-S-A/A) at Week 12|Mean Change From Baseline in Clinical Global Impression-Severity-Global Functioning (CGI-S-GF) at Week 12|Mean Change From Baseline in the 14-Item Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog14) at Week 12",Eli Lilly and Company,All,"60 Years and older   (Adult, Older Adult)",Phase 2,132,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12541|H6N-MC-LEAQ,Feb-09,Jun-11,Jun-11,13-Feb-09,29-Nov-17,29-Nov-17,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Costa Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Easton, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flowood, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toms River, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hickory, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norristown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waukesha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00843518
NCT00842673,Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: ST101|Drug: Placebo,"Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-cog)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Neuropsychiatric Inventory (NPI)|Alzheimer's Disease Cooperative Study- Clinical Global Impression (ADCS-CGI)","Sonexa Therapeutics, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 2,168,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ST101-A001-201,Feb-09,Sep-10,Sep-10,12-Feb-09,null,7-Jun-12,"Costa Mesa, California, United States|Redlands, California, United States|San Diego, California, United States|Walnut Creek, California, United States|Deerfield Beach, Florida, United States|Delray Beach, Florida, United States|Orlando, Florida, United States|West Palm Beach, Florida, United States|Indianapolis, Indiana, United States|Shreveport, Louisiana, United States|Durham, North Carolina, United States|Toledo, Ohio, United States|Jenkinton, Pennsylvania, United States|Wichita Falls, Texas, United States|Bennington, Vermont, United States|Peterborough, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00842673
NCT00842816,Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: ST101|Drug: Placebo,"Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-cog)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Neuropsychiatric Inventory (NPI)|Alzheimer's Disease Cooperative Study- Clinical Global Impression (ADCS-CGI)","Sonexa Therapeutics, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 2,210,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ST101-A001-202,Feb-09,May-11,May-11,12-Feb-09,null,7-Jun-12,"Tucson, Arizona, United States|Costa Mesa, California, United States|Redlands, California, United States|San Diego, California, United States|Walnut Creek, California, United States|Hamden, Connecticut, United States|Brooksville, Florida, United States|Deerfield Beach, Florida, United States|Delray Beach, Florida, United States|Orlando, Florida, United States|St. Petersburg, Florida, United States|West Palm Beach, Florida, United States|Decatur, Georgia, United States|Indianapolis, Indiana, United States|Shreveport, Louisiana, United States|Summit, New Jersey, United States|Toms River, New Jersey, United States|Durham, North Carolina, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Jenkinton, Pennsylvania, United States|Norristown, Pennsylvania, United States|East Providence, Rhode Island, United States|Houston, Texas, United States|Wichita Falls, Texas, United States|Bennington, Vermont, United States|Kirkland, Washington, United States|Peterborough, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00842816
NCT00838877,"Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid",PET,Completed,No Results Available,Alzheimer's Disease,Drug: radioligand [18F]AZD4694|Drug: radioligand [11C]AZD2184,"Positron emission tomography using the radioligand [18F]AZD4694 and/or [11C]AZD2184|To assess safety and tolerability of [18F]AZD4694 and the study procedures, by assessment of adverse events, vital signs, and laboratory variables.",AstraZeneca,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,26,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D2750C00001|2008-006747-39,Jan-09,null,Oct-09,9-Feb-09,null,23-Oct-09,"Research Site, Huddinge, Sweden|Research Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00838877
NCT00838084,A Safety Study of LY2811376 Single Doses in Healthy Subjects,,Completed,No Results Available,Alzheimer's Disease,Drug: LY2811376|Drug: Placebo,Clinical Effects|Plasma concentration of LY2811376 (Cmax)|Plasma concentration of LY2811376 (AUC)|Amyloid beta 1-40 plasma concentrations|Cerebrospinal fluid (CSF) concentration of LY2811376 (Cmax) (Part 2 only)|Cerebrospinal fluid (CSF) concentration of LY2811376 (AUC) (Part 2 only)|Amyloid beta 1-40 cerebrospinal fluid CSF concentrations (Part 2 only),Eli Lilly and Company,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,61,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",12852|I3J-MC-LACE,Dec-08,Jun-09,Jun-09,6-Feb-09,null,15-Jul-09,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT00838084
NCT00838110,A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Dimebon|Drug: Placebo,Percentage of Participants With Abnormal Clinically Significant Vital Signs in Cohort 1|Percentage of Participants With Abnormal Clinically Significant Vital Signs in Cohort 2|Percentage of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings in Cohort 1|Percentage of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings in Cohort 2|Percentage of Participants With Abnormal Clinically Significant Laboratory Values in Cohort 1|Percentage of Participants With Abnormal Clinically Significant Laboratory Values in Cohort 2|Percentage of Participants With Adverse Events (AEs) in Cohort 1|Percentage of Participants With Adverse Events (AEs) in Cohort 2,"Pfizer|Medivation, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,742,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B1451027,Feb-09,Jan-10,Jan-10,6-Feb-09,8-Feb-13,6-Dec-18,"Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Northport, Alabama, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, Oceanside, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Santa Rosa, California, United States|Pfizer Investigational Site, Pueblo, Colorado, United States|Pfizer Investigational Site, Hockessin, Delaware, United States|Pfizer Investigational Site, Bradenton, Florida, United States|Pfizer Investigational Site, Brooksville, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, Destin, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Fort Walton Beach, Florida, United States|Pfizer Investigational Site, Fruitland Park, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Naples, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Plant City, Florida, United States|Pfizer Investigational Site, Port Charlotte, Florida, United States|Pfizer Investigational Site, Port Orange, Florida, United States|Pfizer Investigational Site, Saint Petersburg, Florida, United States|Pfizer Investigational Site, Saint Petersburg, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Burr Ridge, Illinois, United States|Pfizer Investigational Site, Elk Grove Village, Illinois, United States|Pfizer Investigational Site, Elkhart, Indiana, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Fort Wayne, Indiana, United States|Pfizer Investigational Site, Greenfield, Indiana, United States|Pfizer Investigational Site, Prairie Village, Kansas, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Lake Charles, Louisiana, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, West Yarmouth, Massachusetts, United States|Pfizer Investigational Site, Flowood, Mississippi, United States|Pfizer Investigational Site, Olive Branch, Mississippi, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Springfield, Missouri, United States|Pfizer Investigational Site, Great Falls, Montana, United States|Pfizer Investigational Site, Eatontown, New Jersey, United States|Pfizer Investigational Site, Oakhurst, New Jersey, United States|Pfizer Investigational Site, Toms River, New Jersey, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Amherst, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Orchard Park, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Altoona, Pennsylvania, United States|Pfizer Investigational Site, Beaver, Pennsylvania, United States|Pfizer Investigational Site, Bridgeville, Pennsylvania, United States|Pfizer Investigational Site, Grove City, Pennsylvania, United States|Pfizer Investigational Site, Indiana, Pennsylvania, United States|Pfizer Investigational Site, Norristown, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Scotland, Pennsylvania, United States|Pfizer Investigational Site, Upper Saint Clair, Pennsylvania, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Greer, South Carolina, United States|Pfizer Investigational Site, Murrells Inlet, South Carolina, United States|Pfizer Investigational Site, North Charleston, South Carolina, United States|Pfizer Investigational Site, Orangeburg, South Carolina, United States|Pfizer Investigational Site, Sioux Falls, South Dakota, United States|Pfizer Investigational Site, Franklin, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Carrollton, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Grand Prairie, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Lake Jackson, Texas, United States|Pfizer Investigational Site, Williamsburg, Virginia, United States|Pfizer Investigational Site, Kirkland, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Charleston, West Virginia, United States|Pfizer Investigational Site, La Crosse, Wisconsin, United States|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Medicine Hat, Alberta, Canada|Pfizer Investigational Site, Surrey, British Columbia, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Saint John, New Brunswick, Canada|Pfizer Investigational Site, Bay Roberts, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Kentville, Nova Scotia, Canada|Pfizer Investigational Site, Pictou, Nova Scotia, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, Corunna, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Greenfield Park, Quebec, Canada|Pfizer Investigational Site, L'Ancienne-Lorette, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, St-Jean-sur-Richelieu, Quebec, Canada|Pfizer Investigational Site, St. Leonard, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Cayey, Puerto Rico|Pfizer Investigational Site, Cidra, Puerto Rico|Pfizer Investigational Site, Rio Piedras, Puerto Rico|Pfizer Investigational Site, San Juan, Puerto Rico|Pfizer Investigational Site, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00838110
NCT00833274,Evaluation of Apathy Using Attentional Reaction Test in Neurodegenerative Diseases,,Completed,No Results Available,Alzheimer Disease,Behavioral: computerized test,"Reaction times (ms), using a computerized test|Apathy severity, using a specific apathy scale (Apathy Inventory)",Centre Hospitalier Universitaire de Nice,All,65 Years to 75 Years   (Older Adult),Not Applicable,70,Other,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,06-CIR-01,Feb-09,Oct-11,Oct-11,2-Feb-09,null,9-Dec-11,"CM2R, Nice University Hospital, Nice, France",,https://ClinicalTrials.gov/show/NCT00833274
NCT00831506,Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects,,Completed,No Results Available,Alzheimer Disease|Huntington Disease,Drug: digoxin|Drug: dimebon,"AUC24 and Cmin of digoxin on Day 14|Cmax, Tmax, Ae, and renal clearance of digoxin on Day 14|Adverse event monitoring through Day 14 including physical/neurological examination findings|Clinical safety assessments through Day 14 including chemistry, hematology, and vital signs|12-lead ECGs through Day 14","Pfizer|Medivation, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,12,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B1451021,Feb-09,May-09,May-09,29-Jan-09,null,12-Jun-09,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00831506
NCT00831298,Assessment of Sleep Disturbance in Alzheimer Disease,,Completed,No Results Available,Alzheimer Disease,Other: Analysis of sleep disturbance,assessment of apathy|assessment of sleep disturbance|determine a genetic relationship between sleep disturbance and alzheimer disease,Centre Hospitalier Universitaire de Nice,All,65 Years and older   (Older Adult),Not Applicable,70,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,08-PP-07,Jul-10,Nov-11,Nov-11,28-Jan-09,null,9-Dec-11,"Centre Mémoire de Ressources et de Recherche, CHU de Nice, Nice, France",,https://ClinicalTrials.gov/show/NCT00831298
NCT00829374,Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,CONCERT,Completed,No Results Available,Alzheimer's Disease,Drug: Dimebon|Drug: Placebo comparator,"Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Alzheimer's Disease Assessment Scale - Cognitive Subscale|Clinician's Interview Based Impression of Change, plus caregiver input (CIBIC-plus)|Neuropsychiatric Inventory (NPI)|Resource Utilization in Dementia Lite (RUD lite)|Euro Quality of Life 5 (EQ-5D)","Medivation, Inc.|Pfizer",All,"50 Years and older   (Adult, Older Adult)",Phase 3,1003,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DIM18,Mar-09,Dec-11,Dec-11,27-Jan-09,null,27-Sep-16,"Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Encino, California, United States|Escondido, California, United States|Fresno, California, United States|Garden Grove, California, United States|La Jolla, California, United States|Los Alamitos, California, United States|Los Angeles, California, United States|Martinez, California, United States|Newport, California, United States|Paramount, California, United States|Pasadena, California, United States|San Diego, California, United States|San Francisco, California, United States|Boulder, Colorado, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Deerfield Beach, Florida, United States|Delray Beach, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Eaton, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Las Vegas, Nevada, United States|Mt Arlington, New Jersey, United States|Princeton, New Jersey, United States|Albany, New York, United States|Cedarhurst, New York, United States|New York, New York, United States|Rochester, New York, United States|Durham, North Carolina, United States|Beachwood, Ohio, United States|Toledo, Ohio, United States|Jenkintown, Pennsylvania, United States|Norristown, Pennsylvania, United States|Providence, Rhode Island, United States|Austin, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Middleton, Wisconsin, United States|Newcastle, New South Wales, Australia|Sydney, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Perth, Western Australia, Australia|Antwerp, Belgium|Leuven, Belgium|Sint-Truiden, Belgium|Kuppio, Finland|Oulu, Finland|Turku, Finland|Bordeaux, France|Concert, France|Lille, France|Montpellier, France|Nice, France|Toulouse, France|Berlin, Germany|Bochum, Germany|Freiburg, Germany|Hattingen, Germany|Mannheim, Germany|Munich, Germany|Brescia, Italy|Florence, Italy|Genoa, Italy|Perugia, Italy|Rome, Italy|Christchurch, Canterbury, New Zealand|Auckland, New Zealand|Malmo, Sweden|Norrkoping, Sweden|Stockholm, Sweden|Brentford, Middlesex, United Kingdom|Rushden, Northhamptonshire, United Kingdom|Glasgow, Scotland, United Kingdom|Worthington, West Sussex, United Kingdom|Bath, United Kingdom|Blackpool, United Kingdom|Bradford, United Kingdom|Greater Manchester, United Kingdom|London, United Kingdom|Newcastle upon Tyne, United Kingdom|Norfolk, United Kingdom|Oxford, United Kingdom|Southampton, United Kingdom|Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00829374
NCT00829816,"Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil",,Completed,No Results Available,Alzheimer's Disease,Drug: Dimebon|Drug: Placebo,"To assess the safety and tolerability of orally administered dimebon in patients with Alzheimer's disease (AD) on a stable dose and regimen of memantine, or memantine plus donepezil.|To assess the steady-state pharmacokinetics (PK) of orally-administered dimebon in patients with AD on a stable dose and regimen of memantine, or memantine plus donepezil.","Medivation, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 1,46,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DIM17,Dec-08,Apr-09,Aug-10,27-Jan-09,null,10-Nov-15,"Los Alamitos, California, United States|National City, California, United States|Delray Beach, Florida, United States|Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT00829816
NCT00827034,"A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects",,Completed,No Results Available,Alzheimer's Disease|Huntington's Disease,Drug: Warfarin|Drug: Dimebon,"Single dose pharmacokinetics (Cmax, AUCinf) of warfarin 25 mg with and without co-administration of steady-state Dimebon 20 mg TID in healthy adult subjects.|Single dose pharmacodynamics (INRmax, AUC-INR) of warfarin 25 mg with and without co-administration of steady-state Dimebon 20 mg TID in healthy adult subjects.|Safety and tolerability ( adverse event monitoring, physical examinations, vital signs, ECG's and clinical laboratory tests) of multiple doses of Dimebon 20 mg TID with a single dose of warfarin 25 mg in healthy adult subjects.","Pfizer|Medivation, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,14,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B1451020,Feb-09,Apr-09,Apr-09,22-Jan-09,null,16-Oct-18,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00827034
NCT00824590,"A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function",,Completed,No Results Available,Alzheimer's Disease|Huntington's Disease,Drug: Dimebon,"Plasma drug concentrations|Safety assessment including physical/neurological examination findings, clinical safety laboratory assessments, 12-lead ECGs, vital sign measurements, and adverse event monitoring.","Pfizer|Medivation, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B1451019,Feb-09,Oct-09,Oct-09,19-Jan-09,null,30-Dec-09,"Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, St. Paul, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00824590
NCT00824967,Non Pharmacological Management of Behavioural Symptoms in Nursing Home,,Terminated,No Results Available,ALZHEIMER Disease,Other: Training and valuation of the treating personnel,"Changes at the behavioural assessment (CMAI, OS, NPI) after 8 weeks of intervention|Changes at the behavioural assessment (CMAI, OS, NPI) 16 weeks after the end of the intervention",Centre Hospitalier Universitaire de Nice,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,306,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),07-PP-03,Oct-07,Oct-09,Oct-09,19-Jan-09,null,26-Mar-12,"CHU de Nice - 4 avenue Reine Victoria, Nice, Alpes-Maritimes, France",,https://ClinicalTrials.gov/show/NCT00824967
NCT00825084,"A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects",,Completed,No Results Available,Alzheimer's Disease|Huntington's Disease,Drug: Dimebon,"plasma drug concentrations|Safety will be including physical/neurological examination findings, clinical safety laboratory assessments, 12-lead ECGs, vital sign measurements and adverse event monitoring","Pfizer|Medivation, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B1451014,Feb-09,May-09,May-09,19-Jan-09,null,26-Apr-11,"Pfizer Investigational Site, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT00825084
NCT00820937,Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI),DatScan,Completed,No Results Available,Lewy Body Dementia,Procedure: Single photon emission computed tomography and Magnetic Resonance Imaging,SPECT and MRI differential imaging|Neuropsychological analysis,"University Hospital, Limoges",All,65 Years to 90 Years   (Older Adult),Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic,I04014,Mar-06,Mar-08,Mar-08,12-Jan-09,null,27-Aug-09,"Département de Gérontologie - Chu Limoges, Limoges, France|Pôle de psychiatrie du sujet âgé - CH Esquirol, Limoges, France|Service de Neurologie - CHU de Limoges, Limoges, France",,https://ClinicalTrials.gov/show/NCT00820937
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,,Completed,Has Results,Alzheimer´s Disease,"Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg|Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg","Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Change From Baseline at 9 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment|Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment|Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination|Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment|Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response|Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test|Number of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class|Number of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class|Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class|Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class|Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)|Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)|Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)|Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (>1.5 g/dL) Between Consecutive Visits|Number of Participants Experiencing a Clinically Significant Rash",Baxalta now part of Shire|Alzheimer's Disease Cooperative Study (ADCS)|Shire,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 3,390,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",160701,Dec-08,Dec-12,Dec-12,8-Jan-09,28-Oct-14,24-Nov-17,"Birmingham, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Irvine, California, United States|La Jolla, California, United States|Los Angeles, California, United States|National City, California, United States|Orange, California, United States|New Haven, Connecticut, United States|Washington, D.C., District of Columbia, United States|Miami Beach, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Lexington, Kentucky, United States|Burlington, Massachusetts, United States|Paw Paw, Michigan, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Liverpool, New York, United States|New York, New York, United States|Rochester, New York, United States|Cleveland, Ohio, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Providence, Rhode Island, United States|North Charleston, South Carolina, United States|Franklin, Tennessee, United States|Dallas, Texas, United States|Salt Lake City, Utah, United States|Madison, Wisconsin, United States|Vancouver, British Columbia, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00818662
NCT00814502,Zolpidem CR and Hospitalized Patients With Dementia,,Completed,Has Results,"Dementia|Alzheimer Disease|Dementia, Vascular|Sleep Disorders|Circadian Dysregulation",Drug: Zolpidem CR|Drug: Placebo,"Sleep Efficiency|Sleep Minutes|Measures of Aggression, Psychosis, General Clinical Status, Cognitive Measures, Mood Symptoms",Massachusetts General Hospital|Sanofi,All,"60 Years to 99 Years   (Adult, Older Adult)",Not Applicable,20,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2008-P-001434/1,Dec-08,Dec-13,Dec-13,25-Dec-08,22-May-17,22-May-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00814502
NCT00814697,Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease|Aphasia|Dementia,Device: Repetitive Transcranial Magnetic Coil Stimulation (rTMS),"Cognitive Assessment Task Scores Before, During and After rTMS.",The New York Memory Services,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,91913-5,Dec-08,Dec-11,Aug-12,25-Dec-08,28-Jan-14,28-Jan-14,"The NY Memory Services, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00814697
NCT00814801,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Galantamine 16 mg/day|Drug: Galantamine 24 mg/day,Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)|Distribution of Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)|Change From Baseline in the Disability Assessment for Dementia (DAD)|Change From Baseline in the Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)|Change From Baseline in the Mental Function Impairment Scale (MENFIS),Janssen Pharmaceutical K.K.,All,"45 Years and older   (Adult, Older Adult)",Phase 3,580,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",CR010297|GAL-JPN-5,Feb-07,Sep-08,Sep-08,25-Dec-08,4-Jul-12,17-Apr-14,"Fukuoka, Japan",,https://ClinicalTrials.gov/show/NCT00814801
NCT00814346,Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions,,Completed,Has Results,Alzheimer's Disease|Cognitive Impairment,Drug: EGb761®|Drug: Placebo,Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)|Change in Brain Glucose Metabolism in the MC and CNE Groups|Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups|Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups|Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups|Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups|Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups|Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups|Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)|Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups|Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups|Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups|Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)|Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)|Change in Cognitive Tests-CDR Score in MC and CNE Groups|Change in Cognitive Tests-GDS Score in MC and CNE Groups|Change in Cognitive Tests-MMSE Score in MC and CNE Groups|Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT|Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups|Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups|Incidence of Adverse Events (AEs)|Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size,Ipsen,All,65 Years and older   (Older Adult),Phase 2,49,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2-39-00240-134|2007-005377-63,Oct-08,Jul-12,Jul-12,24-Dec-08,28-Mar-16,8-Feb-19,"Hôpital Corentin Celton 4 parvis Corentin Celton, Issy-Les-Moulineaux, France|Hôpital de Juvisy, Juvisy sur Orge, France|CMPI ""Les Rives de Seine"", Le Vesinet, France|Centre Hospitalier d'Orsay 4 place du Général Leclerc, Orsay, France|Private practice, Paris, France|Hôpital Broca 54-56 rue Pascal, Paris, France|Observatoire de l'âge, Paris, France|Hôpital Paul Brousse 12 av Paul-Vaillant-Couturier, Villejuif, France",,https://ClinicalTrials.gov/show/NCT00814346
NCT00812565,Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Biological: octagam 10%,"Change in the Area Under the Curve of Plasma Aβ1-40 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion|Change in Plasma Concentration of Aβ1-40 and Aβ1-42 From Baseline to the End of the Study (Week 24)|Change in Plasma Concentration of Anti-Aβ Autoantibodies From Baseline to the End of the Study (Week 24)|Change in the Area Under the Curve of Plasma Aβ1-42 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion|Change in the Area Under the Curve of Plasma Anti-Aβ Autoantibodies in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion|Change From Baseline in Aβ1-40 and Aβ1-42 in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion|Change From Baseline in Anti-Aβ Autoantibodies in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion|Change From Baseline in Tau and Phosphorylated Tau in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion|Change From Baseline in the Mini Mental Status Examination (MMSE) Score at Week 12 and Week 24|Change From Baseline in the Alzheimer's Disease Assessment Scale, Cognitive Part (ADAS Cog) Score at Week 12 and Week 24|Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADAS-ADL) Score at Week 12 and Week 24|Change From Baseline in the Clinical Dementia Ratio, Sum of Boxes (CDR-SOB) Score at Week 12 and Week 24|Change From Screening in Whole Brain and Hippocampal Volume at Week 12 and Week 24|Left and Right Hippocampal Cerebral Glucose Metabolism at Baseline and at Week 24",Octapharma,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GAM10-04,Feb-09,Sep-10,Sep-10,22-Dec-08,5-May-14,5-May-14,"Octapharma USA, Hoboken, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00812565
NCT00811122,"Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly",11C-PIB PET,Unknown status,No Results Available,Alzheimer's Disease,Radiation: 11C-PIB PET Scan|Radiation: FDG-PET Scan,"The agent 11C-PIB has similar biodistribution outside the brain in AD, FTD, and cognitively normal elderly individuals.|Patients with AD scanned with 11C-PIB will have higher standardized uptake values (SUVs) than cognitively normal elderly in brain regions where beta amyloid are expected to be over-expressed.",University of Utah,All,"30 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,17991,Nov-09,Apr-18,Apr-18,18-Dec-08,null,9-May-17,"University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00811122
NCT00809510,A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study,,Terminated,No Results Available,Alzheimer's Disease,Drug: ABT-089,"Safety Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)|ADAS-Cog, CIBIC-plus, MMSE, QoL-AD",Abbott,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,63,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M10-745,Jan-09,Jun-09,null,17-Dec-08,null,2-Sep-11,"Site Reference ID/Investigator# 16543, Phoenix, Arizona, United States|Site Reference ID/Investigator# 16528, Sun City, Arizona, United States|Site Reference ID/Investigator# 16524, Fresno, California, United States|Site Reference ID/Investigator# 16520, San Diego, California, United States|Site Reference ID/Investigator# 16521, Santa Monica, California, United States|Site Reference ID/Investigator# 16533, Hamden, Connecticut, United States|Site Reference ID/Investigator# 16516, Brooksville, Florida, United States|Site Reference ID/Investigator# 16510, Deerfield Beach, Florida, United States|Site Reference ID/Investigator# 16508, Delray Beach, Florida, United States|Site Reference ID/Investigator# 16515, Miami, Florida, United States|Site Reference ID/Investigator# 16545, Palm Beach Gardens, Florida, United States|Site Reference ID/Investigator# 16541, Sunrise, Florida, United States|Site Reference ID/Investigator# 16542, Tampa, Florida, United States|Site Reference ID/Investigator# 16529, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 16526, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 16527, Eatontown, New Jersey, United States|Site Reference ID/Investigator# 16523, Ridgewood, New Jersey, United States|Site Reference ID/Investigator# 16532, New York, New York, United States|Site Reference ID/Investigator# 16519, Winston Salem, North Carolina, United States|Site Reference ID/Investigator# 16525, Centerville, Ohio, United States|Site Reference ID/Investigator# 16507, Wichita Falls, Texas, United States|Site Reference ID/Investigator# 16509, Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00809510
NCT00810147,"A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Drug: BMS-708163|Drug: Placebo,"Adverse Events|Pharmacodynamics effects of Cerebral Spinal Fluid|Pharmacodynamics effects of the Alzheimer's Disease Assessment Scale - Cognitive Subscale|Pharmacodynamics effects of the Alzheimer's Disease Collaborative Study - Activities of Daily Living scale|Pharmacodynamics effects of the Global clinical impression as assessed with the Clinical Dementia Rating-Sum of Boxes|Characterize Pharmacodynamics/Pharmacokinetics effects of the plasma exposure of BMS-708163 and variability in a population with Alzheimer's disease|Characterize Pharmacodynamics/Pharmacokinetics effects in refining the Pharmacokinetics/Pharmacodynamics model with Phase 2 data|Characterize Pharmacodynamics/Pharmacokinetics effects by exploring correlations between exposure, biomarkers, and clinical effects|Characterize Pharmacodynamics/Pharmacokinetics effects by exploring Pharmacokinetics variability, including the correlation between polymorphisms of CYP enzymes",Bristol-Myers Squibb,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,209,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CN156-013|EUDRACT: 2008-005929-11,Feb-09,Jun-10,Jun-10,17-Dec-08,null,12-Oct-15,"University Of Alabama At Birmingham, Birmingham, Alabama, United States|21st Century Neurology, Phoenix, Arizona, United States|Banner Alzheimer'S Institute, Phoenix, Arizona, United States|Sun Health Research Institue, Sun City, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Pacific Institute For Medical Research, Inc., Los Angeles, California, United States|Mary S. Easton Center, Los Angeles, California, United States|Pacific Research Network, Inc, San Diego, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Md Clinical, Hallandale Beach, Florida, United States|Compass Research, Llc, Orlando, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Usf Suncoast Alzheimer'S And Gerontology Center, Tampa, Florida, United States|Center For Clinical Trials, Venice, Florida, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Four Rivers Clinical Research, Inc, Paducah, Kentucky, United States|Memory Enhancement Center Of Amercia, Inc., Eatontown, New Jersey, United States|Global Medical Institutes, Llc, Princeton, New Jersey, United States|Columbia University, New York, New York, United States|University Of Rochester, Rochester, New York, United States|Richard H. Weisler, Md, Pa & Associates, Raleigh, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Neurology & Neuroscience Center Of Ohio, Toledo, Ohio, United States|Tulsa Clinical Research, Llc, Tulsa, Oklahoma, United States|Professional Neurological Associates, Pc, Dunmore, Pennsylvania, United States|The Clinical Trial Center Llc, Jenkintown, Pennsylvania, United States|R.I. Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|The University Of Texas, Dallas, Texas, United States|Dean Foundation For Health Research & Education, Middleton, Wisconsin, United States|Local Institution, Odense, Denmark|Local Institution, Kuopio, Finland|Local Institution, Turku, Finland|Local Institution, Malmo, Sweden|Local Institution, Molndal, Sweden|Local Institution, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00810147
NCT00804271,Memantine and Validation of a New Alzheimer's Disease Scale,,Completed,No Results Available,Alzheimer's Disease,Drug: memantine,"Validation of new scale regarding content, reliability and responsiveness for DAT symptoms|Assessment of treatment response and correlation of new scale against ADAScog, SIB, NPI, DAD.",Merz Pharmaceuticals GmbH,All,"50 Years and older   (Adult, Older Adult)",Phase 3,487,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),MRZ 90001/AD/3001|EudraCT No. 2008-005144-16,Dec-08,Nov-09,Nov-09,8-Dec-08,null,22-Feb-13,"University Clinic Gustav Carus, Dresden, Saxony, Germany",,https://ClinicalTrials.gov/show/NCT00804271
NCT00800709,Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Memantine,biological markers of CSF|18[F]-FDG-PET of brain|cognitive function|behavior and activities of daily living|short term memory,Shanghai Mental Health Center|H. Lundbeck A/S,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,26,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IIT_12484A,Jul-08,Oct-10,Oct-10,2-Dec-08,null,3-Dec-10,"Department of Psychogeriatrics，Shanghai Mental Health Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT00800709
NCT00795418,Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients,,Completed,No Results Available,Alzheimer's Disease,Biological: Placebo|Biological: CAD106,"Safety/tolerability of repeated injection of CAD106 at multiple timepoints including but not limited to screening, baseline and through the end of the study (adverse events, physical/neurologic exams, vital signs, 12- lead ECGs, clinical labs, brain MRI)|Immune response at multiple timepoints including but not limited to screening, baseline and through the end of the study.|Cognitive assessments at multiple timepoints including but not limited to screening, baseline and through the end of the study.|Functional assessments at multiple timepoints including but not limited to screening, baseline and through the end of the study.",Novartis,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,31,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCAD106A2202,Oct-08,Nov-10,null,21-Nov-08,null,4-May-12,"ATP Clinical Research, Costa Mesa, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|MidAmerica NeuroScience Research Foundation, Lenexa, Kansas, United States|Columbia University Medical Center, New York, New York, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|NOCCR Knoxville, Knoxville, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00795418
NCT00795730,Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789,,Terminated,No Results Available,Alzheimer Disease|Healthy Subjects,Drug: NSA-789|Other: placebo,"Adverse event monitoring as specific tests that will be done to monitor safety (ECGs, certain laboratory tests, vital signs) and tolerability|Pharmacokinetic and pharmcodynamic parameters",Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",3230A1-1002,Jan-09,Jun-09,Jun-09,21-Nov-08,null,21-Jul-09,"Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT00795730
NCT00792662,"Improving Function, Quality of Life, Glycemia in Diabetics With Dementia",,Withdrawn,No Results Available,Diabetes Mellitus|Alzheimer's Disease|Apathy|Dementia,Drug: Methylphenidate|Drug: Placebo,"Hemoglobin A1C (HbA1c) will be used as marker for glycemic control. It is accepted as the best marker for glycemic control in the previous 120 days. Changes in HbA1c are clinically meaningful.|Apathy Evaluation Scale-Clinician (AES-C): The clinician-rated version will be used for this project. This 18 item scale with scores ranging from 18 to 72, assesses apathy in behavioral, cognitive and emotional domains over the previous four weeks.|Clinical Global Impression (CGI): This is an observational scale of global evaluation, which assesses the change in degree of illness in relation to the original assessment.|Instrumental Activities of Daily Living (IADL): It is a survey assessing eight domains of higher functions necessary to live independently. It is rated from 0-23 based on the independent living of the patient.",University of Nebraska|Alzheimer's Association,All,"60 Years and older   (Adult, Older Adult)",Phase 4,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",470-08-FB,Nov-08,Dec-11,Dec-11,18-Nov-08,null,29-Mar-18,"Veterans Affairs Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00792662
NCT00788047,A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan,,Completed,No Results Available,Huntington Disease|Alzheimer Disease,Drug: Dextromethorphan|Drug: Dimebon + Dextromethorphan,"Dextromethorphan exposure in combination with Dimebon 20 mg TID relative to Dextromethorphan exposure alone|Safety and Tolerability (Adverse Events, Vital Signs, Clinical Labs, Electrocardiograms)|Dextrorphan (the metabolite of dextromethorphan) exposure","Pfizer|Medivation, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,14,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B1451022,Nov-08,Jan-09,Jan-09,10-Nov-08,null,9-Mar-09,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00788047
NCT00785759,"Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers",ALZ201,Completed,No Results Available,Alzheimer's Disease|Amnestic Mild Cognitive Impairment,Drug: AH110690 (18F) Injection,"Examine the efficacy and determine visual assessment of raised [18F] brain uptake for separating subjects with probable Alzheimer's Disease from healthy volunteers and assigning amnestic mild cognitive impairment cases to an AD or HV category.|Examine the efficacy and parameters of brain [18F] uptake for separating 25 subjects with probable AD from 25 HV, assigning 20 amnestic MCI cases to an AD or HV category by measuring ranges of regional cerebral to cerebellum tracer uptake ratios.","GE Healthcare|i3 Statprobe|Medpace, Inc.|Hvidovre Hospital Center Demark Danish Research Centre for Magnetic Resonance",All,"25 Years and older   (Adult, Older Adult)",Phase 2,78,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,ALZ201,Sep-08,Mar-09,Dec-09,5-Nov-08,null,7-Dec-09,"GE Healthcare, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00785759
NCT00777361,"Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers",MB,Terminated,No Results Available,Alzheimer's Disease,Drug: AZD3480,"Recovery (% dose) of radioactivity retrieved in urine and faeces Total radioactivity in blood and plasma, AUC, Cmax , tmax, t1/2 and blood/plasma ratio.|Plasma and urine concentration (AUC, Cmax, tmax, t1/2, F, CL, CLR, fe, Ae, and Vss)|identity of major metabolites in plasma and excreta|Adverse Events, vital signs (supine blood pressure and pulse rate), ECG, hematology, clinical chemistry and urinalysis.",AstraZeneca,Male,"35 Years to 65 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D3690C00017|EudraCT No.: 2007-005903-16,Oct-08,Oct-09,Oct-09,22-Oct-08,null,18-Nov-10,"Research site, Macclesfield, Cheshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00777361
NCT00777608,A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED),,Completed,Has Results,Alzheimer's Disease,Drug: Comparator: Placebo 5mg (run in)|Drug: Donepezil 5 - 10 mg|Drug: Comparator: Placebo 5-10 mg|Drug: Donepezil 10 mg,"Change in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4|Evaluate the Efficacy of Donepezil by Determining the Change in Mean CogState Composite Score at Week 2, Week 8 and Week 12|Evaluate the Efficacy of Donepezil by Determining the Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score at Week 4, Week 8 and Week 12",Merck Sharp & Dohme Corp.,All,"55 Years and older   (Adult, Older Adult)",Phase 1,106,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0000-086|2008_573,Dec-08,Oct-09,Apr-10,22-Oct-08,24-Feb-11,25-Aug-15,,,https://ClinicalTrials.gov/show/NCT00777608
NCT00768261,Corticolimbic Degeneration and Treatment of Dementia,,Completed,Has Results,Dementia,Drug: Memantine (Namenda®)|Drug: Donepezil (Aricept®),Rate of Change of Hippocampal Volume Slope|Comparison of Combined DAT Patients' Mean (SD) Hippocampal Volume Slope (mm^3/Year) Rate of Change,Washington University School of Medicine|Northwestern University,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 4,39,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5R01MH060883-06,Nov-04,Oct-09,Oct-09,8-Oct-08,11-Sep-18,11-Sep-18,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT00768261/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00768261
NCT00766363,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease",,Completed,Has Results,Alzheimer's Disease|Central Nervous System Diseases,Drug: EVP-6124 (0.1 mg/day)|Drug: EVP-6124 (0.3 mg/day)|Drug: EVP-6124 (1.0 mg/day)|Drug: Comparator: Placebo|Drug: Donepezil|Drug: Rivastigmine,Safety and Tolerability of Multiple Doses of EVP-6124 or Placebo in Subjects With Alzheimer's Disease|EVP-6124 PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)|EVP-6124 PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)|EVP-6124 PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])|Donepezil PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)|Donepezil PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)|Donepezil PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])|Rivastigmine PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)|Rivastigmine PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)|Rivastigmine PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h]),FORUM Pharmaceuticals Inc|Syneos Health,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,49,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EVP-6124-007,Oct-08,Mar-09,Mar-09,3-Oct-08,14-Jul-11,20-Apr-12,"Pacific Research Network, Inc., San Diego, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Global Medical Institutes, LLC, Princeton, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00766363
NCT00765115,A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.,,Completed,No Results Available,Alzheimer Disease,Drug: LY450139|Drug: placebo,"To test hypothesis that LY450139, a gamma-secretase inhibitor, will reduce the rate of synthesis of 13C6-leucine-labeled Aβ (newly synthesized) in lumbar cerebrospinal fluid (CSF).|To test the hypothesis that LY450139 has an effect on fractional clearance rate of Amyloid Beta assayed from CSF samples in LY450139-treated subjects compared to placebo-treated subjects.|To study and evaluate other biomarkers, such as sAPPB and sAPPA that may enable drug effectiveness to be predicted.|To measure concentrations of Amyloid Beta(1-40), Amyloid Beta(1-42), and leucine in CSF by mass spectrometry.|To explore the relationship between Amyloid Beta plasma decrease and Amyloid Beta synthesis rate as determined by CSF measurements.",Eli Lilly and Company,Male,21 Years to 50 Years   (Adult),Phase 1,27,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",9384|H6L-MC-LFAM,Jul-06,Sep-07,Sep-07,2-Oct-08,null,2-Oct-08,"For additional information regarding investigtive sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00765115
NCT00762411,"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo",IDENTITY-2,Completed,Has Results,Alzheimer's Disease,Drug: LY450139|Drug: Placebo,Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at 76 Weeks|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at 16 Weeks After Cessation of Study Drug|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) at 76 Weeks|Change From Baseline in Neuropsychiatric Inventory (NPI) at 76 Weeks|Change From Baseline in the Resource Utilization in Dementia-Lite (RUD-Lite) up to 76 Weeks|Change From Baseline in the EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) at 76 Weeks|Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) at 76 Weeks|Change From Baseline in Mini Mental State Examination (MMSE) at 76 Weeks|Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks|Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks|Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks|Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks|Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks|LY450139 Population Pharmacokinetics: Clearance of LY450139|LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Neuropsychiatric Inventory (NPI) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) at 4 Weeks After Cessation of Study Drug|Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Mini Mental State Examination (MMSE) 4 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale (ADAS-Cog14) at 76 Weeks|Change From Baseline in Phosphorylated-Tau (P-tau) Concentration in Spinal Fluid up to 76 Weeks|Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Assessment Scale (ADAS-Cog14) at 16 Weeks After Cessation of Study Drug,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1111,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11271|H6L-MC-LFBC,Sep-08,Apr-11,Apr-11,30-Sep-08,25-Sep-14,16-Feb-15,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Costa Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laguna Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxnard, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hallandale Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Orleans, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hattiesburg, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manhasset, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salvador, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sofia, Bulgaria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint John, New Brunswick, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peterborough, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenfield Park, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Verdun, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Xi'An, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poitiers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Esztergom, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boggiovara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cassino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Akita, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ibaraki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iwate, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aguascalientes, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saltillo, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timisoara, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ekaterinburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kazan, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saratov, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belgrade, Serbia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kragujevac, Serbia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eskisehir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Samsun, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dnipropetrovsk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Donetsk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kherson, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyiv, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odesa, Ukraine",,https://ClinicalTrials.gov/show/NCT00762411
NCT00759863,LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia,Lifezig,Completed,Has Results,Alzheimer's Disease|Dementia,Behavioral: Lifezig,Multidimensional Observation Scale for Elderly Subject|Revised Memory and Behavior Problems Checklist|Center for Epidemiologic Studies Depression Scale,"Photozig, Inc.",All,"21 Years and older   (Adult, Older Adult)",Phase 2,242,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pz-A102b|R44AG022261,Aug-06,Apr-09,Apr-09,25-Sep-08,23-Feb-10,2-Mar-10,"Photozig, Inc., Moffett Field, California, United States",,https://ClinicalTrials.gov/show/NCT00759863
NCT00757939,A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED),,Completed,No Results Available,Alzheimer's Disease,Other: MRI|Other: FDG-PET,"Regional cerebral blood flow, as measured by dASL.|Rate of cerebral glucose consumption, MRglc, as measured by fludeoxyglucose-PET (FDG-PET)|Resting state functional MRI blood-oxygen-level-dependent (fMRI BOLD) response",Merck Sharp & Dohme Corp.,All,"55 Years and older   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,0000-068|2008_547,Sep-08,Oct-10,Oct-10,23-Sep-08,null,11-Aug-15,,,https://ClinicalTrials.gov/show/NCT00757939
NCT00753662,Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease,TMS in AD,Unknown status,No Results Available,Alzheimer's Disease,Device: 1Hz TMS with H2 coil|Device: 10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|Device: SHAM TMS with H2 coil,"ADAS-COG|CGI-C, Neuropsychological computerized test (Mindstream),CGI-C,FAB,ADL, Beck Depression Inventory.",Tel-Aviv Sourasky Medical Center|Brainsway,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,45,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",TASMC-08-AA-0397-CTIL,Nov-08,Nov-12,Nov-12,16-Sep-08,null,13-Sep-11,"Tel Aviv Sourasky Medical Center, Neurology Department, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT00753662
NCT00752232,Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer Disease,Biological: ACC-001|Other: QS-21|Other: PBS,Incidence of Treatment-emergent Adverse Events (AEs) by Severity|Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data|Number of Participants With Abnormalities in Neurological Examination|Anti-a-beta IgG Titer at Specified Visits|Anti-a-beta IgM Titer at Specified Visits,"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3134K1-2202|B2571006,Dec-08,Jul-12,Jul-12,15-Sep-08,1-Jan-16,1-Jan-16,"Suwa Red Cross Hospital, Suwa, Nagano, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|Meitetsu Hospital, Aichi, Japan|Ibaraki Prefectural Central Hospital, Ibaraki, Japan|Shonan Atsugi Hospital, Kanagawa, Japan|Kitasato University East Hospital, Kanagawa, Japan|Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Kanto Ctrl Hp of the Mutual Aid Asso of Public school Teache, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00752232
NCT00751907,Cerebral and Peripheral Perfusion Pilot Study,CAPP,Completed,No Results Available,Alzheimer's Disease,Drug: atorvastatin|Drug: Placebo,Perfusion in the posterior cingulate|Endothelial function and pulse wave velocity,"University of Wisconsin, Madison|National Institute on Aging (NIA)",All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 2,16,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",IA0138|1R01AG031790,Jun-06,Apr-07,Apr-07,12-Sep-08,null,28-Sep-10,"University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00751907
NCT00750282,Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers,,Completed,Has Results,Alzheimer Disease|Amyloid Beta-Protein,Drug: Florbetaben (BAY94-9172),Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth|Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.|Sensitivity and Specificity for All Participants Using Two Additional Imaging Windows for the Visual Assessment|Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)|Standard Uptake Value Ratios for Florbetaben Signal,Life Molecular Imaging SA,All,"55 Years and older   (Adult, Older Adult)",Phase 2,422,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,311741|2007-002256-42,Aug-08,Nov-10,Nov-10,10-Sep-08,16-Jul-14,24-Jul-14,"Sun City, Arizona, United States|Stanford, California, United States|New Haven, Connecticut, United States|Bronx, New York, United States|New York, New York, United States|New York, New York, United States|Providence, Rhode Island, United States|Westmead, New South Wales, Australia|Adelaide, South Australia, Australia|Heidelberg, Victoria, Australia|Erlangen, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Essen, Nordrhein-Westfalen, Germany|Jülich, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Bunkyo-ku, Tokyo, Japan|Zürich, Switzerland",,https://ClinicalTrials.gov/show/NCT00750282
NCT00750529,Alzheimer and Sleep,,Completed,No Results Available,Alzheimer's Disease,Drug: Galantamine and Donepezil,Comparison of the percentage of paradoxical sleep recorded with polysomonography in 65 years old patients with administration of Galantamine or Donépézil|Describe the iatrogenic modifications of rhythm and architecture of sleep. describe the iatrogenic modifications of rythm and architecture of sleep,"University Hospital, Clermont-Ferrand|Janssen-Cilag Farmaceutica Ltda.",All,65 Years and older   (Older Adult),Phase 1,15,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHU-0038,Nov-08,Sep-13,Sep-13,10-Sep-08,null,8-Jul-14,"CHU Clermont-Ferrand, Clermont-Ferrand, France|CPC-CIC, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT00750529
NCT00749216,Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Solanezumab,Adverse events|Changes in the extended ADAS-Cog stand for Alzheimer's Disease Assessment Scale-Cognitive subscale|pharmacodynamic of Aβ1-40 and Aβ1-42|Pharmacokinetics,Eli Lilly and Company,All,"50 Years and older   (Adult, Older Adult)",Phase 2,33,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12025|H8A-JE-LZAK,Sep-08,Jul-09,Jul-09,9-Sep-08,null,2-Jun-10,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokushima, Japan",,https://ClinicalTrials.gov/show/NCT00749216
NCT00745576,Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered,,Completed,No Results Available,Alzheimer Disease,Drug: SAM-531,"blood samples|Safety based on supine vital signs evaluations, 12-lead ECGs and routine lab tests",Wyeth is now a wholly owned subsidiary of Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,14,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3193A1-1112,Oct-08,Dec-08,Dec-08,3-Sep-08,null,8-Feb-10,"Gieres, France",,https://ClinicalTrials.gov/show/NCT00745576
NCT00744978,"Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease",,Completed,Has Results,Alzheimer's Disease,Drug: Varenicline|Drug: Placebo,Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6|Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3|Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3|Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6|Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6|Neuropsychiatric Inventory (NPI) Total Score at Week 3|Neuropsychiatric Inventory (NPI) Total Score at Week 6|Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1|Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3|Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6|Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1|Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3|Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6|Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1|Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3|Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6|Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1|Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3|Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6|Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1|Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3|Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6,Pfizer,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,66,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",A3051101,Jul-09,Nov-10,Nov-10,1-Sep-08,22-Nov-11,22-Nov-11,"Pfizer Investigational Site, Seongnam, Gyunggido, Korea, Republic of|Pfizer Investigational Site, Busan, Korea, Republic of|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Incheon, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Suwon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00744978
NCT00743743,Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer's Disease,,Withdrawn,No Results Available,Alzheimer Disease,Dietary Supplement: Longevinex brand resveratrol supplement|Dietary Supplement: placebo,cognition|function|behavior,Medical College of Wisconsin,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Resveratrol2008,Sep-08,Jun-10,Dec-10,29-Aug-08,null,24-Aug-15,,,https://ClinicalTrials.gov/show/NCT00743743
NCT00743418,Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease,SenTra,Unknown status,No Results Available,Dementia,Device: GPS modem and RFID,"Evaluation tools include: Geriatric Depression Scale, functional health questionnaire (SF-36), Emotional well-being questionnaire (Positive and Negative Affect Schedule; PANAS), single Life Satisfaction question and the Zarit Burden Interview",Tel-Aviv Sourasky Medical Center,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,300,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,DIP-K.3.1.,Jun-07,Dec-12,null,28-Aug-08,null,28-Aug-08,"Psychogeriatric clinic, Sourasky Medical Center, Tel-Aviv, Israel",,https://ClinicalTrials.gov/show/NCT00743418
NCT00742417,Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid,,Completed,Has Results,Alzheimer's Disease,Biological: Albutein 5%|Other: Control,"Change From Baseline in Aβ1-42 Cerebrospinal Fluid (CSF) Levels.|P-Tau and Tau CSF Levels Throughout the Study.|Aβ1−40 Plasma Levels Before and After Each Study Period (The Genetics Company).|Aβ1−42 Plasma Levels Before and After Each Study Period (The Genetics Company).|Aβ1−42 Plasma Levels Before and After Each Study Period (Innotest).|Change From Baseline to Week 44 in Cognitive, Functional and Neuropsychiatric Scores (MMSE, ADAS-Cog, NPS Battery and CSDD)|Change From Baseline to Week 44 in Cognitive, Functional and Neuropsychiatric Scores (ADCS-ADL, NPI, CDR-Sb and ADCS-CGIC).|Magnetic Resonance Imaging (MRI) Structural Changes Variations Versus Baseline.|Variations in Hypoperfusion Based on Single Photon Emission Computed Tomography (SPECT)","Instituto Grifols, S.A.|Grifols Biologicals, LLC",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,42,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IG0602,Jul-07,Feb-11,Mar-11,27-Aug-08,14-Jun-16,14-Jun-16,"Howard University, Washington, District of Columbia, United States|Mid-Atlantic Geriatric/ARC, Manchester Township, New Jersey, United States|Fundació ACE, Barcelona, Catalunya, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT00742417
NCT00739037,Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease,,Terminated,No Results Available,Alzheimer Disease,Drug: Placebo|Drug: PAZ-417,"This study is the measurement of a biomarker known as amyloid beta peptide 40 (Ab40) in Cerebrospinal Fluid (CSF), following a single oral dose of PAZ-417 in subjects with Alzheimer Disease (AD).|To measure both amyloid beta peptide 42 (Ab42) and PAZ-417 in both plasma and CSF and assess safety using the results of physical examinations, vital sign measurements, ECGs, cardiac telemetry, standard laboratory tests and collection of AES.",Wyeth is now a wholly owned subsidiary of Pfizer,All,"55 Years and older   (Adult, Older Adult)",Phase 1,10,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)",3186A1-1103,Aug-08,Dec-08,Dec-08,21-Aug-08,null,4-Aug-09,"California Clinical Trials, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT00739037
NCT00736775,"A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Drug: anti-Abeta|Drug: placebo,Safety and tolerability of single and multiple doses of MABT5102A|Pharmacokinetics of MABT5102A after single and multiple doses|Immunogenicity of MABT5102A after single and multiple doses,"Genentech, Inc.",All,"50 Years to 86 Years   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ABE4427g,Aug-08,May-10,null,18-Aug-08,null,27-Oct-10,,,https://ClinicalTrials.gov/show/NCT00736775
NCT00735800,Telephone Support for Dementia Caregivers,,Completed,No Results Available,Dementia,Behavioral: Family Intervention:Telephone Tracking Support- Caregiver|Behavioral: Telephone Support,"Depression, burden, reaction to memory and behavior problems|Cost-effectiveness and resource use",Rhode Island Hospital|National Institute of Nursing Research (NINR),All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,250,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,R01NR010559,Feb-08,May-13,May-13,15-Aug-08,null,5-May-15,"Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00735800
NCT00733642,Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Biological: PF-04360365 1 mg/kg|Biological: PF-04360365 3 mg/kg|Biological: PF-04360365 5 mg/kg|Biological: PF-04360365 10 mg/kg,To examine the safety and tolerability of a single dose of PF-04360365 in subjects with mild-to-moderate AD.|To characterize the pharmacokinetic profile of PF-04360365 following administration of an IV infusion in subjects with mild-to-moderate AD.|To evaluate the relationship of PF-04360365 plasma exposure and Aβ plasma exposure.,Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 1,15,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A9951008,Aug-08,Jul-09,Jul-09,13-Aug-08,null,28-Jul-09,"Pfizer Investigational Site, Glendale, California, United States|Pfizer Investigational Site, Eatontown, New Jersey, United States|Pfizer Investigational Site, Oakhurst, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00733642
NCT00733785,"PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers",Rosi XR,Completed,No Results Available,Alzheimer's Disease,Drug: Rosiglitazone XR,"•For the single dose period: AUC(0-inf) and Cmax of RSG XR.•For repeat dose period on Day 1 and 6:, AUC(0-24) and Cmax of RSG XR.|For single dose period: AUC(0-t), Tmax, lz, and t1/2 of RSG XR as data permit|For repeat dose period: Tmax, concentration at the end of the dosing interval (Ct), minimum observed concentration (Cmin),|Average concentration during a dosing interval (Cav), t1/2, , accumulation ratio(Rs) Rs= (AUC(0-t) last day)/(AUC(0-t) first day) and degree of fluctuation DF= (Cmax-Cmin)/Cave.|• Safety reporting (adverse events, laboratory testing, ECG, vital signs)",GlaxoSmithKline,All,18 Years to 55 Years   (Adult),Phase 1,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVA109939,13-Aug-08,28-Nov-08,28-Nov-08,13-Aug-08,null,21-Jul-17,"GSK Investigational Site, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00733785
NCT00733863,Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.,,Completed,No Results Available,Alzheimer Disease,Biological: Placebo|Biological: CAD106,"Safety/tolerability assessments at multiple timepoints including but not limited to screening, baseline, and through the end of the study to Week 52.|Immune response, cognitive and functional assessments at multiple timepoints including but not limited to baseline and through the end of the study to Week 52.",Novartis,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,27,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCAD106A2201,Jul-08,Feb-10,null,13-Aug-08,null,12-May-10,"Centre Hospitalier Universitaire Pellegrin, Bordeaux, France|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|NeuroPsychologieZentrum, Basel, Switzerland|Moorgreen Hospital, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00733863
NCT00731224,Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.,CARE,Completed,No Results Available,Alzheimer's Disease,Drug: Rivastigmine transdermal patch,"Proportion of patients who can reach the target rivastigmine patch size of 10 cm2 and stay on it for at least 8 weeks.|Mini-Mental State Examination (MMSE), Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), Global Deterioration Scale (GDS), caregiver burden (Zarit Burden Interview).|Patient compliance (drug accounting)",Novartis Pharmaceuticals|Novartis,All,"50 Years and older   (Adult, Older Adult)",Phase 4,380,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713DAU01,Jul-08,Oct-11,Oct-11,8-Aug-08,null,28-Mar-17,"Novartis Investigative Site, East Gosford, New South Wales, Australia|Novartis Investigative Site, Gosford, New South Wales, Australia|Novartis Investigative Site, Hornsby, New South Wales, Australia|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Chemside, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Woodville, South Australia, Australia|Novartis Investigative Site, Ballarat, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Nedlands, Australia|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Bundang, Seongnam, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Johor Bahru, Johor, Malaysia|Novartis Investigative Site, Seremban, Negeri Sembilan, Malaysia|Novartis Investigative Site, Ipoh, Perak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Selangor, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Atakum / Samsun, Turkey|Novartis Investigative Site, Bursa, Turkey|Novartis Investigative Site, Emek / Ankara, Turkey|Novartis Investigative Site, Etlik / Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Konya, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, Meselik / Eskisehir, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey|Novartis Investigative Site, Uskudar / Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT00731224
NCT00726726,Drug Interaction Study With a Potential Alzheimer's Disease Compound,,Completed,No Results Available,Alzheimer Disease,"Drug: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Drug: BMS-708163|Drug: BMS-708163 + Cooperstown Cocktail","Pharmacokinetic effects of BMS-708163 on interacting drugs (midazolam, warfarin, caffeine, omeprazole, and dextromethorphan)|Safety variables (adverse events, vital signs, safety labs)",Bristol-Myers Squibb,Male,18 Years to 45 Years   (Adult),Phase 1,22,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CN156-005,Aug-08,Oct-08,Oct-08,1-Aug-08,null,5-Nov-08,"Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00726726
NCT00726115,"Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531",,Completed,No Results Available,Alzheimer Disease,Drug: SAM-531|Drug: placebo,"Pharmacokinetics, routine Lab tests, Vital signs, ECG",Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3193A1-1111,Aug-08,Feb-09,Feb-09,31-Jul-08,null,30-Jul-09,"Rueil Malmaison, France",,https://ClinicalTrials.gov/show/NCT00726115
NCT00722046,Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Biological: PF-04360365 0.1 mg/kg|Biological: PF-04360365 0.5 mg/kg|Biological: PF-04360365 1 mg/kg|Drug: Placebo|Biological: PF-04360365 3 mg/kg|Biological: PF-04360365 8.5 mg/kg,"Safety/tolerability of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 18 months. (adverse events, physical/neurologic exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)|Pharmacokinetics of PF-04360365 following administration of multiple doses in subjects with mild to moderate Alzheimer's disease. (plasma and cerebrospinal fluid (as available) PF-04360365 concentrations)|Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma/CSF Abeta; CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; Immunogenicity (anti-drug antibodies)",Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 2,198,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",A9951002,Dec-08,Aug-11,Aug-11,25-Jul-08,null,5-May-16,"Pfizer Investigational Site, Peoria, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, Elk Grove Village, Illinois, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Eatontown, New Jersey, United States|Pfizer Investigational Site, Oakhurst, New Jersey, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Adelaide, South Australia, Australia|Pfizer Investigational Site, Woodville South, South Australia, Australia|Pfizer Investigational Site, Heidelberg West, Victoria, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, Antwerpen, Belgium|Pfizer Investigational Site, Edegem, Belgium|Pfizer Investigational Site, Jette, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Peterborough, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Sungnam-si, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Trafford Park, Manchester, United Kingdom|Pfizer Investigational Site, Swindon, Wiltshire, United Kingdom|Pfizer Investigational Site, Swindon, Wiltshire, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00722046
NCT00721383,Telephone Resources and Assistance for Caregivers (TRAC),TRAC,Completed,No Results Available,Alzheimer's Disease,Behavioral: Enhancing Physical Activity Intervention|Behavioral: CSBI,self-reported physical activity|caregiving burden|caregiver positive well-being|self-reported physical health|physical function,Rush University Medical Center|Stanford University,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,211,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,4092307,May-07,Feb-13,Feb-13,24-Jul-08,null,31-Dec-14,"Stanford University School of Medicine, Stanford, California, United States|Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00721383
NCT00718731,Study GSI-136 in Healthy Young and Healthy Elderly Subjects,,Completed,No Results Available,Alzheimer Disease|Healthy,Drug: GSI-136|Other: Placebo,"Safety and tolerability of GSI-136 as evaluated from reported adverse events, scheduled physical examinations, vital sign measurements, orthostatic vital sign measurements, cardiac rhythm monitoring, 12-lead ECGs, and clinical laboratory test results.|Pharmacokinetics as evaluated from the blood and urine concentrations of GSI-136; Pharmacodynamics as evaluated from the levels of select biomarkers in the blood and the administration of a visual analog scale to measure sedation effects.",Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3225A1-1000,Mar-08,Aug-08,Aug-08,21-Jul-08,null,2-Apr-10,"New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00718731
NCT00719394,Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males,,Completed,No Results Available,Alzheimer Disease|Healthy,Drug: GSI 136|Drug: placebo,"Safety and tolerability of GSI-136 as evaluated from reported adverse events, scheduled physical examinations, vital sign measurements, orthostatic vital sign measurements, cardiac rhythm monitoring, 12-lead ECGs, and clinical laboratory test results.|Pharmacokinetics as evaluated from the blood and urine concentrations of GSI-136; Pharmacodynamics as evaluated from the levels of select biomarkers in the blood and the administration of a visual analog scale to measure sedation effects.",Wyeth is now a wholly owned subsidiary of Pfizer,Male,"20 Years and older   (Adult, Older Adult)",Phase 1,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3225A1-1001,Mar-08,Aug-08,Aug-08,21-Jul-08,null,10-Jul-09,"Tokyo Heat Center, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00719394
NCT00715858,A Pilot Study of Inflammatory Markers in Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease,Drug: doxycycline|Drug: rifampin|Drug: placebo,IL-1beta|TNF-alpha|MCP-1|IL-4|IL-10|Other inflammatory markers.,McMaster University|The Physicians' Services Incorporated Foundation,All,"50 Years and older   (Adult, Older Adult)",Phase 3,21,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",R07-63,May-08,Aug-09,Oct-09,15-Jul-08,null,4-Feb-09,"St.Peter's Hospital, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00715858
NCT00714571,Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI),,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease|Traumatic Brain Injury,Behavioral: Mnemonic strategy training (MST)|Behavioral: Repeated exposure (XP)|Behavioral: Subtracting Cues training,Memory Test Accuracy on Trained Stimuli,VA Office of Research and Development|Emory University,All,"18 Years to 88 Years   (Adult, Older Adult)",Phase 1,82,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,B6366-W,Jul-08,Sep-14,Sep-14,14-Jul-08,4-Jan-17,4-Jan-17,"Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00714571
NCT00713765,Pharmacokinetic Interaction Between AZD3480 and Donepezil,,Terminated,No Results Available,Alzheimer's Disease,Drug: AZD3480|Drug: Donepezil,"PK variables|Safety variables (adverse events, blood pressure, pulse, safety lab)",AstraZeneca,All,20 Years to 60 Years   (Adult),Phase 1,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",D3690C00005|EudraCt No.2008-002847-17,Dec-08,Dec-08,Dec-08,11-Jul-08,null,15-Aug-14,"Research Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00713765
NCT00711204,Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease,,Withdrawn,No Results Available,Severe Alzheimer's Disease,Drug: Donepezil Hydrochloride (Aricept),"CSDD (Cornell Scale for Depression in Dementia).|FAST (Functional Assessment Staging), NPI-10, MMSE (Mini Mental State Examination), DemQol (Dementia Quality of Life).",Eisai Inc.|Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 4,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E2020-A001-417,Jan-08,Jun-09,null,8-Jul-08,null,10-Dec-12,"Kettlie Joseph Daniels, M.D. Inc., Toledo, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00711204
NCT00710684,"A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease",,Completed,Has Results,Alzheimer's Disease,Drug: SB-742457 15mg|Drug: SB-742457 35mg|Drug: Placebo|Drug: donepezil 5-10mg,"Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 24|Change From Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score at Week 24|Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Score at Week 24|Change From Baseline in ADAS-Cog Total Score at Week 12, 36 and 48|Change From Baseline in CDR-SB Score at Week 12, 36 and 48|Change From Baseline in RBANS Score at Week 12, 36 and 48|Change From Baseline in Alzheimer's Disease Co-operative Study Group - Activities of Daily Living Inventory (ADCS- ADL) Total Score at Weeks 12, 24, 36 and 48|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Week 24 and 48|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During Treatment Phase|Number of Participants With Parameters of Clinical Concern - Hematology|Number of Participants With Parameters of Clinical Concern - Clinical Chemistry|Exposure Estimates for SB-742457 : Area Under the Concentration Time Curve Over the Dosing Interval at Steady State (AUCτss)|Exposure Estimates for SB-742457 : Minimum Concentrations at Steady State (Cmin-ss)|Exposure Estimates for Donepezil (Cavgss)|Change From Baseline in ADAS-Cog Scale in Participants With APOE4 Gene|Change From Baseline in CDR-SB Scale in Participants With APOE4 Gene|Change From Baseline in RBANS Scale in Participants With APOE4 Gene",GlaxoSmithKline,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,682,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AZ3110866,1-Jul-08,21-May-10,16-Nov-10,4-Jul-08,7-Dec-17,7-Dec-17,"GSK Investigational Site, Litchfield Park, Arizona, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Rancho Mirage, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Hallandale Beach, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Manchester, New Jersey, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Bennington, Vermont, United States|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, La Plata, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Kogarah, New South Wales, Australia|GSK Investigational Site, Herston, Queensland, Australia|GSK Investigational Site, Woodville, South Australia, Australia|GSK Investigational Site, Ballarat, Victoria, Australia|GSK Investigational Site, Heidelberg West, Victoria, Australia|GSK Investigational Site, Kew, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Saint John, New Brunswick, Canada|GSK Investigational Site, Kentville, Nova Scotia, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Québec, Canada|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Melnik, Czechia|GSK Investigational Site, Olomouc, Czechia|GSK Investigational Site, Ostrava, Czechia|GSK Investigational Site, Pardubice, Czechia|GSK Investigational Site, Plzen, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 1, Czechia|GSK Investigational Site, Praha 4, Czechia|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Alzenau, Bayern, Germany|GSK Investigational Site, Guenzburg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bad Honnef, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Chieti Scalo, Abruzzo, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, San Felice A Cancello - Caserta, Campania, Italy|GSK Investigational Site, Cassino (FR), Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Brescia, Lombardia, Italy|GSK Investigational Site, Castellanza (VA), Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Rho, Lombardia, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Lido Di Camaiore (LU), Toscana, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Perugia, Umbria, Italy|GSK Investigational Site, Valdagno (VI), Veneto, Italy|GSK Investigational Site, Verona, Veneto, Italy|GSK Investigational Site, Baracaldo/Vizcaya, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Burgos, Spain|GSK Investigational Site, Castellón, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Salamanca, Spain|GSK Investigational Site, San Sebastián, Spain|GSK Investigational Site, San Vicente Del Raspeig/Alicante, Spain|GSK Investigational Site, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT00710684
NCT00708552,Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: SB-742457|Drug: Donepezil|Drug: Placebo,"Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 24|Clinician's Interview-Based Impression of Change - Plus (CIBIC+) Score at Week 24|Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Score at Week 24|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline Mini Mental State Examination [MMSE] Scores 16-26) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 24|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline [MMSE Scores 10-20) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 24|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 16-26) on the CIBIC+ Score at Week 24|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 10-20) on the CIBIC+ Score at Week 24|Change From Baseline in ADAS-Cog Total Score at Week 12|CIBIC+ Score at Week 12|Change From Baseline in RBANS Total Score at Week 12|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 16-26) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 12|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 10-20) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 12|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 16-26) on the CIBIC+ Score at Week 12|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 10-20) on the CIBIC+ Score at Week 12|Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Total Score at Weeks 12 and 24|Change From Baseline in Cornell Scale for Depression in Dementia (CSDD) Total Score at Week 24|Change From Baseline in MMSE Total Score at Week 24|Change From Baseline in ADCS-ADL-Basic Score; ADCS-ADL: Instrumental Score and ADCS-ADL: Total Independence Score at Weeks 12 and 24|Number of Participants With Any Adverse Event (Serious and Non-serious) and Serious Adverse Events (SAEs)|Number of Participants With Vital Signs Data of Potential Clinical Concern (PCC) Any Time on Treatment (ATOT)|Number of Participants With Hematology Data of PCC ATOT|Number of Participants With Chemistry Data of PCC ATOT|Change From Baseline in Clinical Chemistry Parameters Alanine Amino Transferase, Alkaline Phosphatase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Week 24|Change From Baseline in Clinical Chemistry Parameters Albumin and Total Protein at Week 24|Change From Baseline in Clinical Chemistry Parameter Blood Urea Nitrogen /Creatinine Ratio at Week 24|Change From Baseline in Clinical Chemistry Parameters Calcium, CO2 Content/Bicarbonate, Chloride, Glucose, HDL Cholesterol, LDL Cholesterol, Magnesium, Phosphorus, Potassium, Sodium, Triglycerides, Urea/Blood Urea Nitrogen at Week 24|Change From Baseline in Clinical Chemistry Parameters Creatinine, Direct Bilirubin and Total Bilirubin at Week 24|Change From Baseline in Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Segmented Neutrophils, Total Neutrophils, White Blood Cell Count at Week 24|Change From Baseline in Hematology Parameter Hematocrit|Change From Baseline in Hematology Parameters Hemoglobin and Mean Corpuscle Hemoglobin Concentration at Week 24|Change From Baseline in Hematology Parameter Mean Corpuscle Hemoglobin at Week 24|Change From Baseline in Hematology Parameter Mean Corpuscle Volume and Mean Platelet Volume at Week 24|Change From Baseline in Hematology Parameter Red Blood Cell Count at Week 24|Number of Participants With Electrocardiogram (ECG) Findings as Assessed by Investigator and Central Cardiologist|Exposure Estimates for SB-742457 Area Under Curve Over the Dosing Interval at Steady State (AUCτss)|Exposure Estimates for SB-742457 Minimum Concentration at Steady State (Cmin-ss)|Exposure Estimates for Donepezil Average Concentration at Steady State (Cavgss)",GlaxoSmithKline,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,576,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AZ3110865,4-Jul-08,1-Mar-10,9-Mar-10,2-Jul-08,12-Feb-18,27-Jul-18,"GSK Investigational Site, Shumen, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Olomouc, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 1, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Neuburg / Donau, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Erbach, Hessen, Germany|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dueren, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Siegen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Melissia, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Aguascalientes, Ags, Aguascalientes, Mexico|GSK Investigational Site, Tijuana, Baja California Norte, Mexico|GSK Investigational Site, Saltillo, Coahuila, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico City, Mexico|GSK Investigational Site, Mexico, D.F., Mexico|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Mosina, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Sopot, Poland|GSK Investigational Site, Warsaw, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, Durban, South Africa|GSK Investigational Site, Loeventstein, South Africa|GSK Investigational Site, Oakdale, South Africa|GSK Investigational Site, Pretoria, South Africa|GSK Investigational Site, Rosebank, South Africa|GSK Investigational Site, Sunninghill, South Africa",,https://ClinicalTrials.gov/show/NCT00708552
NCT00704782,Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: dimebon,To assess the safety of Dimebon in combination with donepezil (Aricept),"Medivation, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 2,50,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIM13,Apr-08,Aug-10,Aug-10,25-Jun-08,null,10-Dec-15,"Xenoscience, Inc., Phoenix, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00704782
NCT00703430,Memantine on Aggression and Agitation of Alzheimer's Disease (AD),,Unknown status,No Results Available,Alzheimer's Disease,Drug: Memantine,CMAI score|CBI score|RUD|NPI score,Peking University|H. Lundbeck A/S,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,50,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CN-IIT-12292,Mar-08,Dec-13,Jun-14,23-Jun-08,null,25-Jan-13,"Peking University Institute of Mental Health, Beijing, China",,https://ClinicalTrials.gov/show/NCT00703430
NCT00702143,"A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",,Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: florbetapir F 18,Qualitative Amyloid Image Assessment|Mean Cortical to Cerebellum SUVR|Proportion of Positive Florbetapir-PET Scans,Avid Radiopharmaceuticals,All,"50 Years and older   (Adult, Older Adult)",Phase 2,184,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,18F-AV-45-A05,Jun-08,Dec-08,Dec-08,20-Jun-08,3-May-12,10-May-12,"Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Sun City, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Costa Mesa, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Sunrise, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Albany, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00702143
NCT00702780,Progression Delaying Effect of Escitalopram in Alzheimer's Disease,ESAD,Completed,Has Results,Alzheimer's Disease,Drug: escitalopram|Drug: placebo,% Change of Hippocampus Volume|% Change of Whole Brain Volume,Seoul National University Hospital|H. Lundbeck A/S,All,"40 Years to 90 Years   (Adult, Older Adult)",Not Applicable,74,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SNUDC001,Nov-08,Sep-11,Sep-11,20-Jun-08,13-Jun-14,13-Jun-14,"Kangwon National University Hospital, Chuncheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00702780
NCT00701532,Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction,CAIMAN,Completed,No Results Available,Cocaine Addiction|Cocaine Dependence,Drug: Modafinil and PET (brain imaging)|Drug: placebo,"Decreased DAT occupation rates in the modafinil group versus placebo from day 3 to day of cocaine detoxification.|Evaluation of the clinical efficacy of modafinil during therapeutic cocaine withdrawal.|Correlation between craving measurements, depressive symptom measurements and cognitive deficit measurements observed and modifications of DAT density.|Study of DAT from D3 to D21 versus a pre-existing data base of control subjects.|Tolerance and safety evaluation of high modafinil doses, measured by adverse events and biological parameters.",Assistance Publique - Hôpitaux de Paris|Mission Interministérielle de Lutte contre la Drogue et la Toxicomanie,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,29,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P070150,Apr-09,Oct-12,Jan-13,19-Jun-08,null,11-Apr-13,"Unité de recherche U797 Inserm - CEA - Université Paris-Sud. "" Neuroimagerie & Psychiatrie "" Service Hospitalier Frédéric Joliot, Orsay, France|Centre d'Enseignement, de Recherche et de Traitements des Addictions - Hopital Universitaire Paul Brousse, Villejuif, France",,https://ClinicalTrials.gov/show/NCT00701532
NCT00693888,"Lighthouse Project on Dementia, Ulm, Germany",ULTDEM,Unknown status,No Results Available,Dementia,"Behavioral: advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)","Quality of life|health economical effects, progress of disease, level of evidence based on diagnosis, institutionalization, hospitalization, using support possibilities, use of drugs","University of Ulm|Federal Ministry of Health, Germany|Geriatric Center Ulm|Robert Bosch Medical Center",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,LTDemenz-44-052,Jun-08,Feb-10,Sep-10,9-Jun-08,null,17-Aug-10,"Geriatric Center Ulm (GZU), Bethesda Geriatrische Klinik Ulm, Ulm, Baden-Württemberg, Germany",,https://ClinicalTrials.gov/show/NCT00693888
NCT00692510,Drug Interaction Study Between AZD3480 and Cytochrome P450,Cocktail,Completed,No Results Available,Metabolism|Alzheimer's Disease,"Drug: AZD3480|Drug: Placebo|Drug: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)","PK variables|Safety variables (adverse events, blood pressure, pulse, safety lab)",AstraZeneca,Male,18 Years to 55 Years   (Adult),Phase 1,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",D3690C00016|EudraCt nr 2007-002456-10,Nov-07,Sep-08,Sep-08,6-Jun-08,null,26-Nov-08,"Research Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00692510
NCT00692705,"Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid",PET,Completed,No Results Available,Alzheimer´s Disease,Drug: Radioligand (11C)AZD2995|Drug: Radioligand (11C)AZD2184,"Positron emission tomography using the radioligand (11C)AZD2995 or (11C)AZD2184|To assess safety and tolerability of [11C]AZD2995, [11C]AZD2184 and the study procedures, by assessment of adverse events, vital signs and laboratory variables.",AstraZeneca,All,"20 Years to 85 Years   (Adult, Older Adult)",Phase 1,13,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D0180C00018|Eudract No. 2007-004842-33,Jan-08,Dec-08,Dec-08,6-Jun-08,null,23-Jan-09,"Research Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00692705
NCT00693004,Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: PRX-03140|Drug: Donepezil|Drug: Placebo,Alzheimer's Disease Assessment Scale-Cognitive subscale.,"Epix Pharmaceuticals, Inc.",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,236,Industry,Interventional,Primary Purpose: Treatment,Protocol 03140-203,May-08,Jan-10,null,6-Jun-08,null,30-Jul-09,"Barrow Neurological Institute, Phoenix, Arizona, United States|PsyPharma Clinical Research, Inc., Phoenix, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Synergy Clinical Research Center, National City, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Torrance Clinical Research, Torrance, California, United States|Bradenton Research Center, Bradenton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Compass Research, Orlando, Florida, United States|Berma Research Group, Plantation, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Roskamp Institute, Tampa, Florida, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Maine Neurology, Scarborough, Maine, United States|The ICPS Group, Norwood, Massachusetts, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Global Medical Institutes, Princeton, New Jersey, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|The Mount Sinai Medical Center, New York, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|The Neurological Institute, P.A., Charlotte, North Carolina, United States|MedArk, Morgantown, North Carolina, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Todd Swick, MD, PA, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|The Glennan Center for Geriatrics & Gerontology, Eastern Virginia Medical School, Norfolk, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00693004
NCT00689559,Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects,,Completed,No Results Available,Alzheimer's Disease,Drug: AZD3480|Drug: Placebo|Drug: Aripiprazole,"PK variables|Safety variables (adverse events, blood pressure, pulse, safety lab)",AstraZeneca,Male,18 Years to 45 Years   (Adult),Phase 1,52,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",D3691C00001|EudraCt nr 2008-000310-74,Mar-08,null,Apr-09,3-Jun-08,null,2-Jul-09,"Research Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00689559
NCT00689637,Drug Interaction Study Between AZD3480 and Warfarin,DDI,Completed,No Results Available,Alzheimer's Disease,Drug: AZD3480|Drug: Placebo|Drug: Warfarin,"PK variables|Safety variables (adverse events, blood pressure, pulse, safety lab)",AstraZeneca,Male,18 Years to 45 Years   (Adult),Phase 1,26,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",D3690C00014|EudraCt nr 2007-004756-37,Sep-07,null,Feb-09,3-Jun-08,null,2-Jul-09,"Research SIte, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00689637
NCT00688207,Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR),,Completed,No Results Available,Alzheimer's Disease,Drug: Rosiglitazone (Extended Release),"AUC (0-inf) and Cmax of RSG XR|AUC(0-t), t1/2 and tmax for RSG XR",GlaxoSmithKline,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,14,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVA109941,Apr-08,Sep-08,Sep-08,2-Jun-08,null,7-Nov-16,"GSK Investigational Site, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00688207
NCT00687141,"Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects",,Completed,No Results Available,Alzheimer's Disease,Drug: AZD0328|Drug: Placebo,"Safety and tolerability of AZD0328 by assessment of vital signs, laboratory variables and ECG|Safety and tolerability of AZD0328 by assessment of adverse events|Determine the single and multiple dose pharmacokinetics (PK) of AZD0328|Evaluate the cognitive dose response relationship for AZD0328",AstraZeneca,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1,112,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",D0190C00006|EudractCT 2007-004598-25,Nov-07,Jun-08,Jun-08,30-May-08,null,10-Dec-10,"Research Site, Linkoping, Sweden|Research Site, Lulea, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00687141
NCT00684710,"Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects",,Completed,No Results Available,Alzheimer Disease|Healthy,Drug: PAZ-417|Drug: Placebo,Safety and Tolerability|Pharmacokinetics,Wyeth is now a wholly owned subsidiary of Pfizer,Male,"20 Years and older   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3186A1-101,Apr-08,Aug-08,Aug-08,28-May-08,null,30-Jan-09,"Kitashinagawa, Shinagawa-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00684710
NCT00684944,Open Label Study of TRx0014 in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: TRx0014,Cognitive ability measured by the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) and by the Mini-Mental State Examination (MMSE).|Dementia severity assessed by the Clinical Dementia Rating - sum of the boxes (CDR-sb).|Daily living activities assessed by the Alzheimer's Disease functional Assessment and Change Scale (ADFACS),TauRx Therapeutics Ltd,All,"Child, Adult, Older Adult",Phase 2,111,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TRx-014-009,13-Sep-07,2-Dec-10,2-Dec-10,28-May-08,null,27-Apr-18,,,https://ClinicalTrials.gov/show/NCT00684944
NCT00684281,"Early Diagnosis of Alzheimer's Disease: Clinical, Neuropsychological and Neuroimaging Follow-up of a Cohort of Patients With an Isolated Memory Impairment",,Completed,No Results Available,Alzheimer's Disease,"Other: Neurological and neuropsychological consultation, MRI|Other: Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA","Pursue the longitudinal study of a troop of subjects presenting an amnestic MCI in 36 months after the initial diagnosis|Characterize the clinical evolution of these subjects: escalation with appearance of an insanity (of type Alzheimer's disease or of another type: degenerations fronto-temporal, insanity with body of Lewy), stabilization even improvement.|Identify the neuropsychological markers and of neuroimaging structural and metabolic useful in clinical practice which allow to predict an escalation|Identify the neuropsychological markers and of neuroimaging structural and metabolic useful in clinical practice which allow to predict a stabilization or an improvement.|Improve the state of the knowledge on the origin of the confusions mnésiques isolated at the persons of fifty and more years old.|Establish diagnostic criteria which allow to improve the sensibility and the specificity of the premature diagnosis of MY.|Determine if the ultra-premature diagnosis of MY at a stage where the hurts are still confined in the structures under - hippocampiques is possible.|Determine the specific character or not of the infringement of the memory of visual recognition in the novice Alzheimer's disease.|Determine the specific character or not the atrophy and the metabolic modifications of regions under - hippocampiques in the novice Alzheimer's disease.|Inform the existence of process of functional compensation in the population of aMCI, notably to those who show themselves stable or improve.",Assistance Publique Hopitaux De Marseille,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2007-A00851-52|2007-27,Jul-08,Apr-11,Dec-11,26-May-08,null,28-Aug-14,"Hopital de la Timone- Service de neurologie et de neuropsychologie, Marseille, France",,https://ClinicalTrials.gov/show/NCT00684281
NCT00679627,A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease,,Terminated,Has Results,Alzheimer's Disease,Drug: Galantamine|Drug: Placebo,"Change From Baseline in the Mini-Mental State Examination (MMSE) Score|The Number of Deaths Reported in Participants|Change From Baseline in Disability Assessment in Dementia (DAD) Scores|Change From Baseline in Patient Accommodation Measured Using the Assessment of Subject Accommodation Status and Caregiver Burden (APAS-CarB)|Change From Baseline in Caregiver Time Spent With the Patient Measured Using the Assessment of Subject Accommodation Status and Caregiver Burden (APAS-CarB)|Change From Baseline in Institutional Status|Change From Baseline in the Mini-Mental State Examination (MMSE) Subscales (Orientation, Registration, Attention and Calculation, Recall, and Language)|Change From Baseline in the Disability Assessment in Dementia (DAD) Subscales (Initiation, Planning and Organization, Effective Performance, Basic, Instrumental, and Leisure)","Janssen Research & Development, LLC",All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 3,2051,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR012463|GALALZ3005,Jun-08,Apr-12,May-12,19-May-08,2-Sep-13,19-Sep-13,"Hradec Kralove, Czech Republic|Mìlník 1, Czech Republic|Olomouc, Czech Republic|Ostrava 3, Czech Republic|Ostrava, Czech Republic|Praha 2, Czech Republic|Praha 8, Czech Republic|Tallinn N/A, Estonia|Tallinn, Estonia|Tartu, Estonia|Viljandi N/A, Estonia|Vorumaa, Estonia|Limoges, France|Bad Aibling, Germany|Bad Homburg, Germany|Bad Honnef, Germany|Bamberg, Germany|Berlin, Germany|Bielefeld, Germany|Bochum, Germany|Butzbach, Germany|Franfurt, Germany|Fürth, Germany|Gelsenkirchen, Germany|Göttingen, Germany|Hamburg, Germany|Hannover, Germany|Hattingen, Germany|Karlstadt, Germany|Leverkusen, Germany|Lüneburg, Germany|Mittweida, Germany|Mönchengladbach, Germany|Nürnberg, Germany|Oldenburg, Germany|Ulm, Germany|Unterhaching, Germany|Westerstede, Germany|Wiesbaden, Germany|Athens, Greece|Heraklion Crete, Greece|Thessalonikis, Greece|Riga, Latvia|Kaunas, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Arad, Romania|Bucharest Sector 5, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Constanta, Romania|Craiova, Romania|Iasi, Romania|Tg Mures, Romania|Ekaterinburg, Russian Federation|Kazan N/A, Russian Federation|Kazan, Russian Federation|Kirov, Russian Federation|Krasnodar N/A, Russian Federation|Krasnodar, Russian Federation|Lipetsk, Russian Federation|Moscow Russia, Russian Federation|Moscow, Russian Federation|Nizny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Rostov-On-Don, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|Smolensk Region N/A, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St-Petersburg, Russian Federation|St.Petersburg, Russian Federation|Tomsk Na, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Bratislava, Slovakia|Dubnica Nad Vahom, Slovakia|Kosice, Slovakia|Plesivec, Slovakia|Senkvice, Slovakia|Spisska Nova Ves, Slovakia|Vranov Nad Toplou, Slovakia|Kamnik, Slovenia|Lesce, Slovenia|Ljubljana, Slovenia|Maribor, Slovenia|Chernivtsy, Ukraine|Dnepropetrovsk, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Kharkov, Ukraine|Kherson, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Lvov, Ukraine|Odessa, Ukraine|Poltava, Ukraine|Simferopol, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine",,https://ClinicalTrials.gov/show/NCT00679627
NCT00678431,Randomized Trial of a Nutritional Supplement in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,"Dietary Supplement: Resveratrol with Glucose, and Malate|Dietary Supplement: Placebo",Alzheimer Disease Assessment Scale (ADAScog)|CGIC,US Department of Veterans Affairs|Alzheimer's Association|Icahn School of Medicine at Mount Sinai|VA Office of Research and Development,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,27,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0553-06-071,Jan-08,Dec-10,Jun-11,15-May-08,null,15-Nov-12,"James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00678431
NCT00676143,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,,Terminated,Has Results,Alzheimer Disease,Drug: bapineuzumab|Drug: placebo,"Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78|Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 78|Change From Baseline in Brain Amyloid Burden at Week 71|Change From Baseline in Cerebrospinal Fluid (CSF) Phospho-tau Levels at Week 71|Change From Baseline in Brain Volume, as Assessed by Magnetic Resonance Imaging Brain Boundary Shift Integral (MRI BBSI), at Week 71|Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78|Divergence of Effect on the DAD Total Scores From Week 39 to Week 78|Time to First Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)|Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)|Time to First Median Placebo Deterioration on DAD Total Score (EU Analysis Plan)|Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis)|Change From Baseline in Dependence Scale Total Score at Week 78|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (EU Analysis Plan)|Percentage of Responders for ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (EU Analysis Plan)|Percentage of Responders for DAD Total Score at Week 78 (US Analysis Plan)|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78",Pfizer,All,"50 Years to 88 Years   (Adult, Older Adult)",Phase 3,1100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3133K1-3001|B2521002|2007-005995-14,Jan-08,Oct-12,Nov-12,12-May-08,10-Jun-16,10-Jun-16,"Center for Psychiatric Medicine, Birmingham, Alabama, United States|Participant and Clinical Interactions Resources, Birmingham, Alabama, United States|UAB Clinical Research Pharmacy-Russell Clinic, Birmingham, Alabama, United States|University of Alabama-Birmingham, Birmingham, Alabama, United States|Dedicated Clinical Research, Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Jeffrey S. Gitt, DO, PC, Phoenix, Arizona, United States|The Compounding Center, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|AC Institute, Incorporated, Carson, California, United States|Collaborative Neuroscience Network, Inc, Long Beach, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Associated Neurologists, PC, Boulder, Colorado, United States|Mile HIgh Research Center, Denver, Colorado, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Bendheim Cancer Center, Greenwich, Connecticut, United States|Center for Healthy Aging, Greenwich, Connecticut, United States|Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Hospital Research Unit, New Haven, Connecticut, United States|Investigational Drug Service, New Haven, Connecticut, United States|Moshe Hasbani, MD, New Haven, Connecticut, United States|Norman S. Werdiger, MD, New Haven, Connecticut, United States|MR Research Center, New Haven, Connecticut, United States|Yale PET Center, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|JEM Research Institute, LLC, Atlantis, Florida, United States|JEM Research Institute, Atlantis, Florida, United States|Medical Specialist of the Palm Beaches, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|University of South Florida, Tampa, Florida, United States|Dekalb Neurology Associates, LLC/NeuroStudies.net, LLC, Decatur, Georgia, United States|Neurostudies.net, Decatur, Georgia, United States|NeuroStudies.net, Lawrenceville, Georgia, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Southern Illinois University School of Medicine Department, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hosptial, Boston, Massachusetts, United States|Brigham & Womens Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Univeristy ADCRP, Boston, Massachusetts, United States|General Clincial Research Center (Infusion Location), Boston, Massachusetts, United States|IDS Pharmacy (Drug Receipt). Attn:Hyesson Hong, Boston, Massachusetts, United States|Shields MRI, Dartmouth, Massachusetts, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|University of Michigan Health System, Ann Arbor,, Michigan, United States|University of Michigan Hospital and Health System, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|The Center for Pharmaceutical Research P.C., Kansas City, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pharmcare USA, Edison, New Jersey, United States|Alzheimer's Research Corp./Merician Institute for Aging, Manchester, New Jersey, United States|Neurological Care of Central New York, Liverpool, New York, United States|Carolina Neuropsychological Services, Inc, Raleigh, North Carolina, United States|Healthsouth Blue Ridge Surgery Center, Raleigh, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Radiology Associates, Raleigh, North Carolina, United States|Ohio State University Imaging@Martha Moorehouse, Columbs, Ohio, United States|The Ohio State University, Columbs, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Summit Research Network(Oregon) Inc., Portland, Oregon, United States|Providence Brain Institute, Portland, Oregon, United States|Providence Cognitive Assessment Clinic, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Dr. Michael Gabe (Clinic), Silverton, Oregon, United States|Abington Memorial Hosptial, Abington, Pennsylvania, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Abington Neurological Assoc, Abington, Pennsylvania, United States|Andorra MRI of Flourtown, Flourtown, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Investigational New Drug Services, Philadelphia, Pennsylvania, United States|University of Pennsylvania-Penn Memory Center, Philadelphia, Pennsylvania, United States|UPENN Clinical and Transitional Research Center, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Simpson's Pharmacy, Pawtucket, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Hospitals and Clinics, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|MUSC, Charleston, South Carolina, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Texas Neurology, P.A., Dallas, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Vista Infusions, San Antonio, Texas, United States|Inventive Infusion Solutions, San Antonio, Texas, United States|Inventive Infusions Solutions, San Antonio, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|The Pharmacy, Bennington, Vermont, United States|Waisman Center (PET only), Madison, Wisconsin, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Wm S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States|University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Instituto Medico Congreso, Buenos Aires, Argentina|Cemic University Hospital, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Instituto Kremer, Cordoba, Argentina|Gosford Hospital; Pharmacy Dept, Gosford, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Hornsby Kuringai Hospital, Hornsby, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|CDAMS Ballarat Base Hospital, Ballarat, Victoria, Australia|Heidelberg Repatriation Hospital, West Heidelberg, Victoria, Australia|Hollywood Hospital; Pharmacy Dept, Nedlands, Western Australia, Australia|McCusker Alzheimer's Research Foundation, Inc., Nedlands, Western Australia, Australia|Medizinische Universitaet Graz, Graz, Austria|Landeskrankenhaus Klagenfurt, Klagenfurt, Austria|Allg. Krankenhaus der Stadt Wien, Wien, Austria|SZ Sued - Kaiser-Franz-Josef-Spital, Wien, Austria|Donauspital, Wien, Austria|ZNA Middelheim, Antwerpen, Belgium|Az. St. Jan Ruddershove 35, Brugge, Belgium|Cliniques Universitaires St Luc, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|Psicomedica Research Group, Santiago, Chile|Especialidades Medicas LyS, Santiago, Chile|University Hospital Center Zagreb, Zagreb, Croatia|Ita-Suomen Yliopisto, Kuopio, Finland|University of Turku / CRST, Turku, Finland|CHU Pellegrin, Bordeaux Cedex, France|Hopital neurologique du Pr A. Vighetto, Bron, France|Centre d'Imagerie medicale de Basse Normandie, Caen, France|CHU de Caen, Caen, France|Hôpitaux Civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|CHRU de Lille, Lille, France|Hôpital la Timone, Marseille, France|CHU Hôpital Gui de Chaulliac, Montpellier, France|CHU Nord - Hôpital Guillaume et René Laënnec, Nantes - Saint Herblain, France|Hôpital Cimiez C.M.R.R., Nice, France|Service d'Imagerie Medicale, Nice, France|Groupe Hospitalier Broca-La Rochefoucauld, Paris, France|Hôpital Pitié-Salpétrière, Paris, France|Hospital Jean Bernard CIC, Poitiers, France|C.H.U de Reims, Reims, France|CHU de Rennes, Rennes Cedex, France|CHU - Hopital Charles Nicolle, Rouen, France|Hôpital Purpan, Toulouse, France|CHU Toulouse - Site Casselardit, Toulouse, France|Charite-Universitätsmedizin Berlin, Berlin, Germany|St. Josef-Klinikum, Bochum, Germany|Universitaetsklinikum Dresden, Dresden, Germany|Klinikum der Albert-Ludwigs-Universitaet Freiburg, Freiburg, Germany|Ortenau Klinikum Offenburg, Offenburg, Germany|Universitaetsklinikum Ulm, Ulm, Germany|A.O. Umberto I, Ancona, Italy|Sezione di Neurologia - Dipartimento di Neuroscienze, Ancona, Italy|Clinica Neurologica - II Neurologia, Brescia, Italy|Dipartimento di Neuroscienze,, Catania, Italy|Unita' Operativa Complessa di Neurologia, Catania, Italy|CeSI (Centro di Scienze dell'invecchiamento) -, Chieti, Italy|Fondazione IRCCS- Istituto Neurologico Carlo Besta, Milano, Italy|Ospedale S. Gerardo, Monza, Italy|Clinica Neurologica, Roma, Italy|Unita' Operativa C - Riabilitazione Neurologica, Roma, Italy|Universita degli Studi di Siena, Siena, Italy|Nagoya City University Hospital, Nagoya, Aichi,, Japan|National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo, Japan|Yachiyo Hospital, Aichi, Japan|Kashiwado Hospital, Chiba, Japan|National Hospital Organization Chiba-East Hospital, Chiba, Japan|Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan|National Hospital Organization Kokura Medical Center, Fukuoka, Japan|Maebashi Red Cross Hospital, Gunma, Japan|Gunma University Hospital, Gunma, Japan|Shinozuka Hospital, Gunma, Japan|National Hospital Organization Hiroshima-nishi Medical Ctr., Hiroshima, Japan|Kobe University Hospital, Hyogo, Japan|Nishi-Kobe Medical Center, Hyogo, Japan|Kobe City Hospital Org Kobe City Medical Cente West Hp, Hyogo, Japan|Iwate Medical University Hospital, Iwate, Japan|Kagawa University Hospital, Kagawa, Japan|Nippon Medical School Musashi Kosugi Hospital, Kanagawa, Japan|Yokohama City University Medical Center, Kanagawa, Japan|Shonan Atsugi Hospital, Kanagawa, Japan|Rakuwakai Otowa Hospital, Kyoto, Japan|National Hospital Organization Minami-Kyoto Hospital, Kyoto, Japan|National Hospital Organization Maizuru Medical Center, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|National Hospital Organization Niigata National Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Kansai Medical University Takii Hospital, Osaka, Japan|National HP.Org.Shizuoka Inst.Epilepsy,Neurological Disorder, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Tokyo Metropolitan Health and Med. Treatment Co. Ebara Hosp, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|OCA Hospital, Monterrey, Nuevo León, Mexico|Instituto Biomedico de Investigacion A.C, Aguascalientes, Mexico|Amphia Ziekenhuis, Breda, Noord Brabant, Netherlands|Tergooi Ziekenhuizen, Hilversum, Noord Holland, Netherlands|Kennemer Gasthuis, Haarlem, The Netherlands, Netherlands|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Erasmus MC, Rotterdam, Netherlands|The Memory Clinic, Auckland, NZ, New Zealand|Signet Research, Christchurch, New Zealand|NZOZ Dom Suer Ryder, Pallmed Sp. z o.o., Bydgoszcz, Poland|Szpital Uniwersytecki, Oddzial Kliniczny Klinik Chorob Wewnetrznych i, Krakow, Poland|NZOZ ""NEURO-KARD"" ""ILKOWSKI I PARTNERZY"" Spolka Partnerska Lekarzy, Poznan, Poland|Oddzial Neurologiczny i Udarowy Szpital Wolski im. dr Anny Gostynskiej,, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika, Warszawa, Poland|Hospital Fernando da Fonseca, Amadora, Portugal|Hospitais Da Universidade De Coimbra, Coimbra, Portugal|Hospital Santa Maria, Lisboa, Portugal|Klinicki centar Srbije, Belgrade, Serbia|Clinical Centre Kragujevac, Clinic of Psichiatry, Kragujevac, Serbia|Klinicki Centar Vojvodina, Novi Sad, Serbia|Diagnostic Imaging Center, Sremska Kamenica, Serbia|Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia|Psychiatricka ambulancia, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Psychiatricka nemocnica Michalovce, n.o., Michalovce, Slovakia|Vseobecna nemocnica Rimavska Sobota, Rimavska Sobota, Slovakia|Boithuso Caregivers, Johannesburg, Gauteng, South Africa|The Osteoporosis and Memory Centre, Johannesburg, Gauteng, South Africa|Denmar Clinic, Pretoria, Gauteng, South Africa|St Augustine's Medical Centre 2, Durban, Kwa Zulu Natal, South Africa|Flexivest Fourteen Research Center, Bellville, Western Cape, South Africa|Panorama Psychiatry and Memory Clinic, Panorama, Western Cape, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto, Plasencia, Caceres, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain|CLONUS, Palma de Mallorca, Islas Baleares, Spain|Hospital de Donostia, San Sebastian, Pais Vasco, Spain|Hospital de Cruces, Baracaldo, Vizcalla, Spain|Hospital del Mar, Barcelona, Spain|Fundacio ACE Institut Catala de Neurociences Aplicades, Barcelona, Spain|Centro Internacional de Medicina Avanzda (CIMA), Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Divino Valles, Burgos, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Malmo University Hospital, Malmo, Sweden|Uppsala Imanet AB, Uppsala, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|ORKI, enheten for radiologi, Uppsala, Sweden|Memory Clinic Neuro-Psychologie Zentrum, Basel, BS, Switzerland|Hopitaux Universitaires de Geneve, Les Acacias, GE, Switzerland|CHUV Lausanne, Lausanne, VD, Switzerland|Hopitaux Universitaires de Geneve, Thonex-Geneva, Switzerland|MAC UK Neuroscience Ltd, Blackpool, Lancashire, United Kingdom|MAC UK Neuroscience, Research Assessment Centre, Trafford Park, Manchester, United Kingdom|Pollard Park Health Centre, Bradford, United Kingdom|Clinical Investigation and Research Unit (CIRU), Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|Dept. of Neurosciences Charing Cross Hospital, London, United Kingdom|Newcastle General Hospital, Newcastle upon Tyne, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Llandough Hospital, Penarth, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Grenoside Grange Hospital, Sheffield, United Kingdom|Victoria Hospital, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00676143
NCT00675623,A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease,CONNECTION,Completed,No Results Available,Alzheimer's Disease,Drug: Dimebon|Drug: Placebo,"To determine the effect of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog).|To determine the effect of Dimebon as compared to placebo on the primary measure of global function, the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus).|To determine the effect of Dimebon as compared to placebo on a measure of self care and daily function, the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL).|To determine the effect of Dimebon as compared to placebo on a measure of behavior, the Neuropsychiatric Inventory (NPI).","Medivation, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,598,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CONNECTION|DIM14,May-08,Dec-09,null,9-May-08,null,27-Sep-16,"Phoenix, Arizona, United States|Costa Mesa, California, United States|Fresno, California, United States|Rancho Mirage, California, United States|Hamden,, Connecticut, United States|New Haven, Connecticut, United States|Norwalk, Connecticut, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|North Miami, Florida, United States|Sunrise, Florida, United States|West Palm Beach, Florida, United States|Indianapolis, Indiana, United States|Paducah, Kentucky, United States|Newton, Massachusetts, United States|Ann Arbor, Michigan, United States|St. Louis, Missouri, United States|Brooklyn, New York, United States|Cedarhurst, New York, United States|New York City, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Morganton, North Carolina, United States|Centerville, Ohio, United States|Norristown, Pennsylvania, United States|Austin, Texas, United States|Middleton, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00675623
NCT00675090,Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: GSK239512|Drug: Placebo,"Safety and tolerability as measured by adverse events, vital signs clinical laboratory measurements and validated clinical assessment scales.|Pharmacodynamics measured by computerized cognitive tests and validated clinical rating scales. Also investigating the Pharmacokineticsat trough concentrations (Cmin) after GSK239512 repeat dosing on days 8, 15, 22 and 29 and 15.",GlaxoSmithKline,All,"50 Years and older   (Adult, Older Adult)",Phase 1,28,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",H3B109689,21-Feb-08,16-Jun-09,16-Jun-09,8-May-08,null,7-Jul-17,"GSK Investigational Site, Randwick, New South Wales, Australia|GSK Investigational Site, Heidelberg Heights, Victoria, Australia|GSK Investigational Site, Prague 10, Czechia|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Cambridgeshire, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Southall, United Kingdom",,https://ClinicalTrials.gov/show/NCT00675090
NCT00672945,A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil,,Terminated,No Results Available,Alzheimer's Disease,Drug: PRX-03140|Drug: Placebo,Alzheimer's Disease Assessment Scale-Cognitive subscale.,"Epix Pharmaceuticals, Inc.",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,420,Industry,Interventional,Primary Purpose: Treatment,Protocol 01340-202,Apr-08,Jan-10,null,6-May-08,null,30-Jul-09,"Barrow Neurological Institute, Phoenix, Arizona, United States|PsyPharma Clinical Research, Inc., Phoenix, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Synergy Clinical Research Center, National City, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Torrance Clinical Research, Torrance, California, United States|Bradenton Research Center, Bradenton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, Orlando, Florida, United States|Berma Research Group, Plantation, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Roskamp Institute, Tampa, Florida, United States|Alexian Brothers Neroscience Institute, Elk Grove Village, Illinois, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|J. Gary Booker, MD, Shreveport, Louisiana, United States|Maine Neurology, Scarborough, Maine, United States|The ICPS Group, Norwood, Massachusetts, United States|Memory Center of America, Long Beach, New Jersey, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Global Medical Institutes, Princeton, New Jersey, United States|Neurological Associates of Albany, P.C., Albany, New York, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|The Mount Sinai Medical Center, New York, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|The Neurological Institute, P.A., Charlotte, North Carolina, United States|MedArk, Morgantown, North Carolina, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|RI Mood and Memory Research Institute, East Providence, Rhode Island, United States|Todd Swick, MD, PA, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|University of Vermont, Burlington, Vermont, United States|The Glennan Center for Geriatrics & Gerontology, Eastern Virginia Medical School, Norfolk, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00672945
NCT00667810,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,,Terminated,Has Results,Alzheimer Disease,Drug: bapineuzumab|Drug: placebo,The Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)/11 Total Score at Week 78|The Change From Baseline in the Disability Assessment for Demential (DAD) Total Score at Week 78|The Change From Baseline in Brain Amyloid Burden at Week 71.|The Change From Baseline in Phospho-tau Levels in the Cerebrospinal Fluid (CSF) at Week 71.|The Change From Baseline in Brain Volume at Week 71|Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78|Divergence of Effect on the DAD Total Scores From Week 39 to Week 78|Time to Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)|Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)|Time to Median Placebo Deterioration on DAD Total Score|Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (European Union Analysis Plan)|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (European Union Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (US Analysis Plan)|Change From Baseline in Dependence Scale Total Score at Week 78|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78,Pfizer,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 3,901,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3133K1-3000|B2521001|2007-005994-79,Jun-08,Oct-12,Aug-13,28-Apr-08,8-Jan-16,8-Jan-16,"University of Alabama-Birmingham, Birmingham, Alabama, United States|Dedicated Clinical Research, Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Jeffrey S. Gitt, DO, PC, Phoenix, Arizona, United States|The Compounding Center (IP Mixing Only), Phoenix, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|ATP Clinical Research, Incorporated, Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Infusion Care Pharmacey, Laguna Hills, California, United States|Senior Clinical Trials, Incorporated, Laguna Hills, California, United States|Faculty Physicians and Surgeons of Loma Linda University School of Medicine, Loma Linda, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Collaborative Neuroscience Network, Inc., Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Coordinated Clinical Research, San Diego, California, United States|LabCorp, San Diego, California, United States|Sharp and Children's MRI Center, LLC, San Diego, California, United States|Sharp Infusion Therapy Center, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Associated Neurologists, PC, Boulder, Colorado, United States|The Mile High Research Center, Denver, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Bendheim Cancer Center, Greenwich, Connecticut, United States|Center for Healthy Aging, Greenwich, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Norman S. Werdiger, MD, New Haven, Connecticut, United States|Institutional Review Board / Ethics Committee, New Haven, Connecticut, United States|Yale PET Center, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|JEM Research Institute LLC, Atlantis, Florida, United States|Medical Specialists of the Palm Beaches, Atlantis, Florida, United States|Bradenton Research Center, Incorporated, Bradenton, Florida, United States|North Broward Medical Center, Deerfield Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Advanced Imaging, Ocala, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|South Bay Internal Medicine, Sun City, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|NeuroTrials Research, Incorporated, Atlanta, Georgia, United States|Columbus Diagnostic Center (MRI), Columbus, Georgia, United States|Medical Research and Health Education Foundation, Incorporated, Columbus, Georgia, United States|Dekalb Neurology Associates, LLC/NeuroStudies.net, LLC, Decatur, Georgia, United States|NeuroStudies.net, Decatur, Georgia, United States|Neurostudies.net, Lawerenceville, Georgia, United States|Neurostudies.net, Lawrenceville, Georgia, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Methodist Center for Senior Health, Peoria, Illinois, United States|Methodist Medical Center Research Department, Peoria, Illinois, United States|Methodist Diagnostic Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Psychology Associates, Mishawaka, Indiana, United States|KU - Wichita, Wichita, Kansas, United States|Drug Shipment/ Storage, Wichitia, Kansas, United States|Four Rivers Clinical Research, Incorporated, Paducah, Kentucky, United States|Radio Pharmacy, Paducah, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Research Associates Inc, New Orleans, Louisiana, United States|James Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Foers Medical Arts Pharmacy, Bethesda, Maryland, United States|CBH Health, LLC, Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Bringham and Women's Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|General Clinical Research Center, Boston, Massachusetts, United States|IDS Pharmacy, Boston, Massachusetts, United States|ActivMed Practices and Research, Inc., Haverhill, Massachusetts, United States|Neurocare, Incorporated, Newton, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|University of Michigan Hospital, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Michigan State University, Lansing, Michigan, United States|Marty's Pharmacy, Flowood, Mississippi, United States|Precise Research Centers, Flowood, Mississippi, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|Spectrum Home Solutions, Great Falls, Montana, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Memory Enhancement Center of New Jersey, Inc., Toms River, New Jersey, United States|Northeast Radiology, Brewster, New York, United States|Neurological Care of Central New York, Liverpool, New York, United States|AD-CARE, University of Rochester Medical Center, Rochester, New York, United States|University of Rochester/Strong Memorial Hospital, Rochester, New York, United States|Clinical Study Center of Asheville, LLC, Asheville, North Carolina, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Clinical Trials of America, Incorporated, Hickory, North Carolina, United States|The Compounding Pharmacy, Hickory, North Carolina, United States|Carolina Neuropsychological Services, Inc., Raleigh, North Carolina, United States|Healthsouth Blue Ridge Surgery Center, Raleigh, North Carolina, United States|Raleigh Neurology Associates, PA, Raleigh, North Carolina, United States|Wake Radiology Associates, Raleigh, North Carolina, United States|Ohio State University Imaging at Martha Morehouse, Columbus, Ohio, United States|The Ohio State University Hospitals Clinic, Columbus, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|Professional Corporation of Psychiatry, Oklahoma City, Oklahoma, United States|Red River Medical Recearch Center, LLC, Oklahoma City, Oklahoma, United States|Flourish Integrative Pharmacy, Oklahoma City, Oklahoma, United States|Providence Brain Institute, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Hospital of the University of Pennslyvania, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania (PET), Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Investigational New Drug Services, IDS Pharmacy, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|UPENN Clinical and Translational Research Center (CTRC), Philadelphia, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburgh, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Simpson's Pharmacy, Pawtucket, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Hospitals and Clinics, Charleston, South Carolina, United States|Medical University of South Carolina Investigational Drug Service, Charleston, South Carolina, United States|Radiant Research, Incorporated, Greer, South Carolina, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Austin Infusion Centers, Austin, Texas, United States|Senior Adults Specialty Research, Austin, Texas, United States|Texas Neurology, P.A., Dallas, Texas, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Vista Infusions, San Antonio, Texas, United States|Inventive Infusion Solutions, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Southwestern Vermont Healthcare, Bennington, Vermont, United States|The Memory Clinic, Bennington, Vermont, United States|University of Virginia Neurology, Charlottesville, Virginia, United States|University of Virginia General Clinical Research Center, Charlottesville, Virginia, United States|University of Viriginia Investigational Pharmacy, Charlottesville, Virginia, United States|Pacific Medical Centers, Bothell, Washington, United States|Pacific Medical Centers, Seattle, Washington, United States|Cemic University Hospital, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Gosford Hospital, Gosford, New South Wales, Australia|Hornsby Kuringai Hospital, Hornsby, New South Wales, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|CDAMS Ballarat Base Hospital, Ballarat, Victoria, Australia|Heidelberg Repatriation Hospital/ Medical and Cognitive Research Unit, West Heidelberg, Victoria, Australia|Hollywood Private Hospital, Nedlands, Western Australia, Australia|McCusker Alzheimer's Research Foundation Inc., Nedlands, Western Australia, Australia|Royal Adelaide Hospital, Adelaide SA, Australia|ZNA Middelheim / Neurologie, Antwerpen, Belgium|Az. St. Jan Ruddershove 35, Brugge, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|University Hospital Gathuisberg, Leuven, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|Centre for Memory and Aging, North York, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre de Recherche ADAPRA Inc., L'Ancienne-Lorette, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Recherche Clinique de Neurologie, Montreal, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|ALPHA Recherche Clinique, Quebec, Canada|Psicomedica Research Group, Santiago, Chile|Especialidades Medicas L&S, Santiago, Chile|Sestre milosrdnice Zagreb, Zagreb, Croatia|University Hospital Center Zagreb, Zagreb, Croatia|Ita-Suomen Yliopisto, Kuopio, Finland|Turku University Hospital, Turku, Finland|CHRU Hôtel Dieu, Rennes, Cedex, France|CHU Hopital Nord, Amiens, France|Hôpital Neurologique, Bron, France|CHU de Caen, Caen, France|Hôpitaux Civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|Hôpital Roger Salengro, Lille, France|Hopital Sainte Marguerite, Marseille, France|Hôpital la Timone, Marseille, France|CHU Hôpital Gui de Chaulliac, Montpellier, France|CHU Nord - Hôpital Guillaume et René Laënnec, Nantes - Saint Herblain, France|Hôpital Cimiez, Nice, France|Groupe Hospitalier Pitie-Salpetriere, Paris Cedex 13, France|Groupe Hospitalier Broca-La Rochefoucauld, Paris, France|CHU La Milétrie, Poitiers, France|C.H.U de Reims, Reims, France|CHU - Hopital Charles Nicolle, Rouen, France|Hôpital Purpan, Toulouse, France|CHU Purpan - Hôpital Casselardit, Toulouse, France|Klinik fur Psychiatrie und Psychotherapie, Berlin, Germany|St. Josef-Klinikum, Bochum, Germany|Ortenau Klinikum, Offenburg, Germany|Universitaet Regensburg, Regensburg, Germany|Universita Politecnica delle Marche, Ancona, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Unita' Operativa Complessa di Neurologia, Catania, Italy|CeSI (Centro di Scienze dell'invecchiamento) -, Chieti, Italy|Universita degli Studi di Firenze, Firenze, Italy|Ospedale S. Raffaele, Milano, Italy|Ospedale S. Raffaele, Milano, Italy|Fondazione IRCCS- Istituto Neurologico Carlo Besta, Milano, Italy|Azienda Ospedaliera S. Gerardo di Monza Università di Milano Bicocca, Monza, Italy|Ospedale S. Gerardo, Monza, Italy|Clinica Neurologica, Roma, Italy|Unita' Operativa C - Riabilitazione Neurologica, Roma, Italy|Universita degli Studi di Siena, Siena, Italy|Nagoya City University Hospital, Nagoya, Aichi,, Japan|Tokyo Metoropolitan Health and Med. Treatment Co. Ebara Hosp, Ota-ku, Tokyo, Japan|Yachiyo Hospital, Aichi, Japan|Kashiwado Hospital, Chiba, Japan|National Hospital Organization Chiba-East Hospital, Chiba, Japan|Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan|National Hospital Organization Kokura Medical Center, Fukuoka, Japan|Maebashi Red Cross Hospital, Gunma, Japan|Gunma University Hospital, Gunma, Japan|Shinozuka Hospital, Gunma, Japan|National Hospital Organization Hiroshima-nishi Medical Ctr., Hiroshima, Japan|Kobe University Hospital, Hyogo, Japan|Nishi-Kobe Medical Center, Hyogo, Japan|Kobe City Hospital Org Kobe City Medical Cente West Hp, Hyogo, Japan|Iwate Medical University Hospital, Iwate, Japan|Kagawa University Hospital, Kagawa, Japan|Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan|Yokohama City University Medical Center, Kanagawa, Japan|Shonan Atsugi Hospital, Kanagawa, Japan|Rakuwakai Otowa Hospital, Kyoto, Japan|National Hospital Organization Minami-Kyoto Hospital, Kyoto, Japan|National Hospital Organization Maizuru Medical Center, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|National Hospital Organization Niigata National Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Kansai Medical University Takii Hospital, Osaka, Japan|National HP.Org.Shizuoka Inst.Epilepsy,Neurological Disorder, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|National Hospital Organization Tokyo National Hospital, Tokyo, Japan|Seoul National University Bundang Hospital, Department of Psychiatry, Seongnam-si, Gyeonggi-do, Korea, Republic of|KonKuk University Hospital, Department of NeuroPsychiatry, Seoul, Korea, Republic of|OCA Hospital, Monterrey, Nuevo León, Mexico|Instituto Biomedico de Investigacion A.C, Aguascalientes, Mexico|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Kennemer Gasthuis, Haarlem, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Jeroen Bosch Ziekenhuis, s. Hertogenbosch, Netherlands|The Memory Clinic, Auckland, NZ, New Zealand|Signet Research, Christchurch, New Zealand|NZOZ Dom Suer Ryder, Pallmed Sp. z o.o., Bydgoszcz, Poland|NZOZ ""SYNAPSA"", ul. Niska 5/1, Kielce, Poland|Szpital Uniwersytecki w Krakowie,Oddzial Kliniczny Klinik Chorób Wewnetrznych, Krakow, Poland|NZOZ ""NEURO-KARD"" ""ILKOWSKI I PARTNERZY"" Spolka Partnerska Lekarzy, Poznan, Poland|Oddzial Neurologiczny i Udarowy Szpital Wolski im. dr Anny Gostynskiej,, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika, Warszawa, Poland|Hospital Fernando da Fonseca, Amadora, Portugal|Hospitais Da Universidade De Coimbra, Coimbra, Portugal|Hospital Santa Maria, Lisboa, Portugal|Interregional clinicodiagnostic center, Kazan, Russian Federation|Nizhny Novgorod regional clinical hospital n.a. N.A.Semashko, Nizhny Novgorod, Russian Federation|Saint-Petersburg State institution of healthcare, City geriatric medico-social center, Saint-Petersburg, Russian Federation|Saint Petersburg Psychoneurological Research Institute n.a. V.M.Bekhterev, Saint-Petersburg, Russian Federation|Saint-Petersburg Psychoneurological Research Institute n.a. V.M.Bekhterev, Saint-Petersburg, Russian Federation|Chair of nervous system diseases, Saint-Petersburg, Russian Federation|Klinicki centar Vojvodine, Novi Sad, Vojvodina, Serbia|Klinicki centar Srbije, Belgrade, Serbia|Klinicki centar Srbije, Beograd, Serbia|Clinical Centre Kragujevac, Kragujevac, Serbia|1. Neurologicka klinika, Bratislava, Slovakia|Psychiatricka ambulancia, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Neurologicka klinika, Martin, Slovakia|Psychiatricka nemocnica Michalovce, n.o., Michalovce, Slovakia|Vseobecna nemocnica Rimavska Sobota, Rimavska Sobota, Slovakia|Neurologicke oddelenie FNsP Zilina, Zilina, Slovakia|Boithuso Caregivers, Johannesburg, Gauteng, South Africa|The Osteoporosis and Memory Centre, Johannesburg, Gauteng, South Africa|Denmar Clinic, Pretoria, Gauteng, South Africa|St Augustine's Medical Centre 2, Durban, Kwa Zulu Natal, South Africa|Panorama Psychiatry and Memory Clinic, Panorama, Western Cape, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Mutua de Terrasa, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto, Plasencia, Caceres, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain|CLONUS, Palma de Mallorca, Islas Baleares, Spain|Hospital de Cruces, Baracaldo, Spain|Hospital del Mar, Barcelona, Spain|Fundació ACE Institut Catala de Neurociences Aplicades, Barcelona, Spain|Clínica CIMA, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Divino Valles, Burgos, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Skanes Universitetssjukhus, Neuropsykiatriska, Malmo, Sweden|PET center, Uppsala, Sweden|The clinic: Minnes- och geriatrikmottagningen, Uppsala, Sweden|MRI Dept: ORKI, Uppsala, Sweden|Memory Clinic Neuro-Psychologie Zentrum, Basel, BS, Switzerland|Hopitaux Universitaires de Geneve, Les Acacias, GE, Switzerland|CHUV Lausanne, Lausanne, VD, Switzerland|Hopitaux Universitaires de Geneve, Thonex-Geneva, Switzerland|MAC UK Neuroscience Ltd, Blackpool, Lancashire, United Kingdom|MAC UK Neuroscience, Ltd., Bradford, West Yorkshire, United Kingdom|Clinical Investigation and Research Unit (CIRU), Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|Dept. of Neurosciences Charing Cross Hospital, London, United Kingdom|Newcastle General Hospital, Newcastle upon Tyne, United Kingdom|Northampton General Hospital NHS Trust, Northampton, United Kingdom|Llandough Hospital, Penarth, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Grenoside Grange Hospital, Sheffield, United Kingdom|Kingshill Research Centre, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00667810
NCT00663936,Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: T-817MA|Drug: Placebo,"Evaluation of the efficacy of T-817MA in AD patients to treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive assessment.|Secondary objectives are to evaluate the safety of T-817MA and the activities of daily living (ADCS-ADL) of AD patients taking T-817MA, and to evaluate the efficacy of T-817MA in AD patients with an overall global assessment using the ADCS-CGIC.","FUJIFILM Toyama Chemical Co., Ltd.",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,373,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AA4437420,Apr-08,May-11,Jun-11,22-Apr-08,null,5-Nov-13,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Northwest NeuroSpecialists, Tucson, Arizona, United States|Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Southwest Institute for Clinical Research, Inc., Rancho Mirage, California, United States|Pacific Research Network, Inc., San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Radiant Research, Denver, Colorado, United States|Geriatric and Adult Psychiatry, LCC, Hamden, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|NeuroPsychiatric Center of the Palm Beaches, Boynton Beach, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Anchor Research Center, Naples, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Columbus Research & Wellness Institute, Columbus, Georgia, United States|Agewell, Indianapolis, Indiana, United States|Cleveland Clinic - Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Memory Enhancement Center of America, Toms River, New Jersey, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|SPRI Clinical Trials, Brooklyn, New York, United States|Alzheimer's Disease Center, U. of Rochester Medical Center, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|The Alzheimer's Memory Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Clinical Trials of America, Inc., Winston Salem, North Carolina, United States|The Clinical Trials Center, Jenkintown, Pennsylvania, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|Innovative Clinical Trials, San Antonio, Texas, United States|IPC Research, Waukesha, Wisconsin, United States|St. Joseph's Hospital, St. John, New Brunswick, Canada|Toronto Memory Program, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00663936
NCT00663026,Study Evaluating Bapineuzumab In Alzheimer Disease Subjects,,Completed,Has Results,Alzheimer Disease,Drug: bapineuzumab|Drug: placebo,"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Maximum Observed Serum Concentration (Cmax)|Average Serum Concentration at Steady State (Cavg,ss)|Serum Decay Half-Life (t1/2)|Time to Reach Maximum Observed Serum Concentration (Tmax)|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)|Apparent Systemic Clearance (CL/F)",Pfizer,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,79,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",3133L1-2203|B2521008,Nov-08,Oct-10,Oct-10,21-Apr-08,15-Nov-13,15-Nov-13,"Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Sun City, Arizona, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, Los Alamitos, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Delray Beach, Florida, United States|Pfizer Investigational Site, Hallandale, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Lawrenceville, Georgia, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, East Providence, Rhode Island, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Bennington, Vermont, United States|Pfizer Investigational Site, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00663026
NCT00657813,Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition,,Terminated,No Results Available,Alzheimer Disease,Drug: MNI-330 as a brain SPECT tracer of Beta-Amyloid,"The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, 123-I MNI-330.",Institute for Neurodegenerative Disorders|Molecular NeuroImaging,All,"50 Years and older   (Adult, Older Adult)",Phase 1,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,MNI-330-01,Mar-08,30-Sep-08,30-Sep-08,14-Apr-08,null,3-Apr-19,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00657813
NCT00658125,Deep Brain Stimulation (DBS) for Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer Disease,Procedure: Deep Brain Stimulation (Fornix DBS),memory performance on neuropsychological tests,"University Health Network, Toronto",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06-0095-B,Mar-07,Jun-10,Jun-10,14-Apr-08,null,8-Apr-10,"Toronto Western Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00658125
NCT00649220,Memantine and Antipsychotics Use,MemAP,Terminated,Has Results,Alzheimer's Disease,Drug: Memantine,"Maximum Dose Reduction of Antipsychotics (AP) in Percent of Defined Daily Dose (DDD) From Baseline to a Post-baseline Visit at Which the Value of the Visual Analogue Scale (VAS) Compared With the Baseline Value Was =< 15 Percent.|Reduction of Antipsychotic Drug Dose From Baseline to Week 8, 12, 16 and/or 20.|Change in the Mini-Mental State Examination (MMSE) Score Value From Baseline to Week 20.|Change of ""Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]"" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - First Part: Total Dementia|Change of ""Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]"" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - Second Part: Total Depression|Change of Modified Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADLB19) Score Value From Baseline to Week 4, 8, 12, 16, and/or 20.|Change of Nurses' Observation Scale for Geriatric Patients [NOSGER] Total Score Value From Baseline to Week 4, 8, 12, 16, and/or 20|Change in the VAS Score From Baseline to Week 8, 12, 16 and/or 20.",Merz Pharmaceuticals GmbH,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,19,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MRZ 90001-0716/1|2007-004489-41,Jul-08,May-09,Jun-09,1-Apr-08,13-Sep-11,26-Sep-11,"Alexianer Hospital, Krefeld, North-Rhine-Westphalia, Germany",,https://ClinicalTrials.gov/show/NCT00649220
NCT00646074,Self- Care TALK Study - Promoting Alzheimer's Disease (AD) Spousal Caregiver Health,,Completed,No Results Available,Caregiving,Behavioral: Self-Care Talk,"SF-36v2, PCS (perceived physical health), SF-36v2, MCS (perceived mental health)|M-CSI; modified (caregiver strain), SRAHP (self-efficacy for health), CES-D (depression)",University of Kansas|National Institutes of Health (NIH)|National Institute of Nursing Research (NINR)|University of Kansas Medical Center,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,46,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),1R21NR009560,Jul-06,Mar-08,Aug-08,28-Mar-08,null,7-Mar-12,,,https://ClinicalTrials.gov/show/NCT00646074
NCT00646269,Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease,ETNA3,Completed,No Results Available,Alzheimer's Disease,"Behavioral: Standard intervention protocol|Behavioral: Standard intervention protocol + Cognitive training therapy|Behavioral: Standard intervention protocol + Reminiscence therapy|Behavioral: Standard intervention protocol + ""Made-to-measure"" program",Proportion of progression to the severe stage of Alzheimer's disease (MMSE score of 15 or lower)|Cognitive abilities (ADAS-cog)|Functional abilities in activities of daily living (DAD scale)|Behavioural disturbance (NPI)|Apathy (Apathy Inventory)|Quality of life (Quol-AD)|Depression (MADRS),"University Hospital, Bordeaux|Caisse Nationale de Solidarité pour l'Autonomie|National Health Insurance Fund for Unemployed Workers|Direction Générale de la Santé, France|Institut National de la Santé Et de la Recherche Médicale, France|Université Victor Segalen Bordeaux 2",All,"50 Years and older   (Adult, Older Adult)",Phase 3,640,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2007/17,Mar-08,Dec-10,Dec-12,28-Mar-08,null,1-Aug-13,"CH Agen, Agen, France|CHU Amiens Nord, Amiens, France|Centre Mémoire de Ressources et de Recherches de Bordeaux, CHU de Bordeaux, Bordeaux, France|Hôpital Pellegrin, Bordeaux, France|CHU Côte de Nacre, Caen, France|Centre pour Personnes Agées, Colmar, France|Centre de Gériatrie, DAX, France|Hôpital Dupuytren, Draveil, France|Pôle de Gérontologie CHICAS, Gap, France|Les Fontaines de Monjous, Gradignan, France|CMRR & Neuropsychologie, Pavillon de Neurologie, CHU de Grenoble, Grenoble, France|Centre Hospitalier La Rochelle, La rochelle, France|Association AA83 Alzheimer Aidants Var Etablissement "" Les pensées "", La Seyne sur Mer, France|Centre Hospitalier de Libourne, Libourne, France|CHU Limoges, Limoges, France|Hôpital Privé Gériatrique Les Magnolias, Longjumeau, France|Centre Hospitalier Bretagne Sud, Lorient, France|Groupe Hospitalier Saint-Augustin, Malestroit, France|Hôpital Sainte-Marguerite, Marseille, France|Centre Antonin Balmes, Montpellier, France|Hôpital Gui de Chauliac, Montpellier, France|Clinique Neurologique, CHU Nord, Nantes, France|Centre Mémoire, Hôpital Pasteur,, Nice, France|Hôpital Broca, Paris, France|Hôpital de la Salpétrière,, Paris, France|Centre Hospitalier des Pyrénées, Pau, France|Hôpital de Jour Gériatrique, Pau, France|Hôpital Xavier-Arnozan, Pessac, France|CHI Poissy-saint-germain-en-laye, Poissy, France|Hôpital de Jour gériatrique, Poitiers, France|CHU de Rennes, Rennes, France|Hôpital de Jour Gériatrique, Saint Raphaël, France|CHRU de Saint-Etienne, Saint-Etienne, France|Centre hospitalier Ariège Couserans, Saint-Girons, France|Hôpitaux universitaires de Strasbourg, Strasbourg, France|Bagatelle, Talence, France|CHIC Marmande - Tonneins, Tonneins, France|CHU Purpan-Casselardit, Toulouse, France|Hôpital des Charpennes, Villeurbanne, France",,https://ClinicalTrials.gov/show/NCT00646269
NCT00645190,"A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease",,Completed,No Results Available,Alzheimer Disease,Drug: Galantamine HBr,"Primary endpoint (ADAS-cog/11) decreased 5.4 ± 6.4 and 4 .0 ± 7.3 in galantamine and Donepezil group respectively after 16-week treatment from baseline of 22.5 ± 9.3 and 23.3 ± 9.7 respectively, showing the non-inferiority in term of efficacy.|Secondary endpoint is responder rate. It showed 78% responder rate in galantamine group and 58% responder rate in Donepezil group after 16 weeks.",Xian-Janssen Pharmaceutical Ltd.,All,"40 Years and older   (Adult, Older Adult)",Phase 3,215,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CR005803,Mar-04,null,Feb-05,27-Mar-08,null,19-May-11,,,https://ClinicalTrials.gov/show/NCT00645190
NCT00637442,Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD),CASL-AD-01,Unknown status,No Results Available,Alzheimer's Disease,Drug: Reminyl retard,"Cerebral perfusion|Change of Alzheimer Disease Assessment Scale, cognitive part (ADAScog)|Alzheimer's Disease Functional Assessment and Change Scale (ADFACS)|Neuropsychiatric Inventory (NPI)|Mini-Mental-Status-Examination (MMSE)","University Hospital, Bonn|Federal Ministry of Health, Germany",All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,University Bonn,Feb-08,Dec-10,null,18-Mar-08,null,9-Nov-10,"Department of Psychiatry, University Bonn, Bonn, Germany",,https://ClinicalTrials.gov/show/NCT00637442
NCT00633841,Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Biological: AFFITOPE AD02,Tolerability|Immunological and clinical efficacy (evaluated in explorative manner),Affiris AG,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Affiris 002,Feb-08,Sep-09,Sep-09,12-Mar-08,null,19-Oct-10,"Ordination Univ. Doz. Dr. Margot Schmitz, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT00633841
NCT00630500,Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB),MEMPDD,Completed,No Results Available,Dementia Associated With Parkinson's Disease|Dementia With Lewy Bodies,Drug: Memantine|Drug: Placebo,"Clinical Global Impression of Change|MMSE|Alzheimer's QUick Test|Cognitive Drug Research test|Neuropsychiatric Inventory|Unified Parkinson's Disease Rating Scale, part III|Epworth Sleep Scale|Stavanger Sleep Scale",Helse Stavanger HF|King's College London|Lund University,All,"Child, Adult, Older Adult",Phase 2,75,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MEMPDD-130206,Feb-06,Feb-09,Mar-09,7-Mar-08,null,28-Jul-15,"Stavanger University Hospital, Old Age Psychiatry Clinic, Stavanger, Norway|Clinical Memory Research Unit, Neuropsychiatric Clinic, University Hospital Malmo, Malmo, Sweden|Mental Health Unit, Epping, Essex, United Kingdom|King's COllege London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00630500
NCT00630851,A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes,,Completed,No Results Available,Alzheimer Disease,Drug: Donepezil (Aricept)|Drug: Placebo,Change from baseline in modified Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory for Severe Alzheimer's Disease (ADCS-ADL-severe) total score|Change from baseline in Severe Impairment Battery (SIB) total score|Change from baseline in SIB total score|Change from baseline in Neuropsychiatric Inventory (NPI) total score|Change from inclusion in Mini Mental State Examination (MMSE) total score|Change from baseline in Clinical Global Impression of Improvement (CGI-I) score|Adverse events and laboratory value changes|Change from baseline in modified ADCS-ADL-severe total score,Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 3,249,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A2501017,Oct-02,null,Oct-04,7-Mar-08,null,5-Mar-15,"Pfizer Investigational Site, Akersberga, Sweden|Pfizer Investigational Site, Alunda, Sweden|Pfizer Investigational Site, Aneby, Sweden|Pfizer Investigational Site, Arsta, Sweden|Pfizer Investigational Site, Avesta, Sweden|Pfizer Investigational Site, Bengtsfors, Sweden|Pfizer Investigational Site, Bergsjo, Sweden|Pfizer Investigational Site, Boden, Sweden|Pfizer Investigational Site, Borlange, Sweden|Pfizer Investigational Site, Degerfors, Sweden|Pfizer Investigational Site, Eskilstuna, Sweden|Pfizer Investigational Site, Eskilstuna, Sweden|Pfizer Investigational Site, Fritsla, Sweden|Pfizer Investigational Site, Gislaved, Sweden|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Gullspang, Sweden|Pfizer Investigational Site, Gustavsberg, Sweden|Pfizer Investigational Site, Hedemora, Sweden|Pfizer Investigational Site, Helsingborg, Sweden|Pfizer Investigational Site, Ingelstad, Sweden|Pfizer Investigational Site, Jönköping, Sweden|Pfizer Investigational Site, Kalix, Sweden|Pfizer Investigational Site, Karlstad, Sweden|Pfizer Investigational Site, Katrineholm, Sweden|Pfizer Investigational Site, Kristinehamn, Sweden|Pfizer Investigational Site, Lidkoping, Sweden|Pfizer Investigational Site, Malmo, Sweden|Pfizer Investigational Site, Munkfors, Sweden|Pfizer Investigational Site, Nassjo, Sweden|Pfizer Investigational Site, Ostersund, Sweden|Pfizer Investigational Site, Oxie, Sweden|Pfizer Investigational Site, Partille, Sweden|Pfizer Investigational Site, Rattvik, Sweden|Pfizer Investigational Site, Sandviken, Sweden|Pfizer Investigational Site, Saro, Sweden|Pfizer Investigational Site, Sjuntorp, Sweden|Pfizer Investigational Site, Sollebrunn, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Sunne, Sweden|Pfizer Investigational Site, Trollhattan, Sweden|Pfizer Investigational Site, Tullinge, Sweden|Pfizer Investigational Site, Tyreso, Sweden|Pfizer Investigational Site, Umeå, Sweden|Pfizer Investigational Site, Upplands Väsby, Sweden|Pfizer Investigational Site, Uppsala, Sweden|Pfizer Investigational Site, Varnamo, Sweden|Pfizer Investigational Site, Vaxjo, Sweden|Pfizer Investigational Site, Visby, Sweden|Pfizer Investigational Site, Vännäs, Sweden|Pfizer Investigational Site, Västerås, Sweden|Pfizer Investigational Site, Växjö, Sweden|Pfizer Investigational Site",,https://ClinicalTrials.gov/show/NCT00630851
NCT00628017,Preliminary Study of Fish Oil and Dementia,,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Dietary Supplement: omega-3 polyunsaturated fatty acids ( EPA+DHA),the Clinician's Interview-Based Impression of Change Scale (CIBIC-plus)|the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog)|Mini Mental Status Examination (MMSE) scores|17-item Hamilton Depression Scale (HDRS)|adverse events,"Taipei City Psychiatric Center, Taiwan|Department of Health, Executive Yuan, R.O.C. (Taiwan)",All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DOH-92-TD-1095,Jan-03,Mar-05,Mar-05,4-Mar-08,null,4-Mar-08,"Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00628017
NCT00627848,"Rivastigmine in Mild Alzheimer's Disease, FMRI Study",ADFRMI,Completed,No Results Available,Alzheimer' Disease,Drug: rivastigmine,FMRI response in face recognition task|treatment response measured by ADAS-cog,Kuopio University Hospital,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",KUH5772749,Mar-07,Dec-08,Dec-08,3-Mar-08,null,28-Oct-11,"Kuopio University Hospital, Kuopio, Finland",,https://ClinicalTrials.gov/show/NCT00627848
NCT00626210,Modafinil Treatment for Sleep/Wake Disturbances in Older Adults,,Terminated,Has Results,Insomnia|Sleep Initiation and Maintenance Disorders|Alzheimer Disease,Drug: modafinil,Nocturnal Sleep Length at 1 Month|Improvement of Daytime Alertness and Quality of Life.,VA Palo Alto Health Care System,All,"50 Years and older   (Adult, Older Adult)",Phase 4,2,U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8564,Feb-08,Apr-11,Oct-12,29-Feb-08,30-Oct-14,29-Jan-18,"VA Palo Alto Health Care System, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT00626210
NCT00627029,Evaluation of Programs of Coordinated Care and Disease Management,Coca,Unknown status,No Results Available,Congestive Heart Failure|Diabetes|Coronary Artery Disease|Chronic Obstructive Pulmonary Disease|Cancer|Cerebrovascular Disease|Alzheimer's Disease|Psychotic Disorder|Major Depression,Behavioral: Care Coordination,Medicare program expenditures|Claims-based and patient-reported quality of care,"Mathematica Policy Research, Inc.|Centers for Medicare and Medicaid Services",All,"Child, Adult, Older Adult",Not Applicable,18277,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,MPR 8756|CMS 500-95-0047(09,Sep-00,Aug-15,Dec-16,29-Feb-08,null,1-Oct-15,"Hospice of the Valley MediCaring Project, Phoenix, Arizona, United States|Georgetown University Medical Center-Mind My Heart Program, Washington, District of Columbia, United States|Quality Oncology/Matria Healthcare, Sunrise, Florida, United States|CorSolutions/Matria Healthcare, Rosemont, Illinois, United States|Carle Foundation and Hospital, Urbana, Illinois, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Medical Care Development, Augusta, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Charlestown/Erickson Retirement Communities, Catonsville, Maryland, United States|Washington University-St.Louis School of Medicine/Barnes-Jewish Hospital, St. Louis, Missouri, United States|QMed, Inc., Eatontown, New Jersey, United States|Lovelace Health Systems, Albuquerque, New Mexico, United States|Jewish Home Lifecare, New York, New York, United States|Avera McKennan Hospital and University Health Center, Sioux Falls, South Dakota, United States|CenVaNet, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00627029
NCT00624026,Memantine - Communication Study,,Completed,No Results Available,Alzheimer's Disease,Drug: Memantine-HCl,To assess the efficacy of the memantine OD IR treatment using the Consortium to establish a registry for Alzheimer's Disease (CERAD-NP) total score,Merz Pharmaceuticals GmbH,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,107,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MRZ 90001-0608/1,Nov-07,Dec-08,Dec-08,26-Feb-08,null,1-Nov-11,"Central Medical Affairs, Frankfurt/Main, Germany",,https://ClinicalTrials.gov/show/NCT00624026
NCT00622713,"A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)",EXTRA,Completed,Has Results,Alzheimer's Disease,Drug: Rivastigmine transdermal patch,Percentage of Patients Who Achieved and Maintained the Maximum Dose of 10 cm^2 Rivastigmine Patch for at Least 8 Weeks During 24 Weeks Study|Clinical Global Impression of Change (CGI-C) by Physician|Mean Change From Baseline to Week 24 in the 4-item Instrumental Activities of Daily Living (4-IADL) Score|Mean Change From Baseline to Week 24 in the Mini-Mental State Examination (MMSE) Score|Mean Change From Baseline to Week 24 in the Mini-Zarit Inventory Score,Novartis,All,"50 Years and older   (Adult, Older Adult)",Phase 4,228,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713DFR08|N° EudraCT : 2007-003405-27,Jan-08,Jan-09,Jan-09,25-Feb-08,26-Jul-11,26-Jul-11,"Novartis Investigative Site, Rueil-Malmaison, France",,https://ClinicalTrials.gov/show/NCT00622713
NCT00621010,Safety Study of CTS21166 to Treat Alzheimer Disease,CTS,Completed,No Results Available,Alzheimer's Disease,Drug: CTS21166 (ZPQ-21166),To evaluate the safety and tolerability of single ascending doses of CTS21166 following intravenous administration|To evaluate the pharmacokinetics(PK) of CTS21166 and its major metabolites as assessed in plasma,CoMentis,Male,"22 Years and older   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,Primary Purpose: Treatment,CTS21166-101,Jun-07,Feb-08,Feb-08,22-Feb-08,null,9-Jul-08,"Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00621010
NCT00621647,Seroquel- Agitation Associated With Dementia,,Completed,No Results Available,Alzheimer's Disease|Vascular Dementia,Drug: Quetiapine Fumarate|Drug: Placebo,To assess the efficacy of 2 fixed doses of quetiapine compared with placebo|To assess the efficacy of quetiapine compared with placebo,AstraZeneca,All,"55 Years and older   (Adult, Older Adult)",Phase 3,333,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",5077US/0046|D1446L00002,Sep-02,Nov-03,Nov-03,22-Feb-08,null,25-Mar-09,,,https://ClinicalTrials.gov/show/NCT00621647
NCT00620191,Metformin in Amnestic Mild Cognitive Impairment,MCI,Completed,No Results Available,Amnestic Mild Cognitive Impairment,Drug: metformin|Drug: placebo,Total Recall in the Selective Reminding Test|ADAS-cog|rCMRgl in the posterior cingulate-precuneus.,Columbia University|Institute for the Study of Aging (ISOA)|National Institute on Aging (NIA),All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,80,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",AAAC7231|R0153596,Feb-08,Feb-12,Feb-12,21-Feb-08,null,14-Mar-13,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00620191
NCT00612872,Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects,CLINDE,Terminated,No Results Available,Parkinson Disease|Alzheimer Disease|Healthy Controls|Multiple Sclerosis,Drug: [123I]CLINDE,"To assess the dynamic uptake and washout of 123-I CLINDE, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and subjects with Alzheimer (AD) or Parkinson disease (PD).",Institute for Neurodegenerative Disorders,All,30 Years to 50 Years   (Adult),Phase 1,46,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"CLINDE 001|IND 100,863",Jan-08,1-Nov-09,1-Nov-09,12-Feb-08,null,3-Apr-19,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00612872
NCT00611312,Effects of Delivery Mode of Cognition Intervention in Early Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Behavioral: Cognitive Training,"Composite score of 5 cognitive tests including 1)WAIS digit span, 2) word fluency, 3) trail making test-A 4) Rey Osterrieth complex figure and 5) MMSE|Brain activity during functional brain imaging",University of Kansas|Alzheimer's Association|University of Kansas Medical Center,All,"60 Years and older   (Adult, Older Adult)",Phase 2,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IIRG-07-57789|11008,Feb-08,May-12,Sep-12,8-Feb-08,null,3-Oct-12,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00611312
NCT00608946,Treatment With Copper in Patients With Mild Alzheimer´s Dementia,,Completed,No Results Available,Alzheimer´s Disease,Dietary Supplement: copper|Dietary Supplement: placebo,"change of cognitive function, measured by ADAS-cog|change of beta amyloid in the CSF and volumetric changes in the brain","University Hospital, Saarland|University of Goettingen, Section Neurobiology (Head: Prof. Dr. T. Bayer), Germany",All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,68,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UKS-PSY-DEM-01,Mar-04,Aug-07,null,6-Feb-08,null,6-Feb-08,,,https://ClinicalTrials.gov/show/NCT00608946
NCT00607308,"A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Biological: PF-04360365|Drug: Placebo,"To examine the safety and tolerability of a single dose of PF-04360365 in Japanese subjects with mild to moderate AD for one year following dosing.|To characterize the pharmacokinetic, pharmacodynamic and immunogenicity profile of PF-04360365 for one year following dosing.",Pfizer,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",A9951005,Feb-08,Oct-10,Oct-10,5-Feb-08,null,7-Dec-10,"Pfizer Investigational Site, Hirosaki, Aomori, Japan|Pfizer Investigational Site, Fukuoka-shi, Fukuoka, Japan|Pfizer Investigational Site, Fukuyama city, Hiroshima, Japan|Pfizer Investigational Site, Tsukuba, Ibaraki, Japan|Pfizer Investigational Site, Niigata-shi, Niigata, Japan|Pfizer Investigational Site, Bunkyo-ku, Tokyo, Japan|Pfizer Investigational Site, Kodaira, Tokyo, Japan|Pfizer Investigational Site, Kanazawa, Japan|Pfizer Investigational Site, Kyoto, Japan",,https://ClinicalTrials.gov/show/NCT00607308
NCT00606476,"AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease",,Terminated,No Results Available,Alzheimer's Disease,Drug: Bapineuzumab (AAB-001),To assess the safety and tolerability of long-term treatment of bapineuzumab in subjects with AD.|To evaluate the efficacy of long-term treatment of bapineuzumab in subjects with AD.,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",All,"Child, Adult, Older Adult",Phase 2,194,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),AAB-001-251,Dec-06,Sep-12,Sep-12,4-Feb-08,null,25-Nov-13,"Janssen AI Investigational Site, Peoria, Arizona, United States|Janssen AI Investigational Site, Sun City, Arizona, United States|Janssen AI Investigational Site, Encino, California, United States|Janssen AI Investigational Site, Irvine, California, United States|Janssen AI Investigational Site, La Jolla, California, United States|Janssen AI Investigational Site, Los Alamitos, California, United States|Janssen AI Investigational Site, Sacramento, California, United States|Janssen AI Investigational Site, San Francisco, California, United States|Janssen AI Investigational Site, New Haven, Connecticut, United States|Janssen AI Investigational Site, Washington, District of Columbia, United States|Janssen AI Investigational Site, Delray Beach, Florida, United States|Janssen AI Investigational Site, Jacksonville, Florida, United States|Janssen AI Investigational Site, Chicago, Illinois, United States|Janssen AI Investigational Site, Indianapolis, Indiana, United States|Janssen AI Investigational Site, Boston, Massachusetts, United States|Janssen AI Investigational Site, Ann Arbor, Michigan, United States|Janssen AI Investigational Site, Rochester, Minnesota, United States|Janssen AI Investigational Site, St. Louis, Missouri, United States|Janssen AI Investigational Site, Eatontown, New Jersey, United States|Janssen AI Investigational Site, New York City, New York, United States|Janssen AI Investigational Site, Rochester, New York, United States|Janssen AI Investigational Site, Durham, North Carolina, United States|Janssen AI Investigational Site, Portland, Oregon, United States|Janssen AI Investigational Site, PIttsburgh, Pennsylvania, United States|Janssen AI Investigational Site, Providence, Rhode Island, United States|Janssen AI Investigational Site, Dallas, Texas, United States|Janssen AI Investigational Site, Houstan, Texas, United States|Janssen AI Investigational Site, Bennington, Vermont, United States|Janssen AI Investigational Site, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00606476
NCT00606164,"Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease",,Unknown status,No Results Available,Alzheimer's Disease,Drug: Bryostatin for Injection|Drug: Placebo,Adverse Events|Alzheimer's Disease Assessment Scale|Clinician's Interview Based Impression of Change|Clinical Dementia Rating Battery|Alzheimer's Disease Cooperative Study - Activities of Daily Living|Severe Impairment Battery|Hopkins Verbal Learning Test-Revised|Temperature|Respiratory rate|Blood pressure|Heart rate|Electrocardiogram|Physical Exam|Hematology|Blood chemistry|Urinalysis|Pharmacokinetics|Protein kinase C activity (pharmacodynamics),Blanchette Rockefeller Neurosciences Insitute,All,"50 Years and older   (Adult, Older Adult)",Phase 2,9,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BRY-201,Apr-08,Dec-08,Dec-08,1-Feb-08,null,1-Feb-08,"Chestnut Ridge Center West Virginia University Department of Behavioral Medicine and Psychiatry, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00606164
NCT00605046,Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects,AV151,Terminated,No Results Available,Alzheimer Disease,Drug: SPECT scan,AV151-01: Evaluation of [123I] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects,Institute for Neurodegenerative Disorders,All,"50 Years and older   (Adult, Older Adult)",Phase 1,1,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,AV151,Aug-07,Jun-08,Jun-08,30-Jan-08,null,6-Oct-10,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00605046
NCT00605059,Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects,AV94,Terminated,No Results Available,Alzheimer Disease,Drug: [123I]AV94,"To assess the dynamic uptake and washout of 123-I AV94, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects|To perform blood metabolite characterization of 123-I AV94 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of 123-I AV94 as a single photon computed tomography (SPECT) brain imaging agent|Evaluate the test/retest reproducibility of 123-I AV94 and SPECT in AD subjects and healthy controls",Institute for Neurodegenerative Disorders,All,"50 Years and older   (Adult, Older Adult)",Phase 1,3,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AV94,Aug-07,Jun-08,Jun-08,30-Jan-08,null,6-Oct-10,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00605059
NCT00602680,Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: SSR180711C|Drug: donepezil|Drug: placebo,"Change in cognitive performance|Cognitive, global, functional and behaviorial assessments",Sanofi,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PDY10400|SSR180711|EudraCT 2007-001639-80,Jan-08,Jul-08,Jul-08,28-Jan-08,null,20-Jul-09,"Sanofi-Aventis Administrative Office, Paris, France",,https://ClinicalTrials.gov/show/NCT00602680
NCT00599469,Far Infrared Treatment for Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer Disease,Radiation: Far Infrared Radiation (5μm to 20μm wavelength),Management and Cure of Alzheimer's Disease|Management and Cure of Dementia,GAAD Medical Research Institute Inc.,All,"Child, Adult, Older Adult",Phase 1,4,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GAAD-AD-CTP1,Feb-08,Mar-09,Apr-09,23-Jan-08,null,17-Aug-09,"The Centre for Incurable Diseases, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00599469
NCT00597376,Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints,,Completed,Has Results,Subjective Memory Loss in Older Persons,Other: Cerefolin NAC (a medical food)|Other: Cerefolin NAC placebo,"Six Month Blood Levels of Homocysteine, Glutathione, and the Ratio of Aβ42 to Aβ40 (as a Percent of Baseline Levels) After Daily Intake of Cerefolin NAC Plus a Multivitamin Versus a Multivitamin Only|Tolerability of Cerefolin NAC and a Multivitamin Versus a Multivitamin Only|Six Month Levels of Inflammation and Oxidative Stress Markers(as a Percent of Baseline Levels) After Daily Treatment With Cerefolin NAC and a Multivitamin or a Multivitamin Only","Rush University Medical Center|Pamlab, Inc.",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,104,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Pamlab-Cerefolin NAC-001-01,Nov-07,May-11,May-11,18-Jan-08,23-May-13,23-May-13,"Rush Alzheimer's Disease Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00597376
NCT00596024,Lutein and Alzheimer's Disease Study,LAD,Unknown status,No Results Available,Alzheimer's Disease,Dietary Supplement: lutein/zeaxanthin|Dietary Supplement: placebo,oxidative damage markers,Oregon Health and Science University|Oregon Partnership for Alzheimer's Research,All,"55 Years and older   (Adult, Older Adult)",Phase 2,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",LAD|Alzheimer research fund,Dec-07,Dec-08,null,16-Jan-08,null,16-Jan-08,"Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00596024
NCT00596284,Cognitive Behavior Therapy for Treating Anxiety in People With Dementia,,Completed,No Results Available,Anxiety Disorders|Dementia,Behavioral: Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Behavioral: Enhanced Usual Care (EUC),Rating Anxiety in Dementia (RAID) and Neuropsychiatric Inventory (NPI)- Anxiety subscales|Quality of Life in Alzheimer's Disease (QOL-AD)|Geriatric Depression Scale (GDS)|Penn State Worry Questionnaire (PSWQ)|Geriatric Anxiety Inventory (GAI),Baylor College of Medicine|National Institute of Mental Health (NIMH),All,"50 Years and older   (Adult, Older Adult)",Phase 1,34,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R34MH078925|DATR A4-GPS,Jan-08,Jun-10,Jun-10,16-Jan-08,null,13-Aug-15,"Baylor College of Medicine, Houston, Texas, United States|Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00596284
NCT00593372,Treatment of Language and Memory in Patients With Alzheimer's Disease,,Completed,Has Results,Alzheimer Disease,Behavioral: Spaced Retrieval Training,Number of Successful Memory Tasks Completed Over Study Period.|Change on Mini-Mental State Examination,University of Arkansas,All,"21 Years and older   (Adult, Older Adult)",Phase 1,11,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,g1-10532-03-07,Aug-03,Apr-10,Apr-10,15-Jan-08,20-Jul-10,9-Jan-17,"UAMS Medical Center, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT00593372
NCT00594568,Effect of LY450139 on the Long Term Progression of Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: LY450139|Drug: Placebo,Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 76 Weeks|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 16 Weeks After Cessation of Study Drug|Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks|Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks|Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks|Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks|Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks|LY450139 Population Pharmacokinetics: Clearance of LY450139|LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 76 Weeks|Change From Baseline in Mini Mental State Examination (MMSE) Score at 76 Weeks|Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 76 Weeks|Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 76 Weeks|Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 76 Weeks|Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) up to 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 16 Weeks After Cessation of Study Drug|Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in Mini Mental State Examination (MMSE) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks|Change From Baseline in Phosphorylated-Tau (P-Tau) Concentration in Spinal Fluid,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1537,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",7666|H6L-MC-LFAN|CTRI/2009/091/000090,Mar-08,May-11,May-11,15-Jan-08,25-Sep-14,17-Mar-15,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lomita, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sacramento, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooksville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Lauderdale, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pompano Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Petersburg, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunrise, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa Bay, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Yarmouth, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jenkintown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Providence, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hornsby, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Randwick, Sydney, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adelaide, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Geelong, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg West, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kew, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalst, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antwerp, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brugge, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Penticton, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antofagasta, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concepcion, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago De Chile, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valdivia, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vina Del Mar, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobenhavn, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roskilde, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Svendborg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuopio, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mikkeli, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rouen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goettingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muenchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chennai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabaad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkatta, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thiruvananthapuram, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tirupati, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Varanasi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashkelon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beer Sheva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukui, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdynia, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellair, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellville, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cape Town, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-",,
NCT00592943,PET Study Examining the Dopaminergic Activity of Armodafinil in Adults,,Completed,Has Results,Healthy,Drug: armodafinil,Armodafinil DAT Occupancy in Caudate|Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (With Outlier)|Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (Without Outlier),Massachusetts General Hospital,All,18 Years to 35 Years   (Adult),Phase 1|Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),2007-P-001659,Oct-07,May-08,May-10,14-Jan-08,10-Jun-11,13-Nov-13,"Massachusetts General Hospital, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00592943
NCT00593138,Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate,,Completed,No Results Available,Drug Binding to DAT Receptors,Drug: dex-methylphenidate,DAT occupancy from PET scan results,Massachusetts General Hospital,All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,23,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2006-p-001610,Dec-06,Dec-07,Dec-09,14-Jan-08,null,22-Oct-13,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00593138
NCT00586430,The Impact of Lorazepam on Cognition in APOE e4 Carriers,,Completed,No Results Available,Alzheimer's Disease,Drug: lorazepam|Drug: placebo,Groton Maze Learning Task|Auditory Verbal Learning Test|1-back test,Mayo Clinic|National Institute of Mental Health (NIMH),All,"50 Years to 65 Years   (Adult, Older Adult)",Not Applicable,36,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Screening",929-05,Dec-05,Jul-07,Jul-07,4-Jan-08,null,4-Jan-08,"Mayo Clinic, Scottsdale, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00586430
NCT00581867,Memory and Insulin in Early Alzheimer's Disease,MAIN,Completed,Has Results,Alzheimer's Disease,Drug: Insulin Aspart|Drug: Placebo,fMRI Measure of Hippocampal Activation|Global Cognition,"Jeff Burns, MD|University of Kansas Medical Center",All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,31,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",10896,Oct-07,May-12,May-12,28-Dec-07,14-Jul-15,14-Jul-15,"University of Kansas Medical Center, Hoglund Brain Imaging Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00581867
NCT00582855,Effect of AQW051 in Patients With Memory Impairment,,Terminated,No Results Available,Mild Alzheimer's Disease|Amnestic Mild Cognitive Impairment,Drug: AQW051|Drug: Placebo,"Validated computerized cognitive assessment scores|Validated computerized cognitive assessment scores, the different scores from the Alzheimer's Disease Assessment Score-cognitive subscale (ADAS-Cog), Quality of Life-Alzheimer disease scale and the Disability Assessment for Dementia scale",Novartis Pharmaceuticals|Novartis,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,54,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CAQW051A2104,Dec-07,Feb-09,null,28-Dec-07,null,19-Apr-16,"Novartis Investigator Site, Halifax, Canada|Novartis Investigator Site, Montreal, Canada|Novartis Investigator Site, Toronto, Canada|Novartis Investigator Site, Bloemfontein, South Africa|Novartis Investigator Site, George, South Africa|Novartis Investigator Site, Port Elizabeth, South Africa|Novartis Investigator Site, Blackpool, United Kingdom|Novartis Investigator Site, Epping, United Kingdom|Novartis Investigator Site, Glasgow, United Kingdom|Novartis Investigator Site, Manchester, United Kingdom|Novartis Investigator Site, Southampton, United Kingdom|Novartis Investigator Site, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00582855
NCT00580931,Safety Study of Nicotinamide to Treat Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Nicotinamide|Drug: Enduramide placebo,Alzheimer's Disease Assessment Scale-Cognitive Subscale,"University of California, Irvine|Alzheimer's Association",All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 1|Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IIRG-07-61197,Jan-08,Jul-14,Jul-14,27-Dec-07,null,25-Jan-17,"UC Irvine School of Medicine, Irvine, California, United States",,https://ClinicalTrials.gov/show/NCT00580931
NCT00574132,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),,Completed,No Results Available,Alzheimer's Disease,Drug: Bapineuzumab 0.5 mg/kg|Drug: Placebo Control|Drug: Bapineuzumab 1.0 m/kg,Cognitive and Functional|Cognitive and Global|Imaging and biochemical biomarkers of disease status,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer",All,"50 Years to 88 Years   (Adult, Older Adult)",Phase 3,1331,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ELN115727-301,Dec-07,Jun-12,Jun-12,17-Dec-07,null,25-Nov-13,"University of Alabama Hospital (UAB), Birmingham, Alabama, United States|Dedicated Clinical Research, Inc., Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|HOPE Research Institute, LLC, Phoenix, Arizona, United States|Banner Research Institute, Sun City, Arizona, United States|University of Arizona College of Medicine, Health Science Center, Tucson, Arizona, United States|Northwest Neurospecialists, PLLC, Tucson, Arizona, United States|Clinical Trials Inc., Little Rock, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|AVI Clinical Research, Carson, California, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Integrated Medical and Behavioral Associates, Glendale, California, United States|Sun Valley Behavioral Medical Center, Imperial, California, United States|Coordinated Clinical Research, La Jolla, California, United States|University of California San Diego/Shela Marcos Alzheimer's Disease Research Center, La Jolla, California, United States|Senior Clinical Trials, Laguna Hills, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Vintage Institute for Clinical Research, Inc, Los Angeles, California, United States|UCLA Department of Neurology, Los Angeles, California, United States|Synergy Research, National City, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|The Neurology Center, Oceanside, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|The Southwest Institute for Clinical Research, Inc., Rancho Mirage, California, United States|Sutter Neuroscience Medical Group, Sacramento, California, United States|University of California, Davis, Alzheimer's Disease Center, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Diablo Clinical Research, Inc, Walnut Creek, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|JEM Research, LLC, Atlantis, Florida, United States|Bradenton Research Center, Inc, Bradenton, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|Clinical Physiology Associates, Inc., Fort Myers, Florida, United States|Emerald Coast Mood & Memory, PA., Fort Walton Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Ft. Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Sunrise Clinical Research, Inc., Hollywood, Florida, United States|Mayo Clinic College of Medicine, Jacksonville, Florida, United States|Neurology Associates, Maitland, Florida, United States|Melbourne International Medicine Associates, MIMA, Melbourne, Florida, United States|Pharmax Research Clinic, LLC, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Allied Clinical Trials, Inc., Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center/Advanced Research Consultants, Palm Beach Gardens, Florida, United States|Broward Research Group, Inc., Pembroke Pines, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Suncoast Neuroscience Associates, Inc., St Petersburg, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University/School of Medicine, Atlanta, Georgia, United States|MS Center of Atlanta, Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Medical Research and Health Education Foundation, Inc., Columbus, Georgia, United States|Dekalb Neurology Associates, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Kansas Multi-Specialist Group, Kansas City, Kansas, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mid America Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Research Associates, Inc., New Orleans, Louisiana, United States|Louisana State University Health Sciences Center, Shreveport, Louisiana, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Maine Medical Partners Neurology, Scarborough, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|CBH Health, LLC, Rockville, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|ActivMed Practices and Research, Inc, Haverhill, Massachusetts, United States|Neurocare, Inc., Newton, Massachusetts, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Donald S. Marks, MD, P.C., Plymouth, Massachusetts, United States|Memory Wellness Clinic, Springfield, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Coastal Research Associates, Inc., Weymouth, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Borgess Medical Center/Borgess Research Institute, Kalamazoo, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Precise Research Centers, Flowood, Mississippi, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Saint Luke's Hospital, Mid America Brain and Stroke Institute, Kansas City, Missouri, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|St. Louis University School of Medicine, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Deaconess Billings Clinical Research Center, Billings, Montana, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Coastal Neurology, PA, Dover, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Dept of Neurology, Lebanon, New Hampshire, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|The Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation (ARC), Manchester, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States|Shore Neurology, P.A., Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Neurological Associates of Albany, P.C., Albany, New York, United States|Neuroscience Research Center at Albany Medical Center, Albany, New York, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Five Towns Neuroscience Research, Cedarhurst, New York, United States|Advanced Bio-Behavioral Sciences, Elmsford, New York, United States|Empire Neurology, PC, Latham, New York, United States|Neurological Care of CNY, Liverpool, New York, United States|Parker Jewish Institute for Health Care & Rehabilitation, New Hyde Park, New York, United States|NYU School of Medicine/Psychiatry, New York, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Columbia University/Medical Center, New York, New York, United States|Dent Neurologic Institute, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center @ Monroe Community Hospital, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Inc, Hickory, North Carolina, United States|New Hope Clinical Research, Hickory, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Rakesh Ranjan, M.D. & Associates, Inc., Beachwood, Ohio, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|NeuroCare Center, Inc, Canton, Ohio, United States|University Memory and Aging Center University Hospitals of Cleveland/Case Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Providence Medical Group-Medford Neurology, Medford, Oregon, United States|Summit Research Group, Inc., Portland, Oregon, United States|Providence Health Service System, AD Center, Brain Institute, Portland, Oregon, United States|Oregon Health & Sciences University, Portland, Oregon, United States|Abington Neurological Associates, Ltd, Abington, Pennsylvania, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburg, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, N. Charleston, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|East Tennessee State University, Johnson City, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Senior Adults Specialty Research (SASR), Austin, Texas, United States|Texas Neurology, PA, Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|University of North Texas/Health Sciences Center-Fort Worth, Fort Worth, Texas, United States|Claghorn-Lesem Research Clinic, Ltd., Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Inc, Wichita Falls, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|University of Utah, Dept of Neurology, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|University of Washington Veterans Affairs, Seattle, Washington, United States|Pacific Medical Centers, Seattle, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|University of Wisconson Medical School of Medicine and Public Health, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Independent Pyschiatric Consultants, Waukesha, Wisconsin, United States|Medizinische Universität Graz, Graz, Styria, Austria|Medizinische Universität Wien, Wien, Vienna, Austria|University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada|Medical Arts Health Research Group, Kamloops, British Columbia, Canada|Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Medical Arts Health Research Group, Penticton, British Columbia, Canada|University of British Columbia (UBC) Hospital, Vancouver, British Columbia, Canada|Hotel Dieu Hospital/Queens University Memorial Clinics, Kingston, Ontario, Canada|Saint Joseph's Health Care London, Saint Joseph's Hospital, London, Ontario, Canada|Parkwood Hospital, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Neurology Research Inch./Toronto Memory Program, Toronto, Ontario, Canada|Toronto Centre for Memory and Aging, Toronto, Ontario, Canada|Ontario Shores Centre for Mental Health Scienes, Whitby, Ontario, Canada|Neuro Rive-Sud Memory Clinic, Greenfield Park, Quebec, Canada|Hopital Maisonneuve-Rosemont, Comite d' ethique de la recherche, Montreal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Douglas Mental Health University Institute, Verdun, Quebec, Canada|Universitätsklinik Tübingen, Tübingen, Baden-wuerttemberg, Germany|Universitätsklinik Ulm, Ulm, Baden-wuerttemberg, Germany|Universitätsklinik Freiburg, Freiburg, Baden-Württemberg, Germany|Universitätsklinikum Ulm, Günzburg, Bayern, Germany|Ludwig-Maximilians-Universität München, München, Bayern, Germany|Klinikum Rechts der Isar der Technischen Universität München, München, Bayern, Germany|Universitätsklinikum Regensburg, Regensburg, Byern, Germany|Saint Josefs Hospital, Bochum, Nordrhein-westfalen, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Saarland, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Sachen, Germany|ABX-CRO advanced pharmaceutical services Forschungsgesellschaft GmbH, Dresden, Saschen, Germany|UKE Hamburg, Hamburg, Germany",,https://ClinicalTrials.gov/show/NCT00574132
NCT00575055,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),,Completed,No Results Available,Alzheimer's Disease,Drug: Bapineuzumab 0.5 mg/kg|Drug: Placebo Control|Drug: Bapineuzumab 1.0 m/kg,Cognitive and Functional|Cognitive and Global|Imaging and biochemical biomarkers of disease status,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer",All,"50 Years to 88 Years   (Adult, Older Adult)",Phase 3,1121,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ELN115727-302,Dec-07,Apr-12,Apr-12,17-Dec-07,null,25-Nov-13,"University of Alabama Hospital (UAB), Birmingham, Alabama, United States|Dedicated Clinical Research, Inc., Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|HOPE Research Institute, LLC, Phoenix, Arizona, United States|Banner Research Institute, Sun City, Arizona, United States|University of Arizona College of Medicine, Health Sciences Center, Tucson, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Clinical Trials Inc., Little Rock, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|AVI Clinical Research, Carson, California, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Coordinated Clinical Research, La Jolla, California, United States|University of California San Diego, La Jolla, California, United States|Senior Clinical Trials, Inc, Laguna Hills, California, United States|Collaborative NeuroScience Network, Inc., Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Vintage Institute for Clinical Research, Inc, Los Angeles, California, United States|UCLA Department of Neurology, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Neurology Center, Oceanside, California, United States|University of California Irvine Medical Center, Orange, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|Sutter Neuroscience Medical Group, Sacramento, California, United States|University of California Davis Alzheimer's Disease Research Center, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|University of California at San Francisco Medical Center at Parnassus, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|JEM Research, LLC, Atlantis, Florida, United States|Bradenton Research Center, Inc, Bradenton, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|Clinical Physiology Associates, Inc., Fort Myers, Florida, United States|Emerald Coast Mood & Memory, PA., Fort Walton Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Ft. Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Mayo Clinic College of Medicine, Jacksonville, Florida, United States|Neurology Associates, Maitland, Florida, United States|Melbourne Internal Medicine Associates, MIMA, Melbourne, Florida, United States|Pharmax Research Clinic, LLC, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Allied Clinical Trials, Inc., Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center/Advanced Research Consultants, Palm Beach Gardens, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|The Roskamp Institute, Inc, Sarasota, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Suncoast Neuroscience Associates, Inc., St Petersburg, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, School of Medicine, Atlanta, Georgia, United States|Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Medical Research and Health Educational Foundation, Inc, Columbus, Georgia, United States|DeKalb Neurology Associates, LLC, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mid America Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Four Rivers Clinical Research, Inc, Paducah, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Maine Medical Partners Neurology, Scarborough, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|ActivMed Practices and Research, Inc, Haverhill, Massachusetts, United States|Neurocare, Inc, Newton, Massachusetts, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Donald S. Marks, MD, P.C., Plymouth, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Borgess Medical Center/Borgess Research Institute, Kalamazoo, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Saint Luke's Hospital, Mid America Brain and Stroke Institute, Kansas City, Missouri, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|St. Louis University School of Medicine, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Deaconess Billings Clinical Research Center, Billings, Montana, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation (ARC), Manchester, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Neurological Associates Albany PC, Albany, New York, United States|Neuroscience Research Center at Albany Medical Center, Albany, New York, United States|Five Towns Neuroscience Research, Cedarhurst, New York, United States|Advanced BioBehavioral Sciences, Elmsford, New York, United States|Empire Neurology, PC, Latham, New York, United States|Neurological Care of CNY, Liverpool, New York, United States|Parker Jewish Institute for Health Care & Rehabilitation, New Hyde Park, New York, United States|NYU School of Medicine/Psychiatry, New York, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center @ Monroe Community Hospital, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Inc, Hickory, North Carolina, United States|New Hope Clinical Research, Hickory, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals of Cleveland, Case Medical Center, Memory and Cognition Center, Beachwood, Ohio, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|NeuroCare Center, Inc, Canton, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Providence Medical Group-Medford Neurology, Medford, Oregon, United States|Summit Research Group, LLC, Portland, Oregon, United States|Providence Health Service System, AD Center, Brain Institute, Portland, Oregon, United States|Oregon Health & Sciences University, Portland, Oregon, United States|Abington Neurological Assoc, Abington, Pennsylvania, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburgh, Pennsylvania, United States|University of Virginia, Pittsburgh, Pennsylvania, United States|Universtiy of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, N. Charleston, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|East Tennessee State University, Johnson City, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Texas Neurology, PA, Dallas, Texas, United States|University of North Texas/Health Sciences Center-Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|University of Utah, Dept. of Neurology, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|University of Washington Veterans Affairs, Seattle, Washington, United States|Pacific Medical Centers, Seattle, Washington, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00575055
NCT00571025,Risk Evaluation and Education for Alzheimer's Disease,REVEAL I,Completed,No Results Available,Alzheimer's Disease,Behavioral: APOE Disclosure,Center for Epidemiological Studies-Depression Scale (CES-D)|Beck Anxiety Inventory (BAI)|Impact of Events Scale (IES)|Future Attitudes Scale (FAS)|Positive and Negative Affect Schedule (PANAS),National Human Genome Research Institute (NHGRI)|National Institute on Aging (NIA),All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,301,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,IA0126|5R01HG002213,Aug-00,null,Apr-04,11-Dec-07,null,23-Jul-09,"Boston University School of Medicine, Boston, Massachusetts, United States|Weill Medical College of Cornell University, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00571025
NCT00571064,The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility,,Completed,Has Results,Mild to Severe Alzheimer's Disease,Drug: Donepezil HCl,Mini Mental State Examination (MMSE) Total Scores by Visit|Change From Baseline in MMSE Total Score by Visit|Caregiver Activity Survey (CAS) Total Time by Visit|Change From Baseline in CAS Total Time by Visit|Neuropsychiatric Inventory (NPI-8) Total Score by Visit|Change From Baseline in NPI-8 Total Score by Visit|Alzheimer Disease-related Quality of Life (ADRQL) Total Score by Visit|Change From Baseline in ADRQL Total Score by Visit|Disability Assessment in Dementia (DAD) Total Score by Visit|Change From Baseline in DAD Total Score by Visit,Eisai Inc.|Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 4,97,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E2020-A001-415,Jan-08,Dec-08,22-Apr-09,11-Dec-07,12-Mar-18,27-Sep-18,"Senior Care, Birmingham, Alabama, United States|21st Century Neurology, Phoenix, Arizona, United States|Psypharma Clinical Research, Phoenix, Arizona, United States|South Coast Clinical Trials, Anaheim, California, United States|AVI Clinical Research, Carson, California, United States|Margolin Brain Institute, Fresno, California, United States|Sarah Sam Olelewe, MD Inc, Hawthorne, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Danbury Clinical Research, LLC, Danbury, Connecticut, United States|Research Center for Clinical Studies, Norwalk, Connecticut, United States|Galiz Research, Miami Springs, Florida, United States|Neuroscience Consultants, Miami, Florida, United States|Universal Clinical research and Technology, Orlando, Florida, United States|Byrd's Alzheimer Institute, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Center for Clinical Trials, Venice, Florida, United States|Rush Alzheimer Disease Center, Chicago, Illinois, United States|Alexian Brothers Neuroscience Institute, Elk Grove, Illinois, United States|Agewell Health Ltd, Indianapolis, Indiana, United States|Venture Resource Group Inc, Mission, Kansas, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|McLean Hospital Geriatric Psychiatry, Belmont, Massachusetts, United States|Neuroscience Research of the Bershires, Pittsfield, Massachusetts, United States|Horne Research, Las Vegas, Nevada, United States|Bio Behavioral Health, Toms River, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Neurological Associates of Albany, PC, Albany, New York, United States|University Of Buffalo, Buffalo, New York, United States|University of Rochester, Monroe Community Hospital, Rochester, New York, United States|Valley Medical Research, Centerville, Ohio, United States|Infinity Research Group, Oklahoma City, Oklahoma, United States|University of Pennsylvania, Section of Geriatric Psychiatry, Philadelphia, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|CNS Research, INC, East Providence, Rhode Island, United States|Senior Adults Specialty Research, Austin, Texas, United States|Mech Center, Plano, Texas, United States",,https://ClinicalTrials.gov/show/NCT00571064
NCT00568776,ELND005 in Patients With Mild to Moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer Disease,Drug: Placebo Control|Drug: ELND005,Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Full Analysis Set; FAS)|Additional Analysis of Primary Outcome Measure: Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Per Protocol Set; PPS)|Change From Baseline to Week 78 in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score (Full Analysis Set; FAS)|Additional Analysis of Primary Outcome Measure: Change From Baseline to Week 78 in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score (Per Protocol Set; PPS)|Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Score From Baseline to Week 78 (Full Analysis Set; FAS)|Change in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score From Baseline to Week 78 (Full Analysis Set; FAS)|Change in Neuropsychiatric Inventory (NPI) Score From Baseline to Week 78 (Full Analysis Set; FAS),Transition Therapeutics Ireland Limited|Transition Therapeutics,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,353,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ELND005-AD201,Dec-07,May-10,May-10,6-Dec-07,29-Mar-12,16-May-16,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona, Health Sciences Center, Dept. of Neurology, Tucson, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative NeuroScience Network, Inc., Garden Grove, California, United States|UCLA Alzheimer's Disease Center, Dept. of Neurology, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|UCSF Medical Center, Dept. of Neurology, San Francisco, California, United States|Yale University School of Medicine, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Georgetown University Medical Center, Dept. of Neurology, Washington, District of Columbia, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Sunrise Clinical Research, Inc, Hollywood, Florida, United States|Miami Jewish Home and Hospital For The Aged, Miami, Florida, United States|Avision Research Associates, LLC, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Neurology Clinical Research, Inc., Sunrise, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Dept. of Neurology, Atlanta, Georgia, United States|Dekalb Neurology Associates, LLC, Decatur, Georgia, United States|Department of Neurology - Indiana University Medical Center, Indianapolis, Indiana, United States|University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, United States|Innovative Clinical Concepts, Paducah, Kentucky, United States|Brigham and Women's Hospital, Dept. of Neurology, Boston, Massachusetts, United States|University of Michigan, Taubman Health Care Center, Dept. of Neurology, Ann Arbor, Michigan, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|The Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Global Medical Institutes, Princeton, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Sergievsky Center, New York, New York, United States|AD-CARE, Monroe Community Hospital, Rochester, New York, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|Medford Neurological and Spine Clinic, Medford, Oregon, United States|Summit Research Newtwork, Inc., Portland, Oregon, United States|Abington Neurological Associates, Inc., Abington, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|University of Pittsburgh Alzheimer Disease Research Clinic, Pittsburgh, Pennsylvania, United States|Butler Hospital, Memory and Aging Center, Providence, Rhode Island, United States|Alliance for Neuro Research, LLC dba Absher Neurology, PA, Greenville, South Carolina, United States|Radiant Research San Antonio, San Antonio, Texas, United States|University of Utah, Dept. of Neurology, Salt Lake City, Utah, United States|Clinical Neuroscience Research Associates, Inc-The Memory Clinic, Bennington, Vermont, United States|University of Vermont Medical Center, Fletcher Allen Health Care, Dept. of Neurology, Burlington, Vermont, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada|University of British Columbia Hospital, Division of Neurology, Vancouver, British Columbia, Canada|Hotel Dieu Hospital, Kingston, Ontario, Canada|Saint Joseph's Health Care London, Saint Joseph's Hospital, Dept. of Cognitive Neurology, London, Ontario, Canada|Parkwood Hospital, London, Ontario, Canada|Sisters of Charity of Ottawa Health Service, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Whitby Mental Health Memory Clinic, Toronto, Ontario, Canada|Gerontion Research, Inc., Toronto, Ontario, Canada|Neuro-Rive-Sud Memory Clinic, Greenfield Park, Quebec, Canada|Recherche Clinique de Neurologie (Hospital Maisonneuve Rosemont), Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00568776
NCT00566397,A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: PF-04494700|Drug: Placebo,"Evaluate the efficacy of PF 04494700 relative to placebo. Change from baseline in a standardized cognitive measure after 18 months of treatment.|Examine the safety and tolerability of PF 04494700 relative to placebo. Adverse events, vital signs, physical exam, neuro exam, 12-lead ECG, lab tests (hematology, blood chemistry, urinalysis) and brain magnetic resonance imaging (MRI).|Evaluate the effects of PF 04494700 on potential biomarkers of RAGE inhibition and amyloid imaging (AV-45, F18 PET)|Evaluate the potential dose response of PF 04494700|Evaluate the pharmacokinetics and characterize the pharmacokinetic (PK)/ pharmacodynamic (PD) relationship of PF 04494700 to potential biomarkers and relevant efficacy and safety endpoints",Pfizer|Alzheimer's Disease Cooperative Study (ADCS),All,"50 Years and older   (Adult, Older Adult)",Phase 2,402,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B0341002,Dec-07,Dec-10,Dec-10,3-Dec-07,null,30-Nov-18,"Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Sun City, Arizona, United States|Pfizer Investigational Site, Irvine, California, United States|Pfizer Investigational Site, Irvine, California, United States|Pfizer Investigational Site, Irvine, California, United States|Pfizer Investigational Site, Irvine, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Martinez, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Palo Alto, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Vista, California, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Miami Beach, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Grand Rapids, Michigan, United States|Pfizer Investigational Site, Saint Louis, Missouri, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Beachwood, Ohio, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, North Charleston, South Carolina, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00566397
NCT00566501,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: 23 mg SR in Study 326|Drug: 10 mg IR in Study 326,Long-term Safety as Measured by Incidence of Adverse Events During the 12 Month Treatment Period|Mean Change From Baseline in MMSE Score|Mean Change From Baseline in SIB Score,Eisai Inc.|Eisai Limited,All,"45 Years to 91 Years   (Adult, Older Adult)",Phase 3,915,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E2020-G000-328|2006-004890-93,Dec-07,Aug-10,Aug-10,3-Dec-07,19-Jun-12,11-Jul-14,"Apex Research Institute, Santa Ana, California, United States",,https://ClinicalTrials.gov/show/NCT00566501
NCT00563732,Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin,,Completed,No Results Available,Alzheimer Disease,Drug: Lecozotan,Evaluation of the effects of multiple doses of lecozotan SR on the PK profile of a single dose of digoxin in healthy adult subjects,Wyeth is now a wholly owned subsidiary of Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,null,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3098B1-1142,Dec-07,Sep-08,Sep-08,26-Nov-07,null,9-Sep-08,,,https://ClinicalTrials.gov/show/NCT00563732
NCT00561392,Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease,ADEPT,Completed,Has Results,Alzheimer's Disease,Drug: Rivastigmine 5 and 10 cm^2 patch,Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Who Completed the Study|Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Regardless Whether They Completed the Study|Percentage of Participants Who Were Compliant to the 10 cm^2 Patch|Mean Change From Baseline in the Mini-Mental State Examination (MMSE) Score at Week 24|Mean Change From Baseline in the Trail-making Test Part A Score at Week 24|Mean Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score at Week 24|Change From Baseline in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) at Week 24 Assessed by the Physician|Mean Change From Baseline in the Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (ADCS-CGIC) at Week 24 Assessed by the Caregiver|Mean Change From Baseline in the Mini-Zarit Inventory Score of Caregiver Burden at Week 24,Novartis,All,"50 Years and older   (Adult, Older Adult)",Phase 4,208,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713DDE15,Nov-07,Nov-08,Nov-08,21-Nov-07,11-Mar-11,16-Apr-12,"Novartis Investigative Site, Munich, Germany",,https://ClinicalTrials.gov/show/NCT00561392
NCT00558402,Meditation or Education for Alzheimer Caregivers,,Completed,No Results Available,Caregivers|Alzheimer's Disease,Behavioral: Meditation|Behavioral: Education|Behavioral: Respite only,Caregiver stress (Revised Memory and Behavior Problems Checklist)|5-Facet Mindfulness Questionnaire|Perceived Self-Efficacy|EEG measuring reaction time,Oregon Health and Science University,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB00002226,Nov-07,Jul-11,Jul-11,15-Nov-07,null,29-Oct-14,"Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00558402
NCT00556660,Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects,,Completed,No Results Available,Alzheimer Disease,Drug: [123I] AV-151,"To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects",Institute for Neurodegenerative Disorders,All,"50 Years and older   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,AV51 001,Sep-07,Jul-08,Jul-08,12-Nov-07,null,14-Mar-19,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00556660
NCT00555204,Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: ABT-089|Drug: placebo,Safety and Tolerability|Pharmacokinetics (how the body handles the study drug)|Pharmacodynamic (how the study drug affects cognitive functions such as thinking and memory),Abbott,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,337,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M06-876,Nov-07,Jun-09,null,8-Nov-07,null,23-Aug-11,"Phoenix, Arizona, United States|Sun City, Arizona, United States|Fresno, California, United States|San Diego, California, United States|Santa Ana, California, United States|Santa Monica, California, United States|Hamden, Connecticut, United States|New Haven, Connecticut, United States|Brooksville, Florida, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Hallendale, Florida, United States|Hialeah, Florida, United States|Largo, Florida, United States|Miami, Florida, United States|Palm Beach Gardens, Florida, United States|Sunrise, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|West Palm Beach, Florida, United States|Indianapolis, Indiana, United States|Paducah, Kentucky, United States|Pittsfield, Massachusetts, United States|Grand Rapids, Michigan, United States|St Louis, Missouri, United States|Long Branch, New Jersey, United States|Nutley, New Jersey, United States|Princeton, New Jersey, United States|Ridgewood, New Jersey, United States|Albany, New York, United States|Bronx, New York, United States|New York, New York, United States|Staten Island, New York, United States|Hickory, North Carolina, United States|Winston-Salem, North Carolina, United States|Centerville, Ohio, United States|Cleveland, Ohio, United States|Jenkintown, Pennsylvania, United States|Norristown, Pennsylvania, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00555204
NCT00551772,A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.,,Completed,No Results Available,Alzheimer's Disease,Drug: SB-742457,"To characterise pharmacokinetics ( AUC(0-inf) and Cmax ) of SB-742457 from pre-dose to 96 hours following single doses formulated as a capsule and a tablet.|To assess safety and tolerability (adverse events, blood pressure, heart rate, 12-lead ECG, blood haematology/clinical chemistry and urinalysis) of SB-742457 following single doses formulated as a capsule and a tablet over the 6 week study period.",GlaxoSmithKline,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AZ3110291,Aug-07,null,null,31-Oct-07,null,25-Dec-08,"GSK Investigational Site, Evansville, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00551772
NCT00551161,Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease,,Completed,Has Results,Alzheimer Disease,Drug: memantine,"Changes in the Metabolite Ratios of N-acetylaspartate (NAA) to Creatine (Cr), Myo-inositol (mI) to Cr, Choline (Cho) to Cr, NAA to Cho, and NAA to mI, on Cholinesterase Monotherapy vs Combination of Memantine and Cholinesterase Inhibitor",Northwell Health|Forest Laboratories,All,"50 Years and older   (Adult, Older Adult)",Phase 4,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NAM-MD-50,Aug-07,Dec-11,Dec-11,30-Oct-07,18-Dec-13,28-Jan-14,"The Litwin-Zucker Research Center, Manhasset, New York, United States",,https://ClinicalTrials.gov/show/NCT00551161
NCT00550420,Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers,,Terminated,Has Results,Alzheimer's Disease,Drug: Rosiglitazone XR,"Number of Participants With Any Adverse Events (AEs) and Severity of AEs|Number of Participants With Serious AEs and Deaths|Percentage of Participants With AEs of Edema|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Heart Rate (HR)|Number of Participants With Abnormal SBP and DBP at Any Time During Treatment Period|Number of Participants With Abnormal HR at Any Time During Treatment Period|Change From Baseline in Body Weight (BW)|Number of Participants With Abnormal BW at Any Time During Treatment Period|Change From Baseline in Non-fasting Measures of Lipid Metabolism Including Total Cholesterol, High Density Lipoprotein, Low Density Lipoprotein and Triglycerides at Indicated Timepoints.|Number of Participants With Hematological Parameters of Potential Clinical Concern|Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) Total Score as a Function of Apolipoprotein E (APOE) 4 Status at W24 and W52|Mean Clinician Interview-Based Impression of Change Plus Caregiver Input (CIBIC+) Score as a Function of APOE 4 Status|Change From Baseline in Mini Mental State Examination (MMSE) Total Score as a Function of APOE 4 Status at W24 and W52|Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score as a Function of APOEe 4 Status|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score as a Function of APOE 4 Status at W24 and W52|Change From Baseline in Glycosylated Haemoglobin (HbA1c)",GlaxoSmithKline,All,"51 Years to 91 Years   (Adult, Older Adult)",Phase 3,331,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVA102677,1-Oct-07,12-Feb-09,12-Feb-09,29-Oct-07,8-Nov-17,8-Nov-17,"GSK Investigational Site, Palo Alto, California, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Melbourne, Florida, United States|GSK Investigational Site, Plantation, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Centerville, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Graz-Eggenberg, Austria|GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Guenzburg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Baesweiler, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Juelich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Seongnam-si,, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Saltillo, Coahuila, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Pasig City, Philippines|GSK Investigational Site, San Juan, Puerto Rico|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT00550420
NCT00549601,"Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease",KAPA,Completed,Has Results,Alzheimer's Disease,Drug: Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|Drug: Rivastigmine patch (9.5 mg/day)|Drug: Rivastigmine capsules (6 mg to 12 mg/day),Percentage of Patients Who Had a Gastrointestinal Adverse Event (AE) at Any Time During the Study|Percentage of Patients With an AE Involving the Skin (Local Tolerance) Recorded Over the Course of the Study Period (Patch Groups Only)|Percentage of Patients With at Least 1 AE of Any Kind Recorded During the Period of the Study.|Overall Caregiver Satisfaction With Treatment|Overall Patient Satisfaction With Treatment|Change in the Total Mini-Mental State Examination (MMSE) Score From Baseline to Month 1 and Month 3,Novartis,All,"60 Years and older   (Adult, Older Adult)",Phase 4,142,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713DES07,Sep-07,Apr-09,Apr-09,26-Oct-07,24-Mar-11,24-Mar-11,"Novartis Investigative Site, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00549601
NCT00548951,Alzheimer Patients and the Snoezelen Program,,Completed,No Results Available,Dementia,Other: Snoezelen Room|Other: Control,To evaluate improvement of the residents who are given Snoezelen sessions.,Queen's University,All,65 Years and older   (Older Adult),Phase 1,18,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PSIY-205-05,Sep-05,Dec-06,Dec-06,24-Oct-07,null,16-Dec-15,"Rideaucrest Home, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00548951
NCT00548145,The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease,PIT-ROAD,Terminated,Has Results,Alzheimer Disease|Hypercholesterolemia,"Drug: Pitavastatin|Drug: cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)","Alzheimer's Disease Assessment Scale-cognitive Component-Japanese Version(ADAS-Jcog)|MMSE, Neuropsychiatric Inventory, GDS-15, Zarit Burden Scale, Physical Self-Maintenance Scale, IADL, Everyday Memory Checklist, TC, HDL-C, Non HDL-C*, Apo A1, Apo B, Apo E *: Non HDL-C = (TC) - (HDL-C)","Osaka University|Kowa Company, Ltd.",All,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,38,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSK-07098,Nov-07,Oct-11,Mar-12,23-Oct-07,14-Jun-12,14-Jun-12,"Osaka University Hospital, Suita, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT00548145
NCT00547560,Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population,,Completed,No Results Available,Healthy,Drug: GSI-953,The pharmacokinetic and pharmacodynamic profile for the elderly subjects.|Pharmacokinetics (PK)|Pharmacodynamics (PD),Wyeth is now a wholly owned subsidiary of Pfizer|Pfizer,All,65 Years and older   (Older Adult),Phase 1,49,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3183A1-102|B1941003,Aug-07,Oct-09,Oct-09,22-Oct-07,null,4-Apr-11,"Pfizer Investigational Site, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00547560
NCT00546767,Home-Based Assessment for Alzheimer Disease Prevention,HBA,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Behavioral: Mail and Live Phone|Behavioral: Interactive Voice Response (IVR)|Behavioral: Home-based Computer Kiosk|Behavioral: Traditional Evaluation Instruments,"Feasibility Data -- the number of subjects recruited, screened, enrolled, and retained|Efficiency Data -- staff time required to successfully complete data collection|Transition from cognitive health to impairment|Method-Specific Adherence, including medication adherence|Rate of change in domains of assessment|Research blood samples|Safety Assessments: symptom checklist and adverse event checklist",Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA),All,75 Years and older   (Older Adult),Not Applicable,640,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,IA0123|1RC2AG036535|ADC-030-HBA,Sep-07,Jun-13,Jun-13,19-Oct-07,null,16-Sep-14,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Sun Health Reseach Institute, Sun City, Arizona, United States|University of California, Irvine Institute for Brain Aging and Dementia, Irvine, California, United States|University of California-San Diego ADRC/Neurosciences, La Jolla, California, United States|University of California, Davis, Martinez, California, United States|Stanford University / PAIRE, Palo Alto, California, United States|Yale University Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Mayo Clinic Jacksonville Neurology, Jacksonville, Florida, United States|Wien Center, Miami Beach, Florida, United States|University of South Florida, Suncoast Alzheimer's & Gerontology Center, Tampa, Florida, United States|Northwestern University Cognitive Neurology & Alzheimer's Disease, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kentucky Sanders-Brown Center on Aging, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston University Alzheimer's Disease Clinical and Research Program, Boston, Massachusetts, United States|University of Michigan Psychiatry - Neuropsychology, Ann Arbor, Michigan, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|New York University Aging and Dementia Research Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Neurological Care of CNY, Syracuse, New York, United States|Wake Forest University Gerontology and Geriatric Medicine, Winston-Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania Geriatrics, Philadelphia, Pennsylvania, United States|University of Utah Center for Alzheimer's Care, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00546767
NCT00545974,Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia,,Completed,Has Results,Frontal Lobe Dementia|Frontotemporal Lobe Dementia|Semantic Dementia,Drug: memantine|Drug: Placebo pill,"Change in Neuropsychiatric Inventory (NPI)|Clinical Global Impression of Change (CGIC)|CDR-FTD, MMSE, FAQ, TFLS, EXIT25, UCSF FTD-Neuropsychological Test Battery: CVLT, Verbal Fluency, Modified BNT, Backward Digit Span, Digit Symbol Test, Modified Trails B, Modified Unified Parkinson's Disease Rating Scale, Antipsychotic Therapy","University of California, San Francisco|Forest Laboratories",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 4,81,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NAM-53:memantineplacebo,Oct-07,Dec-12,Dec-12,18-Oct-07,5-Feb-14,5-Feb-14,"University of California, Los Angeles, Los Angeles, California, United States|University California, San Francisco, San Francisco, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University Hospitals of Cleveland / Case Medical Center, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00545974
NCT00544453,Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC,,Terminated,No Results Available,Alzheimer Disease,Drug: [123I] MNI-308,,Molecular NeuroImaging,All,"50 Years and older   (Adult, Older Adult)",Phase 1,2,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,MNI-308-01,Oct-07,Oct-07,Jul-08,16-Oct-07,null,21-Aug-09,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00544453
NCT00544856,Effects of a Complex Cognitive Training in Mild Cognitive Impairment and Mild Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Cognitive Impairment,Behavioral: complex cognitive training,"cognition: MMSE, ADAS-cog.|quality of life",Ludwig-Maximilians - University of Munich,All,"55 Years to 95 Years   (Adult, Older Adult)",Not Applicable,39,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,cogT001,Oct-07,Oct-08,Oct-08,16-Oct-07,null,29-Jan-09,,,https://ClinicalTrials.gov/show/NCT00544856
NCT00539305,Hormone and Information Processing Study,HIP,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease,Drug: testosterone gel|Drug: placebo gel,Behavioral & Mood Measure: Profile of Mood States (POMS)|Cognitive Changes Measured by Neuropsychological Tests: Rey Auditory Verbal Learning Test|Geriatric Depression Scale (GDS)|Short-Form Health Survey (SF-36),University of Washington|National Institute on Aging (NIA)|Solvay Pharmaceuticals,Male,"60 Years to 90 Years   (Adult, Older Adult)",Phase 3,22,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",29975-A|R01AG027156|1R01AG027156-01A2,Jul-09,Jul-11,May-12,4-Oct-07,14-Jul-14,14-Jul-14,"VA Puget Sound Health Care Systems, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00539305
NCT00531804,A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.,,Completed,No Results Available,Alzheimer's Disease,Drug: gantenerumab,"AEs, laboratory parameters, vital signs.|Pharmacokinetic parameters of R1450 in plasma|CSF biomarkers, clinical efficacy parameters.",Hoffmann-La Roche,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN19866,Dec-06,Sep-10,Sep-10,19-Sep-07,null,2-Nov-16,"København, Denmark|Ramat Gan, Israel|Amsterdam, Netherlands|Malmoe, Sweden|Stockholm, Sweden|Blackpool, United Kingdom|Glasgow, United Kingdom|Southampton, United Kingdom|Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00531804
NCT00523666,Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®),,Unknown status,No Results Available,Alzheimer's Disease,Drug: Galantamine (Reminyl®)|Drug: Placebo/Galantamine (Reminyl®),,Ludwig-Maximilians - University of Munich,All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DTI001|EudraCT 2005-003762-41,Sep-06,null,Sep-08,31-Aug-07,null,31-Aug-07,"Ludwig-Maximilian University of Munich, Munich, Germany",,https://ClinicalTrials.gov/show/NCT00523666
NCT00519298,Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects,,Completed,No Results Available,Healthy|Adult,Drug: SAM-531|Other: placebo|Drug: Donepezil,Evaluation of the pharmacologic effect of SAM-531 on sleep EEG in healthy subjects,Wyeth is now a wholly owned subsidiary of Pfizer,All,18 Years to 50 Years   (Adult),Phase 1,25,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",3193A1-1110,Oct-07,Mar-08,Mar-08,22-Aug-07,null,22-Apr-08,"Rouffach, France",,https://ClinicalTrials.gov/show/NCT00519298
NCT00515333,TRx0014 in Patients With Mild or Moderate Alzheimer's Disease,,Completed,No Results Available,"Dementia, Alzheimer Type",Drug: TRx0014|Drug: Placebo,Cognitive ability (ADAS-cog)|Behavioural and psychological symptoms (NPI)|Global performance (ADCS-CGIC)|Dementia severity (CDR-sb)|Cognition (MMSE)|Dementia caseness (Short CAMDEX)|Cognitive function (ADAS-cog)|Daily activities of living (BADLS)|Changes in cerebral perfusion pattern (SPECT or PET),TauRx Therapeutics Ltd,All,"Child, Adult, Older Adult",Phase 2,323,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TRx-014-001,Aug-04,Dec-07,Dec-07,13-Aug-07,null,20-Feb-08,,,https://ClinicalTrials.gov/show/NCT00515333
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",,Completed,Has Results,Alzheimer Disease,Drug: Rivastigmine 5 cm^2|Drug: Rivastigmine 10 cm^2|Drug: Rivastigmine 15 cm^2|Drug: Placebo to 15 cm^2 patch|Drug: Placebo to 10 cm^2 patch,"Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period|Change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale Score From Baseline to Week 48 of Double Blind Period|Time to Functional Decline as Measured by Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale During the Double Blind Period|Change in Attention and Executive Function as Assessed by the Trail Making Test (Part A) at Week 48 of the Double Blind Period|Change in Attention and Executive Function as Assessed by the Trail Making Test (Part B) at Week 48 of Double Blind Period|Change From Baseline in Neuropsychiatric Inventory (NPI)-10 Score at Week 48 of Double Blind Period|Number of Patients With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events",Novartis Pharmaceuticals|Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1584,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CENA713D2340,Jun-07,May-11,May-11,25-Jul-07,19-Sep-12,19-Sep-12,"Novartis investigative site, Birmingham, Alabama, United States|Novartis investigative site, Gilbert, Arizona, United States|Novartis investigative site, Phoenix, Arizona, United States|Novartis investigative site, Sun City, Arizona, United States|Novartis investigative site, Anaheim, California, United States|Novartis investigative site, Carson, California, United States|Novartis investigative site, Costa Mesa, California, United States|Novartis investigative site, Fullerton, California, United States|Novartis investigative site, La Habra, California, United States|Novartis investigative site, La Jolla, California, United States|Novartis investigative site, National City, California, United States|Novartis investigative site, Redlands, California, United States|Novartis investigative site, San Francisco, California, United States|Novartis investigative site, Fort Collins, Colorado, United States|Novartis investigative site, Longmont, Colorado, United States|Novartis investigative site, Boca Raton, Florida, United States|Novartis investigative site, Bradenton, Florida, United States|Novartis investigative site, Deerfield Beach, Florida, United States|Novartis investigative site, Delray Beach, Florida, United States|Novartis investigative site, Fort Lauderdale, Florida, United States|Novartis investigative site, Gainesville, Florida, United States|Novartis investigative site, Miami Beach, Florida, United States|Novartis investigative site, Pompano Beach, Florida, United States|Novartis investigative site, Port Charlotte, Florida, United States|Novartis investigative site, Sunrise, Florida, United States|Novartis investigative site, West Palm Beach, Florida, United States|Novartis investigative site, Atlanta, Georgia, United States|Novartis investigative site, Macon, Georgia, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis investigative site, Chicago, Illinois, United States|Novartis investigative site, Springfield, Massachusetts, United States|Novartis investigative site, Flint, Michigan, United States|Novartis investigative site, Flushing, Michigan, United States|Novartis investigative site, Roseville, Michigan, United States|Novartis investigative site, Traverse City, Michigan, United States|Novartis investigative site, Hattiesburg, Mississippi, United States|Novartis investigative site, Ocean Springs, Mississippi, United States|Novartis investigative site, Columbia, Missouri, United States|Novartis investigative site, St. Louis, Missouri, United States|Novartis investigative site, Flemington, New Jersey, United States|Novartis investigative site, Nutley, New Jersey, United States|Novartis investigative site, Somerset, New Jersey, United States|Novartis investigative site, Albany, New York, United States|Novartis investigative site, Syracuse, New York, United States|Novartis investigative site, Greensboro, North Carolina, United States|Novartis investigative site, Morganton, North Carolina, United States|Novartis investigative site, Winston-Salem, North Carolina, United States|Novartis investigative site, Winston-Salem, North Carolina, United States|Novartis investigative site, Canton, Ohio, United States|Novartis investigative site, Columbus, Ohio, United States|Novartis investigative site, Corvallis, Oregon, United States|Novartis investigative site, Portland, Oregon, United States|Novartis investigative site, Beaver, Pennsylvania, United States|Novartis investigative site, Erie, Pennsylvania, United States|Novartis investigative site, Greensburg, Pennsylvania, United States|Novartis investigative site, Pittsburgh, Pennsylvania, United States|Novartis investigative site, Beaufort, South Carolina, United States|Novartis investigative site, Summerville, South Carolina, United States|Novartis investigative site, Brentwood, Tennessee, United States|Novartis investigative site, Nashville, Tennessee, United States|Novartis investigative site, Dallas, Texas, United States|Novartis investigative site, Fort Worth, Texas, United States|Novartis investigative site, Irving, Texas, United States|Novartis investigative site, Charleston, West Virginia, United States|Novartis investigative site, Huntington, West Virginia, United States|Novartis investigative site, Toronto, Ontario, Canada|Novartis investigative site, Calgary, Canada|Novartis investigative site, Edmonton, Canada|Novartis investigative site, Greenfield Park, Canada|Novartis investigative site, Halifax, Canada|Novartis investigative site, London, Canada|Novartis investigative site, Montreal, Canada|Novartis investigative site, Ottawa, Canada|Novartis investigative site, Peterborough, Canada|Novartis investigative site, Quebec, Canada|Novartis investigative site, Regina, Canada|Novartis investigative site, Toronto, Canada|Novartis investigative site, Vancouver, Canada|Novartis investigative site, Winnipeg, Canada|Novartis investigative site, Fains Veel, Alsace Lorraine, France|Novartis investigative site, Dijon, Burgundy, France|Novartis investigative site, Reims, Champagne-Ardenne, France|Novartis investigative site, Bordeaux, France|Novartis investigative site, Bourg en Bresse, France|Novartis investigative site, Caen, France|Novartis investigative site, Cherbourg, France|Novartis investigative site, Dijon, France|Novartis investigative site, Limoges, France|Novartis investigative site, Montpellier, France|Novartis investigative site, Nice, France|Novartis investigative site, Paris, France|Novartis investigative site, Rennes, France|Novartis investigative site, Rodez, France|Novartis investigative site, Bad Neustadt/Saale, Germany|Novartis investigative site, Berlin, Germany|Novartis investigative site, Bonn, Germany|Novartis investigative site, Burg, Germany|Novartis investigative site, Duesseldorf, Germany|Novartis investigative site, Frankfurt, Germany|Novartis investigative site, Giessen, Germany|Novartis investigative site, Koln, Germany|Novartis investigative site, Krefeld, Germany|Novartis investigative site, Leipzig, Germany|Novartis investigative site, Magdeburg, Germany|Novartis investigative site, Mannheim, Germany|Novartis investigative site, Marburg, Germany|Novartis investigative site, Muenchen, Germany|Novartis investigative site, Muenster, Germany|Novartis investigative site, Nuernberg, Germany|Novartis investigative site, Stralsund, Germany|Novartis investigative site, Stuttgart, Germany|Novartis investigative site, Wurzburg, Germany|Novartis investigative site, Milano, Milan, Italy|Novartis investigative site, Ancona, Italy|Novartis investigative site, Arcugnano, Italy|Novartis investigative site, Arezzo, Italy|Novartis investigative site, Bari, Italy|Novartis investigative site, Bologna, Italy|Novartis investigative site, Brescia, Italy|Novartis investigative site, Cagliari, Italy|Novartis investigative site, Catania, Italy|Novartis investigative site, Città di Castello, Italy|Novartis investigative site, Cremona, Italy|Novartis investigative site, Ferrara, Italy|Novartis investigative site, Firenze, Italy|Novartis investigative site, Foggia, Italy|Novartis investigative site, Genova, Italy|Novartis investigative site, La Spezia, Italy|Novartis investigative site, Milano, Italy|Novartis investigative site, Milan, Italy|Novartis investigative site, Modena, Italy|Novartis investigative site, Napoli, Italy|Novartis investigative site, Padova, Italy|Novartis investigative site, Pavia, Italy|Novartis investigative site, Perugia, Italy|Novartis investigative site, Pisa, Italy|Novartis investigative site, Rho, Italy|Novartis investigative site, Rome, Italy|Novartis investigative site, Torino, Italy|Novartis investigative site, Verona, Italy|Novartis investigative site, Barcelona, Spain|Novartis investigative site, Palma de Mallorca, Spain|Novartis investigative site, Basel, Switzerland|Novartis investigative site, Biel, Switzerland|Novartis investigative site, Mendrisio, Switzerland",,https://ClinicalTrials.gov/show/NCT00506415
NCT00505167,Memantine Versus Donepezil in Early Stages of Alzheimer's Disease,,Completed,No Results Available,"Dementia, Alzheimer Type",Drug: Memantine|Drug: Donepezil,Changes in the Levels of the metabolite N-acetyl-aspartate in several areas of the brain.|Changes in the clinical scales observed after treatment,Hospital Miguel Servet|Clinica Quiron de Zaragoza|Universidad de Zaragoza|Hospital de Barbastro|Hospital Royo Villanova,All,"Child, Adult, Older Adult",Phase 4,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,0910-0459,Jul-07,Jul-08,Dec-08,23-Jul-07,null,29-Dec-08,"Hospital de Barbastro, Barbastro, Huesca, Spain|Cenro de especialidades San José. Hospital Miguel Servet, Zaragoza, Spain|Hospital Royo Villanova, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT00505167
NCT00501111,Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease,Sirocco,Completed,No Results Available,Alzheimer Disease,Drug: AZD3480|Drug: Donepezil,"Change in ADAS-Cog|Change in ADCS-CGIC, Computerized neurological test battery (CDR) and MMSE",AstraZeneca,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,659,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3690C00010|EuDract 2007-00835-24,Jul-07,Aug-08,Aug-08,13-Jul-07,null,23-Jul-14,"Research Site, Graz, Osterreich, Austria|Research Site, Innsbruck, Osterreich, Austria|Research Site, Wien, Osterreich, Austria|Research Site, Linz, Austria|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Hasselt, Belgium|Research Site, Leuven, Belgium|Research Site, Sint-truiden, Belgium|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Verdun, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czech Republic|Research Site, Havlickuv Brod, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Kladno, Czech Republic|Research Site, Litomerice, Czech Republic|Research Site, Novy Jicin, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Ostrava - Poruba, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Prostejov, Czech Republic|Research Site, Bad Saarow, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Freiburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kiel-kronshagen, Germany|Research Site, Leipzig, Germany|Research Site, Lubeck, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Munchen, Germany|Research Site, Nurnberg, Germany|Research Site, Pitesti, Arges, Romania|Research Site, Targu Mures, Mures, Romania|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Sibiu, Romania|Research Site, Moscow, Russian Federation|Research Site, Saint-petersburg, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Salamanca, Castilla Leon, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Hospitalet de Llobregat(barcel, Cataluna, Spain|Research Site, Salt (girona), Cataluna, Spain|Research Site, Terrassa, Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Castellon, Comunidad Valenciana, Spain|Research Site, Palma de Mallorca, Islas Baleares, Spain|Research Site, Baracaldo (vizcaya), Spain|Research Site, Uckfield, E Sussex, United Kingdom|Research Site, Southampton, Hampshire, United Kingdom|Research Site, Blackpool, Lancashire, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, London, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00501111
NCT00500500,Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease,,Terminated,No Results Available,Alzheimer Disease,Drug: EGb 761® (Tanakan®),Effect of EGb 761® on the ratio of the isoform of the protein precursor of beta amyloid platelets.|Efficacy of EGb 761® on the cognitive functions and safety of EGb 761® at a dosage of 240 mg per day,Ipsen,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2-29-00240-127,Jul-05,Apr-08,Apr-08,12-Jul-07,null,11-Oct-13,"Hôpital La Timone, Marseille, France",,https://ClinicalTrials.gov/show/NCT00500500
NCT00499200,"Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy",,Completed,No Results Available,Alzheimer's Disease,Drug: SRA-444,To assess the safety and tolerability of ascending single oral doses of SRA-444 in healthy elderly subjects and subjects with Alzheimer's disease|To obtain PK profiles and determine the level and duration of 5-HT1A RO of SRA-444 by PET,Wyeth is now a wholly owned subsidiary of Pfizer,All,"60 Years and older   (Adult, Older Adult)",Phase 1,42,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3197A1-1104,Oct-07,Jun-08,Jun-08,11-Jul-07,null,9-Jul-08,"Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00499200
NCT00499642,Study Evaluating the Effect of Lecozotan SR on the QTc Interval,,Completed,No Results Available,Alzheimer Disease|Healthy,Drug: Lecozotan SR|Drug: Moxifloxacin,To assess the effect of drug administration on QTc interval.,Wyeth is now a wholly owned subsidiary of Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,null,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,3098B1-133,Jun-07,null,Aug-07,11-Jul-07,null,28-Dec-07,"Rennes, France|Rueil-Malmaison, France",,https://ClinicalTrials.gov/show/NCT00499642
NCT00498602,Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer Disease,Biological: ACC-001 + QS-21|Biological: QS-21|Other: Diluent: Phosphate Buffered Saline|Biological: ACC-001,"Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)|Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104|GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104|Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,160,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3134K1-2201|B2571005,Nov-07,Feb-13,Feb-13,10-Jul-07,1-Jan-16,1-Jan-16,"Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|Banner Boswell Medical Center, Sun City, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States|University of California - San Francisco, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|General Clinical Research Center, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|General Clinical Research Center, Washington, District of Columbia, United States|GUMC, Washington, District of Columbia, United States|MD Clinical, Hallandale Beach, Florida, United States|Palm Beach Neurology - Premiere Research Institute, West Palm Beach, Florida, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Barnes-Jewish Hospital, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Barrnes-Jewish Hospital at Washington University, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pharmcare USA, Edison, New Jersey, United States|Columbia Univ/Taub Institute Irving Ctr for Clinical Researc, New York, New York, United States|CUMC Research Pharmacy, New York, New York, United States|Butler Hospital, Providence, Rhode Island, United States|The Memory Clinic, Bennington, Vermont, United States|The Pharmacy, Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00498602
NCT00495417,Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Biological: AFFITOPE AD01|Biological: AFFITOPE AD01 adjuvanted,Tolerability|Immunological and clinical efficacy (evaluated in explorative manner),Affiris AG,All,"50 Years and older   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Affiris 001|EUDRACT Number 2006-007063-90,Jul-07,Aug-09,Aug-09,3-Jul-07,null,19-Oct-10,"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT00495417
NCT00495820,Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study,,Completed,Has Results,Alzheimer's Disease|Apathy|Dementia,Drug: Methylphenidate|Other: Placebo,Apathy Evaluation Scale Score at 12 Weeks|Mini-mental State Examination (MMSE) at 12 Weeks|Clinical Global Impression,VA Office of Research and Development,All,"55 Years and older   (Adult, Older Adult)",Phase 4,60,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MHBB-011-06F,Aug-07,Mar-10,Jun-10,3-Jul-07,20-Nov-15,20-Nov-15,"VA Medical Center, Omaha, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00495820
NCT00494962,Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects,,Completed,No Results Available,Alzheimer Disease,Drug: lecozotan SR,Pharmacokinetic (PK) analyses,Wyeth is now a wholly owned subsidiary of Pfizer,All,18 Years to 50 Years   (Adult),Phase 1,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,3098B1-1147,Jun-07,null,Jun-07,2-Jul-07,null,5-Dec-07,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00494962
NCT00490568,Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers,,Terminated,Has Results,Alzheimer's Disease,Drug: Rosiglitazone XR,"Number of Participants With Any Adverse Events (AEs) and Severity of AEs|Number Participants With Serious Adverse Events (SAEs) and Deaths|Number of Participants With Adverse Event of Oedema|Change From Baseline in Vital Sign Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Vital Sign Heart Rate (HR)|Change From Baseline in Vital Sign Body Weight (BW)|Change From Baseline in Non-fasting Measures of Lipid Metabolism Namely Total Cholesterol (TC), High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Triglycerides|Number of Participants With SBP and DBP Values of Potential Clinical Concern (PCC)|Number of Participants With HR Values of PCC ATOT|Number of Participants With BW Values of PCC ATOT|Number of Participants With Hematology Parameters of PCC ATOT|Number of Participants With Clinical Chemistry Parameters (Including Lipids) of PCC ATOT|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total Score as a Function of Apolipoprotein E (APOE) ε4 Status.|Change From Baseline in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score as a Function of APOE ε4 Status.|Change From Baseline in Mini Mental State Examination (MMSE) Total Score as a Function of APOE ε4 Status.|Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score as a Function of APOE ε4 Status.|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score as a Function of APOE ε4 Status.",GlaxoSmithKline,All,"51 Years to 91 Years   (Adult, Older Adult)",Phase 3,1461,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVA102675,8-Aug-07,1-Jun-09,1-Jun-09,22-Jun-07,13-Nov-17,13-Nov-17,"GSK Investigational Site, Litchfield Park, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Rancho Mirage, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Sherman Oaks, California, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Norwalk, Connecticut, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Delray Beach, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Fort Wayne, Indiana, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Springfield, Massachusetts, United States|GSK Investigational Site, West Yarmouth, Massachusetts, United States|GSK Investigational Site, Saint Paul, Minnesota, United States|GSK Investigational Site, Morristown, New Jersey, United States|GSK Investigational Site, Stratford, New Jersey, United States|GSK Investigational Site, Toms River, New Jersey, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, South Ogden, Utah, United States|GSK Investigational Site, Bennington, Vermont, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Godoy Cruz, Mendoza, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Hornsby, New South Wales, Australia|GSK Investigational Site, Randwick, New South Wales, Australia|GSK Investigational Site, Auchenflower, Queensland, Australia|GSK Investigational Site, Chermside, Queensland, Australia|GSK Investigational Site, Kippa Ring, Queensland, Australia|GSK Investigational Site, Woodville, South Australia, Australia|GSK Investigational Site, Cheltenham, Victoria, Australia|GSK Investigational Site, Heidelberg Heights, Victoria, Australia|GSK Investigational Site, Kew, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Kortrijk, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Woluwe-Saint-Lambert, Belgium|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Saint John, New Brunswick, Canada|GSK Investigational Site, Kentville, Nova Scotia, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Whitby, Ontario, Canada|GSK Investigational Site, Charlottetown, Prince Edward Island, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Regina, Saskatchewan, Canada|GSK Investigational Site, Québec, Canada|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Olomouc, Czechia|GSK Investigational Site, Ostrava, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Praha 7, Czechia|GSK Investigational Site, Praha 8, Czechia|GSK Investigational Site, Trutnov, Czechia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Kuopio, Finland|GSK Investigational Site, Bourg en Bresse, France|GSK Investigational Site, Caen, France|GSK Investigational Site, Dijon, France|GSK Investigational Site, Ivry, France|GSK Investigational Site, La Seyne sur Mer, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Limoges, France|GSK Investigational Site, Luynes, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Marseille, France|GSK Investigational Site, Marseille, France|GSK Investigational Site, Metz, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nice, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pau, France|GSK Investigational Site, Rodez, France|GSK Investigational Site, Saint Ouen la Rouerie, France|GSK Investigational Site, Saint-Etienne, France|GSK Investigational Site, Sautron, France|GSK Investigational Site, Tinteniac, France|GSK Investigational Site, Toulon, France|GSK Investigational Site, Toulouse, France|GSK Investigational Site, Tours, France|GSK Investigational Site, Vichy, France|GSK Investigational Site, Aalen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ludwigsburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ostfildern, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Alzenau, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Saarow, Brandenburg, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Erbach, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Bockhorn, Niedersachsen, Germany|GSK Investigational Site, Ganderkesee, Niedersachsen, Germany|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Lueneburg, Niedersachsen, Germany|GSK Investigational Site, Westerstede, Niedersachsen, Germany|GSK Investigational Site, Bad Honnef, Nordrhein-Westfalen, Germany|GSK Investigational Site, Baesweiler, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bergisch Gladbach, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dueren, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Juelich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Krefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Siegen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Chemnitz, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Gera, Thueringen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Melissia, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Varanasi, India|GSK Investigational Site, Chieti Scalo, Abruzzo, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, San Felice a Cancello Caserta, Campania, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Brescia, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Rho, Lombardia, Italy|GSK Investigational Site, Torrette (AN), Marche, Italy|GSK Investigational Site, Arezzo, Toscana, Italy|GSK Investigational Site, Firenze, Toscana, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Seongnam-si,, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Blaricum, Netherlands|GSK Investigational Site, Den Bosch, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Hengelo, Netherlands|GSK Investigational Site, Hilversum, Netherlands|GSK Investigational Site, Pasig City, Philippines|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Mosina, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Sopot, Poland|GSK Investigational Site, Warsaw, Poland|GSK Investigational Site, Coimbra, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Ljubljana, Slovenia|GSK Investigational Site, Šempeter, Slovenia|GSK Investigational Site, Loeventstein, South Africa|GSK Investigational Site, Oakdale, South Africa|GSK Investigational Site, Richards Bay, South Africa|GSK Investigational Site, Rosebank, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Waverley, Bloemfontein, South Africa|GSK Investigational Site, Willows, X14, Pretoria, South Africa|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Burgos, Spain|GSK Investigational Site, Castellón, Spain|GSK Investigational Site, Elche (Alicante), Spain|GSK Investigational Site, Gerona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Jönköping, Sweden|GSK Investigational Site, Kalix, Sweden|GSK Investigational Site, Mölndal, Sweden|GSK Investigational Site, Sundsvall, Sweden|GSK Investigational Site, Umeå, Sweden|GSK Investigational Site, Blackpool, Lancashire, United Kingdom|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT00490568
NCT00488670,Escitalopram and Depression in Elderly Alzheimer's Patients,,Terminated,No Results Available,Depressive Disorder,Drug: Escitalopram,Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.|Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study,University of British Columbia,All,"50 Years and older   (Adult, Older Adult)",Phase 3,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H07-00050,Dec-10,Jun-11,Jun-11,20-Jun-07,null,6-Jun-11,"Mt. St. Joseph's Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00488670
NCT00488007,"Clinical Trial on Alzheimer Disease, Presbycusis and Hearing Aids",,Completed,No Results Available,Alzheimer Disease|Presbycusis,Device: Hearing aids used : PHONAK Savia and Valeo,"Cognitive benefit evaluated thanks to the ADAS-Cog scale|Cognitive scales: MMSE, Grober and Buschke, Digit symbol test|Behavioural scales: IADL, NPI|Quality of life scales: Zarit scale and ADRQL|Consumption questionnaire",Hospices Civils de Lyon,All,65 Years and older   (Older Adult),Not Applicable,51,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2006.414,May-07,Jun-13,Sep-13,19-Jun-07,null,30-Aug-16,"Xavier PERROT, Lyon, France",,https://ClinicalTrials.gov/show/NCT00488007
NCT00486044,Evaluating Simvastatin's Potential Role in Therapy,ESPRIT,Completed,Has Results,Alzheimer Disease,Drug: Simvastatin|Drug: Placebo,Change in Cerebrospinal Fluid (CSF) Beta-amyloid-42|Changes in Regional Cerebral Blood Flow on MRI|Change in Inflammatory Markers|Changes in Cognitive Performance,"University of Wisconsin, Madison|National Institute on Aging (NIA)|Paul Beeson Faculty Scholars Program|The John A. Hartford Foundation|The Atlantic Philanthropies|Starr Foundation|American Federation for Aging Research|Merck Sharp & Dohme Corp.",All,"35 Years to 69 Years   (Adult, Older Adult)",Phase 2,103,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",IA0116|1K23AG026752-01,Feb-05,Jun-09,Jun-09,13-Jun-07,5-Nov-15,5-Mar-19,"University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00486044
NCT00483028,"A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI",,Completed,No Results Available,Alzheimer's Disease,Drug: donezepil (Aricept),"Neuropsychologic test scores: GMLT, DSST, Cog State TM including PAL test, RAVLT, ADAS-cog at baseline (pre-dose) 5 and 8 hours after the first dose and 2 and 6 weeks. (Continues in next bullet.)|MRS (Magnetic Resonance Spectroscopy) profile including but not limited to NAA (N-acetyl-aspartate), NAA/Cr (N-acetyl-aspartate/creatinine ratio), MI (Myoinositol) and MI/Cr (Myoinositol/creatinine ratio).",Pfizer,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,38,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A9001134,Jun-04,null,Jan-07,6-Jun-07,null,5-Feb-08,"Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Albany, New York, United States",,https://ClinicalTrials.gov/show/NCT00483028
NCT00481520,"Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease",,Completed,No Results Available,Alzheimer Disease,Drug: SAM-531|Other: placebo,"Routine safety and tolerability will be evaluated.|This study will also investigate the pharmacokinetics(PK, how the drug is metabolized) and pharmacodynamics (PD, how the drug affects bodily and mental function) of SAM-531 compared to placebo.",Wyeth is now a wholly owned subsidiary of Pfizer,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",3193A1-2000,Jun-07,Jan-08,Jan-08,1-Jun-07,null,30-Sep-09,"Delray Beach, Florida, United States|Hallandale, Florida, United States|St. Petersburg, Florida, United States|Atlanta, Georgia, United States|Long Branch, New Jersey, United States|New York, New York, United States|Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00481520
NCT00480467,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males",,Completed,No Results Available,Alzheimer Disease,Drug: SAM-315,Safety and tolerability|Pharmacokinetics and pharmacodynamics,Wyeth is now a wholly owned subsidiary of Pfizer,Male,20 Years to 45 Years   (Adult),Phase 1,32,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,3182A1-102,Sep-06,null,Aug-07,31-May-07,null,5-Dec-07,"Ibaraki Pref, Japan",,https://ClinicalTrials.gov/show/NCT00480467
NCT00480701,Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease,IBVM001,Completed,No Results Available,Alzheimer Disease|Parkinson Disease,Drug: [123I]-IBVM,Does 123-I IBVM SPECT provide a quantitative measure of acetylcholinergic transporters in Healthy controls and AD patients?|Does 123-I IBVM SPECT demonstrate reduced acetylcholinergic transporter binding in AD compared to healthy controls?|Does 123-I IBVM SPECT provide a reliable measure of acetylcholinergic transporters in healthy controls and AD patients?,Institute for Neurodegenerative Disorders,All,"50 Years and older   (Adult, Older Adult)",Phase 2,26,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),IBVM001,Feb-07,Oct-11,Oct-11,31-May-07,null,7-May-14,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00480701
NCT00480818,"Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects",,Completed,No Results Available,Alzheimer Disease,Drug: SAM-531,Safety and tolerability|Pharmacokinetics and pharmacodynamics,Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,3193A1-102,Sep-06,null,Jul-07,31-May-07,null,11-Dec-07,"Rennes, France",,https://ClinicalTrials.gov/show/NCT00480818
NCT00480220,Specific Care and Assistance Plan for Alzheimer's Disease,PLASA,Completed,No Results Available,Alzheimer's Disease,Procedure: Global care and support program,"Evaluate the efficacy of the specific care and assistance plan for Alzheimer's disease in a study randomised within each centre. The main aim of the care plan is to reduce loss of independence.|Impact of the care and assistance plan: - on the mode of the patient's admission to an institution - on utilization of assistance, support and healthcare services (RUD questionnaire) - and on overall clinical evaluation of change (ADCS-CGIC).","University Hospital, Toulouse",All,65 Years and older   (Older Adult),Not Applicable,1200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,0200601|PHRC,Aug-03,Aug-07,Aug-07,30-May-07,null,19-Aug-15,"Hospital, Albi, France|Hospital Center, Ales, France|University Hospital, Angers, France|Hospital, Annecy, France|Hospital Center, Bar Le Duc, France|University Hospital, Brest, France|Hospital Center, Carcassonne, France|Service de Gérontologie, Carvin, France|Hospital, Chambery, France|Georges Clémenceau Hospital, Champcueil, France|Hospital Center, Grasse, France|University Hospital, Grenoble, France|Hôpital Charles Foix - La Triade, Ivry-sur-seine, France|Hospital Center, Lannemezan, France|Hospital Center, Lavaur, France|Hospital, Lens, France|University Hospital, Lille, France|Hospital Center, Louviers, France|University Hospital, Lyon, France|University Hospital Sainte Marguerite, Marseille, France|University Hospital, Montpellier, France|University Hospital, Nice, France|University Hospital, Nimes, France|Hospital Center, Niort, France|Hospital Bichat - Claude Bernard, Paris, France|Hospital Center Notre Dame du Bon Secours, Paris, France|University Hospital BROCA - La Rochefoucauld, Paris, France|University Hospital Pitié-Salpétrière, Paris, France|University Hospital Sainte Perrine, Paris, France|Hospital center, Plaisir, France|University Hospital, Reims, France|Hospital Center, Roubaix, France|University Hospital, Rouen, France|Hospital Center, Saint Dizier, France|Hospital Center, Sezanne, France|University Hospital, Hôpital Xavier Arnozan, Toulouse, France|University Hospital, Toulouse, France|Hospital, Valenciennes, France|Hospital Center, Villejuif, France|Hospital, Wasquehal, France",,https://ClinicalTrials.gov/show/NCT00480220
NCT00479219,Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients,,Completed,No Results Available,Alzheimer Disease,Drug: GSI-953|Other: Placebo,"We will assess the pharmacodynamics (PD) of biomarkers amyloid beta 40 and 42 in CSF, following single oral doses of GSI-953 in healthy young and Alzheimer's Patients.",Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,17,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3183A1-103,May-07,Oct-07,Oct-07,28-May-07,null,10-Jul-08,"Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT00479219
NCT00479271,Evaluating the Effectiveness of a Community Based Intervention for Persons With Dementia and Their Caregivers in a Developing Country,,Completed,No Results Available,Dementia|Behavioral Symptoms|Mental Health,"Behavioral: Home based, flexible, stepped care intervention|Behavioral: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.","Primary Outcome Measure(s) evaluate the efficacy and cost-effectiveness of the intervention in reducing carer burden, improving behaviour problems in elderly persons with dementia and reducing the costs of illness.|Measure the service requirements, average number of visits by Home Care Advisor, visits by Psychiatrists, need for medication, effect of intervention on survival and overall quality of life of the person with dementia as well as the carer","London School of Hygiene and Tropical Medicine|The Dementia Society of Goa, India|Goa Medical College",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,null,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Supportive Care,DSG001,Oct-03,Feb-05,Feb-05,28-May-07,null,1-Apr-15,"The Dementia Society of Goa, Porvorim, Goa, India",,https://ClinicalTrials.gov/show/NCT00479271
NCT00479297,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males",,Completed,No Results Available,Alzheimer Disease,Drug: SAM-531,Safety and tolerability|Pharmacokinetics and pharmacodynamics,Wyeth is now a wholly owned subsidiary of Pfizer,Male,20 Years to 45 Years   (Adult),Phase 1,72,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,3193A1-101,May-06,Feb-07,Feb-07,28-May-07,null,7-Aug-09,,,https://ClinicalTrials.gov/show/NCT00479297
NCT00479349,"Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531",,Completed,No Results Available,Alzheimer Disease,Drug: SAM-531,Safety and tolerability|Pharmacokinetics and pharmacodynamics,Wyeth is now a wholly owned subsidiary of Pfizer,Male,"20 Years and older   (Adult, Older Adult)",Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3193A1-1104,May-07,Jan-08,Jan-08,28-May-07,null,7-Jul-09,"Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00479349
NCT00479440,"Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults",,Completed,No Results Available,Alzheimer Disease,Drug: SAM-315,Safety and tolerability|Pharmacokinetics and pharmacodynamics,Wyeth is now a wholly owned subsidiary of Pfizer,All,18 Years to 45 Years   (Adult),Phase 1,56,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,3182A1-100,Aug-06,null,Mar-07,28-May-07,null,5-Dec-07,,,https://ClinicalTrials.gov/show/NCT00479440
NCT00479557,"Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease",,Completed,Has Results,Alzheimer Disease,Biological: ACC-001 + QS-21|Biological: ACC-001|Biological: QS-21|Drug: Placebo: Phosphate buffered saline,"Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)|Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104|GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104|Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)","Pfizer|Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,86,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3134K1-200|B2571004|2006-002061-39,May-07,Jan-13,Jan-13,28-May-07,1-Jan-16,1-Jan-16,"Groupe Hospitalier Pitie-Salpetriere, Paris, Cedex 13 (MRI), France|Hôpital Pitié-Salpétrière, Paris Cedex 13, Paris, France|Hopital Pellegrin-Centre Mémoire de Recherche et de Ressources, Bordeaux, France|CHRU de Lille, Lille (MRI), France|CHRU de Lille, Lille, France|Hôpital Sainte-Marguerite, MARSEILLE cedex 5, France|CHU Hôpital Gui de Chaulliac, Montpellier, France|Groupe Hospitalier Broca-La Rochefoucauld, Paris, France|Clinique de L'Union, St JEAN, France|Hôpital LA GRAVE, TOULOUSE Cedex 9, France|Chru Purpan, Toulouse, France|Clinique PASTEUR, Toulouse, France|Unversitätsklinikum Freiburg, Freiburg, Baden- Württemberg, Germany|Klinik fuer Psychiatrie und Psychotherapie, Charite Universitaetsmedizin Berlin, Berlin, Germany|Zentralinstitut fuer Seelische Gesundheit, Frankenthal, Germany|Klinik fuer Psychiatrie und Psychotherapie, Goettingen, Germany|Zentralinstitut fuer Seelische Gesundheit, Mannheim, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Technische Universitaet Muenchen, Klinikum rechts der Isar, München, Germany|Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clinico y Provincial, Barcelona, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT00479557
NCT00479700,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects",,Completed,No Results Available,Alzheimer Disease,Drug: SAM-531,Safety and tolerability|Pharmacokinetics and pharmacodynamics,Wyeth is now a wholly owned subsidiary of Pfizer,All,18 Years to 45 Years   (Adult),Phase 1,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,3193A1-100,May-06,null,Jul-06,28-May-07,null,10-Dec-07,,,https://ClinicalTrials.gov/show/NCT00479700
NCT00479843,Nutritional Programme for Dementia Elderly Patient,,Completed,No Results Available,Alzheimer's Disease|Dementia,Behavioral: Nutritional programme,Evaluation of the effectiveness of the intervention -The main evaluation criteria which will allow the effectiveness of this intervention to be evaluated are the reduction in the loss of autonomy measured by the DA/IDA scale.|-Improvement in the patient's state of nutrition -Reducing the burden on carers with the Zarit scale. -Evaluation of the use of healthcare and social resources with the RUD scale. -Improvement of medical practice regarding nutrition.,"Nestlé|Institut Català de l'envelliment, Barcelona, Spain|Hospital Purpan|NESTEC R&D, Switzerland|Group MAPI-NAXIS, CRO, Lyon, France",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,946,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,05.19.CLI,Jul-05,Jul-07,Jul-07,28-May-07,null,24-Jan-14,"Institut Català de l'envelliment, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00479843
NCT00477659,Neural Correlates In Mild Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: donepezil HCl (Aricept),"Functional magnetic resonance imaging to identify neural correlates of cognitive improvement after 3 months of donepezil HCl in subjects w/ mild AD, using the Functional Hippocampus Connectivity Index (HCI) and Cerebral Blood Flow (CBF) Perfusion|Mini Mental State Exam, Alzheimer's Disease Assess,emt Scale-cognitive subscale, Neuropsychiatric Inventory and Instrumental Activities of Daily Living scales at screen and week 12.",Eisai Inc.|Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 4,14,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2501055|E2020-A001-416,Jul-07,Aug-08,Aug-08,24-May-07,null,7-May-09,"Pfizer Investigational Site, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00477659
NCT00478205,Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Aricept (donepezil SR 23 mg)|Drug: Aricept (donepezil IR 10 mg),Change From Baseline to Week 24 in SIB Total Score|Overall Change From Baseline in Modified CIBIC+ to Week 24|Change From Baseline to Week 24 in ADCS-ADL Total Score|Change From Baseline to Week 24 in MMSE Total Score,Eisai Inc.|Eisai Limited,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 3,1467,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E2020-G000-326|2006-004888-54,Jun-07,Jun-09,null,24-May-07,5-Feb-13,11-Jul-14,"MedTrials, Inc., Hickory, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00478205
NCT00476008,Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Memantine|Drug: Placebo,The Primary Outcome Measure is the Number of Subjects in Each Group Who Are Able to Pass the DriveABLE On-Road Test at Month 12 (Endpoint).|Fuld Object Memory Evaluation|Rey Complex Figure Test|Trail Making Test - Part A|Trail Making Test - Part B|Mini Mental Status Exam|Useful Field of View|Motor Free Visual Perception Test - Visual Closure Subtest|Cognitive Dementia Rating Scale|Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog),Florida Atlantic University|Forest Laboratories,All,"60 Years and older   (Adult, Older Adult)",Phase 4,60,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NAM-MD-49,Jul-07,Oct-12,Oct-12,21-May-07,3-Jun-14,11-Aug-14,"Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, United States",,https://ClinicalTrials.gov/show/NCT00476008
NCT00474552,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315",,Terminated,No Results Available,Alzheimer Disease,Drug: SAM-315,"safety, tolerability and PK",Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3182A1-101,Jun-07,Oct-07,Oct-07,17-May-07,null,18-Feb-08,"Paris, France",,https://ClinicalTrials.gov/show/NCT00474552
NCT00471211,"Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Drug: PBT2,Safety|Change from baseline in biomarkers; Change from baseline in cognitive and global function scales,Prana Biotechnology Limited,All,"56 Years and older   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PBT2-201,Dec-06,Dec-07,Dec-07,9-May-07,null,16-Jan-08,"Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Adelaide, South Australia, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Falkoping, Sweden|Kalix, Sweden|Kalmar, Sweden|Lund, Sweden|Malmo, Sweden|Stockholm, Sweden|Umea, Sweden|Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00471211
NCT00470418,Development of NIC5-15 in the Treatment of Alzheimer's Disease,,Completed,Has Results,Alzheimer Disease|Dementia,Drug: NIC5-15|Drug: Placebo,Safety Assessments: Number of Participants With Adverse Events|Changes From Baseline in Clinical Measures of Cognition at Terminal Visit,VA Office of Research and Development|National Center for Complementary and Integrative Health (NCCIH)|Humanetics Corporation,All,"Child, Adult, Older Adult",Phase 2,15,U.S. Fed|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MHBB-009-06S|R21AT003302-01A1,Jan-07,Aug-08,Mar-10,7-May-07,9-Jan-17,9-Jan-17,"VA Medical Center, Bronx, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00470418
NCT00469456,Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Memantine|Drug: placebo,Change From Baseline in Functional Linguistic Communication Inventory (FLCI) at Week 12|Change From Baseline in American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS) [Total Score of Social Communication and Communication of Basic Needs Subscores] at Week 12,Forest Laboratories,All,"50 Years and older   (Adult, Older Adult)",Phase 4,265,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MEM-MD-71,Apr-07,Nov-08,Nov-08,4-May-07,7-Dec-09,24-Dec-09,"Forest Investigative Site, East Gosford, New South Wales, Australia|Forest Investigative Site, Hornsby, New South Wales, Australia|Forest Investigative Site, Kogarah, New South Wales, Australia|Forest Investigative Site, Newcastle, New South Wales, Australia|Forest Investigative Site, Randwick, New South Wales, Australia|Forest Investigative Site, Chermside, Queensland, Australia|Forest Investigative Site, Toowoomba, Queensland, Australia|Forest Investigative Site, Adelaide, South Australia, Australia|Forest Investigative Site, Woodville, South Australia, Australia|Forest Investigative Site, Box Hill, Victoria, Australia|Forest Investigative Site, Frankston, Victoria, Australia|Forest Investigative Site, Heidelberg West, Victoria, Australia|Forest Investigative Site, Kew, Victoria, Australia|Forest Investigative Site, Perth, Western Australia, Australia|Forest Investigative Site, Christchurch, New Zealand|Forest Investigative Site, North Shore, New Zealand|Forest Investigative Site, Timaru, New Zealand|Forest Investigative Site, George, E. Cape, South Africa|Forest Investigative Site, Port Elizabeth, E. Cape, South Africa|Forest Investigative Site, Johannesburg, Gauteng, South Africa|Forest Investigative Site, Johannesburg, Gauteng, South Africa|Forest Investigative Site, Pretoria, Gauteng, South Africa|Forest Investigative Site, Durban, KZ-Natal, South Africa|Forest Investigative Site, Cape Town, W. Cape, South Africa|Forest Investigative Site, Cape Town, W. Cape, South Africa",,https://ClinicalTrials.gov/show/NCT00469456
NCT00468897,A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.,,Completed,No Results Available,Alzheimer's Disease,Drug: RSG XR,"PK samples|Safety and tolerability as measured by adverse events, vital signs clinical laboratory measurements.",GlaxoSmithKline,All,18 Years to 55 Years   (Adult),Phase 1,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AXR107453,21-Mar-07,2-May-07,2-May-07,3-May-07,null,7-Aug-17,"GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany",,https://ClinicalTrials.gov/show/NCT00468897
NCT00464334,A Study of V950 in People With Alzheimer Disease (V950-001 AM7),,Completed,Has Results,Alzheimer Disease,Biological: V950|Biological: ISCOMATRIX™|Biological: Placebo to V950,Number of Participants Who Experienced at Least One Adverse Event|Number of Participants Who Discontinued Study Drug Due to an Adverse Event|Geometric Mean Titer (GMT) of Amyloid Beta (Aβ) Peptide 1-40 Specific Antibodies at Month 7|Mean Fold Change From Baseline in GMT of Aβ Peptide 1-40 Specific Antibodies,Merck Sharp & Dohme Corp.,All,"55 Years and older   (Adult, Older Adult)",Phase 1,86,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic",V950-001|2007_518,Mar-07,Jan-12,Jan-12,23-Apr-07,18-Dec-12,25-Sep-15,,,https://ClinicalTrials.gov/show/NCT00464334
NCT00462917,REVEAL III: Risk Evaluation and Education for Alzheimer's Disease,REVEAL,Completed,Has Results,Alzheimer Disease,"Behavioral: Pleiotropic info, in-person disclosure|Behavioral: AD-only info, in-person disclosure|Behavioral: Pleiotropic info, phone disclosure|Behavioral: AD-only info, phone disclosure",Center for Epidemiological Studies-Depression Scale (CES-D)|Beck Anxiety Inventory (BAI)|Impact of Events Scale (IES),Brigham and Women's Hospital|National Human Genome Research Institute (NHGRI),All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,290,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,IA0113|R01HG002213,Mar-07,Oct-09,Oct-09,19-Apr-07,11-Sep-14,23-Oct-18,"Howard University, Washington, District of Columbia, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Case Western Reserve University, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00462917
NCT00459550,A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: GSK933776|Drug: Placebo to match GSK933776,"Adverse events. Changes suggesting potential adverse events detected in the physical & neurological examination, brain MRI, cognitive status, laboratory parameters, ECG & vital signs.|Plasma pharmacokinetic parameters of GSK933776. Pharmacodynamic effects of GSK 933776. CSF detectable levels of GSK933776. Effects of GSK933776 on plasma and CSF biomarkers. Titre & neutralising activity of anti-GSK933776 antibodies. Exploratory PET scan",GlaxoSmithKline,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,106006,12-Mar-07,30-May-11,30-May-11,12-Apr-07,null,21-Jul-17,"GSK Investigational Site, Herston, Queensland, Australia|GSK Investigational Site, Heidelberg Heights, Victoria, Australia|GSK Investigational Site, Fremantle, Western Australia, Australia|GSK Investigational Site, Lørenskog, Norway|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Mölndal, Sweden|GSK Investigational Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00459550
NCT00459693,PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD),,Terminated,No Results Available,HIV-Dementia|HIV-Associated Cognitive Motor Complex|AIDS Encephalopathy|AIDS Dementia Complex|AIDS-Related Dementia Complex|HIV Infections|Healthy,Drug: [11C]PBR28,Brain uptake of [11C]PBR28 (measured as distribution volume).,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,18 Years to 50 Years   (Adult),Not Applicable,40,NIH,Interventional,Primary Purpose: Treatment,070129|07-M-0129,9-Apr-07,6-Apr-14,6-Apr-14,12-Apr-07,null,20-May-19,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00459693
NCT00459355,Home Safety Clinical Trial for Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease|Dementia,Behavioral: Home Safety Toolkit,Caregiver Strain|Caregiver Self-efficacy|Care Recipient Risky Behaviors and Accidents,US Department of Veterans Affairs|Boston Medical Center|VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Phase 1,254,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,NRH 05-056,Jul-07,May-10,Dec-11,11-Apr-07,29-Sep-14,28-Apr-15,"Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00459355
NCT00456417,Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects,,Completed,No Results Available,Alzheimers Disease,Drug: 123-I MNI-187 Injection and Imaging Procedures,To assess the dynamic uptake and washout of 123-I MNI-187|Blood metabolite characterization of 123-I MNI-187 in healthy and AD subjects to determine the metabolic fate and nature of metabolites; Evaluate the test/retest reproducibility of 123-I MNI-187 and SPECT in AD subjects and healthy controls,Institute for Neurodegenerative Disorders|Molecular NeuroImaging,All,"50 Years and older   (Adult, Older Adult)",Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,MNI-187-01,Apr-07,Dec-07,Dec-07,5-Apr-07,null,14-Mar-19,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00456417
NCT00454870,Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: MEM 3454,,Memory Pharmaceuticals,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,MEM 3454-003,Feb-07,Oct-07,Oct-07,2-Apr-07,null,6-May-08,"Phoenix, Arizona, United States|Glendale, California, United States|Atlanta, Georgia, United States|Wichita, Kansas, United States|Wichita, Kansas, United States|Willingboro, New Jersey, United States|Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00454870
NCT00455000,"A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Biological: PF-04360365|Drug: Placebo,"To examine the safety, tolerability, and pharmacokinetics of a single dose of PF-04360365 in subjects with mild to moderate AD for one year following dosing.|To characterize the pharmacokinetic, pharmacodynamic and immunogenicity profile of PF-04360365 for one year following dosing.",Pfizer,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,37,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",A9951001,Mar-07,Sep-09,Sep-09,2-Apr-07,null,14-Oct-09,"Pfizer Investigational Site, Heidelberg West, Victoria, Australia|Pfizer Investigational Site, Fremantle, Western Australia, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Southampton, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00455000
NCT00453544,Enhancing Consent for Alzheimer's Research,BWP-AD,Completed,No Results Available,Alzheimer Disease,Other: Enhanced Consent Procedure|Other: Routine Consent Procedure,Level of Understanding|Appreciation|Reasoning|Expression of a Choice regarding hypothetical protocol|Level of Satisfaction with consent process|Expressed willingness to participate in the hypothetical protocol,"University of California, San Diego|National Institute on Aging (NIA)",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,252,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),IA0110|1R01AG028827,Apr-06,Sep-12,Sep-12,29-Mar-07,null,28-Oct-16,"Veterans Affairs San Diego Healthcare System, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00453544
NCT00452504,Single Ascending Dose Study of SRA-444 in Healthy Subjects,,Completed,No Results Available,Alzheimer Disease,Drug: SRA-444,Assessment of the safety and tolerability of SRA-444,Wyeth is now a wholly owned subsidiary of Pfizer,Male,18 Years to 50 Years   (Adult),Phase 1,64,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,3197A1-100,Feb-07,null,Jun-07,27-Mar-07,null,5-Dec-07,"Zuidlaren, Netherlands",,https://ClinicalTrials.gov/show/NCT00452504
NCT00448799,Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls,,Completed,No Results Available,Alzheimers Disease,Radiation: [123-I] AV-83 Injection and Imaging Procedures,Assess the dynamic uptake and washout of 123-I AV83|Blood metabolite characterization of 123-I AV39 in healthy and AD subjects to determine the metabolic fate and nature of metabolites|Evaluate the test/retest reproducibility of 123-IAv83 and SPECT in AD subjects and healthy controls.,Molecular NeuroImaging|Institute for Neurodegenerative Disorders,All,"50 Years and older   (Adult, Older Adult)",Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AV-83 001|07-033,Mar-07,Mar-08,Mar-08,19-Mar-07,null,13-May-08,"Molecular NeuroImaging, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00448799
NCT00448318,Evaluating the Effects of Music Interventions on Hospitalised People With Dementia,,Unknown status,No Results Available,"Dementia|Alzheimer's Disease|Dementia, Vascular|Lewy Body Disease",Procedure: Music Therapy,Mini Mental State Examination: baseline cf. post intervention scores.|Hierarchic Dementia Scale: baseline cf. post intervention scores.|Geriatric Depression Scale: baseline cf. post intervention scores.|Note: post intervention measures taken within 24 hours of final therapeutic intervention session|EEG fast/slow ratio: baseline cf. post intervention scores.|EEG Coherence: baseline cf. post intervention scores.|EEG evoked potentials:baseline cf. post intervention scores.,"National Ageing Research Institute, Australia",All,"60 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,WKG_07_BB,Mar-07,null,Oct-08,16-Mar-07,null,16-Mar-07,"National Ageing Research Institute, Parkville, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT00448318
NCT00443417,A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: SK-PC-B70M,ADAS-cog(Alzheimer's Disease Assessment Scale-Cognitive subscale)|MMSE(Mini Mental State Examination)|CDR-SB(Clinical Dementia Rating Sum of Box)|QOL-AD(Quality of Life in Alzheimer's Disease)|Delayed Word-Recall Task|Symbol Digit Modalities Test|Digit Backward|Maze Task|Digit Cancellation Task|Verbal Fluency-Categories|Concentration / Distractibility|GDS,"SK Chemicals Co., Ltd.",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,188,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SMART_II_2006,Apr-07,Jan-09,Jan-09,6-Mar-07,null,9-Dec-09,"SKchemicalsI nvestigational Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00443417
NCT00443014,The Dementia Study in Northern Norway,,Completed,No Results Available,Alzheimer Disease,"Device: Cognitive, physical and social stimulation",The cognitive function is measured with the Alzheimer's Disease Assessment|Changes in Activity of Daily Living (ADL) measured by standardized tests.,"University Hospital of North Norway|County Officer of Nordland, Moloveien 2, 8006 Bodø, Norway|Norwegian Foundation for Health and Rehabilitation|Norwegian Department of Health and Social Affairs",All,65 Years and older   (Older Adult),Phase 4,187,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",200201054-12/12BMA2/400,Jun-03,Jun-09,Jun-09,5-Mar-07,null,10-Nov-11,"Arran Lulesami Centre, Drag, Nordland, Norway",,https://ClinicalTrials.gov/show/NCT00443014
NCT00441987,Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953,,Completed,No Results Available,Alzheimer Disease|Healthy,Drug: GSI-953,Safety,Wyeth is now a wholly owned subsidiary of Pfizer,Male,"20 Years and older   (Adult, Older Adult)",Phase 1,96,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3183A1-101,Feb-07,Jul-09,Jul-09,1-Mar-07,null,22-Jun-10,"5-4-12, Kitashinagawa, Shinagawa-ku, Japan",,https://ClinicalTrials.gov/show/NCT00441987
NCT00440050,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",DHA,Completed,Has Results,Alzheimer's Disease,Drug: DHA (Docosahexaenoic Acid)|Drug: Placebo,Rate of Change on the ADAS-Cog 11.|Rate of Change on CDR-SOB|ADCS-ADL|Neuropsychiatric Inventory (NPI),"Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)|DSM Nutritional Products, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,402,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IA0099|1RC2AG036535|ADC-027-DHA,Feb-07,May-09,May-09,26-Feb-07,30-Aug-10,25-Sep-14,"University of Alabama, Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Sun Health Research Institute/Arizona Consortium, Sun City, Arizona, United States|University of California Irvine, Irvine, California, United States|UCSD Shiley-Marcos Alzheimer's Research Center, La Jolla, California, United States|University of Southern California Psychiatry and Behavioral Sciences, Los Angeles, California, United States|UCLA Neurology, Los Angeles, California, United States|Palo Alto Institute for Research & Education, Palo Alto, California, United States|UC-Davis Alzheimer's Disease Center, Sacramento, California, United States|Pacific Research Network, San Diego, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University Medical Center, Dept. of Neurology, Washington, District of Columbia, United States|Howard University College of Medicine, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center, Miami Beach, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Byrd Alzheimer's Institute, Tampa, Florida, United States|Emory University Dept. of Psychiatry, Atlanta, Georgia, United States|Northwestern University Cognitive Neurology and Alzheimer Disease Center, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Sanders-Brown Center on Aging/Neurology, Lexington, Kentucky, United States|Johns Hopkins University Division of Cognitive Neuroscience, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University Alzheimer's Disease Clinical and Research Program, Boston, Massachusetts, United States|University of Michigan Dept. of Neurology, Ann Arbor, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Mayo Clinic Rochester, Alzheimer's Disease Research Center, Rochester, Minnesota, United States|Saint Louis University, Department of Psychiatry, St. Louis, Missouri, United States|Washington University ADRC-Memory and Aging Project, St. Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|Mount Sinai School of Medicine, Bronx, New York, United States|New York University Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Services, Winston-Salem, North Carolina, United States|Case Western Reserve University Memory and Aging Center, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University Neurology, Portland, Oregon, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital Neurology, Providence, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Meharry Medical College, Nashville, Tennessee, United States|University of Texas Southwestern-Memory Research Unit, Dallas, Texas, United States|Baylor University Department of Neurology, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|University of Washington/Seattle Institute for Biomedical & Clinical Research, Seattle, Washington, United States|University of Wisconsin Department of Medicine, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00440050
NCT00439166,Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,,Completed,No Results Available,Alzheimer's Disease,Drug: doxycycline|Drug: rifampicin|Drug: Placebo matched to doxycycline|Drug: Placebo matched to Rifampin,Clinical Dementia Rating scale|Standardized Alzheimer's disease Assessment Scale -cognitive subscale,Hamilton Health Sciences Corporation|The Physicians' Services Incorporated Foundation|McMaster University,All,"50 Years and older   (Adult, Older Adult)",Phase 3,100,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PSI 06-47,Feb-07,Apr-10,Dec-10,23-Feb-07,null,19-Mar-18,"St.Peter's Hospital, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00439166
NCT00438568,SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days),SNIFF 120,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Drug: Regular Insulin|Drug: Placebo,Changes in cognition|glucose metabolism|plasma biological markers|CSF biological markers|cerebral glucose metabolism,University of Washington|National Institute on Aging (NIA),All,"55 Years and older   (Adult, Older Adult)",Phase 2,173,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",30579-B|5R01AG027415|1R01AG027415-01,Jun-06,Dec-11,Dec-11,22-Feb-07,null,14-Sep-12,"Veterans Administration Puget Sound Health Care System, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00438568
NCT00438724,Couples Coping With Alzheimer's Disease,,Unknown status,No Results Available,Aging|Alzheimer Disease|Dementia,"Behavioral: Information, counseling and support",Changes in dyadic (couple) adjustment|depression|Level of anxiety|satisfaction with social support,Alzheimer's Association|National Institute on Aging (NIA),All,"21 Years to 90 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),IA0103|ZEN-04-1011,Nov-04,null,Nov-07,22-Feb-07,null,20-Sep-07,"Aging and Dementia Research Center, Silberstein Institute, NYU School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00438724
NCT00439010,Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects,,Completed,No Results Available,Alzheimers Disease,Drug: [123I] AV 39,Assess the dynamic uptake and washout of 123-I AV39|Blood metabolite characterization of 123-I AV39 in healthy and AD subjects to determine the metabolic fate and nature of metabolites|Evaluate the test/retest reproducibility of 123-I AV39 and SPECT in AD subjects and healthy controls,Molecular NeuroImaging|Institute for Neurodegenerative Disorders,All,"50 Years and older   (Adult, Older Adult)",Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Diagnostic,AV-39 001,Feb-07,Jan-08,Jan-08,22-Feb-07,null,24-Apr-08,"Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00439010
NCT00432081,Effect of Indomethacin on the Progression of Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Drug: indomethacin,Score on the Cognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months.|Score on the Noncognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months|Score on the Clinician Interview-Based Impression of Change with caregiver input at 12 months|Score on the Mini-Mental State Examination at 12 months|Score on the Neuropsychiatric Inventory at 12 months|Score on the The Interview for Deterioration in Daily living activities in Dementia at 12 months|The occurrence of adverse events during 12 months of treatment,Radboud University|American Health Assistance Foundation|Netherlands Brain Foundation|Netherlands Alzheimer Foundation,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 3,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A2001-15-DDJ|917.46.331,May-00,null,Aug-05,6-Feb-07,null,6-Feb-07,"Rijnstate Hospital, Arnhem, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT00432081
NCT00428389,Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Rivastigmine 5 cm^2 transdermal patch|Drug: Rivastigmine 10 cm^2 transdermal patch,Number of Participants Who Discontinued From the Study Due to Any Reason During the Core Phase of the Study|Number of Participants Who Discontinued From the Study Due to Any Adverse Event (AE) During the Combined Core and Extension Phases of the Study|Number of Participants Who Discontinued From Study Due to Any Reason During Extension Phase|Mean Change From Baseline in the Clinical Global Impression of Change (CGIC) Score at Week 5 and Week 25|Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 25 and at the End of Study|Mean Change From Baseline in Neuropsychiatric Inventory - 10 Item (NPI-10) Score at Week 25 and at the End of Study.|Mean Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score at Week 25 and at the End of Study,Novartis,All,"50 Years and older   (Adult, Older Adult)",Phase 3,262,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713DUS38|CENA713DUS38E1,Jan-07,Feb-08,Feb-08,30-Jan-07,27-Jun-11,11-Jun-14,"Dedicated Clinical Research, Sun City, Arizona, United States|ATP Clinical Research, Costa Mesa, California, United States|Margolin Brain Institute, Fresno, California, United States|Investigative site, Denver, Colorado, United States|Berma Research Group, Hialeah, Florida, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Center for Clinical Trials, Venice, Florida, United States|Premiere Research Institute @ Palm Beach Neurology, West Palm Beach, Florida, United States|Medical Associates of North Georgia, Canton, Georgia, United States|Medical Associates of North Georgia, Cumming, Georgia, United States|Witham Health Services, Lebanon, Indiana, United States|Investigative site, Pittsfield, Massachusetts, United States|Rochester Center For Behavioral Medicine, Rochester Hills, Michigan, United States|Alzheimer's Research Corporation, Manchester, New Hampshire, United States|Investigative site, Long Branch, New Jersey, United States|Neurobehavioral Research, Inc, Cedarhurst, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Investigative site, Centerville, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Investigative site, Eugene, Oregon, United States|The Clinical Trial Center, Jenkintown, Pennsylvania, United States|Senior Adults Specialty Research, Austin, Texas, United States|Investigative site, Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00428389
NCT00428090,Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Rosiglitazone,"Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Apolipoprotein epsilon4 (APOE e4) Negative Cohort|Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in All Except e4/e4's Cohort|Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Full Population Cohort|Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W24 as a Function of APOE e4 Status in APOE4 Negative Cohort|Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W24 as a Function of APOE e4 Status in All Except e4/e4's Cohort|Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W24 as a Function of APOE e4 Status in Full Population Cohort|Change From Baseline (W0) in Mean ADAS-Cog Total Score at W8, W16, W24|Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W8, W16, W24|Change From Baseline (W0) in Mean Neuropsychiatric Inventory (NPI) Total Score at W8, W16, W24|Change From Baseline (W0) in Mean Disability Assessment for Dementia (DAD) Scale Total Score at W8, W16, W24|Change From Baseline (W0) in Mean Short Term Memory Assessment Total Score (ADAS-Cog Q1 Plus Q7) at W8, W16, W24|Change From Baseline (W0) in Mean European Quality of Life -5 Dimensions Proxy Version (EQ-5D Proxy) Total Score at W12, W24 Assessed by Utility|Change From Baseline (W0) in Mean European Quality of Life -5 Dimensions Proxy Version (EQ-5D Proxy) Total Score at W12, W24 Assessed by Thermometer (Visual Analog Scale [VAS])|Time Spent Caring for Basic and Instrumental Activities Resource Utilization in Dementia (RUD) Scale at W12 and W24|Change From Baseline (W0) in Alzheimer's Carer's Quality of Life Instrument (ACQLI) Score at W12 and W24.|Change From Baseline (W0) in Mini Mental State Examination (MMSE) Total Score at W24.|Change From Baseline (W0) in Glycosylated Hemoglobin (HbA1c) at W24.|Number of Participants With Adverse Events Defined by Severity|Number of Participants With Systolic and Diastolic Blood Pressure (SBP and DBP), Heart Rate (HR) and Weight Values of Potential Clinical Concern (PCC) Any Time on Treatment (ATOT).|Change From Baseline (W0) in 12-lead Electrocardiogram (ECG)|Change From Baseline (W0) in Heart Rate (HR) Measured From 12-lead Electrocardiogram (ECG)|Change From Baseline (W0) in Body Weight|Change From Baseline (W0) in Hemoglobin|Change From Baseline (W0) in Hematocrit|Change From Baseline (W0) in Periodic HbA1c Assessment|Number of Par. With Hematology Data of Potential Clinical Concern Any Time on Treatment|Number of Par. With Clinical Chemistry Values of Potential Clinical Concern Any Time on Treatment",GlaxoSmithKline,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,862,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",105640,27-Feb-07,1-Sep-08,5-Sep-08,29-Jan-07,19-May-17,19-May-17,"GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Newport Beach, California, United States|GSK Investigational Site, Palo Alto, California, United States|GSK Investigational Site, Reseda, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Fairfield, Connecticut, United States|GSK Investigational Site, Norwalk, Connecticut, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Delray Beach, Florida, United States|GSK Investigational Site, Destin, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Melbourne, Florida, United States|GSK Investigational Site, Plantation, Florida, United States|GSK Investigational Site, Sunrise, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, St. Paul, Minnesota, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Kenilworth, New Jersey, United States|GSK Investigational Site, Toms River, New Jersey, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Centerville, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Jenkintown, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, DeSoto, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Middleton, Wisconsin, United States|GSK Investigational Site, Graz-Eggenberg, Austria|GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Puente Alto - Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Dubrovnik, Croatia|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Guenzburg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Baesweiler, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bielefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Juelich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, Germany|GSK Investigational Site, Chemnitz, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Itzehoe, Schleswig-Holstein, Germany|GSK Investigational Site, Gera, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Melissia, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Gyula, Hungary|GSK Investigational Site, Kaposvár, Hungary|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, Tirupati, India|GSK Investigational Site, Seongnam-si,, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Saltillo, Coahuila, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Pasig City, Philippines|GSK Investigational Site, Quezon City, Philippines|GSK Investigational Site, Cabo Rojo, Puerto Rico|GSK Investigational Site, San Juan, Puerto Rico|GSK Investigational Site, San Juan, Puerto Rico|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Derriford, Plymouth, United Kingdom|GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT00428090
NCT00423228,Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease,BRAINz,Completed,No Results Available,Moderate Alzheimer's Disease,Drug: ZT-1|Drug: Donepezil,Change in the MMSE score from baseline to week 25|Responder rate as defined by at least 2 points improvement in the MMSE score;|Change on the ADAS-Cog 11 items subscale;|Change in the NPI-Q;|Change on the IADL scale;|Patient's convenience questionnaire.,Debiopharm International SA,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,228,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DEB-ZTSR-201|EUDRACT no. 2006-005161-18,Feb-07,Apr-09,Apr-09,18-Jan-07,null,14-Jan-15,"Central Coast Neuroscience Research, East Gosford, New South Wales, Australia|Hornsby-Kuring-gai Health Service, Hornsby, New South Wales, Australia|Southern Neurology, Kogarah, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Adelaide Hospital, Adelaïde, South Australia, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|St George's Hospital, Kew, Victoria, Australia|Austin Health Repatriation Hospital, West Heidelberg, Victoria, Australia|Hollywood Specialist Centre, Nedlands (Perth), Western Australia, Australia|Calgary West Medical Centre, Calgary, Alberta, Canada|Castledowns Medicentre, Edmonton, Alberta, Canada|Saibal Nandy Professional Corporation, Medicine Hat, Alberta, Canada|Parkwood Hospital, London, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Gerontion Research Inc., Toronto, Ontario, Canada|Neuro Rive-Sud, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|The Medical Arts Health Research Group, Kelowna, Canada|Douglas Hospital Research Center, Montréal, Canada|The Medical Arts Health Research Group, Penticton, Canada|OPMHS, Crowborough, East Sussex, United Kingdom|Glasgow Memory Clinic, Glasgow, Scotland, United Kingdom|Llandough Hospital, Penarth, Wales, United Kingdom|Royal Blackburn Hospital, Blackburn, United Kingdom|Camden and Islington Mental Health Trust, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|New Castle General Hospital, Newcastle upon Tyne, United Kingdom|MARC - Moorgreen Hospital, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00423228
NCT00423085,Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Rivastigmine transdermal patch|Drug: Placebo,Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)|Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)|Change From Baseline in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)|Change From Baseline in CIBIC Plus-J Score Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)|Change From Baseline in CIBIC Plus-J Score Mental Function Impairment Scale (MENFIS)|Change From Baseline in Mini-Mental State Examination (MMSE)|Extension Phase: Change From Extension Phase Baseline to End of Extension in Mini-Mental State Examination (MMSE)|Extension Phase: Change From Extension Phase Baseline to End of Extension in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)|Extension Phase: Change From Extension Phase Baseline to End of Extension in Modified Crichton Scale,Novartis Pharmaceuticals|Ono Pharmaceutical Co. Ltd|Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,859,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CENA713D1301|CENA713D1301E1,Jan-07,Mar-09,Apr-10,17-Jan-07,25-May-11,10-Feb-14,"Novartis Investigative Site, Hokkaido region, Hokkaido, Japan",,https://ClinicalTrials.gov/show/NCT00423085
NCT00420420,MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011),,Completed,Has Results,Alzheimer's Disease,Drug: MK0249|Drug: Comparator: Placebo (unspecified),Week 4 Change From Baseline in Computerized Neuropsychological Test Battery (CNTB): Short CNTB Summary Score.|Week 4 Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): ADAS-Cog Total Score|Week 4 Change From Baseline in Cognition Summary Score (CSS),Merck Sharp & Dohme Corp.,All,"55 Years and older   (Adult, Older Adult)",Phase 2,144,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0249-011|2006_534,Nov-06,Aug-08,Aug-08,11-Jan-07,18-Nov-10,12-Feb-15,,,https://ClinicalTrials.gov/show/NCT00420420
NCT00417482,Antipsychotic Discontinuation in Alzheimer's Disease,ADAD,Completed,Has Results,Alzheimer Disease|Psychotic Disorders|Agitation|Aggression,Drug: risperidone,Relapse by Study Week 32|Relapse by Study Week 48|Mini Mental State Exam (MMSE)|Treatment Emergent Symptoms Scale (TESS)|Extrapyramidal Signs (EPS)|AIMS|Physical Self-Maintenance Scale (PSMS)|Weight,New York State Psychiatric Institute|National Institute on Aging (NIA)|Columbia University,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 4,180,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",#5598R|5R01AG021488,Aug-04,Apr-11,Apr-11,1-Jan-07,24-Apr-13,24-Apr-13,"Tuscaloosa VA Medical Center, Department of Psychiatry, Tuscaloosa, Alabama, United States|WLA VA Medical Center/UCLA, Psychiatry, Los Angeles, California, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|University of Iowa College of Medicine, Iowa City, Iowa, United States|Mount Sinai School of Medicine, Alzheimer's Disease Research Center, New York, New York, United States|New York State Psychiatric Institute, Columbia University, New York, New York, United States|Medical University of South Carolina, North Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00417482
NCT00416078,Online Caregiver Psychoeducation and Support for Alzheimer's,,Completed,Has Results,Alzheimer's Disease,Behavioral: caregiver website support|Behavioral: caregiver brief supportive phone calls,Change in Caregiver Burden From Baseline|Change in Frequency of Patient Problematic Behavioral Patterns From Baseline|Change in Caregiver Negative Reactions to Problematic Behavioral Patterns From Baseline|Change in Caregiver Depression From Baseline|Change in Caregiver Report of Patient Medication Adherence From Baseline,US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 2|Phase 3,53,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IIR 05-107,Aug-07,Jun-12,Dec-12,27-Dec-06,29-Apr-15,29-Apr-15,"VA Greater Los Angeles Healthcare System, West LA, West Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00416078
NCT00414622,GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease,,Completed,No Results Available,Alzheimer Disease,Drug: DMXB-A,CDR|ADAS-cog,CoMentis,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,GTS21-201,Nov-06,null,Apr-07,21-Dec-06,null,19-Apr-07,"Clinical Dept., 280 South San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00414622
NCT00412048,Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease,,Withdrawn,No Results Available,Alzheimer's Disease,Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease,"Comparing fMRI data between 3 groups of subjects: MCI, Alzheimer's disease and normal subjects|Follow-up of MCI patients at 6, 12 and 18 months to detect a conversion to Alzheimer's disease","University Hospital, Strasbourg, France",All,"55 Years to 75 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,3659,Apr-12,Feb-18,Feb-18,15-Dec-06,null,14-Nov-12,,,https://ClinicalTrials.gov/show/NCT00412048
NCT00411580,Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD),,Completed,No Results Available,Alzheimer's Disease,Biological: CAD106|Drug: Placebo,"Tolerability/safety assessments (physical/neurol.exam., ECG, vital signs, standard and special immunological laboratory evaluations, MRIs, EEGs, AE/SAE monitoring).|Antibody titers (IgM and IgM titers against amyloid and carrier protein).|Immune response, cognitive and functional assessments",Novartis Pharmaceuticals|Novartis,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCAD106A2101,Jun-05,Dec-08,Dec-08,14-Dec-06,null,29-Mar-13,"Novartis Investigative Site, Malmo, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00411580
NCT00409279,An Innovative Psychosocial Intervention for Adult-Child Caregivers of Parents With Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer Disease,"Behavioral: Information, counseling and support","Changes in measures of depression, stress, and anxiety",The Jacob and Valeria Langeloth Foundation|National Institute on Aging (NIA),All,"21 Years to 90 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator),IA0097|Project #195,Sep-03,Apr-08,Apr-08,8-Dec-06,null,3-Mar-08,"Aging and Dementia Research Center, Silberstein Institute, NYU School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00409279
NCT00408525,Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: donepezil,Changes in brain activation patterns as measured in an fMRI.,Vanderbilt University|Vanderbilt University Medical Center,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 1,41,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,40686,Dec-06,24-Aug-12,24-Aug-12,7-Dec-06,null,5-Feb-18,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00408525
NCT00407576,PET Imaging of Brain Amyloid Using [11C]MeS-IMPY,,Completed,No Results Available,Alzheimer's Disease|Healthy,Drug: [11C]MeS-IMPY,,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,30,NIH,Interventional,Primary Purpose: Treatment,070036|07-M-0036,1-Dec-06,7-Nov-08,null,5-Dec-06,null,2-Jul-17,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00407576
NCT00403507,Exercise Treatment of Mild-Stage Probable Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease|Memory Disorders|Dementia,Behavioral: Participation in a monitored exercise program|Behavioral: Personalized aerobic and strength training.,"For the intervention group: Change in cognitive performance relative to baseline|Group differences in cognitive performance following intervention and relative to wait-list control group|For the intervention group: Change in attitudes, including self-report of well-being and cognitive abilities relative to baseline|Group differences in attitudes, including self-report of well-being, following intervention and relative to wait-list control group|For the intervention group: Change in knowledgeable informant's ratings of function, behavior, and attitudes|Group differences in knowledgeable informant's ratings of function, behavior, and attitudes following intervention and relative to wait-list control group","Intermountain Health Care, Inc.|Deseret Foundation",All,65 Years to 89 Years   (Older Adult),Phase 2,79,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Kelly Garrett,Oct-06,Oct-09,Oct-09,23-Nov-06,null,11-May-11,"LDS Hospital, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00403507
NCT00403520,Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers,,Completed,No Results Available,Alzheimer's Disease,Drug: Experimental 1|Drug: Placebo Comparator,"Evolution of the volume of the Hippocampi, measured by magnetic resonance imaging (MRI), between D0 and final visit (12 months ).|Evolution of the neuropsychological scores between Day 0 and final visit.",Eisai Inc.,All,"50 Years and older   (Adult, Older Adult)",Phase 4,240,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E2020-E033-415,Nov-06,Mar-08,Aug-10,23-Nov-06,null,14-Jul-14,"CHU Gui de Chauliac, Montpellier cedex, France",,https://ClinicalTrials.gov/show/NCT00403520
NCT00401167,Memantine for Agitation and Aggression in Severe Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: memantine,Neuropsychiatric Inventory Nursing Home Version|Clinical Global Impression of Change|Neuropsychiatric Inventory Burden Subscale|Cohen Mansfield Agitation Inventory|Modified Nursing Care Assessment Scale|Activities of Daily Living|Quality of Life in Late Stage Dementia,Sunnybrook Health Sciences Centre|Lundbeck Canada Inc.,All,65 Years and older   (Older Adult),Phase 4,32,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Lundbeck-11267,Nov-06,Jan-10,Jan-10,17-Nov-06,null,25-May-12,"North York General Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00401167
NCT00397891,Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease,,Completed,Has Results,Alzheimer Disease,Drug: bapineuzumab,Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Changes in Physical Examinations|Number of Participants With Vital Signs of Potential Clinical Importance|Number of Participants With Electrocardiogram (ECG) Results of Potential Clinical Importance|Number of Participants With Laboratory Test Results of Potential Clinical Importance|Number of Participants With Clinically Significant Changes in Neurological Examinations|Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 6|Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 16|Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 52|Maximum Observed Serum Concentration (Cmax) of Bapineuzumab|Time to Reach Maximum Observed Serum Concentration (Tmax) of Bapineuzumab|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Bapineuzumab|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Bapineuzumab|Systemic Clearance (CL) of Bapineuzumab|Volume of Distribution at Steady State (Vss) of Bapineuzumab|Mean Residence Time of Bapineuzumab|Serum Decay Half-Life (t1/2) of Bapineuzumab|Serum Bapineuzumab Concentrations|Number of Participants With Positive Serum Anti-Bapineuzumab Antibody|Plasma Amyloid-beta (x-40) Concentrations,Wyeth is now a wholly owned subsidiary of Pfizer,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",3133K1-102,Oct-06,Feb-10,Feb-10,10-Nov-06,4-Sep-14,4-Sep-14,"Pfizer Investigational Site, Chiba, Japan|Pfizer Investigational Site, Saitama, Japan|Pfizer Investigational Site, Shizuoka, Japan|Pfizer Investigational Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00397891
NCT00396825,Video-Based Coping Skills Training for Caregivers,,Completed,No Results Available,Caregivers,Behavioral: Video-based coping skills training with telephone coaching,"Center for Epidemiological Studies Depression scale|Spielberger State-Trait Anger and Anxiety Scales|Perceived Stress Scale|Pittsburgh Sleep Quality Index|Heart rate and blood pressure at rest and during recall of caregiver situation|Salivary cortisol upon awakening, 30 minutes later, and prior to going to bed at night",Williams LifeSkills|National Institute on Aging (NIA),All,"Child, Adult, Older Adult",Phase 2,116,Industry|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2R44AG025593-04A;|2R44AG025593,Jan-07,May-09,May-09,8-Nov-06,null,13-Aug-12,"Williams LifeSkills, Inc., Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00396825
NCT00393627,Behavioral Sleep Intervention in Adult Family Homes,,Completed,No Results Available,Dementia,Behavioral: Sleep Education Program,Actigraphy sleep estimates,University of Washington|Alzheimer's Association,All,"Child, Adult, Older Adult",Phase 2,47,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,24091-G|03-7612-G 04,Jun-06,Aug-09,Aug-09,30-Oct-06,null,14-Jun-12,"University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00393627
NCT00392912,Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone,,Completed,No Results Available,Alzheimer's Disease|Hypogonadism,Drug: AndroGel (Solvay Pharmaceuticals),Calculated difference image of pre-treatment and on-treatment PET scans.|Change in cognitive function at 8-week intervals over a 6-month period.,"VA Medical Center, Houston|Solvay Pharmaceuticals",Male,"55 Years and older   (Adult, Older Adult)",Not Applicable,10,U.S. Fed|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GR-294,Apr-07,Nov-09,Jul-10,26-Oct-06,null,19-Aug-10,"Michael E. DeBakey VA Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00392912
NCT00391794,Efficacy of Early Stage Alzheimer's Support Groups,,Completed,No Results Available,Memory Loss|Alzheimer's Disease|Dementia,Behavioral: Early Stage Memory Loss Support Group|Behavioral: Educational Seminar,Quality of life|Mood|Social support|Family Relationships,University of Washington|National Institute on Aging (NIA),All,"Child, Adult, Older Adult",Not Applicable,154,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,29920-J|5R01AG023091|06-1324-G01|5R01AG023091-02|1A0131,Sep-06,May-11,May-11,24-Oct-06,null,10-Jan-14,"University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00391794
NCT00391833,Effect of Panax Ginseng on the Cognitive Performance in Alzheimer’s Disease,,Completed,No Results Available,Alzheimer's Disease|Memory Decline,Drug: Panax Ginseng,Cognitive performances monitored by MMSE and Alzheimer’s disease assessment scales.|Biomarkers including hematopoietic progenitor cell count.,Seoul National University Hospital,Female,"40 Years to 83 Years   (Adult, Older Adult)",Phase 1|Phase 2,null,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ginseng-AD,Apr-04,null,Oct-05,24-Oct-06,null,24-Oct-06,,,https://ClinicalTrials.gov/show/NCT00391833
NCT00388544,Enhancing Quality of Life for Nursing Home Residents,,Completed,No Results Available,Alzheimer's Disease,Behavioral: Activity matched to interest|Behavioral: Activity matched to function|Behavioral: Activity matched to both interest and function,Agitation|Passivity|Mood|Affect|Engagement,Penn State University|National Institute of Nursing Research (NINR),All,65 Years and older   (Older Adult),Phase 2,128,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic",19150|R01NR008910|R01NR008910-01A1,May-05,Feb-10,Feb-10,17-Oct-06,null,9-May-12,"Nursing homes in Central and Northeast Pennsylvania, University Park, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00388544
NCT00385684,Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),LDOT,Completed,Has Results,"Alzheimer Disease|Dementia|Dementia, Vascular|Pain",Drug: hydrocodone/APAP w placebo PRN|Drug: hydrocodone/APAP|Drug: placebo with hydrocodone/APAP PRN,Pain Assessment in Advanced Dementia (PAINAD),VA Office of Research and Development,All,"55 Years and older   (Adult, Older Adult)",Phase 4,11,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",F4483-I,Oct-07,Dec-11,Jun-14,11-Oct-06,20-Nov-15,20-Nov-15,"Tuscaloosa VA Medical Center, Tuscaloosa, Alabama, United States|Tuscaloosa Veterans Affairs Medical Center, Tuscaloosa, Alabama, United States|VA Medical Center, Tuscaloosa, Tuscaloosa, Alabama, United States",,https://ClinicalTrials.gov/show/NCT00385684
NCT00384423,Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept,,Completed,No Results Available,Alzheimer's Disease,Drug: PRX-03140,Safety and tolerability of PRX-03140 during 2 weeks of treatment.|Electroencephalogram (EEG) changes through 14 days of treatment.|Changes in cognition after 2 weeks of treatment.|Blood concentrations of PRX-03140 and Aricept during 14 days of treatment.,"Epix Pharmaceuticals, Inc.",All,"60 Years and older   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PRX-CP-018,Oct-06,Oct-07,null,6-Oct-06,null,30-Jan-08,"California Clinical Trials Medical Group, Inc, Paramount, California, United States|Southwest CLinical Research, Rancho Mirage, California, United States|Pacific Research Network, Inc, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Torrance Clinical Research, Torrance, California, United States|Research Center for Clinical Studies, Darien, Connecticut, United States|Miami Jewish Home and Hospital for the Aged, Miami, Florida, United States|Berma Research, Plantation, Florida, United States|Meridien Research, St Petersburg, Florida, United States|Comprehensive NeuroScience, Inc, St. Petersburg, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|J. Gary Booker, MD, Shreveport, Louisiana, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Neurology Specialists, Dayton, Ohio, United States|Saint Johns Office Building, Tulsa, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Alliance for Neuro Research, LLC, Greenville, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00384423
NCT00381238,Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: rosiglitazone,Number of Participants With Adverse Events (AE's)|Mean Change From Baseline in Mini Mental State Examination (MMSE) Total Score|Number of Participants With SAEs|Number of Participants With AE of Peripheral Edema by Grade|Mean Change From Baseline in Vital Signs- Systolic and Diastolic Blood Pressure|Mean Change From Baseline in Vital Signs-heart Rate (HR)|Number of Participants With Vital Signs of Clinical Concern.|Mean Change From Baseline in Vital Signs- Weight|Number of Participants With Clinical Chemistry Parameters of Clinical Concern|Number of Participants With Clinical Chemistry Parameters of Clinical Concern-lipids|Number of Participant's With Hematology Parameters of Clinical Concern,GlaxoSmithKline,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,33,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVA104617,20-Jun-06,1-Feb-09,3-Feb-09,27-Sep-06,23-May-17,23-May-17,"GSK Investigational Site, Litchfield Park, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Sun City, Arizona, United States|GSK Investigational Site, Belmont, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00381238
NCT00381381,The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: Donepezil,CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease)|CERAD-K|Neuropsychiatry Inventory (NPI)|GDS-K (Geriatric Depression Scale-Korean) Score After Treatment,Eisai Korea Inc.|Eisai Inc.,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 4,199,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EKI-6-004,May-06,Aug-08,Dec-08,27-Sep-06,27-Jul-12,31-Aug-12,"Seoul National University Bundang Hospital, Bundang, Korea, Republic of|Hallym University Medical Center, Changwon, Korea, Republic of|Kangwon National University Hospital, Chuncheon, Korea, Republic of|Kunkuk University Chungju Hospital, Chungju, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Gyeonggi Province Geriatric Hospital, Gyeonggi, Korea, Republic of|Uijeongbu St. Mary's Hospital, Gyeonggi, Korea, Republic of|Jeju National University Hospital, Jeju, Korea, Republic of|Jeonju City Welfare Hospital, Jeonju, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Korea, Republic of|Inje University Pusan Paik Hospital, Pusan, Korea, Republic of|Kunkuk University Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00381381
NCT00380276,Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol,,Terminated,No Results Available,Alzheimer's Disease,Drug: MPC-7869,Primary Safety,Myrexis Inc.,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1000,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MPC-7869-05-009,Sep-06,null,Dec-08,25-Sep-06,null,5-Aug-08,"Alabaster, Alabama, United States|Huntsville, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Irvine, California, United States|Lafayette, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Rancho Mirage, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Vista, California, United States|Danbury, Connecticut, United States|Darien, Connecticut, United States|New Haven, Connecticut, United States|Washington D.C, District of Columbia, United States|Deerfield Beach, Florida, United States|Fort Myers, Florida, United States|Ft Meyers, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|Sunrise, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Baltimore, Maryland, United States|Glen Burnie, Maryland, United States|Boston, Massachusetts, United States|West Yarmouth, Massachusetts, United States|Ann Arbor, Michigan, United States|Grand Rapids, Michigan, United States|Rochester, Minnesota, United States|St. Louis, Missouri, United States|Lebanon, New Hampshire, United States|Kenilworth, New Jersey, United States|Morristown, New Jersey, United States|Princeton, New Jersey, United States|Stratford, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Elmsford, New York, United States|New York, New York, United States|Olean, New York, United States|Rochester, New York, United States|Syracuse, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Centerville, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Jenkintown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburg, Pennsylvania, United States|Scotland, Pennsylvania, United States|East Providence, Rhode Island, United States|Beaufort, South Carolina, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Alexandria, Virginia, United States|Charlottesville, Virginia, United States|Virginia Beach, Virginia, United States|Middleton, Wisconsin, United States|Milwaukee, Wisconsin, United States|Winnepeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|Kingston, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Regina, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT00380276
NCT00380302,Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.,,Completed,No Results Available,Alzheimer Disease,Drug: AVE1625,"Safety and tolerability throughout the study:adverse events collected by spontaneous report|physical examination and neurological assessment|vital sign monitoring, clinical laboratories, and ECGs.|Efficacy variables:measures of change in cognition, global functioning and behavior at week 12.|Pharmacokinetic parameters will be assessed throughout the 12-week treatment period.",Sanofi,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,162,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACT10019|EUDRACT: 2006-002317-12,Sep-06,Jul-07,Jul-07,25-Sep-06,null,19-Dec-08,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Bromma, Sweden",,https://ClinicalTrials.gov/show/NCT00380302
NCT00377715,"Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease",,Completed,No Results Available,Alzheimer's Disease,Drug: Dimebon|Drug: Placebo,Alzheimer's Disease Assessment Scale - cognitive subscale|Clinical Global Impression of Change|Safety Assessed By Number of Participants With Adverse Events|Pharmacokinetic (PK) parameter of Dimebon: Cmax,"Medivation, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 2,183,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DIM02,Sep-05,Aug-06,null,18-Sep-06,null,11-Nov-15,"Mental Health Research Center of Russian Academy of Medical Sciences, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT00377715
NCT00375557,Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients,,Withdrawn,No Results Available,Alzheimer's Disease|Dementia|Behavioral Symptoms,Drug: Divalproex ER|Drug: Quetiapine,The change from the Baseline to the End of the Study/Early Termination visit in the CMAI & Quality of life scale scores.,University of Cincinnati|Abbott,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 4,0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06-08-25-06,Oct-06,null,Sep-07,13-Sep-06,null,27-May-15,"Cincinnati VA Hospital, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00375557
NCT00369603,Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients,,Terminated,No Results Available,Alzheimer's Disease,Drug: Razadyne ER|Drug: Aricept,"Brain activity patterns, as collected via functional magnetic resonance imaging (fMRI), at rest and associated with task performance after 4 weeks of low-dose treatment and after 8-weeks of higher-dose treatment.|Differences in cognitive testing and functional status at pre-treatment baseline and after completion of the 12-week treatment trial.","Duke University|Ortho-McNeil Neurologics, Inc.",All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 4,4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Pro00011149|GAL-EMR-4026,Oct-06,Oct-07,Nov-07,29-Aug-06,null,11-Apr-13,"Joseph & Kathleen Bryan Alzheimer's Disease Research Unit, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00369603
NCT00368459,Raloxifene for Women With Alzheimer's Disease,,Completed,Has Results,Alzheimer Disease,Drug: raloxifene|Drug: Placebo,"Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-cog)|Global Rating, Clinical Dementia Rating (CDR) Sum of Boxes|Function, Activities of Daily Living (ADL)|Behavior|Cognitive (Neuropsychological)|ADAS-cog|Clinical Dementia Rating, Sum of Boxes|Function, Activities of Daily Living|Cognition (Neuropsychological)",Stanford University|Kaiser Permanente|Indiana University|Southern Illinois University,Female,"60 Years and older   (Adult, Older Adult)",Phase 2,42,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IA0096,Aug-06,Mar-11,Jan-12,24-Aug-06,2-Apr-15,2-Apr-15,"Kaiser Permanente Santa Rosa, Santa Rosa, California, United States|Stanford University School of Medicine, Stanford, California, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00368459
NCT00366483,Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects,,Completed,No Results Available,Alzheimer Disease,Drug: Lecozotan SR,"The incidence of adverse events and adverse reactions will be calculated. The safety variables (vital signs, ECG parameters, and routine laboratory tests) and PK parameters will be measured throughout study period.|Pharmacokinetic analysis after single and multiple dosing",Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,3098B1-130,May-06,null,null,21-Aug-06,null,16-Mar-07,"Paris, France",,https://ClinicalTrials.gov/show/NCT00366483
NCT00362024,MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED),,Terminated,No Results Available,Alzheimer's Disease,Drug: MK0952|Drug: Comparator: Placebo,,Merck Sharp & Dohme Corp.,All,"55 Years and older   (Adult, Older Adult)",Phase 2,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0952-004|2006_026,Nov-06,Nov-07,Nov-07,9-Aug-06,null,16-May-16,,,https://ClinicalTrials.gov/show/NCT00362024
NCT00362284,Comprehensive Support for Alzheimer's Disease Caregivers,,Completed,No Results Available,Caregivers|Stress|Depression,Behavioral: NYUCI-AC,Care recipient nursing home/institutional placement|Caregiver emotional stress|caregiver depression|caregiver social support|Caregiver subjective health|secondary stressors,University of Minnesota - Clinical and Translational Science Institute|National Institute on Aging (NIA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,161,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,IA0095|R01AG022066,Sep-05,Dec-11,Jan-12,9-Aug-06,null,7-May-19,"University of Minnesota, School of Nursing, 6-150 Weaver-Densford Hall, Minneapolis, Minnesota, United States|Silberstein Institute for Aging and Dementia, Department of Psychiatry, NYU School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00362284
NCT00359944,Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease,Drug: AC-3933|Other: Sugar Pill,Total Score of Alzheimer's Disease Assessment Scale - Cognition Subscale (ADAS-COG)From Best Total Score (0) to Worst Total Score (70)|Clinicians Interview Based Impression of Change (CIBIC)-Plus|Disability Assessment for Dementia (DAD),Sunovion,All,"55 Years and older   (Adult, Older Adult)",Phase 2,171,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AC-3933-271,Feb-06,Sep-08,Sep-08,3-Aug-06,2-Jul-13,2-Jul-13,"Clinical Trials Inc., LIttle Rock, Alaska, United States|PsyPharma Clinical Research Inc., Phoenix, Arizona, United States|ClinicalStudies Center LLC, Little Rock, Arkansas, United States|Vertex Clinical Research, Bakersfield, California, United States|East Bay Physicians Medical Grou[, Berkeley, California, United States|Margolin Brain Institute, Fresno, California, United States|Clinical Trials Associates, Mission Viejo, California, United States|University of California, Orange, California, United States|Pacific Research Network, San Diego, California, United States|Memory Disorder Clinic, Deerfield Beach, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Advanced Research Institute of Miami, Miami, Florida, United States|Research Institute of Miami, Miami, Florida, United States|Research Center of Florida Inc., Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Compass Research LLC, Orlando, Florida, United States|Department of Psychiatry and Behavioral Medicine, Tampa, Florida, United States|Stedman Clinical Trials LLC, Tampa, Florida, United States|Four Rivers Clinical Research Inc., Paducah, Kentucky, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Minneapolis, Minnesota, United States|Clinical Psychopharmacology Consultants PA, Saint Louis Park, Minnesota, United States|Precise Research Centers INc., Flowood, Mississippi, United States|Psych Care Consultants Research, Saint Louis, Missouri, United States|Odyssey Researcfh, Fargo, North Dakota, United States|Paradigm Research Professionals LLP, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research LLC, Tulsa, Oklahoma, United States|The Clinical Trial Center, Jenkintown, Pennsylvania, United States|UT Medical Group Inc., Memphis, Tennessee, United States|Neurological Research Center, Inc., Bennington, Vermont, United States|International Clinical Research Associates LLC, Richmond, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States|Internal Medicine Northwest, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00359944
NCT00357357,European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients,,Completed,No Results Available,Alzheimer's Disease,Drug: HF0220,Safety/tolerability of HF 0220 in mild to moderate Alzheimer's patients|Validate biochemical markers relevant to Alzheimer's disease|Assess the suitability of chosen HF0220 dose levels for future studies,Hunter-Fleming Ltd,All,"55 Years and older   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HF0220/003|2005-005791-32,Jul-06,Aug-08,Aug-08,27-Jul-06,null,21-Aug-08,"King George Hospital, Visakhapatnam, Andh Prad, India|Manipal Hospital,, Bangalore, Karna, India|Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India|Nizam's Institute of Medical Sciences,, Hyderabaad, Panjagutta, India|Madras Medical College & Government General Hospital, Chennai, Tamilnadu, India|Malmo University Hospital, Malmo, Sweden|Karolinksa Institute, Stockholm, Sweden|Research Institute for Care of the Elderly, Bath, United Kingdom|Memory Assessment and Research Centre, Southampton, United Kingdom|Kingshill Research Centre, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00357357
NCT00348140,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,REFLECT-3,Completed,Has Results,Alzheimer's Disease,Drug: Rosiglitazone Extended Release 2mg|Drug: Rosiglitazone Extended Release 8mg|Other: Placebo,"Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives Cohort|Change From Baseline in ADAS-Cog Total Score at Week 48, as a Function of APOE ε4 Status in All Except E4/E4s Cohort|Change From Baseline in ADAS-Cog Total Score at Week 48, as a Function of APOE ε4 Status in Full Population Cohort|Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives Cohort|Change From Baseline in CDR-SB Score at Week 48, as a Function of APOE ε4 Status in All Except E4/E4s Cohort|Change From Baseline in CDR-SB Score at Week 48, as a Function of APOE ε4 Status in Full Population Cohort|Change From Baseline in ADAS-Cog Total Score at Weeks 8, 16, 24 and 36|Change From Baseline in CDR-SB Score at Weeks 12, 24 and 36|Change From Screening in Mini Mental State Examination (MMSE) Total Score|Change From Baseline in Disability Assessment for Dementia (DAD) Total Score|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score|Change From Baseline in Domains of the Resource Utilization in Dementia Scale (RUD)- Q1 and Q2 Caregiver Hours|Change From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Scale Total Score- Thermometer Score|Change From Baseline in EQ-5D Scale Total Score- Utility Score|Change From Baseline in Alzheimer's Carer's Quality of Life Instrument (ACQLI) Score|Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48|Change in CDR-SB Total Score for Observed Cases at Week 54 Compared to Week 48|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48|Number of Participants With On-treatment Adverse Events (AEs), Serious Adverse Events (SAEs) and Severity of AEs|Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Weight|Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Heart Rate (HR)|Change From Baseline in Weight|Change From Baseline in Hemoglobin|Change From Baseline in Hematocrit|Any Time on Treatment Differences in Frequencies of Hematology Data Outside the Reference Range|Any Time on Treatment Differences in Frequencies of Clinical Chemistry Data Outside the Reference Range|Changes From Baseline in Electrocardiogram (ECG) Parameters- HR|Changes From Baseline in ECG Parameters- RR Interval, QT Interval, QTcB, QTcF, PR Interval and QRS Duration|Change From Baseline in HbA1c up to Week 54|Change From Baseline in Short Term Memory Assessment",GlaxoSmithKline,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,1468,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AVA102670,12-Jul-06,20-Mar-09,20-Mar-09,4-Jul-06,5-Sep-17,5-Sep-17,"GSK Investigational Site, Sun City, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Laguna Hills, California, United States|GSK Investigational Site, Redlands, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Norwalk, Connecticut, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Delray Beach, Florida, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Springfield, Massachusetts, United States|GSK Investigational Site, West Yarmouth, Massachusetts, United States|GSK Investigational Site, Eatontown, New Jersey, United States|GSK Investigational Site, Manchester Township, New Jersey, United States|GSK Investigational Site, Toms River, New Jersey, United States|GSK Investigational Site, Amherst, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Centerville, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Jenkintown, Pennsylvania, United States|GSK Investigational Site, Norristown, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, East Providence, Rhode Island, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Greer, South Carolina, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Wichita Falls, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Charlottesville, Virginia, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Middleton, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Hornsby, New South Wales, Australia|GSK Investigational Site, Randwick, New South Wales, Australia|GSK Investigational Site, Auchenflower, Queensland, Australia|GSK Investigational Site, Chermside, Queensland, Australia|GSK Investigational Site, Kippa Ring, Queensland, Australia|GSK Investigational Site, Adelaide, South Australia, Australia|GSK Investigational Site, Woodville, South Australia, Australia|GSK Investigational Site, Cheltenham, Victoria, Australia|GSK Investigational Site, Heidelberg West, Victoria, Australia|GSK Investigational Site, Kew, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Kortrijk, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Woluwe-Saint-Lambert, Belgium|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Saint John, New Brunswick, Canada|GSK Investigational Site, Kentville, Nova Scotia, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Mirabel, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Québec, Canada|GSK Investigational Site, Olomouc, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 8, Czechia|GSK Investigational Site, Trutnov, Czechia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Joensuu, Finland|GSK Investigational Site, Kuopio, Finland|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, La Chapelle sur Erdre, France|GSK Investigational Site, La Seyne sur Mer, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Limoges, France|GSK Investigational Site, Metz, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Sautron, France|GSK Investigational Site, Toulon, France|GSK Investigational Site, Toulouse, France|GSK Investigational Site, Valence, France|GSK Investigational Site, Aalen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Calw, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ludwigsburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Wiesloch, Baden-Wuerttemberg, Germany|GSK Investigational Site, Alzenau, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Saarow, Brandenburg, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Erbach, Hessen, Germany|GSK Investigational Site, Chemnitz, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Gera, Thueringen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Seongnam-si,, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Bandar Tun Razak, Cheras, Malaysia|GSK Investigational Site, Bandar Tun Razak, Cheras, Malaysia|GSK Investigational Site, Ipoh, Malaysia|GSK Investigational Site, Kelantan, Malaysia|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Blaricum, Netherlands|GSK Investigational Site, Den Bosch, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Hengelo, Netherlands|GSK Investigational Site, Hilversum, Netherlands|GSK Investigational Site, Manila, Philippines|GSK Investigational Site, Pasig City, Philippines|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Torun, Poland|GSK Investigational Site, Warsaw, Poland|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Ljubljana, Slovenia|GSK Investigational Site, Šempeter, Slovenia|GSK Investigational Site, Loeventstein, South Africa|GSK Investigational Site, Oakdale, South Africa|GSK Investigational Site, Richards Bay, South Africa|GSK Investigational Site, Rosebank, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Waverley, Bloemfontein, South Africa|GSK Investigational Site, Willows, X14, Pretoria, South Africa|GSK Investigational Site, Baracaldo/Vizcaya, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain|GSK Investigational Site, Falköping, Sweden|GSK Investigational Site, Jönköping, Sweden|GSK Investigational Site, Kalix, Sweden|GSK Investigational Site, Mölndal, Sweden|GSK Investigational Site, Sundsvall, Sweden|GSK Investigational Site, Umeå, Sweden|GSK Investigational Site, Blackpool, Lancashire, United Kingdom|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, Stirling, United Kingdom|GSK Investigational Site, West End, Southampton, United Kingdom|GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT00348140
NCT00348192,SB-742457 And Donepezil In Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: SB-742457|Drug: donepezil,"Change in cognition and function after 24 weeks.|Change in behavioral symptoms, activities of daily living and caregiver burden after 24 weeks Changes in all symptoms at 8 and 12 weeks Safety and tolerability PK (pharmacokinetic) profiling. Efficacy related to ApoE and HTR6 status",GlaxoSmithKline,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AZ3106242,May-06,null,null,4-Jul-06,null,2-Jun-09,"GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Valparaiso, Valparaíso, Chile|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Ostfildern, Baden-Wuerttemberg, Germany|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Baesweiler, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Swindon, United Kingdom|GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT00348192
NCT00348309,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease,REFLECT-2,Completed,Has Results,Alzheimer's Disease,Drug: Rosiglitazone Extended Release 2mg|Drug: Rosiglitazone Extended Release 8mg|Other: Placebo|Other: Donepezil,"Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48|Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4|Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score|Change From Screening in Mini Mental State Examination (MMSE) Total Score|Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD)|Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility|Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48|Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48|Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48|Change in CDR-SB Total Score at Week 54 Compared to Week 48|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48|Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP)|Mean Change From Baseline in Heart Rate|Mean Change From Baseline in Weight|Change From Baseline in Hemoglobin Values|Change From Baseline in Hematocrit Values|Mean Change From Baseline in Short Term Memory Assessment Score|Change From Baseline in HbA1c at Week 12, Week 24 and Week 36|Number of Participants With Laboratory Potential Clinical Concern (PCC) Values|Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score",GlaxoSmithKline,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,1496,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AVA102672,6-Jul-06,1-Jan-09,28-Jan-09,4-Jul-06,28-Nov-17,28-Nov-17,"GSK Investigational Site, Litchfield Park, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Rancho Mirage, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Sherman Oaks, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Delray Beach, Florida, United States|GSK Investigational Site, Hallandale Beach, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Hoffman Estates, Illinois, United States|GSK Investigational Site, Fort Wayne, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Glen Burnie, Maryland, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Saint Paul, Minnesota, United States|GSK Investigational Site, Lebanon, New Hampshire, United States|GSK Investigational Site, Morristown, New Jersey, United States|GSK Investigational Site, Nutley, New Jersey, United States|GSK Investigational Site, Princeton, New Jersey, United States|GSK Investigational Site, Stratford, New Jersey, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, South Ogden, Utah, United States|GSK Investigational Site, Bennington, Vermont, United States|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Godoy Cruz, Mendoza, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Belo Horizonte, Brazil|GSK Investigational Site, Ribeirão Preto, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Medicine Hat, Alberta, Canada|GSK Investigational Site, Victoria, British Columbia, Canada|GSK Investigational Site, Moncton, New Brunswick, Canada|GSK Investigational Site, Barrie, Ontario, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Whitby, Ontario, Canada|GSK Investigational Site, Charlottetown, Prince Edward Island, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Regina, Saskatchewan, Canada|GSK Investigational Site, Québec, Canada|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Puente Alto - Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Ostrava, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Praha 7, Czechia|GSK Investigational Site, Angoulême, France|GSK Investigational Site, Arcachon, France|GSK Investigational Site, Avignon, France|GSK Investigational Site, Bourg en Bresse, France|GSK Investigational Site, Caen, France|GSK Investigational Site, Dijon, France|GSK Investigational Site, Issy Les Moulineaux, France|GSK Investigational Site, Ivry, France|GSK Investigational Site, Luynes, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Marseille, France|GSK Investigational Site, Marseille, France|GSK Investigational Site, Metz, France|GSK Investigational Site, Montpellier, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nice, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pau, France|GSK Investigational Site, Pessac, France|GSK Investigational Site, Reims, France|GSK Investigational Site, Rennes, France|GSK Investigational Site, Rodez, France|GSK Investigational Site, Saint Jean de Luz, France|GSK Investigational Site, Saint Ouen la Rouerie, France|GSK Investigational Site, Saint-Etienne, France|GSK Investigational Site, Saint-Nicolas de Port, France|GSK Investigational Site, Tinteniac, France|GSK Investigational Site, Tours, France|GSK Investigational Site, Verny, France|GSK Investigational Site, Vichy, France|GSK Investigational Site, Boeblingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ostfildern, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Neuburg / Donau, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Bockhorn, Niedersachsen, Germany|GSK Investigational Site, Ganderkesee, Niedersachsen, Germany|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hildesheim, Niedersachsen, Germany|GSK Investigational Site, Lueneburg, Niedersachsen, Germany|GSK Investigational Site, Westerstede, Niedersachsen, Germany|GSK Investigational Site, Bad Honnef, Nordrhein-Westfalen, Germany|GSK Investigational Site, Baesweiler, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bergisch Gladbach, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dueren, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Juelich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Krefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Remscheid, Nordrhein-Westfalen, Germany|GSK Investigational Site, Siegen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Melissia, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Varanasi, India|GSK Investigational Site, Chieti Scalo, Abruzzo, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, San Felice a Cancello Caserta, Campania, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Brescia, Lombardia, Italy|GSK Investigational Site, Brescia, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Rho, Lombardia, Italy|GSK Investigational Site, Ancona, Marche, Italy|GSK Investigational Site, Bari, Puglia, Italy|GSK Investigational Site, Arezzo, Toscana, Italy|GSK Investigational Site, Firenze, Toscana, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Verona, Veneto, Italy|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Gunma, Japan|GSK Investigational Site, Hiroshima, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kochi, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Kyoto, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Saltillo, Coahuila, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Mosina, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Sopot, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Coimbra, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Burgos, Spain|GSK Investigational Site, Castellón, Spain|GSK Investigational Site, Elche (Alicante), Spain|GSK Investigational Site, Galdakano, Spain|GSK Investigational Site, Gerona, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, La Coruña, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Pamplona, Spain|GSK Investigational Site, San Sebastián, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Zuerich, Switzerland",,https://ClinicalTrials.gov/show/NCT00348309
NCT00334568,Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: Rosiglitazone XR (extended release) oral tablets|Drug: Placebo,Change in global and regional cerebral glucose metabolism/Cerebral Metabolic Rate for glucose (CMRglu) as measured by the ratio of Ki to K1|Changes in global and regional CMRglu as measured by [18F]FDG uptake.|Global changes in brain structure from baseline as measured by structural MRI from baseline.Vital signs and ECGs.,GlaxoSmithKline,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,12,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AVA100930,Dec-04,Jul-07,Jul-07,8-Jun-06,null,14-Jan-13,"GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00334568
NCT00334906,Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease),,Completed,No Results Available,Alzheimer's Disease,Drug: memantine HCl,"Efficacy|Total brain atrophy on MRI|Other measures of brain atrophy on MRI, change from baseline in selected cognitive measures assessing multiple cognitive domains including memory, attention, motor-speed, auditory comprehension, and verbal fluency|Safety",Forest Laboratories,All,"50 Years and older   (Adult, Older Adult)",Phase 4,75,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEM-MD-15,Jul-05,Nov-07,null,8-Jun-06,null,7-Jan-08,"Forest Laboratories, Jersey City, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00334906
NCT00329706,Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID),,Completed,No Results Available,Dementia,Procedure: FDG-PET brain scan,"change from baseline in neuropsychological (cognitive,functional) test results|utilization of healthcare resources|PET results, compared with working diagnoses made before and after time of PET|rates of prescription of AD-specific therapies","University of California, Los Angeles|Centers for Medicare and Medicaid Services",All,65 Years and older   (Older Adult),Not Applicable,710,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"02-10-079, 03-04-026",Jun-06,Jan-17,Jan-17,25-May-06,null,2-May-17,"Mayo Clinic, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Santa Monica-UCLA Medical Center, Santa Monica, California, United States|Gene E. Myers Cardiac and Vascular Consultants, Sarasota, Florida, United States|Lahey Clinic Hospital, Burlington, Massachusetts, United States|University of Buffalo, Buffalo, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00329706
NCT00329082,Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers,,Completed,No Results Available,Alzheimer's Disease,Drug: LY2062430|Drug: Placebo,Safety and tolerability|To determine the plasma pharmacokinetics of LY2062430|To evaluate the pharmacokinetic/pharmacodynamic relationships between LY2062430 concentrations and plasma peptide amyloid beta concentrations|To evaluate the changes in thinking and memory,Eli Lilly and Company,All,"50 Years and older   (Adult, Older Adult)",Phase 2,25,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",6649|H8A-MC-LZAJ,May-06,May-08,May-08,24-May-06,null,7-Oct-09,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00329082
NCT00325728,Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Chronic Insomnia,Drug: Ramelteon|Drug: Placebo,Mean Nighttime Total Sleep Time as determined by actigraphy.|Change from Baseline in Nighttime Total Sleep Time|Change from Baseline in Nighttime Wake After Sleep Onset per Actigraphy|Change from Baseline in Nighttime Number Of Awakenings per Actigraphy|Change from Baseline in Daytime Total Sleep Time|Change from Baseline in the ratio of Daytime Total Sleep Time to Nighttime Total Sleep Time.|Change from Baseline in Sleep Efficiency.|Percentage of subjects who experience Increase in Nighttime Total Sleep Time of 30 minutes.|Number of Daytime Naps.,Takeda,All,"55 Years and older   (Adult, Older Adult)",Phase 2,74,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-05-TL-375-061|U1111-1115-1644,21-Mar-06,1-Aug-07,20-Aug-07,15-May-06,null,14-Aug-17,"Alabaster, Alabama, United States|Huntsville, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Fresno, California, United States|Irvine, California, United States|Los Angeles, California, United States|National City, California, United States|Oxnard, California, United States|San Diego, California, United States|San Francisco, California, United States|Darien, Connecticut, United States|Waterbury, Connecticut, United States|Boynton Beach, Florida, United States|Bradenton, Florida, United States|Brooksville, Florida, United States|Deerfield Beach, Florida, United States|Fort Myers, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Largo, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|Orange City, Florida, United States|Pompano Beach, Florida, United States|Port Charlotte, Florida, United States|Sarasota, Florida, United States|Sunrise, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Savannah, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Boston, Massachusetts, United States|West Yarmouth, Massachusetts, United States|Grand Rapids, Michigan, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Dover, New Hampshire, United States|Manchester Township, New Jersey, United States|Piscataway, New Jersey, United States|Princeton, New Jersey, United States|Stratford, New Jersey, United States|Toms River, New Jersey, United States|Albuquerque, New Mexico, United States|Brooklyn, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Havertown, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|Moon, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Beaufort, South Carolina, United States|Greer, South Carolina, United States|North Charleston, South Carolina, United States|Bellaire, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Bennington, Vermont, United States|Burlington, Vermont, United States|Middleton, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00325728
NCT00322153,A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease,,Completed,Has Results,Dementia of the Alzheimer's Type,Drug: memantine ER|Drug: Placebo,Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF)|Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus) at Week 24 (LOCF)|Change From Baseline in the 19-Item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) Scale at Week 24 (LOCF),Forest Laboratories,All,"50 Years and older   (Adult, Older Adult)",Phase 3,677,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MEM-MD-50,Jun-05,Oct-07,Jan-08,5-May-06,16-Sep-10,16-Sep-10,"Forest Investigative Site 010, Phoenix, Arizona, United States|Forest Investigative Site 062, Costa Mesa, California, United States|Forest Investigative Site 050, Fresno, California, United States|Forest Investigative Site 024, San Francisco, California, United States|Forest Investigative Site 071, Santa Ana, California, United States|Forest Investigative Site 002, Denver, Colorado, United States|Forest Investigative Site 021, Boca Raton, Florida, United States|Forest Investigative Site 052, Boynton Beach, Florida, United States|Forest Investigative Site 070, Delray Beach, Florida, United States|Forest Investigative Site 065, Fort Myers, Florida, United States|Forest Investigative Site 043, Hallandale Beach, Florida, United States|Forest Investigative Site 044, Hallandale Beach, Florida, United States|Forest Investigative Site 001, Miami, Florida, United States|Forest Investigative Site 034, North Miami, Florida, United States|Forest Investigative Site 068, Orlando, Florida, United States|Forest Investigative Site 038, Palm Beach Gardens, Florida, United States|Forest Investigative Site 008, Saint Petersburg, Florida, United States|Forest Investigative Site 028, Tampa, Florida, United States|Forest Investigative Site 009, Snellville, Georgia, United States|Forest Investigative Site 069, Joliet, Illinois, United States|Forest Investigative Site 045, Kalamazoo, Michigan, United States|Forest Investigative Site 014, Saint Loius, Missouri, United States|Forest Investigative Site 064, Long Branch, New Jersey, United States|Forest Investigative Site 011, Morristown, New Jersey, United States|Forest Investigative Site 003, New Brunswick, New Jersey, United States|Forest Investigative Site 048, Albany, New York, United States|Forest Investigative Site 006, Buffalo, New York, United States|Forest Investigative Site 004, White Plains, New York, United States|Forest Investigative Site 027, Centerville, Ohio, United States|Forest Investigative Site 012, Toledo, Ohio, United States|Forest Investigative Site 020, Portland, Oregon, United States|Forest Investigative Site 032, Greensburg, Pennsylvania, United States|Forest Investigative Site 018, Jenkintown, Pennsylvania, United States|Forest Investigative Site 067, East Providence, Rhode Island, United States|Forest Investigative Site 041, Austin, Texas, United States|Forest Investigative Site 017, San Antonio, Texas, United States|Forest Investigative Site 013, Richmond, Virginia, United States|Forest Investigative Site 026, Tacoma, Washington, United States|Forest Investigative Site 103, Banfield, Buenos Aires, Argentina|Forest Investigative Site 105, La Plata, Buenos Aires, Argentina|Forest Investigative Site 123, Lanus, Buenos Aires, Argentina|Forest Investigative Site 113, Rosario, Santa Fe, Argentina|Forest Investigative Site 102, Buenos Aires, Argentina|Forest Investigative Site 118, Buenos Aires, Argentina|Forest Investigative Site 109, Buenos Aires, Argentina|Forest Investigative Site 104, Buenos Aires, Argentina|Forest Investigative Site 108, Buenos Aires, Argentina|Forest Investigative Site 114, Buenos Aires, Argentina|Forest Investigative Site 106, Buenos Aires, Argentina|Forest Investigative Site 119, Buenos Aires, Argentina|Forest Investigative Site 122, Buenos Aires, Argentina|Forest Investigative Site 107, Buenos Aires, Argentina|Forest Investigative Site 111, Buenos Aires, Argentina|Forest Investigative Site 121, Buenos Aires, Argentina|Forest Investigative Site 115, Buenos Aires, Argentina|Forest Investigative Site 116, Buenos Aires, Argentina|Forest Investigative Site 112, Cordoba, Argentina|Forest Investigative Site 124, Cordoba, Argentina|Forest Investigative Site 110, Mendoza, Argentina|Forest Investigative Site 125, Mendoza, Argentina|Forest Investigative Site 120, Santa Fe, Argentina|Forest Investigative Site 308, Coquimbo, Elqui, Chile|Forest Investigative Site 301, Las Condes, Santiago, Chile|Forest Investigative Site 309, Las Condes, Santiago, Chile|Forest Investigative Site 303, Providencia, Santiago, Chile|Forest Investigative Site 310, Providencia, Santiago, Chile|Forest Investigative Site 313, Recoleta, Santiago, Chile|Forest Investigative Site 305, San Ramon, Santiago, Chile|Forest Investigative Site 302, Antofagasta, Chile|Forest Investigative Site 304, Santiago, Chile|Forest Investigative Site 312, Santiago, Chile|Forest Investigative Site 306, Valdivia, Chile|Forest Investigative Site 212, Saltillo, Coahuila, Mexico|Forest Investigative Site 202, Mexico City, Federal District, Mexico|Forest Investigative Site 207, Mexico City, Federal District, Mexico|Forest Investigative Site 211, Leon, Guanajuato, Mexico|Forest Investigative Site 205, Guadalajara, Jalisco, Mexico|Forest Investigative Site 203, Zapopan, Jalisco, Mexico|Forest Investigative Site 208, Monterrey, Nuevo Leon, Mexico|Forest Investigative Site 204, Monterrey, Nuevo Leon, Mexico|Forest Investigative Site 213, Culiacan, Sinaloa, Mexico|Forest Investigative Site 206, Aguascalientes, Mexico|Forest Investigative Site 210, San Luis Potosi, Mexico",,https://ClinicalTrials.gov/show/NCT00322153
NCT00321971,Prevention of Depression in Spouses of People With Cognitive Impairment,,Completed,Has Results,Depression,Behavioral: PST-MCI/AD Caregiving|Behavioral: NT-MCI/AD Caregiving,Depressive Symptoms,University of Pittsburgh|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,73,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,K23MH070719,Feb-07,Dec-11,Dec-11,4-May-06,7-Mar-18,3-Apr-18,"University of Pittsburgh Alzheimer's Disease Research Center (ADRC), Pittsburgh, Pennsylvania, United States|Duquesne Univeristy, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00321971
NCT00322036,Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's,,Terminated,No Results Available,Alzheimer Disease|Dementia,Drug: MPC-7869,Cognition and activities of daily living|Global function and cognition,Myrexis Inc.,All,"55 Years and older   (Adult, Older Adult)",Phase 3,800,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MPC-7869-05-010.01,May-06,null,Dec-08,4-May-06,null,5-Aug-08,"Phoenix, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Deerfield Beach, Florida, United States|DelRay Beach, Florida, United States|Gainsville, Florida, United States|Hollywood, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Boston, Massachusetts, United States|Farmington Hills, Michigan, United States|St. Louis, Missouri, United States|Rochester, New York, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Dallas, Texas, United States|Salt Lake City, Utah, United States|Aalst, Belgium|Antwerpen, Belgium|Edegem, Belgium|Hasselt, Belgium|Leuven, Belgium|Sint-truiden, Belgium|Calgary, Alberta, Canada|Medicine Hat, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Moncton, New Brunswick, Canada|Saint John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Montreal, Quebec, Canada|Verdun, Quebec, Canada|Regina, Saskatchewan, Canada|Odense C, Denmark|Odense, Denmark|Bordeaux, France|Dijon, France|Marseille, France|Montpellier, France|Nice, France|Reims, France|Rennes, France|Saint Herblain, France|Toulouse, France|Tours, France|Berlin, Germany|Bochum, Germany|Bonn, Germany|Darmstadt, Germany|Dusseldorf, Germany|Freiburg, Germany|Hamburg, Germany|Heidelberg, Germany|Leipzig, Germany|Mannheim, Germany|Munchen, Germany|Schwerin, Germany|Brescia, Italy|Milano, Italy|Perugia, Italy|Pisa, Italy|Roma, Italy|Amsterdam, Netherlands|Blaricum, Netherlands|Hertogenbosch, Netherlands|Barcelona, Spain|Bilbao, Spain|Getafe. Madrid, Spain|Madrid, Spain|Lund, Sweden|Basel, Switzerland|Bath, England, United Kingdom|London, England, United Kingdom|Oxford, England, United Kingdom|Sheffield, England, United Kingdom|Swindon, England, United Kingdom|Belfast, N. Ireland, United Kingdom|Glasgow, Scotland, United Kingdom|Penarth, Wales, United Kingdom|Southhampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00322036
NCT00319891,Computer-Based Training for Mild Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Procedure: Computer-based Cognitive Training,The primary objective of this trial will be to assess the feasibility of using computer-based|cognitive training in an a population with early Alzheimer's Disease.|A standardized set of neuropsychological assessments will be conducted pre- and post-|compuer-based training.,"Posit Science Corporation|University of California, San Francisco",All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 1,6,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OUT-109-2005,Sep-04,Oct-06,Oct-06,27-Apr-06,null,15-May-13,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00319891
NCT00314912,Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease,Drug: Tramiprosate (3APS),To evaluate the long-term safety of Tramiprosate (3APS).|To provide additional long-term data on the efficacy of Tramiprosate (3APS).,Bellus Health Inc,All,"50 Years and older   (Adult, Older Adult)",Phase 3,650,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CL-758017,May-06,null,null,17-Apr-06,null,16-Jul-07,"San Francisco Clinical Research Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00314912
NCT00305903,Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,"Drug: Rivastigmine, memantine","Safety and tolerability of treatment with memantine and rivastigmine, measured by the incidence of GI adverse events (nausea and vomiting)|Whether patients on rivastigmine and memantine are able to reach and maintain higher doses of rivastigmine compared to historical data of rivastigmine monotherapy",Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,150,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713BUS32,Mar-06,null,Aug-07,22-Mar-06,null,21-Dec-07,"Manchester, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00305903
NCT00306124,Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment,,Unknown status,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment|Healthy,Drug: Levodopa,Cognitive performance assessed by neuropsychological tests and learning paradigms under placebo and levodopa in healthy subjects and patients with dementia or Mild Cognitive Impairment.|Brain activity pattern during learning under levodopa as compared to placebo in healthy subjects.|Long-term stability of learning performance after 1 month in healthy subjects.,University Hospital Muenster,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,120,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,LL_001 Project on Dementia/MCI,Jan-06,null,Mar-08,22-Mar-06,null,25-Oct-07,"University of Muenster, Department of Neurology, Muenster, North-Rhine Westphalia, Germany",,https://ClinicalTrials.gov/show/NCT00306124
NCT00304629,Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Drug: galantamine,"The primary outcome is safety as measured by adverse events, laboratory tests, vital signs, weight, physical exam and electrocardiogram|The secondary outcome is effectiveness as measured by a cognitive scale (ADAS) and by activities of daily living (DAD).","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"45 Years and older   (Adult, Older Adult)",Phase 3,241,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR012070,Mar-00,null,Mar-02,20-Mar-06,null,1-Feb-11,,,https://ClinicalTrials.gov/show/NCT00304629
NCT00303277,Do HMG CoA Reductase Inhibitors Affect Abeta Levels?,,Completed,No Results Available,Alzheimer's Disease|Aging,Drug: simvastatin|Drug: pravastatin,CSF abeta levels|CSF biomarkers,Seattle Institute for Biomedical and Clinical Research,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,35,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",21974,Aug-02,Apr-05,Apr-05,16-Mar-06,null,13-Apr-10,"VA Puget Sound Health Care System, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00303277
NCT00301574,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.,,Completed,No Results Available,Alzheimer Disease,Drug: galantamine,"Change from baseline to the end of the study in the Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) and the Clinician's Interview-Based Impression of Change plus - Japan (CIBIC plus-J)|Change from baseline to the end of the study in CIBIC plus-J subscales (Disability Assessment for Dementia [DAD], Behavioral Pathology in Alzheimer's Disease Rating Scale [Behave-AD], the Mental Function Impairment Scale [MENFIS ]).",Janssen Pharmaceutical K.K.,All,"45 Years and older   (Adult, Older Adult)",Phase 3,398,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CR003301,Apr-01,null,Feb-04,13-Mar-06,null,17-May-11,,,https://ClinicalTrials.gov/show/NCT00301574
NCT00299988,Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Intravenous Immunoglobulin,ADAS-Cog|ADCS-CGIC|3MS|ADCS-ADL|NPI|GDS|QOL|ADCS Pharmacoeconomic Assessment|Plasma and CSF anti-amyloid antibody titers|Plasma and CSF beta amyloid levels|FDG Cerebral Glucose Utilization|PIB Cerebral Amyloid Distribution (PET)|PK11195 Microglial Activation (PET)|Adverse Event Frequency and Severity,Weill Medical College of Cornell University|Baxter BioScience|National Institutes of Health (NIH),All,"50 Years and older   (Adult, Older Adult)",Phase 2,24,Other|Industry|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,512008265,Feb-06,Jan-09,Apr-10,7-Mar-06,null,10-Nov-10,"Weill Medical College of Cornell University, New York City, New York, United States",,https://ClinicalTrials.gov/show/NCT00299988
NCT00295152,Effects of Community Occupational Therapy in Older Patients With Dementia and Their Caregivers.,,Unknown status,No Results Available,Community Occupational Therapy|Dementia Patients|Primary Caregivers of Dementia Patients,Behavioral: community occupational therapy in dementia,"1.process skills scores of the patients on the Assessment of Motor and Process Skills (AMPS);|2. performance scores in daily activities of the patients on the Interview of Deterioration in Daily Activities in Dementia (IDDD);|3. Sense of competence scores of the primary caregivers on the Sense of Competence Questionnaire (SCQ).|Patients:|1. motor skills scores on the AMPS|2. initiative in performing daily activities on the IDDD|3. general health scores on the General Health Questionnaire (GHQ-12)|4.Quality of life scored on the Dementia Quality of Life Instrument (DQOL)|5. Self-perception scores in occupational performance and satisfaction scores with this performance, scored on the Canadian Occupational Performance Measurement (COPM)|6. Mood/depression scored on the Cornell Depression Scale (CDS)|Caregiver:|1. mastery skills scored on the Mastery Scale|2. general health scores on the GHQ-12|3. quality of life scores on the DQOL|4. self-perception scores in occupational performance and satisfaction scores on the COPM|5. mood/depression scores on the Center for Epidemiologic Studies Depression Scales (Ces-D)|6. Copings skills scores on the JCS",Radboud University|Alzheimer's Association|VCVGZ Fund;|Dutch Occupational Therapy Association,All,65 Years and older   (Older Adult),Not Applicable,135,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Treatment,EDO project|Grant V-1999-023.,Apr-01,null,Feb-05,22-Feb-06,null,17-Nov-11,"Memory Clinic and Geriatic Department Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT00295152
NCT00291161,Partners in Dementia Care: A Telephone Care Consultation Intervention Provided to Veterans in Partnership With Local Alzheimer's Association Chapters,PDC,Completed,Has Results,Dementia|Alzheimer Disease,Behavioral: Partners in Dementia Care,Caregiver Outcomes|Veteran Outcomes,VA Office of Research and Development|Benjamin Rose Institute|Alzheimer's Association,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,994,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IIR 04-238,Dec-06,Sep-10,Feb-11,13-Feb-06,19-May-16,19-May-16,"VA Boston Health Care System, Jamaica Plain, Boston, Massachusetts, United States|VA Boston Healthcare System, Brockton Campus, Brockton, Massachusetts, United States|Oklahoma City, OK, Oklahoma City, Oklahoma, United States|VA Medical Center, Providence, Providence, Rhode Island, United States|Beaumont VA Outpatient Clinic, Beaumont, Texas, United States|Michael E DeBakey VA Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00291161
NCT00287742,A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease|Dementia,Drug: risperidone,"Change in Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) psychotic symptom cluster score from baseline and intermediate visits to study end (Week 9) compared with placebo.|Changes in BEHAVE-AD total, subscales and items scores, changes in CMAI aggressiveness and non-aggressiveness item scores and changes in CGI-C from baseline and intermediate visits to study end (Week 9) compared with placebo. Safety evaluations.",Janssen Pharmaceutical K.K.,All,"Child, Adult, Older Adult",Phase 3,33,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CR003172,Mar-02,null,Mar-03,7-Feb-06,null,24-May-11,,,https://ClinicalTrials.gov/show/NCT00287742
NCT00287248,Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain,,Completed,No Results Available,Alzheimer Disease,Drug: [123I] IMPY & SPECT Imaging,Does 123-I IMPY demonstrate qualitatively increased radiotracer uptake in cortical regions consistent with β-amyloid deposition in AD patients relative to controls|Can 123-I IMPY and SPECT provide a quantitative and reproducible measure of amyloid deposition,Institute for Neurodegenerative Disorders|Alzheimer's Association|Molecular NeuroImaging,All,"50 Years and older   (Adult, Older Adult)",Phase 1,38,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AMYLOID001,Feb-06,Feb-08,Mar-08,6-Feb-06,null,7-Mar-14,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00287248
NCT00285025,Study of the Effect of SR57667B in Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Drug: SR57667B,"ADAS-cog, CDR measured at baseline and at 2, 6, 9 and 12 months.|MMSE, CGIC, ADCS-ADL, NPI measured at baseline and at 2, 6, 9 and 12 months.",Sanofi,All,"50 Years and older   (Adult, Older Adult)",Phase 2,500,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,EFC5286|SR57667B,Mar-05,null,Sep-05,1-Feb-06,null,1-Feb-06,,,https://ClinicalTrials.gov/show/NCT00285025
NCT00285077,Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Drug: SR57667B,"Adverse events recorded quarterly.|ADAS-cog, CDR, MMSE, CGIC, ADCS-ADL, NPI measured at baseline and at 2,6,9 and 12 months.",Sanofi,All,"50 Years and older   (Adult, Older Adult)",Phase 2,390,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LTS5283,Mar-04,Nov-06,Nov-06,1-Feb-06,null,23-Dec-08,"Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Horslholm, Denmark|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Midrand, South Africa|Sanofi-Aventis Administrative Office, Bromma, Sweden",,https://ClinicalTrials.gov/show/NCT00285077
NCT00277810,"Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease",,Completed,No Results Available,Alzheimer Disease,Drug: lecozotan SR (SRA-333),All events and physical and neurological function and score change from baseline to 24 weeks in ratings for cognitive and global function scales|Score change from baseline to 24 weeks on functional and behavioral scales,Wyeth is now a wholly owned subsidiary of Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,250,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3098B1-203, 3098B1-204",Mar-06,Jun-08,Jun-08,16-Jan-06,null,21-Feb-13,"Phoenix, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Fresno, California, United States|La Jolla, California, United States|Orange, California, United States|Delray Beach, Florida, United States|Ft. Lauderdale, Florida, United States|Ft. Myers, Florida, United States|Hallandale, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|S. Miami, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|St. Louis, Missouri, United States|Long Branch, New Jersey, United States|Manchester Twp., New Jersey, United States|Albany, New York, United States|Cedarhurst, New York, United States|Staten Island, New York, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|East Providence, Rhode Island, United States|Memphis, Tennessee, United States|Houston, Texas, United States|Bennington, Vermont, United States|Av. Belgrano, Argentina|Buenos Aires, Argentina|Calle Adolfo Alsina, Argentina|Cervino, Argentina|Galvan, Argentina|Gascon, Argentina|Larrea, Argentina|Nueva York, Argentina|Pilar, Argentina|Adelaide, Australia|East Gosford, Australia|Hornsby, Australia|Randwick, Australia|Victoria, Australia|Edmonton, Alberta, Canada|Medicine Hat, Alberta, Canada|Moncton, New Brunswick, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Helsinki, Finland|Joensuu, Finland|Kuopio, Finland|Bordeaux, France|Montpellier, France|Nice, France|Toulouse, France|Roma, Italy|Roma, Italy|Gdansk - Wrzeszcz, Poland|Krakow, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Sopot, Poland|Szczecin, Poland|Bloemfontein, South Africa|Cape Town, South Africa|Johannesburg, South Africa|Somerset West, South Africa|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Belfast, United Kingdom|Glasgow, United Kingdom|Sheffield, United Kingdom|Southampton, United Kingdom|Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00277810
NCT00276510,A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints,,Completed,No Results Available,"Memory Disorders, Age-Related|Retention Disorders, Cognitive",Drug: EGb 761® (Tanakan®)|Other: Placebo,EGb 761® efficacy on conversion rate of memory complaint to dementia of Alzheimer type by a survival analysis|Efficacy on rate of cognitive abilities decline|Effect on concomitant diseases|Concomitant treatments' reports|Global evaluation of memory complaint by the patient|Clinical safety,Ipsen,All,70 Years and older   (Older Adult),Phase 4,2878,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2-31-00240-011,Feb-02,Nov-09,Nov-09,13-Jan-06,null,15-Jan-19,"1 rue de l'Orient, Agde, France|3 Avenue de Marlioz, Aix les Bains, France|3 rue Auguste Delaune, Ales, France|17 rue du Cardinal Georges d'Amboise, Amboise, France|17 rue Manuel, Amboise, France|83 rue Nicolas et Paul Paquet, Ancerville, France|10 bd De La Republique, Andernos Les Bains, France|107 bd De La Republique, Andernos Les Bains, France|19 rue Jean Saccheti, Andernos, France|128 Rue Bressigny, Angers, France|18 rue Martin Luther King, Angers, France|2 boulevard Jacques Millot, Angers, France|21 bd Roi René, Angers, France|25, rue St Nicolas, Angers, France|59 Boulevard Joseph Bédier, Angers, France|61 Ave Jean XXIII, Angers, France|68A rue d'Orgemont, Angers, France|Residence le Paradis Bat 17, 74-78 rue Volney, Angers, France|Centre Hospitalier Universitaire Hotel Dieu Gerontologie Clinique 4 rue Larrey, Angers, France|111 rue de la Chalouère, Angers, France|4 rue Saint Jacques, Angers, France|4, rue St Jacques, Angers, France|7 rue Thiers, Angers, France|1172 route de Grasse Ste Elisabeth, Antibes, France|20 boulevard Albert 1er, Antibes, France|700 av. Jules Grec, Antibes, France|26 R Pres Wilson, Ars sur Moselle, France|Avenue Joseph Lafont, Aubagne, France|Groupe Piettot Bâtiment 2, Aubagne, France|37-39 boulevard Anatole France, Aubervilliers, France|26 av. Charles de Gaulle, Aubevoye, France|3 Avenue de Verdun, Audenge, France|27 rue Maréchal Foch, Aumetz, France|2 bis route de Miremont, Auterive, France|70 bis rue Etienne Billieres, Auterive, France|17 rue des Ecoles, Avoine, France|17, rue des Ecoles, Avoine, France|10 Allée Des Rochers, Avrille, France|30 Ter Avenue Pierre Mendès, Avrille, France|5 Place Maréchal Juin, Avrille, France|Rd point de Gal de Gaulle, Avrille, France|1 Résidence Marcel Paul, Bachant, France|11 rue du pont Fouchard, Bagneux, France|13, rue Denis Papin, Bagnolet, France|11 rue du Général Cheroutre, Bailleul, France|17 rue de la Croix de Pierre, Bain De Bretagne, France|9 av Pierre Coupeau, Balma, France|43 rue Ducs de Bar, Bar le Duc, France|33 rue Jean Jaures, Bassens, France|21, rue Georges Clémenceau, Bauge, France|24, rue Julien Daillière, Baune, France|Centre Commercial Tertifume 9 rue de Montreuil, Beaucouze, France|42 rue de la Petite Porte, Beaufort en Vallee, France|14 rue Moulin du Roy, Beaulieu sur Layon, France|L'Helvetia 10 rue Paul Doumer, Beaulieu Sur Mer, France|31, rue du Parc, Beaumont en Veron, France|Rue Lapeyrère, Beaumont Sur Leze, France|2 r Des Muriers, Beauzelle, France|Route de Toulouse, Berat, France|24bis, rue de la Motte, Bersee, France|1 Avenue Gambetta, Beziers, France|1, rue du Pinot, Beziers, France|Centre Médical Sémard 39, place Semard, Beziers, France|9 bis Chemin Aussonne, Blagnac, France|208 Cours Saint Louis, Bordeaux, France|28 bd Du President Wilson, Bordeaux, France|8, Boulevard Albert 1er, Bordeaux, France|Centre Hospitalier Pellegrin-Tripode Service de Neurologie Place Amelie Raba-Leon, Bordeaux, France|Résidence Mozart- Apt 56, 2 rue Jean Artus, Bordeaux, France|183 Cours De La Marne, Bordeaux, France|Les Suriaux Rue du Stade, Bouce, France|2 allée Port Larron, Bouchemaine, France|60 Rue Du Moulin, Bouguenais, France|1 Rue Roeckel, Bourg La Reine, France|12 Esplanade du Prado, Bourges, France|121 Avenue du Général de Gaulle, Bourges, France|14 rue Calvin, Bourges, France|16 rue Emile Martin, Bourges, France|24 Boulevard Clémenceau, Bourges, France|86 Avenue Haegelen, Bourges, France|Centre Hospitalier Jacques Coeur Hopital Taillegrain Centre de Gerontologie des Pres Fichaux 6 rue Taillegrain, Bourges, France|Centre Hospitalier Jacques Coeur Hôpital Taillegrain, Bourges, France|9, rue du Lavoir, Brain-sur-Allonnes, France|106, rue du Docteur Lahaye, Breteuil Sur Iton, France|30 rue de Bayeux, Bretteville L'orgueilleuse, France|1 rue mar Leclerc, Broglie, France|Avenue du Gal de Gaulle, Bruges, France|57 impasse des Cades, Cabrieres, France|114, rue Authie, Caen, France|29 rue Lucien Nelle, Caen, France|36, Avenue Du 6 Juin, Caen, France|6 Avenue Du 6 Juin 1944, Caen, France|98 Boulevard du Maréchal Lyautey, Caen, France|Hopital Cote de Nacre Service de Neurologie avenue de la cote de Nacre, Caen, France|Hôpital Côte de Nacre, Caen, France|12 Grand Rue, Calmont, France|16, rue d'Alger, Cambrai, France|Square la Gare, Cande, France|Avenue Buchholz, Cantaleu, France|8 Boulevard Ronceray, Cantenay Epinard, France|3 rue Lucien Cassagne, Carbonne, France|La Chohonniere Im. la Rotonde, Carquefou, France|10 avenue Victor Hugo, Cassis, France|4 route de Toulouse, Castelmaurou, France|311 chemin Draye du Marbre, Castelnau le Lez, France|Avenue A Briand, Castelnau le Lez, France|Villa 54. Résidence le Village, Castelnau le Lez, France|2 rue Clairval, Castelnau-le-Lez, France|Place d'Armes, Cazeres, France|27 rue Emile Landais, Chace, France|15 rue des Sables, Chalonnes sur Loire, France|8 rue Sainte Croix, Chateaugiron, France|16 Bis rue Cherré, Chateauneuf sur Sarthe, France|48 rue Henri Bouriché, Chemellier, France|290 rue du Bocage, Cheux, France|11 rue du 11 Novembre 1945, Chinon, France|Place Pierre Robbe, Chinon, France|14 rue Faidherbe, Cholet, France|16 Av de l'Europe, Cholet, France|18, avenue des Calins, Cholet, France|25 av de Nantes, Cholet, France|43 Bis Rue Nationale, Cholet, France|6 Allée des forgerons, Cholet, France|83 Rue du Paradis, Cholet, France|8 rue Seguin, Château Gontier Bazouges, France|55, rue Eugène Lecoq, Clary, France|7 rue du Docteur Doussain, Clisson, France|5 rue du Couderc, Colomiers, France|7 rue d'Auch, Colomiers, France|13 rue du Docteur Malabouche, Cournonterral, France|4 Bld Jean-Baptiste Oudry, Creteil, France|61 Rue de l'amiral Courbet, Croix, France|9 rue Peyrere, Cubzac les Ponts, France|14 rue du Cezerou, Cugnaux, France|14, rue Cézerou, Cugnaux, France|3 avenue de Toulouse, Cugnaux, France|6 place de Vivier, Cugnaux, France|2 rue Abbé Bernier, Daon, France|116 rue Henri Barbusse, Denain, France|221 rue Villars, Denain, France|25 place de I'Eglise, Deville Les Rouen, France|11 rue Principale, Diebling, France|1 Avenue Edouard VII, Dinard, France|10 rue Mathieu de Dombasle, Dombasle Sur Meurthe, France|La Tour des Charmettes, Domene, France|18, rue Danton, Drancy, France|97, rue Winston Churchill, Dunkerque, France|Résidence Emeraude 71 av Adolphe Geeraert, Dunkerque, France|72 rue Saint Pierre, Durtal, France|2 rue Jean Monnet, Eaunes, France|108 Faubourg Ambrail, Epinal, France|4 rue du Général de Gaulle, Essey les Nancy, France|3 Place de l'Eglise, Etalondes, France|1 rue du Jardin Botanique, Evreux, France|24, rue des Lombards, Evreux, France|41 rue Victor Hugo, Evreux, France|6 Centre Commercial les Peupliers, Evreux, France|Route Nationale 75, Eyguians, France|7 rue Pasteur, Fabregues, France|3 route de Caen, Falaise, France|33 rue du Camp Fermé, Falaise, France|1 rue Renelles, Fecamp, France|2 rue de I'Eglise, Fenouillet, France|126 Route d'Harcourt, Fleury sur Orne, France|11 bis av. Ambroise Croisat, Fontaine, France|3 place Louis Maisonnat, Fontaine, France|1, rue Pierre et Marie Curie, Fontes, France|21 rue Nationale, Forbach, France|2 pl Clemenceau, Fresnes En Woevre, France|34 rue du Marechal Soult, Fresnes, France|10, Rue Du 8 Mai, Fronton, France|10 route des Mares, Frossay, France|74 avenue de la Liberation, Frouard, France|2 avenue des Camelias, Gan, France|2 bis rue Abon, Gap, France|2 bis rue d'Abon, Gap, France|Residence Le Gaughin Bat 1 68 rue Borely, Gardanne, France|Villa Pinede Route St Tropez, Gassin, France|18, avenue de Verdun, Gemenos, France|24, rue de la République, Gemenos, France|12 rue Cohue, Gennes, France|10 rue de la Sèvre, Getigne, France|18 r Stade, Gironde Sur Dropt, France|4 ave de la Gare, Gourdan Polignan, France|Centre Commercial Malartic, Gradignan, France|41, rue Saint-Yves, Grand-Champ, France|12, Place Jean Moulin, Grenoble, France|13 bis rue du General Champon, Grenoble, France|15, chemin Joseph Brun, Grenoble, France|22 av. Leon Blum, Grenoble, France|28 rue Elie Cartan, Grenoble, France|35 Bd Marechal Foch, Grenoble, France|46 boulevard Joseph Vallier, Grenoble, France|6, Boulevard Joseph Vallier, Grenoble, France|9A place Saint-Bruno, Grenoble, France|Centre de Prevention des Alpes 3 place de Metz, Grenoble, France|15, chemin Joseph Brun, Grenoble, France|28 rue Général Ferrié, Grenoble, France|32 rue Gay-Lussac, Grenoble, France|34 avenue de l'Europe Immeuble le Trident A1er etage, Grenoble, France|4 avenue de la Bouexiere, Guerande, France|117 cours de Verdun, Gujan Mestras, France|117, avenue du Maréchal de Lattre de Tassigny, Gujan Mestras, France|6 pl Du Marché - La Hume, Gujan Mestras, France|14 rue de la Liberation, Halluin, France|14 rue Libération, Halluin, France|3, rue Paul Vaillant Couturier, Haulchin, France|12 rue de Maubeuge, Hautmont, France|206 rue Gambetta, Hautmont, France|1 rue Franz Schubert Saint Martin d'Hères, Heres, France|136 av. Ambroise Croizat Saint Martin d'Heres, Heres, France|20 av. Paul Eluard, Heres, France|137 Route de Dax, Hinx, France|2 bis, route de Belin, Hostens, France|5 rue Mairie, Ingrandes Sur Loire, France|10 rue Gaston Monmousseau, Ivry Sur Seine, France|Hopital Charles Foix Service de Gerontologie 37 avenue de la Republique, Ivry Sur Seine, France|119 rue Franchepre, Joeuf, France|6 rue des Ponts, Jort, France|20 avenue de l'Amiral Courbet, Juan Les Pins, France|117 Boulevard du Président Wilson, Juan Les Pins, France|4 Chemin du Tanit, Juan Les Pins, France|Le Tanagra- 10 pl du Pont du Lys, Juan-Les-Pins, France|7 Route de Gagnebert, Juigne sur Loire, France|2 rue Roger Salengro, L'hay Les Roses, France|76, avenue Gabriel Péri, L'Hay les Roses, France|Le Moulin, La Batie-Neuve, France|33 rue Georges Clemenceau, La Bernerie en Retz, France|La buffaie Route du Doreur, La Breille Les Pins, France|Avenue du Général de Gaulle, La Calmette, France|Maison Médicale av. Géneral de Gaulle, La Calmette, France|4 rue Meriadec Laennec, La Chapelle Basse Mer, France|4 rue Mériadec Laënnec, La Chapelle Basse Mer, France|10 rue Aristide Briand, La Chapelle Heulin, France|17 rue de l'Erdre, La Chapelle sur Erdre, France|53 rue Martin Luther King, La chapelle sur Erdre, France|53 rue Martin Luther King, La Chapelle, France|10 , rue Adolphe Abeille, La Ciotat, France|62, ru du Maréchal de Lattre de Tass, La Foret Sur Sevre, France|8 Chemin des Vendéens, La Jubaudiere, France|149 route de Bouguenais, La Montagne, France|9 av. de la Liberation, La Montagne, France|9 rue de la Liberation, La Montagne, France|Village Retraite, La Motte du Caire, France|4 route de Balaruc, La Peyrade, France|11 Place Sainte Anne, La Riche, France|7 route Targon, La Sauve, France|1 rue Joffre, La Teste, France|4 place de la République, La Trinite, France|16 Grand'rue, La Tronche, France|24 boulevard de la Chantourne, La Tronche, France|8 Place Vincent Auriol, Labarthe sur Leze, France|4, chemin Banque, Labastidette, France|34, rue Vacheresse, Lagny-Sur-Marne, France|23 avenue Pasteur, Laragne Monteglin, France|23 rue Louis Pasteur, Laragne Monteglin, France|23 rue Pasteur, Laragne, France|52 Place de la Fontaine, Laragne, France|43 rue Raymond Poincaré, Laxou, France|44 bis rue Paul Bert, Laxou, France|44b rue Paul Bert, Laxou, France|49 r Theophile Gautier, Le Bouscat, France|5 Av. Gauthier Lagardère, Le Bouscat, France|26 Avenue Jean Macé, Le Cailar, France|8 Avenue Louis Blanc, Le Cailar, France|6 rue Colbert, Le Canet, France|1 rue des Orangers, Le Cannet, France|50 Bd Sadi Carnot, Le Cannet, France|69 av. F. Roosevelt, Le Cannet, France|Route de Marignac, Le Fousseret, France|7 place du Commerce, Le Fuilet, France|17 rue du Dr Leveillé, Le Grand Pressigny, France|35 Avenue du Président Kennedy, Le Grand Quevilly, France|60 rue des Moussaillons, Le Grau Du Roi, France|1 Quai de Bretagne, Le Lion D'angers, France|1 rue Pasteur, Le May, France|48 rue des Mauges, Le Mesnil En Vallée, France|111 route de Paris, Le Mesnil Esnard, France|Impasse Mérite, Résidence Lamiot rue L'ecalier, Le Neubourg, France|31 rue Promenade, Le Puy Saint Bonnet, France|21 rue de Nantes, Le Temple de Bretagne, France|364 rue Pasteur, Le Versoud, France|23 rue Jeanne d'Arc, Les Epesses, France|46 rue de Paris, Les Lilas, France|2 rue des Pleiades, Les Mureaux, France|8 Avenue Amiral Chauvin, Les Ponts De Ce, France|68 ter Rue Marjolin, Levallois Perret, France|11 place de l'Eglise, Lherm, France|34 avenue Georges Clémenceau, Libourne, France|46 avenue François Mitterand, Liffre, France|110 BD de la liberté, Lille, France|115 bis rue d'Artois, Lille, France|129 Rue Des Postes, Lille, France|19 Rue Des Postes, Lille, France|236 rue du Faubourg des Postes, Lille, France|24 rue P. Legrand, Lille, France|Hopital Roger Salengro Service de Neurologie C rue Emile Laine, Lille, France|Hôpital Roger Salengro, Lille, France|Parc du Segrais, Lognes, France|928 avenue de Dunkerque, Lomme, France|Place de la Halle, Longages, France|2, Rue Abbée Rappine, Longeville-les-Saint-Avold, France|47, rue Racine, Longue Jumelles, France|126 Avenue des Graves, Lormont, France|126 Avenue des Gravières, Lormont, France|126 rue des Gravieres, Lormont, France|36 avenue de Leuze, Loudun, France|15 ter Bd Clémenceau, Louviers, France|57 rue Dupont de l'Eure, Louviers, France|Chemin des Diligences, Louvigne de Bais, France|70 rue Andre Auguste, Lunel Viel, France|L'ancien Presbytere, Lussan Adeilhac, France|10, avenue Robert Daugey, Luynes, France|1 Place Bellecroix, Manduel, France|1 bis avenue des Coteaux, Marly, France|2 Avenue Long Pré, Marly, France|8 Rue Georges Thiebaux, Mars La Tour, France|1 boulevard Montricher, Marseille, France|134, rue Félix Pyat, Marseille, France|81 rue Jaubert, Marseille, France|81 rue Jaubert, Marseille, France|12 Bld Des Neiges, Marseille, France|325 avenue de Mazargues, Marseille, France|38 bld Rodocanachi, Marseille, France|431 avenue de Marzargues, Marseille, France|63, boulevard Rabateau, Marseille, France|Hopital St Joseph Service de Neurologie 26 boulevard Louvain, Marseille, France|2 Avenue Jean Bouin, Marseille, France|2 chemin de Morgiou, Marseille, France|23 Bd de la Concorde, Marseille, France|250 Bd Romain Rolland, Marseille, France|Groupe Medical de Mazargues 1 av de la Martheline, Marseille, France|13 rue St Eloi, Marseille, France|90 Boulevard de Saint Loup, Marseille, France|Les Camoins 58 Traverse de St Menet, Marseille, France|21 Traverse des Rosiers, Marseille, France|253 ch. de la Madrague-Ville, Marseille, France|Hopital STe Marguerite Unite de Neurologie 270 boulevard de STe Marguerite, Marseille, France|6 av. des martyrs de la Resistance, Martignas, France|5 Avenue du Pdt Allende, Martigues, France|Espace Vénitien 1 av Pres Salvador Allende, Martigues, France|Espace Vénitien, Martigues, France|75 rue Principale, Maze, France|1 Square Chardin, Meaux, France|Centre Commercial La Verriere place Beauval, Meaux, France|11 rue des Tilleuls, Mercy Le Bas, France|206 av de l'Argonne, Merignac, France|Hôpital Felix Marechal 1 rue Xavier Roussel, Metz, France|203 Rue de Vallieres, Metz, France|10 rue de la Republique, Meudon, France|41, Avenue Plaine Fleurie, Meylan, France|7 rue de l'Oisans, Meylan, France|Domus Médica, Meze, France|2 bis Place du Castellas, Milhaud, France|27 rue de la Croix Thomas, Miniac Morvan, France|32 rue Cité, Mire, France|12 Rue Du 8 Mai 1945, Moirans, France|221 R de Pont A Mousson, Montigny les Metz, France|5 rue des Roses, Montigny les Metz, France|2 place de L'Eglise, Montjean-sur-Loire, France|2, rue Delpech, Montpellier, France|25 av de St Lazare - Le Prieure II, Montpellier, France|32 avenue G Clémenceau, Montpellier, France|32, Avenue Georges Clémenceau, Montpellier, France|41 Bld Du Jeu de Paume, Montpellier, France|7 ter rue Rigaud, Montpellier, France|82 avenue d'Assas, Montpellier, France|82, avenue d'ASSAS, Montpellier, France|9 avenue d'Assas, Montpellier, France|9, Avenue d'Assas, Montpellier, France|11 rue Monge, Montpellier, France|11 rue Mongre, Montpellier, France|20 avenue de Toulouse, Montpellier, France|48 rue Robespierre, Montpellier, France|57, route de Lavérune, Montpellier, France|59 av. de Toulouse- Bat B, Montpellier, France|7 rue du Grau, Montpellier, France|12 Faubourg Boutonnet, Montpellier, France|22 Faubourg Boutonnet, Montpellier, France|Hopital Gui de Chauliac 80 rue Augustin Fliche, Montpellier, France|8 rue Pierre Mendès France, Montreuil-Juigne, France|9 rue Sadi Carnot, Montrouge, France|113 Route de Douai, Mouchin, France|11 Rue du Maine, Mouliherne, France|6, route d'Anjou, Mouliherne, France|18 Rue de Metz, Moulin Les Metz, France|Rue du Rieu, Moussac, France|13 rue Clémenceau, Moutiers, France|48, ave Jacques Douzans, Muret, France|48, avenue Jacques Douzans, Muret, France|25 rue Valentin Desormeaux, Murs Erigne, France|34 Rue de Metz, Nancy, France|82 rue Saint Georges, Nancy, France|15 rue Jeanne d'Arc, Nantes, France|181 rue Paul Bellamy, Nantes, France|2 Bd Amiral Courbet, Nantes, France|23 rue Racine, Nantes, France|29 bis rue Pelleterie, Nantes, France|46 bis bd Gabriel Guist'Hau, Nantes, France|59 bld Gaston Serpette, Nantes, France|71 rue du Coudray, Nantes, France|88 rue Gambetta, Nantes, France|Hopital Bellier Service de Geronotologie 41 rue Curie, Nantes, France|42 rue du Roi Baco, Nantes, France|7 rue Blancho, Nantes, France|Cabinet de Neurologie - Consultations, Nantes, France|101 bld de Doulon, Nantes, France|134 rue du Croissant, Nantes, France|142 bld Robert Schuman, Nantes, France|15 rue Guillaume Grootaers, Nantes, France|23 bld Chauviniere, Nantes, France|27 boulevard des Americians, Nantes, France|34 rue de la Gourmette, Nantes, France|46, boulevard Jules Verne, Nantes, France|58 bld Jules Verne, Nantes, France|63 rue de la Bottière, Nantes, France|Route de Morlaas, Navailles Angos, France|12 rue Pasteur, Neuville Sur Escaut, France|12, rue Pasteur, Neuville sur Escaut, France|16 rue Vernier, Nice, France|30, rue Gioffredo, Nice, France|54 bld François Grosso, Nice, France|6, rue Rossini, Nice, France|Hopital de Cimiez Pavillon Mossa 4 avenue de la Reine Victoria, Nice, France|Hôpital Pasteur, Nice, France|32 rue Auguste Gal, Nice, France|47 Bis, Rue Barberis, Nice, France|5 boulevard du General Delfino, Nice, France|5 rue Smolett, Nice, France|L'Esperanza 9 rue de la République, Nice, France|Maison Médical Mutualiste, Nimes, France|Centre Raymond Ruffi 12 rue Alexandre Ducros, Nimes, France|Cabinet Medical place des Goelands, Nimes, France|30 Bd de la Gare, Nort Sur Erdre, France|4 bld de Strasbourg, Nort Sur Erdre, France|8 rue Foch, Noveant Sur Moselle, France|20 Place d'Armes, Nueil, France|2 Allée des Glycines, Orly, France|2 avenue Pesqué, Orthez, France|2, Avenue Pesqué, Orthez, France|3 rue Madame, Orthez, France|125, rue Gambetta, Ouistreham, France|16 rue Aristide Briand, Pacy sur Eure, France|31 rue Jean L'olive, Pantin, France|route de Gizeux, Parcay Les Pins, France|19 boulevard Morland, Paris, France|1 rue Villersexel, Paris, France|6 rue de la Motte-Piquet, Paris, France|88 rue de Sevres, Paris, France|9 Rue de Montessuy, Paris, France|3, Rue Pierre Le Grand, Paris, France|40 rue du Faubourg Montmartre, Paris, France|15 rue de Chabrol, Paris, France|41 rue de la Grange aux Belles, Paris, France|26, rue Picpus, Paris, France|167, boulevard Vincent Auriol, Paris, France|74 rue Dunois, Paris, France|Hôpital Broca - Service de Gérontologie Clinique 54-56 rue Pascal, Paris, France|191 rue d'Alésia, Paris, France|2 rue de la Briqueterie, Paris, France|96 avenue Maine, Paris, France|81, rue de Rome, Paris, France|33, rue Marx Dormoy, Paris, France|34 rue Hermel, Paris, France|13 Villa Curial, Paris, France|20, rue du Télégraphe, Paris, France|7 Rue Saint Blaise, Paris, France|79 rue Boissiere, Paris, France|1 Avenue Mirabelle, Pau, France|28 rue Castelnau, Pau, France|69 rue du 14 Juillet, Pau, France|Centre Hospitalier des Pyrenees Department de Psychogeriatrie 29 av du Marechal Leclerc, Pau, France|Centre Hospitalier des Pyrénées, Pau, France|2, rue de l'Hôtel de Ville, Perols, France|153 Avenue du Général Leclerc, Pessac, France|Le forum, Pignan, France|1 Impasse Pasteur, Pinsaguel, France|83 rue Andorre, Pinsaguel, France|18 place Gambetta, Podensac, France|14 Rue Philippe de Gueldres, Pont A Mousson, France|170 , avenue des Etats-Unis, Pont A Mousson, France|47, boulevard Ney, Pont A Mousson, France|7 rue du Cardinal Mathieu, Pont A Mousson, France|3 bis rue Cacheleux, Pont De L'arche, France|35bis rue du Général de Gaulle, Pont-de-l'Arche, France|1 place Aristide Briand, Pornichet, France|16 av. du Littoral Ste Marguerite, Pornichet, France|26, rue de Tourte, Pornic, France|Immeuble ""Le Roc Rose"", Port De Bouc, France|69 rue du Général Leclerc, Potigny, France|69, rue du Général Leclerc, Potigny, France|169 , rue de l'Avenir, Poulx, France|BP 22-23 rue republique, Preignac, France|24 avenue Charles de Gaulle, Pulnoy, France|7 rue Gambetta, Quarouble, France|Cours Goudouli, Quint Fonsegrives, France|141 rue Roger Salengro, Raimbeaucourt, France|22 avenue de Tolosane, Ramonville Saint Agne, France|22 avenue Tolosane, Ramonville Saint Agne, France|12, rue Louis Braille, Ramonville, France|La Garenne, Rauzan, France|11, rue du Fresne, Renaze, France|Rue Fresnes, Renaze, France|15 rue Emile Souvestre, Rennes, France|Cabinet de Neurologie 4 av Charles Tillon, Rennes, France|Cabinet de Neurologie, Rennes, France|Centre Commercial La Bellangerais, Rennes, France|Centre Espace Performance, Rennes, France|3, Rue de la petite Mairie, Restigne, France|Immeuble Athéna 62 bis rue Aristide Briand, Reze, France|11 rue Sagazan, Rieumes, France|9 Place de la Mairie, Roquemaure, France|Quai le Repos, ZAC St Estève, Roquevaire, France|13 rue de Messan, Rouans, France|91 avenue Jean Lebas, Roubaix, France|106 bis Rampe Bouvreuil, Rouen, France|45 Boulevard de l'Yser, Rouen, France|Hôpital Charles Nicolle Department de Neurologie 1, rue de Germont, Rouen, France|102 rue Méridienne, Rouen, France|6 rue Soye, Sains Orens De Gameville, France|30 Avenue du Général de Gaulle, Saint Avertin, France|4, rue Manet, Saint Barthelemy d'Anjou, France|13 rue du Commandant Thoreux, Saint Briac, France|4 rue Orme, Saint Broladre, France|103 rue Fleurie, Saint Cyr Sur Loire, France|6, rue de Courpouyran, Saint Georges d'Orques, France|15 bis Avenue Marcellin Berthelot, Saint Gilles, France|30 bis avenue Gallieni, Saint Girons, France|2 impasse Dublin, Saint Herblain, France|27 rue d'Aquitaine, Saint Herblain, France|48 avenue Condamine, Saint Just, France|22 avenue du Général Leclerc Les Bougainvillées, Saint Laurent Du Var, France|63 Chaussée du Sillon, Saint Malo, France|Impasse Dr Adrien Gory, Saint Mamert Du Gard, France|3, Rue Du 3 Août 1944, Saint Mars du Désert, France|34 rue Prieuré, Saint martin du Bois, France|9, Résidence Haut Rivage, Rue Jean Xxiii, Saint Max, France|3, rue du Pertuischaud, Saint Nazaire, France|9, Route du Fort de l'Eve, Saint Nazaire, France|1 bis rue Godillot, Saint Ouen, France|1 rue Canot, Saint Privat la Montagne, France|16, Boulevard Darby - Valescure, Saint Raphael, France|7 place Cambronne, Saint Sebastein Sur Loire, France|2, rue Jean Jaurès, Saint Sebastien, France|25, avenue de la Martellière, Saint Sebastien, France|19, Avenue de Verdun, Saint Serin, France|61 rue Anatole France, Saint-Amand Mont-Rond, France|59 Pl. Du 11 Novembre 1918, Saint-Amand, France|Rue des Oratoires, Saint-Anastaise, France|245, avenue Mindin, Saint-Brevin-les-Pins, France|Rue de Clairdouy, Saint-Georges-d-Orques, France|106, Place du Gué des Joncs, Saint-Georges-de-Montaigu, France|2 rue du Prieuré, Saint-Georges-des-Groseilliers, France|60, Impasses des deux moulins, Saint-Georges, France|Boulevard du Général de Gaulle, Saint-Girons, France|22 av. des Thebaudieres, Saint-Herblain, France|ZA la Petite Croix, Saint-Hilaire-de-Chaleons, France|11 Route de La Foret, Saint-Jean-des-Linieres, France|53 Bd du 8 mai 1945, Saint-Macaire-en-Mauges, France|1 Place du 11 Novembre, Saint-Mandrier, France|38 rue Hector Berlioz, Saint-Max, France|112 av Montesquieu, Saint-Medard-en-Jalles, France|69 avenue Montaigne, Saint-Medard, France|4, avenue du Petit Montrevault, Saint-Pierre-Montlimart, France|50 rue Bosq, Saint-Pierre-sur-Dives, France|Avenue du 14 Juillet, Saint-Quentin-la-Poterie, France|1 allee Jean Restout, Saint-Sebastien-de-Morsent, France|Route Lombez, Sainte Foy De Peyrollieres, France|Route Lombez, Sainte-Foy De Peyrollieres, France|146 av de la République, Sainte-Foy-la-Grande, France|3 rue Moulin du Pain, Sainte-Gemmes, France|Quart Thermal, Salies De Bearn, France|6 Allee Du Merlot, Saussan, France|30 rue de la Vallee, Sautron, France|30 rue Vallée, Sautron, France|1, Allée du Mistral, Savigny le Temple, France|21 rue Chatonnay, Savonnieres, France|Place du Port, Segre, France|3 place de la Gare, Sens de Bretagne, France|72, route Châtel, Sercoeur, France|12 rue Jean Boyer, Serifontaine, France|2 route de Sauvagnon, Serres Castets, France|11 rue Football, Sete, France|12 rue Gabriel Péri, Sete, France|41 rue Pierre Sémard, Sete, France|9 rue Alsace Lorraine, Sete, France|Résidence Tarentelle Place E. Herriot, Sete, France|14 rue Boltar, Seysses, France|60 route d'Ox, Seysses, France|22 Place du Docteur Robert, Sisteron, France|41 rue Faidherbe, Somain, France|43, rue Faidherbe, Somain, France|10 rue Benoît Malon, Sotteville les Rouen, France|33 rue Littre, Sotteville les Rouen, France|5 rue Daniel Casanova Le Parc des Amandiers, St Jean De Vedas, France|63 rue Alexandre 1er, St Max, France|15, avenue Montaigne, St Medard en Jalles, France|107 rue de Pornichet, St Nazaire, France|50 rue Bosq, St Pierre Sur Dives, France|27 rue Gaston Chéreau, Thouars, France|1 Ave des Erables, Tierce, France|1 Chemin Courperron, Tilly Sur Seulles, France|1 rue de l'Ecotay, Tinteniac, France|1 Rue des Deportés, Toufflers, France|1, rue des Ecoles, Toufflers, France|60 av Du 8 Mai 1945, Toulenne, France|11 rue De Metz, Toulouse, France|2, rue Paradoux, Toulouse, France|26 av. Jean Rieux, Toulouse, France|35 rue Remusat, Toulouse, France|68 allee Jean Jaures, Toulouse, France|76 allee Jean Jaures, Toulouse, France|Centre Hospitalier de Purpan Service de Neurologie place du Docteur Baylac, Toulouse, France|135 rue Henri Desbals, Toulouse, France|3 rue Vincent Van Gogh, Toulouse, France|3 rue Vincent Van Gough, Toulouse, France|25 Bld des minimes, Toulouse, France|3 rue Saint Famille, Toulouse, France|44 av Etienne Billieres, Toulouse, France|48 all. Charles de Fitte, Toulouse, France|52 av. de Grande Bretagne, Toulouse, France|8 pl. Interieure St Cyprien, Toulouse, France|1 rue Notre Dame, Toulouse, France|14 rue Jean Duplessis, Toulouse, France|2 Boulevard Griffoul Dorval, Toulouse, France|25 av. Marcel Langer, Toulouse, France|28 rue des Arts, Toulouse, France|28, rue des Arts, Toulouse, France|40, bouleard des Récollets, Toulouse, France|7 avenue Frizac, Toulouse, France|12 rue Jean Poncelet, Toulouse, France|150 avenue Jean Chaubet, Toulouse, France|23, rue Limayrac, Toulouse, France|24 av. du Cimetiere, Toulouse, France|44 av. Leon Blum, Toulouse, France|53 r Du Faubourg Bonnefoy, Toulouse, France|7 pl Commerciale Jolimont, Toulouse, France|7 rue Raymond Boulogne Batiment C- apt 23, Toulouse, France|1 et 3 rue Maryse Bastié, Tours, France|1, rue Maryse Bartié, Tours, France|11 rue de Clocheville, Tours, France|15 rue Jacques Marie Rouge, Tours, France|2 rue du Plat d'Etain, Tours, France|26 rue Boisdenier, Tours, France|29 Bis rue Roger Salengro, Tours, France|3 rue Victor Hugo, Tours, France|31, rue Léon Boyer, Tours, France|63 rue Léon Boyer, Tours, France|8 rue de Montbazon, Tours, France|89 rue Jean-Jacques Noirmant, Tours, France|110 rue de Jemmapes, Tours, France|5 rue de la Halle, Treviere, France|26 rue Victor Hugo, Tullins, France|14 Place de l'Eglise, Uchaud, France|Avenue Georges Chauvin, Uzes, France|Batiment Le Sirius place des Cordeliers, Uzes, France|Hotel des Cordeliers, Uzes, France|Hôtel les Cordeliers place des Cordeliers, Uzes, France|Maison de retraite publique Centre de Memoire Route de Nimes, Uzes, France|Hotel les Cordeliers place des Cordeliers, Uzes, France|route de Montpellier, Vailhauques, France|16 rue Anatole France, Valenciennes, France|Res. Saly-2 rue S. Lebourg, Valenciennes, France|11, Boulevard de la République, Valras Plage, France|23 Bd de l'Europe, Vandoeuvre Les Nancy, France|12 Place de la République, Varces, France|Le Mistral II, Vauvert, France|5 avenue de Libourne, Vayres, France|12 lotissement Figeac, Venerque, France|41 rue de la Pomme d'Or, Verneuil sur Avre, France|3 Rue Fontaine, Verny, France|Rue de la Poste, Vers-Pont-du-Gard, France|18 rue de Noailles, Versailles, France|57 rue Charles Lecour, Vertou, France|7 rue Mortaliere, Vertou, France|4 rue du Chapelet, Vezins, France|15 rue du Jard, Vicherey, France|5 rue des Halles, Vieillevigne, France|200 rue Jean Jaures, Vieux, France|4 Rue Beaurepaire, Vihiers, France|145 rue de Chevilly, Villejuif, France|1 bis avenue Outrebon, Villemomble, France|8 Av G. Clémenceau, Villenave D'ornon, France|8 Av. du Gal Clémenceau, Villenave D'ornon, France|Centre Commercial Chamboparc, Villenave D'ornon, France|1 Rue René Cassin, Villeneuve Tolosane, France|164 boulevard des Fontaines, Villeneuve-les-Maguelonne, France|22, rue du Maréchal Foche, Villerupt, France|1, rue des Charmes, Villette D'Anthon, France|10 Chemin Vignes d'Oule, Villeveque, France|88 rue Liverdun, Villey-Saint-Etienne, France|Rue du 8 Mai 1945, Vinay, France|3 avenue Segond, Vincennes, France|56, avenue de Paris, Vincennes, France|11 rue du Faton, Voiron, France|15 route de la Gare, Vourey, France|9, place Sainte Anne, Vue, France|85 rue Jean Jaurès, Vue, France|64 avenue du 14 Juillet, Wattignies, France|Maison Medicale Bichat, Wattrelos, France",,https://ClinicalTrials.gov/show/NCT00276510
NCT00267163,Brain Imaging and Mental Disorders of Aging Intervention,,Completed,No Results Available,Cognition Disorders,Drug: donepezil|Drug: Placebo,"Changes in cognition and brain metabolism measured by PET and MRI scans, and neuropsychological testing",National Institute on Aging (NIA),All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 4,64,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,IA0090|9R01AG018487-06,Sep-00,Jul-07,Jul-07,20-Dec-05,null,29-Aug-08,"UCLA, The Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00267163
NCT00265148,Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Rosiglitazone|Other: Placebo,"Change from baseline in global and regional functional brain activity at 12 months|Change in functional brain activity at other timepoints; changes in cognition and clinical scales of AD status; changes in brain structure; safety and tolerability; changes in blood biomarkers and insulin sensitivity; genetic (apolipoprotein E) status|Changes in global and regional CMRglu between baseline and other scan time points as measured by [18F]FDG uptake.|Changes in cognitive tests and clinical scales of AD status from baseline.|Global changes in brain structure from baseline as measured by structural MRI from baseline.|Changes in blood borne biomarkers from baseline: Markers of glucose metabolism (fasting plasma glucose; fasting plasma insulin: HbA1C); Lipid levels; Inflammatory markers; Immunology markers; Putative markers of disease burden.|Changes in insulin sensitivity from baseline: Homeostasis Model Assessment; Body Mass Index|Polymorphism status with respect to genetic markers: Apolipoprotein-E|Measures of safety and tolerability: Vital signs, 12-Lead ECGs, Haematology and clinical chemistry evaluations, Adverse events, Measures of fluid retention: body weight; haematocrit; clinical examination",GlaxoSmithKline,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BRL-49653/461,May-04,Jul-08,Jul-08,14-Dec-05,null,16-Nov-16,"GSK Investigational Site, Litchfield Park, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sun City, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Belmont, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Swindon, United Kingdom|GSK Investigational Site, West End, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00265148
NCT00260624,Escitalopram Treatment of Patients With Agitated Dementia,,Completed,No Results Available,Alzheimer's Disease|Psychomotor Agitation,Drug: Escitalopram (Lexapro),Agitation factor on the Neurobehavioral Rating Scale (NBRS)|Total NBRS scores|Cohen-Mansfield Agitation Inventory|Neuropsychiatric Inventory|Global Clinical Impression of Change,University of Rochester|Forest Laboratories,All,"61 Years and older   (Adult, Older Adult)",Phase 4,20,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LXP MD 43,Feb-03,Dec-06,Dec-06,1-Dec-05,null,24-Feb-12,"Fairport Baptist Home, Fairport, New York, United States|The Highlands at Brighton, Rochester, New York, United States|University of Rochester, Rochester, New York, United States",,https://ClinicalTrials.gov/show/NCT00260624
NCT00259415,Telesupport: Evaluation of Professionally Led Support Groups for Caregivers,,Completed,No Results Available,Caregiver Burden,Behavioral: Caregiver support via telephone,Caregiver depression|Caregiver burdern|Caregiver social support,Thomas Jefferson University,Female,"55 Years and older   (Adult, Older Adult)",Phase 1,null,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single,IIRG-00-1998,Sep-00,null,null,29-Nov-05,null,8-Jul-15,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00259415
NCT00259454,Project COPE:Managing Dementia at Home,,Completed,No Results Available,"Dementia, Alzheimer Type",Behavioral: In-home intervention,ADL/IADL|Caregiver upset|Caregiver confidence|Behaviors,Thomas Jefferson University|Pennsylvania Department of Health,All,"21 Years and older   (Adult, Older Adult)",Phase 3,278,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),SAP 4100027298,Jun-05,Apr-09,Jul-09,29-Nov-05,null,16-Mar-10,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00259454
NCT00259467,Project TAP: Tailored Activities Project,,Completed,No Results Available,Alzheimer's Disease,Behavioral: Home-Based Behavorial Intervention,Behavioral occurrence|Care recipient depressive mood|Caregiver upset|Activity engagement and vigilance,Thomas Jefferson University,All,"21 Years and older   (Adult, Older Adult)",Phase 1,60,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double,R21MH069425,Feb-04,null,Jan-07,29-Nov-05,null,25-Aug-10,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00259467
NCT00259480,Project ACT: Advancing Caregiving Techniques,,Completed,No Results Available,Alzheimer's Disease,Behavioral: Home Based Intervention,Caregiver upset|Care recipient behaviors|Caregiver self-efficacy|Nursing home placement|Caregiver depression,Thomas Jefferson University,All,"21 Years and older   (Adult, Older Adult)",Phase 3,272,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator),R01AG022254,Aug-01,Mar-14,Mar-15,29-Nov-05,null,13-May-15,"Laura N. Gitlin,Ph.D, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00259480
NCT00257673,Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: MEM 1003|Drug: Placebo for MEM 1003,"Cognitive function|Other Cognitive Assessments, activities of daily living, functional assessments and safety",Memory Pharmaceuticals,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,183,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MEM 1003-004,Nov-05,Oct-07,Oct-07,23-Nov-05,null,6-May-08,"Northport, Alabama, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|El Centro, California, United States|Riverside, California, United States|San Francisco, California, United States|Torrence, California, United States|Hamden, Connecticut, United States|Washington, DC, District of Columbia, United States|Brooksville, Florida, United States|Chiefland, Florida, United States|Coral Springs, Florida, United States|Deerfield Beach, Florida, United States|Delray Beach, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Port Charlotte, Florida, United States|Sarasota, Florida, United States|St. Petersburg, Florida, United States|Sunrise, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Towson, Maryland, United States|Fall River, Massachusetts, United States|St Loius, Missouri, United States|Berlin, New Jersey, United States|Long Branch, New Jersey, United States|Princeton, New Jersey, United States|Ridgewood, New Jersey, United States|Toms River, New Jersey, United States|Albany, New York, United States|Staten Island, New York, United States|Morganton, North Carolina, United States|Portland, Oregon, United States|Colmar, Pennsylvania, United States|Media, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Spartanburg, South Carolina, United States|Johnson City, Tennessee, United States|Bedford, Texas, United States|Bulverde, Texas, United States|San Antonio, Texas, United States|Midvale, Utah, United States|Bennington, Vermont, United States|Norfolk, Virginia, United States|Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT00257673
NCT00257712,"SMART: Somatotrophics, Memory, and Aging Research Trial",,Completed,No Results Available,Aging|Mild Cognitive Impairment,Drug: TH9507 human growth hormone releasing hormone (GHRH),"Change in declarative memory, including total recall scores on three tests of memory and on dual task response time (RT), a test of executive function.|Changes in other areas of cognitive function, including other tests of executive function, tests of lexical access, and tests of cognitive and perceptual-motor processing speed.",University of Washington|National Institute on Aging (NIA),All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,151,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",28287-K|R01AG025515|R01AG025525-01A1,Feb-06,Dec-11,Dec-11,23-Nov-05,null,19-Dec-13,"University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00257712
NCT00255866,Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their Caregivers,,Completed,No Results Available,Dementia|Alzheimer Disease,Behavioral: Skills training for the care of dementia patients,"Skills to effectively deal with resident behavioral problems|Resident depression, anxiety, behavioral problems, and quality of life",University of Washington|National Institute of Mental Health (NIMH),All,"21 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,90,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),26082-ED|R21MH069651|DSIR 82-SEDR,Jan-04,Dec-06,Dec-06,21-Nov-05,null,2-Dec-15,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Rush University School of Nursing, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00255866
NCT00255086,The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,,Completed,Has Results,Alzheimer Disease,Drug: Memantine|Drug: Placebo pill,NAA/Cr Ratio|Mean Change on the ADAS-Cog Score After 1 Year,Stanford University|Palo Alto Veterans Institute for Research|Forest Laboratories,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 3,17,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",95722,May-05,Jun-09,Feb-10,17-Nov-05,7-Apr-17,7-Apr-17,"VA Palo Alto Health Care System, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT00255086
NCT00253214,Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation,,Completed,No Results Available,Alzheimer Disease|Dementia,Drug: galantamine hydrobromide,"Change from baseline to end of treatment for controlled release group in ADAS-cog/11 (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and CIBIC-plus (Clinician's Interview Based Impression of Change - Plus Caregiver Input) scores|Change from baseline in ADAS-cog/13, /10, /mem scores, NPI, and ADCS/ADL; safety and tolerability of controlled-release formulation; difference in effects between the controlled-release and immediate-release formulations","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"40 Years and older   (Adult, Older Adult)",Phase 3,973,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CR006037,Mar-01,null,Jul-02,15-Nov-05,null,23-May-11,,,https://ClinicalTrials.gov/show/NCT00253214
NCT00254033,Apathy Associated With Alzheimer's Disease,,Completed,No Results Available,Dementia|Alzheimer Disease,Drug: Dextroamphetamine|Drug: Methylphenidate,Addiction Research Centre Inventory (ARCI)|Apathy Evaluation Scale-Caregiver (AES-C)|Profile of Mood States (POMS)|Continuous Performance Test (CPT)|Neuropsychiatric Inventory (NPI),Sunnybrook Health Sciences Centre|American Health Assistance Foundation,All,"55 Years and older   (Adult, Older Adult)",Phase 4,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,065-2003|AHAF Grant Number: A2003-236,Oct-03,null,Oct-06,15-Nov-05,null,28-Apr-17,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00254033
NCT00246896,Care Management for Patients With Alzheimer Disease and Their Family Caregivers,,Completed,No Results Available,Alzheimer's Disease|Dementia,Behavioral: care management,Neuropsychiatric Inventory|Cornell Depression in Dementia Scale|Activities of Daily Living|Nursing home placement|hospitalization,Agency for Healthcare Research and Quality (AHRQ),All,65 Years and older   (Older Adult),Not Applicable,220,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment,R01HS010884,Aug-01,null,Aug-05,1-Nov-05,null,27-Jul-06,"Indiana University, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00246896
NCT00245206,Side Effects of Newer Antipsychotics in Older Adults,,Completed,No Results Available,Schizophrenia|Alzheimer's Disease|Dementia,Drug: Aripiprazole|Drug: Olanzapine|Drug: Risperidone,"Change in Body Mass Index|Change in Fasting Plasma Glucose (FPG)|Change in LDL cholesterol, HDL cholesterol, and triglycerides",Veterans Medical Research Foundation|National Institute of Mental Health (NIMH),All,"40 Years and older   (Adult, Older Adult)",Phase 4,406,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH071536|DATR A5-ETSE,Aug-05,Oct-10,Oct-10,27-Oct-05,null,17-Dec-18,"University of California, San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00245206
NCT00244322,Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: LY450139 dihydrate|Drug: placebo,Safety and tolerability|Determine levels of peptides in blood and spinal fluid that might relate to Alzheimer's disease|Evaluate changes in thinking and memory|Evaluate changes in daily living activities|Determine levels of study drug in blood and spinal fluid,Eli Lilly and Company,All,"50 Years and older   (Adult, Older Adult)",Phase 2,45,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Diagnostic,9097|H6L-MC-LFAJ,Oct-05,null,Dec-06,26-Oct-05,null,28-May-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00244322
NCT00242593,Rosiglitazone Effects on Cognition for Adults in Later Life,RECALL,Unknown status,No Results Available,Mild Cognitive Impairment,Drug: Rosiglitazone,"Cognitive measures: delayed list recall, Stroop Interference test|Biological outcomes: plasma insulin, IDE, AB40, AB42, inflammatory cytokines, and F2-isoprostanes|MRI outcome: Whole brain and medial temporal lobe atrophy rate|Cognitive measures: ADAS-cog total score, story recall verbal fluency, paired associate learning, SOPT, rating scales",University of Washington|National Institute on Aging (NIA)|GlaxoSmithKline,All,"55 Years and older   (Adult, Older Adult)",Phase 2,120,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IA0087|1R01AG025502-01A1,Jun-06,Dec-11,Dec-11,20-Oct-05,null,5-Aug-11,"Banner Alzheimer Institute, Phoenix, Arizona, United States|UCLA Alzheimer's Disease Center, Los Angeles, California, United States|University of Washington/VA Puget Sound Health Care System, Seattle/Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00242593
NCT00240695,A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment,,Completed,No Results Available,Cognition Disorder|Nervous System Diseases|Mental Disorders|Brain Diseases,Drug: galantamine hydrobromide,"Incidence of adverse events; Changes in laboratory tests, ECGs, and physical examinations|Change in CDR, ADAS-Cog/MCI version, CDR-SB and SF-36 scores from baseline to end of treatment; resource use; time to conversion to dementia","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,724,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR005947,May-03,null,May-04,18-Oct-05,null,18-May-11,,,https://ClinicalTrials.gov/show/NCT00240695
NCT00239746,BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories,,Unknown status,No Results Available,Alzheimer's Disease,Drug: Ibuprofen|Drug: Placebo,Changes in biomarker assays,National Institute on Aging (NIA),All,"59 Years and older   (Adult, Older Adult)",Phase 1,40,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IA0086|R01AG024010,Oct-05,Aug-09,Aug-09,17-Oct-05,null,29-Apr-09,"Layton Aging & Alzheimer's Disease Center, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00239746
NCT00236431,A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment,,Completed,No Results Available,Dementia|Alzheimer Disease,Drug: Galantamine hydrobromide,"Memory and cognition (ADAS-COG/MCI and CDR-SB scores), global functional skills and overall severity of dementia (the CDR-SB and the overall Clinical Dementia Rating) measured at 12 and 24 months.|Digit Symbol Coding and Alzheimer's Disease Cooperative Study-ADL scale (MCI version) at 12 and 24 months. Safety assessment (reports of adverse events, laboratory values, results of physical examinations, and electrocardiograms) throughout the study.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,1063,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CR002014,May-01,null,Dec-03,12-Oct-05,null,8-Jun-11,,,https://ClinicalTrials.gov/show/NCT00236431
NCT00236574,A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment,,Completed,No Results Available,Dementia|Alzheimer Disease,Drug: Galantamine hydrobromide,"Memory and cognition (ADAS-cog/MCI and CDR-SB scores) at 12 months and Global functional skills and the overall severity of dementia (the CDR-SB and the overall CDR) at 24 months.|Brain atrophy assessed by MRI, Digit Symbol Coding, Alzheimer's Disease Cooperative Study-ADL scale(MCI version) at 24 months. Safety evaluations (adverse event reports, vital signs, laboratory tests, physical examination, electrocardiograms) throughout.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,974,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CR003145,May-01,null,Nov-03,12-Oct-05,null,8-Jun-11,,,https://ClinicalTrials.gov/show/NCT00236574
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",TEAM-AD,Completed,Has Results,Alzheimer's Disease,Drug: dl-alpha-tocopherol|Drug: Memantine|Drug: Placebo,Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory Change From Baseline|Mini-Mental State Examination Change From Baseline|Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Change From Baseline|Neuropsychiatric Inventory Change From Baseline|Caregiver Activity Survey Change From Baseline|Dependence Scale: Time to Event Analysis (Increase of of One Dependence Level),"US Department of Veterans Affairs|Forest Laboratories|DSM Nutritional Products, Inc.|VA Office of Research and Development",All,"40 Years and older   (Adult, Older Adult)",Phase 3,613,U.S. Fed|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",546,Aug-07,Sep-12,Oct-12,10-Oct-05,29-Jan-14,23-Jul-14,"VA Medical Center, Bay Pines, Bay Pines, Florida, United States|VA Medical Center, Miami, Miami, Florida, United States|VA Medical Center, Iowa City, Iowa City, Iowa, United States|VA Maryland Health Care System, Baltimore, Baltimore, Maryland, United States|VA Medical Center, Jamaica Plain Campus, Boston, Massachusetts, United States|VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States|VA Medical Center, Minneapolis, Minneapolis, Minnesota, United States|Salisbury VAMC, Salisbury, North Carolina, United States|VA Medical Center, Cleveland, Cleveland, Ohio, United States|Ralph H Johnson VA Medical Center, Charleston, Charleston, South Carolina, United States|VA North Texas Health Care System, Dallas, Dallas, Texas, United States|VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States|Wlliam S. Middleton Memorial Veterans Hospital, Madison, Madison, Wisconsin, United States|VA Medical Center, San Juan, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00235716
NCT00234637,Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment,,Completed,No Results Available,Alzheimer's Disease,"Drug: Rivastigmine, memantine",The proportion of responders (cognitive function stable or improved) at the end of phase 2 (vs. end of phase 1).|Change in cognition at weeks 16 and 28 (end of period 1) compared to baseline|Change in caregiver burden at weeks 16 and 28 (end of period 1) compared to baseline|Change in behavior at weeks 16 and 28 (end of period 1) compared to baseline|Change in executive function at weeks 16 and 28 (end of period 1) compared to baseline,Novartis,All,"50 Years and older   (Adult, Older Adult)",Phase 4,204,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713BFR05,Nov-03,Jun-05,Jun-05,7-Oct-05,null,17-Nov-11,"Département de Gérontologie Clinique, Limoges, Cedex, France",,https://ClinicalTrials.gov/show/NCT00234637
NCT00231946,ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301),,Completed,No Results Available,Alzheimer's Disease,Drug: VP4896,"Cognitive assessment and Caregiver's impression of change at baseline and at weeks 8, 24, 34, and 50.|Ability to perform Activities of Daily Living (ADL) at baseline and weeks 8, 24, 34, and 50. Impression of disease severity assessment at week 50.",Voyager Pharmaceutical Corporation|National Institute on Aging (NIA),All,"60 Years and older   (Adult, Older Adult)",Phase 3,555,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,IA0084,Sep-05,null,null,4-Oct-05,null,20-Sep-07,"Pivotal Research Centers, Peoria, Arizona, United States|NeuroSpecialists, PLLC, Tucson, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Bay Area Research Institute, Lafayette, California, United States|Anderson Clinical Research, Loma Linda, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|David Trader, Los Angeles, California, United States|Synergy Clinical Research, National City, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pharmacology Research Institute, Northridge, California, United States|North County Neurology Assoc., Oceanside, California, United States|Pharmacology Research Institute, Riverside, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Torrance Clinical Research, Torrance, California, United States|Radiant Research, Denver, Colorado, United States|Colorado Neurology & Headache Center, Denver, Colorado, United States|Comprehensive Neuroscience, Inc., Darien, Connecticut, United States|Geriatric and Adult Psychiatry, Hamden, Connecticut, United States|Meridien Research, Brookville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Neurology Clinical Research, LLC, Plantation, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Meridien Research, Tampa, Florida, United States|Palm Beach Neurological Group, West Palm Beach, Florida, United States|Quantum Laboratories, West Palm Beach, Florida, United States|Kuakani Medical Center, Honolulu, Hawaii, United States|Booker, J. Gary, MD, APMC, Shreveport, Louisiana, United States|ICPS Group, Boston, Massachusetts, United States|Pivotal Research Centers, Royal Oak, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Albuquerque Neuroscience Inc., Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Medark Clinical Trials, Morgantown, North Carolina, United States|Raleigh Neurology Associates, P.A., Raleigh, North Carolina, United States|Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Neurology Center of Ohio, Toledo, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Pharmaceutical Research-Oregon, Inc., Eugene, Oregon, United States|Clinical Trial Center, LLC., Jenkintown, Pennsylvania, United States|Pearl Clinical Research, Inc., Norristown, Pennsylvania, United States|Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Norman Gordon, MD, Providence, Rhode Island, United States|Radiant Research - Greer, Greer, South Carolina, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Bexar Diagnostic Medicine Associates, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Southwestern Vermont Medical Center, Bennington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Novabyss Inc., Sherbrooke, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00231946
NCT00232570,Quetiapine for the Treatment of Insomnia in Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease|Insomnia,Drug: quetiapine,"The primary objective is to determine whether quetiapine can increase total sleep time and reduce time awake in patients with AD and sleep disturbance.|Dose-response relationship of quetiapine and sleep in AD patients?|Are there sleep architecture changes from quetiapine?|Do the primary sleep variables change relative to placebo at any weekly time or dose point?|Are caregivers, blind to treatment status, able to detect changes in sleep quality in the patients for quetiapine relative to placebo?|Does quetiapine used at single bedtime dosing for potential nighttime soporific effect have a measurable impact on neuropsychiatric symptoms other than insomnia?",University of Vermont|AstraZeneca|National Center for Research Resources (NCRR),All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,18,Other|Industry|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,05-234,Nov-05,Dec-09,Jan-10,4-Oct-05,null,5-May-09,"Fletcher Allen Health Care-Clinical Neuroscience Research Unit, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00232570
NCT00230568,EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD),,Completed,No Results Available,Alzheimer's Disease,Drug: Aricept,FOME (Fuld Object Memory Evaluation); SDMT (Symbol Digit Modalities Test); NPI (Neuropsychiatric Inventory); MMSE (the Mini-Mental State Examination).,Eisai Inc.|Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 4,100,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E2020-A001-413,Dec-05,Apr-07,Dec-07,3-Oct-05,null,1-Apr-11,"21st Century Neurology, Phoenix, Arizona, United States|Alzheimer's Disease and Cognitive Disorders Clinic at Barrow Neurology Institute, Phoenix, Arizona, United States|Pacific Sleep Medicine Services, Inc., El Centro, California, United States|Pacific Sleep Medicine Services, Inc., Los Angeles, California, United States|Pacific Sleep Medicine Services, Inc., San Diego, California, United States|Parkinson's Disease Movement Disorders Center - Boca Raton, Boca Raton, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Eastern Research, Hialeah, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Cuervo Research Group, Miami, Florida, United States|Seth Hochman, MD, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Segal Institute for Clinical Research, North Miami, Florida, United States|Ocala Neurodiagnostic Center, Ocala, Florida, United States|Memory Disorder Center, Pompano Beach, Florida, United States|Liliana Montoya, MD, Port Charlotte, Florida, United States|Roskamp Institute Memory Clinic, Tampa, Florida, United States|Palm Beach Neurology, West Palm Beach, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|The Northwestern Alzheimer's Center, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Lozano, Cosme, MD, Joliet, Illinois, United States|University of Nevada School of Medicine,, Las Vegas, Nevada, United States|ClinSearch Inc., Kenilworth, New Jersey, United States|University of New Mexico School of Medicine, Department of Psychiatry, Albuquerque, New Mexico, United States|New York University School of Medicine, Aging and Dementia Research Center, New York, New York, United States|The Burke Rehabilitation Hospital, White Plains, New York, United States|North Carolina Neuropsychiatry, PA, Charlotte, North Carolina, United States|Clinical Research Associates, Inc., Oklahoma City, Oklahoma, United States|Clinical Research Center, Jenkintown, Pennsylvania, United States|The Penn Ralston Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas Mental Sciences Insitute, Houston, Texas, United States|Christopher Ticknor, MD, San Antonio, Texas, United States|University of Texas, Health Science Center-San Antonio, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00230568
NCT00229333,"Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia",,Unknown status,No Results Available,Depressive Syndrome,Drug: Escitalopram,Cornell Scale for Depression in Dementia (CSDD) total score|Cohen-Mansfield Agitation Inventory (CMAI; Cohen-Mansfield et al. 1989),Sheba Medical Center|H. Lundbeck A/S,All,"60 Years and older   (Adult, Older Adult)",Phase 4,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,SHEBA-03-3124-AS-CTIL,Dec-04,null,null,29-Sep-05,null,29-Aug-06,"Sheba Medical Center, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT00229333
NCT00224497,A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: SB-742457,"Change in cognition and function after 24 weeks.|Change in behavioural symptoms, activities of daily living and caregiver burden after 24 weeks. Changes in all symptoms at 8 and 12 weeks. Safety and tolerability. PK and dose response profiling. Efficacy related to ApoE status.",GlaxoSmithKline,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,380,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AZ3100603,Sep-05,null,null,23-Sep-05,null,24-Dec-09,"GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Retz, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Valparaiso, Valparaíso, Chile|GSK Investigational Site, Split, Croatia|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Olomouc, Czech Republic|GSK Investigational Site, Ostrava, Czech Republic|GSK Investigational Site, Praha 5, Czech Republic|GSK Investigational Site, Rychnov Nad Kneznou, Czech Republic|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Melissia, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Christchurch, New Zealand|GSK Investigational Site, Mosina, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Rimavska Sobota, Slovakia|GSK Investigational Site, Oakdale, South Africa|GSK Investigational Site, Rosebank, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Sant Cugat Del Vallés/, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00224497
NCT00216502,A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease|Dementia|Mental Disorders|Brain Diseases,Drug: galantamine hydrobromide,"Time to worsening of symptoms, defined as the time from the beginning of the double-blind portion of the study to the time of an increase in ADAS-cog score of > or = to 4 points|Change in ADAS-cog, CIBIC-plus and DAD scores over time; Safety parameters assessed by adverse events; laboratory tests, vital signs, weight and ECGs.",Janssen-Cilag S.p.A.,All,"50 Years and older   (Adult, Older Adult)",Phase 3,254,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CR004996,Aug-01,null,Nov-05,22-Sep-05,null,24-Jan-11,,,https://ClinicalTrials.gov/show/NCT00216502
NCT00216515,The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type,,Completed,No Results Available,Alzheimer Disease,Drug: galantamine hydrobromide,"Attention and Executive function: Visual CPT, Visual Span, Color Trail Making test, Stroop test|Cognition: Mini-Mental Sate Examination-Korean version (MMSE-K);Activities of Daily living: Seoul- Instrumental Activities of daily livings (S-IADL);Behavior: NPI-Q;Global Change: Global Deterioration Scale (GDS)","Janssen Korea, Ltd., Korea",All,"50 Years and older   (Adult, Older Adult)",Phase 4,102,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR005047,Mar-04,null,Nov-05,22-Sep-05,null,24-Jan-11,,,https://ClinicalTrials.gov/show/NCT00216515
NCT00216593,Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study,,Completed,No Results Available,Dementia|Alzheimer Disease,Drug: galantamine hydrobromide,"Change in scores from baseline to week 26 on measuring cognition Severe Impairment Battery test and the Minimum Data Set Activities of Daily Living test.|Results from Neuro Psychiatric Inventory-nursing home version test. Safety assessments include reports of adverse events, physical exam, vital signs, electrocardiograms, and laboratory test results.","Janssen Pharmaceutica N.V., Belgium",All,"40 Years and older   (Adult, Older Adult)",Phase 3,415,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CR003940,Dec-03,Sep-07,Mar-08,22-Sep-05,null,21-Jun-11,,,https://ClinicalTrials.gov/show/NCT00216593
NCT00217763,European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients,,Unknown status,No Results Available,Alzheimer's Disease,Drug: 3APS,,Bellus Health Inc,All,"50 Years and older   (Adult, Older Adult)",Phase 3,930,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,CL-758010,Sep-05,null,Dec-07,22-Sep-05,null,10-Dec-07,"Middelheim Ziekenhuis Lindendreef, Antwerp, Belgium|University Hospital Antwerp - Neurology - Prof. Dr. Patrick Cras, MD, PhD, Edegem, Belgium|Memory Clinic University Hospital Gasthuisberg, Neurology Department, Leuven, Belgium|Memory Centre, Polycliniques Brull, CHU de Liège, Liege, Belgium|Besançon, France|Hôpital Pellegrin CHU de Bordeaux, Bordeaux, France|Dijon, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Hôpital Sainte Marguerite Service de neuro-geriatrie, Marseille, France|Hôpital Gui de Chauliac - Service de Neurologie du Pr J. Touchon, Montpellier, France|Centre Mémoire de Ressources et de Recherche Hôpital Pasteur, Nice, France|Hôpital BROCA, Paris, France|CHU Reims- Hôpital Sébastopol-Service de médecine interne et Gérontologie Clinique, Reims, France|Hôpital Hôtel Dieu - Consultation de Gérontologie, Rennes, France|CHU Purpan, Toulouse, France|Tours, France|Charité Campus Benjamin Franklin - Universitätsmedizin Berlin - Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Berlin, Germany|Gemeinschaftspraxis, Bochum (Langendreer), Germany|Johann-Wolfgang Goethe-Universität - Klinik für Psychiatrie und Psychotherapie, Frankfurt, Germany|Klinik für Psychiatrie und Psychotherapie - University Hospital Hamburg-Eppendorf - Dept. of Psychiatry and Psychotherapy, Hamburg, Germany|Psychiatrische Universitätsklinik Heidelberg - Sektion für Gerontopsychiatrie - Gedächtnisambulanz, Heidelberg, Germany|Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Abteilung für Geriatrische Psychiatrie - Zentralinstitut für seelische Gesundheit - Universität Heidelberg, Mannheim, Germany|Munich, Germany|IRCCS Centro San Giovanni di Dio- Fatebenefratelli, Brescia, Italy|San Martino Hospital - Padiglione Specialita' Fondi, Genova, Italy|Dept. of Neurosciences TCR - University of Modena and Reggio Emilia, Modena, Italy|Perugia, Italy|Department of Neuroscience - Section of Neurology - University of Pisa, Pisa, Italy|Universita' Cattolica del Sacro Cuore, Rome, Italy|Rome, Italy|Vicenza, Italy|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Dept. of Neurology and Alzheimer Center - Vrije Universiteit Medical Center, Amsterdam, Netherlands|Blaricum, Netherlands|Memory Clinic UMC St Radboud - Alzheimer Centre, Nijmegen, Netherlands|Bydgoszcz, Poland|Krakow, Poland|Lodz, Poland|Sopot, Poland|Warsaw, Poland|Wroclaw, Poland|Baracaldo, Spain|Fundaciò ACE- Institut Català de Neurociències Aplicades, Barcelona, Spain|Hospital del Mar- Servicio de Neurologia, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Servicio de Neurología, Unitad de Memoria, Barcelona, Spain|Unitat de Valoració de la Memòria i les Demències - Hospital Santa Caterina - Institut d'Assistència Sanitària, Girona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitairo La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal - Unidad de Geriatria, Madrid, Spain|Pamplona, Spain|Linkoping, Sweden|Lund, Sweden|Neuropsychiatric Clinic - University Hospital MAS, Malmo, Sweden|Mölndal, Sweden|Enheten för klinisk Läkemedelsforskning - Minnesmottagningen - Karolinska Universitetssjukhuset - Huddinge, Stockholm, Sweden|Memory clinic - Uddevalla Hospital, Uddevalla, Sweden|Memory Clinic -Geriatric Centre - Academic Hospital, Uppsala, Sweden|Memory Clinic - Neuropsychology Center - University Hospital, Basel, Switzerland|Geneva, Switzerland|Research Institute for Care of Elderly - St Martin's Hospital, Bath, United Kingdom|Fylde Medical Clinic, Blackpool, United Kingdom|Memory Assessment Centre, Blackpool, United Kingdom|Wales College of Medicine - Llandough Hospital, Cardiff, United Kingdom|East Sussex, United Kingdom|Glasgow Memory Clinic - Golden Jubilee National Hospital, Glasgow, United Kingdom|Murray Royal Hospital, Perth, United Kingdom|Memory Assessment Centre - Moorgreen Hospital, Southampton, United Kingdom|Kingshill Research Centre - Victoria Hospital, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00217763
NCT00219232,An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Rivastigmine Transdermal Patch,"Safety and tolerability as measured by adverse events, vital signs and skin irritation for up to 28 weeks treatment|Change in cognition from baseline (week 24 of the double blind phase) at week 52|Clinical global impression of change from baseline at week 52|Change in activities of daily living from baseline at week 52|Change in behavioral symptoms from baseline at week 52|Change in executive function from baseline at week 52",Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,868,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713D2320E1,Feb-03,Jul-06,Jul-06,22-Sep-05,null,23-Feb-17,,,https://ClinicalTrials.gov/show/NCT00219232
NCT00208819,A Comparison of Two Standard Therapies in the Management of Dementia With Agitation,,Completed,No Results Available,"Senile Dementia, Alzheimer Type|Dementia, Alzheimer Type|Alzheimer Disease|Dementia",Drug: risperidone|Drug: quetiapine|Drug: olanzapine|Drug: divalproex,Pittsburgh Agitation Scale (PAS)|DiMarco Rating Scale for Extrapyramidal Symptoms|UKU side effect rating scale:autonomic subscale|Behavioral Activity Rating Scale (BARS)|Visual Analog Scale for Nighttime Sleep and Daytime drowsiness (VAS)|Confusion Assessment Method (CAM)|Mini-Mental State Exam (MMSE)|Cohen-Mansfield Agitation Inventory,Emory University|Abbott,All,65 Years and older   (Older Adult),Phase 4,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0673-2003,Sep-03,null,Jul-07,21-Sep-05,null,13-Nov-13,"Wesley Woods Geriatric Hospital, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00208819
NCT00209456,Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia,,Completed,No Results Available,Lewy Body Dementia|Non-DLB Dementia|Alzheimer’s|Vascular Dementia,Drug: DatSCAN,"Sensitivity and specificity of DaTSCAN SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects.|Accuracy, positive predictive value and negative predictive value of DaTSCAN SPECT|Semi-quantitative analysis of the striatal uptake ratios of DaTSCAN SPECT images.|Impact of DaTSCAN SPECT analysis on the confidence of diagnosis.|Findings in relation to probable, possible and no-DLB.|Efficacy analysis at 12-month follow-up period.|Safety profile",GE Healthcare,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,326,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PDT301,Nov-03,null,null,21-Sep-05,null,16-May-07,"Amersham Buchler GmbH Co. KG, Ismaning, Germany",,https://ClinicalTrials.gov/show/NCT00209456
NCT00211159,OmegAD (Omega-3 and Alzheimer's Disease),,Completed,No Results Available,Alzheimer's Disease,Drug: EPAX 1050TG,"Cognition measured according to ADAS-cog, MMSE scales|Safety, tolerability, blood pressure|Gene expression|Dose-response studies in relation to APOE4 status, to body weight and to gender",Karolinska University Hospital,All,"Child, Adult, Older Adult",Not Applicable,204,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,OmegAD#1,Dec-00,null,null,21-Sep-05,null,31-Jul-17,"Karolinska University Hospital Huddinge, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00211159
NCT00202124,Double Blind Study of Trp01 in Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Tryptophan,"1. MMSE score|2. Alzheimer’s Disease Assessment Scale, cognitive subpart (ADAS-Cog) as an evaluation of cognitive functioning|1. Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC)|2. Neuropsychiatric Inventory (NPI)|3. Disability Assessment for Dementia (DAD)|4. Physical Self-Maintenance Scale (PSMS)|5. Functional Activities Questionnaire (FAQ)",Queen's University,All,"Child, Adult, Older Adult",Phase 4,12,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,DFW-TRP01,Apr-01,null,Mar-02,20-Sep-05,null,20-Sep-05,"Queen's University, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00202124
NCT00203320,TNF-Alpha Inhibition for Treatment of Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: etanercept given by perispinal administration,ADAS-Cog|SIB|MMSE|ADCS-ADLsev|Category fluency,"Tobinick, Edward Lewis, M.D.",All,"Child, Adult, Older Adult",Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10007,Apr-05,null,Jan-06,20-Sep-05,null,24-Apr-06,"100 UCLA Medical Plaza, Suites 205-210, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00203320
NCT00203359,TNF-Alpha Inhibition for Treatment of Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: etanercept given by perispinal administration,ADAS-Cog|SIB|MMSE|Category fluency|other neuropsychological tests,"Tobinick, Edward Lewis, M.D.",All,"Child, Adult, Older Adult",Phase 1,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10005,Sep-04,null,Apr-06,20-Sep-05,null,24-Apr-06,"Edward Tobinick, MD (private medical office), Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00203359
NCT00205179,Alzheimer's Disease: Potential Benefit of Isoflavones,,Completed,No Results Available,Alzheimer's Disease,Drug: Novasoy|Drug: Placebo,Cognitive Data|biological assays of isoflavones and hormones,"University of Wisconsin, Madison|National Institutes of Health (NIH)",All,"55 Years and older   (Adult, Older Adult)",Phase 2,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2003-0048|5K23AG024302-03,Jan-05,Dec-09,Dec-09,20-Sep-05,null,5-Oct-15,"University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00205179
NCT00205621,Positron Emission Tomography of Amyloid in Alzheimer's Disease,,Suspended,No Results Available,Alzheimer's Disease,Device: Positron Emission Tomography,quantification of amyloid binding,VU University Medical Center,Male,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2005/90,Oct-05,null,Dec-09,20-Sep-05,null,8-Sep-06,"VU University Medical Center, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00205621
NCT00190372,AIDMA: A Psycho-educational Program Designed to Support and Train Carers of Alzheimer's Disease (AD) Patients,,Completed,No Results Available,Alzheimer's Disease,Behavioral: Controlled diet|Behavioral: Self-hypnotic relaxation,"DAD scale (Disability Assessment for Dementia)|cardiovascular mortality|functional status|for the patient: NPI and ADAS-Cog|for the caregiver: ZARIT scale, questionnaire of feeling of competency, Montgomery and Asberg Depression Rating Scale (MADRS), Geriatric Depression Scale (GDS)|all cause mortality|score on a depression rating scale",Assistance Publique - Hôpitaux de Paris,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Health Services Research,P030437,Oct-04,May-08,May-08,19-Sep-05,null,17-Feb-11,"Assistance Publique-Hôpitaux de Paris, Paris, Ile de France, France",,https://ClinicalTrials.gov/show/NCT00190372
NCT00191009,Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Drug: atomoxetine hydrochloride|Drug: placebo,"To see if Alzheimer's patients receiving a stable dose of an Alzheimer's drug randomly assigned to atomoxetine for approximately 6 months will have cognitive performance improved as measured by the Alzheimer's Disease Assessment Scale - Cognitive|To see if patients taking an Alzheimer's medication plus atomoxetine for approximately 6 months will be superior to an Alzheimer's medication alone as assessed by the Clinician's Interview-Based Impression of Change (CIBIC+) score.|To see if patients taking an Alzheimer's medication plus atomoxetine will display less comorbid psychological symptoms, such as depression, as assessed by the Neuropsychiatric Inventory (NPI). Patients will receive the NPI once before randomization|To see if current Alzheimer's medications plus atomoxetine compared to Alzheimer's medications plus placebo is better at preserving or slowing cognitive decline as measured by the Alzheimer's Disease Cooperative Study Inventory - Activities of|To show that current Alzheimer's drugs can be taken with atomoxetine without significant side effects.",Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,124,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,7951|B4Z-MC-LYCG,Oct-03,null,Jan-06,19-Sep-05,null,6-Nov-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sherman Oaks, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Wichita Falls, Texas, United States",,https://ClinicalTrials.gov/show/NCT00191009
NCT00182897,PACT: Providers and Alzheimer's Caregivers Together,,Completed,No Results Available,Alzheimer's Disease|Dementia,Behavioral: Skills Building for Caregiver Health and Care-recipient,"General well-being, measured with the revised Rand General Well-Being Scale|caregiver’s level of distress with care recipient behaviors, measured with the Revised Memory and Behavior Problems Checklist at Baseline, within 2 weeks of home care ending and six months.|Determine the cost-effectiveness of home-based intervention; data will be collected at Baseline, within 2 weeks of home care ending and six months.",National Institute on Aging (NIA)|National Institute of Nursing Research (NINR),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,120,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IA0081|5R01AG016328,Oct-00,null,Nov-05,16-Sep-05,null,14-Nov-06,"University of Tennessee Health Science Center, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00182897
NCT00183378,Using Behavioral Programs to Treat Sleep Problems in Individuals With Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease|Sleep Initiation and Maintenance Disorders,"Behavioral: Walking Program|Behavioral: Light Exposure Program|Behavioral: Combined Education, Walking and Light Exposure Program|Behavioral: Routine Medical Care with Education","Patient total wake time (actigraphy)|Caregiver reports of patient behavioral disturbances at night (Sleep Disorders Inventory)|Additional patient actigraphy outcomes|Patient daytime sleepiness, behavioral problems, and residential status|Caregiver sleep",University of Washington|National Institute of Mental Health (NIMH),All,"55 Years and older   (Adult, Older Adult)",Not Applicable,132,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH072736|DATR A4-GPS,Sep-05,Sep-09,Mar-11,16-Sep-05,null,13-Jan-12,"University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00183378
NCT00174382,Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia,,Terminated,Has Results,"Dementia, Vascular|Dementia, Mixed",Drug: Donepezil,"Change in Total Score of Standardized Mini-Mental State Examination (sMMSE); Full Analysis Set|Disability Assessment for Dementia Change From Baseline; Activities of Daily Living (ADL) Domain.|Disability Assessment for Dementia Change From Baseline; Instrumental ADL (IADL) Domain.|Disability Assessment for Dementia (DAD) Change From Baseline Total Score; Full Analysis Set (FAS)|Free-hand Drawing Test (CLOX 1) Change From Baseline; Full Analysis Set (FAS)|Copied Clock Drawing Test (CLOX 2) Change From Baseline; Full Analysis Set (FAS)|CLOX Differential Score Change From Baseline; Full Analysis Set (FAS)|Phonectic Fluency Total Score From Baseline; Full Analysis Set (FAS)|Neuropsychiatric Inventory Questionnaire (NPI-Q) Score Change From Baseline; Full Analysis Set (FAS)|Neuropsychiatric Inventory Questionnaire Distress (NPI-Q-D) Score Change From Baseline; Full Analysis Set (FAS)|Clinical Global Impressions Severity Score (CGI-S) Clinical Global Impressions Severity Score Improvement(CGI-I)Change From Baseline, Full Analysis Set (FAS)|Clinical Global Impressions Severity (CGI-S)|Clinical Global Impressions Improvement (CGI-I)|Clinical Global Impressions Improvement (CGI-I) Dichotomized Response",Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 3,149,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2501026,Jun-05,Apr-08,Apr-08,15-Sep-05,12-Jun-09,24-Mar-15,"Pfizer Investigational Site, Belvedere, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Abbotsford, British Columbia, Canada|Pfizer Investigational Site, Coquitlam, British Columbia, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Saint John, New Brunswick, Canada|Pfizer Investigational Site, Amherst, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Pictou, Nova Scotia, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, Corunna, Ontario, Canada|Pfizer Investigational Site, Fort Erie, Ontario, Canada|Pfizer Investigational Site, Hawkesbury, Ontario, Canada|Pfizer Investigational Site, North Bay, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Peterborough, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Beauport, Quebec, Canada|Pfizer Investigational Site, Cowansville, Quebec, Canada|Pfizer Investigational Site, L'Ancienne-Lorette, Quebec, Canada|Pfizer Investigational Site, Montréal, Quebec, Canada|Pfizer Investigational Site, Rimouski, Quebec, Canada|Pfizer Investigational Site, St-Jean-sur-Richelieu, Quebec, Canada|Pfizer Investigational Site, St. Leonard, Quebec, Canada|Pfizer Investigational Site, Regina, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT00174382
NCT00174525,Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease,,Unknown status,No Results Available,Alzheimer's Disease,Drug: AAB-001,Safety assessments|Blood levels of administered study drug|Cognitive and functional assessments,Pharmacology Research Institute,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,null,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PRI#585,Apr-05,null,Apr-08,15-Sep-05,null,9-May-12,"Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Northridge, California, United States",,https://ClinicalTrials.gov/show/NCT00174525
NCT00177489,Coordinating Center for Caregiver Intervention Trial,REACH,Completed,No Results Available,Dementia|Alzheimer Disease,Behavioral: multicomponent psychosocial intervention|Other: Control arm,"multivariate quality of life indicator- assessed caregiver burden, depressive symptoms, self-care, social support and patient problem behaviors. Assessed at six months post-randomization.|Caregiver clinical depression and patient institutional placement-six months post-randomization.",University of Pittsburgh|National Institute on Aging (NIA)|National Institute of Nursing Research (NINR),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,613,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,AG13305,Jun-02,Sep-05,Sep-05,15-Sep-05,null,5-Jan-16,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University and Veterans Affairs, Menlo Park, California, United States|University of Miami at Miami, Center on Adult Development and Aging, Miami, Florida, United States|Thomas Jefferson University at Philadelphia, Center for Applied Research on Aging and Health, Philadelphia, Pennsylvania, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00177489
NCT00177671,Antidepressant Medication Plus Donepezil for Treating Late-life Depression,,Completed,Has Results,Depression|Dementia,Drug: Escitalopram|Drug: Donepezil|Drug: Venlafaxine|Drug: Placebo|Drug: Duloxetine,Global Cognitive Performance|Cognitive Instrumental Activities of Daily Living (IADL)|Number of Participants With Recurrence of Major Depression,University of Pittsburgh|National Institute of Mental Health (NIMH),All,65 Years and older   (Older Adult),Phase 4,220,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01MH043832-03|R01MH043832|0312018|DATR A4-GPS,Dec-03,Sep-09,Sep-09,15-Sep-05,8-Jun-11,6-Feb-13,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00177671
NCT00164749,A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Placebo and ginkgo extract|Drug: Curcumin and ginkgo extract,Change in isoprostane level in plasma|Change in A-beta level in serum|Change in cognitive function (MMSE score)|Change in cholesterol and triglycerides in serum|Change in metals in serum|Level of curcumin in plasma vs. dose,Chinese University of Hong Kong|BUPA Foundation|Kwong Wah Hospital,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CRE-2003.090-T,Oct-04,Jul-06,Jul-06,14-Sep-05,null,30-Apr-08,"The Chinese University of Hong Kong, Shatin, Hong Kong",,https://ClinicalTrials.gov/show/NCT00164749
NCT00165100,Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer,,Completed,No Results Available,Malignant Tumors|Subcutaneous Tumors|Lymph Node Tumors,Procedure: Dynamic Area Telethermometry (DAT),To assess the feasibility of DAT in tumors detected by conventional imaging and evaluation of therapy induced changes in DAT imaging profile over time.,Dana-Farber Cancer Institute|Brigham and Women's Hospital,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,99-331,Jan-00,Oct-02,Oct-02,14-Sep-05,null,28-Dec-07,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00165100
NCT00165659,"A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020",,Completed,No Results Available,Alzheimer Disease,Drug: DONEPEZIL HYDROCHLORIDE,"Primary Outcomes: Efficacy:|CIBIC plus*, SIB**|(*for overall evalution of clinical symtoms)|(**for cognitive function test)|Safety:|Adverse event, adverse drug reaction, vital sign, clinical laboratory parameter, electrocardiogram|Efficacy|Behave-AD, ADCS-ADL-sev",Eisai Limited|Eisai Inc.,All,"50 Years and older   (Adult, Older Adult)",Phase 2,null,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,E2020-J081-231,Nov-02,May-05,null,14-Sep-05,null,29-Jan-10,"Chita, Aichi-prefecture, Japan|Nagoya, Aichi-prefecture, Japan|Toyohashi, Aichi-prefecture, Japan|Akita, Akita-prefecture, Japan|Akita, Akita-prefecture, Japan|Daisen, Akita-prefecture, Japan|Kashiwa, Chiba-prefecture, Japan|Fukui, Fukui-prefecture, Japan|Fukuoka, Fukuoka-prefecture, Japan|Fukuoka, Fukuoka-prefecture, Japan|Fukuoka, Fukuoka-prefecture, Japan|Fukuoka, Fukuoka-prefecture, Japan|Kita-kyusyu, Fukuoka-prefecture, Japan|Fukushima, Fukushima-prefecture, Japan|Koriyama, Fukushima-prefecture, Japan|Fujioka, Gunma-prefecture, Japan|Numata, Gunma-prefecture, Japan|Hiroshima, Hiroshima-prefecture, Japan|Hiroshima, Hiroshima-prefecture, Japan|Otake, Hiroshima-prefecture, Japan|Asahikawa, Hokkaido-prefecture, Japan|Aio, Hyogo-prefecture, Japan|Asago, Hyogo-prefecture, Japan|Kako, Hyogo-prefecture, Japan|Kobe, Hyogo-prefecture, Japan|Kobe, Hyogo-prefecture, Japan|Tsuchiura, Ibaraki-prefecture, Japan|Tsukuba, Ibaraki-prefecture, Japan|Kanazawa, Ishikawa-prefecture, Japan|Kawasaki, Kanagawa-prefecture, Japan|Kawasaki, Kanagawa-prefecture, Japan|Sagamihara, Kanagawa-prefecture, Japan|Kochi, Kochi-prefecture, Japan|Kyoto, Kyoto-prefecture, Japan|Kyoto, Kyoto-prefecture, Japan|Nagasaki, Nagasaki-prefecture, Japan|Nagasaki, Nagasaki-prefecture, Japan|Sasebo, Nagasaki-prefecture, Japan|Kashihara, Nara-prefecture, Japan|Joetsu, Niigata-prefecture, Japan|Kashiwazaki, Niigata-prefecture, Japan|Tsukubo, Okayama-prefecture, Japan|Moriguchi, Osaka-prefecture, Japan|Neyagawa, Osaka-prefecture, Japan|Osaka, Osaka-prefecture, Japan|Osaka, Osaka-prefecture, Japan|Osaka, Osaka-prefecture, Japan|Suita, Osaka-prefecture, Japan|Takatsuki, Osaka-prefecture, Japan|Saitama, Saitama-prefecture, Japan|Izumo, Shimane-prefecture, Japan|Shizuoka, Shizuoka-prefecture, Japan|Kawachi, Tochigi-prefecture, Japan|Shimotsuga, Tochigi-prefecture, Japan|Chiyoda-ku, Tokyo-prefecture, Japan|Hachioji, Tokyo-prefecture, Japan|Higashimurayama, Tokyo-prefecture, Japan|Itabashi-ku, Tokyo-prefecture, Japan|Kodaira, Tokyo-prefecture, Japan|Machida, Tokyo-prefecture, Japan|Shinjuku-ku, Tokyo-prefecture, Japan|Nanto, Toyama-prefecture, Japan|Gobo, Wakayama-prefecture, Japan|Wakayama, Wakayama-prefecture, Japan|Hofu, Yamaguchi-prefecture, Japan",,https://ClinicalTrials.gov/show/NCT00165659
NCT00165724,Alzheimer's Disease Long-term Follow-up Study (ALF Study),,Completed,No Results Available,Alzheimer's Disease,Drug: Donepezil Hydrochloride,"ADAS-cog|MMSE, CDR, GDS, NPI, ADL, SSDQ",Eisai Korea Inc.|Eisai Inc.,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 4,114,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EKI-1002,Jun-04,Jul-06,Dec-06,14-Sep-05,null,4-May-12,"Bobath Memorial Hospital, Bundang, Korea, Republic of|Bundang Seoul National University Hospital, Bundang, Korea, Republic of|Changwon Fatima Hospital, Changwon, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Catholic University Hospital, Seoul, Korea, Republic of|Eulji University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00165724
NCT00165750,Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients,,Terminated,No Results Available,Alzheimer's Disease,Drug: DONEPEZIL HYDROCHLORIDE,"MRI, ADAS-cog|ADL, BPSD, CDR-SB, ZBI, GHQ, CIBIC plus",Eisai Korea Inc.|Eisai Inc.,All,"60 Years and older   (Adult, Older Adult)",Phase 4,40,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AS-019 (EKI-5-003),Mar-05,Aug-08,Nov-08,14-Sep-05,null,20-Nov-13,"Cheonnam University Hospital, Gwangju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00165750
NCT00153010,An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type,,Completed,No Results Available,Alzheimer Disease,Drug: NS 2330 (Tesofensine),Changes in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)|Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change|Alzheimer's Disease Cooperative Study-Activities of Daily Living|Neuropsychiatric Inventory|Mini-Mental State Examination|ADAS-Cog Extension|ADAS-Cog total score including Extension|types and frequencies of adverse events|proportion of patients discontinued from the trial because of adverse events|changes from baseline in vital signs|changes from baseline in laboratory measurements|changes from baseline in ECG readings|comparison of study groups for drug plasma concentrations|population PK parameters,Boehringer Ingelheim,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,430,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1198.52,Feb-03,Mar-05,null,12-Sep-05,null,29-Oct-13,"Pivotal Research Center, Mesa, Arizona, United States|Pivotal Research Center, Peoria, Arizona, United States|Xenoscience, Phoenix, Arizona, United States|Boehringer Ingelheim Investigational Site, Berkeley, California, United States|California Clinical Trials Medical Group, Culver City, California, United States|Margolin Brain Institute, Fresno, California, United States|Care@ Granada Hills Community Hospital, Granada Hills, California, United States|Optimum Health Services, LaMesa, California, United States|Optimum Health Services, Oceanside, California, United States|Southwest Institute for Clinical Research, Rancho Mirage, California, United States|Health Quest Clinical Trials, San Diego, California, United States|Institute on Aging Research Center, San Francisco, California, United States|Torrance Clinical Research, Torrance, California, United States|Associated Neurologists PC - Danbury, Danbury, Connecticut, United States|Center for Geriatric & Adult Psychiatry, Hamden, Connecticut, United States|Neurology Associates PA, Wilmington, Delaware, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Florida, United States|Baumel-Eisner Neuromedical Institute, Fort Lauderdale, Florida, United States|Neurologic Consulting/PA, Fort Lauderdale, Florida, United States|Clinical Physiology Associates Study Center, Fort Meyers, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami, Florida, United States|Miami Jewish Home and Hospital for the Aged, Miami, Florida, United States|Segal Institute for Clinical Research, N. Miami, Florida, United States|Magnolia Research Group, Ocala, Florida, United States|Memory Disorder Clinic, Pompano Beach, Florida, United States|Boehringer Ingelheim Investigational Site, Tampa, Florida, United States|USF Suncoast Gerontology Center, Tampa, Florida, United States|Palm Beach Neurology/Premier Research Institute, W. Palm Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Peryam and Kroll Healthcare Research, Chicago, Illinois, United States|LaGrange Hospital, LaGrange, Illinois, United States|Agewell, Ltd., Indianapolis, Indiana, United States|University of Iowa College of Medicine, Iowa City, Iowa, United States|Hartford Research Group, Florence, Kentucky, United States|Associates in Neurology-Research, Lexington, Kentucky, United States|Louisiana State University Medical Center, New Orleans, Louisiana, United States|Attn: M. Lannom, RN, MS, Sharon, Massachusetts, United States|Future Care Studies, Springfield, Massachusetts, United States|Saginaw Cooperative Hosp. Inc./ Internal medicine, Saginaw, Michigan, United States|North Michigan Neurology, Traverse City, Michigan, United States|University of Missouri, Columbia, Missouri, United States|St. Louis University, St. Louis, Missouri, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Atlantic Coast Research, Tom's River, New Jersey, United States|Albuquerque Neuroscience, Albuquerque, New Mexico, United States|Neurological Associates of Albany, Albany, New York, United States|Upstate Clinical Research, Albany, New York, United States|Dent Neurologic Institute, Amherst, New York, United States|Eastside Comprehensive Medical Services, New York, New York, United States|Social Psychiatry Research Institute, New York, New York, United States|The Jewish Home and Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Triangle Medical Research, Lexington Road, North Carolina, United States|Boehringer Ingelheim Investigational Site, Winston-Salem, North Carolina, United States|North Coast Clinical Trials, Inc., Beachwood, Ohio, United States|Boehringer Ingelheim Investigational Site, Cincinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Neurology Center of Ohio, Toledo, Ohio, United States|Linden Research Consultants, Oklahoma City, Oklahoma, United States|Pahl Brain Associates, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigators, Inc., Eugene, Oregon, United States|PRO Research, Eugene, Oregon, United States|Attn: Valerie MacDonald, Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Crosswords Counseling and Consulting Associates, Moon Township, Pennsylvania, United States|Pearl Clinical Research, Inc., Norristown, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, E. Providence, Rhode Island, United States|Butler Hospital Dept. of Neurology, Providence, Rhode Island, United States|Medical Univ. of South Carolina, Alzheimer's Research, N Charleston., South Carolina, United States|Psychiatric Consultants, Nashville, Tennessee, United States|Baylor College of Medicine VA Medical Center, Houston, Texas, United States|University of Texas Medical Science Institute, Houston, Texas, United States|Caprock Clinical Trials Center, Lubbock, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|The Memory Clinic/Southwestern Vermont Medical Center, Bennington, Vermont, United States|UVA Dept. of Neurology, Charlottesville, Virginia, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada|Infectious Disease, Moncton, New Brunswick, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Clinical Research Consultant Group, Beaconsfield, Quebec, Canada|Boehringer Ingelheim Investigational Site, Greenfield Park, Quebec, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT00153010
NCT00154635,Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease,,Unknown status,No Results Available,"Dementia, Alzheimer Type",Drug: DCB-AD1,ADAS-Cog|CIBIC-PLUS|IADL|Behav-AD|MMSE|CDR,"National Taiwan University Hospital|Development Center for Biotechnology, Taiwan|Taipei Veterans General Hospital, Taiwan|Program Office, National Science & Technology, Biotechnology & Pharmaceuticals",All,"50 Years and older   (Adult, Older Adult)",Phase 2,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,931006|NTUH IRB 931006|VGH IRB 93-11-06|DCB-AD1-01-01,Sep-05,null,null,12-Sep-05,null,12-Sep-05,"NTUH, Taipei, Taiwan|VGH, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00154635
NCT00160147,Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,,Terminated,No Results Available,Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,Drug: bifeprunox|Drug: Placebo,Brief Psychiatric Rating Scale (BPRS) Total Score|Adverse events,Solvay Pharmaceuticals,All,65 Years to 90 Years   (Older Adult),Phase 3,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",S154.3.016|2005-003475-20,Dec-05,Jan-08,Jan-08,12-Sep-05,null,9-Feb-15,"Site 912, Phoenix, Arizona, United States|Site 902, Carson, California, United States|Site 903, Long Beach, California, United States|Site 911, Pasadena, California, United States|Site 922, San Marino, California, United States|Site 910, Santa Ana, California, United States|Site 929, Hamden, Connecticut, United States|Site 914, New Britain, Connecticut, United States|Site 931, Norwalk, Connecticut, United States|Site 901, Miami, Florida, United States|Site 907, North Miami, Florida, United States|Site 933, Orange City, Florida, United States|Site 934, Atlanta, Georgia, United States|Site 917, Blue Ridge, Georgia, United States|Site 925, Newnan, Georgia, United States|Site 904, New Orleans, Louisiana, United States|Site 905, Shreveport, Louisiana, United States|Site 906, Shreveport, Louisiana, United States|Site 919, Bedford, Massachusetts, United States|Site 923, Boston, Massachusetts, United States|Site 942, Flowood, Mississippi, United States|Site 927, St. Louis, Missouri, United States|Site 930, St. Louis, Missouri, United States|Site 940, St. Louis, Missouri, United States|Site 941, Olean, New York, United States|Site 921, Staten Island, New York, United States|Site 909, Cincinnati, Ohio, United States|Site 908, Oklahoma City, Oklahoma, United States|Site 916, Oklahoma City, Oklahoma, United States|Site 935, Philadelphia, Pennsylvania, United States|Site 932, Humboldt, Tennessee, United States|Site 936, Austin, Texas, United States|Site 928, Dallas, Texas, United States|Site 913, Williamsburg, Virginia, United States|Site 918, Waukesha, Wisconsin, United States|Site 803, Litomerice, Czech Republic|Site 802, Lnare, Czech Republic|Site 804, Praha, Czech Republic|Site 805, Skvorec, Czech Republic|Site 801, Tabor, Czech Republic|Site 807, Viljandimaa, Estonia|Site 806, Voru Maakond, Estonia|Site 812, Bat Yam, Israel|Site 808, Beer Yaakov, Israel|Site 811, Hadera, Israel|Site 816, Pardes Hana, Israel|Site 810, Rehovot, Israel|Site 809, Tirat HaCarmel, Israel|Site 814, Choroszcz, Poland|Site 813, Gdansk, Poland|Site 815, Torun, Poland",,https://ClinicalTrials.gov/show/NCT00160147
NCT00161473,Alzheimer's in Long-Term Care--Treatment for Agitation,,Completed,Has Results,Alzheimer Disease|Psychomotor Agitation,Drug: prazosin|Drug: placebo (inert substance),Mean Clinical Global Impression of Change (CGIC) at Last Observation|Change in Neuropsychiatric Inventory (NPI) Total Score Over the Course of Study Participation|Number of Behavioral Assessment Visits Completed|Change in Brief Psychiatric Rating Scale (BPRS) Total Score Over the Course of Study Participation,University of Washington|National Institute on Aging (NIA),All,"Child, Adult, Older Adult",Not Applicable,24,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",16508-A|5R01AG018644|5P50AG005136,Jan-01,Sep-09,Sep-09,12-Sep-05,2-Aug-12,2-Aug-12,"Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00161473
NCT00151502,To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.,,Completed,No Results Available,Alzheimer's Disease,Drug: Atorvastatin,"If the results of this study demonstrate efficacy and lead to the approval by the FDA of atorvastatin for use in humans for the treatment of Alzheimer's disease, this would be available as an additional treatment option for patients.|If the results of this study demonstrate efficacy and lead to the approval by the Food and Drug Administration of atorvastatin for use in humans, subject activities of daily living are being assessed.",Pfizer,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A2581078,Nov-02,null,Jul-07,9-Sep-05,null,11-Jul-08,"Pfizer Investigational Site, Sun City, Arizona, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Laguna Hills, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Fort Meyers, Florida, United States|Pfizer Investigational Site, Miami Beach, Florida, United States|Pfizer Investigational Site, Pompano Beach, Florida, United States|Pfizer Investigational Site, St Petersburg, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Fort Wayne, Indiana, United States|Pfizer Investigational Site, Paducah, Kentucky, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Dartmouth, Massachusetts, United States|Pfizer Investigational Site, W Yarmouth, Massachusetts, United States|Pfizer Investigational Site, Worcester, Massachusetts, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Jamesburg, New Jersey, United States|Pfizer Investigational Site, Princeton, New Jersey, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Albany, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Troy, New York, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Jenkintown, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, East Providence, Rhode Island, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Madison, Tennessee, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Wichita Falls, Texas, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States|Pfizer Investigational Site, East Gosford, New South Wales, Australia|Pfizer Investigational Site, Randwick, New South Wales, Australia|Pfizer Investigational Site, Daw Park, South Australia, Australia|Pfizer Investigational Site, Woodville South, South Australia, Australia|Pfizer Investigational Site, Ballarat, Victoria, Australia|Pfizer Investigational Site, West Heidelberg, Victoria, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, Wein, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Verdun, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Aarhus, Denmark|Pfizer Investigational Site, Copenhagen, Denmark|Pfizer Investigational Site, Hillerod, Denmark|Pfizer Investigational Site, Rudkobing, Denmark|Pfizer Investigational Site, Svendborg, Denmark|Pfizer Investigational Site, Bad Honnef, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bochum, Germany|Pfizer Investigational Site, Bonn, Germany|Pfizer Investigational Site, Goettingen, Germany|Pfizer Investigational Site, Hannover, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Tuebingen, Germany|Pfizer Investigational Site, Rosebank, Gauteng, South Africa|Pfizer Investigational Site, Willows, Gauteng, South Africa|Pfizer Investigational Site, Pinetown, Kwazulu Natal, South Africa|Pfizer Investigational Site, Belleville, South Africa|Pfizer Investigational Site, Westville, South Africa|Pfizer Investigational Site, Terrassa, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Linkoeping, Sweden|Pfizer Investigational Site, Malmoe, Sweden|Pfizer Investigational Site, Moelndal, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Uddevalla, Sweden|Pfizer Investigational Site, Bradford, England, United Kingdom|Pfizer Investigational Site, Stirling, Stirlingshire, United Kingdom|Pfizer Investigational Site, Swindon, Wiltshire, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Penarth, United Kingdom|Pfizer Investigational Site, Southhampton, United Kingdom|Pfizer Investigational Site, Stirling, United Kingdom",,https://ClinicalTrials.gov/show/NCT00151502
NCT00151333,Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD),,Completed,No Results Available,Alzheimer's Disease,Drug: SRA-333,To determine the safety and tolerability of multiple ascending fixed oral dose in subject with mild to moderate Alzheimer's Disease|To assess the pharmacokinetics and pharmacodynamics of multiple ascending fixed dose.,Wyeth is now a wholly owned subsidiary of Pfizer,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,16,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,3098A1-200,Feb-05,Apr-05,Apr-05,8-Sep-05,null,4-Sep-09,"Phoenix, Arizona, United States|Ft. Lauderdale, Florida, United States|Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00151333
NCT00151398,Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD),,Completed,No Results Available,Alzheimer Disease,Drug: lecozotan SR|Drug: Donepezil,"The primary endpoints will be the change from baseline in ADAS-Cog total score and ADCS-CGIC total score.|Secondary efficacy outcome variables include additional cognitive, functional,and behavioral measures.",Wyeth is now a wholly owned subsidiary of Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 2,229,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3098B1-201, 3098B1-202|B343-1057, B343-1058",Sep-05,Mar-08,Mar-08,8-Sep-05,null,11-Feb-13,"Phoenix, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Fresno, California, United States|La Jolla, California, United States|Orange, California, United States|Boca Raton, Florida, United States|Delray Beach, Florida, United States|Ft. Lauderdale, Florida, United States|Ft. Myers, Florida, United States|Hallandale, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|St. Louis, Missouri, United States|Long Branch, New Jersey, United States|Manchester Twp., New Jersey, United States|Albany, New York, United States|Cedarhurst, New York, United States|Lawrence, New York, United States|Staten Island, New York, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|East Providence, Rhode Island, United States|Memphis, Tennessee, United States|Houston, Texas, United States|Bennington, Vermont, United States|Av. Belgrano, Argentina|Calle Adolfo Alsina, Argentina|Cervino, Argentina|Galvan, Argentina|Gascon, Argentina|Larrea, Argentina|Nueva York, Argentina|Pilar, Argentina|Hornsby, New South Wales, Australia|Heidelberg Heights, Victoria, Australia|Edmonton, Alberta, Canada|Medicine Hat, Alberta, Canada|Moncton, New Brunswick, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Regina, Saskatchewan, Canada|Westdene, Bloemfontein, South Africa|Observatory, Cape Town, South Africa|Panorama, Cape Town, South Africa|Florida, Johannesburg, South Africa|Bellville, Western Cape, South Africa",,https://ClinicalTrials.gov/show/NCT00151398
NCT00146263,Cognitive Training in the Elderly,,Unknown status,No Results Available,Dementia,Behavioral: computerized cognitive training,changes in cognitive function,Beersheva Mental Health Center,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BMHC-4018CTIL,Sep-05,null,Jun-07,7-Sep-05,null,8-Sep-10,"Beersheva Mental Health Center, Beersheva, Israel",,https://ClinicalTrials.gov/show/NCT00146263
NCT00147693,Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach?,,Completed,No Results Available,"Dementia, Vascular|Dementia|Alzheimer Disease|Lewy Body Disease",Behavioral: Diagnosis of caregivers' problems|Behavioral: Professional service: treatment of problems by counseling or practical support,"Patients admissions to nursing homes or residential homes. This outcome is the most important input for the estimation of cost differences between the intervention group and controls.|Secondary outcome for cost estimation is patient and caregiver related costs estimated by ""Resource Utilisation in Dementia"" (RUD), including time spent on caregiving, use of health care services by caregivers and patients and additional productivity.",Radboud University|ZonMw: The Netherlands Organisation for Health Research and Development,All,"Child, Adult, Older Adult",Not Applicable,304,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,SCAD|ZonMw grant no 945-04-152,Jun-05,Feb-06,Feb-06,7-Sep-05,null,1-Oct-08,"Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT00147693
NCT00145132,Beta-CIT-SPECT and Neurophysiology in Depression,,Completed,No Results Available,Depression,"Procedure: β-CIT-SPECT, Neurophysiology",changes in β-CIT/neurophysiological measurements from baseline to week 4,Ludwig-Maximilians - University of Munich|H. Lundbeck A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 4,30,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,ESCIT-SPECT-Pogarell|EK287/98,Jun-05,Dec-09,Dec-09,5-Sep-05,null,2-Jun-10,"Depts. of Psychiatry and Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany",,https://ClinicalTrials.gov/show/NCT00145132
NCT00142324,CALM-AD,,Unknown status,No Results Available,Alzheimer's Disease,Drug: Donepezil,Cohen Mansfield Agitation Inventory|Neuropsychiatric Inventory|Standardized Mini-Mental State Examination|Severe Impairment Battery|Clinical Global Impression of Severity/Change,"Institute of Psychiatry, London|Medical Research Council|Alzheimer's Society",All,"40 Years and older   (Adult, Older Adult)",Phase 4,190,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention,ISRCTN62185868,Nov-03,null,Dec-05,2-Sep-05,null,14-Dec-05,"Queen Elizabeth Psychiatric Hospital, Birmingham, United Kingdom|Department of Psychiatry for the Elderly, Leicester General Hospital, Leicester, United Kingdom|Institute of Psychiatry, King's College, London, London, United Kingdom|Old Age Psychiatry, Wythenshawe Hospital, Manchester, Manchester, United Kingdom|Institute for Ageing and Health, Newcastle General Hospital, Newcastle, Newcastle upon Tyne, United Kingdom|Department of Psychiatry, Warneford Hospital, Oxford, Oxford, United Kingdom|MARC, Moorgreen Hospital, Southamptom, Southampton, United Kingdom|Department of Old Age Psychiatry, Victoria Hospital, Swindon, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00142324
NCT00142805,Ketasyn in Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Ketasyn™ (AC-1202),"Changes measured by Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) at all 5 visits|Alzheimer's Disease Cooperative Study - Clinician's Global Impression of Change (ADCS-CGIC) at visits 2 through 5|Mini-Mental State Exam (MMSE) at all 5 visits|Changes measured by Electrocardiogram (ECG) at visits 1 and 5|Beta-Hydroxybutyrate pre-dose levels at all 5 visits|Beta-Hydroxybutyrate 2-hour post-dose levels at visits 2, 3, and 4","Accera, Inc.|National Institute on Aging (NIA)",All,"50 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,IA0076,Oct-04,null,Mar-06,2-Sep-05,null,31-Dec-08,"21st Century Neurology, a division of Xenoscience Inc., Phoenix, Arizona, United States|Comprehensive NeuroScience, Cerritos, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pharmacology Research Institute, Northridge, California, United States|The Southwest Institute for Clinical Research, Rancho Mirage, California, United States|Pharmacology Research Institute, Riverside, California, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Baumel-Eisner Neuromedical Institute, Inc., Ft. Lauderdale, Florida, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Comprehensive NeuroScience, Melbourne, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami Beach, Florida, United States|Anchor Research Center, Naples, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Comprehensive NeuroScience, St. Petersburg, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Meridien Research, Tampa, Florida, United States|Radiant Research, Chicago, Illinois, United States|Multi-Specialty Research Associates of North Carolina, Raleigh, North Carolina, United States|Radiant Research, Portland, Oregon, United States|Radiant Research, Dallas, Texas, United States|Research Across America, Dallas, Texas, United States|Radiant Research, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States",,https://ClinicalTrials.gov/show/NCT00142805
NCT00141661,A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients,,Completed,No Results Available,Alzheimer Disease,Drug: PF-04494700 - Low Dose Arm|Drug: PF-04494700 - High Dose Arm|Drug: Placebo Comparator,"Safety Measures include Adverse Events|Laboratory Tests|12-Lead Electrocardiogram|24-Hour 12-Lead Serial ECGs|Surrogate Efficacy Markers in Plasma: A-Beta, C-Reactive Protein, IL-1, IL-6, Isoprostanes, TNF-alpha, TNF-beta|Cognitive Function Tests: ADAS-Cog, CDR-Sum of Boxes, MMSE, ADCS-ADL|Pharmacokinetic Profile",Pfizer|Trans Tech Pharmaceuticals,All,"50 Years and older   (Adult, Older Adult)",Phase 2,67,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B0341008|TTP488-201,Oct-05,Jun-06,Jun-06,1-Sep-05,null,20-Aug-09,"Pfizer Investigational Site, Sun City, Arizona, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Hallandale Beach, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Largo, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, West palm Beach, Florida, United States|Pfizer Investigational Site, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00141661
NCT00134953,Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment,,Terminated,No Results Available,Cognitive Symptoms,Drug: Rivastigmine,"16 week's treatment with rivastigmine on alertness, memory, attention, cognitive flexibility, orientation and language in patients with mild cognitive impairment|Safety of 16 week's treatment with rivastigmine in patients with mild cognitive impairment",Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CENA713BDE05,Jan-03,null,May-04,25-Aug-05,null,17-Dec-07,,,https://ClinicalTrials.gov/show/NCT00134953
NCT00130429,Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: PYM50028,"Hopkins verbal learning test (revised) total word recall after 12 weeks|Cambridge neuropsychological test automated battery (CANTAB) paired associate learning (Phytopharm modified form) total adjusted error score after 12 weeks|Mini mental state examination score|Clinical dementia rating (overall and sum of boxes)|CANTAB rapid visual information processing (RVIP) mean latency|CANTAB RVIP total correct hits|CANTAB spatial working memory within error, between error and strategy scores|Clinicians global impression of change|Disability assessment for dementia score",Phytopharm,All,"50 Years and older   (Adult, Older Adult)",Phase 2,250,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,P58/09ME/03/04,Jan-04,null,Sep-05,15-Aug-05,null,21-Aug-09,"Oxford Project to Investigate Memory and Ageing, Oxford, Oxfordshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00130429
NCT00120874,"Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training",,Completed,Has Results,Alzheimer's Disease,Behavioral: Individualized management of AD including caregiver training|Drug: Memantine,Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version)|Change From Baseline of The Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Modified for Severe Dementia Abbreviated Version (ADCS-ADLsev-abv)|Change From Baseline of the Severe Impairment Battery (SIB)|Change From Baseline of the Mini-Mental State Examination (MMSE)|Change From Baseline of the Functional Assessment Staging Disability Score (FAST-DS)|Change From Baseline of The Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale (BEHAVE-AD-FW)|Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Frequency|Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Caregiver Reaction,New York University School of Medicine|Forest Laboratories|Fisher Center for Alzheimer's Research Foundation,All,"50 Years and older   (Adult, Older Adult)",Phase 4,20,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),H12444-01 A|NAM MD 18,Aug-06,Nov-11,Nov-11,19-Jul-05,14-Jul-16,25-Oct-16,"Fisher Alzheimer's Program, New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00120874
NCT00119561,Testing the Effectiveness of Telephone Support for Dementia Caregivers,CONNECT,Completed,No Results Available,Dementia|Alzheimer Disease,Behavioral: Telephone Support,"General well-being (revised Rand General Well-Being Scale); and caregiver's level of distress with care recipient behaviors (Revised Memory and Behavior Problems Checklist). Data is collected at baseline, 6 and 12 months in a face to face interview.|Cost-Effectiveness|Time spent providing care",US Department of Veterans Affairs|VA Office of Research and Development,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,154,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIR 03-287,Feb-05,Jun-07,Jan-14,13-Jul-05,null,7-Apr-15,"Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00119561
NCT00117403,Anti-Oxidant Treatment of Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,"Drug: Vitamin E, Vitamin C, and Alpha-lipoic Acid|Drug: Coenzyme Q|Drug: Placebo capsules|Drug: Placebo wafers",effect on cerebrospinal fluid (CSF) biomarkers related to oxidative damage|change in plasma and CSF concentrations of a-beta42 and a-beta40,National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS),All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,75,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IA0067,Jan-06,Sep-07,Sep-07,6-Jul-05,null,3-Apr-09,"University of Arizona, Tucson, Arizona, United States|University of California- Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Wien Center, Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, United States|Neurological Care of CNY, Syracuse, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00117403
NCT00112073,AAB-001 in Patients With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: bapineuzumab|Other: placebo,safety assessments|blood levels of administered study drug|cognitive and functional assessments,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,234,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAB-001-201,Apr-05,Nov-08,Dec-08,30-May-05,null,14-Mar-12,"Cleo Roberts Center for Clinical Research / Sun Health Research Institute, Sun City, Arizona, United States|UC Irvine, Irvine, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Northridge, California, United States|UCSD Shiley-Marcos Alzheimer's Disease Research Center, San Diego, California, United States|Memory & Aging Center, UCSF, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Mayo Clinic - Department of Neurology, Jacksonville, Florida, United States|Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States|Department of Neurology - Indiana University Medical Center, Indianapolis, Indiana, United States|Behavioral Neurology, Boston, Massachusetts, United States|University of Michigan Health System, Department of Neurology, Ann Arbor, Michigan, United States|Mayo Clinic Department of Neurology - Alzheimer's Disease Research Center, Rochester, Minnesota, United States|The Memory Enhancement Center, Long Branch, New Jersey, United States|Sergievsky Center, Columbia University, New York City, New York, United States|University of Rochester / Monroe Community Hospital, Rochester, New York, United States|Department of Psychiatry and Behavioral Sciences, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Memory and Aging Program, Butler Hospital, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00112073
NCT00110552,Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients,,Completed,No Results Available,Alzheimer Disease,Drug: Salvia officinalis (sage),Cognitive function|Stress|cognitive electrophysiology,Oregon Health and Science University|National Center for Complementary and Integrative Health (NCCIH),All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,111,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,U19AT002656-03,Jul-05,Dec-12,Oct-14,11-May-05,null,29-Oct-14,"Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00110552
NCT00105638,Telehealth Education Program for Caregivers of Veterans With Dementia,,Completed,No Results Available,Dementia|Alzheimer Disease,"Behavioral: educational program, by telephone",Reduction in veteran agitation and symptoms of depression; increase in caregiver management skills|Veterans will experience fewer hospitalizations and nursing home admissions,US Department of Veterans Affairs|VA Office of Research and Development,All,"Child, Adult, Older Adult",Not Applicable,160,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),IIR 03-076,Sep-05,null,Apr-07,17-Mar-05,null,7-Apr-15,"Albany VA Medical Center Samuel S. Stratton, Albany, NY, Albany, New York, United States|VA Western New York Healthcare System, Buffalo, NY, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT00105638
NCT00105547,Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's,,Completed,No Results Available,Alzheimer Disease|Dementia,Drug: MPC-7869,Cognition and activities of daily living|Global function and behavior,Myrexis Inc.,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1600,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MPC-7869-04-005.02,Feb-05,null,May-08,16-Mar-05,null,5-May-09,"Alabaster, Alabama, United States|Huntsville, Alabama, United States|Mesa, Arizona, United States|Peoria, Arizona, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Fresno, California, United States|Irvine, California, United States|La Jolla, California, United States|Lafayette, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Newport Beach, California, United States|Oceanside, California, United States|Rancho Mirage, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|San Francisco, California, United States|Vista, California, United States|Denver, Colorado, United States|Danbury, Connecticut, United States|Darien, Connecticut, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Bay Harbor, Florida, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Derrfield Beach, Florida, United States|Fort Myers, Florida, United States|Ft. Lauderdale, Florida, United States|Ft. Myers, Florida, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|North Miami, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Plantation, Florida, United States|Pompano Beach, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Ft. Wayne, Indiana, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore,, Maryland, United States|Glen Burnie, Maryland, United States|Boston, Massachusetts, United States|Brockton, Massachusetts, United States|West Yarmouth, Massachusetts, United States|Farmington Hills, Michigan, United States|Grand Rapids, Michigan, United States|Rochester, Minnesota, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Lebanon, New Hampshire, United States|Kenilworth, New Jersey, United States|Morristown, New Jersey, United States|Piscataway, New Jersey, United States|Princeton, New Jersey, United States|Stratford, New Jersey, United States|Toms River, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Brooklyn, New York, United States|Elmsford, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Olean, New York, United States|Rochester, New York, United States|Syracuse, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Centerville, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Bala Cynwyd, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburg, Pennsylvania, United States|Scotland, Pennsylvania, United States|East Providence, Rhode Island, United States|East Providence, Rhode Island, United States|Providence, Rhode Island, United States|Beaufort, South Carolina, United States|Greer, South Carolina, United States|North Charleston, South Carolina, United States|Johnson City, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Galveston, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Alexandria, Virginia, United States|Charlottesville, Virginia, United States|Virginia Beach, Virginia, United States|Middleton, Wisconsin, United States|Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00105547
NCT00105612,Memory Aid for Informed Consent in Alzheimer's Research,,Completed,No Results Available,Alzheimer's Disease|Aging,Device: Memory and Organizational Aid|Behavioral: Standard Informed Consent Process,MacArthur Competency Assessment Tool for Clinical Research (MacCAT-CR) to quantify decision making abilities|Participant competency,National Institute on Aging (NIA),All,"Child, Adult, Older Adult",Not Applicable,110,NIH,Interventional,Allocation: Randomized,IA0070|1R01AG020627-01A2,Sep-04,Mar-07,Mar-07,16-Mar-05,null,29-Dec-09,"University of Pennsylvania, Memory Disorders Clinic, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00105612
NCT00105105,Mifepristone as Adjunctive Therapy in Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: Mifepristone,effects on cognition|effects on behavior and activities of daily living,Corcept Therapeutics|Institute for the Study of Aging (ISOA)|National Institute on Aging (NIA),All,"Child, Adult, Older Adult",Phase 2,160,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,IA0069,Apr-03,Nov-05,Nov-05,7-Mar-05,null,11-Dec-09,"Pivotal Research Center, Mesa, Arizona, United States|Pivotal Research Center, Peoria, Arizona, United States|ATP Clinical Trials, Fountain Valley, California, United States|UCI Irvine Medical Center, Orange, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|AVI Clinical Research, Torrance, California, United States|Baumel-Eisner Neuromed Inst, Boca Raton, Florida, United States|Baumel-Eisner Neuromed Inst, Ft. Lauderdale, Florida, United States|Clinical Physiology Associates, Ft. Myers, Florida, United States|Baumel-Eisner Neuromed Inst, Miami Beach, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Johnnie B. Byrd, Sr. Alzheimer's Center & Research Inst, Tampa, Florida, United States|Memory Enhancement Center, Long Branch, New Jersey, United States|Eastside Medical Research, New York, New York, United States|Neuro Center of Ohio, Toledo, Ohio, United States|Pahl Pharmaceutical Research, LLC, Oklahoma City, Oklahoma, United States|Clinical Pharmaceutical Trials, Inc., Tulsa, Oklahoma, United States|Clinical Trials Research Services, Pittsburgh, Pennsylvania, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|International Clinical Research Associates, Richmond, Virginia, United States|International Clinical Research Associates, Virginia Beach, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00105105
NCT00104442,Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Rivastigmine,Changes in specific brain enzyme activity from baseline to week 13|Correlate changes in specific brain enzyme activity at week 13 to cognition and behavior|Changes in levels of protein biomarkers in Alzheimer's disease and neurodegeneration from baseline to week 13|Correlate changes in specific brain enzyme activity after 13 weeks treatment to changes in global functioning at 13 and 26 weeks,Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CENA713BUS25,Oct-03,null,Apr-06,1-Mar-05,null,21-Dec-07,"Novartis Pharmaceuticals, East Hanover, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00104442
NCT00104273,Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD),,Completed,No Results Available,Dementia|Alzheimer's Disease,Drug: Rasagiline,Cognitive Function|Other Cognitive Assessments; Activities of Daily Living (ADLs); Functional Assessments; Safety; Tolerability.,Teva Pharmaceutical Industries|Eisai Inc.,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 2,376,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TVP-1012-A001-201,Aug-04,Mar-07,null,25-Feb-05,null,15-Jul-09,"Collaborative Neuroscience Network, Huntsville, Alabama, United States|North Alabama Neuroscience Research, Huntsville, Alabama, United States|Northwest Neurospecialists, PLLC, Tucson, Arizona, United States|Clinical Study Centers, LLC, Little Rock, Arkansas, United States|East Bay Region Associates in Neurology, Berkeley, California, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Premiere Research Institute, West Palm Beach, Florida, United States|North Broward Medical Center/Memory Disorder Center, West Palm Beach, Florida, United States|Emory University Wesley Woods Health Center, Altanta, Georgia, United States|Dekalb Neurology Associates, LLC, Decatur, Georgia, United States|Radiant Research, Chicago, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Mid America Neuroscience Institute, Lenexa, Kansas, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|Tulane University Health Sciences Center, Dept of Psychiatry and Neurology, New Orleans, Louisiana, United States|Department of Neurology - Brigham and Women's Hospital, Boston, Massachusetts, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|University Behavioral Healthcare Centre Department of Psychiatry, Piscataway, New Jersey, United States|Odyssey Research, Fargo, North Dakota, United States|Ohio State University, Department of Neurology, Columbus, Ohio, United States|Pahl Brain Associates, Oklahoma City, Oklahoma, United States|Medical University of South Carolina Alzheimer's Research and Clinical Programs, North Charleston, South Carolina, United States|Department of Neurology Baylor College of Medicine, Houston, Texas, United States|Premiere Research Institute, Houston, Texas, United States|University of Texas Mental Sciences Institute, Houston, Texas, United States|Peninsula Internal Medicine Associates, Gig Harbor, Washington, United States|Internal Medicine Northwest, Tacoma, Washington, United States|Ballarat Health Service - Queen Elizabeth Center, Ballarat, Australia|Aged Mental Health Research Unit - Kingston Centre, Cheltenham, Australia|Prince Charles Hospital - Dept. of Geriatrics, Chermside, Australia|Central Coast Neuroscience Research, East Gosford, Australia|Heidelberg Repatriation Hospital, Heidelberg West, Australia|Hornsby Kur-ing-gai Hospital, Rehabilitation and Aged Care Service, Hornsby, Australia|St. George's Hospital, Kew, Australia|McCusker Foundation for Alzheimer's Disease Research, Nedlands, Australia|The Queen Elizabeth Hospital, Woodville, Australia|Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada|Memory Disorder Clinic/Winnipeg Clinic, Winnipeg, Manitoba, Canada|Dept. of Clinical Neurological Sciences - University of Western Ontario, London, Ontario, Canada|155974 Ont. Inc., Peterborough, Ontario, Canada|Neurology Research Inc., Toronto, Ontario, Canada|Bloemfontein Medi Clinic, Westdene, Bloemfontein, South Africa|Westdene Research Centre, Westdene, Bloemfontein, South Africa|Suite C, Black C, Sandton, Gauteng, South Africa|St. Augustine's Medical Mews., Durban, South Africa|The Memory Centre, Johannesburg, South Africa|Dr. Felix Potocnik, Oakdale, South Africa|Panorama Medical Centre, Panorama, South Africa|Milpark Hospital, Parktown, South Africa|Crompton Medical Centre West, Pinetown, South Africa|Constantiaberg Medi Clinic, Plumstead, South Africa|Willows Medical Center, Pretoria, South Africa|Little Company of Mary Hospital, Pretoria, South Africa|Richard's Bay Trial Centre, Richard's Bay, South Africa",,https://ClinicalTrials.gov/show/NCT00104273
NCT00104013,Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type,,Completed,No Results Available,Alzheimer Disease,Drug: xaliproden (SR57746A),"Alzheimer's Disease assessment scale-cognitive, clinical dementia rating sum of boxes.|Mini-Mental State Examination, Alzheimer's Disease assessment scale-activities of daily life.",Sanofi,All,"50 Years and older   (Adult, Older Adult)",Phase 3,1455,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,EFC2724|SR57746A,Nov-03,Nov-07,Nov-07,21-Feb-05,null,21-Aug-08,"Neurological Physicians of Arizona, Inc., Mesa, Arizona, United States|Pivotal Research Centers, Mesa, Arizona, United States|Pivotal Research Centers, Peoria, Arizona, United States|Northwest NeuroSpecialists, Tucson, Arizona, United States|Optimum Health Services, Oceanside, California, United States|Anderson Clinical Research, Redlands, California, United States|Univ. of CT Health Center, Farmington, Connecticut, United States|CNS Healthcare, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Memory Disorder Center, Pompano Beach, Florida, United States|Neurological Center, Fort Wayne, Indiana, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Hartford Research Group, Florence, Kentucky, United States|Lexington Clinic, Lexington, Kentucky, United States|LSUHSC Geriatric Psychiatry, New Orleans, Louisiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Synergy Medical, Saginaw, Michigan, United States|University Medical Center, Dept. of Psychiatry Clinical Trials, Jackson, Mississippi, United States|Radiant Research, Inc., St. Louis, Missouri, United States|Center For Emotional Fitness, Moorestown, New Jersey, United States|Ubhc/Umdnj667, Piscataway, New Jersey, United States|The Ohio State University, Columbus, Ohio, United States|The Clinical Trial Center, Jenkintown, Pennsylvania, United States|Radiant Research, Greer, South Carolina, United States|Alzheimer's Research & Clinical Programs, North Charleston, South Carolina, United States|Harmony Research, Inc, Johnson City, Tennessee, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|Grayline Clinical Drug Trial, Wichita Falls, Texas, United States|The Innovative Clinical Research Center, Alexandria, Virginia, United States|Eastern Virginia Medical School - The Glennan Center For Geriatrics ""Gerontology"", Norfolk, Virginia, United States|National Clinical Research, Inc, Richmond, Virginia, United States|sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Causeway Bay, Hong Kong|Sanfoi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Singapore, Singapore|Sanofi-Aventis Administrative Office, Midrand, South Africa|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00104013
NCT00103649,18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type,,Completed,No Results Available,Alzheimer Disease,Drug: xaliproden (SR57746A),"Alzheimer's Disease assessment scale-cognitive, clinical dementia rating sum of boxes.|Mini-Mental State Examination, Alzheimer's Disease assessment scale-activities of daily life.",Sanofi,All,"50 Years and older   (Adult, Older Adult)",Phase 3,1306,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,EFC2946|SR57746,Nov-03,Oct-07,Oct-07,14-Feb-05,null,21-Aug-08,"UAB Memory Disorders Clinic, Birmingham, Alabama, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|PsyPharma Clinical Research, Inc., Phoenix, Arizona, United States|Radiant Research, Scottsdale, Arizona, United States|Anaheim Research Center, Anaheim, California, United States|Margolin Brain Institute, Fresno, California, United States|Coordinated Clinical Research, La Jolla, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pharmacology Research Institute, Northridge, California, United States|Pharmacology Research Institute, Riverside, California, United States|Pacific Research Network, San Diego,, California, United States|California Neuroscience Research Medical Group, Sherman Oaks, California, United States|Pacific Research Network, Vista,, California, United States|Radiant Research, Denver, Colorado, United States|Associated Neurologist, Danbury,, Connecticut, United States|Geriatric and Adult Psychiatry, LLC, Hamden, Connecticut, United States|Yale University School of Medicine AD Research Unit, New Haven, Connecticut, United States|Healthcore, Newark, Delaware, United States|Neurology Associates, PA, Wilmington, Delaware, United States|Atlantic Institute of Clinical Research, Daytona Beach, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Miami Research Associates, Miami, Florida, United States|Baumel-Eisner Neuromedical Institute in Miami Beach, Miami, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami, Florida, United States|Anchor Research Center, Naples, Florida, United States|Segal Institute for Clinical Research, North Miami, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens,, Florida, United States|Neurology Clinical Research, Inc., Plantation, Florida, United States|CNS Clinical Trials, St Petersburg, Florida, United States|Baumel-Eisner Neuromedical Institute in Miami Beach, Tamarac, Florida, United States|Meridien Research, Tampa, Florida, United States|Suncoast Gerontology Center USF, Tampa, Florida, United States|Radiant Research, Marietta, Georgia, United States|Southeastern Geriatric Healthcare, Snellville, Georgia, United States|Chicago Center for Clinical Research, Chicago, Illinois, United States|Radiant Research Center, Hoffman Estates, Illinois, United States|Elkhart Clinic, LLC, Elkhart,, Indiana, United States|Ruan Neurology, Des Moines, Iowa, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|J. Gary Booker MD, Shreveport,, Louisiana, United States|Clinical Insights, Glen Burnie, Maryland, United States|Summit Research Network Michigan, Inc., Okemos, Michigan, United States|Pivotal Research Centers, Detroit Office, Royal Oak,, Michigan, United States|Minneapolis VA Medical Center, Minneapolis, Minnesota, United States|Radiant Research, Las Vegas, Nevada, United States|ClinSearch, Inc., Kenilworth,, New Jersey, United States|The Neuroscience Center of Northern New Jersey, Morristown, New Jersey, United States|Princeton Medical Institute, Princeton,, New Jersey, United States|Neurology Group of Bergen County, Ridgewood, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Neurological Association of Albany P.C., Albany, New York, United States|Social Psychiatry Research Institute, Brooklyn,, New York, United States|Parker Jewish Institute for Healthcare and Rehabilitation, Hyde Park,, New York, United States|Neurobehavioral Research, Inc., Lawrence, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Behavioral Medical Research of Staten Island, New York, New York, United States|Global Research and Consulting, Olean, New York, United States|Duke University Medical Center (DUMC) - Dept. of Psychiatry, Durham, North Carolina, United States|MedARK Clinical Research, Morganton, North Carolina, United States|Piedmont Medical Research Assoc, Inc., Winston-Salem, North Carolina, United States|DayStar Clinical Research, Inc., Akron, Ohio, United States|North East Ohio Health Services, Beachwood, Ohio, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Remington-Davis Clinical Research, Columbus, Ohio, United States|TriPhase Research, Franklin,, Ohio, United States|Triphase Research, Ltd., Franklin, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Radiant Research Eugene, Eugene, Oregon, United States|Clinical Research Institute of Southern Oregon, Medford, Oregon, United States|Summit Research Network Inc, Portland, Oregon, United States|Coatesville VA Medical Center, Coatesville, Pennsylvania, United States|Pearl Clinical Research, Norristown, Pennsylvania, United States|Memory Disorders Clinic, Philadelphia, Pennsylvania, United States|Radiant Research, Philadelphia, Pennsylvania, United States|Clinical Trials Research Services, Pittsburgh, Pennsylvania, United States|JRMC Clinical Trials Center, Pittsburgh, Pennsylvania, United States|RI Mood and Memory, East Providence, Rhode Island, United States|Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|CNS Healthcare, Memphis, Tennessee, United States|Vanderbilt University Medical Center - Geriatric Psychiatry, Nashville, Tennessee, United States|University of Texas - Southwestern Medical Center at Dallas, Dallas,, Texas, United States|Houston Sleep Center, Houston, Texas, United States|AD Research Center, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|North Texas Neurology Research, Wichita Falls, Texas, United States|Radiant Research SLC, Salt Lake City, Utah, United States|The Memory Clinic, Bennington,, Vermont, United States|Charlottesville Medical Research, Charlottesville, Virginia, United States|Internal Medicine Northwest, Tacoma, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Dean Foundation, Middleton, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|IPC Research, Waukesha, Wisconsin, United States|Glenrose Rehabilitation Hospital, Edmonton,, Alberta, Canada|Kelowna, British Columbia, Canada|Medical Arts Health Research Group, Penticton, British Columbia, Canada|Can-Med Clinical Research Inc., Victoria, British Columbia, Canada|Winnipeg Clinic, Winnipeg,, Manitoba, Canada|Winnipeg Clinic, Winnipeg, Manitoba, Canada|Davidson Memory Clinic, Moncton,, New Brunswick, Canada|St. Joseph's Hospital, Saint John,, New Brunswick, Canada|St. Joseph's Healthcare Hamilton, Hamilton,, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|St. Joseph's Health Care, London, Ontario, Canada|Parkwood Hospital - Geriatric Medicine, London, Ontario, Canada|S.C.O. Health Centre, Ottawa,, Ontario, Canada|Parkinson's & Neurodegenerative Disorders, Ottawa, Ontario, Canada|Toronto Memory Program, Toronto,, Ontario, Canada|University Health Network - The Toronto, Toronto, Ontario, Canada|NeuroSearch Developments Inc, Greenfield Park, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|Quebec Memory & Motor Skills Disorders, Quebec City, Quebec, Canada|Institut Universitaire de Geriatrie de Sherbrooke, Sherbrooke, Quebec, Canada|Douglas Hospital Research Centre, Verdun, Quebec, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada|Centre de Hospitalier Affilie, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00103649
NCT00100334,Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: PPI-1019 (APAN),Safety will be assessed through the occurrence of clinical adverse events and the occurrence of clinically significant changes from baseline.,PRAECIS Pharmaceuticals Inc.,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1019-04-01,Dec-04,null,Aug-05,30-Dec-04,null,19-Sep-06,"Silverado Senior Living, San Juan Capistrano, California, United States",,https://ClinicalTrials.gov/show/NCT00100334
NCT00100282,Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer’s Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: PPI-1019 (APAN),"Clinical (adverse events, vital signs, ECG) and laboratory (chemistry, hematology) parameters|Single dose pharmacokinetic parameters",PRAECIS Pharmaceuticals Inc.,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,125,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1019-03-01,May-03,null,Jun-05,28-Dec-04,null,19-Sep-06,"Department of Psychiatry & Human Behavior at the University California, Irvine, Orange, California, United States|Global Medical Institutes LLC, Princeton, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00100282
NCT00099710,Curcumin in Patients With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Dietary Supplement: Curcumin C3 Complex,"Side effect checklist|Oxidative damage|Inflammation/gliosis|A-beta levels|Tau levels|Total plasma cholesterol, LDL and HDL; ApoE|Plasma curcumin and metabolites|Cognitive and behavioral measures",John Douglas French Foundation|Institute for the Study of Aging (ISOA)|National Institute on Aging (NIA),All,"50 Years and older   (Adult, Older Adult)",Phase 2,33,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,IA0065,Jul-03,Dec-07,Dec-07,20-Dec-04,null,3-Dec-09,"UCLA Medical Center, Westwood, California, United States",,https://ClinicalTrials.gov/show/NCT00099710
NCT00099242,Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,,Completed,No Results Available,"Alzheimer's Disease|Dementia, Alzheimer Type",Drug: rivastigmine transdermal patch,Change in cognition from baseline at week 24|Global clinical impression of change from baseline at week 24|Change from baseline at week 24 in activities of daily living|Change from baseline at week 24 in behavioral symptoms|Change from baseline at week 24 in global cognitive testing|Change from baseline at week 24 in executive function|Change from baseline at week 24 in attention,Novartis Pharmaceuticals|Novartis,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1040,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CENA713D2320,Nov-03,null,Jan-06,10-Dec-04,null,13-Oct-17,"Orange, California, United States|San Francisco, California, United States|Boca Raton, Florida, United States|Fort Lauderdale, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Port Charlotte, Florida, United States|West Palm Beach, Florida, United States|Snellville, Georgia, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Long Branch, New Jersey, United States|Manchester Township, New Jersey, United States|Toms River, New Jersey, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Oklahoma City, Oklahoma, United States|Greensburg, Pennsylvania, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|Tacoma, Washington, United States|Santiago, Chile|Valparaiso, Chile|Brno-Bohunice, Czechia|Brno, Czechia|Hradec Kralove, Czechia|Olomouc, Czechia|Prague, Czechia|Glostrup, Denmark|Hillerod, Denmark|Kobenhavn, Denmark|Kuopio, Finland|Investigative sites, Germany|Guatemala City, Guatemala|Beersheva, Israel|Hifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Tel Aviv, Israel|Lido di Camaiore, Italy|Milano, Italy|Pescara, Italy|Chungbuk, Korea, Republic of|KyungKi-province, Korea, Republic of|Seoul, Korea, Republic of|Guadalajara Jalisco, Mexico|Mexico D.F., Mexico|Monterrey Nuevo Leon, Mexico|Bodo, Norway|Oslo, Norway|Tromso, Norway|Trondheim, Norway|Lima, Peru|Gdansk, Poland|Lublin, Poland|Poznan, Poland|Szczecin, Poland|Warszawa, Poland|Amadora, Portugal|Coimbra, Portugal|Bayamon, Puerto Rico|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|Bratislava, Slovakia|Michalovce, Slovakia|Goteborg, Sweden|Kalmar, Sweden|Stockholm, Sweden|Uppsala, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Tao-Yuan, Taiwan|Ciudad Merida, Estado Merida, Venezuela",,https://ClinicalTrials.gov/show/NCT00099242
NCT00097916,An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: memantine HCl,Neuropsychiatric Inventory|Cohen Mansfield Agitation Inventory|Clinical Global Impression Scale|ADCS-ADL|Agitation/aggression domain of Neuropsychiatric Inventory (NPI),Forest Laboratories,All,"50 Years and older   (Adult, Older Adult)",Phase 3,34,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,MEM-MD-23,Sep-04,Apr-06,Apr-06,2-Dec-04,null,5-Mar-12,"The Forves Norris MDA/ALS Research Center, San Francisco, California, United States|Coastal Communities Hospital, Westminster, California, United States|Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Berma Research Group, Hialeah, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Geriatric Medicine, Honolulu, Hawaii, United States|The Memory Clinic, Bennington, Vermont, United States|Hampton Roads Center for Clinical Research, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00097916
NCT00096473,Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Dementia,Drug: Donepezil hydrochloride,Assessments of global and cognitive function of Severe AD patients|Assessment of behavior and performance on Activity of Daily Living in severe AD patients|Assessment of caregiver burden,Eisai Inc.|Pfizer,All,"50 Years and older   (Adult, Older Adult)",Phase 3,229,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,E2020-A001-315,Jan-01,Jun-05,Sep-05,10-Nov-04,null,1-Apr-11,"Northport, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|San Francisco, California, United States|Santa Monica, California, United States|Torrance, California, United States|Denver, Colorado, United States|Ft. Lauderdale, Florida, United States|Ft. Myers, Florida, United States|North Miami, Florida, United States|St. Petersburg, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|New Orleans, Louisiana, United States|Springfield, Massachusetts, United States|Long Branch, New Jersey, United States|Piscataway, New Jersey, United States|New Hyde Park, New York, United States|Greenville, North Carolina, United States|Raleigh, North Carolina, United States|Centerville, Ohio, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Portland, Oregon, United States|Jenkintown, Pennsylvania, United States|Austin, Texas, United States|Houston, Texas, United States|Randwick, New South Wales, Australia|Brisbane, Queensland, Australia|Woodville South, South Australia, Australia|Heidelberg West, Victoria, Australia|Nedlands, Western Australia, Australia|Toronto, Ontario, Canada|Hôpital Broca-La Rochefoucauld, Paris, France|Belfast, Ireland|St. Leonards on Sea, East Sussex, United Kingdom|West End, Southampton, United Kingdom|Swindon, Wilshire, United Kingdom|Bath, United Kingdom|Blackpool, United Kingdom|Bradford, United Kingdom",,https://ClinicalTrials.gov/show/NCT00096473
NCT00095719,Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia,,Completed,No Results Available,Dementia|Alzheimer's Disease,Drug: Aripiprazole|Drug: Placebo,tolerability|safety assessments,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical",All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 3,125,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CN138-131,Dec-03,Mar-05,Mar-05,9-Nov-04,null,11-Nov-13,"Local Institution, Santa Ana, California, United States|Local Institution, Hamden, Connecticut, United States|Local Institution, Hialeah, Florida, United States|Local Institution, Miami, Florida, United States|Local Institution, North Miami, Florida, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, New York, New York, United States|Local Institution, Staten Island, New York, United States|Local Institution, Dayton, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Tulsa, Oklahoma, United States|Local Institution, Hershey, Pennsylvania, United States|Local Institution, Austin, Texas, United States|Local Institution, Midvale, Utah, United States",,https://ClinicalTrials.gov/show/NCT00095719
NCT00093951,SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD),,Completed,No Results Available,Alzheimer's Disease,Drug: SGS742,,Saegis Pharmaceuticals|National Institute on Aging (NIA),All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,280,Industry,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,IA0061,Apr-04,Sep-07,Sep-07,8-Oct-04,null,11-Dec-09,"Phoenix, Arizona, United States|Dedicated Clinical Research, Sun City, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Clinical Trials Incorporated, Little Rock, Arkansas, United States|Margolin Brain Institute, Fresno, California, United States|NervePro Research, Irvine, California, United States|Center for Neurologic Studies, La Jolla, California, United States|Neuro Therapeutics, Inc., Pasadena, California, United States|Pacific Research Network, Inc., San Diego, California, United States|Affiliated Research Institute, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Southern California Clinical Research, Inc., San Marino, California, United States|The Mile High Research Center, Denver, Colorado, United States|Research Center for Clinical Studies, Inc., Darien, Connecticut, United States|Stamford, Connecticut, United States|Baumel-Eisner Neuromedical Institute, Inc., Boca Raton, Florida, United States|Bradenton Neurology, Inc., Bradenton, Florida, United States|Brain Matters, Inc., Delray Beach, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami Beach, Florida, United States|Allied Clinical Trials, The Neurology Group, Miami, Florida, United States|Tukoi Institute for Clinical Research, Miami, Florida, United States|Ocala Neurodiagnostic Center, Ocala, Florida, United States|Orange City, Florida, United States|Palm Springs, Florida, United States|Pompano Beach, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|CSI Research, Decatur, Georgia, United States|DeKalb Neurology Associates, LLC, Decatur, Georgia, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, United States|Neurology Department, LSU Health Sciences Center, Shreveport, Louisiana, United States|Baystate Medical Center, Springfield, Massachusetts, United States|SW Medical Associates, Las Vegas, Nevada, United States|Manchester, New Jersey, United States|Psychopharmacology Research Association of Princeton, P.C., Princeton, New Jersey, United States|United Health Services Office of Clinical Trials, Johnson City, New York, United States|New York, New York, United States|Raleigh Neurology, Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|University Memory and Aging Center, Cleveland, Ohio, United States|Toledo, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Eugene, Oregon, United States|Medford, Oregon, United States|Bala Cynwyd, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|RI Mood & Memory Research Institute, E Providence, Rhode Island, United States|Madison, Tennessee, United States|Senior Adults Specialty Research, Inc., Austin, Texas, United States|Claghorn-Lesem Research Clinic, Ltd., Bellaire, Texas, United States|Radiant Research San Antonio, San Antonio, Texas, United States|Texas Medical Research Associates, LLC, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Bennington, Vermont, United States|National Clinical Research, Inc., Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00093951
NCT00090116,The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Neramexane,,Forest Laboratories,All,"50 Years and older   (Adult, Older Adult)",Phase 3,400,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NER-MD-02,Mar-03,Mar-05,Mar-05,26-Aug-04,null,5-Mar-12,"Pivotal Research Centers, Peoria, Arizona, United States|21st Century Neurology, Phoenix, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Pharmacology Research Institute, Northridge, California, United States|UCI Medical Center, Orange, California, United States|Pacific Research Network, San Diego, California, United States|Affiliated Research Institute, San Diego, California, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Baumel-Eisner Neuromedical Institute, Fort Lauderdale, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Neurology Clinical Research, Inc., Plantation, Florida, United States|University of South Florida, Tampa, Florida, United States|Palm Beach Neurology, West Palm Beach, Florida, United States|Indiana Universisty Medical Center, Indianapolis, Indiana, United States|Lexington Clinic, Lexington, Kentucky, United States|J. Gary Booker, MD, Shreveport, Louisiana, United States|Mood and Memory Clinic of Michigan, Farmington Hills,, Michigan, United States|St. Louis University, St. Louis, Missouri, United States|Alzheimer's Research Corporation, Lakehurst, New Jersey, United States|Joel Ross, MD, Long Branch, New Jersey, United States|Ubhc/Umdnj, Piscataway, New Jersey, United States|Upstate Clinical Research, Albany, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|Monroe Community Hospital, Rochester, New York, United States|Behavioral Medical Research of Saten Island, PC, Staten Island, New York, United States|Piedmont Medical Research, Winston Salem, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Summit Research Network, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|North Texas Neurology Research, Wichita, Texas, United States|Pioneer Pharmaceutical Research, Midvale, Utah, United States",,https://ClinicalTrials.gov/show/NCT00090116
NCT00090402,Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease,,Completed,Has Results,Alzheimer's Disease|Oxidative Stress|Dementia|Hyperlipidemia|Inflammation,Dietary Supplement: Fish Oil|Dietary Supplement: Lipoic Acid|Other: Fish Oil Placebo|Other: Lipoic Acid Placebo,F2-isoprostane Level Urine F2-Isoprostanes|Change in Mini-Mental State Exam (MMSE) Score From Baseline to 12 Months|Change in Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL) Scores From Baseline to 12 Months,Oregon Health and Science University|National Institute on Aging (NIA)|National Center for Research Resources (NCRR),All,"55 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,39,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IA0062|1R21AG023805-01|5R21AG023805-02|AG08017|M01RR000334,Apr-04,3-Jan-06,Aug-07,26-Aug-04,26-Feb-10,21-Jul-17,"Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00090402
NCT00088673,Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease,,Unknown status,No Results Available,Alzheimer Disease,Drug: 3APS,"The two primary efficacy parameters are the change from baseline to month 18 in the Alzheimer's Disease Assessment Scale, cognitive subpart (ADAS-cog) and the clinical Deterioration Scale Sum of Boxes (CDR-SB) scores.|The brain volume change from baseline as measured by Magnetic Resonance Imaging will also be assessed.",Bellus Health Inc,All,"50 Years and older   (Adult, Older Adult)",Phase 3,950,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CL-758007,Jun-04,null,null,3-Aug-04,null,28-Feb-07,"Pivotal Research Centers, Peoria, Arizona, United States|21st Century Neurology, a division of Xenoscience, Phoenix, Arizona, United States|Central Arkansas Research, Hot Springs, Arkansas, United States|Margolin Brain Institute, Fresno, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Pacific Research Network, Inc., San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Radiant Research, Denver, Colorado, United States|Research Center for Clinical Studies, Inc., Darien, Connecticut, United States|Yale University, Alzheimer's Disesase Research Unit, New Haven, Connecticut, United States|New England Research Institute, Stamford, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Neuropsychiatric Research Center of SouthWest Florida, Fort Myers, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Tukoi Institute for Clinical Research, Miami, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Quantum Laboratories Inc at the Memory Disorders Clinic, North Broward Medical Center, Pompano Beach, Florida, United States|Axiom Clinical Research, Tampa, Florida, United States|Byrd Alzheimer’s Center and Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|University of South Florida, Suncoast Gerontology Center, Tampa, Florida, United States|Premiere Research Institute Palm Beach Neurology, West Palm Beach, Florida, United States|Comprehensive Neurology Specialists, PC, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Southern Illinois University (SIU) School of Medicine, Department of Neurology, Springfield, Illinois, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Mood & Memory Clinic - Dr Aronson, Farmington Hills, Michigan, United States|Memory Enhancement Center, Long Branch, New Jersey, United States|Neurological Associates of Albany, Albany, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|NYU School of Medicine, New York, New York, United States|Global Research and Consulting, Olean, New York, United States|Nathan S. Kline Institute, Orangeburg, New York, United States|University of Rochester-Program in Neurobehavioral Therapeutics, Rochester, New York, United States|Richard H. Weisler, MD, PA and Associates, Raleigh, North Carolina, United States|Wake Forest University School of Medicine, Department of Psychiatry and Behavioral Medicine, Winston-Salem, North Carolina, United States|University Memory and Aging Center, Cleveland, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Clinical Pharmaceuticals Trials, Inc., Tulsa, Oklahoma, United States|CNS Research Institute, Philadelphia, Pennsylvania, United States|Farber Institute for Neurosciences, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh ADRC, Pittsburgh, Pennsylvania, United States|CNS Research, Inc., East Providence, Rhode Island, United States|Memory and Aging Program, Butler Hospital, Providence, Rhode Island, United States|MUSC - Alzheimer's Research and Clinical Programs, North Charleston, South Carolina, United States|Clinical Research Services at Tennessee Christian Medical Center, Madison, Tennessee, United States|University of Texas Mental Sciences Institute, Houston, Texas, United States|Air Force Villages-Freedom House Research (Study open to Air Force Village residents only), San Antonio, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|Calgary, Alberta, Canada|The Medical Arts Health Research Group, a Division of PCT Networks, Inc., Penticton, British Columbia, Canada|St. Joseph's Hospital, Saint-John, New Brunswick, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Queen's University, Kingston, Ontario, Canada|Geriatric Clinical Trials Group, Parkwood Hospital, London, Ontario, Canada|Ottawa, Ontario, Canada|Gerontion Research, Toronto, Ontario, Canada|Sunnybrook and Women's College Health Science Centre, Toronto, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Recherche Clinique de Neurologie, Montreal, Quebec, Canada|Jewish General Hospital- Memory Clinic, Montreal, Quebec, Canada|Centre de recherche Novabyss, Sherbrooke, Quebec, Canada|McGill Centre for Studies in Aging, Verdun (Montreal), Quebec, Canada|Hôpital de l'Enfant-Jésus, Ville de Quebec, Quebec, Canada|Memory & Motor Skills Disorders Clinic, Ville de Québec, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00088673
NCT00088387,Effect of Lithium and Divalproex in Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Drug: Divalproex|Drug: Lithium,,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 2,35,NIH,Interventional,Primary Purpose: Treatment,040243|04-N-0243,Jul-04,null,Mar-05,26-Jul-04,null,4-Mar-08,"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00088387
NCT00087789,CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF,Safety and tolerability of three different doses of CERE-110 in subjects with mild to moderate Alzheimer's disease,Ceregene|Sangamo Therapeutics,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,10,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CERE-110-01,Jun-04,May-10,May-10,16-Jul-04,null,31-Oct-16,"University of California San Diego, San Diego, California, United States|Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00087789
NCT00087724,A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: FK962,,"Astellas Pharma Inc|Astellas Pharma US, Inc.",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,510,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,03-0-189,Jul-04,null,Sep-06,14-Jul-04,null,7-Jun-12,"Investigational Site, Phoenix, Arizona, United States|Investigational Site, Phoenix, Arizona, United States|Sun City, Arizona, United States|Investigational Site, Tucson, Arizona, United States|Investigational Site, Little Rock, Arkansas, United States|Investigational Site, Little Rock, Arkansas, United States|Investigational Site, Fresno, California, United States|Investigational Site, Irvine, California, United States|Investigational Site, Orange, California, United States|Investigational Site, San Francisco, California, United States|Investigational Site, Sherman Oaks, California, United States|Investigational Site, Torrance, California, United States|Investigative Site, Denver, Colorado, United States|Investigational Site, Denver, Colorado, United States|Investigational Site, Darien, Connecticut, United States|Investigational Site, Hamden, Connecticut, United States|Hamden, Connecticut, United States|Investigational Site, Stamford, Connecticut, United States|Investigational Site, Fort Myers, Florida, United States|Investigational Site, Hialeah, Florida, United States|Investigational Site, Hollywood, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, North Miami, Florida, United States|Investigational Site, Ocala, Florida, United States|Investigational Site, Port Charlotte, Florida, United States|Investigational Site, Sarasota, Florida, United States|Investigational Site, Sebring, Florida, United States|Investigational Site, Tampa, Florida, United States|West Palm Beach, Florida, United States|Investigational Site, Snellville, Georgia, United States|Snellville, Georgia, United States|Investigational Site, Elk Grove, Illinois, United States|Investigational Site, Wichita, Kansas, United States|Investigational Site, New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Investigational Site, Newton, Massachusetts, United States|Livonia, Michigan, United States|Hattiesburg, Mississippi, United States|Investigational Site, St. Louis, Missouri, United States|Investigational Site, Las Vegas, Nevada, United States|Investigational Site, Long Branch, New Jersey, United States|Investigational Site, Manchester, New Jersey, United States|Investigational Site, Piscataway, New Jersey, United States|Investigational Site, Albuquerque, New Mexico, United States|Investigational Site, Albany, New York, United States|Investigational Site, Buffalo, New York, United States|Investigational Site, Lawrence, New York, United States|Investigational Site, New York, New York, United States|Investigational Site, White Plains, New York, United States|Charlotte, North Carolina, United States|Investigational Site, Centerville, Ohio, United States|Investigational Site, Columbus, Ohio, United States|Dayton, Ohio, United States|Investigational Site, Dayton, Ohio, United States|Investigational Site, Toledo, Ohio, United States|Investigational Site, Oklahoma City, Oklahoma, United States|Investigational Site, Tulsa, Oklahoma, United States|Investigational Site, Eugene, Oregon, United States|Investigational Site, Medford, Oregon, United States|Investigational Site, Bala Cynwyd, Pennsylvania, United States|Investigational Site, Jenkintown, Pennsylvania, United States|Investigational Site, Pawtucket, Rhode Island, United States|Investigational Site, Johnson City, Tennessee, United States|Investigational Site, Nashville, Tennessee, United States|Investigational Site, Houston, Texas, United States|Investigational Site, San Antonio, Texas, United States|Investigational Site, Wichita Falls, Texas, United States|Investigational Site, Salt Lake City, Utah, United States|Investigational Site, Bennington, Vermont, United States|Burlington, Vermont, United States|Investigational Site, Norfolk, Virginia, United States|Investigational Site, Milwaukee, Wisconsin, United States|Investigational Site, Kelowna, British Columbia, Canada|Investigational Site, Penticton, British Columbia, Canada|Investigational Site, Victoria, British Columbia, Canada|Investigational Site, Sydney, Nova Scotia, Canada|Investigational Site, Barrie, Ontario, Canada|Investigational Site, North York, Ontario, Canada|Investigational Site, North York, Ontario, Canada|Investigational Site, Ottawa, Ontario, Canada|Investigational Site, Sudbury, Ontario, Canada|Investigational Site, Toronto, Ontario, Canada|Investigational Site, Willowdale, Ontario, Canada|Investigational Site, Regina, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT00087724
NCT00086138,Depression in Alzheimer's Disease-2,DIADS-2,Completed,Has Results,Alzheimer's Disease|Depression,Drug: Sertraline (Zoloft)|Drug: Placebo,Modfied Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (mADCS-CGIC)|Remission According to Cornell Scale for Depression in Dementia Scale,Johns Hopkins University|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,131,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",U01MH066136|DATR A4-GPX,Jul-04,Jul-08,Jul-09,28-Jun-04,11-Apr-17,11-Apr-17,"University of Southern California, Los Angeles, California, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Rochester, Rochester, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, North Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00086138
NCT00083421,Effects of ONO-2506PO in Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: ONO-2506PO,Cognitive Function Scale|Global Function Scale|ADL Scale|Psychiatric Symptom Scale,Ono Pharma USA Inc|Ono Pharmaceutical Co. Ltd,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,647,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,ONO-2506POU010,Jun-04,null,Jul-07,18-Jun-04,null,13-Jun-12,"Kirkland Clinic, Birmingham, Alabama, United States|Alzheimers Disease Research Center, Birmingham, Alabama, United States|Pivotal Research Center, Mesa, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|UCI Medical Center Neuropsychiatric Center, Orange, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|The Southwest Institute for Clinical Research, Inc, Rancho Mirage, California, United States|Hamid Rabiee, MD, Redding, California, United States|Alzheimers Disease Research Center, Univ of CA, San Diego, San Diego, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Apex Research Institute, Santa Ana, California, United States|Pacific Neuroscience Medical Group, Santa Barbara, California, United States|Neurological Research Institute, Santa Monica, California, United States|Radiant Research, Denver, Colorado, United States|Research Center for Clinical Studies, Inc., Darien, Connecticut, United States|GAP Clinical Care & Research Center, Hamden, Connecticut, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Florida, United States|Neurologic Consultants, Ft. Lauderdale, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Florida, United States|Gainsville Open MRI, Gainsville, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami Beach, Florida, United States|Miami Jewish and Hospital for the Aged, Miami, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Research Site, Port Charlotte, Florida, United States|Suncoast Neuroscience Associates, St. Petersburg, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|DeKalb Neurology Associates, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Mercer University, Atlanta, Georgia, United States|Rush Alzheimers Disease Center, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Radiant Research, Hoffman Estates, Illinois, United States|Southern Illinois School of Medicine, Springfield, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Center for Alzheimers Disease and Related Disorders, Indianapolis, Indiana, United States|Agewell, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Cntr - Dept of Psychiatry, New Orleans, Louisiana, United States|J. Gary Booker, M.D., APMC, Shreveport, Louisiana, United States|St. Louis University Medical Center, St. Louis, Missouri, United States|University of Nevada, Las Vegas, Nevada, United States|Meridian Institue for Aging, Manchester, New Jersey, United States|Mid Atlantic Geriatric Association, Ocean Township, New Jersey, United States|St. Francis Medical Center, Trenton, New Jersey, United States|Upstate Clinical Reserach, LLC, Albany, New York, United States|Upstate Neurology Consults, LLP, Albany, New York, United States|Neurological Associates of Albany, Albany, New York, United States|Neurobehavioral Research Inc., Lawrence, New York, United States|Eastside Comprehensive Medical Services, New York, New York, United States|Global Reserach & Consulting, Olean, New York, United States|Monroe Community Hospital, Rochester, New York, United States|Behavioral Medical Research, Staten Island, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Metrohealth Medical Center, Cleveland, Ohio, United States|Ohio State University Hospital, Columbus, Ohio, United States|Infinity Research Group, LLC, Oklahoma City, Oklahoma, United States|Clinical Pharmaceutical Trials, Tulsa, Oklahoma, United States|Medford Neurological and Spine Clinic, Medford, Oregon, United States|Summit Research Network, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Westmoreland Neurology Associates, Inc., Greensburg, Pennsylvania, United States|University of PA, Section Geriatric Psychiatry, Philadelphia, Pennsylvania, United States|Alzheimer Disease Research Center, Univ of Pittsburg, Pittsburg, Pennsylvania, United States|Miriam Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Alzheimers Research and Clinical Programs, North Charleston, South Carolina, United States|Claghorn Lesem Research Clinic, Bellaire, Texas, United States|Memory Research Unit, Univ of Texas Southwest Med Ctr at Dallas, Dallas, Texas, United States|Radiant Research San Antonio, San Antonio, Texas, United States|Neurological Consultants, PC, Bennington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|Medical College of Wisconsin, Department of Neurology, Milwaukee, Wisconsin, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Inova Health Research, Inc., Kelowna, British Columbia, Canada|University of British Columbia Hospital, Vancouver, British Columbia, Canada|Davidson Memory Clinic, Moncton, New Brunswick, Canada|Parkwood Hospital, Geriatric Medicine, London, Ontario, Canada|SCO Health Centre, Ottawa, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT00083421
NCT00083590,Huperzine A in Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Drug: Huperzine A,,National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS)|Neuro-Hitech,All,"55 Years and older   (Adult, Older Adult)",Phase 2,150,NIH|Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"IA0052|ADC-023|IND 63,997",Apr-04,Nov-07,Nov-07,27-May-04,null,21-Feb-08,"University of Alabama, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, Alzheimer's Disease Research Center, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States|Howard University School of Medicine, Washington, DC, District of Columbia, United States|Georgetown University Medical Center, Memory Disorders Program, Washington, District of Columbia, United States|MD Clinical, Fort Lauderdale, Florida, United States|Roskamp Institute Memory Clinic, Tampa, Florida, United States|University of South Florida, Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, United States|ICPS Group, Boston, Massachusetts, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, United States|Albany Medical Center, Albany, New York, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Vermont College of Medicine, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00083590
NCT00082602,Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: galantamine ER,The primary end point occurs at Week 8. The primary outcome measures will be tolerability and safety through rates of adverse events.|The secondary end point occurs at Week 12. The secondary outcome measure will be the Mini Mental State Examination score.,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc.",All,"60 Years and older   (Adult, Older Adult)",Phase 3,83,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR004699,May-04,null,Apr-05,17-May-04,null,20-May-11,,,https://ClinicalTrials.gov/show/NCT00082602
NCT00076440,Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study,,Completed,No Results Available,Alzheimer Disease,Drug: Leuprolide acetate,,Voyager Pharmaceutical Corporation|National Institute on Aging (NIA),Male,65 Years and older   (Older Adult),Phase 2,90,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,IA0051,Dec-03,Mar-07,Mar-07,26-Jan-04,null,11-Dec-09,"Margolin Brain Institute, Fresno, California, United States|Bay Area Research Institute, Lafayette, California, United States|Southwest Clinical Research, Rancho Mirage, California, United States|Geriatric and Adult Psychiatry LLC, Hamden, Connecticut, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami Beach, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|Middleton VA Wisconsin Alzheimer's Institute, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00076440
NCT00074529,Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED),,Completed,No Results Available,Alzheimer's Disease,Drug: MK0677,Cognitive function over 12 month period; safety and tolerability|AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.,Merck Sharp & Dohme Corp.,All,"50 Years and older   (Adult, Older Adult)",Phase 2,512,Industry,Interventional,"Allocation: Randomized|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0677-030|Formally-BG0812AZ|MK0677-030|2006_412,Oct-03,Jan-06,Jan-06,16-Dec-03,null,24-Jul-15,,,https://ClinicalTrials.gov/show/NCT00074529
NCT00073658,Treating Behavioral Disturbances in Individuals With Dementia,,Completed,No Results Available,Dementia,Drug: Citalopram|Drug: Risperidone,,University of Pittsburgh|National Institute of Mental Health (NIMH),All,"50 Years and older   (Adult, Older Adult)",Phase 2,137,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R01MH059666-02|DSIR GT-GP,Jan-00,Jun-05,Jun-05,3-Dec-03,null,10-Mar-14,"University of Pittsburgh Medical Center/Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00073658
NCT00071721,Valproate in Dementia (VALID),,Completed,Has Results,Alzheimer Disease,Drug: Valproate|Drug: Placebo,"Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change Rated by the Study Clinician|Cognitive Performance Assessed by the Alzheimer's Disease Assessment Scale-cognitive Subtest (ADAS-cog)|Functional Performance Assessed by the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory|Global Severity of Dementia Using the CDR Sum of Boxes|Agitation Measured by the Cohen-Mansfield Agitation Inventory (CMAI), Community Version|Participant's Clinical Condition or Endpoint Assessed With the ADCS-Clinical Global Impression of Change (ADCS-CGIC)",Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA),All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,313,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0043|1RC2AG036535|IND 67,222|ADCS Protocol ADC-022-VN",Oct-03,Feb-09,Dec-09,31-Oct-03,20-Oct-10,25-Sep-14,"Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, ADRC, San Diego, La Jolla, California, United States|VA Healthcare System Long Beach, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|University of California ADRC, Los Angeles, California, United States|University of California, LA (Olive View), Los Angeles, California, United States|Pacific Research Network, San Diego, California, United States|Stanford University, VA Aging Clinical Research Center, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, DC, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|Wein Center, Mount Sinai Medical Center, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Byrd Institute, Tampa, Florida, United States|Premier Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas, Kansas City, Kansas, United States|Lahey Clinic, Research Neurology, Burlington, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|St. Louis University, St. Louis, Missouri, United States|University of Nevada, Las Vegas, Nevada, United States|Albany Medical Center, Albany, New York, United States|Dent Neurologic Institute, Amherst, New York, United States|New York University Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|Global Research and Consulting, Olean, New York, United States|University of Rochester, Rochester, New York, United States|Syracuse VA Medical Center, Syracuse, New York, United States|North East Ohio Health Services, Beachwood, Ohio, United States|Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Memorial Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina-Columbia, Columbia, South Carolina, United States|Medical University of South Carolina-Florence, Florence, South Carolina, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Psychiatric Consultants, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Southwestern Vermont Medical Center, Bennington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00071721
NCT00069849,A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease,,Terminated,No Results Available,Alzheimer's Disease,Drug: ABT-089,MMSE,Abbott,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,64,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,M03-614,Jul-03,null,null,2-Oct-03,null,4-Sep-06,"Fresno, California, United States|San Diego, California, United States|Orlando, Florida, United States|West Palm Beach, Florida, United States|Florence, Kentucky, United States|Portland, Oregon, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00069849
NCT00066157,Alzheimer's Disease: Therapeutic Potential of Estrogen,,Completed,No Results Available,Alzheimer Disease,Drug: Transdermal estradiol|Drug: Medroxyprogesterone|Drug: Placebo Patch|Drug: Placebo,"Cognition: delayed recall on Buschke Selective Reminding Test; Stroop Interference condition--completion time and errors; Clinician-rated Interview Based Impression of Change|Skills of Independent Living: Physical functioning Performance (PFP)|Bioassays (Estradiol, estrone, medroxyprogesterone, FSH, influence of ApoE genotype in responsivity to estrogen)","University of Wisconsin, Madison|National Institute on Aging (NIA)",Female,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,42,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2001-477|R01AG017196-03|FDA IRB approval M1285|NIH grant AG17196-03|IA0048,Sep-01,Dec-07,Dec-07,5-Aug-03,null,23-Aug-18,"University of Wisconsin Memory Research Program, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00066157
NCT00065767,Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Drug: Raloxifene,,"University of Wisconsin, Madison|National Institute on Aging (NIA)",Female,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,20,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,IA0049|1R01AG029624-01|IRB M1285,Sep-01,Mar-05,Mar-05,4-Aug-03,null,5-Oct-15,"University of Wisconsin Memory Research Program, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00065767
NCT00065689,High Intensity Light Therapy in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Dementia,Device: high-intensity light therapy,,National Center for Complementary and Integrative Health (NCCIH),All,"55 Years and older   (Adult, Older Adult)",Phase 3,107,NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Treatment,R01AT000212-01A1|SloaneP,Mar-03,null,Sep-05,1-Aug-03,null,26-Jul-06,"John Umstead Hospital, Butner, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00065689
NCT00065169,Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs,,Completed,No Results Available,Alzheimer Disease|Dementia,Drug: Celecoxib,,"University of California, Los Angeles|National Institute of Mental Health (NIMH)",All,"40 Years to 90 Years   (Adult, Older Adult)",Not Applicable,138,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,R01MH058156|DSIR AT-GP,Nov-00,Nov-05,Nov-05,18-Jul-03,null,16-Oct-18,"UCLA Neuropsychiatric Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00065169
NCT00063310,ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation,,Completed,No Results Available,Alzheimer Disease,Drug: Leuprolide acetate,,Voyager Pharmaceutical Corporation|National Institute on Aging (NIA),Female,65 Years and older   (Older Adult),Phase 2,90,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"IA0047|IND 66,415",Mar-03,Feb-06,Feb-06,26-Jun-03,null,11-Dec-09,"Sun Health Research Institute, Sun City, Arizona, United States|Baumel-Eisner Neuromedical Institute, Fort Lauderdale, Florida, United States|Meridien Research, St. Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT00063310
NCT00062569,Bathing Persons With Alzheimer's Disease aT Home (The BATH Study),,Completed,No Results Available,Alzheimer Disease,Behavioral: Bathing Support Intervention (BSI)|Behavioral: Caregiver reminiscence with coaching,Care Recipient: Resistiveness to care; discomfort|Caregiver: Self-efficacy; interactive behaviors|Caregiver burden & satisfaction,National Institute of Nursing Research (NINR),All,"60 Years and older   (Adult, Older Adult)",Not Applicable,90,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),IA0044|R01NR007893-01A1,Sep-02,Jun-06,Jun-06,12-Jun-03,null,12-Mar-09,"Boston College, William F. Connell School of Nursing, Chestnut Hill, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00062569
NCT00056628,COGNIShunt® System for Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Device: The COGNIShunt® System,,Eunoe|National Institute on Aging (NIA),All,"62 Years to 85 Years   (Adult, Older Adult)",Phase 3,250,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,IA0040|Eunoe protocol ID 2000-01|IDE G970117,Jan-01,null,Oct-04,20-Mar-03,null,12-Sep-06,,,https://ClinicalTrials.gov/show/NCT00056628
NCT00056524,Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter),,Completed,No Results Available,Alzheimer's Disease|Stroke|Parkinson's Disease|Traumatic Brain Injury,Drug: AVP-923,emotional control,Avanir Pharmaceuticals,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,600,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,02-AVR-107|AVP-923,Feb-03,Jun-07,Jun-07,18-Mar-03,null,14-Jul-16,"Barrow Neurological Institute, Phoenix, Arizona, United States|Center for Neurologic Study, La Jolla, California, United States|UCLA School of Medicine, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Research Center for Clinical Studies, Inc., Darien, Connecticut, United States|George Washington University Medical Faculty Assoc., Washington, District of Columbia, United States|Neurological Associates, Ft. Lauderdale, Florida, United States|University of Miami Dept. of Neurology, Miami, Florida, United States|Miami Jewish Home & Hospital for the Aged, Miami, Florida, United States|Allied Clinical Trials, Miami, Florida, United States|Renstar Medical Research, Plantation, Florida, United States|Suncoast Neuroscience Associates Inc., St. Petersburg, Florida, United States|Tampa, Florida, United States|Neurology & Headache Specialist of Atlanta, L.L.C., Decatur, Georgia, United States|Consultants in Neurology LTD, Northbrook, Illinois, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|Neurological Associates, P.C., Lincoln, Nebraska, United States|Upstate Clinical Research, Albany, New York, United States|DENT Neurologic Group L.L.P., Amherst, New York, United States|Hospital for Joint Diseases MS Care Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, PA, Raleigh, North Carolina, United States|NeuroCare Center, Inc., Canton, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|University Memory and Aging Center, Cleveland, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Clinical Pharmaceutical Trials, Inc., Tulsa, Oklahoma, United States|Lehigh Valley Neurosciences and Pain Research Center, Allentown, Pennsylvania, United States|Westmoreland Neurology, Greensburg, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|MCP-Hahnemann University, Philadelphia, Pennsylvania, United States|Penn Neurological Institute, Philadelphia, Pennsylvania, United States|Neurological Associates of Delaware Valley, Upland, Pennsylvania, United States|Claghorn-Lesem Research Clinic, Bellaire, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Neurology and Neurosurgery Associates of Tacoma, Tacoma, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00056524
NCT00056329,Vitamin E in Aging Persons With Down Syndrome,,Unknown status,No Results Available,Down Syndrome|Alzheimer Disease,Drug: Vitamin E|Drug: multivitamin|Drug: Placebo,"Brief Praxis Test, measuring cognitive functions expressed as performances of simple, short, sequences of voluntary movements|Fuld Object Memory Test (Modified), New Dot Test, Orientation Test, Vocabulary Test, Behavior & Function Down Syndrome Rating Scale, Clinical Global Impression of Change (CGI-C)",New York State Institute for Basic Research|National Institute on Aging (NIA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Complementary and Integrative Health (NCCIH),All,"50 Years and older   (Adult, Older Adult)",Phase 3,350,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IA0039|R01AG016381|NIA Grant AG16381,Apr-02,May-12,May-12,12-Mar-03,null,4-May-12,"University of Connecticut Health Center, Farmington, Connecticut, United States|Roskamp Institute Memory Clinic, Tampa, Florida, United States|Institute for the Study of Disadvantage and Disability, Atlanta, Georgia, United States|May South, Inc., Atlanta, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Third Age, Inc., Lexington, Kentucky, United States|McLean Hospital, Belmont, Massachusetts, United States|Clinical Research Center of New Jersey, Voorhees, New Jersey, United States|University at Albany, SUNY, Albany, New York, United States|Nathan Kline Institute, Orangeburg, New York, United States|George Jervis Clinic, Staten Island, New York, United States|Westchester Institute for Human Development, Valhalla, New York, United States|University Memory and Aging Center, Case Western Reserve University, Cleveland, Ohio, United States|Centre for Developmental Disabilities Studies, Ryde, New South Wales, Australia|Down Syndrome Research Foundation, Port Coquitlam, British Columbia, Canada|Surrey Place Centre, Toronto, Ontario, Canada|Saskatoon City Hospital, Saskatoon, Saskatchewan, Canada|University of Cambridge, Cambridge, England, United Kingdom|Greenfields Monyhull Hospital, Kings Norton, Birmingham, England, United Kingdom|Kings College: London, London, England, United Kingdom|Mercer Institute for Research on Ageing, St. James Hospital, Dublin, Ireland, United Kingdom",,https://ClinicalTrials.gov/show/NCT00056329
NCT00056225,VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study),,Completed,No Results Available,Alzheimer's Disease,Drug: Folate|Drug: Vitamin B6|Drug: Vitamin B12,,National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS),All,"55 Years and older   (Adult, Older Adult)",Phase 3,340,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,IA0041,Jan-03,Jun-07,Jun-07,10-Mar-03,null,12-Jun-09,"University of Alabama, Birmingham, Alabama, United States|Mayo Clinic, Scottsdale, Scottsdale, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona, Arizona Health Sciences Center, Tucson, Arizona, United States|University of California, Irvine, Institute for Brain Aging and Dementia, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California, Davis, Sacramento, California, United States|Yale University, New Haven, Connecticut, United States|Georgetown University, Washington, DC, District of Columbia, United States|Howard University, Washington, DC, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush Presbyterian/St. Lukes Medical Center, Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Nevada School of Medicine, Center for Cognitive Aging, Las Vegas, Nevada, United States|ClinSearch, Kenilworth, New Jersey, United States|New York University Medical Center, New York, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Alzheimer's Disease Center, Rochester, New York, United States|University Memory and Aging Center, Case Western Reserve University/University Hospitals of Cleveland, Cleveland, Ohio, United States|Oregon Health and Science University, Oregon Aging and Alzheimer's Disease Center, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Memorial Hospital of Rhode Island, Alzheimer's Disease and Memory Disorder Clinic, Pawtucket, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas, Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00056225
NCT00053599,Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study,,Completed,No Results Available,Alzheimer Disease,Drug: Simvastatin,,National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS),All,"50 Years and older   (Adult, Older Adult)",Phase 3,400,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,IA0038|ADC-015-LL,Dec-02,Oct-07,Oct-07,4-Feb-03,null,28-Jul-09,"University of Alabama, Birmingham, Birmingham, Alabama, United States|Barrow Neurology Group, Phoenix, Arizona, United States|Arizona Health Sciences Center, University of Arizona, Tucson, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Stanford University/VA Aging Clinical Research Center, Palo Alto, California, United States|University of California, Davis, Sacramento, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Memory Disorder Program, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Baumel Eisner Neuromedical Institute, Boca Raton, Florida, United States|Mayo Clinic (Jacksonville), Jacksonville, Florida, United States|Wein Center, Miami Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Rush University, Chicago, Illinois, United States|Indiana University Alzheimer's Center, Indianapolis, Indiana, United States|University of Kentucky, Sanders-Brown Center on Aging, Lexington, Kentucky, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan at Ann Arbor, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|St. Louis University, St. Louis, Missouri, United States|Washington University, St. Louis School of Medicine, St. Louis, Missouri, United States|SUNY Downstate, Brooklyn, New York, United States|New York University School Of Medicine, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Stony Brook, Stonybrook, New York, United States|Neurological Care of NY, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Memory and Aging Center, Case Western Reserve University/University Hospitals of Cleveland, Cleveland, Ohio, United States|Oregon Health and Sciences University, Portland, Oregon, United States|University of Pennsylvania School of Medicine, Alzheimer's Disease Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Brown University-Memorial Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas, Southwestern Medical School, Dallas, Texas, United States|Baylor College of Medicine, Alzheimer's Disease Research Center, Houston, Texas, United States|Southwestern Vermont Medical Center, Bennington, Vermont, United States|University of Washington at Seattle, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00053599
NCT00051909,Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: LY451395,,Eli Lilly and Company,All,"50 Years and older   (Adult, Older Adult)",Phase 2,200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,6764|H6N-MC-LEAM,Nov-02,null,Jun-03,20-Jan-03,null,19-Jul-06,"Beverly Hills, California, United States|Fresno, California, United States|Boca Raton, Florida, United States|Fort Lauderdale, Florida, United States|Miami Beach, Florida, United States|Boston, Massachusetts, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Wichita Falls, Texas, United States",,https://ClinicalTrials.gov/show/NCT00051909
NCT00046358,"The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease",,Completed,No Results Available,Alzheimer Disease,Drug: Lovostatin|Drug: Ibuprofen,,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 4,50,NIH,Interventional,Primary Purpose: Treatment,020305|02-M-0305,Sep-02,null,Aug-05,27-Sep-02,null,4-Mar-08,"National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00046358
NCT00042172,Treatment for Early Memory Loss,,Completed,No Results Available,Cognition Disorders|Alzheimer Disease,Drug: Donepezil|Drug: Ginkgo Biloba Extract,,University of Iowa|National Institute of Mental Health (NIMH),All,65 Years and older   (Older Adult),Phase 4,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R21MH061801|DSIR AT-GP,Jun-02,Sep-04,Sep-04,26-Jul-02,null,3-Mar-14,"University of Iowa Department of Psychiatry, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT00042172
NCT00041678,Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type,,Completed,No Results Available,Alzheimer Disease,Drug: aripiprazole,,"Otsuka Pharmaceutical Development & Commercialization, Inc.",All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 3,null,Industry,Interventional,Primary Purpose: Treatment,CN138-005,Jan-00,Mar-03,Mar-03,15-Jul-02,null,11-Nov-13,"Local Institution, Rosemead, California, United States|Local Institution, Miami, Florida, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Bennington, Vermont, United States|Local Institution, Burlington, Vermont, United States|Local Institution, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00041678
NCT00040443,Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.,,Completed,Has Results,Mild Cognitive Impairment,Drug: CX516|Drug: Placebo,15-Item Word List Delayed Recall,RespireRx,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,175,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CORX-CX516-012.1,Apr-02,Aug-03,Jun-04,28-Jun-02,23-Jul-18,23-Jul-18,"Pivotal Research Centers, Peoria, Arizona, United States|University of California Irvine, Irvine, California, United States|University of California at Los Angeles, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Sun Coast Gerontology Center, University of South Florida, Tampa, Florida, United States|Mercy Mayo Clinic, Des Moines, Iowa, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00040443
NCT00036114,Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type,,Completed,No Results Available,Alzheimer Disease,Drug: aripiprazole,,"Otsuka Pharmaceutical Development & Commercialization, Inc.",All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 3,null,Industry,Interventional,Primary Purpose: Treatment,CN138-004,Mar-00,Aug-03,Aug-03,9-May-02,null,11-Nov-13,"Local Institution, Tuscaloosa, Alabama, United States|Local Institution, Scottsdale, Arizona, United States|Local Institution, Cerritos, California, United States|Local Institution, Granada Hills, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, San Diego, California, United States|Local Institution, Torrance, California, United States|Local Institution, Denver, Colorado, United States|Local Institution, Hamden, Connecticut, United States|Local Institution, Miami, Florida, United States|Local Institution, North Miami Beach, Florida, United States|Local Institution, West Palm Beach, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Augusta, Georgia, United States|Local Institution, Macon, Georgia, United States|Local Institution, Honolulu, Hawaii, United States|Local Institution, North Chicago, Illinois, United States|Local Institution, Springfield, Illinois, United States|Local Institution, New Orleans, Louisiana, United States|Local Institution, Shreveport, Louisiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Newton Center, Massachusetts, United States|Local Institution, Springfield, Massachusetts, United States|Local Institution, Wellesley Hills, Massachusetts, United States|Local Institution, Lyons, New Jersey, United States|Local Institution, Albany, New York, United States|Local Institution, Lawrence, New York, United States|Local Institution, Montrose, New York, United States|Local Institution, Northport, New York, United States|Local Institution, White Plains, New York, United States|Local Institution, Raleigh, North Carolina, United States|Local Institution, Beachwood, Ohio, United States|Local Institution, Portland, Oregon, United States|Local Institution, Hershey, Pennsylvania, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Wichita Falls, Texas, United States|Local Institution, Bennington, Vermont, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00036114
NCT00034762,Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease,,Completed,No Results Available,Dementia|Alzheimer Disease|Mental Disorders,Drug: risperidone,Change from baseline to end of treatment (Week 8) in Psychosis Cluster Score of Pathology from the Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) Rating Scale and Clinical Global Impression (CGI).|Change in BEHAVE-AD total score and subscales (other than Psychosis Cluster subscale) from baseline; improvement in CGI scores during treatment; incidence of adverse events throughout study.,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"55 Years and older   (Adult, Older Adult)",Phase 3,473,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CR002764,Dec-00,null,Jan-03,3-May-02,null,1-Feb-11,,,https://ClinicalTrials.gov/show/NCT00034762
NCT00024531,Lipitor as a Treatment for Alzheimer's Disease,,Completed,No Results Available,Alzheimer Disease,Drug: Atorvastatin calcium,,Institute for the Study of Aging (ISOA)|Pfizer|National Institute on Aging (NIA),All,"50 Years and older   (Adult, Older Adult)",Phase 2,98,Other|Industry,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,IA0031,Oct-00,null,Aug-04,20-Sep-01,null,9-Nov-06,"Sun Health Research Institute, Sun City, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00024531
NCT00021723,"Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease",,Terminated,No Results Available,Alzheimer's Disease,Biological: AN-1792 also known as AIP-001,,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Wyeth is now a wholly owned subsidiary of Pfizer",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,375,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AN-1792-201,Sep-01,null,Sep-03,6-Aug-01,null,24-Sep-09,"Pivotal Research Centers, Peoria, Arizona, United States|21st Century Neurology, Phoenix, Arizona, United States|California Clinical Trials, Beverly Hills, California, United States|UCSD Medical Center, La Jolla, California, United States|Pharmacology Research Institute, Northridge, California, United States|Baumel-Eisner Neuromedical Institute, Bay Harbor Islands, Florida, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Clinical Pharmaceutical Trials, Inc., Tulsa, Oklahoma, United States|Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00021723
NCT00018291,Specific Interventions for Agitation in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Dementia,Drug: Risperidone|Drug: Gabapentin,,US Department of Veterans Affairs|VA Office of Research and Development,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,null,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,AGCG-005-00S,Jan-01,null,Jan-05,5-Jul-01,null,21-Jan-09,"Palo Alto VA Health Care System, Menlo Park, California, United States",,https://ClinicalTrials.gov/show/NCT00018291
NCT00015548,CATIE-Alzheimer's Disease Trial,,Completed,No Results Available,Alzheimer's Disease,Drug: Olanzapine|Drug: Quetiapine|Drug: Risperidone|Drug: Citalopram,,National Institute of Mental Health (NIMH),All,"Child, Adult, Older Adult",Not Applicable,450,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,N01 MH090001-05|N01 MH90001-AD|DSIR AT,Mar-01,null,Oct-04,23-Apr-01,null,17-Jun-15,"Tuscaloosa VA Medical Center, Tuscaloosa, Alabama, United States|University of California, Irvine Medical Center, Irvine, California, United States|University of Southern California Dept of Psychiatry& Behavioral Sciences, Los Angeles, California, United States|University of California, Los Angeles, VA Medical Center, Los Angeles, California, United States|University of California-San Diego, VA Medical Center, San Diego, California, United States|Stanford University School of Medicine, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Mental Health Advocates, Inc., Boca Raton, Florida, United States|Berma Research Group, Hialeah, Florida, United States|University of South Florida Suncoast Gerontology Center, Tampa, Florida, United States|Palm Beach Neurology/Premiere Research Institute, West Palm Beach, Florida, United States|Emory University - Wesley Woods Health Center, Atlanta, Georgia, United States|University of Hawaii, Honolulu, Hawaii, United States|Northwestern University Medical School, Chicago, Illinois, United States|Southern Illinois School of Medicine, Springfield, Illinois, United States|University of Iowa College of Medicine, Iowa City, Iowa, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Millennium Psychiatric Associates, St. Louis, Missouri, United States|University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, United States|University of Medicine and Dentistry of New Jersey-Stratford, Stratford, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Global Research and Consulting, Olean, New York, United States|Monroe Community Hospital, Rochester, New York, United States|Staten Island University Hospital, Staten Island, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University School of Medicine, Winston Salem, North Carolina, United States|University Hospital Health Systems-Laurelwood Hospital, Willoughby, Ohio, United States|VA Medical Center, Coatesville, Pennsylvania, United States|Mental Illness Research Education and Clinical Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Southwestern Vermont Medical Center- The Memory Clinic, Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00015548
NCT00013650,Effects of an Anti-Inflammatory Drug in Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Drug: Cyclophosphamate,,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 1,60,NIH,Interventional,Primary Purpose: Treatment,010128|01-M-0128,22-Mar-01,null,21-Apr-08,28-Mar-01,null,2-Jul-17,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00013650
NCT00010803,Ginkgo Biloba Prevention Trial in Older Individuals,,Completed,Has Results,Dementia|Alzheimer's Disease,Drug: Ginkgo biloba|Drug: Placebo,Number of Participants With Incident Dementia|Number of Participants With the Indicated Cardiovascular Disease or Mortality|Progression of Cognitive Decline in Standardized Z-score Scale. Higher Z-scores Indicate Worse Performance.,"National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS)|National Institute of Neurological Disorders and Stroke (NINDS)|National Institute on Aging (NIA)|National Heart, Lung, and Blood Institute (NHLBI)",All,75 Years and older   (Older Adult),Phase 3,3069,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",U01 AT000162-01M,Oct-00,Apr-08,Jul-11,5-Feb-01,16-Sep-10,14-Mar-13,"University of California, Davis, Sacramento, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Pittsburgh/University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00010803
NCT00009191,The Depression in Alzheimer's Disease Study (DIADS),,Completed,No Results Available,Alzheimer Disease|Depression,Drug: Sertraline [Zoloft],,Johns Hopkins University|National Institute of Mental Health (NIMH),All,"Child, Adult, Older Adult",Phase 4,null,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,R01MH056511|IA0010|DSIR AT-GP,Nov-05,Nov-06,Nov-07,24-Jan-01,null,20-Aug-18,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00009191
NCT00007189,Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT),,Completed,No Results Available,Alzheimer Disease,Drug: Naproxen Sodium (Aleve)|Drug: Celecoxib (Celebrex),,Seattle Institute for Biomedical and Clinical Research|National Institute on Aging (NIA)|VA Puget Sound Health Care System|University of Washington|Johns Hopkins University,All,70 Years and older   (Older Adult),Phase 3,2625,Other|NIH|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,IA0026|U01AG015477,Jan-01,May-07,null,14-Dec-00,null,19-Oct-16,"Sun Health Research Institute, Sun City, Arizona, United States|Roskamp Institute Memory Clinic, 10770 N. 46th Street, Tampa, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Rochester, Rochester, New York, United States|Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00007189
